Identification	B-UNK
of	O
APC2	O
,	O
a	O
homologue	B-UNK
of	O
the	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
tumour	B-UNK
suppressor	I-UNK
.	O

The	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
APC	B-UNK
)	O
tumour	B-UNK
-	O
suppressor	B-UNK
protein	B-UNK
controls	O
the	O
Wnt	O
signalling	O
pathway	B-UNK
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	B-UNK
3beta	O
(	O
GSK-3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Complex	O
formation	B-UNK
induces	O
the	O
rapid	O
degradation	O
of	O
betacatenin	O
.	O

In	O
colon	B-DISEASE
carcinoma	I-DISEASE
cells	B-UNK
,	O
loss	B-UNK
of	O
APC	B-UNK
leads	B-UNK
to	O
the	O
accumulation	B-UNK
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf-4	O
transcription	B-UNK
factor	I-UNK
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O

Here	O
,	O
we	O
report	B-UNK
the	O
identification	B-UNK
and	O
genomic	B-UNK
structure	B-UNK
of	O
APC	B-UNK
homologues	O
.	O

Mammalian	O
APC2	O
,	O
which	O
closely	B-UNK
resembles	O
APC	B-UNK
in	O
overall	O
domain	B-UNK
structure	B-UNK
,	O
was	O
functionally	O
analyzed	B-UNK
and	O
shown	B-UNK
to	O
contain	O
two	O
SAMP	O
domains	B-UNK
,	O
both	O
of	O
which	O
are	O
required	B-UNK
for	O
binding	B-UNK
to	O
conductin	O
.	O

Like	O
APC	B-UNK
,	O
APC2	O
regulates	O
the	O
formation	B-UNK
of	O
active	B-UNK
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC-/-colon	O
carcinoma	B-DISEASE
cells	B-UNK
.	O

Human	B-UNK
APC2	O
maps	B-UNK
to	O
chromosome	B-UNK
19p13	O
.	O

3	O
.	O

APC	B-UNK
and	O
APC2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	B-UNK
and	O
cancer	B-UNK
.	O

A	O
common	B-UNK
MSH2	B-UNK
mutation	B-UNK
in	O
English	O
and	O
North	B-UNK
American	B-UNK
HNPCC	O
families	B-UNK
:	O
origin	O
,	O
phenotypic	B-UNK
expression	B-UNK
,	O
and	O
sex	B-UNK
specific	B-UNK
differences	B-UNK
in	O
colorectal	B-UNK
cancer	I-UNK
.	O

The	O
frequency	B-UNK
,	O
origin	O
,	O
and	O
phenotypic	B-UNK
expression	B-UNK
of	O
a	O
germline	B-UNK
MSH2	B-UNK
gene	B-UNK
mutation	B-UNK
previously	B-UNK
identified	I-UNK
in	O
seven	O
kindreds	O
with	O
hereditary	B-UNK
non-polyposis	O
cancer	B-UNK
syndrome	B-DISEASE
(	O
HNPCC	O
)	O
was	O
investigated	O
.	O

The	O
mutation	B-UNK
(	O
A--	O
>	O
T	O
at	O
nt943	O
+	O
3	O
)	O
disrupts	O
the	O
3	O
splice	B-UNK
site	I-UNK
of	O
exon	B-UNK
5	O
leading	B-UNK
to	O
the	O
deletion	B-UNK
of	O
this	O
exon	B-UNK
from	O
MSH2	B-UNK
mRNA	O
and	O
represents	O
the	O
only	O
frequent	B-UNK
MSH2	B-UNK
mutation	B-UNK
so	O
far	O
reported	B-UNK
.	O

Although	O
this	O
mutation	B-UNK
was	O
initially	O
detected	B-UNK
in	O
four	O
of	O
33	O
colorectal	B-DISEASE
cancer	I-DISEASE
families	B-UNK
analysed	O
from	O
eastern	B-UNK
England	O
,	O
more	O
extensive	B-UNK
analysis	B-UNK
has	O
reduced	O
the	O
frequency	B-UNK
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	O
kindreds	O
analysed	O
.	O

In	O
contrast	B-UNK
,	O
the	O
MSH2	B-UNK
mutation	B-UNK
was	O
identified	B-UNK
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	B-UNK
colorectal	B-UNK
families	B-UNK
from	O
Newfoundland	O
.	O

To	O
investigate	B-UNK
the	O
origin	O
of	O
this	O
mutation	B-UNK
in	O
colorectal	B-DISEASE
cancer	I-DISEASE
families	B-UNK
from	O
England	O
(	O
n	O
=	O
4	O
)	O
,	O
Newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	B-UNK
analysis	I-UNK
using	O
microsatellite	B-UNK
markers	I-UNK
linked	B-UNK
to	O
MSH2	B-UNK
was	O
performed	O
.	O

Within	O
the	O
English	O
and	O
US	O
families	B-UNK
there	O
was	O
little	O
evidence	B-UNK
for	O
a	O
recent	O
common	B-UNK
origin	O
of	O
the	O
MSH2	B-UNK
splice	B-UNK
site	I-UNK
mutation	I-UNK
in	O
most	O
families	B-UNK
.	O

In	O
contrast	B-UNK
,	O
a	O
common	B-UNK
haplotype	B-UNK
was	O
identified	B-UNK
at	O
the	O
two	O
flanking	O
markers	B-UNK
(	O
CA5	O
and	O
D2S288	O
)	O
in	O
eight	O
of	O
the	O
Newfoundland	O
families	B-UNK
.	O

These	O
findings	B-UNK
suggested	O
a	O
founder	B-UNK
effect	I-UNK
within	O
Newfoundland	O
similar	B-UNK
to	O
that	O
reported	B-UNK
by	O
others	O
for	O
two	O
MLH1	O
mutations	B-UNK
in	O
Finnish	B-UNK
HNPCC	O
families	B-UNK
.	O

We	O
calculated	O
age	B-UNK
related	B-UNK
risks	O
of	O
all	O
,	O
colorectal	B-UNK
,	O
endometrial	O
,	O
and	O
ovarian	B-UNK
cancers	I-UNK
in	O
nt943	O
+	O
3	O
A--	O
>	O
T	O
MSH2	B-UNK
mutation	B-UNK
carriers	B-UNK
(	O
n	O
=	O
76	O
)	O
for	O
all	O
patients	B-UNK
and	O
for	O
men	B-UNK
and	O
women	B-UNK
separately	O
.	O

For	O
both	O
sexes	O
combined	O
,	O
the	O
penetrances	O
at	O
age	B-UNK
60	O
years	O
for	O
all	O
cancers	B-UNK
and	O
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
were	O
0	O
.	O

86	O
and	O
0	O
.	O

57	O
,	O
respectively	O
.	O

The	O
risk	B-UNK
of	O
colorectal	B-UNK
cancer	I-UNK
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	B-UNK
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

For	O
females	O
there	O
was	O
a	O
high	B-UNK
risk	I-UNK
of	O
endometrial	B-DISEASE
cancer	I-DISEASE
(	O
0	O
.	O
5	O
at	O
age	B-UNK
60	O
years	O
)	O
and	O
premenopausal	O
ovarian	B-UNK
cancer	I-UNK
(	O
0	O
.	O
2	O
at	O
50	O
years	O
)	O
.	O

These	O
intersex	O
differences	B-UNK
in	O
colorectal	B-UNK
cancer	I-UNK
risks	O
have	O
implications	B-UNK
for	O
screening	B-UNK
programmes	O
and	O
for	O
attempts	O
to	O
identify	B-UNK
colorectal	B-DISEASE
cancer	I-DISEASE
susceptibility	B-UNK
modifiers	O
.	O

Age	B-UNK
of	I-UNK
onset	I-UNK
in	O
Huntington	B-UNK
disease	I-UNK
:	O
sex	B-UNK
specific	B-UNK
influence	O
of	O
apolipoprotein	B-UNK
E	O
genotype	B-UNK
and	O
normal	B-UNK
CAG	B-UNK
repeat	I-UNK
length	B-UNK
.	O

Age	B-UNK
of	I-UNK
onset	I-UNK
(	O
AO	B-UNK
)	O
of	O
Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
is	O
known	O
to	O
be	O
correlated	B-UNK
with	O
the	O
length	B-UNK
of	O
an	O
expanded	B-UNK
CAG	B-UNK
repeat	I-UNK
in	O
the	O
HD	B-UNK
gene	B-UNK
.	O

Apolipoprotein	B-UNK
E	O
(	O
APOE	B-UNK
)	O
genotype	B-UNK
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
AO	B-UNK
in	O
Alzheimer	B-DISEASE
disease	I-DISEASE
,	O
rendering	O
the	O
APOE	B-UNK
gene	B-UNK
a	O
likely	O
candidate	B-UNK
to	O
affect	O
AO	B-UNK
in	O
other	O
neurological	B-UNK
diseases	B-UNK
too	O
.	O

We	O
therefore	O
determined	B-UNK
APOE	B-UNK
genotype	B-UNK
and	O
normal	B-UNK
CAG	B-UNK
repeat	I-UNK
length	B-UNK
in	O
the	O
HD	B-UNK
gene	B-UNK
for	O
138	O
HD	B-UNK
patients	B-UNK
who	O
were	O
previously	B-UNK
analysed	O
with	O
respect	O
to	O
CAG	B-UNK
repeat	I-UNK
length	B-UNK
.	O

Genotyping	O
for	O
APOE	B-UNK
was	O
performed	O
blind	B-DISEASE
to	O
clinical	B-UNK
information	B-UNK
.	O

In	O
addition	B-UNK
to	O
highlighting	O
the	O
effect	B-UNK
of	O
the	O
normal	B-UNK
repeat	B-UNK
length	I-UNK
upon	O
AO	B-UNK
in	O
maternally	O
inherited	B-UNK
HD	B-UNK
and	O
in	O
male	B-UNK
patients	B-UNK
,	O
we	O
show	O
that	O
the	O
APOE	B-UNK
epsilon2epsilon3	O
genotype	B-UNK
is	O
associated	O
with	O
significantly	O
earlier	O
AO	B-UNK
in	O
males	B-UNK
than	O
in	O
females	O
.	O

Such	O
a	O
sex	B-UNK
difference	O
in	O
AO	B-UNK
was	O
not	O
apparent	O
for	O
any	O
of	O
the	O
other	O
APOE	B-UNK
genotypes	O
.	O

Our	O
findings	B-UNK
suggest	B-UNK
that	O
subtle	O
differences	B-UNK
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-DISEASE
in	O
HD	B-UNK
may	O
allow	O
interacting	O
genes	B-UNK
to	O
exert	O
gender	O
specific	B-UNK
effects	B-UNK
upon	O
AO	B-UNK
.	O

Familial	B-UNK
deficiency	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
associated	O
with	O
recurrent	O
bacteremic	O
infections	B-DISEASE
due	O
to	O
Neisseria	O
.	O

The	O
serum	B-UNK
of	O
a	O
29-year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	O
gonococcal	O
infection	B-DISEASE
and	O
a	O
history	B-UNK
of	O
meningococcal	B-UNK
meningitis	B-DISEASE
and	O
arthritis	B-UNK
as	O
a	O
child	B-UNK
was	O
found	O
to	O
lack	B-UNK
serum	B-UNK
hemolytic	B-DISEASE
complement	B-UNK
activity	B-UNK
.	O

The	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C7	B-UNK
)	O
was	O
not	O
detected	B-UNK
by	O
functional	O
or	O
immunochemical	O
assays	O
,	O
whereas	O
other	O
components	O
were	O
normal	B-UNK
by	O
hemolytic	B-DISEASE
and	O
immunochemical	O
assessment	O
.	O

Her	O
fresh	O
serum	B-UNK
lacked	O
complement	B-UNK
-	O
mediated	O
bactericidal	O
activity	B-UNK
against	O
Neisseria	O
gonorrhoeae	O
,	O
but	O
the	O
addition	B-UNK
of	O
fresh	O
normal	B-UNK
serum	B-UNK
or	O
purified	O
C7	B-UNK
restored	O
bactericidal	O
activity	B-UNK
as	O
well	O
as	O
hemolytic	B-UNK
activity	B-UNK
.	O

The	O
absence	B-UNK
of	O
functional	O
C7	B-UNK
activity	B-UNK
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	B-UNK
of	O
an	O
inhibitor	O
.	O

Opsonization	O
and	O
generation	O
of	O
chemotactic	O
activity	B-UNK
functioned	O
normally	O
.	O

Complete	O
absence	B-UNK
of	O
C7	B-UNK
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	B-UNK
syndrome	B-DISEASE
of	O
meningococcal	B-UNK
meningitis	B-DISEASE
and	O
arthritis	B-UNK
as	O
a	O
child	B-UNK
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O

HLA	B-UNK
histocompatibility	B-UNK
typing	O
of	O
the	O
family	B-UNK
members	I-UNK
did	O
not	O
demonstrate	B-UNK
evidence	B-UNK
for	O
genetic	B-UNK
linkage	I-UNK
of	O
C7	B-UNK
deficiency	I-UNK
with	O
the	O
major	B-UNK
histocompatibility	B-UNK
loci	O
.	O

This	O
report	B-UNK
represents	O
the	O
first	O
cases	B-UNK
of	O
C7	B-UNK
deficiency	I-UNK
associated	O
with	O
infectious	O
complications	B-DISEASE
and	O
suggests	O
that	O
bactericidal	O
activity	B-UNK
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	O
neisseria	O
infections	B-UNK
.	O

Increased	B-UNK
incidence	B-UNK
of	O
cancer	B-UNK
in	O
patients	B-UNK
with	O
cartilage	B-DISEASE
-	I-DISEASE
hair	I-DISEASE
hypoplasia	I-DISEASE
.	O

OBJECTIVE	B-UNK
Previous	B-UNK
reports	O
have	O
suggested	O
an	O
increased	B-UNK
risk	B-UNK
of	O
cancer	B-UNK
among	O
patients	B-UNK
with	O
cartilage	B-DISEASE
-	I-DISEASE
hair	I-DISEASE
hypoplasia	I-DISEASE
(	O
CHH	O
)	O
.	O

This	O
study	B-UNK
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	B-UNK
among	O
patients	B-UNK
with	O
CHH	O
and	O
their	O
first	O
-	O
degree	B-UNK
relatives	B-UNK
.	O

STUDY	B-UNK
DESIGN	O
One	O
hundred	O
twenty	O
-	O
two	O
patients	B-UNK
with	O
CHH	O
were	O
identified	B-UNK
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986	O
.	O

Their	O
parents	O
and	O
nonaffected	O
siblings	O
were	O
identified	B-UNK
through	O
the	O
Population	B-UNK
Register	O
Center	O
.	O

This	O
cohort	B-UNK
underwent	O
follow	O
-	O
up	O
for	O
cancer	B-UNK
incidence	B-UNK
through	O
the	O
Finnish	B-UNK
Cancer	B-DISEASE
Registry	O
to	O
the	O
end	B-UNK
of	O
1995	O
.	O

RESULTS	B-UNK
A	O
statistically	O
significant	B-UNK
excess	B-UNK
risk	B-UNK
of	O
cancer	B-UNK
was	O
seen	O
among	O
the	O
patients	B-UNK
with	O
CHH	O
(	O
standardized	O
incidence	B-UNK
ratio	B-UNK
6	O
.	O
9	O
,	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
2	O
.	O
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non-Hodgkins	O
lymphoma	B-DISEASE
(	O
standardized	O
incidence	B-UNK
ratio	B-UNK
90	O
,	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
18	O
to	O
264	O
)	O
.	O

In	O
addition	B-UNK
,	O
a	O
significant	B-UNK
excess	B-UNK
risk	B-UNK
of	O
basal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
was	O
seen	O
(	O
standardized	O
incidence	B-UNK
ratio	B-UNK
35	O
,	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
7	O
.	O
2	O
to	O
102	O
)	O
.	O

The	O
cancer	B-DISEASE
incidence	B-UNK
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-DISEASE
incidence	B-UNK
in	O
the	O
Finnish	B-UNK
population	B-UNK
.	O

CONCLUSIONS	B-UNK
This	O
study	B-UNK
confirms	O
an	O
increased	B-UNK
risk	B-UNK
of	O
cancer	B-DISEASE
,	O
especially	O
non-Hodgkins	O
lymphoma	B-DISEASE
,	O
probably	O
attributable	O
to	O
defective	O
immunity	O
,	O
among	O
patients	B-UNK
with	O
CHH	O
.	O

Genotype	B-UNK
and	O
phenotype	B-UNK
in	O
patients	B-UNK
with	O
dihydropyrimidine	B-DISEASE
dehydrogenase	I-DISEASE
deficiency	I-DISEASE
.	O

Dihydropyrimidine	O
dehydrogenase	B-UNK
(	O
DPD	O
)	O
deficiency	B-UNK
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disease	B-UNK
characterised	O
by	O
thymine	O
-	O
uraciluria	O
in	O
homozygous	B-UNK
deficient	B-UNK
patients	B-UNK
and	O
has	O
been	O
associated	O
with	O
a	O
variable	B-UNK
clinical	B-UNK
phenotype	B-UNK
.	O

In	O
order	B-UNK
to	O
understand	O
the	O
genetic	B-UNK
and	O
phenotypic	B-UNK
basis	B-UNK
for	O
DPD	O
deficiency	B-UNK
,	O
we	O
have	O
reviewed	O
17	O
families	B-UNK
presenting	B-UNK
22	O
patients	B-UNK
with	O
complete	O
deficiency	B-UNK
of	O
DPD	O
.	O

In	O
this	O
group	B-UNK
of	O
patients	B-UNK
,	O
7	O
different	O
mutations	B-UNK
have	O
been	O
identified	B-UNK
,	O
including	O
2	O
deletions	O
[	O
295	O
-	O
298delTCAT	O
,	O
1897delC	O
]	O
,	O
1	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
[	O
IVS14	O
+	O
1	O
G	O
>	O
A	O
)	O
]	O
and	O
4	O
missense	B-UNK
mutations	I-UNK
(	O
85	O
T	O
>	O
C	O
,	O
703C	O
>	O
T	O
,	O
2658	O
G	O
>	O
A	O
,	O
2983	O
G	O
>	O
T	O
)	O
.	O

Analysis	B-UNK
of	O
the	O
prevalence	B-UNK
of	O
the	O
various	O
mutations	B-UNK
among	O
DPD	O
patients	B-UNK
has	O
shown	B-UNK
that	O
the	O
G--	O
>	O
A	O
point	B-UNK
mutation	I-UNK
in	O
the	O
invariant	O
splice	B-UNK
donor	I-UNK
site	I-UNK
is	O
by	O
far	O
the	O
most	O
common	B-UNK
(	O
52	O
%	O
)	O
,	O
whereas	O
the	O
other	O
six	O
mutations	B-UNK
are	O
less	O
frequently	O
observed	B-UNK
.	O

A	O
large	B-UNK
phenotypic	B-UNK
variability	B-UNK
has	O
been	O
observed	B-UNK
,	O
with	O
convulsive	B-DISEASE
disorders	B-UNK
,	O
motor	O
retardation	B-UNK
and	O
mental	B-UNK
retardation	I-UNK
being	O
the	O
most	O
abundant	O
manifestations	B-UNK
.	O

A	O
clear	O
correlation	B-UNK
between	O
the	O
genotype	B-UNK
and	O
phenotype	B-UNK
has	O
not	O
been	O
established	O
.	O

An	O
altered	O
beta-alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B-UNK
abnormalities	B-UNK
encountered	O
in	O
patients	B-UNK
with	O
DPD	O
deficiency	B-UNK
.	O

Fibroblast	O
growth	B-UNK
factor	I-UNK
homologous	B-UNK
factor	B-UNK
2	O
(	O
FHF2	O
):	O
gene	B-UNK
structure	B-UNK
,	O
expression	B-UNK
and	O
mapping	B-UNK
to	O
the	O
Borjeson	B-DISEASE
-	I-DISEASE
Forssman	I-DISEASE
-	I-DISEASE
Lehmann	I-DISEASE
syndrome	I-DISEASE
region	B-UNK
in	O
Xq26	O
delineated	O
by	O
a	O
duplication	B-UNK
breakpoint	O
in	O
a	O
BFLS	O
-	O
like	O
patient	B-UNK
.	O

Borjeson	B-DISEASE
-	I-DISEASE
Forssman	I-DISEASE
-	I-DISEASE
Lehmann	I-DISEASE
syndrome	I-DISEASE
(	O
BFLS	O
)	O
is	O
a	O
syndromal	O
X	O
-	O
linked	B-UNK
mental	B-UNK
retardation	I-UNK
,	O
which	O
maps	B-UNK
by	O
linkage	B-UNK
to	O
the	O
q26	O
region	B-UNK
of	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
.	O

We	O
have	O
identified	B-UNK
a	O
male	B-UNK
patient	B-UNK
with	O
BFLS	O
-	O
like	O
features	B-UNK
and	O
a	O
duplication	B-UNK
,	O
46	O
,	O
Y	O
,	O
dup	O
(	O
X	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	B-UNK
from	O
his	O
phenotypically	O
normal	B-UNK
mother	O
.	O

Fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridisation	O
using	O
yeast	B-UNK
artificial	O
chromosome	B-UNK
clones	O
from	O
Xq26	O
localised	O
the	O
duplication	B-UNK
breakpoint	O
to	O
an	O
approximately	O
400-kb	O
interval	B-UNK
in	O
the	O
Xq26	O
.	O

3	O
region	B-UNK
between	O
DXS155	O
and	O
DXS294	O
/	O
DXS730	O
.	O

Database	O
searches	O
and	O
analysis	B-UNK
of	O
available	O
genomic	B-UNK
DNA	I-UNK
sequence	B-UNK
from	O
the	O
region	B-UNK
revealed	B-UNK
the	O
presence	O
of	O
the	O
fibroblast	O
growth	B-UNK
factor	I-UNK
homologous	B-UNK
factor	B-UNK
gene	B-UNK
,	O
FHF2	O
,	O
within	O
the	O
duplication	B-UNK
breakpoint	O
interval	B-UNK
.	O

The	O
gene	B-UNK
structure	B-UNK
of	O
FHF2	O
was	O
determined	B-UNK
and	O
two	O
new	O
exons	O
were	O
identified	B-UNK
,	O
including	O
a	O
new	O
5	O
end	B-UNK
exon	B-UNK
,	O
1B.	O

FHF2	O
is	O
a	O
large	B-UNK
gene	B-UNK
extending	O
over	O
approximately	O
200	O
kb	B-UNK
in	O
Xq26	O
.	O

3	O
and	O
is	O
composed	O
of	O
at	O
least	O
seven	O
exons	O
.	O

It	O
shows	O
tissue	B-UNK
-	O
specific	B-UNK
alternative	B-UNK
splicing	B-UNK
and	O
alternative	B-UNK
transcription	B-UNK
starts	O
.	O

Northern	B-UNK
blot	B-UNK
hybridisation	O
showed	O
highest	O
expression	B-UNK
in	O
brain	B-UNK
and	O
skeletal	B-UNK
muscle	I-UNK
.	O

The	O
FHF2	O
gene	B-UNK
localisation	O
and	O
tissue	B-UNK
-	O
specific	B-UNK
expression	B-UNK
pattern	B-UNK
suggest	B-UNK
it	O
to	O
be	O
a	O
candidate	B-UNK
gene	I-UNK
for	O
familial	B-UNK
cases	I-UNK
of	O
the	O
BFLS	O
syndrome	B-UNK
and	O
other	O
syndromal	O
and	O
non-specific	O
forms	B-UNK
of	O
X	O
-	O
linked	B-UNK
mental	B-UNK
retardation	I-UNK
mapping	B-UNK
to	O
the	O
region	B-UNK
.	O

Germline	B-UNK
E-cadherin	O
gene	B-UNK
(	O
CDH1	B-UNK
)	O
mutations	B-UNK
predispose	O
to	O
familial	B-UNK
gastric	B-DISEASE
cancer	I-DISEASE
and	O
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

Inherited	B-UNK
mutations	B-UNK
in	O
the	O
E-cadherin	O
gene	B-UNK
(	O
CDH1	B-UNK
)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	B-UNK
gastric	B-UNK
cancer	I-UNK
.	O

Familial	B-UNK
gastric	B-DISEASE
cancer	I-DISEASE
is	O
genetically	B-UNK
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	B-UNK
of	O
gastric	B-UNK
cancer	I-UNK
susceptibility	B-UNK
in	O
non-Maori	O
populations	O
is	O
due	O
to	O
germline	B-UNK
CDH1	B-UNK
mutations	B-UNK
.	O

Therefore	O
,	O
we	O
screened	B-UNK
eight	O
familial	B-UNK
gastric	B-UNK
cancer	I-UNK
kindreds	O
of	O
British	B-UNK
and	O
Irish	B-UNK
origin	O
for	O
germline	B-UNK
CDH1	B-UNK
mutations	B-UNK
,	O
by	O
SSCP	B-UNK
analysis	B-UNK
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O

Each	O
family	B-UNK
contained	O
(	O
i	O
)	O
two	O
cases	B-UNK
of	O
gastric	B-UNK
cancer	I-UNK
in	O
first	O
degree	B-UNK
relatives	B-UNK
with	O
one	O
affected	B-UNK
before	O
age	B-UNK
50	O
years	O
;	O
or	O
(	O
ii	B-UNK
)	O
three	O
or	O
more	O
cases	B-UNK
of	O
gastric	B-DISEASE
cancer	I-DISEASE
.	O

Novel	O
germline	B-UNK
CDH1	B-UNK
mutations	B-UNK
(	O
a	O
nonsense	B-UNK
and	O
a	O
splice	B-UNK
site	I-UNK
)	O
were	O
detected	B-UNK
in	O
two	O
families	B-UNK
(	O
25	O
%	O
)	O
.	O

Both	O
mutations	B-UNK
were	O
predicted	B-UNK
to	O
truncate	O
the	O
E-cadherin	O
protein	B-UNK
in	O
the	O
signal	B-UNK
peptide	B-UNK
domain	B-UNK
.	O

In	O
one	O
family	B-UNK
there	O
was	O
evidence	B-UNK
of	O
non-penetrance	O
and	O
susceptibility	B-UNK
to	O
both	O
gastric	B-UNK
and	O
colorectal	B-UNK
cancer	I-UNK
;	O
thus	O
,	O
in	O
addition	B-UNK
to	O
six	O
cases	B-UNK
of	O
gastric	B-UNK
cancer	I-UNK
,	O
a	O
CDH1	B-UNK
mutation	B-UNK
carrier	B-UNK
developed	O
colorectal	B-UNK
cancer	I-UNK
at	O
age	B-UNK
30	O
years	O
.	O

We	O
have	O
confirmed	B-UNK
that	O
germline	B-UNK
mutations	I-UNK
in	O
the	O
CDH1	B-UNK
gene	B-UNK
cause	O
familial	B-UNK
gastric	B-UNK
cancer	I-UNK
in	O
non-Maori	O
populations	O
.	O

However	O
,	O
only	O
a	O
minority	O
of	O
familial	B-UNK
gastric	B-UNK
cancers	B-DISEASE
can	O
be	O
accounted	O
for	O
by	O
CDH1	B-UNK
mutations	B-UNK
.	O

Loss	B-UNK
of	O
E-cadherin	O
function	B-UNK
has	O
been	O
implicated	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
sporadic	B-UNK
colorectal	B-UNK
and	O
other	O
cancers	B-DISEASE
,	O
and	O
our	O
findings	B-UNK
provide	B-UNK
evidence	I-UNK
that	O
germline	B-UNK
CDH1	B-UNK
mutations	B-UNK
predispose	O
to	O
early	B-UNK
onset	I-UNK
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

Thus	O
,	O
CDH1	B-UNK
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	B-UNK
susceptibility	B-UNK
to	O
both	O
gastric	B-UNK
and	O
colorectal	B-UNK
cancers	B-UNK
.	O

A	O
zinc	B-UNK
finger	I-UNK
truncation	B-UNK
of	O
murine	O
WT1	B-UNK
results	B-UNK
in	O
the	O
characteristic	B-UNK
urogenital	B-DISEASE
abnormalities	I-DISEASE
of	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
Wilms	B-UNK
tumor	I-UNK
-	O
suppressor	B-UNK
gene	B-UNK
,	O
WT1	B-UNK
,	O
plays	O
a	O
key	B-UNK
role	B-UNK
in	O
urogenital	O
development	B-UNK
,	O
and	O
WT1	B-UNK
dysfunction	B-UNK
is	O
implicated	B-UNK
in	O
both	O
neoplastic	O
(	O
Wilms	B-DISEASE
tumor	I-DISEASE
,	O
mesothelioma	B-DISEASE
,	O
leukemias	O
,	O
and	O
breast	B-UNK
cancer	I-UNK
)	O
and	O
nonneoplastic	O
(	O
glomerulosclerosis	B-DISEASE
)	O
disease	B-DISEASE
.	O

The	O
analysis	B-UNK
of	O
diseases	B-UNK
linked	B-UNK
specifically	B-UNK
with	O
WT1	B-UNK
mutations	B-UNK
,	O
such	O
as	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
(	O
DDS	B-UNK
)	O
,	O
can	O
provide	B-UNK
valuable	O
insight	O
concerning	O
the	O
role	B-UNK
of	O
WT1	B-UNK
in	O
development	B-UNK
and	O
disease	B-UNK
.	O

DDS	B-UNK
is	O
a	O
rare	B-UNK
childhood	O
disease	B-DISEASE
characterized	B-UNK
by	O
a	O
nephropathy	B-DISEASE
involving	O
mesangial	O
sclerosis	B-DISEASE
,	O
XY	O
pseudohermaphroditism	O
,	O
and	O
/	O
or	O
Wilms	B-DISEASE
tumor	I-DISEASE
(	O
WT	O
)	O
.	O

DDS	B-UNK
patients	B-UNK
are	O
constitutionally	O
heterozygous	B-UNK
for	O
exonic	O
point	B-UNK
mutations	I-UNK
in	O
WT1	B-UNK
,	O
which	O
include	O
mutations	B-UNK
predicted	B-UNK
to	O
truncate	O
the	O
protein	B-UNK
within	O
the	O
C	O
-	O
terminal	B-UNK
zinc	B-UNK
finger	I-UNK
(	O
ZF	O
)	O
region	B-UNK
.	O

We	O
report	B-UNK
that	O
heterozygosity	B-UNK
for	O
a	O
targeted	B-UNK
murine	O
Wt1	B-UNK
allele	B-UNK
,	O
Wt1	B-UNK
(	O
tmT396	O
)	O
,	O
which	O
truncates	O
ZF3	O
at	O
codon	B-UNK
396	O
,	O
induces	O
mesangial	O
sclerosis	B-DISEASE
characteristic	B-UNK
of	O
DDS	B-UNK
in	O
adult	B-UNK
heterozygous	B-UNK
and	O
chimeric	O
mice	B-UNK
.	O

Male	B-UNK
genital	O
defects	B-UNK
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	B-UNK
case	B-UNK
of	O
Wilms	B-DISEASE
tumor	I-DISEASE
in	O
which	O
the	O
transcript	B-UNK
of	O
the	O
nontargeted	O
allele	B-UNK
showed	O
an	O
exon	B-UNK
9	O
skipping	O
event	O
,	O
implying	O
a	O
causal	O
link	O
between	O
Wt1	B-UNK
dysfunction	B-UNK
and	O
Wilms	B-UNK
tumorigenesis	O
in	O
mice	B-UNK
.	O

However	O
,	O
the	O
mutant	B-UNK
WT1	B-UNK
(	O
tmT396	O
)	O
protein	B-UNK
accounted	O
for	O
only	O
5	O
%	O
of	O
WT1	B-UNK
in	O
both	O
heterozygous	B-UNK
embryonic	B-UNK
stem	B-UNK
cells	B-UNK
and	O
the	O
WT	O
.	O

This	O
has	O
implications	B-UNK
regarding	O
the	O
mechanism	B-UNK
by	O
which	O
the	O
mutant	B-UNK
allele	B-UNK
exerts	O
its	O
effect	B-UNK
.	O

Mechanism	B-UNK
of	O
increased	B-UNK
iron	B-UNK
absorption	O
in	O
murine	O
model	B-UNK
of	O
hereditary	B-UNK
hemochromatosis	I-UNK
:	O
increased	B-UNK
duodenal	O
expression	B-UNK
of	O
the	O
iron	B-UNK
transporter	B-UNK
DMT1	B-UNK
.	O

Hereditary	B-UNK
hemochromatosis	I-UNK
(	O
HH	B-UNK
)	O
is	O
a	O
common	B-UNK
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
tissue	B-UNK
iron	B-UNK
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	B-UNK
absorption	O
.	O

We	O
recently	O
reported	B-UNK
that	O
HFE	B-UNK
,	O
the	O
protein	B-UNK
defective	O
in	O
HH	B-UNK
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	B-UNK
(	O
TfR	B-UNK
)	O
in	O
duodenal	O
crypt	O
cells	B-UNK
and	O
proposed	O
that	O
mutations	B-UNK
in	O
HFE	B-UNK
attenuate	O
the	O
uptake	O
of	O
transferrin	O
-	O
bound	O
iron	B-UNK
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	B-UNK
,	O
leading	B-UNK
to	O
up	O
-	O
regulation	B-UNK
of	O
transporters	O
for	O
dietary	O
iron	B-UNK
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	B-UNK
that	O
HFE-/-mice	O
have	O
increased	B-UNK
duodenal	O
expression	B-UNK
of	O
the	O
divalent	O
metal	O
transporter	B-UNK
(	O
DMT1	B-UNK
)	O
.	O

By	O
4	O
weeks	O
of	O
age	B-UNK
,	O
the	O
HFE-/-mice	O
demonstrated	O
iron	B-UNK
loading	O
when	O
compared	B-UNK
with	O
HFE	B-UNK
+	O
/+	O
littermates	O
,	O
with	O
elevated	B-UNK
transferrin	O
saturations	O
(	O
68	O
.	O
4	O
%	O
vs	O
.	O
49	O
.	O
8	O
%	O
)	O
and	O
elevated	B-UNK
liver	B-UNK
iron	B-UNK
concentrations	O
(	O
985	O
micrograms	O
vs	O
.	O
381	O
micrograms	O
)	O
.	O

By	O
using	O
Northern	B-UNK
blot	B-UNK
analyses	O
,	O
we	O
quantitated	O
duodenal	O
expression	B-UNK
of	O
both	O
classes	O
of	O
DMT1	B-UNK
transcripts	O
one	O
containing	O
an	O
iron	B-UNK
responsive	O
element	O
(	O
IRE	O
)	O
,	O
called	O
DMT1	B-UNK
(	O
IRE	O
)	O
,	O
and	O
one	O
containing	O
no	O
IRE	O
,	O
called	O
DMT1	B-UNK
(	O
non-IRE	O
)	O
.	O

The	O
positive	O
control	B-UNK
for	O
DMT1	B-UNK
up	O
-	O
regulation	B-UNK
was	O
a	O
murine	O
model	B-UNK
of	O
dietary	O
iron	B-UNK
deficiency	B-UNK
that	O
demonstrated	O
greatly	O
increased	B-UNK
levels	B-UNK
of	O
duodenal	O
DMT1	B-UNK
(	O
IRE	O
)	O
mRNA	O
.	O

HFE-/-mice	O
also	O
demonstrated	O
an	O
increase	B-UNK
in	O
duodenal	O
DMT1	B-UNK
(	O
IRE	O
)	O
mRNA	O
(	O
average	O
7	O
.	O
7-fold	O
)	O
,	O
despite	O
their	O
elevated	B-UNK
transferrin	O
saturation	O
and	O
hepatic	B-UNK
iron	B-UNK
content	O
.	O

Duodenal	O
expression	B-UNK
of	O
DMT1	B-UNK
(	O
non-IRE	O
)	O
was	O
not	O
increased	B-UNK
,	O
nor	O
was	O
hepatic	B-UNK
expression	B-UNK
of	O
DMT1	B-UNK
increased	B-UNK
.	O

These	O
data	B-UNK
support	O
the	O
model	B-UNK
for	O
HH	B-UNK
in	O
which	O
HFE	B-UNK
mutations	B-UNK
lead	B-UNK
to	O
inappropriately	O
low	B-UNK
crypt	O
cell	B-UNK
iron	B-UNK
,	O
with	O
resultant	O
stabilization	O
of	O
DMT1	B-UNK
(	O
IRE	O
)	O
mRNA	O
,	O
up	O
-	O
regulation	B-UNK
of	O
DMT1	B-UNK
,	O
and	O
increased	B-UNK
absorption	O
of	O
dietary	O
iron	B-UNK
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	B-UNK
-	O
term	O
dietary	O
treatment	O
in	O
adult	B-UNK
-	O
onset	B-UNK
adrenoleukodystrophy	B-DISEASE
.	O

OBJECTIVE	B-UNK
To	O
monitor	O
the	O
effects	B-UNK
of	O
dietary	O
treatment	O
in	O
adult	B-UNK
-	O
onset	B-UNK
adrenoleukodystrophy	B-DISEASE
(	O
ALD	B-UNK
)	O
by	O
means	B-UNK
of	O
somatosensory	O
evoked	O
potentials	O
(	O
SEPs	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
MEPs	O
)	O
.	O

BACKGROUND	O
SEPs	O
and	O
MEPs	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	B-UNK
of	O
progressively	O
severe	B-UNK
,	O
central	B-UNK
dying	O
-	O
back	O
axonopathy	O
in	O
early	B-UNK
stages	O
of	O
adult	B-UNK
-	O
onset	B-UNK
ALD	B-UNK
.	O

METHODS	O
Eight	O
patients	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
ALD	B-UNK
underwent	O
clinical	B-UNK
examination	B-UNK
,	O
brain	B-UNK
and	O
spine	O
MRI	B-UNK
,	O
and	O
SEP	O
and	O
MEP	O
studies	B-UNK
before	O
and	O
after	O
3	O
years	O
of	O
Lorenzos	O
oil	O
dietary	O
therapy	B-UNK
.	O

RESULTS	B-UNK
Before	O
treatment	O
,	O
brain	B-UNK
MRI	B-UNK
was	O
normal	B-UNK
in	O
five	O
patients	B-UNK
.	O

Three	O
of	O
these	O
patients	B-UNK
had	O
pure	O
spinal	B-UNK
SEP	O
abnormalities	B-UNK
and	O
in	O
the	O
remaining	O
two	O
patients	B-UNK
SEPs	O
showed	O
signs	B-UNK
of	O
involvement	B-UNK
of	O
both	O
the	O
spinal	B-UNK
and	O
cerebral	B-UNK
somatosensory	O
tracts	O
.	O

After	O
treatment	O
,	O
the	O
three	O
patients	B-UNK
with	O
pure	O
spinal	B-UNK
abnormalities	B-UNK
showed	O
clinical	B-UNK
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	B-UNK
with	O
a	O
more	O
advanced	O
stage	B-UNK
of	O
disease	B-UNK
(	O
exhibited	O
by	O
SEPs	O
)	O
showed	O
substantially	O
unchanged	O
clinical	B-UNK
and	O
neurophysiologic	O
features	B-UNK
.	O

The	O
patients	B-UNK
with	O
abnormal	O
brain	B-UNK
MRI	B-UNK
at	O
the	O
onset	B-UNK
of	O
treatment	O
showed	O
clinical	B-UNK
and	O
neurophysiologic	O
worsening	O
.	O

CONCLUSIONS	B-UNK
Lorenzos	O
oil	O
therapy	B-UNK
had	O
no	O
effect	B-UNK
on	O
patients	B-UNK
with	O
evidence	B-UNK
of	O
inflammatory	O
brain	B-UNK
lesions	B-UNK
.	O

Moreover	O
,	O
in	O
patients	B-UNK
without	O
clear	O
signs	B-UNK
of	O
inflammatory	O
damage	B-UNK
,	O
this	O
treatment	O
does	O
not	O
modify	O
significantly	O
the	O
natural	O
course	O
of	O
the	O
disease	B-UNK
.	O

However	O
,	O
because	O
effective	O
treatments	O
should	O
begin	O
before	O
the	O
onset	B-UNK
of	O
severe	B-UNK
neurologic	O
symptoms	B-UNK
,	O
SEPs	O
and	O
MEPs	O
should	O
be	O
considered	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
other	O
experimental	O
treatments	O
in	O
the	O
patient	B-UNK
with	O
a	O
negative	B-UNK
brain	B-UNK
MRI	B-UNK
.	O

GCH1	O
mutation	B-UNK
in	O
a	O
patient	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
oromandibular	B-DISEASE
dystonia	I-DISEASE
.	O

The	O
authors	O
report	B-UNK
a	O
mutation	B-UNK
in	O
exon	B-UNK
5	O
of	O
GCH1	O
in	O
a	O
patient	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
oromandibular	B-DISEASE
dystonia	I-DISEASE
and	O
no	O
obvious	O
family	B-UNK
history	B-UNK
of	O
dystonia	B-DISEASE
.	O

The	O
patient	B-UNK
responded	O
positively	O
to	O
treatment	O
with	O
L	O
-	O
dopa	O
.	O

These	O
findings	B-UNK
demonstrate	B-UNK
that	O
GCH1	O
mutations	B-UNK
must	O
be	O
considered	O
even	O
in	O
patients	B-UNK
with	O
dystonic	B-DISEASE
symptoms	B-UNK
not	O
typical	O
of	O
dopa	O
-	O
responsive	O
dystonia	B-DISEASE
.	O

Germline	B-UNK
mutations	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
in	O
Korean	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
patients	B-UNK
.	O

We	O
extensively	O
analyzed	B-UNK
genomic	B-UNK
DNA	I-UNK
and	O
messenger	B-UNK
RNA	I-UNK
(	O
mRNA	O
)	O
from	O
62	O
unrelated	B-UNK
Korean	O
patients	B-UNK
with	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
for	O
identification	B-UNK
of	O
germline	B-UNK
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
gene	B-UNK
mutations	B-UNK
.	O

We	O
adopted	O
both	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
analysis	B-UNK
and	O
a	O
method	O
of	O
analysis	B-UNK
involving	O
the	O
reverse	B-UNK
transcription	B-UNK
-	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
RT	O
-	O
PCR	B-UNK
)	O
followed	O
by	O
a	O
protein	B-UNK
truncation	I-UNK
test	I-UNK
(	O
PTT	B-UNK
)	O
.	O

DNA	B-UNK
sequencing	I-UNK
confirmed	B-UNK
all	O
alterations	B-UNK
represented	O
by	O
aberrant	B-UNK
bands	O
.	O

Germline	B-UNK
mutations	I-UNK
were	O
identified	B-UNK
in	O
38	O
patients	B-UNK
(	O
61	O
%	O
)	O
.	O

Nineteen	O
of	O
the	O
detected	B-UNK
mutations	B-UNK
were	O
presumed	O
to	O
be	O
novel	O
,	O
thus	O
emphasizing	O
the	O
heterogeneity	B-UNK
of	O
the	O
mutational	O
spectrum	B-UNK
in	O
Korean	O
FAP	B-UNK
patients	I-UNK
.	O

In	O
the	O
initial	O
48	O
patients	B-UNK
,	O
SSCP	B-UNK
analysis	B-UNK
was	O
followed	O
by	O
PTT	B-UNK
for	O
those	O
patients	B-UNK
for	O
whom	O
no	O
detectable	O
mutations	B-UNK
were	O
found	O
by	O
SSCP	B-UNK
.	O

Using	O
this	O
combined	O
approach	O
,	O
we	O
identified	B-UNK
germline	B-UNK
APC	B-UNK
gene	B-UNK
mutations	B-UNK
in	O
29	O
of	O
the	O
48	O
FAP	B-UNK
patients	I-UNK
(	O
60	O
%	O
)	O
,	O
including	O
6	O
patients	B-UNK
in	O
whom	O
SSCP	B-UNK
analysis	B-UNK
failed	O
to	O
distinguish	O
the	O
mutant	B-UNK
allele	B-UNK
.	O

In	O
the	O
14	O
later	O
patients	B-UNK
,	O
we	O
identified	B-UNK
truncating	B-UNK
mutations	I-UNK
in	O
9	O
patients	B-UNK
(	O
64	O
%	O
)	O
using	O
PTT	B-UNK
only	O
.	O

Our	O
results	B-UNK
confirm	O
that	O
the	O
mutation	B-UNK
detection	I-UNK
rate	B-UNK
with	O
PTT	B-UNK
was	O
superior	O
to	O
that	O
with	O
SSCP	B-UNK
,	O
and	O
suggest	B-UNK
that	O
PTT	B-UNK
would	O
be	O
a	O
more	O
practical	O
screening	B-UNK
method	O
to	O
detect	B-UNK
germline	B-UNK
mutations	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
in	O
FAP	B-UNK
patients	I-UNK
.	O

Molecular	B-UNK
epidemiology	O
of	O
C9	B-UNK
deficiency	I-UNK
heterozygotes	B-UNK
with	O
an	O
Arg95Stop	O
mutation	B-UNK
of	O
the	O
C9	B-UNK
gene	B-UNK
in	O
Japan	B-UNK
.	O

Deficiency	B-UNK
of	O
the	O
ninth	O
component	B-UNK
of	O
human	B-UNK
complement	I-UNK
(	O
C9	B-UNK
)	O
is	O
the	O
most	O
common	B-UNK
complement	B-UNK
deficiency	B-UNK
in	O
Japan	B-UNK
,	O
with	O
an	O
incidence	B-UNK
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	B-UNK
in	O
other	O
countries	B-UNK
.	O

Genetic	B-UNK
analyses	O
of	O
Japanese	B-UNK
C9	B-UNK
deficiency	I-UNK
have	O
shown	B-UNK
that	O
a	O
C	O
-	O
to	O
-T	O
transition	B-UNK
leading	B-UNK
to	O
TGA	O
stop	B-UNK
codon	I-UNK
for	O
Arg95	O
in	O
exon	B-UNK
4	O
of	O
the	O
C9	B-UNK
gene	B-UNK
(	O
Arg95Stop	O
)	O
is	O
common	B-UNK
in	O
Japanese	B-UNK
C9	B-DISEASE
deficiency	I-DISEASE
.	O

To	O
determine	B-UNK
the	O
prevalence	B-UNK
of	O
heterozygous	B-UNK
carriers	B-UNK
of	O
the	O
Arg95Stop	O
mutation	B-UNK
in	O
a	O
Japanese	B-UNK
population	B-UNK
,	O
we	O
collected	O
DNA	B-UNK
samples	B-UNK
from	O
300	O
individuals	B-UNK
in	O
two	O
of	O
the	O
four	O
main	O
islands	O
of	O
Japan	B-UNK
.	O

Heterozygote	B-UNK
detection	B-UNK
was	O
performed	O
with	O
an	O
allele	B-UNK
-	O
specific	B-UNK
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
system	O
designed	O
to	O
detect	B-UNK
exclusively	O
only	O
one	O
of	O
the	O
normal	B-UNK
and	O
mutant	B-UNK
alleles	I-UNK
,	O
followed	O
by	O
confirmation	O
with	O
PCR	B-UNK
/	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
analysis	B-UNK
and	O
direct	B-UNK
sequencing	I-UNK
.	O

Twenty	O
individuals	B-UNK
were	O
heterozygous	B-UNK
for	O
the	O
Arg95Stop	O
mutation	B-UNK
.	O

None	O
was	O
homozygous	B-UNK
.	O

The	O
prevalence	B-UNK
of	O
carriers	B-UNK
of	O
the	O
Arg95Stop	O
mutation	B-UNK
was	O
6	O
.	O

7	O
%	O
(	O
20/300	O
)	O
.	O

An	O
estimated	B-UNK
frequency	B-UNK
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B-UNK
deficiency	I-UNK
due	O
to	O
homozygous	B-UNK
Arg95Stop	O
mutation	B-UNK
was	O
consistent	B-UNK
with	O
frequencies	O
determined	B-UNK
by	O
serological	O
studies	B-UNK

The	O
hereditary	B-UNK
hemochromatosis	I-UNK
protein	B-UNK
,	O
HFE	B-UNK
,	O
specifically	B-UNK
regulates	O
transferrin	O
-	O
mediated	O
iron	B-UNK
uptake	O
in	O
HeLa	O
cells	B-UNK
.	O

HFE	B-UNK
is	O
the	O
protein	B-UNK
product	I-UNK
of	O
the	O
gene	B-UNK
mutated	B-UNK
in	O
the	O
autosomal	B-UNK
recessive	I-UNK
disease	B-UNK
hereditary	B-UNK
hemochromatosis	I-UNK
(	O
Feder	O
,	O
J.	O

N.	O
,	O
Gnirke	O
,	O
A.	O
,	O
Thomas	O
,	O
W.	O
,	O
Tsuchihashi	O
,	O
Z.	O
,	O
Ruddy	O
,	O
D.	O

A.	O
,	O
Basava	O
,	O
A.	O
,	O
Dormishian	O
,	O
F.	O
,	O
Domingo	O
,	O
R.	O

J.	O
,	O
Ellis	O
,	O
M.	O

C.	O
,	O
Fullan	O
,	O
A.	O
,	O
Hinton	O
,	O
L.	O

M.	O
,	O
Jones	O
,	O
N.	O

L.	O
,	O
Kimmel	O
,	O
B.	O

E.	O
,	O
Kronmal	O
,	O
G.	O

S.	O
,	O
Lauer	O
,	O
P.	O
,	O
Lee	O
,	O
V.	O

K.	O
,	O
Loeb	O
,	O
D.	O

B.	O
,	O
Mapa	O
,	O
F.	O

A.	O
,	O
McClelland	O
,	O
E.	O
,	O
Meyer	O
,	O
N.	O

C.	O
,	O
Mintier	O
,	O
G.	O

A.	O
,	O
Moeller	O
,	O
N.	O
,	O
Moore	O
,	O
T.	O
,	O
Morikang	O
,	O
E.	O
,	O
Prasss	O
,	O
C.	O

E.	O
,	O
Quintana	O
,	O
L.	O
,	O
Starnes	O
,	O
S.	O

M.	O
,	O
Schatzman	O
,	O
R.	O

C.	O
,	O
Brunke	O
,	O
K.	O

J.	O
,	O
Drayna	O
,	O
D.	O

T.	O
,	O
Risch	O
,	O
N.	O

J.	O
,	O
Bacon	O
,	O
B.	O

R.	O
,	O
and	O
Wolff	O
,	O
R.	O

R.	O

(	O
1996	O
)	O
Nat	O
.	O

Genet	B-UNK
.	O

13	O
,	O
399	O
-	O
408	O
)	O
.	O

At	O
the	O
cell	B-UNK
surface	O
,	O
HFE	B-UNK
complexes	O
with	O
transferrin	O
receptor	B-UNK
(	O
TfR	B-UNK
)	O
,	O
increasing	O
the	O
dissociation	O
constant	O
of	O
transferrin	O
(	O
Tf	B-UNK
)	O
for	O
its	O
receptor	B-UNK
10-fold	O
(	O
Gross	O
,	O
C.	O

N.	O
,	O
Irrinki	O
,	O
A.	O
,	O
Feder	O
,	O
J.	O
N.	O
,	O
and	O
Enns	O
,	O
C.	O
A.	O
(	O
1998	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
273	O
,	O
22068	O
-	O
22074	O
;	O
Feder	O
,	O
J.	O
N.	O
,	O
Penny	O
,	O
D.	O
M.	O
,	O
Irrinki	O
,	O
A.	O
,	O
Lee	O
,	O
V.	O
K.	O
,	O
Lebron	O
,	O
J.	O
A.	O
,	O
Watson	O
,	O
N.	O
,	O
Tsuchihashi	O
,	O
Z.	O
,	O
Sigal	O
,	O
E.	O
,	O
Bjorkman	O
,	O
P.	O
J.	O
,	O
and	O
Schatzman	O
,	O
R.	O
C.	O
(	O
1998	O
)	O
Proc	O
.	O
Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
S	O
A	O
95	O
,	O
1472	O
-	O
1477	O
)	O
.	O

HFE	B-UNK
does	O
not	O
remain	O
at	O
the	O
cell	B-UNK
surface	O
,	O
but	O
traffics	O
with	O
TfR	B-UNK
to	O
Tf	B-UNK
-	O
positive	O
internal	O
compartments	O
(	O
Gross	O
et	O
al	B-DISEASE
.	O
,	O
1998	O
)	O
.	O

Using	O
a	O
HeLa	O
cell	B-UNK
line	I-UNK
in	O
which	O
the	O
expression	B-UNK
of	O
HFE	B-UNK
is	O
controlled	O
by	O
tetracycline	O
,	O
we	O
show	O
that	O
the	O
expression	B-UNK
of	O
HFE	B-UNK
reduces	O
55Fe	O
uptake	O
from	O
Tf	B-UNK
by	O
33	O
%	O
but	O
does	O
not	O
affect	O
the	O
endocytic	O
or	O
exocytic	O
rates	O
of	O
TfR	B-UNK
cycling	O
.	O

Therefore	O
,	O
HFE	B-UNK
appears	B-UNK
to	O
reduce	O
cellular	O
acquisition	O
of	O
iron	B-UNK
from	O
Tf	B-UNK
within	O
endocytic	O
compartments	O
.	O

HFE	B-UNK
specifically	B-UNK
reduces	O
iron	B-UNK
uptake	O
from	O
Tf	B-UNK
,	O
as	O
non-Tf-mediated	O
iron	B-UNK
uptake	O
from	O
Fe	O
-	O
nitrilotriacetic	O
acid	B-UNK
is	O
not	O
altered	O
.	O

These	O
results	B-UNK
explain	O
the	O
decreased	B-UNK
ferritin	O
levels	B-UNK
seen	O
in	O
our	O
HeLa	O
cell	B-UNK
system	O
and	O
demonstrate	B-UNK
the	O
specific	B-UNK
control	B-UNK
of	O
HFE	B-UNK
over	O
the	O
Tf	B-UNK
-	O
mediated	O
pathway	B-UNK
of	O
iron	B-UNK
uptake	O
.	O

These	O
results	B-UNK
also	O
have	O
implications	B-UNK
for	O
the	O
understanding	B-UNK
of	O
cellular	O
iron	B-UNK
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver	B-UNK
,	O
pancreas	O
,	O
heart	B-UNK
,	O
and	O
spleen	O
that	O
are	O
iron	B-UNK
loaded	O
in	O
hereditary	B-UNK
hemochromatotic	O
individuals	B-UNK
lacking	O
functional	O
HFE	B-UNK
.	O

Mutation	B-UNK
and	O
haplotype	B-UNK
studies	B-UNK
of	O
familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	B-UNK
for	O
a	O
high	B-UNK
carrier	B-UNK
frequency	I-UNK
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	B-UNK
Jewish	I-UNK
population	B-UNK
.	O

Familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
(	O
FMF	B-UNK
)	O
is	O
a	O
recessive	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
episodes	O
of	O
fever	B-DISEASE
with	O
serositis	B-DISEASE
or	O
synovitis	B-DISEASE
.	O

The	O
FMF	B-UNK
gene	B-UNK
(	O
MEFV	B-UNK
)	O
was	O
cloned	O
recently	O
,	O
and	O
four	O
missense	B-UNK
mutations	I-UNK
were	O
identified	B-UNK
.	O

Here	O
we	O
present	B-UNK
data	B-UNK
from	O
non-Ashkenazi	O
Jewish	B-UNK
and	O
Arab	O
patients	B-UNK
in	O
whom	O
we	O
had	O
not	O
originally	O
found	O
mutations	B-UNK
and	O
from	O
a	O
new	O
,	O
more	O
ethnically	O
diverse	B-UNK
panel	B-UNK
.	O

Among	O
90	O
symptomatic	O
mutation	B-UNK
-	O
positive	O
individuals	B-UNK
,	O
11	O
mutations	B-UNK
accounted	O
for	O
79	O
%	O
of	O
carrier	B-UNK
chromosomes	O
.	O

Of	O
the	O
two	O
mutations	B-UNK
that	O
are	O
novel	O
,	O
one	O
alters	O
the	O
same	O
residue	O
(	O
680	O
)	O
as	O
a	O
previously	B-UNK
known	O
mutation	B-UNK
,	O
and	O
the	O
other	O
(	O
P369S	O
)	O
is	O
located	B-UNK
in	O
exon	B-UNK
3	O
.	O

Consistent	B-UNK
with	O
another	O
recent	O
report	B-UNK
,	O
the	O
E148Q	O
mutation	B-UNK
was	O
observed	B-UNK
in	O
patients	B-UNK
of	O
several	O
ethnicities	O
and	O
on	O
multiple	B-UNK
microsatellite	B-UNK
haplotypes	O
,	O
but	O
haplotype	B-UNK
data	B-UNK
indicate	O
an	O
ancestral	O
relationships	O
between	O
non-Jewish	O
Italian	B-UNK
and	O
Ashkenazi	B-UNK
Jewish	I-UNK
patients	B-UNK
with	O
FMF	B-UNK
and	O
other	O
affected	B-UNK
populations	O
.	O

Among	O
approximately	O
200	O
anonymous	O
Ashkenazi	B-UNK
Jewish	I-UNK
DNA	B-UNK
samples	B-UNK
,	O
the	O
MEFV	B-UNK
carrier	B-UNK
frequency	I-UNK
was	O
21	O
%	O
,	O
with	O
E148Q	O
the	O
most	O
common	B-UNK
mutation	B-UNK
.	O

Several	O
lines	B-UNK
of	O
evidence	B-UNK
indicate	O
reduced	O
penetrance	O
among	O
Ashkenazi	B-UNK
Jews	B-UNK
,	O
especially	O
for	O
E148Q	O
,	O
P369S	O
,	O
and	O
K695R.	O

Nevertheless	O
,	O
E148Q	O
helps	O
account	B-UNK
for	O
recessive	B-UNK
inheritance	B-UNK
in	O
an	O
Ashkenazi	B-UNK
family	B-UNK
previously	B-UNK
reported	I-UNK
as	O
an	O
unusual	O
case	B-UNK
of	O
dominantly	O
inherited	B-UNK
FMF	B-UNK
.	O

The	O
presence	O
of	O
three	O
frequent	B-UNK
MEFV	B-UNK
mutations	B-UNK
in	O
multiple	B-UNK
Mediterranean	B-UNK
populations	O
strongly	O
suggests	O
a	O
heterozygote	B-UNK
advantage	B-UNK
in	O
this	O
geographic	O
region	B-UNK
.	O

Autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
with	O
defective	O
Fas	B-UNK
:	O
genotype	B-UNK
influences	O
penetrance	O
.	O

Autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
(	O
ALPS	B-UNK
)	O
is	O
a	O
disorder	B-UNK
of	O
lymphocyte	B-UNK
homeostasis	O
and	O
immunological	O
tolerance	O
.	O

Most	O
patients	B-UNK
have	O
a	O
heterozygous	B-UNK
mutation	B-UNK
in	O
the	O
APT1	O
gene	B-UNK
,	O
which	O
encodes	B-UNK
Fas	B-UNK
(	O
CD95	O
,	O
APO-1	O
)	O
,	O
mediator	O
of	O
an	O
apoptotic	O
pathway	B-UNK
crucial	O
to	O
lymphocyte	B-UNK
homeostasis	O
.	O

Of	O
17	O
unique	O
APT1	O
mutations	B-UNK
in	O
unrelated	B-UNK
ALPS	B-UNK
probands	O
,	O
12	O
(	O
71	O
%	O
)	O
occurred	B-UNK
in	O
exons	O
7	O
-	O
9	O
,	O
which	O
encode	O
the	O
intracellular	O
portion	B-UNK
of	O
Fas	B-UNK
.	O

In	O
vitro	O
,	O
activated	O
lymphocytes	O
from	O
all	O
17	O
patients	B-UNK
showed	O
apoptotic	O
defects	B-UNK
when	O
exposed	O
to	O
an	O
anti-Fas	O
agonist	O
monoclonal	O
antibody	B-UNK
.	O

Similar	B-UNK
defects	B-UNK
were	O
found	O
in	O
a	O
Fas	B-UNK
-	O
negative	B-UNK
cell	B-UNK
line	I-UNK
transfected	O
with	O
cDNAs	O
bearing	O
each	O
of	O
the	O
mutations	B-UNK
.	O

In	O
cotransfection	O
experiments	O
,	O
Fas	B-UNK
constructs	O
with	O
either	O
intra-or	O
extracellular	B-UNK
mutations	B-UNK
caused	B-UNK
dominant	B-UNK
inhibition	O
of	O
apoptosis	O
mediated	O
by	O
wild	B-UNK
-	O
type	B-UNK
Fas	B-UNK
.	O

Two	O
missense	B-UNK
Fas	B-UNK
variants	B-UNK
,	O
not	O
restricted	O
to	O
patients	B-UNK
with	O
ALPS	B-UNK
,	O
were	O
identified	B-UNK
.	O

Variant	O
A	O
(	O
-1	O
)	O
T	O
at	O
the	O
Fas	B-UNK
signal	B-UNK
-	O
sequence	B-UNK
cleavage	O
site	B-UNK
,	O
which	O
mediates	O
apoptosis	O
less	O
well	O
than	O
wild	B-UNK
-	O
type	B-UNK
Fas	B-UNK
and	O
is	O
partially	O
inhibitory	O
,	O
was	O
present	B-UNK
in	O
13	O
%	O
of	O
African	B-UNK
American	B-UNK
alleles	B-UNK
.	O

Among	O
the	O
ALPS	B-UNK
-	O
associated	O
Fas	B-UNK
mutants	O
,	O
dominant	B-UNK
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular	O
,	O
versus	O
extracellular	B-UNK
,	O
portion	B-UNK
of	O
the	O
Fas	B-UNK
receptor	B-UNK
.	O

Mutations	B-UNK
causing	B-UNK
disruption	O
of	O
the	O
intracellular	O
Fas	B-UNK
death	B-UNK
domain	B-UNK
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	B-UNK
phenotype	B-UNK
features	B-UNK
in	O
mutation	B-UNK
-	O
bearing	O
relatives	B-UNK
.	O

Significant	B-UNK
ALPS	B-UNK
-	O
related	B-UNK
morbidity	O
occurred	B-UNK
in	O
44	O
%	O
of	O
relatives	B-UNK
with	O
intracellular	O
mutations	B-UNK
,	O
versus	O
0	O
%	O
of	O
relatives	B-UNK
with	O
extracellular	B-UNK
mutations	B-UNK
.	O

Thus	O
,	O
the	O
location	B-UNK
of	O
mutations	B-UNK
within	O
APT1	O
strongly	O
influences	O
the	O
development	B-UNK
and	O
the	O
severity	B-UNK
of	O
ALPS	B-UNK
.	O

Multicentric	O
origin	O
of	O
hemochromatosis	B-UNK
gene	B-UNK
(	O
HFE	B-UNK
)	O
mutations	B-UNK
.	O

Genetic	B-UNK
hemochromatosis	B-DISEASE
(	O
GH	O
)	O
is	O
believed	O
to	O
be	O
a	O
disease	B-UNK
restricted	O
to	O
those	O
of	O
European	B-UNK
ancestry	O
.	O

In	O
northwestern	O
Europe	B-UNK
,	O
>	O
80	O
%	O
of	O
GH	O
patients	B-UNK
are	O
homozygous	B-UNK
for	O
one	O
mutation	B-UNK
,	O
the	O
substitution	B-UNK
of	O
tyrosine	O
for	O
cysteine	B-UNK
at	O
position	B-UNK
282	O
(	O
C282Y	B-UNK
)	O
in	O
the	O
unprocessed	O
protein	B-UNK
.	O

In	O
a	O
proportion	B-UNK
of	O
GH	O
patients	B-UNK
,	O
two	O
mutations	B-UNK
are	O
present	B-UNK
,	O
C282Y	B-UNK
and	O
H63D.	O

The	O
clinical	B-UNK
significance	O
of	O
this	O
second	O
mutation	B-UNK
is	O
such	O
that	O
it	O
appears	B-UNK
to	O
predispose	O
1%-2	O
%	O
of	O
compound	B-UNK
heterozygotes	I-UNK
to	O
expression	B-UNK
of	O
the	O
disease	B-DISEASE
.	O

The	O
distribution	B-UNK
of	O
the	O
two	O
mutations	B-UNK
differ	O
,	O
C282Y	B-UNK
being	O
limited	O
to	O
those	O
of	O
northwestern	O
European	B-UNK
ancestry	O
and	O
H63D	B-UNK
being	O
found	O
at	O
allele	B-UNK
frequencies	O
>	O
5	O
%	O
,	O
in	O
Europe	B-UNK
,	O
in	O
countries	B-UNK
bordering	O
the	O
Mediterranean	B-UNK
,	O
in	O
the	O
Middle	O
East	O
,	O
and	O
in	O
the	O
Indian	O
subcontinent	O
.	O

The	O
C282Y	B-UNK
mutation	B-UNK
occurs	O
on	O
a	O
haplotype	B-UNK
that	O
extends	O
<	O
/=	O
6	O
Mb	B-DISEASE
,	O
suggesting	O
that	O
this	O
mutation	B-UNK
has	O
arisen	O
during	O
the	O
past	O
2	O
,	O
000	O
years	O
.	O

The	O
H63D	B-UNK
mutation	B-UNK
is	O
older	O
and	O
does	O
not	O
occur	B-UNK
on	O
such	O
a	O
large	B-UNK
extended	O
haplotype	B-UNK
,	O
the	O
haplotype	B-UNK
in	O
this	O
case	B-UNK
extending	O
<	O
/=	O
700	O
kb	B-UNK
.	O

Here	O
we	O
report	B-UNK
the	O
finding	O
of	O
the	O
H63D	B-UNK
and	O
C282Y	B-UNK
mutations	B-UNK
on	O
new	O
haplotypes	O
.	O

In	O
Sri	O
Lanka	O
we	O
have	O
found	O
H63D	B-UNK
on	O
three	O
new	O
haplotypes	O
and	O
have	O
found	O
C282Y	B-UNK
on	O
one	O
new	O
haplotype	B-UNK
,	O
demonstrating	O
that	O
these	O
mutations	B-UNK
have	O
arisen	O
independently	O
on	O
this	O
island	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
HFE	B-UNK
gene	B-UNK
has	O
been	O
the	O
subject	O
of	O
selection	B-UNK
pressure	O
.	O

These	O
selection	B-UNK
pressures	O
could	O
be	O
due	O
to	O
infectious	O
diseases	B-DISEASE
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B-UNK
disorders	B-UNK
such	O
as	O
anemia	B-UNK
.	O

A	O
retrospective	O
anonymous	O
pilot	O
study	B-UNK
in	O
screening	B-UNK
newborns	O
for	O
HFE	B-UNK
mutations	B-UNK
in	O
Scandinavian	O
populations	O
.	O

We	O
have	O
retrospectively	O
analyzed	B-UNK
837	O
random	B-UNK
anonymized	O
dried	O
blood	B-UNK
spot	O
(	O
DBS	O
)	O
samples	B-UNK
from	O
neonatal	B-UNK
screening	B-UNK
programs	O
in	O
Scandinavia	O
for	O
mutations	B-UNK
in	O
HFE	B-UNK
,	O
the	O
candidate	B-UNK
gene	I-UNK
for	O
hemochromatosis	B-UNK
.	O

We	O
have	O
found	O
C282Y	B-UNK
allele	B-UNK
frequencies	O
of	O
2	O
.	O

3	O
%	O
(	O
+	O
2	O
.	O
0	O
%	O
)	O
(	O
-1	O
.	O
3	O
%	O
)	O
in	O
Greenland	O
,	O
4	O
.	O

5	O
%	O
+	O
/-1	O
.	O

9	O
%	O
in	O
Iceland	O
,	O
5	O
.	O

1	O
%	O
+	O
/-2	O
.	O

3	O
%	O
in	O
the	O
Faeroe	O
Islands	O
,	O
and	O
8	O
.	O

2	O
%	O
+	O
/-2	O
.	O

7	O
%	O
in	O
Denmark	O
.	O

The	O
high	B-UNK
prevalence	B-UNK
of	O
HFE	B-UNK
mutations	B-UNK
in	O
Denmark	O
suggests	O
that	O
population	B-UNK
screening	B-UNK
for	O
the	O
C282Y	B-UNK
mutation	B-UNK
could	O
be	O
highly	B-UNK
advantageous	O
in	O
terms	O
of	O
preventive	O
health	O
care	O
.	O

Long	B-UNK
-	O
term	O
follow	O
-	O
up	O
evaluation	B-UNK
of	O
C282Y	B-UNK
homozygotes	O
and	O
H63D	B-UNK
/	O
C282Y	B-UNK
compound	B-UNK
heterozygotes	I-UNK
will	O
give	O
an	O
indication	O
of	O
the	O
penetrance	O
of	O
the	O
mutations	B-UNK
.	O

Identification	B-UNK
of	O
the	O
mutation	B-UNK
in	O
the	O
alkaptonuria	B-UNK
mouse	B-UNK
model	I-UNK
.	O

Alkaptonuria	B-UNK
(	O
aku	O
)	O
,	O
an	O
inborn	O
error	O
of	O
metabolism	B-UNK
caused	B-UNK
by	O
the	O
loss	B-UNK
of	O
homogentisate	O
1	O
,	O
2-dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	B-UNK
model	I-UNK
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	B-UNK
in	O
these	O
mice	B-UNK
has	O
not	O
previously	B-UNK
been	O
identified	B-UNK
.	O

We	O
used	O
RT	O
-	O
PCR	B-UNK
to	O
amplify	O
the	O
Hgd	O
cDNA	O
from	O
Hgd	O
(	O
aku)/Hgd	O
(	O
aku	O
)	O
mice	B-UNK
.	O

Two	O
products	B-UNK
shorter	O
than	O
the	O
wild	B-UNK
-	O
type	B-UNK
product	B-UNK
were	O
amplified	O
.	O

Restriction	B-UNK
mapping	B-UNK
and	O
DNA	B-UNK
sequencing	I-UNK
were	O
then	O
used	O
to	O
identify	B-UNK
the	O
Hgd	O
(	O
aku	O
)	O
mouse	B-UNK
mutation	B-UNK
,	O
found	O
to	O
be	O
a	O
single	B-UNK
base	I-UNK
change	B-UNK
in	O
a	O
splice	B-UNK
donor	I-UNK
consensus	B-UNK
sequence	B-UNK
,	O
causing	B-UNK
exon	B-UNK
skipping	O
and	O
frame	B-UNK
-	O
shifted	O
products	B-UNK
.	O

This	O
base	B-UNK
change	B-UNK
allowed	O
us	O
to	O
create	O
a	O
non-radioactive	O
genotyping	O
assay	B-UNK
for	O
this	O
allele	B-UNK
.	O

Non-syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
with	O
enlarged	O
vestibular	O
aqueduct	O
is	O
caused	B-UNK
by	O
PDS	B-UNK
mutations	B-UNK
.	O

Enlarged	O
vestibular	O
aqueduct	O
(	O
EVA	O
)	O
,	O
known	O
as	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
inner	O
ear	O
abnormality	O
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	B-UNK
interest	O
because	O
this	O
anomaly	B-UNK
is	O
inherited	B-UNK
in	O
a	O
recessive	B-UNK
manner	O
.	O

The	O
locus	B-UNK
for	O
non-syndromic	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
with	O
EVA	O
has	O
been	O
mapped	B-UNK
to	O
the	O
same	O
chromosomal	B-UNK
region	B-UNK
,	O
7q31	O
,	O
as	O
the	O
Pendred	B-UNK
syndrome	I-UNK
locus	B-UNK
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
seven	O
mutations	B-UNK
in	O
the	O
PDS	B-UNK
gene	B-UNK
(	O
PDS	B-UNK
)	O
,	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
Pendred	B-UNK
syndrome	I-UNK
,	O
have	O
been	O
found	O
in	O
families	B-UNK
of	O
non-syndromic	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
with	O
EVA	O
.	O

One	O
family	B-UNK
is	O
homozygous	B-UNK
,	O
three	O
families	B-UNK
are	O
compound	B-UNK
heterozygotes	I-UNK
,	O
and	O
two	O
families	B-UNK
are	O
heterozygous	B-UNK
but	O
with	O
no	O
other	O
mutation	B-UNK
detected	B-UNK
.	O

The	O
present	B-UNK
results	B-UNK
provide	I-UNK
evidence	B-UNK
that	O
mutations	B-UNK
in	O
PDS	B-UNK
cause	O
both	O
syndromic	O
and	O
non-syndromic	O
hearing	B-UNK
loss	I-UNK
..	O

Mutational	O
analysis	B-UNK
and	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
of	O
29	O
unrelated	B-UNK
Japanese	B-UNK
patients	B-UNK
with	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
.	O

BACKGROUND	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
(	O
ALD	B-UNK
)	O
is	O
an	O
inherited	B-UNK
disease	B-DISEASE
characterized	B-UNK
by	O
progressive	B-UNK
neurologic	O
dysfunction	B-UNK
,	O
occasionally	O
associated	O
with	O
adrenal	B-DISEASE
insufficiency	I-DISEASE
.	O

The	O
classic	B-UNK
form	B-UNK
of	O
ALD	B-UNK
usually	O
has	O
onset	B-UNK
in	O
childhood	O
(	O
childhood	O
cerebral	B-UNK
ALD	I-UNK
)	O
,	O
with	O
rapid	O
neurologic	B-DISEASE
deterioration	I-DISEASE
leading	B-UNK
to	O
a	O
vegetative	B-DISEASE
state	I-DISEASE
.	O

Adult	B-UNK
-	O
onset	B-UNK
cerebral	B-UNK
ALD	I-UNK
also	O
presents	O
with	O
rapidly	O
progressive	B-UNK
neurologic	O
dysfunction	B-UNK
.	O

Milder	B-UNK
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	O
and	O
Addison	B-DISEASE
disease	I-DISEASE
only	O
also	O
have	O
been	O
recognized	O
.	O

Despite	O
discovery	O
of	O
the	O
causative	O
gene	B-UNK
,	O
a	O
molecular	B-UNK
basis	I-UNK
for	O
the	O
diverse	B-UNK
clinical	B-UNK
presentations	O
remains	O
to	O
be	O
elucidated	O
.	O

OBJECTIVES	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	B-UNK
patients	B-UNK
with	O
ALD	B-UNK
from	O
29	O
unrelated	B-UNK
families	I-UNK
,	O
to	O
obtain	O
knowledge	B-UNK
of	O
the	O
spectrum	B-UNK
of	O
mutations	B-UNK
in	O
this	O
gene	B-UNK
,	O
and	O
to	O
study	B-UNK
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
in	O
Japanese	B-UNK
patients	B-UNK
.	O

METHODS	O
The	O
29	O
patients	B-UNK
comprised	O
13	O
patients	B-UNK
with	O
childhood	O
cerebral	B-UNK
ALD	I-UNK
,	O
11	O
patients	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
cerebral	B-UNK
ALD	I-UNK
,	O
and	O
5	O
patients	B-UNK
with	O
adrenomyeloneuropathy	O
.	O

We	O
conducted	O
detailed	B-UNK
mutational	O
analyses	O
of	O
29	O
unrelated	B-UNK
Japanese	B-UNK
patients	B-UNK
with	O
ALD	B-UNK
by	O
genomic	B-UNK
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
and	O
direct	B-UNK
nucleotide	B-UNK
sequence	I-UNK
analysis	B-UNK
of	O
reverse	B-UNK
transcriptase	O
-	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
products	B-UNK
derived	B-UNK
from	O
total	B-UNK
RNA	B-UNK
that	O
was	O
extracted	O
from	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
,	O
lymphoblastoid	O
cells	B-UNK
,	O
or	O
peripheral	B-UNK
blood	I-UNK
leukocytes	O
.	O

RESULTS	B-UNK
Three	O
patients	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
cerebral	B-UNK
ALD	I-UNK
were	O
identified	B-UNK
as	O
having	O
large	B-UNK
genomic	B-UNK
rearrangements	O
.	O

The	O
remaining	O
26	O
patients	B-UNK
were	O
identified	B-UNK
as	O
having	O
21	O
independent	O
mutations	B-UNK
,	O
including	O
12	O
novel	O
mutations	B-UNK
resulting	B-UNK
in	O
small	O
nucleotide	B-UNK
alterations	B-UNK
in	O
the	O
ALD	B-UNK
gene	B-UNK
.	O

Eighteen	O
(	O
69	O
%	O
)	O
of	O
26	O
mutations	B-UNK
were	O
missense	B-UNK
mutations	I-UNK
.	O

Most	O
missense	B-UNK
mutations	I-UNK
involved	B-UNK
amino	B-UNK
acids	I-UNK
conserved	B-UNK
in	O
homologous	B-UNK
gene	B-UNK
products	B-UNK
,	O
including	O
PMP70	O
,	O
mALDRP	O
,	O
and	O
Pxa1p	O
.	O

The	O
AG	B-UNK
dinucleotide	B-UNK
deletion	B-UNK
at	O
position	B-UNK
1081	O
-	O
1082	O
,	O
which	O
has	O
been	O
reported	B-UNK
previously	B-UNK
to	O
be	O
the	O
most	O
common	B-UNK
mutation	B-UNK
in	O
white	B-UNK
patients	B-UNK
(	O
12%-17	O
%	O
)	O
,	O
was	O
also	O
identified	B-UNK
as	O
the	O
most	O
common	B-UNK
mutation	B-UNK
in	O
Japanese	B-UNK
patients	B-UNK
(	O
12	O
%	O
)	O
.	O

All	O
phenotypes	O
were	O
associated	O
with	O
mutations	B-UNK
resulting	B-UNK
in	O
protein	B-UNK
truncation	I-UNK
or	O
subtle	O
amino	B-UNK
acid	I-UNK
changes	O
.	O

There	O
were	O
no	O
differences	B-UNK
in	O
phenotypic	B-UNK
expressions	O
between	O
missense	B-UNK
mutations	I-UNK
involving	O
conserved	B-UNK
amino	B-UNK
acids	I-UNK
and	O
those	O
involving	O
nonconserved	O
amino	B-UNK
acids	I-UNK
.	O

CONCLUSIONS	B-UNK
There	O
are	O
no	O
obvious	O
correlations	B-UNK
between	O
the	O
phenotypes	O
of	O
patients	B-UNK
with	O
ALD	B-UNK
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	B-UNK
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	B-UNK
expressions	O
of	O
ALD	B-UNK
..	O

A	O
common	B-UNK
human	B-UNK
skin	B-UNK
tumour	B-DISEASE
is	O
caused	B-UNK
by	O
activating	O
mutations	B-UNK
in	O
beta-catenin	O
.	O

WNT	O
signalling	O
orchestrates	O
a	O
number	B-UNK
of	O
developmental	O
programs	O
.	O

In	O
response	B-UNK
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta-catenin	O
(	O
encoded	B-UNK
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	B-UNK
of	O
the	O
LEF	O
/	O
TCF	O
family	B-UNK
.	O

One	O
of	O
the	O
target	O
genes	B-UNK
for	O
beta	B-UNK
-	O
catenin	O
/	O
TCF	O
encodes	B-UNK
c	O
-	O
MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	B-UNK
can	O
lead	B-UNK
to	O
cancer	B-UNK
,	O
particularly	O
in	O
the	O
colon	B-UNK
.	O

Most	O
colon	B-UNK
cancers	B-UNK
arise	O
from	O
mutations	B-UNK
in	O
the	O
gene	B-UNK
encoding	B-UNK
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
,	O
a	O
protein	B-UNK
required	B-UNK
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta-catenin	O
,	O
but	O
a	O
small	O
percentage	B-UNK
of	O
colon	B-UNK
and	O
some	O
other	O
cancers	B-UNK
harbour	O
beta-catenin-stabilizing	O
mutations	B-UNK
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	B-UNK
mice	I-UNK
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-UNK
tumours	B-DISEASE
resembling	O
pilomatricomas	O
.	O

Given	O
that	O
the	O
skin	B-UNK
of	O
these	O
adult	B-UNK
mice	B-UNK
also	O
exhibits	O
signs	B-UNK
of	O
de	O
novo	O
hair	B-UNK
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	B-UNK
pilomatricomas	O
might	O
originate	O
from	O
hair	B-UNK
matrix	O
cells	B-UNK
and	O
whether	O
they	O
might	O
possess	O
beta-catenin-stabilizing	O
mutations	B-UNK
.	O

Here	O
,	O
we	O
explore	O
the	O
cell	B-UNK
origin	O
and	O
aetiology	O
of	O
this	O
common	B-UNK
human	B-UNK
skin	B-UNK
tumour	B-DISEASE
.	O

We	O
found	O
nuclear	B-UNK
LEF-1	O
in	O
the	O
dividing	O
tumour	B-UNK
cells	B-UNK
,	O
providing	O
biochemical	O
evidence	B-UNK
that	O
pilomatricomas	O
are	O
derived	B-UNK
from	O
hair	B-UNK
matrix	O
cells	B-UNK
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-DISEASE
possess	O
mutations	B-UNK
affecting	O
the	O
amino	B-UNK
-	O
terminal	B-UNK
segment	O
,	O
normally	O
involved	B-UNK
in	O
phosphorylation	B-UNK
-	O
dependent	B-UNK
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	B-UNK
.	O

This	O
percentage	B-UNK
of	O
CTNNB1	O
mutations	B-UNK
is	O
greater	B-UNK
than	O
in	O
all	O
other	O
human	B-UNK
tumours	B-DISEASE
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	B-UNK
-	O
catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	B-UNK
cause	O
of	O
hair	B-UNK
matrix	O
cell	B-UNK
tumorigenesis	O
in	O
humans	B-UNK
..	O

The	O
Pendred	B-DISEASE
syndrome	I-DISEASE
gene	B-UNK
encodes	B-UNK
a	O
chloride	B-UNK
-	O
iodide	B-UNK
transport	B-UNK
protein	B-UNK
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
syndromic	O
deafness	B-DISEASE
and	O
characterized	B-UNK
by	O
congenital	B-UNK
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
goitre	O
.	O

This	O
disorder	B-UNK
was	O
mapped	B-UNK
to	O
chromosome	B-UNK
7	O
and	O
the	O
gene	B-UNK
causing	B-UNK
Pendred	B-UNK
syndrome	I-UNK
(	O
PDS	B-UNK
)	O
was	O
subsequently	B-UNK
identified	B-UNK
by	O
positional	O
cloning	B-UNK
.	O

PDS	B-UNK
encodes	B-UNK
a	O
putative	O
transmembrane	B-UNK
protein	B-UNK
designated	O
pendrin	B-UNK
.	O

Pendrin	B-UNK
is	O
closely	B-UNK
related	B-UNK
to	O
a	O
family	B-UNK
of	O
sulfate	B-UNK
transport	B-UNK
proteins	B-UNK
that	O
includes	O
the	O
rat	O
sulfate	B-UNK
-	O
anion	O
transporter	B-UNK
(	O
encoded	B-UNK
by	O
Sat-1	O
;	O
29	O
%	O
amino	B-UNK
acid	I-UNK
sequence	B-UNK
identity	O
)	O
,	O
the	O
human	B-UNK
diastrophic	B-UNK
dysplasia	I-UNK
sulfate	B-UNK
transporter	I-UNK
(	O
encoded	B-UNK
by	O
DTD	B-UNK
;	O
32	O
%	O
)	O
and	O
the	O
human	B-UNK
sulfate	B-UNK
transporter	I-UNK
downregulated	O
in	O
adenoma	B-DISEASE
(	O
encoded	B-UNK
by	O
DRA	O
;	O
45	O
%	O
)	O
.	O

On	O
the	O
basis	B-UNK
of	O
this	O
homology	B-UNK
and	O
the	O
presence	O
of	O
a	O
slightly	O
modified	O
sulfate	B-UNK
-	O
transporter	B-UNK
signature	O
sequence	B-UNK
comprising	O
its	O
putative	O
second	O
transmembrane	B-UNK
domain	B-UNK
,	O
pendrin	B-UNK
has	O
been	O
proposed	O
to	O
function	B-UNK
as	O
a	O
sulfate	B-UNK
transporter	I-UNK
.	O

We	O
were	O
unable	O
to	O
detect	B-UNK
evidence	B-UNK
of	O
sulfate	B-UNK
transport	B-UNK
following	O
the	O
expression	B-UNK
of	O
pendrin	B-UNK
in	O
Xenopus	O
laevis	O
oocytes	O
by	O
microinjection	O
of	O
PDS	B-UNK
cRNA	O
or	O
in	O
Sf9	O
cells	B-UNK
following	O
infection	B-UNK
with	O
PDS	B-UNK
-	O
recombinant	B-UNK
baculovirus	O
.	O

The	O
rates	O
of	O
transport	B-UNK
for	O
iodide	B-UNK
and	O
chloride	B-UNK
were	O
significantly	O
increased	B-UNK
following	O
the	O
expression	B-UNK
of	O
pendrin	B-UNK
in	O
both	O
cell	B-UNK
systems	O
.	O

Our	O
results	B-UNK
demonstrate	B-UNK
that	O
pendrin	B-UNK
functions	O
as	O
a	O
transporter	B-UNK
of	O
chloride	B-UNK
and	O
iodide	B-UNK
,	O
but	O
not	O
sulfate	B-UNK
,	O
and	O
may	O
provide	B-UNK
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
..	O

HFE	B-UNK
mutations	B-UNK
analysis	B-UNK
in	O
711	O
hemochromatosis	B-DISEASE
probands	O
:	O
evidence	B-UNK
for	O
S65C	O
implication	O
in	O
mild	O
form	B-UNK
of	O
hemochromatosis	B-UNK
.	O

Hereditary	B-UNK
hemochromatosis	I-UNK
(	O
HH	B-UNK
)	O
is	O
a	O
common	B-UNK
autosomal	B-UNK
recessive	I-UNK
genetic	B-UNK
disorder	I-UNK
of	O
iron	B-UNK
metabolism	B-UNK
.	O

The	O
HFE	B-UNK
candidate	B-UNK
gene	I-UNK
encoding	B-UNK
an	O
HLA	B-UNK
class	O
I	O
-	O
like	O
protein	B-UNK
involved	B-UNK
in	O
HH	B-UNK
was	O
identified	B-UNK
in	O
1996	O
.	O

Two	O
missense	B-UNK
mutations	I-UNK
have	O
been	O
described	O
C282Y	B-UNK
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-UNK
chromosomes	O
,	O
and	O
H63D	B-UNK
,	O
which	O
is	O
associated	O
with	O
a	O
milder	B-UNK
form	B-UNK
of	O
the	O
disease	B-DISEASE
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	B-UNK
HH	B-UNK
chromosomes	O
.	O

We	O
report	B-UNK
here	O
on	O
the	O
analysis	B-UNK
of	O
C282Y	B-UNK
,	O
H63D	B-UNK
,	O
and	O
the	O
193A--	O
>	O
T	O
substitution	B-UNK
leading	B-UNK
to	O
the	O
S65C	O
missense	B-UNK
substitution	B-UNK
in	O
a	O
large	B-UNK
series	B-UNK
of	O
probands	O
and	O
controls	O
.	O

The	O
results	B-UNK
confirm	O
that	O
the	O
C282Y	B-UNK
substitution	B-UNK
was	O
the	O
main	O
mutation	B-UNK
involved	B-UNK
in	O
hemochromatosis	B-UNK
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	B-UNK
chromosomes	O
,	O
whereas	O
the	O
H63D	B-UNK
substitution	B-UNK
represented	O
39	O
%	O
of	O
the	O
HH	B-UNK
chromosomes	O
that	O
did	O
not	O
carry	B-UNK
the	O
C282Y	B-UNK
mutation	B-UNK
.	O

In	O
addition	B-UNK
,	O
our	O
screening	B-UNK
showed	O
that	O
the	O
S65C	O
substitution	B-UNK
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	B-UNK
without	O
an	O
assigned	O
mutation	B-UNK
.	O

This	O
substitution	B-UNK
accounted	O
for	O
7	O
.	O

8	O
%	O
of	O
HH	B-UNK
chromosomes	O
that	O
were	O
neither	O
C282Y	B-UNK
nor	O
H63D.	O

This	O
enrichment	O
of	O
S65C	O
among	O
HH	B-UNK
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	B-UNK
is	O
associated	O
with	O
the	O
mild	O
form	B-UNK
of	O
hemochromatosis	B-UNK
.	O

Germline	B-UNK
BRCA1	B-UNK
alterations	B-UNK
in	O
a	O
population	B-UNK
-	O
based	B-UNK
series	B-UNK
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	B-UNK
.	O

The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
provide	B-UNK
more	O
accurate	O
frequency	B-UNK
estimates	O
of	O
breast	B-UNK
cancer	B-UNK
susceptibility	I-UNK
gene	I-UNK
1	O
(	O
BRCA1	B-UNK
)	O
germline	B-UNK
alterations	B-UNK
in	O
the	O
ovarian	B-UNK
cancer	I-UNK
population	B-UNK
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	B-UNK
the	O
prevalence	B-UNK
of	O
BRCA1	B-UNK
alterations	B-UNK
in	O
a	O
population	B-UNK
-	O
based	B-UNK
series	B-UNK
of	O
consecutive	O
ovarian	B-UNK
cancer	I-UNK
cases	B-UNK
.	O

This	O
is	O
the	O
first	O
population	B-UNK
-	O
based	B-UNK
ovarian	B-DISEASE
cancer	I-DISEASE
study	B-UNK
reporting	O
BRCA1	B-UNK
alterations	B-UNK
derived	B-UNK
from	O
a	O
comprehensive	O
screen	B-UNK
of	O
the	O
entire	O
coding	B-UNK
region	I-UNK
.	O

One	O
hundred	O
and	O
seven	O
ovarian	B-UNK
cancer	I-UNK
cases	B-UNK
were	O
analyzed	B-UNK
for	O
BRCA1	B-UNK
alterations	B-UNK
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	B-UNK
followed	O
by	O
direct	B-UNK
sequencing	I-UNK
.	O

Two	O
truncating	B-UNK
mutations	I-UNK
,	O
962del4	O
and	O
3600del11	O
,	O
were	O
identified	B-UNK
.	O

Both	O
patients	B-UNK
had	O
a	O
family	B-UNK
history	B-UNK
of	O
breast	B-UNK
or	O
ovarian	B-UNK
cancer	I-UNK
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	B-UNK
reported	I-UNK
uncharacterized	O
variants	B-UNK
were	O
also	O
identified	B-UNK
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	B-UNK
history	B-UNK
of	O
cancer	B-DISEASE
.	O

The	O
frequency	B-UNK
distribution	B-UNK
of	O
common	B-UNK
polymorphisms	B-UNK
was	O
determined	B-UNK
in	O
the	O
91	O
Caucasian	B-UNK
cancer	B-DISEASE
cases	B-UNK
in	O
this	O
series	B-UNK
and	O
24	O
sister	O
controls	O
using	O
allele	B-UNK
-	O
specific	B-UNK
amplification	B-UNK
.	O

The	O
rare	B-UNK
form	B-UNK
of	O
the	O
Q356R	O
polymorphism	B-UNK
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
associated	O
with	O
a	O
family	B-UNK
history	B-UNK
of	O
ovarian	B-UNK
cancer	I-UNK
,	O
suggesting	O
that	O
this	O
polymorphism	B-UNK
may	O
influence	O
ovarian	B-UNK
cancer	I-UNK
risk	B-UNK
.	O

In	O
summary	O
,	O
our	O
data	B-UNK
suggest	B-UNK
a	O
role	B-UNK
for	O
some	O
uncharacterized	O
variants	B-UNK
and	O
rare	B-UNK
forms	B-UNK
of	O
polymorphisms	B-UNK
in	O
determining	O
ovarian	B-UNK
cancer	I-UNK
risk	B-UNK
,	O
and	O
highlight	O
the	O
necessity	O
to	O
screen	B-UNK
for	O
missense	B-UNK
alterations	B-UNK
as	O
well	O
as	O
truncating	B-UNK
mutations	I-UNK
in	O
this	O
population	B-UNK
.	O

Adrenoleukodystrophy	B-UNK
-	O
related	B-UNK
protein	B-UNK
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-DISEASE
protein	B-DISEASE
deficiency	I-DISEASE
(	O
X	O
-	O
ALD	B-UNK
):	O
implications	B-UNK
for	O
therapy	B-UNK
.	O

Inherited	B-UNK
defects	B-UNK
in	O
the	O
peroxisomal	B-UNK
ATP	B-UNK
-	O
binding	B-UNK
cassette	O
(	O
ABC	O
)	O
transporter	B-UNK
adrenoleukodystrophy	B-UNK
protein	B-UNK
(	O
ALDP	O
)	O
lead	B-UNK
to	O
the	O
lethal	O
peroxisomal	B-UNK
disorder	B-UNK
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
(	O
X	O
-	O
ALD	B-UNK
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Three	O
other	O
peroxisomal	B-UNK
ABC	O
transporters	O
currently	O
are	O
known	O
adrenoleukodystrophy	B-DISEASE
-	O
related	B-UNK
protein	B-UNK
(	O
ALDRP	O
)	O
,	O
70	O
kDa	O
peroxisomal	B-UNK
membrane	B-UNK
protein	I-UNK
(	O
PMP70	O
)	O
and	O
PMP70-related	O
protein	B-UNK
.	O

By	O
using	O
transient	O
and	O
stable	B-UNK
overexpression	B-UNK
of	O
human	B-UNK
cDNAs	O
encoding	B-UNK
ALDP	O
and	O
its	O
closest	O
relative	B-UNK
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	B-UNK
peroxisomal	B-UNK
beta-oxidation	O
in	O
fibroblasts	B-UNK
of	O
X	O
-	O
ALD	B-UNK
patients	B-UNK
.	O

The	O
pathognomonic	O
accumulation	B-UNK
of	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
could	O
also	O
be	O
prevented	O
by	O
overexpression	B-UNK
of	O
ALDRP	O
in	O
immortalized	O
X	O
-	O
ALD	B-UNK
cells	B-UNK
.	O

Immunofluorescence	O
analysis	B-UNK
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	B-UNK
ALDP	O
itself	O
.	O

Moreover	O
,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	B-UNK
beta-oxidation	O
defect	B-UNK
in	O
the	O
liver	B-UNK
of	O
ALDP	O
-	O
deficient	B-UNK
mice	I-UNK
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	B-UNK
expression	I-UNK
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate	O
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	B-UNK
in	O
X	O
-	O
ALD	B-UNK
could	O
be	O
possible	O
by	O
drug	O
-	O
induced	O
overexpression	B-UNK
or	O
ectopic	O
expression	B-UNK
of	O
ALDRP	O
..	O

Centrosome	O
amplification	B-UNK
and	O
a	O
defective	O
G2-M	O
cell	B-UNK
cycle	I-UNK
checkpoint	O
induce	O
genetic	B-UNK
instability	B-UNK
in	O
BRCA1	B-UNK
exon	B-UNK
11	O
isoform	O
-	O
deficient	B-UNK
cells	B-UNK
.	O

Germline	B-UNK
mutations	I-UNK
of	O
the	O
Brca1	B-UNK
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
predispose	O
women	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
.	O

To	O
study	B-UNK
mechanisms	O
underlying	O
BRCA1-related	O
tumorigenesis	O
,	O
we	O
derived	B-UNK
mouse	B-UNK
embryonic	B-UNK
fibroblast	O
cells	B-UNK
carrying	B-UNK
a	O
targeted	B-UNK
deletion	B-UNK
of	O
exon	B-UNK
11	O
of	O
the	O
Brca1	B-UNK
gene	B-UNK
.	O

We	O
show	O
that	O
the	O
mutant	B-UNK
cells	B-UNK
maintain	O
an	O
intact	O
G1-S	O
cell	B-UNK
cycle	I-UNK
checkpoint	O
and	O
proliferate	O
poorly	O
.	O

However	O
,	O
a	O
defective	O
G2-M	O
checkpoint	O
in	O
these	O
cells	B-UNK
is	O
accompanied	O
by	O
extensive	B-UNK
chromosomal	B-UNK
abnormalities	B-UNK
.	O

Mutant	B-UNK
fibroblasts	B-UNK
contain	O
multiple	B-UNK
,	O
functional	O
centrosomes	O
,	O
which	O
lead	B-UNK
to	O
unequal	O
chromosome	B-UNK
segregation	B-UNK
,	O
abnormal	O
nuclear	B-UNK
division	O
,	O
and	O
aneuploidy	B-DISEASE
.	O

These	O
data	B-UNK
uncover	O
an	O
essential	B-UNK
role	B-UNK
of	O
BRCA1	B-UNK
in	O
maintaining	O
genetic	B-UNK
stability	O
through	O
the	O
regulation	B-UNK
of	O
centrosome	O
duplication	B-UNK
and	O
the	O
G2-M	O
checkpoint	O
and	O
provide	B-UNK
a	O
molecular	B-UNK
basis	I-UNK
for	O
the	O
role	B-UNK
of	O
BRCA1	B-UNK
in	O
tumorigenesis	O
..	O

Defective	O
CD95	O
/	O
APO-1	O
/	O
Fas	B-UNK
signal	B-UNK
complex	O
formation	B-UNK
in	O
the	O
human	B-UNK
autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
,	I-DISEASE
type	I-DISEASE
Ia	I-DISEASE
.	O

Heterozygous	B-UNK
mutations	B-UNK
in	O
the	O
CD95	O
(	O
APO-1	O
/	O
Fas	B-UNK
)	O
receptor	B-UNK
occur	B-UNK
in	O
most	O
individuals	B-UNK
with	O
autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
(	O
ALPS	B-UNK
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	B-UNK
.	O

We	O
show	O
that	O
local	O
or	O
global	O
alterations	B-UNK
in	O
the	O
structure	B-UNK
of	O
the	O
cytoplasmic	O
death	B-UNK
domain	B-UNK
from	O
nine	O
independent	O
ALPS	B-UNK
CD95	O
death	B-DISEASE
-	O
domain	B-UNK
mutations	B-UNK
result	B-UNK
in	O
a	O
failure	B-UNK
to	O
bind	O
the	O
FADD	O
/	O
MORT1	O
signaling	O
protein	B-UNK
.	O

Despite	O
heterozygosity	B-UNK
for	O
the	O
abnormal	O
allele	B-UNK
,	O
lymphocytes	O
from	O
ALPS	B-UNK
patients	B-UNK
showed	O
markedly	B-UNK
decreased	B-UNK
FADD	O
association	B-UNK
and	O
a	O
loss	B-UNK
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
intracytoplasmic	O
CD95	O
mutations	B-UNK
in	O
ALPS	B-UNK
impair	O
apoptosis	O
chiefly	O
by	O
disrupting	O
death	B-DISEASE
-	O
domain	B-UNK
interactions	O
with	O
the	O
signaling	O
protein	B-UNK
FADD	O
/	O
MORT1	O
..	O

Analysis	B-UNK
of	O
alkaptonuria	B-DISEASE
(	O
AKU	O
)	O
mutations	B-UNK
and	O
polymorphisms	B-UNK
reveals	O
that	O
the	O
CCC	O
sequence	B-UNK
motif	B-UNK
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	B-UNK
(	O
HGO	B-UNK
)	O
.	O

We	O
recently	O
showed	O
that	O
alkaptonuria	B-DISEASE
(	O
AKU	O
)	O
is	O
caused	B-UNK
by	O
loss	B-UNK
-	O
of	O
-	O
function	B-UNK
mutations	B-UNK
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	B-UNK
(	O
HGO	B-UNK
)	O
.	O

Herein	O
we	O
describe	O
haplotype	B-UNK
and	O
mutational	O
analyses	O
of	O
HGO	B-UNK
in	O
seven	O
new	O
AKU	O
pedigrees	O
.	O

These	O
analyses	O
identified	B-UNK
two	O
novel	O
single	B-UNK
-	O
nucleotide	B-UNK
polymorphisms	B-UNK
(	O
INV4	O
+	O
31A--	O
>	O
G	O
and	O
INV11	O
+	O
18A--	O
>	O
G	O
)	O
and	O
six	O
novel	O
AKU	O
mutations	B-UNK
(	O
INV1	O
-	O
1G--	O
>	O
A	O
,	O
W60	O
G	O
,	O
Y62C	O
,	O
A122D	O
,	O
P230	O
T	O
,	O
and	O
D291E	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	B-UNK
found	O
in	O
AKU	O
.	O

Reexamination	O
of	O
all	O
29	O
mutations	B-UNK
and	O
polymorphisms	B-UNK
thus	O
far	O
described	O
in	O
HGO	B-UNK
shows	O
that	O
these	O
nucleotide	B-UNK
changes	O
are	O
not	O
randomly	O
distributed	O
;	O
the	O
CCC	O
sequence	B-UNK
motif	B-UNK
and	O
its	O
inverted	O
complement	B-UNK
,	O
GGG	O
,	O
are	O
preferentially	O
mutated	B-UNK
.	O

These	O
analyses	O
also	O
demonstrated	O
that	O
the	O
nucleotide	B-UNK
substitutions	B-UNK
in	O
HGO	B-UNK
do	O
not	O
involve	O
CpG	B-UNK
dinucleotides	O
,	O
which	O
illustrates	O
important	O
differences	B-UNK
between	O
HGO	B-UNK
and	O
other	O
genes	B-UNK
for	O
the	O
occurrence	B-UNK
of	O
mutation	B-UNK
at	O
specific	B-UNK
short	B-UNK
-	O
sequence	B-UNK
motifs	O
.	O

Because	O
the	O
CCC	O
sequence	B-UNK
motifs	O
comprise	O
a	O
significant	B-UNK
proportion	B-UNK
(	O
34	O
.	O
5	O
%	O
)	O
of	O
all	O
mutated	B-UNK
bases	O
that	O
have	O
been	O
observed	B-UNK
in	O
HGO	B-UNK
,	O
we	O
conclude	O
that	O
the	O
CCC	O
triplet	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
HGO	B-UNK
.	O

Fabry	B-DISEASE
disease	I-DISEASE
:	O
identification	B-UNK
of	O
novel	O
alpha	B-UNK
-	O
galactosidase	O
A	O
mutations	B-UNK
and	O
molecular	B-UNK
carrier	B-UNK
detection	I-UNK
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O

Fabry	B-DISEASE
disease	I-DISEASE
(	O
FD	O
)	O
(	O
angiokeratoma	B-DISEASE
corporis	O
diffusum	O
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
inborn	O
error	O
of	O
glycosphingolipid	O
metabolism	B-UNK
caused	B-UNK
by	O
defects	B-UNK
in	O
the	O
lysosomal	B-UNK
alpha	B-UNK
-	O
galactosidase	O
A	O
gene	B-UNK
(	O
GLA	O
)	O
.	O

The	O
enzymatic	B-UNK
defect	B-UNK
leads	B-UNK
to	O
the	O
systemic	O
accumulation	B-UNK
of	O
neutral	O
glycosphingolipids	O
with	O
terminal	B-UNK
alpha	B-UNK
-	O
galactosyl	O
moieties	O
.	O

Clinically	O
,	O
affected	B-UNK
hemizygous	B-UNK
males	B-UNK
have	O
angiokeratoma	B-DISEASE
,	O
severe	B-UNK
acroparesthesia	O
,	O
renal	B-DISEASE
failure	I-DISEASE
,	O
and	O
vasculopathy	O
of	O
the	O
heart	B-UNK
and	O
brain	B-UNK
.	O

While	O
demonstration	O
of	O
alpha	B-UNK
-	O
galactosidase	O
deficiency	B-UNK
in	O
leukocytes	O
is	O
diagnostic	B-UNK
in	O
affected	B-UNK
males	I-UNK
,	O
enzymatic	B-UNK
detection	B-UNK
of	O
female	O
carriers	B-UNK
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	B-UNK
X	O
-	O
chromosomal	B-UNK
inactivation	B-UNK
,	O
underlining	O
the	O
need	O
of	O
molecular	B-UNK
investigations	O
for	O
accurate	O
genetic	B-UNK
counseling	I-UNK
.	O

By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	B-UNK
-	O
based	B-UNK
detection	B-UNK
systems	O
,	O
we	O
have	O
characterized	B-UNK
the	O
mutations	B-UNK
underlying	O
alpha	B-UNK
-	O
Gal	O
A	O
deficiency	B-UNK
in	O
16	O
individuals	B-UNK
from	O
six	O
unrelated	B-UNK
families	I-UNK
with	O
FD	O
.	O

The	O
mutational	O
spectrum	B-UNK
included	O
five	O
missense	B-UNK
mutations	I-UNK
(	O
C202W	O
,	O
C223	O
G	O
,	O
N224D	O
,	O
R301Q	O
,	O
and	O
Q327	O
K	O
)	O
and	O
one	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
[	O
IVS3	O
G	O
(	O
-1)--	O
>	O
C].	O

Studies	B-UNK
at	O
the	O
mRNA	O
level	B-UNK
showed	O
that	O
the	O
latter	O
led	B-UNK
to	O
altered	O
pre	O
-	O
mRNA	O
splicing	B-UNK
with	O
consequent	O
alteration	O
of	O
the	O
mRNA	O
translational	O
reading	B-UNK
frame	I-UNK
and	O
generation	O
of	O
a	O
premature	B-UNK
termination	I-UNK
codon	B-UNK
of	O
translation	O
.	O

By	O
use	O
of	O
this	O
strategy	O
,	O
carrier	B-UNK
status	I-UNK
was	O
accurately	O
assessed	O
in	O
all	O
seven	O
at	O
-	O
risk	B-UNK
females	O
tested	O
,	O
whereas	O
enzymatic	B-UNK
dosages	O
failed	O
to	O
diagnose	O
or	O
exclude	O
heterozygosity	B-UNK
..	O

Prenatal	B-UNK
diagnosis	I-UNK
by	O
FISH	B-UNK
in	O
a	O
family	B-UNK
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
caused	B-UNK
by	O
duplication	B-UNK
of	O
PLP	B-UNK
gene	B-UNK
.	O

A	O
diagnosis	B-UNK
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	B-UNK
boy	B-UNK
.	O

No	O
mutation	B-UNK
in	O
the	O
coding	B-UNK
region	I-UNK
of	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
had	O
been	O
found	O
.	O

The	O
boys	O
maternal	O
aunt	O
came	O
for	O
prenatal	B-UNK
diagnosis	I-UNK
when	O
16	O
+	O
weeks	O
pregnant	O
and	O
carrying	B-UNK
a	O
male	B-UNK
fetus	O
.	O

Samples	B-UNK
were	O
tested	O
for	O
duplication	B-UNK
of	O
the	O
PLP	B-UNK
gene	B-UNK
,	O
by	O
interphase	O
FISH	B-UNK
,	O
in	O
lymphocyte	B-UNK
preparations	O
from	O
the	O
proband	B-UNK
,	O
his	O
aunt	O
and	O
an	O
amniotic	O
fluid	O
cell	B-UNK
preparation	O
from	O
the	O
fetus	O
.	O

The	O
proband	B-UNK
was	O
found	O
to	O
carry	B-UNK
the	O
duplication	B-UNK
,	O
thus	O
confirming	O
the	O
diagnosis	B-UNK
of	O
Pelizaeus	B-UNK
Merzbacher	I-UNK
disease	I-UNK
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	B-UNK
..	O

Dominant	B-UNK
negative	I-UNK
effect	B-UNK
of	O
the	O
APC1309	O
mutation	B-UNK
:	O
a	O
possible	O
explanation	O
for	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
.	O

Inactivation	B-UNK
of	O
the	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
APC	B-UNK
)	O
gene	B-UNK
product	I-UNK
initiates	O
colorectal	B-UNK
tumorigenesis	O
.	O

Patients	B-UNK
with	O
familial	B-UNK
APC	B-UNK
(	O
FAP	B-UNK
)	O
carry	B-UNK
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
and	O
develop	O
multiple	B-UNK
colorectal	B-DISEASE
adenomas	I-DISEASE
and	O
subsequent	B-UNK
carcinomas	B-UNK
early	B-UNK
in	O
life	B-UNK
.	O

The	O
severity	B-UNK
of	O
the	O
disease	B-DISEASE
correlates	O
with	O
the	O
position	B-UNK
of	O
the	O
inherited	B-UNK
APC	B-UNK
mutation	B-UNK
(	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
)	O
.	O

Together	O
with	O
the	O
fact	B-UNK
that	O
both	O
germ	B-UNK
-	O
line	B-UNK
and	O
sporadic	B-UNK
APC	B-UNK
mutations	B-UNK
cluster	B-UNK
in	O
the	O
central	B-UNK
region	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
,	O
this	O
points	O
to	O
a	O
dominant	B-UNK
negative	I-UNK
effect	B-UNK
of	O
certain	O
APC	B-UNK
mutants	O
.	O

Loss	B-UNK
of	O
APC	B-UNK
function	B-UNK
was	O
recently	O
shown	B-UNK
to	O
result	B-UNK
in	O
enhanced	O
beta	B-UNK
-	O
catenin-/Tcf	O
-	O
mediated	O
transcription	B-UNK
in	O
colon	B-UNK
epithelial	B-UNK
cells	B-UNK
.	O

Here	O
,	O
we	O
provide	B-UNK
experimental	O
evidence	B-UNK
for	O
a	O
dominant	B-UNK
negative	I-UNK
effect	B-UNK
of	O
APC	B-UNK
gene	B-UNK
products	B-UNK
associated	O
with	O
severe	B-UNK
polyposis	B-UNK
.	O

Wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
activity	B-UNK
in	O
beta	B-UNK
-	O
catenin-/Tcf	O
-	O
mediated	O
transcription	B-UNK
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	B-UNK
APC	B-UNK
that	O
is	O
truncated	O
at	O
codon	B-UNK
1309	O
.	O

In	O
contrast	B-UNK
,	O
mutant	B-UNK
APC	B-UNK
gene	B-UNK
products	B-UNK
that	O
are	O
associated	O
with	O
attenuated	B-UNK
polyposis	B-UNK
(	O
codon	B-UNK
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
activity	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
a	O
molecular	B-UNK
explanation	O
for	O
the	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
in	O
FAP	B-UNK
patients	I-UNK
and	O
support	O
the	O
idea	O
that	O
colorectal	B-UNK
tumor	B-DISEASE
growth	B-UNK
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	B-UNK
for	O
a	O
mutation	B-UNK
in	O
the	O
mutation	B-UNK
cluster	B-UNK
region	B-UNK
..	O

BRCA1	B-UNK
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
.	O

Germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
tumor	B-UNK
-	O
suppressor	B-UNK
gene	B-UNK
are	O
associated	O
with	O
an	O
increased	B-UNK
susceptibility	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
.	O

BRCA1	B-UNK
contains	O
a	O
carboxyl	O
-	O
terminal	B-UNK
domain	B-UNK
(	O
BRCT	O
)	O
that	O
is	O
shared	O
with	O
several	O
other	O
proteins	B-UNK
involved	B-UNK
in	O
maintaining	O
genome	B-UNK
integrity	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
function	B-UNK
of	O
BRCA1	B-UNK
,	O
we	O
sought	O
to	O
isolate	O
proteins	B-UNK
that	O
interact	O
with	O
the	O
BRCT	O
domain	B-UNK
.	O

Purified	O
BRCT	O
polypeptide	O
was	O
used	O
as	O
a	O
probe	O
to	O
screen	B-UNK
a	O
human	B-UNK
placenta	O
cDNA	O
expression	B-UNK
library	O
by	O
Far	O
Western	B-UNK
analysis	B-UNK
.	O

Here	O
we	O
report	B-UNK
that	O
BRCA1	B-UNK
interacts	O
in	O
vivo	B-UNK
and	O
in	O
vitro	O
with	O
the	O
Rb	O
-	O
binding	B-UNK
proteins	B-UNK
,	O
RbAp46	O
and	O
RbAp48	O
,	O
as	O
well	O
as	O
with	O
Rb	O
.	O

Moreover	O
,	O
the	O
BRCT	O
domain	B-UNK
associates	O
with	O
the	O
histone	O
deacetylases	O
HDAC1	O
and	O
HDAC2	O
.	O

These	O
results	B-UNK
demonstrate	B-UNK
that	O
BRCA1	B-UNK
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
,	O
and	O
therefore	O
may	O
explain	O
the	O
involvement	B-UNK
of	O
BRCA1	B-UNK
in	O
multiple	B-UNK
processes	O
such	O
as	O
transcription	B-UNK
,	O
DNA	B-UNK
repair	B-UNK
,	O
and	O
recombination	B-UNK
..	O

Combined	O
genetic	B-UNK
deficiency	B-UNK
of	O
C6	B-UNK
and	O
C7	B-UNK
in	O
man	B-UNK
.	O

By	O
routine	O
screening	B-UNK
of	O
sera	B-UNK
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub-total	O
deficiency	B-UNK
of	O
C6	B-UNK
and	O
C7	B-UNK
.	O

No	O
clinical	B-UNK
disease	B-DISEASE
was	O
associated	O
with	O
this	O
deficiency	B-UNK
which	O
was	O
transmitted	O
through	O
the	O
subjects	B-UNK
family	B-UNK
as	O
a	O
single	B-UNK
genetic	B-UNK
characteristic	B-UNK
,	O
the	O
C6	B-UNK
deficiency	I-UNK
being	O
associated	O
with	O
a	O
silent	O
allele	B-UNK
at	O
the	O
structural	B-UNK
locus	B-UNK
.	O

The	O
propositus	O
was	O
found	O
to	O
have	O
low	B-UNK
quantities	O
of	O
an	O
abnormal	O
C6	B-UNK
which	O
was	O
both	O
antigenically	O
deficient	B-UNK
and	O
smaller	O
in	O
size	B-UNK
than	O
normal	B-UNK
C6	B-UNK
(	O
110	O
,	O
000	O
daltons	O
compared	B-UNK
with	O
140	O
,	O
000	O
daltons	O
)	O
and	O
small	O
quantities	O
of	O
apparently	O
normal	B-UNK
C7	B-UNK
.	O

It	O
is	O
concluded	O
that	O
the	O
most	O
likely	O
explanation	O
for	O
this	O
defect	B-UNK
is	O
that	O
the	O
subject	O
has	O
a	O
structural	B-UNK
mutation	B-UNK
in	O
his	O
C6	B-UNK
gene	B-UNK
which	O
produces	O
hyopsynthesis	O
not	O
only	O
of	O
C6	B-UNK
but	O
also	O
of	O
the	O
closely	B-UNK
linked	I-UNK
gene	B-UNK
for	O
C7	B-UNK
.	O

These	O
findings	B-UNK
suggest	B-UNK
the	O
possibility	B-UNK
that	O
C6	B-UNK
and	O
C7	B-UNK
may	O
function	B-UNK
as	O
a	O
single	B-UNK
genetic	B-UNK
unit	O
and	O
that	O
the	O
primary	B-UNK
transcript	B-UNK
copied	O
from	O
the	O
genome	B-UNK
includes	O
information	B-UNK
for	O
both	O
proteins	B-UNK
..	O

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein	B-UNK
-	O
protein	B-UNK
interactions	O
resulting	B-UNK
in	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
.	O

Emery	O
-	O
Dreifuss	O
muscular	B-DISEASE
dystrophy	I-DISEASE
(	O
EDMD	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
muscular	B-UNK
dystrophy	I-UNK
characterized	B-UNK
by	O
early	B-UNK
contractures	B-DISEASE
of	O
the	O
elbows	O
,	O
Achilles	O
tendons	O
and	O
spine	O
,	O
slowly	O
progressive	B-UNK
muscle	B-UNK
wasting	O
and	O
weakness	B-DISEASE
,	O
and	O
cardiomyopathy	B-UNK
associated	O
with	O
cardiac	B-UNK
conduction	O
defects	B-UNK
.	O

The	O
emerin	O
gene	B-UNK
has	O
been	O
mapped	B-UNK
to	O
Xq28	B-UNK
and	O
encodes	B-UNK
a	O
34-kDa	O
serine	O
-	O
rich	O
protein	B-UNK
,	O
emerin	O
,	O
which	O
has	O
been	O
localized	B-UNK
to	O
the	O
nuclear	B-UNK
envelope	O
in	O
a	O
wide	B-UNK
variety	O
of	O
tissues	O
,	O
including	O
skeletal	B-UNK
and	O
cardiac	B-UNK
muscle	B-UNK
.	O

Mutations	B-UNK
spanning	O
the	O
emerin	O
gene	B-UNK
have	O
been	O
identified	B-UNK
in	O
patients	B-UNK
with	O
EDMD	B-UNK
.	O

We	O
present	B-UNK
here	O
the	O
effect	B-UNK
,	O
on	O
emerin	O
protein	B-UNK
expression	B-UNK
,	O
of	O
two	O
missense	B-UNK
mutations	I-UNK
identified	B-UNK
in	O
unrelated	B-UNK
EDMD	B-UNK
patients	B-UNK
.	O

These	O
alterations	B-UNK
predict	O
the	O
replacement	O
of	O
a	O
proline	O
residue	O
at	O
position	B-UNK
183	O
with	O
either	O
a	O
histidine	O
or	O
a	O
threonine	O
.	O

Biochemical	O
analysis	B-UNK
has	O
demonstrated	O
that	O
the	O
mobility	O
and	O
expression	B-UNK
levels	B-UNK
of	O
the	O
mutant	B-UNK
forms	B-UNK
of	O
emerin	O
are	O
indistinguishable	O
from	O
that	O
of	O
wild	B-UNK
-	O
type	B-UNK
emerin	O
,	O
but	O
that	O
they	O
have	O
weakened	O
interactions	O
with	O
nuclear	B-UNK
lamina	O
components	O
.	O

In	O
comparison	B-UNK
with	O
the	O
usual	O
EDMD	B-UNK
phenotype	B-UNK
,	O
patients	B-UNK
with	O
P183	O
missense	B-UNK
mutations	I-UNK
have	O
a	O
later	O
age	B-UNK
at	O
onset	B-UNK
of	O
first	O
symptoms	B-UNK
,	O
elbow	O
contractures	B-DISEASE
,	O
ankle	O
contractures	B-DISEASE
,	O
upper	O
limb	O
weakness	B-DISEASE
and	O
lower	O
limb	O
weakness	B-DISEASE
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	B-UNK
at	O
onset	B-UNK
of	O
cardiac	B-UNK
involvement	B-UNK
.	O

This	O
is	O
the	O
first	O
report	B-UNK
of	O
protein	B-UNK
studies	B-UNK
on	O
patients	B-UNK
with	O
missense	B-UNK
mutations	I-UNK
resulting	B-UNK
in	O
the	O
clinical	B-UNK
features	I-UNK
of	O
EDMD	B-UNK
.	O

These	O
studies	B-UNK
demonstrate	B-UNK
the	O
importance	O
of	O
proline	O
183	O
for	O
the	O
proper	O
structure	B-UNK
/	O
function	B-UNK
of	O
emerin	O
..	O

Microdeletions	O
at	O
chromosome	B-UNK
bands	O
1q32-q41	O
as	O
a	O
cause	O
of	O
Van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
.	O

Van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
(	O
VWS	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
disorder	B-UNK
comprising	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
/	O
or	O
cleft	B-DISEASE
palate	I-DISEASE
and	O
lip	B-UNK
pits	O
.	O

We	O
reported	B-UNK
previously	B-UNK
a	O
family	B-UNK
whose	O
underlying	O
mutation	B-UNK
is	O
a	O
500	O
-	O
800	O
kb	B-UNK
deletion	B-UNK
localized	B-UNK
to	O
chromosome	B-UNK
bands	O
1q32-q41	O
[	O
Sander	O
et	O
al	B-DISEASE
.	O
,	O
1994	O
Hum	O
Mol	O
Genet	B-UNK
3	O
576	O
-	O
578].	O

Along	O
with	O
cleft	B-DISEASE
lip	I-DISEASE
/	O
palate	B-UNK
and	O
lip	B-UNK
pits	O
,	O
affected	B-UNK
relatives	B-UNK
exhibit	O
developmental	O
delays	O
,	O
suggesting	O
that	O
the	O
function	B-UNK
of	O
a	O
gene	B-UNK
nearby	O
may	O
also	O
be	O
disrupted	O
.	O

To	O
further	O
localize	O
the	O
VWS	B-UNK
gene	B-UNK
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
VWS	B-UNK
.	O

An	O
allele	B-UNK
loss	B-UNK
assay	B-UNK
was	O
performed	O
using	O
a	O
novel	O
highly	B-UNK
polymorphic	B-UNK
marker	B-UNK
,	O
D1S3753	O
.	O

From	O
a	O
panel	B-UNK
of	O
37	O
unrelated	B-UNK
individuals	B-UNK
,	O
we	O
detected	B-UNK
an	O
allele	B-UNK
loss	B-UNK
in	O
one	O
family	B-UNK
,	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	B-UNK
.	O

In	O
this	O
family	B-UNK
,	O
the	O
phenotype	B-UNK
in	O
three	O
generations	O
of	O
affected	B-UNK
individuals	I-UNK
was	O
confined	O
to	O
the	O
cardinal	O
signs	B-UNK
of	O
VWS	B-UNK
.	O

Surprisingly	O
,	O
mapping	B-UNK
of	O
the	O
new	O
deletion	B-UNK
showed	O
that	O
it	O
extended	O
0	O
.	O

2	O
-	O
1	O
Mb	B-UNK
beyond	O
the	O
proximal	B-UNK
breakpoint	O
for	O
the	O
deletion	B-UNK
described	O
previously	B-UNK
.	O

No	O
deletions	O
were	O
detected	B-UNK
in	O
seven	O
cases	B-UNK
of	O
popliteal	O
pterygia	O
syndrome	B-UNK
,	O
76	O
cases	B-UNK
of	O
mixed	O
syndromic	O
forms	B-UNK
of	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
palate	B-UNK
,	O
and	O
178	O
cases	B-UNK
of	O
nonsyndromic	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
palate	B-UNK
.	O

Splicing	B-UNK
defects	B-UNK
in	O
the	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
gene	B-UNK
,	O
ATM	B-UNK
:	O
underlying	O
mutations	B-UNK
and	O
consequences	O
.	O

Mutations	B-UNK
resulting	B-UNK
in	O
defective	O
splicing	B-UNK
constitute	O
a	O
significant	B-UNK
proportion	B-UNK
(	O
30/62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	B-UNK
of	O
mutations	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
in	O
patients	B-UNK
with	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
AT	O
)	O
that	O
were	O
detected	B-UNK
by	O
the	O
protein	B-UNK
-	O
truncation	B-UNK
assay	B-UNK
followed	O
by	O
sequence	B-UNK
analysis	I-UNK
of	O
genomic	B-UNK
DNA	I-UNK
.	O

Fewer	O
than	O
half	B-UNK
of	O
the	O
splicing	B-UNK
mutations	B-UNK
involved	B-UNK
the	O
canonical	O
AG	B-UNK
splice	B-UNK
-	O
acceptor	B-UNK
site	B-UNK
or	O
GT	B-UNK
splice	B-UNK
-	O
donor	B-UNK
site	B-UNK
.	O

A	O
higher	O
percentage	B-UNK
of	O
mutations	B-UNK
occurred	B-UNK
at	O
less	O
stringently	O
conserved	B-UNK
sites	O
,	O
including	O
silent	O
mutations	B-UNK
of	O
the	O
last	O
nucleotide	B-UNK
of	O
exons	O
,	O
mutations	B-UNK
in	O
nucleotides	O
other	O
than	O
the	O
conserved	B-UNK
AG	B-UNK
and	O
GT	B-UNK
in	O
the	O
consensus	B-UNK
splice	B-UNK
sites	O
,	O
and	O
creation	O
of	O
splice	B-UNK
-	O
acceptor	B-UNK
or	O
splice	B-UNK
-	O
donor	B-UNK
sites	O
in	O
either	O
introns	O
or	O
exons	O
.	O

These	O
splicing	B-UNK
mutations	B-UNK
led	B-UNK
to	O
a	O
variety	O
of	O
consequences	O
,	O
including	O
exon	B-UNK
skipping	O
and	O
,	O
to	O
a	O
lesser	O
degree	B-UNK
,	O
intron	B-UNK
retention	O
,	O
activation	O
of	O
cryptic	O
splice	B-UNK
sites	O
,	O
or	O
creation	O
of	O
new	O
splice	B-UNK
sites	O
.	O

In	O
addition	B-UNK
,	O
5	O
of	O
12	O
nonsense	B-UNK
mutations	I-UNK
and	O
1	O
missense	B-UNK
mutation	I-UNK
were	O
associated	O
with	O
deletion	B-UNK
in	O
the	O
cDNA	O
of	O
the	O
exons	O
in	O
which	O
the	O
mutations	B-UNK
occurred	B-UNK
.	O

No	O
ATM	B-UNK
protein	B-UNK
was	O
detected	B-UNK
by	O
western	B-UNK
blotting	O
in	O
any	O
AT	O
cell	B-UNK
line	I-UNK
in	O
which	O
splicing	B-UNK
mutations	B-UNK
were	O
identified	B-UNK
.	O

Several	O
cases	B-UNK
of	O
exon	B-UNK
skipping	O
in	O
both	O
normal	B-UNK
controls	O
and	O
patients	B-UNK
for	O
whom	O
no	O
underlying	O
defect	B-UNK
could	O
be	O
found	O
in	O
genomic	B-UNK
DNA	I-UNK
were	O
also	O
observed	B-UNK
,	O
suggesting	O
caution	O
in	O
the	O
interpretation	O
of	O
exon	B-UNK
deletions	O
observed	B-UNK
in	O
ATM	B-UNK
cDNA	O
when	O
there	O
is	O
no	O
accompanying	O
identification	B-UNK
of	O
genomic	B-UNK
mutations	B-UNK
..	O

Alpha	B-UNK
-	O
cardiac	B-UNK
actin	B-UNK
is	O
a	O
novel	O
disease	B-UNK
gene	B-UNK
in	O
familial	B-UNK
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
.	O

We	O
identified	B-UNK
the	O
alpha	B-UNK
-	O
cardiac	B-UNK
actin	B-UNK
gene	B-UNK
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	B-DISEASE
gene	B-UNK
in	O
a	O
pedigree	B-UNK
suffering	O
from	O
familial	B-UNK
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
(	O
FHC	O
)	O
.	O

Linkage	B-UNK
analyses	O
excluded	O
all	O
the	O
previously	B-UNK
reported	I-UNK
FHC	O
loci	O
as	O
possible	O
disease	B-DISEASE
loci	O
in	O
the	O
family	B-UNK
studied	O
,	O
with	O
lod	B-UNK
scores	I-UNK
varying	O
between-2	O
.	O

5	O
and-6	O
.	O

0	O
0	O
.	O

Further	O
linkage	B-UNK
analyses	O
of	O
plausible	O
candidate	B-UNK
genes	B-UNK
highly	B-UNK
expressed	B-UNK
in	O
the	O
adult	B-UNK
human	B-UNK
heart	B-UNK
identified	B-UNK
ACTC	O
as	O
the	O
most	O
likely	O
disease	B-UNK
gene	B-UNK
,	O
showing	O
a	O
maximal	O
lod	B-UNK
score	I-UNK
of	O
3	O
.	O

6	O
6	O
.	O

Mutation	B-UNK
analysis	B-UNK
of	O
ACTC	O
revealed	B-UNK
an	O
Ala295Ser	O
mutation	B-UNK
in	O
exon	B-UNK
5	O
close	B-UNK
to	O
2	O
missense	B-UNK
mutations	I-UNK
recently	O
described	O
to	O
cause	O
the	O
inherited	B-UNK
form	B-UNK
of	O
idiopathic	B-DISEASE
dilated	I-DISEASE
cardiomyopathy	I-DISEASE
(	O
IDC	O
)	O
.	O

Overgrowth	O
of	O
oral	B-UNK
mucosa	O
and	O
facial	B-UNK
skin	B-UNK
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B-DISEASE
.	O

Aspartylglucosaminuria	B-DISEASE
(	O
AGU	B-UNK
)	O
is	O
a	O
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
deficiency	B-UNK
of	O
aspartylglucosaminidase	O
(	O
AGA	B-UNK
)	O
.	O

The	O
main	O
symptom	O
is	O
progressive	B-UNK
mental	B-UNK
retardation	I-UNK
.	O

A	O
spectrum	B-UNK
of	O
different	O
mutations	B-UNK
has	O
been	O
reported	B-UNK
in	O
this	O
disease	B-UNK
,	O
one	O
missense	B-UNK
mutation	I-UNK
(	O
Cys163Ser	O
)	O
being	O
responsible	B-UNK
for	O
the	O
majority	O
of	O
Finnish	B-UNK
cases	B-UNK
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	B-UNK
AGU	B-UNK
patients	B-UNK
for	O
changes	O
in	O
the	O
oral	B-UNK
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	B-UNK
skin	B-UNK
.	O

Biopsy	B-UNK
specimens	O
of	O
16	O
oral	B-UNK
lesions	B-UNK
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B-UNK
lesions	B-UNK
were	O
studied	O
histologically	O
.	O

Immunohistochemical	O
staining	O
for	O
AGA	B-UNK
was	O
performed	O
on	O
15	O
oral	B-UNK
specimens	O
.	O

Skin	B-UNK
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	B-UNK
patients	B-UNK
,	O
with	O
erythema	B-DISEASE
of	O
the	O
facial	B-UNK
skin	B-UNK
already	O
common	B-UNK
in	O
childhood	O
.	O

Of	O
44	O
patients	B-UNK
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B-UNK
angiofibromas	O
,	O
tumours	B-DISEASE
primarily	O
occurring	O
in	O
association	B-UNK
with	O
tuberous	B-DISEASE
sclerosis	I-DISEASE
.	O

Oedemic	O
buccal	O
mucosa	O
(	O
leucoedema	O
)	O
and	O
gingival	O
overgrowths	O
were	O
more	O
frequent	B-UNK
in	O
AGU	B-UNK
patients	B-UNK
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Of	O
16	O
oral	B-UNK
mucosal	O
lesions	B-UNK
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	O
or	O
epithelial	B-UNK
hyperplasias	O
and	O
were	O
reactive	O
in	O
nature	B-UNK
.	O

Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four	O
.	O

Immunohistochemically	O
,	O
expression	B-UNK
of	O
AGA	B-UNK
in	O
AGU	B-UNK
patients	B-UNK
mucosal	O
lesions	B-UNK
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	B-UNK
of	O
normal	B-UNK
subjects	B-UNK
.	O

Thus	O
,	O
the	O
high	B-UNK
frequency	I-UNK
of	O
mucosal	O
overgrowth	O
in	O
AGU	B-UNK
patients	B-UNK
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	B-UNK
storage	I-UNK
or	O
with	O
alterations	B-UNK
in	O
the	O
level	B-UNK
of	O
AGA	B-UNK
expression	B-UNK
.	O

Characterization	B-UNK
of	O
a	O
germline	B-UNK
mosaicism	O
in	O
families	B-UNK
with	O
Lowe	O
syndrome	B-UNK
,	O
and	O
identification	B-UNK
of	O
seven	O
novel	O
mutations	B-UNK
in	O
the	O
OCRL1	O
gene	B-UNK
.	O

The	O
oculocerebrorenal	B-DISEASE
syndrome	I-DISEASE
of	O
Lowe	O
(	O
OCRL	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
major	B-UNK
abnormalities	B-UNK
of	O
eyes	O
,	O
nervous	O
system	O
,	O
and	O
kidneys	O
.	O

Mutations	B-UNK
in	O
the	O
OCRL1	O
gene	B-UNK
have	O
been	O
associated	O
with	O
the	O
disease	B-DISEASE
.	O

OCRL1	O
encodes	B-UNK
a	O
phosphatidylinositol	O
4	O
,	O
5-biphosphate	O
(	O
PtdIns	O
[	O
4	O
,	O
5	O
]	O
P2	O
)	O
5-phosphatase	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	B-UNK
in	O
eight	O
unrelated	B-UNK
patients	B-UNK
with	O
OCRL	B-UNK
and	O
have	O
found	O
seven	O
new	O
mutations	B-UNK
and	O
one	O
recurrent	O
in	O
-	O
frame	B-UNK
deletion	B-UNK
.	O

Among	O
the	O
new	O
mutations	B-UNK
,	O
two	O
nonsense	B-UNK
mutations	I-UNK
(	O
R317X	O
and	O
E558X	O
)	O
and	O
three	O
other	O
frameshift	B-UNK
mutations	B-UNK
caused	B-UNK
premature	B-UNK
termination	I-UNK
of	O
the	O
protein	B-UNK
.	O

A	O
missense	B-UNK
mutation	I-UNK
,	O
R483	O
G	O
,	O
was	O
located	B-UNK
in	O
the	O
highly	B-UNK
conserved	I-UNK
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
5-phosphatase	O
domain	B-UNK
.	O

Finally	B-UNK
,	O
one	O
frameshift	B-UNK
mutation	I-UNK
,	O
2799delC	O
,	O
modifies	O
the	O
C	O
-	O
terminal	B-UNK
part	O
of	O
OCRL1	O
,	O
with	O
an	O
extension	O
of	O
six	O
amino	B-UNK
acids	I-UNK
.	O

Altogether	O
,	O
70	O
%	O
of	O
missense	B-UNK
mutations	I-UNK
are	O
located	B-UNK
in	O
exon	B-UNK
15	O
,	O
and	O
52	O
%	O
of	O
all	O
mutations	B-UNK
cluster	B-UNK
in	O
exons	O
11	O
-	O
15	O
.	O

We	O
also	O
identified	B-UNK
two	O
new	O
microsatellite	B-UNK
markers	I-UNK
for	O
the	O
OCRL1	O
locus	B-UNK
,	O
and	O
we	O
detected	B-UNK
a	O
germline	B-UNK
mosaicism	O
in	O
one	O
family	B-UNK
.	O

This	O
observation	O
has	O
direct	B-UNK
implications	B-UNK
for	O
genetic	B-UNK
counseling	I-UNK
of	O
Lowe	O
syndrome	B-UNK
families	B-UNK
..	O

MEFV	B-UNK
-	O
Gene	B-UNK
analysis	B-UNK
in	O
armenian	O
patients	B-UNK
with	O
Familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
:	O
diagnostic	B-UNK
value	O
and	O
unfavorable	O
renal	B-UNK
prognosis	O
of	O
the	O
M694V	O
homozygous	B-UNK
genotype	B-UNK
-	O
genetic	B-UNK
and	O
therapeutic	O
implications	B-UNK
.	O

Familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
(	O
FMF	B-UNK
)	O
is	O
a	O
recessively	O
inherited	B-UNK
disorder	B-UNK
that	O
is	O
common	B-UNK
in	O
patients	B-UNK
of	O
Armenian	O
ancestry	O
.	O

To	O
date	B-UNK
,	O
its	O
diagnosis	B-UNK
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	B-UNK
entirely	O
on	O
nonspecific	O
clinical	B-UNK
signs	B-UNK
that	O
result	B-UNK
from	O
serosal	O
inflammation	B-DISEASE
and	O
that	O
may	O
lead	B-UNK
to	O
unnecessary	O
surgery	O
.	O

Renal	B-UNK
amyloidosis	B-DISEASE
,	O
prevented	O
by	O
colchicine	B-UNK
,	O
is	O
the	O
most	O
severe	B-UNK
complication	O
of	O
FMF	B-UNK
,	O
a	O
disorder	B-UNK
associated	O
with	O
mutations	B-UNK
in	O
the	O
MEFV	B-UNK
gene	B-UNK
.	O

To	O
evaluate	O
the	O
diagnostic	B-UNK
and	O
prognostic	O
value	O
of	O
MEFV	B-UNK
-	O
gene	B-UNK
analysis	B-UNK
,	O
we	O
investigated	O
90	O
Armenian	O
FMF	B-UNK
patients	B-UNK
from	O
77	O
unrelated	B-UNK
families	I-UNK
that	O
were	O
not	O
selected	O
through	O
genetic	B-UNK
-	O
linkage	B-UNK
analysis	I-UNK
.	O

Eight	O
mutations	B-UNK
,	O
one	O
of	O
which	O
(	O
R408Q	O
)	O
is	O
new	O
,	O
were	O
found	O
to	O
account	B-UNK
for	O
93	O
%	O
of	O
the	O
163	O
independent	O
FMF	B-UNK
alleles	B-UNK
,	O
with	O
both	O
FMF	B-UNK
alleles	B-UNK
identified	B-UNK
in	O
89	O
%	O
of	O
the	O
patients	B-UNK
.	O

In	O
several	O
instances	O
,	O
family	B-UNK
studies	B-UNK
provided	O
molecular	B-UNK
evidence	B-UNK
for	O
pseudodominant	O
transmission	B-UNK
and	O
incomplete	O
penetrance	O
of	O
the	O
disease	B-UNK
phenotype	B-UNK
.	O

The	O
M694V	O
homozygous	B-UNK
genotype	B-UNK
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	B-UNK
of	O
renal	B-UNK
amyloidosis	B-DISEASE
and	O
arthritis	B-UNK
,	O
compared	B-UNK
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O

The	O
demonstration	O
of	O
both	O
the	O
diagnostic	B-UNK
and	O
prognostic	O
value	O
of	O
MEFV	B-UNK
analysis	B-UNK
and	O
particular	O
modes	O
of	O
inheritance	B-UNK
should	O
lead	B-UNK
to	O
new	O
ways	O
for	O
management	O
of	O
FMF	B-UNK
-	O
including	O
genetic	B-UNK
counseling	I-UNK
and	O
therapeutic	O
decisions	O
in	O
affected	B-UNK
families	B-UNK
.	O

Noninvasive	O
test	B-UNK
for	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
,	O
using	O
hair	B-UNK
root	O
analysis	B-UNK
.	O

Identification	B-UNK
of	O
the	O
FMR1	B-UNK
gene	B-UNK
and	O
the	O
repeat	B-UNK
-	O
amplification	B-UNK
mechanism	B-UNK
causing	B-UNK
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
led	B-UNK
to	O
development	B-UNK
of	O
reliable	O
DNA	B-UNK
-	O
based	B-UNK
diagnostic	B-UNK
methods	O
,	O
including	O
Southern	B-UNK
blot	I-UNK
hybridization	B-UNK
and	O
PCR	B-UNK
.	O

Both	O
methods	O
are	O
performed	O
on	O
DNA	B-UNK
isolated	B-UNK
from	O
peripheral	B-UNK
blood	I-UNK
cells	B-UNK
and	O
measure	O
the	O
repeat	B-UNK
size	B-UNK
in	O
FMR1	B-UNK
.	O

Using	O
an	O
immunocytochemical	O
technique	O
on	O
blood	B-UNK
smears	O
,	O
we	O
recently	O
developed	O
a	O
novel	O
test	B-UNK
for	O
identification	B-UNK
of	O
patients	B-UNK
with	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
.	O

This	O
method	O
,	O
also	O
called	O
"	O
antibody	B-UNK
test	B-UNK
,	O
"	O
uses	O
monoclonal	O
antibodies	B-UNK
against	O
the	O
FMR1	B-UNK
gene	B-UNK
product	I-UNK
(	O
FMRP	B-UNK
)	O
and	O
is	O
based	B-UNK
on	O
absence	B-UNK
of	O
FMRP	B-UNK
in	O
patients	B-UNK
cells	B-UNK
.	O

Here	O
we	O
describe	O
a	O
new	O
diagnostic	B-UNK
test	B-UNK
to	O
identify	B-UNK
male	B-UNK
patients	B-UNK
with	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
,	O
on	O
the	O
basis	B-UNK
of	O
lack	B-UNK
of	O
FMRP	B-UNK
in	O
their	O
hair	B-UNK
roots	O
.	O

Expression	B-UNK
of	O
FMRP	B-UNK
in	O
hair	B-UNK
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
FMRP	B-UNK
-	O
specific	B-UNK
antibody	B-UNK
test	B-UNK
,	O
and	O
the	O
percentage	B-UNK
of	O
FMRP	B-UNK
-	O
expressing	O
hair	B-UNK
roots	O
in	O
controls	O
and	O
in	O
male	B-UNK
fragile	B-UNK
X	O
patients	B-UNK
was	O
determined	B-UNK
.	O

Control	B-UNK
individuals	B-UNK
showed	O
clear	O
expression	B-UNK
of	O
FMRP	B-UNK
in	O
nearly	O
every	O
hair	B-UNK
root	O
,	O
whereas	O
male	B-UNK
fragile	B-UNK
X	O
patients	B-UNK
lacked	O
expression	B-UNK
of	O
FMRP	B-UNK
in	O
almost	O
all	O
their	O
hair	B-UNK
roots	O
.	O

Mentally	O
retarded	O
female	O
patients	B-UNK
with	O
a	O
full	O
mutation	B-UNK
showed	O
FMRP	B-UNK
expression	B-UNK
in	O
only	O
some	O
of	O
their	O
hair	B-UNK
roots	O
(	O
<	O
55	O
%	O
)	O
,	O
and	O
no	O
overlap	O
with	O
normal	B-UNK
female	O
controls	O
was	O
observed	B-UNK
.	O

The	O
advantages	O
of	O
this	O
test	B-UNK
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	B-UNK
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	O
retarded	O
patient	B-UNK
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	B-UNK
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	B-UNK
of	O
the	O
test	B-UNK
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O

In	O
addition	B-UNK
,	O
this	O
test	B-UNK
enabled	O
us	O
to	O
identify	B-UNK
two	O
fragile	B-UNK
X	O
patients	B-UNK
who	O
did	O
not	O
show	O
the	O
full	O
mutation	B-UNK
by	O
analysis	B-UNK
of	O
DNA	B-UNK
isolated	B-UNK
from	O
blood	B-UNK
cells	B-UNK
..	O

In	O
Swedish	O
families	B-UNK
with	O
hereditary	B-UNK
prostate	B-UNK
cancer	I-UNK
,	O
linkage	B-UNK
to	O
the	O
HPC1	O
locus	B-UNK
on	O
chromosome	B-UNK
1q24	O
-	O
25	O
is	O
restricted	O
to	O
families	B-UNK
with	O
early	B-UNK
-	O
onset	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
.	O

Prostate	B-DISEASE
cancer	I-DISEASE
clusters	O
in	O
some	O
families	B-UNK
,	O
and	O
an	O
estimated	B-UNK
5%-10	O
%	O
of	O
all	O
cases	B-UNK
are	O
estimated	B-UNK
to	O
result	B-UNK
from	O
inheritance	B-UNK
of	O
prostate	B-UNK
cancer	I-UNK
-	O
susceptibility	B-UNK
genes	B-UNK
.	O

We	O
previously	B-UNK
reported	I-UNK
evidence	B-UNK
of	O
linkage	B-UNK
to	O
the	O
1q24	O
-	O
25	O
region	B-UNK
(	O
HPC1	O
)	O
in	O
91	O
North	B-UNK
American	B-UNK
and	O
Swedish	O
families	B-UNK
each	O
with	O
multiple	B-UNK
cases	B-UNK
of	O
prostate	B-UNK
cancer	I-UNK
(	O
Smith	O
et	O
al	B-DISEASE
.	O
1996	O
)	O
.	O

In	O
the	O
present	B-UNK
report	B-UNK
we	O
analyze	O
40	O
(	O
12	O
original	O
and	O
28	O
newly	O
identified	B-UNK
)	O
Swedish	O
families	B-UNK
with	O
hereditary	B-UNK
prostate	B-UNK
cancer	I-UNK
(	O
HPC	O
)	O
that	O
,	O
on	O
the	O
basis	B-UNK
of	O
40	O
markers	B-UNK
spanning	O
a	O
25-cM	O
interval	B-UNK
within	O
1q24	O
-	O
25	O
,	O
have	O
evidence	B-UNK
of	O
linkage	B-UNK
.	O

In	O
the	O
complete	O
set	B-UNK
of	O
families	B-UNK
,	O
a	O
maximum	B-UNK
two	O
-	O
point	B-UNK
LOD	B-UNK
score	I-UNK
of	O
1	O
.	O

10	O
was	O
observed	B-UNK
at	O
D1S413	O
(	O
at	O
a	O
recombination	B-UNK
fraction	B-UNK
[	O
theta	B-UNK
]	O
of	O
.	O
1	O
)	O
,	O
with	O
a	O
maximum	B-UNK
NPL	O
(	O
nonparametric	O
linkage	B-UNK
)	O
Z	O
score	B-UNK
of	O
1	O
.	O

64	O
at	O
D1S202	O
(	O
P	O
=	O
.	O
05	O
)	O
.	O

The	O
evidence	B-UNK
of	O
linkage	B-UNK
to	O
this	O
region	B-UNK
originated	O
almost	O
exclusively	O
from	O
the	O
subset	O
of	O
12	O
early	B-UNK
-	O
onset	B-UNK
(	O
age	B-UNK
<	O
65	O
years	O
)	O
families	B-UNK
,	O
which	O
yielded	O
a	O
maximum	B-UNK
LOD	B-UNK
score	I-UNK
of	O
2	O
.	O

38	O
at	O
D1S413	O
(	O
straight	O
theta	B-UNK
=	O
0	O
)	O
and	O
an	O
NPL	O
Z	O
score	B-UNK
of	O
1	O
.	O

95	O
at	O
D1S422	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

Estimates	O
from	O
heterogeneity	B-UNK
tests	O
suggest	B-UNK
that	O
,	O
within	O
Sweden	O
,	O
as	O
many	O
as	O
50	O
%	O
of	O
early	B-UNK
-	O
onset	B-UNK
families	B-UNK
had	O
evidence	B-UNK
of	O
linkage	B-UNK
to	O
the	O
HPC1	O
region	B-UNK
.	O

These	O
results	B-UNK
are	O
consistent	B-UNK
with	O
the	O
hypothesis	B-UNK
of	O
linkage	B-UNK
to	O
HPC1	O
in	O
a	O
subset	O
of	O
families	B-UNK
with	O
prostate	B-DISEASE
cancer	I-DISEASE
,	O
particularly	O
those	O
with	O
an	O
early	B-UNK
age	B-UNK
at	I-UNK
diagnosis	I-UNK
.	O

Molecular	B-UNK
basis	I-UNK
of	O
feline	O
beta-glucuronidase	O
deficiency	B-UNK
:	O
an	O
animal	B-UNK
model	I-UNK
of	O
mucopolysaccharidosis	B-DISEASE
VII	I-DISEASE
.	O

A	O
family	B-UNK
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	B-UNK
and	O
biochemical	O
abnormalities	B-UNK
consistent	B-UNK
with	O
mucopolysaccharidosis	B-DISEASE
VII	I-DISEASE
,	O
an	O
autosomal	B-UNK
recessive	I-UNK
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
beta-glucuronidase	O
deficiency	B-UNK
.	O

beta-Glucuronidase	O
activity	B-UNK
was	O
undetectable	O
in	O
affected	B-UNK
cat	O
fibroblasts	B-UNK
and	O
restored	O
by	O
retroviral	O
gene	B-UNK
transfer	B-UNK
of	O
rat	O
beta-glucuronidase	O
cDNA	O
.	O

beta-Glucuronidase	O
mRNA	O
was	O
normal	B-UNK
in	O
affected	B-UNK
cat	O
testis	O
by	O
Northern	B-UNK
blot	B-UNK
analysis	B-UNK
.	O

Normal	B-UNK
feline	O
beta-glucuronidase	O
cDNA	O
was	O
cloned	O
and	O
characterized	B-UNK
,	O
and	O
amplified	O
from	O
affected	B-UNK
cat	O
fibroblasts	B-UNK
by	O
reverse	B-UNK
transcription	B-UNK
coupled	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
.	O

There	O
was	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-UNK
in	O
the	O
affected	B-UNK
cat	O
cDNA	O
that	O
predicted	B-UNK
an	O
E351	O
K	O
substitution	B-UNK
,	O
destroyed	O
a	O
BssSI	O
site	B-UNK
,	O
and	O
eliminated	O
GUSB	O
enzymatic	B-UNK
activity	I-UNK
in	O
expression	B-UNK
studies	B-UNK
.	O

Multiple	B-UNK
species	B-UNK
comparison	B-UNK
and	O
the	O
crystal	O
structure	B-UNK
of	O
human	B-UNK
beta-glucuronidase	O
indicated	O
that	O
E351	O
is	O
a	O
highly	B-UNK
conserved	I-UNK
residue	O
most	O
likely	O
essential	B-UNK
in	O
maintenance	O
of	O
the	O
enzymes	B-UNK
conformation	B-UNK
.	O

BssSI	O
digestion	O
of	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
products	B-UNK
amplified	O
from	O
genomic	B-UNK
DNA	I-UNK
indicated	O
that	O
affected	B-UNK
cats	O
were	O
homozygous	B-UNK
and	O
cats	O
with	O
half	B-UNK
-	O
normal	B-UNK
beta-glucuronidase	O
activity	B-UNK
were	O
heterozygous	B-UNK
for	O
the	O
missense	B-UNK
mutation	I-UNK
.	O

Carriers	B-UNK
identified	B-UNK
in	O
this	O
manner	O
produced	O
affected	B-UNK
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
MPS	B-UNK
VII	O
breeding	O
colony	O
has	O
been	O
established	O
..	O

A	O
common	B-UNK
molecular	B-UNK
basis	I-UNK
for	O
rearrangement	B-UNK
disorders	B-UNK
on	O
chromosome	B-UNK
22q11	O
.	O

The	O
chromosome	B-UNK
22q11	O
region	B-UNK
is	O
susceptible	O
to	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-UNK
anomaly	B-UNK
disorders	B-UNK
and	O
malignant	B-UNK
tumors	B-UNK
.	O

Three	O
congenital	B-UNK
anomaly	B-UNK
disorders	B-UNK
,	O
cat	O
-	O
eye	B-UNK
syndrome	B-UNK
,	O
der	B-UNK
(	O
)	O
syndrome	B-UNK
and	O
velo	B-DISEASE
-	I-DISEASE
cardio	I-DISEASE
-	I-DISEASE
facial	I-DISEASE
syndrome	I-DISEASE
/	O
DiGeorge	B-DISEASE
syndrome	I-DISEASE
(	O
VCFS	O
/	O
DGS	B-UNK
)	O
are	O
associated	O
with	O
tetrasomy	B-DISEASE
,	O
trisomy	B-DISEASE
or	O
monosomy	B-DISEASE
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	B-UNK
22q11	O
.	O

VCFS	O
/	O
DGS	B-UNK
is	O
the	O
most	O
common	B-UNK
syndrome	B-DISEASE
associated	O
with	O
22q11	O
rearrangements	O
.	O

In	O
order	B-UNK
to	O
determine	B-UNK
whether	O
there	O
are	O
particular	O
regions	B-UNK
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements	O
,	O
the	O
deletion	B-UNK
end	B-UNK
-	O
points	O
in	O
a	O
large	B-UNK
number	B-UNK
of	O
VCFS	O
/	O
DGS	B-UNK
patients	B-UNK
were	O
defined	B-UNK
by	O
haplotype	B-UNK
analysis	I-UNK
.	O

Most	O
VCFS	O
/	O
DGS	B-UNK
patients	B-UNK
have	O
a	O
similar	B-UNK
3	O
Mb	B-UNK
deletion	B-UNK
,	O
some	O
have	O
a	O
nested	O
distal	B-UNK
deletion	B-UNK
breakpoint	O
resulting	B-UNK
in	O
a	O
1	O
.	O

5	O
Mb	B-DISEASE
deletion	B-UNK
and	O
a	O
few	O
rare	B-UNK
patients	B-UNK
have	O
unique	O
deletions	O
or	O
translocations	O
.	O

The	O
high	B-UNK
prevalence	B-UNK
of	O
the	O
disorder	B-UNK
in	O
the	O
population	B-UNK
and	O
the	O
fact	B-UNK
that	O
most	O
cases	B-UNK
occur	B-UNK
sporadically	O
suggest	B-UNK
that	O
sequences	O
at	O
or	O
near	O
the	O
breakpoints	O
confer	O
susceptibility	B-UNK
to	O
chromosome	B-UNK
rearrangements	O
.	O

To	O
investigate	B-UNK
this	O
hypothesis	B-UNK
,	O
we	O
developed	O
hamster	O
-	O
human	B-UNK
somatic	B-UNK
hybrid	O
cell	B-UNK
lines	I-UNK
from	O
VCFS	O
/	O
DGS	B-UNK
patients	B-UNK
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	B-UNK
within	O
similar	B-UNK
low	B-UNK
copy	B-UNK
repeats	B-UNK
,	O
termed	O
LCR22s	O
.	O

To	O
support	O
this	O
idea	O
further	O
,	O
we	O
identified	B-UNK
a	O
family	B-UNK
that	O
carries	O
an	O
interstitial	O
duplication	B-UNK
of	O
the	O
same	O
3	O
Mb	B-UNK
region	B-UNK
that	O
is	O
deleted	B-UNK
in	O
VCFS	O
/	O
DGS	B-UNK
patients	B-UNK
.	O

We	O
present	B-UNK
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	B-UNK
recombination	B-UNK
events	O
,	O
thereby	O
generating	O
a	O
number	B-UNK
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-UNK
anomaly	B-UNK
disorders	B-UNK
.	O

We	O
identified	B-UNK
five	O
additional	O
copies	O
of	O
the	O
LCR22	O
on	O
22q11	O
that	O
may	O
mediate	O
other	O
rearrangements	O
leading	B-UNK
to	O
disease	B-UNK
.	O

Functional	O
consequences	O
of	O
mutations	B-UNK
in	O
the	O
early	B-UNK
growth	B-UNK
response	B-UNK
2	O
gene	B-UNK
(	O
EGR2	O
)	O
correlate	O
with	O
severity	B-UNK
of	O
human	B-UNK
myelinopathies	O
.	O

The	O
early	B-UNK
growth	B-UNK
response	B-UNK
2	O
gene	B-UNK
(	O
EGR2	O
)	O
is	O
a	O
Cys2His2zinc	O
finger	B-UNK
transcription	B-UNK
factor	I-UNK
which	O
is	O
thought	B-UNK
to	O
play	O
a	O
role	B-UNK
in	O
the	O
regulation	B-UNK
of	O
peripheral	B-UNK
nervous	O
system	O
myelination	O
.	O

This	O
idea	O
is	O
based	B-UNK
partly	O
on	O
the	O
phenotype	B-UNK
of	O
homozygous	B-UNK
Krox20	O
(	O
Egr2	O
)	O
knockout	B-UNK
mice	B-UNK
,	O
which	O
display	O
hypomyelination	O
of	O
the	O
PNS	O
and	O
a	O
block	O
of	O
Schwann	O
cells	B-UNK
at	O
an	O
early	B-UNK
stage	B-UNK
of	O
differentiation	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
human	B-UNK
EGR2	O
gene	B-UNK
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B-UNK
peripheral	B-UNK
neuropathies	B-DISEASE
Charcot	O
-	O
Marie	O
-	O
Tooth	O
type	B-UNK
1	O
,	O
Dejerine	O
-	O
Sottas	O
syndrome	B-UNK
and	O
congenital	B-UNK
hypomyelinating	O
neuropathy	B-DISEASE
.	O

Three	O
of	O
the	O
four	O
EGR2	O
mutations	B-UNK
are	O
dominant	B-UNK
and	O
occur	B-UNK
within	O
the	O
zinc	B-UNK
finger	I-UNK
DNA	B-UNK
-	O
binding	B-UNK
domain	I-UNK
.	O

The	O
fourth	B-UNK
mutation	B-UNK
is	O
recessive	B-UNK
and	O
affects	O
the	O
inhibitory	O
domain	B-UNK
(	O
R1	O
)	O
that	O
binds	O
the	O
NAB	O
transcriptional	O
co-repressors	O
.	O

A	O
combination	B-UNK
of	O
DNA	B-UNK
-	O
binding	B-UNK
assays	O
and	O
transcriptional	O
analysis	B-UNK
was	O
used	O
to	O
determine	B-UNK
the	O
functional	O
consequences	O
of	O
these	O
mutations	B-UNK
.	O

The	O
zinc	B-UNK
finger	I-UNK
mutations	B-UNK
affect	O
DNA	B-UNK
binding	I-UNK
and	O
the	O
amount	O
of	O
residual	B-UNK
binding	B-UNK
directly	O
correlates	O
with	O
disease	B-UNK
severity	B-UNK
.	O

The	O
R1	O
domain	B-UNK
mutation	B-UNK
prevents	O
interaction	O
of	O
EGR2	O
with	O
the	O
NAB	O
co-repressors	O
and	O
thereby	O
increases	O
transcriptional	O
activity	B-UNK
.	O

These	O
data	B-UNK
provide	B-UNK
insight	O
into	O
the	O
possible	O
disease	B-UNK
mechanisms	O
underlying	O
EGR2	O
mutations	B-UNK
and	O
the	O
reason	O
for	O
varying	O
severity	B-UNK
and	O
differences	B-UNK
in	O
inheritance	B-UNK
patterns	B-UNK
..	O

Autosomal	B-UNK
recessive	I-UNK
familial	B-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
with	O
continued	O
secretion	O
of	O
mutant	B-UNK
weakly	O
active	B-UNK
vasopressin	O
.	O

Familial	B-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
post-natal	O
development	B-UNK
of	O
arginine	O
vasopressin	O
(	O
AVP	B-UNK
)	O
deficiency	B-UNK
due	O
to	O
mutations	B-UNK
in	O
the	O
AVP	B-UNK
gene	B-UNK
.	O

All	O
published	O
mutations	B-UNK
affect	O
the	O
signal	B-UNK
peptide	B-UNK
or	O
the	O
neurophysin	O
-	O
II	B-UNK
carrier	B-UNK
protein	B-UNK
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	B-UNK
to	O
neuronal	B-DISEASE
damage	I-DISEASE
.	O

We	O
studied	O
an	O
unusual	O
Palestinian	O
family	B-UNK
consisting	O
of	O
asymptomatic	B-UNK
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	B-UNK
with	O
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
,	O
suggesting	O
autosomal	B-UNK
recessive	I-UNK
inheritance	B-UNK
.	O

All	O
three	O
affected	B-UNK
children	O
were	O
homozygous	B-UNK
and	O
the	O
parents	O
heterozygous	B-UNK
for	O
a	O
single	B-UNK
novel	O
mutation	B-UNK
(	O
C301-	O
>	O
T	O
)	O
in	O
exon	B-UNK
1	O
,	O
replacing	O
Pro7	O
of	O
mature	O
AVP	B-UNK
with	O
Leu	B-UNK
(	O
Leu	B-UNK
-	O
AVP	B-UNK
)	O
.	O

Leu	B-UNK
-	O
AVP	B-UNK
was	O
a	O
weak	O
agonist	O
with	O
approximately	O
30-fold	O
reduced	O
binding	B-UNK
to	O
the	O
human	B-UNK
V2	O
receptor	B-UNK
.	O

Measured	O
by	O
radioimmunoassay	O
with	O
a	O
synthetic	O
Leu	B-UNK
-	O
AVP	B-UNK
standard	O
,	O
serum	B-UNK
Leu	B-UNK
-	O
AVP	B-UNK
levels	B-UNK
were	O
elevated	B-UNK
in	O
all	O
three	O
children	O
and	O
further	O
increased	B-UNK
during	O
water	O
deprivation	O
to	O
as	O
high	B-UNK
as	O
30	O
times	O
normal	B-UNK
.	O

The	O
youngest	O
child	B-UNK
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	B-UNK
but	O
had	O
Leu	B-UNK
-	O
AVP	B-UNK
levels	B-UNK
similar	B-UNK
to	O
her	O
severely	O
affected	B-UNK
8-year	O
-	O
old	O
brother	B-UNK
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B-UNK
of	O
active	B-UNK
AVP	B-UNK
in	O
very	O
young	B-UNK
children	O
..	O

X	O
inactivation	B-UNK
and	O
somatic	B-UNK
cell	I-UNK
selection	B-UNK
rescue	O
female	O
mice	B-UNK
carrying	I-UNK
a	O
Piga	O
-	O
null	O
mutation	B-UNK
.	O

A	O
somatic	B-UNK
mutation	B-UNK
in	O
the	O
X	O
linked	B-UNK
PIGA	O
gene	B-UNK
is	O
responsible	B-UNK
for	O
the	O
deficiency	B-UNK
of	O
glycosyl	O
phosphatidylinositol	O
(	O
GPI)-anchored	O
proteins	B-UNK
on	O
blood	B-UNK
cells	B-UNK
from	O
patients	B-UNK
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	B-DISEASE
.	O

No	O
inherited	B-UNK
form	B-UNK
of	O
GPI	O
-	O
anchor	O
deficiency	B-UNK
has	O
been	O
described	O
.	O

Because	O
conventional	O
Piga	O
gene	B-UNK
knockout	B-UNK
is	O
associated	O
with	O
high	B-UNK
embryonic	B-UNK
lethality	O
in	O
chimeric	O
mice	B-UNK
,	O
we	O
used	O
the	O
Cre	O
/	O
loxP	O
system	O
.	O

We	O
generated	O
mice	B-UNK
in	O
which	O
two	O
loxP	O
sites	O
flank	O
part	O
of	O
Piga	O
exon	B-UNK
2	O
.	O

After	O
crossbreeding	O
with	O
female	O
mice	B-UNK
of	O
the	O
EIIa	O
-	O
cre	O
strain	O
,	O
the	O
floxed	O
allele	B-UNK
undergoes	O
Cre	O
-	O
mediated	O
recombination	B-UNK
with	O
high	B-UNK
efficiency	O
during	O
early	B-UNK
embryonic	B-UNK
development	B-UNK
.	O

Because	O
of	O
X	O
chromosome	B-UNK
inactivation	B-UNK
,	O
female	O
offspring	O
are	O
mosaic	O
for	O
cells	B-UNK
that	O
express	O
or	O
lack	B-UNK
GPI	O
-	O
linked	B-UNK
proteins	B-UNK
.	O

Analysis	B-UNK
of	O
mosaic	O
mice	B-UNK
showed	O
that	O
in	O
heart	B-UNK
,	O
lung	O
,	O
kidney	B-UNK
,	O
brain	B-UNK
,	O
and	O
liver	B-UNK
,	O
mainly	O
wild	B-UNK
-	O
type	B-UNK
Piga	O
is	O
active	B-UNK
,	O
suggesting	O
that	O
these	O
tissues	O
require	O
GPI	O
-	O
linked	B-UNK
proteins	B-UNK
.	O

The	O
salient	O
exceptions	O
were	O
spleen	O
,	O
thymus	O
,	O
and	O
red	B-UNK
blood	B-UNK
cells	B-UNK
,	O
which	O
had	O
almost	O
equal	O
numbers	O
of	O
cells	B-UNK
expressing	O
the	O
wild	B-UNK
-	O
type	B-UNK
or	O
the	O
recombined	O
allele	B-UNK
,	O
implying	O
that	O
GPI	O
-	O
linked	B-UNK
proteins	B-UNK
are	O
not	O
essential	B-UNK
for	O
the	O
derivation	O
of	O
these	O
tissues	O
.	O

PIGA	O
(	O
-	O
)	O
cells	B-UNK
had	O
no	O
growth	B-UNK
advantage	B-UNK
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	B-UNK
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	B-DISEASE
..	O

The	O
C282Y	B-UNK
mutation	B-UNK
causing	I-UNK
hereditary	B-UNK
hemochromatosis	I-UNK
does	O
not	O
produce	B-UNK
a	O
null	O
allele	B-UNK
.	O

Targeted	B-UNK
mutagenesis	O
was	O
used	O
to	O
produce	B-UNK
two	O
mutations	B-UNK
in	O
the	O
murine	O
hemochromatosis	B-DISEASE
gene	B-UNK
(	O
Hfe	B-UNK
)	O
locus	B-UNK
.	O

The	O
first	O
mutation	B-UNK
deletes	O
a	O
large	B-UNK
portion	B-UNK
of	O
the	O
coding	B-UNK
sequence	I-UNK
,	O
generating	O
a	O
null	O
allele	B-UNK
.	O

The	O
second	O
mutation	B-UNK
introduces	O
a	O
missense	B-UNK
mutation	I-UNK
(	O
C282Y	B-UNK
)	O
into	O
the	O
Hfe	B-UNK
locus	B-UNK
,	O
but	O
otherwise	O
leaves	O
the	O
gene	B-UNK
intact	O
.	O

This	O
mutation	B-UNK
is	O
identical	B-UNK
to	O
the	O
disease	B-UNK
-	O
causing	B-UNK
mutation	B-UNK
in	O
patients	B-UNK
with	O
hereditary	B-UNK
hemochromatosis	I-UNK
.	O

Mice	B-UNK
carrying	I-UNK
each	O
of	O
the	O
two	O
mutations	B-UNK
were	O
bred	O
and	O
analyzed	B-UNK
.	O

Homozygosity	B-UNK
for	O
either	O
mutation	B-UNK
results	B-UNK
in	O
postnatal	O
iron	B-UNK
loading	O
.	O

The	O
effects	B-UNK
of	O
the	O
null	O
mutation	B-UNK
are	O
more	O
severe	B-UNK
than	O
the	O
effects	B-UNK
of	O
the	O
C282Y	B-UNK
mutation	B-UNK
.	O

Mice	B-UNK
heterozygous	B-UNK
for	O
either	O
mutation	B-UNK
accumulate	O
more	O
iron	B-UNK
than	O
normal	B-UNK
controls	O
.	O

Interestingly	B-UNK
,	O
although	O
liver	B-UNK
iron	B-UNK
stores	O
are	O
greatly	O
increased	B-UNK
,	O
splenic	O
iron	B-UNK
is	O
decreased	B-UNK
.	O

We	O
conclude	O
that	O
the	O
C282Y	B-UNK
mutation	B-UNK
does	O
not	O
result	B-UNK
in	O
a	O
null	O
allele	B-UNK
..	O

Genotype	B-UNK
-	O
phenotype	B-UNK
analysis	B-UNK
in	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
and	O
identification	B-UNK
of	O
a	O
missense	B-UNK
mutation	I-UNK
associated	O
with	O
a	O
milder	B-UNK
phenotype	B-UNK
.	O

Direct	B-UNK
sequencing	I-UNK
of	O
the	O
emerin	O
gene	B-UNK
in	O
22	O
families	B-UNK
with	O
Emery	O
-	O
Dreifuss	O
muscular	B-DISEASE
dystrophy	I-DISEASE
(	O
EMD	O
)	O
revealed	B-UNK
mutations	B-UNK
in	O
21	O
(	O
95	O
%	O
)	O
,	O
confirming	O
that	O
emerin	O
mutations	B-UNK
can	O
be	O
identified	B-UNK
in	O
the	O
majority	O
of	O
families	B-UNK
with	O
X	O
-	O
linked	B-UNK
EMD	O
.	O

Most	O
emerin	O
mutations	B-UNK
result	B-UNK
in	O
absence	B-UNK
of	O
the	O
protein	B-UNK
.	O

In	O
this	O
study	B-UNK
three	O
mutations	B-UNK
(	O
a	O
missense	B-UNK
mutation	I-UNK
Pro183Thr	O
and	O
two	O
in	O
-	O
frame	B-UNK
deletions	O
removing	O
residues	O
95	O
-	O
99	O
and	O
236	O
-	O
241	O
,	O
respectively	O
)	O
were	O
unusual	O
in	O
being	O
associated	O
with	O
expression	B-UNK
of	O
mutant	B-UNK
protein	B-UNK
.	O

The	O
phenotype	B-UNK
in	O
these	O
families	B-UNK
was	O
compared	B-UNK
in	O
detail	O
with	O
the	O
clinical	B-UNK
features	I-UNK
in	O
cases	B-UNK
with	O
typical	O
null	O
mutations	B-UNK
.	O

For	O
the	O
in	O
-	O
frame	B-UNK
deletions	O
there	O
were	O
no	O
significant	B-UNK
differences	B-UNK
.	O

In	O
the	O
family	B-UNK
with	O
the	O
missense	B-UNK
mutation	I-UNK
the	O
phenotype	B-UNK
was	O
milder	B-UNK
.	O

Age	B-UNK
at	O
onset	B-UNK
was	O
later	O
for	O
first	O
symptoms	B-UNK
and	O
for	O
development	B-UNK
of	O
ankle	O
contractures	B-DISEASE
and	O
muscle	B-DISEASE
weakness	I-DISEASE
.	O

These	O
findings	B-UNK
have	O
diagnostic	B-UNK
implications	B-UNK
as	O
well	O
as	O
pointing	O
to	O
functionally	O
important	O
regions	B-UNK
of	O
the	O
emerin	O
protein	B-UNK
..	O

Severe	B-UNK
clinical	B-UNK
expression	B-UNK
in	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
.	O

X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
(	O
EDMD	B-UNK
)	O
is	O
a	O
relatively	O
rare	B-UNK
benign	O
neuromuscular	O
disorder	B-UNK
which	O
can	O
vary	O
remarkably	O
in	O
onset	B-UNK
,	O
course	O
and	O
severity	B-UNK
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
a	O
TCTAC	O
deletion	B-UNK
spanning	O
the	O
nucleotides	O
631	O
-	O
635	O
of	O
the	O
emerin	O
gene	B-UNK
caused	B-UNK
an	O
unusually	O
severe	B-UNK
disease	B-UNK
phenotype	B-UNK
including	O
loss	B-UNK
of	O
ambulation	O
and	O
severe	B-UNK
muscle	B-UNK
wasting	O
in	O
two	O
affected	B-UNK
brothers	O
.	O

The	O
same	O
mutation	B-UNK
has	O
been	O
reported	B-UNK
previously	B-UNK
in	O
an	O
unrelated	B-UNK
family	B-UNK
showing	O
a	O
significantly	O
milder	B-UNK
phenotype	B-UNK
.	O

The	O
interfamilial	O
heterogeneity	B-UNK
in	O
distribution	B-UNK
and	O
in	O
severity	B-UNK
of	O
the	O
features	B-UNK
in	O
the	O
two	O
families	B-UNK
point	B-UNK
to	O
environmental	O
or	O
genetic	B-UNK
modification	O
as	O
the	O
cause	O
of	O
clinical	B-UNK
variability	B-UNK
in	O
Emery	O
-	O
Dreifuss	O
muscular	B-UNK
dystrophy	I-UNK
..	O

Common	B-UNK
mutations	B-UNK
in	O
BRCA1	B-UNK
and	I-UNK
BRCA2	I-UNK
do	O
not	O
contribute	B-UNK
to	O
early	B-UNK
prostate	B-UNK
cancer	I-UNK
in	O
Jewish	B-UNK
men	B-UNK
.	O

BACKGROUND	O
Families	B-UNK
with	O
a	O
high	B-UNK
incidence	B-UNK
of	O
hereditary	B-UNK
breast	I-UNK
cancer	B-UNK
,	O
and	O
subsequently	B-UNK
shown	B-UNK
to	O
have	O
terminating	O
mutations	B-UNK
in	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	B-UNK
of	O
prostate	B-DISEASE
cancer	I-DISEASE
among	O
male	B-UNK
relatives	B-UNK
.	O

We	O
aimed	O
to	O
determine	B-UNK
whether	O
the	O
common	B-UNK
germline	B-UNK
mutations	I-UNK
of	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
in	O
Ashkenazi	B-UNK
Jewish	I-UNK
men	B-UNK
predisposed	O
them	O
to	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O

METHODS	O
We	O
examined	O
genomic	B-UNK
DNA	I-UNK
from	O
83	O
(	O
for	O
BRCA1	B-UNK
185delAG	O
)	O
or	O
82	O
(	O
for	O
BRCA2	B-UNK
6174delT	O
)	O
Ashkenazi	B-UNK
Jewish	I-UNK
prostate	B-DISEASE
cancer	I-DISEASE
patients	B-UNK
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	B-UNK
age	B-UNK
,	O
for	O
the	O
most	O
common	B-UNK
germline	B-UNK
mutation	I-UNK
in	O
each	O
gene	B-UNK
seen	O
in	O
the	O
Ashkenazi	B-UNK
population	B-UNK
.	O

RESULTS	B-UNK
Our	O
study	B-UNK
should	O
have	O
been	O
able	O
to	O
detect	B-UNK
a	O
4	O
-	O
5-fold	O
increase	B-UNK
in	O
the	O
risk	B-UNK
of	O
prostate	B-UNK
cancer	I-UNK
due	O
to	O
mutation	B-UNK
of	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
.	O

However	O
,	O
only	O
one	O
(	O
1	O
.	O
15	O
%	O
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
0	O
-	O
3	O
.	O
6	O
%	O
)	O
of	O
the	O
patients	B-UNK
was	O
heterozygous	B-UNK
for	O
the	O
BRCA1	B-UNK
mutant	B-UNK
allele	B-UNK
,	O
and	O
only	O
two	O
were	O
heterozygous	B-UNK
for	O
the	O
BRCA2	B-UNK
mutation	B-UNK
(	O
2	O
.	O
4	O
%	O
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
0	O
-	O
6	O
.	O
2	O
%	O
)	O
.	O

CONCLUSIONS	B-UNK
The	O
incidence	B-UNK
of	O
each	O
of	O
the	O
germline	B-UNK
mutations	I-UNK
in	O
these	O
prostate	B-UNK
cancer	I-UNK
patients	B-UNK
closely	B-UNK
matched	O
their	O
incidence	B-UNK
(	O
about	O
1	O
%	O
)	O
in	O
the	O
general	B-UNK
Ashkenazi	B-UNK
Jewish	I-UNK
population	B-UNK
.	O

This	O
suggests	O
that	O
unlike	O
cases	B-UNK
of	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
,	O
mutations	B-UNK
in	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
do	O
not	O
significantly	O
predispose	O
men	B-UNK
to	O
prostate	B-UNK
cancer	I-UNK

Beta-catenin	O
accumulation	B-UNK
and	O
mutation	B-UNK
of	O
the	O
CTNNB1	O
gene	B-UNK
in	O
hepatoblastoma	B-DISEASE
.	O

Hepatoblastoma	B-DISEASE
is	O
a	O
rare	B-UNK
malignant	B-DISEASE
tumor	I-DISEASE
of	O
the	O
liver	B-UNK
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	B-UNK
of	O
2	O
to	O
3	O
years	O
.	O

Epidemiologic	O
studies	B-UNK
have	O
shown	B-UNK
an	O
increased	B-UNK
frequency	B-UNK
of	O
this	O
tumor	B-UNK
type	B-UNK
in	O
families	B-UNK
affected	B-UNK
by	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
.	O

In	O
addition	B-UNK
to	O
the	O
epidemiologic	O
data	B-UNK
,	O
molecular	B-UNK
genetic	I-UNK
studies	B-UNK
suggest	B-UNK
that	O
inactivation	B-UNK
of	O
the	O
APC	B-UNK
tumor	B-UNK
suppressor	I-UNK
may	O
be	O
involved	B-UNK
in	O
hepatoblastoma	B-DISEASE
tumorigenesis	O
.	O

A	O
major	B-UNK
function	B-UNK
of	O
APC	B-UNK
is	O
the	O
downregulation	O
of	O
beta-catenin	O
,	O
a	O
transcription	B-UNK
-	O
activating	O
protein	B-UNK
with	O
oncogenic	O
potential	B-UNK
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	B-UNK
of	O
beta-catenin	O
expression	B-UNK
in	O
sporadic	B-UNK
cases	B-UNK
of	O
tumor	B-DISEASE
types	B-UNK
that	O
are	O
associated	O
with	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
,	O
we	O
observed	B-UNK
increased	B-UNK
beta-catenin	O
levels	B-UNK
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	O
.	O

Sequencing	B-UNK
of	O
exon	B-UNK
3	O
of	O
the	O
beta-catenin	O
gene	B-UNK
(	O
CTNNB1	O
)	O
revealed	B-UNK
an	O
activating	O
mutation	B-UNK
in	O
one	O
of	O
the	O
tumor	B-UNK
samples	B-UNK
.	O

Our	O
data	B-UNK
indicate	O
for	O
the	O
first	O
time	O
that	O
beta-catenin	O
accumulation	B-UNK
may	O
play	O
a	O
role	B-UNK
in	O
the	O
development	B-UNK
of	O
hepatoblastoma	B-DISEASE
and	O
that	O
activating	O
mutations	B-UNK
of	O
the	O
beta-catenin	O
gene	B-UNK
may	O
substitute	O
biallelic	O
APC	B-UNK
inactivation	B-UNK
in	O
this	O
tumor	B-DISEASE
type	B-UNK
.	O

Genes	B-UNK
Chromosomes	O
Cancer	B-UNK
25	O
399	O
-	O
402	O
,	O
1999	O
..	O

Decrease	O
in	O
GTP	O
cyclohydrolase	O
I	O
gene	B-UNK
expression	I-UNK
caused	B-UNK
by	O
inactivation	B-UNK
of	O
one	O
allele	B-UNK
in	O
hereditary	B-UNK
progressive	B-UNK
dystonia	B-UNK
with	O
marked	B-UNK
diurnal	O
fluctuation	O
.	O

Hereditary	B-UNK
progressive	B-UNK
dystonia	B-DISEASE
with	O
marked	B-UNK
diurnal	O
fluctuation	O
(	O
HPD	O
;	O
dopa	O
-	O
responsive	O
dystonia	B-UNK
,	O
DRD	O
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	B-UNK
by	O
a	O
genetic	B-UNK
defect	B-UNK
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(	O
GCH1	O
)	O
gene	B-UNK
.	O

In	O
this	O
study	B-UNK
,	O
we	O
quantified	O
the	O
mRNA	O
level	B-UNK
of	O
GCH1	O
in	O
phytohemagglutinin	O
(	O
PHA)-stimulated	O
mononuclear	O
blood	B-UNK
cells	B-UNK
from	O
one	O
Japanese	B-UNK
family	B-UNK
that	O
do	O
not	O
have	O
a	O
mutation	B-UNK
in	O
the	O
coding	B-UNK
region	I-UNK
or	O
splice	B-UNK
junctions	O
of	O
the	O
gene	B-UNK
.	O

The	O
results	B-UNK
showed	O
that	O
the	O
amounts	B-UNK
of	O
the	O
GCH1	O
mRNA	O
were	O
decreased	B-UNK
to	O
about	O
40	O
%	O
of	O
the	O
normal	B-UNK
level	B-UNK
in	O
both	O
patients	B-UNK
and	O
carriers	B-UNK
.	O

In	O
addition	B-UNK
,	O
we	O
found	O
that	O
the	O
GCH1	O
mRNA	O
was	O
transcribed	O
from	O
only	O
one	O
allele	B-UNK
,	O
indicating	O
that	O
the	O
other	O
allele	B-UNK
was	O
in	O
an	O
inactive	O
state	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
some	O
novel	O
mutations	B-UNK
should	O
exist	O
on	O
one	O
of	O
the	O
alleles	B-UNK
in	O
some	O
unknown	O
region	B-UNK
of	O
the	O
GCH1	O
gene	B-UNK
,	O
and	O
may	O
decrease	O
the	O
GCH1	O
mRNA	O
causing	B-UNK
the	O
HPD	O
/	O
DRD	O
symptoms	B-UNK
..	O

Sulfate	B-UNK
transport	B-UNK
is	O
not	O
impaired	B-UNK
in	O
pendred	B-UNK
syndrome	I-UNK
thyrocytes	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
syndromic	O
deafness	B-DISEASE
,	O
characterized	B-UNK
by	O
dyshormonogenic	O
goiter	B-DISEASE
associated	O
with	O
sensory	O
-	O
neural	O
deafness	B-DISEASE
.	O

The	O
gene	B-UNK
responsible	B-UNK
for	O
the	O
disease	B-DISEASE
(	O
PDS	B-UNK
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	B-UNK
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	O
goiter	B-DISEASE
and	O
sensory	O
-	O
neural	O
deafness	B-DISEASE
remains	O
an	O
enigma	O
.	O

PDS	B-UNK
codes	O
for	O
a	O
novel	O
protein	B-UNK
,	O
pendrin	B-UNK
,	O
which	O
is	O
closely	B-UNK
related	B-UNK
to	O
a	O
number	B-UNK
of	O
sufate	O
transporters	O
.	O

Mechanisms	O
by	O
which	O
abnormal	O
sulfate	B-UNK
transport	B-UNK
could	O
deleteriously	O
affect	O
iodide	B-UNK
organification	O
have	O
been	O
proposed	O
.	O

We	O
tested	O
sulfate	B-UNK
transport	B-UNK
in	O
thyrocytes	O
obtained	B-UNK
from	O
Pendred	B-DISEASE
syndrome	I-DISEASE
patients	B-UNK
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

This	O
suggests	O
that	O
pendrin	B-UNK
in	O
fact	B-UNK
may	O
not	O
be	O
a	O
sulfate	B-UNK
transporter	I-UNK
,	O
and	O
emphasizes	O
the	O
importance	O
of	O
functional	O
studies	B-UNK
on	O
this	O
novel	O
protein	B-UNK
..	O

Small	O
deletions	O
in	O
the	O
type	B-UNK
II	I-UNK
collagen	O
triple	O
helix	O
produce	B-UNK
kniest	B-DISEASE
dysplasia	I-DISEASE
.	O

Kniest	B-DISEASE
dysplasia	I-DISEASE
is	O
a	O
moderately	O
severe	B-UNK
type	B-UNK
II	I-UNK
collagenopathy	O
,	O
characterized	B-UNK
by	O
short	B-UNK
trunk	O
and	O
limbs	O
,	O
kyphoscoliosis	O
,	O
midface	O
hypoplasia	B-UNK
,	O
severe	B-UNK
myopia	B-DISEASE
,	O
and	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Mutations	B-UNK
in	O
the	O
gene	B-UNK
that	O
encodes	B-UNK
type	B-UNK
II	I-UNK
collagen	O
(	O
COL2A1	O
)	O
,	O
the	O
predominant	O
protein	B-UNK
of	O
cartilage	O
,	O
have	O
been	O
identified	B-UNK
in	O
a	O
number	B-UNK
of	O
individuals	B-UNK
with	O
Kniest	B-UNK
dysplasia	I-UNK
.	O

All	O
but	O
two	O
of	O
these	O
previously	B-UNK
described	O
mutations	B-UNK
cause	O
in	O
-	O
frame	B-UNK
deletions	O
in	O
type	B-UNK
II	I-UNK
collagen	O
,	O
either	O
by	O
small	O
deletions	O
in	O
the	O
gene	B-UNK
or	O
splice	B-UNK
site	I-UNK
alterations	B-UNK
.	O

Furthermore	O
,	O
all	O
but	O
one	O
of	O
these	O
mutations	B-UNK
is	O
located	B-UNK
between	O
exons	O
12	O
and	O
24	O
in	O
the	O
COL2A1	O
gene	B-UNK
.	O

We	O
used	O
heteroduplex	B-UNK
analysis	I-UNK
to	O
identify	B-UNK
sequence	B-UNK
anomalies	B-UNK
in	O
five	O
individuals	B-UNK
with	O
Kniest	B-UNK
dysplasia	I-UNK
.	O

Sequencing	B-UNK
of	O
the	O
index	O
patients	B-UNK
genomic	B-UNK
DNA	I-UNK
identified	B-UNK
four	O
new	O
dominant	B-UNK
mutations	B-UNK
in	O
COL2A1	O
that	O
result	B-UNK
in	O
Kniest	B-DISEASE
dysplasia	I-DISEASE
a	O
21-bp	O
deletion	B-UNK
in	O
exon	B-UNK
16	O
,	O
an	O
18-bp	O
deletion	B-UNK
in	O
exon	B-UNK
19	O
,	O
and	O
4-bp	O
deletions	O
in	O
the	O
splice	B-UNK
donor	I-UNK
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O

A	O
previously	B-UNK
described	O
28-bp	O
deletion	B-UNK
at	O
the	O
COL2A1	O
exon	B-UNK
12-intron	O
12	O
junction	O
,	O
deleting	O
the	O
splice	B-UNK
donor	I-UNK
site	I-UNK
,	O
was	O
identified	B-UNK
in	O
the	O
fifth	O
case	B-UNK
.	O

The	O
latter	O
three	O
mutations	B-UNK
are	O
predicted	B-UNK
to	O
result	B-UNK
in	O
exon	B-UNK
skipping	O
in	O
the	O
mRNA	O
encoded	B-UNK
from	O
the	O
mutant	B-UNK
allele	B-UNK
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
Kniest	B-UNK
dysplasia	I-UNK
results	B-UNK
from	O
shorter	O
type	B-UNK
II	I-UNK
collagen	O
monomers	O
,	O
and	O
support	O
the	O
hypothesis	B-UNK
that	O
alteration	O
of	O
a	O
specific	B-UNK
COL2A1	O
domain	B-UNK
,	O
which	O
may	O
span	O
from	O
exons	O
12	O
to	O
24	O
,	O
leads	B-UNK
to	O
the	O
Kniest	B-UNK
dysplasia	I-UNK
phenotype	B-UNK
..	O

Classical	O
galactosemia	O
and	O
mutations	B-UNK
at	O
the	O
galactose-1-phosphate	O
uridyl	O
transferase	O
(	O
GALT	B-UNK
)	O
gene	B-UNK
.	O

Classical	O
galactosemia	O
is	O
caused	B-UNK
by	O
a	O
deficiency	B-UNK
in	O
activity	B-UNK
of	O
the	O
enzyme	B-UNK
galactose-1-phosphate	O
uridyl	O
transferase	O
(	O
GALT	B-UNK
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
at	O
the	O
GALT	B-UNK
gene	B-UNK
.	O

The	O
disorder	B-UNK
exhibits	O
considerable	B-UNK
allelic	O
heterogeneity	B-UNK
and	O
,	O
at	O
the	O
end	B-UNK
of	O
1998	O
,	O
more	O
than	O
150	O
different	O
base	B-UNK
changes	O
were	O
recorded	O
in	O
24	O
different	O
populations	O
and	O
ethnic	B-UNK
groups	I-UNK
in	O
15	O
countries	B-UNK
worldwide	O
.	O

The	O
mutations	B-UNK
most	O
frequently	O
cited	O
are	O
Q188R	B-UNK
,	O
K285N	O
,	O
S135L	B-UNK
,	O
and	O
N314D.	O

Q188R	B-UNK
is	O
the	O
most	O
common	B-UNK
mutation	B-UNK
in	O
European	B-UNK
populations	O
or	O
in	O
those	O
predominantly	O
of	O
European	B-UNK
descent	O
.	O

Overall	O
,	O
it	O
accounts	O
for	O
60	O
-	O
70	O
%	O
of	O
mutant	B-UNK
chromosomes	O
,	O
but	O
there	O
are	O
significant	B-UNK
differences	B-UNK
in	O
its	O
relative	B-UNK
frequency	B-UNK
in	O
individual	O
populations	O
.	O

Individuals	B-UNK
homoallelic	O
for	O
Q188R	B-UNK
tend	O
to	O
have	O
a	O
severe	B-UNK
phenotype	I-UNK
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
virtually	O
complete	O
loss	B-UNK
of	O
enzyme	B-UNK
activity	I-UNK
observed	B-UNK
in	O
in	O
vitro	O
expression	B-UNK
systems	O
.	O

Globally	O
,	O
K285N	O
is	O
rarer	O
,	O
but	O
in	O
many	O
European	B-UNK
populations	O
it	O
can	O
be	O
found	O
on	O
25	O
-	O
40	O
%	O
of	O
mutant	B-UNK
chromosomes	O
.	O

It	O
is	O
invariably	O
associated	O
with	O
a	O
severe	B-UNK
phenotype	I-UNK
.	O

S135L	B-UNK
is	O
found	O
almost	O
exclusively	O
in	O
African	B-UNK
Americans	O
.	O

In	O
vitro	O
expression	B-UNK
results	B-UNK
are	O
discrepant	O
,	O
but	O
some	O
individuals	B-UNK
carrying	B-UNK
S135L	B-UNK
appear	O
to	O
exhibit	O
GALT	B-UNK
activity	B-UNK
in	O
some	O
tissues	O
.	O

Duarte	B-UNK
1	O
(	O
or	O
Los	O
Angeles	O
)	O
and	O
Duarte	B-UNK
2	O
(	O
or	O
Duarte	B-UNK
)	O
variants	B-UNK
carry	B-UNK
the	O
same	O
amino	B-UNK
acid	I-UNK
substitution	I-UNK
,	O
N314D	B-UNK
,	O
even	O
though	O
D1	O
is	O
associated	O
with	O
increased	B-UNK
erythrocyte	B-UNK
GALT	B-UNK
activity	B-UNK
and	O
D2	B-UNK
with	O
reduced	O
activity	B-UNK
.	O

N314D	B-UNK
is	O
in	O
linkage	B-UNK
disequilibrium	I-UNK
with	O
other	O
base	B-UNK
changes	O
that	O
differ	O
on	O
the	O
D1	O
and	O
D2	B-UNK
alleles	B-UNK
.	O

N314D	B-UNK
does	O
not	O
impair	O
GALT	B-UNK
activity	B-UNK
in	O
in	O
vitro	O
expression	B-UNK
systems	O
.	O

However	O
,	O
there	O
are	O
differences	B-UNK
in	O
the	O
abundance	O
of	O
GALT	B-UNK
protein	B-UNK
in	O
lymphoblastoid	O
cells	B-UNK
lines	B-UNK
from	O
D2	B-UNK
and	O
D1	O
individuals	B-UNK
.	O

It	O
is	O
unclear	O
whether	O
the	O
specific	B-UNK
molecular	B-UNK
changes	O
that	O
distinguish	O
the	O
D1	O
and	O
D2	B-UNK
alleles	B-UNK
account	B-UNK
for	O
the	O
different	O
activities	O
.	O

The	O
considerable	B-UNK
genetic	B-UNK
heterogeneity	I-UNK
documented	O
to	O
date	B-UNK
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	B-UNK
heterogeneity	B-UNK
that	O
is	O
observed	B-UNK
in	O
galactosemia	O
.	O

The	O
additional	O
effects	B-UNK
of	O
nonallelic	O
variation	B-UNK
and	O
other	O
constitutional	B-UNK
factors	O
on	O
phenotypic	B-UNK
variability	B-UNK
remain	O
to	O
be	O
elucidated	O
..	O

Mutations	B-UNK
of	O
the	O
VHL	B-UNK
gene	B-UNK
in	O
sporadic	B-UNK
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
:	O
definition	O
of	O
a	O
risk	B-UNK
factor	B-UNK
for	O
VHL	B-UNK
patients	B-UNK
to	O
develop	O
an	O
RCC	B-UNK
.	O

To	O
investigate	B-UNK
the	O
nature	B-UNK
of	O
somatic	B-UNK
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
mutations	B-UNK
,	O
we	O
analyzed	B-UNK
173	O
primary	B-UNK
sporadic	B-UNK
human	B-UNK
renal	B-UNK
cell	I-UNK
carcinomas	I-UNK
for	O
mutations	B-UNK
of	O
the	O
VHL	B-UNK
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
,	O
using	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
and	O
single	B-UNK
-	O
strand	B-UNK
conformational	B-UNK
polymorphism	B-UNK
analysis	B-UNK
(	O
SSCP	B-UNK
)	O
of	O
DNA	B-UNK
.	O

We	O
detected	B-UNK
abnormal	O
SSCP	B-UNK
pattern	B-UNK
in	O
73	O
samples	B-UNK
.	O

After	O
sequencing	B-UNK
,	O
we	O
identified	B-UNK
microdeletions	O
in	O
58	O
%	O
of	O
cases	B-UNK
,	O
microinsertions	O
in	O
17	O
%	O
,	O
nonsense	B-UNK
mutations	I-UNK
in	O
8	O
%	O
,	O
and	O
missense	B-UNK
mutations	I-UNK
in	O
17	O
%	O
.	O

Among	O
these	O
mutations	B-UNK
,	O
50	O
%	O
correspond	O
to	O
new	O
mutations	B-UNK
.	O

VHL	B-UNK
mutations	B-UNK
were	O
found	O
only	O
in	O
the	O
nonpapillary	O
renal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
(	O
RCC	B-UNK
)	O
subtype	O
,	O
as	O
previously	B-UNK
reported	I-UNK
.	O

To	O
compare	O
somatic	B-UNK
and	O
germline	B-UNK
mutations	I-UNK
,	O
we	O
used	O
the	O
VHL	B-UNK
database	O
,	O
which	O
includes	O
507	O
mutations	B-UNK
.	O

The	O
study	B-UNK
of	O
mutational	O
events	O
revealed	B-UNK
a	O
significant	B-UNK
difference	O
between	O
somatic	B-UNK
and	O
germline	B-UNK
mutations	I-UNK
with	O
mutations	B-UNK
leading	B-UNK
to	O
truncated	O
proteins	B-UNK
observed	B-UNK
in	O
78	O
%	O
of	O
somatic	B-UNK
mutations	I-UNK
vs	O
only	O
37	O
%	O
in	O
germline	B-UNK
mutations	I-UNK
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
postulated	O
that	O
a	O
specific	B-UNK
pattern	B-UNK
of	O
VHL	B-UNK
mutations	B-UNK
is	O
associated	O
with	O
sporadic	B-UNK
RCC	B-UNK
.	O

This	O
pattern	B-UNK
corresponds	O
to	O
mutations	B-UNK
leading	B-UNK
mainly	O
to	O
truncated	O
proteins	B-UNK
with	O
few	O
specific	B-UNK
missense	B-UNK
mutations	I-UNK
.	O

We	O
then	O
analyzed	B-UNK
the	O
occurrence	B-UNK
of	O
RCC	B-UNK
in	O
VHL	B-UNK
families	B-UNK
,	O
based	B-UNK
on	O
the	O
nature	B-UNK
of	O
mutations	B-UNK
.	O

We	O
observed	B-UNK
RCC	B-UNK
in	O
at	O
least	O
one	O
member	B-UNK
of	O
the	O
VHL	B-UNK
families	B-UNK
in	O
77	O
%	O
of	O
cases	B-UNK
with	O
mutations	B-UNK
leading	B-UNK
to	O
truncated	O
proteins	B-UNK
versus	O
55	O
%	O
in	O
cases	B-UNK
with	O
missense	B-UNK
mutations	I-UNK
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Thus	O
,	O
mutations	B-UNK
resulting	B-UNK
in	O
truncated	O
proteins	B-UNK
may	O
lead	B-UNK
to	O
a	O
higher	O
risk	B-UNK
of	O
RCC	B-UNK
in	O
VHL	B-UNK
patients	B-UNK

Defective	O
CTLA-4	O
cycling	O
pathway	B-UNK
in	O
Chediak	B-DISEASE
-	I-DISEASE
Higashi	I-DISEASE
syndrome	I-DISEASE
:	O
a	O
possible	O
mechanism	B-UNK
for	O
deregulation	O
of	O
T	O
lymphocyte	B-UNK
activation	O
.	O

Cytotoxic	O
T	O
lymphocyte	B-UNK
-	O
associated	O
antigen	O
4	O
(	O
CTLA-4	O
,	O
also	O
known	O
as	O
CD152	O
)	O
has	O
been	O
shown	B-UNK
to	O
play	O
a	O
major	B-UNK
role	B-UNK
in	O
the	O
regulation	B-UNK
of	O
T	O
cell	B-UNK
activation	O
.	O

Its	O
membrane	B-UNK
expression	B-UNK
is	O
highly	B-UNK
regulated	O
by	O
endocytosis	O
and	O
trafficking	O
through	O
the	O
secretory	O
lysosome	O
pathway	B-UNK
.	O

Chediak	B-DISEASE
-	I-DISEASE
Higashi	I-DISEASE
syndrome	I-DISEASE
(	O
CHS	O
)	O
is	O
an	O
inherited	B-UNK
disorder	B-UNK
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
lysosomal	B-UNK
trafficking	O
regulator	O
gene	B-UNK
,	O
LYST	O
.	O

It	O
results	B-UNK
in	O
defective	O
membrane	B-UNK
targeting	B-UNK
of	O
the	O
proteins	B-UNK
present	B-UNK
in	O
secretory	O
lysosomes	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
variety	O
of	O
features	B-UNK
,	O
including	O
a	O
lymphoproliferative	B-UNK
syndrome	B-UNK
with	O
hemophagocytosis	O
.	O

The	O
murine	O
equivalent	O
of	O
CHS	O
,	O
beige	O
mice	B-UNK
,	O
present	B-UNK
similar	B-UNK
characteristics	B-UNK
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B-UNK
syndrome	B-DISEASE
.	O

We	O
show	O
herein	O
that	O
CTLA-4	O
is	O
present	B-UNK
in	O
enlarged	O
,	O
abnormal	O
vesicles	O
in	O
CHS	O
T	O
cells	B-UNK
and	O
is	O
not	O
properly	O
expressed	B-UNK
at	O
the	O
cell	B-UNK
surface	O
after	O
T	O
cell	B-UNK
activation	O
,	O
whereas	O
its	O
surface	O
expression	B-UNK
is	O
not	O
impaired	B-UNK
.	O

It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	B-UNK
of	O
CTLA-4	O
by	O
CHS	O
T	O
cells	B-UNK
is	O
involved	B-UNK
in	O
the	O
generation	O
of	O
lymphoproliferative	B-UNK
disease	B-UNK
.	O

This	O
observation	O
may	O
provide	B-UNK
insight	O
into	O
the	O
role	B-UNK
of	O
CTLA-4	O
in	O
humans	B-UNK
..	O

Proteolipoprotein	O
gene	B-UNK
analysis	B-UNK
in	O
82	O
patients	B-UNK
with	O
sporadic	B-UNK
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
Disease	I-DISEASE
:	O
duplications	O
,	O
the	O
major	B-UNK
cause	O
of	O
the	O
disease	B-UNK
,	O
originate	O
more	O
frequently	O
in	O
male	B-UNK
germ	B-UNK
cells	B-UNK
,	O
but	O
point	B-UNK
mutations	I-UNK
do	O
not	O
.	O

The	O
Clinical	B-UNK
European	B-UNK
Network	O
on	O
Brain	B-UNK
Dysmyelinating	O
Disease	B-UNK
.	O

Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
Disease	I-DISEASE
(	O
PMD	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
developmental	O
defect	B-UNK
of	O
myelination	O
affecting	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
PLP	B-UNK
)	O
locus	B-UNK
.	O

Investigating	O
82	O
strictly	O
selected	O
sporadic	B-UNK
cases	B-UNK
of	O
PMD	B-UNK
,	O
we	O
found	O
PLP	B-UNK
mutations	B-UNK
in	O
77	O
%	O
;	O
complete	O
PLP	B-UNK
-	O
gene	B-UNK
duplications	O
were	O
the	O
most	O
frequent	B-UNK
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	B-UNK
mutations	I-UNK
in	O
coding	B-UNK
or	O
splice	B-UNK
-	O
site	B-UNK
regions	B-UNK
of	O
the	O
gene	B-UNK
were	O
involved	B-UNK
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O

We	O
analyzed	B-UNK
the	O
maternal	O
status	B-UNK
of	O
56	O
cases	B-UNK
to	O
determine	B-UNK
the	O
origin	O
of	O
both	O
types	B-UNK
of	O
PLP	B-UNK
mutation	B-UNK
,	O
since	O
this	O
is	O
relevant	O
to	O
genetic	B-UNK
counseling	I-UNK
.	O

In	O
the	O
22	O
point	B-UNK
mutations	I-UNK
,	O
68	O
%	O
of	O
mothers	O
were	O
heterozygous	B-UNK
for	O
the	O
mutation	B-UNK
,	O
a	O
value	O
identical	B-UNK
to	O
the	O
two	O
-	O
thirds	O
of	O
carrier	B-UNK
mothers	O
that	O
would	O
be	O
expected	O
if	O
there	O
were	O
an	O
equal	O
mutation	B-UNK
rate	B-UNK
in	O
male	B-UNK
and	O
female	O
germ	B-UNK
cells	B-UNK
.	O

In	O
sharp	O
contrast	B-UNK
,	O
among	O
the	O
34	O
duplicated	O
cases	B-UNK
,	O
91	O
%	O
of	O
mothers	O
were	O
carriers	B-UNK
,	O
a	O
value	O
significantly	O
(	O
chi2	O
=	O
9	O
.	O
20	O
,	O
P	O
<	O
.	O
01	O
)	O
in	O
favor	O
of	O
a	O
male	B-UNK
bias	O
,	O
with	O
an	O
estimation	O
of	O
the	O
male	B-UNK
/	O
female	O
mutation	B-UNK
frequency	B-UNK
(	O
k	O
)	O
of	O
9	O
.	O

3	O
3	O
.	O

Moreover	O
,	O
we	O
observed	B-UNK
the	O
occurrence	B-UNK
of	O
de	O
novo	O
mutations	B-UNK
between	O
parental	O
and	O
grandparental	O
generations	O
in	O
17	O
three	O
-	O
generation	O
families	B-UNK
,	O
which	O
allowed	O
a	O
direct	B-UNK
estimation	O
of	O
the	O
k	O
value	O
(	O
k	O
=	O
11	O
)	O
.	O

Again	O
,	O
a	O
significant	B-UNK
male	B-UNK
mutation	B-UNK
imbalance	O
was	O
observed	B-UNK
only	O
for	O
the	O
duplications	O
.	O

Chromosome	B-DISEASE
breakage	I-DISEASE
in	O
the	O
Prader	O
-	O
Willi	O
and	O
Angelman	B-UNK
syndromes	O
involves	O
recombination	B-UNK
between	O
large	B-UNK
,	O
transcribed	O
repeats	B-UNK
at	O
proximal	B-UNK
and	O
distal	B-UNK
breakpoints	O
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
and	O
Angelman	B-DISEASE
syndrome	I-DISEASE
(	O
AS	O
)	O
are	O
distinct	O
neurobehavioral	O
disorders	B-UNK
that	O
most	O
often	O
arise	O
from	O
a	O
4-Mb	O
deletion	B-UNK
of	O
chromosome	B-UNK
15q11-q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O

At	O
a	O
de	O
novo	O
frequency	B-UNK
of	O
approximately	O
.	O

67	O
-	O
1/10	O
,	O
000	O
births	O
,	O
these	O
deletions	O
represent	O
a	O
common	B-UNK
structural	B-UNK
chromosome	B-UNK
change	B-UNK
in	O
the	O
human	B-UNK
genome	B-UNK
.	O

To	O
elucidate	O
the	O
mechanism	B-UNK
underlying	O
these	O
events	O
,	O
we	O
characterized	B-UNK
the	O
regions	B-UNK
that	O
contain	O
two	O
proximal	B-UNK
breakpoint	O
clusters	O
and	O
a	O
distal	B-UNK
cluster	B-UNK
.	O

Novel	O
DNA	B-UNK
sequences	O
potentially	O
associated	O
with	O
the	O
breakpoints	O
were	O
positionally	O
cloned	O
from	O
YACs	O
within	O
or	O
near	O
these	O
regions	B-UNK
.	O

Analyses	O
of	O
rodent	O
-	O
human	B-UNK
somatic	B-UNK
-	O
cell	B-UNK
hybrids	B-UNK
,	O
YAC	B-UNK
contigs	O
,	O
and	O
FISH	B-UNK
of	O
normal	B-UNK
or	O
rearranged	O
chromosomes	O
15	O
identified	B-UNK
duplicated	O
sequences	O
(	O
the	O
END	B-UNK
repeats	B-UNK
)	O
at	O
or	O
near	O
the	O
breakpoints	O
.	O

The	O
END	B-UNK
-	O
repeat	B-UNK
units	O
are	O
derived	B-UNK
from	O
large	B-UNK
genomic	B-UNK
duplications	O
of	O
a	O
novel	O
gene	B-UNK
(	O
HERC2	O
)	O
,	O
many	O
copies	O
of	O
which	O
are	O
transcriptionally	O
active	B-UNK
in	O
germline	B-UNK
tissues	O
.	O

One	O
of	O
five	O
PWS	B-UNK
/	O
AS	O
patients	B-UNK
analyzed	B-UNK
to	O
date	B-UNK
has	O
an	O
identifiable	O
,	O
rearranged	O
HERC2	O
transcript	B-UNK
derived	B-UNK
from	O
the	O
deletion	B-UNK
event	O
.	O

We	O
postulate	O
that	O
the	O
END	B-UNK
repeats	B-UNK
flanking	O
15q11-q13	O
mediate	O
homologous	B-UNK
recombination	B-UNK
resulting	B-UNK
in	O
deletion	B-UNK
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
active	B-UNK
transcription	B-UNK
of	O
these	O
repeats	B-UNK
in	O
male	B-UNK
and	O
female	O
germ	B-UNK
cells	B-UNK
may	O
facilitate	O
the	O
homologous	B-UNK
recombination	B-UNK
process	B-UNK
.	O

Linkage	B-UNK
analysis	I-UNK
in	O
a	O
large	B-UNK
Brazilian	O
family	B-UNK
with	O
van	B-DISEASE
der	I-DISEASE
Woude	I-DISEASE
syndrome	I-DISEASE
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	B-UNK
locus	B-UNK
for	O
cleft	B-DISEASE
palate	I-DISEASE
at	O
17p11	O
.	O
2	O
-	O
11	O
.	O
1	O
.	O

van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
(	O
VWS	B-UNK
)	O
,	O
which	O
has	O
been	O
mapped	B-UNK
to	O
1q32	O
-	O
41	O
,	O
is	O
characterized	B-UNK
by	O
pits	O
and	O
/	O
or	O
sinuses	O
of	O
the	O
lower	O
lip	B-UNK
,	O
cleft	B-DISEASE
lip	I-DISEASE
/	O
palate	B-UNK
(	O
CL	O
/	O
P	O
)	O
,	O
cleft	B-DISEASE
palate	I-DISEASE
(	O
CP	B-DISEASE
)	O
,	O
bifid	O
uvula	O
,	O
and	O
hypodontia	O
(	O
H	O
)	O
.	O

The	O
expression	B-UNK
of	O
VWS	B-UNK
,	O
which	O
has	O
incomplete	O
penetrance	O
,	O
is	O
highly	B-UNK
variable	B-UNK
.	O

Both	O
the	O
occurrence	B-UNK
of	O
CL	O
/	O
P	O
and	O
CP	B-DISEASE
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	B-DISEASE
risk	B-UNK
<	O
40	O
%	O
for	O
CP	B-DISEASE
among	O
descendants	O
with	O
VWS	B-UNK
have	O
suggested	O
that	O
the	O
development	B-UNK
of	O
clefts	O
in	O
this	O
syndrome	B-UNK
is	O
influenced	O
by	O
modifying	O
genes	B-UNK
at	O
other	O
loci	O
.	O

To	O
test	B-UNK
this	O
hypothesis	B-UNK
,	O
we	O
have	O
conducted	O
linkage	B-UNK
analysis	I-UNK
in	O
a	O
large	B-UNK
Brazilian	O
kindred	O
with	O
VWS	B-UNK
,	O
considering	O
as	O
affected	B-UNK
the	O
individuals	B-UNK
with	O
CP	B-DISEASE
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	B-UNK
signs	B-UNK
of	O
VWS	B-UNK
.	O

Our	O
results	B-UNK
suggest	B-UNK
that	O
a	O
gene	B-UNK
at	O
17p11	O
.	O

2	O
-	O
11	O
2	O
-	O
11	O
.	O

1	O
,	O
together	O
with	O
the	O
VWS	B-UNK
gene	B-UNK
at	O
1p32	O
-	O
41	O
,	O
enhances	O
the	O
probability	B-UNK
of	O
CP	B-UNK
in	O
an	O
individual	O
carrying	B-UNK
the	O
two	O
at	O
-	O
risk	B-UNK
genes	B-UNK
.	O

If	O
this	O
hypothesis	B-UNK
is	O
confirmed	B-UNK
in	O
other	O
VWS	B-UNK
pedigrees	O
,	O
it	O
will	O
represent	O
one	O
of	O
the	O
first	O
examples	O
of	O
a	O
gene	B-UNK
,	O
mapped	B-UNK
through	O
linkage	B-UNK
analysis	I-UNK
,	O
which	O
modifies	O
the	O
expression	B-UNK
of	O
a	O
major	B-UNK
gene	B-UNK
.	O

New	O
mutations	B-UNK
,	O
polymorphisms	B-UNK
,	O
and	O
rare	B-UNK
variants	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
detected	B-UNK
by	O
a	O
novel	O
SSCP	B-UNK
strategy	O
.	O

The	O
gene	B-UNK
for	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
,	O
ATM	B-UNK
,	O
spans	O
about	O
150	O
kb	B-UNK
of	O
genomic	B-UNK
DNA	I-UNK
.	O

ATM	B-UNK
mutations	B-UNK
are	O
found	O
along	O
the	O
entire	O
gene	B-UNK
,	O
with	O
no	O
evidence	B-UNK
of	O
a	O
mutational	O
hot	O
spot	O
.	O

Using	O
DNA	B-UNK
as	O
the	O
starting	O
material	O
,	O
we	O
screened	B-UNK
the	O
ATM	B-UNK
gene	B-UNK
in	O
92	O
A	O
-T	O
patients	B-UNK
,	O
using	O
an	O
optimized	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
technique	O
that	O
detected	B-UNK
all	O
previously	B-UNK
known	O
mutations	B-UNK
in	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
segments	O
being	O
analyzed	B-UNK
.	O

To	O
expedite	O
screening	B-UNK
,	O
we	O
sequentially	O
loaded	O
the	O
SSCP	B-UNK
gels	O
with	O
three	O
different	O
sets	O
of	O
PCR	B-UNK
products	I-UNK
that	O
were	O
pretested	O
to	O
avoid	O
overlapping	O
patterns	B-UNK
.	O

Many	O
of	O
the	O
DNA	B-UNK
changes	O
we	O
detected	B-UNK
were	O
intragenic	O
polymorphisms	B-UNK
.	O

Of	O
an	O
expected	O
177	O
unknown	O
mutations	B-UNK
,	O
we	O
detected	B-UNK
approximately	O
70	O
%	O
,	O
mostly	O
protein	B-UNK
truncating	B-UNK
mutations	I-UNK
(	O
that	O
would	O
have	O
been	O
detectable	O
by	O
protein	B-UNK
truncation	I-UNK
testing	B-UNK
if	O
RNA	B-UNK
starting	O
material	O
had	O
been	O
available	O
)	O
.	O

Mutations	B-UNK
have	O
now	O
been	O
defined	B-UNK
for	O
every	O
exon	B-UNK
of	O
the	O
ATM	B-UNK
gene	B-UNK
.	O

Herein	O
,	O
we	O
present	B-UNK
35	O
new	O
mutations	B-UNK
and	O
34	O
new	O
intragenic	O
polymorphisms	B-UNK
or	O
rare	B-UNK
variants	B-UNK
within	O
the	O
ATM	B-UNK
gene	B-UNK
.	O

This	O
is	O
the	O
most	O
comprehensive	O
compilation	O
of	O
ATM	B-UNK
polymorphisms	B-UNK
assembled	O
to	O
date	B-UNK
.	O

Defining	O
polymorphic	B-UNK
sites	O
as	O
well	O
as	O
mutations	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
will	O
be	O
of	O
great	O
importance	O
in	O
designing	O
automated	O
methods	O
for	O
detecting	O
mutations	B-UNK
..	O

A	O
novel	O
frameshift	B-UNK
mutation	I-UNK
in	O
the	O
McLeod	O
syndrome	B-UNK
gene	B-UNK
in	O
a	O
Japanese	B-UNK
family	B-UNK
.	O

We	O
report	B-UNK
a	O
novel	O
mutation	B-UNK
in	O
the	O
XK	O
gene	B-UNK
(	O
XK	O
)	O
in	O
a	O
Japanese	B-UNK
patient	B-UNK
with	O
McLeod	O
syndrome	B-DISEASE
.	O

A	O
50-year	O
-	O
old	O
man	B-UNK
showed	O
progressive	B-UNK
muscular	B-DISEASE
atrophy	I-DISEASE
,	O
choreic	O
movement	O
,	O
elevated	B-UNK
level	B-UNK
of	O
serum	B-UNK
creatinine	O
kinase	B-UNK
,	O
and	O
acanthocytosis	O
.	O

The	O
expression	B-UNK
level	B-UNK
of	O
all	O
the	O
Kell	O
antigens	O
in	O
erythrocyte	B-UNK
was	O
decreased	B-UNK
and	O
molecular	B-UNK
analysis	I-UNK
revealed	B-UNK
a	O
single	B-UNK
-	O
base	B-UNK
(	O
T	O
)	O
deletion	B-UNK
at	O
the	O
nucleotide	B-UNK
position	I-UNK
1095	O
in	O
XK	O
.	O

This	O
deletion	B-UNK
caused	B-UNK
a	O
frameshift	B-UNK
in	O
translation	O
,	O
leading	B-UNK
to	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
at	O
the	O
amino	B-UNK
acid	I-UNK
position	B-UNK
408	O
.	O

We	O
conclude	O
this	O
single	B-UNK
-	O
base	B-UNK
deletion	B-UNK
causes	O
defective	O
Kx	O
protein	B-UNK
,	O
which	O
is	O
responsible	B-UNK
for	O
the	O
McLeod	O
phenotype	B-UNK
in	O
this	O
patient	B-UNK
..	O

Association	B-UNK
of	O
BRCA1	B-UNK
with	O
the	O
hRad50-hMre11-p95	O
complex	O
and	O
the	O
DNA	B-UNK
damage	I-UNK
response	B-UNK
.	O

BRCA1	B-UNK
encodes	B-UNK
a	O
tumor	B-UNK
suppressor	I-UNK
that	O
is	O
mutated	B-UNK
in	O
familial	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
.	O

Here	O
,	O
it	O
is	O
shown	B-UNK
that	O
BRCA1	B-UNK
interacts	O
in	O
vitro	O
and	O
in	O
vivo	B-UNK
with	O
hRad50	O
,	O
which	O
forms	B-UNK
a	O
complex	O
with	O
hMre11	B-UNK
and	O
p95	O
/	O
nibrin	O
.	O

Upon	O
irradiation	O
,	O
BRCA1	B-UNK
was	O
detected	B-UNK
in	O
discrete	O
foci	O
in	O
the	O
nucleus	O
,	O
which	O
colocalize	O
with	O
hRad50	O
.	O

Formation	B-UNK
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	B-UNK
,	O
hRad50	O
,	O
hMre11	B-UNK
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC/1937	O
breast	B-UNK
cancer	I-UNK
cells	B-UNK
carrying	B-UNK
a	O
homozygous	B-UNK
mutation	B-UNK
in	O
BRCA1	B-UNK
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	B-UNK
-	O
type	B-UNK
BRCA1	B-UNK
.	O

Ectopic	O
expression	B-UNK
of	O
wild	B-UNK
-	O
type	B-UNK
,	O
but	O
not	O
mutated	B-UNK
,	O
BRCA1	B-UNK
in	O
these	O
cells	B-UNK
rendered	O
them	O
less	O
sensitive	B-UNK
to	O
the	O
DNA	B-UNK
damage	I-UNK
agent	O
,	O
methyl	O
methanesulfonate	O
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
BRCA1	B-UNK
is	O
important	O
for	O
the	O
cellular	O
responses	B-UNK
to	O
DNA	B-UNK
damage	I-UNK
that	O
are	O
mediated	O
by	O
the	O
hRad50-hMre11-p95	O
complex	O
..	O

Relationship	B-UNK
among	O
genotype	B-UNK
,	O
biochemical	O
phenotype	B-UNK
,	O
and	O
cognitive	B-UNK
performance	O
in	O
females	O
with	O
phenylalanine	B-UNK
hydroxylase	I-UNK
deficiency	B-UNK
:	O
report	B-UNK
from	O
the	O
Maternal	O
Phenylketonuria	O
Collaborative	O
Study	B-UNK
.	O

OBJECTIVE	B-UNK
To	O
examine	O
the	O
relationship	B-UNK
of	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
genotypes	O
to	O
biochemical	O
phenotype	B-UNK
and	O
cognitive	B-UNK
development	B-UNK
in	O
maternal	O
phenylketonuria	O
(	O
PKU	B-UNK
)	O
.	O

METHODOLOGY	O
PAH	B-UNK
gene	B-UNK
mutations	B-UNK
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	O
females	O
enrolled	O
in	O
the	O
Maternal	O
PKU	B-UNK
Collaborative	O
Study	B-UNK
(	O
MPKUCS	O
)	O
.	O

A	O
total	B-UNK
of	O
84	O
different	O
mutations	B-UNK
were	O
detected	B-UNK
,	O
and	O
complete	O
genotype	B-UNK
was	O
obtained	B-UNK
in	O
199	O
individuals	B-UNK
.	O

Based	B-UNK
on	O
previous	B-UNK
knowledge	B-UNK
about	O
mutation	B-UNK
-	O
phenotype	B-UNK
associations	O
,	O
78	O
of	O
the	O
mutations	B-UNK
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	B-UNK
(	O
severe	B-UNK
PKU	B-UNK
,	O
moderate	B-UNK
PKU	B-UNK
,	O
mild	O
PKU	B-UNK
,	O
and	O
mild	O
hyperphenylalaninemia	O
[	O
MHP	O
]	O
)	O
.	O

Then	O
,	O
189	O
MPKUCS	O
subjects	B-UNK
were	O
grouped	O
according	O
to	O
the	O
various	O
combinations	O
of	O
mutation	B-UNK
classifications	O
.	O

The	O
sample	O
sizes	O
were	O
large	B-UNK
enough	O
for	O
statistical	O
testing	B-UNK
in	O
four	O
groups	B-UNK
with	O
at	O
least	O
one	O
mutation	B-UNK
that	O
completely	O
abolishes	O
enzyme	B-UNK
activity	I-UNK
.	O

These	O
patients	B-UNK
are	O
considered	O
functionally	O
hemizygous	B-UNK
.	O

RESULTS	B-UNK
The	O
biochemical	O
phenotype	B-UNK
predicted	B-UNK
from	O
the	O
genotype	B-UNK
in	O
functionally	O
hemizygous	B-UNK
patients	B-UNK
was	O
related	B-UNK
significantly	O
to	O
the	O
assigned	O
phenylalanine	B-UNK
level	B-UNK
.	O

Cognitive	B-UNK
performance	O
(	O
IQ	B-UNK
)	O
was	O
also	O
significantly	O
related	B-UNK
to	O
genotype	B-UNK
.	O

The	O
IQ	B-UNK
of	O
PAH	B-UNK
-	O
deficient	B-UNK
mothers	O
with	O
a	O
severe	B-UNK
PKU	B-UNK
mutation	B-UNK
in	O
combination	B-UNK
with	O
a	O
MHP	O
mutation	B-UNK
or	O
a	O
mild	O
PKU	B-UNK
mutation	B-UNK
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
IQ	B-UNK
of	O
PKU	B-UNK
mothers	O
with	O
two	O
severe	B-UNK
PKU	B-UNK
mutations	B-UNK
or	O
with	O
one	O
severe	B-UNK
and	O
one	O
moderate	B-UNK
PKU	B-UNK
mutation	B-UNK
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O

Of	O
the	O
patients	B-UNK
with	O
PKU	B-UNK
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O

Those	O
who	O
were	O
untreated	O
or	O
treated	O
late	B-UNK
had	O
lower	O
than	O
average	O
IQ	B-UNK
scores	B-UNK
for	O
their	O
group	B-UNK
of	O
mutation	B-UNK
combinations	O
.	O

Females	O
with	O
moderate	B-UNK
or	O
mild	O
PKU	B-UNK
who	O
were	O
treated	O
early	B-UNK
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
IQ	B-UNK
scores	B-UNK
10	O
points	O
above	O
average	O
for	O
their	O
group	B-UNK
.	O

CONCLUSIONS	B-UNK
The	O
reproductive	O
outcome	O
in	O
maternal	O
phenylketonuria	O
is	O
dependent	B-UNK
on	O
prenatal	B-UNK
metabolic	B-UNK
control	B-UNK
and	O
postnatal	O
environmental	O
circumstances	O
.	O

Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	B-UNK
.	O

The	O
significant	B-UNK
relationship	B-UNK
among	O
genotype	B-UNK
,	O
biochemical	O
phenotype	B-UNK
,	O
and	O
cognitive	B-UNK
performance	O
observed	B-UNK
in	O
the	O
present	B-UNK
study	B-UNK
is	O
of	O
importance	O
for	O
the	O
development	B-UNK
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	B-UNK
who	O
plan	O
pregnancy	O
..	O

Spinal	B-UNK
xanthomatosis	B-DISEASE
:	O
a	O
variant	O
of	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
.	O

We	O
describe	O
seven	O
Dutch	B-UNK
patients	B-UNK
from	O
six	O
families	B-UNK
with	O
a	O
slowly	O
progressive	B-UNK
,	O
mainly	O
spinal	B-UNK
cord	O
syndrome	B-UNK
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	B-UNK
of	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
)	O
.	O

MRI	B-UNK
demonstrated	O
white	B-DISEASE
matter	I-DISEASE
abnormalities	I-DISEASE
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	B-UNK
cord	O
.	O

Post-mortem	O
examination	B-UNK
of	O
one	O
of	O
the	O
patients	B-UNK
showed	O
extensive	B-UNK
myelin	B-UNK
loss	B-UNK
in	O
these	O
columns	O
.	O

An	O
array	O
of	O
genotypes	O
was	O
found	O
in	O
these	O
patients	B-UNK
.	O

We	O
conclude	O
that	O
spinal	B-UNK
xanthomatosis	B-DISEASE
is	O
a	O
clinical	B-UNK
and	O
radiological	O
separate	O
entity	O
of	O
CTX	B-UNK
that	O
should	O
be	O
included	O
in	O
the	O
differential	B-UNK
diagnosis	B-UNK
of	O
chronic	B-UNK
myelopathy	B-DISEASE
..	O

A	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	B-DISEASE
deletion	I-DISEASE
mouse	B-UNK
model	I-UNK
of	O
Prader	O
-	O
Willi	O
and	O
angelman	B-UNK
syndromes	O
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
and	O
Angelman	B-DISEASE
syndrome	I-DISEASE
(	O
AS	O
)	O
result	B-UNK
from	O
the	O
loss	B-UNK
of	O
function	B-UNK
of	O
imprinted	O
genes	B-UNK
in	O
human	B-UNK
chromosome	I-UNK
15q11-q13	O
.	O

The	O
central	B-UNK
part	O
of	O
mouse	B-UNK
chromosome	I-UNK
7	O
is	O
homologous	B-UNK
to	O
human	B-UNK
15q11-q13	O
,	O
with	O
conservation	B-UNK
of	O
both	O
gene	B-UNK
order	B-UNK
and	O
imprinted	O
features	B-UNK
.	O

We	O
report	B-UNK
here	O
the	O
characterization	B-UNK
of	O
a	O
transgene	O
insertion	O
(	O
Epstein	O
-	O
Barr	O
virus	O
Latent	O
Membrane	B-UNK
Protein	I-UNK
2A	O
,	O
LMP2A	O
)	O
into	O
mouse	B-UNK
chromosome	I-UNK
7C	O
,	O
which	O
has	O
resulted	B-UNK
in	O
mouse	B-UNK
models	O
for	O
PWS	B-UNK
and	O
AS	O
dependent	B-UNK
on	O
the	O
sex	B-UNK
of	O
the	O
transmitting	O
parent	O
.	O

Epigenotype	O
(	O
allelic	O
expression	B-UNK
and	O
DNA	B-UNK
methylation	B-UNK
)	O
and	O
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
analyses	O
indicate	O
that	O
the	O
transgene	O
-	O
induced	O
mutation	B-UNK
has	O
generated	O
a	O
complete	O
deletion	B-UNK
of	O
the	O
PWS	B-UNK
/	O
AS	O
-	O
homologous	B-UNK
region	B-UNK
but	O
has	O
not	O
deleted	B-UNK
flanking	O
loci	O
.	O

Because	O
the	O
intact	O
chromosome	B-UNK
7	O
,	O
opposite	O
the	O
deleted	B-UNK
homolog	O
,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	B-UNK
cells	B-UNK
of	O
PWS	B-UNK
and	O
AS	O
mice	B-UNK
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	B-UNK
and	O
female	O
germ	B-UNK
cells	B-UNK
of	O
AS	O
mice	B-UNK
,	O
homologous	B-UNK
association	B-UNK
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	B-UNK
mechanism	B-UNK
.	O

This	O
heritable	O
-	O
deletion	B-UNK
mouse	B-UNK
model	I-UNK
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	B-UNK
of	O
the	O
etiological	O
genes	B-UNK
and	O
mechanisms	O
,	O
phenotypic	B-UNK
basis	B-UNK
,	O
and	O
investigation	B-UNK
of	O
therapeutic	O
approaches	O
for	O
PWS	B-UNK
..	O

Linkage	B-UNK
analysis	I-UNK
of	O
5	O
novel	O
van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
kindreds	O
to	O
1q32-q41	O
markers	B-UNK
further	O
supports	O
locus	B-UNK
homogeneity	O
of	O
the	O
disease	B-UNK
trait	O
.	O

van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
(	O
vWS	B-UNK
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	B-UNK
autosomal	B-UNK
dominant	I-UNK
clefting	O
condition	B-UNK
with	O
cardinal	O
features	B-UNK
of	O
mucous	O
cysts	B-DISEASE
(	O
lower	O
-	O
lip	B-UNK
pits	O
)	O
and	O
clefts	O
to	O
the	O
lip	B-UNK
and	O
/	O
or	O
palate	B-UNK
.	O

The	O
vWS	B-UNK
gene	B-UNK
has	O
been	O
assigned	O
to	O
a	O
locus	B-UNK
in	O
1q32-q41	O
by	O
linkage	B-UNK
analysis	I-UNK
and	O
physical	B-UNK
mapping	B-UNK
.	O

We	O
have	O
investigated	O
5	O
novel	O
vWS	B-UNK
families	B-UNK
through	O
probands	O
attended	O
for	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
/	O
or	O
palate	B-UNK
repair	B-UNK
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	B-UNK
to	O
tentatively	O
refine	O
the	O
genetic	B-UNK
map	B-UNK
of	O
the	O
vWS	B-UNK
region	B-UNK
in	O
1q32-q41	O
and	O
possibly	O
identify	B-UNK
unlinked	O
pedigrees	O
.	O

Linkage	B-UNK
analysis	I-UNK
was	O
carried	O
out	O
to	O
6	O
microsatellite	B-UNK
markers	I-UNK
(	O
D1S249	O
,	O
D1S425	O
,	O
D1S491	O
,	O
D1S205	O
,	O
D1S414	O
,	O
D1S425	O
)	O
,	O
yielding	O
a	O
maximum	B-UNK
cumulative	O
LOD	B-UNK
score	I-UNK
of	O
Z	O
=	O
3	O
.	O

27	O
at	O
theta	B-UNK
=	O
0	O
.	O

00	O
for	O
D1S245	O
.	O

The	O
innermost	O
four	O
markers	B-UNK
were	O
found	O
to	O
be	O
tightly	B-UNK
linked	I-UNK
to	O
one	O
another	O
,	O
with	O
no	O
evidence	B-UNK
for	O
recombination	B-UNK
.	O

Our	O
results	B-UNK
support	O
linkage	B-UNK
of	O
vWS	B-UNK
within	O
a	O
region	B-UNK
of	O
tightly	B-UNK
linked	I-UNK
markers	B-UNK
and	O
do	O
not	O
favour	O
locus	B-UNK
heterogeneity	B-UNK
of	O
the	O
disease	B-DISEASE
trait	O
.	O

Null	O
mutation	B-UNK
of	O
the	O
murine	O
ATP7B	B-UNK
(	O
Wilson	B-DISEASE
disease	I-DISEASE
)	O
gene	B-UNK
results	B-UNK
in	O
intracellular	O
copper	B-UNK
accumulation	B-UNK
and	O
late	B-UNK
-	O
onset	B-UNK
hepatic	B-UNK
nodular	O
transformation	O
.	O

The	O
Atp7b	B-UNK
protein	B-UNK
is	O
a	O
copper	B-UNK
-	O
transporting	O
ATPase	O
expressed	B-UNK
predominantly	O
in	O
the	O
liver	B-UNK
and	O
to	O
a	O
lesser	O
extent	O
in	O
most	O
other	O
tissues	O
.	O

Mutations	B-UNK
in	O
the	O
ATP7B	B-UNK
gene	B-UNK
lead	B-UNK
to	O
Wilson	B-DISEASE
disease	I-DISEASE
,	O
a	O
copper	B-UNK
toxicity	B-DISEASE
disorder	B-UNK
characterized	B-UNK
by	O
dramatic	O
build	O
-	O
up	O
of	O
intracellular	O
hepatic	B-UNK
copper	B-UNK
with	O
subsequent	B-UNK
hepatic	B-UNK
and	O
neuro-logical	O
abnormalities	B-UNK
.	O

Using	O
homologous	B-UNK
recombination	B-UNK
to	O
disrupt	O
the	O
normal	B-UNK
translation	O
of	O
ATP7B	B-UNK
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	B-UNK
that	O
are	O
homozygous	B-UNK
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B-UNK
disease	I-UNK
gene	B-UNK
.	O

The	O
ATP7B	B-UNK
null	O
mice	B-UNK
display	O
a	O
gradual	O
accumulation	B-UNK
of	O
hepatic	B-UNK
copper	B-UNK
that	O
increases	O
to	O
a	O
level	B-UNK
60-fold	O
greater	B-UNK
than	O
normal	B-UNK
by	O
5	O
months	O
of	O
age	B-UNK
.	O

An	O
increase	B-UNK
in	O
copper	B-UNK
concentration	O
was	O
also	O
observed	B-UNK
in	O
the	O
kidney	B-UNK
,	O
brain	B-UNK
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo	O
-	O
zygous	O
mutants	O
,	O
although	O
milk	B-UNK
from	O
the	O
mutant	B-UNK
glands	O
was	O
copper	B-UNK
deficient	B-UNK
.	O

Morphological	O
abnormalities	B-UNK
resembling	O
cirrhosis	B-DISEASE
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	B-UNK
mutants	O
older	O
than	O
7	O
months	O
of	O
age	B-UNK
.	O

Progeny	O
of	O
the	O
homozygous	B-UNK
mutant	B-UNK
females	O
demonstrated	O
neurological	B-DISEASE
abnormalities	I-DISEASE
and	O
growth	B-DISEASE
retardation	I-DISEASE
characteristic	B-UNK
of	O
copper	B-UNK
deficiency	B-UNK
.	O

Copper	B-UNK
concentration	O
in	O
the	O
livers	O
of	O
the	O
newborn	O
homozygous	B-UNK
null	O
mutants	O
was	O
decreased	B-UNK
dramatically	O
.	O

In	O
summary	O
,	O
inactivation	B-UNK
of	O
the	O
murine	O
ATP7B	B-UNK
gene	B-UNK
produces	O
a	O
form	B-UNK
of	O
cirrhotic	B-DISEASE
liver	B-DISEASE
disease	I-DISEASE
that	O
resembles	O
Wilson	B-UNK
disease	I-UNK
in	O
humans	B-UNK
and	O
the	O
toxic	O
milk	B-UNK
phenotype	B-UNK
in	O
the	O
mouse	B-UNK
..	O

French	B-UNK
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
patients	B-UNK
do	O
not	O
exhibit	O
gametic	O
segregation	B-UNK
distortion	I-UNK
:	O
a	O
sperm	O
typing	O
analysis	B-UNK
.	O

Segregation	B-UNK
distortion	I-UNK
has	O
been	O
reported	B-UNK
to	O
occur	B-UNK
in	O
a	O
number	B-UNK
of	O
the	O
trinucleotide	B-UNK
repeat	I-UNK
disorders	B-UNK
.	O

On	O
the	O
basis	B-UNK
of	O
a	O
sperm	O
typing	O
study	B-UNK
performed	O
in	O
patients	B-UNK
of	O
Japanese	B-UNK
descent	O
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
,	O
it	O
was	O
reported	B-UNK
that	O
disease	B-UNK
alleles	B-UNK
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O

We	O
performed	O
a	O
sperm	O
typing	O
study	B-UNK
of	O
five	O
MJD	B-UNK
patients	B-UNK
of	O
French	B-UNK
descent	O
and	O
analysis	B-UNK
of	O
the	O
pooled	O
data	B-UNK
shows	O
a	O
ratio	B-UNK
of	O
mutant	B-UNK
to	O
normal	B-UNK
alleles	B-UNK
of	O
379	O
436	O
(	O
46	O
.	O
5	O
53	O
.	O
5	O
%	O
)	O
,	O
which	O
does	O
not	O
support	O
meiotic	B-UNK
segregation	B-UNK
distortion	I-UNK
.	O

To	O
confirm	O
these	O
results	B-UNK
,	O
sperm	O
typing	O
analysis	B-UNK
was	O
also	O
performed	O
using	O
a	O
polymorphic	B-UNK
marker	B-UNK
,	O
D14S1050	O
,	O
closely	B-UNK
linked	I-UNK
to	O
the	O
MJD1	O
gene	B-UNK
.	O

Among	O
910	O
sperm	O
analyzed	B-UNK
,	O
the	O
allele	B-UNK
linked	B-UNK
to	O
the	O
disease	B-UNK
chromosome	B-UNK
was	O
detected	B-UNK
in	O
50	O
.	O

3	O
%	O
of	O
the	O
samples	B-UNK
and	O
the	O
allele	B-UNK
linked	B-UNK
to	O
the	O
normal	B-UNK
chromosome	B-UNK
was	O
found	O
in	O
49	O
.	O

6	O
%	O
of	O
the	O
sperm	O
.	O

The	O
difference	O
in	O
frequency	B-UNK
of	O
these	O
two	O
alleles	B-UNK
is	O
not	O
significant	B-UNK
(	O
P	O
=	O
0	O
.	O
8423	O
)	O
.	O

Likelihood	O
-	O
based	B-UNK
analysis	B-UNK
of	O
segregation	B-UNK
distortion	I-UNK
in	O
the	O
single	B-UNK
sperm	O
data	B-UNK
using	O
the	O
SPERMSEG	O
program	O
also	O
showed	O
no	O
support	O
for	O
segregation	B-UNK
distortion	I-UNK
at	O
the	O
gamete	O
level	B-UNK
in	O
this	O
patient	B-UNK
population	B-UNK
.	O

The	O
previous	B-UNK
report	B-UNK
on	O
the	O
Japanese	B-UNK
patients	B-UNK
also	O
suggested	O
that	O
disease	B-UNK
allele	B-UNK
stability	O
may	O
be	O
influenced	O
by	O
a	O
trans	O
effect	B-UNK
of	O
an	O
intragenic	O
polymorphism	B-UNK
(	O
987	O
G	O
/	O
C	O
)	O
in	O
the	O
wild	B-UNK
-	O
type	B-UNK
allele	B-UNK
.	O

All	O
of	O
the	O
French	B-UNK
patients	B-UNK
were	O
heterozygous	B-UNK
for	O
this	O
polymorphism	B-UNK
.	O

However	O
,	O
analysis	B-UNK
of	O
the	O
variance	O
in	O
repeat	B-UNK
number	B-UNK
in	O
sperm	O
from	O
the	O
French	B-UNK
MJD	B-UNK
patients	B-UNK
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	B-UNK
number	B-UNK
observed	B-UNK
in	O
the	O
C	O
/	O
C	O
homozygous	B-UNK
Japanese	B-UNK
patients	B-UNK
.	O

Missense	B-UNK
mutation	I-UNK
in	O
the	O
alternative	B-UNK
splice	B-UNK
region	B-UNK
of	O
the	O
PAX6	B-UNK
gene	B-UNK
in	O
eye	B-UNK
anomalies	B-UNK
.	O

The	O
PAX6	B-UNK
gene	B-UNK
is	O
involved	B-UNK
in	O
ocular	O
morphogenesis	O
,	O
and	O
PAX6	B-UNK
mutations	B-UNK
have	O
been	O
detected	B-UNK
in	O
various	O
types	B-UNK
of	O
ocular	O
anomalies	B-UNK
,	O
including	O
aniridia	B-DISEASE
,	O
Peters	B-DISEASE
anomaly	I-DISEASE
,	O
corneal	O
dystrophy	B-UNK
,	O
congenital	B-UNK
cataract	B-DISEASE
,	O
and	O
foveal	O
hypoplasia	B-UNK
.	O

The	O
gene	B-UNK
encodes	B-UNK
a	O
transcriptional	O
regulator	O
that	O
recognizes	O
target	O
genes	B-UNK
through	O
its	O
paired	O
-	O
type	B-UNK
DNA	B-UNK
-	O
binding	B-UNK
domain	I-UNK
.	O

The	O
paired	O
domain	B-UNK
is	O
composed	O
of	O
two	O
distinct	O
DNA	B-UNK
-	O
binding	B-UNK
subdomains	O
,	O
the	O
N	O
-	O
terminal	B-UNK
subdomain	O
(	O
NTS	O
)	O
and	O
the	O
C	O
-	O
terminal	B-UNK
subdomain	O
(	O
CTS	O
)	O
,	O
which	O
bind	O
respective	O
consensus	B-UNK
DNA	B-UNK
sequences	O
.	O

The	O
human	B-UNK
PAX6	B-UNK
gene	B-UNK
produces	O
two	O
alternative	B-UNK
splice	B-UNK
isoforms	O
that	O
have	O
the	O
distinct	O
structure	B-UNK
of	O
the	O
paired	O
domain	B-UNK
.	O

The	O
insertion	O
,	O
into	O
the	O
NTS	O
,	O
of	O
14	O
additional	O
amino	B-UNK
acids	I-UNK
encoded	B-UNK
by	O
exon	B-UNK
5a	O
abolishes	O
the	O
DNA	B-UNK
-	O
binding	B-UNK
activity	B-UNK
of	O
the	O
NTS	O
and	O
unmasks	O
the	O
DNA	B-UNK
-	O
binding	B-UNK
ability	B-UNK
of	O
the	O
CTS	O
.	O

Thus	O
,	O
exon	B-UNK
5a	O
appears	B-UNK
to	O
function	B-UNK
as	O
a	O
molecular	B-UNK
switch	O
that	O
specifies	O
target	O
genes	B-UNK
.	O

We	O
ascertained	O
a	O
novel	O
missense	B-UNK
mutation	I-UNK
in	O
four	O
pedigrees	O
with	O
Peters	B-DISEASE
anomaly	I-DISEASE
,	O
congenital	B-UNK
cataract	B-DISEASE
,	O
Axenfeldt	O
anomaly	B-UNK
,	O
and	O
/	O
or	O
foveal	O
hypoplasia	B-UNK
,	O
which	O
,	O
to	O
our	O
knowledge	B-UNK
,	O
is	O
the	O
first	O
mutation	B-UNK
identified	B-UNK
in	O
the	O
splice	B-UNK
-	O
variant	O
region	B-UNK
.	O

A	O
T--	O
>	O
A	O
transition	B-UNK
at	O
the	O
20th	O
nucleotide	B-UNK
position	I-UNK
of	O
exon	B-UNK
5a	O
results	B-UNK
in	O
a	O
Val--	O
>	O
Asp	O
(	O
GTC--	O
>	O
GAC	O
)	O
substitution	B-UNK
at	O
the	O
7th	O
codon	B-UNK
of	O
the	O
alternative	B-UNK
splice	B-UNK
region	B-UNK
.	O

Functional	O
analyses	O
demonstrated	O
that	O
the	O
V54D	O
mutation	B-UNK
slightly	O
increased	B-UNK
NTS	O
binding	B-UNK
and	O
decreased	B-UNK
CTS	O
transactivation	O
activity	B-UNK
to	O
almost	O
half	B-UNK
..	O

Penetrances	O
of	O
BRCA1	B-UNK
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	B-UNK
cancer	I-UNK
and	O
ovarian	B-UNK
cancer	I-UNK
.	O

For	O
genetic	B-UNK
counseling	I-UNK
and	O
predictive	O
testing	B-UNK
in	O
families	B-UNK
with	O
inherited	B-UNK
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	B-UNK
should	O
be	O
known	O
.	O

We	O
have	O
previously	B-UNK
reported	I-UNK
two	O
BRCA1	B-UNK
founder	B-UNK
mutations	B-UNK
in	O
the	O
Norwegian	O
population	B-UNK
.	O

Index	O
cases	B-UNK
for	O
the	O
present	B-UNK
study	B-UNK
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	B-UNK
of	O
consecutive	O
ovarian	B-UNK
cancers	I-UNK
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	B-UNK
cancer	B-UNK
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O

Altogether	O
,	O
20	O
of	O
the	O
patients	B-UNK
had	O
BRCA1	B-UNK
1675delA	O
,	O
and	O
10	O
had	O
1135insA.	O

Their	O
relatives	B-UNK
were	O
described	O
with	O
respect	O
to	O
absence	B-UNK
/	O
presence	O
of	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
.	O

Of	O
133	O
living	O
female	O
relatives	B-UNK
,	O
83	O
(	O
62	O
%	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
a	O
mutation	B-UNK
.	O

No	O
difference	O
,	O
in	O
penetrance	O
and	O
expression	B-UNK
,	O
between	O
the	O
two	O
mutations	B-UNK
were	O
found	O
,	O
whereas	O
differences	B-UNK
according	O
to	O
method	O
of	O
ascertainment	O
were	O
seen	O
.	O

The	O
overall	O
findings	B-UNK
were	O
that	O
disease	B-DISEASE
started	O
to	O
occur	B-UNK
at	O
age	B-UNK
30	O
years	O
and	O
that	O
by	O
age	B-UNK
50	O
years	O
48	O
%	O
of	O
the	O
mutation	B-UNK
-	O
carrying	B-UNK
women	B-UNK
had	O
experienced	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
.	O

More	O
ovarian	B-UNK
cancers	I-UNK
than	O
breast	B-UNK
cancers	B-DISEASE
were	O
recorded	O
.	O

Both	O
penetrance	O
and	O
expression	B-UNK
(	O
breast	B-UNK
cancer	I-UNK
vs	O
.	O
ovarian	B-UNK
cancer	I-UNK
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
Ashkenazi	B-UNK
founder	B-UNK
mutations	B-UNK
.	O

Whether	O
the	O
reported	B-UNK
differences	B-UNK
reflect	O
true	O
differences	B-UNK
and	O
/	O
or	O
methodological	O
problems	O
is	O
discussed	O
.	O

An	O
observed	B-UNK
excess	B-UNK
of	O
mutation	B-UNK
carriers	B-UNK
could	O
not	O
be	O
accounted	O
for	O
by	O
methodological	O
problems	O
;	O
possible	O
explanations	O
were	O
a	O
"	O
true	O
"	O
low	B-UNK
penetrance	O
or	O
preferential	O
segregation	B-UNK
..	O

The	O
dermatofibrosarcoma	B-DISEASE
protuberans	O
-	O
associated	O
collagen	O
type	B-UNK
Ialpha1	O
/	O
platelet	B-UNK
-	O
derived	B-UNK
growth	B-UNK
factor	I-UNK
(	O
PDGF	O
)	O
B	O
-	O
chain	B-UNK
fusion	B-UNK
gene	B-UNK
generates	O
a	O
transforming	O
protein	B-UNK
that	O
is	O
processed	O
to	O
functional	O
PDGF	O
-	O
BB	O
.	O

Dermatofibrosarcoma	B-DISEASE
protuberans	O
(	O
DFSP	O
)	O
displays	O
chromosomal	B-UNK
rearrangements	O
involving	O
chromosome	B-UNK
17	O
and	O
22	O
,	O
which	O
fuse	O
the	O
collagen	O
type	B-UNK
Ialpha1	O
(	O
COLIA1	O
)	O
gene	B-UNK
to	O
the	O
platelet	B-UNK
-	O
derived	B-UNK
growth	B-UNK
factor	I-UNK
(	O
PDGF	O
)	O
B	O
-	O
chain	B-UNK
(	O
PDGFB	B-UNK
)	O
gene	B-UNK
.	O

To	O
characterize	O
the	O
functional	O
and	O
structural	B-UNK
properties	B-UNK
of	O
the	O
COLIA1	O
/	O
PDGFB	B-UNK
fusion	B-UNK
protein	B-UNK
,	O
we	O
generated	O
a	O
stable	B-UNK
NIH3T3	O
cell	B-UNK
line	I-UNK
that	O
contained	O
a	O
tumor	B-DISEASE
-	O
derived	B-UNK
chimeric	O
gene	B-UNK
resulting	B-UNK
from	O
a	O
COIA1	O
intron	B-UNK
7-PDGFB	O
intron	B-UNK
1	O
fusion	B-UNK
.	O

Expression	B-UNK
of	O
the	O
fusion	B-UNK
protein	B-UNK
led	B-UNK
to	O
morphological	O
transformation	O
and	O
increased	B-UNK
growth	B-UNK
rate	B-UNK
of	O
these	O
cells	B-UNK
.	O

The	O
PDGF	O
receptor	B-UNK
kinase	B-UNK
inhibitor	O
CGP57148B	O
reversed	O
the	O
transformed	O
phenotype	B-UNK
and	O
reduced	O
the	O
growth	B-UNK
rate	B-UNK
of	O
COLIA1	O
/	O
PDGFB	B-UNK
-	O
expressing	O
cells	B-UNK
but	O
had	O
no	O
effects	B-UNK
on	O
control	B-UNK
cells	B-UNK
.	O

The	O
presence	O
of	O
dimeric	O
COLIA1	O
/	O
PDGFB	B-UNK
precursors	O
was	O
demonstrated	O
through	O
PDGFB	B-UNK
immunoprecipitations	O
of	O
metabolically	O
labeled	O
cells	B-UNK
and	O
also	O
by	O
PDGFB	B-UNK
immunoprecipitations	O
followed	O
by	O
immunoblotting	O
with	O
COLIA1	O
antibodies	B-UNK
.	O

Pulse	O
-	O
chase	O
studies	B-UNK
demonstrated	O
that	O
the	O
COLIA1	O
/	O
PDGFB	B-UNK
precursor	O
was	O
processed	O
to	O
an	O
end	B-UNK
product	B-UNK
that	O
was	O
indistinguishable	O
from	O
wild	B-UNK
-	O
type	B-UNK
PDGF	O
-	O
BB	O
.	O

Finally	B-UNK
,	O
COLIA1	O
/	O
PDGFB	B-UNK
-	O
expressing	O
cells	B-UNK
generated	O
tumors	B-UNK
after	O
s.	O

c	O
c.	O
injection	O
into	O
nude	O
mice	B-UNK
,	O
and	O
tumor	B-UNK
growth	B-UNK
was	O
reduced	O
by	O
treatment	O
with	O
CGP57148B.	O

We	O
conclude	O
that	O
the	O
COLIA1	O
/	O
PDGFB	B-UNK
fusion	B-UNK
associated	O
with	O
DFSP	O
contributes	O
to	O
tumor	B-UNK
development	B-UNK
through	O
ectopic	O
production	O
of	O
PDGF	O
-	O
BB	O
and	O
the	O
formation	B-UNK
of	O
an	O
autocrine	O
loop	O
.	O

Our	O
findings	B-UNK
,	O
thus	O
,	O
suggest	B-UNK
that	O
PDGF	O
receptors	O
could	O
be	O
a	O
target	O
for	O
pharmacological	O
treatment	O
of	O
DFSP	O
and	O
giant	O
cell	B-UNK
fibroblastoma	O
,	O
e.	O
g.	O
,	O
through	O
the	O
use	O
of	O
PDGF	O
receptor	B-UNK
kinase	B-UNK
inhibitors	O
such	O
as	O
CGP57148B.	O

Identification	B-UNK
of	O
a	O
common	B-UNK
PEX1	O
mutation	B-UNK
in	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
Zellweger	O
spectrum	B-UNK
of	O
disease	B-DISEASE
,	O
encompassing	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
and	O
the	O
progressively	O
milder	B-UNK
phenotypes	O
of	O
neonatal	B-UNK
adrenoleukodystrophy	B-UNK
and	O
infantile	B-UNK
Refsum	B-DISEASE
disease	I-DISEASE
,	O
is	O
due	O
to	O
a	O
failure	B-UNK
to	O
form	B-UNK
functional	O
peroxisomes	O
.	O

Cell	B-UNK
fusion	B-UNK
complementation	O
studies	B-UNK
demonstrated	O
that	O
these	O
diseases	B-UNK
are	O
genetically	B-UNK
heterogeneous	O
,	O
with	O
two	O
-	O
thirds	O
of	O
all	O
patients	B-UNK
lying	O
within	O
a	O
single	B-UNK
complementation	O
group	B-UNK
,	O
CG1	O
.	O

Molecular	B-UNK
genetic	I-UNK
and	O
cell	B-UNK
biology	O
studies	B-UNK
have	O
shown	B-UNK
that	O
PEX1	O
is	O
deficient	B-UNK
in	O
many	O
CG1	O
patients	B-UNK
.	O

However	O
,	O
previous	B-UNK
studies	B-UNK
have	O
focused	O
on	O
mildly	O
affected	B-UNK
patients	B-UNK
and	O
there	O
is	O
still	O
no	O
report	B-UNK
of	O
two	O
mutant	B-UNK
PEX1	O
alleles	B-UNK
in	O
any	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
patient	B-UNK
.	O

Furthermore	O
,	O
mutations	B-UNK
in	O
the	O
PMP70	O
gene	B-UNK
have	O
also	O
been	O
identified	B-UNK
in	O
two	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
patients	B-UNK
from	O
CG1	O
,	O
raising	O
the	O
possibility	B-UNK
that	O
CG1	O
patients	B-UNK
may	O
represent	O
a	O
mixture	O
of	O
PEX1-deficient	O
and	O
PMP70-deficient	O
individuals	B-UNK
.	O

To	O
address	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
disease	B-UNK
in	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
patients	B-UNK
from	O
CG1	O
,	O
we	O
examined	O
all	O
24	O
PEX1	O
exons	O
in	O
four	O
patients	B-UNK
,	O
including	O
both	O
patients	B-UNK
that	O
have	O
mutations	B-UNK
in	O
PMP70	O
.	O

PEX1	O
mutations	B-UNK
were	O
detected	B-UNK
in	O
all	O
four	O
patients	B-UNK
,	O
including	O
a	O
1-bp	O
insertion	O
(	O
c.	O
2097insT	O
)	O
in	O
exon	B-UNK
13	O
that	O
was	O
present	B-UNK
in	O
three	O
of	O
the	O
four	O
patients	B-UNK
.	O

Subsequent	B-UNK
studies	B-UNK
demonstrated	O
that	O
this	O
mutation	B-UNK
is	O
present	B-UNK
in	O
one	O
-	O
half	B-UNK
of	O
all	O
CG1	O
patients	B-UNK
and	O
correlates	O
with	O
the	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
phenotype	B-UNK
.	O

As	O
this	O
mutation	B-UNK
leads	B-UNK
to	O
a	O
loss	B-UNK
of	O
protein	B-UNK
function	B-UNK
its	O
frequency	B-UNK
makes	O
it	O
the	O
most	O
common	B-UNK
cause	O
of	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
,	O
helping	O
to	O
explain	O
the	O
high	B-UNK
percentage	B-UNK
of	O
patients	B-UNK
that	O
belong	O
to	O
CG1	O
.	O

Novel	O
mutations	B-UNK
in	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
protein	B-UNK
gene	B-UNK
and	O
their	O
effects	B-UNK
on	O
transcriptional	O
,	O
translational	O
,	O
and	O
clinical	B-UNK
phenotypes	O
.	O

Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
immunodeficiency	B-UNK
characterized	B-UNK
by	O
thrombocytopenia	B-DISEASE
,	O
eczema	B-DISEASE
,	O
and	O
recurrent	O
infections	B-UNK
,	O
and	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
WAS	O
protein	B-UNK
(	O
WASP	B-UNK
)	O
gene	B-UNK
.	O

WASP	B-UNK
contains	O
several	O
functional	O
domains	B-UNK
through	O
which	O
it	O
interacts	O
with	O
proteins	B-UNK
involved	B-UNK
in	O
intracellular	O
signaling	O
and	O
regulation	B-UNK
of	O
the	O
actin	B-UNK
cytoskeleton	O
.	O

In	O
this	O
report	B-UNK
,	O
17	O
WASP	B-UNK
gene	B-UNK
mutations	B-UNK
were	O
identified	B-UNK
,	O
12	O
of	O
which	O
are	O
novel	O
.	O

DNA	B-UNK
of	O
affected	B-UNK
males	I-UNK
and	O
obligate	B-UNK
carriers	B-UNK
was	O
PCR	B-UNK
amplified	O
and	O
analyzed	B-UNK
by	O
SSCA	O
,	O
heteroduplex	B-UNK
analysis	I-UNK
,	O
and	O
direct	B-UNK
sequencing	I-UNK
.	O

The	O
effects	B-UNK
of	O
the	O
mutations	B-UNK
at	O
the	O
mRNA	O
and	O
protein	B-UNK
level	B-UNK
were	O
ascertained	O
by	O
RT	O
-	O
PCR	B-UNK
and	O
Western	B-UNK
blot	B-UNK
analyses	O
.	O

All	O
missense	B-UNK
mutations	I-UNK
were	O
located	B-UNK
in	O
exons	O
1	O
-	O
4	O
.	O

Most	O
of	O
the	O
nonsense	B-UNK
,	O
frameshift	B-UNK
and	O
splice	B-UNK
site	I-UNK
mutations	B-UNK
were	O
found	O
in	O
exons	O
6	O
-	O
11	O
.	O

Mutations	B-UNK
that	O
alter	O
splice	B-UNK
sites	O
led	B-UNK
to	O
the	O
synthesis	B-UNK
of	O
several	O
types	B-UNK
of	O
mRNAs	O
,	O
a	O
fraction	B-UNK
of	O
which	O
represented	O
the	O
normally	O
spliced	O
product	B-UNK
.	O

The	O
presence	O
of	O
normally	O
spliced	O
transcripts	O
was	O
correlated	B-UNK
with	O
a	O
milder	B-UNK
phenotype	B-UNK
.	O

When	O
one	O
such	O
case	B-UNK
was	O
studied	O
by	O
Western	B-UNK
blotting	O
,	O
reduced	O
amounts	B-UNK
of	O
normal	B-UNK
-	O
size	B-UNK
WASP	B-UNK
were	O
present	B-UNK
.	O

In	O
other	O
cases	B-UNK
as	O
well	O
,	O
a	O
correlation	B-UNK
was	O
found	O
between	O
the	O
amount	O
of	O
normal	B-UNK
or	O
mutant	B-UNK
WASP	B-UNK
present	B-UNK
and	O
the	O
phenotypes	O
of	O
the	O
affected	B-UNK
individuals	I-UNK
.	O

No	O
protein	B-UNK
was	O
detected	B-UNK
in	O
two	O
individuals	B-UNK
with	O
severe	B-UNK
WAS	O
.	O

Reduced	O
levels	B-UNK
of	O
a	O
normal	B-UNK
-	O
size	B-UNK
WASP	B-UNK
with	O
a	O
missense	B-UNK
mutation	I-UNK
were	O
seen	O
in	O
two	O
individuals	B-UNK
with	O
XLT	O
.	O

It	O
is	O
concluded	O
that	O
mutation	B-UNK
analysis	B-UNK
at	O
the	O
DNA	B-UNK
level	B-UNK
is	O
not	O
sufficient	O
for	O
predicting	O
clinical	B-UNK
course	O
.	O

Studies	B-UNK
at	O
the	O
transcript	B-UNK
and	O
protein	B-UNK
level	B-UNK
are	O
needed	O
for	O
a	O
better	O
assessment	O
..	O

Aminoglycoside	O
antibiotics	O
restore	O
dystrophin	B-UNK
function	B-UNK
to	O
skeletal	B-UNK
muscles	O
of	O
mdx	O
mice	B-UNK
.	O

Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
dystrophin	B-UNK
gene	I-UNK
,	O
leading	B-UNK
to	O
the	O
absence	B-UNK
of	O
the	O
dystrophin	B-UNK
protein	B-UNK
in	O
striated	O
muscle	B-UNK
.	O

A	O
significant	B-UNK
number	B-UNK
of	O
these	O
mutations	B-UNK
are	O
premature	B-UNK
stop	I-UNK
codons	O
.	O

On	O
the	O
basis	B-UNK
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	B-UNK
codons	O
in	O
cultured	O
cells	B-UNK
,	O
we	O
tested	O
the	O
effect	B-UNK
of	O
gentamicin	O
on	O
cultured	O
muscle	B-UNK
cells	B-UNK
from	O
the	O
mdx	O
mouse	B-UNK
-	O
an	O
animal	B-UNK
model	I-UNK
for	O
DMD	B-UNK
that	O
possesses	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
in	O
the	O
dystrophin	B-UNK
gene	I-UNK
.	O

Exposure	O
of	O
mdx	O
myotubes	O
to	O
gentamicin	O
led	B-UNK
to	O
the	O
expression	B-UNK
and	O
localization	B-UNK
of	O
dystrophin	B-UNK
to	O
the	O
cell	B-UNK
membrane	B-UNK
.	O

We	O
then	O
evaluated	O
the	O
effects	B-UNK
of	O
differing	O
dosages	O
of	O
gentamicin	O
on	O
expression	B-UNK
and	O
functional	O
protection	O
of	O
the	O
muscles	O
of	O
mdx	O
mice	B-UNK
.	O

We	O
identified	B-UNK
a	O
treatment	O
regimen	O
that	O
resulted	B-UNK
in	O
the	O
presence	O
of	O
dystrophin	B-UNK
in	O
the	O
cell	B-UNK
membrane	B-UNK
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	B-UNK
injury	O
.	O

To	O
our	O
knowledge	B-UNK
,	O
our	O
results	B-UNK
are	O
the	O
first	O
to	O
demonstrate	B-UNK
that	O
aminoglycosides	O
can	O
suppress	O
stop	B-UNK
codons	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	B-UNK
.	O

Furthermore	O
,	O
these	O
results	B-UNK
raise	O
the	O
possibility	B-UNK
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B-DISEASE
dystrophy	I-DISEASE
and	O
other	O
diseases	B-UNK
caused	B-UNK
by	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
mutations	B-UNK
.	O

This	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15	O
%	O
of	O
patients	B-UNK
with	O
DMD	B-UNK
..	O

Loss	B-UNK
of	O
the	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
gene	B-UNK
product	I-UNK
causes	O
oxidative	O
damage	B-UNK
in	O
target	O
organs	O
.	O

Ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
is	O
characterized	B-UNK
by	O
a	O
markedly	B-UNK
increased	B-UNK
sensitivity	O
to	O
ionizing	B-UNK
radiation	I-UNK
,	O
increased	B-UNK
incidence	B-UNK
of	O
cancer	B-DISEASE
,	O
and	O
neurodegeneration	B-DISEASE
,	O
especially	O
of	O
the	O
cerebellar	B-UNK
Purkinje	O
cells	B-UNK
.	O

Ionizing	B-UNK
radiation	I-UNK
oxidizes	O
macromolecules	O
and	O
causes	O
tissue	B-DISEASE
damage	I-DISEASE
through	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	B-UNK
(	O
ROS	O
)	O
.	O

We	O
therefore	O
hypothesized	O
that	O
A	O
-T	O
is	O
due	O
to	O
oxidative	O
damage	B-UNK
resulting	B-UNK
from	O
loss	B-UNK
of	O
function	B-UNK
of	O
the	O
A	O
-T	O
gene	B-UNK
product	I-UNK
.	O

To	O
assess	B-UNK
this	O
hypothesis	B-UNK
,	O
we	O
employed	O
an	O
animal	B-UNK
model	I-UNK
of	O
A	O
-T	O
,	O
the	O
mouse	B-UNK
with	O
a	O
disrupted	O
Atm	B-UNK
gene	B-UNK
.	O

We	O
show	O
that	O
organs	O
which	O
develop	O
pathologic	O
changes	O
in	O
the	O
Atm	B-UNK
-	O
deficient	B-UNK
mice	I-UNK
are	O
targets	O
of	O
oxidative	O
damage	B-UNK
,	O
and	O
that	O
cerebellar	B-UNK
Purkinje	O
cells	B-UNK
are	O
particularly	O
affected	B-UNK
.	O

These	O
observations	B-UNK
provide	B-UNK
a	O
mechanistic	O
basis	B-UNK
for	O
the	O
A	O
-T	O
phenotype	B-UNK
and	O
lay	O
a	O
rational	O
foundation	O
for	O
therapeutic	O
intervention	O
..	O

Recessively	O
inherited	B-UNK
multiple	B-UNK
epiphyseal	O
dysplasia	B-UNK
with	O
normal	B-UNK
stature	O
,	O
club	O
foot	O
,	O
and	O
double	B-UNK
layered	O
patella	O
caused	B-UNK
by	O
a	O
DTDST	B-UNK
mutation	B-UNK
.	O

We	O
have	O
observed	B-UNK
over	O
25	O
different	O
mutations	B-UNK
in	O
the	O
diastrophic	B-UNK
dysplasia	I-UNK
sulphate	O
transporter	B-UNK
gene	B-UNK
(	O
DTDST	B-UNK
)	O
in	O
association	B-UNK
with	O
the	O
recessive	B-UNK
disorders	B-UNK
achondrogenesis	B-DISEASE
1B	O
,	O
atelosteogenesis	O
2	O
,	O
and	O
diastrophic	B-UNK
dysplasia	I-UNK
.	O

The	O
c862	O
t	O
(	O
R279W	O
)	O
transition	B-UNK
is	O
the	O
most	O
common	B-UNK
mutation	B-UNK
in	O
non-Finnish	O
patients	B-UNK
,	O
but	O
in	O
these	O
disorders	B-UNK
it	O
is	O
usually	O
combined	O
with	O
other	O
DTDST	B-UNK
mutations	B-UNK
.	O

We	O
had	O
not	O
seen	O
a	O
case	B-UNK
of	O
homozygosity	B-UNK
for	O
c862	O
t	O
(	O
R279W	O
)	O
until	O
we	O
analysed	O
DNA	B-UNK
from	O
a	O
36	O
year	O
old	O
male	B-UNK
with	O
tall	O
-	O
normal	B-UNK
stature	O
(	O
180	O
cm	B-DISEASE
)	O
who	O
asked	O
for	O
genetic	B-UNK
counselling	O
for	O
suspected	O
multiple	B-UNK
epiphyseal	O
dysplasia	B-UNK
.	O

He	O
was	O
treated	O
for	O
club	O
foot	O
and	O
hip	O
dysplasia	B-UNK
at	O
birth	O
.	O

Skeletal	B-UNK
changes	O
consistent	B-UNK
with	O
multiple	B-UNK
epiphyseal	O
dysplasia	B-UNK
,	O
with	O
the	O
peculiar	O
finding	O
of	O
a	O
double	B-UNK
layered	O
patella	O
,	O
were	O
recognised	O
during	O
childhood	O
.	O

Cleft	B-DISEASE
palate	I-DISEASE
,	O
swelling	B-DISEASE
of	O
the	O
ear	O
pinna	O
,	O
and	O
hitch	O
hiker	O
thumb	O
were	O
absent	O
.	O

He	O
was	O
found	O
to	O
be	O
homozygous	B-UNK
,	O
and	O
both	O
healthy	O
parents	O
heterozygous	B-UNK
,	O
for	O
the	O
R279W	O
mutation	B-UNK
in	O
DTDST	B-UNK
,	O
and	O
his	O
fibroblasts	B-UNK
showed	O
a	O
sulphate	O
incorporation	O
defect	B-UNK
typical	O
of	O
DTDST	B-UNK
disorders	B-UNK
.	O

Counselling	O
was	O
given	O
for	O
a	O
recessive	B-UNK
disorder	B-UNK
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	B-UNK
of	O
affected	B-UNK
offspring	O
.	O

Multiple	B-UNK
epiphyseal	O
dysplasia	B-UNK
is	O
more	O
frequently	O
caused	B-UNK
by	O
dominant	B-UNK
mutations	B-UNK
in	O
the	O
COMP	O
(	O
EDM1	O
,	O
McKusick	O
132400	O
)	O
and	O
COL9A2	O
genes	B-UNK
(	O
EDM2	O
,	O
McKusick	O
600204	O
)	O
.	O

A	O
few	O
other	O
patients	B-UNK
and	O
families	B-UNK
with	O
features	B-UNK
similar	B-UNK
to	O
our	O
proband	B-UNK
have	O
been	O
described	O
previously	B-UNK
and	O
considered	O
to	O
have	O
autosomal	B-UNK
recessive	I-UNK
MED	O
(	O
EDM4	O
,	O
McKusick	O
226900	O
)	O
.	O

This	O
observation	O
confirms	O
the	O
existence	O
of	O
this	O
entity	O
and	O
assigns	O
it	O
to	O
the	O
phenotypic	B-UNK
spectrum	B-UNK
associated	O
with	O
mutations	B-UNK
at	O
the	O
DTDST	B-UNK
locus	B-UNK
..	O

Homozygosity	B-UNK
for	O
a	O
novel	O
DTDST	B-UNK
mutation	B-UNK
in	O
a	O
child	B-UNK
with	O
a	O
'	O
broad	O
bone-platyspondylic	O
'	O
variant	O
of	O
diastrophic	B-DISEASE
dysplasia	I-DISEASE
.	O

Atypical	O
or	O
variant	O
forms	B-UNK
of	O
well	O
-	O
known	O
chondrodysplasias	O
may	O
pose	O
diagnostic	B-UNK
problems	O
.	O

We	O
report	B-UNK
on	O
a	O
girl	O
with	O
clinical	B-UNK
features	I-UNK
suggesting	O
diastrophic	B-UNK
dysplasia	I-UNK
but	O
with	O
unusual	O
radiographic	O
features	B-UNK
including	O
severe	B-UNK
platyspondyly	O
,	O
wide	B-UNK
metaphyses	O
,	O
and	O
fibular	O
overgrowth	O
,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	O
dysplasia	B-UNK
.	O

The	O
diagnosis	B-UNK
was	O
clarified	O
by	O
molecular	B-UNK
analysis	I-UNK
of	O
the	O
DTDST	B-UNK
gene	B-UNK
,	O
which	O
revealed	B-UNK
homozygosity	B-UNK
for	O
a	O
previously	B-UNK
undescribed	O
mutation	B-UNK
leading	B-UNK
to	O
a	O
Q454P	O
substitution	B-UNK
in	O
the	O
10th	O
transmembrane	B-UNK
domain	B-UNK
of	O
the	O
DTDST	B-UNK
sulfate	B-UNK
transporter	I-UNK
.	O

Molecular	B-UNK
analysis	I-UNK
may	O
be	O
of	O
particular	O
value	O
in	O
such	O
atypical	O
cases	B-UNK
..	O

The	O
type	B-UNK
of	O
somatic	B-UNK
mutation	B-UNK
at	O
APC	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
is	O
determined	B-UNK
by	O
the	O
site	B-UNK
of	O
the	O
germline	B-UNK
mutation	I-UNK
:	O
a	O
new	O
facet	O
to	O
Knudson'	O
s	O
'	O
two	O
-	O
hit	B-DISEASE
'	O
hypothesis	B-UNK
.	O

APC	B-UNK
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
.	O

Truncating	B-UNK
germline	B-UNK
and	O
somatic	B-UNK
mutations	I-UNK
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	B-UNK
)	O
occur	B-UNK
in	O
tumors	B-DISEASE
in	O
FAP	B-UNK
(	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
)	O
.	O

Most	O
sporadic	B-UNK
colorectal	B-UNK
cancers	B-UNK
also	O
have	O
two	O
APC	B-UNK
mutations	B-UNK
.	O

Clues	O
from	O
attenuated	B-UNK
polyposis	B-UNK
,	O
missense	B-UNK
germline	B-UNK
variants	B-UNK
with	O
mild	O
disease	B-UNK
and	O
the	O
somatic	B-UNK
mutation	B-UNK
cluster	B-UNK
region	B-UNK
(	O
codons	O
1	O
,	O
250	O
-	O
1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
APC	B-UNK
mutations	B-UNK
might	O
not	O
result	B-UNK
in	O
simple	O
loss	B-UNK
of	O
protein	B-UNK
function	B-UNK
.	O

We	O
have	O
found	O
that	O
FAP	B-UNK
patients	I-UNK
with	O
germline	B-UNK
APC	B-UNK
mutations	B-UNK
within	O
a	O
small	O
region	B-UNK
(	O
codons	O
1	O
,	O
194	O
-	O
1	O
,	O
392	O
at	O
most	O
)	O
mainly	O
show	O
allelic	O
loss	B-UNK
in	O
their	O
colorectal	B-DISEASE
adenomas	I-DISEASE
,	O
in	O
contrast	B-UNK
to	O
other	O
FAP	B-UNK
patients	I-UNK
,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	B-UNK
by	O
truncating	B-UNK
mutations	I-UNK
in	O
the	O
mutation	B-UNK
cluster	B-UNK
region	B-UNK
.	O

Our	O
results	B-UNK
indicate	O
that	O
different	O
APC	B-UNK
mutations	B-UNK
provide	B-UNK
cells	B-UNK
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	B-UNK
close	B-UNK
to	O
codon	B-UNK
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	B-UNK
.	O

Allelic	O
loss	B-UNK
is	O
selected	O
strongly	O
in	O
cells	B-UNK
with	O
one	O
mutation	B-UNK
near	O
codon	B-UNK
1	O
,	O
300	O
.	O

A	O
different	O
germline	B-UNK
-	O
somatic	B-UNK
APC	B-UNK
mutation	B-UNK
association	B-UNK
exists	O
in	O
FAP	B-UNK
desmoids	O
.	O

APC	B-UNK
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B-UNK
suppressor	I-UNK
.	O

Our	O
findings	B-UNK
also	O
indicate	O
a	O
new	O
mechanism	B-UNK
for	O
disease	B-DISEASE
severity	B-UNK
if	O
a	O
broader	O
spectrum	B-UNK
of	O
mutations	B-UNK
is	O
selected	O
in	O
tumors	B-UNK
,	O
the	O
somatic	B-UNK
mutation	B-UNK
rate	B-UNK
is	O
effectively	O
higher	O
and	O
more	O
tumors	B-DISEASE
grow	O
..	O

Mxi1	O
mutations	B-UNK
in	O
human	B-UNK
neurofibrosarcomas	O
.	O

Mxi1	O
is	O
thought	B-UNK
to	O
negatively	O
regulate	O
Myc	O
function	B-UNK
and	O
may	O
therefore	O
be	O
a	O
potential	B-UNK
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
.	O

Little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	B-UNK
involving	O
this	O
gene	B-UNK
in	O
human	B-UNK
solid	O
tumors	B-DISEASE
.	O

We	O
screened	B-UNK
31	O
human	B-UNK
gastric	B-UNK
cancers	B-DISEASE
,	O
7	O
esophageal	O
cancers	B-UNK
,	O
85	O
bone	B-UNK
and	O
soft	O
tissue	B-UNK
tumors	B-UNK
of	O
various	O
types	B-UNK
,	O
including	O
4	O
neurofibrosarcomas	O
.	O

We	O
also	O
examined	O
29	O
human	B-UNK
tumor	B-DISEASE
cell	B-UNK
lines	I-UNK
consisting	O
of	O
12	O
esophageal	O
cancers	B-DISEASE
,	O
7	O
glioma	B-DISEASE
/	O
glioblastomas	B-DISEASE
and	O
10	O
others	O
for	O
Mxi1	O
mutations	B-UNK
in	O
exons	O
1	O
,	O
2	O
,	O
4	O
(	O
HLH	O
domain	B-UNK
)	O
,	O
5	O
and	O
6	O
.	O

Polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
PCR	B-UNK
-	O
SSCP	B-UNK
)	O
and	O
subsequent	B-UNK
sequencing	B-UNK
revealed	B-UNK
three	O
distinct	O
polymorphisms	B-UNK
in	O
the	O
intron	B-UNK
-	O
exon	B-UNK
boundary	O
upstream	O
from	O
exon	B-UNK
6	O
.	O

We	O
discovered	O
a	O
missense	B-UNK
mutation	I-UNK
,	O
GCA	O
to	O
GTA	O
(	O
Ala	B-UNK
54	O
Val	B-UNK
)	O
,	O
in	O
exon	B-UNK
2	O
in	O
a	O
neurofibrosarcoma	B-DISEASE
patient	B-UNK
(	O
case	B-UNK
1	O
)	O
,	O
two	O
missense	B-UNK
mutations	I-UNK
,	O
AAA	O
to	O
CAA	B-DISEASE
(	O
Lys	O
118	O
Gln	O
)	O
and	O
GAA	B-UNK
to	O
GGA	O
(	O
Glu	B-UNK
154	O
Gly	B-UNK
)	O
in	O
exon	B-UNK
5	O
of	O
another	O
neurofibrosarcoma	B-DISEASE
patient	B-UNK
(	O
case	B-UNK
2	O
)	O
,	O
and	O
3	O
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
,	O
GTG	O
to	O
GCG	O
(	O
Val	B-UNK
179	O
Ala	B-UNK
)	O
,	O
GTT	O
to	O
GCT	O
(	O
Val	B-UNK
181	O
Ala	B-UNK
)	O
and	O
TTC	O
to	O
CTC	O
(	O
Phe	O
186	O
Leu	B-UNK
)	O
,	O
in	O
a	O
third	O
neurofibrosarcoma	B-DISEASE
patient	B-UNK
(	O
case	B-UNK
3	O
)	O
.	O

In	O
case	B-UNK
3	O
,	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
was	O
also	O
demonstrated	O
by	O
informative	O
(	O
TTC	O
)	O
3/(TTC	O
)	O
2	O
polymorphism	B-UNK
.	O

Our	O
data	B-UNK
demonstrate	B-UNK
that	O
mutations	B-UNK
occur	B-UNK
in	O
the	O
Mxi1	O
gene	B-UNK
in	O
neurofibrosarcoma	B-DISEASE
.	O

Missense	B-UNK
mutations	I-UNK
in	O
the	O
functional	O
domain	B-UNK
of	O
Mxi1	O
in	O
these	O
cases	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
neurofibrosarcoma	B-DISEASE
..	O

A	O
population	B-UNK
-	O
based	B-UNK
study	B-UNK
of	O
the	O
clinical	B-UNK
expression	B-UNK
of	O
the	O
hemochromatosis	B-DISEASE
gene	B-UNK
.	O

BACKGROUND	O
AND	O
METHODS	O
Hereditary	B-UNK
hemochromatosis	I-UNK
is	O
associated	O
with	O
homozygosity	B-UNK
for	O
the	O
C282Y	B-UNK
mutation	B-UNK
in	O
the	O
hemochromatosis	B-DISEASE
(	O
HFE	B-UNK
)	O
gene	B-UNK
on	O
chromosome	B-UNK
6	O
,	O
elevated	B-UNK
serum	B-UNK
transferrin	O
saturation	O
,	O
and	O
excess	B-UNK
iron	B-UNK
deposits	O
throughout	O
the	O
body	O
.	O

To	O
assess	B-UNK
the	O
prevalence	B-UNK
and	O
clinical	B-UNK
expression	B-UNK
of	O
the	O
HFE	B-UNK
gene	B-UNK
,	O
we	O
conducted	O
a	O
population	B-UNK
-	O
based	B-UNK
study	B-UNK
in	O
Busselton	O
,	O
Australia	O
.	O

In	O
1994	O
,	O
we	O
obtained	B-UNK
blood	B-UNK
samples	B-UNK
for	O
the	O
determination	B-UNK
of	O
serum	B-UNK
transferrin	O
saturation	O
and	O
ferritin	O
levels	B-UNK
and	O
the	O
presence	O
or	O
absence	B-UNK
of	O
the	O
C282Y	B-UNK
mutation	B-UNK
and	O
the	O
H63D	B-UNK
mutation	B-UNK
(	O
which	O
may	O
contribute	B-UNK
to	O
increased	B-UNK
hepatic	B-UNK
iron	B-UNK
levels	B-UNK
)	O
in	O
3011	O
unrelated	B-UNK
white	B-UNK
adults	O
.	O

We	O
evaluated	O
all	O
subjects	B-UNK
who	O
had	O
persistently	O
elevated	B-UNK
transferrin	O
-	O
saturation	O
values	O
(	O
45	O
percent	B-UNK
or	O
higher	O
)	O
or	O
were	O
homozygous	B-UNK
for	O
the	O
C282Y	B-UNK
mutation	B-UNK
.	O

We	O
recommended	O
liver	B-UNK
biopsy	B-UNK
for	O
subjects	B-UNK
with	O
serum	B-UNK
ferritin	O
levels	B-UNK
of	O
300	O
ng	O
per	O
milliliter	O
or	O
higher	O
.	O

The	O
subjects	B-UNK
were	O
followed	O
for	O
up	O
to	O
four	O
years	O
.	O

RESULTS	B-UNK
Sixteen	O
of	O
the	O
subjects	B-UNK
(	O
0	O
.	O
5	O
percent	B-UNK
)	O
were	O
homozygous	B-UNK
for	O
the	O
C282Y	B-UNK
mutation	B-UNK
,	O
and	O
424	O
(	O
14	O
.	O
1	O
percent	B-UNK
)	O
were	O
heterozygous	B-UNK
.	O

The	O
serum	B-UNK
transferrin	O
saturation	O
was	O
45	O
percent	B-UNK
or	O
higher	O
in	O
15	O
of	O
the	O
16	O
who	O
were	O
homozygous	B-UNK
;	O
in	O
1	O
subject	O
it	O
was	O
43	O
percent	B-UNK
.	O

Four	O
of	O
the	O
homozygous	B-UNK
subjects	B-UNK
had	O
previously	B-UNK
been	O
given	O
a	O
diagnosis	B-UNK
of	O
hemochromatosis	B-DISEASE
,	O
and	O
12	O
had	O
not	O
.	O

Seven	O
of	O
these	O
12	O
patients	B-UNK
had	O
elevated	B-UNK
serum	B-UNK
ferritin	O
levels	B-UNK
in	O
1994	O
;	O
6	O
of	O
the	O
7	O
had	O
further	O
increases	O
in	O
1998	O
,	O
and	O
1	O
had	O
a	O
decrease	O
,	O
although	O
the	O
value	O
remained	O
elevated	B-UNK
.	O

The	O
serum	B-UNK
ferritin	O
levels	B-UNK
in	O
the	O
four	O
other	O
homozygous	B-UNK
patients	B-UNK
remained	O
in	O
the	O
normal	B-UNK
range	B-UNK
.	O

Eleven	O
of	O
the	O
16	O
homozygous	B-UNK
subjects	B-UNK
underwent	O
liver	B-UNK
biopsy	B-UNK
;	O
3	O
had	O
hepatic	B-UNK
fibrosis	B-DISEASE
,	O
and	O
1	O
,	O
who	O
had	O
a	O
history	B-UNK
of	O
excessive	O
alcohol	O
consumption	O
,	O
had	O
cirrhosis	B-DISEASE
and	O
mild	O
microvesicular	O
steatosis	B-DISEASE
.	O

Eight	O
of	O
the	O
16	O
homozygous	B-UNK
subjects	B-UNK
had	O
clinical	B-UNK
findings	B-UNK
that	O
were	O
consistent	B-UNK
with	O
the	O
presence	O
of	O
hereditary	B-UNK
hemochromatosis	I-UNK
,	O
such	O
as	O
hepatomegaly	B-DISEASE
,	O
skin	B-UNK
pigmentation	O
,	O
and	O
arthritis	B-UNK
.	O

CONCLUSIONS	B-UNK
In	O
a	O
population	B-UNK
of	O
white	B-UNK
adults	O
of	O
northern	B-UNK
European	B-UNK
ancestry	O
,	O
0	O
.	O

5	O
percent	B-UNK
were	O
homozygous	B-UNK
for	O
the	O
C282Y	B-UNK
mutation	B-UNK
in	O
the	O
HFE	B-UNK
gene	B-UNK
.	O

However	O
,	O
only	O
half	B-UNK
of	O
those	O
who	O
were	O
homozygous	B-UNK
had	O
clinical	B-UNK
features	I-UNK
of	O
hemochromatosis	B-UNK
,	O
and	O
one	O
quarter	O
had	O
serum	B-UNK
ferritin	O
levels	B-UNK
that	O
remained	O
normal	B-UNK
over	O
a	O
four	O
-	O
year	O
period	O
.	O

Large	B-UNK
heterozygous	B-UNK
deletion	B-UNK
masquerading	O
as	O
homozygous	B-UNK
missense	B-UNK
mutation	I-UNK
:	O
a	O
pitfall	O
in	O
diagnostic	B-UNK
mutation	B-UNK
analysis	B-UNK
.	O

The	O
clinical	B-UNK
use	O
of	O
molecular	B-UNK
analyses	O
in	O
recessive	B-UNK
disorders	B-UNK
relies	O
on	O
the	O
exact	O
characterization	B-UNK
of	O
both	O
mutant	B-UNK
alleles	I-UNK
in	O
the	O
affected	B-UNK
patient	B-UNK
.	O

This	O
can	O
be	O
problematic	O
when	O
only	O
part	O
of	O
the	O
gene	B-UNK
is	O
examined	O
or	O
when	O
relevant	O
DNA	B-UNK
alterations	B-UNK
are	O
not	O
recognized	O
by	O
standard	O
methods	O
.	O

We	O
present	B-UNK
a	O
child	B-UNK
in	O
whom	O
phenylketonuria	O
was	O
apparently	O
caused	B-UNK
by	O
homozygosity	B-UNK
for	O
the	O
mutation	B-UNK
E390	O
G	O
in	O
exon	B-UNK
11	O
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
gene	B-UNK
.	O

However	O
,	O
the	O
clinical	B-UNK
severity	B-UNK
of	O
the	O
disease	B-UNK
was	O
not	O
quite	O
as	O
mild	O
as	O
expected	O
,	O
the	O
mutation	B-UNK
was	O
not	O
identified	B-UNK
in	O
the	O
father	O
despite	O
confirmed	B-UNK
paternity	O
,	O
and	O
the	O
paternal	O
allele	B-UNK
showed	O
a	O
highly	B-UNK
unusual	O
pattern	B-UNK
of	O
polymorphic	B-UNK
markers	I-UNK
in	O
the	O
PAH	B-UNK
gene	B-UNK
.	O

Presence	O
of	O
a	O
large	B-UNK
deletion	B-UNK
involving	O
exons	O
9	O
,	O
10	O
and	O
11	O
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
was	O
confirmed	B-UNK
by	O
long	B-UNK
-	O
range	B-UNK
PCR	B-UNK
.	O

Diagnostic	B-UNK
DNA	B-UNK
analyses	O
should	O
include	O
a	O
comprehensive	O
examination	B-UNK
of	O
the	O
whole	O
relevant	O
gene	B-UNK
in	O
the	O
patient	B-UNK
and	O
confirmation	O
of	O
carrier	B-UNK
status	I-UNK
in	O
both	O
parents	O
..	O

Early	B-UNK
onset	I-UNK
of	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
in	O
a	O
boy	B-UNK
with	O
emerin	O
gene	B-UNK
deletion	B-UNK
.	O

A	O
boy	B-UNK
developed	O
contractures	B-DISEASE
of	O
the	O
Achilles	O
tendons	O
at	O
3	O
years	O
and	O
of	O
the	O
postcervical	O
muscles	O
at	O
7	O
years	O
,	O
although	O
neither	O
contractures	B-DISEASE
of	O
the	O
elbows	O
nor	O
cardiac	B-UNK
abnormality	O
were	O
recognized	O
by	O
the	O
age	B-UNK
of	O
9	O
years	O
.	O

Muscle	B-UNK
computed	O
tomography	O
scanning	O
revealed	B-UNK
changes	O
characteristic	B-UNK
of	O
muscle	B-UNK
involvement	B-UNK
.	O

Emerin	O
was	O
not	O
detected	B-UNK
in	O
the	O
biopsied	O
muscle	B-UNK
,	O
and	O
RT	O
-	O
PCR	B-UNK
and	O
PCR	B-UNK
-	O
based	B-UNK
genomic	B-UNK
DNA	I-UNK
analyses	O
of	O
the	O
emerin	O
gene	B-UNK
demonstrated	O
no	O
amplification	B-UNK
product	B-UNK
in	O
the	O
patient	B-UNK
.	O

These	O
results	B-UNK
confirmed	B-UNK
the	O
diagnosis	B-UNK
of	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
(	O
EDMD	B-UNK
)	O
,	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	B-UNK
genetic	I-UNK
diagnosis	B-UNK
of	O
the	O
membrane	B-UNK
protein	I-UNK
emerin	O
in	O
younger	O
patients	B-UNK
with	O
possible	O
EDMD	B-UNK
before	O
appearance	O
of	O
the	O
typical	O
symptoms	B-UNK
,	O
to	O
avoid	O
sudden	B-DISEASE
cardiac	I-DISEASE
death	I-DISEASE
..	O

Duchenne	B-UNK
/	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
:	O
correlation	B-UNK
of	O
phenotype	B-UNK
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	B-UNK
mutations	B-UNK
.	O

The	O
dark	O
-	O
adapted	O
electroretinogram	O
(	O
ERG	B-UNK
)	O
of	O
patients	B-UNK
with	O
Duchenne	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
/	O
BMD	B-UNK
)	O
shows	O
a	O
marked	B-UNK
reduction	B-UNK
in	O
b	O
-	O
wave	O
amplitude	O
.	O

Genotype	B-UNK
-	O
phenotype	B-UNK
studies	B-UNK
of	O
mouse	B-UNK
models	O
for	O
DMD	B-UNK
show	O
position	B-UNK
-	O
specific	B-UNK
effects	B-UNK
of	O
the	O
mutations	B-UNK
upon	O
the	O
phenotype	B-UNK
mice	B-UNK
with	O
5	O
defects	B-UNK
of	O
dystrophin	B-UNK
have	O
normal	B-UNK
ERGs	O
,	O
those	O
with	O
defects	B-UNK
in	O
the	O
central	B-UNK
region	B-UNK
have	O
a	O
normal	B-UNK
b	O
-	O
wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b	O
-	O
wave	O
and	O
oscillatory	O
potentials	O
,	O
and	O
mice	B-UNK
with	O
3	O
defects	B-UNK
have	O
a	O
phenotype	B-UNK
similar	B-UNK
to	O
that	O
seen	O
in	O
DMD	B-UNK
/	O
BMD	B-UNK
patients	B-UNK
.	O

The	O
mouse	B-UNK
studies	B-UNK
suggest	B-UNK
a	O
key	B-UNK
role	B-UNK
for	O
the	O
carboxyl	O
terminal	B-UNK
dystrophin	B-UNK
isoform	O
,	O
Dp260	O
,	O
in	O
retinal	B-UNK
electrophysiology	O
.	O

We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	B-UNK
of	O
DMD	B-UNK
/	O
BMD	B-UNK
patients	B-UNK
through	O
clinical	B-UNK
examination	B-UNK
and	O
review	O
of	O
the	O
literature	O
in	O
order	B-UNK
to	O
determine	B-UNK
whether	O
the	O
position	B-UNK
-	O
specific	B-UNK
effects	B-UNK
of	O
mutations	B-UNK
noted	O
in	O
the	O
mouse	B-UNK
are	O
present	B-UNK
in	O
man	B-UNK
.	O

We	O
have	O
found	O
that	O
,	O
in	O
man	B-UNK
,	O
a	O
wider	O
variation	B-UNK
of	O
DMD	B-UNK
defects	B-UNK
correlate	O
with	O
reductions	O
in	O
the	O
b	O
-	O
wave	O
amplitude	O
.	O

Individuals	B-UNK
with	O
normal	B-UNK
ERGs	O
have	O
mutations	B-UNK
predominantly	O
located	B-UNK
5	O
of	O
the	O
transcript	B-UNK
initiation	O
site	B-UNK
of	O
Dp260	O
.	O

Our	O
results	B-UNK
suggest	B-UNK
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	B-UNK
b	O
-	O
wave	O
phenotype	B-UNK
is	O
the	O
mutation	B-UNK
position	B-UNK
,	O
rather	O
than	O
muscle	B-UNK
disease	B-DISEASE
severity	B-UNK
.	O

Forty	O
-	O
six	O
per	O
cent	O
of	O
patients	B-UNK
with	O
mutations	B-UNK
5	O
of	O
the	O
Dp260	O
transcript	B-UNK
start	O
site	B-UNK
have	O
abnormal	O
ERGs	O
,	O
as	O
opposed	O
to	O
94	O
%	O
with	O
more	O
distal	B-UNK
mutations	B-UNK
.	O

The	O
human	B-UNK
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
are	O
consistent	B-UNK
with	O
a	O
role	B-UNK
for	O
Dp260	O
in	O
normal	B-UNK
retinal	B-UNK
electrophysiology	O
and	O
may	O
also	O
reflect	O
the	O
expression	B-UNK
of	O
other	O
C	O
-	O
terminal	B-UNK
dystrophin	B-UNK
isoforms	O
and	O
their	O
contributions	O
to	O
retinal	B-UNK
signal	B-UNK
transmission	B-UNK
..	O

Cis	B-UNK
and	O
trans	O
effects	B-UNK
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
mutation	B-UNK
in	O
a	O
cell	B-UNK
culture	B-UNK
model	B-UNK
.	O

The	O
mutation	B-UNK
causing	I-UNK
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
has	O
been	O
identified	B-UNK
as	O
a	O
CTG	B-UNK
expansion	B-UNK
in	O
the	O
3-untranslated	O
region	B-UNK
(	O
3-UTR	O
)	O
of	O
the	O
DM	B-DISEASE
protein	B-UNK
kinase	I-UNK
gene	B-UNK
(	O
DMPK	B-UNK
)	O
,	O
but	O
the	O
mechanism	B-UNK
(	O
s	O
)	O
of	O
pathogenesis	B-UNK
remain	O
unknown	O
.	O

Studies	B-UNK
using	O
DM	B-DISEASE
patient	B-UNK
materials	O
have	O
often	O
produced	O
confusing	O
results	B-UNK
.	O

Therefore	O
,	O
to	O
study	B-UNK
the	O
effects	B-UNK
of	O
the	O
DM	B-DISEASE
mutation	B-UNK
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	B-UNK
culture	B-UNK
model	B-UNK
system	O
using	O
C2C12	O
mouse	B-UNK
myoblasts	O
.	O

By	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	B-UNK
fused	O
to	O
a	O
human	B-UNK
DMPK	B-UNK
3-UTR	O
,	O
we	O
identified	B-UNK
both	O
cis	B-UNK
and	O
trans	O
effects	B-UNK
that	O
are	O
mediated	O
by	O
the	O
DM	B-UNK
mutation	B-UNK
.	O

Our	O
data	B-UNK
show	O
that	O
a	O
mutant	B-UNK
DMPK	B-UNK
3-UTR	O
,	O
with	O
as	O
few	O
as	O
57	O
CTGs	O
,	O
had	O
a	O
negative	B-UNK
cis	B-UNK
effect	B-UNK
on	O
protein	B-UNK
expression	B-UNK
and	O
resulted	B-UNK
in	O
the	O
aggregation	O
of	O
reporter	O
transcripts	O
into	O
discrete	O
nuclear	B-UNK
foci	O
.	O

We	O
determined	B-UNK
by	O
deletion	B-UNK
analysis	B-UNK
that	O
an	O
expanded	B-UNK
(	O
CTG	B-UNK
)	O
(	O
n	O
)	O
tract	O
alone	O
was	O
sufficient	O
to	O
mediate	O
these	O
cis	B-UNK
effects	B-UNK
.	O

Furthermore	O
,	O
in	O
contrast	B-UNK
to	O
the	O
normal	B-UNK
DMPK	B-UNK
3-UTR	O
mRNA	O
,	O
a	O
mutant	B-UNK
DMPK	B-UNK
3-UTR	O
mRNA	O
with	O
(	O
CUG	B-UNK
)	O
(	O
200	O
)	O
selectively	O
inhibited	O
myogenic	O
differentiation	B-UNK
of	O
C2C12	O
myoblasts	O
.	O

Genetic	B-UNK
analysis	I-UNK
and	O
the	O
Cre	O
-	O
loxP	O
system	O
were	O
used	O
to	O
clearly	O
demonstrate	B-UNK
that	O
the	O
myoblast	O
fusion	B-UNK
defect	B-UNK
could	O
be	O
rescued	O
by	O
eliminating	O
the	O
expression	B-UNK
of	O
the	O
mutant	B-UNK
DMPK	B-UNK
3-UTR	O
transcript	B-UNK
.	O

Characterization	B-UNK
of	O
spontaneous	O
deletion	B-UNK
events	O
mapped	B-UNK
the	O
inhibitory	O
effect	B-UNK
to	O
the	O
(	O
CTG	B-UNK
)	O
(	O
n	O
)	O
expansion	B-UNK
and	O
/	O
or	O
the	O
3	O
end	B-UNK
of	O
the	O
DMPK	B-UNK
3-UTR	O
.	O

These	O
results	B-UNK
provide	I-UNK
evidence	B-UNK
that	O
the	O
DM	B-UNK
mutation	B-UNK
acts	O
in	O
cis	B-UNK
to	O
reduce	O
protein	B-UNK
production	O
(	O
consistent	B-UNK
with	O
DMPK	B-UNK
haploinsufficiency	O
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
..	O

Coats	O
'	O
disease	B-DISEASE
of	O
the	O
retina	O
(	O
unilateral	O
retinal	B-DISEASE
telangiectasis	I-DISEASE
)	O
caused	B-UNK
by	O
somatic	B-UNK
mutation	B-UNK
in	O
the	O
NDP	B-UNK
gene	B-UNK
:	O
a	O
role	B-UNK
for	O
norrin	O
in	O
retinal	B-UNK
angiogenesis	O
.	O

Coats	O
disease	B-DISEASE
is	O
characterized	B-UNK
by	O
abnormal	O
retinal	B-UNK
vascular	O
development	B-UNK
(	O
so	O
-	O
called	O
retinal	B-DISEASE
telangiectasis	I-DISEASE
)	O
which	O
results	B-UNK
in	O
massive	O
intraretinal	O
and	O
subretinal	O
lipid	O
accumulation	B-UNK
(	O
exudative	O
retinal	B-DISEASE
detachment	I-DISEASE
)	O
.	O

The	O
classical	O
form	B-UNK
of	O
Coats	O
disease	B-DISEASE
is	O
almost	O
invariably	O
isolated	B-UNK
,	O
unilateral	O
and	O
seen	O
in	O
males	B-UNK
.	O

A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	O
disease	B-DISEASE
gave	O
birth	O
to	O
a	O
son	O
affected	B-UNK
by	O
Norrie	B-DISEASE
disease	I-DISEASE
.	O

Both	O
carried	O
a	O
missense	B-UNK
mutation	I-UNK
within	O
the	O
NDP	B-UNK
gene	B-UNK
on	O
chromosome	B-UNK
Xp11	O
.	O

2	O
2	O
.	O

Subsequently	B-UNK
analysis	B-UNK
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	B-UNK
with	O
Coats	O
disease	B-UNK
demonstrated	O
in	O
one	O
a	O
somatic	B-UNK
mutation	B-UNK
in	O
the	O
NDP	B-UNK
gene	B-UNK
which	O
was	O
not	O
present	B-UNK
within	O
non-retinal	O
tissue	B-UNK
.	O

We	O
suggest	B-UNK
that	O
Coats	O
telangiectasis	B-DISEASE
is	O
secondary	O
to	O
somatic	B-UNK
mutation	B-UNK
in	O
the	O
NDP	B-UNK
gene	B-UNK
which	O
results	B-UNK
in	O
a	O
deficiency	B-UNK
of	O
norrin	O
(	O
the	O
protein	B-UNK
product	I-UNK
of	O
the	O
NDP	B-UNK
gene	B-UNK
)	O
within	O
the	O
developing	O
retina	O
.	O

This	O
supports	O
recent	O
observations	B-UNK
that	O
the	O
protein	B-UNK
is	O
critical	B-UNK
for	O
normal	B-UNK
retinal	B-UNK
vasculogenesis	O
.	O

Hereditary	B-UNK
TP53	B-UNK
codon	B-UNK
292	O
and	O
somatic	B-UNK
P16INK4A	B-UNK
codon	B-UNK
94	O
mutations	B-UNK
in	O
a	O
Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
family	B-UNK
.	O

Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
disorder	B-UNK
that	O
is	O
characterized	B-UNK
by	O
various	O
types	B-UNK
of	O
cancer	B-UNK
in	O
childhood	O
and	O
adult	B-UNK
cases	B-UNK
.	O

Although	O
hereditary	B-UNK
TP53	B-UNK
mutation	B-UNK
is	O
very	O
rare	B-UNK
in	O
different	O
human	B-UNK
cancers	B-UNK
,	O
it	O
has	O
been	O
frequently	O
reported	B-UNK
in	O
Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
.	O

On	O
the	O
other	O
hand	O
,	O
hereditary	B-UNK
mutations	B-UNK
of	O
TP57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	B-UNK
,	O
which	O
affect	O
the	O
cell	B-UNK
cycle	I-UNK
similar	B-UNK
to	O
TP53	B-UNK
,	O
were	O
observed	B-UNK
in	O
some	O
types	B-UNK
of	O
cancer	B-DISEASE
.	O

In	O
a	O
Turkish	O
family	B-UNK
with	O
the	O
diagnosis	B-UNK
of	O
Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
,	O
we	O
analyzed	B-UNK
the	O
mutation	B-UNK
pattern	B-UNK
of	O
TP53	B-UNK
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	B-UNK
in	O
the	O
peripheral	B-UNK
blood	I-UNK
,	O
and	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
(	O
homo	O
/	O
hemizygous	B-UNK
deletion	B-UNK
)	O
pattern	B-UNK
of	O
TP53	B-UNK
and	O
P15INK4B	O
/	O
P16INK4A	B-UNK
in	O
two	O
tumor	B-UNK
tissues	O
.	O

The	O
propositus	O
had	O
a	O
seminoma	B-DISEASE
,	O
his	O
daughter	O
a	O
medulloblastoma	B-DISEASE
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
TP53	B-UNK
codon	B-UNK
292	O
missense	B-UNK
point	B-UNK
mutation	I-UNK
(	O
AAA--	O
>	O
ATA	O
;	O
Lys--	O
>	O
Ile	O
)	O
in	O
the	O
peripheral	B-UNK
blood	I-UNK
cells	B-UNK
.	O

Tumor	B-UNK
tissue	B-UNK
obtained	B-UNK
from	O
the	O
propositus	O
with	O
the	O
seminoma	B-DISEASE
revealed	B-UNK
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
in	O
the	O
TP53	B-UNK
gene	B-UNK
.	O

In	O
the	O
analyses	O
of	O
tumor	B-DISEASE
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
P16INK4A	B-UNK
codon	B-UNK
94	O
missense	B-UNK
point	B-UNK
mutation	I-UNK
(	O
GCG--	O
>	O
GAG	O
;	O
Ala--	O
>	O
Glu	B-UNK
)	O
was	O
observed	B-UNK
with	O
the	O
hereditary	B-UNK
TP53	B-UNK
mutation	B-UNK
.	O

P16INK4A	B-UNK
codon	B-UNK
94	O
mutation	B-UNK
observed	B-UNK
in	O
our	O
family	B-UNK
is	O
a	O
novel	O
mutation	B-UNK
in	O
Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
.	O

No	O
other	O
gene	B-UNK
alteration	O
in	O
TP53	B-UNK
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	B-UNK
was	O
observed	B-UNK
.	O

Existence	O
of	O
the	O
P16INK4A	B-UNK
mutation	B-UNK
and	O
the	O
hereditary	B-UNK
TP53	B-UNK
mutation	B-UNK
with	O
or	O
without	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
in	O
the	O
TP53	B-UNK
gene	B-UNK
(	O
seminoma	B-DISEASE
/	O
medulloblastoma	B-DISEASE
)	O
may	O
be	O
evidence	B-UNK
for	O
a	O
common	B-UNK
mechanism	B-UNK
involved	B-UNK
in	O
tumorogenesis	O
.	O

The	O
gene	B-UNK
alterations	B-UNK
in	O
TP53	B-UNK
and	O
P16INK4A	B-UNK
genes	B-UNK
may	O
be	O
used	O
as	O
tumor	B-DISEASE
markers	B-UNK
in	O
our	O
family	B-UNK
..	O

A	O
novel	O
mutation	B-UNK
in	O
the	O
sodium	B-UNK
/	O
iodide	B-UNK
symporter	O
gene	B-UNK
in	O
the	O
largest	O
family	B-UNK
with	O
iodide	B-UNK
transport	B-UNK
defect	B-UNK
.	O

We	O
previously	B-UNK
reported	I-UNK
nine	O
children	O
with	O
an	O
autosomally	O
recessive	B-UNK
form	B-UNK
of	O
congenital	B-DISEASE
hypothyroidism	I-DISEASE
due	O
to	O
an	O
iodide	B-UNK
transport	B-UNK
defect	B-UNK
in	O
a	O
large	B-UNK
Hutterite	O
family	B-UNK
with	O
extensive	B-UNK
consanguinity	O
living	O
in	O
central	B-UNK
Canada	O
.	O

Since	O
the	O
original	O
report	B-UNK
,	O
we	O
have	O
diagnosed	O
congenital	B-DISEASE
hypothyroidism	I-DISEASE
by	O
newborn	O
TSH	O
screening	B-UNK
in	O
9	O
additional	O
children	O
from	O
the	O
family	B-UNK
.	O

We	O
performed	O
direct	B-UNK
sequencing	I-UNK
of	O
the	O
PCR	B-UNK
products	I-UNK
of	O
each	O
NIS	O
(	O
sodium	B-UNK
/	O
iodide	B-UNK
symporter	O
)	O
gene	B-UNK
exon	B-UNK
with	O
flanking	O
introns	O
amplified	O
from	O
genomic	B-UNK
DNA	I-UNK
extracted	O
from	O
peripheral	B-UNK
blood	I-UNK
cells	B-UNK
of	O
the	O
patients	B-UNK
.	O

We	O
identified	B-UNK
a	O
novel	O
NIS	O
gene	B-UNK
mutation	B-UNK
,	O
G395R	O
(	O
Gly395	O
-	O
-	O
>	O
Arg	B-UNK
;	O
GGA--	O
>	O
AGA	B-UNK
)	O
,	O
in	O
10	O
patients	B-UNK
examined	O
in	O
the	O
present	B-UNK
study	B-UNK
.	O

All	O
of	O
the	O
parents	O
tested	O
were	O
heterozygous	B-UNK
for	O
the	O
mutation	B-UNK
,	O
suggesting	O
that	O
the	O
patients	B-UNK
were	O
homozygous	B-UNK
.	O

The	O
mutation	B-UNK
was	O
located	B-UNK
in	O
the	O
10th	O
transmembrane	B-UNK
helix	O
.	O

Expression	B-UNK
experiments	O
by	O
transfection	O
of	O
the	O
mutant	B-UNK
NIS	O
complimentary	O
DNA	B-UNK
into	O
COS-7	O
cells	B-UNK
showed	O
no	O
perchlorate	O
-	O
sensitive	B-UNK
iodide	B-UNK
uptake	O
,	O
confirming	O
that	O
the	O
mutation	B-UNK
is	O
the	O
direct	B-UNK
cause	O
of	O
the	O
iodide	B-UNK
transport	B-UNK
defect	B-UNK
in	O
these	O
patients	B-UNK
.	O

A	O
patient	B-UNK
who	O
showed	O
an	O
intermediate	O
saliva	O
/	O
serum	B-UNK
technetium	O
ratio	B-UNK
(	O
14	O
.	O
0	O
;	O
normal	B-UNK
,	O
>	O
or	O
=	O
20	O
)	O
and	O
was	O
considered	O
to	O
have	O
a	O
partial	O
or	O
less	O
severe	B-UNK
defect	B-UNK
in	O
the	O
previous	B-UNK
report	B-UNK
(	O
IX-24	O
)	O
did	O
not	O
have	O
a	O
NIS	O
gene	B-UNK
mutation	B-UNK
.	O

It	O
is	O
now	O
possible	O
to	O
use	O
gene	B-UNK
diagnostics	O
of	O
this	O
unique	O
NIS	O
mutation	B-UNK
to	O
identify	B-UNK
patients	B-UNK
with	O
congenital	B-DISEASE
hypothyroidism	I-DISEASE
due	O
to	O
an	O
iodide	B-UNK
transport	B-UNK
defect	B-UNK
in	O
this	O
family	B-UNK
and	O
to	O
determine	B-UNK
the	O
carrier	B-UNK
state	B-UNK
of	O
potential	B-UNK
parents	O
for	O
genetic	B-UNK
counseling	I-UNK
and	O
arranging	O
rapid	O
and	O
early	B-UNK
diagnosis	B-UNK
of	O
their	O
infants	O
.	O

Molecular	B-UNK
analysis	I-UNK
in	O
familial	B-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
:	O
early	B-UNK
diagnosis	B-UNK
of	O
an	O
asymptomatic	B-UNK
carrier	B-UNK
.	O

Familial	B-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
(	O
FNDI	O
)	O
is	O
an	O
inherited	B-UNK
deficiency	B-UNK
of	O
the	O
hormone	B-UNK
arginine	O
vasopressin	O
(	O
AVP	B-UNK
)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	B-UNK
dominant	I-UNK
trait	O
.	O

In	O
the	O
present	B-UNK
study	B-UNK
we	O
have	O
analyzed	B-UNK
the	O
AVP	B-UNK
-	O
neurophysin	O
II	B-UNK
(	O
AVP	B-UNK
-	O
NPII	B-UNK
)	O
gene	B-UNK
in	O
a	O
Spanish	O
kindred	O
.	O

Studies	B-UNK
were	O
performed	O
on	O
seven	O
members	B-UNK
(	O
four	O
clinically	O
affected	B-UNK
)	O
of	O
the	O
family	B-UNK
.	O

Patients	B-UNK
were	O
diagnosed	O
at	O
the	O
Hospital	O
Universitario	O
Gregorio	O
Maranon	O
(	O
Madrid	O
,	O
Spain	O
)	O
.	O

The	O
entire	O
coding	B-UNK
region	I-UNK
of	O
the	O
AVP	B-UNK
-	O
NPII	B-UNK
gene	B-UNK
of	O
all	O
family	B-UNK
members	I-UNK
was	O
amplified	O
by	O
PCR	B-UNK
and	O
sequenced	O
.	O

All	O
affected	B-UNK
individuals	I-UNK
presented	B-UNK
a	O
missense	B-UNK
mutation	I-UNK
(	O
G1757	O
-	O
-	O
>	O
A	O
)	O
that	O
replaces	O
glycine	O
at	O
position	B-UNK
23	O
with	O
arginine	O
within	O
the	O
NPII	B-UNK
domain	B-UNK
.	O

The	O
substitution	B-UNK
was	O
confirmed	B-UNK
by	O
restriction	B-UNK
endonuclease	O
analysis	B-UNK
and	O
was	O
present	B-UNK
in	O
heterozygosis	O
.	O

Additionally	O
,	O
one	O
of	O
the	O
asymptomatic	B-UNK
relatives	B-UNK
(	O
a	O
girl	O
8	O
months	O
old	O
at	O
the	O
time	O
of	O
study	B-UNK
)	O
was	O
identified	B-UNK
as	O
carrier	B-UNK
of	O
the	O
same	O
mutation	B-UNK
and	O
developed	O
the	O
disease	B-DISEASE
3	O
months	O
later	O
.	O

The	O
alteration	O
found	O
in	O
the	O
second	O
exon	B-UNK
of	O
the	O
gene	B-UNK
in	O
this	O
family	B-UNK
seems	O
to	O
be	O
responsible	B-UNK
for	O
the	O
disease	B-UNK
,	O
as	O
all	O
individuals	B-UNK
harboring	O
the	O
mutation	B-UNK
had	O
been	O
previously	B-UNK
diagnosed	O
or	O
have	O
eventually	O
developed	O
FNDI	O
.	O

Identification	B-UNK
of	O
the	O
molecular	B-UNK
defect	B-UNK
underlying	O
FNDI	O
in	O
affected	B-UNK
families	B-UNK
is	O
a	O
powerful	O
tool	O
for	O
early	B-UNK
asymptomatic	B-UNK
diagnosis	B-UNK
in	O
infants	O
..	O

Deficit	O
of	O
in	O
vivo	B-UNK
mitochondrial	B-UNK
ATP	B-UNK
production	O
in	O
patients	B-UNK
with	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
.	O

Friedreich	B-UNK
ataxia	I-UNK
(	O
FRDA	B-UNK
)	O
,	O
the	O
most	O
common	B-UNK
of	O
the	O
inherited	B-UNK
ataxias	O
,	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
degenerative	O
disorder	B-UNK
,	O
characterized	B-UNK
clinically	O
by	O
onset	B-UNK
before	O
the	O
age	B-UNK
of	O
25	O
of	O
progressive	B-UNK
gait	O
and	O
limb	O
ataxia	B-UNK
,	O
absence	B-UNK
of	O
deep	O
tendon	O
reflexes	O
,	O
extensor	O
plantar	O
responses	B-UNK
,	O
and	O
loss	B-UNK
of	O
position	B-UNK
and	O
vibration	O
sense	O
in	O
the	O
lower	O
limbs	O
.	O

FRDA	B-UNK
is	O
caused	B-UNK
by	O
a	O
GAA	B-UNK
triplet	O
expansion	B-UNK
in	O
the	O
first	O
intron	B-UNK
of	O
the	O
FRDA	B-UNK
gene	B-UNK
on	O
chromosome	B-UNK
9q13	O
in	O
97	O
%	O
of	O
patients	B-UNK
.	O

The	O
FRDA	B-UNK
gene	B-UNK
encodes	B-UNK
a	O
widely	O
expressed	B-UNK
210-aa	O
protein	B-UNK
,	O
frataxin	B-UNK
,	O
which	O
is	O
located	B-UNK
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	B-UNK
patients	B-UNK
.	O

Frataxin	B-UNK
function	B-UNK
is	O
still	O
unknown	O
but	O
the	O
knockout	B-UNK
of	O
the	O
yeast	B-UNK
frataxin	B-UNK
homologue	B-UNK
gene	B-UNK
(	O
YFH1	O
)	O
showed	O
a	O
severe	B-UNK
defect	B-UNK
of	O
mitochondrial	B-UNK
respiration	O
and	O
loss	B-UNK
of	O
mtDNA	O
associated	O
with	O
elevated	B-UNK
intramitochondrial	O
iron	B-UNK
.	O

Here	O
we	O
report	B-UNK
in	O
vivo	B-UNK
evidence	B-UNK
of	O
impaired	B-UNK
mitochondrial	B-UNK
respiration	O
in	O
skeletal	B-UNK
muscle	I-UNK
of	O
FRDA	B-UNK
patients	B-UNK
.	O

Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	B-UNK
rate	B-UNK
of	O
muscle	B-UNK
mitochondrial	B-UNK
ATP	B-UNK
production	O
(	O
V	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	B-UNK
range	B-UNK
in	O
all	O
12	O
FRDA	B-UNK
patients	B-UNK
and	O
a	O
strong	B-UNK
negative	B-UNK
correlation	B-UNK
between	O
mitochondrial	B-UNK
V	O
(	O
max	O
)	O
and	O
the	O
number	B-UNK
of	O
GAA	B-UNK
repeats	B-UNK
in	O
the	O
smaller	O
allele	B-UNK
.	O

Our	O
results	B-UNK
show	O
that	O
FRDA	B-UNK
is	O
a	O
nuclear	B-UNK
-	O
encoded	B-UNK
mitochondrial	B-UNK
disorder	B-UNK
affecting	O
oxidative	O
phosphorylation	B-UNK
and	O
give	O
a	O
rationale	O
for	O
treatments	O
aimed	O
to	O
improve	O
mitochondrial	B-UNK
function	B-UNK
in	O
this	O
condition	B-UNK
..	O

Identification	B-UNK
of	O
a	O
novel	O
R21X	O
mutation	B-UNK
in	O
the	O
liver	B-UNK
-	O
type	B-UNK
arginase	O
gene	B-UNK
(	O
ARG1	O
)	O
in	O
four	O
Portuguese	O
patients	B-UNK
with	O
argininemia	O
.	O

Argininemia	O
is	O
a	O
rare	B-UNK
autossomal	O
recessive	B-UNK
disorder	B-UNK
caused	B-UNK
by	O
deficiency	B-UNK
in	O
the	O
cytosolic	O
liver	B-UNK
-	O
type	B-UNK
arginase	O
enzyme	B-UNK
(	O
L	O
-	O
arginine	O
urea	O
-	O
hydrolase	O
;	O
E.	O
C.	O
3	O
.	O
5	O
.	O
3	O
.	O
1	O
)	O
.	O

In	O
order	B-UNK
to	O
investigate	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
for	O
argininemia	O
in	O
four	O
unrelated	B-UNK
Portuguese	O
patients	B-UNK
(	O
two	O
from	O
northern	B-UNK
Portugal	O
and	O
two	O
from	O
Madeira	O
Island	B-UNK
)	O
we	O
performed	O
a	O
DNA	B-UNK
sequence	I-UNK
analysis	B-UNK
of	O
all	O
the	O
exons	O
and	O
exon	B-UNK
/	O
intron	B-UNK
boundaries	O
of	O
the	O
liver	B-UNK
-	O
type	B-UNK
arginase	O
gene	B-UNK
(	O
ARG1	O
)	O
.	O

All	O
patients	B-UNK
were	O
found	O
to	O
be	O
homozygous	B-UNK
for	O
a	O
newly	O
identified	B-UNK
C-	O
>	O
T	O
transition	B-UNK
in	O
codon	B-UNK
21	O
(	O
exon	B-UNK
2	O
)	O
substituting	O
arginine	O
for	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
(	O
R21X	O
CGA	O
to	O
TGA	O
)	O
and	O
generating	O
a	O
NlaIII	O
restriction	B-UNK
site	B-UNK
.	O

Restriction	B-UNK
digestion	O
following	O
PCR	B-UNK
amplification	B-UNK
of	O
ARG1	O
exon	B-UNK
2	O
confirmed	B-UNK
the	O
presence	O
of	O
the	O
mutation	B-UNK
.	O

Mutation	B-UNK
of	O
the	O
sterol	O
27-hydroxylase	O
gene	B-UNK
(	O
CYP27	B-UNK
)	O
results	B-UNK
in	O
truncation	B-UNK
of	O
mRNA	O
expressed	B-UNK
in	O
leucocytes	O
in	O
a	O
Japanese	B-UNK
family	B-UNK
with	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
.	O

OBJECTIVES	O
A	O
Japanese	B-UNK
family	B-UNK
with	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
)	O
was	O
investigated	O
for	O
a	O
sequence	B-UNK
alteration	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	B-UNK
(	O
CYP27	B-UNK
)	O
.	O

The	O
expression	B-UNK
of	O
CYP27	B-UNK
has	O
been	O
mostly	O
explored	O
using	O
cultured	O
fibroblasts	B-UNK
,	O
prompting	O
the	O
examination	B-UNK
of	O
the	O
transcripts	O
from	O
blood	B-UNK
leucocytes	O
as	O
a	O
simple	O
and	O
rapid	O
technique	O
.	O

METHODS	O
An	O
alteration	O
in	O
CYP27	B-UNK
of	O
the	O
proband	B-UNK
was	O
searched	O
for	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
single	B-UNK
strand	I-UNK
conformation	I-UNK
polymorphism	I-UNK
(	O
PCR	B-UNK
-	O
SSCP	B-UNK
)	O
analysis	B-UNK
and	O
subsequent	B-UNK
sequencing	B-UNK
.	O

Samples	B-UNK
of	O
RNA	B-UNK
were	O
subjected	O
to	O
reverse	B-UNK
transcription	B-UNK
PCR	B-UNK
(	O
RT	O
-	O
PCR	B-UNK
)	O
and	O
the	O
product	B-UNK
of	O
the	O
proband	B-UNK
was	O
amplified	O
with	O
nested	O
primers	O
and	O
sequenced	O
.	O

RESULTS	B-UNK
A	O
homozygous	B-UNK
G	O
to	O
A	O
transition	B-UNK
at	O
the	O
5	O
end	B-UNK
of	O
intron	B-UNK
7	O
was	O
detected	B-UNK
in	O
the	O
patient	B-UNK
.	O

In	O
RT	O
-	O
PCR	B-UNK
analysis	B-UNK
,	O
only	O
a	O
truncated	O
transcript	B-UNK
was	O
detected	B-UNK
in	O
the	O
patient	B-UNK
,	O
whereas	O
both	O
normal	B-UNK
and	O
truncated	O
transcripts	O
were	O
detected	B-UNK
in	O
the	O
siblings	O
.	O

The	O
sequencing	B-UNK
of	O
the	O
patients	B-UNK
cDNA	O
fragment	B-UNK
disclosed	O
a	O
direct	B-UNK
conjuction	O
of	O
exon	B-UNK
6	O
and	O
exon	B-UNK
8	O
.	O

CONCLUSION	B-UNK
The	O
mutation	B-UNK
at	O
splice	B-UNK
donor	I-UNK
site	I-UNK
and	O
the	O
truncation	B-UNK
of	O
mRNA	O
were	O
identical	B-UNK
with	O
those	O
of	O
a	O
recently	O
reported	B-UNK
Italian	B-UNK
patient	B-UNK
,	O
although	O
different	O
in	O
symptomatology	O
.	O

The	O
application	O
of	O
blood	B-UNK
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	O
of	O
CYP27	B-UNK
mRNA	O
..	O

Clinical	B-UNK
and	O
molecular	B-UNK
genetic	I-UNK
analysis	B-UNK
of	O
19	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
kindreds	O
demonstrating	O
a	O
wide	B-UNK
spectrum	B-UNK
of	O
mutations	B-UNK
in	O
WFS1	O
.	O

Wolfram	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
neurodegenerative	B-DISEASE
disorder	I-DISEASE
characterized	B-UNK
by	O
juvenile	O
-	O
onset	B-UNK
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
progressive	B-UNK
optic	B-DISEASE
atrophy	I-DISEASE
.	O

mtDNA	O
deletions	O
have	O
been	O
described	O
,	O
and	O
a	O
gene	B-UNK
(	O
WFS1	O
)	O
recently	O
has	O
been	O
identified	B-UNK
,	O
on	O
chromosome	B-UNK
4p16	O
,	O
encoding	B-UNK
a	O
predicted	B-UNK
890	O
amino	B-UNK
acid	I-UNK
transmembrane	B-UNK
protein	B-UNK
.	O

Direct	B-UNK
DNA	B-UNK
sequencing	I-UNK
was	O
done	O
to	O
screen	B-UNK
the	O
entire	O
coding	B-UNK
region	I-UNK
of	O
the	O
WFS1	O
gene	B-UNK
in	O
30	O
patients	B-UNK
from	O
19	O
British	B-UNK
kindreds	O
with	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
.	O

DNA	B-UNK
was	O
also	O
screened	B-UNK
for	O
structural	B-UNK
rearrangements	O
(	O
deletions	O
and	O
duplications	O
)	O
and	O
point	B-UNK
mutations	I-UNK
in	O
mtDNA	O
.	O

No	O
pathogenic	O
mtDNA	O
mutations	B-UNK
were	O
found	O
in	O
our	O
cohort	B-UNK
.	O

We	O
identified	B-UNK
24	O
mutations	B-UNK
in	O
the	O
WFS1	O
gene	B-UNK
8	O
nonsense	B-UNK
mutations	I-UNK
,	O
8	O
missense	B-UNK
mutations	I-UNK
,	O
3	O
in	O
-	O
frame	B-UNK
deletions	O
,	O
1	O
in	O
-	O
frame	B-UNK
insertion	O
,	O
and	O
4	O
frameshift	B-UNK
mutations	B-UNK
.	O

Of	O
these	O
,	O
23	O
were	O
novel	O
mutations	B-UNK
,	O
and	O
most	O
occurred	B-UNK
in	O
exon	B-UNK
8	O
.	O

The	O
majority	O
of	O
patients	B-UNK
were	O
compound	B-UNK
heterozygotes	I-UNK
for	O
two	O
mutations	B-UNK
,	O
and	O
there	O
was	O
no	O
common	B-UNK
founder	B-UNK
mutation	B-UNK
.	O

The	O
data	B-UNK
were	O
also	O
analyzed	B-UNK
for	O
genotype	B-UNK
-	O
phenotype	B-UNK
relationships	O
.	O

Although	O
some	O
interesting	O
cases	B-UNK
were	O
noted	O
,	O
consideration	O
of	O
the	O
small	O
sample	O
size	B-UNK
and	O
frequency	B-UNK
of	O
each	O
mutation	B-UNK
indicated	O
no	O
clear	O
-	O
cut	O
correlations	B-UNK
between	O
any	O
of	O
the	O
observed	B-UNK
mutations	B-UNK
and	O
disease	B-DISEASE
severity	B-UNK
.	O

There	O
were	O
no	O
obvious	O
mutation	B-UNK
hot	O
spots	O
or	O
clusters	O
.	O

Hence	O
,	O
molecular	B-UNK
screening	B-UNK
for	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
in	O
affected	B-UNK
families	B-UNK
and	O
for	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
-	O
carrier	B-UNK
status	I-UNK
in	O
subjects	B-UNK
with	O
psychiatric	B-DISEASE
disorders	I-DISEASE
or	O
diabetes	B-UNK
mellitus	I-UNK
will	O
require	O
complete	O
analysis	B-UNK
of	O
exon	B-UNK
8	O
and	O
upstream	O
exons	O
..	O

Late	B-UNK
-	O
onset	B-UNK
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
(	O
FMF	B-UNK
):	O
a	O
subset	O
with	O
distinct	O
clinical	B-UNK
,	O
demographic	O
,	O
and	O
molecular	B-UNK
genetic	I-UNK
characteristics	B-UNK
.	O

To	O
determine	B-UNK
the	O
prevalence	B-UNK
and	O
characterize	O
demographic	O
,	O
clinical	B-UNK
,	O
and	O
genetic	B-UNK
features	B-UNK
of	O
familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
(	O
FMF	B-UNK
)	O
of	O
late	B-UNK
onset	I-UNK
,	O
all	O
patients	B-UNK
experiencing	O
their	O
first	O
FMF	B-UNK
attack	O
at	O
age	B-UNK
40	O
years	O
or	O
more	O
were	O
identified	B-UNK
using	O
the	O
computerized	O
registry	O
of	O
our	O
FMF	B-UNK
clinic	O
,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined	O
.	O

The	O
control	B-UNK
group	B-UNK
consisted	O
of	O
40	O
consecutive	O
FMF	B-UNK
patients	B-UNK
,	O
who	O
arrived	O
at	O
the	O
FMF	B-UNK
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	B-UNK
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	B-UNK
.	O

The	O
severity	B-UNK
of	O
the	O
disease	B-DISEASE
in	O
patients	B-UNK
and	O
controls	O
was	O
determined	B-UNK
using	O
a	O
modified	O
score	B-UNK
,	O
developed	O
previously	B-UNK
.	O

Mutational	O
analysis	B-UNK
in	O
the	O
FMF	B-UNK
gene	B-UNK
was	O
performed	O
using	O
a	O
commercial	O
kit	B-UNK
.	O

Only	O
20	O
of	O
4000	O
(	O
0	O
.	O
5	O
%	O
)	O
patients	B-UNK
had	O
late	B-UNK
-	O
onset	B-UNK
FMF	B-UNK
.	O

These	O
patients	B-UNK
were	O
mostly	O
men	B-UNK
,	O
of	O
non-North	O
African	B-UNK
origin	O
,	O
P	O
<	O
0	O
.	O

05	O
compared	B-UNK
to	O
controls	O
.	O

All	O
had	O
abdominal	O
attacks	O
and	O
in	O
most	O
these	O
were	O
the	O
only	O
manifestation	B-UNK
of	O
their	O
disease	B-DISEASE
,	O
P	O
<	O
0	O
.	O

001	O
001	O
.	O

None	O
had	O
chronic	B-UNK
or	O
prolonged	O
manifestations	B-UNK
of	O
FMF	B-UNK
,	O
for	O
example	O
,	O
amyloidosis	B-DISEASE
,	O
chronic	B-UNK
arthritis	B-DISEASE
,	O
or	O
protracted	O
myalgia	B-DISEASE
,	O
P	O
<	O
0	O
.	O

001	O
.	O

The	O
response	B-UNK
to	O
treatment	O
was	O
good	O
despite	O
using	O
low	B-UNK
colchicine	B-UNK
dose	O
,	O
P	O
<	O
0	O
.	O

05	O
.	O

The	O
overall	O
severity	B-UNK
score	B-UNK
indicated	O
a	O
mild	O
disease	B-DISEASE
,	O
P	O
<	O
0	O
.	O

001	O
.	O

Mutational	O
analysis	B-UNK
revealed	I-UNK
absence	B-UNK
of	O
M694V	O
homozygosity	B-UNK
,	O
P	O
<	O
0	O
.	O

01	O
,	O
compared	B-UNK
to	O
our	O
regular	O
FMF	B-UNK
population	B-UNK
.	O

We	O
conclude	O
that	O
the	O
onset	B-UNK
of	O
FMF	B-UNK
in	O
a	O
late	B-UNK
age	B-UNK
defines	O
a	O
milder	B-UNK
form	B-UNK
of	O
disease	B-UNK
with	O
typical	O
clinical	B-UNK
,	O
demographic	O
,	O
and	O
molecular	B-UNK
genetic	I-UNK
characteristics	B-UNK

A	O
highly	B-UNK
accurate	O
,	O
low	B-UNK
cost	O
test	B-UNK
for	O
BRCA1	B-UNK
mutations	B-UNK
.	O

The	O
hereditary	B-DISEASE
breast	I-DISEASE
and	I-DISEASE
ovarian	I-DISEASE
cancer	I-DISEASE
syndrome	I-DISEASE
is	O
associated	O
with	O
a	O
high	B-UNK
frequency	I-UNK
of	O
BRCA1	B-UNK
mutations	B-UNK
.	O

However	O
,	O
the	O
widespread	O
use	O
of	O
BRCA1	B-UNK
testing	B-UNK
has	O
been	O
limited	O
to	O
date	B-UNK
by	O
three	O
principal	O
concerns	O
the	O
fear	O
of	O
loss	B-UNK
of	O
health	O
and	O
life	B-UNK
insurance	O
,	O
the	O
uncertain	O
clinical	B-UNK
value	O
of	O
a	O
positive	O
test	B-UNK
result	B-UNK
,	O
and	O
the	O
current	B-UNK
lack	B-UNK
of	O
an	O
inexpensive	O
and	O
sensitive	B-UNK
screening	B-UNK
test	B-UNK
for	O
BRCA1	B-UNK
mutations	B-UNK
.	O

We	O
have	O
developed	O
an	O
inexpensive	O
system	O
for	O
gene	B-UNK
mutational	O
scanning	O
,	O
based	B-UNK
on	O
a	O
combination	B-UNK
of	O
extensive	B-UNK
multiplex	O
PCR	B-UNK
amplification	B-UNK
and	O
two	O
dimensional	O
electrophoresis	B-UNK
.	O

The	O
efficiency	O
of	O
this	O
system	O
,	O
as	O
a	O
screening	B-UNK
test	B-UNK
for	O
BRCA1	B-UNK
mutations	B-UNK
,	O
was	O
evaluated	O
in	O
a	O
panel	B-UNK
of	O
60	O
samples	B-UNK
from	O
high	B-UNK
risk	I-UNK
women	B-UNK
,	O
14	O
of	O
which	O
contained	O
a	O
previously	B-UNK
identified	I-UNK
mutation	B-UNK
in	O
BRCA1	B-UNK
.	O

All	O
14	O
mutations	B-UNK
were	O
identified	B-UNK
,	O
as	O
well	O
as	O
an	O
additional	O
five	O
that	O
had	O
previously	B-UNK
escaped	O
detection	B-UNK
.	O

In	O
addition	B-UNK
to	O
the	O
19	O
mutations	B-UNK
,	O
a	O
total	B-UNK
of	O
15	O
different	O
polymorphic	B-UNK
variants	B-UNK
were	O
scored	O
,	O
most	O
of	O
which	O
were	O
recurring	O
.	O

All	O
were	O
confirmed	B-UNK
by	O
nucleotide	B-UNK
sequencing	B-UNK
.	O

The	O
cost	O
of	O
screening	B-UNK
per	O
sample	O
was	O
calculated	O
to	O
be	O
approximately	O
US	O
$	O
70	O
for	O
the	O
manual	O
technique	O
used	O
in	O
this	O
study	B-UNK
,	O
and	O
may	O
be	O
reduced	O
to	O
approximately	O
US	O
$	O
10	O
with	O
the	O
introduction	O
of	O
commercially	O
available	O
PCR	B-UNK
robotics	O
and	O
fluorescent	O
imaging	O
.	O

Implementation	O
of	O
this	O
method	O
of	O
mutation	B-UNK
screening	B-UNK
in	O
the	O
research	O
and	O
clinical	B-UNK
setting	O
should	O
permit	O
rapid	O
accrual	O
of	O
quantitative	B-UNK
data	B-UNK
on	O
genotype	B-UNK
-	O
phenotype	B-UNK
associations	O
for	O
the	O
evaluation	B-UNK
of	O
diagnostic	B-UNK
testing	B-UNK
..	O

Maternal	O
uniparental	B-DISEASE
disomy	I-DISEASE
for	O
chromosome	B-UNK
14	O
in	O
a	O
boy	B-UNK
with	O
a	O
normal	B-UNK
karyotype	O
.	O

We	O
report	B-UNK
on	O
a	O
boy	B-UNK
with	O
a	O
maternal	O
uniparental	B-DISEASE
disomy	I-DISEASE
for	O
chromosome	B-UNK
14	O
(	O
UPD	O
(	O
14	O
)	O
)	O
.	O

At	O
7	O
years	O
of	O
age	B-UNK
he	O
was	O
referred	O
to	O
us	O
by	O
the	O
paediatrician	O
because	O
of	O
symptoms	B-UNK
of	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

He	O
showed	O
short	B-UNK
stature	O
,	O
obesity	B-DISEASE
,	O
mild	O
developmental	O
delay	O
,	O
cryptorchidism	B-DISEASE
,	O
and	O
some	O
mild	O
dysmorphic	O
features	B-UNK
.	O

The	O
history	B-UNK
further	O
indicated	O
intrauterine	B-DISEASE
growth	I-DISEASE
retardation	I-DISEASE
at	O
the	O
end	B-UNK
of	O
the	O
pregnancy	O
.	O

His	O
mother	O
was	O
44	O
years	O
of	O
age	B-UNK
at	O
the	O
time	O
of	O
his	O
birth	O
.	O

After	O
birth	O
he	O
showed	O
hypotonia	B-DISEASE
with	O
poor	O
sucking	O
,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed	O
.	O

Motor	O
development	B-UNK
was	O
delayed	O
.	O

After	O
1	O
year	O
he	O
became	O
obese	B-DISEASE
despite	O
a	O
normal	B-UNK
appetite	O
.	O

Recurrent	O
middle	O
ear	O
infections	B-UNK
,	O
a	O
high	B-UNK
pain	B-DISEASE
threshold	O
,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported	B-UNK
.	O

There	O
were	O
no	O
behavioural	O
problems	O
or	O
sleep	B-DISEASE
disturbance	I-DISEASE
.	O

Chromosomal	B-UNK
analysis	B-UNK
was	O
normal	B-UNK
(	O
46	O
,	O
XY	O
)	O
.	O

DNA	B-UNK
analysis	I-UNK
for	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
showed	O
no	O
abnormalities	B-UNK
.	O

Two	O
years	O
later	O
he	O
was	O
re-examined	O
because	O
we	O
thought	B-UNK
his	O
features	B-UNK
fitted	O
the	O
PWS	B-UNK
-	O
like	O
phenotype	B-UNK
associated	O
with	O
maternal	O
UPD	O
(	O
14	O
)	O
.	O

At	O
that	O
time	O
precocious	O
puberty	O
was	O
evident	O
.	O

DNA	B-UNK
analysis	I-UNK
showed	O
maternal	O
heterodisomy	O
for	O
chromosome	B-UNK
14	O
.	O

In	O
all	O
the	O
previously	B-UNK
described	O
11	O
cases	B-UNK
with	O
maternal	O
UPD	O
(	O
14	O
)	O
,	O
a	O
Robertsonian	O
translocation	B-UNK
involving	O
chromosome	B-UNK
14	O
was	O
detected	B-UNK
cytogenetically	O
before	O
DNA	B-UNK
analysis	I-UNK
.	O

This	O
is	O
the	O
first	O
report	B-UNK
of	O
diagnosis	B-UNK
of	O
maternal	O
UPD	O
(	O
14	O
)	O
based	B-UNK
on	O
clinical	B-UNK
features	I-UNK
.	O

This	O
finding	O
underlines	O
the	O
importance	O
of	O
DNA	B-UNK
analysis	I-UNK
for	O
maternal	O
UPD	O
(	O
14	O
)	O
in	O
patients	B-UNK
with	O
a	O
similar	B-UNK
PWS	B-UNK
-	O
like	O
phenotype	B-UNK
even	O
without	O
previous	B-UNK
identification	B-UNK
of	O
a	O
Robertsonian	O
translocation	B-UNK
involving	O
chromosome	B-UNK
14	O
..	O

Clinical	B-UNK
and	O
genetic	B-UNK
study	B-UNK
of	O
Friedreich	B-UNK
ataxia	I-UNK
in	O
an	O
Australian	O
population	B-UNK
.	O

Friedreich	B-DISEASE
ataxia	I-DISEASE
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
FRDA	B-UNK
gene	B-UNK
that	O
encodes	B-UNK
a	O
210-amino	O
acid	B-UNK
protein	B-UNK
called	O
frataxin	B-UNK
.	O

An	O
expansion	B-UNK
of	O
a	O
GAA	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
in	O
intron	B-UNK
1	O
of	O
the	O
gene	B-UNK
is	O
present	B-UNK
in	O
more	O
than	O
95	O
%	O
of	O
mutant	B-UNK
alleles	I-UNK
.	O

Of	O
the	O
83	O
people	O
we	O
studied	O
who	O
have	O
mutations	B-UNK
in	O
FRDA	B-UNK
,	O
78	O
are	O
homozygous	B-UNK
for	O
an	O
expanded	B-UNK
GAA	B-UNK
repeat	B-UNK
;	O
the	O
other	O
five	O
patients	B-UNK
have	O
an	O
expansion	B-UNK
in	O
one	O
allele	B-UNK
and	O
a	O
point	B-UNK
mutation	I-UNK
in	O
the	O
other	O
.	O

Here	O
we	O
present	B-UNK
a	O
detailed	B-UNK
clinical	B-UNK
and	O
genetic	B-UNK
study	B-UNK
of	O
a	O
subset	O
of	O
51	O
patients	B-UNK
homozygous	B-UNK
for	O
an	O
expansion	B-UNK
of	O
the	O
GAA	B-UNK
repeat	B-UNK
.	O

We	O
found	O
a	O
correlation	B-UNK
between	O
the	O
size	B-UNK
of	O
the	O
smaller	O
of	O
the	O
two	O
expanded	B-UNK
alleles	B-UNK
and	O
age	B-UNK
at	O
onset	B-UNK
,	O
age	B-UNK
into	O
wheelchair	O
,	O
scoliosis	B-DISEASE
,	O
impaired	B-UNK
vibration	O
sense	O
,	O
and	O
the	O
presence	O
of	O
foot	O
deformity	B-DISEASE
.	O

There	O
was	O
no	O
significant	B-UNK
correlation	B-UNK
between	O
the	O
size	B-UNK
of	O
the	O
smaller	O
allele	B-UNK
and	O
cardiomyopathy	B-UNK
,	O
diabetes	B-UNK
mellitus	I-UNK
,	O
loss	B-UNK
of	O
proprioception	O
,	O
or	O
bladder	O
symptoms	B-UNK
.	O

The	O
larger	O
allele	B-UNK
size	B-UNK
correlated	B-UNK
with	O
bladder	O
symptoms	B-UNK
and	O
the	O
presence	O
of	O
foot	O
deformity	B-DISEASE
.	O

The	O
duration	O
of	O
disease	B-UNK
is	O
correlated	B-UNK
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	B-UNK
,	O
scoliosis	B-DISEASE
,	O
bladder	O
symptoms	B-UNK
and	O
impaired	B-UNK
proprioception	O
,	O
and	O
vibration	O
sense	O
but	O
no	O
other	O
complications	B-DISEASE
studied	O
..	O

Novel	O
mutations	B-UNK
in	O
XLRS1	B-UNK
causing	B-UNK
retinoschisis	B-DISEASE
,	O
including	O
first	O
evidence	B-UNK
of	O
putative	O
leader	O
sequence	B-UNK
change	B-UNK
.	O

Juvenile	O
retinoschisis	B-DISEASE
is	O
an	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
disease	B-DISEASE
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
XLRS1	B-UNK
gene	B-UNK
.	O

We	O
screened	B-UNK
31	O
new	O
unrelated	B-UNK
patients	B-UNK
and	O
families	B-UNK
for	O
XLRS1	B-UNK
mutations	B-UNK
in	O
addition	B-UNK
to	O
previously	B-UNK
reported	I-UNK
mutations	B-UNK
for	O
60	O
of	O
our	O
families	B-UNK
(	O
Retinoschisis	B-DISEASE
Consortium	O
,	O
Hum	O
Mol	O
Genet	B-UNK
1998	O
;	O
7	O
1185	O
-	O
1192	O
)	O
.	O

Twenty	O
-	O
three	O
different	O
mutations	B-UNK
including	O
12	O
novel	O
ones	O
were	O
identified	B-UNK
in	O
28	O
patients	B-UNK
.	O

Mutations	B-UNK
identified	B-UNK
in	O
this	O
study	B-UNK
include	O
19	O
missense	B-UNK
mutations	I-UNK
,	O
two	O
nonsense	B-UNK
mutations	I-UNK
,	O
one	O
intragenic	O
deletion	B-UNK
,	O
four	O
microdeletions	O
,	O
one	O
insertion	O
,	O
and	O
one	O
intronic	O
sequence	B-UNK
substitution	B-UNK
that	O
is	O
likely	O
to	O
result	B-UNK
in	O
a	O
splice	B-UNK
site	I-UNK
defect	B-UNK
.	O

Two	O
novel	O
mutations	B-UNK
,	O
c.	O

38T--	O
>	O
C	O
(	O
L13P	O
)	O
and	O
c.	O

667T--	O
>	O
C	O
(	O
C223R	O
)	O
,	O
respectively	O
,	O
present	B-UNK
the	O
first	O
genetic	B-UNK
evidence	B-UNK
for	O
the	O
functional	O
significance	O
of	O
the	O
putative	O
leader	O
peptide	B-UNK
sequence	B-UNK
and	O
for	O
the	O
functional	O
significance	O
at	O
the	O
carboxyl	O
terminal	B-UNK
of	O
the	O
XLRS1	B-UNK
protein	B-UNK
beyond	O
the	O
discoidin	O
domain	B-UNK
.	O

Mutations	B-UNK
in	O
25	O
of	O
the	O
families	B-UNK
were	O
localized	B-UNK
to	O
exons	O
4	O
-	O
6	O
,	O
emphasizing	O
the	O
critical	B-UNK
functional	O
significance	O
of	O
the	O
discoidin	O
domain	B-UNK
of	O
the	O
XLRS1	B-UNK
protein	B-UNK

Growth	B-UNK
hormone	B-UNK
treatment	O
increases	O
CO	O
(	O
2	O
)	O
response	B-UNK
,	O
ventilation	O
and	O
central	B-UNK
inspiratory	O
drive	O
in	O
children	O
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

We	O
studied	O
whether	O
the	O
beneficial	O
effects	B-UNK
of	O
growth	B-UNK
hormone	B-UNK
(	O
GH	O
)	O
treatment	O
on	O
growth	B-UNK
and	O
body	O
composition	O
in	O
PWS	B-UNK
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function	B-UNK
.	O

We	O
measured	O
resting	O
ventilation	O
,	O
airway	O
occlusion	O
pressure	O
(	O
P	O
(	O
0	O
.	O
1	O
)	O
)	O
and	O
ventilatory	O
response	B-UNK
to	O
CO	O
(	O
2	O
)	O
in	O
nine	O
children	O
,	O
aged	O
7	O
-	O
14	O
years	O
,	O
before	O
and	O
6	O
-	O
9	O
months	O
after	O
the	O
start	O
of	O
GH	O
treatment	O
.	O

During	O
GH	O
treatment	O
,	O
resting	O
ventilation	O
increased	B-UNK
by	O
26	O
%	O
,	O
P	O
(	O
0	O
.	O
1	O
)	O
by	O
72	O
%	O
and	O
the	O
response	B-UNK
to	O
CO	O
(	O
2	O
)	O
by	O
65	O
%	O
(	O
P	O
<	O
0	O
.	O
002	O
,	O
<	O
0	O
.	O
04	O
and	O
<	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

This	O
observed	B-UNK
increase	B-UNK
in	O
ventilatory	O
output	O
was	O
not	O
correlated	B-UNK
to	O
changes	O
in	O
body	O
mass	B-UNK
index	O
.	O

CONCLUSION	B-UNK
Treatment	O
of	O
children	O
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	B-UNK
on	O
central	B-UNK
respiratory	O
structures	O
.	O

The	O
observed	B-UNK
increase	B-UNK
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	B-UNK
to	O
the	O
improved	O
activity	B-UNK
level	B-UNK
reported	B-UNK
by	O
parents	O
of	O
PWS	B-UNK
children	O
during	O
growth	B-UNK
hormone	B-UNK
therapy	B-UNK

G130V	O
,	O
a	O
common	B-UNK
FRDA	B-UNK
point	B-UNK
mutation	I-UNK
,	O
appears	B-UNK
to	O
have	O
arisen	O
from	O
a	O
common	B-UNK
founder	B-UNK
.	O

Friedreich	B-DISEASE
ataxia	I-DISEASE
(	O
FRDA	B-UNK
)	O
is	O
the	O
most	O
common	B-UNK
inherited	B-UNK
ataxia	B-UNK
.	O

About	O
98	O
%	O
of	O
mutant	B-UNK
alleles	I-UNK
have	O
an	O
expansion	B-UNK
of	O
a	O
GAA	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
in	O
intron	B-UNK
1	O
of	O
the	O
affected	B-UNK
gene	B-UNK
,	O
FRDA	B-UNK
.	O

The	O
other	O
2	O
%	O
are	O
point	B-UNK
mutations	I-UNK
.	O

Of	O
the	O
17	O
point	B-UNK
mutations	I-UNK
so	O
far	O
described	O
,	O
three	O
appear	O
to	O
be	O
more	O
common	B-UNK
.	O

One	O
of	O
these	O
is	O
the	O
G130V	O
mutation	B-UNK
in	O
exon	B-UNK
4	O
of	O
FRDA	B-UNK
.	O

G130V	O
,	O
when	O
present	B-UNK
with	O
an	O
expanded	B-UNK
GAA	B-UNK
repeat	B-UNK
on	O
the	O
other	O
allele	B-UNK
,	O
is	O
associated	O
with	O
an	O
atypical	O
FRDA	B-UNK
phenotype	B-UNK
.	O

Haplotype	B-UNK
analysis	I-UNK
was	O
undertaken	O
on	O
the	O
four	O
families	B-UNK
who	O
have	O
been	O
described	O
with	O
this	O
mutation	B-UNK
.	O

The	O
results	B-UNK
suggest	B-UNK
a	O
common	B-UNK
founder	B-UNK
for	O
this	O
mutation	B-UNK
.	O

Although	O
marked	B-UNK
differences	B-UNK
in	O
extragenic	O
marker	B-UNK
haplotypes	O
were	O
seen	O
in	O
one	O
family	B-UNK
,	O
similar	B-UNK
intragenic	O
haplotyping	O
suggests	O
the	O
same	O
mutation	B-UNK
founder	B-UNK
for	O
this	O
family	B-UNK
with	O
the	O
differences	B-UNK
explicable	O
by	O
two	O
recombination	B-UNK
events	O
..	O

Synergistic	O
effect	B-UNK
of	O
histone	O
hyperacetylation	O
and	O
DNA	B-UNK
demethylation	O
in	O
the	O
reactivation	O
of	O
the	O
FMR1	B-UNK
gene	B-UNK
.	O

Most	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
patients	B-UNK
have	O
expansion	B-UNK
of	O
a	O
(	O
CGG	O
)	O
(	O
n	O
)	O
sequence	B-UNK
with	O
>	O
200	O
repeats	B-UNK
(	O
full	O
mutation	B-UNK
)	O
in	O
the	O
FMR1	B-UNK
gene	B-UNK
responsible	B-UNK
for	O
this	O
condition	B-UNK
.	O

Hypermethylation	O
of	O
the	O
expanded	B-UNK
repeat	B-UNK
and	O
of	O
the	O
FMR1	B-UNK
promoter	O
is	O
almost	O
always	O
present	B-UNK
and	O
apparently	O
suppresses	O
transcription	B-UNK
,	O
resulting	B-UNK
in	O
absence	B-UNK
of	O
the	O
FMR1	B-UNK
protein	B-UNK
.	O

We	O
recently	O
showed	O
that	O
transcriptional	O
reactivation	O
of	O
FMR1	B-UNK
full	O
mutations	B-UNK
can	O
be	O
achieved	O
by	O
inducing	O
DNA	B-UNK
demethylation	O
with	O
5-azadeoxycytidine	O
(	O
5-azadC	O
)	O
.	O

The	O
level	B-UNK
of	O
histone	O
acetylation	O
is	O
another	O
important	O
factor	B-UNK
in	O
regulating	O
gene	B-UNK
expression	I-UNK
;	O
therefore	O
,	O
we	O
treated	O
lymphoblastoid	O
cell	B-UNK
lines	I-UNK
of	O
non-mosaic	O
full	O
mutation	B-UNK
patients	B-UNK
with	O
three	O
drugs	O
capable	O
of	O
inducing	O
histone	O
hyperacetylation	O
.	O

We	O
observed	B-UNK
a	O
consistent	B-UNK
,	O
although	O
modest	O
,	O
reactivation	O
of	O
the	O
FMR1	B-UNK
gene	B-UNK
with	O
4-phenylbutyrate	O
,	O
sodium	B-UNK
butyrate	O
and	O
trichostatin	O
A	O
,	O
as	O
shown	B-UNK
by	O
RT	O
-	O
PCR	B-UNK
.	O

However	O
,	O
we	O
report	B-UNK
that	O
combining	O
these	O
drugs	O
with	O
5-azadC	O
results	B-UNK
in	O
a	O
2-to	O
5-fold	O
increase	B-UNK
in	O
FMR1	B-UNK
mRNA	O
levels	B-UNK
obtained	B-UNK
with	O
5-azadC	O
alone	O
,	O
thus	O
showing	O
a	O
marked	B-UNK
synergistic	O
effect	B-UNK
of	O
histone	O
hyperacetylation	O
and	O
DNA	B-UNK
demethylation	O
in	O
the	O
reactivation	O
of	O
FMR1	B-UNK
full	O
mutations	B-UNK
..	O

Constitutional	B-UNK
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
gene	B-UNK
deletions	O
detected	B-UNK
in	O
VHL	B-UNK
families	B-UNK
by	O
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
.	O

von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
disease	B-UNK
is	O
an	O
autosomal	B-UNK
dominantly	O
inherited	B-UNK
cancer	B-UNK
syndrome	B-DISEASE
predisposing	O
to	O
a	O
variety	O
of	O
tumor	B-DISEASE
types	B-UNK
that	O
include	O
retinal	B-UNK
hemangioblastomas	O
,	O
hemangioblastomas	O
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
renal	B-UNK
cell	I-UNK
carcinomas	I-UNK
,	O
pancreatic	B-UNK
cysts	B-DISEASE
and	O
tumors	B-UNK
,	O
pheochromocytomas	O
,	O
endolymphatic	O
sac	O
tumors	B-DISEASE
,	O
and	O
epididymal	O
cystadenomas	O
[	O
W.	O

M.	O

Linehan	O
et	O
al	B-DISEASE
.	O
,	O
J.	O

Am	O
.	O
Med	O
.	O
Assoc	O
.	O
,	O
273	O
564	O
-	O
570	O
,	O
1995	O
;	O
E.	O
A.	O
Maher	O
and	O
W.	O
G.	O
Kaelin	O
,	O
Jr	O
.	O
,	O
Medicine	O
(	O
Baltimore	O
)	O
,	O
76	O
381	O
-	O
391	O
,	O
1997	O
;	O
W.	O
M.	O
Linehan	O
and	O
R.	O
D.	O
Klausner	O
,	O
In	O
B.	O
Vogelstein	O
and	O
K.	O
Kinzler	O
(	O
eds	O
.	O
)	O
,	O
The	O
Genetic	B-UNK
Basis	B-UNK
of	O
Human	B-UNK
Cancer	B-UNK
,	O
pp.	O

455	O
-	O
473	O
,	O
McGraw	O
-	O
Hill	O
,	O
1998].	O

The	O
VHL	B-UNK
gene	B-UNK
was	O
localized	B-UNK
to	O
chromosome	B-UNK
3p25	O
-	O
26	O
and	O
cloned	O
[	O
F.	O
Latif	O
et	O
al	B-DISEASE
.	O
,	O
Science	O
(	O
Washington	O
DC	O
)	O
,	O
260	O
1317	O
-	O
1320	O
,	O
1993].	O

Germline	B-UNK
mutations	I-UNK
in	O
the	O
VHL	B-UNK
gene	B-UNK
have	O
been	O
detected	B-UNK
in	O
the	O
majority	O
of	O
VHL	B-UNK
kindreds	O
.	O

The	O
reported	B-UNK
frequency	B-UNK
of	O
detection	B-UNK
of	O
VHL	B-UNK
germline	B-UNK
mutations	I-UNK
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
J.	O
M.	O
Whaley	O
et	O
al	B-DISEASE
.	O
,	O
Am	O
.	O
J.	O
Hum	O
.	O
Genet	B-UNK
.	O
,	O
55	O
1092	O
-	O
1102	O
,	O
1994	O
;	O
Clinical	B-UNK
Research	O
Group	B-UNK
for	O
Japan	B-UNK
,	O
Hum	O
.	O
Mol	O
.	O
Genet	B-UNK
.	O
,	O
4	O
2233	O
-	O
2237	O
,	O
1995	O
;	O
F.	O
Chen	O
et	O
al	B-DISEASE
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
5	O
66	O
-	O
75	O
,	O
1995	O
;	O
E.	O
R.	O
Maher	O
et	O
al	B-DISEASE
.	O
,	O
J.	O
Med	O
.	O
Genet	B-UNK
.	O
,	O
33	O
328	O
-	O
332	O
,	O
1996	O
;	O
B.	O
Zbar	O
,	O
Cancer	B-UNK
Surv	O
.	O
,	O
25	O
219	O
-	O
232	O
,	O
1995	O
)	O
.	O

Recently	O
a	O
quantitative	B-UNK
Southern	B-UNK
blotting	O
procedure	O
was	O
found	O
to	O
improve	O
this	O
frequency	B-UNK
(	O
C.	O
Stolle	O
et	O
al	B-DISEASE
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
12	O
417	O
-	O
423	O
,	O
1998	O
)	O
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
report	B-UNK
the	O
use	O
of	O
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
(	O
FISH	B-UNK
)	O
as	O
a	O
method	O
to	O
detect	B-UNK
and	O
characterize	O
VHL	B-UNK
germline	B-UNK
deletions	O
.	O

We	O
reexamined	O
a	O
group	B-UNK
of	O
VHL	B-UNK
patients	B-UNK
shown	B-UNK
previously	B-UNK
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
and	O
sequencing	B-UNK
analysis	B-UNK
not	O
to	O
harbor	O
point	B-UNK
mutations	I-UNK
in	O
the	O
VHL	B-UNK
locus	B-UNK
.	O

We	O
found	O
constitutional	B-UNK
deletions	O
in	O
29	O
of	O
30	O
VHL	B-UNK
patients	B-UNK
in	O
this	O
group	B-UNK
using	O
cosmid	O
and	O
P1	O
probes	O
that	O
cover	O
the	O
VHL	B-UNK
locus	B-UNK
.	O

We	O
then	O
tested	O
six	O
phenotypically	O
normal	B-UNK
offspring	O
from	O
four	O
of	O
these	O
VHL	B-UNK
families	B-UNK
two	O
were	O
found	O
to	O
carry	B-UNK
the	O
deletion	B-UNK
and	O
the	O
other	O
four	O
were	O
deletion	B-UNK
-	O
free	O
.	O

In	O
addition	B-UNK
,	O
germline	B-UNK
mosaicism	O
of	O
the	O
VHL	B-UNK
gene	B-UNK
was	O
identified	B-UNK
in	O
one	O
family	B-UNK
.	O

In	O
sum	O
,	O
FISH	B-UNK
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	B-UNK
VHL	B-UNK
germline	B-UNK
deletions	O
and	O
practically	O
useful	O
in	O
cases	B-UNK
where	O
other	O
methods	O
of	O
screening	B-UNK
have	O
failed	O
to	O
detect	B-UNK
a	O
VHL	B-UNK
gene	B-UNK
abnormality	O

Spectrum	B-UNK
of	O
hSNF5	O
/	O
INI1	O
somatic	B-UNK
mutations	I-UNK
in	O
human	B-UNK
cancer	B-UNK
and	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
.	O

The	O
hSNF5	O
/	O
INI1	O
gene	B-UNK
which	O
encodes	B-UNK
a	O
member	B-UNK
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
ATP	B-UNK
-	O
dependent	B-UNK
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
localized	B-UNK
on	O
chromosome	B-UNK
22q11	O
.	O

2	O
and	O
recently	O
shown	B-UNK
to	O
be	O
mutated	B-UNK
in	O
malignant	B-UNK
rhabdoid	O
tumors	B-UNK
.	O

We	O
have	O
searched	O
for	O
hSNF5	O
/	O
INI1	O
mutations	B-UNK
in	O
229	O
tumors	B-UNK
of	O
various	O
origins	O
using	O
a	O
screening	B-UNK
method	O
based	B-UNK
on	O
denaturing	O
high	B-UNK
-	O
performance	O
liquid	O
chromatography	O
.	O

A	O
total	B-UNK
of	O
31	O
homozygous	B-UNK
deletions	O
and	O
36	O
point	B-UNK
alterations	B-UNK
were	O
identified	B-UNK
.	O

Point	B-UNK
mutations	I-UNK
were	O
scattered	O
along	O
the	O
coding	B-UNK
sequence	I-UNK
and	O
included	O
15	O
nonsense	B-UNK
,	O
15	O
frameshift	B-UNK
,	O
three	O
splice	B-UNK
site	I-UNK
,	O
two	O
missense	B-UNK
and	O
one	O
editing	O
mutations	B-UNK
.	O

Mutations	B-UNK
were	O
retrieved	O
in	O
most	O
rhabdoid	O
tumors	B-UNK
,	O
whatever	O
their	O
sites	O
of	O
occurrence	B-UNK
,	O
indicating	O
the	O
common	B-UNK
pathogenetic	O
origin	O
of	O
these	O
tumors	B-DISEASE
.	O

Recurrent	O
hSNF5	O
/	O
INI1	O
alterations	B-UNK
were	O
also	O
observed	B-UNK
in	O
choroid	O
plexus	O
carcinomas	B-UNK
and	O
in	O
a	O
subset	O
of	O
central	B-UNK
primitive	O
neuroectodermal	B-DISEASE
tumors	I-DISEASE
(	O
cPNETs	O
)	O
and	O
medulloblastomas	O
.	O

In	O
contrast	B-UNK
,	O
hSNF5	O
/	O
INI1	O
point	B-UNK
mutations	I-UNK
were	O
not	O
detected	B-UNK
in	O
breast	B-UNK
cancers	B-UNK
,	O
Wilms	B-UNK
tumors	B-UNK
,	O
gliomas	B-DISEASE
,	O
ependymomas	O
,	O
sarcomas	B-DISEASE
and	O
other	O
tumor	B-UNK
types	B-UNK
,	O
even	O
though	O
most	O
analyzed	B-UNK
cases	B-UNK
harbored	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
at	O
22q11	O
.	O

2	O
loci	O
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
rhabdoid	O
tumors	B-DISEASE
,	O
choroid	O
plexus	O
carcinomas	B-UNK
and	O
a	O
subset	O
of	O
medulloblastomas	O
and	O
cPNETs	O
share	O
common	B-UNK
pathways	O
of	O
oncogenesis	O
related	B-UNK
to	O
hSNF5	O
/	O
INI1	O
alteration	O
and	O
that	O
hSNF5	O
/	O
INI1	O
mutations	B-UNK
define	B-UNK
a	O
genetically	B-UNK
homogeneous	O
family	B-UNK
of	O
highly	B-UNK
aggressive	O
cancers	B-DISEASE
mainly	O
occurring	O
in	O
young	B-UNK
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	O
phenotype	B-UNK

Ataxin-3	O
with	O
an	O
altered	O
conformation	B-UNK
that	O
exposes	O
the	O
polyglutamine	O
domain	B-UNK
is	O
associated	O
with	O
the	O
nuclear	B-UNK
matrix	O
.	O

Spinocerebellar	O
ataxia	B-DISEASE
type-3	O
or	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
SCA3	B-UNK
/	O
MJD	B-UNK
)	O
is	O
a	O
member	B-UNK
of	O
the	O
CAG	B-UNK
/	O
polyglutamine	O
repeat	B-UNK
disease	B-UNK
family	B-UNK
.	O

In	O
this	O
family	B-UNK
of	O
disorders	B-UNK
,	O
a	O
normally	O
polymorphic	B-UNK
CAG	B-UNK
repeat	I-UNK
becomes	O
expanded	B-UNK
,	O
resulting	B-UNK
in	O
expression	B-UNK
of	O
an	O
expanded	B-UNK
polyglutamine	O
domain	B-UNK
in	O
the	O
disease	B-DISEASE
gene	B-UNK
product	I-UNK
.	O

Experimental	O
models	O
of	O
polyglutamine	O
disease	B-DISEASE
implicate	O
the	O
nucleus	O
in	O
pathogenesis	B-UNK
;	O
however	O
,	O
the	O
link	O
between	O
intranuclear	O
expression	B-UNK
of	O
expanded	B-UNK
polyglutamine	O
and	O
neuronal	B-DISEASE
dysfunction	I-DISEASE
remains	O
unclear	O
.	O

Here	O
we	O
demonstrate	B-UNK
that	O
ataxin-3	O
,	O
the	O
disease	B-UNK
protein	B-UNK
in	O
SCA3	B-UNK
/	O
MJD	B-UNK
,	O
adopts	O
a	O
unique	O
conformation	B-UNK
when	O
expressed	B-UNK
within	O
the	O
nucleus	O
of	O
transfected	O
cells	B-UNK
.	O

The	O
monoclonal	O
antibody	B-UNK
1C2	O
is	O
known	O
preferentially	O
to	O
bind	O
expanded	B-UNK
polyglutamine	O
,	O
but	O
we	O
find	O
that	O
it	O
also	O
binds	O
a	O
fragment	B-UNK
of	O
ataxin-3	O
containing	O
a	O
normal	B-UNK
glutamine	O
repeat	B-UNK
.	O

In	O
addition	B-UNK
,	O
expression	B-UNK
of	O
ataxin-3	O
within	O
the	O
nucleus	O
exposes	O
the	O
glutamine	O
domain	B-UNK
of	O
the	O
full	O
-	O
length	B-UNK
non-pathological	O
protein	B-UNK
,	O
allowing	O
it	O
to	O
bind	O
the	O
monoclonal	O
antibody	B-UNK
1C2	O
.	O

Fractionation	O
and	O
immunochemical	O
experiments	O
indicate	O
that	O
this	O
novel	O
conformation	B-UNK
of	O
intranuclear	O
ataxin-3	O
is	O
not	O
due	O
to	O
proteolysis	O
,	O
suggesting	O
instead	O
that	O
association	B-UNK
with	O
nuclear	B-UNK
protein	B-UNK
(	O
s	O
)	O
alters	O
the	O
structure	B-UNK
of	O
full	O
-	O
length	B-UNK
ataxin-3	O
which	O
exposes	O
the	O
polyglutamine	O
domain	B-UNK
.	O

This	O
conformationally	O
altered	O
ataxin-3	O
is	O
bound	O
to	O
the	O
nuclear	B-UNK
matrix	O
.	O

The	O
pathological	O
form	B-UNK
of	O
ataxin-3	O
with	O
an	O
expanded	B-UNK
polyglutamine	O
domain	B-UNK
also	O
associates	O
with	O
the	O
nuclear	B-UNK
matrix	O
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
an	O
early	B-UNK
event	O
in	O
the	O
pathogenesis	B-UNK
of	O
SCA3	B-UNK
/	O
MJD	B-UNK
may	O
be	O
an	O
altered	O
conformation	B-UNK
of	O
ataxin-3	O
within	O
the	O
nucleus	O
that	O
exposes	O
the	O
polyglutamine	O
domain	B-UNK
..	O

The	O
human	B-UNK
MAGEL2	B-UNK
gene	B-UNK
and	O
its	O
mouse	B-UNK
homologue	B-UNK
are	O
paternally	O
expressed	B-UNK
and	O
mapped	B-UNK
to	O
the	O
Prader	O
-	O
Willi	O
region	B-UNK
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
is	O
a	O
complex	O
neurogenetic	O
disorder	B-UNK
.	O

The	O
phenotype	B-UNK
is	O
likely	O
to	O
be	O
a	O
contiguous	O
gene	B-UNK
syndrome	B-UNK
involving	O
genes	B-UNK
which	O
are	O
paternally	O
expressed	B-UNK
only	O
,	O
located	B-UNK
in	O
the	O
human	B-UNK
15q11-q13	O
region	B-UNK
.	O

Four	O
mouse	B-UNK
models	O
of	O
PWS	B-UNK
have	O
been	O
reported	B-UNK
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	B-UNK
region	I-UNK
and	O
the	O
associated	O
genes	B-UNK
involved	B-UNK
in	O
the	O
aetiology	O
of	O
PWS	B-UNK
.	O

Moreover	O
,	O
targeted	B-UNK
mutagenesis	O
of	O
mouse	B-UNK
homologues	O
of	O
the	O
human	B-UNK
candidate	B-UNK
PWS	B-UNK
genes	B-UNK
does	O
not	O
appear	O
to	O
result	B-UNK
in	O
any	O
of	O
the	O
features	B-UNK
of	O
PWS	B-UNK
.	O

Therefore	O
,	O
the	O
isolation	B-UNK
of	O
new	O
genes	B-UNK
in	O
this	O
region	B-UNK
remains	O
crucial	O
for	O
a	O
better	O
understanding	B-UNK
of	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
PWS	B-UNK
.	O

In	O
this	O
manuscript	O
,	O
we	O
report	B-UNK
the	O
characterization	B-UNK
of	O
MAGEL2	B-UNK
and	O
its	O
mouse	B-UNK
homologue	B-UNK
Magel2	B-UNK
.	O

These	O
are	O
located	B-UNK
in	O
the	O
human	B-UNK
15q11-q13	O
and	O
mouse	B-UNK
7C	O
regions	B-UNK
,	O
in	O
close	B-UNK
proximity	O
to	O
NDN	O
/	O
Ndn	O
.	O

By	O
northern	B-UNK
blot	B-UNK
analysis	B-UNK
we	O
did	O
not	O
detect	B-UNK
any	O
expression	B-UNK
of	O
MAGEL2	B-UNK
/	O
Magel2	B-UNK
but	O
by	O
RT	O
-	O
PCR	B-UNK
analysis	B-UNK
,	O
specific	B-UNK
expression	B-UNK
was	O
detected	B-UNK
in	O
fetal	O
and	O
adult	B-UNK
brain	B-UNK
and	O
in	O
placenta	O
.	O

Both	O
genes	B-UNK
are	O
intronless	O
with	O
tandem	O
direct	B-UNK
repeat	B-UNK
sequences	O
contained	O
within	O
a	O
CpG	B-UNK
island	B-UNK
in	O
the	O
5-untranscribed	O
region	B-UNK
.	O

The	O
transcripts	O
encode	O
putative	O
proteins	B-UNK
that	O
are	O
homologous	B-UNK
to	O
the	O
MAGE	O
proteins	B-UNK
and	O
NDN	O
.	O

Moreover	O
,	O
MAGEL2	B-UNK
/	O
Magel2	B-UNK
are	O
expressed	B-UNK
only	O
from	O
the	O
paternal	O
allele	B-UNK
in	O
brain	B-UNK
,	O
suggesting	O
a	O
potential	B-UNK
role	B-UNK
in	O
the	O
aetiology	O
of	O
PWS	B-UNK
and	O
its	O
mouse	B-UNK
model	I-UNK
,	O
respectively	O
..	O

cDNA	O
microarrays	O
detect	B-UNK
activation	O
of	O
a	O
myogenic	O
transcription	B-UNK
program	O
by	O
the	O
PAX3-FKHR	O
fusion	B-UNK
oncogene	O
.	O

Alveolar	O
rhabdomyosarcoma	B-DISEASE
is	O
an	O
aggressive	O
pediatric	O
cancer	B-UNK
of	O
striated	O
muscle	B-UNK
characterized	B-UNK
in	O
60	O
%	O
of	O
cases	B-UNK
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O

This	O
results	B-UNK
in	O
the	O
fusion	B-UNK
of	O
PAX3	B-UNK
,	O
a	O
developmental	O
transcription	B-UNK
factor	I-UNK
required	B-UNK
for	O
limb	O
myogenesis	O
,	O
with	O
FKHR	B-UNK
,	O
a	O
member	B-UNK
of	O
the	O
forkhead	O
family	B-UNK
of	O
transcription	B-UNK
factors	O
.	O

The	O
resultant	O
PAX3-FKHR	O
gene	B-UNK
possesses	O
transforming	O
properties	B-UNK
;	O
however	O
,	O
the	O
effects	B-UNK
of	O
this	O
chimeric	O
oncogene	O
on	O
gene	B-UNK
expression	I-UNK
are	O
largely	O
unknown	O
.	O

To	O
investigate	B-UNK
the	O
actions	O
of	O
these	O
transcription	B-UNK
factors	O
,	O
both	O
Pax3	B-UNK
and	O
PAX3-FKHR	O
were	O
introduced	O
into	O
NIH	O
3T3	O
cells	B-UNK
,	O
and	O
the	O
resultant	O
gene	B-UNK
expression	I-UNK
changes	O
were	O
analyzed	B-UNK
with	O
a	O
murine	O
cDNA	O
microarray	O
containing	O
2	O
,	O
225	O
elements	O
.	O

We	O
found	O
that	O
PAX3-FKHR	O
but	O
not	O
PAX3	B-UNK
activated	O
a	O
myogenic	O
transcription	B-UNK
program	O
including	O
the	O
induction	O
of	O
transcription	B-UNK
factors	O
MyoD	O
,	O
Myogenin	O
,	O
Six1	O
,	O
and	O
Slug	O
as	O
well	O
as	O
a	O
battery	O
of	O
genes	B-UNK
involved	B-UNK
in	O
several	O
aspects	O
of	O
muscle	B-UNK
function	B-UNK
.	O

Notable	O
among	O
this	O
group	B-UNK
were	O
the	O
growth	B-UNK
factor	I-UNK
gene	B-UNK
Igf2	O
and	O
its	O
binding	B-UNK
protein	B-UNK
Igfbp5	O
.	O

Relevance	O
of	O
this	O
model	B-UNK
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	B-UNK
(	O
IGFBP5	O
,	O
HSIX1	O
,	O
and	O
Slug	O
)	O
were	O
also	O
expressed	B-UNK
in	O
alveolar	O
rhabdomyosarcoma	B-DISEASE
cell	B-UNK
lines	I-UNK
.	O

This	O
study	B-UNK
utilizes	O
cDNA	O
microarrays	O
to	O
elucidate	O
the	O
pattern	B-UNK
of	O
gene	B-UNK
expression	I-UNK
induced	O
by	O
an	O
oncogenic	O
transcription	B-UNK
factor	I-UNK
and	O
demonstrates	O
the	O
profound	O
myogenic	O
properties	B-UNK
of	O
PAX3-FKHR	O
in	O
NIH	O
3T3	O
cells	B-UNK
..	O

Experimental	O
hemochromatosis	B-DISEASE
due	O
to	O
MHC	B-UNK
class	O
I	O
HFE	B-UNK
deficiency	B-UNK
:	O
immune	B-UNK
status	B-UNK
and	O
iron	B-UNK
metabolism	B-UNK
.	O

The	O
puzzling	O
linkage	B-UNK
between	O
genetic	B-UNK
hemochromatosis	B-DISEASE
and	O
histocompatibility	B-UNK
loci	O
became	O
even	O
more	O
so	O
when	O
the	O
gene	B-UNK
involved	B-UNK
,	O
HFE	B-UNK
,	O
was	O
identified	B-UNK
.	O

Indeed	O
,	O
within	O
the	O
well	O
defined	B-UNK
,	O
mainly	O
peptide	B-UNK
-	O
binding	B-UNK
,	O
MHC	B-UNK
class	O
I	O
family	B-UNK
of	O
molecules	O
,	O
HFE	B-UNK
seems	O
to	O
perform	O
an	O
unusual	O
yet	O
essential	B-UNK
function	B-UNK
.	O

As	O
yet	O
,	O
our	O
understanding	B-UNK
of	O
HFE	B-UNK
function	B-UNK
in	O
iron	B-UNK
homeostasis	O
is	O
only	O
partial	O
;	O
an	O
even	O
more	O
open	O
question	O
is	O
its	O
possible	O
role	B-UNK
in	O
the	O
immune	B-UNK
system	O
.	O

To	O
advance	O
on	O
both	O
of	O
these	O
avenues	O
,	O
we	O
report	B-UNK
the	O
deletion	B-UNK
of	O
HFE	B-UNK
alpha1	O
and	O
alpha2	O
putative	O
ligand	O
binding	B-UNK
domains	B-UNK
in	O
vivo	B-UNK
.	O

HFE	B-UNK
-	O
deficient	B-UNK
animals	O
were	O
analyzed	B-UNK
for	O
a	O
comprehensive	O
set	B-UNK
of	O
metabolic	B-UNK
and	O
immune	B-UNK
parameters	O
.	O

Faithfully	O
mimicking	O
human	B-UNK
hemochromatosis	B-UNK
,	O
mice	B-UNK
homozygous	B-UNK
for	O
this	O
deletion	B-UNK
develop	O
iron	B-DISEASE
overload	I-DISEASE
,	O
characterized	B-UNK
by	O
a	O
higher	O
plasma	O
iron	B-UNK
content	O
and	O
a	O
raised	O
transferrin	O
saturation	O
as	O
well	O
as	O
an	O
elevated	B-UNK
hepatic	B-UNK
iron	B-UNK
load	O
.	O

The	O
primary	B-UNK
defect	B-UNK
could	O
,	O
indeed	O
,	O
be	O
traced	O
to	O
an	O
augmented	O
duodenal	O
iron	B-UNK
absorption	O
.	O

In	O
parallel	O
,	O
measurement	O
of	O
the	O
gut	O
mucosal	O
iron	B-UNK
content	O
as	O
well	O
as	O
iron	B-UNK
regulatory	O
proteins	B-UNK
allows	O
a	O
more	O
informed	O
evaluation	B-UNK
of	O
various	O
hypotheses	O
regarding	O
the	O
precise	O
role	B-UNK
of	O
HFE	B-UNK
in	O
iron	B-UNK
homeostasis	O
.	O

Finally	B-UNK
,	O
an	O
extensive	B-UNK
phenotyping	O
of	O
primary	B-UNK
and	O
secondary	O
lymphoid	O
organs	O
including	O
the	O
gut	O
provides	O
no	O
compelling	O
evidence	B-UNK
for	O
an	O
obvious	O
immune	B-UNK
-	O
linked	B-UNK
function	B-UNK
for	O
HFE	B-UNK
..	O

Somatic	B-UNK
rearrangement	B-UNK
of	O
chromosome	B-UNK
14	O
in	O
human	B-UNK
lymphocytes	O
.	O

Ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
is	O
a	O
rare	B-UNK
genetic	B-UNK
disorder	I-UNK
associated	O
with	O
immune	B-UNK
deficiency	B-UNK
,	O
chromosome	B-UNK
instability	B-UNK
,	O
and	O
a	O
predisposition	B-UNK
to	O
lymphoid	O
malignancy	B-DISEASE
.	O

We	O
have	O
detected	B-UNK
chromosomally	O
anomalous	O
clones	O
of	O
lymphocytes	O
in	O
eight	O
patients	B-UNK
with	O
this	O
disorder	B-UNK
.	O

Chromosome	B-UNK
banding	O
disclosed	O
that	O
the	O
clones	O
are	O
consistently	O
marked	B-UNK
by	O
structural	B-UNK
rearrangement	B-UNK
of	O
the	O
long	B-UNK
arm	B-UNK
(	O
q	O
)	O
of	O
chromosome	B-UNK
14	O
.	O

A	O
translocation	B-UNK
involving	O
14q	O
was	O
found	O
in	O
clones	O
obtained	B-UNK
from	O
seven	O
of	O
the	O
eight	O
patients	B-UNK
whereas	O
a	O
ring	O
14	O
chromosome	B-UNK
was	O
found	O
in	O
a	O
clone	O
obtained	B-UNK
from	O
the	O
other	O
.	O

These	O
findings	B-UNK
as	O
well	O
as	O
data	B-UNK
obtained	B-UNK
by	O
others	O
for	O
patients	B-UNK
with	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
suggest	B-UNK
that	O
structural	B-UNK
rearrangement	B-UNK
of	O
14q	O
is	O
the	O
initial	O
chromosomal	B-UNK
change	B-UNK
in	O
lymphocyte	B-UNK
clones	O
of	O
patients	B-UNK
with	O
this	O
disorder	B-UNK
.	O

Chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	B-UNK
were	O
studied	O
before	O
and	O
after	O
the	O
onset	B-UNK
of	O
chronic	B-DISEASE
lymphocytic	I-DISEASE
leukemia	I-DISEASE
.	O

Before	O
leukemia	B-DISEASE
was	O
diagnosed	O
,	O
the	O
patient	B-UNK
had	O
a	O
lymphocyte	B-UNK
clone	O
with	O
a	O
14q	O
translocation	B-UNK
.	O

This	O
clone	O
appears	B-UNK
to	O
have	O
given	O
rise	B-UNK
to	O
the	O
leukemic	B-DISEASE
cells	B-UNK
.	O

We	O
hypothesize	O
that	O
structural	B-UNK
rearrangement	B-UNK
of	O
14q	O
is	O
directly	O
related	B-UNK
to	O
abnormal	O
growth	B-UNK
of	O
lymphocytes	O
and	O
that	O
it	O
may	O
be	O
a	O
step	O
toward	O
the	O
development	B-UNK
of	O
lymphoid	O
malignancies	B-DISEASE
.	O

Increasing	O
evidence	B-UNK
,	O
provided	O
by	O
others	O
,	O
for	O
the	O
nonrandom	O
involvement	B-UNK
of	O
14q	O
in	O
African	B-UNK
-	O
type	B-UNK
Burkitts	O
lymphoma	B-DISEASE
and	O
other	O
lymphoid	O
neoplasms	B-UNK
further	O
strengthens	O
this	O
hypothesis	B-UNK
..	O

Exon	B-UNK
9	O
mutations	B-UNK
in	O
the	O
WT1	B-UNK
gene	B-UNK
,	O
without	O
influencing	O
KTS	O
splice	B-UNK
isoforms	O
,	O
are	O
also	O
responsible	B-UNK
for	O
Frasier	B-DISEASE
syndrome	I-DISEASE
.	O

We	O
report	B-UNK
new	O
mutations	B-UNK
in	O
exon	B-UNK
9	O
of	O
the	O
WT1	B-UNK
gene	B-UNK
that	O
did	O
not	O
alter	O
the	O
ratio	B-UNK
of	O
+	O
/-KTS	O
splice	B-UNK
isoforms	O
in	O
two	O
unrelated	B-UNK
patients	B-UNK
with	O
Frasier	B-DISEASE
syndrome	I-DISEASE
(	O
FS	O
)	O
.	O

The	O
mutation	B-UNK
of	O
intron	B-UNK
9	O
inducing	O
defective	O
alternative	B-UNK
splicing	B-UNK
was	O
reported	B-UNK
to	O
be	O
responsible	B-UNK
for	O
this	O
syndrome	B-UNK
.	O

The	O
mutations	B-UNK
found	O
in	O
our	O
cases	B-UNK
occurred	B-UNK
in	O
the	O
same	O
exon	B-UNK
of	O
the	O
WT1	B-UNK
gene	B-UNK
as	O
detected	B-UNK
in	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
(	O
DDS	B-UNK
)	O
and	O
could	O
not	O
be	O
explained	O
by	O
the	O
previously	B-UNK
proposed	O
mechanism	B-UNK
.	O

The	O
results	B-UNK
suggest	B-UNK
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
WT1	B-UNK
gene	B-UNK
abnormality	O
.	O

From	O
a	O
molecular	B-UNK
biological	O
point	B-UNK
of	O
view	O
,	O
we	O
concluded	O
that	O
the	O
two	O
diseases	B-UNK
were	O
not	O
separable	O
,	O
and	O
that	O
FS	O
should	O
be	O
included	O
as	O
an	O
atypical	O
form	B-UNK
of	O
DDS	B-UNK
..	O

Splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
in	O
the	O
PDS	B-UNK
gene	B-UNK
may	O
result	B-UNK
in	O
intrafamilial	O
variability	B-UNK
for	O
deafness	B-DISEASE
in	O
Pendred	B-DISEASE
syndrome	I-DISEASE
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
a	O
recessive	B-UNK
inherited	B-UNK
disorder	B-UNK
that	O
consists	O
of	O
developmental	O
abnormalities	B-UNK
of	O
the	O
cochlea	O
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
and	O
diffuse	O
thyroid	O
enlargement	O
(	O
goiter	B-DISEASE
)	O
.	O

This	O
disorder	B-UNK
may	O
account	B-UNK
for	O
up	O
to	O
10	O
%	O
of	O
cases	B-UNK
of	O
hereditary	B-UNK
deafness	B-DISEASE
.	O

The	O
disease	B-DISEASE
gene	B-UNK
(	O
PDS	B-UNK
)	O
has	O
been	O
mapped	B-UNK
to	O
chromosome	B-UNK
7q22-q31	O
,	O
and	O
encodes	B-UNK
a	O
chloride	B-UNK
-	O
iodide	B-UNK
transport	B-UNK
protein	B-UNK
.	O

We	O
performed	O
mutation	B-UNK
analysis	B-UNK
of	O
individual	O
exons	O
of	O
the	O
PDS	B-UNK
gene	B-UNK
in	O
one	O
Spanish	O
family	B-UNK
that	O
shows	O
intrafamilial	O
variability	B-UNK
of	O
the	O
deafness	B-DISEASE
phenotype	B-UNK
(	O
two	O
patients	B-UNK
with	O
profound	O
and	O
one	O
with	O
moderate	B-UNK
-	O
severe	B-UNK
deafness	B-DISEASE
)	O
.	O

We	O
identified	B-UNK
a	O
new	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
affecting	O
intron	B-UNK
4	O
of	O
the	O
PDS	B-UNK
gene	B-UNK
,	O
at	O
nucleotide	B-UNK
position	I-UNK
639	O
+	O
7	O
.	O

RNA	B-UNK
analysis	B-UNK
from	O
lymphocytes	O
of	O
the	O
affected	B-UNK
patients	B-UNK
showed	O
that	O
mutation	B-UNK
639	O
+	O
7A--	O
>	O
G	O
generates	O
a	O
new	O
donor	B-UNK
splice	I-UNK
site	I-UNK
,	O
leading	B-UNK
to	O
an	O
mRNA	O
with	O
an	O
insertion	O
of	O
six	O
nucleotides	O
from	O
intron	B-UNK
4	O
of	O
PDS	B-UNK
.	O

Since	O
the	O
newly	O
created	O
donor	B-UNK
splice	I-UNK
site	I-UNK
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	B-UNK
one	O
,	O
variations	O
of	O
the	O
levels	B-UNK
of	O
normal	B-UNK
and	O
aberrant	B-UNK
transcripts	O
of	O
the	O
PDS	B-UNK
gene	B-UNK
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	B-UNK
in	O
the	O
deafness	B-DISEASE
presentation	O
..	O

The	O
molecular	B-UNK
basis	I-UNK
of	O
Sjogren	B-DISEASE
-	I-DISEASE
Larsson	I-DISEASE
syndrome	I-DISEASE
:	O
mutation	B-UNK
analysis	B-UNK
of	O
the	O
fatty	B-UNK
aldehyde	O
dehydrogenase	B-UNK
gene	B-UNK
.	O

Sjogren	B-DISEASE
-	I-DISEASE
Larsson	I-DISEASE
syndrome	I-DISEASE
(	O
SLS	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
ichthyosis	B-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
spasticity	B-DISEASE
,	O
and	O
deficient	B-UNK
activity	B-UNK
of	O
fatty	B-UNK
aldehyde	O
dehydrogenase	B-UNK
(	O
FALDH	O
)	O
.	O

To	O
define	B-UNK
the	O
molecular	B-UNK
defects	B-UNK
causing	B-UNK
SLS	B-UNK
,	O
we	O
performed	O
mutation	B-UNK
analysis	B-UNK
of	O
the	O
FALDH	O
gene	B-UNK
in	O
probands	O
from	O
63	O
kindreds	O
with	O
SLS	B-UNK
.	O

Among	O
these	O
patients	B-UNK
,	O
49	O
different	O
mutations	B-UNK
-	O
including	O
10	O
deletions	O
,	O
2	O
insertions	O
,	O
22	O
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
,	O
3	O
nonsense	B-UNK
mutations	I-UNK
,	O
9	O
splice	B-UNK
-	O
site	B-UNK
defects	B-UNK
,	O
and	O
3	O
complex	O
mutations	B-UNK
-	O
were	O
found	O
.	O

All	O
of	O
the	O
patients	B-UNK
with	O
SLS	B-UNK
were	O
found	O
to	O
carry	B-UNK
mutations	B-UNK
.	O

Nineteen	O
of	O
the	O
missense	B-UNK
mutations	I-UNK
resulted	B-UNK
in	O
a	O
severe	B-UNK
reduction	B-UNK
of	O
FALDH	O
enzyme	B-UNK
catalytic	O
activity	B-UNK
when	O
expressed	B-UNK
in	O
mammalian	O
cells	B-UNK
,	O
but	O
one	O
mutation	B-UNK
(	O
798G--	O
>	O
C	O
[	O
K266N	O
]	O
)	O
seemed	O
to	O
have	O
a	O
greater	B-UNK
effect	B-UNK
on	O
mRNA	O
stability	O
.	O

The	O
splice	B-UNK
-	O
site	B-UNK
mutations	B-UNK
led	B-UNK
to	O
exon	B-UNK
skipping	O
or	O
utilization	O
of	O
cryptic	O
acceptor	B-UNK
-	O
splice	B-UNK
sites	O
.	O

Thirty	O
-	O
seven	O
mutations	B-UNK
were	O
private	O
,	O
and	O
12	O
mutations	B-UNK
were	O
seen	O
in	O
two	O
or	O
more	O
probands	O
of	O
European	B-UNK
or	O
Middle	O
Eastern	B-UNK
descent	O
.	O

Four	O
single	B-UNK
-	O
nucleotide	B-UNK
polymorphisms	B-UNK
(	O
SNPs	O
)	O
were	O
found	O
in	O
the	O
FALDH	O
gene	B-UNK
.	O

At	O
least	O
four	O
of	O
the	O
common	B-UNK
mutations	B-UNK
(	O
551C--	O
>	O
T	O
,	O
682C--	O
>	O
T	O
,	O
733G--	O
>	O
A	O
,	O
and	O
798	O
+	O
1delG	O
)	O
were	O
associated	O
with	O
multiple	B-UNK
SNP	O
haplotypes	O
,	O
suggesting	O
that	O
these	O
mutations	B-UNK
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
SLS	B-UNK
genes	B-UNK
that	O
had	O
undergone	O
intragenic	O
recombination	B-UNK
.	O

Our	O
results	B-UNK
demonstrate	B-UNK
that	O
SLS	B-UNK
is	O
caused	B-UNK
by	O
a	O
strikingly	O
heterogeneous	O
group	B-UNK
of	O
mutations	B-UNK
in	O
the	O
FALDH	O
gene	B-UNK
and	O
provide	B-UNK
a	O
framework	O
for	O
understanding	B-UNK
the	O
genetic	B-UNK
basis	B-UNK
of	O
SLS	B-UNK
and	O
the	O
development	B-UNK
of	O
DNA	B-UNK
-	O
based	B-UNK
diagnostic	B-UNK
tests	O
..	O

Loss	B-UNK
-	O
of	O
-	O
function	B-UNK
mutations	B-UNK
in	O
the	O
cathepsin	O
C	O
gene	B-UNK
result	B-UNK
in	O
periodontal	O
disease	B-DISEASE
and	O
palmoplantar	O
keratosis	B-DISEASE
.	O

Papillon	O
-	O
Lefevre	O
syndrome	B-UNK
,	O
or	O
keratosis	B-DISEASE
palmoplantaris	O
with	O
periodontopathia	O
(	O
PLS	B-UNK
,	O
MIM	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	B-UNK
periodontitis	B-DISEASE
that	O
afflicts	O
patients	B-UNK
.	O

Both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected	B-UNK
,	O
resulting	B-UNK
in	O
premature	B-UNK
tooth	B-DISEASE
loss	I-DISEASE
.	O

Palmoplantar	O
keratosis	B-DISEASE
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	B-UNK
to	O
overt	O
hyperkeratosis	O
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	B-UNK
.	O

Keratosis	B-DISEASE
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees	O
.	O

Most	O
PLS	B-UNK
patients	B-UNK
display	O
both	O
periodontitis	B-DISEASE
and	O
hyperkeratosis	O
.	O

Some	O
patients	B-UNK
have	O
only	O
palmoplantar	O
keratosis	B-DISEASE
or	O
periodontitis	B-DISEASE
,	O
and	O
in	O
rare	B-UNK
individuals	B-UNK
the	O
periodontitis	B-DISEASE
is	O
mild	O
and	O
of	O
late	B-UNK
onset	I-UNK
.	O

The	O
PLS	B-UNK
locus	B-UNK
has	O
been	O
mapped	B-UNK
to	O
chromosome	B-UNK
11q14-q21	O
(	O
refs	O
7	O
,	O
8	O
,	O
9	O
)	O
.	O

Using	O
homozygosity	B-UNK
mapping	B-UNK
in	O
eight	O
small	O
consanguineous	O
families	B-UNK
,	O
we	O
have	O
narrowed	O
the	O
candidate	B-UNK
region	B-UNK
to	O
a	O
1	O
.	O

2-cM	O
interval	B-UNK
between	O
D11S4082	O
and	O
D11S931	O
.	O

The	O
gene	B-UNK
(	O
CTSC	O
)	O
encoding	B-UNK
the	O
lysosomal	B-UNK
protease	O
cathepsin	O
C	O
(	O
or	O
dipeptidyl	O
aminopeptidase	O
I	O
)	O
lies	O
within	O
this	O
interval	B-UNK
.	O

We	O
defined	B-UNK
the	O
genomic	B-UNK
structure	B-UNK
of	O
CTSC	O
and	O
found	O
mutations	B-UNK
in	O
all	O
eight	O
families	B-UNK
.	O

In	O
two	O
of	O
these	O
families	B-UNK
we	O
used	O
a	O
functional	O
assay	B-UNK
to	O
demonstrate	B-UNK
an	O
almost	O
total	B-UNK
loss	B-UNK
of	O
cathepsin	O
C	O
activity	B-UNK
in	O
PLS	B-UNK
patients	B-UNK
and	O
reduced	O
activity	B-UNK
in	O
obligate	B-UNK
carriers	B-UNK
.	O

Confirmation	O
of	O
linkage	B-UNK
of	O
Van	B-DISEASE
der	I-DISEASE
Woude	I-DISEASE
syndrome	I-DISEASE
to	O
chromosome	B-UNK
1q32	O
:	O
evidence	B-UNK
of	O
association	B-UNK
with	O
STR	O
alleles	B-UNK
suggests	O
possible	O
unique	O
origin	O
of	O
the	O
disease	B-DISEASE
mutation	B-UNK
.	O

Van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
(	O
VWS	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
craniofacial	O
disorder	B-UNK
with	O
high	B-UNK
penetrance	O
and	O
variable	B-UNK
expression	B-UNK
.	O

Its	O
clinical	B-UNK
features	I-UNK
are	O
variably	O
expressed	B-UNK
,	O
but	O
include	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
/	O
or	O
cleft	B-DISEASE
palate	I-DISEASE
,	O
lip	B-UNK
pits	O
and	O
hypodontia	O
.	O

All	O
VWS	B-UNK
families	B-UNK
studied	O
to	O
date	B-UNK
map	B-UNK
the	O
disease	B-DISEASE
gene	B-UNK
to	O
a	O
<	O
2	O
cM	B-DISEASE
region	B-UNK
of	O
chromosome	B-UNK
1q32	O
,	O
with	O
no	O
evidence	B-UNK
of	O
locus	B-UNK
heterogeneity	B-UNK
.	O

The	O
aim	O
of	O
this	O
study	B-UNK
is	O
to	O
refine	O
the	O
localization	B-UNK
of	O
the	O
VWS	B-UNK
gene	B-UNK
and	O
to	O
further	O
assess	B-UNK
possible	O
heterogeneity	B-UNK
.	O

We	O
analyzed	B-UNK
four	O
multiplex	O
VWS	B-UNK
families	B-UNK
.	O

All	O
available	O
members	B-UNK
were	O
clinically	O
assessed	O
and	O
genotyped	O
for	O
19	O
short	B-UNK
tandem	O
repeat	B-UNK
markers	B-UNK
on	O
chromosome	B-UNK
1	O
in	O
the	O
VWS	B-UNK
candidate	B-UNK
gene	I-UNK
region	B-UNK
.	O

We	O
performed	O
two	O
-	O
point	B-UNK
and	O
multipoint	B-UNK
limit	O
of	O
detection	B-UNK
(	O
LOD	B-UNK
)	O
score	B-UNK
analyses	O
using	O
a	O
high	B-UNK
penetrance	O
autosomal	B-UNK
dominant	I-UNK
model	B-UNK
.	O

All	O
families	B-UNK
showed	O
positive	O
LOD	B-UNK
scores	I-UNK
without	O
any	O
recombination	B-UNK
in	O
the	O
candidate	B-UNK
region	B-UNK
.	O

The	O
largest	O
two	O
-	O
point	B-UNK
LOD	B-UNK
score	I-UNK
was	O
5	O
.	O

87	O
87	O
.	O

Our	O
assay	B-UNK
method	O
for	O
short	B-UNK
tandem	O
repeat	B-UNK
(	O
STR	O
)	O
markers	B-UNK
provided	O
highly	B-UNK
accurate	O
size	B-UNK
estimation	O
of	O
marker	B-UNK
allele	B-UNK
fragment	B-UNK
sizes	O
,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	B-UNK
the	O
specific	B-UNK
alleles	B-UNK
segregating	O
with	O
the	O
VWS	B-UNK
gene	B-UNK
in	O
each	O
of	O
our	O
four	O
families	B-UNK
.	O

We	O
observed	B-UNK
a	O
striking	O
pattern	B-UNK
of	O
STR	O
allele	B-UNK
sharing	O
at	O
several	O
closely	B-UNK
linked	I-UNK
loci	O
among	O
our	O
four	O
Caucasian	B-UNK
VWS	B-UNK
families	B-UNK
recruited	O
at	O
three	O
different	O
locations	O
in	O
the	O
US	O
.	O

These	O
results	B-UNK
suggest	B-UNK
the	O
possibility	B-UNK
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	B-UNK
responsible	B-UNK
for	O
many	O
or	O
most	O
cases	B-UNK
of	O
VWS	B-UNK
.	O

A	O
point	B-UNK
mutation	I-UNK
Thr	B-UNK
(	O
799	O
)	O
Met	B-UNK
on	O
the	O
alpha	B-UNK
(	O
2	O
)	O
integrin	O
leads	B-UNK
to	O
the	O
formation	B-UNK
of	O
new	O
human	B-UNK
platelet	B-UNK
alloantigen	O
Sit	B-UNK
(	O
a	O
)	O
and	O
affects	O
collagen	O
-	O
induced	O
aggregation	O
.	O

A	O
new	O
platelet	B-UNK
-	O
specific	B-UNK
alloantigen	O
,	O
termed	O
Sit	B-UNK
(	O
a	O
)	O
,	O
was	O
identified	B-UNK
in	O
a	O
severe	B-UNK
case	B-UNK
of	O
neonatal	B-UNK
alloimmune	O
thrombocytopenia	B-DISEASE
.	O

The	O
Sit	B-UNK
(	O
a	O
)	O
alloantigen	O
is	O
of	O
low	B-UNK
frequency	B-UNK
(	O
1/400	O
)	O
in	O
the	O
German	O
population	B-UNK
.	O

Immunochemical	O
studies	B-UNK
demonstrated	O
that	O
the	O
Sit	B-UNK
(	O
a	O
)	O
epitopes	O
reside	O
on	O
platelet	B-UNK
glycoprotein	O
(	O
GP	O
)	O
Ia	O
.	O

Nucleotide	B-UNK
sequence	I-UNK
analysis	B-UNK
of	O
GPIa	O
cDNA	O
derived	B-UNK
from	O
Sit	B-UNK
(	O
a)-positive	O
platelets	O
showed	O
C	O
(	O
2531)--	O
>	O
T	O
(	O
2531	O
)	O
point	B-UNK
mutation	I-UNK
,	O
resulting	B-UNK
in	O
Thr	B-UNK
(	O
799	O
)	O
Met	B-UNK
dimorphism	O
.	O

Analysis	B-UNK
of	O
genomic	B-UNK
DNA	I-UNK
from	O
22	O
Sit	B-UNK
(	O
a)-negative	O
normal	B-UNK
individuals	B-UNK
showed	O
that	O
the	O
Thr	B-UNK
(	O
799	O
)	O
is	O
encoded	B-UNK
by	O
ACG	O
(	O
2532	O
)	O
(	O
90	O
.	O
9	O
%	O
)	O
or	O
ACA	O
(	O
2532	O
)	O
(	O
9	O
.	O
1	O
%	O
)	O
.	O

To	O
establish	O
a	O
DNA	B-UNK
typing	O
technique	O
,	O
we	O
elucidated	O
the	O
organization	B-UNK
of	O
the	O
GPIa	O
gene	B-UNK
adjacent	O
to	O
the	O
polymorphic	B-UNK
bases	O
.	O

The	O
introns	O
(	O
421	O
bp	B-UNK
and	O
1	O
.	O
2	O
kb	B-UNK
)	O
encompass	O
a	O
142-bp	O
exon	B-UNK
with	O
the	O
2	O
polymorphic	B-UNK
bases	O
2531	O
and	O
2532	O
.	O

Polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
analysis	B-UNK
on	O
DNA	B-UNK
derived	B-UNK
from	O
100	O
donors	O
using	O
the	O
restriction	B-UNK
enzyme	B-UNK
Mae	O
III	B-UNK
showed	O
that	O
the	O
Met	B-UNK
(	O
799	O
)	O
form	B-UNK
of	O
GPIa	O
is	O
restricted	O
to	O
Sit	B-UNK
(	O
a	O
)	O
(	O
+	O
)	O
phenotype	B-UNK
.	O

Analysis	B-UNK
of	O
stable	B-UNK
Chinese	B-UNK
hamster	O
ovary	O
transfectants	O
expressing	O
allele	B-UNK
-	O
specific	B-UNK
recombinant	B-UNK
forms	B-UNK
of	O
GPIa	O
showed	O
that	O
anti-Sit	O
(	O
a	O
)	O
exclusively	O
reacted	O
with	O
the	O
Glu	B-UNK
(	O
505	O
)	O
Met	B-UNK
(	O
799	O
)	O
,	O
but	O
not	O
with	O
the	O
Glu	B-UNK
(	O
505	O
)	O
Thr	B-UNK
(	O
799	O
)	O
and	O
the	O
Lys	O
(	O
505	O
)	O
Thr	B-UNK
(	O
799	O
)	O
isoforms	O
.	O

In	O
contrast	B-UNK
,	O
anti-Br	O
(	O
a	O
)	O
(	O
HPA-5b	O
)	O
only	O
recognized	O
the	O
Lys	O
(	O
505	O
)	O
Thr	B-UNK
(	O
799	O
)	O
form	B-UNK
,	O
whereas	O
anti-Br	O
(	O
b	O
)	O
(	O
HPA-5a	O
)	O
reacted	O
with	O
both	O
Glu	B-UNK
(	O
505	O
)	O
Thr	B-UNK
(	O
799	O
)	O
and	O
Glu	B-UNK
(	O
505	O
)	O
Met	B-UNK
(	O
799	O
)	O
isoforms	O
.	O

These	O
results	B-UNK
demonstrated	O
that	O
the	O
Met	B-UNK
(	O
799	O
)	O
is	O
responsible	B-UNK
for	O
formation	B-UNK
of	O
the	O
Sit	B-UNK
(	O
a	O
)	O
alloantigenic	O
determinants	O
,	O
whereas	O
amino	B-UNK
acid	I-UNK
505	O
(	O
Lys	O
or	O
Glu	B-UNK
)	O
specifically	B-UNK
controls	O
the	O
expression	B-UNK
of	O
Br	O
(	O
a	O
)	O
and	O
Br	O
(	O
b	O
)	O
epitopes	O
,	O
respectively	O
.	O

Platelet	B-DISEASE
aggregation	I-DISEASE
responses	B-UNK
of	O
Sit	B-UNK
(	O
a	O
)	O
(	O
+	O
)	O
individuals	B-UNK
were	O
diminished	O
in	O
response	B-UNK
to	O
collagen	O
,	O
indicating	O
that	O
the	O
Thr	B-UNK
(	O
799	O
)	O
Met	B-UNK
mutation	B-UNK
affects	O
the	O
function	B-UNK
of	O
the	O
GPIa	O
/	O
IIa	O
complex	O

Mutations	B-UNK
of	O
the	O
cathepsin	O
C	O
gene	B-UNK
are	O
responsible	B-UNK
for	O
Papillon	O
-	O
Lefevre	O
syndrome	B-DISEASE
.	O

Papillon	O
-	O
Lefevre	O
syndrome	B-UNK
(	O
PLS	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterised	O
by	O
palmoplantar	O
hyperkeratosis	O
and	O
severe	B-UNK
early	B-UNK
onset	I-UNK
periodontitis	B-DISEASE
that	O
results	B-UNK
in	O
the	O
premature	B-UNK
loss	B-UNK
of	O
the	O
primary	B-UNK
and	O
secondary	O
dentitions	O
.	O

A	O
major	B-UNK
gene	B-UNK
locus	B-UNK
for	O
PLS	B-UNK
has	O
been	O
mapped	B-UNK
to	O
a	O
2	O
.	O

8	O
cM	B-DISEASE
interval	B-UNK
on	O
chromosome	B-UNK
11q14	O
.	O

Correlation	B-UNK
of	O
physical	B-UNK
and	O
genetic	B-UNK
maps	B-UNK
of	O
this	O
interval	B-UNK
indicate	O
it	O
includes	O
at	O
least	O
40	O
ESTs	O
and	O
six	O
known	O
genes	B-UNK
including	O
the	O
lysosomal	B-UNK
protease	O
cathepsin	O
C	O
gene	B-UNK
(	O
CTSC	O
)	O
.	O

The	O
CTSC	O
message	O
is	O
expressed	B-UNK
at	O
high	B-UNK
levels	B-UNK
in	O
a	O
variety	O
of	O
immune	B-UNK
cells	B-UNK
including	O
polymorphonuclear	O
leucocytes	O
,	O
macrophages	O
,	O
and	O
their	O
precursors	O
.	O

By	O
RT	O
-	O
PCR	B-UNK
,	O
we	O
found	O
CTSC	O
is	O
also	O
expressed	B-UNK
in	O
epithelial	B-UNK
regions	B-UNK
commonly	O
affected	B-UNK
by	O
PLS	B-UNK
,	O
including	O
the	O
palms	O
,	O
soles	O
,	O
knees	O
,	O
and	O
oral	B-UNK
keratinised	O
gingiva	O
.	O

The	O
4	O
.	O

7	O
kb	B-UNK
CTSC	O
gene	B-UNK
consists	O
of	O
two	O
exons	O
.	O

Sequence	B-UNK
analysis	I-UNK
of	O
CTSC	O
from	O
subjects	B-UNK
affected	B-UNK
with	O
PLS	B-UNK
from	O
five	O
consanguineous	O
Turkish	O
families	B-UNK
identified	B-UNK
four	O
different	O
mutations	B-UNK
.	O

An	O
exon	B-UNK
1	O
nonsense	B-UNK
mutation	I-UNK
(	O
856C--	O
>	O
T	O
)	O
introduces	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
at	O
amino	B-UNK
acid	I-UNK
286	O
.	O

Three	O
exon	B-UNK
2	O
mutations	B-UNK
were	O
identified	B-UNK
,	O
including	O
a	O
single	B-UNK
nucleotide	I-UNK
deletion	B-UNK
(	O
2692delA	O
)	O
of	O
codon	B-UNK
349	O
introducing	O
a	O
frameshift	B-UNK
and	O
premature	B-UNK
termination	I-UNK
codon	B-UNK
,	O
a	O
2	O
bp	B-UNK
deletion	I-UNK
(	O
2673	O
-	O
2674delCT	O
)	O
that	O
results	B-UNK
in	O
introduction	O
of	O
a	O
stop	B-UNK
codon	I-UNK
at	O
amino	B-UNK
acid	I-UNK
343	O
,	O
and	O
a	O
G--	O
>	O
A	O
substitution	B-UNK
in	O
codon	B-UNK
429	O
(	O
2931G--	O
>	O
A	O
)	O
introducing	O
a	O
premature	B-UNK
termination	I-UNK
codon	B-UNK
.	O

All	O
PLS	B-UNK
patients	B-UNK
were	O
homozygous	B-UNK
for	O
cathepsin	O
C	O
mutations	B-UNK
inherited	B-UNK
from	O
a	O
common	B-UNK
ancestor	O
.	O

Parents	O
and	O
sibs	O
heterozygous	B-UNK
for	O
cathepsin	O
C	O
mutations	B-UNK
do	O
not	O
show	O
either	O
the	O
palmoplantar	O
hyperkeratosis	O
or	O
severe	B-UNK
early	B-UNK
onset	I-UNK
periodontitis	B-DISEASE
characteristic	B-UNK
of	O
PLS	B-UNK
.	O

A	O
more	O
complete	O
understanding	B-UNK
of	O
the	O
functional	O
physiology	O
of	O
cathepsin	O
C	O
carries	O
significant	B-UNK
implications	B-UNK
for	O
understanding	B-UNK
normal	B-UNK
and	O
abnormal	O
skin	B-UNK
development	B-UNK
and	O
periodontal	O
disease	B-DISEASE
susceptibility	I-DISEASE

Mutational	O
analysis	B-UNK
of	O
the	O
HGO	B-UNK
gene	B-UNK
in	O
Finnish	B-UNK
alkaptonuria	B-DISEASE
patients	B-UNK
.	O

Alkaptonuria	B-UNK
(	O
AKU	O
)	O
,	O
the	O
prototypic	O
inborn	O
error	O
of	O
metabolism	B-UNK
,	O
has	O
recently	O
been	O
shown	B-UNK
to	O
be	O
caused	B-UNK
by	O
loss	B-UNK
of	O
function	B-UNK
mutations	B-UNK
in	O
the	O
homogentisate-1	O
,	O
2-dioxygenase	O
gene	B-UNK
(	O
HGO	B-UNK
)	O
.	O

So	O
far	O
17	O
mutations	B-UNK
have	O
been	O
characterised	O
in	O
AKU	O
patients	B-UNK
of	O
different	O
ethnic	B-UNK
origin	O
.	O

We	O
describe	O
three	O
novel	O
mutations	B-UNK
(	O
R58fs	O
,	O
R330S	O
,	O
and	O
H371R	O
)	O
and	O
one	O
common	B-UNK
AKU	O
mutation	B-UNK
(	O
M368V	O
)	O
,	O
detected	B-UNK
by	O
mutational	O
and	O
polymorphism	B-UNK
analysis	B-UNK
of	O
the	O
HGO	B-UNK
gene	B-UNK
in	O
five	O
Finnish	B-UNK
AKU	O
pedigrees	O
.	O

The	O
three	O
novel	O
AKU	O
mutations	B-UNK
are	O
most	O
likely	O
specific	B-UNK
for	O
the	O
Finnish	B-UNK
population	B-UNK
and	O
have	O
originated	O
recently	O
..	O

The	O
identical	B-UNK
5'splice	O
-	O
site	B-UNK
acceptor	B-UNK
mutation	B-UNK
in	O
five	O
attenuated	B-UNK
APC	B-UNK
families	B-UNK
from	O
Newfoundland	O
demonstrates	O
a	O
founder	B-UNK
effect	I-UNK
.	O

Inherited	B-UNK
mutations	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
predispose	O
carriers	B-UNK
to	O
multiple	B-UNK
adenomatous	B-DISEASE
polyps	I-DISEASE
of	O
the	O
colon	B-UNK
and	O
rectum	O
and	O
to	O
colorectal	B-UNK
cancer	I-UNK
.	O

Mutations	B-UNK
located	B-UNK
at	O
the	O
extreme	O
5	O
end	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
,	O
however	O
,	O
are	O
associated	O
with	O
a	O
less	O
severe	B-UNK
disease	B-DISEASE
known	O
as	O
attenuated	B-UNK
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
AAPC	B-UNK
)	O
.	O

Many	O
individuals	B-UNK
with	O
AAPC	B-UNK
develop	O
relatively	O
few	O
colorectal	B-UNK
polyps	B-DISEASE
but	O
are	O
still	O
at	O
high	B-UNK
risk	I-UNK
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

We	O
report	B-UNK
here	O
the	O
identification	B-UNK
of	O
a	O
5	O
APC	B-UNK
germline	B-UNK
mutation	I-UNK
in	O
five	O
separately	O
ascertained	O
AAPC	B-UNK
families	B-UNK
from	O
Newfoundland	O
,	O
Canada	O
.	O

This	O
disease	B-DISEASE
-	O
causing	B-UNK
mutation	B-UNK
is	O
a	O
single	B-UNK
basepair	O
change	B-UNK
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	B-UNK
-	O
acceptor	B-UNK
region	B-UNK
of	O
APC	B-UNK
intron	B-UNK
3	O
that	O
creates	O
a	O
mutant	B-UNK
RNA	B-UNK
without	O
exon	B-UNK
4	O
of	O
APC	B-UNK
.	O

The	O
observation	O
of	O
the	O
same	O
APC	B-UNK
mutation	B-UNK
in	O
five	O
families	B-UNK
from	O
the	O
same	O
geographic	O
area	B-UNK
demonstrates	O
a	O
founder	B-UNK
effect	I-UNK
.	O

Furthermore	O
,	O
the	O
identification	B-UNK
of	O
this	O
germline	B-UNK
mutation	I-UNK
strengthens	O
the	O
correlation	B-UNK
between	O
the	O
5	O
location	B-UNK
of	O
an	O
APC	B-UNK
disease	B-DISEASE
-	O
causing	B-UNK
mutation	B-UNK
and	O
the	O
attenuated	B-UNK
polyposis	B-UNK
phenotype	B-UNK
..	O

Alstrom	B-DISEASE
syndrome	I-DISEASE
:	O
further	O
evidence	B-UNK
for	O
linkage	B-UNK
to	O
human	B-UNK
chromosome	I-UNK
2p13	O
.	O

Alstrom	B-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	B-UNK
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
retinal	B-DISEASE
degeneration	I-DISEASE
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
early	B-UNK
-	O
onset	B-UNK
obesity	B-DISEASE
,	O
and	O
non-insulin-dependent	O
diabetes	B-UNK
mellitus	I-UNK
.	O

The	O
gene	B-UNK
for	O
Alstrom	B-DISEASE
syndrome	I-DISEASE
(	O
ALMS1	O
)	O
has	O
been	O
previously	B-UNK
localized	B-UNK
to	O
human	B-UNK
chromosome	I-UNK
2p13	O
by	O
homozygosity	B-UNK
mapping	B-UNK
in	O
two	O
distinct	O
isolated	B-UNK
populations	O
-	O
French	B-UNK
Acadian	O
and	O
North	B-UNK
African	B-UNK
.	O

Pair	B-UNK
-	O
wise	O
analyses	O
resulted	B-UNK
in	O
maximum	B-UNK
lod	B-UNK
(	O
logarithm	O
of	O
the	O
odds	O
ratio	B-UNK
)	O
scores	B-UNK
of	O
3	O
.	O

84	O
and	O
2	O
.	O

9	O
,	O
respectively	O
.	O

To	O
confirm	O
these	O
findings	B-UNK
,	O
a	O
large	B-UNK
linkage	B-UNK
study	B-UNK
was	O
performed	O
in	O
twelve	O
additional	O
families	B-UNK
segregating	O
for	O
Alstrom	B-DISEASE
syndrome	I-DISEASE
.	O

A	O
maximum	B-UNK
two	O
-	O
point	B-UNK
lod	B-UNK
score	I-UNK
of	O
7	O
.	O

13	O
(	O
theta	B-UNK
=	O
0	O
.	O
00	O
)	O
for	O
marker	B-UNK
D2S2110	O
and	O
a	O
maximum	B-UNK
cumulative	O
multipoint	B-UNK
lod	B-UNK
score	I-UNK
of	O
9	O
.	O

16	O
for	O
marker	B-UNK
D2S2110	O
were	O
observed	B-UNK
,	O
further	O
supporting	O
linkage	B-UNK
to	O
chromosome	B-UNK
2p13	O
.	O

No	O
evidence	B-UNK
of	O
genetic	B-UNK
heterogeneity	I-UNK
was	O
observed	B-UNK
in	O
these	O
families	B-UNK
.	O

Meiotic	B-UNK
recombination	B-UNK
events	O
have	O
localized	B-UNK
the	O
critical	B-UNK
region	I-UNK
containing	O
ALMS1	O
to	O
a	O
6	O
.	O

1-cM	O
interval	B-UNK
flanked	O
by	O
markers	B-UNK
D2S327	O
and	O
D2S286	O
.	O

A	O
fine	O
resolution	O
radiation	B-UNK
hybrid	O
map	B-UNK
of	O
31	O
genes	B-UNK
and	O
markers	B-UNK
has	O
been	O
constructed	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
:	O
phenotypic	B-UNK
variability	B-UNK
in	O
two	O
families	B-UNK
carrying	B-UNK
the	O
same	O
PDS	B-UNK
missense	B-UNK
mutation	I-UNK
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
comprises	O
congenital	B-UNK
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
thyroid	O
goiter	B-DISEASE
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	B-UNK
.	O

Recently	O
,	O
this	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
was	O
shown	B-UNK
to	O
be	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
PDS	B-UNK
gene	B-UNK
,	O
which	O
encodes	B-UNK
an	O
anion	O
transporter	B-UNK
called	O
pendrin	B-UNK
.	O

Molecular	B-UNK
analysis	I-UNK
of	O
the	O
PDS	B-UNK
gene	B-UNK
was	O
performed	O
in	O
two	O
consanguineous	O
large	B-UNK
families	B-UNK
from	O
Southern	B-UNK
Tunisia	O
comprising	O
a	O
total	B-UNK
of	O
23	O
individuals	B-UNK
affected	B-UNK
with	O
profound	O
congenital	B-UNK
deafness	B-DISEASE
;	O
the	O
same	O
missense	B-UNK
mutation	I-UNK
,	O
L445W	O
,	O
was	O
identified	B-UNK
in	O
all	O
affected	B-UNK
individuals	I-UNK
.	O

A	O
widened	O
vestibular	O
aqueduct	O
was	O
found	O
in	O
all	O
patients	B-UNK
who	O
underwent	O
computed	O
tomography	O
(	O
CT	B-UNK
)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear	O
.	O

In	O
contrast	B-UNK
,	O
goiter	B-DISEASE
was	O
present	B-UNK
in	O
only	O
11	O
affected	B-UNK
individuals	I-UNK
,	O
who	O
interestingly	B-UNK
had	O
a	O
normal	B-UNK
result	B-UNK
of	O
the	O
perchlorate	O
discharge	O
test	B-UNK
whenever	O
performed	O
.	O

The	O
present	B-UNK
results	B-UNK
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	B-UNK
for	O
the	O
diagnosis	B-UNK
of	O
Pendred	B-UNK
syndrome	I-UNK
and	O
support	O
the	O
use	O
of	O
a	O
molecular	B-UNK
analysis	I-UNK
of	O
the	O
PDS	B-UNK
gene	B-UNK
in	O
the	O
assessment	O
of	O
individuals	B-UNK
with	O
severe	B-UNK
to	O
profound	O
congenital	B-UNK
hearing	B-UNK
loss	I-UNK
associated	O
with	O
inner	O
ear	O
morphological	O
anomaly	B-UNK
even	O
in	O
the	O
absence	B-UNK
of	O
a	O
thyroid	O
goiter	B-DISEASE
..	O

Knobloch	B-DISEASE
syndrome	I-DISEASE
involving	O
midline	O
scalp	O
defect	B-UNK
of	O
the	O
frontal	O
region	B-UNK
.	O

We	O
report	B-UNK
on	O
a	O
4-year	O
-	O
old	O
boy	B-UNK
with	O
Knobloch	B-DISEASE
syndrome	I-DISEASE
.	O

He	O
has	O
vitreoretinal	O
degeneration	B-UNK
,	O
high	B-UNK
myopia	B-DISEASE
,	O
cataract	B-DISEASE
,	O
telecanthus	B-DISEASE
,	O
hypertelorism	B-DISEASE
,	O
and	O
a	O
high	B-UNK
-	O
arched	O
palate	B-UNK
.	O

He	O
also	O
has	O
a	O
defect	B-UNK
of	O
the	O
anterior	O
midline	O
scalp	O
with	O
involvement	B-UNK
of	O
the	O
frontal	O
bone	B-UNK
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(	O
CT	B-UNK
)	O
scan	O
.	O

The	O
brain	B-UNK
was	O
normal	B-UNK
on	O
CT	B-UNK
scan	O
and	O
magnetic	O
resonance	O
imaging	O
.	O

We	O
present	B-UNK
a	O
review	O
of	O
the	O
23	O
published	O
cases	B-UNK
with	O
this	O
syndrome	B-DISEASE
.	O

Our	O
patient	B-UNK
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	B-UNK
nervous	I-UNK
system	I-UNK
pathology	O
whenever	O
midline	O
scalp	O
defects	B-UNK
are	O
present	B-UNK
..	O

The	O
DNA	B-UNK
double-strand	O
break	O
repair	B-UNK
gene	B-UNK
hMRE11	B-UNK
is	O
mutated	B-UNK
in	O
individuals	B-UNK
with	O
an	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
-	O
like	O
disorder	B-UNK
.	O

We	O
show	O
that	O
hypomorphic	O
mutations	B-UNK
in	O
hMRE11	B-UNK
,	O
but	O
not	O
in	O
ATM	B-UNK
,	O
are	O
present	B-UNK
in	O
certain	O
individuals	B-UNK
with	O
an	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
-	O
like	O
disorder	B-UNK
(	O
ATLD	O
)	O
.	O

The	O
cellular	O
features	B-UNK
resulting	B-UNK
from	O
these	O
hMRE11	B-UNK
mutations	B-UNK
are	O
similar	B-UNK
to	O
those	O
seen	O
in	O
A	O
-T	O
as	O
well	O
as	O
NBS	B-UNK
and	O
include	O
hypersensitivity	B-DISEASE
to	O
ionizing	B-UNK
radiation	I-UNK
,	O
radioresistant	O
DNA	B-UNK
synthesis	B-UNK
,	O
and	O
abrogation	O
of	O
ATM	B-UNK
-	O
dependent	B-UNK
events	O
,	O
such	O
as	O
the	O
activation	O
of	O
Jun	O
kinase	B-UNK
following	O
exposure	O
to	O
gamma	B-UNK
irradiation	O
.	O

Although	O
the	O
mutant	B-UNK
hMre11	B-UNK
proteins	B-UNK
retain	O
some	O
ability	B-UNK
to	O
interact	O
with	O
hRad50	O
and	O
Nbs1	O
,	O
formation	B-UNK
of	O
ionizing	B-UNK
radiation	I-UNK
-	O
induced	O
hMre11	B-UNK
and	O
Nbs1	O
foci	O
was	O
absent	O
in	O
hMRE11	B-UNK
mutant	B-UNK
cells	B-UNK
.	O

These	O
data	B-UNK
demonstrate	B-UNK
that	O
ATM	B-UNK
and	O
the	O
hMre11	B-UNK
/	O
hRad50	O
/	O
Nbs1	O
protein	B-UNK
complex	O
act	O
in	O
the	O
same	O
DNA	B-UNK
damage	I-UNK
response	B-UNK
pathway	B-UNK
and	O
link	O
hMre11	B-UNK
to	O
the	O
complex	O
pathology	O
of	O
A	O
-T	O
..	O

Mutations	B-UNK
in	O
TNFRSF11A	O
,	O
affecting	O
the	O
signal	B-UNK
peptide	B-UNK
of	O
RANK	O
,	O
cause	O
familial	B-UNK
expansile	O
osteolysis	B-DISEASE
.	O

Familial	B-UNK
expansile	O
osteolysis	B-DISEASE
(	O
FEO	O
,	O
MIM	O
174810	O
)	O
is	O
a	O
rare	B-UNK
,	O
autosomal	B-UNK
dominant	I-UNK
bone	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
focal	O
areas	O
of	O
increased	B-UNK
bone	B-UNK
remodelling	O
.	O

The	O
osteolytic	O
lesions	B-UNK
,	O
which	O
develop	O
usually	O
in	O
the	O
long	B-UNK
bones	O
during	O
early	B-UNK
adulthood	O
,	O
show	O
increased	B-UNK
osteoblast	O
and	O
osteoclast	O
activity	B-UNK
.	O

Our	O
previous	B-UNK
linkage	B-UNK
studies	B-UNK
mapped	B-UNK
the	O
gene	B-UNK
responsible	B-UNK
for	O
FEO	O
to	O
an	O
interval	B-UNK
of	O
less	O
than	O
5	O
cM	B-DISEASE
between	O
D18S64	O
and	O
D18S51	O
on	O
chromosome	B-UNK
18q21	O
.	O

2	O
-	O
21	O
2	O
-	O
21	O
.	O

3	O
in	O
a	O
large	B-UNK
Northern	B-UNK
Irish	B-UNK
family	B-UNK
.	O

The	O
gene	B-UNK
encoding	B-UNK
receptor	B-UNK
activator	O
of	O
nuclear	B-UNK
factor	B-UNK
-	O
kappa	O
B	O
(	O
RANK	O
;	O
ref	O
.	O
5	O
)	O
,	O
TNFRSF11A	O
,	O
maps	B-UNK
to	O
this	O
region	B-UNK
.	O

RANK	O
is	O
essential	B-UNK
in	O
osteoclast	O
formation	B-UNK
.	O

We	O
identified	B-UNK
two	O
heterozygous	B-UNK
insertion	O
mutations	B-UNK
in	O
exon	B-UNK
1	O
of	O
TNFRSF11A	O
in	O
affected	B-UNK
members	B-UNK
of	O
four	O
families	B-UNK
with	O
FEO	O
or	O
familial	B-UNK
Paget	O
disease	B-UNK
of	O
bone	B-UNK
(	O
PDB	O
)	O
.	O

One	O
was	O
a	O
duplication	B-UNK
of	O
18	O
bases	O
and	O
the	O
other	O
a	O
duplication	B-UNK
of	O
27	O
bases	O
,	O
both	O
of	O
which	O
affected	B-UNK
the	O
signal	B-UNK
peptide	B-UNK
region	B-UNK
of	O
the	O
RANK	O
molecule	O
.	O

Expression	B-UNK
of	O
recombinant	B-UNK
forms	B-UNK
of	O
the	O
mutant	B-UNK
RANK	O
proteins	B-UNK
revealed	B-UNK
perturbations	O
in	O
expression	B-UNK
levels	B-UNK
and	O
lack	B-UNK
of	O
normal	B-UNK
cleavage	O
of	O
the	O
signal	B-UNK
peptide	B-UNK
.	O

Both	O
mutations	B-UNK
caused	B-UNK
an	O
increase	B-UNK
in	O
RANK	O
-	O
mediated	O
nuclear	B-UNK
factor	B-UNK
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
signalling	O
in	O
vitro	O
,	O
consistent	B-UNK
with	O
the	O
presence	O
of	O
an	O
activating	O
mutation	B-UNK
.	O

Cardiac	B-UNK
Na	B-UNK
(	O
+	O
)	O
channel	B-UNK
dysfunction	B-UNK
in	O
Brugada	B-DISEASE
syndrome	I-DISEASE
is	O
aggravated	O
by	O
beta	B-UNK
(	O
1)-subunit	O
.	O

BACKGROUND	O
Mutations	B-UNK
in	O
the	O
gene	B-UNK
encoding	B-UNK
the	O
human	B-UNK
cardiac	B-UNK
Na	B-UNK
(	O
+	O
)	O
channel	B-UNK
alpha	B-UNK
-	O
subunit	B-UNK
(	O
hH1	O
)	O
are	O
responsible	B-UNK
for	O
chromosome	B-UNK
3-linked	O
congenital	B-UNK
long	B-DISEASE
-	I-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
LQT3	O
)	O
and	O
idiopathic	B-DISEASE
ventricular	I-DISEASE
fibrillation	I-DISEASE
(	O
IVF	O
)	O
.	O

An	O
auxiliary	O
beta	B-UNK
(	O
1)-subunit	O
,	O
widely	O
expressed	B-UNK
in	O
excitable	O
tissues	O
,	O
shifts	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	B-UNK
inactivation	B-UNK
toward	O
more	O
negative	B-UNK
potentials	O
and	O
restores	O
normal	B-UNK
gating	O
kinetics	O
of	O
brain	B-UNK
and	O
skeletal	B-UNK
muscle	I-UNK
Na	B-UNK
(	O
+	O
)	O
channels	O
expressed	B-UNK
in	O
Xenopus	O
oocytes	O
but	O
has	O
little	O
if	O
any	O
functional	O
effect	B-UNK
on	O
the	O
cardiac	B-UNK
isoform	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	B-UNK
of	O
a	O
human	B-UNK
beta	B-UNK
(	O
1)-subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	B-UNK
hH1	O
mutation	B-UNK
(	O
T1620	O
M	O
)	O
previously	B-UNK
associated	O
with	O
IVF	O
.	O

METHODS	O
AND	O
RESULTS	B-UNK
When	O
expressed	B-UNK
alone	O
in	O
Xenopus	O
oocytes	O
,	O
T1620	O
M	O
exhibited	O
no	O
persistent	O
currents	O
,	O
in	O
contrast	B-UNK
to	O
the	O
LQT3	O
mutant	B-UNK
channels	O
,	O
but	O
the	O
midpoint	O
of	O
steady	O
-	O
state	B-UNK
inactivation	B-UNK
(	O
V	O
(	O
1/2	O
)	O
)	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild	B-UNK
-	O
type	B-UNK
hH1	O
.	O

Coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
did	O
not	O
significantly	O
alter	O
current	B-UNK
decay	O
or	O
recovery	O
from	O
inactivation	B-UNK
of	O
wild	B-UNK
-	O
type	B-UNK
hH1	O
;	O
however	O
,	O
it	O
further	O
shifted	O
the	O
V	O
(	O
1/2	O
)	O
and	O
accelerated	O
the	O
recovery	O
from	O
inactivation	B-UNK
of	O
T1620M.	O

Oocyte	O
macropatch	O
analysis	B-UNK
revealed	I-UNK
that	O
the	O
activation	O
kinetics	O
of	O
T1620	O
M	O
were	O
normal	B-UNK
.	O

CONCLUSIONS	B-UNK
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	B-UNK
functional	O
defect	B-UNK
that	O
results	B-UNK
in	O
a	O
greater	B-UNK
overlap	O
in	O
the	O
relationship	B-UNK
between	O
channel	B-UNK
inactivation	B-UNK
and	O
activation	O
(	O
window	O
current	B-UNK
)	O
in	O
T1620	O
M	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	B-UNK
pathophysiological	O
mechanism	B-UNK
of	O
IVF	O
in	O
vivo	B-UNK
.	O

One	O
possible	O
explanation	O
for	O
our	O
finding	O
is	O
an	O
altered	O
alpha-/beta	O
(	O
1)-subunit	O
association	B-UNK
in	O
the	O
mutant	B-UNK
..	O

Meiotic	B-UNK
segregation	B-UNK
analysis	B-UNK
of	O
RB1	B-UNK
alleles	B-UNK
in	O
retinoblastoma	B-DISEASE
pedigrees	O
by	O
use	O
of	O
single	B-UNK
-	O
sperm	O
typing	O
.	O

In	O
hereditary	B-UNK
retinoblastoma	B-DISEASE
,	O
different	O
epidemiological	O
studies	B-UNK
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	B-UNK
of	O
mutant	B-UNK
retinoblastoma	B-DISEASE
alleles	B-UNK
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	B-UNK
of	O
a	O
meiotic	B-UNK
drive	O
.	O

To	O
investigate	B-UNK
this	O
mechanism	B-UNK
,	O
we	O
analyzed	B-UNK
sperm	O
samples	B-UNK
from	O
six	O
individuals	B-UNK
from	O
five	O
unrelated	B-UNK
families	I-UNK
affected	B-UNK
with	O
hereditary	B-UNK
retinoblastoma	B-DISEASE
.	O

Single	B-UNK
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	B-UNK
of	O
two	O
informative	O
short	B-UNK
tandem	O
repeats	B-UNK
located	B-UNK
either	O
in	O
or	O
close	B-UNK
to	O
the	O
retinoblastoma	B-DISEASE
gene	B-UNK
(	O
RB1	B-UNK
)	O
.	O

The	O
segregation	B-UNK
probability	B-UNK
of	O
mutant	B-UNK
RB1	B-UNK
alleles	B-UNK
in	O
sperm	O
samples	B-UNK
was	O
assessed	O
by	O
use	O
of	O
the	O
SPERMSEG	O
program	O
,	O
which	O
includes	O
experimental	O
parameters	O
,	O
recombination	B-UNK
fractions	O
between	O
the	O
markers	B-UNK
,	O
and	O
segregation	B-UNK
parameters	O
.	O

A	O
total	B-UNK
of	O
2	O
,	O
952	O
single	B-UNK
sperm	O
from	O
the	O
six	O
donors	O
were	O
analyzed	B-UNK
.	O

We	O
detected	B-UNK
a	O
significant	B-UNK
segregation	B-UNK
distortion	I-UNK
in	O
the	O
data	B-UNK
as	O
a	O
whole	O
(	O
P	O
=	O
.	O
0099	O
)	O
and	O
a	O
significant	B-UNK
heterogeneity	B-UNK
in	O
the	O
segregation	B-UNK
rate	B-UNK
across	O
donors	O
(	O
.	O
0092	O
)	O
.	O

Further	O
analysis	B-UNK
shows	O
that	O
this	O
result	B-UNK
can	O
be	O
explained	O
by	O
segregation	B-UNK
distortion	I-UNK
in	O
favor	O
of	O
the	O
normal	B-UNK
allele	B-UNK
in	O
one	O
donor	B-UNK
only	O
and	O
that	O
it	O
does	O
not	O
provide	B-UNK
evidence	I-UNK
of	O
a	O
significant	B-UNK
segregation	B-UNK
distortion	I-UNK
in	O
the	O
other	O
donors	O
.	O

The	O
segregation	B-UNK
distortion	I-UNK
favoring	O
the	O
mutant	B-UNK
RB1	B-UNK
allele	B-UNK
does	O
not	O
seem	O
to	O
occur	B-UNK
during	O
spermatogenesis	O
,	O
and	O
,	O
thus	O
,	O
meiotic	B-UNK
drive	O
may	O
result	B-UNK
either	O
from	O
various	O
mechanisms	O
,	O
including	O
a	O
fertilization	O
advantage	B-UNK
or	O
a	O
better	O
mobility	O
in	O
sperm	O
bearing	O
a	O
mutant	B-UNK
RB1	B-UNK
gene	B-UNK
,	O
or	O
from	O
the	O
existence	O
of	O
a	O
defectively	O
imprinted	O
gene	B-UNK
located	B-UNK
on	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
.	O

Friedreich	B-UNK
ataxia	I-UNK
:	O
an	O
overview	O
.	O

Friedreich	B-DISEASE
ataxia	I-DISEASE
,	O
an	O
autosomal	B-UNK
recessive	I-UNK
neurodegenerative	B-DISEASE
disease	I-DISEASE
,	O
is	O
the	O
most	O
common	B-UNK
of	O
the	O
inherited	B-UNK
ataxias	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
gene	B-UNK
that	O
is	O
mutated	B-UNK
in	O
this	O
condition	B-UNK
,	O
FRDA	B-UNK
,	O
has	O
led	B-UNK
to	O
rapid	O
advances	O
in	O
the	O
understanding	B-UNK
of	O
the	O
pathogenesis	B-UNK
of	O
Friedreich	B-UNK
ataxia	I-UNK
.	O

About	O
98	O
%	O
of	O
mutant	B-UNK
alleles	I-UNK
have	O
an	O
expansion	B-UNK
of	O
a	O
GAA	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
in	O
intron	B-UNK
1	O
of	O
the	O
gene	B-UNK
.	O

This	O
leads	B-UNK
to	O
reduced	O
levels	B-UNK
of	O
the	O
protein	B-UNK
,	O
frataxin	B-UNK
.	O

There	O
is	O
mounting	O
evidence	B-UNK
to	O
suggest	B-UNK
that	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
is	O
the	O
result	B-UNK
of	O
accumulation	B-UNK
of	O
iron	B-UNK
in	O
mitochondria	O
leading	B-UNK
to	O
excess	B-UNK
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	B-UNK
in	O
cellular	O
damage	B-UNK
and	O
death	B-DISEASE
.	O

Currently	O
there	O
is	O
no	O
known	O
treatment	O
that	O
alters	O
the	O
natural	O
course	O
of	O
the	O
disease	B-UNK
.	O

The	O
discovery	O
of	O
the	O
FRDA	B-UNK
gene	B-UNK
and	O
its	O
possible	O
function	B-UNK
has	O
raised	O
hope	O
that	O
rational	O
therapeutic	O
strategies	O
will	O
be	O
developed	O
..	O

X	O
-	O
linked	B-UNK
retinoschisis	B-DISEASE
with	O
point	B-UNK
mutations	I-UNK
in	O
the	O
XLRS1	B-UNK
gene	B-UNK
.	O

BACKGROUND	O
X	O
-	O
linked	B-UNK
retinoschisis	B-DISEASE
(	O
XLRS	O
)	O
is	O
a	O
relatively	O
rare	B-UNK
vitreoretinal	O
dystrophy	B-UNK
that	O
causes	O
visual	B-DISEASE
loss	I-DISEASE
in	O
young	B-UNK
men	B-UNK
.	O

Recently	O
,	O
a	O
gene	B-UNK
responsible	B-UNK
for	O
this	O
disease	B-UNK
,	O
designated	O
XLRS1	B-UNK
,	O
was	O
identified	B-UNK
,	O
and	O
several	O
deleterious	O
gene	B-UNK
mutations	B-UNK
were	O
reported	B-UNK
.	O

OBJECTIVE	B-UNK
To	O
analyze	O
Japanese	B-UNK
patients	B-UNK
clinically	O
diagnosed	O
as	O
having	O
XLRS	O
formutational	O
changes	O
in	O
the	O
XLRS1	B-UNK
gene	B-UNK
.	O

METHODS	O
Ten	O
patients	B-UNK
with	O
XLRS	O
underwent	O
full	O
ophthalmologic	O
examination	B-UNK
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy	O
.	O

Genomic	B-UNK
DNA	I-UNK
was	O
isolated	B-UNK
from	O
leukocytes	O
,	O
and	O
all	O
exons	O
of	O
the	O
XLRS1	B-UNK
gene	B-UNK
were	O
amplified	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
and	O
analyzed	B-UNK
using	O
a	O
direct	B-UNK
sequencing	I-UNK
method	O
.	O

RESULTS	B-UNK
Point	B-UNK
mutations	I-UNK
in	O
the	O
XLRS1	B-UNK
gene	B-UNK
were	O
identified	B-UNK
in	O
all	O
10	O
patients	B-UNK
.	O

The	O
mutations	B-UNK
were	O
identical	B-UNK
in	O
each	O
of	O
2	O
pairs	B-UNK
of	O
brothers	O
.	O

Six	O
of	O
the	O
point	B-UNK
mutations	I-UNK
represented	O
missense	B-UNK
mutations	I-UNK
,	O
1	O
was	O
a	O
nonsense	B-UNK
mutation	I-UNK
,	O
and	O
1	O
was	O
a	O
frameshift	B-UNK
mutation	I-UNK
.	O

Five	O
of	O
the	O
mutations	B-UNK
are	O
newly	O
reported	B-UNK
herein	O
.	O

CONCLUSIONS	B-UNK
The	O
discovery	O
of	O
new	O
point	B-UNK
mutations	I-UNK
in	O
this	O
study	B-UNK
increases	O
the	O
available	O
information	B-UNK
regarding	O
the	O
spectrum	B-UNK
of	O
genetic	B-UNK
abnormalities	B-UNK
and	O
clinical	B-UNK
manifestations	I-UNK
of	O
XLRS	O
.	O

However	O
,	O
the	O
limited	O
data	B-UNK
failed	O
to	O
reveal	O
a	O
correlation	B-UNK
between	O
mutation	B-UNK
and	O
disease	B-UNK
phenotype	B-UNK
.	O

CLINICAL	B-UNK
RELEVANCE	O
Identification	B-UNK
of	O
mutations	B-UNK
in	O
the	O
XLRS1	B-UNK
gene	B-UNK
and	O
expanded	B-UNK
information	B-UNK
on	O
clinical	B-UNK
manifestations	I-UNK
will	O
facilitate	O
early	B-UNK
diagnosis	B-UNK
,	O
appropriate	O
early	B-UNK
therapy	B-UNK
,	O
and	O
genetic	B-UNK
counseling	I-UNK
regarding	O
the	O
prognosis	O
of	O
XLRS	O
..	O

Atm	B-UNK
and	O
Bax	O
cooperate	O
in	O
ionizing	B-UNK
radiation	I-UNK
-	O
induced	O
apoptosis	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
.	O

Ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
is	O
a	O
hereditary	B-UNK
multisystemic	O
disease	B-UNK
resulting	B-UNK
from	O
mutations	B-UNK
of	O
ataxia	B-DISEASE
telangiectasia	I-DISEASE
,	O
mutated	B-UNK
(	O
ATM	B-UNK
)	O
and	O
is	O
characterized	B-UNK
by	O
neurodegeneration	B-DISEASE
,	O
cancer	B-UNK
,	O
immune	B-UNK
defects	B-UNK
,	O
and	O
hypersensitivity	B-DISEASE
to	O
ionizing	B-UNK
radiation	I-UNK
.	O

The	O
molecular	B-UNK
details	O
of	O
ATM	B-UNK
function	B-UNK
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B-UNK
lesion	O
in	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
becomes	O
apparent	O
early	B-UNK
in	O
life	B-UNK
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O

The	O
central	B-UNK
nervous	I-UNK
system	I-UNK
(	O
CNS	O
)	O
of	O
Atm	B-UNK
-	O
null	O
mice	B-UNK
shows	O
a	O
pronounced	O
defect	B-UNK
in	O
apoptosis	O
induced	O
by	O
genotoxic	O
stress	B-DISEASE
,	O
suggesting	O
ATM	B-UNK
functions	O
to	O
eliminate	O
neurons	O
with	O
excessive	O
genomic	B-UNK
damage	B-UNK
.	O

Here	O
,	O
we	O
report	B-UNK
that	O
the	O
death	B-UNK
effector	O
Bax	O
is	O
required	B-UNK
for	O
a	O
large	B-UNK
proportion	B-UNK
of	O
Atm	B-UNK
-	O
dependent	B-UNK
apoptosis	O
in	O
the	O
developing	O
CNS	O
after	O
ionizing	B-UNK
radiation	I-UNK
(	O
IR	O
)	O
.	O

Although	O
many	O
of	O
the	O
same	O
regions	B-UNK
of	O
the	O
CNS	O
in	O
both	O
Bax-/-and	O
Atm-/-mice	O
were	O
radioresistant	O
,	O
mice	B-UNK
nullizygous	O
for	O
both	O
Bax	O
and	O
Atm	B-UNK
showed	O
additional	O
reduction	B-UNK
in	O
IR	O
-	O
induced	O
apoptosis	O
in	O
the	O
CNS	O
.	O

Therefore	O
,	O
although	O
the	O
major	B-UNK
IR	O
-	O
induced	O
apoptotic	O
pathway	B-UNK
in	O
the	O
CNS	O
requires	O
Atm	B-UNK
and	O
Bax	O
,	O
a	O
p53-dependent	O
collateral	O
pathway	B-UNK
exists	O
that	O
has	O
both	O
Atm	B-UNK
-	O
and	O
Bax	O
-	O
independent	O
branches	O
.	O

Further	O
,	O
Atm	B-UNK
-	O
and	O
Bax	O
-	O
dependent	B-UNK
apoptosis	O
in	O
the	O
CNS	O
also	O
required	B-UNK
caspase-3	O
activation	O
.	O

These	O
data	B-UNK
implicate	O
Bax	O
and	O
caspase-3	O
as	O
death	B-DISEASE
effectors	O
in	O
neurodegenerative	B-UNK
pathways	O
..	O

Haim	O
-	O
Munk	O
syndrome	B-UNK
and	O
Papillon	O
-	O
Lefevre	O
syndrome	B-DISEASE
are	O
allelic	O
mutations	B-UNK
in	O
cathepsin	O
C.	O

Of	O
the	O
many	O
palmoplantar	O
keratoderma	O
(	O
PPK	O
)	O
conditions	O
,	O
only	O
Papillon	O
-	O
Lefevre	O
syndrome	B-DISEASE
(	O
PLS	B-UNK
)	O
and	O
Haim	O
-	O
Munk	O
syndrome	B-UNK
(	O
HMS	B-UNK
)	O
are	O
associated	O
with	O
premature	B-UNK
periodontal	O
destruction	O
.	O

Although	O
both	O
PLS	B-UNK
and	O
HMS	B-UNK
share	O
the	O
cardinal	O
features	B-UNK
of	O
PPK	O
and	O
severe	B-UNK
periodontitis	B-DISEASE
,	O
a	O
number	B-UNK
of	O
additional	O
findings	B-UNK
are	O
reported	B-UNK
in	O
HMS	B-UNK
including	O
arachnodactyly	B-DISEASE
,	O
acro	B-DISEASE
-	I-DISEASE
osteolysis	I-DISEASE
,	O
atrophic	O
changes	O
of	O
the	O
nails	O
,	O
and	O
a	O
radiographic	O
deformity	B-DISEASE
of	O
the	O
fingers	O
.	O

While	O
PLS	B-UNK
cases	B-UNK
have	O
been	O
identified	B-UNK
throughout	O
the	O
world	O
,	O
HMS	B-UNK
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
Cochin	O
,	O
India	O
.	O

Parental	O
consanguinity	O
is	O
a	O
characteristic	B-UNK
of	O
many	O
cases	B-UNK
of	O
both	O
conditions	O
.	O

Although	O
autosomal	B-UNK
recessive	I-UNK
transmission	B-UNK
of	O
PLS	B-UNK
is	O
evident	O
,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	B-UNK
recessive	I-UNK
pattern	B-UNK
of	O
inheritance	B-UNK
with	O
phenotypic	B-UNK
influences	O
from	O
a	O
closely	B-UNK
linked	I-UNK
modifying	O
locus	B-UNK
has	O
been	O
hypothesised	O
for	O
HMS	B-UNK
.	O

Recently	O
,	O
mutations	B-UNK
of	O
the	O
cathepsin	O
C	O
gene	B-UNK
have	O
been	O
identified	B-UNK
as	O
the	O
underlying	O
genetic	B-UNK
defect	B-UNK
in	O
PLS	B-UNK
.	O

To	O
determine	B-UNK
if	O
a	O
cathepsin	O
C	O
mutation	B-UNK
is	O
also	O
responsible	B-UNK
for	O
HMS	B-UNK
,	O
we	O
sequenced	O
the	O
gene	B-UNK
in	O
affected	B-UNK
and	O
unaffected	O
subjects	B-UNK
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	B-UNK
and	O
HMS	B-UNK
phenotypes	O
appear	O
.	O

Here	O
we	O
report	B-UNK
identification	B-UNK
of	O
a	O
mutation	B-UNK
of	O
cathepsin	O
C	O
(	O
exon	B-UNK
6	O
,	O
2127A--	O
>	O
G	O
)	O
that	O
changes	O
a	O
highly	B-UNK
conserved	I-UNK
amino	B-UNK
acid	I-UNK
in	O
the	O
cathepsin	O
C	O
peptide	B-UNK
.	O

This	O
mutation	B-UNK
segregates	O
with	O
HMS	B-UNK
in	O
four	O
nuclear	B-UNK
families	B-UNK
.	O

Additionally	O
,	O
the	O
existence	O
of	O
a	O
shared	O
common	B-UNK
haplotype	B-UNK
for	O
genetic	B-UNK
loci	O
flanking	O
the	O
cathepsin	O
C	O
gene	B-UNK
suggests	O
that	O
affected	B-UNK
subjects	B-UNK
descended	O
from	O
the	O
Cochin	O
isolate	O
are	O
homozygous	B-UNK
for	O
a	O
mutation	B-UNK
inherited	B-UNK
"	O
identical	B-UNK
by	O
descent	O
"	O
from	O
a	O
common	B-UNK
ancestor	O
.	O

This	O
finding	O
supports	O
simple	O
autosomal	B-UNK
recessive	I-UNK
inheritance	B-UNK
for	O
HMS	B-UNK
in	O
these	O
families	B-UNK
.	O

We	O
also	O
report	B-UNK
a	O
mutation	B-UNK
of	O
the	O
same	O
exon	B-UNK
6	O
CTSC	O
codon	B-UNK
(	O
2126C--	O
>	O
T	O
)	O
in	O
a	O
Turkish	O
family	B-UNK
with	O
classical	O
PLS	B-UNK
.	O

These	O
findings	B-UNK
provide	B-UNK
evidence	I-UNK
that	O
PLS	B-UNK
and	O
HMS	B-UNK
are	O
allelic	O
variants	B-UNK
of	O
cathepsin	O
C	O
gene	B-UNK
mutations	B-UNK
..	O

ATM	B-UNK
-	O
heterozygous	B-UNK
germline	B-UNK
mutations	I-UNK
contribute	B-UNK
to	O
breast	B-DISEASE
cancer	I-DISEASE
-	O
susceptibility	B-UNK
.	O

Approximately	O
0	O
.	O

5%-1	O
%	O
of	O
the	O
general	B-UNK
population	B-UNK
has	O
been	O
estimated	B-UNK
to	O
be	O
heterozygous	B-UNK
for	O
a	O
germline	B-UNK
mutation	I-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
are	O
responsible	B-UNK
for	O
the	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
(	O
MIM	O
208900	O
)	O
.	O

The	O
finding	O
that	O
ATM	B-UNK
-	O
heterozygotes	B-UNK
have	O
an	O
increased	B-UNK
relative	B-UNK
risk	B-UNK
for	O
breast	B-UNK
cancer	I-UNK
was	O
supported	O
by	O
some	O
studies	B-UNK
but	O
not	O
confirmed	B-UNK
by	O
others	O
.	O

In	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	B-UNK
of	O
ATM	B-UNK
germline	B-UNK
mutations	I-UNK
in	O
a	O
selected	O
group	B-UNK
of	O
Dutch	B-UNK
patients	B-UNK
with	O
breast	B-UNK
cancer	I-UNK
.	O

We	O
have	O
analyzed	B-UNK
ATM	B-UNK
germline	B-UNK
mutations	I-UNK
in	O
normal	B-UNK
blood	B-UNK
lymphocytes	O
,	O
using	O
the	O
protein	B-UNK
-	O
truncation	B-UNK
test	B-UNK
followed	O
by	O
genomic	B-UNK
-	O
sequence	B-UNK
analysis	I-UNK
.	O

A	O
high	B-UNK
percentage	B-UNK
of	O
ATM	B-UNK
germline	B-UNK
mutations	I-UNK
was	O
demonstrated	O
among	O
patients	B-UNK
with	O
sporadic	B-UNK
breast	I-UNK
cancer	B-DISEASE
.	O

The	O
82	O
patients	B-UNK
included	O
in	O
this	O
study	B-UNK
had	O
developed	O
breast	B-UNK
cancer	I-UNK
at	O
age	B-UNK
<	O
45	O
and	O
had	O
survived	O
>	O
/=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	B-UNK
a	O
contralateral	O
breast	B-UNK
tumor	B-UNK
had	O
been	O
diagnosed	O
.	O

Among	O
these	O
patients	B-UNK
we	O
identified	B-UNK
seven	O
(	O
8	O
.	O
5	O
%	O
)	O
ATM	B-UNK
germline	B-UNK
mutations	I-UNK
,	O
of	O
which	O
five	O
are	O
distinct	O
.	O

One	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
(	O
IVS10	O
-	O
6T--	O
>	O
G	O
)	O
was	O
detected	B-UNK
three	O
times	O
in	O
our	O
series	B-UNK
.	O

Four	O
heterozygous	B-UNK
carriers	B-UNK
were	O
patients	B-UNK
with	O
bilateral	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

Our	O
results	B-UNK
indicate	O
that	O
the	O
mutations	B-UNK
identified	B-UNK
in	O
this	O
study	B-UNK
are	O
"	O
A	O
-T	O
disease	B-DISEASE
-	O
causing	B-UNK
"	O
mutations	B-UNK
that	O
might	O
be	O
associated	O
with	O
an	O
increased	B-UNK
risk	B-UNK
of	O
breast	B-UNK
cancer	I-UNK
in	O
heterozygotes	B-UNK
.	O

We	O
conclude	O
that	O
ATM	B-UNK
heterozygotes	B-UNK
have	O
an	O
approximately	O
ninefold	O
-	O
increased	B-UNK
risk	B-UNK
of	O
developing	O
a	O
type	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
characterized	B-UNK
by	O
frequent	B-UNK
bilateral	O
occurrence	B-UNK
,	O
early	B-UNK
age	B-UNK
at	O
onset	B-UNK
,	O
and	O
long	B-UNK
-	O
term	O
survival	B-UNK
.	O

The	O
specific	B-UNK
characteristics	B-UNK
of	O
our	O
population	B-UNK
of	O
patients	B-UNK
may	O
explain	O
why	O
such	O
a	O
high	B-UNK
frequency	I-UNK
was	O
not	O
found	O
in	O
other	O
series	B-UNK
.	O

Human	B-UNK
mutations	B-UNK
in	O
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
reflect	O
evolutionary	O
history	B-UNK
.	O

Glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
is	O
a	O
cytosolic	O
enzyme	B-UNK
encoded	B-UNK
by	O
a	O
housekeeping	O
X	O
-	O
linked	B-UNK
gene	B-UNK
whose	O
main	O
function	B-UNK
is	O
to	O
produce	B-UNK
NADPH	O
,	O
a	O
key	B-UNK
electron	O
donor	B-UNK
in	O
the	O
defense	O
against	O
oxidizing	O
agents	O
and	O
in	O
reductive	O
biosynthetic	O
reactions	O
.	O

Inherited	B-UNK
G6PD	B-UNK
deficiency	I-UNK
is	O
associated	O
with	O
either	O
episodic	O
hemolytic	B-DISEASE
anemia	I-DISEASE
(	O
triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents	O
)	O
or	O
life	B-UNK
-	O
long	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O

We	O
show	O
here	O
that	O
an	O
evolutionary	O
analysis	B-UNK
is	O
a	O
key	B-UNK
to	O
understanding	B-UNK
the	O
biology	O
of	O
a	O
housekeeping	O
gene	B-UNK
.	O

From	O
the	O
alignment	O
of	O
the	O
amino	B-UNK
acid	I-UNK
(	O
aa	O
)	O
sequence	B-UNK
of	O
52	O
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
species	B-UNK
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	B-UNK
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	B-UNK
deficiency	I-UNK
in	O
humans	B-UNK
and	O
the	O
sequence	B-UNK
conservation	B-UNK
of	O
G6PD	B-UNK
two	O
-	O
thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	B-UNK
and	O
moderately	O
conserved	B-UNK
(	O
50	O
-	O
99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	B-UNK
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	B-UNK
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	B-UNK
deficiency	I-UNK
.	O

This	O
is	O
consistent	B-UNK
with	O
the	O
notion	O
that	O
all	O
human	B-UNK
mutants	O
have	O
residual	B-UNK
enzyme	B-UNK
activity	I-UNK
and	O
that	O
null	O
mutations	B-UNK
are	O
lethal	O
at	O
some	O
stage	B-UNK
of	O
development	B-UNK
.	O

Comparing	O
the	O
distribution	B-UNK
of	O
mutations	B-UNK
in	O
a	O
human	B-UNK
housekeeping	O
gene	B-UNK
with	O
evolutionary	O
conservation	B-UNK
is	O
a	O
useful	O
tool	O
for	O
pinpointing	O
amino	B-UNK
acid	I-UNK
residues	O
important	O
for	O
the	O
stability	O
or	O
the	O
function	B-UNK
of	O
the	O
corresponding	O
protein	B-UNK
.	O

In	O
view	O
of	O
the	O
current	B-UNK
explosive	O
increase	B-UNK
in	O
full	O
genome	B-UNK
sequencing	B-UNK
projects	O
,	O
this	O
tool	O
will	O
become	O
rapidly	O
available	O
for	O
numerous	O
other	O
genes	B-UNK
..	O

Constitutive	O
and	O
regulated	O
modes	O
of	O
splicing	B-UNK
produce	B-UNK
six	O
major	B-UNK
myotonic	B-UNK
dystrophy	I-UNK
protein	B-UNK
kinase	I-UNK
(	O
DMPK	B-UNK
)	O
isoforms	O
with	O
distinct	O
properties	B-UNK
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
is	O
the	O
most	O
prevalent	O
inherited	B-UNK
neuromuscular	B-DISEASE
disease	I-DISEASE
in	O
adults	O
.	O

The	O
genetic	B-UNK
defect	B-UNK
is	O
a	O
CTG	B-UNK
triplet	O
repeat	B-UNK
expansion	I-UNK
in	O
the	O
3-untranslated	O
region	B-UNK
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
protein	B-UNK
kinase	I-UNK
(	O
DMPK	B-UNK
)	O
gene	B-UNK
,	O
consisting	O
of	O
15	O
exons	O
.	O

Using	O
a	O
transgenic	B-UNK
DMPK	B-UNK
-	O
overexpressor	O
mouse	B-UNK
model	I-UNK
,	O
we	O
demonstrate	B-UNK
here	O
that	O
the	O
endogenous	O
mouse	B-UNK
DMPK	B-UNK
gene	B-UNK
and	O
the	O
human	B-UNK
DMPK	B-UNK
transgene	O
produce	B-UNK
six	O
major	B-UNK
alternatively	O
spliced	O
mRNAs	O
which	O
have	O
almost	O
identical	B-UNK
cell	B-UNK
type	B-UNK
-	O
dependent	B-UNK
distribution	B-UNK
frequencies	O
and	O
expression	B-UNK
patterns	B-UNK
.	O

Use	O
of	O
a	O
cryptic	O
5	O
splice	B-UNK
site	I-UNK
in	O
exon	B-UNK
8	O
,	O
which	O
results	B-UNK
in	O
absence	B-UNK
or	O
presence	O
of	O
15	O
nucleotides	O
specifying	O
a	O
VSGGG	O
peptide	B-UNK
motif	B-UNK
,	O
and	O
/	O
or	O
use	O
of	O
a	O
cryptic	O
3	O
splice	B-UNK
site	I-UNK
in	O
exon	B-UNK
14	O
,	O
which	O
leads	B-UNK
to	O
a	O
frameshift	B-UNK
in	O
the	O
mRNA	O
reading	B-UNK
frame	I-UNK
,	O
occur	B-UNK
as	O
independent	O
stochastic	O
events	O
in	O
all	O
tissues	O
examined	O
.	O

In	O
contrast	B-UNK
,	O
the	O
excision	O
of	O
exons	O
13/14	O
that	O
causes	O
a	O
frameshift	B-UNK
and	O
creates	O
a	O
C	O
-	O
terminally	O
truncated	O
protein	B-UNK
is	O
clearly	O
cell	B-UNK
type	B-UNK
dependent	B-UNK
and	O
occurs	O
predominantly	O
in	O
smooth	O
muscle	B-UNK
.	O

We	O
generated	O
all	O
six	O
full	O
-	O
length	B-UNK
mouse	B-UNK
cDNAs	O
that	O
result	B-UNK
from	O
combinations	O
of	O
these	O
three	O
major	B-UNK
splicing	B-UNK
events	O
and	O
show	O
that	O
their	O
transfection	O
into	O
cells	B-UNK
in	O
culture	B-UNK
leads	B-UNK
to	O
production	O
of	O
four	O
different	O
approximately	O
74	O
kDa	O
full	O
-	O
length	B-UNK
(	O
heart-	O
,	O
skeletal	B-UNK
muscle	I-UNK
-	O
or	O
brain	B-UNK
-	O
specific	B-UNK
)	O
and	O
two	O
C	O
-	O
terminally	O
truncated	O
approximately	O
68	O
kDa	O
(	O
smooth	O
muscle	B-UNK
-	O
specific	B-UNK
)	O
isoforms	O
.	O

Information	B-UNK
on	O
DMPK	B-UNK
mRNA	O
and	O
protein	B-UNK
isoform	O
expression	B-UNK
patterns	B-UNK
will	O
be	O
useful	O
for	O
recognizing	O
differential	B-UNK
effects	B-UNK
of	O
(	O
CTG	B-UNK
)	O
(	O
n	O
)	O
expansion	B-UNK
in	O
DM	B-DISEASE
manifestation	B-UNK
..	O

Genetic	B-UNK
analysis	I-UNK
,	O
phenotypic	B-UNK
diagnosis	B-UNK
,	O
and	O
risk	B-UNK
of	O
venous	B-DISEASE
thrombosis	I-DISEASE
in	O
families	B-UNK
with	O
inherited	B-UNK
deficiencies	B-UNK
of	O
protein	B-UNK
S.	O

Protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
is	O
a	O
recognized	O
risk	B-UNK
factor	B-UNK
for	O
venous	B-DISEASE
thrombosis	I-DISEASE
.	O

Of	O
all	O
the	O
inherited	B-UNK
thrombophilic	O
conditions	O
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	B-UNK
variability	B-UNK
,	O
which	O
can	O
lead	B-UNK
to	O
inconclusive	O
results	B-UNK
.	O

We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	B-UNK
of	O
patients	B-UNK
from	O
a	O
single	B-UNK
center	O
where	O
the	O
diagnosis	B-UNK
was	O
confirmed	B-UNK
at	O
the	O
genetic	B-UNK
level	B-UNK
.	O

Twenty	O
-	O
eight	O
index	O
patients	B-UNK
with	O
protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
and	O
a	O
PROS1	O
gene	B-UNK
defect	B-UNK
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	B-UNK
relatives	B-UNK
.	O

To	O
avoid	O
selection	B-UNK
bias	O
,	O
we	O
confined	O
analysis	B-UNK
of	O
total	B-UNK
and	O
free	O
protein	B-UNK
S	O
levels	B-UNK
and	O
thrombotic	B-DISEASE
risk	B-UNK
to	O
the	O
patients	B-UNK
relatives	B-UNK
.	O

In	O
this	O
group	B-UNK
of	O
relatives	B-UNK
,	O
a	O
low	B-UNK
free	O
protein	B-UNK
S	O
level	B-UNK
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	O
gene	B-UNK
defect	B-UNK
(	O
sensitivity	O
97	O
.	O
7	O
%	O
,	O
specificity	O
100	O
%	O
)	O
.	O

First	O
-	O
degree	B-UNK
relatives	B-UNK
with	O
a	O
PROS1	O
gene	B-UNK
defect	B-UNK
had	O
a	O
5	O
.	O

0-fold	O
higher	O
risk	B-UNK
of	O
thrombosis	B-DISEASE
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
1	O
.	O
5	O
-	O
16	O
.	O
8)	O
than	O
those	O
with	O
a	O
normal	B-UNK
PROS1	O
gene	B-UNK
and	O
no	O
other	O
recognized	O
thrombophilic	O
defect	B-UNK
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B-DISEASE
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B-DISEASE
,	O
almost	O
half	B-UNK
of	O
the	O
events	O
were	O
spontaneous	O
.	O

Relatives	B-UNK
with	O
splice	B-UNK
-	O
site	B-UNK
or	O
major	B-UNK
structural	B-UNK
defects	B-UNK
in	O
the	O
PROS1	O
gene	B-UNK
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	B-DISEASE
event	O
and	O
had	O
significantly	O
lower	O
total	B-UNK
and	O
free	O
protein	B-UNK
S	O
levels	B-UNK
than	O
those	O
relatives	B-UNK
having	O
missense	B-UNK
mutations	I-UNK
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	O
gene	B-UNK
defects	B-UNK
and	O
protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
are	O
at	O
increased	B-UNK
risk	B-UNK
of	O
thrombosis	B-DISEASE
and	O
that	O
free	O
protein	B-UNK
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	B-UNK
.	O

(	O
Blood	B-UNK
.	O
2000	O
;	O
95	O
1935	O
-	O
1941	O
)	O
.	O

Autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
(	O
ALPS	B-UNK
)	O
in	O
a	O
child	B-UNK
from	O
consanguineous	O
parents	O
:	O
a	O
dominant	B-UNK
or	O
recessive	B-UNK
disease	B-UNK
?	O

Autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
(	O
ALPS	B-UNK
)	O
is	O
characterized	B-UNK
by	O
autoimmune	B-UNK
features	B-UNK
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	B-UNK
by	O
defective	O
Fas	B-UNK
-	O
mediated	O
apoptosis	O
.	O

This	O
report	B-UNK
describes	O
a	O
child	B-UNK
with	O
clinical	B-UNK
features	I-UNK
of	O
ALPS	B-UNK
without	O
detectable	O
Fas	B-UNK
expression	B-UNK
on	O
freshly	O
isolated	B-UNK
blood	B-UNK
leukocytes	O
.	O

Detection	B-UNK
of	O
FAS	B-UNK
transcripts	O
via	O
real	O
-	O
time	O
quantitative	B-UNK
PCR	B-UNK
made	O
a	O
severe	B-UNK
transcriptional	O
defect	B-UNK
unlikely	O
.	O

Sequencing	B-UNK
of	O
the	O
FAS	B-UNK
gene	B-UNK
revealed	B-UNK
a	O
20-nucleotide	O
duplication	B-UNK
in	O
the	O
last	O
exon	B-UNK
affecting	O
the	O
cytoplasmic	O
signaling	O
domain	B-UNK
.	O

The	O
patient	B-UNK
was	O
homozygous	B-UNK
for	O
this	O
mutation	B-UNK
,	O
whereas	O
the	O
consanguineous	O
parents	O
and	O
the	O
siblings	O
were	O
heterozygous	B-UNK
.	O

The	O
patient	B-UNK
reported	B-UNK
here	O
is	O
a	O
human	B-UNK
homologue	B-UNK
of	O
the	O
Fas	B-UNK
-	O
null	O
mouse	B-UNK
,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	B-UNK
homozygous	B-UNK
mutation	B-UNK
in	O
the	O
FAS	B-UNK
gene	B-UNK
and	O
she	O
shows	O
the	O
severe	B-UNK
and	O
accelerated	O
ALPS	B-UNK
phenotype	B-UNK
.	O

The	O
heterozygous	B-UNK
family	B-UNK
members	I-UNK
did	O
not	O
have	O
the	O
ALPS	B-UNK
phenotype	B-UNK
,	O
indicating	O
that	O
the	O
disease	B-DISEASE
-	O
causing	B-UNK
FAS	B-UNK
mutation	B-UNK
in	O
this	O
family	B-UNK
is	O
autosomal	B-UNK
recessive	I-UNK
..	O

Identification	B-UNK
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
and	O
Angelman	B-DISEASE
syndrome	I-DISEASE
deletion	B-UNK
region	B-UNK
:	O
further	O
evidence	B-UNK
for	O
regional	O
imprinting	B-UNK
control	B-UNK
.	O

Deletions	O
and	O
other	O
abnormalities	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
15q11-q13	O
are	O
associated	O
with	O
two	O
developmental	O
disorders	B-UNK
,	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
and	O
Angelman	B-DISEASE
syndrome	I-DISEASE
(	O
AS	O
)	O
.	O

Loss	B-UNK
of	O
expression	B-UNK
of	O
imprinted	O
,	O
paternally	O
expressed	B-UNK
genes	B-UNK
has	O
been	O
implicated	B-UNK
in	O
PWS	B-UNK
.	O

However	O
,	O
the	O
number	B-UNK
of	O
imprinted	O
genes	B-UNK
that	O
contribute	B-UNK
to	O
PWS	B-UNK
,	O
and	O
the	O
range	B-UNK
over	O
which	O
the	O
imprinting	B-UNK
signal	B-UNK
acts	O
to	O
silence	O
one	O
copy	B-UNK
of	O
the	O
gene	B-UNK
in	O
a	O
parent	O
-	O
of	O
-	O
origin	O
-	O
specific	B-UNK
manner	O
,	O
are	O
unknown	O
.	O

To	O
identify	B-UNK
additional	O
imprinted	O
genes	B-UNK
that	O
could	O
contribute	B-UNK
to	O
the	O
PWS	B-UNK
phenotype	B-UNK
and	O
to	O
understand	O
the	O
regional	O
control	B-UNK
of	O
imprinting	B-UNK
in	O
15q11-q13	O
,	O
we	O
have	O
constructed	O
an	O
imprinted	O
transcript	B-UNK
map	B-UNK
of	O
the	O
PWS	B-UNK
-	O
AS	O
deletion	B-UNK
interval	B-UNK
.	O

The	O
imprinting	B-UNK
status	B-UNK
of	O
22	O
expressed	B-UNK
sequence	B-UNK
tags	O
derived	B-UNK
from	O
the	O
radiation	B-UNK
-	O
hybrid	O
human	B-UNK
transcript	B-UNK
maps	B-UNK
or	O
physical	B-UNK
maps	B-UNK
was	O
determined	B-UNK
in	O
a	O
reverse	B-UNK
transcriptase	O
-	O
PCR	B-UNK
assay	B-UNK
and	O
correlated	B-UNK
with	O
the	O
position	B-UNK
of	O
the	O
transcripts	O
on	O
the	O
physical	B-UNK
map	B-UNK
.	O

Seven	O
new	O
paternally	O
expressed	B-UNK
transcripts	O
localize	O
to	O
an	O
approximately	O
1	O
.	O

5-Mb	O
domain	B-UNK
surrounding	O
the	O
SNRPN	B-UNK
-	O
associated	O
imprinting	B-UNK
center	O
,	O
which	O
already	O
includes	O
four	O
imprinted	O
,	O
paternally	O
expressed	B-UNK
genes	B-UNK
.	O

All	O
other	O
tested	O
new	O
transcripts	O
in	O
the	O
deletion	B-UNK
region	B-UNK
were	O
expressed	B-UNK
from	O
both	O
alleles	B-UNK
.	O

A	O
domain	B-UNK
of	O
exclusive	O
paternal	O
expression	B-UNK
surrounding	O
the	O
imprinting	B-UNK
center	O
suggests	O
strong	B-UNK
regional	O
control	B-UNK
of	O
the	O
imprinting	B-UNK
process	B-UNK
.	O

This	O
study	B-UNK
provides	O
the	O
means	B-UNK
for	O
further	O
investigation	B-UNK
of	O
additional	O
genes	B-UNK
that	O
cause	O
or	O
modify	O
the	O
phenotypes	O
associated	O
with	O
rearrangements	O
of	O
15q11-q13	O
.	O

Combined	O
analysis	B-UNK
of	O
hereditary	B-UNK
prostate	B-UNK
cancer	I-UNK
linkage	B-UNK
to	O
1q24	O
-	O
25	O
:	O
results	B-UNK
from	O
772	O
hereditary	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
families	B-UNK
from	O
the	O
International	O
Consortium	O
for	O
Prostate	B-UNK
Cancer	I-UNK
Genetics	B-UNK
.	O

A	O
previous	B-UNK
linkage	B-UNK
study	B-UNK
provided	O
evidence	B-UNK
for	O
a	O
prostate	B-DISEASE
cancer	I-DISEASE
-	O
susceptibility	B-UNK
locus	B-UNK
at	O
1q24	O
-	O
25	O
.	O

Subsequent	B-UNK
reports	O
in	O
additional	O
collections	O
of	O
families	B-UNK
have	O
yielded	O
conflicting	O
results	B-UNK
.	O

In	O
addition	B-UNK
,	O
evidence	B-UNK
for	O
locus	B-UNK
heterogeneity	B-UNK
has	O
been	O
provided	O
by	O
the	O
identification	B-UNK
of	O
other	O
putative	O
hereditary	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
loci	O
on	O
Xq27	O
-	O
28	O
,	O
1q42	O
-	O
43	O
,	O
and	O
1p36	O
.	O

The	O
present	B-UNK
study	B-UNK
describes	O
a	O
combined	O
analysis	B-UNK
for	O
six	O
markers	B-UNK
in	O
the	O
1q24	O
-	O
25	O
region	B-UNK
in	O
772	O
families	B-UNK
affected	B-UNK
by	O
hereditary	B-UNK
prostate	B-UNK
cancer	I-UNK
and	O
ascertained	O
by	O
the	O
members	B-UNK
of	O
the	O
International	O
Consortium	O
for	O
Prostate	B-UNK
Cancer	I-UNK
Genetics	B-UNK
(	O
ICPCG	O
)	O
from	O
North	B-UNK
America	O
,	O
Australia	O
,	O
Finland	O
,	O
Norway	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O

Overall	O
,	O
there	O
was	O
some	O
evidence	B-UNK
for	O
linkage	B-UNK
,	O
with	O
a	O
peak	O
parametric	O
multipoint	B-UNK
LOD	B-UNK
score	I-UNK
assuming	O
heterogeneity	B-UNK
(	O
HLOD	O
)	O
of	O
1	O
.	O

40	O
(	O
P	O
=	O
.	O
01	O
)	O
at	O
D1S212	O
.	O

The	O
estimated	B-UNK
proportion	B-UNK
of	O
families	B-UNK
(	O
alpha	B-UNK
)	O
linked	B-UNK
to	O
the	O
locus	B-UNK
was	O
.	O

06	O
(	O
1-LOD	O
support	O
interval	B-UNK
.	O
01-	O
.	O
12	O
)	O
.	O

This	O
evidence	B-UNK
was	O
not	O
observed	B-UNK
by	O
a	O
nonparametric	O
approach	O
,	O
presumably	O
because	O
of	O
the	O
extensive	B-UNK
heterogeneity	B-UNK
.	O

Further	O
parametric	O
analysis	B-UNK
revealed	I-UNK
a	O
significant	B-UNK
effect	B-UNK
of	O
the	O
presence	O
of	O
male	B-UNK
-	O
to	O
-	O
male	B-UNK
disease	B-UNK
transmission	B-UNK
within	O
the	O
families	B-UNK
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	B-UNK
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	B-UNK
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

56	O
(	O
P	O
=	O
.	O
0006	O
)	O
and	O
alpha	B-UNK
=	O
.	O

11	O
(	O
1-LOD	O
support	O
interval	B-UNK
.	O
04-	O
.	O
19	O
)	O
,	O
compared	B-UNK
with	O
HLODs	O
of	O
0	O
in	O
the	O
remaining	O
281	O
families	B-UNK
.	O

Within	O
the	O
families	B-UNK
with	O
male	B-UNK
-	O
to	O
-	O
male	B-UNK
disease	B-UNK
transmission	B-UNK
,	O
alpha	B-UNK
increased	B-UNK
with	O
the	O
early	B-UNK
mean	O
age	B-UNK
at	I-UNK
diagnosis	I-UNK
(	O
<	O
65	O
years	O
,	O
alpha	B-UNK
=	O
.	O
19	O
,	O
with	O
1-LOD	O
support	O
interval	B-UNK
.	O
06-	O
.	O
34	O
)	O
and	O
the	O
number	B-UNK
of	O
affected	B-UNK
family	B-UNK
members	I-UNK
(	O
five	O
or	O
more	O
family	B-UNK
members	I-UNK
,	O
alpha	B-UNK
=	O
.	O
15	O
,	O
with	O
1-LOD	O
support	O
interval	B-UNK
.	O
04-	O
.	O
28	O
)	O
.	O

The	O
highest	O
value	O
of	O
alpha	B-UNK
was	O
observed	B-UNK
for	O
the	O
48	O
families	B-UNK
that	O
met	B-UNK
all	O
three	O
criteria	O
(	O
peak	O
HLOD	O
=	O
2	O
.	O
25	O
,	O
P	O
=	O
.	O
001	O
,	O
alpha	B-UNK
=	O
.	O
29	O
,	O
with	O
1-LOD	O
support	O
interval	B-UNK
.	O
08-	O
.	O
53	O
)	O
.	O

These	O
results	B-UNK
support	O
the	O
finding	O
of	O
a	O
prostate	B-DISEASE
cancer	I-DISEASE
-	O
susceptibility	B-UNK
gene	I-UNK
linked	B-UNK
to	O
1q24	O
-	O
25	O
,	O
albeit	O
in	O
a	O
defined	B-UNK
subset	O
of	O
prostate	B-UNK
cancer	I-UNK
families	B-UNK
.	O

Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	B-UNK
of	O
all	O
families	B-UNK
affected	B-UNK
by	O
hereditary	B-UNK
prostate	B-UNK
cancer	I-UNK
,	O
it	O
appears	B-UNK
to	O
play	O
a	O
more	O
prominent	O
role	B-UNK
in	O
the	O
subset	O
of	O
families	B-UNK
with	O
several	O
members	B-UNK
affected	B-UNK
at	O
an	O
early	B-UNK
age	B-UNK
and	O
with	O
male	B-UNK
-	O
to	O
-	O
male	B-UNK
disease	B-UNK
transmission	B-UNK
.	O

A	O
recurrent	O
expansion	B-UNK
of	O
a	O
maternal	O
allele	B-UNK
with	O
36	O
CAG	B-UNK
repeats	I-UNK
causes	O
Huntington	B-UNK
disease	I-UNK
in	O
two	O
sisters	O
.	O

Large	B-UNK
intergenerational	O
repeat	B-UNK
expansions	O
of	O
the	O
CAG	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
in	O
the	O
HD	B-UNK
gene	B-UNK
have	O
been	O
well	O
documented	O
for	O
the	O
male	B-UNK
germline	B-UNK
.	O

We	O
describe	O
a	O
recurrent	O
large	B-UNK
expansion	B-UNK
of	O
a	O
maternal	O
allele	B-UNK
with	O
36	O
CAG	B-UNK
repeats	I-UNK
(	O
to	O
66	O
and	O
57	O
repeats	B-UNK
,	O
respectively	O
,	O
in	O
two	O
daughters	O
)	O
associated	O
with	O
onset	B-UNK
of	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
in	O
the	O
second	O
and	O
third	O
decade	O
in	O
a	O
family	B-UNK
without	O
history	B-UNK
of	O
HD	B-UNK
.	O

Our	O
findings	B-UNK
give	O
evidence	B-UNK
of	O
a	O
gonadal	O
mosaicism	O
in	O
the	O
unaffected	O
mother	O
.	O

We	O
hypothesize	O
that	O
large	B-UNK
expansions	O
also	O
occur	B-UNK
in	O
the	O
female	O
germline	B-UNK
and	O
that	O
a	O
negative	B-UNK
selection	B-UNK
of	O
oocytes	O
with	O
long	B-UNK
repeats	B-UNK
might	O
explain	O
the	O
different	O
instability	B-UNK
behavior	O
of	O
the	O
male	B-UNK
and	O
the	O
female	O
germlines	O
..	O

Abnormal	O
development	B-UNK
of	O
Purkinje	O
cells	B-UNK
and	O
lymphocytes	O
in	O
Atm	B-UNK
mutant	B-UNK
mice	I-UNK
.	O

Motor	O
incoordination	B-DISEASE
,	O
immune	B-UNK
deficiencies	B-UNK
,	O
and	O
an	O
increased	B-UNK
risk	B-UNK
of	O
cancer	B-DISEASE
are	O
the	O
characteristic	B-UNK
features	B-UNK
of	O
the	O
hereditary	B-UNK
disease	B-UNK
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
,	O
which	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
.	O

Through	O
gene	B-UNK
targeting	B-UNK
,	O
we	O
have	O
generated	O
a	O
line	B-UNK
of	O
Atm	B-UNK
mutant	B-UNK
mice	I-UNK
,	O
Atm	B-UNK
(	O
y	O
/	O
y	O
)	O
mice	B-UNK
.	O

In	O
contrast	B-UNK
to	O
other	O
Atm	B-UNK
mutant	B-UNK
mice	I-UNK
,	O
Atm	B-UNK
(	O
y	O
/	O
y	O
)	O
mice	B-UNK
show	O
a	O
lower	O
incidence	B-UNK
of	O
thymic	O
lymphoma	B-DISEASE
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age	B-UNK
.	O

Atm	B-UNK
(	O
y	O
/	O
y	O
)	O
mice	B-UNK
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B-DISEASE
dysfunction	I-DISEASE
.	O

Even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	B-UNK
degeneration	B-UNK
in	O
older	O
Atm	B-UNK
(	O
y	O
/	O
y	O
)	O
animals	O
,	O
ectopic	O
and	O
abnormally	O
differentiated	O
Purkinje	O
cells	B-UNK
were	O
apparent	O
in	O
mutant	B-UNK
mice	I-UNK
of	O
all	O
ages	O
.	O

These	O
findings	B-UNK
establish	O
that	O
some	O
neuropathological	O
abnormalities	B-UNK
seen	O
in	O
A	O
-T	O
patients	B-UNK
also	O
are	O
present	B-UNK
in	O
Atm	B-UNK
mutant	B-UNK
mice	I-UNK
.	O

In	O
addition	B-UNK
,	O
we	O
report	B-UNK
a	O
previously	B-UNK
unrecognized	O
effect	B-UNK
of	O
Atm	B-UNK
deficiency	B-UNK
on	O
development	B-UNK
or	O
maintenance	O
of	O
CD4	O
(	O
+	O
)	O
8	O
(	O
+	O
)	O
thymocytes	O
.	O

We	O
discuss	O
these	O
findings	B-UNK
in	O
the	O
context	O
of	O
the	O
hypothesis	B-UNK
that	O
abnormal	O
development	B-UNK
of	O
Purkinje	O
cells	B-UNK
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	B-UNK
of	O
A	O
-T	O
..	O

Novel	O
mutations	B-UNK
of	O
the	O
ATP7B	B-UNK
gene	B-UNK
in	O
Japanese	B-UNK
patients	B-UNK
with	O
Wilson	B-DISEASE
disease	I-DISEASE
.	O

Wilson	B-DISEASE
disease	I-DISEASE
(	O
WD	O
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
copper	B-UNK
accumulation	B-UNK
in	O
the	O
liver	B-UNK
,	O
brain	B-UNK
,	O
kidneys	O
,	O
and	O
corneas	O
,	O
and	O
culminating	O
in	O
copper	B-UNK
toxication	O
in	O
these	O
organs	O
.	O

In	O
this	O
study	B-UNK
,	O
we	O
analyzed	B-UNK
mutations	B-UNK
of	O
the	O
responsible	B-UNK
gene	B-UNK
,	O
ATP7B	B-UNK
,	O
in	O
four	O
Japanese	B-UNK
patients	B-UNK
with	O
WD	O
.	O

By	O
direct	B-UNK
sequencing	I-UNK
,	O
we	O
identified	B-UNK
five	O
mutations	B-UNK
,	O
of	O
which	O
two	O
were	O
novel	O
,	O
and	O
16	O
polymorphisms	B-UNK
,	O
of	O
which	O
6	O
were	O
novel	O
.	O

The	O
mutations	B-UNK
2871delC	O
and	O
2513delA	O
shift	O
the	O
reading	B-UNK
frame	I-UNK
so	O
that	O
truncated	O
abnormal	O
protein	B-UNK
is	O
expected	O
.	O

In	O
contrast	B-UNK
to	O
these	O
mutations	B-UNK
found	O
in	O
patients	B-UNK
with	O
hepatic	B-UNK
-	O
type	B-UNK
of	O
early	B-UNK
onset	I-UNK
,	O
the	O
mutations	B-UNK
A874V	O
,	O
R778L	O
,	O
and	O
3892delGTC	O
were	O
either	O
missense	B-UNK
mutations	I-UNK
or	O
in	O
frame	B-UNK
1-amino	O
acid	B-UNK
deletion	B-UNK
,	O
and	O
occurred	B-UNK
in	O
the	O
patients	B-UNK
with	O
hepato	O
-	O
neurologic	O
type	B-UNK
of	O
late	B-UNK
onset	I-UNK
.	O

The	O
mutations	B-UNK
2871delC	O
and	O
R778L	O
have	O
been	O
previously	B-UNK
reported	I-UNK
in	O
a	O
relatively	O
large	B-UNK
number	B-UNK
of	O
Japanese	B-UNK
patients	B-UNK
.	O

In	O
particular	O
,	O
R778L	O
is	O
known	O
to	O
be	O
more	O
prevalent	O
in	O
Asian	O
countries	B-UNK
than	O
in	O
other	O
countries	B-UNK
of	O
the	O
world	O
.	O

Our	O
data	B-UNK
are	O
compatible	B-UNK
with	O
the	O
hypothesis	B-UNK
that	O
the	O
mutations	B-UNK
tend	O
to	O
occur	B-UNK
in	O
a	O
population	B-UNK
-	O
specific	B-UNK
manner	O
.	O

Therefore	O
,	O
the	O
accumulation	B-UNK
of	O
the	O
types	B-UNK
of	O
mutations	B-UNK
in	O
Japanese	B-UNK
patients	B-UNK
with	O
WD	O
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	B-UNK
diagnosis	B-UNK
of	O
WD	O
in	O
Japanese	B-UNK
patients	B-UNK
..	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
protein	B-UNK
.	O

The	O
Rho	O
-	O
family	B-UNK
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	B-UNK
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
protein	B-UNK
(	O
WASP	B-UNK
)	O
family	B-UNK
members	I-UNK
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	B-UNK
domain	I-UNK
and	O
the	O
carboxy	O
-	O
terminal	B-UNK
region	B-UNK
of	O
WASP	B-UNK
proteins	B-UNK
.	O

Here	O
we	O
report	B-UNK
the	O
autoinhibited	O
structure	B-UNK
of	O
the	O
GTPase	O
-	O
binding	B-UNK
domain	I-UNK
of	O
WASP	B-UNK
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	B-UNK
region	B-UNK
or	O
by	O
organic	O
co-solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	B-UNK
domain	I-UNK
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2/3	O
actin	B-UNK
-	O
nucleating	O
complex	O
.	O

Binding	B-UNK
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	B-UNK
domain	I-UNK
causes	O
a	O
dramatic	O
conformational	B-UNK
change	B-UNK
,	O
resulting	B-UNK
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	B-UNK
regulatory	O
machinery	O
.	O

These	O
data	B-UNK
show	O
that	O
intrinsically	O
unstructured	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	B-UNK
domain	I-UNK
of	O
WASP	B-UNK
can	O
be	O
induced	O
into	O
distinct	O
structural	B-UNK
and	O
functional	O
states	O
depending	O
on	O
context	O
..	O

hCds1-mediated	O
phosphorylation	B-UNK
of	O
BRCA1	B-UNK
regulates	O
the	O
DNA	B-UNK
damage	I-UNK
response	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
(	O
ref	O
.	O
1	O
)	O
tumour	B-UNK
suppressor	I-UNK
gene	B-UNK
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	B-UNK
with	O
inherited	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
and	O
about	O
half	B-UNK
of	O
the	O
families	B-UNK
with	O
only	O
breast	B-UNK
cancer	I-UNK
.	O

Although	O
the	O
biochemical	O
function	B-UNK
of	O
BRCA1	B-UNK
is	O
not	O
well	O
understood	O
,	O
it	O
is	O
important	O
for	O
DNA	B-UNK
damage	I-UNK
repair	B-UNK
and	O
cell	B-UNK
-	O
cycle	O
checkpoint	O
.	O

BRCA1	B-UNK
exists	O
in	O
nuclear	B-UNK
foci	O
but	O
is	O
hyperphosphorylated	O
and	O
disperses	O
after	O
DNA	B-UNK
damage	I-UNK
.	O

It	O
is	O
not	O
known	O
whether	O
BRCA1	B-UNK
phosphorylation	B-UNK
and	O
dispersion	O
and	O
its	O
function	B-UNK
in	O
DNA	B-UNK
damage	I-UNK
response	B-UNK
are	O
related	B-UNK
.	O

In	O
yeast	B-UNK
the	O
DNA	B-UNK
damage	I-UNK
response	B-UNK
and	O
the	O
replication	O
-	O
block	O
checkpoint	O
are	O
mediated	O
partly	O
through	O
the	O
Cds1	O
kinase	B-UNK
family	B-UNK
.	O

Here	O
we	O
report	B-UNK
that	O
the	O
human	B-UNK
Cds1	O
kinase	B-UNK
(	O
hCds1	O
/	O
Chk2	O
)	O
regulates	O
BRCA1	B-UNK
function	B-UNK
after	O
DNA	B-UNK
damage	I-UNK
by	O
phosphorylating	O
serine	O
988	O
of	O
BRCA1	B-UNK
.	O

We	O
show	O
that	O
hCds1	O
and	O
BRCA1	B-UNK
interact	O
and	O
co-localize	O
within	O
discrete	O
nuclear	B-UNK
foci	O
but	O
separate	O
after	O
gamma	B-UNK
irradiation	O
.	O

Phosphorylation	B-UNK
of	O
BRCA1	B-UNK
at	O
serine	O
988	O
is	O
required	B-UNK
for	O
the	O
release	O
of	O
BRCA1	B-UNK
from	O
hCds1	O
.	O

This	O
phosphorylation	B-UNK
is	O
also	O
important	O
for	O
the	O
ability	B-UNK
of	O
BRCA1	B-UNK
to	O
restore	O
survival	B-UNK
after	O
DNA	B-UNK
damage	I-UNK
in	O
the	O
BRCA1-mutated	O
cell	B-UNK
line	I-UNK
HCC1937	O
..	O

Characterization	B-UNK
of	O
the	O
rat	O
spinocerebellar	O
ataxia	B-DISEASE
type	B-UNK
3	O
gene	B-UNK
.	O

Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
belongs	O
to	O
a	O
group	B-UNK
of	O
clinically	O
and	O
genetically	B-UNK
heterogeneous	O
neurodegenerative	B-DISEASE
disorders	I-DISEASE
characterized	B-UNK
by	O
progressive	B-UNK
cerebellar	B-DISEASE
ataxia	I-DISEASE
.	O

The	O
disease	B-DISEASE
-	O
causing	B-UNK
mutation	B-UNK
has	O
recently	O
been	O
identified	B-UNK
as	O
an	O
unstable	O
and	O
expanded	B-UNK
(	O
CAG	B-UNK
)	O
n	O
trinucleotide	B-UNK
repeat	I-UNK
in	O
a	O
novel	O
gene	B-UNK
of	O
unknown	O
function	B-UNK
.	O

In	O
Caucasians	B-UNK
,	O
repeat	B-UNK
expansions	O
in	O
the	O
MJD1	O
gene	B-UNK
have	O
also	O
been	O
found	O
in	O
patients	B-UNK
with	O
the	O
clinically	O
distinct	O
autosomal	B-UNK
dominant	I-UNK
spinocerebellar	O
ataxia	B-UNK
type	B-UNK
3	O
(	O
SCA3	B-UNK
)	O
.	O

In	O
order	B-UNK
to	O
gain	O
insight	O
into	O
the	O
biology	O
of	O
the	O
MJD1	O
/	O
SCA3	B-UNK
gene	B-UNK
we	O
cloned	O
the	O
rat	O
homologue	B-UNK
and	O
studied	O
its	O
expression	B-UNK
.	O

The	O
rat	O
and	O
human	B-UNK
ataxin-3	O
genes	B-UNK
are	O
highly	B-UNK
homologous	B-UNK
with	O
an	O
overall	O
sequence	B-UNK
identity	O
of	O
approximately	O
88	O
%	O
.	O

However	O
,	O
the	O
C	O
-	O
terminal	B-UNK
end	B-UNK
of	O
the	O
putative	O
protein	B-UNK
differs	O
strongly	O
from	O
the	O
published	O
human	B-UNK
sequence	B-UNK
.	O

The	O
(	O
CAG	B-UNK
)	O
n	O
block	O
in	O
the	O
rat	O
cDNA	O
consists	O
of	O
just	O
three	O
interrupted	O
units	O
suggesting	O
that	O
a	O
long	B-UNK
polyglutamine	O
stretch	O
is	O
not	O
essential	B-UNK
for	O
the	O
normal	B-UNK
function	B-UNK
of	O
the	O
ataxin-3	O
protein	B-UNK
in	O
rodents	O
.	O

The	O
expression	B-UNK
pattern	B-UNK
of	O
the	O
SCA3	B-UNK
gene	B-UNK
in	O
various	O
rat	O
and	O
human	B-UNK
tissues	O
was	O
investigated	O
by	O
Northern	B-UNK
blot	B-UNK
analyses	O
.	O

The	O
mature	O
transcript	B-UNK
is	O
approximately	O
6	O
kb	B-UNK
in	O
length	B-UNK
.	O

In	O
rat	O
testis	O
,	O
a	O
smaller	O
transcript	B-UNK
of	O
1	O
.	O

3	O
kb	B-UNK
was	O
identified	B-UNK
.	O

Transcription	B-UNK
of	O
rsca3	O
was	O
detected	B-UNK
in	O
most	O
rat	O
tissues	O
including	O
brain	B-UNK
.	O

Analyzing	O
the	O
expression	B-UNK
level	B-UNK
of	O
the	O
SCA3	B-UNK
gene	B-UNK
in	O
several	O
human	B-UNK
brain	B-UNK
sections	O
revealed	B-UNK
no	O
significant	B-UNK
higher	O
mRNA	O
level	B-UNK
in	O
regions	B-UNK
predominantly	O
affected	B-UNK
in	O
MJD	B-UNK
.	O

Thus	O
additional	O
molecules	O
and	O
/	O
or	O
regulatory	O
events	O
are	O
necessary	O
to	O
explain	O
the	O
exclusive	O
degeneration	B-UNK
of	O
certain	O
brain	B-UNK
areas	O
.	O

Emerin	O
,	O
deficiency	B-UNK
of	O
which	O
causes	O
Emery	O
-	O
Dreifuss	O
muscular	B-UNK
dystrophy	I-UNK
,	O
is	O
localized	B-UNK
at	O
the	O
inner	O
nuclear	B-UNK
membrane	I-UNK
.	O

X	O
-	O
linked	B-UNK
recessive	B-UNK
Emery	O
-	O
Dreifuss	O
muscular	B-DISEASE
dystrophy	I-DISEASE
(	O
EDMD	B-UNK
)	O
is	O
an	O
inherited	B-UNK
muscle	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
the	O
clinical	B-UNK
triad	O
of	O
progressive	B-UNK
wasting	O
of	O
humero	O
-	O
peroneal	O
muscles	O
,	O
early	B-UNK
contractures	B-DISEASE
of	O
the	O
elbows	O
,	O
Achilles	O
tendons	O
and	O
postcervical	O
muscles	O
,	O
and	O
cardiac	B-UNK
conduction	O
block	O
with	O
a	O
high	B-UNK
risk	I-UNK
of	O
sudden	B-DISEASE
death	I-DISEASE
.	O

The	O
gene	B-UNK
for	O
EDMD	B-UNK
on	O
Xq28	B-UNK
encodes	B-UNK
a	O
novel	O
protein	B-UNK
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	B-UNK
membrane	I-UNK
of	O
skeletal	B-UNK
,	O
cardiac	B-UNK
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non-muscle	O
tissues	O
.	O

To	O
investigate	B-UNK
a	O
possible	O
physiological	O
role	B-UNK
for	O
emerin	O
,	O
we	O
examined	O
the	O
ultrastructural	O
localization	B-UNK
of	O
the	O
protein	B-UNK
in	O
human	B-UNK
skeletal	B-UNK
muscle	I-UNK
and	O
HeLa	O
cells	B-UNK
,	O
using	O
ultrathin	O
cryosections	O
.	O

We	O
found	O
that	O
the	O
immune	B-UNK
-	O
labeled	O
colloidal	O
gold	O
particles	O
were	O
localized	B-UNK
on	O
the	O
nucleoplasmic	O
surface	O
of	O
the	O
inner	O
nuclear	B-UNK
membrane	I-UNK
,	O
but	O
not	O
on	O
the	O
nuclear	B-UNK
pore	O
.	O

Emerin	O
stayed	O
on	O
the	O
cytoplasmic	O
surface	O
of	O
the	O
nuclear	B-UNK
lamina	O
,	O
even	O
after	O
detergent	O
treatment	O
that	O
solubilizes	O
membrane	B-UNK
lipids	O
and	O
washes	O
out	O
membrane	B-UNK
proteins	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
emerin	O
anchors	O
at	O
the	O
inner	O
nuclear	B-UNK
membrane	I-UNK
through	O
the	O
hydrophobic	O
stretch	O
,	O
and	O
protrudes	O
from	O
the	O
hydrophilic	O
region	B-UNK
to	O
the	O
nucleoplasm	O
where	O
it	O
interacts	O
with	O
the	O
nuclear	B-UNK
lamina	O
.	O

We	O
speculate	O
that	O
emerin	O
contributes	O
to	O
maintain	O
the	O
nuclear	B-UNK
structure	B-UNK
and	O
stability	O
,	O
as	O
well	O
as	O
nuclear	B-UNK
functions	O
,	O
particularly	O
in	O
muscle	B-UNK
tissues	O
that	O
have	O
severe	B-UNK
stress	B-DISEASE
with	O
rigorous	O
contraction	O
-	O
relaxation	O
movements	O
and	O
calcium	O
flux	O
..	O

Locus	B-UNK
heterogeneity	B-UNK
in	O
Friedreich	B-UNK
ataxia	I-UNK
.	O

Friedreich	B-DISEASE
ataxia	I-DISEASE
(	O
FRDA	B-UNK
)	O
is	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
autosomal	B-UNK
recessive	I-UNK
ataxia	B-UNK
.	O

The	O
disease	B-DISEASE
locus	B-UNK
was	O
assigned	O
to	O
chromosome	B-UNK
9	O
and	O
the	O
disease	B-UNK
gene	B-UNK
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	B-UNK
.	O

To	O
date	B-UNK
most	O
data	B-UNK
suggest	B-UNK
locus	B-UNK
homogeneity	O
in	O
FRDA	B-UNK
.	O

We	O
now	O
provide	B-UNK
strong	B-UNK
evidence	B-UNK
of	O
a	O
second	O
FRDA	B-UNK
locus	B-UNK
.	O

Studying	O
two	O
siblings	O
with	O
FRDA	B-UNK
from	O
two	O
families	B-UNK
we	O
did	O
not	O
detect	B-UNK
a	O
mutation	B-UNK
in	O
STM7	O
/	O
X25	O
.	O

Haplotype	B-UNK
analysis	I-UNK
of	O
the	O
STM7	O
/	O
X25	O
region	B-UNK
of	O
chromosome	B-UNK
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	B-UNK
of	O
chromosome	B-UNK
9	O
differs	O
in	O
the	O
patients	B-UNK
.	O

Although	O
the	O
patients	B-UNK
studied	O
had	O
typical	O
FRDA	B-UNK
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

In	O
order	B-UNK
to	O
investigate	B-UNK
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	B-UNK
of	O
FRDA	B-UNK
caused	B-UNK
by	O
the	O
second	O
locus	B-UNK
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	B-UNK
FRDA	B-UNK
patient	B-UNK
with	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	B-UNK
in	O
STM7	O
/	O
X25	O
(	O
GAA	B-UNK
expansions	O
)	O
in	O
this	O
patient	B-UNK
demonstrates	O
that	O
the	O
two	O
genetically	B-UNK
different	O
forms	B-UNK
of	O
FRDA	B-UNK
cannot	O
be	O
distinguished	O
clinically	O
..	O

Glycerol	B-UNK
as	O
a	O
correlate	O
of	O
impaired	B-DISEASE
glucose	I-DISEASE
tolerance	I-DISEASE
:	O
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	B-UNK
trait	O
.	O

Glycerol	B-UNK
kinase	B-UNK
(	O
GK	O
)	O
represents	O
the	O
primary	B-UNK
entry	O
of	O
glycerol	B-UNK
into	O
glucose	B-UNK
and	O
triglyceride	O
metabolism	B-UNK
.	O

Impaired	B-DISEASE
glucose	I-DISEASE
tolerance	I-DISEASE
(	O
IGT	O
)	O
and	O
hypertriglyceridemia	B-DISEASE
are	O
associated	O
with	O
an	O
increased	B-UNK
risk	B-UNK
of	O
diabetes	B-UNK
mellitus	I-UNK
and	O
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O

The	O
relationship	B-UNK
between	O
glycerol	B-UNK
and	O
the	O
risk	B-UNK
of	O
IGT	O
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O

We	O
therefore	O
undertook	O
the	O
study	B-UNK
of	O
fasting	O
plasma	O
glycerol	B-UNK
levels	B-UNK
in	O
a	O
cohort	B-UNK
of	O
1	O
,	O
056	O
unrelated	B-UNK
men	B-UNK
and	O
women	B-UNK
of	O
French	B-UNK
-	O
Canadian	B-UNK
descent	O
.	O

Family	B-UNK
screening	B-UNK
in	O
the	O
initial	O
cohort	B-UNK
identified	B-UNK
18	O
men	B-UNK
from	O
five	O
families	B-UNK
with	O
severe	B-UNK
hyperglycerolemia	O
(	O
values	O
above	O
2	O
.	O
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
X	O
-	O
linked	B-UNK
pattern	B-UNK
of	O
inheritance	B-UNK
.	O

Linkage	B-UNK
analysis	I-UNK
of	O
the	O
data	B-UNK
from	O
12	O
microsatellite	B-UNK
markers	I-UNK
surrounding	O
the	O
Xp21	B-UNK
.	O

3	O
GK	O
gene	B-UNK
resulted	B-UNK
in	O
a	O
peak	O
LOD	B-UNK
score	I-UNK
of	O
3	O
.	O

46	O
,	O
centered	O
around	O
marker	B-UNK
DXS8039	O
.	O

In	O
addition	B-UNK
,	O
since	O
all	O
of	O
the	O
families	B-UNK
originated	O
in	O
a	O
population	B-UNK
with	O
a	O
proven	O
founder	B-UNK
effect	I-UNK
-	O
the	O
Saguenay	O
Lac	O
-	O
St.-Jean	O
region	B-UNK
of	O
Quebec	O
-	O
a	O
common	B-UNK
disease	B-UNK
haplotype	B-UNK
was	O
sought	O
.	O

Indeed	O
,	O
a	O
six	O
-	O
marker	B-UNK
haplotype	B-UNK
extending	O
over	O
a	O
region	B-UNK
of	O
5	O
.	O

5	O
cM	B-DISEASE
was	O
observed	B-UNK
in	O
all	O
families	B-UNK
.	O

Resequencing	O
of	O
the	O
GK	O
gene	B-UNK
in	O
family	B-UNK
members	I-UNK
led	B-UNK
to	O
the	O
discovery	O
of	O
a	O
N288D	O
missense	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
10	O
,	O
which	O
resulted	B-UNK
in	O
the	O
substitution	B-UNK
of	O
a	O
highly	B-UNK
conserved	I-UNK
asparagine	O
residue	O
by	O
a	O
negatively	O
charged	O
aspartic	O
acid	B-UNK
.	O

Clinical	B-UNK
and	O
molecular	B-UNK
genetics	B-UNK
of	O
primary	B-UNK
dystonias	B-DISEASE
.	O

Primary	B-UNK
dystonias	B-DISEASE
are	O
movement	B-DISEASE
disorders	I-DISEASE
with	O
dystonia	B-UNK
as	O
a	O
major	B-UNK
symptom	O
.	O

They	O
are	O
frequently	O
inherited	B-UNK
as	O
Mendelian	O
traits	O
.	O

There	O
are	O
at	O
least	O
eight	O
clinically	O
distinct	O
autosomal	B-UNK
dominant	I-UNK
and	O
two	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
forms	B-UNK
.	O

In	O
addition	B-UNK
,	O
pedigree	B-UNK
analyses	O
suggest	B-UNK
the	O
occurrence	B-UNK
of	O
an	O
autosomal	B-UNK
recessive	I-UNK
variant	O
.	O

The	O
clinical	B-UNK
classification	O
is	O
increasingly	O
being	O
replaced	O
by	O
a	O
genetic	B-UNK
one	O
.	O

To	O
date	B-UNK
gene	B-UNK
loci	O
have	O
been	O
identified	B-UNK
in	O
at	O
least	O
six	O
autosomal	B-UNK
dominant	I-UNK
forms	B-UNK
,	O
i.	O
e.	O
,	O
in	O
idiopathic	B-UNK
torsion	O
dystonia	B-UNK
(	O
9q34	O
)	O
,	O
focal	O
dystonia	B-UNK
(	O
18p	O
)	O
,	O
adult	B-UNK
-	O
onset	B-UNK
idiopathic	B-UNK
torsion	O
dystonia	B-UNK
of	O
mixed	O
type	B-UNK
(	O
8p21-q22	O
)	O
,	O
dopa	O
-	O
responsive	O
dystonia	B-UNK
(	O
14q22	O
.	O
1-q22	O
.	O
2	O
)	O
,	O
and	O
paroxysmal	O
dystonic	B-DISEASE
choreoathetosis	B-DISEASE
(	O
2q25-q33	O
;	O
1p21-p13	O
.	O
3	O
)	O
.	O

Gene	B-UNK
loci	O
in	O
the	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
forms	B-UNK
have	O
been	O
assigned	O
to	O
Xq13	O
.	O

1	O
in	O
the	O
X	O
-	O
linked	B-UNK
dystonia	B-UNK
parkinsonism	B-DISEASE
syndrome	B-DISEASE
and	O
to	O
Xq22	O
in	O
X	O
-	O
linked	B-UNK
sensorineural	B-UNK
deafness	B-DISEASE
,	O
dystonia	B-UNK
,	O
and	O
mental	B-UNK
retardation	I-UNK
.	O

The	O
disease	B-DISEASE
genes	B-UNK
have	O
been	O
identified	B-UNK
in	O
two	O
autosomal	B-UNK
dominant	I-UNK
forms	B-UNK
and	O
in	O
one	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
form	B-UNK
.	O

Mutations	B-UNK
in	O
a	O
gene	B-UNK
coding	B-UNK
for	O
an	O
ATP	B-UNK
-	O
binding	B-UNK
protein	B-UNK
were	O
detected	B-UNK
in	O
idiopathic	B-UNK
torsion	O
dystonia	B-UNK
(	O
DYT1	O
)	O
,	O
and	O
the	O
GTP	O
cyclohydrolase	O
1	O
gene	B-UNK
is	O
mutated	B-UNK
in	O
dopa	O
-	O
responsive	O
dystonia	B-DISEASE
(	O
DYT5	O
)	O
.	O

In	O
sensorineural	B-UNK
deafness	B-DISEASE
,	O
dystonia	B-DISEASE
,	O
and	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
mutations	B-UNK
were	O
found	O
in	O
the	O
gene	B-UNK
DDP	O
coding	B-UNK
for	O
a	O
polypeptide	O
of	O
unknown	O
function	B-UNK
.	O

This	O
article	O
reviews	O
the	O
clinical	B-UNK
and	O
molecular	B-UNK
genetics	B-UNK
of	O
primary	B-UNK
dystonias	B-DISEASE
,	O
critically	O
discusses	O
present	B-UNK
findings	B-UNK
,	O
and	O
proposes	O
referring	O
to	O
the	O
known	O
forms	B-UNK
,	O
most	O
of	O
which	O
can	O
be	O
distinguished	O
by	O
genetic	B-UNK
criteria	O
,	O
as	O
dystonias	B-DISEASE
1	O
-	O
12	O
.	O

Determination	B-UNK
of	O
30	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
mutations	B-UNK
,	O
including	O
15	O
not	O
previously	B-UNK
described	O
.	O

X	O
-	O
linked	B-UNK
Adrenoleukodystrophy	B-UNK
(	O
X	O
-	O
ALD	B-UNK
)	O
is	O
the	O
most	O
frequent	B-UNK
peroxisomal	B-UNK
disease	B-DISEASE
.	O

It	O
mainly	O
involves	O
the	O
nervous	O
system	O
white	B-UNK
matter	O
,	O
adrenal	B-UNK
cortex	O
and	O
testes	O
.	O

Several	O
distinct	O
clinical	B-UNK
phenotypes	O
are	O
known	O
.	O

The	O
principal	O
biochemical	O
abnormality	O
is	O
the	O
accumulation	B-UNK
of	O
saturated	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
(	O
VLCFAs	O
>	O
C22	O
0	O
,	O
mainly	O
C26	O
0	O
)	O
,	O
which	O
is	O
due	O
to	O
impaired	B-UNK
capacity	O
for	O
beta-oxidation	O
in	O
peroxisomes	O
.	O

Diagnosis	B-UNK
is	O
usually	O
based	B-UNK
on	O
the	O
VLCFA	O
levels	B-UNK
in	O
plasma	O
or	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
in	O
both	O
patients	B-UNK
and	O
carriers	B-UNK
.	O

In	O
0	O
.	O

1	O
%	O
of	O
affected	B-UNK
males	I-UNK
,	O
however	O
,	O
the	O
plasma	O
C26	O
0	O
level	B-UNK
is	O
borderline	O
normal	B-UNK
,	O
and	O
15	O
%	O
of	O
obligate	B-UNK
female	O
carriers	B-UNK
have	O
normal	B-UNK
results	B-UNK
.	O

Effective	O
mutation	B-UNK
detection	I-UNK
in	O
these	O
families	B-UNK
is	O
therefore	O
fundamental	O
to	O
unambiguously	O
determine	B-UNK
the	O
genetic	B-UNK
status	B-UNK
of	O
each	O
individual	O
at	O
risk	B-UNK
.	O

Of	O
particular	O
concern	O
are	O
female	O
members	B-UNK
of	O
kindreds	O
segregating	O
X	O
-	O
ALD	B-UNK
mutations	B-UNK
,	O
because	O
normal	B-UNK
VLCFA	O
levels	B-UNK
do	O
not	O
guarantee	O
lack	B-UNK
of	O
carrier	B-UNK
status	I-UNK
.	O

We	O
describe	O
a	O
fast	O
method	O
for	O
detection	B-UNK
of	O
X	O
-	O
ALD	B-UNK
mutations	B-UNK
.	O

The	O
method	O
is	O
based	B-UNK
on	O
SSCP	B-UNK
analysis	B-UNK
of	O
nested	O
PCR	B-UNK
fragments	O
followed	O
by	O
sequence	B-UNK
-	O
determination	B-UNK
reactions	O
.	O

Using	O
this	O
methodology	O
we	O
have	O
found	O
X	O
-	O
ALD	B-UNK
mutations	B-UNK
in	O
30	O
kindreds	O
,	O
including	O
15	O
not	O
previously	B-UNK
reported	I-UNK
.	O

beta-galactosidase	O
gene	B-UNK
mutations	B-UNK
affecting	O
the	O
lysosomal	B-UNK
enzyme	B-UNK
and	O
the	O
elastin	O
-	O
binding	B-UNK
protein	B-UNK
in	O
GM1-gangliosidosis	O
patients	B-UNK
with	O
cardiac	B-UNK
involvement	B-UNK
.	O

GM1-gangliosidosis	O
is	O
a	O
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
deficiency	B-UNK
of	O
acid	B-UNK
beta-galactosidase	O
(	O
GLB1	O
)	O
.	O

We	O
report	B-UNK
five	O
new	O
beta-galactosidase	O
gene	B-UNK
mutations	B-UNK
in	O
nine	O
Italian	B-UNK
patients	B-UNK
and	O
one	O
fetus	O
,	O
segregating	O
in	O
seven	O
unrelated	B-UNK
families	I-UNK
.	O

Six	O
of	O
the	O
eight	O
patients	B-UNK
with	O
the	O
infantile	B-UNK
,	O
severe	B-UNK
form	B-UNK
of	O
the	O
disease	B-UNK
presented	B-UNK
cardiac	B-UNK
involvement	B-UNK
,	O
a	O
feature	O
rarely	O
associated	O
with	O
GM1-gangliosidosis	O
.	O

Molecular	B-UNK
analysis	I-UNK
of	O
the	O
patients	B-UNK
RNA	B-UNK
and	O
DNA	B-UNK
identified	B-UNK
two	O
new	O
RNA	B-UNK
splicing	B-UNK
defects	B-UNK
,	O
three	O
new	O
and	O
three	O
previously	B-UNK
described	O
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
.	O

Interestingly	B-UNK
,	O
all	O
patients	B-UNK
with	O
cardiac	B-UNK
involvement	B-UNK
were	O
homozygous	B-UNK
for	O
one	O
of	O
these	O
mutations	B-UNK
R59H	O
,	O
Y591C	O
,	O
Y591N	O
,	O
or	O
IVS14	O
-	O
2A	O
>	O
G.	O

In	O
contrast	B-UNK
,	O
all	O
other	O
patients	B-UNK
were	O
compound	B-UNK
heterozygous	B-UNK
for	O
one	O
of	O
the	O
following	O
mutations	B-UNK
R201H	O
,	O
R482H	O
,	O
G579D	O
,	O
IVS8	O
+	O
2	O
T	O
>	O
C.	O

Although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	B-DISEASE
abnormalities	I-DISEASE
with	O
specific	B-UNK
genetic	B-UNK
lesions	B-UNK
,	O
the	O
mutations	B-UNK
identified	B-UNK
in	O
patients	B-UNK
with	O
cardiomyopathy	B-UNK
fell	O
in	O
the	O
GLB1	O
cDNA	O
region	B-UNK
common	B-UNK
to	O
the	O
lysosomal	B-UNK
enzyme	B-UNK
and	O
the	O
Hbeta	O
-	O
Gal	O
-	O
related	B-UNK
protein	B-UNK
,	O
also	O
known	O
as	O
the	O
elastin	O
binding	B-UNK
protein	B-UNK
(	O
EBP	O
)	O
.	O

Consequently	O
,	O
both	O
molecules	O
are	O
affected	B-UNK
by	O
the	O
mutations	B-UNK
,	O
and	O
they	O
may	O
contribute	B-UNK
differently	O
to	O
the	O
occurrence	B-UNK
of	O
specific	B-UNK
clinical	B-UNK
manifestations	I-UNK
..	O

In	O
vivo	B-UNK
modulation	O
of	O
Hmgic	B-UNK
reduces	O
obesity	B-UNK
.	O

The	O
HMGI	O
family	B-UNK
of	O
proteins	B-UNK
consists	O
of	O
three	O
members	B-UNK
,	O
HMGIC	B-UNK
,	O
HMGI	O
and	O
HMGI	O
(	O
Y	O
)	O
,	O
that	O
function	B-UNK
as	O
architectural	O
factors	O
and	O
are	O
essential	B-UNK
components	O
of	O
the	O
enhancesome	O
.	O

HMGIC	B-UNK
is	O
predominantly	O
expressed	B-UNK
in	O
proliferating	O
,	O
undifferentiated	O
mesenchymal	O
cells	B-UNK
and	O
is	O
not	O
detected	B-UNK
in	O
adult	B-UNK
tissues	O
.	O

It	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	B-UNK
of	O
mesenchymal	O
tumour	B-UNK
cell	B-UNK
types	B-UNK
,	O
including	O
fat	O
-	O
cell	B-UNK
tumours	B-DISEASE
(	O
lipomas	O
)	O
.	O

In	O
addition	B-UNK
Hmgic-/-mice	O
have	O
a	O
deficiency	B-UNK
in	O
fat	O
tissue	B-UNK
.	O

To	O
study	B-UNK
its	O
role	B-UNK
in	O
adipogenesis	O
and	O
obesity	B-UNK
,	O
we	O
examined	O
Hmgic	B-UNK
expression	B-UNK
in	O
the	O
adipose	O
tissue	B-UNK
of	O
adult	B-UNK
,	O
obese	B-DISEASE
mice	B-UNK
.	O

Mice	B-UNK
with	O
a	O
partial	O
or	O
complete	O
deficiency	B-UNK
of	O
Hmgic	B-UNK
resisted	O
diet	O
-	O
induced	O
obesity	B-UNK
.	O

Disruption	O
of	O
Hmgic	B-UNK
caused	B-UNK
a	O
reduction	B-UNK
in	O
the	O
obesity	B-DISEASE
induced	O
by	O
leptin	O
deficiency	B-UNK
(	O
Lepob	O
/	O
Lepob	O
)	O
in	O
a	O
gene	B-UNK
-	O
dose	O
-	O
dependent	B-UNK
manner	O
.	O

Our	O
studies	B-UNK
implicate	O
a	O
role	B-UNK
for	O
HMGIC	B-UNK
in	O
fat	O
-	O
cell	B-UNK
proliferation	O
,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose	O
-	O
specific	B-UNK
target	O
for	O
the	O
treatment	O
of	O
obesity	B-UNK
..	O

Molecular	B-UNK
analysis	I-UNK
of	O
the	O
genotype	B-UNK
-	O
phenotype	B-UNK
relationship	B-UNK
in	O
factor	B-DISEASE
X	I-DISEASE
deficiency	I-DISEASE
.	O

Factor	B-DISEASE
X	I-DISEASE
deficiency	I-DISEASE
is	O
a	O
rare	B-UNK
haemorrhagic	B-DISEASE
condition	B-UNK
,	O
normally	O
inherited	B-UNK
as	O
an	O
autosomal	B-UNK
recessive	I-UNK
trait	O
,	O
in	O
which	O
a	O
variable	B-UNK
clinical	B-UNK
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	B-UNK
.	O

The	O
factor	B-UNK
X	O
(	O
F10	O
)	O
genes	B-UNK
of	O
14	O
unrelated	B-UNK
individuals	B-UNK
with	O
factor	B-DISEASE
X	I-DISEASE
deficiency	I-DISEASE
(	O
12	O
familial	B-UNK
and	O
two	O
sporadic	B-UNK
cases	B-UNK
)	O
were	O
sequenced	O
yielding	O
a	O
total	B-UNK
of	O
13	O
novel	O
mutations	B-UNK
.	O

Family	B-UNK
studies	B-UNK
were	O
performed	O
in	O
order	B-UNK
to	O
distinguish	O
the	O
contributions	O
of	O
individual	O
mutant	B-UNK
F10	O
alleles	B-UNK
to	O
the	O
clinical	B-UNK
and	O
laboratory	O
phenotypes	O
.	O

Missense	B-UNK
mutations	I-UNK
were	O
studied	O
by	O
means	B-UNK
of	O
molecular	B-UNK
modelling	O
,	O
whereas	O
single	B-UNK
basepair	O
substitutions	B-UNK
in	O
splice	B-UNK
sites	O
and	O
the	O
5	O
flanking	O
region	B-UNK
were	O
examined	O
by	O
in	O
vitro	O
splicing	B-UNK
assay	B-UNK
and	O
luciferase	O
reporter	O
gene	B-UNK
assay	B-UNK
respectively	O
.	O

The	O
deletion	B-UNK
allele	B-UNK
of	O
a	O
novel	O
hexanucleotide	O
insertion	O
/	O
deletion	B-UNK
polymorphism	B-UNK
in	O
the	O
F10	O
gene	B-UNK
promoter	O
region	B-UNK
was	O
shown	B-UNK
by	O
reporter	O
gene	B-UNK
assay	B-UNK
,	O
to	O
reduce	O
promoter	O
activity	B-UNK
by	O
approximately	O
20	O
%	O
.	O

One	O
family	B-UNK
manifesting	O
an	O
autosomal	B-UNK
dominant	I-UNK
pattern	B-UNK
of	O
inheritance	B-UNK
possessed	O
three	O
clinically	O
affected	B-UNK
members	B-UNK
who	O
were	O
heterozygous	B-UNK
for	O
a	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
that	O
was	O
predicted	B-UNK
to	O
lead	B-UNK
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	B-UNK
product	I-UNK
.	O

A	O
model	B-UNK
which	O
accounts	O
for	O
the	O
dominant	B-UNK
negative	I-UNK
effect	B-UNK
of	O
this	O
lesion	O
is	O
presented	B-UNK
.	O

Variation	B-UNK
in	O
the	O
antigen	O
level	B-UNK
of	O
heterozygous	B-UNK
relatives	B-UNK
of	O
probands	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
between	O
families	B-UNK
than	O
within	O
families	B-UNK
,	O
consistent	B-UNK
with	O
the	O
view	O
that	O
the	O
nature	B-UNK
of	O
the	O
F10	O
lesion	O
(	O
s	O
)	O
segregating	O
in	O
a	O
given	O
family	B-UNK
is	O
a	O
prime	O
determinant	O
of	O
the	O
laboratory	O
phenotype	B-UNK
.	O

By	O
contrast	B-UNK
,	O
no	O
such	O
relationship	B-UNK
could	O
be	O
discerned	O
between	O
laboratory	O
phenotype	B-UNK
and	O
polymorphism	B-UNK
genotype	B-UNK
..	O

Transgenic	B-UNK
mice	I-UNK
expressing	O
a	O
truncated	O
form	B-UNK
of	O
the	O
high	B-UNK
mobility	O
group	B-UNK
I	O
-	O
C	O
protein	B-UNK
develop	O
adiposity	O
and	O
an	O
abnormally	O
high	B-UNK
prevalence	B-UNK
of	O
lipomas	O
.	O

Chromosomal	B-UNK
translocations	O
in	O
human	B-UNK
lipomas	O
frequently	O
create	O
fusion	B-UNK
transcripts	O
encoding	B-UNK
high	B-UNK
mobility	O
group	B-UNK
(	O
HMG	O
)	O
I	O
-	O
C	O
DNA	B-UNK
-	O
binding	B-UNK
domains	B-UNK
and	O
C	O
-	O
terminal	B-UNK
sequences	O
from	O
different	O
presumed	O
transcription	B-UNK
factors	O
,	O
suggesting	O
a	O
potential	B-UNK
role	B-UNK
for	O
HMG	O
I	O
-	O
C	O
in	O
the	O
development	B-UNK
of	O
lipomas	O
.	O

To	O
evaluate	O
the	O
role	B-UNK
of	O
the	O
HMG	O
I	O
-	O
C	O
component	B-UNK
,	O
the	O
three	O
DNA	B-UNK
-	O
binding	B-UNK
domains	B-UNK
of	O
HMG	O
I	O
-	O
C	O
have	O
now	O
been	O
expressed	B-UNK
in	O
transgenic	B-UNK
mice	I-UNK
.	O

Despite	O
the	O
ubiquitous	O
expression	B-UNK
of	O
the	O
truncated	O
HMG	O
I	O
-	O
C	O
protein	B-UNK
,	O
the	O
transgenic	B-UNK
mice	I-UNK
develop	O
a	O
selective	O
abundance	O
of	O
fat	O
tissue	B-UNK
early	B-UNK
in	O
life	B-UNK
,	O
show	O
marked	B-UNK
adipose	O
tissue	B-UNK
inflammation	B-DISEASE
,	O
and	O
have	O
an	O
abnormally	O
high	B-UNK
incidence	B-UNK
of	O
lipomas	O
.	O

These	O
findings	B-UNK
demonstrate	B-UNK
that	O
the	O
DNA	B-UNK
-	O
binding	B-UNK
domains	B-UNK
of	O
HMG	O
I	O
-	O
C	O
,	O
in	O
the	O
absence	B-UNK
of	O
a	O
C	O
-	O
terminal	B-UNK
fusion	B-UNK
partner	O
,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	O
.	O

We	O
provide	B-UNK
data	B-UNK
supporting	O
the	O
central	B-UNK
utility	O
of	O
this	O
animal	B-UNK
model	I-UNK
as	O
a	O
tool	O
to	O
understand	O
the	O
molecular	B-UNK
mechanisms	O
underlying	O
the	O
development	B-UNK
of	O
one	O
of	O
the	O
most	O
common	B-UNK
kind	O
of	O
human	B-UNK
benign	O
tumors	B-UNK
..	O

ATM	B-UNK
phosphorylates	O
p95	O
/	O
nbs1	O
in	O
an	O
S	O
-	O
phase	B-UNK
checkpoint	O
pathway	B-UNK
.	O

The	O
rare	B-DISEASE
diseases	I-DISEASE
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
(	O
AT	O
)	O
,	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
ATM	B-UNK
gene	B-UNK
,	O
and	O
Nijmegen	B-DISEASE
breakage	I-DISEASE
syndrome	I-DISEASE
(	O
NBS	B-UNK
)	O
,	O
with	O
mutations	B-UNK
in	O
the	O
p95	O
/	O
nbs1	O
gene	B-UNK
,	O
share	O
a	O
variety	O
of	O
phenotypic	B-UNK
abnormalities	B-UNK
such	O
as	O
chromosomal	B-DISEASE
instability	I-DISEASE
,	O
radiation	B-UNK
sensitivity	O
and	O
defects	B-UNK
in	O
cell	B-UNK
-	O
cycle	O
checkpoints	O
in	O
response	B-UNK
to	O
ionizing	B-UNK
radiation	I-UNK
.	O

The	O
ATM	B-UNK
gene	B-UNK
encodes	B-UNK
a	O
protein	B-UNK
kinase	I-UNK
that	O
is	O
activated	O
by	O
ionizing	B-UNK
radiation	I-UNK
or	O
radiomimetic	O
drugs	O
,	O
whereas	O
p95	O
/	O
nbs1	O
is	O
part	O
of	O
a	O
protein	B-UNK
complex	O
that	O
is	O
involved	B-UNK
in	O
responses	B-UNK
to	O
DNA	B-UNK
double-strand	O
breaks	O
.	O

Here	O
,	O
because	O
of	O
the	O
similarities	O
between	O
AT	O
and	O
NBS	B-UNK
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
ATM	B-UNK
and	O
p95	O
/	O
nbs1	O
.	O

Activation	O
of	O
the	O
ATM	B-UNK
kinase	B-UNK
by	O
ionizing	B-UNK
radiation	I-UNK
and	O
induction	O
of	O
ATM	B-UNK
-	O
dependent	B-UNK
responses	B-UNK
in	O
NBS	B-UNK
cells	B-UNK
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	B-UNK
for	O
signalling	O
to	O
ATM	B-UNK
after	O
ionizing	B-UNK
radiation	I-UNK
.	O

However	O
,	O
p95	O
/	O
nbs1	O
was	O
phosphorylated	O
on	O
serine	O
343	O
in	O
an	O
ATM	B-UNK
-	O
dependent	B-UNK
manner	O
in	O
vitro	O
and	O
in	O
vivo	B-UNK
after	O
ionizing	B-UNK
radiation	I-UNK
.	O

A	O
p95	O
/	O
nbs1	O
construct	O
mutated	B-UNK
at	O
the	O
ATM	B-UNK
phosphorylation	B-UNK
site	B-UNK
abrogated	O
an	O
S	O
-	O
phase	B-UNK
checkpoint	O
induced	O
by	O
ionizing	B-UNK
radiation	I-UNK
in	O
normal	B-UNK
cells	B-UNK
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	B-UNK
in	O
NBS	B-UNK
cells	B-UNK
.	O

These	O
observations	B-UNK
link	O
ATM	B-UNK
and	O
p95	O
/	O
nbs1	O
in	O
a	O
common	B-UNK
signalling	O
pathway	B-UNK
and	O
provide	B-UNK
an	O
explanation	O
for	O
phenotypic	B-UNK
similarities	O
in	O
these	O
two	O
diseases	B-DISEASE
..	O

Understanding	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
of	O
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
.	O

Fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
,	O
a	O
common	B-UNK
form	B-UNK
of	O
inherited	B-UNK
mental	B-UNK
retardation	I-UNK
,	O
is	O
mainly	O
caused	B-UNK
by	O
massive	O
expansion	B-UNK
of	O
CGG	O
triplet	O
repeats	B-UNK
located	B-UNK
in	O
the	O
5-untranslated	O
region	B-UNK
of	O
the	O
fragile	B-UNK
X	O
mental	B-UNK
retardation-1	O
(	O
FMR1	B-UNK
)	O
gene	B-UNK
.	O

In	O
patients	B-UNK
with	O
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
,	O
the	O
expanded	B-UNK
CGG	O
triplet	O
repeats	B-UNK
are	O
hypermethylated	O
and	O
the	O
expression	B-UNK
of	O
the	O
FMR1	B-UNK
gene	B-UNK
is	O
repressed	O
,	O
which	O
leads	B-UNK
to	O
the	O
absence	B-UNK
of	O
FMR1	B-UNK
protein	B-UNK
(	O
FMRP	B-UNK
)	O
and	O
subsequent	B-UNK
mental	B-UNK
retardation	I-UNK
.	O

FMRP	B-UNK
is	O
an	O
RNA	B-UNK
-	O
binding	B-UNK
protein	B-UNK
that	O
shuttles	O
between	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O

This	O
protein	B-UNK
has	O
been	O
implicated	B-UNK
in	O
protein	B-UNK
translation	O
as	O
it	O
is	O
found	O
associated	O
with	O
polyribosomes	O
and	O
the	O
rough	O
endoplasmic	O
reticulum	O
.	O

We	O
discuss	O
here	O
the	O
recent	O
progress	O
made	O
towards	O
understanding	B-UNK
the	O
molecular	B-UNK
mechanism	B-UNK
of	O
CGG	O
repeat	B-UNK
expansion	I-UNK
and	O
physiological	O
function	B-UNK
(	O
s	O
)	O
of	O
FMRP	B-UNK
.	O

These	O
studies	B-UNK
will	O
not	O
only	O
help	O
to	O
illuminate	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
the	O
general	B-UNK
class	O
of	O
human	B-UNK
diseases	B-UNK
with	O
trinucleotide	B-UNK
repeat	I-UNK
expansion	B-UNK
but	O
also	O
provide	B-UNK
an	O
avenue	O
to	O
understand	O
aspects	O
of	O
human	B-UNK
cognition	O
and	O
intelligence	O
..	O

Haploinsufficiency	O
of	O
the	O
transcription	B-UNK
factors	O
FOXC1	O
and	O
FOXC2	O
results	B-UNK
in	O
aberrant	B-UNK
ocular	O
development	B-UNK
.	O

Anterior	O
segment	O
developmental	O
disorders	B-UNK
,	O
including	O
Axenfeld	O
-	O
Rieger	O
anomaly	B-UNK
(	O
ARA	O
)	O
,	O
variably	O
associate	O
with	O
harmfully	O
elevated	B-DISEASE
intraocular	I-DISEASE
pressure	I-DISEASE
(	O
IOP	O
)	O
,	O
which	O
causes	O
glaucoma	B-DISEASE
.	O

Clinically	O
observed	B-UNK
dysgenesis	O
does	O
not	O
correlate	O
with	O
IOP	O
,	O
however	O
,	O
and	O
the	O
etiology	O
of	O
glaucoma	B-DISEASE
development	B-UNK
is	O
not	O
understood	O
.	O

The	O
forkhead	O
transcription	B-UNK
factor	I-UNK
genes	B-UNK
Foxc1	O
(	O
formerly	O
Mf1	O
)	O
and	O
Foxc2	O
(	O
formerly	O
Mfh1	O
)	O
are	O
expressed	B-UNK
in	O
the	O
mesenchyme	O
from	O
which	O
the	O
ocular	O
drainage	O
structures	O
derive	O
.	O

Mutations	B-UNK
in	O
the	O
human	B-UNK
homolog	O
of	O
Foxc1	O
,	O
FKHL7	O
,	O
cause	O
dominant	B-UNK
anterior	O
segment	O
defects	B-UNK
and	O
glaucoma	B-DISEASE
in	O
various	O
families	B-UNK
.	O

We	O
show	O
that	O
Foxc1	O
(	O
+	O
/-	O
)	O
mice	B-UNK
have	O
anterior	O
segment	O
abnormalities	B-UNK
similar	B-UNK
to	O
those	O
reported	B-UNK
in	O
human	B-UNK
patients	B-UNK
.	O

These	O
abnormalities	B-UNK
include	O
small	O
or	O
absent	O
Schlemms	O
canal	O
,	O
aberrantly	O
developed	O
trabecular	O
meshwork	O
,	O
iris	O
hypoplasia	B-UNK
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
Schwalbes	O
line	B-UNK
.	O

The	O
penetrance	O
of	O
clinically	O
obvious	O
abnormalities	B-UNK
varies	O
with	O
genetic	B-UNK
background	O
.	O

In	O
some	O
affected	B-UNK
eyes	O
,	O
collagen	O
bundles	O
were	O
half	B-UNK
normal	B-UNK
diameter	O
,	O
or	O
collagen	O
and	O
elastic	O
tissue	B-UNK
were	O
very	O
sparse	O
.	O

Thus	O
,	O
abnormalities	B-UNK
in	O
extracellular	B-UNK
matrix	O
synthesis	B-UNK
or	O
organization	B-UNK
may	O
contribute	B-UNK
to	O
development	B-UNK
of	O
the	O
ocular	O
phenotypes	O
.	O

Despite	O
the	O
abnormalities	B-UNK
in	O
ocular	O
drainage	O
structures	O
in	O
Foxc1	O
(	O
+	O
/-	O
)	O
mice	B-UNK
,	O
IOP	O
was	O
normal	B-UNK
in	O
almost	O
all	O
mice	B-UNK
analyzed	B-UNK
,	O
on	O
all	O
genetic	B-UNK
backgrounds	O
and	O
at	O
all	O
ages	O
.	O

Similar	B-UNK
abnormalities	B-UNK
were	O
found	O
in	O
Foxc2	O
(	O
+	O
/-	O
)	O
mice	B-UNK
,	O
but	O
no	O
disease	B-DISEASE
-	O
associated	O
mutations	B-UNK
were	O
identified	B-UNK
in	O
the	O
human	B-UNK
homolog	O
FKHL14	O
in	O
32	O
ARA	O
patients	B-UNK
.	O

Foxc1	O
(	O
+	O
/-	O
)	O
and	O
Foxc2	O
(	O
+	O
/-	O
)	O
mice	B-UNK
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	B-UNK
and	O
its	O
anomalies	B-UNK
,	O
and	O
may	O
allow	O
identification	B-UNK
of	O
genes	B-UNK
that	O
interact	O
with	O
Foxc1	O
and	O
Foxc2	O
(	O
or	O
FKHL7	O
and	O
FKHL14	O
)	O
to	O
produce	B-UNK
a	O
phenotype	B-UNK
with	O
elevated	B-UNK
IOP	O
and	O
glaucoma	B-DISEASE
..	O

(	O
Over	O
)	O
correction	O
of	O
FMR1	B-UNK
deficiency	B-UNK
with	O
YAC	B-UNK
transgenics	O
:	O
behavioral	B-UNK
and	O
physical	B-UNK
features	B-UNK
.	O

Fragile	B-UNK
X	I-UNK
syndrome	I-UNK
is	O
a	O
common	B-UNK
cause	O
of	O
mental	B-DISEASE
retardation	I-DISEASE
involving	O
loss	B-UNK
of	O
expression	B-UNK
of	O
the	O
FMR1	B-UNK
gene	B-UNK
.	O

The	O
role	B-UNK
of	O
FMR1	B-UNK
remains	O
undetermined	O
but	O
the	O
protein	B-UNK
appears	B-UNK
to	O
be	O
involved	B-UNK
in	O
RNA	B-UNK
metabolism	B-UNK
.	O

Fmr1	B-UNK
knockout	B-UNK
mice	B-UNK
exhibit	O
a	O
phenotype	B-UNK
with	O
some	O
similarities	O
to	O
humans	B-UNK
,	O
such	O
as	O
macroorchidism	O
and	O
behavioral	B-DISEASE
abnormalities	I-DISEASE
.	O

As	O
a	O
step	O
toward	O
understanding	B-UNK
the	O
function	B-UNK
of	O
FMR1	B-UNK
and	O
the	O
determination	B-UNK
of	O
the	O
potential	B-UNK
for	O
therapeutic	O
approaches	O
to	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
,	O
yeast	B-UNK
artificial	O
chromosome	B-UNK
(	O
YAC	B-UNK
)	O
transgenic	B-UNK
mice	I-UNK
were	O
generated	O
in	O
order	B-UNK
to	O
determine	B-UNK
whether	O
the	O
Fmr1	B-UNK
knockout	B-UNK
mouse	B-UNK
phenotype	B-UNK
could	O
be	O
rescued	O
.	O

Several	O
transgenic	B-UNK
lines	B-UNK
were	O
generated	O
that	O
carried	O
the	O
entire	O
FMR1	B-UNK
locus	B-UNK
with	O
extensive	B-UNK
amounts	B-UNK
of	O
flanking	O
sequence	B-UNK
.	O

We	O
observed	B-UNK
that	O
the	O
YAC	B-UNK
transgene	O
supported	O
production	O
of	O
the	O
human	B-UNK
protein	B-UNK
(	O
FMRP	B-UNK
)	O
which	O
was	O
present	B-UNK
at	O
levels	B-UNK
10	O
to	O
15	O
times	O
that	O
of	O
endogenous	O
protein	B-UNK
and	O
was	O
expressed	B-UNK
in	O
a	O
cell	B-UNK
-	O
and	O
tissue	B-UNK
-	O
specific	B-UNK
manner	O
.	O

Macro-orchidism	O
was	O
absent	O
in	O
knockout	B-UNK
mice	B-UNK
carrying	I-UNK
the	O
YAC	B-UNK
transgene	O
indicating	O
functional	O
rescue	O
by	O
the	O
human	B-UNK
protein	B-UNK
.	O

Given	O
the	O
complex	O
behavioral	B-UNK
phenotype	B-UNK
in	O
fragile	B-UNK
X	O
patients	B-UNK
and	O
the	O
mild	O
phenotype	B-UNK
previously	B-UNK
reported	I-UNK
for	O
the	O
Fmr1	B-UNK
knockout	B-UNK
mouse	B-UNK
,	O
we	O
performed	O
a	O
more	O
thorough	O
evaluation	B-UNK
of	O
the	O
Fmr1	B-UNK
knockout	B-UNK
phenotype	B-UNK
using	O
additional	O
behavioral	B-UNK
assays	O
that	O
had	O
not	O
previously	B-UNK
been	O
reported	B-UNK
for	O
this	O
animal	B-UNK
model	I-UNK
.	O

The	O
mouse	B-UNK
displayed	O
reduced	O
anxiety	B-DISEASE
-	O
related	B-UNK
responses	B-UNK
with	O
increased	B-UNK
exploratory	O
behavior	O
.	O

FMR1	B-UNK
YAC	B-UNK
transgenic	B-UNK
mice	I-UNK
overexpressing	O
the	O
human	B-UNK
protein	B-UNK
did	O
produce	B-UNK
opposing	O
behavioral	B-UNK
responses	B-UNK
and	O
additional	O
abnormal	O
behaviors	O
were	O
also	O
observed	B-UNK
.	O

These	O
findings	B-UNK
have	O
significant	B-UNK
implications	B-UNK
for	O
gene	B-UNK
therapy	B-UNK
for	O
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
since	O
overexpression	B-UNK
of	O
the	O
gene	B-UNK
may	O
harbor	O
its	O
own	O
phenotype	B-UNK
..	O

Transgenic	B-UNK
mice	I-UNK
carrying	B-UNK
large	B-UNK
human	B-UNK
genomic	B-UNK
sequences	O
with	O
expanded	B-UNK
CTG	B-UNK
repeat	I-UNK
mimic	O
closely	B-UNK
the	O
DM	B-DISEASE
CTG	B-UNK
repeat	I-UNK
intergenerational	O
and	O
somatic	B-UNK
instability	B-UNK
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
is	O
caused	B-UNK
by	O
a	O
CTG	B-UNK
repeat	I-UNK
expansion	B-UNK
in	O
the	O
3UTR	O
of	O
the	O
DM	B-UNK
protein	B-UNK
kinase	I-UNK
(	O
DMPK	B-UNK
)	O
gene	B-UNK
.	O

A	O
very	O
high	B-UNK
level	B-UNK
of	O
instability	B-UNK
is	O
observed	B-UNK
through	O
successive	O
generations	O
and	O
the	O
size	B-UNK
of	O
the	O
repeat	B-UNK
is	O
generally	O
correlated	B-UNK
with	O
the	O
severity	B-UNK
of	O
the	O
disease	B-DISEASE
and	O
with	O
age	B-UNK
at	O
onset	B-UNK
.	O

Furthermore	O
,	O
tissues	O
from	O
DM	B-DISEASE
patients	B-UNK
exhibit	O
somatic	B-UNK
mosaicism	O
that	O
increases	O
with	O
age	B-UNK
.	O

We	O
generated	O
transgenic	B-UNK
mice	I-UNK
carrying	B-UNK
large	B-UNK
human	B-UNK
genomic	B-UNK
sequences	O
with	O
20	O
,	O
55	O
or	O
>	O
300	O
CTG	B-UNK
,	O
cloned	O
from	O
patients	B-UNK
from	O
the	O
same	O
affected	B-UNK
DM	B-DISEASE
family	B-UNK
.	O

Using	O
large	B-UNK
human	B-UNK
flanking	O
sequences	O
and	O
a	O
large	B-UNK
amplification	B-UNK
,	O
we	O
demonstrate	B-UNK
that	O
the	O
intergenerational	O
CTG	B-UNK
repeat	I-UNK
instability	B-UNK
is	O
reproduced	O
in	O
mice	B-UNK
,	O
with	O
a	O
strong	B-UNK
bias	O
towards	O
expansions	O
and	O
with	O
the	O
same	O
sex	B-UNK
-	O
and	O
size	B-UNK
-	O
dependent	B-UNK
characteristics	B-UNK
as	O
in	O
humans	B-UNK
.	O

Moreover	O
,	O
a	O
high	B-UNK
level	B-UNK
of	O
instability	B-UNK
,	O
increasing	O
with	O
age	B-UNK
,	O
can	O
be	O
observed	B-UNK
in	O
tissues	O
and	O
in	O
sperm	O
.	O

Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	B-UNK
repeats	B-UNK
)	O
as	O
in	O
congenital	B-UNK
forms	B-UNK
of	O
DM	B-UNK
,	O
our	O
model	B-UNK
carrying	B-UNK
>	O
300	O
CTG	B-UNK
is	O
the	O
first	O
to	O
show	O
instability	B-UNK
so	O
close	B-UNK
to	O
the	O
human	B-UNK
DM	B-UNK
situation	O
.	O

Our	O
three	O
models	O
carrying	B-UNK
different	O
sizes	O
of	O
CTG	B-UNK
repeat	I-UNK
provide	B-UNK
insight	O
on	O
the	O
different	O
factors	O
modulating	O
the	O
CTG	B-UNK
repeat	I-UNK
instability	B-UNK
..	O

Inactivation	B-UNK
of	O
the	O
Friedreich	B-UNK
ataxia	I-UNK
mouse	B-UNK
gene	B-UNK
leads	B-UNK
to	O
early	B-UNK
embryonic	B-UNK
lethality	O
without	O
iron	B-UNK
accumulation	B-UNK
.	O

Friedreich	B-UNK
ataxia	I-UNK
(	O
FRDA	B-UNK
)	O
,	O
the	O
most	O
common	B-UNK
autosomal	B-UNK
recessive	I-UNK
ataxia	B-DISEASE
,	O
is	O
caused	B-UNK
in	O
almost	O
all	O
cases	B-UNK
by	O
homozygous	B-UNK
intronic	O
expansions	O
resulting	B-UNK
in	O
the	O
loss	B-UNK
of	O
frataxin	B-UNK
,	O
a	O
mitochondrial	B-UNK
protein	B-UNK
conserved	B-UNK
through	O
evolution	O
,	O
and	O
involved	B-UNK
in	O
mitochondrial	B-UNK
iron	B-UNK
homeostasis	O
.	O

Yeast	B-UNK
knockout	B-UNK
models	O
,	O
and	O
histological	O
and	O
biochemical	O
data	B-UNK
from	O
patient	B-UNK
heart	B-UNK
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	B-UNK
defect	B-UNK
causes	O
a	O
specific	B-UNK
iron	B-UNK
-	O
sulfur	O
protein	B-DISEASE
deficiency	I-DISEASE
and	O
mitochondrial	B-UNK
iron	B-UNK
accumulation	B-UNK
leading	B-UNK
to	O
the	O
pathological	O
changes	O
.	O

Affected	B-UNK
human	B-UNK
tissues	O
are	O
rarely	O
available	O
to	O
further	O
examine	O
this	O
hypothesis	B-UNK
.	O

To	O
study	B-UNK
the	O
mechanism	B-UNK
of	O
the	O
disease	B-UNK
,	O
we	O
generated	O
a	O
mouse	B-UNK
model	I-UNK
by	O
deletion	B-UNK
of	O
exon	B-UNK
4	O
leading	B-UNK
to	O
inactivation	B-UNK
of	O
the	O
Frda	B-UNK
gene	B-UNK
product	I-UNK
.	O

We	O
show	O
that	O
homozygous	B-UNK
deletions	O
cause	O
embryonic	B-UNK
lethality	O
a	O
few	O
days	O
after	O
implantation	O
,	O
demonstrating	O
an	O
important	O
role	B-UNK
for	O
frataxin	B-UNK
during	O
early	B-UNK
development	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
milder	B-UNK
phenotype	B-UNK
in	O
humans	B-UNK
is	O
due	O
to	O
residual	B-UNK
frataxin	B-UNK
expression	B-UNK
associated	O
with	O
the	O
expansion	B-UNK
mutations	B-UNK
.	O

Surprisingly	O
,	O
in	O
the	O
frataxin	B-UNK
knockout	B-UNK
mouse	B-UNK
,	O
no	O
iron	B-UNK
accumulation	B-UNK
was	O
observed	B-UNK
during	O
embryonic	B-UNK
resorption	O
,	O
suggesting	O
that	O
cell	B-UNK
death	B-DISEASE
could	O
be	O
due	O
to	O
a	O
mechanism	B-UNK
independent	O
of	O
iron	B-UNK
accumulation	B-UNK
..	O

Gaucher	B-DISEASE
disease	I-DISEASE
:	O
the	O
origins	O
of	O
the	O
Ashkenazi	B-UNK
Jewish	I-UNK
N370S	B-UNK
and	O
84GG	O
acid	B-UNK
beta-glucosidase	O
mutations	B-UNK
.	O

Type	B-UNK
1	O
Gaucher	B-DISEASE
disease	I-DISEASE
(	O
GD	B-UNK
)	O
,	O
a	O
non-neuronopathic	O
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
,	O
results	B-UNK
from	O
the	O
deficient	B-UNK
activity	B-UNK
of	O
acid	B-UNK
beta-glucosidase	O
(	O
GBA	O
)	O
.	O

Type	B-UNK
1	O
disease	B-DISEASE
is	O
panethnic	O
but	O
is	O
more	O
prevalent	O
in	O
individuals	B-UNK
of	O
Ashkenazi	B-UNK
Jewish	I-UNK
(	O
AJ	B-UNK
)	O
descent	O
.	O

Of	O
the	O
causative	O
GBA	O
mutations	B-UNK
,	O
N370S	B-UNK
is	O
particularly	O
frequent	B-UNK
in	O
the	O
AJ	B-UNK
population	B-UNK
,	O
(	O
q	O
approximately	O
.	O
03	O
)	O
,	O
whereas	O
the	O
84GG	O
insertion	O
(	O
q	O
approximately	O
.	O
003	O
)	O
occurs	O
exclusively	O
in	O
the	O
Ashkenazim	O
.	O

To	O
investigate	B-UNK
the	O
genetic	B-UNK
history	B-UNK
of	O
these	O
mutations	B-UNK
in	O
the	O
AJ	B-UNK
population	B-UNK
,	O
short	B-UNK
tandem	O
repeat	B-UNK
(	O
STR	O
)	O
markers	B-UNK
were	O
used	O
to	O
map	B-UNK
a	O
9	O
.	O

3-cM	O
region	B-UNK
containing	O
the	O
GBA	O
locus	B-UNK
and	O
to	O
genotype	B-UNK
261	O
AJ	B-UNK
N370S	B-UNK
chromosomes	O
,	O
60	O
European	B-UNK
non-Jewish	O
N370S	B-UNK
chromosomes	O
,	O
and	O
62	O
AJ	B-UNK
84GG	O
chromosomes	O
.	O

A	O
highly	B-UNK
conserved	I-UNK
haplotype	B-UNK
at	O
four	O
markers	B-UNK
flanking	O
GBA	O
(	O
PKLR	O
,	O
D1S1595	O
,	O
D1S2721	O
,	O
and	O
D1S2777	O
)	O
was	O
observed	B-UNK
on	O
both	O
the	O
AJ	B-UNK
chromosomes	O
and	O
the	O
non-Jewish	O
N370S	B-UNK
chromosomes	O
,	O
suggesting	O
the	O
occurrence	B-UNK
of	O
a	O
founder	B-UNK
common	B-UNK
to	O
both	O
populations	O
.	O

Of	O
note	O
,	O
the	O
presence	O
of	O
different	O
divergent	O
haplotypes	O
suggested	O
the	O
occurrence	B-UNK
of	O
de	O
novo	O
,	O
recurrent	O
N370S	B-UNK
mutations	B-UNK
.	O

In	O
contrast	B-UNK
,	O
a	O
different	O
conserved	B-UNK
haplotype	B-UNK
at	O
these	O
markers	B-UNK
was	O
identified	B-UNK
on	O
the	O
84GG	O
chromosomes	O
,	O
which	O
was	O
unique	O
to	O
the	O
AJ	B-UNK
population	B-UNK
.	O

On	O
the	O
basis	B-UNK
of	O
the	O
linkage	B-UNK
disequilibrium	I-UNK
(	O
LD	O
)	O
delta	O
values	O
,	O
the	O
non-Jewish	O
European	B-UNK
N370S	B-UNK
chromosomes	O
had	O
greater	B-UNK
haplotype	B-UNK
diversity	O
and	O
less	O
LD	O
at	O
the	O
markers	B-UNK
flanking	O
the	O
conserved	B-UNK
haplotype	B-UNK
than	O
did	O
the	O
AJ	B-UNK
N370S	B-UNK
chromosomes	O
.	O

This	O
finding	O
is	O
consistent	B-UNK
with	O
the	O
presence	O
of	O
the	O
N370S	B-UNK
mutation	B-UNK
in	O
the	O
non-Jewish	O
European	B-UNK
population	B-UNK
prior	O
to	O
the	O
founding	O
of	O
the	O
AJ	B-UNK
population	B-UNK
.	O

Coalescence	O
analyses	O
for	O
the	O
N370S	B-UNK
and	O
84GG	O
mutations	B-UNK
estimated	B-UNK
similar	B-UNK
coalescence	O
times	O
,	O
of	O
48	O
and	O
55	O
.	O
5	O
generations	O
ago	O
,	O
respectively	O
.	O

The	O
results	B-UNK
of	O
these	O
studies	B-UNK
are	O
consistent	B-UNK
with	O
a	O
significant	B-UNK
bottleneck	O
occurring	O
in	O
the	O
AJ	B-UNK
population	B-UNK
during	O
the	O
first	O
millennium	O
,	O
when	O
the	O
population	B-UNK
became	O
established	O
in	O
Europe	B-UNK
.	O

HLA	B-UNK
B27	B-UNK
and	O
the	O
genetics	B-UNK
of	O
ankylosing	B-UNK
spondylitis	I-UNK
.	O

One	O
hundred	O
and	O
twenty	O
-	O
eight	O
of	O
145	O
patients	B-UNK
with	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
(	O
AS	O
)	O
were	O
found	O
to	O
be	O
HLA	B-UNK
B27	B-UNK
positive	O
.	O

Five	O
patients	B-UNK
had	O
evidence	B-UNK
of	O
a	O
sero	O
-	O
negative	B-UNK
peripheral	B-UNK
arthritis	B-UNK
resembling	O
peripheral	B-UNK
psoriatic	B-DISEASE
arthritis	I-DISEASE
and	O
3	O
of	O
these	O
were	O
B27	B-UNK
negative	B-UNK
.	O

One	O
further	O
B27	B-UNK
negative	B-UNK
patients	B-UNK
had	O
a	O
sister	O
with	O
ankylosing	B-UNK
spondylitis	I-UNK
and	O
ulcerative	B-DISEASE
colitis	I-DISEASE
and	O
a	O
mother	O
with	O
ulcerative	B-DISEASE
colitis	I-DISEASE
.	O

There	O
was	O
evidence	B-UNK
of	O
a	O
somewhat	O
later	O
age	B-UNK
of	I-UNK
onset	I-UNK
of	O
symptoms	B-UNK
in	O
B27	B-UNK
negative	B-UNK
patients	B-UNK
.	O

These	O
findings	B-UNK
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	B-UNK
of	O
clinical	B-UNK
and	O
genetic	B-UNK
heterogeneity	I-UNK
in	O
ankylosing	B-UNK
spondylitis	I-UNK
with	O
genes	B-UNK
for	O
psoriasis	B-DISEASE
and	O
inflammatory	B-DISEASE
bowel	I-DISEASE
disease	I-DISEASE
being	O
important	O
in	O
some	O
individuals	B-UNK
,	O
particularly	O
those	O
who	O
are	O
B27	B-UNK
negative	B-UNK
.	O

Twenty	O
-	O
five	O
first	O
-	O
degree	B-UNK
relatives	B-UNK
with	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
were	O
all	O
B27	B-UNK
positive	O
.	O

The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	B-UNK
and	O
spondylitis	B-DISEASE
in	O
a	O
family	B-UNK
was	O
where	O
the	O
proband	B-UNK
had	O
ulcerative	B-DISEASE
colitis	I-DISEASE
as	O
well	O
as	O
spondylitis	B-UNK
.	O

Of	O
13	O
B27	B-UNK
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	B-UNK
spondylitis	I-UNK
(	O
23	O
%	O
)	O
.	O

These	O
findings	B-UNK
are	O
thought	B-UNK
to	O
provide	B-UNK
evidence	I-UNK
against	O
the	O
concept	O
that	O
the	O
gene	B-UNK
for	O
ankylosing	B-UNK
spondylitis	I-UNK
is	O
not	O
B27	B-UNK
but	O
a	O
closely	B-UNK
linked	I-UNK
gene	B-UNK
and	O
favour	O
the	O
occurrence	B-UNK
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one	O
-	O
fifth	O
of	O
B27	B-UNK
positive	O
males	B-UNK
to	O
result	B-UNK
in	O
disease	B-UNK
..	O

Founder	B-UNK
mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
in	O
Polish	O
families	B-UNK
with	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
.	O

We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	B-UNK
study	B-UNK
,	O
to	O
identify	B-UNK
possible	O
BRCA1	B-UNK
and	I-UNK
BRCA2	I-UNK
founder	B-UNK
mutations	B-UNK
in	O
the	O
Polish	O
population	B-UNK
.	O

The	O
study	B-UNK
group	B-UNK
consisted	O
of	O
66	O
Polish	O
families	B-UNK
with	O
cancer	B-UNK
who	O
have	O
at	O
least	O
three	O
related	B-UNK
females	O
affected	B-UNK
with	O
breast	B-UNK
or	O
ovarian	B-UNK
cancer	I-UNK
and	O
who	O
had	O
cancer	B-UNK
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	B-UNK
females	O
,	O
at	O
age	B-UNK
<	O
50	O
years	O
.	O

A	O
total	B-UNK
of	O
26	O
families	B-UNK
had	O
both	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
,	O
4	O
families	B-UNK
had	O
ovarian	B-UNK
cancers	I-UNK
only	O
,	O
and	O
36	O
families	B-UNK
had	O
breast	B-UNK
cancers	B-DISEASE
only	O
.	O

Genomic	B-UNK
DNA	I-UNK
was	O
prepared	O
from	O
the	O
peripheral	B-UNK
blood	I-UNK
leukocytes	O
of	O
at	O
least	O
one	O
affected	B-UNK
woman	O
from	O
each	O
family	B-UNK
.	O

The	O
entire	O
coding	B-UNK
region	I-UNK
of	O
BRCA1	B-UNK
and	I-UNK
BRCA2	I-UNK
was	O
screened	B-UNK
for	O
the	O
presence	O
of	O
germline	B-UNK
mutations	I-UNK
,	O
by	O
use	O
of	O
SSCP	B-UNK
followed	O
by	O
direct	B-UNK
sequencing	I-UNK
of	O
observed	B-UNK
variants	B-UNK
.	O

Mutations	B-UNK
were	O
found	O
in	O
35	O
(	O
53	O
%	O
)	O
of	O
the	O
66	O
families	B-UNK
studied	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	B-UNK
were	O
detected	B-UNK
within	O
the	O
BRCA1	B-UNK
gene	B-UNK
.	O

BRCA1	B-UNK
abnormalities	B-UNK
were	O
identified	B-UNK
in	O
all	O
four	O
families	B-UNK
with	O
ovarian	B-UNK
cancer	I-UNK
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	B-UNK
with	O
both	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	B-UNK
with	O
breast	B-UNK
cancer	I-UNK
only	O
.	O

The	O
single	B-UNK
family	B-UNK
with	O
a	O
BRCA2	B-UNK
mutation	B-UNK
had	O
the	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
syndrome	B-UNK
.	O

Seven	O
distinct	O
mutations	B-UNK
were	O
identified	B-UNK
;	O
five	O
of	O
these	O
occurred	B-UNK
in	O
two	O
or	O
more	O
families	B-UNK
.	O

In	O
total	B-UNK
,	O
recurrent	O
mutations	B-UNK
were	O
found	O
in	O
33	O
(	O
94	O
%	O
)	O
of	O
the	O
35	O
families	B-UNK
with	O
detected	B-UNK
mutations	B-UNK
.	O

Three	O
BRCA1	B-UNK
abnormalities-5382insC	O
,	O
C61	O
G	O
,	O
and	O
4153delA	O
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	B-UNK
mutations	B-UNK
,	O
respectively	O
..	O

Molecular	B-UNK
basis	I-UNK
of	O
very	B-UNK
long	I-UNK
chain	I-UNK
acyl	I-UNK
-	O
CoA	B-UNK
dehydrogenase	I-UNK
deficiency	B-UNK
in	O
three	O
Israeli	O
patients	B-UNK
:	O
identification	B-UNK
of	O
a	O
complex	O
mutant	B-UNK
allele	B-UNK
with	O
P65L	O
and	O
K247Q	O
mutations	B-UNK
,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	B-UNK
causing	I-UNK
exon	B-UNK
3	O
skipping	O
.	O

Very	B-UNK
long	I-UNK
chain	I-UNK
acyl	I-UNK
-	O
CoA	B-UNK
dehydrogenase	I-UNK
(	O
VLCAD	B-UNK
)	O
deficiency	B-UNK
is	O
a	O
life	B-UNK
-	O
threatening	O
disorder	B-UNK
of	O
mitochondrial	B-UNK
fatty	B-UNK
acid	B-UNK
beta-oxidation	O
.	O

We	O
identified	B-UNK
four	O
novel	O
mutations	B-UNK
in	O
three	O
unrelated	B-UNK
patients	B-UNK
.	O

All	O
patients	B-UNK
had	O
the	O
severe	B-UNK
childhood	O
form	B-UNK
of	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
with	O
early	B-UNK
onset	I-UNK
and	O
high	B-UNK
mortality	O
.	O

Immunoblot	O
analysis	B-UNK
revealed	I-UNK
that	O
VLCAD	B-UNK
protein	B-UNK
was	O
undetectable	O
in	O
patients	B-UNK
2	O
and	O
3	O
,	O
whereas	O
normal	B-UNK
-	O
size	B-UNK
VLCAD	B-UNK
protein	B-UNK
and	O
an	O
aberrant	B-UNK
form	B-UNK
of	O
VLCAD	B-UNK
(	O
4kDa	O
smaller	O
)	O
were	O
detected	B-UNK
in	O
patient	B-UNK
1	O
.	O

As	O
expected	O
,	O
null	O
mutations	B-UNK
were	O
found	O
in	O
patients	B-UNK
2	O
and	O
3	O
patient	B-UNK
2	O
is	O
homozygous	B-UNK
for	O
a	O
frameshift	B-UNK
mutation	I-UNK
,	O
del	O
4	O
bp	B-UNK
at	O
798	O
-	O
801	O
,	O
and	O
patient	B-UNK
3	O
is	O
homozygous	B-UNK
for	O
a	O
nonsense	B-UNK
mutation	I-UNK
65C	O
>	O
A	O
(	O
S22X	O
)	O
.	O

Patient	B-UNK
1	O
was	O
homozygous	B-UNK
for	O
a	O
complex	O
mutant	B-UNK
allele	B-UNK
containing	O
two	O
alterations	B-UNK
,	O
including	O
a	O
194C	O
>	O
T	O
transition	B-UNK
(	O
P65L	O
)	O
and	O
739A	O
>	O
C	O
transversion	B-UNK
(	O
K247Q	O
)	O
;	O
in	O
the	O
case	B-UNK
of	O
P65L	O
,	O
the	O
amino	B-UNK
acid	I-UNK
change	B-UNK
does	O
not	O
reduce	O
enzyme	B-UNK
activity	I-UNK
.	O

However	O
,	O
the	O
nucleotide	B-UNK
change	B-UNK
resulted	B-UNK
in	O
exon	B-UNK
3	O
skipping	O
,	O
whereas	O
the	O
latter	O
K247Q	O
mutation	B-UNK
had	O
a	O
drastic	O
effect	B-UNK
on	O
enzyme	B-UNK
activity	I-UNK
.	O

We	O
verified	O
these	O
events	O
by	O
in	O
vivo	B-UNK
splicing	B-UNK
experiments	O
and	O
transient	O
expression	B-UNK
analysis	B-UNK
of	O
mutant	B-UNK
cDNAs	O
.	O

The	O
P65L	O
mutation	B-UNK
locates	O
11	O
bases	O
upstream	O
of	O
a	O
splice	B-UNK
donor	I-UNK
site	I-UNK
of	O
intron	B-UNK
3	O
.	O

This	O
is	O
an	O
example	O
of	O
an	O
exonic	O
mutation	B-UNK
which	O
affects	O
exon	B-UNK
-	O
splicing	B-UNK
..	O

Submicroscopic	B-UNK
deletion	B-UNK
in	O
cousins	O
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
causes	O
a	O
grandmatrilineal	O
inheritance	B-UNK
pattern	B-UNK
:	O
effects	B-UNK
of	O
imprinting	B-UNK
.	O

The	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
critical	B-UNK
region	I-UNK
on	O
15q11-q13	O
is	O
subject	O
to	O
imprinting	B-UNK
.	O

PWS	B-UNK
becomes	O
apparent	O
when	O
genes	B-UNK
on	O
the	O
paternally	O
inherited	B-UNK
chromosome	B-UNK
are	O
not	O
expressed	B-UNK
.	O

Familial	B-UNK
PWS	B-UNK
is	O
rare	B-UNK
.	O

We	O
report	B-UNK
on	O
a	O
family	B-UNK
in	O
which	O
a	O
male	B-UNK
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	B-UNK
with	O
cytogenetically	O
normal	B-UNK
karyotypes	O
.	O

Fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
(	O
FISH	B-UNK
)	O
analysis	B-UNK
shows	O
a	O
submicroscopic	B-UNK
deletion	B-UNK
of	O
SNRPN	B-UNK
,	O
but	O
not	O
the	O
closely	B-UNK
associated	O
loci	O
D15S10	O
,	O
D15S11	O
,	O
D15S63	O
,	O
and	O
GABRB3	O
.	O

The	O
cousins	O
fathers	O
and	O
two	O
paternal	O
aunts	O
have	O
the	O
same	O
deletion	B-UNK
and	O
are	O
clinically	O
normal	B-UNK
.	O

The	O
grandmother	O
of	O
the	O
cousins	O
is	O
deceased	O
and	O
not	O
available	O
for	O
study	B-UNK
,	O
and	O
their	O
grandfather	O
is	O
not	O
deleted	B-UNK
for	O
SNRPN	B-UNK
.	O

DNA	B-UNK
methylation	B-UNK
analysis	B-UNK
of	O
D15S63	O
is	O
consistent	B-UNK
with	O
an	O
abnormality	O
of	O
the	O
imprinting	B-UNK
center	O
associated	O
with	O
PWS	B-UNK
.	O

"	O
Grandmatrilineal	O
"	O
inheritance	B-UNK
occurs	O
when	O
a	O
woman	O
with	O
deletion	B-UNK
of	O
an	O
imprinted	O
,	O
paternally	O
expressed	B-UNK
gene	B-UNK
is	O
at	O
risk	B-UNK
of	O
having	O
affected	B-UNK
grandchildren	O
through	O
her	O
sons	O
.	O

In	O
this	O
case	B-UNK
,	O
PWS	B-UNK
does	O
not	O
become	O
evident	O
as	O
long	B-UNK
as	O
the	O
deletion	B-UNK
is	O
passed	O
through	O
the	O
matrilineal	O
line	B-UNK
.	O

This	O
represents	O
a	O
unique	O
inheritance	B-UNK
pattern	B-UNK
due	O
to	O
imprinting	B-UNK
..	O

Human	B-UNK
glycine	O
decarboxylase	O
gene	B-UNK
(	O
GLDC	B-UNK
)	O
and	O
its	O
highly	B-UNK
conserved	I-UNK
processed	O
pseudogene	O
(	O
psiGLDC	O
):	O
their	O
structure	B-UNK
and	O
expression	B-UNK
,	O
and	O
the	O
identification	B-UNK
of	O
a	O
large	B-UNK
deletion	B-UNK
in	O
a	O
family	B-UNK
with	O
nonketotic	B-DISEASE
hyperglycinemia	I-DISEASE
.	O

Mutations	B-UNK
in	O
the	O
glycine	O
decarboxylase	O
gene	B-UNK
(	O
GLDC	B-UNK
)	O
cause	O
nonketotic	B-DISEASE
hyperglycinemia	I-DISEASE
(	O
NKH	O
)	O
,	O
an	O
in	O
-	O
born	O
error	O
of	O
metabolism	B-UNK
characterized	B-UNK
by	O
severe	B-UNK
neurological	B-DISEASE
disturbance	I-DISEASE
.	O

We	O
have	O
determined	B-UNK
the	O
structure	B-UNK
of	O
GLDC	B-UNK
and	O
of	O
its	O
pseudogene	O
(	O
psiGLDC	O
)	O
and	O
studied	O
their	O
expression	B-UNK
for	O
a	O
molecular	B-UNK
analysis	I-UNK
of	O
NKH	O
.	O

The	O
GLDC	B-UNK
gene	B-UNK
spans	O
at	O
least	O
135	O
kb	B-UNK
and	O
consists	O
of	O
25	O
exons	O
.	O

All	O
donor	B-UNK
and	O
acceptor	B-UNK
sites	O
adhere	O
to	O
the	O
canonical	O
GT	B-UNK
-	O
AG	B-UNK
rule	O
,	O
except	O
for	O
the	O
donor	B-UNK
site	B-UNK
of	O
intron	B-UNK
21	O
,	O
where	O
a	O
variant	O
form	B-UNK
GC	O
is	O
used	O
instead	O
of	O
GT	B-UNK
.	O

The	O
transcription	B-UNK
initiation	O
site	B-UNK
has	O
been	O
assigned	O
to	O
a	O
residue	O
163	O
bp	B-UNK
upstream	O
from	O
the	O
translation	O
initiation	O
triplet	O
by	O
primer	O
extension	O
analysis	B-UNK
.	O

The	O
psiGLDC	O
gene	B-UNK
has	O
no	O
intron	B-UNK
and	O
shares	O
97	O
.	O

5	O
%	O
homology	B-UNK
with	O
the	O
coding	B-UNK
region	I-UNK
of	O
functional	O
GLDC	B-UNK
,	O
suggesting	O
that	O
psiGLDC	O
is	O
a	O
processed	O
pseudogene	O
that	O
arose	O
from	O
the	O
GLDC	B-UNK
transcript	B-UNK
about	O
4	O
-	O
8	O
million	O
years	O
ago	O
.	O

RNA	B-UNK
blotting	O
analysis	B-UNK
has	O
revealed	B-UNK
that	O
GLDC	B-UNK
is	O
expressed	B-UNK
in	O
human	B-UNK
liver	B-UNK
,	O
kidney	B-UNK
,	O
brain	B-UNK
,	O
and	O
placenta	O
.	O

We	O
have	O
also	O
examined	O
a	O
patient	B-UNK
with	O
NKH	O
with	O
no	O
detectable	O
GLDC	B-UNK
mRNA	O
in	O
his	O
lymphoblasts	O
.	O

Exons	O
1	O
-	O
3	O
of	O
the	O
functional	O
GLDC	B-UNK
gene	B-UNK
from	O
this	O
patient	B-UNK
are	O
not	O
amplified	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
,	O
whereas	O
those	O
from	O
control	B-UNK
subjects	B-UNK
are	O
.	O

These	O
results	B-UNK
suggest	B-UNK
a	O
large	B-UNK
homozygous	B-UNK
deletion	B-UNK
(	O
at	O
least	O
30	O
kb	B-UNK
)	O
in	O
the	O
patient	B-UNK
.	O

Furthermore	O
,	O
we	O
have	O
devised	O
a	O
semi-quantitative	O
PCR	B-UNK
to	O
estimate	O
the	O
number	B-UNK
of	O
GLDC	B-UNK
alleles	B-UNK
by	O
using	O
psiGLDC	O
as	O
an	O
internal	O
control	B-UNK
and	O
have	O
confirmed	B-UNK
the	O
homozygosity	B-UNK
and	O
heterozygosity	B-UNK
of	O
the	O
deletion	B-UNK
in	O
the	O
patient	B-UNK
and	O
his	O
parents	O
,	O
respectively	O
.	O

Structural	B-UNK
information	B-UNK
of	O
GLDC	B-UNK
and	O
psiGLDC	O
should	O
facilitate	O
the	O
molecular	B-UNK
analysis	I-UNK
of	O
NKH	O
.	O

De	O
novo	O
deletions	O
of	O
SNRPN	B-UNK
exon	B-UNK
1	O
in	O
early	B-UNK
human	B-UNK
and	O
mouse	B-UNK
embryos	B-UNK
result	B-UNK
in	O
a	O
paternal	O
to	O
maternal	O
imprint	O
switch	O
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
is	O
a	O
neurogenetic	O
disease	B-UNK
characterized	B-UNK
by	O
infantile	B-UNK
hypotonia	B-DISEASE
,	O
gonadal	O
hypoplasia	B-UNK
,	O
obsessive	O
behaviour	O
and	O
neonatal	B-UNK
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	B-DISEASE
,	O
leading	B-UNK
to	O
profound	O
obesity	B-UNK
.	O

PWS	B-UNK
is	O
due	O
to	O
a	O
lack	B-UNK
of	O
paternal	O
genetic	B-UNK
information	B-UNK
at	O
15q11-q13	O
(	O
ref	O
.	O
2	O
)	O
.	O

Five	O
imprinted	O
,	O
paternally	O
expressed	B-UNK
genes	B-UNK
map	B-UNK
to	O
the	O
PWS	B-UNK
region	B-UNK
,	O
MKRN3	O
(	O
ref	O
.	O
3	O
)	O
,	O
NDN	O
(	O
ref	O
.	O
4	O
)	O
,	O
NDNL1	O
(	O
ref	O
.	O
5	O
)	O
,	O
SNRPN	B-UNK
(	O
refs	O
6	O
-	O
8)	O
and	O
IPW	O
(	O
ref	O
.	O
9	O
)	O
,	O
as	O
well	O
as	O
two	O
poorly	O
characterized	B-UNK
framents	O
designated	O
PAR-1	O
and	O
PAR-5	O
(	O
ref	O
.	O
10	O
)	O
.	O

Imprinting	B-UNK
of	O
this	O
region	B-UNK
involves	O
a	O
bipartite	O
imprinting	B-UNK
centre	O
(	O
IC	O
)	O
,	O
which	O
overlaps	O
SNRPN	B-UNK
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Deletion	B-UNK
of	O
the	O
SNRPN	B-UNK
promoter	O
/	O
exon	B-UNK
1	O
region	B-UNK
(	O
the	O
PWS	B-UNK
IC	O
element	O
)	O
appears	B-UNK
to	O
impair	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
in	O
the	O
male	B-UNK
germ	B-UNK
line	I-UNK
and	O
leads	B-UNK
to	O
PWS	B-UNK
.	O

Here	O
we	O
report	B-UNK
a	O
PWS	B-UNK
family	B-UNK
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
IC	O
deletion	B-UNK
on	O
his	O
paternal	O
chromosome	B-UNK
.	O

The	O
deletion	B-UNK
chromosome	B-UNK
has	O
acquired	O
a	O
maternal	O
methylation	B-UNK
imprint	O
in	O
his	O
somatic	B-UNK
cells	B-UNK
.	O

We	O
have	O
made	O
identical	B-UNK
findings	B-UNK
in	O
chimaeric	O
mice	B-UNK
generated	O
from	O
two	O
independent	O
embryonic	B-UNK
stem	B-UNK
(	O
ES	O
)	O
cell	B-UNK
lines	I-UNK
harbouring	O
a	O
similar	B-UNK
deletion	B-UNK
.	O

Our	O
studies	B-UNK
demonstrate	B-UNK
that	O
the	O
PWS	B-UNK
IC	O
element	O
is	O
not	O
only	O
required	B-UNK
for	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
,	O
but	O
also	O
for	O
its	O
postzygotic	O
maintenance	O
..	O

Mice	B-UNK
deficient	B-UNK
in	O
Six5	B-UNK
develop	O
cataracts	B-DISEASE
:	O
implications	B-UNK
for	O
myotonic	B-UNK
dystrophy	I-UNK
.	O

Expansion	B-UNK
of	O
a	O
CTG	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
in	O
the	O
3	O
UTR	B-UNK
of	O
the	O
gene	B-UNK
DMPK	B-UNK
at	O
the	O
DM1	O
locus	B-UNK
on	O
chromosome	B-UNK
19	O
causes	O
myotonic	B-UNK
dystrophy	I-UNK
,	O
a	O
dominantly	O
inherited	B-UNK
disease	B-UNK
characterized	B-UNK
by	O
skeletal	B-UNK
muscle	I-UNK
dystrophy	B-UNK
and	O
myotonia	B-UNK
,	O
cataracts	B-DISEASE
and	O
cardiac	B-UNK
conduction	O
defects	B-UNK
.	O

Targeted	B-UNK
deletion	B-UNK
of	O
Dm15	O
,	O
the	O
mouse	B-UNK
orthologue	O
of	O
human	B-UNK
DMPK	B-UNK
,	O
produced	O
mice	B-UNK
with	O
a	O
mild	O
myopathy	B-DISEASE
and	O
cardiac	B-UNK
conduction	O
abnormalities	B-UNK
,	O
but	O
without	O
other	O
features	B-UNK
of	O
myotonic	B-UNK
dystrophy	I-UNK
,	O
such	O
as	O
myotonia	B-DISEASE
and	O
cataracts	B-DISEASE
.	O

We	O
,	O
and	O
others	O
,	O
have	O
demonstrated	O
that	O
repeat	B-UNK
expansion	I-UNK
decreases	O
expression	B-UNK
of	O
the	O
adjacent	O
gene	B-UNK
SIX5	B-UNK
(	O
refs	O
7	O
,	O
8)	O
,	O
which	O
encodes	B-UNK
a	O
homeodomain	O
transcription	B-UNK
factor	I-UNK
.	O

To	O
determine	B-UNK
whether	O
SIX5	B-UNK
deficiency	B-UNK
contributes	O
to	O
the	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
phenotype	B-UNK
,	O
we	O
disrupted	O
mouse	B-UNK
Six5	B-UNK
by	O
replacing	O
the	O
first	O
exon	B-UNK
with	O
a	O
beta-galactosidase	O
reporter	O
.	O

Six5-mutant	O
mice	B-UNK
showed	O
reporter	O
expression	B-UNK
in	O
multiple	B-UNK
tissues	O
,	O
including	O
the	O
developing	O
lens	O
.	O

Homozygous	B-UNK
mutant	B-UNK
mice	I-UNK
had	O
no	O
apparent	O
abnormalities	B-UNK
of	O
skeletal	B-UNK
muscle	I-UNK
function	B-UNK
,	O
but	O
developed	O
lenticular	O
opacities	O
at	O
a	O
higher	O
rate	B-UNK
than	O
controls	O
.	O

Our	O
results	B-UNK
suggest	B-UNK
that	O
SIX5	B-UNK
deficiency	B-UNK
contributes	O
to	O
the	O
cataract	B-DISEASE
phenotype	B-UNK
in	O
myotonic	B-UNK
dystrophy	I-UNK
,	O
and	O
that	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
represents	O
a	O
multigenic	O
disorder	B-UNK
..	O

Heterozygous	B-UNK
loss	B-UNK
of	O
Six5	B-UNK
in	O
mice	B-UNK
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	B-DISEASE
.	O

Myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
skeletal	B-UNK
muscle	I-UNK
wasting	O
,	O
myotonia	B-UNK
,	O
cardiac	B-DISEASE
arrhythmia	I-DISEASE
,	O
hyperinsulinaemia	O
,	O
mental	B-UNK
retardation	I-UNK
and	O
ocular	O
cataracts	B-DISEASE
.	O

The	O
genetic	B-UNK
defect	B-UNK
in	O
DM	B-DISEASE
is	O
a	O
CTG	B-UNK
repeat	I-UNK
expansion	B-UNK
located	B-UNK
in	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
of	O
DMPK	B-UNK
and	O
5	O
of	O
a	O
homeodomain	O
-	O
encoding	B-UNK
gene	B-UNK
,	O
SIX5	B-UNK
(	O
formerly	O
DMAHP	O
;	O
refs	O
2	O
-	O
5	O
)	O
.	O

There	O
are	O
three	O
mechanisms	O
by	O
which	O
CTG	B-UNK
expansion	B-UNK
can	O
result	B-UNK
in	O
DM	B-DISEASE
.	O

First	O
,	O
repeat	B-UNK
expansion	I-UNK
may	O
alter	O
the	O
processing	O
or	O
transport	B-UNK
of	O
the	O
mutant	B-UNK
DMPK	B-UNK
mRNA	O
and	O
consequently	O
reduce	O
DMPK	B-UNK
levels	B-UNK
.	O

Second	O
,	O
CTG	B-UNK
expansion	B-UNK
may	O
establish	O
a	O
region	B-UNK
of	O
heterochromatin	O
3	O
of	O
the	O
repeat	B-UNK
sequence	B-UNK
and	O
decrease	O
SIX5	B-UNK
transcription	B-UNK
.	O

Third	O
,	O
toxic	O
effects	B-UNK
of	O
the	O
repeat	B-UNK
expansion	I-UNK
may	O
be	O
intrinsic	O
to	O
the	O
repeated	O
elements	O
at	O
the	O
level	B-UNK
of	O
DNA	B-UNK
or	O
RNA	B-UNK
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Previous	B-UNK
studies	B-UNK
have	O
demonstrated	O
that	O
a	O
dose	O
-	O
dependent	B-UNK
loss	B-UNK
of	O
Dm15	O
(	O
the	O
mouse	B-UNK
DMPK	B-UNK
homologue	B-UNK
)	O
in	O
mice	B-UNK
produces	O
a	O
partial	O
DM	B-UNK
phenotype	B-UNK
characterized	B-UNK
by	O
decreased	B-UNK
development	B-UNK
of	O
skeletal	B-UNK
muscle	I-UNK
force	O
and	O
cardiac	B-UNK
conduction	O
disorders	B-UNK
.	O

To	O
test	B-UNK
the	O
role	B-UNK
of	O
Six5	B-UNK
loss	B-UNK
in	O
DM	B-DISEASE
,	O
we	O
have	O
analysed	O
a	O
strain	O
of	O
mice	B-UNK
in	O
which	O
Six5	B-UNK
was	O
deleted	B-UNK
.	O

Our	O
results	B-UNK
demonstrate	B-UNK
that	O
the	O
rate	B-UNK
and	O
severity	B-UNK
of	O
cataract	B-DISEASE
formation	B-UNK
is	O
inversely	O
related	B-UNK
to	O
Six5	B-UNK
dosage	O
and	O
is	O
temporally	O
progressive	B-UNK
.	O

Six5	B-UNK
+	O
/-and	O
Six5-/-mice	O
show	O
increased	B-UNK
steady	O
-	O
state	B-UNK
levels	B-UNK
of	O
the	O
Na	B-UNK
+	O
/K	O
+	O
-ATPase	O
alpha-1	O
subunit	B-UNK
and	O
decreased	B-UNK
Dm15	O
mRNA	O
levels	B-UNK
.	O

Thus	O
,	O
altered	O
ion	O
homeostasis	O
within	O
the	O
lens	O
may	O
contribute	B-UNK
to	O
cataract	B-DISEASE
formation	B-UNK
.	O

As	O
ocular	O
cataracts	B-DISEASE
are	O
a	O
characteristic	B-UNK
feature	O
of	O
DM	B-DISEASE
,	O
these	O
results	B-UNK
demonstrate	B-UNK
that	O
decreased	B-UNK
SIX5	B-UNK
transcription	B-UNK
is	O
important	O
in	O
the	O
aetiology	O
of	O
DM	B-DISEASE
.	O

Our	O
data	B-UNK
support	O
the	O
hypothesis	B-UNK
that	O
DM	B-UNK
is	O
a	O
contiguous	O
gene	B-UNK
syndrome	B-DISEASE
associated	O
with	O
the	O
partial	O
loss	B-UNK
of	O
both	O
DMPK	B-UNK
and	O
SIX5	B-UNK
..	O

ATM	B-UNK
-	O
dependent	B-UNK
phosphorylation	B-UNK
of	O
nibrin	O
in	O
response	B-UNK
to	O
radiation	B-UNK
exposure	O
.	O

Mutations	B-UNK
in	O
the	O
gene	B-UNK
ATM	B-UNK
are	O
responsible	B-UNK
for	O
the	O
genetic	B-UNK
disorder	I-UNK
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
,	O
which	O
is	O
characterized	B-UNK
by	O
cerebellar	B-DISEASE
dysfunction	I-DISEASE
,	O
radiosensitivity	O
,	O
chromosomal	B-DISEASE
instability	I-DISEASE
and	O
cancer	B-UNK
predisposition	B-UNK
.	O

Both	O
the	O
A	O
-T	O
phenotype	B-UNK
and	O
the	O
similarity	O
of	O
the	O
ATM	B-UNK
protein	B-UNK
to	O
other	O
DNA	B-UNK
-	O
damage	B-UNK
sensors	O
suggests	O
a	O
role	B-UNK
for	O
ATM	B-UNK
in	O
biochemical	O
pathways	O
involved	B-UNK
in	O
the	O
recognition	O
,	O
signalling	O
and	O
repair	B-UNK
of	O
DNA	B-UNK
double-strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

There	O
are	O
strong	B-UNK
parallels	O
between	O
the	O
pattern	B-UNK
of	O
radiosensitivity	O
,	O
chromosomal	B-DISEASE
instability	I-DISEASE
and	O
cancer	B-UNK
predisposition	B-UNK
in	O
A	O
-T	O
patients	B-UNK
and	O
that	O
in	O
patients	B-UNK
with	O
Nijmegen	B-DISEASE
breakage	I-DISEASE
syndrome	I-DISEASE
(	O
NBS	B-UNK
)	O
.	O

The	O
protein	B-UNK
defective	O
in	O
NBS	B-UNK
,	O
nibrin	O
(	O
encoded	B-UNK
by	O
NBS1	O
)	O
,	O
forms	B-UNK
a	O
complex	O
with	O
MRE11	O
and	O
RAD50	O
(	O
refs	O
1	O
,	O
2	O
)	O
.	O

This	O
complex	O
localizes	O
to	O
DSBs	O
within	O
30	O
minutes	O
after	O
cellular	O
exposure	O
to	O
ionizing	B-UNK
radiation	I-UNK
(	O
IR	O
)	O
and	O
is	O
observed	B-UNK
in	O
brightly	O
staining	O
nuclear	B-UNK
foci	O
after	O
a	O
longer	O
period	O
of	O
time	O
.	O

The	O
overlap	O
between	O
clinical	B-UNK
and	O
cellular	O
phenotypes	O
in	O
A	O
-T	O
and	O
NBS	B-UNK
suggests	O
that	O
ATM	B-UNK
and	O
nibrin	O
may	O
function	B-UNK
in	O
the	O
same	O
biochemical	O
pathway	B-UNK
.	O

Here	O
we	O
demonstrate	B-UNK
that	O
nibrin	O
is	O
phosphorylated	O
within	O
one	O
hour	O
of	O
treatment	O
of	O
cells	B-UNK
with	O
IR	O
.	O

This	O
response	B-UNK
is	O
abrogated	O
in	O
A	O
-T	O
cells	B-UNK
that	O
either	O
do	O
not	O
express	O
ATM	B-UNK
protein	B-UNK
or	O
express	O
near	O
full	O
-	O
length	B-UNK
mutant	B-UNK
protein	B-UNK
.	O

We	O
also	O
show	O
that	O
ATM	B-UNK
physically	O
interacts	O
with	O
and	O
phosphorylates	O
nibrin	O
on	O
serine	O
343	O
both	O
in	O
vivo	B-UNK
and	O
in	O
vitro	O
.	O

Phosphorylation	B-UNK
of	O
this	O
site	B-UNK
appears	B-UNK
to	O
be	O
functionally	O
important	O
because	O
mutated	B-UNK
nibrin	O
(	O
S343A	O
)	O
does	O
not	O
completely	O
complement	B-UNK
radiosensitivity	O
in	O
NBS	B-UNK
cells	B-UNK
.	O

ATM	B-UNK
phosphorylation	B-UNK
of	O
nibrin	O
does	O
not	O
affect	O
nibrin	O
-	O
MRE11-RAD50	O
association	B-UNK
as	O
revealed	B-UNK
by	O
radiation	B-UNK
-	O
induced	O
foci	O
formation	B-UNK
.	O

Our	O
data	B-UNK
provide	B-UNK
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	B-UNK
between	O
A	O
-T	O
and	O
NBS	B-UNK
..	O

Clinicopathologic	O
features	B-UNK
of	O
BRCA	O
-	O
linked	B-UNK
and	O
sporadic	B-UNK
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

CONTEXT	O
Most	O
hereditary	B-UNK
ovarian	B-UNK
cancers	I-UNK
are	O
associated	O
with	O
germline	B-UNK
mutations	I-UNK
in	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
.	O

Attempts	O
to	O
define	B-UNK
the	O
clinical	B-UNK
significance	O
of	O
BRCA	O
mutation	B-UNK
status	B-UNK
in	O
ovarian	B-UNK
cancer	I-UNK
have	O
produced	O
conflicting	O
results	B-UNK
,	O
especially	O
regarding	O
survival	B-UNK
.	O

OBJECTIVE	B-UNK
To	O
determine	B-UNK
whether	O
hereditary	B-UNK
ovarian	B-UNK
cancers	I-UNK
have	O
distinct	O
clinical	B-UNK
and	O
pathological	O
features	B-UNK
compared	B-UNK
with	O
sporadic	B-UNK
(	O
nonhereditary	O
)	O
ovarian	B-UNK
cancers	I-UNK
.	O

DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	B-UNK
study	B-UNK
of	O
a	O
consecutive	O
series	B-UNK
of	O
933	O
ovarian	B-UNK
cancers	I-UNK
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B-DISEASE
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B-UNK
Institute	O
,	O
over	O
a	O
12-year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O

PATIENTS	B-UNK
The	O
study	B-UNK
was	O
restricted	O
to	O
patients	B-UNK
of	O
Jewish	B-UNK
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	B-UNK
and	I-UNK
BRCA2	I-UNK
genotyping	O
in	O
this	O
ethnic	B-UNK
group	B-UNK
.	O

From	O
the	O
189	O
patients	B-UNK
who	O
identified	B-UNK
themselves	O
as	O
Jewish	B-UNK
,	O
88	O
hereditary	B-UNK
cases	B-UNK
were	O
identified	B-UNK
with	O
the	O
presence	O
of	O
a	O
germline	B-UNK
founder	B-UNK
mutation	B-UNK
in	O
BRCA1	B-UNK
or	I-UNK
BRCA2	I-UNK
.	O

The	O
remaining	O
101	O
cases	B-UNK
from	O
the	O
same	O
series	B-UNK
not	O
associated	O
with	O
a	O
BRCA	O
mutation	B-UNK
and	O
2	O
additional	O
groups	B-UNK
(	O
Gynecologic	O
Oncology	O
Group	B-UNK
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B-UNK
cancer	I-UNK
from	O
clinical	B-UNK
trials	O
(	O
for	O
the	O
survival	B-UNK
analysis	B-UNK
)	O
were	O
included	O
for	O
comparison	B-UNK
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Age	B-UNK
at	I-UNK
diagnosis	I-UNK
,	O
surgical	O
stage	B-UNK
,	O
histologic	O
cell	B-UNK
type	B-UNK
and	O
grade	O
,	O
and	O
surgical	O
outcome	O
;	O
and	O
response	B-UNK
to	O
chemotherapy	O
and	O
survival	B-UNK
for	O
advanced	O
-	O
stage	B-UNK
(	O
II	B-UNK
and	O
IV	O
)	O
cases	B-UNK
.	O

RESULTS	B-UNK
Hereditary	B-UNK
cancers	B-DISEASE
were	O
rarely	O
diagnosed	O
before	O
age	B-UNK
40	O
years	O
and	O
were	O
common	B-UNK
after	O
age	B-UNK
60	O
years	O
,	O
with	O
mean	O
age	B-UNK
at	I-UNK
diagnosis	I-UNK
being	O
significantly	O
younger	O
for	O
BRCA1-vs	O
BRCA2-linked	O
patients	B-UNK
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

Histology	O
,	O
grade	O
,	O
stage	B-UNK
,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	B-UNK
for	O
hereditary	B-UNK
and	O
sporadic	B-UNK
cases	B-UNK
.	O

The	O
hereditary	B-UNK
group	B-UNK
had	O
a	O
longer	O
disease	B-UNK
-	O
free	O
interval	B-UNK
following	O
primary	B-UNK
chemotherapy	O
in	O
comparison	B-UNK
with	O
the	O
nonhereditary	O
group	B-UNK
,	O
with	O
a	O
median	O
time	O
to	O
recurrence	B-DISEASE
of	O
14	O
months	O
and	O
7	O
months	O
,	O
respectively	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Those	O
with	O
hereditary	B-UNK
cancers	B-UNK
had	O
improved	O
survival	B-UNK
compared	B-UNK
with	O
the	O
nonhereditary	O
group	B-UNK
(	O
P	O
=	O
.	O
004	O
)	O
.	O

For	O
stage	B-UNK
III	B-UNK
cancers	B-UNK
,	O
BRCA	O
mutation	B-UNK
status	B-UNK
was	O
an	O
independent	O
prognostic	O
variable	B-UNK
(	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	B-UNK
Although	O
BRCA	O
-	O
associated	O
hereditary	B-UNK
ovarian	B-UNK
cancers	I-UNK
in	O
this	O
population	B-UNK
have	O
surgical	O
and	O
pathological	O
characteristics	B-UNK
similar	B-UNK
to	O
those	O
of	O
sporadic	B-UNK
cancers	B-UNK
,	O
advanced	O
-	O
stage	B-UNK
hereditary	B-UNK
cancer	B-UNK
patients	B-UNK
survive	O
longer	O
than	O
nonhereditary	O
cancer	B-DISEASE
patients	B-UNK
.	O

Age	B-UNK
penetrance	O
is	O
greater	B-UNK
for	O
BRCA1-linked	O
than	O
for	O
BRCA2-linked	O
cancers	B-UNK
in	O
this	O
population	B-UNK
.	O

The	O
gene	B-UNK
for	O
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
,	O
MEFV	B-UNK
,	O
is	O
expressed	B-UNK
in	O
early	B-UNK
leukocyte	O
development	B-UNK
and	O
is	O
regulated	O
in	O
response	B-UNK
to	O
inflammatory	O
mediators	O
.	O

Familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
(	O
FMF	B-UNK
)	O
is	O
a	O
recessive	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
episodes	O
of	O
fever	B-DISEASE
and	O
neutrophil	O
-	O
mediated	O
serosal	O
inflammation	B-DISEASE
.	O

We	O
recently	O
identified	B-UNK
the	O
gene	B-UNK
causing	B-UNK
FMF	B-UNK
,	O
designated	O
MEFV	B-UNK
,	O
and	O
found	O
it	O
to	O
be	O
expressed	B-UNK
in	O
mature	O
neutrophils	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
inflammatory	O
regulator	O
.	O

To	O
facilitate	O
our	O
understanding	B-UNK
of	O
the	O
normal	B-UNK
function	B-UNK
of	O
MEFV	B-UNK
,	O
we	O
extended	O
our	O
previous	B-UNK
studies	B-UNK
.	O

MEFV	B-UNK
messenger	B-UNK
RNA	I-UNK
was	O
detected	B-UNK
by	O
reverse	B-UNK
transcriptase	O
-	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
in	O
bone	B-UNK
marrow	O
leukocytes	O
,	O
with	O
differential	B-UNK
expression	B-UNK
observed	B-UNK
among	O
cells	B-UNK
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
.	O

CD34	O
hematopoietic	O
stem	B-UNK
-	O
cell	B-UNK
cultures	O
induced	O
toward	O
the	O
granulocytic	O
lineage	O
expressed	B-UNK
MEFV	B-UNK
at	O
the	O
myelocyte	O
stage	B-UNK
,	O
concurrently	O
with	O
lineage	O
commitment	O
.	O

The	O
prepromyelocytic	O
cell	B-UNK
line	I-UNK
HL60	O
expressed	B-UNK
MEFV	B-UNK
only	O
at	O
granulocytic	O
and	O
monocytic	O
differentiation	B-UNK
.	O

MEFV	B-UNK
was	O
also	O
expressed	B-UNK
in	O
the	O
monocytic	O
cell	B-UNK
lines	I-UNK
U937	O
and	O
THP-1	O
.	O

Among	O
peripheral	B-UNK
blood	I-UNK
leukocytes	O
,	O
MEFV	B-UNK
expression	B-UNK
was	O
detected	B-UNK
in	O
neutrophils	O
,	O
eosinophils	O
,	O
and	O
to	O
varying	O
degrees	O
,	O
monocytes	O
.	O

Consistent	B-UNK
with	O
the	O
tissue	B-UNK
specificity	O
of	O
expression	B-UNK
,	O
complete	O
sequencing	B-UNK
and	O
analysis	B-UNK
of	O
upstream	O
regulatory	O
regions	B-UNK
of	O
MEFV	B-UNK
revealed	B-UNK
homology	B-UNK
to	O
myeloid	O
-	O
specific	B-UNK
promoters	O
and	O
to	O
more	O
broadly	O
expressed	B-UNK
inflammatory	O
promoter	O
elements	O
.	O

In	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(	O
IFN	O
)	O
gamma	B-UNK
,	O
tumor	B-DISEASE
necrosis	B-DISEASE
factor	B-UNK
,	O
and	O
lipopolysaccharide	O
induced	O
MEFV	B-UNK
expression	B-UNK
,	O
whereas	O
the	O
antiinflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
4	O
,	O
IL-10	O
,	O
and	O
transforming	O
growth	B-UNK
factor	I-UNK
beta	B-UNK
inhibited	O
such	O
expression	B-UNK
.	O

Induction	O
by	O
IFN	O
-	O
gamma	B-UNK
occurred	B-UNK
rapidly	O
and	O
was	O
resistant	O
to	O
cycloheximide	O
.	O

IFN	O
-	O
alpha	B-UNK
also	O
induced	O
MEFV	B-UNK
expression	B-UNK
.	O

In	O
granulocytes	O
,	O
MEFV	B-UNK
was	O
up	O
-	O
regulated	O
by	O
IFN	O
-	O
gamma	B-UNK
and	O
the	O
combination	B-UNK
of	O
IFN	O
-	O
alpha	B-UNK
and	O
colchicine	B-UNK
.	O

These	O
results	B-UNK
refine	O
understanding	B-UNK
of	O
MEFV	B-UNK
by	O
placing	O
the	O
gene	B-UNK
in	O
the	O
myelomonocytic	O
-	O
specific	B-UNK
proinflammatory	O
pathway	B-UNK
and	O
identifying	O
it	O
as	O
an	O
IFN	O
-	O
gamma	B-UNK
immediate	O
early	B-UNK
gene	B-UNK
..	O

Biochemical	O
and	O
structural	B-UNK
analysis	B-UNK
of	O
missense	B-UNK
mutations	I-UNK
in	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
causing	B-UNK
mucopolysaccharidosis	B-UNK
IVA	B-UNK
phenotypes	O
.	O

Mucopolysaccharidosis	B-UNK
IVA	B-UNK
(	O
MPS	B-UNK
IVA	I-UNK
;	O
OMIM	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
(	O
GALNS	B-UNK
)	O
,	O
has	O
variable	B-UNK
clinical	B-UNK
phenotypes	O
.	O

To	O
date	B-UNK
we	O
have	O
identified	B-UNK
65	O
missense	B-UNK
mutations	I-UNK
in	O
the	O
GALNS	B-UNK
gene	B-UNK
from	O
MPS	B-UNK
IVA	I-UNK
patients	B-UNK
,	O
but	O
the	O
correlation	B-UNK
between	O
genotype	B-UNK
and	O
phenotype	B-UNK
has	O
remained	O
unclear	O
.	O

We	O
studied	O
17	O
missense	B-UNK
mutations	I-UNK
using	O
biochemical	O
approaches	O
and	O
32	O
missense	B-UNK
mutations	I-UNK
,	O
using	O
structural	B-UNK
analyses	O
.	O

Fifteen	O
missense	B-UNK
mutations	I-UNK
and	O
two	O
newly	O
engineered	O
active	B-UNK
site	B-UNK
mutations	B-UNK
(	O
C79S	O
,	O
C79	O
T	O
)	O
were	O
characterized	B-UNK
by	O
transient	O
expression	B-UNK
analysis	B-UNK
.	O

Mutant	B-UNK
proteins	B-UNK
,	O
except	O
for	O
C79S	O
and	O
C79	O
T	O
,	O
were	O
destabilized	O
and	O
detected	B-UNK
as	O
insoluble	O
precursor	O
forms	B-UNK
while	O
the	O
C79S	O
and	O
C79	O
T	O
mutants	O
were	O
of	O
a	O
soluble	O
mature	O
size	B-UNK
.	O

Mutants	O
found	O
in	O
the	O
severe	B-UNK
phenotype	I-UNK
had	O
no	O
activity	B-UNK
.	O

Mutants	O
found	O
in	O
the	O
mild	O
phenotype	B-UNK
had	O
a	O
considerable	B-UNK
residual	B-UNK
activity	B-UNK
(	O
1	O
.	O
3	O
-	O
13	O
.	O
3	O
%	O
of	O
wild	B-UNK
-	O
type	B-UNK
GALNS	B-UNK
activity	B-UNK
)	O
.	O

Sulfatases	O
,	O
including	O
GALNS	B-UNK
,	O
are	O
members	B-UNK
of	O
a	O
highly	B-UNK
conserved	I-UNK
gene	B-UNK
family	B-UNK
sharing	O
an	O
extensive	B-UNK
sequence	B-UNK
homology	B-UNK
.	O

Thus	O
,	O
a	O
tertiary	O
structural	B-UNK
model	B-UNK
of	O
human	B-UNK
GALNS	B-UNK
was	O
constructed	O
from	O
the	O
X	O
-	O
ray	O
crystal	O
structure	B-UNK
of	O
N	O
-	O
acetylgalacto	O
-	O
samine-4-sulfatase	O
and	O
arylsulfatase	O
A	O
,	O
using	O
homology	B-UNK
modeling	O
,	O
and	O
32	O
missense	B-UNK
mutations	I-UNK
were	O
investigated	O
.	O

Consequently	O
,	O
we	O
propose	O
that	O
there	O
are	O
at	O
least	O
three	O
different	O
reasons	O
for	O
the	O
severe	B-UNK
phenotype	I-UNK
(	O
i	O
)	O
destruction	O
of	O
the	O
hydrophobic	O
core	O
or	O
modification	O
of	O
the	O
packing	O
;	O
(	O
ii	B-UNK
)	O
removal	O
of	O
a	O
salt	O
bridge	O
to	O
destabilize	O
the	O
entire	O
conformation	B-UNK
;	O
(	O
iii	B-UNK
)	O
modification	O
of	O
the	O
active	B-UNK
site	B-UNK
.	O

In	O
contrast	B-UNK
,	O
mild	O
mutations	B-UNK
were	O
mostly	O
located	B-UNK
on	O
the	O
surface	O
of	O
the	O
GALNS	B-UNK
protein	B-UNK
.	O

These	O
studies	B-UNK
shed	O
further	O
light	O
on	O
the	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
of	O
MPS	B-UNK
IVA	I-UNK
and	O
structure	B-UNK
-	O
function	B-UNK
relationship	B-UNK
in	O
the	O
sulfatase	O
family	B-UNK
.	O

Mutations	B-UNK
at	O
the	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
locus	B-UNK
and	O
clinical	B-UNK
phenotypes	O
of	O
A	O
-T	O
patients	B-UNK
.	O

Mutations	B-UNK
at	O
the	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
locus	B-UNK
on	O
chromosome	B-UNK
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	B-UNK
recessive	I-UNK
syndrome	B-DISEASE
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	B-UNK
to	O
cancer	B-UNK
,	O
ischemic	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
and	O
early	B-UNK
mortality	O
.	O

PCR	B-UNK
amplification	B-UNK
from	O
genomic	B-UNK
DNA	I-UNK
and	O
automated	O
sequencing	B-UNK
of	O
the	O
entire	O
coding	B-UNK
region	I-UNK
(	O
66	O
exons	O
)	O
and	O
splice	B-UNK
junctions	O
detected	B-UNK
77	O
mutations	B-UNK
(	O
85	O
%	O
)	O
in	O
90	O
A	O
-T	O
chromosomes	O
.	O

Heteroduplex	B-UNK
analysis	I-UNK
detected	B-UNK
another	O
42	O
mutations	B-UNK
at	O
the	O
A	O
-T	O
locus	B-UNK
.	O

Out	O
of	O
a	O
total	B-UNK
of	O
71	O
unique	O
mutations	B-UNK
,	O
50	O
were	O
found	O
only	O
in	O
a	O
single	B-UNK
family	B-UNK
,	O
and	O
51	O
had	O
not	O
been	O
reported	B-UNK
previously	B-UNK
.	O

Most	O
(	O
58/71	O
,	O
82	O
%	O
)	O
mutations	B-UNK
were	O
frameshift	B-UNK
and	O
nonsense	B-UNK
mutations	I-UNK
that	O
are	O
predicted	B-UNK
to	O
cause	O
truncation	B-UNK
of	O
the	O
A	O
-T	O
protein	B-UNK
;	O
the	O
less	O
common	B-UNK
mutation	B-UNK
types	B-UNK
were	O
missense	B-UNK
(	O
9/71	O
,	O
13	O
%	O
)	O
,	O
splicing	B-UNK
(	O
3/71	O
,	O
4	O
%	O
)	O
and	O
one	O
in	O
-	O
frame	B-UNK
deletion	B-UNK
,	O
2546	O
3	O
(	O
1/71	O
,	O
1	O
%	O
)	O
.	O

The	O
mean	O
survival	B-UNK
and	O
height	O
distribution	B-UNK
of	O
134	O
A	O
-T	O
patients	B-UNK
correlated	B-UNK
significantly	O
with	O
the	O
specific	B-UNK
mutations	B-UNK
present	B-UNK
in	O
the	O
patients	B-UNK
.	O

Patients	B-UNK
homozygous	B-UNK
for	O
a	O
single	B-UNK
truncating	B-UNK
mutation	B-UNK
,	O
typically	O
near	O
the	O
N	O
-	O
terminal	B-UNK
end	B-UNK
of	O
the	O
gene	B-UNK
,	O
or	O
heterozygous	B-UNK
for	O
the	O
in	O
-	O
frame	B-UNK
deletion	B-UNK
2546	O
3	O
,	O
were	O
shorter	O
and	O
had	O
significantly	O
shorter	O
survival	B-UNK
than	O
those	O
heterozygous	B-UNK
for	O
a	O
splice	B-UNK
site	I-UNK
or	O
missense	B-UNK
mutation	I-UNK
,	O
or	O
heterozygous	B-UNK
for	O
two	O
truncating	B-UNK
mutations	I-UNK
.	O

Alterations	B-UNK
of	O
the	O
length	B-UNK
or	O
amino	B-UNK
acid	I-UNK
composition	O
of	O
the	O
A	O
-T	O
gene	B-UNK
product	I-UNK
affect	O
the	O
A	O
-T	O
clinical	B-UNK
phenotype	B-UNK
in	O
different	O
ways	O
.	O

Mutation	B-UNK
analysis	B-UNK
at	O
the	O
A	O
-T	O
locus	B-UNK
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
A	O
-T	O
patients	B-UNK
..	O

Isolation	B-UNK
,	O
genomic	B-UNK
organization	B-UNK
,	O
and	O
expression	B-UNK
analysis	B-UNK
of	O
the	O
mouse	B-UNK
and	O
rat	O
homologs	O
of	O
MEFV	B-UNK
,	O
the	O
gene	B-UNK
for	O
familial	B-UNK
mediterranean	I-UNK
fever	I-UNK
.	O

Familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
(	O
FMF	B-UNK
)	O
is	O
a	O
recessive	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
episodes	O
of	O
fever	B-DISEASE
with	O
serositis	B-DISEASE
or	O
synovitis	B-DISEASE
.	O

Recently	O
the	O
FMF	B-UNK
gene	B-UNK
(	O
MEFV	B-UNK
)	O
was	O
cloned	O
;	O
the	O
protein	B-UNK
product	I-UNK
,	O
pyrin	O
/	O
marenostrin	O
,	O
is	O
thought	B-UNK
to	O
regulate	O
inflammation	B-DISEASE
in	O
myeloid	O
cells	B-UNK
.	O

In	O
this	O
manuscript	O
we	O
report	B-UNK
the	O
mouse	B-UNK
and	O
rat	O
homologs	O
of	O
MEFV	B-UNK
.	O

The	O
murine	O
gene	B-UNK
contains	O
ten	O
exons	O
with	O
a	O
coding	B-UNK
sequence	I-UNK
of	O
2304	O
bp	B-UNK
,	O
while	O
the	O
rat	O
homolog	O
has	O
nine	O
exons	O
with	O
a	O
coding	B-UNK
sequence	I-UNK
of	O
2253	O
bp	B-UNK
.	O

A	O
considerable	B-UNK
amino	B-UNK
acid	I-UNK
sequence	B-UNK
homology	B-UNK
was	O
observed	B-UNK
between	O
the	O
mouse	B-UNK
and	O
human	B-UNK
(	O
47	O
.	O
6	O
%	O
identity	O
and	O
65	O
.	O
5	O
%	O
similarity	O
)	O
and	O
between	O
the	O
mouse	B-UNK
and	O
rat	O
genes	B-UNK
(	O
73	O
.	O
5	O
%	O
identity	O
and	O
82	O
.	O
1	O
%	O
similarity	O
)	O
.	O

The	O
predicted	B-UNK
rodent	O
proteins	B-UNK
have	O
several	O
important	O
domains	B-UNK
and	O
signals	O
found	O
in	O
human	B-UNK
pyrin	O
,	O
including	O
a	O
B	O
-	O
box	O
zinc	B-UNK
finger	I-UNK
domain	B-UNK
,	O
Robbins	O
-	O
Dingwall	O
nuclear	B-UNK
localization	B-UNK
signal	B-UNK
,	O
and	O
coiled	O
-	O
coil	O
domain	B-UNK
.	O

However	O
,	O
perhaps	O
because	O
of	O
an	O
ancient	O
frame	B-UNK
-	O
shift	O
mutation	B-UNK
,	O
neither	O
the	O
mouse	B-UNK
nor	O
the	O
rat	O
protein	B-UNK
has	O
an	O
intact	O
C	O
-	O
terminal	B-UNK
B30	O
.	O

2	O
domain	B-UNK
,	O
in	O
which	O
most	O
FMF	B-UNK
-	O
associated	O
mutations	B-UNK
have	O
been	O
found	O
in	O
human	B-UNK
MEFV	B-UNK
.	O

Nevertheless	O
,	O
like	O
the	O
human	B-UNK
gene	B-UNK
,	O
mouse	B-UNK
Mefv	B-UNK
is	O
expressed	B-UNK
in	O
peripheral	B-UNK
blood	I-UNK
granulocytes	O
but	O
not	O
lymphocytes	O
.	O

Consistent	B-UNK
with	O
its	O
expression	B-UNK
in	O
granulocytes	O
,	O
Mefv	B-UNK
was	O
detected	B-UNK
at	O
high	B-UNK
levels	B-UNK
in	O
the	O
primary	B-UNK
follicles	O
and	O
marginal	O
zones	O
of	O
the	O
splenic	O
white	B-UNK
pulp	O
.	O

Mefv	B-UNK
is	O
localized	B-UNK
on	O
mouse	B-UNK
Chromosome	I-UNK
(	O
Chr	O
)	O
16	O
,	O
region	B-UNK
A3-B1	O
,	O
extending	O
a	O
region	B-UNK
of	O
synteny	O
with	O
human	B-UNK
Chr	O
16p13	O
.	O

3	O
.	O

Development	B-UNK
of	O
knockout	B-UNK
and	O
knockin	O
mouse	B-UNK
models	O
may	O
provide	B-UNK
further	O
insights	O
into	O
the	O
functional	O
evolution	O
of	O
this	O
gene	B-UNK
.	O

Additional	O
copies	O
of	O
the	O
proteolipid	B-UNK
protein	I-UNK
gene	B-UNK
causing	B-UNK
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
arise	O
by	O
separate	O
integration	O
into	O
the	O
X	O
chromosome	B-UNK
.	O

The	O
proteolipid	B-UNK
protein	I-UNK
gene	B-UNK
(	O
PLP	B-UNK
)	O
is	O
normally	O
present	B-UNK
at	O
chromosome	B-UNK
Xq22	O
.	O

Mutations	B-UNK
and	O
duplications	O
of	O
this	O
gene	B-UNK
are	O
associated	O
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
(	O
PMD	B-UNK
)	O
.	O

Here	O
we	O
describe	O
two	O
new	O
families	B-UNK
in	O
which	O
males	B-UNK
affected	B-UNK
with	O
PMD	B-UNK
were	O
found	O
to	O
have	O
a	O
copy	B-UNK
of	O
PLP	B-UNK
on	O
the	O
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
,	O
in	O
addition	B-UNK
to	O
a	O
normal	B-UNK
copy	B-UNK
on	O
Xq22	O
.	O

In	O
the	O
first	O
family	B-UNK
,	O
the	O
extra	O
copy	B-UNK
was	O
first	O
detected	B-UNK
by	O
the	O
presence	O
of	O
heterozygosity	B-UNK
of	O
the	O
AhaII	O
dimorphism	O
within	O
the	O
PLP	B-UNK
gene	B-UNK
.	O

The	O
results	B-UNK
of	O
FISH	B-UNK
analysis	B-UNK
showed	O
an	O
additional	O
copy	B-UNK
of	O
PLP	B-UNK
in	O
Xp22	O
.	O

1	O
,	O
although	O
no	O
chromosomal	B-UNK
rearrangements	O
could	O
be	O
detected	B-UNK
by	O
standard	O
karyotype	O
analysis	B-UNK
.	O

Another	O
three	O
affected	B-UNK
males	I-UNK
from	O
the	O
family	B-UNK
had	O
similar	B-UNK
findings	B-UNK
.	O

In	O
a	O
second	O
unrelated	B-UNK
family	B-UNK
with	O
signs	B-UNK
of	O
PMD	B-UNK
,	O
cytogenetic	B-UNK
analysis	B-UNK
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
X	O
chromosome	B-UNK
.	O

In	O
the	O
inv	O
(	O
X	O
)	O
carried	O
by	O
several	O
affected	B-UNK
family	B-UNK
members	I-UNK
,	O
FISH	B-UNK
showed	O
PLP	B-UNK
signals	O
at	O
Xp11	O
.	O

4	O
and	O
Xq22	O
.	O

A	O
third	O
family	B-UNK
has	O
previously	B-UNK
been	O
reported	B-UNK
,	O
in	O
which	O
affected	B-UNK
members	B-UNK
had	O
an	O
extra	O
copy	B-UNK
of	O
the	O
PLP	B-UNK
gene	B-UNK
detected	B-UNK
at	O
Xq26	O
in	O
a	O
chromosome	B-UNK
with	O
an	O
otherwise	O
normal	B-UNK
banding	O
pattern	B-UNK
.	O

The	O
identification	B-UNK
of	O
three	O
separate	O
families	B-UNK
in	O
which	O
PLP	B-UNK
is	O
duplicated	O
at	O
a	O
noncontiguous	O
site	B-UNK
suggests	O
that	O
such	O
duplications	O
could	O
be	O
a	O
relatively	O
common	B-UNK
but	O
previously	B-UNK
undetected	O
cause	O
of	O
genetic	B-UNK
disorders	B-UNK
.	O

The	O
exon	B-UNK
13	O
duplication	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
is	O
a	O
founder	B-UNK
mutation	B-UNK
present	B-UNK
in	O
geographically	O
diverse	B-UNK
populations	O
.	O

The	O
BRCA1	B-UNK
Exon	B-UNK
13	O
Duplication	B-UNK
Screening	B-UNK
Group	B-UNK
.	O

Recently	O
,	O
a	O
6-kb	O
duplication	B-UNK
of	O
exon	B-UNK
13	O
,	O
which	O
creates	O
a	O
frameshift	B-UNK
in	O
the	O
coding	B-UNK
sequence	I-UNK
of	O
the	O
BRCA1	B-UNK
gene	B-UNK
,	O
has	O
been	O
described	O
in	O
three	O
unrelated	B-UNK
U.	O

S	O
S.	O
families	B-UNK
of	O
European	B-UNK
ancestry	O
and	O
in	O
one	O
Portuguese	O
family	B-UNK
.	O

Here	O
,	O
our	O
goal	O
was	O
to	O
estimate	O
the	O
frequency	B-UNK
and	O
geographic	O
diversity	O
of	O
carriers	B-UNK
of	O
this	O
duplication	B-UNK
.	O

To	O
do	O
this	O
,	O
a	O
collaborative	O
screening	B-UNK
study	B-UNK
was	O
set	B-UNK
up	O
that	O
involved	B-UNK
39	O
institutions	O
from	O
19	O
countries	B-UNK
and	O
included	O
3	O
,	O
580	O
unrelated	B-UNK
individuals	B-UNK
with	O
a	O
family	B-UNK
history	B-UNK
of	O
the	O
disease	B-UNK
and	O
934	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
cases	B-UNK
.	O

A	O
total	B-UNK
of	O
11	O
additional	O
families	B-UNK
carrying	B-UNK
this	O
mutation	B-UNK
were	O
identified	B-UNK
in	O
Australia	O
(	O
1	O
)	O
,	O
Belgium	O
(	O
1	O
)	O
,	O
Canada	O
(	O
1	O
)	O
,	O
Great	O
Britain	O
(	O
6	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
2	O
)	O
.	O

Haplotyping	O
showed	O
that	O
they	O
are	O
likely	O
to	O
derive	O
from	O
a	O
common	B-UNK
ancestor	O
,	O
possibly	O
of	O
northern	B-UNK
British	B-UNK
origin	O
.	O

Our	O
results	B-UNK
demonstrate	B-UNK
that	O
it	O
is	O
strongly	O
advisable	O
,	O
for	O
laboratories	O
carrying	B-UNK
out	O
screening	B-UNK
either	O
in	O
English	O
-	O
speaking	O
countries	B-UNK
or	O
in	O
countries	B-UNK
with	O
historical	O
links	O
with	O
Britain	O
,	O
to	O
include	O
within	O
their	O
BRCA1	B-UNK
screening	B-UNK
protocols	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
based	B-UNK
assay	B-UNK
described	O
in	O
this	O
report	B-UNK
.	O

Genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
in	O
families	B-UNK
with	O
deletions	O
in	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
gene	B-UNK
.	O

Von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
disease	B-UNK
is	O
a	O
hereditary	B-UNK
tumor	B-DISEASE
syndrome	B-UNK
characterized	B-UNK
by	O
predisposition	B-UNK
for	O
bilateral	O
and	O
multi-centric	O
hemangioblastoma	B-DISEASE
in	O
the	O
retina	O
and	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
pheochromocytoma	B-DISEASE
,	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
,	O
and	O
cysts	B-DISEASE
in	O
the	O
kidney	B-UNK
,	O
pancreas	O
,	O
and	O
epididymis	O
.	O

We	O
describe	O
five	O
families	B-UNK
for	O
which	O
direct	B-UNK
sequencing	I-UNK
of	O
the	O
coding	B-UNK
region	I-UNK
of	O
the	O
VHL	B-UNK
gene	B-UNK
had	O
failed	O
to	O
identify	B-UNK
the	O
family	B-UNK
-	O
specific	B-UNK
mutation	B-UNK
.	O

Further	O
molecular	B-UNK
analysis	I-UNK
revealed	B-UNK
deletions	O
involving	O
the	O
VHL	B-UNK
gene	B-UNK
in	O
each	O
of	O
these	O
families	B-UNK
.	O

In	O
four	O
families	B-UNK
,	O
partial	O
deletions	O
of	O
one	O
or	O
more	O
exons	O
were	O
detected	B-UNK
by	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
.	O

In	O
the	O
fifth	O
family	B-UNK
,	O
FISH	B-UNK
analysis	B-UNK
demonstrated	O
the	O
deletion	B-UNK
of	O
the	O
entire	O
VHL	B-UNK
gene	B-UNK
.	O

Our	O
results	B-UNK
show	O
that	O
(	O
quantitative	B-UNK
)	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
is	O
a	O
sensitive	B-UNK
method	O
for	O
detecting	O
germline	B-UNK
deletions	O
of	O
the	O
VHL	B-UNK
gene	B-UNK
and	O
should	O
be	O
implemented	O
in	O
routine	O
DNA	B-UNK
diagnosis	B-UNK
for	O
VHL	B-UNK
disease	B-UNK
.	O

Our	O
data	B-UNK
support	O
the	O
previously	B-UNK
established	O
observation	O
that	O
families	B-UNK
with	O
a	O
germline	B-UNK
deletion	B-UNK
have	O
a	O
low	B-UNK
risk	B-UNK
for	O
pheochromocytoma	B-DISEASE
.	O

Further	O
unraveling	O
of	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
in	O
VHL	B-UNK
disease	B-UNK
has	O
revealed	B-UNK
that	O
families	B-UNK
with	O
a	O
full	O
or	O
partial	O
deletion	B-UNK
of	O
the	O
VHL	B-UNK
gene	B-UNK
exhibit	O
a	O
phenotype	B-UNK
with	O
a	O
preponderance	O
of	O
central	B-UNK
nervous	I-UNK
system	I-UNK
hemangioblastoma	B-DISEASE
..	O

Age	B-UNK
of	O
the	O
intronic	O
GAA	B-UNK
triplet	O
repeat	B-UNK
expansion	I-UNK
mutation	B-UNK
in	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
.	O

Friedreich	B-DISEASE
ataxia	I-DISEASE
(	O
FRDA	B-UNK
)	O
,	O
the	O
most	O
frequently	O
inherited	B-UNK
ataxia	B-UNK
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	B-UNK
to	O
a	O
large	B-UNK
expansion	B-UNK
of	O
an	O
intronic	O
GAA	B-UNK
repeat	B-UNK
.	O

Using	O
linkage	B-UNK
disequilibrium	I-UNK
analysis	B-UNK
based	B-UNK
on	O
haplotype	B-UNK
data	B-UNK
of	O
seven	O
polymorphic	B-UNK
markers	I-UNK
close	B-UNK
to	O
the	O
frataxin	B-UNK
gene	B-UNK
,	O
the	O
age	B-UNK
of	O
FRDA	B-UNK
founding	O
mutational	O
event	O
(	O
s	O
)	O
is	O
estimated	B-UNK
to	O
be	O
at	O
least	O
682	O
+	O
/-203	O
generations	O
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
564	O
-	O
801	O
g	O
)	O
,	O
a	O
dating	O
which	O
is	O
consistent	B-UNK
with	O
little	O
or	O
no	O
negative	B-UNK
selection	B-UNK
and	O
provides	O
further	O
evidence	B-UNK
for	O
an	O
ancient	O
spread	O
of	O
a	O
pre	O
-	O
mutation	B-UNK
(	O
at	O
-	O
risk	B-UNK
alleles	B-UNK
)	O
in	O
western	B-UNK
Europe	B-UNK
..	O

Functional	O
link	O
between	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
and	O
Nijmegen	B-DISEASE
breakage	I-DISEASE
syndrome	I-DISEASE
gene	B-UNK
products	B-UNK
.	O

Ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
and	O
Nijmegen	B-DISEASE
breakage	I-DISEASE
syndrome	I-DISEASE
(	O
NBS	B-UNK
)	O
are	O
recessive	B-UNK
genetic	B-UNK
disorders	B-UNK
with	O
susceptibility	B-UNK
to	O
cancer	B-DISEASE
and	O
similar	B-UNK
cellular	O
phenotypes	O
.	O

The	O
protein	B-UNK
product	I-UNK
of	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
A	O
-T	O
,	O
designated	O
ATM	B-UNK
,	O
is	O
a	O
member	B-UNK
of	O
a	O
family	B-UNK
of	O
kinases	O
characterized	B-UNK
by	O
a	O
carboxy	O
-	O
terminal	B-UNK
phosphatidylinositol	O
3-kinase	O
-	O
like	O
domain	B-UNK
.	O

The	O
NBS1	O
protein	B-UNK
is	O
specifically	B-UNK
mutated	B-UNK
in	O
patients	B-UNK
with	O
Nijmegen	B-DISEASE
breakage	I-DISEASE
syndrome	I-DISEASE
and	O
forms	B-UNK
a	O
complex	O
with	O
the	O
DNA	B-UNK
repair	B-UNK
proteins	B-UNK
Rad50	O
and	O
Mrel1	O
.	O

Here	O
we	O
show	O
that	O
phosphorylation	B-UNK
of	O
NBS1	O
,	O
induced	O
by	O
ionizing	B-UNK
radiation	I-UNK
,	O
requires	O
catalytically	O
active	B-UNK
ATM	B-UNK
.	O

Complexes	O
containing	O
ATM	B-UNK
and	O
NBS1	O
exist	O
in	O
vivo	B-UNK
in	O
both	O
untreated	O
cells	B-UNK
and	O
cells	B-UNK
treated	O
with	O
ionizing	B-UNK
radiation	I-UNK
.	O

We	O
have	O
identified	B-UNK
two	O
residues	O
of	O
NBS1	O
,	O
Ser	O
278	O
and	O
Ser	O
343	O
that	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
ATM	B-UNK
and	O
whose	O
modification	O
in	O
vivo	B-UNK
is	O
essential	B-UNK
for	O
the	O
cellular	O
response	B-UNK
to	O
DNA	B-UNK
damage	I-UNK
.	O

This	O
response	B-UNK
includes	O
S	O
-	O
phase	B-UNK
checkpoint	O
activation	O
,	O
formation	B-UNK
of	O
the	O
NBS1	O
/	O
Mrel1	O
/	O
Rad50	O
nuclear	B-UNK
foci	O
and	O
rescue	O
of	O
hypersensitivity	B-DISEASE
to	O
ionizing	B-UNK
radiation	I-UNK
.	O

Together	O
,	O
these	O
results	B-UNK
demonstrate	B-UNK
a	O
biochemical	O
link	O
between	O
cell	B-UNK
-	O
cycle	O
checkpoints	O
activated	O
by	O
DNA	B-UNK
damage	I-UNK
and	O
DNA	B-UNK
repair	B-UNK
in	O
two	O
genetic	B-UNK
diseases	B-DISEASE
with	O
overlapping	O
phenotypes	O
..	O

Homozygosity	B-UNK
mapping	B-UNK
in	O
a	O
family	B-UNK
with	O
microcephaly	B-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
and	O
short	B-UNK
stature	O
to	O
a	O
Cohen	B-DISEASE
syndrome	I-DISEASE
region	B-UNK
on	O
8q21	O
.	O
3	O
-	O
8q22	O
.	O
1	O
:	O
redefining	O
a	O
clinical	B-UNK
entity	O
.	O

A	O
syndrome	B-DISEASE
of	O
microcephaly	B-DISEASE
,	O
progressive	B-UNK
postnatal	O
growth	B-UNK
deficiency	B-UNK
,	O
and	O
mental	B-UNK
retardation	I-UNK
was	O
observed	B-UNK
in	O
two	O
brothers	O
and	O
their	O
cousin	O
from	O
a	O
multiply	O
consanguineous	O
kindred	O
of	O
Lebanese	O
descent	O
.	O

Hypotonia	B-DISEASE
,	O
chorioretinal	O
dystrophy	B-UNK
,	O
and	O
myopia	B-DISEASE
were	O
also	O
identified	B-UNK
.	O

The	O
severity	B-UNK
of	O
the	O
condition	B-UNK
varied	O
among	O
the	O
closely	B-UNK
related	B-UNK
patients	B-UNK
.	O

Because	O
of	O
absence	B-UNK
of	O
a	O
distinctive	O
facial	B-UNK
appearance	O
,	O
the	O
degree	B-UNK
of	O
mental	B-UNK
retardation	I-UNK
,	O
and	O
short	B-UNK
stature	O
,	O
the	O
initially	O
considered	O
clinical	B-UNK
diagnosis	B-UNK
of	O
Cohen	B-DISEASE
syndrome	I-DISEASE
was	O
withdrawn	O
and	O
a	O
novel	O
genetic	B-UNK
entity	O
was	O
assumed	O
.	O

Homozygosity	B-UNK
mapping	B-UNK
in	O
this	O
family	B-UNK
assigned	O
the	O
gene	B-UNK
to	O
a	O
26	O
.	O

8-cM	O
region	B-UNK
on	O
the	O
chromosome	B-UNK
band	O
8q21	O
.	O

3	O
-	O
22	O
.	O

1	O
,	O
between	O
the	O
microsatellites	O
at	O
D8S270	O
and	O
D8S514	O
.	O

The	O
maximum	B-UNK
two	O
-	O
point	B-UNK
LOD	B-UNK
score	I-UNK
was	O
found	O
for	O
marker	B-UNK
at	O
D8S267	O
(	O
Zmax	O
=	O
3	O
..	O
237	O
at	O
Omax	O
=	O
0	O
.	O
00	O
)	O
.	O

Intriguingly	O
enough	O
,	O
the	O
identified	B-UNK
gene	B-UNK
region	B-UNK
overlaps	O
the	O
refined	O
gene	B-UNK
region	B-UNK
for	O
Cohen	B-DISEASE
syndrome	I-DISEASE
(	O
COH1	O
)	O
[	O
Kolehmainen	O
et	O
al	B-DISEASE
.	O
,	O
1997	O
Euro	O
J	O
Hum	O
Genet	B-UNK
5	O
206	O
-	O
213].	O

This	O
fact	B-UNK
encourages	O
the	O
hypothesis	B-UNK
that	O
the	O
described	O
kindred	O
segregates	O
for	O
a	O
variant	O
of	O
Cohen	B-DISEASE
syndrome	I-DISEASE
and	O
suggests	O
a	O
redefinition	O
of	O
its	O
phenotype	B-UNK

Polymorphisms	B-UNK
of	O
the	O
CYP2D6	O
gene	B-UNK
increase	B-UNK
susceptibility	B-UNK
to	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
.	O

Ankylosing	B-DISEASE
spondylitis	I-DISEASE
(	O
AS	O
)	O
is	O
a	O
common	B-UNK
and	O
highly	B-UNK
familial	B-UNK
rheumatic	O
disorder	B-UNK
.	O

The	O
sibling	O
recurrence	B-DISEASE
risk	B-UNK
ratio	B-UNK
for	O
the	O
disease	B-UNK
is	O
63	O
and	O
heritability	O
assessed	O
in	O
twins	O
>	O
90	O
%	O
.	O

Although	O
MHC	B-UNK
genes	B-UNK
,	O
including	O
HLA	B-UNK
-	O
B27	B-UNK
,	O
contribute	B-UNK
only	O
20	O
-	O
50	O
%	O
of	O
the	O
genetic	B-UNK
risk	B-UNK
for	O
the	O
disease	B-DISEASE
,	O
no	O
non-MHC	O
gene	B-UNK
has	O
yet	O
been	O
convincingly	O
demonstrated	O
to	O
influence	O
either	O
susceptibility	B-UNK
to	O
the	O
disease	B-DISEASE
or	O
its	O
phenotypic	B-UNK
expression	B-UNK
.	O

Previous	B-UNK
linkage	B-UNK
and	O
association	B-UNK
studies	B-UNK
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	B-UNK
gene	I-UNK
for	O
AS	O
close	B-UNK
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	B-UNK
(	O
CYP2D6	O
,	O
debrisoquine	O
hydroxylase	B-UNK
)	O
located	B-UNK
at	O
chromosome	B-UNK
22q13	O
.	O
1	O
.	O

We	O
performed	O
a	O
linkage	B-UNK
study	B-UNK
of	O
chromosome	B-UNK
22	O
in	O
200	O
families	B-UNK
with	O
AS	O
affected	B-UNK
sibling	O
-	O
pairs	B-UNK
.	O

Association	B-UNK
of	O
alleles	B-UNK
of	O
the	O
CYP2D6	O
gene	B-UNK
was	O
examined	O
by	O
both	O
case	B-UNK
-	O
control	B-UNK
and	O
within	O
-	O
family	B-UNK
means	B-UNK
.	O

For	O
case	B-UNK
-	O
control	B-UNK
studies	B-UNK
,	O
617	O
unrelated	B-UNK
individuals	B-UNK
with	O
AS	O
(	O
361	O
probands	O
from	O
sibling	O
-	O
pair	B-UNK
and	O
parent	O
-	O
case	B-UNK
trio	O
families	B-UNK
and	O
256	O
unrelated	B-UNK
non-familial	O
sporadic	B-UNK
cases	B-UNK
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O

For	O
within	O
-	O
family	B-UNK
association	B-UNK
studies	B-UNK
,	O
361	O
families	B-UNK
including	O
161	O
parent	O
-	O
case	B-UNK
trios	O
and	O
200	O
affected	B-UNK
sibling	O
-	O
pair	B-UNK
families	B-UNK
were	O
employed	O
.	O

Homozygosity	B-UNK
for	O
poor	O
metabolizer	O
alleles	B-UNK
was	O
found	O
to	O
be	O
associated	O
with	O
AS	O
.	O

Heterozygosity	B-UNK
for	O
the	O
most	O
frequent	B-UNK
poor	O
metabolizer	O
allele	B-UNK
(	O
CYP2D6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	B-UNK
susceptibility	B-UNK
to	O
AS	O
.	O

Significant	B-UNK
within	O
-	O
family	B-UNK
association	B-UNK
of	O
CYP2D6	O
*	O
4	O
alleles	B-UNK
and	O
AS	O
was	O
demonstrated	O
.	O

Weak	O
linkage	B-UNK
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	O
.	O

We	O
postulate	O
that	O
altered	O
metabolism	B-UNK
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
CYP2D6	O
gene	B-UNK
may	O
increase	B-UNK
susceptibility	B-UNK
to	O
AS	O
.	O

Functional	O
differences	B-UNK
of	O
the	O
PDS	B-UNK
gene	B-UNK
product	I-UNK
are	O
associated	O
with	O
phenotypic	B-UNK
variation	B-UNK
in	O
patients	B-UNK
with	O
Pendred	B-UNK
syndrome	I-UNK
and	O
non-syndromic	O
hearing	B-UNK
loss	I-UNK
(	O
DFNB4	O
)	O
.	O

The	O
PDS	B-UNK
gene	B-UNK
encodes	B-UNK
a	O
transmembrane	B-UNK
protein	B-UNK
,	O
known	O
as	O
pendrin	B-UNK
,	O
which	O
functions	O
as	O
a	O
transporter	B-UNK
of	O
iodide	B-UNK
and	O
chloride	B-UNK
.	O

Mutations	B-UNK
in	O
this	O
gene	B-UNK
are	O
responsible	B-UNK
for	O
Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
autosomal	B-UNK
recessive	I-UNK
non-syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
the	O
DFNB4	O
locus	B-UNK
on	O
chromosome	B-UNK
7q31	O
.	O

A	O
screen	B-UNK
of	O
20	O
individuals	B-UNK
from	O
the	O
midwestern	O
USA	O
with	O
non-syndromic	O
hearing	B-UNK
loss	I-UNK
and	O
dilated	O
vestibular	O
aqueducts	O
identified	B-UNK
three	O
people	O
(	O
15	O
%	O
)	O
with	O
PDS	B-UNK
mutations	B-UNK
.	O

To	O
determine	B-UNK
whether	O
PDS	B-UNK
mutations	B-UNK
in	O
individuals	B-UNK
with	O
Pendred	B-UNK
syndrome	I-UNK
differ	O
functionally	O
from	O
PDS	B-UNK
mutations	B-UNK
in	O
individuals	B-UNK
with	O
non-syndromic	O
hearing	B-UNK
loss	I-UNK
,	O
we	O
compared	B-UNK
three	O
common	B-UNK
Pendred	B-DISEASE
syndrome	I-DISEASE
allele	B-UNK
variants	B-UNK
(	O
L236P	O
,	O
T416P	O
and	O
E384	O
G	O
)	O
,	O
with	O
three	O
PDS	B-UNK
mutations	B-UNK
reported	B-UNK
only	O
in	O
individuals	B-UNK
with	O
non-syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
V480D	O
,	O
V653A	O
and	O
I490L	O
/	O
G497S	O
)	O
.	O

The	O
mutations	B-UNK
associated	O
with	O
Pendred	B-UNK
syndrome	I-UNK
have	O
complete	O
loss	B-UNK
of	O
pendrin	B-UNK
-	O
induced	O
chloride	B-UNK
and	O
iodide	B-UNK
transport	B-UNK
,	O
while	O
alleles	B-UNK
unique	O
to	O
people	O
with	O
DFNB4	O
are	O
able	O
to	O
transport	B-UNK
both	O
iodide	B-UNK
and	O
chloride	B-UNK
,	O
albeit	O
at	O
a	O
much	O
lower	O
level	B-UNK
than	O
wild	B-UNK
-	O
type	B-UNK
pendrin	B-UNK
.	O

We	O
hypothesize	O
that	O
this	O
residual	B-UNK
level	B-UNK
of	O
anion	O
transport	B-UNK
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	B-UNK
of	O
goiter	B-DISEASE
in	O
individuals	B-UNK
with	O
DFNB4	O
.	O

We	O
propose	O
a	O
model	B-UNK
for	O
pendrin	B-UNK
function	B-UNK
in	O
the	O
thyroid	O
in	O
which	O
pendrin	B-UNK
transports	O
iodide	B-UNK
across	O
the	O
apical	O
membrane	B-UNK
of	O
the	O
thyrocyte	O
into	O
the	O
colloid	O
space	O
..	O

The	O
human	B-UNK
factor	B-UNK
IX	O
gene	B-UNK
as	O
germline	B-UNK
mutagen	O
test	B-UNK
:	O
samples	B-UNK
from	O
Mainland	O
China	O
have	O
the	O
putatively	O
endogenous	O
pattern	B-UNK
of	O
mutation	B-UNK
.	O

Germline	B-UNK
mutations	I-UNK
are	O
the	O
major	B-UNK
source	O
of	O
genetic	B-UNK
variation	B-UNK
that	O
allows	O
a	O
species	B-UNK
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
Mendelian	O
disease	B-DISEASE
and	O
genetic	B-UNK
predisposition	B-UNK
to	O
multifactorial	O
diseases	B-UNK
.	O

Previous	B-UNK
analyses	O
have	O
revealed	B-UNK
that	O
the	O
pattern	B-UNK
of	O
germline	B-UNK
mutations	I-UNK
in	O
the	O
factor	B-UNK
IX	O
gene	B-UNK
(	O
F9	O
)	O
is	O
similar	B-UNK
among	O
a	O
variety	O
of	O
ethnically	O
and	O
geographically	O
diverse	B-UNK
populations	O
and	O
compatible	B-UNK
with	O
the	O
ancient	O
pattern	B-UNK
that	O
has	O
shaped	O
the	O
mammalian	O
genome	B-UNK
.	O

Here	O
,	O
we	O
compare	O
the	O
pattern	B-UNK
of	O
germline	B-UNK
mutation	I-UNK
in	O
a	O
population	B-UNK
of	O
hemophilia	B-DISEASE
B	I-DISEASE
patients	B-UNK
from	O
Mainland	O
China	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
U.	O

S.	O

Caucasians	B-UNK
,	O
Blacks	O
,	O
and	O
Mexican	O
Hispanics	O
and	O
stratify	O
by	O
disease	B-DISEASE
severity	B-UNK
and	O
ethnicity	O
.	O

The	O
similar	B-UNK
pattern	B-UNK
of	O
germline	B-UNK
mutation	I-UNK
in	O
all	O
ethnic	B-UNK
groups	I-UNK
studied	O
to	O
date	B-UNK
provides	O
additional	O
data	B-UNK
compatible	B-UNK
with	O
the	O
inference	O
that	O
endogenous	O
processes	O
predominate	O
in	O
germline	B-UNK
mutations	I-UNK
.	O

Fas	B-UNK
preassociation	O
required	B-UNK
for	O
apoptosis	O
signaling	O
and	O
dominant	B-UNK
inhibition	O
by	O
pathogenic	O
mutations	B-UNK
.	O

Heterozygous	B-UNK
mutations	B-UNK
encoding	B-UNK
abnormal	O
forms	B-UNK
of	O
the	O
death	B-UNK
receptor	B-UNK
Fas	B-UNK
dominantly	O
interfere	O
with	O
Fas	B-UNK
-	O
induced	O
lymphocyte	B-UNK
apoptosis	O
in	O
human	B-UNK
autoimmune	B-DISEASE
lymphoproliferative	I-DISEASE
syndrome	I-DISEASE
.	O

This	O
effect	B-UNK
,	O
rather	O
than	O
depending	O
on	O
ligand	O
-	O
induced	O
receptor	B-UNK
oligomerization	O
,	O
was	O
found	O
to	O
stem	B-UNK
from	O
ligand	O
-	O
independent	O
interaction	O
of	O
wild	B-UNK
-	O
type	B-UNK
and	O
mutant	B-UNK
Fas	B-UNK
receptors	O
through	O
a	O
specific	B-UNK
region	B-UNK
in	O
the	O
extracellular	B-UNK
domain	B-UNK
.	O

Preassociated	O
Fas	B-UNK
complexes	O
were	O
found	O
in	O
living	O
cells	B-UNK
by	O
means	B-UNK
of	O
fluorescence	B-UNK
resonance	O
energy	O
transfer	B-UNK
between	O
variants	B-UNK
of	O
green	O
fluorescent	O
protein	B-UNK
.	O

These	O
results	B-UNK
show	O
that	O
formation	B-UNK
of	O
preassociated	O
receptor	B-UNK
complexes	O
is	O
necessary	O
for	O
Fas	B-UNK
signaling	O
and	O
dominant	B-UNK
interference	O
in	O
human	B-UNK
disease	B-UNK
..	O

Determination	B-UNK
of	O
carrier	B-UNK
status	I-UNK
for	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
by	O
flow	O
cytometric	O
analysis	B-UNK
of	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
protein	B-UNK
expression	B-UNK
in	O
peripheral	B-UNK
blood	I-UNK
mononuclear	O
cells	B-UNK
.	O

The	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
is	O
caused	B-UNK
by	O
defects	B-UNK
in	O
the	O
WAS	O
protein	B-UNK
(	O
WASP	B-UNK
)	O
gene	B-UNK
on	O
the	O
X	O
chromosome	B-UNK
.	O

Previous	B-UNK
study	B-UNK
disclosed	O
that	O
flow	O
cytometric	O
analysis	B-UNK
of	O
intracellular	O
WASP	B-UNK
expression	B-UNK
(	O
FCM	O
-	O
WASP	B-UNK
analysis	B-UNK
)	O
in	O
lymphocytes	O
was	O
useful	O
for	O
the	O
diagnosis	B-UNK
of	O
WAS	O
patients	B-UNK
.	O

Lymphocytes	O
from	O
all	O
WAS	O
patients	B-UNK
showed	O
WASPdim	O
instead	O
of	O
WASPbright	O
.	O

Here	O
we	O
report	B-UNK
that	O
FCM	O
-	O
WASP	B-UNK
analysis	B-UNK
in	O
monocytes	O
could	O
be	O
a	O
useful	O
tool	O
for	O
the	O
WAS	O
carrier	B-UNK
diagnosis	B-UNK
.	O

Monocytes	O
from	O
all	O
nine	O
WAS	O
carriers	B-UNK
showed	O
varied	O
population	B-UNK
of	O
WASPdim	O
together	O
with	O
WASPbright	O
.	O

None	O
of	O
control	B-UNK
individuals	B-UNK
possessed	O
the	O
WASPdim	O
population	B-UNK
.	O

In	O
contrast	B-UNK
,	O
lymphocytes	O
from	O
all	O
the	O
carriers	B-UNK
except	O
two	O
lacked	O
the	O
WASPdim	O
population	B-UNK
.	O

The	O
difference	O
of	O
the	O
WASPdim	O
population	B-UNK
in	O
monocytes	O
and	O
lymphocytes	O
observed	B-UNK
in	O
WAS	O
carriers	B-UNK
suggests	O
that	O
WASP	B-UNK
plays	O
a	O
more	O
critical	B-UNK
role	B-UNK
in	O
the	O
development	B-UNK
of	O
lymphocytes	O
than	O
in	O
that	O
of	O
monocytes	O
.	O

The	O
present	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
a	O
skewed	O
X	O
-	O
chromosomal	B-UNK
inactivation	B-UNK
pattern	B-UNK
observed	B-UNK
in	O
WAS	O
carrier	B-UNK
peripheral	B-UNK
blood	I-UNK
cells	B-UNK
is	O
not	O
fixed	O
at	O
the	O
hemopoietic	O
stem	B-UNK
cell	B-UNK
level	B-UNK
but	O
progresses	O
after	O
the	O
lineage	O
commitment	O
..	O

Restoration	O
of	O
photoreceptor	B-UNK
ultrastructure	O
and	O
function	B-UNK
in	O
retinal	B-DISEASE
degeneration	I-DISEASE
slow	O
mice	B-UNK
by	O
gene	B-UNK
therapy	B-UNK
.	O

The	O
gene	B-UNK
Prph2	O
encodes	B-UNK
a	O
photoreceptor	B-UNK
-	O
specific	B-UNK
membrane	B-UNK
glycoprotein	O
,	O
peripherin-2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	B-UNK
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	B-UNK
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom-1	O
(	O
ref	O
.	O
2	O
)	O
.	O

The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	B-UNK
,	O
and	O
which	O
contain	O
the	O
visual	B-UNK
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O

Mutations	B-UNK
in	O
Prph2	O
have	O
been	O
shown	B-UNK
to	O
result	B-UNK
in	O
a	O
variety	O
of	O
photoreceptor	B-UNK
dystrophies	O
,	O
including	O
autosomal	B-UNK
dominant	I-UNK
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
macular	B-UNK
dystrophy	B-UNK
.	O

A	O
common	B-UNK
feature	O
of	O
these	O
diseases	B-DISEASE
is	O
the	O
loss	B-UNK
of	O
photoreceptor	B-UNK
function	B-UNK
,	O
also	O
seen	O
in	O
the	O
retinal	B-DISEASE
degeneration	I-DISEASE
slow	O
(	O
rds	B-UNK
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	B-UNK
,	O
which	O
is	O
homozygous	B-UNK
for	O
a	O
null	O
mutation	B-UNK
in	O
Prph2	O
.	O

It	O
is	O
characterized	B-UNK
by	O
a	O
complete	O
failure	B-UNK
to	O
develop	O
photoreceptor	B-UNK
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	B-UNK
of	O
photoreceptor	B-UNK
cells	B-UNK
.	O

The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	B-UNK
have	O
greatly	O
diminished	O
a	O
-	O
wave	O
and	O
b	O
-	O
wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O

Subretinal	O
injection	O
of	O
recombinant	B-UNK
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
encoding	B-UNK
a	O
Prph2	O
transgene	O
results	B-UNK
in	O
stable	B-UNK
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	B-UNK
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin-2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	B-UNK
are	O
morphologically	O
similar	B-UNK
to	O
normal	B-UNK
outer	O
segments	O
.	O

Moreover	O
,	O
the	O
re-establishment	O
of	O
the	O
structural	B-UNK
integrity	O
of	O
the	O
photoreceptor	B-UNK
layer	O
also	O
results	B-UNK
in	O
electrophysiological	O
correction	O
.	O

These	O
studies	B-UNK
demonstrate	B-UNK
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	B-UNK
defect	B-UNK
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	B-UNK
gene	B-UNK
transfer	B-UNK
..	O

Mutations	B-UNK
in	O
the	O
fibrinogen	O
aalpha	O
gene	B-UNK
account	B-UNK
for	O
the	O
majority	O
of	O
cases	B-UNK
of	O
congenital	B-UNK
afibrinogenemia	B-DISEASE
.	O

Congenital	B-UNK
afibrinogenemia	B-DISEASE
is	O
a	O
rare	B-UNK
,	O
autosomal	B-UNK
,	O
recessive	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
the	O
complete	O
absence	B-UNK
of	O
detectable	O
fibrinogen	O
.	O

We	O
previously	B-UNK
identified	I-UNK
the	O
first	O
causative	O
mutations	B-UNK
in	O
a	O
nonconsanguineous	O
Swiss	O
family	B-UNK
;	O
the	O
4	O
affected	B-UNK
persons	O
have	O
homozygous	B-UNK
deletions	O
of	O
approximately	O
11	O
kb	B-UNK
of	O
the	O
fibrinogen	O
alpha	B-UNK
(	O
FGA	O
)	O
gene	B-UNK
.	O

Haplotype	B-UNK
data	B-UNK
implied	O
that	O
these	O
deletions	O
occurred	B-UNK
on	O
distinct	O
ancestral	O
chromosomes	O
,	O
suggesting	O
that	O
this	O
region	B-UNK
may	O
be	O
susceptible	O
to	O
deletion	B-UNK
by	O
a	O
common	B-UNK
mechanism	B-UNK
.	O

We	O
subsequently	B-UNK
showed	O
that	O
all	O
the	O
deletions	O
were	O
identical	B-UNK
to	O
the	O
base	B-UNK
pair	I-UNK
and	O
probably	O
resulted	B-UNK
from	O
a	O
nonhomologous	O
recombination	B-UNK
mediated	O
by	O
7-bp	O
direct	B-UNK
repeats	B-UNK
.	O

In	O
this	O
study	B-UNK
,	O
we	O
have	O
collected	O
data	B-UNK
on	O
13	O
additional	O
unrelated	B-UNK
patients	B-UNK
to	O
identify	B-UNK
the	O
causative	O
mutations	B-UNK
and	O
to	O
determine	B-UNK
the	O
prevalence	B-UNK
of	O
the	O
11-kb	O
deletion	B-UNK
.	O

A	O
common	B-UNK
recurrent	O
mutation	B-UNK
,	O
at	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
of	O
FGA	O
intron	B-UNK
4	O
(	O
IVS4	O
+	O
1	O
G	O
>	O
T	O
)	O
,	O
accounted	O
for	O
14	O
of	O
the	O
26	O
(	O
54	O
%	O
)	O
alleles	B-UNK
.	O

One	O
patient	B-UNK
was	O
heterozygous	B-UNK
for	O
the	O
previously	B-UNK
identified	I-UNK
deletion	B-UNK
.	O

Three	O
more	O
frameshift	B-UNK
mutations	B-UNK
,	O
2	O
nonsense	B-UNK
mutations	I-UNK
,	O
and	O
a	O
second	O
splice	B-UNK
site	I-UNK
mutation	I-UNK
were	O
also	O
identified	B-UNK
.	O

Consequently	O
,	O
86	O
%	O
of	O
afibrinogenemia	B-DISEASE
alleles	B-UNK
analyzed	B-UNK
to	O
date	B-UNK
have	O
truncating	B-UNK
mutations	I-UNK
of	O
FGA	O
,	O
though	O
mutations	B-UNK
in	O
all	O
3	O
fibrinogen	O
genes	B-UNK
,	O
FGG	O
,	O
FGA	O
,	O
and	O
FGB	O
,	O
might	O
be	O
predicted	B-UNK
to	O
cause	O
congenital	B-UNK
afibrinogenemia	B-DISEASE
..	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
:	O
the	O
role	B-UNK
of	O
the	O
CUG	B-UNK
triplet	O
repeats	B-UNK
in	O
splicing	B-UNK
of	O
a	O
novel	O
DMPK	B-UNK
exon	B-UNK
and	O
altered	O
cytoplasmic	O
DMPK	B-UNK
mRNA	O
isoform	O
ratios	O
.	O

The	O
mechanism	B-UNK
by	O
which	O
(	O
CTG	B-UNK
)	O
n	O
expansion	B-UNK
in	O
the	O
3	O
UTR	B-UNK
of	O
the	O
DMPK	B-UNK
gene	B-UNK
causes	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-DISEASE
)	O
is	O
unknown	O
.	O

We	O
identified	B-UNK
four	O
RNA	B-UNK
splicing	B-UNK
factors	O
--	O
hnRNP	O
C	O
,	O
U2AF	O
(	O
U2	O
auxiliary	O
factor	B-UNK
)	O
,	O
PTB	O
(	O
polypyrimidine	O
tract	O
binding	B-UNK
protein	B-UNK
)	O
,	O
and	O
PSF	O
(	O
PTB	O
associated	O
splicing	B-UNK
factor)--that	O
bind	O
to	O
two	O
short	B-UNK
regions	B-UNK
3	O
of	O
the	O
(	O
CUG	B-UNK
)	O
n	O
,	O
and	O
found	O
a	O
novel	O
3	O
DMPK	B-UNK
exon	B-UNK
resulting	B-UNK
in	O
an	O
mRNA	O
lacking	O
the	O
repeats	B-UNK
.	O

We	O
propose	O
that	O
the	O
(	O
CUG	B-UNK
)	O
n	O
is	O
an	O
essential	B-UNK
cis	B-UNK
acting	O
element	O
for	O
this	O
splicing	B-UNK
event	O
.	O

In	O
contrast	B-UNK
to	O
(	O
CUG	B-UNK
)	O
n	O
containing	O
mRNAs	O
,	O
the	O
novel	O
isoform	O
is	O
not	O
retained	O
in	O
the	O
nucleus	O
in	O
DM	B-DISEASE
cells	B-UNK
,	O
resulting	B-UNK
in	O
imbalances	O
in	O
relative	B-UNK
levels	B-UNK
of	O
cytoplasmic	O
DMPK	B-UNK
mRNA	O
isoforms	O
and	O
a	O
new	O
dominant	B-UNK
effect	B-UNK
of	O
the	O
mutation	B-UNK
on	O
DMPK	B-UNK
..	O

Expression	B-UNK
and	O
imprinting	B-UNK
of	O
MAGEL2	B-UNK
suggest	B-UNK
a	O
role	B-UNK
in	O
Prader	B-DISEASE
-	I-DISEASE
willi	I-DISEASE
syndrome	I-DISEASE
and	O
the	O
homologous	B-UNK
murine	O
imprinting	B-UNK
phenotype	B-UNK
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
is	O
caused	B-UNK
by	O
the	O
loss	B-UNK
of	O
expression	B-UNK
of	O
imprinted	O
genes	B-UNK
in	O
chromosome	B-UNK
15q11-q13	O
.	O

Affected	B-UNK
individuals	I-UNK
exhibit	O
neonatal	B-UNK
hypotonia	B-DISEASE
,	O
developmental	O
delay	O
and	O
childhood	O
-	O
onset	B-UNK
obesity	B-DISEASE
.	O

Necdin	O
,	O
a	O
protein	B-UNK
implicated	B-UNK
in	O
the	O
terminal	B-UNK
differentiation	B-UNK
of	O
neurons	O
,	O
is	O
the	O
only	O
PWS	B-UNK
candidate	B-UNK
gene	I-UNK
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	B-UNK
model	I-UNK
.	O

In	O
this	O
study	B-UNK
,	O
we	O
have	O
characterized	B-UNK
MAGEL2	B-UNK
(	O
also	O
known	O
as	O
NDNL1	O
)	O
,	O
a	O
gene	B-UNK
with	O
51	O
%	O
amino	B-UNK
acid	I-UNK
sequence	B-UNK
similarity	O
to	O
necdin	O
and	O
located	B-UNK
41	O
kb	B-UNK
distal	B-UNK
to	O
NDN	O
in	O
the	O
PWS	B-UNK
deletion	B-UNK
region	B-UNK
.	O

MAGEL2	B-UNK
is	O
expressed	B-UNK
predominantly	O
in	O
brain	B-UNK
,	O
the	O
primary	B-UNK
tissue	B-UNK
affected	B-UNK
in	O
PWS	B-UNK
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	B-UNK
by	O
northern	B-UNK
blot	B-UNK
analysis	B-UNK
.	O

MAGEL2	B-UNK
is	O
imprinted	O
with	O
monoallelic	O
expression	B-UNK
in	O
control	B-UNK
brain	B-UNK
,	O
and	O
paternal	O
-	O
only	O
expression	B-UNK
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
as	O
demonstrated	O
by	O
its	O
lack	B-UNK
of	O
expression	B-UNK
in	O
brain	B-UNK
from	O
a	O
PWS	B-UNK
-	O
affected	B-UNK
individual	O
.	O

The	O
orthologous	O
mouse	B-UNK
gene	B-UNK
(	O
Magel2	B-UNK
)	O
is	O
located	B-UNK
within	O
150	O
kb	B-UNK
of	O
NDN	O
,	O
is	O
imprinted	O
with	O
paternal	O
-	O
only	O
expression	B-UNK
and	O
is	O
expressed	B-UNK
predominantly	O
in	O
late	B-UNK
developmental	O
stages	O
and	O
adult	B-UNK
brain	B-UNK
as	O
shown	B-UNK
by	O
northern	B-UNK
blotting	O
,	O
RT	O
-	O
PCR	B-UNK
and	O
whole	O
-	O
mount	O
RNA	B-UNK
in	B-UNK
situ	I-UNK
hybridization	I-UNK
.	O

Magel2	B-UNK
distribution	B-UNK
partially	O
overlaps	O
that	O
of	O
NDN	O
,	O
with	O
strong	B-UNK
expression	B-UNK
being	O
detected	B-UNK
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
in	O
mid	O
-	O
gestation	O
mouse	B-UNK
embryos	B-UNK
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
.	O

We	O
hypothesize	O
that	O
,	O
although	O
loss	B-UNK
of	O
necdin	O
expression	B-UNK
may	O
be	O
important	O
in	O
the	O
neonatal	B-UNK
presentation	O
of	O
PWS	B-UNK
,	O
loss	B-UNK
of	O
MAGEL2	B-UNK
may	O
be	O
critical	B-UNK
to	O
abnormalities	B-UNK
in	O
brain	B-UNK
development	B-UNK
and	O
dysmorphic	O
features	B-UNK
in	O
individuals	B-UNK
with	O
PWS	B-UNK
..	O

Retinoschisin	O
,	O
the	O
X	O
-	O
linked	B-UNK
retinoschisis	B-DISEASE
protein	B-UNK
,	O
is	O
a	O
secreted	O
photoreceptor	B-UNK
protein	B-UNK
,	O
and	O
is	O
expressed	B-UNK
and	O
released	O
by	O
Weri	O
-	O
Rb1	B-UNK
cells	B-UNK
.	O

X	O
-	O
linked	B-UNK
retinoschisis	B-DISEASE
is	O
characterized	B-UNK
by	O
microcystic	O
-	O
like	O
changes	O
of	O
the	O
macular	B-UNK
region	B-UNK
and	O
schisis	O
within	O
the	O
inner	O
retinal	B-UNK
layers	O
,	O
leading	B-UNK
to	O
visual	B-UNK
deterioration	O
in	O
males	B-UNK
.	O

Many	O
missense	B-UNK
and	O
protein	B-UNK
-	O
truncating	B-UNK
mutations	I-UNK
of	O
the	O
causative	O
gene	B-UNK
RS1	O
have	O
now	O
been	O
identified	B-UNK
and	O
are	O
thought	B-UNK
to	O
be	O
inactivating	O
.	O

RS1	O
encodes	B-UNK
a	O
224	O
amino	B-UNK
acid	I-UNK
protein	B-UNK
,	O
retinoschisin	O
,	O
which	O
contains	O
a	O
discoidin	O
domain	B-UNK
but	O
is	O
of	O
unknown	O
function	B-UNK
.	O

We	O
have	O
generated	O
a	O
polyclonal	O
antibody	B-UNK
against	O
a	O
peptide	B-UNK
from	O
a	O
unique	O
region	B-UNK
within	O
retinoschisin	O
,	O
which	O
detects	O
a	O
protein	B-UNK
of	O
approximately	O
28	O
kDa	O
in	O
retinal	B-UNK
samples	B-UNK
reduced	O
with	O
dithiothreitol	O
,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non-reducing	O
conditions	O
.	O

A	O
screen	B-UNK
of	O
human	B-UNK
tissues	O
with	O
this	O
antibody	B-UNK
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	B-UNK
and	O
the	O
antibody	B-UNK
detects	O
a	O
protein	B-UNK
of	O
similar	B-UNK
size	B-UNK
in	O
bovine	O
and	O
murine	O
retinae	O
.	O

We	O
investigated	O
the	O
expression	B-UNK
pattern	B-UNK
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(	O
using	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
with	O
riboprobes	O
)	O
and	O
retinoschisin	O
(	O
using	O
immunohistochemistry	O
)	O
.	O

The	O
antisense	O
riboprobe	O
detected	B-UNK
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	B-UNK
layer	O
but	O
the	O
protein	B-UNK
product	I-UNK
of	O
the	O
gene	B-UNK
was	O
present	B-UNK
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina	O
.	O

Furthermore	O
,	O
differentiated	O
retinoblastoma	B-DISEASE
cells	B-UNK
(	O
Weri	O
-	O
Rb1	B-UNK
cells	B-UNK
)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin	O
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
retinoschisin	O
is	O
released	O
by	O
photo-receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	B-UNK
layers	O
.	O

Thus	O
,	O
X	O
-	O
linked	B-UNK
retinoschisis	B-DISEASE
is	O
caused	B-UNK
by	O
abnormalities	B-UNK
in	O
a	O
putative	O
secreted	O
photoreceptor	B-UNK
protein	B-UNK
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo-receptor	O
protein	B-UNK
associated	O
with	O
a	O
retinal	B-UNK
dystrophy	B-UNK
..	O

Study	B-UNK
of	O
the	O
voltage	O
-	O
gated	O
sodium	B-UNK
channel	B-UNK
beta	B-UNK
1	O
subunit	B-UNK
gene	B-UNK
(	O
SCN1B	O
)	O
in	O
the	O
benign	O
familial	B-UNK
infantile	B-UNK
convulsions	B-DISEASE
syndrome	B-DISEASE
(	O
BFIC	O
)	O
.	O

Benign	O
familial	B-UNK
infantile	B-UNK
convulsions	B-DISEASE
(	O
BFIC	O
)	O
is	O
a	O
rare	B-UNK
autosomal	B-UNK
dominant	I-UNK
epilepsy	B-DISEASE
syndrome	B-UNK
.	O

This	O
syndrome	B-DISEASE
has	O
been	O
recently	O
described	O
in	O
Italian	B-UNK
and	O
French	B-UNK
pedigrees	O
.	O

Patients	B-UNK
present	B-UNK
with	O
partial	O
,	O
then	O
generalized	B-DISEASE
seizures	I-DISEASE
,	O
with	O
onset	B-UNK
at	O
age	B-UNK
three	O
months	O
.	O

The	O
seizures	B-DISEASE
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B-DISEASE
abnormalities	I-DISEASE
.	O

We	O
have	O
mapped	B-UNK
BFIC	O
to	O
chromosome	B-UNK
19q	O
in	O
five	O
Italian	B-UNK
pedigrees	O
.	O

The	O
sodium	B-UNK
channel	B-UNK
beta1	O
subunit	B-UNK
gene	B-UNK
(	O
SCN1B	O
)	O
maps	B-UNK
to	O
this	O
candidate	B-UNK
region	B-UNK
and	O
has	O
been	O
shown	B-UNK
to	O
be	O
involved	B-UNK
in	O
one	O
Australian	O
pedigree	B-UNK
with	O
generalized	B-UNK
epilepsy	B-DISEASE
and	O
febrile	B-DISEASE
seizures	I-DISEASE
"	O
plus	O
"	O
(	O
GEFS	O
+	O
)	O
.	O

In	O
this	O
family	B-UNK
,	O
a	O
missense	B-UNK
mutation	I-UNK
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	O
+	O
phenotype	B-UNK
.	O

BFIC	O
and	O
GEFS	O
+	O
have	O
clinical	B-UNK
features	I-UNK
in	O
common	B-UNK
,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	B-UNK
gene	I-UNK
for	O
BFIC	O
.	O

We	O
studied	O
SCN1B	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
SSCP	B-UNK
methods	O
in	O
10	O
Caucasian	B-UNK
BFIC	O
probands	O
of	O
Western	B-UNK
Europe	B-UNK
.	O

We	O
found	O
no	O
exon	B-UNK
variants	B-UNK
.	O

One	O
variant	O
was	O
identified	B-UNK
in	O
intron	B-UNK
5	O
(	O
IVS5	O
-	O
10C	O
>	O
G	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	O
and	O
was	O
observed	B-UNK
in	O
9	O
.	O

2	O
%	O
controls	O
.	O

A	O
second	O
variant	O
in	O
intron	B-UNK
5	O
was	O
identified	B-UNK
(	O
IVS5	O
+	O
30	O
G	O
>	O
A	O
)	O
.	O

It	O
was	O
rare	B-UNK
,	O
as	O
not	O
observed	B-UNK
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	O
phenotype	B-UNK
.	O

Inactivation	B-UNK
of	O
germline	B-UNK
mutant	B-UNK
APC	B-UNK
alleles	B-UNK
by	O
attenuated	B-UNK
somatic	B-UNK
mutations	I-UNK
:	O
a	O
molecular	B-UNK
genetic	I-UNK
mechanism	B-UNK
for	O
attenuated	B-DISEASE
familial	I-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
.	O

Germline	B-UNK
mutations	I-UNK
of	O
the	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
APC	B-UNK
)	O
tumor	B-DISEASE
-	O
suppressor	B-UNK
gene	B-UNK
result	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
.	O

Patients	B-UNK
with	O
FAP	B-UNK
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	O
colorectal	B-UNK
tumors	I-UNK
and	O
early	B-UNK
-	O
onset	B-UNK
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

A	O
subset	O
of	O
germline	B-UNK
APC	B-UNK
mutations	B-UNK
results	B-UNK
in	O
an	O
attenuated	B-UNK
FAP	B-UNK
(	O
AFAP	O
)	O
phenotype	B-UNK
,	O
in	O
which	O
patients	B-UNK
develop	O
fewer	O
tumors	B-DISEASE
and	O
develop	O
them	O
at	O
an	O
older	O
age	B-UNK
.	O

Although	O
a	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
between	O
the	O
locations	O
of	O
APC	B-UNK
germline	B-UNK
mutations	I-UNK
and	O
the	O
development	B-UNK
of	O
AFAP	O
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	B-UNK
for	O
AFAP	O
has	O
not	O
been	O
well	O
defined	B-UNK
.	O

We	O
investigated	O
the	O
mechanism	B-UNK
for	O
AFAP	O
in	O
patients	B-UNK
carrying	B-UNK
a	O
mutant	B-UNK
APC	B-UNK
allele	B-UNK
(	O
APC	B-UNK
(	O
AS9	O
)	O
)	O
that	O
has	O
a	O
mutation	B-UNK
in	O
the	O
alternatively	O
spliced	O
region	B-UNK
of	O
exon	B-UNK
9	O
.	O

APC	B-UNK
(	O
AS9	O
)	O
was	O
found	O
to	O
down	O
-	O
regulate	O
beta-catenin-regulated	O
transcription	B-UNK
,	O
the	O
major	B-UNK
tumor	B-DISEASE
-	O
suppressor	B-UNK
function	B-UNK
of	O
APC	B-UNK
,	O
as	O
did	O
the	O
wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
.	O

Mutation	B-UNK
analysis	B-UNK
showed	O
that	O
both	O
APC	B-UNK
(	O
AS9	O
)	O
and	O
the	O
wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
alleles	B-UNK
were	O
somatically	O
mutated	B-UNK
in	O
most	O
colorectal	B-UNK
tumors	I-UNK
from	O
these	O
patients	B-UNK
.	O

Functional	O
analysis	B-UNK
showed	O
that	O
4666insA	O
,	O
a	O
common	B-UNK
somatic	B-UNK
mutation	B-UNK
in	O
APC	B-UNK
(	O
AS9	O
)	O
in	O
these	O
tumors	B-UNK
,	O
did	O
not	O
inactivate	O
the	O
wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
.	O

Our	O
results	B-UNK
indicate	O
that	O
carriers	B-UNK
of	O
APC	B-UNK
(	O
AS9	O
)	O
develop	O
fewer	O
colorectal	B-UNK
tumors	I-UNK
than	O
do	O
typical	O
patients	B-UNK
with	O
FAP	B-UNK
because	O
somatic	B-UNK
inactivation	B-UNK
of	O
both	O
APC	B-UNK
alleles	B-UNK
is	O
necessary	O
for	O
colorectal	B-UNK
tumorigenesis	O
.	O

However	O
,	O
these	O
patients	B-UNK
develop	O
colorectal	B-UNK
tumors	I-UNK
more	O
frequently	O
than	O
does	O
the	O
general	B-UNK
population	B-UNK
because	O
APC	B-UNK
(	O
AS9	O
)	O
is	O
inactivated	O
by	O
mutations	B-UNK
that	O
do	O
not	O
inactivate	O
the	O
wild	B-UNK
-	O
type	B-UNK
APC	B-UNK
..	O

Iron	B-UNK
-	O
dependent	B-UNK
self	O
-	O
assembly	O
of	O
recombinant	B-UNK
yeast	B-UNK
frataxin	B-UNK
:	O
implications	B-UNK
for	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
.	O

Frataxin	B-UNK
deficiency	B-UNK
is	O
the	O
primary	B-UNK
cause	O
of	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
(	O
FRDA	B-UNK
)	O
,	O
an	O
autosomal	B-UNK
recessive	I-UNK
cardiodegenerative	O
and	O
neurodegenerative	B-DISEASE
disease	I-DISEASE
.	O

Frataxin	B-UNK
is	O
a	O
nuclear	B-UNK
-	O
encoded	B-UNK
mitochondrial	B-UNK
protein	B-UNK
that	O
is	O
widely	O
conserved	B-UNK
among	O
eukaryotes	O
.	O

Genetic	B-UNK
inactivation	B-UNK
of	O
the	O
yeast	B-UNK
frataxin	B-UNK
homologue	B-UNK
(	O
Yfh1p	O
)	O
results	B-UNK
in	O
mitochondrial	B-UNK
iron	B-UNK
accumulation	B-UNK
and	O
hypersensitivity	B-DISEASE
to	O
oxidative	O
stress	B-DISEASE
.	O

Increased	B-UNK
iron	B-UNK
deposition	O
and	O
evidence	B-UNK
of	O
oxidative	O
damage	B-UNK
have	O
also	O
been	O
observed	B-UNK
in	O
cardiac	B-UNK
tissue	B-UNK
and	O
cultured	O
fibroblasts	B-UNK
from	O
patients	B-UNK
with	O
FRDA	B-UNK
.	O

These	O
findings	B-UNK
indicate	O
that	O
frataxin	B-UNK
is	O
essential	B-UNK
for	O
mitochondrial	B-UNK
iron	B-UNK
homeostasis	O
and	O
protection	O
from	O
iron	B-UNK
-	O
induced	O
formation	B-UNK
of	O
free	O
radicals	O
.	O

The	O
functional	O
mechanism	B-UNK
of	O
frataxin	B-UNK
,	O
however	O
,	O
is	O
still	O
unknown	O
.	O

We	O
have	O
expressed	B-UNK
the	O
mature	O
form	B-UNK
of	O
Yfh1p	O
(	O
mYfh1p	O
)	O
in	O
Escherichia	O
coli	B-UNK
and	O
have	O
analyzed	B-UNK
its	O
function	B-UNK
in	O
vitro	O
.	O

Isolated	B-UNK
mYfh1p	O
is	O
a	O
soluble	O
monomer	O
(	O
13	O
,	O
783	O
Da	O
)	O
that	O
contains	O
no	O
iron	B-UNK
and	O
shows	O
no	O
significant	B-UNK
tendency	O
to	O
self	O
-	O
associate	O
.	O

Aerobic	O
addition	B-UNK
of	O
ferrous	O
iron	B-UNK
to	O
mYfh1p	O
results	B-UNK
in	O
assembly	O
of	O
regular	O
spherical	O
multimers	O
with	O
a	O
molecular	B-UNK
mass	B-UNK
of	O
approximately	O
1	O
.	O

1	O
MDa	O
(	O
megadaltons	O
)	O
and	O
a	O
diameter	O
of	O
13	O
+	O
/-2	O
nm	O
.	O

Each	O
multimer	O
consists	O
of	O
approximately	O
60	O
subunits	O
and	O
can	O
sequester	O
>	O
3	O
,	O
000	O
atoms	O
of	O
iron	B-UNK
.	O

Titration	O
of	O
mYfh1p	O
with	O
increasing	O
iron	B-UNK
concentrations	O
supports	O
a	O
stepwise	O
mechanism	B-UNK
of	O
multimer	O
assembly	O
.	O

Sequential	O
addition	B-UNK
of	O
an	O
iron	B-UNK
chelator	O
and	O
a	O
reducing	O
agent	O
results	B-UNK
in	O
quantitative	B-UNK
iron	B-UNK
release	O
with	O
concomitant	O
disassembly	O
of	O
the	O
multimer	O
,	O
indicating	O
that	O
mYfh1p	O
sequesters	O
iron	B-UNK
in	O
an	O
available	O
form	B-UNK
.	O

In	O
yeast	B-UNK
mitochondria	O
,	O
native	O
mYfh1p	O
exists	O
as	O
monomer	O
and	O
a	O
higher	O
-	O
order	B-UNK
species	B-UNK
with	O
a	O
molecular	B-UNK
weight	O
>	O
600	O
,	O
000	O
.	O

After	O
addition	B-UNK
of	O
(	O
55	O
)	O
Fe	O
to	O
the	O
medium	O
,	O
immunoprecipitates	O
of	O
this	O
species	B-UNK
contain	O
>	O
16	O
atoms	O
of	O
(	O
55	O
)	O
Fe	O
per	O
molecule	O
of	O
mYfh1p	O
.	O

We	O
propose	O
that	O
iron	B-UNK
-	O
dependent	B-UNK
self	O
-	O
assembly	O
of	O
recombinant	B-UNK
mYfh1p	O
reflects	O
a	O
physiological	O
role	B-UNK
for	O
frataxin	B-UNK
in	O
mitochondrial	B-UNK
iron	B-UNK
sequestration	O
and	O
bioavailability	O
..	O

A	O
mutation	B-UNK
in	O
the	O
pleckstrin	O
homology	B-UNK
(	O
PH	B-UNK
)	O
domain	B-UNK
of	O
the	O
FGD1	O
gene	B-UNK
in	O
an	O
Italian	B-UNK
family	B-UNK
with	O
faciogenital	O
dysplasia	B-UNK
(	O
Aarskog	O
-	O
Scott	B-DISEASE
syndrome	I-DISEASE
)	O
.	O

Aarskog	O
-	O
Scott	B-DISEASE
Syndrome	I-DISEASE
(	O
AAS	O
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
disorder	B-UNK
characterised	O
by	O
short	B-UNK
stature	O
and	O
multiple	B-UNK
facial	B-UNK
,	O
limb	O
and	O
genital	O
abnormalities	B-UNK
.	O

A	O
gene	B-UNK
,	O
FGD1	O
,	O
altered	O
in	O
a	O
patient	B-UNK
with	O
AAS	O
phenotype	B-UNK
,	O
has	O
been	O
identified	B-UNK
and	O
found	O
to	O
encode	O
a	O
protein	B-UNK
with	O
homology	B-UNK
to	O
Rho	O
/	O
Rac	O
guanine	B-UNK
nucleotide	B-UNK
exchange	O
factors	O
(	O
Rho	O
/	O
Rac	O
GEF	O
)	O
.	O

However	O
,	O
since	O
this	O
original	O
report	B-UNK
on	O
identification	B-UNK
of	O
a	O
mutated	B-UNK
FGD1	O
gene	B-UNK
in	O
an	O
AAS	O
patient	B-UNK
,	O
no	O
additional	O
mutations	B-UNK
in	O
the	O
FGD1	O
gene	B-UNK
have	O
been	O
described	O
.	O

We	O
analysed	O
13	O
independent	O
patients	B-UNK
with	O
clinical	B-UNK
diagnosis	B-UNK
of	O
AAS	O
.	O

One	O
patient	B-UNK
presented	B-UNK
a	O
mutation	B-UNK
that	O
results	B-UNK
in	O
a	O
nucleotide	B-UNK
change	B-UNK
in	O
exon	B-UNK
10	O
of	O
the	O
FGD1	O
gene	B-UNK
(	O
G2559	O
>	O
A	O
)	O
substituting	O
a	O
Gln	O
for	O
Arg	B-UNK
in	O
position	B-UNK
610	O
.	O

The	O
mutation	B-UNK
was	O
found	O
to	O
segregate	O
with	O
the	O
AAS	O
phenotype	B-UNK
in	O
affected	B-UNK
males	I-UNK
and	O
carrier	B-UNK
females	O
in	O
the	O
family	B-UNK
of	O
this	O
patient	B-UNK
.	O

Interestingly	B-UNK
,	O
Arg-610	O
is	O
located	B-UNK
within	O
one	O
of	O
the	O
two	O
pleckstrin	O
homology	B-UNK
(	O
PH	B-UNK
)	O
domains	B-UNK
of	O
the	O
FGD1	O
gene	B-UNK
and	O
it	O
corresponds	O
to	O
a	O
highly	B-UNK
conserved	I-UNK
residue	O
which	O
has	O
been	O
involved	B-UNK
in	O
InsP	O
binding	B-UNK
in	O
PH	B-UNK
domains	B-UNK
of	O
other	O
proteins	B-UNK
.	O

The	O
same	O
residue	O
is	O
often	O
mutated	B-UNK
in	O
the	O
Brutons	O
tyrosine	O
kinase	B-UNK
(	O
Btk	O
)	O
gene	B-UNK
in	O
patients	B-UNK
with	O
an	O
X	O
-	O
linked	B-UNK
agammaglobulinemia	B-DISEASE
.	O

The	O
Arg610Gln	O
mutation	B-UNK
represents	O
the	O
first	O
case	B-UNK
of	O
a	O
mutation	B-UNK
in	O
the	O
PH	B-UNK
domain	B-UNK
of	O
the	O
FGD1	O
gene	B-UNK
and	O
additional	O
evidence	B-UNK
that	O
mutations	B-UNK
in	O
PH	B-UNK
domains	B-UNK
can	O
be	O
associated	O
to	O
human	B-UNK
diseases	B-DISEASE
..	O

Amino	B-UNK
-	O
terminal	B-UNK
fragments	O
of	O
mutant	B-UNK
huntingtin	O
show	O
selective	O
accumulation	B-UNK
in	O
striatal	O
neurons	O
and	O
synaptic	O
toxicity	B-DISEASE
.	O

Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
is	O
caused	B-UNK
by	O
expansion	B-UNK
of	O
a	O
glutamine	O
repeat	B-UNK
in	O
the	O
amino	B-UNK
-	O
terminal	B-UNK
region	B-UNK
of	O
huntingtin	O
.	O

Despite	O
its	O
widespread	O
expression	B-UNK
,	O
mutant	B-UNK
huntingtin	O
induces	O
selective	O
neuronal	B-DISEASE
loss	I-DISEASE
in	O
striatal	O
neurons	O
.	O

Here	O
we	O
report	B-UNK
that	O
,	O
in	O
mutant	B-UNK
mice	I-UNK
expressing	O
HD	B-UNK
repeats	B-UNK
,	O
the	O
production	O
and	O
aggregation	O
of	O
N	O
-	O
terminal	B-UNK
huntingtin	O
fragments	O
preferentially	O
occur	B-UNK
in	O
HD	B-UNK
-	O
affected	B-UNK
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals	O
.	O

N	O
-	O
terminal	B-UNK
fragments	O
of	O
mutant	B-UNK
huntingtin	O
form	B-UNK
aggregates	O
and	O
induce	O
neuritic	O
degeneration	B-UNK
in	O
cultured	O
striatal	O
neurons	O
.	O

N	O
-	O
terminal	B-UNK
mutant	B-UNK
huntingtin	O
also	O
binds	O
to	O
synaptic	O
vesicles	O
and	O
inhibits	O
their	O
glutamate	O
uptake	O
in	O
vitro	O
.	O

The	O
specific	B-UNK
processing	O
and	O
accumulation	B-UNK
of	O
toxic	O
fragments	O
of	O
N	O
-	O
terminal	B-UNK
huntingtin	O
in	O
HD	B-UNK
-	O
affected	B-UNK
striatal	O
neurons	O
,	O
especially	O
in	O
their	O
neuronal	B-UNK
processes	O
and	O
axonal	O
terminals	O
,	O
may	O
contribute	B-UNK
to	O
the	O
selective	O
neuropathology	O
of	O
HD	B-UNK
..	O

BRCA1	B-UNK
is	O
associated	O
with	O
a	O
human	B-UNK
SWI	O
/	O
SNF	O
-	O
related	B-UNK
complex	O
:	O
linking	O
chromatin	O
remodeling	O
to	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

Germline	B-UNK
mutations	I-UNK
in	O
the	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
,	O
BRCA1	B-UNK
,	O
predispose	O
individuals	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
.	O

Using	O
a	O
combination	B-UNK
of	O
affinity	B-UNK
-	O
and	O
conventional	O
chromatographic	O
techniques	O
,	O
we	O
have	O
isolated	B-UNK
a	O
predominant	O
form	B-UNK
of	O
a	O
multiprotein	O
BRCA1-containing	O
complex	O
from	O
human	B-UNK
cells	B-UNK
displaying	O
chromatin	O
-	O
remodeling	O
activity	B-UNK
.	O

Mass	B-UNK
spectrometric	O
sequencing	B-UNK
of	O
components	O
of	O
this	O
complex	O
indicated	O
that	O
BRCA1	B-UNK
is	O
associated	O
with	O
a	O
SWI	O
/	O
SNF	O
-	O
related	B-UNK
complex	O
.	O

We	O
show	O
that	O
BRCA1	B-UNK
can	O
directly	O
interact	O
with	O
the	O
BRG1	O
subunit	B-UNK
of	O
the	O
SWI	O
/	O
SNF	O
complex	O
.	O

Moreover	O
,	O
p53-mediated	O
stimulation	O
of	O
transcription	B-UNK
by	O
BRCA1	B-UNK
was	O
completely	O
abrogated	O
by	O
either	O
a	O
dominant	B-UNK
-	O
negative	B-UNK
mutant	B-UNK
of	O
BRG1	O
or	O
the	O
cancer	B-UNK
-	O
causing	B-UNK
deletion	B-UNK
in	O
exon	B-UNK
11	O
of	O
BRCA1	B-UNK
.	O

These	O
findings	B-UNK
reveal	O
a	O
direct	B-UNK
function	B-UNK
for	O
BRCA1	B-UNK
in	O
transcriptional	O
control	B-UNK
through	O
modulation	O
of	O
chromatin	O
structure	B-UNK
..	O

Asef	O
,	O
a	O
link	O
between	O
the	O
tumor	B-UNK
suppressor	I-UNK
APC	B-UNK
and	O
G	O
-	O
protein	B-UNK
signaling	O
.	O

The	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
gene	B-UNK
(	O
APC	B-UNK
)	O
is	O
mutated	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
and	O
in	O
sporadic	B-UNK
colorectal	B-UNK
tumors	I-UNK
.	O

Here	O
the	O
APC	B-UNK
gene	B-UNK
product	I-UNK
is	O
shown	B-UNK
to	O
bind	O
through	O
its	O
armadillo	O
repeat	B-UNK
domain	B-UNK
to	O
a	O
Rac	O
-	O
specific	B-UNK
guanine	B-UNK
nucleotide	B-UNK
exchange	O
factor	B-UNK
(	O
GEF	O
)	O
,	O
termed	O
Asef	O
.	O

Endogenous	O
APC	B-UNK
colocalized	O
with	O
Asef	O
in	O
mouse	B-UNK
colon	B-UNK
epithelial	B-UNK
cells	B-UNK
and	O
neuronal	B-UNK
cells	B-UNK
.	O

Furthermore	O
,	O
APC	B-UNK
enhanced	O
the	O
GEF	O
activity	B-UNK
of	O
Asef	O
and	O
stimulated	O
Asef	O
-	O
mediated	O
cell	B-UNK
flattening	O
,	O
membrane	B-UNK
ruffling	O
,	O
and	O
lamellipodia	O
formation	B-UNK
in	O
MDCK	O
cells	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
APC	B-UNK
-	O
Asef	O
complex	O
may	O
regulate	O
the	O
actin	B-UNK
cytoskeletal	O
network	O
,	O
cell	B-UNK
morphology	O
and	O
migration	O
,	O
and	O
neuronal	B-UNK
function	B-UNK
..	O

Function	B-UNK
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity	B-UNK
.	O

The	O
axonal	O
chemoattractant	O
netrin-1	O
guides	O
spinal	B-UNK
commissural	O
axons	O
by	O
activating	O
its	O
receptor	B-UNK
DCC	B-UNK
(	O
Deleted	B-UNK
in	O
Colorectal	B-DISEASE
Cancer	I-DISEASE
)	O
.	O

We	O
have	O
found	O
that	O
chemical	O
inhibitors	O
of	O
metalloproteases	O
potentiate	O
netrin	O
-	O
mediated	O
axon	O
outgrowth	O
in	O
vitro	O
.	O

We	O
have	O
also	O
found	O
that	O
DCC	B-UNK
is	O
a	O
substrate	O
for	O
metalloprotease	O
-	O
dependent	B-UNK
ectodomain	O
shedding	O
,	O
and	O
that	O
the	O
inhibitors	O
block	O
proteolytic	O
processing	O
of	O
DCC	B-UNK
and	O
cause	O
an	O
increase	B-UNK
in	O
DCC	B-UNK
protein	B-UNK
levels	B-UNK
on	O
axons	O
within	O
spinal	B-UNK
cord	O
explants	O
.	O

Thus	O
,	O
potentiation	O
of	O
netrin	O
activity	B-UNK
by	O
inhibitors	O
may	O
result	B-UNK
from	O
stabilization	O
of	O
DCC	B-UNK
on	O
the	O
axons	O
,	O
and	O
proteolytic	O
activity	B-UNK
may	O
regulate	O
axon	O
migration	O
by	O
controlling	O
the	O
number	B-UNK
of	O
functional	O
extracellular	B-UNK
axon	O
guidance	O
receptors	O
..	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
in	O
transgenic	B-UNK
mice	I-UNK
expressing	O
an	O
expanded	B-UNK
CUG	B-UNK
repeat	B-UNK
.	O

Myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
,	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
muscular	B-UNK
dystrophy	I-UNK
in	O
adult	B-UNK
humans	B-UNK
,	O
results	B-UNK
from	O
expansion	B-UNK
of	O
a	O
CTG	B-UNK
repeat	I-UNK
in	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
of	O
the	O
DMPK	B-UNK
gene	B-UNK
.	O

The	O
mutant	B-UNK
DMPK	B-UNK
messenger	B-UNK
RNA	I-UNK
(	O
mRNA	O
)	O
contains	O
an	O
expanded	B-UNK
CUG	B-UNK
repeat	B-UNK
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O

We	O
have	O
expressed	B-UNK
an	O
untranslated	B-UNK
CUG	B-UNK
repeat	B-UNK
in	O
an	O
unrelated	B-UNK
mRNA	O
in	O
transgenic	B-UNK
mice	I-UNK
.	O

Mice	B-UNK
that	O
expressed	B-UNK
expanded	B-UNK
CUG	B-UNK
repeats	B-UNK
developed	O
myotonia	B-UNK
and	O
myopathy	B-DISEASE
,	O
whereas	O
mice	B-UNK
expressing	O
a	O
nonexpanded	O
repeat	B-UNK
did	O
not	O
.	O

Thus	O
,	O
transcripts	O
with	O
expanded	B-UNK
CUG	B-UNK
repeats	B-UNK
are	O
sufficient	O
to	O
generate	O
a	O
DM	B-DISEASE
phenotype	B-UNK
.	O

This	O
result	B-UNK
supports	O
a	O
role	B-UNK
for	O
RNA	B-UNK
gain	O
of	O
function	B-UNK
in	O
disease	B-DISEASE
pathogenesis	B-UNK
..	O

Genomic	B-UNK
rearrangements	O
of	O
the	O
APC	B-UNK
tumor	B-DISEASE
-	O
suppressor	B-UNK
gene	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
.	O

Germline	B-UNK
mutations	I-UNK
of	O
the	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
APC	B-UNK
)	O
tumor	B-DISEASE
-	O
suppressor	B-UNK
gene	B-UNK
result	B-UNK
in	O
the	O
hereditary	B-UNK
colorectal	B-UNK
cancer	I-UNK
syndrome	B-DISEASE
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
.	O

Almost	O
all	O
APC	B-UNK
mutations	B-UNK
that	O
have	O
been	O
identified	B-UNK
are	O
single	B-UNK
-	O
nucleotide	B-UNK
alterations	B-UNK
,	O
small	O
insertions	O
,	O
or	O
small	O
deletions	O
that	O
would	O
truncate	O
the	O
protein	B-UNK
product	I-UNK
of	O
the	O
gene	B-UNK
.	O

No	O
well	O
-	O
characterized	B-UNK
intragenic	O
rearrangement	B-UNK
of	O
APC	B-UNK
has	O
been	O
described	O
,	O
and	O
the	O
prevalence	B-UNK
of	O
this	O
type	B-UNK
of	O
mutation	B-UNK
in	O
FAP	B-UNK
patients	I-UNK
is	O
not	O
clear	O
.	O

We	O
screened	B-UNK
49	O
potential	B-UNK
FAP	B-UNK
families	B-UNK
and	O
identified	B-UNK
26	O
different	O
germline	B-UNK
APC	B-UNK
mutations	B-UNK
in	O
30	O
families	B-UNK
.	O

Four	O
of	O
these	O
mutations	B-UNK
were	O
genomic	B-UNK
rearrangements	O
resulting	B-UNK
from	O
homologous	B-UNK
and	O
nonhomologous	O
recombinations	O
mediated	O
by	O
Alu	B-UNK
elements	O
.	O

Two	O
of	O
these	O
four	O
rearrangements	O
were	O
complex	O
,	O
involving	O
deletion	B-UNK
and	O
insertion	O
of	O
nucleotides	O
.	O

Of	O
these	O
four	O
rearrangements	O
,	O
one	O
resulted	B-UNK
in	O
the	O
deletion	B-UNK
of	O
exons	O
11	O
and	O
12	O
and	O
two	O
others	O
resulted	B-UNK
in	O
either	O
complete	O
or	O
partial	O
deletion	B-UNK
of	O
exon	B-UNK
14	O
.	O

The	O
fourth	B-UNK
rearrangement	B-UNK
grossly	O
altered	O
the	O
sequence	B-UNK
within	O
intron	B-UNK
14	O
.	O

Although	O
this	O
rearrangement	B-UNK
did	O
not	O
affect	O
any	O
coding	B-UNK
sequence	I-UNK
of	O
APC	B-UNK
at	O
the	O
genomic	B-UNK
DNA	I-UNK
level	B-UNK
,	O
it	O
caused	B-UNK
inappropriate	O
splicing	B-UNK
of	O
exon	B-UNK
14	O
.	O

These	O
rearrangements	O
were	O
initially	O
revealed	B-UNK
by	O
analyzing	O
cDNAs	O
and	O
could	O
not	O
have	O
been	O
identified	B-UNK
by	O
using	O
mutation	B-UNK
detection	I-UNK
methods	O
that	O
screened	B-UNK
each	O
exon	B-UNK
individually	O
.	O

The	O
identification	B-UNK
of	O
a	O
rearrangement	B-UNK
that	O
did	O
not	O
alter	O
any	O
coding	B-UNK
exons	O
yet	O
affected	B-UNK
the	O
splicing	B-UNK
further	O
underscores	O
the	O
importance	O
of	O
using	O
cDNA	O
for	O
mutation	B-UNK
analysis	B-UNK
.	O

The	O
identification	B-UNK
of	O
four	O
genomic	B-UNK
rearrangements	O
among	O
30	O
mutations	B-UNK
suggests	O
that	O
genomic	B-UNK
rearrangements	O
are	O
frequent	B-UNK
germline	B-UNK
APC	B-UNK
mutations	B-UNK
..	O

Detection	B-UNK
of	O
a	O
novel	O
missense	B-UNK
mutation	I-UNK
and	O
second	O
recurrent	O
mutation	B-UNK
in	O
the	O
CACNA1A	O
gene	B-UNK
in	O
individuals	B-UNK
with	O
EA-2	O
and	O
FHM	O
.	O

Mutations	B-UNK
in	O
the	O
brain	B-UNK
specific	B-UNK
P	O
/	O
Q	O
type	B-UNK
Ca2	O
+	O
channel	B-UNK
alpha1	O
subunit	B-UNK
gene	B-UNK
,	O
CACNA1A	O
,	O
have	O
been	O
identified	B-UNK
in	O
three	O
clinically	O
distinct	O
disorders	B-UNK
,	O
viz	O
.	O
episodic	B-DISEASE
ataxia	I-DISEASE
type	B-UNK
2	O
(	O
EA-2	O
)	O
,	O
familial	B-DISEASE
hemiplegic	I-DISEASE
migraine	I-DISEASE
(	O
FHM	O
)	O
and	O
spinocerebellar	O
ataxia	B-UNK
6	O
(	O
SCA6	O
)	O
.	O

For	O
individuals	B-UNK
with	O
EA-2	O
,	O
the	O
mutations	B-UNK
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	B-UNK
in	O
a	O
truncated	O
protein	B-UNK
product	I-UNK
.	O

Several	O
different	O
missense	B-UNK
mutations	I-UNK
have	O
been	O
identified	B-UNK
in	O
patients	B-UNK
with	O
FHM	O
.	O

At	O
least	O
two	O
of	O
these	O
mutations	B-UNK
have	O
been	O
identified	B-UNK
on	O
two	O
different	O
chromosome	B-UNK
19p13	O
haplotypes	O
and	O
thus	O
represent	O
recurrent	O
mutations	B-UNK
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
have	O
screened	B-UNK
several	O
individuals	B-UNK
for	O
mutations	B-UNK
in	O
all	O
47	O
exons	O
in	O
the	O
CACNA1A	O
gene	B-UNK
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
analysis	B-UNK
.	O

We	O
have	O
characterised	O
a	O
novel	O
missense	B-UNK
mutation	I-UNK
,	O
G5260A	O
,	O
in	O
exon	B-UNK
32	O
in	O
a	O
family	B-UNK
segregating	O
for	O
EA-2	O
.	O

The	O
consequence	B-UNK
of	O
this	O
mutation	B-UNK
is	O
an	O
amino	B-UNK
acid	I-UNK
substitution	I-UNK
at	O
a	O
highly	B-UNK
conserved	I-UNK
position	B-UNK
within	O
the	O
CACNA1A	O
gene	B-UNK
.	O

This	O
represents	O
the	O
first	O
point	B-UNK
mutation	I-UNK
not	O
resulting	B-UNK
in	O
a	O
proposed	O
truncated	O
protein	B-UNK
.	O

Furthermore	O
,	O
this	O
mutation	B-UNK
has	O
been	O
detected	B-UNK
in	O
a	O
family	B-UNK
member	B-UNK
with	O
mild	O
clinical	B-UNK
signs	B-UNK
including	O
only	O
migraine	B-DISEASE
.	O

Additionally	O
,	O
a	O
second	O
previously	B-UNK
identified	I-UNK
recurrent	O
muta	O
tion	O
,	O
C2272	O
T	O
,	O
in	O
exon	B-UNK
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	B-UNK
with	O
FHM	O
..	O

Analbuminemia	O
in	O
a	O
neonate	O
.	O

A	O
small	O
-	O
for	O
-	O
gestational	O
-	O
age	B-UNK
infant	O
,	O
found	O
to	O
have	O
analbuminemia	O
in	O
the	O
neonatal	B-UNK
period	O
,	O
is	O
reported	B-UNK
and	O
the	O
twelve	O
cases	B-UNK
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed	O
.	O

Patients	B-UNK
lacking	O
this	O
serum	B-UNK
protein	B-UNK
are	O
essentially	O
asymptomatic	B-UNK
,	O
apart	O
from	O
minimal	O
ankle	O
edema	B-DISEASE
and	O
ease	O
of	O
fatigue	B-DISEASE
.	O

Apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	B-UNK
albumin	O
is	O
low	B-UNK
include	O
prolonged	O
half	B-UNK
-	O
life	B-UNK
of	O
albumin	O
and	O
transferrin	O
,	O
an	O
increase	B-UNK
in	O
serum	B-UNK
globulins	O
,	O
beta	B-UNK
lipoprotein	B-UNK
,	O
and	O
glycoproteins	O
,	O
arterial	B-DISEASE
hypotension	I-DISEASE
with	O
reduced	O
capillary	O
hydrostatic	O
pressure	O
,	O
and	O
the	O
ability	B-UNK
to	O
respond	O
with	O
rapid	O
sodium	B-UNK
and	O
chloride	B-UNK
diuresis	O
in	O
response	B-UNK
to	O
small	O
volume	O
changes	O
.	O

Examination	B-UNK
of	O
plasma	O
amino	B-UNK
acids	I-UNK
,	O
an	O
investigation	B-UNK
not	O
previously	B-UNK
reported	I-UNK
,	O
revealed	B-UNK
an	O
extremely	O
low	B-UNK
plasma	O
tryptophan	O
level	B-UNK
,	O
a	O
finding	O
which	O
may	O
be	O
important	O
in	O
view	O
of	O
the	O
role	B-UNK
of	O
tryptophan	O
in	O
albumin	O
synthesis	B-UNK
..	O

Histidinemia	B-DISEASE
.	O

Classical	O
and	O
atypical	O
form	B-UNK
in	O
siblings	O
.	O

Two	O
brothers	O
,	O
6	O
and	O
13	O
years	O
old	O
,	O
had	O
histidinemia	B-DISEASE
.	O

On	O
the	O
basis	B-UNK
of	O
clinical	B-UNK
and	O
biochemical	O
observations	B-UNK
,	O
the	O
younger	O
boy	B-UNK
was	O
considered	O
to	O
have	O
a	O
classical	O
type	B-UNK
of	O
the	O
disease	B-DISEASE
,	O
while	O
the	O
older	O
boy	B-UNK
had	O
an	O
atypical	O
form	B-UNK
characterized	B-UNK
by	O
partial	O
impairment	B-UNK
of	O
the	O
skin	B-UNK
histidase	O
activity	B-UNK
and	O
a	O
moderately	O
prolonged	O
half	B-UNK
-	O
life	B-UNK
of	O
blood	B-UNK
histidine	O
.	O

The	O
mother	O
is	O
a	O
heterozygous	B-UNK
carrier	B-UNK
,	O
while	O
the	O
father	O
and	O
sister	O
seem	O
to	O
be	O
normal	B-UNK
..	O

Carrier	B-UNK
detection	I-UNK
of	O
pyruvate	O
carboxylase	O
deficiency	B-UNK
in	O
fibroblasts	B-UNK
and	O
lymphocytes	O
.	O

Pyruvate	O
carboxylase	O
(	O
E.	O
C.	O
6	O
.	O
4	O
.	O
1	O
.	O
1	O
)	O
activity	B-UNK
was	O
determined	B-UNK
in	O
the	O
circulating	O
peripheral	B-UNK
lymphocytes	O
and	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
from	O
the	O
family	B-UNK
of	O
a	O
patient	B-UNK
with	O
hepatic	B-UNK
,	O
cerebral	B-UNK
,	O
renal	B-UNK
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	O
carboxylase	O
deficiency	B-UNK
(	O
PC	O
Portland	O
deficiency	B-UNK
)	O
.	O

Lymphocyte	B-UNK
activities	O
were	O
mother	O
,	O
33	O
-	O
-39	O
%	O
;	O
father	O
,	O
11	O
-	O
-29	O
%	O
;	O
brother	B-UNK
,	O
82	O
-	O
-103	O
%	O
;	O
and	O
sister	O
,	O
38	O
-	O
-48	O
%	O
of	O
the	O
lowest	O
normal	B-UNK
.	O

Fibroblasts	B-UNK
from	O
the	O
patients	B-UNK
mother	O
and	O
father	O
had	O
42	O
and	O
34	O
%	O
,	O
respectively	O
,	O
of	O
the	O
activity	B-UNK
of	O
the	O
lowest	O
normal	B-UNK
.	O

These	O
data	B-UNK
demonstrate	B-UNK
that	O
the	O
disease	B-DISEASE
is	O
inherited	B-UNK
in	O
an	O
autosomal	B-UNK
recessive	I-UNK
manner	O
and	O
that	O
lymphocytes	O
and	O
fibroblasts	B-UNK
can	O
be	O
used	O
to	O
detect	B-UNK
carriers	B-UNK
.	O

Neither	O
pyruvate	O
carboxylase	O
nor	O
mitochondrial	B-UNK
PEPCK	O
activity	B-UNK
in	O
lymphocytes	O
was	O
increased	B-UNK
by	O
a	O
21-hr	O
fast	O
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
variants	B-UNK
from	O
Italian	B-UNK
subjects	B-UNK
associated	O
with	O
severe	B-UNK
neonatal	B-UNK
jaundice	B-DISEASE
.	O

Screening	B-UNK
for	O
the	O
G6PD	B-UNK
deficiency	I-UNK
was	O
carried	O
out	O
at	O
the	O
Maternity	O
Division	O
of	O
the	O
Galliera	O
Hospital	O
in	O
Genoa	O
,	O
Italy	O
.	O

Two	O
groups	B-UNK
of	O
subjects	B-UNK
with	O
hyperbilirubinaemia	O
of	O
non-immunological	O
origin	O
were	O
examined	O
(	O
a	O
)	O
302	O
newborn	O
babies	O
of	O
Sardinian	O
extraction	O
(	O
on	O
cord	O
blood	B-UNK
)	O
and	O
(	O
b	O
)	O
201	O
newborn	O
babies	O
of	O
south	O
Italian	B-UNK
ancestry	O
(	O
on	O
peripheral	B-UNK
blood	I-UNK
)	O
.	O

Among	O
503	O
subjects	B-UNK
,	O
43	O
showed	O
an	O
enzyme	B-UNK
deficiency	I-UNK
;	O
in	O
39	O
the	O
defect	B-UNK
was	O
of	O
the	O
Mediterranean	B-UNK
type	B-UNK
.	O

In	O
one	O
case	B-UNK
,	O
previously	B-UNK
described	O
,	O
the	O
enzyme	B-UNK
was	O
of	O
the	O
A	O
-	O
type	B-UNK
.	O

In	O
the	O
remaining	O
cases	B-UNK
three	O
different	O
variants	B-UNK
were	O
identified	B-UNK
.	O

In	O
the	O
present	B-UNK
work	O
these	O
three	O
cases	B-UNK
,	O
each	O
with	O
severe	B-UNK
neonatal	B-UNK
jaundice	B-DISEASE
,	O
are	O
reported	B-UNK
.	O

Their	O
parents	O
originated	O
from	O
Calabria	O
,	O
from	O
Sardinia	O
and	O
from	O
Sicily	O
.	O

The	O
abnormal	O
enzymes	B-UNK
are	O
respectively	O
designated	O
as	O
GdDcbrousse	O
-	O
like	O
,	O
GdGallura	O
and	O
GdAgrigento	O
..	O

Cytogenetic	B-UNK
investigations	O
in	O
families	B-UNK
with	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
.	O

Chromosomal	B-UNK
studies	B-UNK
were	O
performed	O
on	O
peripheral	B-UNK
blood	I-UNK
lymphocytes	O
and	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
from	O
five	O
Israeli	O
-	O
Moroccan	B-UNK
families	B-UNK
with	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
.	O

A	O
total	B-UNK
of	O
24	O
individuals	B-UNK
,	O
including	O
seven	O
propositi	O
,	O
was	O
investigated	O
.	O

Among	O
the	O
probands	O
,	O
significantly	O
elevated	B-UNK
rates	O
of	O
chromosome	B-UNK
damage	B-UNK
were	O
observed	B-UNK
in	O
both	O
blood	B-UNK
and	O
skin	B-UNK
.	O

Skin	B-UNK
fibroblasts	I-UNK
of	O
affected	B-UNK
individuals	I-UNK
showed	O
several	O
orders	O
of	O
magnitude	O
more	O
chromosome	B-DISEASE
breakage	I-DISEASE
than	O
lymphocytes	O
.	O

Increased	B-UNK
rates	O
of	O
chromosome	B-UNK
damage	B-UNK
were	O
also	O
observed	B-UNK
in	O
the	O
fibroblasts	B-UNK
of	O
some	O
phenotypically	O
normal	B-UNK
family	B-UNK
members	I-UNK
(	O
obligate	B-UNK
heterozygotes	B-UNK
and	O
sibs	O
)	O
when	O
compared	B-UNK
to	O
normal	B-UNK
controls	O
.	O

An	O
apparent	O
abnormal	O
clone	O
of	O
cells	B-UNK
,	O
possessing	O
a	O
large	B-UNK
acrocentric	O
marker	B-UNK
chromosome	B-UNK
(	O
14q	O
+	O
)	O
,	O
was	O
observed	B-UNK
in	O
varying	O
proportions	O
among	O
cells	B-UNK
of	O
all	O
the	O
propositi	O
(	O
2	O
-	O
5	O
%	O
of	O
lymphocytes	O
;	O
1	O
-	O
9	O
%	O
of	O
fibroblasts	B-UNK
)	O
..	O

Prenatal	B-UNK
diagnosis	I-UNK
of	O
Wolman	B-DISEASE
disease	I-DISEASE
.	O

Two	O
pregnancies	O
at	O
risk	B-UNK
for	O
Wolman	B-DISEASE
disease	I-DISEASE
were	O
monitored	O
by	O
assay	B-UNK
and	O
electrophoresis	B-UNK
of	O
acid	B-UNK
lipase	O
in	O
cultured	O
amniotic	O
-	O
fluid	O
cells	B-UNK
.	O

Cells	B-UNK
from	O
patient	B-UNK
1	O
had	O
5	O
%	O
of	O
control	B-UNK
levels	B-UNK
of	O
acid	B-UNK
lipase	O
,	O
using	O
14C	O
-	O
triolein	O
as	O
substrate	O
;	O
however	O
,	O
when	O
artificial	O
substrates	O
(	O
esters	O
of	O
4-methylumbelliferone	O
and	O
p	O
-	O
nitrophenol	O
)	O
were	O
used	O
to	O
measure	O
acid	B-UNK
lipase	O
,	O
these	O
cells	B-UNK
had	O
30	O
%	O
of	O
control	B-UNK
levels	B-UNK
.	O

Electrophoresis	B-UNK
of	O
cell	B-UNK
extracts	B-UNK
revealed	B-UNK
the	O
absence	B-UNK
of	O
the	O
A	O
form	B-UNK
of	O
acid	B-UNK
lipase	O
,	O
consistent	B-UNK
with	O
the	O
diagnosis	B-UNK
of	O
Wolman	B-DISEASE
disease	I-DISEASE
.	O

Analysis	B-UNK
of	O
fetal	O
tissues	O
following	O
prostaglandin	O
termination	B-UNK
of	O
this	O
pregnancy	O
confirmed	B-UNK
the	O
diagnosis	B-UNK
.	O

Assay	B-UNK
of	O
fetal	O
-	O
skin	B-UNK
fibroblasts	I-UNK
with	O
14C	O
-	O
triolein	O
,	O
as	O
well	O
as	O
with	O
artificial	O
substrates	O
,	O
showed	O
marked	B-UNK
deficiency	B-UNK
of	O
acid	B-UNK
lipase	O
activity	B-UNK
.	O

Electrophoresis	B-UNK
of	O
fetal	O
-	O
tissue	B-UNK
extracts	B-UNK
also	O
demonstrated	O
the	O
absence	B-UNK
of	O
the	O
A	O
form	B-UNK
of	O
acid	B-UNK
lipase	O
.	O

Amniotic	O
-	O
fluid	O
cells	B-UNK
from	O
patient	B-UNK
2	O
showed	O
normal	B-UNK
levels	B-UNK
of	O
acid	B-UNK
lipase	O
with	O
all	O
substrates	O
tested	O
;	O
the	O
electrophoretic	B-UNK
pattern	B-UNK
of	O
acid	B-UNK
lipase	O
was	O
normal	B-UNK
.	O

The	O
results	B-UNK
suggest	B-UNK
that	O
the	O
prenatal	B-UNK
diagnosis	I-UNK
of	O
Wolman	B-DISEASE
disease	I-DISEASE
be	O
made	O
using	O
the	O
radioassay	O
of	O
acid	B-UNK
lipase	O
and	O
/	O
or	O
electrophoresis	B-UNK
..	O

Malignant	B-UNK
neoplasms	B-DISEASE
in	O
the	O
families	B-UNK
of	O
patients	B-UNK
with	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
.	O

Ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
(	O
A	O
-T	O
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
syndrome	B-DISEASE
associated	O
with	O
a	O
greatly	O
increased	B-UNK
incidence	B-UNK
of	O
malignant	B-UNK
neoplasms	B-UNK
in	O
homozygous	B-UNK
affected	B-UNK
individuals	I-UNK
.	O

Heterozygotes	B-UNK
for	O
the	O
gene	B-UNK
for	O
A	O
-T	O
are	O
thought	B-UNK
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	B-UNK
population	B-UNK
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	B-UNK
also	O
predisposes	O
the	O
heterozygous	B-UNK
carrier	B-UNK
to	O
cancers	B-UNK
.	O

Heterozygous	B-UNK
carriers	B-UNK
of	O
this	O
gene	B-UNK
are	O
common	B-UNK
among	O
the	O
close	B-UNK
relatives	B-UNK
of	O
patients	B-UNK
with	O
A	O
-T	O
,	O
although	O
individual	O
carriers	B-UNK
cannot	O
be	O
identified	B-UNK
by	O
any	O
clinical	B-UNK
criterion	O
or	O
laboratory	O
test	B-UNK
.	O

For	O
this	O
reason	O
,	O
we	O
compared	B-UNK
the	O
incidence	B-UNK
of	O
death	B-UNK
from	O
malignant	B-UNK
neoplasms	B-DISEASE
in	O
2	O
families	B-UNK
of	O
patients	B-UNK
with	O
A	O
-T	O
to	O
that	O
expected	O
in	O
a	O
random	B-UNK
sample	O
of	O
the	O
general	B-UNK
population	B-UNK
.	O

There	O
were	O
59	O
deaths	B-DISEASE
from	O
malignant	B-UNK
neoplasms	B-UNK
in	O
relatives	B-UNK
dying	O
before	O
age	B-UNK
75	O
,	O
compared	B-UNK
to	O
42	O
.	O

6	O
expected	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

For	O
A	O
-T	O
heterozygotes	B-UNK
younger	O
than	O
age	B-UNK
45	O
,	O
the	O
risk	B-UNK
of	O
dying	O
from	O
a	O
malignant	B-UNK
neoplasm	B-DISEASE
was	O
estimated	B-UNK
to	O
be	O
greater	B-UNK
than	O
5	O
times	O
the	O
risk	B-UNK
for	O
the	O
general	B-UNK
population	B-UNK
.	O

A	O
-T	O
heterozygotes	B-UNK
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B-UNK
before	O
age	B-UNK
45	O
.	O

The	O
incidence	B-UNK
of	O
ovarian	B-UNK
,	O
gastric	B-UNK
,	O
and	O
biliary	O
system	O
carcinomas	B-UNK
and	O
of	O
leukemia	B-UNK
and	O
lymphoma	B-DISEASE
was	O
increased	B-UNK
in	O
these	O
A	O
-T	O
families	B-UNK
.	O

Other	O
neoplasms	B-DISEASE
that	O
may	O
be	O
associated	O
with	O
this	O
gene	B-UNK
in	O
heterozygotes	B-UNK
include	O
pancreatic	B-UNK
,	O
basal	O
cell	B-UNK
,	O
colonic	O
,	O
breast	B-UNK
,	O
and	O
cervical	O
carcinomas	B-UNK
.	O

Striking	O
prevalence	B-UNK
of	O
ankylosing	B-UNK
spondylitis	I-UNK
in	O
"	O
healthy	O
"	O
w27	O
positive	O
males	B-UNK
and	O
females	O
.	O

Ankylosing	B-DISEASE
spondylitis	I-DISEASE
is	O
diagnosed	O
once	O
or	O
twice	O
in	O
each	O
1000	O
males	B-UNK
and	O
one	O
tenth	O
as	O
frequently	O
in	O
females	O
,	O
but	O
the	O
true	O
prevalence	B-UNK
is	O
unknown	O
.	O

Indentification	O
of	O
genetic	B-UNK
marker	B-UNK
,	O
HL	B-DISEASE
-	O
A	O
W27	O
,	O
for	O
susceptible	O
persons	O
has	O
provided	O
a	O
tool	O
facilitating	O
epidemiologic	O
studies	B-UNK
and	O
allowing	O
identification	B-UNK
of	O
"	O
control	B-UNK
"	O
populations	O
without	O
the	O
marker	B-UNK
.	O

Evaluation	B-UNK
by	O
postal	O
questionnaires	O
,	O
and	O
pelvic	O
radiography	O
of	O
78	O
HL	B-DISEASE
-	O
A	O
27W	O
-	O
positive	O
blood	B-UNK
donors	O
selected	O
from	O
a	O
group	B-UNK
of	O
apparently	O
healthy	O
subjects	B-UNK
revealed	B-UNK
14	O
who	O
satisfied	O
the	O
criteria	O
for	O
definite	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
.	O

The	O
prevalence	B-UNK
was	O
similar	B-UNK
in	O
both	O
sexes	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
six	O
W27-negative	O
controls	O
matched	O
for	O
race	O
,	O
sex	B-UNK
,	O
and	O
age	B-UNK
failed	O
to	O
yield	O
a	O
single	B-UNK
case	B-UNK
.	O

For	O
a	O
person	O
of	O
either	O
sex	B-UNK
with	O
HL	B-DISEASE
-	O
A	O
W27	O
,	O
there	O
appears	B-UNK
to	O
be	O
about	O
a	O
20	O
per	O
cent	O
chance	O
that	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
will	O
develop	O
,	O
suggesting	O
a	O
prevalence	B-UNK
of	O
10	O
to	O
15	O
per	O
thousand	O
.	O

Hitherto	O
accepted	O
figures	O
may	O
underestimate	O
the	O
frequency	B-UNK
by	O
a	O
factor	B-UNK
of	O
10	O
to	O
20	O
..	O

Analbuminemia	O
in	O
an	O
American	B-UNK
Indian	O
girl	O
.	O

Analbuminemia	O
was	O
fortuitously	O
detected	B-UNK
in	O
a	O
nonedematous	O
12-year	O
-	O
old	O
American	B-UNK
Indian	O
girl	O
with	O
atopic	B-DISEASE
dermatitis	I-DISEASE
,	O
mild	O
bronchial	B-DISEASE
asthma	I-DISEASE
,	O
a	O
mild	O
seizure	B-DISEASE
disorder	I-DISEASE
,	O
and	O
hyperlipoproteinemia	O
with	O
a	O
corneal	O
arcus	O
.	O

Immunologic	O
methods	O
revealed	B-UNK
trace	O
amounts	B-UNK
(	O
17	O
mg/100	O
ml	O
)	O
of	O
apparently	O
normal	B-UNK
serum	B-UNK
albumin	O
.	O

The	O
patients	B-UNK
parents	O
were	O
remotely	O
related	B-UNK
.	O

The	O
pedigree	B-UNK
and	O
clinical	B-UNK
findings	B-UNK
were	O
compatible	B-UNK
with	O
autosomal	B-UNK
recessive	I-UNK
transmission	B-UNK
of	O
analbuminemia	O
.	O

Heterozygotes	B-UNK
had	O
subnormal	O
levels	B-UNK
of	O
serum	B-UNK
albumin	O
.	O

The	O
Gc	O
-	O
locus	B-UNK
is	O
closely	B-UNK
linked	I-UNK
to	O
the	O
structural	B-UNK
albumin	O
locus	B-UNK
.	O

Gc	O
-	O
protein	B-UNK
levels	B-UNK
were	O
normal	B-UNK
in	O
the	O
patient	B-UNK
and	O
together	O
with	O
normal	B-UNK
chromosomal	B-UNK
banding	O
studies	B-UNK
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	B-UNK
deletion	B-UNK
caused	B-UNK
analbuminemia	O
.	O

Gc	O
-	O
types	B-UNK
in	O
the	O
family	B-UNK
were	O
compatible	B-UNK
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	B-UNK
of	O
analbuminemia	O
to	O
the	O
Gc	O
-	O
locus	B-UNK
.	O

These	O
findings	B-UNK
suggest	B-UNK
a	O
"	O
thalassemia	B-DISEASE
"	O
-like	O
mutation	B-UNK
for	O
this	O
disorder	B-UNK
..	O

Deletion	B-UNK
of	O
the	O
KIT	B-UNK
and	O
PDGFRA	O
genes	B-UNK
in	O
a	O
patient	B-UNK
with	O
piebaldism	B-DISEASE
.	O

We	O
have	O
previously	B-UNK
shown	B-UNK
that	O
human	B-UNK
piebaldism	B-UNK
results	B-UNK
from	O
mutations	B-UNK
of	O
the	O
KIT	B-UNK
gene	B-UNK
,	O
which	O
encodes	B-UNK
the	O
receptor	B-UNK
for	O
the	O
mast	O
/	O
stem	B-UNK
cell	B-UNK
growth	B-UNK
factor	I-UNK
and	O
is	O
located	B-UNK
in	O
chromosome	B-UNK
segment	O
4q12	O
.	O

Using	O
DNA	B-UNK
of	O
a	O
patient	B-UNK
with	O
piebaldism	B-UNK
,	O
mental	B-UNK
retardation	I-UNK
,	O
and	O
multiple	B-UNK
congenital	B-DISEASE
anomalies	I-DISEASE
associated	O
with	O
a	O
46	O
,	O
XY	O
,	O
del	O
(	O
4	O
)	O
(	O
q12q21	O
.	O
1	O
)	O
karyotype	O
,	O
we	O
carried	O
out	O
quantitative	B-UNK
Southern	B-UNK
blot	I-UNK
hybridization	B-UNK
analyses	O
of	O
the	O
KIT	B-UNK
gene	B-UNK
and	O
the	O
adjacent	O
PDGFRA	O
(	O
platelet	B-UNK
-	O
derived	B-UNK
growth	B-UNK
factor	I-UNK
receptor	B-UNK
alpha	B-UNK
subunit	I-UNK
)	O
genes	B-UNK
.	O

The	O
patient	B-UNK
was	O
hemizygous	B-UNK
for	O
both	O
the	O
KIT	B-UNK
and	O
PDGFRA	O
genes	B-UNK
,	O
indicating	O
that	O
both	O
of	O
these	O
genes	B-UNK
are	O
included	O
within	O
the	O
deleted	B-UNK
region	B-UNK
.	O

Therefore	O
,	O
deletion	B-UNK
of	O
the	O
KIT	B-UNK
and	O
PDGFRA	O
genes	B-UNK
may	O
account	B-UNK
for	O
the	O
piebald	O
phenotype	B-UNK
in	O
this	O
patient	B-UNK
.	O

A	O
germ	B-UNK
line	I-UNK
mutation	B-UNK
within	O
the	O
coding	B-UNK
sequence	I-UNK
for	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
binding	B-UNK
site	B-UNK
of	O
hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
in	O
a	O
Lesch	O
-	O
Nyhan	O
patient	B-UNK
:	O
missense	B-UNK
mutations	I-UNK
within	O
a	O
functionally	O
important	O
region	B-UNK
probably	O
cause	O
disease	B-DISEASE
.	O

Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
caused	B-UNK
by	O
a	O
complete	O
deficiency	B-UNK
of	O
hypoxanthine	B-UNK
guanine	I-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
is	O
the	O
result	B-UNK
of	O
a	O
heterogeneous	O
group	B-UNK
of	O
germ	B-UNK
line	I-UNK
mutations	B-UNK
.	O

Identification	B-UNK
of	O
each	O
mutant	B-UNK
gene	B-UNK
provides	O
valuable	O
information	B-UNK
as	O
to	O
the	O
type	B-UNK
of	O
mutation	B-UNK
that	O
occurs	O
spontaneously	O
.	O

We	O
report	B-UNK
here	O
a	O
newly	O
identified	B-UNK
HPRT	B-UNK
mutation	B-UNK
in	O
a	O
Japanese	B-UNK
patient	B-UNK
with	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

This	O
gene	B-UNK
,	O
designated	O
HPRT	B-UNK
Tokyo	O
,	O
had	O
a	O
single	B-UNK
nucleotide	I-UNK
change	B-UNK
from	O
G	O
to	O
A	O
,	O
as	O
identified	B-UNK
by	O
sequencing	B-UNK
cDNA	O
amplified	O
by	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
.	O

Allele	B-UNK
specific	I-UNK
oligonucleotide	O
hybridization	B-UNK
analysis	B-UNK
using	O
amplified	O
genomic	B-UNK
DNA	I-UNK
showed	O
that	O
the	O
mutant	B-UNK
gene	B-UNK
was	O
transmitted	O
from	O
the	O
maternal	O
germ	B-UNK
line	I-UNK
.	O

This	O
mutation	B-UNK
would	O
lead	B-UNK
to	O
an	O
amino	B-UNK
acid	I-UNK
substitution	I-UNK
of	O
Asp	O
for	O
Gly	B-UNK
at	O
the	O
amino	B-UNK
acid	I-UNK
position	B-UNK
140	O
located	B-UNK
within	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
(	O
PRPP	O
)	O
binding	B-UNK
region	B-UNK
.	O

Missense	B-UNK
mutations	I-UNK
in	O
human	B-UNK
HPRT	B-UNK
deficient	B-UNK
patients	B-UNK
thus	O
far	O
reported	B-UNK
tend	O
to	O
accumulate	O
in	O
this	O
functionally	O
active	B-UNK
region	B-UNK
.	O

However	O
,	O
a	O
comparison	B-UNK
of	O
the	O
data	B-UNK
suggested	O
that	O
both	O
missense	B-UNK
and	O
synonymous	O
mutations	B-UNK
can	O
occur	B-UNK
at	O
any	O
coding	B-UNK
sequence	I-UNK
of	O
the	O
human	B-UNK
germ	B-UNK
line	I-UNK
HPRT	B-UNK
gene	B-UNK
,	O
but	O
that	O
a	O
limited	O
percentage	B-UNK
of	O
all	O
the	O
missense	B-UNK
mutations	I-UNK
cause	O
disease	B-UNK
.	O

The	O
probability	B-UNK
that	O
a	O
mutation	B-UNK
will	O
cause	O
disease	B-UNK
tends	O
to	O
be	O
higher	O
when	O
the	O
missense	B-UNK
mutation	I-UNK
is	O
within	O
a	O
functionally	O
important	O
sequence	B-UNK
..	O

Characterisation	O
of	O
a	O
new	O
rare	B-UNK
fragile	B-UNK
site	B-UNK
easily	O
confused	O
with	O
the	O
fragile	B-UNK
X.	O

A	O
new	O
fragile	B-UNK
site	B-UNK
(	O
FRAXE	O
)	O
in	O
Xq28	B-UNK
is	O
described	O
.	O

It	O
appears	B-UNK
to	O
be	O
a	O
typical	O
folate	O
sensitive	B-UNK
fragile	B-UNK
site	B-UNK
.	O

The	O
fragile	B-UNK
site	B-UNK
is	O
not	O
associated	O
with	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	B-UNK
when	O
subjected	O
to	O
Southern	B-UNK
analysis	B-UNK
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
DNA	B-UNK
sequence	I-UNK
characteristic	B-UNK
of	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
.	O

In	B-UNK
situ	I-UNK
hybridization	I-UNK
mapping	B-UNK
locates	O
the	O
fragile	B-UNK
site	B-UNK
between	O
150	O
kb	B-UNK
and	O
600	O
kb	B-UNK
distal	B-UNK
to	O
FRAXA	O
.	O

The	O
distinction	O
between	O
the	O
two	O
fragile	B-UNK
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	B-UNK
detection	B-UNK
of	O
FRAXE	O
,	O
without	O
molecular	B-UNK
analysis	I-UNK
,	O
could	O
result	B-UNK
in	O
misdiagnosis	O
of	O
fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
..	O

The	O
Norrie	B-DISEASE
disease	I-DISEASE
gene	B-UNK
maps	B-UNK
to	O
a	O
150	O
kb	B-UNK
region	B-UNK
on	O
chromosome	B-UNK
Xp11	O
.	O
3	O
.	O

Norrie	B-DISEASE
disease	I-DISEASE
is	O
a	O
human	B-UNK
X	O
-	O
linked	B-UNK
recessive	B-UNK
disorder	B-UNK
of	O
unknown	O
etiology	O
characterized	B-UNK
by	O
congenital	B-UNK
blindness	B-DISEASE
,	O
sensory	O
neural	O
deafness	B-DISEASE
and	O
mental	B-UNK
retardation	I-UNK
.	O

This	O
disease	B-DISEASE
gene	B-UNK
was	O
previously	B-UNK
linked	B-UNK
to	O
the	O
DXS7	B-UNK
(	O
L1	B-UNK
.	O
28	O
)	O
locus	B-UNK
and	O
the	O
MAO	O
genes	B-UNK
in	O
band	O
Xp11	O
.	O

3	O
3	O
.	O

We	O
report	B-UNK
here	O
fine	O
physical	B-UNK
mapping	B-UNK
of	O
the	O
obligate	B-UNK
region	B-UNK
containing	O
the	O
Norrie	B-DISEASE
disease	I-DISEASE
gene	B-UNK
(	O
NDP	B-UNK
)	O
defined	B-UNK
by	O
a	O
recombination	B-UNK
and	O
by	O
the	O
smallest	O
submicroscopic	B-UNK
chromosomal	B-UNK
deletion	B-UNK
associated	O
with	O
Norrie	B-UNK
disease	I-UNK
identified	B-UNK
to	O
date	B-UNK
.	O

Analysis	B-UNK
,	O
using	O
in	O
addition	B-UNK
two	O
overlapping	O
YAC	B-UNK
clones	O
from	O
this	O
region	B-UNK
,	O
allowed	O
orientation	O
of	O
the	O
MAOA	O
and	O
MAOB	O
genes	B-UNK
in	O
a	O
5	O
-	O
3	O
-	O
3	O
-	O
5	O
configuration	O
.	O

A	O
recombination	B-UNK
event	O
between	O
a	O
(	O
GT	B-UNK
)	O
n	O
polymorphism	B-UNK
in	O
intron	B-UNK
2	O
of	O
the	O
MAOB	O
gene	B-UNK
and	O
the	O
NDP	B-UNK
locus	B-UNK
,	O
in	O
a	O
family	B-UNK
previously	B-UNK
reported	I-UNK
to	O
have	O
a	O
recombination	B-UNK
between	O
DXS7	B-UNK
and	O
NDP	B-UNK
,	O
delineates	O
a	O
flanking	O
marker	B-UNK
telomeric	O
to	O
this	O
disease	B-DISEASE
gene	B-UNK
.	O

An	O
anonymous	O
DNA	B-UNK
probe	O
,	O
dc12	O
,	O
present	B-UNK
in	O
one	O
of	O
the	O
YACs	O
and	O
in	O
a	O
patient	B-UNK
with	O
a	O
submicroscopic	B-UNK
deletion	B-UNK
which	O
includes	O
MAOA	O
and	O
MAOB	O
but	O
not	O
L1	B-UNK
.	O

28	O
,	O
serves	O
as	O
a	O
flanking	O
marker	B-UNK
centromeric	O
to	O
the	O
disease	B-DISEASE
gene	B-UNK
.	O

An	O
Alu	B-UNK
-	O
PCR	B-UNK
fragment	B-UNK
from	O
the	O
right	O
arm	B-UNK
of	O
the	O
MAO	O
YAC	B-UNK
(	O
YMAO	O
.	O
AluR	O
)	O
is	O
not	O
deleted	B-UNK
in	O
this	O
patient	B-UNK
and	O
also	O
delineates	O
the	O
centromeric	O
extent	O
of	O
the	O
obligate	B-UNK
disease	B-DISEASE
region	B-UNK
.	O

The	O
apparent	O
order	B-UNK
of	O
these	O
loci	O
is	O
telomere	O
.	O

DXS7-MAOA	O
-	O
MAOB	O
-	O
NDP	B-UNK
-	O
dc12-YMAO	O
DXS7-MAOA	O
-	O
MAOB	O
-	O
NDP	B-UNK
-	O
dc12-YMAO	O
.	O

AluR.	O
centromere	O
.	O

Together	O
these	O
data	B-UNK
define	B-UNK
the	O
obligate	B-UNK
region	B-UNK
containing	O
the	O
NDP	B-UNK
gene	B-UNK
to	O
a	O
chromosomal	B-UNK
segment	O
less	O
than	O
150	O
kb	B-UNK
.	O

Molecular	B-UNK
basis	I-UNK
of	O
phenylketonuria	O
and	O
related	B-UNK
hyperphenylalaninemias	O
:	O
mutations	B-UNK
and	O
polymorphisms	B-UNK
in	O
the	O
human	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
human	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
producing	O
phenylketonuria	O
or	O
hyperphenylalaninemia	O
have	O
now	O
been	O
identified	B-UNK
in	O
many	O
patients	B-UNK
from	O
various	O
ethnic	B-UNK
groups	I-UNK
.	O

These	O
mutations	B-UNK
all	O
exhibit	O
a	O
high	B-UNK
degree	B-UNK
of	O
association	B-UNK
with	O
specific	B-UNK
restriction	B-UNK
fragment	I-UNK
-	O
length	B-UNK
polymorphism	B-UNK
haplotypes	O
at	O
the	O
PAH	B-UNK
locus	B-UNK
.	O

About	O
50	O
of	O
these	O
mutations	B-UNK
are	O
single	B-UNK
-	O
base	B-UNK
substitutions	B-UNK
,	O
including	O
six	O
nonsense	B-UNK
mutations	I-UNK
and	O
eight	O
splicing	B-UNK
mutations	B-UNK
,	O
with	O
the	O
remainder	O
being	O
missense	B-UNK
mutations	I-UNK
.	O

One	O
splicing	B-UNK
mutation	B-UNK
results	B-UNK
in	O
a	O
3	O
amino	B-UNK
acid	I-UNK
in	O
-	O
frame	B-UNK
insertion	O
.	O

Two	O
or	O
3	O
large	B-UNK
deletions	O
,	O
2	O
single	B-UNK
codon	B-UNK
deletions	O
,	O
and	O
2	O
single	B-UNK
base	I-UNK
deletions	O
have	O
been	O
found	O
.	O

Twelve	O
of	O
the	O
missense	B-UNK
mutations	I-UNK
apparently	O
result	B-UNK
from	O
the	O
methylation	B-UNK
and	O
subsequent	B-UNK
deamination	O
of	O
highly	B-UNK
mutagenic	O
CpG	B-UNK
dinucleotides	O
.	O

Recurrent	O
mutation	B-UNK
has	O
been	O
observed	B-UNK
at	O
several	O
of	O
these	O
sites	O
,	O
producing	O
associations	O
with	O
different	O
haplotypes	O
in	O
different	O
populations	O
.	O

About	O
half	B-UNK
of	O
all	O
missense	B-UNK
mutations	I-UNK
have	O
been	O
examined	O
by	O
in	O
vitro	O
expression	B-UNK
analysis	B-UNK
,	O
and	O
a	O
significant	B-UNK
correlation	B-UNK
has	O
been	O
observed	B-UNK
between	O
residual	B-UNK
PAH	B-UNK
activity	B-UNK
and	O
disease	B-UNK
phenotype	B-UNK
.	O

Since	O
continuing	O
advances	O
in	O
molecular	B-UNK
methodologies	O
have	O
dramatically	O
accelerated	O
the	O
rate	B-UNK
in	O
which	O
new	O
mutations	B-UNK
are	O
being	O
identified	B-UNK
and	O
characterized	B-UNK
,	O
this	O
register	O
of	O
mutations	B-UNK
will	O
be	O
updated	O
periodically	O
..	O

A	O
glycine250	O
-	O
-	O
>	O
aspartate	O
substitution	B-UNK
in	O
the	O
alpha	B-UNK
-	O
subunit	B-UNK
of	O
hexosaminidase	O
A	O
causes	O
juvenile	O
-	O
onset	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
in	O
a	O
Lebanese	O
-	O
Canadian	B-UNK
family	B-UNK
.	O

The	O
mutation	B-UNK
causing	I-UNK
juvenile	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
in	O
two	O
sibs	O
of	O
Lebanese	O
-	O
Maronite	O
origin	O
is	O
described	O
.	O

An	O
mRNA	O
-	O
containing	O
extract	O
of	O
cultured	O
fibroblasts	B-UNK
obtained	B-UNK
from	O
one	O
of	O
the	O
probands	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
coding	B-UNK
sequence	I-UNK
of	O
the	O
hexosaminidase	O
A	O
(	O
Hex	B-UNK
A	O
)	O
alpha	B-UNK
-	O
subunit	B-UNK
.	O

Sequencing	B-UNK
of	O
amplified	O
cDNA	O
fragments	O
revealed	B-UNK
a	O
single	B-UNK
alteration	O
,	O
guanine	B-UNK
to	O
adenine	O
at	O
nt	B-UNK
749	O
creating	O
a	O
G250D	O
mutation	B-UNK
.	O

The	O
mutation	B-UNK
introduces	O
a	O
new	O
recognition	O
site	B-UNK
for	O
the	O
restriction	B-UNK
enzyme	B-UNK
Eco	O
RV	O
,	O
permitting	O
identification	B-UNK
of	O
heterozygotes	B-UNK
for	O
this	O
allele	B-UNK
following	O
PCR	B-UNK
amplification	B-UNK
and	O
Eco	O
RV	O
digestion	O
of	O
exon	B-UNK
7	O
sequences	O
from	O
genomic	B-UNK
DNA	I-UNK
templates	O
.	O

In	O
order	B-UNK
to	O
test	B-UNK
the	O
effect	B-UNK
of	O
this	O
substitution	B-UNK
,	O
an	O
in	O
vitro	O
mutagenized	O
cDNA	O
construct	O
was	O
introduced	O
into	O
a	O
mammalian	O
expression	B-UNK
vector	O
and	O
transfected	O
into	O
monkey	O
Cos-1	O
cells	B-UNK
separately	O
or	O
along	O
with	O
a	O
beta-cDNA	O
expression	B-UNK
vector	O
.	O

When	O
the	O
mutant	B-UNK
alpha	B-UNK
-	O
cDNA	O
was	O
the	O
only	O
gene	B-UNK
introduced	O
into	O
COS	B-UNK
cells	B-UNK
no	O
enzymatic	B-UNK
activity	I-UNK
above	O
endogenous	O
COS	B-UNK
cell	B-UNK
activity	B-UNK
was	O
detected	B-UNK
.	O

Cotransfection	O
of	O
normal	B-UNK
alpha	B-UNK
-	O
cDNA	O
and	O
beta-cDNA	O
followed	O
by	O
immunoprecipitation	O
of	O
human	B-UNK
Hex	B-UNK
A	O
resulted	B-UNK
in	O
20-fold	O
increase	B-UNK
in	O
the	O
ratio	B-UNK
between	O
positive	O
and	O
negative	B-UNK
(	O
mock	O
transfection	O
)	O
control	B-UNK
values	O
.	O

This	O
allowed	O
the	O
detection	B-UNK
of	O
some	O
residual	B-UNK
activity	B-UNK
(	O
12	O
%	O
of	O
the	O
positive	O
control	B-UNK
)	O
when	O
the	O
mutant	B-UNK
alpha	B-UNK
-	O
cDNA	O
replaced	O
its	O
wild	B-UNK
-	O
type	B-UNK
counterpart	O
.	O

The	O
predicted	B-UNK
protein	B-UNK
environment	O
in	O
which	O
the	O
mutation	B-UNK
occurs	O
is	O
compared	B-UNK
to	O
that	O
of	O
the	O
adult	B-UNK
-	O
onset	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
mutation	B-UNK
caused	B-UNK
by	O
a	O
Gly269	O
-	O
-	O
>	O
Ser	O
substitution	B-UNK
in	O
exon	B-UNK
7	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Novel	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
mutations	B-UNK
from	O
China	O
.	O

We	O
describe	O
three	O
HEXA	B-UNK
mutations	B-UNK
associated	O
with	O
infantile	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
in	O
three	O
unrelated	B-UNK
nonconsanguineous	O
Chinese	B-UNK
families	B-UNK
.	O

Novel	O
mutations	B-UNK
were	O
found	O
in	O
two	O
of	O
these	O
families	B-UNK
.	O

The	O
third	O
is	O
a	O
previously	B-UNK
reported	I-UNK
mutation	B-UNK
(	O
G--	O
>	O
A	O
transition	B-UNK
at	O
nt	B-UNK
1444	O
)	O
(	O
Nakano	O
et	O
al	B-DISEASE
.	O
,	O
1988	O
)	O
.	O

Direct	B-UNK
sequencing	I-UNK
of	O
PCR	B-UNK
products	I-UNK
identified	B-UNK
a	O
novel	O
insertion	O
of	O
an	O
A	O
after	O
nt	B-UNK
547	O
in	O
family	B-UNK
1	O
.	O

This	O
change	B-UNK
generates	O
an	O
early	B-UNK
termination	B-UNK
codon	I-UNK
6	O
bp	B-UNK
downstream	O
from	O
the	O
insertion	O
site	B-UNK
.	O

Allele	B-UNK
-	O
specific	B-UNK
oligonucleotide	O
hybridization	B-UNK
confirmed	B-UNK
homozygosity	B-UNK
in	O
the	O
proband	B-UNK
.	O

Single	B-UNK
strand	I-UNK
conformational	B-UNK
polymorphism	B-UNK
analysis	B-UNK
and	O
direct	B-UNK
sequencing	I-UNK
of	O
amplified	O
exon	B-UNK
13	O
revealed	B-UNK
a	O
T--	O
>	O
C	O
transition	B-UNK
at	O
nt	B-UNK
1453	O
with	O
the	O
corresponding	O
amino	B-UNK
acid	I-UNK
substitution	I-UNK
W485R	O
in	O
the	O
second	O
family	B-UNK
.	O

This	O
mutation	B-UNK
creates	O
an	O
Fnu4HI	O
restriction	B-UNK
site	B-UNK
.	O

The	O
proband	B-UNK
is	O
homozygous	B-UNK
for	O
this	O
allele	B-UNK
.	O

When	O
the	O
site	B-UNK
-	O
specific	B-UNK
mutagenized	O
alpha	B-UNK
cDNA	O
carrying	B-UNK
the	O
T--	O
>	O
C	O
transition	B-UNK
at	O
nt	B-UNK
1453	O
was	O
expressed	B-UNK
in	O
COS	B-UNK
1	O
cells	B-UNK
hexosaminidase	O
S	O
activity	B-UNK
was	O
not	O
detectable	O
above	O
background	O
.	O

A	O
G--	O
>	O
A	O
transition	B-UNK
at	O
nt	B-UNK
1444	O
(	O
exon	B-UNK
13	O
)	O
corresponding	O
to	O
the	O
E482	O
K	O
substitution	B-UNK
was	O
found	O
in	O
the	O
third	O
family	B-UNK
.	O

This	O
mutation	B-UNK
occurs	O
at	O
a	O
CpG	B-UNK
dinucleotide	B-UNK
.	O

It	O
has	O
been	O
reported	B-UNK
in	O
an	O
Italian	B-UNK
TSD	B-UNK
proband	B-UNK
and	O
causes	O
defective	O
intracellular	O
transport	B-UNK
of	O
the	O
alpha	B-UNK
-	O
subunit	B-UNK
from	O
the	O
rough	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Two	O
missense	B-UNK
mutations	I-UNK
causing	B-UNK
mild	O
hyperphenylalaninemia	O
associated	O
with	O
DNA	B-UNK
haplotype	B-UNK
12	O
.	O

The	O
genetic	B-UNK
defects	B-UNK
responsible	B-UNK
for	O
most	O
phenylketonuria	O
(	O
PKU	B-UNK
)	O
and	O
hyperphenylalaninemia	O
(	O
HPA	O
)	O
cases	B-UNK
are	O
located	B-UNK
in	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
gene	B-UNK
.	O

Approximately	O
50	O
-	O
60	O
mutations	B-UNK
have	O
been	O
reported	B-UNK
in	O
Caucasians	B-UNK
and	O
are	O
reflected	O
in	O
a	O
wide	B-UNK
range	B-UNK
of	O
clinical	B-UNK
severities	O
.	O

Most	O
mutations	B-UNK
are	O
linked	B-UNK
to	O
specific	B-UNK
haplotypes	O
,	O
as	O
defined	B-UNK
by	O
eight	O
polymorphic	B-UNK
restriction	B-UNK
sites	O
in	O
the	O
PAH	B-UNK
gene	B-UNK
.	O

We	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	B-UNK
linked	B-UNK
to	O
haplotype	B-UNK
12	O
in	O
the	O
Swedish	O
PKU	B-UNK
/	O
HPA	O
population	B-UNK
,	O
since	O
7	O
of	O
8	O
patients	B-UNK
carrying	B-UNK
haplotype	B-UNK
12	O
had	O
mild	O
HPA	O
.	O

Sequence	B-UNK
analysis	I-UNK
revealed	B-UNK
a	O
C	O
-	O
to	O
-	O
G	O
transversion	B-UNK
at	O
the	O
second	O
base	B-UNK
of	O
codon	B-UNK
322	O
,	O
resulting	B-UNK
in	O
a	O
substitution	B-UNK
of	O
glycine	O
for	O
alanine	O
,	O
in	O
four	O
mutant	B-UNK
haplotype	B-UNK
12	O
genes	B-UNK
,	O
and	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-UNK
at	O
the	O
second	O
base	B-UNK
of	O
codon	B-UNK
408	O
,	O
resulting	B-UNK
in	O
a	O
substitution	B-UNK
of	O
glutamine	O
for	O
arginine	O
,	O
in	O
another	O
three	O
mutant	B-UNK
haplotype	B-UNK
12	O
genes	B-UNK
.	O

These	O
mutations	B-UNK
segregated	O
with	O
mutant	B-UNK
haplotype	B-UNK
12	O
alleles	B-UNK
in	O
nuclear	B-UNK
families	B-UNK
but	O
were	O
not	O
present	B-UNK
on	O
normal	B-UNK
or	O
other	O
mutant	B-UNK
alleles	I-UNK
.	O

Both	O
mutations	B-UNK
were	O
tested	O
in	O
a	O
eukaryotic	O
expression	B-UNK
system	O
in	O
which	O
enzyme	B-UNK
activities	O
of	O
different	O
mutant	B-UNK
PAH	B-UNK
enzymes	B-UNK
reflect	O
the	O
relative	B-UNK
severities	O
of	O
the	O
mutations	B-UNK
,	O
although	O
these	O
in	O
vitro	O
activities	O
cannot	O
be	O
translated	O
directly	O
into	O
in	O
vivo	B-UNK
hepatic	B-UNK
activities	O
.	O

The	O
A322	O
G	O
mutant	B-UNK
PAH	B-UNK
had	O
about	O
75	O
%	O
and	O
the	O
R408Q	O
mutant	B-UNK
PAH	B-UNK
about	O
55	O
%	O
of	O
the	O
wild	B-UNK
-	O
type	B-UNK
PAH	B-UNK
enzyme	B-UNK
activity	I-UNK
.	O

These	O
in	O
vitro	O
activities	O
are	O
the	O
highest	O
reported	B-UNK
for	O
mutant	B-UNK
PAH	B-UNK
enzymes	B-UNK
produced	O
in	O
the	O
same	O
expression	B-UNK
system	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

In	O
vitro	O
and	O
in	O
vivo	B-UNK
correlations	B-UNK
for	O
I65	O
T	O
and	O
M1V	O
mutations	B-UNK
at	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
locus	B-UNK
.	O

Mutations	B-UNK
at	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
locus	B-UNK
are	O
the	O
major	B-UNK
cause	O
of	O
hyperphenylalaninemia	O
.	O

We	O
have	O
previously	B-UNK
described	O
four	O
mutations	B-UNK
(	O
M1V	O
,	O
IVS12nt1	O
,	O
R408W	O
,	O
and	O
S349P	O
)	O
at	O
the	O
PAH	B-UNK
locus	B-UNK
in	O
French	B-UNK
Canadians	O
with	O
ancestry	O
in	O
eastern	B-UNK
Quebec	O
.	O

Here	O
we	O
report	B-UNK
(	O
1	O
)	O
identification	B-UNK
of	O
another	O
mutation	B-UNK
,	O
on	O
a	O
haplotype	B-UNK
9	O
chromosome	B-UNK
,	O
which	O
converts	O
codon	B-UNK
65	O
from	O
isoleucine	O
(	O
ATT	O
)	O
to	O
threonine	O
(	O
ACT	O
)	O
,	O
(	O
2	O
)	O
expression	B-UNK
analysis	B-UNK
of	O
the	O
I65	O
T	O
mutation	B-UNK
in	O
COS	B-UNK
cells	B-UNK
demonstrating	O
75	O
%	O
loss	B-UNK
of	O
both	O
immunoreactive	O
protein	B-UNK
and	O
enzyme	B-UNK
activity	I-UNK
,	O
and	O
(	O
3	O
)	O
expression	B-UNK
analysis	B-UNK
of	O
the	O
most	O
prevalent	O
PKU	B-UNK
allele	B-UNK
(	O
M1V	O
)	O
in	O
eastern	B-UNK
Quebec	O
,	O
showing	O
nondetectable	O
levels	B-UNK
of	O
PAH	B-UNK
protein	B-UNK
and	O
activity	B-UNK
,	O
a	O
finding	O
compatible	B-UNK
with	O
a	O
mutation	B-UNK
in	O
the	O
translation	O
initiation	O
codon	B-UNK
.	O

Homozygosity	B-UNK
for	O
M1V	O
and	O
codominant	O
inheritance	B-UNK
of	O
I65T	O
/	O
R408W	O
were	O
both	O
associated	O
with	O
classical	O
phenylketonuria	O
..	O

Molecular	B-UNK
basis	I-UNK
of	O
hexosaminidase	O
A	O
deficiency	B-UNK
and	O
pseudodeficiency	O
in	O
the	O
Berks	O
County	O
Pennsylvania	O
Dutch	B-UNK
.	O

Following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
,	O
a	O
non-Jewish	O
,	O
Pennsylvania	O
Dutch	B-UNK
kindred	O
was	O
screened	B-UNK
for	O
TSD	B-UNK
carriers	B-UNK
using	O
the	O
biochemical	O
assay	B-UNK
.	O

A	O
high	B-UNK
frequency	I-UNK
of	O
individuals	B-UNK
who	O
appeared	B-UNK
to	O
be	O
TSD	B-UNK
heterozygotes	B-UNK
was	O
detected	B-UNK
(	O
Kelly	O
et	O
al	B-DISEASE
.	O
,	O
1975	O
)	O
.	O

Clinical	B-UNK
and	O
biochemical	O
evidence	B-UNK
suggested	O
that	O
the	O
increased	B-UNK
carrier	B-UNK
frequency	I-UNK
was	O
due	O
to	O
at	O
least	O
two	O
altered	O
alleles	B-UNK
for	O
the	O
hexosaminidase	O
A	O
alpha	B-UNK
-	O
subunit	B-UNK
.	O

We	O
now	O
report	B-UNK
two	O
mutant	B-UNK
alleles	I-UNK
in	O
this	O
Pennsylvania	O
Dutch	B-UNK
kindred	O
,	O
and	O
one	O
polymorphism	B-UNK
.	O

One	O
allele	B-UNK
,	O
reported	B-UNK
originally	O
in	O
a	O
French	B-UNK
TSD	B-UNK
patient	B-UNK
(	O
Akli	O
et	O
al	B-DISEASE
.	O
,	O
1991	O
)	O
,	O
is	O
a	O
GT--	O
>	O
AT	O
transition	B-UNK
at	O
the	O
donor	B-UNK
splice	B-UNK
-	O
site	B-UNK
of	O
intron	B-UNK
9	O
.	O

The	O
second	O
,	O
a	O
C--	O
>	O
T	O
transition	B-UNK
at	O
nucleotide	B-UNK
739	O
(	O
Arg247Trp	O
)	O
,	O
has	O
been	O
shown	B-UNK
by	O
Triggs	O
-	O
Raine	O
et	O
al	B-DISEASE
.	O

(	O
1992	O
)	O
to	O
be	O
a	O
clinically	O
benign	O
"	O
pseudodeficient	O
"	O
allele	B-UNK
associated	O
with	O
reduced	O
enzyme	B-UNK
activity	I-UNK
against	O
artificial	O
substrate	O
.	O

Finally	B-UNK
,	O
a	O
polymorphism	B-UNK
[	O
G--	O
>	O
A	O
(	O
759	O
)	O
]	O
,	O
which	O
leaves	O
valine	O
at	O
codon	B-UNK
253	O
unchanged	O
,	O
is	O
described	O
.	O

A	O
mutation	B-UNK
common	B-UNK
in	O
non-Jewish	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
:	O
frequency	B-UNK
and	O
RNA	B-UNK
studies	B-UNK
.	O

Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
genetic	B-UNK
disorder	I-UNK
resulting	B-UNK
from	O
mutation	B-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
encoding	B-UNK
the	O
alpha	B-UNK
-	O
subunit	B-UNK
of	O
the	O
lysosomal	B-UNK
enzyme	B-UNK
,	O
beta-N-acetylhexosaminidase	O
A	O
(	O
Hex	B-UNK
A	O
)	O
.	O

We	O
have	O
discovered	O
that	O
a	O
Tay	O
-	O
Sachs	O
mutation	B-UNK
,	O
IVS-9	O
+	O
1	O
G--	O
>	O
A	O
,	O
first	O
detected	B-UNK
by	O
Akli	O
et	O
al	B-DISEASE
.	O

(	O
Genomics	O
11	O
124	O
-	O
134	O
,	O
1991	O
)	O
,	O
is	O
a	O
common	B-UNK
disease	B-UNK
allele	B-UNK
in	O
non-Jewish	O
Caucasians	B-UNK
(	O
10/58	O
alleles	B-UNK
examined	O
)	O
.	O

A	O
PCR	B-UNK
-	O
based	B-UNK
diagnostic	B-UNK
test	B-UNK
,	O
which	O
detects	O
an	O
NlaIII	O
site	B-UNK
generated	O
by	O
the	O
mutation	B-UNK
,	O
revealed	B-UNK
a	O
frequency	B-UNK
among	O
enzyme	B-UNK
-	O
defined	B-UNK
carriers	B-UNK
of	O
9/64	O
(	O
14	O
%	O
)	O
.	O

Most	O
of	O
those	O
carrying	B-UNK
the	O
allele	B-UNK
trace	O
their	O
origins	O
to	O
the	O
United	O
Kingdom	O
,	O
Ireland	O
,	O
or	O
Western	B-UNK
Europe	B-UNK
.	O

It	O
was	O
not	O
identified	B-UNK
among	O
12	O
Black	B-UNK
American	B-UNK
TSD	B-UNK
alleles	B-UNK
or	O
in	O
any	O
of	O
18	O
Ashkenazi	B-UNK
Jewish	I-UNK
,	O
enzyme	B-UNK
-	O
defined	B-UNK
carriers	B-UNK
who	O
did	O
not	O
carry	B-UNK
any	O
of	O
the	O
mutations	B-UNK
common	B-UNK
to	O
this	O
population	B-UNK
.	O

No	O
normally	O
spliced	O
RNA	B-UNK
was	O
detected	B-UNK
in	O
PCR	B-UNK
products	I-UNK
generated	O
from	O
reverse	B-UNK
transcription	B-UNK
of	O
RNA	B-UNK
carrying	B-UNK
the	O
IVS-9	O
mutation	B-UNK
.	O

Instead	O
,	O
the	O
low	B-UNK
levels	B-UNK
of	O
mRNA	O
from	O
this	O
allele	B-UNK
were	O
comprised	O
of	O
aberrant	B-UNK
species	B-UNK
resulting	B-UNK
from	O
the	O
use	O
of	O
either	O
of	O
two	O
cryptic	O
donor	B-UNK
sites	O
,	O
one	O
truncating	B-UNK
exon	B-UNK
9	O
and	O
the	O
other	O
within	O
IVS-9	O
,	O
spliced	O
to	O
exon	B-UNK
10	O
.	O

Numerous	O
additional	O
splice	B-UNK
products	B-UNK
were	O
detected	B-UNK
,	O
most	O
involving	O
skipping	O
of	O
one	O
or	O
more	O
surrounding	O
exons	O
.	O

Together	O
with	O
a	O
recently	O
identified	B-UNK
allele	B-UNK
responsible	B-UNK
for	O
Hex	B-UNK
A	O
pseudodeficiency	O
(	O
Triggs	O
-	O
Raine	O
et	O
al	B-DISEASE
.	O
Am	O
J	O
Hum	O
Genet	B-UNK
,	O
1992	O
)	O
,	O
these	O
two	O
alleles	B-UNK
accounted	O
for	O
almost	O
50	O
%	O
(	O
29/64	O
)	O
of	O
TSD	B-UNK
or	O
carrier	B-UNK
alleles	B-UNK
ascertained	O
by	O
enzyme	B-UNK
screening	B-UNK
tests	O
in	O
non-Jewish	O
Caucasians	B-UNK
..	O

Aberrant	B-UNK
splicing	B-UNK
of	O
the	O
CHM	B-UNK
gene	B-UNK
is	O
a	O
significant	B-UNK
cause	O
of	O
choroideremia	B-DISEASE
.	O

Choroideremia	B-UNK
(	O
CHM	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
progressive	B-UNK
degeneration	B-UNK
of	O
the	O
choroid	O
and	O
retina	O
.	O

12	O
%	O
of	O
unrelated	B-UNK
male	B-UNK
patients	B-UNK
carry	B-UNK
deletions	O
of	O
the	O
partially	O
cloned	O
CHM	B-UNK
gene	B-UNK
.	O

In	O
Finland	O
,	O
there	O
are	O
more	O
than	O
120	O
living	O
CHM	B-UNK
patients	B-UNK
belonging	O
to	O
eight	O
apparently	O
unrelated	B-UNK
pedigrees	O
.	O

Molecular	B-UNK
deletions	O
involving	O
the	O
CHM	B-UNK
gene	B-UNK
have	O
been	O
detected	B-UNK
in	O
three	O
families	B-UNK
.	O

We	O
have	O
screened	B-UNK
the	O
remaining	O
five	O
families	B-UNK
for	O
point	B-UNK
mutations	I-UNK
.	O

In	O
one	O
large	B-UNK
family	B-UNK
a	O
single	B-UNK
nucleotide	I-UNK
(	O
T	O
)	O
insertion	O
into	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
of	O
exon	B-UNK
C	O
leads	B-UNK
to	O
two	O
aberrantly	O
spliced	O
mRNAs	O
both	O
producing	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
.	O

The	O
mutation	B-UNK
can	O
be	O
assayed	O
easily	O
by	O
amplification	B-UNK
and	O
digestion	O
with	O
Msel	O
.	O

Our	O
findings	B-UNK
provide	B-UNK
additional	O
evidence	B-UNK
for	O
the	O
pathogenetic	O
role	B-UNK
of	O
CHM	B-UNK
mutations	B-UNK
and	O
provide	B-UNK
a	O
diagnostic	B-UNK
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
CHM	B-UNK
patients	B-UNK
..	O

Germline	B-UNK
intronic	O
and	O
exonic	O
mutations	B-UNK
in	O
the	O
Wilms	B-UNK
'	O
tumour	B-UNK
gene	B-UNK
(	O
WT1	B-UNK
)	O
affecting	O
urogenital	O
development	B-UNK
.	O

Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	B-UNK
human	B-UNK
developmental	O
disorder	B-UNK
affecting	O
the	O
urogenital	O
system	O
and	O
leading	B-UNK
to	O
renal	B-DISEASE
failure	I-DISEASE
,	O
intersex	O
disorders	B-UNK
and	O
Wilms	B-UNK
tumour	B-DISEASE
.	O

In	O
this	O
report	B-UNK
,	O
four	O
individuals	B-UNK
with	O
this	O
syndrome	B-DISEASE
are	O
described	O
carrying	B-UNK
germline	B-UNK
point	B-UNK
mutations	I-UNK
in	O
the	O
Wilms	B-UNK
tumour	B-UNK
suppressor	I-UNK
gene	B-UNK
,	O
WT1	B-UNK
.	O

Three	O
of	O
these	O
mutations	B-UNK
were	O
in	O
the	O
zinc	B-UNK
finger	I-UNK
domains	B-UNK
of	O
WT1	B-UNK
.	O

The	O
fourth	B-UNK
occurred	B-UNK
within	O
intron	B-UNK
9	O
,	O
preventing	O
splicing	B-UNK
at	O
one	O
of	O
the	O
alternatively	O
chosen	O
splice	B-UNK
donor	I-UNK
sites	O
of	O
exon	B-UNK
9	O
when	O
assayed	O
in	O
vitro	O
.	O

These	O
results	B-UNK
provide	I-UNK
genetic	B-UNK
evidence	B-UNK
for	O
distinct	O
functional	O
roles	O
of	O
the	O
WT1	B-UNK
isoforms	O
in	O
urogenital	O
development	B-UNK
..	O

Characterization	B-UNK
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
region	B-UNK
predicts	O
multiple	B-UNK
protein	B-UNK
isoform	O
-	O
encoding	B-UNK
mRNAs	O
.	O

The	O
mutation	B-UNK
underlying	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
has	O
been	O
identified	B-UNK
as	O
an	O
expansion	B-UNK
of	O
a	O
polymorphic	B-UNK
CTG	B-UNK
-	O
repeat	B-UNK
in	O
a	O
gene	B-UNK
encoding	B-UNK
protein	B-UNK
kinase	I-UNK
activity	B-UNK
.	O

Brain	B-UNK
and	O
heart	B-UNK
transcripts	O
of	O
the	O
DM	B-UNK
-	O
kinase	B-UNK
(	O
DMR	O
-	O
B15	O
)	O
gene	B-UNK
are	O
subject	O
to	O
alternative	B-UNK
RNA	B-UNK
splicing	B-UNK
in	O
both	O
human	B-UNK
and	O
mouse	B-UNK
.	O

The	O
unstable	O
[	O
CTG	B-UNK
]	O
5	O
-	O
30	O
motif	B-UNK
is	O
found	O
uniquely	O
in	O
humans	B-UNK
,	O
although	O
the	O
flanking	O
nucleotides	O
are	O
also	O
present	B-UNK
in	O
mouse	B-UNK
.	O

Characterization	B-UNK
of	O
the	O
DM	B-UNK
region	B-UNK
of	O
both	O
species	B-UNK
reveals	O
another	O
active	B-UNK
gene	B-UNK
(	O
DMR	O
-	O
N9	O
)	O
in	O
close	B-UNK
proximity	O
to	O
the	O
kinase	B-UNK
gene	B-UNK
.	O

DMR	O
-	O
N9	O
transcripts	O
,	O
mainly	O
expressed	B-UNK
in	O
brain	B-UNK
and	O
testis	O
,	O
possess	O
a	O
single	B-UNK
,	O
large	B-UNK
open	O
reading	B-UNK
frame	I-UNK
,	O
but	O
the	O
function	B-UNK
of	O
its	O
protein	B-UNK
product	I-UNK
is	O
unknown	O
.	O

Clinical	B-UNK
manifestation	B-UNK
of	O
DM	B-UNK
may	O
be	O
caused	B-UNK
by	O
the	O
expanded	B-UNK
CTG	B-UNK
-	O
repeat	B-UNK
compromising	O
the	O
(	O
alternative	B-UNK
)	O
expression	B-UNK
of	O
DM	B-DISEASE
-	O
kinase	B-UNK
or	O
DMR	O
-	O
N9	O
proteins	B-UNK
..	O

Fragile	B-UNK
X	I-UNK
syndrome	I-UNK
without	O
CCG	O
amplification	B-UNK
has	O
an	O
FMR1	B-UNK
deletion	B-UNK
.	O

We	O
describe	O
a	O
patient	B-UNK
with	O
typical	O
clinical	B-UNK
features	I-UNK
of	O
the	O
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
,	O
but	O
without	O
cytogenetic	B-UNK
expression	B-UNK
of	O
the	O
fragile	B-UNK
X	O
or	O
an	O
amplified	O
CCG	O
trinucleotide	B-UNK
repeat	I-UNK
fragment	B-UNK
.	O

The	O
patient	B-UNK
has	O
a	O
previously	B-UNK
uncharacterized	O
submicroscopic	B-UNK
deletion	B-UNK
encompassing	O
the	O
CCG	O
repeat	B-UNK
,	O
the	O
entire	O
FMR1	B-UNK
gene	B-UNK
and	O
about	O
2	O
.	O

5	O
megabases	O
of	O
flanking	O
sequences	O
.	O

This	O
finding	O
confirms	O
that	O
the	O
fragile	B-UNK
X	O
phenotype	B-UNK
can	O
exist	O
,	O
without	O
amplification	B-UNK
of	O
the	O
CCG	O
repeat	B-UNK
or	O
cytogenetic	B-UNK
expression	B-UNK
of	O
the	O
fragile	B-UNK
X	O
,	O
and	O
that	O
fragile	B-UNK
X	I-UNK
syndrome	I-UNK
is	O
a	O
genetically	B-UNK
homogeneous	O
disorder	B-UNK
involving	O
FMR1	B-UNK
.	O

We	O
also	O
found	O
random	B-UNK
X	O
-	O
inactivation	B-UNK
in	O
the	O
mother	O
of	O
the	O
patient	B-UNK
who	O
was	O
shown	B-UNK
to	O
be	O
a	O
carrier	B-UNK
of	O
this	O
deletion	B-UNK
.	O

Cloning	B-UNK
of	O
the	O
Huntington	B-UNK
disease	I-UNK
region	B-UNK
in	O
yeast	B-UNK
artificial	O
chromosomes	O
.	O

The	O
gene	B-UNK
responsible	B-UNK
for	O
Huntington	B-UNK
disease	I-UNK
has	O
been	O
localized	B-UNK
to	O
a	O
2	O
.	O

5	O
million	O
base	B-UNK
pair	I-UNK
(	O
Mb	B-DISEASE
)	O
region	B-UNK
between	O
the	O
loci	O
D4S10	O
and	O
D4S168	O
on	O
the	O
short	B-UNK
arm	B-UNK
of	O
chromosome	B-UNK
4	O
.	O

As	O
part	O
of	O
a	O
strategy	O
to	O
clone	O
the	O
HD	B-UNK
gene	B-UNK
on	O
the	O
basis	B-UNK
of	O
its	O
chromosomal	B-UNK
location	B-UNK
,	O
we	O
isolated	B-UNK
genomic	B-UNK
DNA	I-UNK
from	O
the	O
HD	B-UNK
region	B-UNK
as	O
a	O
set	B-UNK
of	O
overlapping	O
yeast	B-UNK
artificial	O
chromosome	B-UNK
(	O
YAC	B-UNK
)	O
clones	O
.	O

Twenty	O
-	O
eight	O
YAC	B-UNK
clones	O
were	O
identified	B-UNK
by	O
screening	B-UNK
human	B-UNK
YAC	B-UNK
libraries	O
with	O
twelve	O
PCR	B-UNK
-	O
based	B-UNK
sequence	B-UNK
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
from	O
the	O
region	B-UNK
.	O

We	O
assembled	O
the	O
YAC	B-UNK
clones	O
into	O
overlapping	O
sets	O
by	O
hybridizing	O
them	O
to	O
a	O
large	B-UNK
number	B-UNK
of	O
DNA	B-UNK
probes	O
from	O
the	O
HD	B-UNK
region	B-UNK
,	O
including	O
the	O
STSs	O
.	O

In	O
addition	B-UNK
,	O
we	O
isolated	B-UNK
the	O
ends	O
of	O
the	O
human	B-UNK
DNA	B-UNK
inserts	O
of	O
most	O
of	O
the	O
YAC	B-UNK
clones	O
to	O
assist	O
in	O
the	O
construction	O
of	O
the	O
contig	O
.	O

Although	O
almost	O
half	B-UNK
of	O
the	O
YACs	O
appear	O
to	O
contain	O
chimeric	O
inserts	O
and	O
several	O
contain	O
internal	O
deletions	O
or	O
other	O
rearrangements	O
,	O
we	O
were	O
able	O
to	O
obtain	O
over	O
2	O
.	O

2	O
Mb	B-DISEASE
of	O
the	O
HD	B-UNK
region	B-UNK
in	O
YACs	O
,	O
including	O
one	O
continuous	O
segment	O
of	O
2	O
.	O

0	O
Mb	B-DISEASE
covering	O
the	O
region	B-UNK
that	O
most	O
likely	O
contains	O
the	O
HD	B-UNK
gene	B-UNK
.	O

Ten	O
of	O
the	O
twenty	O
eight	O
YAC	B-UNK
clones	O
comprise	O
a	O
minimal	O
set	B-UNK
spanning	O
the	O
2	O
.	O

2	O
Mb	B-DISEASE
.	O

These	O
clones	O
provide	B-UNK
reagents	O
for	O
the	O
complete	O
characterization	B-UNK
of	O
this	O
region	B-UNK
of	O
the	O
genome	B-UNK
and	O
for	O
the	O
eventual	O
isolation	B-UNK
of	O
the	O
HD	B-UNK
gene	B-UNK
.	O

Characterization	B-UNK
of	O
a	O
YAC	B-UNK
containing	O
part	O
or	O
all	O
of	O
the	O
Norrie	B-DISEASE
disease	I-DISEASE
locus	B-UNK
.	O

It	O
has	O
been	O
shown	B-UNK
from	O
pulsed	O
-	O
field	B-UNK
gel	B-UNK
electrophoresis	I-UNK
(	O
PFGE	O
)	O
that	O
the	O
monoamine	O
oxidase	O
genes	B-UNK
A	O
and	O
B	O
(	O
MAOA	O
&	O
MAOB	O
)	O
and	O
DXS7	B-UNK
loci	O
are	O
physically	O
very	O
close	B-UNK
.	O

We	O
have	O
therefore	O
extended	O
studies	B-UNK
on	O
their	O
relationship	B-UNK
through	O
the	O
characterisation	O
of	O
a	O
650	O
kb	B-UNK
YAC	B-UNK
isolated	B-UNK
using	O
L1	B-UNK
.	O

28	O
(	O
recognising	O
the	O
DXS7	B-UNK
locus	B-UNK
)	O
as	O
a	O
probe	O
.	O

Restriction	B-UNK
mapping	B-UNK
of	O
the	O
YAC	B-UNK
indicates	O
that	O
it	O
contains	O
both	O
MAOA	O
and	O
MAOB	O
genes	B-UNK
in	O
addition	B-UNK
to	O
the	O
DXS7	B-UNK
locus	B-UNK
.	O

The	O
map	B-UNK
derived	B-UNK
from	O
the	O
YL1	O
.	O

28-YAC	O
is	O
compatible	B-UNK
both	O
with	O
the	O
map	B-UNK
from	O
an	O
independently	O
derived	B-UNK
YAC	B-UNK
carrying	B-UNK
MAOA	O
and	O
B	O
genes	B-UNK
and	O
with	O
the	O
long	B-UNK
range	B-UNK
genomic	B-UNK
map	B-UNK
for	O
the	O
region	B-UNK
.	O

A	O
series	B-UNK
of	O
subclones	O
prepared	O
from	O
a	O
phage	O
library	O
(	O
lambda	O
DASH	O
II	B-UNK
)	O
of	O
the	O
YAC	B-UNK
have	O
been	O
characterised	O
and	O
have	O
been	O
employed	O
to	O
determine	B-UNK
the	O
end	B-UNK
point	B-UNK
of	O
the	O
deletion	B-UNK
of	O
a	O
Norrie	B-DISEASE
disease	I-DISEASE
(	O
NDP	B-UNK
)	O
patient	B-UNK
who	O
has	O
been	O
shown	B-UNK
to	O
lack	B-UNK
both	O
DXS7	B-UNK
and	O
MAO	O
coding	B-UNK
sequences	O
.	O

The	O
pattern	B-UNK
of	O
retention	O
of	O
subclones	O
in	O
the	O
deletion	B-UNK
patient	B-UNK
place	O
the	O
end	B-UNK
point	B-UNK
of	O
the	O
deletion	B-UNK
within	O
30	O
-	O
130	O
kb	B-UNK
of	O
the	O
proximal	B-UNK
end	B-UNK
of	O
the	O
YAC	B-UNK
.	O

By	O
combining	O
the	O
data	B-UNK
with	O
established	O
recombination	B-UNK
analysis	B-UNK
,	O
we	O
provide	B-UNK
evidence	I-UNK
that	O
all	O
or	O
part	O
of	O
the	O
NDP	B-UNK
lies	O
in	O
the	O
interval	B-UNK
of	O
approximately	O
250	O
kb	B-UNK
within	O
the	O
YAC	B-UNK
.	O

Both	O
mutations	B-UNK
in	O
G6PD	B-UNK
A	O
-	O
are	O
necessary	O
to	O
produce	B-UNK
the	O
G6PD	B-UNK
deficient	B-UNK
phenotype	B-UNK
.	O

The	O
high	B-UNK
prevalence	B-UNK
of	O
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
African	B-UNK
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	B-UNK
variant	O
A-	O
,	O
which	O
differs	O
from	O
the	O
wild	B-UNK
-	O
type	B-UNK
G6PD	B-UNK
B	O
by	O
two	O
amino	B-UNK
acid	I-UNK
replacements	O
,	O
68	O
Val--	O
>	O
Met	B-UNK
and	O
126	O
Asn--	O
>	O
Asp	O
.	O

The	O
non-deficient	O
polymorphic	B-UNK
variant	O
G6PD	B-UNK
A	O
contains	O
only	O
the	O
mutation	B-UNK
126	O
Asn--	O
>	O
Asp	O
.	O

The	O
frequencies	O
of	O
the	O
G6PD	B-UNK
A	O
and	O
of	O
the	O
G6PD	B-UNK
A	O
-	O
genes	B-UNK
in	O
parts	O
of	O
Africa	B-UNK
are	O
both	O
about	O
0	O
.	O

2	O
.	O

The	O
68	O
Val--	O
>	O
Met	B-UNK
mutation	B-UNK
has	O
not	O
been	O
found	O
in	O
a	O
B	O
background	O
.	O

This	O
could	O
be	O
because	O
the	O
68	O
Val--	O
>	O
Met	B-UNK
mutation	B-UNK
happened	O
to	O
arise	O
in	O
an	O
A	O
gene	B-UNK
in	O
the	O
first	O
instance	O
,	O
or	O
because	O
the	O
68	O
Val--	O
>	O
Met	B-UNK
mutation	B-UNK
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
G6PD	B-UNK
deficiency	I-UNK
.	O

We	O
have	O
approached	O
this	O
question	O
by	O
producing	O
G6PD	B-UNK
B	O
,	O
A	O
,	O
A-	O
,	O
and	O
G6PD	B-UNK
68	O
Val--	O
>	O
Met	B-UNK
in	O
a	O
bacterial	B-UNK
expression	B-UNK
system	O
and	O
analysing	O
their	O
biochemical	O
properties	B-UNK
.	O

With	O
each	O
single	B-UNK
mutation	B-UNK
we	O
found	O
a	O
slight	O
decrease	O
in	O
both	O
the	O
specific	B-UNK
activity	B-UNK
and	O
the	O
yield	O
of	O
enzyme	B-UNK
when	O
compared	B-UNK
to	O
G6PD	B-UNK
B.	O

When	O
both	O
mutations	B-UNK
were	O
introduced	O
together	O
,	O
there	O
was	O
a	O
roughly	O
additive	O
effect	B-UNK
on	O
specific	B-UNK
activity	B-UNK
,	O
but	O
a	O
much	O
more	O
drastic	O
effect	B-UNK
on	O
enzyme	B-UNK
yield	O
(	O
4	O
%	O
of	O
normal	B-UNK
)	O
.	O

This	O
synergistic	O
effect	B-UNK
was	O
also	O
demonstrated	O
on	O
thermal	O
stability	O
,	O
especially	O
at	O
low	B-UNK
NADP	O
concentrations	O
.	O

Comparable	O
results	B-UNK
were	O
produced	O
when	O
the	O
replacement	O
119	O
Gln--	O
>	O
Glu	B-UNK
was	O
studied	O
instead	O
of	O
126	O
Asn--	O
>	O
Asp	O
.	O

We	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	B-UNK
is	O
responsible	B-UNK
for	O
enzyme	B-UNK
deficiency	I-UNK
in	O
G6PD	B-UNK
A	O
-	O
because	O
they	O
act	O
synergistically	O
in	O
causing	B-UNK
instability	B-UNK
of	O
the	O
enzyme	B-UNK
.	O

Small	O
nuclear	B-UNK
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	B-UNK
)	O
,	O
an	O
expressed	B-UNK
gene	B-UNK
in	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
critical	B-UNK
region	I-UNK
.	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
is	O
associated	O
with	O
paternally	O
derived	B-UNK
chromosomal	B-UNK
deletions	O
in	O
region	B-UNK
15q11	B-UNK
-	O
13	O
or	O
with	O
maternal	O
disomy	B-UNK
for	O
chromosome	B-UNK
15	O
.	O

Therefore	O
,	O
loss	B-UNK
of	O
the	O
expressed	B-UNK
paternal	O
alleles	B-UNK
of	O
maternally	O
imprinted	O
genes	B-UNK
must	O
be	O
responsible	B-UNK
for	O
the	O
PWS	B-UNK
phenotype	B-UNK
.	O

We	O
have	O
mapped	B-UNK
the	O
gene	B-UNK
encoding	B-UNK
the	O
small	O
nuclear	B-UNK
RNA	B-UNK
associated	O
polypeptide	O
SmN	O
(	O
SNRPN	B-UNK
)	O
to	O
human	B-UNK
chromosome	I-UNK
15q12	O
and	O
a	O
processed	O
pseudogene	O
SNRPNP1	O
to	O
chromosome	B-UNK
region	B-UNK
6pter	O
-	O
p21	O
.	O

Furthermore	O
,	O
SNRPN	B-UNK
was	O
mapped	B-UNK
to	O
the	O
minimal	O
deletion	B-UNK
interval	B-UNK
that	O
is	O
critical	B-UNK
for	O
PWS	B-UNK
.	O

The	O
fact	B-UNK
that	O
the	O
mouse	B-UNK
Snrpn	B-UNK
gene	B-UNK
is	O
maternally	O
imprinted	O
in	O
brain	B-UNK
suggests	O
that	O
loss	B-UNK
of	O
the	O
paternally	O
derived	B-UNK
SNRPN	B-UNK
allele	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
PWS	B-UNK
phenotype	B-UNK
..	O

The	O
presence	O
of	O
two	O
different	O
infantile	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
mutations	B-UNK
in	O
a	O
Cajun	O
population	B-UNK
.	O

A	O
study	B-UNK
was	O
undertaken	O
to	O
characterize	O
the	O
mutation	B-UNK
(	O
s	O
)	O
responsible	B-UNK
for	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
in	O
a	O
Cajun	O
population	B-UNK
in	O
southwest	O
Louisiana	O
and	O
to	O
identify	B-UNK
the	O
origins	O
of	O
these	O
mutations	B-UNK
.	O

Eleven	O
of	O
12	O
infantile	B-UNK
TSD	B-UNK
alleles	B-UNK
examined	O
in	O
six	O
families	B-UNK
had	O
the	O
beta-hexosaminidase	O
A	O
(	O
Hex	B-UNK
A	O
)	O
alpha	B-UNK
-	O
subunit	B-UNK
exon	B-UNK
11	O
insertion	O
mutation	B-UNK
that	O
is	O
present	B-UNK
in	O
approximately	O
70	O
%	O
of	O
Ashkenazi	B-UNK
Jewish	I-UNK
TSD	B-UNK
heterozygotes	B-UNK
.	O

The	O
mutation	B-UNK
in	O
the	O
remaining	O
allele	B-UNK
was	O
a	O
single	B-UNK
-	O
base	B-UNK
transition	B-UNK
in	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
of	O
the	O
alpha	B-UNK
-	O
subunit	B-UNK
intron	B-UNK
9	O
.	O

To	O
determine	B-UNK
the	O
origins	O
of	O
these	O
two	O
mutations	B-UNK
in	O
the	O
Cajun	O
population	B-UNK
,	O
the	O
TSD	B-UNK
carrier	B-UNK
status	I-UNK
was	O
enzymatically	O
determined	B-UNK
for	O
90	O
members	B-UNK
of	O
four	O
of	O
the	O
six	O
families	B-UNK
,	O
and	O
extensive	B-UNK
pedigrees	O
were	O
constructed	O
for	O
all	O
carriers	B-UNK
.	O

A	O
single	B-UNK
ancestral	O
couple	O
from	O
France	O
was	O
found	O
to	O
be	O
common	B-UNK
to	O
most	O
of	O
the	O
carriers	B-UNK
of	O
the	O
exon	B-UNK
11	O
insertion	O
.	O

Pedigree	B-UNK
data	B-UNK
suggest	B-UNK
that	O
this	O
mutation	B-UNK
has	O
been	O
in	O
the	O
Cajun	O
population	B-UNK
since	O
its	O
founding	O
over	O
2	O
centuries	O
ago	O
and	O
that	O
it	O
may	O
be	O
widely	O
distributed	O
within	O
the	O
population	B-UNK
.	O

In	O
contrast	B-UNK
,	O
the	O
intron	B-UNK
9	O
mutation	B-UNK
apparently	O
was	O
introduced	O
within	O
the	O
last	O
century	O
and	O
probably	O
is	O
limited	O
to	O
a	O
few	O
Louisiana	O
families	B-UNK
..	O

Mutations	B-UNK
in	O
the	O
candidate	B-UNK
gene	I-UNK
for	O
Norrie	B-UNK
disease	I-UNK
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
isolated	B-UNK
a	O
candidate	B-UNK
gene	I-UNK
for	O
X	O
linked	B-UNK
Norrie	B-DISEASE
disease	I-DISEASE
(	O
ND	O
)	O
which	O
was	O
found	O
to	O
be	O
deleted	B-UNK
or	O
disrupted	O
in	O
several	O
patients	B-UNK
.	O

As	O
a	O
prerequisite	O
for	O
the	O
identification	B-UNK
of	O
point	B-UNK
mutations	I-UNK
in	O
the	O
ND	O
gene	B-UNK
we	O
have	O
established	O
the	O
exon	B-UNK
-	O
intron	B-UNK
structure	B-UNK
of	O
this	O
gene	B-UNK
.	O

In	O
17	O
unrelated	B-UNK
patients	B-UNK
and	O
15	O
controls	O
,	O
PCR	B-UNK
products	I-UNK
derived	B-UNK
from	O
the	O
promoter	O
region	B-UNK
,	O
exons	O
1	O
and	O
2	O
as	O
well	O
as	O
the	O
coding	B-UNK
part	O
of	O
exon	B-UNK
3	O
were	O
analysed	O
with	O
the	O
single	B-UNK
strand	I-UNK
conformation	I-UNK
polymorphism	I-UNK
(	O
SSCP	B-UNK
)	O
technique	O
.	O

In	O
12	O
patients	B-UNK
altered	O
PCR	B-UNK
fragments	O
were	O
detected	B-UNK
which	O
were	O
studied	O
in	O
detail	O
by	O
direct	B-UNK
sequencing	I-UNK
.	O

Eleven	O
different	O
mutations	B-UNK
were	O
found	O
,	O
and	O
all	O
but	O
one	O
are	O
likely	O
to	O
give	O
rise	B-UNK
to	O
significant	B-UNK
structural	B-UNK
changes	O
in	O
the	O
predicted	B-UNK
protein	B-UNK
.	O

These	O
findings	B-UNK
,	O
and	O
the	O
absence	B-UNK
of	O
functionally	O
relevant	O
base	B-UNK
changes	O
in	O
healthy	O
controls	O
,	O
emphasize	O
the	O
causal	O
role	B-UNK
of	O
this	O
candidate	B-UNK
gene	I-UNK
in	O
Norrie	B-UNK
disease	I-UNK
and	O
pave	O
the	O
way	O
for	O
reliable	O
diagnosis	B-UNK
and	O
carrier	B-UNK
detection	I-UNK
..	O

Detection	B-UNK
of	O
a	O
nonsense	B-UNK
mutation	I-UNK
in	O
the	O
dystrophin	B-UNK
gene	I-UNK
by	O
multiple	B-UNK
SSCP	B-UNK
.	O

A	O
combination	B-UNK
of	O
multiplex	O
PCR	B-UNK
with	O
the	O
single	B-UNK
strand	I-UNK
conformation	I-UNK
polymorphism	I-UNK
(	O
SSCP	B-UNK
)	O
technique	O
was	O
employed	O
to	O
screen	B-UNK
for	O
point	B-UNK
mutations	I-UNK
in	O
the	O
human	B-UNK
dystrophin	B-UNK
gene	I-UNK
.	O

Co-amplification	O
of	O
11	O
exons	O
from	O
genomic	B-UNK
DNA	I-UNK
of	O
Duchenne	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
/	O
BMD	B-UNK
)	O
patients	B-UNK
with	O
no	O
deletion	B-UNK
or	O
duplication	B-UNK
was	O
performed	O
and	O
the	O
samples	B-UNK
subjected	O
to	O
multiple	B-UNK
SSCP	B-UNK
analysis	B-UNK
.	O

We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
nonsense	B-UNK
mutation	I-UNK
in	O
a	O
Duchenne	B-UNK
patient	B-UNK
identified	B-UNK
by	O
this	O
approach	O
.	O

The	O
mutation	B-UNK
introduces	O
a	O
termination	B-UNK
codon	I-UNK
within	O
exon	B-UNK
8	O
of	O
the	O
dystrophin	B-UNK
gene	I-UNK
.	O

It	O
is	O
predicted	B-UNK
to	O
cause	O
a	O
very	O
premature	B-UNK
translational	O
termination	B-UNK
accounting	O
for	O
the	O
severe	B-UNK
phenotype	I-UNK
observed	B-UNK
.	O

The	O
patient	B-UNK
inherited	B-UNK
this	O
mutation	B-UNK
from	O
his	O
mother	O
.	O

In	O
addition	B-UNK
the	O
analysis	B-UNK
revealed	I-UNK
5	O
polymorphisms	B-UNK
useful	O
for	O
internal	O
control	B-UNK
..	O

Proliferation	O
-	O
related	B-UNK
expression	B-UNK
of	O
p19	O
/	O
nm23	O
nucleoside	O
diphosphate	O
kinase	B-UNK
.	O

High	B-UNK
level	B-UNK
expression	B-UNK
of	O
the	O
nm23-H1	O
gene	B-UNK
,	O
which	O
encodes	B-UNK
for	O
a	O
nucleoside	O
diphosphate	O
kinase	B-UNK
,	O
has	O
been	O
found	O
to	O
correlate	O
with	O
diminished	O
metastasis	B-DISEASE
in	O
some	O
tumors	B-UNK
but	O
not	O
in	O
others	O
.	O

We	O
have	O
previously	B-UNK
identified	I-UNK
the	O
protein	B-UNK
product	I-UNK
of	O
the	O
nm23-H1	O
gene	B-UNK
in	O
two	O
-	O
dimensional	O
electrophoretic	B-UNK
gels	O
and	O
have	O
designated	O
it	O
p19	O
/	O
nm23	O
.	O

In	O
neuroblastoma	B-DISEASE
,	O
higher	O
levels	B-UNK
of	O
p19	O
/	O
nm23	O
,	O
which	O
are	O
associated	O
with	O
amplification	B-UNK
of	O
the	O
N	O
-	O
myc	O
oncogene	O
,	O
large	B-UNK
tumor	B-DISEASE
mass	B-UNK
,	O
and	O
metastasis	B-DISEASE
,	O
were	O
observed	B-UNK
in	O
advanced	O
stage	B-UNK
tumors	B-DISEASE
compared	B-UNK
with	O
limited	O
stage	B-UNK
disease	B-DISEASE
.	O

Because	O
of	O
the	O
variable	B-UNK
expression	B-UNK
of	O
nm23-H1	O
in	O
different	O
tumors	B-UNK
,	O
we	O
have	O
investigated	O
the	O
relationship	B-UNK
between	O
amounts	B-UNK
of	O
the	O
protein	B-UNK
and	O
cell	B-UNK
proliferation	O
.	O

The	O
levels	B-UNK
of	O
p19	O
/	O
nm23	O
were	O
compared	B-UNK
between	O
resting	O
and	O
mitotically	O
stimulated	O
normal	B-UNK
human	B-UNK
PBLs	O
and	O
in	O
leukemia	B-DISEASE
cells	B-UNK
.	O

The	O
amount	O
of	O
p19	O
/	O
nm23	O
increased	B-UNK
in	O
normal	B-UNK
lymphocytes	O
in	O
response	B-UNK
to	O
mitotic	O
stimulation	O
and	O
paralleled	O
the	O
increase	B-UNK
in	O
DNA	B-UNK
synthesis	B-UNK
.	O

In	O
leukemia	B-DISEASE
cells	B-UNK
obtained	B-UNK
from	O
patients	B-UNK
with	O
different	O
subtypes	O
of	O
acute	B-DISEASE
leukemia	I-DISEASE
,	O
p19	O
/	O
nm23	O
levels	B-UNK
were	O
also	O
increased	B-UNK
relative	B-UNK
to	O
resting	O
normal	B-UNK
lymphocytes	O
.	O

Treatment	O
of	O
mitotically	O
stimulated	O
lymphocytes	O
with	O
cyclosporin	O
,	O
which	O
inhibits	O
proliferation	O
,	O
blocked	O
the	O
increase	B-UNK
in	O
p19	O
/	O
nm23	O
;	O
treatment	O
of	O
the	O
leukemia	B-DISEASE
cell	B-UNK
line	I-UNK
HL-60	O
with	O
dimethylsulfoxide	O
,	O
which	O
induces	O
terminal	B-UNK
differentiation	B-UNK
,	O
resulted	B-UNK
in	O
diminished	O
levels	B-UNK
of	O
p19	O
/	O
nm23	O
.	O

Our	O
data	B-UNK
therefore	O
provide	B-UNK
evidence	I-UNK
that	O
nm23-H1	O
expression	B-UNK
is	O
related	B-UNK
to	O
cell	B-UNK
proliferative	O
activity	B-UNK
..	O

An	O
intrachromosomal	O
insertion	O
causing	B-UNK
5q22	O
deletion	B-UNK
and	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
coli	B-UNK
in	O
two	O
generations	O
.	O

We	O
report	B-UNK
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
coli	B-UNK
(	O
FAPC	O
)	O
with	O
epidermoid	O
cysts	B-DISEASE
,	O
osteomata	O
,	O
and	O
areas	O
of	O
congenital	B-UNK
hypertrophy	B-DISEASE
of	O
the	O
retinal	B-UNK
pigment	B-UNK
epithelium	O
(	O
CHRPEs	O
)	O
in	O
a	O
male	B-UNK
patient	B-UNK
and	O
his	O
maternal	O
aunt	O
,	O
both	O
of	O
whom	O
suffered	O
a	O
mild	O
to	O
moderate	B-UNK
degree	B-UNK
of	O
mental	B-UNK
handicap	O
.	O

Both	O
had	O
an	O
interstitial	O
deletion	B-UNK
of	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
5	O
(	O
del	O
(	O
5	O
)	O
(	O
q22q23	O
.	O
2	O
)	O
)	O
.	O

Two	O
other	O
normal	B-UNK
family	B-UNK
members	I-UNK
had	O
the	O
underlying	O
direct	B-UNK
insertion	O
of	O
chromosome	B-UNK
5	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q31	O
.	O
3q22q23	O
3q22q23	O
.	O
2	O
)	O
)	O
.	O

Molecular	B-UNK
genetic	I-UNK
and	O
fluorescent	O
hybridisation	O
studies	B-UNK
have	O
shown	B-UNK
that	O
loci	O
D5S37	O
and	O
D5S98	O
are	O
outside	O
the	O
deletion	B-UNK
whereas	O
loci	O
detected	B-UNK
by	O
probes	O
EF5	O
.	O

44	O
and	O
YN5	O
.	O

48	O
are	O
lost	O
.	O

As	O
expected	O
,	O
the	O
molecular	B-UNK
analyses	O
indicate	O
loss	B-UNK
of	O
one	O
allele	B-UNK
at	O
the	O
MCC	O
and	O
APC	B-UNK
loci	O
.	O

The	O
APC	B-UNK
gene	B-UNK
is	O
located	B-UNK
within	O
band	O
5q22	O
.	O

Familial	B-UNK
direct	B-UNK
insertions	O
should	O
be	O
considered	O
as	O
a	O
cause	O
of	O
recurrent	O
microdeletion	O
syndromes	O
.	O

Chromosome	B-UNK
mapping	B-UNK
of	O
the	O
rod	O
photoreceptor	B-UNK
cGMP	O
phosphodiesterase	O
beta-subunit	O
gene	B-UNK
in	O
mouse	B-UNK
and	O
human	B-UNK
:	O
tight	O
linkage	B-UNK
to	O
the	O
Huntington	B-UNK
disease	I-UNK
region	B-UNK
(	O
4p16	O
.	O
3	O
)	O
.	O

The	O
retinal	B-DISEASE
degeneration	I-DISEASE
mouse	B-UNK
(	O
gene	B-UNK
symbol	O
,	O
rd	O
)	O
is	O
an	O
animal	B-UNK
model	I-UNK
for	O
certain	O
forms	B-UNK
of	O
human	B-UNK
hereditary	B-UNK
retinopathies	O
.	O

Recent	O
findings	B-UNK
of	O
a	O
nonsense	B-UNK
mutation	I-UNK
in	O
the	O
rd	O
mouse	B-UNK
PDE	O
beta-subunit	O
gene	B-UNK
(	O
Pdeb	O
)	O
prompted	O
us	O
to	O
investigate	B-UNK
the	O
chromosome	B-UNK
locations	O
of	O
the	O
mouse	B-UNK
and	O
human	B-UNK
genes	B-UNK
.	O

We	O
have	O
utilized	O
backcross	O
analysis	B-UNK
in	O
mice	B-UNK
to	O
verify	O
and	O
define	B-UNK
more	O
precisely	O
the	O
location	B-UNK
of	O
the	O
Pdeb	O
locus	B-UNK
6	O
.	O

1	O
+	O
/-2	O
.	O

3	O
cM	B-DISEASE
distal	B-UNK
of	O
Mgsa	O
on	O
mouse	B-UNK
chromosome	I-UNK
5	O
.	O

We	O
have	O
determined	B-UNK
that	O
the	O
human	B-UNK
gene	B-UNK
(	O
PDEB	O
)	O
maps	B-UNK
to	O
4p16	O
.	O

3	O
,	O
very	O
close	B-UNK
to	O
the	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
region	B-UNK
.	O

Analysis	B-UNK
of	O
the	O
comparative	O
map	B-UNK
for	O
mice	B-UNK
and	O
humans	B-UNK
shows	O
that	O
the	O
mouse	B-UNK
homologue	B-UNK
of	O
the	O
HD	B-UNK
gene	B-UNK
will	O
reside	O
on	O
chromosome	B-UNK
5	O
.	O

Linkage	B-UNK
of	O
the	O
mouse	B-UNK
Pdeb	O
locus	B-UNK
with	O
other	O
homologues	O
in	O
the	O
human	B-UNK
4p16	O
.	O

3	O
region	B-UNK
is	O
maintained	O
but	O
gene	B-UNK
order	B-UNK
is	O
not	O
,	O
suggesting	O
at	O
least	O
three	O
possible	O
sites	O
for	O
the	O
corresponding	O
mouse	B-UNK
HD	B-UNK
gene	B-UNK
.	O

Coincident	O
Kaposi	O
sarcoma	B-DISEASE
and	O
T	O
-	O
cell	B-UNK
lymphoma	B-UNK
in	O
a	O
patient	B-UNK
with	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
.	O

A	O
24	O
year	O
old	O
male	B-UNK
with	O
a	O
history	B-UNK
of	O
eczema	B-DISEASE
,	O
recurrent	O
mild	O
infections	B-UNK
,	O
and	O
thrombocytopenia	B-DISEASE
consistent	B-UNK
with	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
presented	B-UNK
with	O
a	O
mediastinal	O
mass	B-UNK
,	O
generalized	B-UNK
lymphadenopathy	B-DISEASE
,	O
splenomegaly	B-DISEASE
,	O
and	O
severe	B-UNK
thrombocytopenia	B-DISEASE
.	O

Studies	B-UNK
of	O
immune	B-UNK
function	B-UNK
including	O
immunoglobulin	O
levels	B-UNK
and	O
T	O
-	O
cell	B-UNK
subsets	O
were	O
normal	B-UNK
.	O

Furthermore	O
,	O
his	O
T	O
lymphocytes	O
proliferated	O
normally	O
in	O
response	B-UNK
to	O
phytohemagglutinin	O
,	O
concanavalin	O
A	O
,	O
and	O
the	O
combination	B-UNK
of	O
neuraminidase	O
/	O
galactose	B-UNK
oxidase	O
.	O

However	O
,	O
their	O
proliferative	O
responses	B-UNK
to	O
anti	B-UNK
-	O
CD43	O
antibody	B-UNK
and	O
periodate	O
were	O
diminished	O
,	O
consistent	B-UNK
with	O
the	O
clinical	B-UNK
diagnosis	B-UNK
of	O
WAS	O
.	O

An	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	B-UNK
surprisingly	O
revealed	B-UNK
Kaposi	O
sarcoma	B-DISEASE
.	O

However	O
,	O
following	O
splenectomy	O
to	O
increase	B-UNK
the	O
platelet	B-UNK
count	O
,	O
biopsy	B-UNK
of	O
the	O
mediastinal	O
mass	B-UNK
revealed	B-UNK
T	O
-	O
cell	B-UNK
large	B-UNK
cell	B-UNK
lymphoma	B-DISEASE
.	O

Studies	B-UNK
of	O
biopsied	O
tissue	B-UNK
for	O
the	O
presence	O
of	O
Epstein	O
-	O
Barr	O
virus	O
and	O
cytomegalovirus	B-DISEASE
were	O
negative	B-UNK
,	O
as	O
were	O
studies	B-UNK
of	O
blood	B-UNK
,	O
including	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
,	O
for	O
the	O
presence	O
of	O
the	O
human	B-DISEASE
immunodeficiency	I-DISEASE
virus	I-DISEASE
(	O
HIV	B-DISEASE
)	O
.	O

This	O
is	O
the	O
first	O
report	B-UNK
of	O
Kaposi	O
sarcoma	B-DISEASE
arising	O
in	O
a	O
patient	B-UNK
with	O
a	O
congenital	B-UNK
immunodeficiency	B-DISEASE
syndrome	B-UNK
.	O

Although	O
Kaposi	O
sarcoma	B-DISEASE
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	B-UNK
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	B-UNK
infected	O
with	O
HIV	B-DISEASE
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	B-UNK
factor	B-UNK
in	O
the	O
development	B-UNK
of	O
Kaposi	O
sarcoma	B-DISEASE
in	O
this	O
patient	B-UNK
..	O

The	O
APC	B-UNK
gene	B-UNK
,	O
responsible	B-UNK
for	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
,	O
is	O
mutated	B-UNK
in	O
human	B-UNK
gastric	B-UNK
cancer	I-UNK
.	O

Although	O
gastric	B-DISEASE
cancer	I-DISEASE
is	O
the	O
most	O
common	B-UNK
cancer	B-UNK
in	O
the	O
world	O
,	O
genetic	B-UNK
changes	O
during	O
its	O
carcinogenesis	B-DISEASE
are	O
not	O
well	O
understood	O
.	O

Since	O
some	O
gastric	B-UNK
cancers	B-UNK
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia	B-DISEASE
,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
APC	B-UNK
)	O
gene	B-UNK
,	O
the	O
mutation	B-UNK
of	O
which	O
causes	O
adenomatous	B-DISEASE
polyps	I-DISEASE
in	O
the	O
colon	B-UNK
,	O
is	O
associated	O
with	O
carcinogenesis	B-DISEASE
of	O
gastric	B-UNK
cancer	I-UNK
.	O

Based	B-UNK
on	O
this	O
idea	O
,	O
DNAs	O
isolated	B-UNK
from	O
gastric	B-UNK
cancers	B-UNK
were	O
examined	O
by	O
means	B-UNK
of	O
a	O
RNase	O
protection	O
analysis	B-UNK
coupled	O
with	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
followed	O
by	O
sequencing	B-UNK
of	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
products	B-UNK
.	O

By	O
screening	B-UNK
nearly	O
one	O
-	O
half	B-UNK
of	O
the	O
coding	B-UNK
region	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
in	O
44	O
tumors	B-UNK
,	O
somatic	B-UNK
mutations	I-UNK
were	O
detected	B-UNK
in	O
three	O
tumors	B-DISEASE
a	O
missense	B-UNK
mutation	I-UNK
,	O
a	O
nonsense	B-UNK
mutation	I-UNK
,	O
and	O
a	O
5-base	O
pair	B-UNK
deletion	B-UNK
resulting	B-UNK
in	O
a	O
frame	B-UNK
shift	O
which	O
causes	O
truncation	B-UNK
of	O
the	O
gene	B-UNK
product	I-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
mutation	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
also	O
plays	O
an	O
important	O
role	B-UNK
during	O
the	O
carcinogenesis	B-DISEASE
of	O
at	O
least	O
some	O
gastric	B-UNK
cancers	B-DISEASE
..	O

A	O
71-kilodalton	O
protein	B-UNK
is	O
a	O
major	B-UNK
product	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
in	O
brain	B-UNK
and	O
other	O
nonmuscle	O
tissues	O
.	O

The	O
known	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
products	B-UNK
,	O
the	O
muscle	B-UNK
-	O
and	O
brain	B-UNK
-	O
type	B-UNK
dystrophin	B-UNK
isoforms	O
,	O
are	O
427-kDa	O
proteins	B-UNK
translated	O
from	O
14-kilobase	O
(	O
kb	B-UNK
)	O
mRNAs	O
.	O

Recently	O
we	O
described	O
a	O
6	O
.	O

5-kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

Cloning	B-UNK
and	O
in	O
vitro	O
transcription	B-UNK
and	O
translation	O
of	O
the	O
entire	O
coding	B-UNK
region	I-UNK
show	O
that	O
the	O
6	O
.	O

5-kb	O
mRNA	O
encodes	B-UNK
a	O
70	O
.	O

8-kDa	O
protein	B-UNK
that	O
is	O
a	O
major	B-UNK
product	B-UNK
of	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

It	O
contains	O
the	O
C	O
-	O
terminal	B-UNK
and	O
the	O
cysteine	B-UNK
-	O
rich	O
domains	B-UNK
of	O
dystrophin	B-UNK
,	O
seven	O
additional	O
amino	B-UNK
acids	I-UNK
at	O
the	O
N	O
terminus	O
,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	B-UNK
splicing	B-UNK
in	O
the	O
C	O
-	O
terminal	B-UNK
domain	B-UNK
.	O

It	O
lacks	O
the	O
entire	O
large	B-UNK
domain	B-UNK
of	O
spectrin	O
-	O
like	O
repeats	B-UNK
and	O
the	O
actin	B-UNK
-	O
binding	B-UNK
N	O
-	O
terminal	B-UNK
domain	B-UNK
of	O
dystrophin	B-UNK
.	O

This	O
protein	B-UNK
is	O
the	O
major	B-UNK
DMD	B-UNK
gene	B-UNK
product	I-UNK
in	O
brain	B-UNK
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	B-UNK
muscle	I-UNK
extracts	B-UNK
.	O

Correlation	B-UNK
between	O
the	O
location	B-UNK
of	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
and	O
the	O
number	B-UNK
of	O
colorectal	B-UNK
polyps	B-DISEASE
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
patients	B-UNK
.	O

Recently	O
we	O
have	O
isolated	B-UNK
the	O
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
gene	B-UNK
which	O
causes	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
,	O
and	O
its	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
a	O
substantial	O
number	B-UNK
of	O
FAP	B-UNK
patients	I-UNK
have	O
been	O
identified	B-UNK
.	O

On	O
the	O
basis	B-UNK
of	O
this	O
information	B-UNK
,	O
we	O
compared	B-UNK
the	O
location	B-UNK
of	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
in	O
22	O
unrelated	B-UNK
patients	B-UNK
(	O
12	O
of	O
whom	O
have	O
been	O
reported	B-UNK
previously	B-UNK
)	O
with	O
the	O
number	B-UNK
of	O
colorectal	B-UNK
polyps	B-DISEASE
developed	O
in	O
FAP	B-UNK
patients	I-UNK
;	O
17	O
were	O
sparse	O
types	B-UNK
and	O
five	O
were	O
profuse	O
types	B-UNK
.	O

All	O
but	O
one	O
of	O
the	O
mutations	B-UNK
were	O
considered	O
to	O
cause	O
truncation	B-UNK
of	O
the	O
gene	B-UNK
product	I-UNK
by	O
frame	B-UNK
-	O
shift	O
due	O
to	O
deletion	B-UNK
(	O
14	O
cases	B-UNK
)	O
or	O
nonsense	B-UNK
mutation	I-UNK
(	O
seven	O
cases	B-UNK
)	O
.	O

The	O
location	B-UNK
of	O
the	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
seems	O
to	O
correlate	O
with	O
the	O
two	O
clinical	B-UNK
types	B-UNK
;	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
five	O
FAP	B-UNK
patients	I-UNK
with	O
profuse	O
polyps	B-UNK
were	O
observed	B-UNK
between	O
codon	B-UNK
1250	O
and	O
codon	B-UNK
1464	O
,	O
whereas	O
mutations	B-UNK
in	O
17	O
FAP	B-UNK
patients	I-UNK
with	O
fewer	O
polyps	B-UNK
were	O
observed	B-UNK
in	O
the	O
other	O
regions	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
.	O

The	O
result	B-UNK
suggests	O
that	O
the	O
number	B-UNK
of	O
colorectal	B-UNK
polyps	B-DISEASE
in	O
FAP	B-UNK
patients	I-UNK
may	O
be	O
associated	O
with	O
a	O
difference	O
in	O
the	O
stability	O
or	O
biological	O
function	B-UNK
of	O
the	O
truncated	O
APC	B-UNK
protein	B-UNK
..	O

Identification	B-UNK
and	O
rapid	O
detection	B-UNK
of	O
three	O
Tay	O
-	O
Sachs	O
mutations	B-UNK
in	O
the	O
Moroccan	B-UNK
Jewish	B-UNK
population	B-UNK
.	O

Infantile	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
HEXA	B-UNK
gene	B-UNK
that	O
result	B-UNK
in	O
the	O
complete	O
absence	B-UNK
of	O
beta-hexosaminidase	O
A	O
activity	B-UNK
.	O

It	O
is	O
well	O
known	O
that	O
an	O
elevated	B-UNK
frequency	B-UNK
of	O
TSD	B-UNK
mutations	B-UNK
exists	O
among	O
Ashkenazi	B-UNK
Jews	B-UNK
.	O

More	O
recently	O
it	O
has	O
become	O
apparent	O
that	O
elevated	B-UNK
carrier	B-UNK
frequencies	O
for	O
TSD	B-UNK
also	O
occur	B-UNK
in	O
several	O
other	O
ethnic	B-UNK
groups	I-UNK
,	O
including	O
Moroccan	B-UNK
Jews	B-UNK
,	O
a	O
subgroup	O
of	O
Sephardic	O
Jews	B-UNK
.	O

Elsewhere	O
we	O
reported	B-UNK
an	O
in	O
-	O
frame	B-UNK
deletion	B-UNK
of	O
one	O
of	O
the	O
two	O
adjacent	O
phenylalanine	B-UNK
codons	O
at	O
position	B-UNK
304	O
or	O
305	O
(	O
delta	O
F304/305	O
)	O
in	O
one	O
HEXA	B-UNK
allele	B-UNK
of	O
a	O
Moroccan	B-UNK
Jewish	B-UNK
TSD	B-UNK
patient	B-UNK
and	O
in	O
three	O
obligate	B-UNK
carriers	B-UNK
from	O
six	O
unrelated	B-UNK
Moroccan	B-UNK
Jewish	B-UNK
families	B-UNK
.	O

We	O
have	O
now	O
identified	B-UNK
two	O
additional	O
mutations	B-UNK
within	O
exon	B-UNK
5	O
of	O
the	O
HEXA	B-UNK
gene	B-UNK
that	O
account	B-UNK
for	O
the	O
remaining	O
TSD	B-UNK
alleles	B-UNK
in	O
the	O
patient	B-UNK
and	O
carriers	B-UNK
.	O

One	O
of	O
the	O
mutations	B-UNK
is	O
a	O
novel	O
C	O
-	O
to	O
-	O
G	O
transversion	B-UNK
,	O
resulting	B-UNK
in	O
a	O
replacement	O
of	O
Tyr180	O
by	O
a	O
stop	B-UNK
codon	I-UNK
.	O

The	O
other	O
mutation	B-UNK
is	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-UNK
resulting	B-UNK
in	O
an	O
Arg170-to	O
-	O
Gln	O
substitution	B-UNK
.	O

This	O
mutation	B-UNK
is	O
at	O
a	O
CpG	B-UNK
site	B-UNK
in	O
a	O
Japanese	B-UNK
infant	O
with	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
and	O
was	O
described	O
elsewhere	O
.	O

Analysis	B-UNK
of	O
nine	O
obligate	B-UNK
carriers	B-UNK
from	O
seven	O
unrelated	B-UNK
families	I-UNK
showed	O
that	O
four	O
harbor	O
the	O
delta	O
F304/305	O
mutation	B-UNK
,	O
two	O
the	O
Arg170	O
-	O
---Gln	O
mutation	B-UNK
,	O
and	O
one	O
the	O
Tyr180	O
-	O
---Stop	O
mutation	B-UNK
.	O

We	O
also	O
have	O
developed	O
rapid	O
,	O
nonradioactive	O
assays	O
for	O
the	O
detection	B-UNK
of	O
each	O
mutation	B-UNK
,	O
which	O
should	O
be	O
helpful	O
for	O
carrier	B-UNK
screening	B-UNK
..	O

Molecular	B-UNK
characterization	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
by	O
natural	O
and	O
amplification	B-UNK
created	O
restriction	B-UNK
sites	O
:	O
five	O
mutations	B-UNK
account	B-UNK
for	O
most	O
G6PD	B-UNK
deficiency	I-UNK
cases	B-UNK
in	O
Taiwan	O
.	O

We	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
to	O
diagnose	O
the	O
molecular	B-UNK
defects	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
Chinese	B-UNK
in	O
Taiwan	O
.	O

This	O
method	O
involves	O
the	O
selective	O
amplification	B-UNK
of	O
a	O
DNA	B-UNK
fragment	B-UNK
from	O
human	B-UNK
G6PD	B-UNK
gene	B-UNK
with	O
specific	B-UNK
oligonucleotide	O
primers	O
followed	O
by	O
digestion	O
with	O
restriction	B-UNK
enzymes	B-UNK
that	O
recognize	O
artificially	O
created	O
or	O
naturally	O
occurring	O
restriction	B-UNK
sites	O
.	O

Ninety	O
-	O
four	O
Chinese	B-UNK
males	B-UNK
with	O
G6PD	B-UNK
deficiency	I-UNK
were	O
studied	O
.	O

The	O
results	B-UNK
show	O
that	O
50	O
%	O
(	O
47	O
of	O
94	O
)	O
were	O
G	O
to	O
T	O
mutation	B-UNK
at	O
nucleotide	B-UNK
(	O
nt	B-UNK
)	O
1376	O
,	O
21	O
.	O

3	O
%	O
(	O
20	O
of	O
94	O
)	O
were	O
G	O
to	O
A	O
mutation	B-UNK
at	O
nt	B-UNK
1388	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	B-UNK
at	O
nt	B-UNK
493	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	B-UNK
at	O
nt	B-UNK
95	O
,	O
4	O
.	O

2	O
%	O
(	O
4	O
of	O
94	O
)	O
were	O
C	O
to	O
T	O
mutation	B-UNK
at	O
nt	B-UNK
1024	O
,	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
T	O
mutation	B-UNK
at	O
nt	B-UNK
392	O
,	O
and	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
A	O
mutation	B-UNK
at	O
nt	B-UNK
487	O
.	O

These	O
results	B-UNK
show	O
that	O
the	O
former	O
five	O
mutations	B-UNK
account	B-UNK
for	O
more	O
than	O
90	O
%	O
of	O
G6PD	B-UNK
deficiency	I-UNK
cases	B-UNK
in	O
Taiwan	O
.	O

Aside	O
from	O
showing	O
that	O
G	O
to	O
T	O
change	B-UNK
at	O
nt	B-UNK
1376	O
is	O
the	O
most	O
common	B-UNK
mutation	B-UNK
,	O
our	O
research	O
indicates	O
that	O
nt	B-UNK
493	O
mutation	B-UNK
is	O
a	O
frequent	B-UNK
mutation	B-UNK
among	O
Chinese	B-UNK
in	O
Taiwan	O
.	O

We	O
compared	B-UNK
G6PD	B-UNK
activity	B-UNK
among	O
different	O
mutations	B-UNK
,	O
without	O
discovering	O
significant	B-UNK
differences	B-UNK
between	O
them	O
.	O

Eight	O
novel	O
inactivating	O
germ	B-UNK
line	I-UNK
mutations	B-UNK
at	O
the	O
APC	B-UNK
gene	B-UNK
identified	B-UNK
by	O
denaturing	O
gradient	O
gel	B-UNK
electrophoresis	I-UNK
.	O

Familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
is	O
a	O
dominantly	O
inherited	B-UNK
condition	B-UNK
predisposing	O
to	O
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

The	O
recent	O
isolation	B-UNK
of	O
the	O
responsible	B-UNK
gene	B-UNK
(	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
or	O
APC	B-UNK
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	B-UNK
line	I-UNK
mutations	B-UNK
in	O
affected	B-UNK
individuals	I-UNK
.	O

Previous	B-UNK
authors	O
have	O
used	O
the	O
RNase	O
protection	O
assay	B-UNK
and	O
the	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphisms	B-UNK
procedure	O
to	O
screen	B-UNK
for	O
mutations	B-UNK
.	O

In	O
this	O
study	B-UNK
we	O
used	O
denaturing	O
gradient	O
gel	B-UNK
electrophoresis	I-UNK
(	O
DGGE	O
)	O
.	O

DGGE	O
analysis	B-UNK
of	O
10	O
APC	B-UNK
exons	O
(	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
and	O
part	O
of	O
15	O
)	O
in	O
33	O
unrelated	B-UNK
Dutch	B-UNK
FAP	B-UNK
patients	I-UNK
has	O
led	B-UNK
to	O
the	O
identification	B-UNK
of	O
eight	O
novel	O
germ	B-UNK
line	I-UNK
mutations	B-UNK
resulting	B-UNK
in	O
stop	B-UNK
codons	O
or	O
frameshifts	O
.	O

The	O
results	B-UNK
reported	B-UNK
here	O
indicate	O
that	O
(	O
1	O
)	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
is	O
caused	B-UNK
by	O
an	O
extremely	O
heterogeneous	O
spectrum	B-UNK
of	O
point	B-UNK
mutations	I-UNK
;	O
(	O
2	O
)	O
all	O
the	O
mutations	B-UNK
found	O
in	O
this	O
study	B-UNK
are	O
chain	B-UNK
terminating	O
;	O
and	O
(	O
3	O
)	O
DGGE	O
represents	O
a	O
rapid	O
and	O
sensitive	B-UNK
technique	O
for	O
the	O
detection	B-UNK
of	O
mutations	B-UNK
in	O
the	O
unusually	O
large	B-UNK
APC	B-UNK
gene	B-UNK
.	O

An	O
extension	O
of	O
the	O
DGGE	O
analysis	B-UNK
to	O
the	O
entire	O
coding	B-UNK
region	I-UNK
in	O
a	O
sufficient	O
number	B-UNK
of	O
clinically	O
well	O
-	O
characterized	B-UNK
,	O
unrelated	B-UNK
patients	B-UNK
will	O
facilitate	O
the	O
establishment	O
of	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
occurrence	B-UNK
of	O
an	O
extremely	O
heterogeneous	O
spectrum	B-UNK
of	O
mutations	B-UNK
spread	O
throughout	O
the	O
entire	O
length	B-UNK
of	O
the	O
large	B-UNK
APC	B-UNK
gene	B-UNK
among	O
the	O
FAP	B-UNK
patients	I-UNK
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	B-UNK
procedure	O
in	O
a	O
routine	O
laboratory	O
.	O

Nevertheless	O
,	O
the	O
above	O
DGGE	O
approach	O
has	O
incidentally	O
led	B-UNK
to	O
the	O
identification	B-UNK
of	O
a	O
common	B-UNK
polymorphism	B-UNK
in	O
exon	B-UNK
13	O
.	O

Such	O
intragenic	O
polymorphisms	B-UNK
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	B-UNK
of	O
FAP	B-UNK
by	O
linkage	B-UNK
analysis	I-UNK
in	O
informative	O
families	B-UNK
..	O

Yeast	B-UNK
artificial	O
chromosomes	O
for	O
the	O
molecular	B-UNK
analysis	I-UNK
of	O
the	O
familial	B-UNK
polyposis	B-UNK
APC	B-UNK
gene	B-UNK
region	B-UNK
.	O

Two	O
yeast	B-UNK
artificial	O
chromosomes	O
(	O
YACs	O
)	O
spanning	O
a	O
total	B-UNK
distance	O
of	O
1	O
.	O

1	O
megabase	O
pairs	B-UNK
of	O
DNA	B-UNK
around	O
the	O
MCC	O
(	O
for	O
mutated	B-UNK
in	O
colorectal	B-DISEASE
carcinoma	I-DISEASE
)	O
and	O
APC	B-UNK
(	O
for	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
)	O
genes	B-UNK
at	O
5q21	O
have	O
been	O
isolated	B-UNK
and	O
characterized	B-UNK
.	O

Starting	O
from	O
the	O
MCC	O
gene	B-UNK
,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	B-UNK
constitutional	B-UNK
submicroscopic	B-UNK
deletions	O
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
patients	B-UNK
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
.	O

To	O
this	O
end	B-UNK
,	O
YACs	O
identified	B-UNK
by	O
the	O
MCC	O
gene	B-UNK
were	O
screened	B-UNK
across	O
a	O
chromosome	B-UNK
5-specific	O
cosmid	O
library	O
to	O
provide	B-UNK
a	O
source	O
of	O
DNA	B-UNK
probes	O
for	O
genomic	B-UNK
scanning	O
.	O

The	O
cosmids	O
isolated	B-UNK
from	O
these	O
experiments	O
were	O
used	O
to	O
screen	B-UNK
a	O
panel	B-UNK
of	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
containing	O
chromosome	B-UNK
5	O
segregated	O
from	O
patients	B-UNK
suspected	O
to	O
carry	B-UNK
putative	O
interstitial	O
deletions	O
.	O

This	O
screening	B-UNK
approach	O
led	B-UNK
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	B-UNK
deletion	B-UNK
in	O
a	O
polyposis	B-UNK
patient	B-UNK
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	B-UNK
YACs	O
.	O

This	O
YAC	B-UNK
has	O
been	O
shown	B-UNK
to	O
contain	O
the	O
entire	O
APC	B-UNK
gene	B-UNK
,	O
in	O
addition	B-UNK
to	O
a	O
significant	B-UNK
portion	B-UNK
of	O
DNA	B-UNK
flanking	O
the	O
5	O
end	B-UNK
of	O
the	O
gene	B-UNK
,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	B-UNK
by	O
transfer	B-UNK
to	O
colorectal	B-UNK
tumor	B-DISEASE
-	O
derived	B-UNK
cell	B-UNK
lines	I-UNK
.	O

Inherited	B-UNK
WT1	B-UNK
mutation	B-UNK
in	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
.	O

Patients	B-UNK
with	O
the	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
(	O
Wilms	B-UNK
tumor	I-UNK
,	O
genital	O
anomalies	B-UNK
,	O
and	O
nephropathy	B-DISEASE
)	O
have	O
been	O
demonstrated	O
to	O
carry	B-UNK
de	O
novo	O
constitutional	B-UNK
mutations	B-UNK
in	O
WT1	B-UNK
,	O
the	O
Wilms	B-DISEASE
tumor	I-DISEASE
gene	B-UNK
at	O
chromosome	B-UNK
11p13	O
.	O

We	O
report	B-UNK
three	O
new	O
cases	B-UNK
,	O
two	O
carrying	B-UNK
a	O
previously	B-UNK
described	O
WT1	B-UNK
exon	B-UNK
9	O
mutation	B-UNK
and	O
one	O
with	O
a	O
novel	O
WT1	B-UNK
exon	B-UNK
8	O
mutation	B-UNK
.	O

However	O
,	O
unlike	O
patients	B-UNK
in	O
previous	B-UNK
reports	O
,	O
one	O
of	O
our	O
three	O
patients	B-UNK
inherited	B-UNK
the	O
affected	B-UNK
allele	B-UNK
from	O
his	O
phenotypically	O
unaffected	O
father	O
.	O

This	O
observation	O
indicates	O
that	O
the	O
WT1	B-UNK
exon	B-UNK
9	O
mutation	B-UNK
affecting	O
394Arg	O
demonstrated	O
in	O
over	O
one	O
-	O
half	B-UNK
of	O
the	O
patients	B-UNK
with	O
the	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
may	O
exhibit	O
incomplete	O
penetrance	O
.	O

Consequently	O
,	O
familial	B-UNK
studies	B-UNK
in	O
patients	B-UNK
affected	B-UNK
by	O
this	O
syndrome	B-UNK
are	O
recommended	O
..	O

Submicroscopic	B-UNK
deletions	O
at	O
the	O
WAGR	O
locus	B-UNK
,	O
revealed	B-UNK
by	O
nonradioactive	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
.	O

Fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
(	O
FISH	B-UNK
)	O
with	O
biotin	O
-	O
labeled	O
probes	O
mapping	B-UNK
to	O
11p13	O
has	O
been	O
used	O
for	O
the	O
molecular	B-UNK
analysis	I-UNK
of	O
deletions	O
of	O
the	O
WAGR	O
(	O
Wilms	B-UNK
tumor	I-UNK
,	O
aniridia	B-DISEASE
,	O
genitourinary	O
abnormalities	B-UNK
,	O
and	O
mental	B-UNK
retardation	I-UNK
)	O
locus	B-UNK
.	O

We	O
have	O
detected	B-UNK
a	O
submicroscopic	B-UNK
11p13	O
deletion	B-UNK
in	O
a	O
child	B-UNK
with	O
inherited	B-UNK
aniridia	B-DISEASE
who	O
subsequently	B-UNK
presented	B-UNK
with	O
Wilms	B-DISEASE
tumor	I-DISEASE
in	O
a	O
horseshoe	O
kidney	B-UNK
,	O
only	O
revealed	B-UNK
at	O
surgery	O
.	O

The	O
mother	O
,	O
who	O
has	O
aniridia	B-DISEASE
,	O
was	O
also	O
found	O
to	O
carry	B-UNK
a	O
deletion	B-UNK
including	O
both	O
the	O
aniridia	B-DISEASE
candidate	B-UNK
gene	I-UNK
(	O
AN2	B-UNK
)	O
and	O
the	O
Wilms	B-DISEASE
tumor	I-DISEASE
predisposition	B-UNK
gene	B-UNK
(	O
WT1	B-UNK
)	O
.	O

This	O
is	O
therefore	O
a	O
rare	B-UNK
case	B-UNK
of	O
an	O
inherited	B-UNK
WAGR	O
deletion	B-UNK
.	O

Wilms	B-DISEASE
tumor	I-DISEASE
has	O
so	O
far	O
only	O
been	O
associated	O
with	O
sporadic	B-UNK
de	O
novo	O
aniridia	B-DISEASE
cases	B-UNK
.	O

We	O
have	O
shown	B-UNK
that	O
a	O
cosmid	O
probe	O
for	O
a	O
candidate	B-UNK
aniridia	B-DISEASE
gene	B-UNK
,	O
homologous	B-UNK
to	O
the	O
mouse	B-UNK
Pax-6	O
gene	B-UNK
,	O
is	O
deleted	B-UNK
in	O
cell	B-UNK
lines	I-UNK
from	O
aniridia	B-DISEASE
patients	B-UNK
with	O
previously	B-UNK
characterized	B-UNK
deletions	O
at	O
11p13	O
,	O
while	O
another	O
cosmid	O
marker	B-UNK
mapping	B-UNK
between	O
two	O
aniridia	B-DISEASE
-	O
associated	O
translocation	B-UNK
breakpoints	O
(	O
and	O
hence	O
a	O
second	O
candidate	B-UNK
marker	B-UNK
)	O
is	O
present	B-UNK
on	O
both	O
chromosomes	O
.	O

These	O
results	B-UNK
support	O
the	O
Pax-6	O
homologue	B-UNK
as	O
a	O
strong	B-UNK
candidate	B-UNK
for	O
the	O
AN2	B-UNK
gene	B-UNK
.	O

FISH	B-UNK
with	O
cosmid	O
probes	O
has	O
proved	O
to	O
be	O
a	O
fast	O
and	O
reliable	O
technique	O
for	O
the	O
molecular	B-UNK
analysis	I-UNK
of	O
deletions	O
.	O

It	O
can	O
be	O
used	O
with	O
limited	O
amounts	B-UNK
of	O
material	O
and	O
has	O
strong	B-UNK
potential	B-UNK
for	O
clinical	B-UNK
applications	O
..	O

Linkage	B-UNK
of	O
gene	B-UNK
for	O
C2	B-UNK
deficiency	I-UNK
and	O
the	O
major	B-UNK
histocompatibility	B-UNK
complex	O
MHC	B-UNK
in	O
man	B-UNK
.	O

Family	B-UNK
study	B-UNK
of	O
a	O
further	O
case	B-UNK
.	O

Close	B-UNK
linkage	I-UNK
between	O
HL	B-DISEASE
-	O
A	O
and	O
C2	B-UNK
deficiency	I-UNK
was	O
first	O
reported	B-UNK
by	O
FU	O
and	O
co-workers	O
in	O
1974	O
.	O

We	O
present	B-UNK
here	O
a	O
pedigree	B-UNK
of	O
a	O
31-year	O
-	O
old	O
C2-deficient	O
individual	O
with	O
clinical	B-UNK
manifestations	I-UNK
of	O
Hodgkins	O
disease	B-UNK
.	O

The	O
following	O
markers	B-UNK
were	O
tested	O
C2	B-UNK
levels	B-UNK
,	O
factor	B-UNK
B	O
polymorphism	B-UNK
,	O
blood	B-UNK
groups	B-UNK
,	O
and	O
enzyme	B-UNK
typing	O
.	O

In	O
addition	B-UNK
to	O
close	B-UNK
linkage	I-UNK
between	O
HL	B-DISEASE
-	O
A	O
and	O
C2	B-UNK
deficiency	I-UNK
,	O
both	O
parents	O
were	O
heterozygous	B-UNK
for	O
Bf	O
(	O
HL	B-DISEASE
-	O
A	O
linked	B-UNK
,	O
electrophoretic	B-UNK
variation	B-UNK
of	O
B	O
)	O
.	O

The	O
two	O
HL	B-DISEASE
-	O
A	O
haplotypes	O
closely	B-UNK
linked	I-UNK
to	O
C2	B-UNK
deficiency	I-UNK
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O

They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	B-UNK
7a	O
..	O

Screening	B-UNK
for	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
patients	B-UNK
:	O
61	O
new	O
patients	B-UNK
and	O
a	O
summary	O
of	O
150	O
unrelated	B-UNK
patients	B-UNK
.	O

We	O
report	B-UNK
here	O
the	O
result	B-UNK
of	O
a	O
screening	B-UNK
for	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
gene	B-UNK
in	O
61	O
new	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
patients	B-UNK
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	B-UNK
of	O
150	O
patients	B-UNK
.	O

Examination	B-UNK
of	O
the	O
entire	O
coding	B-UNK
region	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
,	O
based	B-UNK
on	O
a	O
ribonuclease	O
protection	O
assay	B-UNK
coupled	O
with	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
,	O
disclosed	O
mutations	B-UNK
that	O
were	O
considered	O
to	O
cause	O
significant	B-UNK
defects	B-UNK
in	O
the	O
APC	B-UNK
product	B-UNK
in	O
97	O
of	O
150	O
unrelated	B-UNK
FAP	B-UNK
patients	I-UNK
.	O

Our	O
findings	B-UNK
revealed	B-UNK
the	O
following	O
characteristics	B-UNK
of	O
the	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
of	O
APC	B-UNK
1	O
)	O
the	O
great	O
majority	O
of	O
the	O
mutations	B-UNK
were	O
found	O
to	O
truncate	O
the	O
APC	B-UNK
product	B-UNK
;	O
2	O
)	O
almost	O
all	O
of	O
the	O
mutations	B-UNK
were	O
located	B-UNK
within	O
the	O
first	O
half	B-UNK
of	O
the	O
coding	B-UNK
region	I-UNK
;	O
3	O
)	O
no	O
correlation	B-UNK
was	O
observed	B-UNK
between	O
the	O
locations	O
of	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
and	O
extracolonic	O
manifestations	B-UNK
in	O
FAP	B-UNK
patients	I-UNK
;	O
4	O
)	O
more	O
than	O
80	O
%	O
of	O
base	B-UNK
substitutions	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
were	O
from	O
cytosine	O
to	O
other	O
nucleotides	O
,	O
nearly	O
one	O
-	O
third	O
of	O
which	O
occurred	B-UNK
at	O
the	O
GpG	O
site	B-UNK
.	O

Our	O
results	B-UNK
provide	I-UNK
information	B-UNK
helpful	O
to	O
an	O
understanding	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
and	O
will	O
also	O
contribute	B-UNK
to	O
presymptomatic	O
diagnosis	B-UNK
of	O
members	B-UNK
in	O
FAP	B-UNK
families	B-UNK
..	O

Somatic	B-UNK
mutations	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
in	O
colorectal	B-UNK
tumors	I-UNK
:	O
mutation	B-UNK
cluster	B-UNK
region	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
.	O

We	O
examined	O
somatic	B-UNK
mutations	I-UNK
of	O
the	O
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
gene	B-UNK
in	O
63	O
colorectal	B-UNK
tumors	I-UNK
(	O
16	O
adenomas	B-UNK
and	O
47	O
carcinomas	B-UNK
)	O
developed	O
in	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
and	O
non-FAP	O
patients	B-UNK
.	O

In	O
addition	B-UNK
to	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
(	O
LOH	B-UNK
)	O
at	O
the	O
APC	B-UNK
locus	B-UNK
in	O
30	O
tumors	B-DISEASE
,	O
43	O
other	O
somatic	B-UNK
mutations	I-UNK
were	O
detected	B-UNK
.	O

Twenty	O
-	O
one	O
of	O
them	O
were	O
point	B-UNK
mutations	I-UNK
;	O
16	O
nonsense	B-UNK
and	O
two	O
missense	B-UNK
mutations	I-UNK
,	O
and	O
three	O
occurred	B-UNK
in	O
introns	O
at	O
the	O
splicing	B-UNK
site	B-UNK
.	O

Twenty	O
-	O
two	O
tumors	B-UNK
had	O
frameshift	B-UNK
mutations	B-UNK
due	O
to	O
deletion	B-UNK
or	O
insertion	O
;	O
nineteen	O
of	O
them	O
were	O
deletions	O
of	O
one	O
to	O
31	O
bp	B-UNK
and	O
three	O
were	O
a	O
1-bp	O
insertion	O
.	O

One	O
tumor	B-DISEASE
had	O
a	O
1-bp	O
deletion	B-UNK
in	O
an	O
intron	B-UNK
near	O
the	O
splicing	B-UNK
site	B-UNK
.	O

Hence	O
,	O
41	O
(	O
95	O
%	O
)	O
of	O
43	O
mutations	B-UNK
resulted	B-UNK
in	O
truncation	B-UNK
of	O
the	O
APC	B-UNK
protein	B-UNK
.	O

Over	O
60	O
%	O
of	O
the	O
somatic	B-UNK
mutations	I-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
were	O
clustered	O
within	O
a	O
small	O
region	B-UNK
of	O
exon	B-UNK
15	O
,	O
designated	O
as	O
MCR	O
(	O
mutation	B-UNK
cluster	B-UNK
region	B-UNK
)	O
,	O
which	O
accounted	O
for	O
less	O
than	O
10	O
%	O
of	O
the	O
coding	B-UNK
region	I-UNK
.	O

Combining	O
these	O
data	B-UNK
and	O
the	O
results	B-UNK
of	O
LOH	B-UNK
,	O
more	O
than	O
80	O
%	O
of	O
tumors	B-DISEASE
(	O
14	O
adenomas	B-UNK
and	O
39	O
carcinomas	B-UNK
)	O
had	O
at	O
least	O
one	O
mutation	B-UNK
in	O
the	O
APC	B-UNK
gene	B-UNK
,	O
of	O
which	O
more	O
than	O
60	O
%	O
(	O
9	O
adenomas	B-DISEASE
and	O
23	O
carcinomas	B-UNK
)	O
had	O
two	O
mutations	B-UNK
.	O

These	O
results	B-UNK
strongly	O
suggest	B-UNK
that	O
somatic	B-UNK
mutations	I-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
are	O
associated	O
with	O
development	B-UNK
of	O
a	O
great	O
majority	O
of	O
colorectal	B-UNK
tumors	I-UNK
..	O

Constitutional	B-UNK
mutations	B-UNK
in	O
the	O
WT1	B-UNK
gene	B-UNK
in	O
patients	B-UNK
with	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
is	O
characterised	O
by	O
a	O
typical	O
nephropathy	B-DISEASE
,	O
genital	O
abnormalities	B-UNK
and	O
also	O
predisposes	O
to	O
the	O
development	B-UNK
of	O
Wilms	B-UNK
tumor	I-UNK
.	O

These	O
patients	B-UNK
eventually	O
go	O
into	O
end	B-UNK
stage	B-UNK
renal	B-DISEASE
failure	I-DISEASE
.	O

A	O
candidate	B-UNK
Wilms	B-UNK
tumor	I-UNK
gene	B-UNK
,	O
WT1	B-UNK
,	O
from	O
the	O
11p13	O
chromosome	B-UNK
region	B-UNK
has	O
recently	O
been	O
cloned	O
.	O

We	O
have	O
analysed	O
the	O
DNA	B-UNK
sequence	I-UNK
in	O
constitutional	B-UNK
cells	B-UNK
from	O
eight	O
patients	B-UNK
and	O
have	O
shown	B-UNK
heterozygous	B-UNK
mutations	B-UNK
in	O
six	O
of	O
them	O
.	O

Four	O
of	O
the	O
mutations	B-UNK
were	O
in	O
exon	B-UNK
9	O
,	O
all	O
resulting	B-UNK
in	O
missense	B-UNK
mutations	I-UNK
.	O

Three	O
were	O
at	O
nucleotide	B-UNK
position	I-UNK
1180	O
resulting	B-UNK
in	O
an	O
arg	B-UNK
>	O
trp	O
amino	B-UNK
acid	I-UNK
change	B-UNK
.	O

The	O
other	O
was	O
at	O
position	B-UNK
1186	O
converting	O
an	O
asp	O
>	O
asn	O
in	O
the	O
predicted	B-UNK
resultant	O
protein	B-UNK
.	O

One	O
patient	B-UNK
had	O
a	O
missense	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
8	O
,	O
converting	O
an	O
arg	B-UNK
>	O
his	O
.	O

A	O
single	B-UNK
base	I-UNK
pair	B-UNK
insertion	O
at	O
nucleotide	B-UNK
position	I-UNK
821	O
in	O
exon	B-UNK
6	O
resulted	B-UNK
in	O
the	O
generation	O
of	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
in	O
the	O
last	O
patient	B-UNK
.	O

We	O
were	O
unable	O
to	O
find	O
a	O
mutation	B-UNK
in	O
one	O
patient	B-UNK
despite	O
complete	O
sequencing	B-UNK
of	O
the	O
genomic	B-UNK
sequence	B-UNK
of	O
the	O
gene	B-UNK
.	O

The	O
last	O
patient	B-UNK
carried	O
a	O
constitutional	B-UNK
deletion	B-UNK
of	O
the	O
11p13	O
region	B-UNK
and	O
no	O
additional	O
mutation	B-UNK
was	O
found	O
.	O

There	O
was	O
no	O
obvious	O
correlation	B-UNK
between	O
the	O
type	B-UNK
of	O
mutation	B-UNK
and	O
phenotypic	B-UNK
expression	B-UNK
.	O

These	O
results	B-UNK
further	O
demonstrate	B-UNK
that	O
the	O
WT1	B-UNK
gene	B-UNK
is	O
important	O
in	O
both	O
the	O
development	B-UNK
of	O
the	O
kidney	B-UNK
and	O
the	O
genito	O
-	O
urinary	O
system	O
..	O

Linkage	B-UNK
disequilibrium	I-UNK
mapping	B-UNK
in	O
isolated	B-UNK
founder	B-UNK
populations	O
:	O
diastrophic	B-DISEASE
dysplasia	I-DISEASE
in	O
Finland	O
.	O

Linkage	B-UNK
disequilibrium	I-UNK
mapping	B-UNK
in	O
isolated	B-UNK
populations	O
provides	O
a	O
powerful	O
tool	O
for	O
fine	O
structure	B-UNK
localization	B-UNK
of	O
disease	B-DISEASE
genes	B-UNK
.	O

Here	O
,	O
Luria	O
and	O
Delbrucks	O
classical	O
methods	O
for	O
analysing	O
bacterial	B-UNK
cultures	O
are	O
adapted	O
to	O
the	O
study	B-UNK
of	O
human	B-UNK
isolated	B-UNK
founder	B-UNK
populations	O
in	O
order	B-UNK
to	O
estimate	O
(	O
i	O
)	O
the	O
recombination	B-UNK
fraction	B-UNK
between	O
a	O
disease	B-DISEASE
locus	B-UNK
and	O
a	O
marker	B-UNK
;	O
(	O
ii	B-UNK
)	O
the	O
expected	O
degree	B-UNK
of	O
allelic	O
homogeneity	O
in	O
a	O
population	B-UNK
;	O
and	O
(	O
iii	B-UNK
)	O
the	O
mutation	B-UNK
rate	B-UNK
of	O
marker	B-UNK
loci	O
.	O

Using	O
these	O
methods	O
,	O
we	O
report	B-UNK
striking	O
linkage	B-UNK
disequilibrium	I-UNK
for	O
diastrophic	B-DISEASE
dysplasia	I-DISEASE
(	O
DTD	B-UNK
)	O
in	O
Finland	O
indicating	O
that	O
the	O
DTD	B-UNK
gene	B-UNK
should	O
lie	O
within	O
0	O
.	O

06	O
centimorgans	O
(	O
or	O
about	O
60	O
kilobases	O
)	O
of	O
the	O
CSF1R	O
gene	B-UNK
.	O

Predictions	O
about	O
allelic	O
homogeneity	O
in	O
Finland	O
and	O
mutation	B-UNK
rates	O
in	O
simple	O
sequence	B-UNK
repeats	B-UNK
are	O
confirmed	B-UNK
by	O
independent	O
observations	B-UNK
.	O

The	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
:	O
refinement	O
of	O
the	O
localization	B-UNK
on	O
Xp	O
and	O
identification	B-UNK
of	O
another	O
closely	B-UNK
linked	I-UNK
marker	B-UNK
locus	B-UNK
,	O
OATL1	O
.	O

The	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
has	O
previously	B-UNK
been	O
mapped	B-UNK
to	O
the	O
proximal	B-UNK
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
between	O
the	O
DXS14	O
and	O
DXS7	B-UNK
loci	O
.	O

In	O
this	O
study	B-UNK
,	O
further	O
segregation	B-UNK
analysis	B-UNK
has	O
been	O
performed	O
using	O
a	O
newly	O
identified	B-UNK
WAS	O
family	B-UNK
as	O
well	O
as	O
an	O
additional	O
marker	B-UNK
probe	O
,	O
HOATL1	O
.	O

The	O
results	B-UNK
indicate	O
close	B-UNK
linkage	I-UNK
between	O
the	O
WAS	O
and	O
OATL1	O
loci	O
(	O
Z	O
=	O
6	O
.	O
08	O
at	O
theta	B-UNK
=	O
0	O
.	O
00	O
)	O
and	O
localize	O
the	O
TIMP	O
,	O
OATL1	O
,	O
DXS255	O
,	O
and	O
WAS	O
loci	O
distal	B-UNK
to	O
DXS146	O
and	O
the	O
OATL1	O
and	O
WAS	O
loci	O
proximal	B-UNK
to	O
TIMP	O
.	O

These	O
linkage	B-UNK
data	B-UNK
narrow	O
the	O
boundaries	O
within	O
which	O
the	O
WAS	O
locus	B-UNK
maps	B-UNK
to	O
the	O
chromosomal	B-UNK
region	B-UNK
bracketed	O
by	O
TIMP	O
and	O
DXS146	O
and	O
support	O
the	O
loci	O
order	B-UNK
Xpter	O
-	O
DXS7-TIMP-(OATL1	O
,	O
WAS	O
,	O
DXS255)-DXS146	O
.	O

Detection	B-UNK
of	O
an	O
unstable	O
fragment	B-UNK
of	O
DNA	B-UNK
specific	B-UNK
to	O
individuals	B-UNK
with	O
myotonic	B-UNK
dystrophy	I-UNK
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
is	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
adult	B-UNK
muscular	B-UNK
dystrophy	I-UNK
,	O
with	O
a	O
prevalence	B-UNK
of	O
2	O
-	O
14	O
per	O
100	O
,	O
000	O
individuals	B-UNK
.	O

The	O
disease	B-DISEASE
is	O
characterized	B-UNK
by	O
progressive	B-UNK
muscle	B-DISEASE
weakness	I-DISEASE
and	O
sustained	O
muscle	B-UNK
contraction	O
,	O
often	O
with	O
a	O
wide	B-UNK
range	B-UNK
of	O
accompanying	O
symptoms	B-UNK
.	O

The	O
age	B-UNK
at	O
onset	B-UNK
and	O
severity	B-UNK
of	O
the	O
disease	B-DISEASE
show	O
extreme	O
variation	B-UNK
,	O
both	O
within	O
and	O
between	O
families	B-UNK
.	O

Despite	O
its	O
clinical	B-UNK
variability	B-UNK
,	O
this	O
dominant	B-UNK
condition	B-UNK
segregates	O
as	O
a	O
single	B-UNK
locus	B-UNK
at	O
chromosome	B-UNK
19q13	O
.	O

3	O
in	O
every	O
population	B-UNK
studied	O
.	O

It	O
is	O
flanked	O
by	O
the	O
tightly	B-UNK
linked	I-UNK
genetic	B-UNK
markers	B-UNK
ERCC1	O
proximally	O
and	O
D19S51	O
distally	O
;	O
these	O
define	B-UNK
the	O
DM	B-DISEASE
critical	B-UNK
region	I-UNK
.	O

We	O
report	B-UNK
the	O
isolation	B-UNK
of	O
an	O
expressed	B-UNK
sequence	B-UNK
from	O
this	O
region	B-UNK
which	O
detects	O
a	O
DNA	B-UNK
fragment	B-UNK
that	O
is	O
larger	O
in	O
affected	B-UNK
individuals	I-UNK
than	O
in	O
normal	B-UNK
siblings	O
or	O
unaffected	O
controls	O
.	O

The	O
size	B-UNK
of	O
this	O
fragment	B-UNK
varies	O
between	O
affected	B-UNK
siblings	O
,	O
and	O
increases	O
in	O
size	B-UNK
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	B-UNK
of	O
the	O
disease	B-DISEASE
.	O

We	O
postulate	O
that	O
this	O
unstable	O
DNA	B-UNK
sequence	I-UNK
is	O
the	O
molecular	B-UNK
feature	O
that	O
underlies	O
DM	B-UNK
.	O

Common	B-UNK
sequence	B-UNK
motifs	O
at	O
the	O
rearrangement	B-UNK
sites	O
of	O
a	O
constitutional	B-UNK
X	O
/	O
autosome	O
translocation	B-UNK
and	O
associated	O
deletion	B-UNK
.	O

Reciprocal	O
chromosome	B-UNK
translocations	O
are	O
common	B-UNK
de	O
novo	O
rearrangements	O
that	O
occur	B-UNK
randomly	O
throughout	O
the	O
human	B-UNK
genome	B-UNK
.	O

To	O
learn	O
about	O
causative	O
mechanisms	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
breakpoints	O
of	O
a	O
cytologically	O
balanced	O
constitutional	B-UNK
reciprocal	O
translocation	B-UNK
,	O
t	O
(	O
X	O
;	O
4	O
)	O
(	O
p21	O
.	O
2	O
;	O
q31	O
.	O
22	O
)	O
,	O
present	B-UNK
in	O
a	O
girl	O
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

Physical	B-UNK
mapping	B-UNK
of	O
the	O
derivative	O
chromosomes	O
,	O
after	O
their	O
separation	O
in	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
,	O
reveals	O
that	O
the	O
translocation	B-UNK
disrupts	O
the	O
DMD	B-UNK
gene	B-UNK
in	O
Xp21	B-UNK
within	O
the	O
18-kb	O
intron	B-UNK
16	O
.	O

Restriction	B-UNK
mapping	B-UNK
and	O
sequencing	B-UNK
of	O
clones	O
that	O
span	O
both	O
translocation	B-UNK
breakpoints	O
as	O
well	O
as	O
the	O
corresponding	O
normal	B-UNK
regions	B-UNK
indicate	O
the	O
loss	B-UNK
of	O
approximately	O
5	O
kb	B-UNK
in	O
the	O
formation	B-UNK
of	O
the	O
derivative	O
X	O
chromosome	B-UNK
,	O
with	O
4	O
-	O
6	O
bp	B-UNK
deleted	B-UNK
from	O
chromosome	B-UNK
4	O
.	O

RFLP	B-UNK
and	O
Southern	B-UNK
analyses	O
indicate	O
that	O
the	O
de	O
novo	O
translocation	B-UNK
is	O
a	O
paternal	O
origin	O
and	O
that	O
the	O
fathers	O
X	O
chromosome	B-UNK
contains	O
the	O
DNA	B-UNK
that	O
is	O
deleted	B-UNK
in	O
the	O
derivative	O
X.	O

Most	O
likely	O
,	O
deletion	B-UNK
and	O
translation	O
arose	O
simultaneously	O
from	O
a	O
complex	O
rearrangement	B-UNK
event	O
that	O
involves	O
three	O
chromosomal	B-UNK
breakpoints	O
.	O

Short	B-UNK
regions	B-UNK
of	O
sequence	B-UNK
homology	B-UNK
were	O
present	B-UNK
at	O
the	O
three	O
sites	O
.	O

A	O
5-bp	O
sequence	B-UNK
,	O
GGAAT	O
,	O
found	O
exactly	O
at	O
the	O
translocation	B-UNK
breakpoints	O
on	O
both	O
normal	B-UNK
chromosomes	O
X	O
and	O
4	O
,	O
has	O
been	O
preserved	O
only	O
on	O
the	O
der	B-UNK
(	O
4	O
)	O
chromosome	B-UNK
.	O

It	O
is	O
likely	O
that	O
the	O
X	O
-	O
derived	B-UNK
sequence	B-UNK
GGAATCA	O
has	O
been	O
lost	O
in	O
the	O
formation	B-UNK
of	O
the	O
der	B-UNK
(	O
X	O
)	O
chromosome	B-UNK
,	O
as	O
it	O
matches	O
an	O
inverted	O
GAATCA	O
sequence	B-UNK
present	B-UNK
on	O
the	O
opposite	O
strand	B-UNK
exactly	O
at	O
the	O
other	O
end	B-UNK
of	O
the	O
deleted	B-UNK
5-kb	O
fragment	B-UNK
.	O

A	O
genetic	B-UNK
etiology	O
for	O
DiGeorge	B-DISEASE
syndrome	I-DISEASE
:	O
consistent	B-UNK
deletions	O
and	O
microdeletions	O
of	O
22q11	O
.	O

DiGeorge	B-DISEASE
syndrome	I-DISEASE
(	O
DGS	B-UNK
)	O
,	O
a	O
developmental	O
field	B-UNK
defect	B-UNK
of	O
the	O
third	O
and	O
fourth	B-UNK
pharyngeal	O
pouches	O
,	O
is	O
characterized	B-UNK
by	O
aplasia	O
or	O
hypoplasia	B-UNK
of	O
the	O
thymus	O
and	O
parathyroid	O
glands	O
and	O
by	O
conotruncal	O
cardiac	B-DISEASE
malformations	I-DISEASE
.	O

Cytogenetic	B-UNK
studies	B-UNK
support	O
the	O
presence	O
of	O
a	O
DGS	B-UNK
critical	B-UNK
region	I-UNK
in	O
band	O
22q11	O
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
report	B-UNK
the	O
results	B-UNK
of	O
clinical	B-UNK
,	O
cytogenetic	B-UNK
,	O
and	O
molecular	B-UNK
studies	B-UNK
of	O
14	O
patients	B-UNK
with	O
DGS	B-UNK
.	O

Chromosome	B-UNK
analysis	B-UNK
,	O
utilizing	O
high	B-UNK
-	O
resolution	O
banding	O
techniques	O
,	O
detected	B-UNK
interstitial	O
deletions	O
in	O
five	O
probands	O
and	O
was	O
inconclusive	O
for	O
a	O
deletion	B-UNK
in	O
three	O
probands	O
.	O

The	O
remaining	O
six	O
patients	B-UNK
had	O
normal	B-UNK
karyotypes	O
.	O

In	O
contrast	B-UNK
,	O
molecular	B-UNK
analysis	I-UNK
detected	B-UNK
DNA	B-UNK
deletions	O
in	O
all	O
14	O
probands	O
.	O

Two	O
of	O
10	O
loci	O
tested	O
,	O
D22S75	O
and	O
D22S259	O
,	O
are	O
deleted	B-UNK
in	O
all	O
14	O
patients	B-UNK
.	O

A	O
third	O
locus	B-UNK
,	O
D22S66	O
,	O
is	O
deleted	B-UNK
in	O
the	O
eight	O
DGS	B-UNK
probands	O
tested	O
.	O

Physical	B-UNK
mapping	B-UNK
using	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
places	O
D22S66	O
between	O
D22S75	O
and	O
D22S259	O
,	O
suggesting	O
that	O
it	O
should	O
be	O
deleted	B-UNK
in	O
the	O
remaining	O
six	O
cases	B-UNK
.	O

Parent	O
-	O
of	O
-	O
origin	O
studies	B-UNK
were	O
performed	O
in	O
five	O
families	B-UNK
.	O

Four	O
probands	O
failed	O
to	O
inherit	O
a	O
maternal	O
allele	B-UNK
,	O
and	O
one	O
failed	O
to	O
inherit	O
a	O
paternal	O
allele	B-UNK
.	O

On	O
the	O
basis	B-UNK
of	O
these	O
families	B-UNK
,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	B-UNK
unbalanced	O
-	O
translocation	B-UNK
DGS	B-UNK
probands	O
in	O
the	O
literature	O
,	O
parent	O
of	O
origin	O
or	O
imprinting	B-UNK
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
DGS	B-UNK
.	O

Deletion	B-UNK
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
DGS	B-UNK
probands	O
begins	O
to	O
delineate	O
the	O
region	B-UNK
of	O
chromosome	B-UNK
22	O
critical	B-UNK
for	O
DGS	B-UNK
and	O
confirms	O
the	O
hypothesis	B-UNK
that	O
submicroscopic	B-UNK
deletions	O
of	O
22q11	O
are	O
etiologic	O
in	O
the	O
vast	O
majority	O
of	O
cases	B-UNK
..	O

Loss	B-UNK
of	O
normal	B-UNK
allele	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
in	O
an	O
adrenocortical	B-DISEASE
carcinoma	I-DISEASE
from	O
a	O
patient	B-UNK
with	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
.	O

Endocrine	O
neoplasms	B-DISEASE
have	O
been	O
reported	B-UNK
occasionally	O
in	O
patients	B-UNK
with	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
.	O

An	O
adrenocorotical	O
carcinoma	B-DISEASE
was	O
studied	O
in	O
a	O
patient	B-UNK
with	O
a	O
family	B-UNK
history	B-UNK
of	O
FAP	B-UNK
.	O

Loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
(	O
LOH	B-UNK
)	O
in	O
the	O
region	B-UNK
close	B-UNK
to	O
the	O
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
gene	B-UNK
was	O
detected	B-UNK
in	O
this	O
carcinoma	B-UNK
,	O
and	O
evidence	B-UNK
was	O
obtained	B-UNK
that	O
there	O
was	O
a	O
loss	B-UNK
of	O
the	O
normal	B-UNK
allele	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	B-UNK
at	O
the	O
APC	B-UNK
locus	B-UNK
in	O
adrenocortical	O
tumors	B-UNK
.	O

The	O
present	B-UNK
results	B-UNK
and	O
our	O
previous	B-UNK
data	B-UNK
on	O
LOH	B-UNK
in	O
a	O
recurring	O
desmoid	O
tumor	B-UNK
suggest	B-UNK
that	O
the	O
heterozygous	B-UNK
mutant	B-UNK
/	O
wild	B-UNK
-	O
type	B-UNK
condition	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
may	O
give	O
rise	B-UNK
to	O
benign	O
tumors	B-DISEASE
,	O
and	O
that	O
functional	O
loss	B-UNK
of	O
this	O
gene	B-UNK
leads	B-UNK
to	O
development	B-UNK
of	O
tumors	B-UNK
not	O
only	O
in	O
the	O
colon	B-UNK
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	B-UNK
patients	I-UNK
..	O

Oncogenic	O
point	B-UNK
mutations	I-UNK
in	O
exon	B-UNK
20	O
of	O
the	O
RB1	B-UNK
gene	B-UNK
in	O
families	B-UNK
showing	O
incomplete	O
penetrance	O
and	O
mild	O
expression	B-UNK
of	O
the	O
retinoblastoma	B-DISEASE
phenotype	B-UNK
.	O

The	O
retinoblastoma	B-DISEASE
-	O
predisposition	B-UNK
gene	B-UNK
,	O
RB1	B-UNK
,	O
segregates	O
as	O
an	O
autosomal	B-UNK
dominant	I-UNK
trait	O
with	O
high	B-UNK
(	O
90	O
%	O
)	O
penetrance	O
.	O

Certain	O
families	B-UNK
,	O
however	O
,	O
show	O
an	O
unusual	O
low	B-UNK
-	O
penetrance	O
phenotype	B-UNK
with	O
many	O
individuals	B-UNK
being	O
unaffected	O
,	O
unilaterally	O
affected	B-UNK
,	O
or	O
with	O
evidence	B-UNK
of	O
spontaneously	O
regressed	O
tumors	B-UNK
.	O

We	O
have	O
used	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
analysis	B-UNK
and	O
PCR	B-UNK
sequencing	B-UNK
to	O
study	B-UNK
two	O
such	O
families	B-UNK
.	O

Mutations	B-UNK
were	O
found	O
in	O
exon	B-UNK
20	O
of	O
RB1	B-UNK
in	O
both	O
cases	B-UNK
.	O

In	O
one	O
family	B-UNK
a	O
C----T	O
transition	B-UNK
in	O
codon	B-UNK
661	O
converts	O
an	O
arginine	O
(	O
CGG	O
)	O
to	O
a	O
tryptophan	O
(	O
TGG	O
)	O
codon	B-UNK
.	O

In	O
this	O
family	B-UNK
,	O
incomplete	O
penetrance	O
and	O
mild	O
phenotypic	B-UNK
expression	B-UNK
were	O
observed	B-UNK
in	O
virtually	O
all	O
patients	B-UNK
,	O
possibly	O
indicating	O
that	O
single	B-UNK
amino	B-UNK
acid	I-UNK
changes	O
may	O
modify	O
protein	B-UNK
structure	B-UNK
/	O
function	B-UNK
such	O
that	O
tumorigenesis	O
is	O
not	O
inevitable	O
.	O

In	O
the	O
second	O
family	B-UNK
the	O
mutation	B-UNK
in	O
codon	B-UNK
675	O
is	O
a	O
G----T	O
transversion	B-UNK
that	O
converts	O
a	O
glutamine	O
(	O
GAA	B-UNK
)	O
to	O
a	O
stop	B-UNK
(	O
TAA	B-DISEASE
)	O
codon	B-UNK
.	O

However	O
,	O
this	O
mutation	B-UNK
also	O
occurs	O
near	O
a	O
potential	B-UNK
cryptic	O
splice	B-UNK
acceptor	I-UNK
site	B-UNK
,	O
raising	O
the	O
possibility	B-UNK
of	O
alternative	B-UNK
splicing	B-UNK
resulting	B-UNK
in	O
a	O
less	O
severely	O
disrupted	O
protein	B-UNK
..	O

Late	B-UNK
-	O
onset	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
:	O
molecular	B-UNK
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	B-UNK
on	O
a	O
new	O
allele	B-UNK
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
locus	B-UNK
causing	B-UNK
late	B-UNK
-	O
onset	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
.	O

In	O
that	O
allele	B-UNK
arginine84	O
,	O
a	O
residue	O
that	O
is	O
highly	B-UNK
conserved	I-UNK
in	O
the	O
arylsulfatase	O
gene	B-UNK
family	B-UNK
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	B-UNK
to	O
alleles	B-UNK
that	O
cause	O
early	B-UNK
-	O
onset	B-UNK
MLD	B-UNK
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	B-UNK
is	O
associated	O
with	O
some	O
residual	B-UNK
ARSA	B-UNK
activity	B-UNK
.	O

A	O
comparison	B-UNK
of	O
genotypes	O
,	O
ARSA	B-UNK
activities	O
,	O
and	O
clinical	B-UNK
data	B-UNK
on	O
4	O
individuals	B-UNK
carrying	B-UNK
the	O
allele	B-UNK
of	O
81	O
patients	B-UNK
with	O
MLD	B-UNK
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	B-UNK
ARSA	B-UNK
activity	B-UNK
are	O
the	O
basis	B-UNK
of	O
phenotypical	O
variation	B-UNK
in	O
MLD	B-UNK
..	O

Trisomy	B-DISEASE
15	O
with	O
loss	B-UNK
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
due	O
to	O
maternal	O
disomy	B-UNK
.	O

Uniparental	B-DISEASE
disomy	I-DISEASE
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	B-UNK
disorders	B-UNK
,	O
including	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	B-UNK
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B-UNK
disomy	I-UNK
and	O
whose	O
evaluation	B-UNK
provides	O
evidence	B-UNK
that	O
trisomy	B-DISEASE
may	O
precede	O
uniparental	B-DISEASE
disomy	I-DISEASE
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	B-UNK
revealed	B-UNK
trisomy	B-DISEASE
15	O
in	O
all	O
direct	B-UNK
and	O
cultured	O
cells	B-UNK
,	O
though	O
the	O
fetus	O
appeared	B-UNK
normal	B-UNK
.	O

Chromosome	B-UNK
analysis	B-UNK
of	O
amniocytes	O
obtained	B-UNK
at	O
15	O
wk	O
was	O
normal	B-UNK
in	O
over	O
100	O
cells	B-UNK
studied	O
.	O

The	O
child	B-UNK
was	O
hypotonic	O
at	O
birth	O
,	O
and	O
high	B-UNK
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	B-UNK
of	O
15q11	B-UNK
-	O
13	O
,	O
a	O
deletion	B-UNK
which	O
is	O
found	O
in	O
50%-70	O
%	O
of	O
patients	B-UNK
with	O
PWS	B-UNK
.	O

Over	O
time	O
,	O
typical	O
features	B-UNK
of	O
PWS	B-UNK
developed	O
.	O

Molecular	B-UNK
genetic	I-UNK
analysis	B-UNK
using	O
probes	O
for	O
chromosome	B-UNK
15	O
revealed	B-UNK
maternal	O
disomy	B-UNK
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	B-UNK
sperm	O
,	O
followed	O
by	O
loss	B-UNK
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B-UNK
disomy	I-UNK
in	O
this	O
case	B-UNK
of	O
PWS	B-UNK
,	O
and	O
advanced	O
maternal	O
age	B-UNK
may	O
be	O
a	O
predisposing	O
factor	B-UNK
..	O

Genetic	B-UNK
heterogeneity	I-UNK
in	O
X	O
-	O
linked	B-UNK
amelogenesis	B-DISEASE
imperfecta	I-DISEASE
.	O

The	O
AMELX	O
gene	B-UNK
located	B-UNK
at	O
Xp22	O
.	O

1-p22	O
.	O

3	O
encodes	B-UNK
for	O
the	O
enamel	O
protein	B-UNK
amelogenin	O
and	O
has	O
been	O
implicated	B-UNK
as	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
the	O
inherited	B-UNK
dental	O
abnormality	O
X	O
-	O
linked	B-UNK
amelogenesis	B-DISEASE
imperfecta	I-DISEASE
(	O
XAI	O
)	O
.	O

Three	O
families	B-UNK
with	O
XAI	O
have	O
been	O
investigated	O
using	O
polymorphic	B-UNK
DNA	B-UNK
markers	I-UNK
flanking	O
the	O
position	B-UNK
of	O
AMELX	O
.	O

Using	O
two	O
-	O
point	B-UNK
linkage	B-UNK
analysis	I-UNK
,	O
linkage	B-UNK
was	O
established	O
between	O
XAI	O
and	O
several	O
of	O
these	O
markers	B-UNK
in	O
two	O
families	B-UNK
,	O
with	O
a	O
combined	O
lod	B-UNK
score	I-UNK
of	O
6	O
.	O

05	O
for	O
DXS16	O
at	O
theta	B-UNK
=	O
0	O
.	O

04	O
04	O
.	O

This	O
supports	O
the	O
involvement	B-UNK
of	O
AMELX	O
,	O
located	B-UNK
close	B-UNK
to	O
DXS16	O
,	O
in	O
the	O
XAI	O
disease	B-DISEASE
process	B-UNK
(	O
AIH1	O
)	O
in	O
those	O
families	B-UNK
.	O

Using	O
multipoint	B-UNK
linkage	B-UNK
analysis	I-UNK
,	O
the	O
combined	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
for	O
these	O
two	O
families	B-UNK
was	O
7	O
.	O

30	O
for	O
a	O
location	B-UNK
of	O
AIH1	O
at	O
2	O
cM	B-DISEASE
distal	B-UNK
to	O
DXS16	O
.	O

The	O
support	O
interval	B-UNK
around	O
this	O
location	B-UNK
extended	O
about	O
8	O
cM	B-DISEASE
proximal	B-UNK
to	O
DXS92	O
,	O
and	O
the	O
AIH1	O
location	B-UNK
could	O
not	O
be	O
precisely	O
defined	B-UNK
by	O
multipoint	B-UNK
mapping	B-UNK
.	O

Study	B-UNK
of	O
recombination	B-UNK
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	B-UNK
between	O
DXS143	O
and	O
DXS85	O
.	O

There	O
was	O
significant	B-UNK
evidence	B-UNK
against	O
linkage	B-UNK
to	O
this	O
region	B-UNK
in	O
the	O
third	O
family	B-UNK
,	O
indicating	O
locus	B-UNK
heterogeneity	B-UNK
in	O
XAI	O
.	O

Further	O
analysis	B-UNK
with	O
markers	B-UNK
on	O
the	O
long	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
showed	O
evidence	B-UNK
of	O
linkage	B-UNK
to	O
DXS144E	O
and	O
F9	O
with	O
no	O
recombination	B-UNK
with	O
either	O
of	O
these	O
markers	B-UNK
.	O

Two	O
-	O
point	B-UNK
analysis	B-UNK
gave	O
a	O
peak	O
lod	B-UNK
score	I-UNK
at	O
DXS144E	O
with	O
a	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
of	O
2	O
.	O

83	O
at	O
theta	B-UNK
=	O
0	O
,	O
with	O
a	O
peak	O
lod	B-UNK
score	I-UNK
in	O
multipoint	B-UNK
linkage	B-UNK
analysis	I-UNK
of	O
2	O
.	O

84	O
at	O
theta	B-UNK
=	O
0	O
.	O

The	O
support	O
interval	B-UNK
extended	O
9	O
cM	B-DISEASE
proximal	B-UNK
to	O
DXS144E	O
and	O
14	O
cM	B-DISEASE
distal	B-UNK
to	O
F9	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Multiple	B-UNK
origins	O
for	O
phenylketonuria	O
in	O
Europe	B-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
,	O
a	O
disorder	B-DISEASE
of	I-DISEASE
amino	I-DISEASE
acid	I-DISEASE
metabolism	I-DISEASE
prevalent	O
among	O
Caucasians	B-UNK
and	O
other	O
ethnic	B-UNK
groups	I-UNK
,	O
is	O
caused	B-UNK
primarily	O
by	O
a	O
deficiency	B-UNK
of	O
the	O
hepatic	B-UNK
enzyme	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

PKU	B-UNK
is	O
a	O
highly	B-UNK
heterogeneous	O
disorder	B-UNK
,	O
with	O
more	O
than	O
60	O
molecular	B-UNK
lesions	B-UNK
identified	B-UNK
in	O
the	O
PAH	B-UNK
gene	B-UNK
.	O

The	O
haplotype	B-UNK
associations	O
,	O
relative	B-UNK
frequencies	O
,	O
and	O
distributions	O
of	O
five	O
prevalent	O
PAH	B-UNK
mutations	B-UNK
(	O
R158Q	O
,	O
R261Q	O
,	O
IVS10nt546	O
,	O
R408W	O
,	O
and	O
IVS12n1	O
)	O
were	O
established	O
in	O
a	O
comprehensive	O
European	B-UNK
sample	O
population	B-UNK
and	O
subsequently	B-UNK
were	O
examined	O
to	O
determine	B-UNK
the	O
potential	B-UNK
roles	O
of	O
several	O
genetic	B-UNK
mechanisms	O
in	O
explaining	O
the	O
present	B-UNK
distribution	B-UNK
of	O
the	O
major	B-UNK
PKU	B-UNK
alleles	B-UNK
.	O

Each	O
of	O
these	O
five	O
mutations	B-UNK
was	O
strongly	O
associated	O
with	O
only	O
one	O
of	O
the	O
more	O
than	O
70	O
chromosomal	B-UNK
haplotypes	O
defined	B-UNK
by	O
eight	O
RFLPs	B-UNK
in	O
or	O
near	O
the	O
PAH	B-UNK
gene	B-UNK
.	O

These	O
findings	B-UNK
suggest	B-UNK
that	O
each	O
of	O
these	O
mutations	B-UNK
arose	O
through	O
a	O
single	B-UNK
founding	O
event	O
that	O
occurred	B-UNK
within	O
time	O
periods	O
ranging	O
from	O
several	O
hundred	O
to	O
several	O
thousand	O
years	O
ago	O
.	O

From	O
the	O
significant	B-UNK
differences	B-UNK
observed	B-UNK
in	O
the	O
relative	B-UNK
frequencies	O
and	O
distributions	O
of	O
these	O
five	O
alleles	B-UNK
throughout	O
Europe	B-UNK
,	O
four	O
of	O
these	O
putative	O
founding	O
events	O
could	O
be	O
localized	B-UNK
to	O
specific	B-UNK
ethnic	B-UNK
subgroups	O
.	O

Together	O
,	O
these	O
data	B-UNK
suggest	B-UNK
that	O
there	O
were	O
multiple	B-UNK
,	O
geographically	O
and	O
ethnically	O
distinct	O
origins	O
for	O
PKU	B-UNK
within	O
the	O
European	B-UNK
population	B-UNK
..	O

Complement	B-UNK
factor	B-UNK
2	O
deficiency	B-UNK
:	O
a	O
clinical	B-UNK
and	O
serological	O
family	B-UNK
study	B-UNK
.	O

Inherited	B-UNK
complement	B-UNK
deficiencies	B-UNK
are	O
associated	O
with	O
a	O
variety	O
of	O
connective	B-DISEASE
tissue	I-DISEASE
diseases	I-DISEASE
.	O

A	O
family	B-UNK
with	O
inherited	B-UNK
deficiency	B-UNK
of	O
complement	B-UNK
factor	B-UNK
2	O
(	O
C2	B-UNK
)	O
is	O
described	O
in	O
which	O
two	O
family	B-UNK
members	I-UNK
with	O
homozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
developed	O
cutaneous	O
vasculitis	B-DISEASE
and	O
sicca	O
syndrome	B-UNK
.	O

The	O
other	O
family	B-UNK
members	I-UNK
had	O
heterozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
and	O
each	O
member	B-UNK
had	O
the	O
HLA	B-UNK
-	O
A25	O
,	O
B18	O
,	O
DR2	O
(	O
w15	O
)	O
haplotype	B-UNK
.	O

The	O
mother	O
had	O
seropositive	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O

Further	O
studies	B-UNK
showed	O
the	O
presence	O
of	O
cryoglobulins	O
,	O
antibodies	B-UNK
against	O
endothelial	O
cells	B-UNK
,	O
and	O
anticardiolipin	O
antibodies	B-UNK
..	O

New	O
variant	O
in	O
exon	B-UNK
3	O
of	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
in	O
a	O
family	B-UNK
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
.	O

A	O
C	O
--	O
greater	B-UNK
than	O
G	O
transversion	B-UNK
has	O
been	O
found	O
in	O
exon	B-UNK
3	O
of	O
the	O
PLP	B-UNK
gene	B-UNK
of	O
affected	B-UNK
males	I-UNK
and	O
their	O
mother	O
in	O
a	O
single	B-UNK
sibship	O
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
merzbacher	I-DISEASE
disease	I-DISEASE
(	O
PMD	B-UNK
)	O
.	O

The	O
transversion	B-UNK
should	O
not	O
result	B-UNK
in	O
an	O
amino	B-UNK
acid	I-UNK
change	B-UNK
in	O
the	O
protein	B-UNK
but	O
it	O
does	O
result	B-UNK
in	O
the	O
loss	B-UNK
of	O
a	O
HaeIII	O
restriction	B-UNK
endonuclease	O
cleavage	O
site	B-UNK
.	O

It	O
is	O
concordant	O
with	O
the	O
disease	B-DISEASE
in	O
this	O
family	B-UNK
.	O

One	O
-	O
hundred	O
-	O
ten	O
unrelated	B-UNK
X	O
chromosomes	O
are	O
negative	B-UNK
for	O
this	O
mutation	B-UNK
.	O

No	O
other	O
sequence	B-UNK
defect	B-UNK
was	O
found	O
in	O
the	O
PLP	B-UNK
exons	O
of	O
the	O
affected	B-UNK
males	I-UNK
.	O

The	O
cause	O
of	O
disease	B-UNK
in	O
this	O
family	B-UNK
remains	O
unknown	O
,	O
but	O
the	O
association	B-UNK
between	O
this	O
rare	B-UNK
mutation	B-UNK
and	O
PMD	B-UNK
is	O
intriguing	O
.	O

The	O
mutation	B-UNK
can	O
serve	O
as	O
a	O
marker	B-UNK
for	O
following	O
segregation	B-UNK
of	O
the	O
PLP	B-UNK
gene	B-UNK
..	O

Uncoupling	O
of	O
hypomyelination	O
and	O
glial	O
cell	B-UNK
death	B-UNK
by	O
a	O
mutation	B-UNK
in	O
the	O
proteolipid	B-UNK
protein	I-UNK
gene	B-UNK
.	O

Proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
;	O
M	O
(	O
r	O
)	O
30	O
,	O
000	O
)	O
is	O
a	O
highly	B-UNK
conserved	I-UNK
major	B-UNK
polytopic	O
membrane	B-UNK
protein	I-UNK
in	O
myelin	B-UNK
but	O
its	O
cellular	O
function	B-UNK
remains	O
obscure	O
.	O

Neurological	B-UNK
mutant	B-UNK
mice	I-UNK
can	O
often	O
provide	B-UNK
model	B-UNK
systems	O
for	O
human	B-UNK
genetic	B-UNK
disorders	B-UNK
.	O

Mutations	B-UNK
of	O
the	O
X	O
-	O
chromosome	B-UNK
-	O
linked	B-UNK
PLP	B-UNK
gene	B-UNK
are	O
lethal	O
,	O
identified	B-UNK
first	O
in	O
the	O
jimpy	O
mouse	B-UNK
and	O
subsequently	B-UNK
in	O
patients	B-UNK
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
.	O

The	O
unexplained	O
phenotype	B-UNK
of	O
these	O
mutations	B-UNK
includes	O
degeneration	B-UNK
and	O
premature	B-UNK
cell	B-UNK
death	B-DISEASE
of	O
oligodendrocytes	O
with	O
associated	O
hypomyelination	O
.	O

Here	O
we	O
show	O
that	O
a	O
new	O
mouse	B-UNK
mutant	B-UNK
rumpshaker	O
is	O
defined	B-UNK
by	O
the	O
amino	B-UNK
-	O
acid	B-UNK
substitution	B-UNK
Ile	O
-	O
to	O
-	O
Thr	B-UNK
at	O
residue	O
186	O
in	O
a	O
membrane	B-UNK
-	O
embedded	O
domain	B-UNK
of	O
PLP	B-UNK
.	O

Surprisingly	O
,	O
rumpshaker	O
mice	B-UNK
,	O
although	O
myelin	B-UNK
-	O
deficient	B-UNK
,	O
have	O
normal	B-UNK
longevity	O
and	O
a	O
full	O
complement	B-UNK
of	O
morphologically	O
normal	B-UNK
oligodendrocytes	O
.	O

Hypomyelination	O
can	O
thus	O
be	O
genetically	B-UNK
separated	O
from	O
the	O
PLP	B-UNK
-	O
dependent	B-UNK
oligodendrocyte	O
degeneration	B-UNK
.	O

We	O
suggest	B-UNK
that	O
PLP	B-UNK
has	O
a	O
vital	O
function	B-UNK
in	O
glial	O
cell	B-UNK
development	B-UNK
,	O
distinct	O
from	O
its	O
later	O
role	B-UNK
in	O
myelin	B-UNK
assembly	O
,	O
and	O
that	O
this	O
dichotomy	O
of	O
action	O
may	O
explain	O
the	O
clinical	B-UNK
spectrum	B-UNK
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
..	O

A	O
pseudodeficiency	O
allele	B-UNK
common	B-UNK
in	O
non-Jewish	O
Tay	O
-	O
Sachs	O
carriers	B-UNK
:	O
implications	B-UNK
for	O
carrier	B-UNK
screening	B-UNK
.	O

Deficiency	B-UNK
of	O
beta-hexosaminidase	O
A	O
(	O
Hex	B-UNK
A	O
)	O
activity	B-UNK
typically	O
results	B-UNK
in	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
.	O

However	O
,	O
healthy	O
subjects	B-UNK
found	O
to	O
be	O
deficient	B-UNK
in	O
Hex	B-UNK
A	O
activity	B-UNK
(	O
i.	O
e.	O
,	O
pseudodeficient	O
)	O
by	O
means	B-UNK
of	O
in	O
vitro	O
biochemical	O
tests	O
have	O
been	O
described	O
.	O

We	O
analyzed	B-UNK
the	O
HEXA	B-UNK
gene	B-UNK
of	O
one	O
pseudodeficient	O
subject	O
and	O
identified	B-UNK
both	O
a	O
C739-to	O
-T	O
substitution	B-UNK
that	O
changes	O
Arg247	O
-	O
---Trp	O
on	O
one	O
allele	B-UNK
and	O
a	O
previously	B-UNK
identified	I-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
mutation	B-UNK
on	O
the	O
second	O
allele	B-UNK
.	O

Six	O
additional	O
pseudodeficient	O
subjects	B-UNK
were	O
found	O
to	O
have	O
the	O
C739-to	O
-T	O
mutation	B-UNK
.	O

This	O
allele	B-UNK
accounted	O
for	O
32	O
%	O
(	O
20/62	O
)	O
of	O
non-Jewish	O
enzyme	B-UNK
-	O
defined	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
carriers	B-UNK
but	O
for	O
none	O
of	O
36	O
Jewish	B-UNK
enzyme	B-UNK
-	O
defined	B-UNK
carriers	B-UNK
who	O
did	O
not	O
have	O
one	O
of	O
three	O
known	O
mutations	B-UNK
common	B-UNK
to	O
this	O
group	B-UNK
.	O

The	O
C739-to	O
-T	O
allele	B-UNK
,	O
together	O
with	O
a	O
"	O
true	O
"	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
allele	B-UNK
,	O
causes	O
Hex	B-UNK
A	O
pseudodeficiency	O
.	O

Given	O
both	O
the	O
large	B-UNK
proportion	B-UNK
of	O
non-Jewish	O
carriers	B-UNK
with	O
this	O
allele	B-UNK
and	O
that	O
standard	O
biochemical	O
screening	B-UNK
cannot	O
differentiate	O
between	O
heterozygotes	B-UNK
for	O
the	O
C739-to	O
-T	O
mutations	B-UNK
and	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
carriers	B-UNK
,	O
DNA	B-UNK
testing	B-UNK
for	O
this	O
mutation	B-UNK
in	O
at	O
-	O
risk	B-UNK
couples	O
is	O
essential	B-UNK
.	O

Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
:	O
detection	B-UNK
of	O
mutations	B-UNK
Thr181	O
-	O
---Pro	O
and	O
Leu223	O
-	O
---Pro	O
in	O
the	O
proteolipid	B-UNK
protein	I-UNK
gene	B-UNK
,	O
and	O
prenatal	B-UNK
diagnosis	I-UNK
.	O

A	O
family	B-UNK
with	O
an	O
apparent	O
history	B-UNK
of	O
X	O
-	O
linked	B-UNK
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
presented	B-UNK
for	O
genetic	B-UNK
counseling	I-UNK
,	O
requesting	O
carrier	B-UNK
detection	I-UNK
and	O
prenatal	B-UNK
diagnosis	I-UNK
.	O

RFLP	B-UNK
analysis	B-UNK
using	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
probe	O
was	O
uninformative	O
in	O
this	O
family	B-UNK
.	O

A	O
prenatal	B-UNK
diagnosis	I-UNK
on	O
a	O
chorionic	O
villus	O
sample	O
(	O
CVS	O
)	O
was	O
carried	O
out	O
using	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
analysis	B-UNK
of	O
a	O
variant	O
in	O
exon	B-UNK
4	O
of	O
the	O
PLP	B-UNK
gene	B-UNK
.	O

The	O
fetus	O
was	O
predicted	B-UNK
to	O
be	O
unaffected	O
.	O

Sequencing	B-UNK
of	O
the	O
exon	B-UNK
from	O
the	O
CVS	O
,	O
the	O
predicted	B-UNK
-	O
carrier	B-UNK
mother	O
,	O
and	O
the	O
obligate	B-UNK
-	O
carrier	B-UNK
grandmother	O
revealed	B-UNK
an	O
A	O
-	O
to	O
-	O
C	O
change	B-UNK
at	O
nucleotide	B-UNK
541	O
in	O
the	O
two	O
women	B-UNK
but	O
not	O
in	O
the	O
fetus	O
.	O

As	O
this	O
change	B-UNK
results	B-UNK
in	O
a	O
Thr	B-UNK
-	O
to	O
-	O
Pro	O
change	B-UNK
at	O
amino	B-UNK
acid	I-UNK
181	O
in	O
a	O
region	B-UNK
of	O
the	O
gene	B-UNK
predicted	B-UNK
to	O
be	O
part	O
of	O
a	O
transmembrane	B-UNK
segment	O
,	O
it	O
was	O
concluded	O
that	O
this	O
was	O
the	O
mutation	B-UNK
causing	I-UNK
the	O
disease	B-DISEASE
in	O
this	O
family	B-UNK
.	O

In	O
addition	B-UNK
,	O
in	O
a	O
second	O
family	B-UNK
,	O
an	O
exon	B-UNK
5	O
variant	O
band	O
pattern	B-UNK
on	O
SSCP	B-UNK
analysis	B-UNK
was	O
shown	B-UNK
by	O
sequencing	B-UNK
to	O
be	O
due	O
to	O
a	O
T	O
-	O
to	O
-	O
C	O
change	B-UNK
at	O
nucleotide	B-UNK
668	O
.	O

This	O
results	B-UNK
in	O
a	O
Leu	B-UNK
-	O
to	O
-	O
Pro	O
change	B-UNK
in	O
a	O
carrier	B-UNK
mother	O
and	O
in	O
her	O
two	O
affected	B-UNK
sons	O
.	O

These	O
results	B-UNK
provide	I-UNK
further	O
examples	O
of	O
mutations	B-UNK
in	O
PLP	B-UNK
that	O
cause	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
and	O
illustrate	O
the	O
value	O
of	O
SSCP	B-UNK
in	O
genetic	B-UNK
analysis	I-UNK
..	O

von	B-UNK
Willebrand	I-UNK
disease	I-UNK
type	B-UNK
B	O
:	O
a	O
missense	B-UNK
mutation	I-UNK
selectively	O
abolishes	O
ristocetin	O
-	O
induced	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
binding	B-UNK
to	O
platelet	B-UNK
glycoprotein	O
Ib	O
.	O

von	B-UNK
Willebrand	I-UNK
factor	I-UNK
(	O
vWF	B-UNK
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	B-UNK
to	O
platelet	B-UNK
glycoprotein	O
Ib	O
.	O

For	O
human	B-UNK
vWF	B-UNK
,	O
this	O
interaction	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
the	O
antibiotic	O
ristocetin	O
or	O
the	O
snake	O
venom	O
protein	B-UNK
botrocetin	O
.	O

A	O
missense	B-UNK
mutation	I-UNK
,	O
Gly-561	O
-	O
-	O
>	O
Ser	O
,	O
was	O
identified	B-UNK
within	O
the	O
proposed	O
glycoprotein	O
Ib	O
binding	B-UNK
domain	I-UNK
of	O
vWF	B-UNK
in	O
the	O
proband	B-UNK
with	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
type	B-UNK
B	O
,	O
a	O
unique	O
variant	O
characterized	B-UNK
by	O
no	O
ristocetin	O
-	O
induced	O
,	O
but	O
normal	B-UNK
botrocetin	O
-	O
induced	O
,	O
binding	B-UNK
to	O
glycoprotein	O
Ib	O
.	O

The	O
corresponding	O
mutant	B-UNK
recombinant	B-UNK
protein	B-UNK
,	O
rvWF	O
(	O
G561S	O
)	O
,	O
formed	O
normal	B-UNK
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	B-UNK
as	O
the	O
patients	B-UNK
plasma	O
vWF	B-UNK
,	O
confirming	O
that	O
this	O
mutation	B-UNK
causes	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
type	B-UNK
B.	O

These	O
data	B-UNK
show	O
that	O
botrocetin	O
and	O
ristocetin	O
cofactor	O
activities	O
of	O
vWF	B-UNK
can	O
be	O
dissociated	O
by	O
a	O
point	B-UNK
mutation	I-UNK
and	O
confirm	O
that	O
these	O
mediators	O
promote	O
vWF	B-UNK
binding	B-UNK
to	O
platelets	O
by	O
different	O
mechanisms	O
.	O

The	O
normal	B-UNK
botrocetin	O
-	O
induced	O
binding	B-UNK
and	O
the	O
defective	O
ristocetin	O
-	O
induced	O
binding	B-UNK
of	O
rvWF	O
(	O
G561S	O
)	O
suggest	B-UNK
that	O
the	O
primary	B-UNK
defect	B-UNK
in	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
type	B-UNK
B	O
may	O
be	O
a	O
failure	B-UNK
of	O
normal	B-UNK
allosteric	O
regulation	B-UNK
of	O
the	O
glycoprotein	O
Ib	O
binding	B-UNK
function	B-UNK
of	O
vWF	B-UNK
..	O

Typical	O
and	O
partial	O
cat	O
eye	B-UNK
syndrome	B-DISEASE
:	O
identification	B-UNK
of	O
the	O
marker	B-UNK
chromosome	B-UNK
by	O
FISH	B-UNK
.	O

Three	O
children	O
are	O
reported	B-UNK
with	O
typical	O
cat	O
eye	B-UNK
syndrome	B-DISEASE
(	O
CES	O
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	O
because	O
of	O
absence	B-UNK
of	O
coloboma	B-DISEASE
,	O
in	O
which	O
the	O
supernumerary	O
marker	B-UNK
chromosome	B-UNK
was	O
studied	O
by	O
FISH	B-UNK
.	O

Using	O
a	O
genomic	B-UNK
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B-DISEASE
was	O
shown	B-UNK
in	O
all	O
cases	B-UNK
..	O

[	O
Genetic	B-UNK
heterogeneity	I-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
:	O
mutant	B-UNK
alleles	I-UNK
of	O
G6PD	B-UNK
in	O
the	O
Shekii	O
district	O
of	O
Azerbaijan	O
]	O

Examination	B-UNK
on	O
G6PD	B-UNK
deficiency	I-UNK
in	O
349	O
patients	B-UNK
of	O
Shekii	O
district	O
hospital	O
(	O
Azerbaijan	O
)	O
revealed	B-UNK
16	O
hemi-	O
,	O
4	O
homo	O
-	O
and	O
9	O
heterozygotic	O
carriers	B-UNK
of	O
the	O
defect	B-UNK
.	O

Gd	B-UNK
-	O
frequency	B-UNK
,	O
calculated	O
from	O
the	O
data	B-UNK
obtained	B-UNK
(	O
7	O
.	O
7	O
%	O
)	O
,	O
may	O
be	O
compared	B-UNK
to	O
neighbouring	O
regions	B-UNK
frequencies	O
(	O
6	O
-	O
30	O
%	O
)	O
.	O

Carriers	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
are	O
residents	O
of	O
11	O
villages	O
located	B-UNK
in	O
Alasani	O
-	O
Aphtalan	O
valley	O
,	O
highly	B-UNK
endemic	O
with	O
malaria	B-UNK
in	O
the	O
past	O
;	O
nearly	O
all	O
marriages	O
are	O
endogamic	O
.	O

Physico	O
-	O
chemical	O
and	O
kinetic	O
study	B-UNK
of	O
10	O
mutant	B-UNK
forms	B-UNK
of	O
G6PD	B-UNK
,	O
according	O
to	O
WHO	O
program	O
,	O
led	B-UNK
to	O
identification	B-UNK
of	O
5	O
variants	B-UNK
of	O
the	O
II	B-UNK
class	O
(	O
Shekii	O
,	O
Bideiz	O
,	O
Shirin	O
-	O
Bulakh	O
,	O
Okhut	O
I	O
and	O
Zakataly	O
)	O
and	O
2	O
variants	B-UNK
of	O
the	O
III	B-UNK
class	O
(	O
Okhut	O
II	B-UNK
and	O
Martinique	O
-	O
like	O
)	O
.	O

Resemblance	O
of	O
the	O
majority	O
of	O
variants	B-UNK
in	O
electrophoretic	B-UNK
mobility	O
and	O
the	O
level	B-UNK
of	O
erythrocyte	B-UNK
enzyme	B-UNK
activity	I-UNK
permit	O
to	O
suggest	B-UNK
the	O
existence	O
of	O
a	O
common	B-UNK
parental	O
mutant	B-UNK
G6PD	B-UNK
allele	B-UNK
distributed	O
in	O
this	O
area	B-UNK
.	O

Craniofrontonasal	B-DISEASE
dysplasia	I-DISEASE
.	O

We	O
report	B-UNK
on	O
nine	O
patients	B-UNK
with	O
craniofrontonasal	B-DISEASE
dysplasia	I-DISEASE
(	O
CFND	O
)	O
.	O

Seven	O
classical	O
cases	B-UNK
had	O
facial	B-UNK
features	B-UNK
suggestive	O
of	O
frontonasal	B-DISEASE
dysplasia	I-DISEASE
and	O
coronal	O
craniosynostosis	O
.	O

Extracranial	O
abnormalities	B-UNK
such	O
as	O
brittle	O
nails	O
with	O
prominent	O
longitudinal	O
grooves	O
or	O
syndactyly	B-DISEASE
of	O
fingers	O
and	O
toes	O
were	O
observed	B-UNK
in	O
individual	O
patients	B-UNK
.	O

In	O
two	O
families	B-UNK
the	O
father	O
of	O
classical	O
cases	B-UNK
showed	O
a	O
milder	B-UNK
pattern	B-UNK
of	O
abnormalities	B-UNK
,	O
consistent	B-UNK
with	O
the	O
diagnosis	B-UNK
.	O

We	O
present	B-UNK
a	O
2-to	O
13-year	O
follow	O
-	O
up	O
on	O
our	O
patients	B-UNK
.	O

Hypotonia	B-DISEASE
and	O
laxity	O
of	O
joints	O
are	O
common	B-UNK
and	O
may	O
necessitate	O
supportive	O
measures	O
.	O

Mild	O
developmental	O
delay	O
was	O
noted	O
in	O
three	O
out	O
of	O
six	O
classical	O
cases	B-UNK
studied	O
in	O
detail	O
.	O

Unlike	O
almost	O
all	O
other	O
X	O
-	O
linked	B-UNK
disorders	B-UNK
,	O
clinical	B-UNK
expression	B-UNK
in	O
CFND	O
is	O
generally	O
much	O
more	O
severe	B-UNK
in	O
females	O
than	O
in	O
males	B-UNK
.	O

In	O
contrast	B-UNK
to	O
previous	B-UNK
reports	O
of	O
this	O
condition	B-UNK
,	O
one	O
of	O
our	O
severely	O
affected	B-UNK
cases	B-UNK
is	O
a	O
male	B-UNK
..	O

The	O
intron	B-UNK
7	O
donor	B-UNK
splice	I-UNK
site	I-UNK
transition	B-UNK
:	O
a	O
second	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
mutation	B-UNK
in	O
French	B-UNK
Canada	O
.	O

Mutations	B-UNK
at	O
the	O
hexosaminidase	O
A	O
(	O
HEXA	B-UNK
)	O
gene	B-UNK
which	O
cause	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
have	O
elevated	B-UNK
frequency	B-UNK
in	O
the	O
Ashkenazi	B-UNK
Jewish	I-UNK
and	O
French	B-UNK
-	O
Canadian	B-UNK
populations	O
.	O

We	O
report	B-UNK
a	O
novel	O
TSD	B-UNK
allele	B-UNK
in	O
the	O
French	B-UNK
-	O
Canadian	B-UNK
population	B-UNK
associated	O
with	O
the	O
infantile	B-UNK
form	B-UNK
of	O
the	O
disease	B-UNK
.	O

The	O
mutation	B-UNK
,	O
a	O
G--	O
>	O
A	O
transition	B-UNK
at	O
the	O
+	O
1	O
position	B-UNK
of	O
intron	B-UNK
7	O
,	O
abolishes	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
.	O

Cultured	O
human	B-UNK
fibroblasts	B-UNK
from	O
a	O
compound	B-UNK
heterozygote	B-UNK
for	O
this	O
transition	B-UNK
(	O
and	O
for	O
a	O
deletion	B-UNK
mutation	B-UNK
)	O
produce	B-UNK
no	O
detectable	O
HEXA	B-UNK
mRNA	O
.	O

The	O
intron	B-UNK
7	O
+	O
1	O
mutation	B-UNK
occurs	O
in	O
the	O
base	B-UNK
adjacent	O
to	O
the	O
site	B-UNK
of	O
the	O
adult	B-UNK
-	O
onset	B-UNK
TSD	B-UNK
mutation	B-UNK
(	O
G805A	O
)	O
.	O

In	O
both	O
mutations	B-UNK
a	O
restriction	B-UNK
site	B-UNK
for	O
the	O
endonuclease	O
EcoRII	O
is	O
abolished	O
.	O

Unambiguous	O
diagnosis	B-UNK
,	O
therefore	O
,	O
requires	O
allele	B-UNK
-	O
specific	B-UNK
oligonucleotide	O
hybridization	B-UNK
to	O
distinguish	O
between	O
these	O
two	O
mutant	B-UNK
alleles	I-UNK
.	O

The	O
intron	B-UNK
7	O
+	O
1	O
mutation	B-UNK
has	O
been	O
detected	B-UNK
in	O
three	O
unrelated	B-UNK
families	I-UNK
.	O

Obligate	B-UNK
heterozygotes	B-UNK
for	O
the	O
intron	B-UNK
7	O
+	O
1	O
mutation	B-UNK
were	O
born	O
in	O
the	O
Saguenay	O
-	O
Lac	O
-	O
St	O
-	O
Jean	O
region	B-UNK
of	O
Quebec	O
.	O

The	O
most	O
recent	O
ancestors	O
common	B-UNK
to	O
obligate	B-UNK
carriers	B-UNK
of	O
this	O
mutation	B-UNK
were	O
from	O
the	O
Charlevoix	O
region	B-UNK
of	O
the	O
province	O
of	O
Quebec	O
.	O

This	O
mutation	B-UNK
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	B-UNK
than	O
the	O
exon	B-UNK
1	O
deletion	B-UNK
TSD	B-UNK
mutation	B-UNK
in	O
French	B-UNK
Canadians	O
.	O

Neither	O
mutation	B-UNK
has	O
been	O
detected	B-UNK
in	O
France	O
,	O
the	O
ancestral	O
homeland	O
of	O
French	B-UNK
Canada	O
..	O

Assignment	B-UNK
of	O
the	O
aspartylglucosaminidase	O
gene	B-UNK
(	O
AGA	B-UNK
)	O
to	O
4q33	O
-	O
---q35	O
based	B-UNK
on	O
decreased	B-UNK
activity	B-UNK
in	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

Aspartylglucosaminuria	B-DISEASE
(	O
AGU	B-UNK
)	O
is	O
a	O
recessive	B-UNK
autosomally	O
inherited	B-UNK
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
due	O
to	O
deficiency	B-UNK
of	O
the	O
enzyme	B-UNK
aspartylglucosaminidase	O
(	O
AGA	B-UNK
)	O
.	O

The	O
structural	B-UNK
gene	B-UNK
for	O
this	O
human	B-UNK
enzyme	B-UNK
(	O
AGA	B-UNK
)	O
has	O
been	O
assigned	O
to	O
the	O
region	B-UNK
4q21	O
-	O
---qter	O
.	O

We	O
determined	B-UNK
the	O
AGA	B-UNK
activity	B-UNK
in	O
cultured	O
fibroblasts	B-UNK
of	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

The	O
results	B-UNK
indicate	O
that	O
the	O
girl	O
is	O
a	O
hemizygote	O
for	O
AGA	B-UNK
,	O
permitting	O
the	O
assignment	B-UNK
of	O
human	B-UNK
AGA	B-UNK
to	O
the	O
region	B-UNK
4q33	O
-	O
---qter	O
..	O

Resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
,	O
AN1	O
and	O
AN2	B-UNK
,	O
to	O
a	O
single	B-UNK
locus	B-UNK
on	O
chromosome	B-UNK
11p13	O
.	O

Two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	B-DISEASE
;	O
AN1	O
for	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
on	O
chromosome	B-UNK
2p	O
and	O
AN2	B-UNK
for	O
the	O
aniridia	B-DISEASE
in	O
the	O
WAGR	O
contiguous	O
gene	B-UNK
syndrome	B-UNK
on	O
chromosome	B-UNK
11p13	O
.	O

In	O
this	O
report	B-UNK
,	O
the	O
kindred	O
segregating	O
for	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
,	O
which	O
suggested	O
linkage	B-UNK
to	O
acid	B-UNK
phosphatase-1	O
(	O
ACP1	O
)	O
and	O
led	B-UNK
to	O
the	O
assignment	B-UNK
of	O
the	O
AN1	O
locus	B-UNK
on	O
chromosome	B-UNK
2p	O
,	O
has	O
been	O
updated	O
and	O
expanded	B-UNK
.	O

Linkage	B-UNK
analysis	I-UNK
between	O
the	O
aniridia	B-DISEASE
phenotype	B-UNK
and	O
ACP1	O
does	O
not	O
support	O
the	O
original	O
linkage	B-UNK
results	B-UNK
,	O
excluding	O
linkage	B-UNK
up	O
to	O
theta	B-UNK
=	O
0	O
.	O

17	O
with	O
Z	O
=	O
-2	O
.	O

Tests	O
for	O
linkage	B-UNK
to	O
other	O
chromosome	B-UNK
2p	O
markers	B-UNK
.	O

APOB	O
,	O
D2S71	O
,	O
D2S5	O
,	O
and	O
D2S1	O
,	O
also	O
excluded	O
linkage	B-UNK
to	O
aniridia	B-DISEASE
.	O

Markers	B-UNK
that	O
have	O
been	O
isolated	B-UNK
from	O
the	O
chromosome	B-UNK
11p13	O
region	B-UNK
were	O
then	O
analyzed	B-UNK
in	O
this	O
aniridia	B-DISEASE
family	B-UNK
.	O

Two	O
RFLPs	B-UNK
at	O
the	O
D11S323	O
locus	B-UNK
give	O
significant	B-UNK
evidence	B-UNK
for	O
linkage	B-UNK
.	O

The	O
PvuII	O
polymorphism	B-UNK
detected	B-UNK
by	O
probe	O
p5S1	O
.	O

6	O
detects	O
no	O
recombinants	O
,	O
with	O
a	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
of	O
Z	O
=	O
6	O
.	O

97	O
at	O
theta	B-UNK
=	O
0	O
.	O

00	O
00	O
.	O

The	O
HaeIII	O
polymorphism	B-UNK
detected	B-UNK
by	O
the	O
probe	O
p5BE1	O
.	O

2	O
gives	O
a	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
of	O
Z	O
=	O
2	O
.	O

57	O
at	O
theta	B-UNK
=	O
0	O
.	O

00	O
00	O
.	O

Locus	B-UNK
D11S325	O
gives	O
a	O
lod	B-UNK
score	I-UNK
of	O
Z	O
=	O
1	O
.	O

53	O
at	O
theta	B-UNK
=	O
0	O
.	O

00	O
00	O
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
a	O
locus	B-UNK
for	O
aniridia	B-DISEASE
(	O
AN1	O
)	O
on	O
chromosome	B-UNK
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
family	B-UNK
is	O
segregating	O
for	O
an	O
aniridia	B-DISEASE
mutation	B-UNK
linked	B-UNK
to	O
markers	B-UNK
in	O
the	O
11p13	O
region	B-UNK
.	O

Fatal	B-UNK
pyoderma	B-DISEASE
gangrenosum	I-DISEASE
in	O
association	B-UNK
with	O
C7	B-UNK
deficiency	I-UNK
.	O

Although	O
pyoderma	B-DISEASE
gangrenosum	I-DISEASE
(	O
PG	O
)	O
is	O
often	O
associated	O
with	O
systemic	O
diseases	B-DISEASE
,	O
it	O
has	O
not	O
been	O
reported	B-UNK
in	O
association	B-UNK
with	O
congenital	B-UNK
complement	B-UNK
deficiencies	B-UNK
.	O

We	O
describe	O
an	O
aggressive	O
and	O
ultimately	O
fatal	B-UNK
case	B-UNK
of	O
PG	O
in	O
a	O
patient	B-UNK
with	O
a	O
congenital	B-UNK
C7	B-UNK
deficiency	I-UNK
.	O

Deficiencies	B-UNK
of	O
C7	B-UNK
can	O
be	O
associated	O
with	O
decreased	B-UNK
neutrophil	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
opsonization	O
,	O
similar	B-UNK
to	O
the	O
immunologic	O
abnormalities	B-UNK
described	O
in	O
patients	B-UNK
with	O
PG	O
.	O

Our	O
patients	B-UNK
decreased	B-UNK
complement	B-UNK
level	B-UNK
,	O
if	O
not	O
directly	O
related	B-UNK
to	O
the	O
development	B-UNK
of	O
PG	O
,	O
may	O
have	O
contributed	O
to	O
the	O
aggressive	O
nature	B-UNK
of	O
her	O
disease	B-DISEASE
..	O

Diverse	B-UNK
point	B-UNK
mutations	I-UNK
result	B-UNK
in	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
polymorphism	B-UNK
in	O
Taiwan	O
.	O

Glucose-6-PHOSPHATE	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
;	O
EC	B-UNK
1	O
.	O
1	O
.	O
1	O
.	O
49	O
)	O
deficiency	B-UNK
is	O
the	O
most	O
common	B-UNK
human	B-UNK
enzymopathy	O
,	O
affecting	O
more	O
than	O
200	O
million	O
people	O
worldwide	O
.	O

Although	O
greater	B-UNK
than	O
400	O
variants	B-UNK
have	O
been	O
described	O
based	B-UNK
on	O
clinical	B-UNK
and	O
biochemical	O
criteria	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
these	O
G6PD	B-UNK
deficiencies	B-UNK
.	O

Recently	O
,	O
the	O
gene	B-UNK
that	O
encodes	B-UNK
human	B-UNK
G6PD	B-UNK
has	O
been	O
cloned	O
and	O
sequenced	O
,	O
which	O
enables	O
us	O
to	O
examine	O
directly	O
the	O
heterogeneity	B-UNK
of	O
G6PD	B-UNK
at	O
the	O
DNA	B-UNK
level	B-UNK
.	O

During	O
the	O
past	O
10	O
years	O
,	O
we	O
examined	O
the	O
G6PD	B-UNK
activity	B-UNK
in	O
21	O
,	O
271	O
newborn	O
Chinese	B-UNK
infants	O
(	O
11	O
,	O
400	O
males	B-UNK
and	O
9	O
,	O
871	O
females	O
)	O
and	O
identified	B-UNK
314	O
(	O
2	O
.	O
8	O
%	O
)	O
males	B-UNK
and	O
246	O
(	O
2	O
.	O
5	O
%	O
)	O
females	O
having	O
low	B-UNK
G6PD	B-UNK
activity	B-UNK
.	O

The	O
G6PD	B-UNK
gene	B-UNK
from	O
10	O
randomly	O
selected	O
affected	B-UNK
individuals	I-UNK
and	O
their	O
relatives	B-UNK
was	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
amplified	O
,	O
subcloned	O
,	O
and	O
sequenced	O
.	O

Our	O
results	B-UNK
indicate	O
that	O
at	O
least	O
four	O
types	B-UNK
of	O
mutation	B-UNK
are	O
responsible	B-UNK
for	O
the	O
G6PD	B-UNK
polymorphism	B-UNK
in	O
Taiwan	O
.	O

The	O
first	O
type	B-UNK
of	O
mutation	B-UNK
(	O
487	O
G----A	O
)	O
was	O
found	O
in	O
an	O
affected	B-UNK
Chinese	B-UNK
with	O
a	O
G	O
to	O
A	O
change	B-UNK
at	O
nucleotide	B-UNK
487	O
,	O
which	O
results	B-UNK
in	O
a	O
(	O
163	O
)	O
Gly	B-UNK
to	O
Ser	O
substitution	B-UNK
.	O

The	O
second	O
type	B-UNK
of	O
mutation	B-UNK
(	O
493	O
A----G	O
)	O
is	O
a	O
novel	O
mutation	B-UNK
that	O
has	O
not	O
been	O
reported	B-UNK
in	O
any	O
other	O
ethnic	B-UNK
group	B-UNK
and	O
was	O
identified	B-UNK
in	O
two	O
affected	B-UNK
Chinese	B-UNK
.	O

This	O
mutation	B-UNK
causes	O
an	O
A	O
to	O
G	O
change	B-UNK
at	O
nucleotide	B-UNK
position	I-UNK
493	O
,	O
producing	O
an	O
(	O
165	O
)	O
Asn	O
to	O
Asp	O
substitution	B-UNK
.	O

Interestingly	B-UNK
,	O
the	O
487	O
G----A	O
and	O
493	O
A----G	O
mutations	B-UNK
create	O
Alu	B-UNK
I	O
and	O
Ava	O
II	B-UNK
recognition	O
sites	O
,	O
respectively	O
,	O
which	O
enabled	O
us	O
to	O
rapidly	O
detect	B-UNK
these	O
two	O
mutations	B-UNK
by	O
PCR	B-UNK
/	O
restriction	B-UNK
enzyme	B-UNK
(	O
RE	O
)	O
digestion	O
method	O
.	O

The	O
third	O
mutation	B-UNK
(	O
1376	O
G----T	O
)	O
was	O
found	O
in	O
four	O
affected	B-UNK
Chinese	B-UNK
.	O

This	O
mutation	B-UNK
causes	O
a	O
G	O
to	O
T	O
change	B-UNK
at	O
nucleotide	B-UNK
position	I-UNK
1376	O
that	O
results	B-UNK
in	O
an	O
(	O
459	O
)	O
Arg	B-UNK
to	O
Leu	B-UNK
substitution	B-UNK
.	O

The	O
1376	O
G----T	O
mutation	B-UNK
seems	O
to	O
be	O
the	O
dominant	B-UNK
allele	B-UNK
that	O
causes	O
G6PD	B-UNK
deficiency	I-UNK
in	O
Taiwan	O
.	O

Finally	B-UNK
,	O
two	O
affected	B-UNK
Chinese	B-UNK
were	O
identified	B-UNK
as	O
having	O
the	O
fourth	B-UNK
mutation	B-UNK
(	O
1388	O
G----A	O
)	O
.	O

This	O
mutation	B-UNK
causes	O
a	O
G	O
to	O
A	O
change	B-UNK
at	O
nucleotide	B-UNK
1388	O
that	O
produces	O
an	O
(	O
463	O
)	O
Arg	B-UNK
to	O
His	O
substitution	B-UNK
.	O

Our	O
studies	B-UNK
provide	B-UNK
the	O
direct	B-UNK
proof	O
of	O
the	O
genetic	B-UNK
heterogeneity	I-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
in	O
the	O
Chinese	B-UNK
populations	O
of	O
Taiwan	O
and	O
the	O
PCR	B-UNK
/	O
RE	O
digestion	O
method	O
is	O
suitable	O
for	O
simultaneous	O
detection	B-UNK
of	O
the	O
487	O
G----A	O
and	O
493	O
A----G	O
mutations	B-UNK
.	O

An	O
error	O
in	O
dystrophin	B-UNK
mRNA	O
processing	O
in	O
golden	O
retriever	O
muscular	B-UNK
dystrophy	I-UNK
,	O
an	O
animal	B-UNK
homologue	B-UNK
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

Golden	O
retriever	O
muscular	B-UNK
dystrophy	I-UNK
(	O
GRMD	O
)	O
is	O
a	O
spontaneous	O
,	O
X	O
-	O
linked	B-UNK
,	O
progressively	O
fatal	B-UNK
disease	B-UNK
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	B-UNK
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

Two	O
-	O
thirds	O
of	O
DMD	B-UNK
patients	B-UNK
carry	B-UNK
detectable	O
deletions	O
in	O
their	O
dystrophin	B-UNK
gene	I-UNK
.	O

The	O
defect	B-UNK
underlying	O
the	O
remaining	O
one	O
-	O
third	O
of	O
DMD	B-UNK
patients	B-UNK
is	O
undetermined	O
.	O

Analysis	B-UNK
of	O
the	O
canine	O
dystrophin	B-UNK
gene	I-UNK
in	O
normal	B-UNK
and	O
GRMD	O
dogs	O
has	O
failed	O
to	O
demonstrate	B-UNK
any	O
detectable	O
loss	B-UNK
of	O
exons	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
a	O
RNA	B-UNK
processing	O
error	O
in	O
GRMD	O
that	O
results	B-UNK
from	O
a	O
single	B-UNK
base	I-UNK
change	B-UNK
in	O
the	O
3	O
consensus	B-UNK
splice	B-UNK
site	I-UNK
of	O
intron	B-UNK
6	O
.	O

The	O
seventh	O
exon	B-UNK
is	O
then	O
skipped	O
,	O
which	O
predicts	O
a	O
termination	B-UNK
of	O
the	O
dystrophin	B-UNK
reading	B-UNK
frame	I-UNK
within	O
its	O
N	O
-	O
terminal	B-UNK
domain	B-UNK
in	O
exon	B-UNK
8	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
dystrophin	B-UNK
deficiency	B-UNK
caused	B-UNK
by	O
a	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
..	O

Type	B-UNK
I	O
human	B-UNK
complement	I-UNK
C2	B-UNK
deficiency	I-UNK
.	O

A	O
28-base	O
pair	B-UNK
gene	B-UNK
deletion	B-UNK
causes	O
skipping	O
of	O
exon	B-UNK
6	O
during	O
RNA	B-UNK
splicing	B-UNK
.	O

Two	O
variants	B-UNK
of	O
a	O
genetic	B-UNK
deficiency	B-UNK
of	O
complement	B-UNK
protein	B-UNK
C2	B-UNK
(	O
C2D	O
)	O
have	O
been	O
previously	B-UNK
identified	I-UNK
.	O

No	O
C2	B-UNK
protein	B-UNK
translation	O
is	O
detected	B-UNK
in	O
type	B-UNK
I	O
deficiency	B-UNK
,	O
while	O
type	B-UNK
II	I-UNK
deficiency	B-UNK
is	O
characterized	B-UNK
by	O
a	O
selective	O
block	O
in	O
C2	B-UNK
secretion	O
.	O

Type	B-UNK
I	O
C2	B-UNK
deficiency	I-UNK
was	O
described	O
in	O
a	O
family	B-UNK
in	O
which	O
the	O
C2	B-UNK
null	O
allele	B-UNK
(	O
C2Q0	B-UNK
)	O
is	O
associated	O
with	O
the	O
major	B-UNK
histocompatibility	B-UNK
haplotype	B-UNK
/	O
complotype	O
HLA	B-UNK
-	O
A25	O
,	O
B18	O
,	O
C2Q0	B-UNK
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
;	O
this	O
extended	O
haplotype	B-UNK
occurs	O
in	O
over	O
90	O
%	O
of	O
C2-deficient	O
individuals	B-UNK
(	O
common	B-UNK
complotype	O
/	O
haplotype	B-UNK
)	O
.	O

To	O
determine	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
of	O
type	B-UNK
I	O
C2	B-UNK
deficiency	I-UNK
,	O
the	O
C2	B-UNK
gene	B-UNK
and	O
cDNA	O
were	O
characterized	B-UNK
from	O
a	O
homozygous	B-UNK
type	B-UNK
I	O
C2-deficient	O
individual	O
with	O
the	O
common	B-UNK
associated	O
haplotype	B-UNK
/	O
complotype	O
.	O

We	O
found	O
a	O
28-base	O
pair	B-UNK
deletion	B-UNK
in	O
the	O
type	B-UNK
I	O
C2Q0	B-UNK
gene	B-UNK
,	O
beginning	O
9	O
base	B-UNK
pairs	B-UNK
upstream	O
of	O
the	O
3-end	O
of	O
exon	B-UNK
6	O
,	O
that	O
generates	O
a	O
C2	B-UNK
transcript	B-UNK
with	O
a	O
complete	O
deletion	B-UNK
of	O
exon	B-UNK
6	O
(	O
134	O
base	B-UNK
pair	I-UNK
)	O
and	O
a	O
premature	B-UNK
termination	I-UNK
codon	B-UNK
.	O

In	O
studies	B-UNK
of	O
eight	O
kindred	O
,	O
the	O
28-base	O
pair	B-UNK
deletion	B-UNK
was	O
observed	B-UNK
in	O
all	O
C2Q0	B-UNK
alleles	B-UNK
associated	O
with	O
the	O
common	B-UNK
type	B-UNK
I	O
deficient	B-UNK
complotype	O
/	O
haplotype	B-UNK
;	O
this	O
deletion	B-UNK
was	O
not	O
present	B-UNK
in	O
normal	B-UNK
C2	B-UNK
nor	O
in	O
type	B-UNK
II	I-UNK
C2-deficient	O
genes	B-UNK
.	O

These	O
data	B-UNK
demonstrate	B-UNK
that	O
1	O
)	O
type	B-UNK
I	O
human	B-UNK
complement	I-UNK
C2	B-UNK
deficiency	I-UNK
is	O
caused	B-UNK
by	O
a	O
28-base	O
pair	B-UNK
genomic	B-UNK
deletion	B-UNK
that	O
causes	O
skipping	O
of	O
exon	B-UNK
6	O
during	O
RNA	B-UNK
splicing	B-UNK
,	O
resulting	B-UNK
in	O
generation	O
of	O
a	O
premature	B-UNK
termination	I-UNK
codon	B-UNK
,	O
2	O
)	O
the	O
28-base	O
pair	B-UNK
deletion	B-UNK
in	O
the	O
type	B-UNK
I	O
C2Q0	B-UNK
gene	B-UNK
is	O
strongly	O
associated	O
with	O
the	O
HLA	B-UNK
haplotype	B-UNK
/	O
complotype	O
A25	O
,	O
B18	O
,	O
C2Q0	B-UNK
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
,	O
suggesting	O
that	O
all	O
C2-deficient	O
individuals	B-UNK
with	O
this	O
haplotype	B-UNK
/	O
complotype	O
will	O
harbor	O
the	O
28-base	O
pair	B-UNK
C2	B-UNK
gene	B-UNK
deletion	B-UNK
,	O
and	O
3	O
)	O
type	B-UNK
II	I-UNK
C2	B-UNK
deficiency	I-UNK
is	O
caused	B-UNK
by	O
a	O
different	O
,	O
as	O
yet	O
uncharacterized	O
,	O
molecular	B-UNK
genetic	I-UNK
defect	B-UNK
..	O

Molecular	B-UNK
characterization	B-UNK
of	O
two	O
galactosemia	O
mutations	B-UNK
and	O
one	O
polymorphism	B-UNK
:	O
implications	B-UNK
for	O
structure	B-UNK
-	O
function	B-UNK
analysis	B-UNK
of	O
human	B-UNK
galactose-1-phosphate	O
uridyltransferase	O
.	O

We	O
report	B-UNK
here	O
the	O
molecular	B-UNK
characterization	B-UNK
of	O
two	O
galactosemia	O
mutations	B-UNK
,	O
L74P	O
and	O
F171S	O
,	O
and	O
one	O
polymorphism	B-UNK
,	O
S135L	B-UNK
,	O
in	O
human	B-UNK
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	B-UNK
)	O
.	O

Both	O
galactosemia	O
mutations	B-UNK
result	B-UNK
in	O
reduced	O
enzymatic	B-UNK
activity	I-UNK
when	O
reconstructed	O
in	O
the	O
cDNA	O
and	O
overexpressed	O
.	O

The	O
polymorphism	B-UNK
,	O
in	O
contrast	B-UNK
,	O
has	O
near	O
normal	B-UNK
activity	B-UNK
.	O

Both	O
mutations	B-UNK
affect	O
evolutionarily	O
conserved	B-UNK
residues	O
,	O
suggesting	O
that	O
they	O
are	O
functionally	O
important	O
,	O
while	O
the	O
polymorphism	B-UNK
occurs	O
in	O
a	O
nonconserved	O
domain	B-UNK
which	O
is	O
presumably	O
not	O
critical	B-UNK
for	O
enzymatic	B-UNK
function	B-UNK
.	O

The	O
F171S	O
mutation	B-UNK
is	O
close	B-UNK
to	O
the	O
putative	O
active	B-UNK
-	O
site	B-UNK
nucleophile	O
.	O

Our	O
data	B-UNK
further	O
support	O
the	O
notion	O
of	O
molecular	B-UNK
heterogeneity	B-UNK
of	O
galactosemia	O
and	O
suggest	B-UNK
that	O
galactosemia	O
mutations	B-UNK
and	O
GALT	B-UNK
polymorphisms	B-UNK
may	O
be	O
useful	O
tools	O
in	O
highlighting	O
different	O
functional	O
domains	B-UNK
in	O
human	B-UNK
GALT	B-UNK
..	O

Linkage	B-UNK
relationship	B-UNK
of	O
C2	B-UNK
deficiency	I-UNK
,	O
HLA	B-UNK
and	O
glyoxalase	O
I	O
loci	O
.	O

Immunogenetic	O
analysis	B-UNK
of	O
a	O
homozygous	B-UNK
C2-deficient	O
individual	O
and	O
family	B-UNK
members	I-UNK
demonstrated	O
linkage	B-UNK
of	O
HLA	B-UNK
-	O
A25	O
,	O
B18	O
and	O
C2o	O
.	O

HLA	B-UNK
-	O
D	O
typing	O
showed	O
that	O
5	O
members	B-UNK
typed	O
with	O
homozygous	B-UNK
Dw2	O
typing	O
cells	B-UNK
from	O
an	O
individual	O
with	O
C2	B-UNK
deficiency	I-UNK
but	O
not	O
with	O
Dw2	O
typing	O
cells	B-UNK
from	O
2	O
individuals	B-UNK
with	O
normal	B-UNK
C2	B-UNK
.	O

The	O
homozygous	B-UNK
C2-deficient	O
propositus	O
and	O
brother	B-UNK
were	O
HLA	B-UNK
-	O
A	O
and	O
B	O
homozygous	B-UNK
but	O
heterozygous	B-UNK
at	O
the	O
HLA	B-UNK
-	O
D	O
and	O
glyoxalase	O
I	O
loci	O
.	O

Therefore	O
,	O
in	O
this	O
family	B-UNK
,	O
the	O
C2o	O
gene	B-UNK
is	O
linked	B-UNK
with	O
two	O
distinct	O
haplotypes	O
HLA	B-UNK
-	O
A25	O
,	O
B18	O
,	O
Dw2	O
,	O
GLO1	O
and	O
HLA	B-UNK
-	O
A25	O
,	O
B18	O
,	O
D	O
unknown	O
,	O
GL02	O
.	O

These	O
results	B-UNK
could	O
be	O
explained	O
by	O
an	O
ancestral	O
recombinant	B-UNK
event	O
,	O
which	O
occurred	B-UNK
between	O
the	O
C2o	O
locus	B-UNK
and	O
HLA	B-UNK
-	O
D	O
locus	B-UNK
in	O
which	O
C2o	O
segregated	O
with	O
HLA	B-UNK
-	O
B.	O

This	O
would	O
suggest	B-UNK
that	O
the	O
locus	B-UNK
for	O
the	O
C2o	O
gene	B-UNK
maps	B-UNK
between	O
HLA	B-UNK
-	O
B	O
and	O
HLA	B-UNK
-	O
D	O
on	O
the	O
sixth	O
chromosome	B-UNK
..	O

Germline	B-UNK
mutations	I-UNK
in	O
the	O
Wilms	B-UNK
'	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
are	O
associated	O
with	O
abnormal	O
urogenital	O
development	B-UNK
in	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
.	O

Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	B-UNK
human	B-UNK
condition	B-UNK
in	O
which	O
severe	B-UNK
urogenital	O
aberrations	O
result	B-UNK
in	O
renal	B-DISEASE
failure	I-DISEASE
,	O
pseudohermaphroditism	O
,	O
and	O
Wilms	B-UNK
tumor	I-UNK
(	O
nephroblastoma	O
)	O
.	O

To	O
investigate	B-UNK
its	O
possible	O
role	B-UNK
,	O
we	O
have	O
analyzed	B-UNK
the	O
coding	B-UNK
exons	O
of	O
the	O
Wilms	B-UNK
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
(	O
WT1	B-UNK
)	O
for	O
germline	B-UNK
mutations	I-UNK
.	O

In	O
ten	O
independent	O
cases	B-UNK
of	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
,	O
point	B-UNK
mutations	I-UNK
in	O
the	O
zinc	B-UNK
finger	I-UNK
domains	B-UNK
of	O
one	O
WT1	B-UNK
gene	B-UNK
copy	B-UNK
were	O
found	O
.	O

Nine	O
of	O
these	O
mutations	B-UNK
are	O
found	O
within	O
exon	B-UNK
9	O
(	O
zinc	B-UNK
finger	I-UNK
III	B-UNK
)	O
;	O
the	O
remaining	O
mutation	B-UNK
is	O
in	O
exon	B-UNK
8	O
(	O
zinc	B-UNK
finger	I-UNK
II	B-UNK
)	O
.	O

These	O
mutations	B-UNK
directly	O
affect	O
DNA	B-UNK
sequence	I-UNK
recognition	O
.	O

In	O
two	O
families	B-UNK
analyzed	B-UNK
,	O
the	O
mutations	B-UNK
were	O
shown	B-UNK
to	O
arise	O
de	O
novo	O
.	O

Wilms	B-UNK
tumors	B-DISEASE
from	O
three	O
individuals	B-UNK
and	O
one	O
juvenile	O
granulosa	B-DISEASE
cell	I-DISEASE
tumor	I-DISEASE
demonstrate	B-UNK
reduction	B-UNK
to	O
homozygosity	B-UNK
for	O
the	O
mutated	B-UNK
WT1	B-UNK
allele	B-UNK
.	O

Our	O
results	B-UNK
provide	I-UNK
evidence	B-UNK
of	O
a	O
direct	B-UNK
role	B-UNK
for	O
WT1	B-UNK
in	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
and	O
thus	O
urogenital	O
system	O
development	B-UNK
..	O

Linkage	B-UNK
analysis	I-UNK
in	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
and	O
application	O
in	O
post-and	O
prenatal	B-UNK
diagnosis	I-UNK
.	O

We	O
have	O
performed	O
linkage	B-UNK
analysis	I-UNK
with	O
the	O
DNA	B-UNK
markers	I-UNK
DXS52	O
and	O
the	O
clotting	O
factor	B-UNK
VIII	O
gene	B-UNK
(	O
F8C	O
)	O
,	O
in	O
several	O
large	B-UNK
families	B-UNK
with	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
.	O

The	O
tight	O
linkage	B-UNK
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	B-UNK
score	I-UNK
of	O
22	O
.	O

5	O
at	O
1	O
cM.	O

F8C	O
was	O
also	O
tightly	B-UNK
linked	I-UNK
to	O
ALD	B-UNK
with	O
a	O
maximal	O
LOD	B-UNK
score	I-UNK
of	O
7	O
.	O

8	O
without	O
recombination	B-UNK
.	O

Multipoint	B-UNK
linkage	B-UNK
analysis	I-UNK
with	O
the	O
markers	B-UNK
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	B-UNK
for	O
ALD	B-UNK
and	O
for	O
F8C	O
are	O
distal	B-UNK
to	O
DXS52	O
.	O

In	O
four	O
patients	B-UNK
with	O
ALD	B-UNK
,	O
no	O
major	B-UNK
structural	B-UNK
rearrangement	B-UNK
in	O
the	O
Xqter	O
region	B-UNK
was	O
observed	B-UNK
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B-UNK
in	O
the	O
vision	B-UNK
blindness	B-DISEASE
genes	B-UNK
.	O

DNA	B-UNK
analysis	I-UNK
appeared	B-UNK
to	O
be	O
of	O
use	O
in	O
determination	B-UNK
of	O
the	O
carrier	B-UNK
status	I-UNK
of	O
females	O
at	O
risk	B-UNK
,	O
for	O
the	O
determination	B-UNK
of	O
the	O
origin	O
of	O
the	O
mutation	B-UNK
in	O
a	O
particular	O
family	B-UNK
,	O
and	O
for	O
prenatal	B-UNK
diagnosis	I-UNK
.	O

Two	O
distinct	O
mutations	B-UNK
at	O
a	O
single	B-UNK
BamHI	O
site	B-UNK
in	O
phenylketonuria	O
.	O

Classical	O
phenylketonuria	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disease	B-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
hepatic	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	B-UNK
located	B-UNK
in	O
the	O
coding	B-UNK
sequence	I-UNK
of	O
the	O
PAH	B-UNK
gene	B-UNK
(	O
exon	B-UNK
7	O
)	O
led	B-UNK
to	O
the	O
recognition	O
of	O
two	O
new	O
point	B-UNK
mutations	I-UNK
at	O
codon	B-UNK
272	O
and	O
273	O
(	O
272gly----stop	O
and	O
273ser----phe	O
,	O
respectively	O
)	O
.	O

Both	O
mutations	B-UNK
were	O
detected	B-UNK
in	O
north	B-UNK
eastern	B-UNK
France	O
or	O
Belgium	O
and	O
occurred	B-UNK
on	O
the	O
background	O
of	O
RFLP	B-UNK
haplotype	B-UNK
7	O
alleles	B-UNK
.	O

The	O
present	B-UNK
study	B-UNK
supports	O
the	O
view	O
that	O
the	O
clinical	B-UNK
heterogeneity	B-UNK
in	O
PKU	B-UNK
is	O
accounted	O
for	O
by	O
the	O
large	B-UNK
variety	O
of	O
mutant	B-UNK
genotypes	O
associated	O
with	O
PAH	B-UNK
deficiencies	B-UNK
..	O

A	O
detailed	B-UNK
multipoint	B-UNK
map	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
4	O
provides	O
evidence	B-UNK
for	O
linkage	B-UNK
heterogeneity	B-UNK
and	O
position	B-UNK
-	O
specific	B-UNK
recombination	B-UNK
rates	O
.	O

Utilizing	O
the	O
CEPH	O
reference	O
panel	B-UNK
and	O
genotypic	O
data	B-UNK
for	O
53	O
markers	B-UNK
,	O
we	O
have	O
constructed	O
a	O
20-locus	O
multipoint	B-UNK
genetic	B-UNK
map	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
4	O
.	O

New	O
RFLPs	B-UNK
are	O
reported	B-UNK
for	O
four	O
loci	O
.	O

The	O
map	B-UNK
integrates	O
a	O
high	B-UNK
-	O
resolution	O
genetic	B-UNK
map	B-UNK
of	O
4p16	O
into	O
a	O
continuous	O
map	B-UNK
extending	O
to	O
4q31	O
and	O
an	O
unlinked	O
cluster	B-UNK
of	O
three	O
loci	O
at	O
4q35	O
.	O

The	O
20	O
linked	B-UNK
markers	B-UNK
form	B-UNK
a	O
continuous	O
linkage	B-UNK
group	B-UNK
of	O
152	O
cM	B-DISEASE
in	O
males	B-UNK
and	O
202	O
cM	B-DISEASE
in	O
females	O
.	O

Likely	O
genetic	B-UNK
locations	O
are	O
provided	O
for	O
25	O
polymorphic	B-UNK
anonymous	O
sequences	O
and	O
28	O
gene	B-UNK
-	O
specific	B-UNK
RFLPs	B-UNK
.	O

The	O
map	B-UNK
was	O
constructed	O
employing	O
the	O
LINKAGE	B-UNK
and	O
CRIMAP	O
computational	O
methodologies	O
to	O
build	O
the	O
multipoint	B-UNK
map	B-UNK
via	O
a	O
stepwise	O
algorithm	O
.	O

A	O
detailed	B-UNK
10-point	O
map	B-UNK
of	O
the	O
4p16	O
region	B-UNK
constructed	O
from	O
the	O
CEPH	O
panel	B-UNK
provides	O
evidence	B-UNK
for	O
heterogeneity	B-UNK
in	O
the	O
linkage	B-UNK
maps	B-UNK
constructed	O
from	O
families	B-UNK
segregating	O
for	O
Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
.	O

It	O
additionally	O
provides	O
evidence	B-UNK
for	O
position	B-UNK
-	O
specific	B-UNK
recombination	B-UNK
frequencies	O
in	O
the	O
telomeric	O
region	B-UNK
of	O
4p	O
..	O

Carrier	B-UNK
detection	I-UNK
and	O
prenatal	B-UNK
diagnosis	I-UNK
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
using	O
a	O
combination	B-UNK
of	O
anonymous	O
DNA	B-UNK
polymorphisms	B-UNK
and	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
cDNA	O
.	O

We	O
report	B-UNK
carrier	B-UNK
identification	B-UNK
and	O
a	O
prenatal	B-UNK
diagnosis	I-UNK
using	O
DNA	B-UNK
polymorphisms	B-UNK
in	O
2	O
families	B-UNK
with	O
X	O
-	O
linked	B-UNK
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
(	O
PMD	B-UNK
)	O
.	O

In	O
both	O
families	B-UNK
,	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
in	O
the	O
single	B-UNK
affected	B-UNK
male	B-UNK
could	O
be	O
traced	O
back	O
to	O
his	O
unaffected	O
maternal	O
grandfather	O
.	O

Therefore	O
,	O
each	O
family	B-UNK
contains	O
a	O
new	O
mutation	B-UNK
.	O

In	O
the	O
case	B-UNK
of	O
the	O
prenatal	B-UNK
diagnosis	I-UNK
,	O
the	O
fetus	O
was	O
shown	B-UNK
by	O
cytogenetic	B-UNK
analysis	B-UNK
to	O
be	O
a	O
female	O
,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
PMD	B-UNK
based	B-UNK
on	O
her	O
genotype	B-UNK
with	O
the	O
PLP	B-UNK
intragenic	O
polymorphism	B-UNK
..	O

Identification	B-UNK
of	O
deletion	B-UNK
mutations	B-UNK
and	O
three	O
new	O
genes	B-UNK
at	O
the	O
familial	B-UNK
polyposis	B-UNK
locus	B-UNK
.	O

Small	O
(	O
100	O
-	O
260	O
kb	B-UNK
)	O
,	O
nested	O
deletions	O
were	O
characterized	B-UNK
in	O
DNA	B-UNK
from	O
two	O
unrelated	B-UNK
patients	B-UNK
with	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
coli	B-UNK
(	O
APC	B-UNK
)	O
.	O

Three	O
candidate	B-UNK
genes	B-UNK
located	B-UNK
within	O
the	O
deleted	B-UNK
region	B-UNK
were	O
ascertained	O
and	O
a	O
previous	B-UNK
candidate	B-UNK
gene	I-UNK
,	O
MCC	O
,	O
was	O
shown	B-UNK
to	O
be	O
located	B-UNK
outside	O
the	O
deleted	B-UNK
region	B-UNK
.	O

One	O
of	O
the	O
new	O
genes	B-UNK
contained	O
sequence	B-UNK
identical	B-UNK
to	O
SRP19	O
,	O
the	O
gene	B-UNK
coding	B-UNK
for	O
the	O
19	O
kd	O
component	B-UNK
of	O
the	O
ribosomal	O
signal	B-UNK
recognition	O
particle	O
.	O

The	O
second	O
,	O
provisionally	O
designated	O
DP1	O
(	O
deleted	B-UNK
in	O
polyposis	B-UNK
1	O
)	O
,	O
was	O
found	O
to	O
be	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
MCC	O
.	O

Two	O
other	O
cDNAs	O
,	O
DP2	O
and	O
DP3	O
,	O
were	O
found	O
to	O
overlap	O
,	O
forming	O
a	O
single	B-UNK
gene	B-UNK
,	O
DP2	O
.	O

5	O
,	O
that	O
is	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
SRP19	O
.	O

Exclusion	O
of	O
linkage	B-UNK
between	O
familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
and	O
the	O
human	B-UNK
serum	B-UNK
amyloid	O
A	O
(	O
SAA	O
)	O
gene	B-UNK
cluster	B-UNK
.	O

We	O
studied	O
the	O
relationship	B-UNK
between	O
the	O
autosomal	B-UNK
recessive	I-UNK
trait	O
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
(	O
FMF	B-UNK
)	O
and	O
the	O
serum	B-UNK
amyloid	O
A	O
(	O
SAA	O
)	O
genes	B-UNK
by	O
comparing	O
alleles	B-UNK
of	O
a	O
highly	B-UNK
polymorphic	B-UNK
dinucleotide	B-UNK
repeat	B-UNK
and	O
a	O
conventional	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
(	O
RFLP	B-UNK
)	O
in	O
the	O
SAA	O
gene	B-UNK
cluster	B-UNK
in	O
Israeli	O
FMF	B-UNK
kindreds	O
.	O

By	O
haplotype	B-UNK
analysis	I-UNK
,	O
our	O
data	B-UNK
indicate	O
a	O
minimum	O
crossover	O
frequency	B-UNK
of	O
22	O
%	O
between	O
the	O
SAA	O
gene	B-UNK
marker	B-UNK
and	O
FMF	B-UNK
.	O

By	O
conventional	O
linkage	B-UNK
analysis	I-UNK
this	O
eliminates	O
a	O
minimum	O
of	O
10	O
.	O

4	O
cM	B-DISEASE
including	O
and	O
surrounding	O
the	O
SAA	O
gene	B-UNK
cluster	B-UNK
as	O
the	O
site	B-UNK
of	O
the	O
FMF	B-UNK
mutation	B-UNK
although	O
SAA	O
proteins	B-UNK
are	O
prominent	O
physiologic	O
markers	B-UNK
of	O
the	O
acute	B-UNK
attacks	O
.	O

PRAD1	O
,	O
a	O
candidate	B-UNK
BCL1	O
oncogene	O
:	O
mapping	B-UNK
and	O
expression	B-UNK
in	O
centrocytic	O
lymphoma	B-DISEASE
.	O

Rearrangement	B-UNK
of	O
the	O
BCL1	O
(	O
B	O
-	O
cell	B-UNK
lymphoma	B-DISEASE
1	O
)	O
region	B-UNK
on	O
chromosome	B-UNK
11q13	O
appears	B-UNK
to	O
be	O
highly	B-UNK
characteristic	B-UNK
of	O
centrocytic	O
lymphoma	B-UNK
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
B	O
-	O
cell	B-UNK
neoplasms	B-DISEASE
.	O

Rearrangement	B-UNK
is	O
thought	B-UNK
to	O
deregulate	O
a	O
nearby	O
protooncogene	O
,	O
but	O
transcribed	O
sequences	O
in	O
the	O
immediate	O
vicinity	O
of	O
BCL1	O
breakpoints	O
had	O
not	O
been	O
identified	B-UNK
.	O

PRAD1	O
,	O
previously	B-UNK
designated	O
D11S287E	O
,	O
was	O
identified	B-UNK
on	O
11q13	O
as	O
a	O
chromosomal	B-UNK
breakpoint	O
region	B-UNK
rearranged	O
with	O
the	O
parathyroid	O
hormone	B-UNK
gene	B-UNK
in	O
a	O
subset	O
of	O
parathyroid	O
adenomas	B-UNK
;	O
this	O
highly	B-UNK
conserved	I-UNK
putative	O
oncogene	O
,	O
which	O
encodes	B-UNK
a	O
novel	O
cyclin	O
,	O
has	O
been	O
linked	B-UNK
to	O
BCL1	O
and	O
implicated	B-UNK
also	O
in	O
subsets	O
of	O
breast	B-UNK
and	O
squamous	O
cell	B-UNK
neoplasms	B-UNK
with	O
11q13	O
amplification	B-UNK
.	O

We	O
report	B-UNK
pulsed	O
-	O
field	B-UNK
gel	B-UNK
electrophoresis	I-UNK
data	B-UNK
showing	O
BCL1	O
and	O
PRAD1	O
to	O
be	O
no	O
more	O
than	O
130	O
kilobases	O
apart	O
.	O

PRAD1	O
mRNA	O
is	O
abundantly	O
expressed	B-UNK
in	O
seven	O
of	O
seven	O
centrocytic	O
lymphomas	B-DISEASE
(	O
Kiel	O
classification	O
)	O
,	O
in	O
contrast	B-UNK
to	O
13	O
closely	B-UNK
related	B-UNK
but	O
noncentrocytic	O
lymphomas	B-DISEASE
.	O

Three	O
of	O
the	O
seven	O
centrocytic	O
lymphomas	B-DISEASE
had	O
detectable	O
BCL1	O
DNA	B-UNK
rearrangement	B-UNK
.	O

Also	O
,	O
two	O
unusual	O
cases	B-UNK
of	O
CLL	O
with	O
BCL1	O
rearrangement	B-UNK
overexpressed	O
PRAD1	O
,	O
in	O
contrast	B-UNK
to	O
five	O
CLL	O
controls	O
.	O

Thus	O
,	O
PRAD1	O
is	O
an	O
excellent	O
candidate	B-UNK
"	O
BCL1	O
oncogene	O
.	O

"	O
Its	O
overexpression	B-UNK
may	O
be	O
a	O
key	B-UNK
consequence	B-UNK
of	O
rearrangement	B-UNK
of	O
the	O
BCL1	O
vicinity	O
in	O
B	O
-	O
cell	B-UNK
neoplasms	B-DISEASE
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	O
lymphoma	B-UNK
.	O

Two	O
new	O
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
mutations	B-UNK
in	O
a	O
juvenile	O
metachromatic	B-UNK
leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
patient	B-UNK
.	O

Fragments	O
of	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
gene	B-UNK
from	O
a	O
patient	B-UNK
with	O
juvenile	O
-	O
onset	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
were	O
amplified	O
by	O
PCR	B-UNK
and	O
ligated	O
into	O
MP13	O
cloning	B-UNK
vectors	O
.	O

Clones	O
hybridizing	O
with	O
cDNA	O
for	O
human	B-UNK
ARSA	B-UNK
were	O
selected	O
,	O
examined	O
for	O
appropriate	O
size	B-UNK
inserts	O
,	O
and	O
used	O
to	O
prepare	O
single	B-UNK
-	O
stranded	O
phage	O
DNA	B-UNK
.	O

Examination	B-UNK
of	O
the	O
entire	O
coding	B-UNK
and	O
most	O
of	O
the	O
intronic	O
sequence	B-UNK
revealed	B-UNK
two	O
putative	O
disease	B-DISEASE
-	O
related	B-UNK
mutations	B-UNK
.	O

One	O
,	O
a	O
point	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
3	O
,	O
resulted	B-UNK
in	O
the	O
substitution	B-UNK
of	O
isoleucine	O
by	O
serine	O
.	O

Introduction	O
of	O
this	O
alteration	O
into	O
the	O
normal	B-UNK
ARSA	B-UNK
cDNA	O
sequence	B-UNK
resulted	B-UNK
in	O
a	O
substantial	O
decrease	O
in	O
ARSA	B-UNK
activity	B-UNK
on	O
transient	O
expression	B-UNK
in	O
cultured	O
baby	O
hamster	O
kidney	B-UNK
cells	B-UNK
.	O

About	O
5	O
%	O
of	O
the	O
control	B-UNK
expression	B-UNK
was	O
observed	B-UNK
,	O
suggesting	O
a	O
small	O
residual	B-UNK
activity	B-UNK
in	O
the	O
mutated	B-UNK
ARSA	B-UNK
.	O

The	O
second	O
mutation	B-UNK
,	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-UNK
,	O
occurred	B-UNK
in	O
the	O
other	O
allele	B-UNK
and	O
resulted	B-UNK
in	O
an	O
altered	O
splice	B-UNK
-	O
recognition	O
sequence	B-UNK
between	O
exon	B-UNK
7	O
and	O
the	O
following	O
intron	B-UNK
.	O

The	O
mutation	B-UNK
also	O
resulted	B-UNK
in	O
the	O
loss	B-UNK
of	O
a	O
restriction	B-UNK
site	B-UNK
.	O

Apparently	O
normal	B-UNK
levels	B-UNK
of	O
mRNA	O
were	O
generated	O
from	O
this	O
allele	B-UNK
,	O
but	O
no	O
ARSA	B-UNK
activity	B-UNK
or	O
immuno	O
-	O
cross	O
-	O
reactive	O
material	O
could	O
be	O
detected	B-UNK
.	O

A	O
collection	O
of	O
DNA	B-UNK
samples	B-UNK
from	O
known	O
or	O
suspected	O
MLD	B-UNK
patients	B-UNK
,	O
members	B-UNK
of	O
their	O
families	B-UNK
,	O
and	O
normal	B-UNK
controls	O
was	O
screened	B-UNK
for	O
these	O
mutations	B-UNK
.	O

Four	O
additional	O
individuals	B-UNK
carrying	B-UNK
each	O
of	O
the	O
mutations	B-UNK
were	O
found	O
among	O
the	O
nearly	O
100	O
MLD	B-UNK
patients	B-UNK
in	O
the	O
sample	O
.	O

Gene	B-UNK
segregation	B-UNK
in	O
the	O
original	O
patients	B-UNK
family	B-UNK
was	O
consistent	B-UNK
with	O
available	O
clinical	B-UNK
and	O
biochemical	O
data	B-UNK
.	O

No	O
individuals	B-UNK
homozygous	B-UNK
for	O
either	O
of	O
these	O
two	O
mutations	B-UNK
were	O
identified	B-UNK
.	O

However	O
,	O
combinations	O
with	O
other	O
MLD	B-UNK
mutations	B-UNK
suggest	B-UNK
that	O
the	O
point	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
3	O
does	O
result	B-UNK
in	O
some	O
residual	B-UNK
enzyme	B-UNK
activity	I-UNK
and	O
is	O
associated	O
with	O
late	B-UNK
-	O
onset	B-UNK
forms	B-UNK
of	O
the	O
disease	B-UNK
.	O

The	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
following	O
exon	B-UNK
7	O
produces	O
late	B-UNK
-	O
infantile	B-UNK
MLD	B-UNK
when	O
combined	O
with	O
other	O
enzyme	B-UNK
-	O
null	O
mutations	B-UNK
,	O
implying	O
that	O
it	O
is	O
completely	O
silent	O
enzymatically	O
..	O

Analysis	B-UNK
of	O
X	O
-	O
chromosome	B-UNK
inactivation	B-UNK
and	O
presumptive	O
expression	B-UNK
of	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
gene	B-UNK
in	O
hematopoietic	O
cell	B-UNK
lineages	O
of	O
a	O
thrombocytopenic	O
carrier	B-UNK
female	O
of	O
WAS	O
.	O

We	O
report	B-UNK
on	O
a	O
thrombocytopenic	O
female	O
belonging	O
to	O
a	O
pedigree	B-UNK
with	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
.	O

Restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
(	O
RFLP	B-UNK
)	O
analysis	B-UNK
with	O
probe	O
M27	O
beta	B-UNK
,	O
closely	B-UNK
linked	I-UNK
to	O
the	O
WAS	O
gene	B-UNK
,	O
demonstrated	O
that	O
she	O
is	O
a	O
carrier	B-UNK
of	O
WAS	O
.	O

Both	O
small	O
-	O
sized	O
and	O
normal	B-UNK
-	O
sized	O
platelets	O
were	O
present	B-UNK
,	O
suggesting	O
that	O
,	O
unlike	O
the	O
vast	O
majority	O
of	O
WAS	O
carriers	B-UNK
,	O
she	O
does	O
not	O
manifest	O
nonrandom	O
X	O
-	O
chromosome	B-UNK
inactivation	B-UNK
in	O
the	O
thrombopoietic	O
cell	B-UNK
lineage	O
.	O

Study	B-UNK
of	O
X	O
-	O
chromosome	B-UNK
inactivation	B-UNK
by	O
means	B-UNK
of	O
RFLP	B-UNK
and	O
methylation	B-UNK
analysis	B-UNK
demonstrated	O
that	O
the	O
pattern	B-UNK
of	O
X	O
-	O
chromosome	B-UNK
inactivation	B-UNK
was	O
nonrandom	O
in	O
T	O
lymphocytes	O
,	O
but	O
random	B-UNK
in	O
granulocytes	O
.	O

While	O
this	O
is	O
the	O
first	O
complete	O
report	B-UNK
on	O
the	O
occurrence	B-UNK
of	O
thrombocytopenia	B-DISEASE
in	O
a	O
carrier	B-UNK
female	O
of	O
WAS	O
as	O
the	O
result	B-UNK
of	O
atypical	O
lyonization	O
,	O
it	O
also	O
suggests	O
that	O
expression	B-UNK
of	O
the	O
WAS	O
gene	B-UNK
occurs	O
at	O
(	O
or	O
extends	O
up	O
to	O
)	O
a	O
later	O
stage	B-UNK
than	O
the	O
multipotent	O
stem	B-UNK
cell	B-UNK
along	O
the	O
hematopoietic	O
differentiation	B-UNK
pathway	B-UNK
..	O

A	O
new	O
mutation	B-UNK
in	O
the	O
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
in	O
a	O
German	O
family	B-UNK
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
.	O

A	O
C	O
-	O
to	O
-T	O
transition	B-UNK
in	O
exon	B-UNK
4	O
of	O
the	O
PLP	B-UNK
gene	B-UNK
was	O
found	O
in	O
2	O
affected	B-UNK
males	I-UNK
and	O
two	O
obligate	B-UNK
carriers	B-UNK
in	O
a	O
German	O
family	B-UNK
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
.	O

The	O
mutation	B-UNK
,	O
which	O
causes	O
loss	B-UNK
of	O
an	O
HphI	O
site	B-UNK
and	O
changes	O
amino	B-UNK
acid	I-UNK
155	O
from	O
threonine	O
to	O
isoleucine	O
,	O
was	O
absent	O
from	O
108	O
normal	B-UNK
chromosomes	O
.	O

There	O
are	O
5	O
concordances	O
and	O
1	O
discrepancy	O
between	O
these	O
results	B-UNK
and	O
those	O
obtained	B-UNK
by	O
magnetic	O
resonance	O
imaging	O
in	O
this	O
family	B-UNK
..	O

A	O
3-base	O
pair	B-UNK
in	O
-	O
frame	B-UNK
deletion	B-UNK
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
results	B-UNK
in	O
a	O
kinetic	O
variant	O
of	O
phenylketonuria	O
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disease	B-DISEASE
due	O
to	O
deficiency	B-UNK
of	O
a	O
hepatic	B-UNK
enzyme	B-UNK
,	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

The	O
absence	B-UNK
of	O
PAH	B-UNK
activity	B-UNK
results	B-UNK
in	O
typical	O
PKU	B-UNK
while	O
persistence	O
of	O
a	O
residual	B-UNK
enzyme	B-UNK
activity	I-UNK
gives	O
rise	B-UNK
to	O
variant	O
forms	B-UNK
of	O
the	O
disease	B-DISEASE
.	O

We	O
report	B-UNK
here	O
a	O
3-base	O
pair	B-UNK
in	O
-	O
frame	B-UNK
deletion	B-UNK
of	O
the	O
PAH	B-UNK
gene	B-UNK
(	O
delta	O
194	O
)	O
in	O
a	O
mild	O
variant	O
,	O
with	O
markedly	B-UNK
reduced	O
affinity	B-UNK
of	O
the	O
enzyme	B-UNK
for	O
phenylalanine	B-UNK
(	O
Km	O
=	O
160	O
nM	O
)	O
,	O
and	O
we	O
provide	B-UNK
functional	O
evidence	B-UNK
for	O
responsibility	O
of	O
the	O
deletion	B-UNK
in	O
the	O
mutant	B-UNK
phenotype	B-UNK
.	O

Since	O
the	O
deletion	B-UNK
was	O
located	B-UNK
in	O
the	O
third	O
exon	B-UNK
of	O
the	O
gene	B-UNK
,	O
which	O
presents	O
no	O
homology	B-UNK
with	O
other	O
hydroxylases	O
,	O
we	O
suggest	B-UNK
that	O
exon	B-UNK
3	O
is	O
involved	B-UNK
in	O
the	O
specificity	O
of	O
the	O
enzyme	B-UNK
for	O
phenylalanine	B-UNK
.	O

Finally	B-UNK
,	O
since	O
none	O
of	O
the	O
98	O
PKU	B-UNK
patients	B-UNK
tested	O
were	O
found	O
to	O
carry	B-UNK
this	O
particular	O
deletion	B-UNK
,	O
our	O
study	B-UNK
suggests	O
that	O
this	O
molecular	B-UNK
event	O
probably	O
occurred	B-UNK
recently	O
on	O
the	O
background	O
of	O
a	O
haplotype	B-UNK
2	O
gene	B-UNK
in	O
Portugal	O
..	O

Mutation	B-UNK
of	O
the	O
KIT	B-UNK
(	O
mast	O
/	O
stem	B-UNK
cell	B-UNK
growth	B-UNK
factor	I-UNK
receptor	B-UNK
)	O
protooncogene	O
in	O
human	B-UNK
piebaldism	B-UNK
.	O

Piebaldism	B-UNK
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
genetic	B-UNK
disorder	I-UNK
characterized	B-UNK
by	O
cogenital	O
patches	O
of	O
skin	B-UNK
and	O
hair	B-UNK
from	O
which	O
melanocytes	O
are	O
completely	O
absent	O
.	O

A	O
similar	B-UNK
disorder	B-UNK
of	O
mouse	B-UNK
,	O
dominant	B-UNK
white	B-UNK
spotting	O
(	O
W	O
)	O
,	O
results	B-UNK
from	O
mutations	B-UNK
of	O
the	O
c	O
-	O
Kit	B-UNK
protooncogene	O
,	O
which	O
encodes	B-UNK
and	O
receptor	B-UNK
for	O
mast	O
/	O
stem	B-UNK
cell	B-UNK
growth	B-UNK
factor	I-UNK
.	O

We	O
identified	B-UNK
a	O
KIT	B-UNK
gene	B-UNK
mutation	B-UNK
in	O
a	O
proband	B-UNK
with	O
classic	B-UNK
autosomal	B-UNK
dominant	I-UNK
piebaldism	B-UNK
.	O

This	O
mutation	B-UNK
results	B-UNK
in	O
a	O
Gly----Arg	O
substitution	B-UNK
at	O
codon	B-UNK
664	O
,	O
within	O
the	O
tyrosine	O
kinase	B-UNK
domain	B-UNK
.	O

This	O
substitution	B-UNK
was	O
not	O
seen	O
in	O
any	O
normal	B-UNK
individuals	B-UNK
and	O
was	O
completely	O
linked	B-UNK
to	O
the	O
piebald	O
phenotype	B-UNK
in	O
the	O
probands	O
family	B-UNK
.	O

Piebaldism	B-UNK
in	O
this	O
family	B-UNK
thus	O
appears	B-UNK
to	O
be	O
the	O
human	B-UNK
homologue	B-UNK
to	O
dominant	B-UNK
white	B-UNK
spotting	O
(	O
W	O
)	O
of	O
the	O
mouse	B-UNK
..	O

Genetic	B-UNK
analysis	I-UNK
of	O
a	O
Japanese	B-UNK
family	B-UNK
with	O
normotriglyceridemic	O
abetalipoproteinemia	B-DISEASE
indicates	O
a	O
lack	B-UNK
of	O
linkage	B-UNK
to	O
the	O
apolipoprotein	B-UNK
B	O
gene	B-UNK
.	O

Normotriglyceridemic	O
abetalipoproteinemia	B-DISEASE
is	O
a	O
rare	B-UNK
familial	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
an	O
isolated	B-UNK
deficiency	B-UNK
of	O
apoB-100	O
.	O

We	O
have	O
previously	B-UNK
reported	I-UNK
a	O
patient	B-UNK
with	O
this	O
disease	B-DISEASE
,	O
who	O
had	O
normal	B-UNK
apoB-48	O
but	O
no	O
apoB-100	O
.	O

To	O
elucidate	O
the	O
genetic	B-UNK
abnormalities	B-UNK
in	O
this	O
family	B-UNK
,	O
we	O
studied	O
the	O
linkage	B-UNK
of	O
apoB	O
gene	B-UNK
using	O
three	O
genetic	B-UNK
markers	B-UNK
.	O

The	O
proband	B-UNK
and	O
her	O
affected	B-UNK
brother	B-UNK
showed	O
completely	O
different	O
apoB	O
gene	B-UNK
alleles	B-UNK
,	O
suggesting	O
that	O
the	O
apoB	O
gene	B-UNK
itself	O
is	O
not	O
related	B-UNK
to	O
this	O
disorder	B-UNK
in	O
this	O
family	B-UNK
.	O

By	O
contrast	B-UNK
,	O
an	O
American	B-UNK
case	B-UNK
had	O
a	O
point	B-UNK
substitution	B-UNK
in	O
the	O
apoB	O
gene	B-UNK
generating	O
an	O
in	O
-	O
frame	B-UNK
stop	B-UNK
codon	I-UNK
.	O

These	O
results	B-UNK
indicate	O
that	O
this	O
disorder	B-UNK
can	O
be	O
caused	B-UNK
by	O
defect	B-UNK
(	O
s	O
)	O
of	O
either	O
an	O
apoB	O
gene	B-UNK
or	O
other	O
genes	B-UNK
..	O

Localisation	O
of	O
the	O
gene	B-UNK
for	O
Norrie	B-UNK
disease	I-UNK
to	O
between	O
DXS7	B-UNK
and	O
DXS426	O
on	O
Xp	O
.	O

A	O
highly	B-UNK
informative	O
microsatellite	B-UNK
marker	B-UNK
,	O
DXS426	O
,	O
which	O
maps	B-UNK
proximal	B-UNK
to	O
DXS7	B-UNK
in	O
the	O
interval	B-UNK
Xp11	O
.	O

4-Xp11	O
4-Xp11	O
.	O

23	O
,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	B-UNK
for	O
Norrie	B-UNK
disease	I-UNK
(	O
NDP	B-UNK
)	O
.	O

The	O
results	B-UNK
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
NDP	B-UNK
gene	B-UNK
proximal	B-UNK
to	O
DXS7	B-UNK
.	O

In	O
conjunction	O
with	O
information	B-UNK
from	O
2	O
NDP	B-UNK
patients	B-UNK
who	O
have	O
a	O
deletion	B-UNK
for	O
DXS7	B-UNK
but	O
not	O
for	O
DSX426	O
,	O
our	O
data	B-UNK
indicate	O
that	O
the	O
NDP	B-UNK
gene	B-UNK
lies	O
between	O
DXS7	B-UNK
and	O
DXS426	O
on	O
proximal	B-UNK
Xp	O
.	O

Aberrant	B-UNK
splicing	B-UNK
of	O
phenylalanine	B-UNK
hydroxylase	I-UNK
mRNA	O
:	O
the	O
major	B-UNK
cause	O
for	O
phenylketonuria	O
in	O
parts	O
of	O
southern	B-UNK
Europe	B-UNK
.	O

We	O
report	B-UNK
a	O
mutation	B-UNK
within	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
gene	B-UNK
that	O
causes	O
aberrant	B-UNK
splicing	B-UNK
of	O
the	O
mRNA	O
and	O
that	O
is	O
in	O
tight	O
association	B-UNK
with	O
chromosomal	B-UNK
haplotypes	O
6	O
,	O
10	O
,	O
and	O
36	O
.	O

Because	O
of	O
the	O
high	B-UNK
frequency	I-UNK
of	O
these	O
particular	O
haplotypes	O
in	O
Bulgaria	O
,	O
Italy	O
,	O
and	O
Turkey	O
,	O
it	O
appears	B-UNK
to	O
be	O
one	O
of	O
the	O
more	O
frequent	B-UNK
defects	B-UNK
in	O
the	O
PAH	B-UNK
gene	B-UNK
causing	B-UNK
classical	O
phenylketonuria	O
in	O
this	O
part	O
of	O
Europe	B-UNK
.	O

The	O
mutation	B-UNK
is	O
a	O
G	O
to	O
A	O
transition	B-UNK
at	O
position	B-UNK
546	O
in	O
intron	B-UNK
10	O
of	O
the	O
PAH	B-UNK
gene	B-UNK
,	O
11	O
bp	B-UNK
upstream	O
from	O
the	O
intron	B-UNK
10	O
/	O
exon	B-UNK
11	O
boundary	O
.	O

It	O
activates	O
a	O
cryptic	O
splice	B-UNK
site	I-UNK
and	O
results	B-UNK
in	O
an	O
in	O
-	O
frame	B-UNK
insertion	O
of	O
9	O
nucleotides	O
between	O
exon	B-UNK
10	O
and	O
exon	B-UNK
11	O
of	O
the	O
processed	O
mRNA	O
.	O

Normal	B-UNK
amounts	B-UNK
of	O
liver	B-UNK
PAH	B-UNK
protein	B-UNK
are	O
present	B-UNK
in	O
homozygous	B-UNK
patients	B-UNK
,	O
but	O
no	O
catalytic	O
activity	B-UNK
can	O
be	O
detected	B-UNK
.	O

This	O
loss	B-UNK
of	O
enzyme	B-UNK
activity	I-UNK
is	O
probably	O
caused	B-UNK
by	O
conformational	B-UNK
changes	O
resulting	B-UNK
from	O
the	O
insertion	O
of	O
three	O
additional	O
amino	B-UNK
acids	I-UNK
(	O
Gly	B-UNK
-	O
Leu	B-UNK
-	O
Gln	O
)	O
between	O
the	O
normal	B-UNK
sequences	O
encoded	B-UNK
by	O
exon	B-UNK
10	O
and	O
exon	B-UNK
11	O
..	O

Gardner	B-DISEASE
syndrome	I-DISEASE
in	O
a	O
boy	B-UNK
with	O
interstitial	O
deletion	B-UNK
of	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
5	O
.	O

We	O
described	O
a	O
15-year	O
-	O
old	O
boy	B-UNK
with	O
Gardner	B-DISEASE
syndrome	I-DISEASE
(	O
GS	B-UNK
)	O
,	O
mental	B-UNK
retardation	I-UNK
,	O
and	O
craniofacial	B-DISEASE
abnormalities	I-DISEASE
.	O

High	B-UNK
-	O
resolution	O
banding	O
analysis	B-UNK
showed	O
an	O
interstitial	O
deletion	B-UNK
of	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
5	O
(	O
q22	O
.	O
1	O
-	O
---q31	O
1	O
-	O
---q31	O
.	O
1	O
)	O
.	O

The	O
breakpoints	O
in	O
the	O
present	B-UNK
case	B-UNK
and	O
in	O
3	O
previously	B-UNK
reported	I-UNK
5q	O
-	O
patients	B-UNK
with	O
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
suggest	B-UNK
that	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
GS	B-UNK
/	O
or	O
familial	B-UNK
polyposis	B-UNK
coli	I-UNK
(	O
FPC	O
)	O
is	O
in	O
the	O
5q22	O
region	B-UNK
,	O
a	O
result	B-UNK
consistent	B-UNK
with	O
the	O
findings	B-UNK
of	O
linkage	B-UNK
studies	B-UNK

Huntington	B-DISEASE
disease	I-DISEASE
and	O
childhood	O
-	O
onset	B-UNK
Tourette	B-DISEASE
syndrome	I-DISEASE
.	O

A	O
40-year	O
-	O
old	O
man	B-UNK
with	O
childhood	O
-	O
onset	B-UNK
Tourette	B-DISEASE
syndrome	I-DISEASE
(	O
TS	B-DISEASE
)	O
developed	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
.	O

We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
childhood	O
-	O
onset	B-UNK
TS	B-DISEASE
with	O
adult	B-UNK
onset	I-UNK
HD	B-UNK
.	O

Discovery	O
of	O
other	O
cases	B-UNK
with	O
both	O
disorders	B-UNK
may	O
provide	B-UNK
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
..	O

Sequence	B-UNK
of	O
DNA	B-UNK
flanking	O
the	O
exons	O
of	O
the	O
HEXA	B-UNK
gene	B-UNK
,	O
and	O
identification	B-UNK
of	O
mutations	B-UNK
in	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
.	O

The	O
rapid	O
identification	B-UNK
of	O
mutations	B-UNK
causing	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
requires	O
the	O
capacity	O
to	O
readily	O
screen	B-UNK
the	O
regions	B-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
most	O
likely	O
to	O
be	O
affected	B-UNK
by	O
mutation	B-UNK
.	O

We	O
have	O
sequenced	O
the	O
portions	O
of	O
the	O
introns	O
flanking	O
each	O
of	O
the	O
14	O
HEXA	B-UNK
exons	O
in	O
order	B-UNK
to	O
specify	O
oligonucleotide	O
primers	O
for	O
the	O
PCR	B-UNK
-	O
dependent	B-UNK
amplification	B-UNK
of	O
each	O
exon	B-UNK
and	O
splice	B-UNK
-	O
junction	O
sequence	B-UNK
.	O

The	O
amplified	O
products	B-UNK
were	O
analyzed	B-UNK
,	O
by	O
electrophoresis	B-UNK
in	O
nondenaturing	O
polyacrylamide	O
gels	O
,	O
for	O
the	O
presence	O
of	O
either	O
heteroduplexes	O
,	O
derived	B-UNK
from	O
the	O
annealing	O
of	O
normal	B-UNK
and	O
mutant	B-UNK
DNA	B-UNK
strands	O
,	O
or	O
single	B-UNK
-	O
strand	B-UNK
conformational	B-UNK
polymorphisms	B-UNK
(	O
SSCP	B-UNK
)	O
,	O
derived	B-UNK
from	O
the	O
renaturation	O
of	O
single	B-UNK
-	O
stranded	O
DNA	B-UNK
.	O

Five	O
novel	O
mutations	B-UNK
from	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
patients	B-UNK
were	O
detected	B-UNK
a	O
5-bp	O
deletion	B-UNK
of	O
TCTCC	O
in	O
IVS-9	O
;	O
a	O
2-bp	O
deletion	B-UNK
of	O
TG	O
in	O
exon	B-UNK
5	O
;	O
G78	O
to	O
A	O
,	O
giving	O
a	O
stop	B-UNK
codon	I-UNK
in	O
exon	B-UNK
1	O
;	O
G533	O
to	O
T	O
in	O
exon	B-UNK
5	O
,	O
producing	O
the	O
third	O
amino	B-UNK
acid	I-UNK
substitution	I-UNK
detected	B-UNK
at	O
this	O
site	B-UNK
;	O
and	O
G	O
to	O
C	O
at	O
position	B-UNK
1	O
of	O
IVS-2	O
,	O
expected	O
to	O
produce	B-UNK
abnormal	O
splicing	B-UNK
.	O

In	O
addition	B-UNK
,	O
two	O
mutations	B-UNK
,	O
(	O
G1496	O
to	O
A	O
in	O
exon	B-UNK
13	O
and	O
a	O
4-bp	O
insertion	O
in	O
exon	B-UNK
11	O
)	O
that	O
have	O
previously	B-UNK
been	O
reported	B-UNK
were	O
identified	B-UNK
..	O

Molecular	B-UNK
characterization	B-UNK
of	O
two	O
galactosemia	O
mutations	B-UNK
:	O
correlation	B-UNK
of	O
mutations	B-UNK
with	O
highly	B-UNK
conserved	I-UNK
domains	B-UNK
in	O
galactose-1-phosphate	O
uridyl	O
transferase	O
.	O

Galactosemia	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
of	O
human	B-UNK
galactose	B-UNK
metabolism	B-UNK
caused	B-UNK
by	O
deficiency	B-UNK
of	O
the	O
enzyme	B-UNK
galactose-1-phosphate	O
uridyl	O
transferase	O
(	O
GALT	B-UNK
)	O
.	O

The	O
molecular	B-UNK
basis	I-UNK
of	O
this	O
disorder	B-UNK
is	O
at	O
present	B-UNK
not	O
well	O
understood	O
.	O

We	O
report	B-UNK
here	O
two	O
missense	B-UNK
mutations	I-UNK
which	O
result	B-UNK
in	O
low	B-UNK
or	O
undetectable	O
enzymatic	B-UNK
activity	I-UNK
.	O

First	O
,	O
we	O
identified	B-UNK
at	O
nucleotide	B-UNK
591	O
a	O
transition	B-UNK
which	O
substitutes	O
glutamine	O
188	O
by	O
arginine	O
.	O

The	O
mutated	B-UNK
glutamine	O
is	O
not	O
only	O
highly	B-UNK
conserved	I-UNK
in	O
evolution	O
(	O
conserved	B-UNK
also	O
in	O
Escherichia	O
coli	B-UNK
and	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
but	O
is	O
also	O
two	O
amino	B-UNK
acid	I-UNK
residues	O
downstream	O
from	O
the	O
active	B-UNK
site	B-UNK
histidine	O
-	O
proline	O
-	O
histidine	O
triad	O
and	O
results	B-UNK
in	O
about	O
10	O
%	O
of	O
normal	B-UNK
enzymatic	B-UNK
activity	I-UNK
.	O

The	O
arginine	O
188	O
mutation	B-UNK
is	O
the	O
most	O
common	B-UNK
galactosemia	O
mutation	B-UNK
characterized	B-UNK
to	O
date	B-UNK
.	O

It	O
accounts	O
for	O
one	O
-	O
fourth	B-UNK
of	O
the	O
galactosemia	O
alleles	B-UNK
studied	O
.	O

Second	O
,	O
we	O
report	B-UNK
the	O
substitution	B-UNK
of	O
arginine	O
333	O
by	O
tryptophan	O
,	O
caused	B-UNK
by	O
a	O
transition	B-UNK
at	O
nucleotide	B-UNK
1025	O
.	O

The	O
area	B-UNK
surrounding	O
this	O
missense	B-UNK
mutation	I-UNK
is	O
the	O
most	O
highly	B-UNK
conserved	I-UNK
domain	B-UNK
in	O
the	O
homologous	B-UNK
enzymes	B-UNK
from	O
E.	B-DISEASE
coli	I-DISEASE
,	O
yeast	B-UNK
,	O
and	O
humans	B-UNK
,	O
and	O
this	O
mutation	B-UNK
results	B-UNK
in	O
undetectable	O
enzymatic	B-UNK
activity	I-UNK
,	O
suggesting	O
that	O
this	O
is	O
a	O
severe	B-UNK
mutation	B-UNK
.	O

This	O
second	O
mutation	B-UNK
appears	B-UNK
to	O
be	O
rare	B-UNK
,	O
since	O
it	O
was	O
found	O
only	O
in	O
the	O
patient	B-UNK
we	O
sequenced	O
.	O

Our	O
data	B-UNK
provide	B-UNK
further	O
evidence	B-UNK
for	O
the	O
heterogeneity	B-UNK
of	O
galactosemia	O
at	O
the	O
molecular	B-UNK
level	B-UNK
,	O
heterogeneity	B-UNK
which	O
might	O
be	O
related	B-UNK
to	O
the	O
variable	B-UNK
clinical	B-UNK
outcome	O
observed	B-UNK
in	O
this	O
disorder	B-UNK
..	O

Hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
deficiency	B-UNK
:	O
analysis	B-UNK
of	O
HPRT	B-UNK
mutations	B-UNK
by	O
direct	B-UNK
sequencing	I-UNK
and	O
allele	B-UNK
-	O
specific	B-UNK
amplification	B-UNK
.	O

The	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
severe	B-UNK
X	O
chromosome	B-UNK
-	O
linked	B-UNK
human	B-UNK
disease	B-UNK
caused	B-UNK
by	O
a	O
virtual	O
absence	B-UNK
of	O
hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
activity	B-UNK
.	O

A	O
partial	O
deficiency	B-UNK
in	O
the	O
activity	B-UNK
of	O
this	O
enzyme	B-UNK
can	O
result	B-UNK
in	O
gouty	B-DISEASE
arthritis	I-DISEASE
.	O

To	O
determine	B-UNK
the	O
genetic	B-UNK
basis	B-UNK
for	O
reduction	B-UNK
or	O
loss	B-UNK
of	O
enzyme	B-UNK
activity	I-UNK
,	O
we	O
have	O
amplified	O
and	O
sequenced	O
the	O
coding	B-UNK
region	I-UNK
of	O
HPRT	B-UNK
cDNA	O
from	O
four	O
patients	B-UNK
one	O
with	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
(	O
HPRTPerth	O
)	O
and	O
three	O
with	O
partial	O
deficiencies	B-UNK
of	O
HPRT	B-UNK
activity	B-UNK
,	O
which	O
have	O
been	O
designated	O
HPRTUrangan	O
,	O
HPRTSwan	O
and	O
HPRTToowong	O
.	O

In	O
all	O
four	O
patients	B-UNK
,	O
the	O
only	O
mutation	B-UNK
identified	B-UNK
was	O
a	O
single	B-UNK
base	I-UNK
substitution	B-UNK
in	O
exons	O
2	O
or	O
3	O
of	O
the	O
coding	B-UNK
region	I-UNK
,	O
which	O
in	O
each	O
case	B-UNK
predicts	O
a	O
single	B-UNK
amino	B-UNK
acid	I-UNK
substitution	I-UNK
in	O
the	O
translated	O
protein	B-UNK
.	O

Each	O
base	B-UNK
change	B-UNK
was	O
confirmed	B-UNK
by	O
allele	B-UNK
-	O
specific	B-UNK
amplification	B-UNK
of	O
the	O
patients	B-UNK
genomic	B-UNK
DNA	I-UNK
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
mutation	B-UNK
found	O
for	O
HPRTPerth	O
is	O
identical	B-UNK
to	O
that	O
reported	B-UNK
for	O
HPRTFlint	O
.	O

It	O
appears	B-UNK
that	O
the	O
two	O
mutations	B-UNK
are	O
de	O
novo	O
events	O
..	O

Molecular	B-UNK
and	O
metabolic	B-UNK
basis	B-UNK
for	O
the	O
metabolic	B-UNK
disorder	B-UNK
normotriglyceridemic	O
abetalipoproteinemia	B-DISEASE
.	O

We	O
have	O
previously	B-UNK
described	O
a	O
disorder	B-UNK
,	O
normotriglyceridemic	O
abetalipoproteinemia	B-DISEASE
,	O
that	O
is	O
characterized	B-UNK
by	O
the	O
virtual	O
absence	B-UNK
of	O
plasma	O
low	B-UNK
density	B-UNK
lipoproteins	O
and	O
complete	O
absence	B-UNK
of	O
apoB-100	O
,	O
but	O
with	O
apparently	O
normal	B-UNK
secretion	O
of	O
triglyceride	O
-	O
rich	O
lipoproteins	O
containing	O
apoB-48	O
.	O

The	O
patients	B-UNK
plasma	O
lipoproteins	O
were	O
shown	B-UNK
on	O
polyacrylamide	O
gels	O
and	O
by	O
antibody	B-UNK
mapping	B-UNK
to	O
have	O
a	O
new	O
truncated	O
apoB	O
variant	O
,	O
apoB-50	O
,	O
circulating	O
along	O
with	O
her	O
apoB-48	O
.	O

We	O
have	O
found	O
this	O
individual	O
to	O
be	O
homozygous	B-UNK
for	O
a	O
single	B-UNK
C	O
-	O
to	O
-T	O
nucleotide	B-UNK
substitution	B-UNK
at	O
apoB	O
codon	B-UNK
2252	O
,	O
which	O
produces	O
a	O
premature	B-UNK
in	O
-	O
frame	B-UNK
stop	B-UNK
codon	I-UNK
.	O

Thus	O
,	O
this	O
is	O
a	O
rare	B-UNK
example	O
of	O
homozygous	B-UNK
hypobetalipoproteinemia	O
.	O

Electron	O
photomicrographs	O
revealed	B-UNK
that	O
the	O
diameters	O
of	O
particles	O
in	O
the	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoprotein	B-UNK
fraction	B-UNK
,	O
in	O
both	O
the	O
postprandial	O
and	O
postabsorptive	O
state	B-UNK
,	O
are	O
bimodally	O
distributed	O
.	O

The	O
molar	O
ratio	B-UNK
of	O
apoE	B-UNK
to	O
apoB	O
in	O
these	O
particles	O
is	O
3	O
.	O

5	O
1	O
,	O
similar	B-UNK
to	O
normal	B-UNK
VLDL	O
.	O

The	O
plasma	O
LDL	O
interval	B-UNK
contains	O
both	O
spherical	O
and	O
cuboidal	O
particles	O
.	O

Autologous	O
reinfusion	O
of	O
labeled	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoproteins	O
showed	O
exponential	O
disappearance	O
from	O
plasma	O
,	O
with	O
an	O
apparent	O
half	B-UNK
-	O
removal	O
time	O
of	O
50	O
min	O
,	O
somewhat	O
slower	O
than	O
for	O
normal	B-UNK
chylomicrons	O
but	O
within	O
the	O
normal	B-UNK
range	B-UNK
for	O
VLDL	O
.	O

The	O
calculated	O
production	O
rate	B-UNK
for	O
apoB	O
was	O
within	O
the	O
normal	B-UNK
range	B-UNK
in	O
this	O
subject	O
.	O

A	O
single	B-UNK
origin	O
of	O
phenylketonuria	O
in	O
Yemenite	O
Jews	B-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
a	O
metabolic	B-UNK
disease	B-UNK
caused	B-UNK
by	O
recessive	B-UNK
mutations	B-UNK
of	O
the	O
gene	B-UNK
encoding	B-UNK
the	O
hepatic	B-UNK
enzyme	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

The	O
incidence	B-UNK
of	O
PKU	B-UNK
varies	O
widely	O
across	O
different	O
geographic	O
areas	O
,	O
and	O
is	O
highest	O
(	O
about	O
1	O
in	O
5	O
,	O
000	O
live	O
births	O
)	O
in	O
Ireland	O
and	O
western	B-UNK
Scotland	O
,	O
and	O
among	O
Yemenite	O
Jews	B-UNK
.	O

A	O
limited	O
number	B-UNK
of	O
point	B-UNK
mutations	I-UNK
account	B-UNK
for	O
most	O
of	O
the	O
PKU	B-UNK
cases	B-UNK
in	O
the	O
European	B-UNK
population	B-UNK
.	O

Here	O
we	O
report	B-UNK
that	O
a	O
single	B-UNK
molecular	B-UNK
defect	B-UNK
--	O
a	O
deletion	B-UNK
spanning	O
the	O
third	O
exon	B-UNK
of	O
the	O
PAH	B-UNK
gene	B-UNK
--	O
is	O
responsible	B-UNK
for	O
all	O
the	O
PKU	B-UNK
cases	B-UNK
among	O
the	O
Yemenite	O
Jews	B-UNK
.	O

Examination	B-UNK
of	O
a	O
random	B-UNK
sample	O
of	O
Yemenite	O
Jews	B-UNK
using	O
a	O
molecular	B-UNK
probe	O
that	O
detects	O
the	O
carriers	B-UNK
of	O
this	O
deletion	B-UNK
indicated	O
a	O
high	B-UNK
frequency	I-UNK
of	O
the	O
defective	O
gene	B-UNK
in	O
this	O
community	O
.	O

Although	O
the	O
deleted	B-UNK
PAH	B-UNK
gene	B-UNK
was	O
traced	O
to	O
25	O
different	O
locations	O
throughout	O
Yemen	O
,	O
family	B-UNK
histories	O
and	O
official	O
documents	O
of	O
the	O
Yemenite	O
Jewish	B-UNK
community	O
showed	O
that	O
the	O
common	B-UNK
ancestor	O
of	O
all	O
the	O
carriers	B-UNK
of	O
this	O
genetic	B-UNK
defect	B-UNK
lived	O
in	O
Sana	O
,	O
the	O
capital	O
of	O
Yemen	O
,	O
before	O
the	O
eighteenth	O
century	O
..	O

Linkage	B-UNK
of	O
aspartylglucosaminuria	B-DISEASE
(	O
AGU	B-UNK
)	O
to	O
marker	B-UNK
loci	O
on	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
4	O
.	O

Aspartylglucosaminuria	B-DISEASE
(	O
AGU	B-UNK
)	O
is	O
caused	B-UNK
by	O
deficient	B-UNK
activity	B-UNK
of	O
the	O
enzyme	B-UNK
aspartylglucosaminidase	O
(	O
AGA	B-UNK
)	O
.	O

The	O
structural	B-UNK
gene	B-UNK
for	O
AGA	B-UNK
has	O
been	O
assigned	O
to	O
the	O
region	B-UNK
4q21-qter	O
of	O
chromosome	B-UNK
4	O
.	O

We	O
have	O
studied	O
the	O
map	B-UNK
position	B-UNK
of	O
the	O
AGU	B-UNK
locus	B-UNK
in	O
relation	O
to	O
other	O
marker	B-UNK
loci	O
on	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
4	O
using	O
linkage	B-UNK
analyses	O
.	O

Restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
alleles	B-UNK
for	O
the	O
ADH2	O
,	O
ADH3	O
,	O
EGF	O
,	O
FG	O
alpha	B-UNK
and	O
FG	O
beta	B-UNK
loci	O
and	O
blood	B-UNK
group	B-UNK
antigens	O
for	O
the	O
MNS	O
locus	B-UNK
were	O
determined	B-UNK
in	O
a	O
panel	B-UNK
of	O
12	O
Finnish	B-UNK
AGU	B-UNK
families	B-UNK
.	O

The	O
heterozygous	B-UNK
family	B-UNK
members	I-UNK
were	O
identified	B-UNK
by	O
reduced	O
activity	B-UNK
of	O
AGA	B-UNK
in	O
lymphocytes	O
.	O

Linkage	B-UNK
studies	B-UNK
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	B-UNK
analyses	O
.	O

Loose	O
linkage	B-UNK
of	O
the	O
AGU	B-UNK
locus	B-UNK
to	O
the	O
FG	O
and	O
MNS	O
loci	O
was	O
observed	B-UNK
(	O
z	O
=	O
1	O
.	O
16	O
,	O
z	O
=	O
1	O
.	O
39	O
,	O
respectively	O
)	O
.	O

Multipoint	B-UNK
analysis	B-UNK
to	O
the	O
fixed	O
map	B-UNK
[	O
ADH-(0	O
.	O
03)-EGF-(0	O
.	O
35)-FG-(0	O
.	O
11)-MNS	O
]	O
suggests	O
that	O
the	O
location	B-UNK
of	O
the	O
AGU	B-UNK
locus	B-UNK
is	O
0	O
.	O

05	O
-	O
0	O
.	O

30	O
recombination	B-UNK
units	O
distal	B-UNK
to	O
MNS	O
(	O
z	O
=	O
3	O
.	O
03	O
)	O
.	O

The	O
order	B-UNK
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
FG	O
-	O
MNS	O
-	O
AGU	B-UNK
is	O
35	O
times	O
more	O
likely	O
than	O
the	O
next	O
best	O
order	B-UNK
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
AGU	B-UNK
-	O
FG	O
-	O
MNS	O
.	O

Linkage	B-UNK
relationships	O
of	O
the	O
apolipoprotein	B-UNK
C1	O
gene	B-UNK
and	O
a	O
cytochrome	O
P450	O
gene	B-UNK
(	O
CYP2A	O
)	O
to	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
.	O

We	O
have	O
studied	O
the	O
genetic	B-UNK
linkage	I-UNK
of	O
two	O
markers	B-UNK
,	O
the	O
apolipoprotein	B-UNK
C1	O
(	O
APOC1	O
)	O
gene	B-UNK
and	O
a	O
cytochrome	O
P450	O
(	O
CYP2A	O
)	O
gene	B-UNK
,	O
in	O
relation	O
to	O
the	O
gene	B-UNK
for	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
.	O

A	O
peak	O
lod	B-UNK
score	I-UNK
of	O
9	O
.	O

29	O
at	O
2	O
cM	B-DISEASE
was	O
observed	B-UNK
for	O
APOC1-DM	O
,	O
with	O
a	O
lod	B-UNK
score	I-UNK
of	O
8	O
.	O

55	O
at	O
4	O
cM	B-DISEASE
for	O
CYP2A	O
-	O
DM	B-DISEASE
.	O

These	O
two	O
markers	B-UNK
also	O
show	O
close	B-UNK
linkage	I-UNK
to	O
each	O
other	O
(	O
theta	B-UNK
max	O
=	O
0	O
.	O
05	O
,	O
Zmax	O
=	O
9	O
.	O
09	O
)	O
.	O

From	O
examination	B-UNK
of	O
the	O
genotypes	O
of	O
the	O
recombinant	B-UNK
individuals	B-UNK
,	O
CYP2A	O
appears	B-UNK
to	O
map	B-UNK
proximal	B-UNK
to	O
DM	B-UNK
because	O
in	O
one	O
recombinant	B-UNK
individual	O
CYP2A	O
,	O
APOC2	B-UNK
and	O
CKMM	O
had	O
all	O
recombined	O
with	O
DM	B-DISEASE
.	O

Evidence	B-UNK
from	O
another	O
CYP2A	O
-	O
DM	B-DISEASE
recombinant	B-UNK
individual	O
places	O
CYP2A	O
proximal	B-UNK
to	O
APOC2	B-UNK
and	O
CKMM	O
.	O

Localisation	O
of	O
CYP2A	O
on	O
a	O
panel	B-UNK
of	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
also	O
suggests	O
that	O
it	O
is	O
proximal	B-UNK
to	O
DM	B-UNK
and	O
APOC2	B-UNK
/	O
C1	O
/	O
E	O
gene	B-UNK
cluster	B-UNK
.	O

Genetic	B-UNK
linkage	I-UNK
map	B-UNK
of	O
six	O
polymorphic	B-UNK
DNA	B-UNK
markers	I-UNK
around	O
the	O
gene	B-UNK
for	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
on	O
chromosome	B-UNK
5	O
.	O

A	O
genetic	B-UNK
linkage	I-UNK
map	B-UNK
of	O
six	O
polymorphic	B-UNK
DNA	B-UNK
markers	I-UNK
close	B-UNK
to	O
the	O
gene	B-UNK
(	O
APC	B-UNK
)	O
for	O
familial	B-UNK
adenomatous	I-UNK
polyposis	I-UNK
(	O
FAP	B-UNK
)	O
on	O
chromosome	B-UNK
5q	O
is	O
reported	B-UNK
.	O

One	O
hundred	O
fifty	O
-	O
five	O
typed	O
members	B-UNK
of	O
nine	O
FAP	B-UNK
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	B-UNK
analysis	I-UNK
.	O

A	O
number	B-UNK
of	O
crucial	O
recombination	B-UNK
events	O
have	O
been	O
identified	B-UNK
which	O
are	O
informative	O
at	O
three	O
or	O
more	O
loci	O
,	O
allowing	O
confident	O
ordering	O
of	O
parts	O
of	O
the	O
map	B-UNK
.	O

There	O
was	O
no	O
evidence	B-UNK
of	O
genetic	B-UNK
heterogeneity	I-UNK
,	O
with	O
all	O
families	B-UNK
showing	O
linkage	B-UNK
of	O
at	O
least	O
one	O
chromosome	B-UNK
5	O
marker	B-UNK
to	O
the	O
gene	B-UNK
.	O

Recombination	B-UNK
data	B-UNK
and	O
two	O
-	O
point	B-UNK
linkage	B-UNK
analysis	I-UNK
support	O
a	O
locus	B-UNK
order	B-UNK
of	O
centromere	O
-	O
pi	O
227-C11P11-ECB27-L5	O
.	O

62-APC	O
-	O
EF5	O
62-APC	O
-	O
EF5	O
.	O

44-YN5	O
44-YN5	O
.	O

48-telomer	O
e	O
,	O
although	O
EF5	O
.	O

44	O
could	O
lie	O
in	O
the	O
interval	B-UNK
L5	O
.	O

62-APC	O
or	O
ECB27-L5	O
.	O

62	O
.	O

No	O
recombinants	O
were	O
identified	B-UNK
between	O
APC	B-UNK
and	O
either	O
EF5	O
.	O

44	O
or	O
YN5	O
.	O

48	O
,	O
but	O
published	O
deletion	B-UNK
mapping	B-UNK
in	O
colorectal	B-UNK
carcinomas	B-UNK
and	O
linkage	B-UNK
analysis	I-UNK
in	O
FAP	B-UNK
suggest	B-UNK
that	O
YN5	O
.	O

48	O
is	O
1	O
-	O
3	O
cM	B-DISEASE
from	O
APC	B-UNK
.	O

The	O
present	B-UNK
study	B-UNK
suggests	O
that	O
YN5	O
.	O

48	O
and	O
L5	O
.	O

62	O
delineate	O
a	O
small	O
region	B-UNK
of	O
chromosome	B-UNK
5	O
within	O
which	O
the	O
EF5	O
.	O

44	O
locus	B-UNK
lies	O
very	O
close	B-UNK
to	O
the	O
APC	B-UNK
gene	B-UNK
.	O

These	O
data	B-UNK
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	B-UNK
for	O
presymptomatic	O
diagnosis	B-UNK
of	O
FAP	B-UNK
but	O
also	O
provide	B-UNK
a	O
high	B-UNK
-	O
density	B-UNK
map	B-UNK
of	O
the	O
region	B-UNK
for	O
isolation	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	B-UNK
of	O
chromosome	B-UNK
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	B-UNK
colorectal	B-UNK
cancer	I-UNK
.	O

Serum	B-UNK
amyloid	O
A	O
and	O
P	O
protein	B-UNK
genes	B-UNK
in	O
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
.	O

Two	O
recent	O
studies	B-UNK
have	O
suggested	O
the	O
involvement	B-UNK
of	O
serum	B-UNK
amyloid	O
A	O
(	O
SAA	O
)	O
and	O
P	O
(	O
APCS	O
)	O
genes	B-UNK
in	O
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
(	O
MEF	O
)	O
.	O

To	O
test	B-UNK
the	O
role	B-UNK
of	O
SAA	O
and	O
APCS	O
in	O
MEF	O
and	O
MEF	O
-	O
amyloidosis	B-DISEASE
,	O
we	O
studied	O
17	O
informative	O
families	B-UNK
(	O
15	O
Armenians	O
,	O
2	O
non-Ashkenazi	O
Jews	B-UNK
)	O
and	O
8	O
MEF	O
patients	B-UNK
with	O
amyloidosis	B-DISEASE
using	O
a	O
candidate	B-UNK
gene	I-UNK
approach	O
.	O

No	O
evidence	B-UNK
for	O
any	O
MEF	O
-	O
associated	O
polymorphism	B-UNK
was	O
found	O
in	O
any	O
of	O
the	O
41	O
Armenian	O
and	O
Jewish	B-UNK
MEF	O
patients	B-UNK
tested	O
.	O

Our	O
family	B-UNK
studies	B-UNK
allowed	O
us	O
to	O
rule	O
out	O
tight	O
linkage	B-UNK
between	O
SAA	O
and	O
MEF	O
(	O
lod	B-UNK
score	I-UNK
=	O
-2	O
.	O
16	O
,	O
theta	B-UNK
less	O
than	O
or	O
equal	O
to	O
0	O
.	O
06	O
)	O
.	O

For	O
APCS	O
we	O
found	O
that	O
the	O
allele	B-UNK
frequency	B-UNK
in	O
the	O
MEF	O
-	O
amyloidosis	B-DISEASE
patients	B-UNK
was	O
similar	B-UNK
to	O
that	O
in	O
18	O
unrelated	B-UNK
MEF	O
patients	B-UNK
without	O
amyloidosis	B-DISEASE
and	O
their	O
33	O
healthy	O
parents	O
.	O

Some	O
Mexican	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
variants	B-UNK
revisited	O
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
appears	B-UNK
to	O
be	O
fairly	O
common	B-UNK
in	O
Mexico	O
.	O

We	O
have	O
now	O
examined	O
the	O
DNA	B-UNK
of	O
three	O
previously	B-UNK
reported	I-UNK
electrophoretically	O
fast	O
Mexican	O
G6PD	B-UNK
variants,-G6PD	O
Distrito	O
Federal	O
,	O
G6PD	B-UNK
Tepic	O
,	O
and	O
G6PD	B-UNK
Castilla	O
.	O

All	O
three	O
of	O
these	O
variants	B-UNK
,	O
believed	O
on	O
the	O
basis	B-UNK
of	O
biochemical	O
characterization	B-UNK
and	O
population	B-UNK
origin	O
to	O
be	O
unique	O
,	O
have	O
the	O
G----A	O
transition	B-UNK
at	O
nucleotide	B-UNK
202	O
and	O
the	O
A----G	O
transition	B-UNK
at	O
nucleotide	B-UNK
376	O
,	O
mutations	B-UNK
that	O
we	O
now	O
recognize	O
to	O
be	O
characteristic	B-UNK
of	O
G6PD	B-UNK
A-	O
.	O

Two	O
other	O
Mexican	O
males	B-UNK
with	O
G6PD	B-UNK
deficiency	I-UNK
were	O
found	O
to	O
have	O
the	O
same	O
mutation	B-UNK
.	O

All	O
five	O
have	O
the	O
(	O
NlaIII	O
/	O
FokI	O
/	O
PvuII	O
/	O
PstI	O
)	O
haplotype	B-UNK
characteristic	B-UNK
of	O
G6PD	B-UNK
A	O
-	O
in	O
Africa	B-UNK
.	O

Since	O
the	O
PvuII	O
+	O
genotype	B-UNK
seems	O
to	O
be	O
rare	B-UNK
in	O
Europe	B-UNK
,	O
we	O
conclude	O
that	O
all	O
of	O
these	O
G6PD	B-UNK
A	O
-	O
genes	B-UNK
had	O
their	O
ancient	O
origin	O
in	O
Africa	B-UNK
,	O
although	O
in	O
many	O
of	O
the	O
Mexican	O
patients	B-UNK
with	O
G6PD	B-UNK
A-202A/376	O
G	O
the	O
gene	B-UNK
may	O
have	O
been	O
imported	O
more	O
recently	O
from	O
Spain	O
,	O
where	O
this	O
variant	O
,	O
formerly	O
known	O
as	O
G6PD	B-UNK
Betica	O
,	O
is	O
also	O
prevalent	O
..	O

Hereditary	B-UNK
deficiency	B-UNK
of	O
C5	B-UNK
in	O
association	B-UNK
with	O
discoid	O
lupus	B-DISEASE
erythematosus	I-DISEASE
.	O

A	O
29-year	O
-	O
old	O
woman	O
with	O
discoid	O
lupus	B-DISEASE
erythematosus	I-DISEASE
had	O
undetectable	O
classic	B-UNK
pathway	B-UNK
complement	B-UNK
activity	B-UNK
.	O

Hypocomplementemia	O
was	O
due	O
to	O
selective	O
deficiency	B-UNK
of	O
C5	B-UNK
.	O

One	O
of	O
her	O
children	O
was	O
also	O
deficient	B-UNK
.	O

To	O
our	O
knowledge	B-UNK
this	O
is	O
the	O
first	O
documented	O
case	B-UNK
of	O
an	O
association	B-UNK
between	O
discoid	O
lupus	B-DISEASE
erythematosus	I-DISEASE
and	O
C5	B-UNK
deficiency	B-UNK
..	O

Founder	B-UNK
effect	I-UNK
of	O
a	O
prevalent	O
phenylketonuria	O
mutation	B-UNK
in	O
the	O
Oriental	O
population	B-UNK
.	O

A	O
missense	B-UNK
mutation	I-UNK
has	O
been	O
identified	B-UNK
in	O
the	O
human	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
[	O
PAH	B-UNK
;	O
phenylalanine	B-UNK
4-monooxygenase	O
;	O
L	O
-	O
phenylalanine	B-UNK
,	O
tetrahydrobiopterin	O
oxygen	O
oxidoreductase	O
(	O
4-hydroxylating	O
)	O
,	O
EC	B-UNK
1	O
.	O
14	O
.	O
16	O
.	O
1	O
]	O
gene	B-UNK
in	O
a	O
Chinese	B-UNK
patient	B-UNK
with	O
classic	B-UNK
phenylketonuria	O
(	O
PKU	B-UNK
)	O
.	O

A	O
G	O
-	O
to	O
-	O
C	O
transition	B-UNK
at	O
the	O
second	O
base	B-UNK
of	O
codon	B-UNK
413	O
in	O
exon	B-UNK
12	O
of	O
the	O
gene	B-UNK
results	B-UNK
in	O
the	O
substitution	B-UNK
of	O
Pro413	O
for	O
Arg413	O
in	O
the	O
mutant	B-UNK
protein	B-UNK
.	O

This	O
mutation	B-UNK
(	O
R413P	O
)	O
results	B-UNK
in	O
negligible	O
enzymatic	B-UNK
activity	I-UNK
when	O
expressed	B-UNK
in	O
heterologous	O
mammalian	O
cells	B-UNK
and	O
is	O
compatible	B-UNK
with	O
a	O
classic	B-UNK
PKU	B-UNK
phenotype	B-UNK
in	O
the	O
patient	B-UNK
.	O

Population	B-UNK
genetic	B-UNK
studies	B-UNK
reveal	O
that	O
this	O
mutation	B-UNK
is	O
tightly	B-UNK
linked	I-UNK
to	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
haplotype	B-UNK
4	O
,	O
which	O
is	O
the	O
predominant	O
haplotype	B-UNK
of	O
the	O
PAH	B-UNK
locus	B-UNK
in	O
the	O
Oriental	O
population	B-UNK
.	O

It	O
accounts	O
for	O
13	O
.	O

8	O
%	O
of	O
northern	B-UNK
Chinese	B-UNK
and	O
27	O
%	O
of	O
Japanese	B-UNK
PKU	B-UNK
alleles	B-UNK
,	O
but	O
it	O
is	O
rare	B-UNK
in	O
southern	B-UNK
Chinese	B-UNK
(	O
2	O
.	O
2	O
%	O
)	O
and	O
is	O
absent	O
in	O
the	O
Caucasian	B-UNK
population	B-UNK
.	O

The	O
data	B-UNK
demonstrate	B-UNK
unambiguously	O
that	O
the	O
mutation	B-UNK
occurred	B-UNK
after	O
racial	O
divergence	O
of	O
Orientals	O
and	O
Caucasians	B-UNK
and	O
suggest	B-UNK
that	O
the	O
allele	B-UNK
has	O
spread	O
throughout	O
the	O
Orient	O
by	O
a	O
founder	B-UNK
effect	I-UNK
.	O

Previous	B-UNK
protein	B-UNK
polymorphism	B-UNK
studies	B-UNK
in	O
eastern	B-UNK
Asia	O
have	O
led	B-UNK
to	O
the	O
hypothesis	B-UNK
that	O
"	O
northern	B-UNK
Mongoloids	O
"	O
represented	O
a	O
founding	O
population	B-UNK
in	O
Asia	O
.	O

Our	O
results	B-UNK
are	O
compatible	B-UNK
with	O
this	O
hypothesis	B-UNK
in	O
that	O
the	O
PKU	B-UNK
mutation	B-UNK
might	O
have	O
occurred	B-UNK
in	O
northern	B-UNK
Mongoloids	O
and	O
subsequently	B-UNK
spread	O
to	O
the	O
Chinese	B-UNK
and	O
Japanese	B-UNK
populations	O
.	O

Glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
caused	B-UNK
by	O
a	O
defect	B-UNK
in	O
the	O
Na	B-UNK
+	O
/glucose	O
cotransporter	O
.	O

Glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
(	O
GGM	O
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disease	B-DISEASE
manifesting	O
within	O
the	O
first	O
weeks	O
of	O
life	B-UNK
and	O
characterized	B-UNK
by	O
a	O
selective	O
failure	B-UNK
to	O
absorb	O
dietary	O
glucose	B-UNK
and	O
galactose	B-UNK
from	O
the	O
intestine	O
.	O

The	O
consequent	O
severe	B-UNK
diarrhoea	B-DISEASE
and	O
dehydration	B-DISEASE
are	O
usually	O
fatal	B-UNK
unless	O
these	O
sugars	O
are	O
eliminated	O
from	O
the	O
diet	O
.	O

Intestinal	O
biopsies	O
of	O
GGM	O
patients	B-UNK
have	O
revealed	B-UNK
a	O
specific	B-UNK
defect	B-UNK
in	O
Na	B-UNK
(	O
+	O
)	O
-dependent	O
absorption	O
of	O
glucose	B-UNK
in	O
the	O
brush	O
border	O
.	O

Normal	B-UNK
glucose	B-UNK
absorption	O
is	O
mediated	O
by	O
the	O
Na	B-UNK
+	O
/glucose	O
cotransporter	O
in	O
the	O
brush	O
border	O
membrane	B-UNK
of	O
the	O
intestinal	O
epithelium	O
.	O

Cellular	O
influx	O
is	O
driven	O
by	O
the	O
transmembrane	B-UNK
Na	B-UNK
+	O
electrochemical	O
potential	B-UNK
gradient	O
;	O
thereafter	O
the	O
sugar	O
moves	O
to	O
the	O
blood	B-UNK
across	O
the	O
basolateral	O
membrane	B-UNK
via	O
the	O
facilitated	O
glucose	B-UNK
carrier	B-UNK
.	O

We	O
have	O
previously	B-UNK
cloned	O
and	O
sequenced	O
a	O
Na	B-UNK
+	O
/glucose	O
cotransporter	O
from	O
normal	B-UNK
human	B-UNK
ileum	O
and	O
shown	B-UNK
that	O
this	O
gene	B-UNK
,	O
SGLT1	B-UNK
,	O
resides	O
on	O
the	O
distal	B-UNK
q	O
arm	B-UNK
of	O
chromosome	B-UNK
22	O
.	O

We	O
have	O
now	O
amplified	O
SGLT1	B-UNK
complementary	O
DNA	B-UNK
and	O
genomic	B-UNK
DNA	I-UNK
from	O
members	B-UNK
of	O
a	O
family	B-UNK
affected	B-UNK
with	O
GGM	O
by	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
.	O

Sequence	B-UNK
analysis	I-UNK
of	O
the	O
amplified	O
products	B-UNK
has	O
revealed	B-UNK
a	O
single	B-UNK
missense	B-UNK
mutation	I-UNK
in	O
SGLT1	B-UNK
which	O
cosegregates	O
with	O
the	O
GGM	O
phenotype	B-UNK
and	O
results	B-UNK
in	O
a	O
complete	O
loss	B-UNK
of	O
Na	B-UNK
(	O
+	O
)	O
-dependent	O
glucose	B-UNK
transport	B-UNK
in	O
Xenopus	O
oocytes	O
injected	O
with	O
this	O
complementary	O
RNA	B-UNK
..	O

A	O
de	O
novo	O
unbalanced	O
reciprocal	O
translocation	B-UNK
identified	B-UNK
as	O
paternal	O
in	O
origin	O
in	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

Interstitial	O
cytogenetic	B-UNK
deletions	O
involving	O
the	O
paternally	O
derived	B-UNK
chromosome	B-UNK
15q11	B-UNK
-	O
13	O
have	O
been	O
described	O
in	O
patients	B-UNK
with	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

We	O
report	B-UNK
a	O
child	B-UNK
with	O
PWS	B-UNK
and	O
a	O
de	O
novo	O
unbalanced	O
karyotype-45	O
,	O
XY,-9,-15	O
,	O
+	O
der	B-UNK
(	O
9	O
)	O
t	O
(	O
9	O
;	O
15	O
)	O
(	O
q34	O
;	O
q13	B-UNK
)	O
.	O

Molecular	B-UNK
studies	B-UNK
with	O
the	O
DNA	B-UNK
probe	O
pML34	O
confirmed	B-UNK
that	O
only	O
a	O
single	B-UNK
Prader	B-UNK
Willi	I-UNK
critical	B-UNK
region	I-UNK
(	O
PWCR	O
15q11	B-UNK
.	O
2-q12	O
)	O
copy	B-UNK
was	O
present	B-UNK
.	O

Hybridisation	O
of	O
patient	B-UNK
and	O
parental	O
DNA	B-UNK
with	O
the	O
multi-allelic	O
probe	O
CMW1	O
,	O
which	O
maps	B-UNK
to	O
pter-15q13	O
,	O
showed	O
that	O
the	O
chromosome	B-UNK
involved	B-UNK
in	O
the	O
translocation	B-UNK
was	O
paternal	O
in	O
origin	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
paternally	O
-	O
derived	B-UNK
PWCR	O
allele	B-UNK
loss	B-UNK
caused	B-UNK
by	O
an	O
unbalanced	O
translocation	B-UNK
that	O
has	O
arisen	O
de	O
novo	O
.	O

Localisation	O
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
locus	B-UNK
to	O
19q13	O
.	O
2	O
-	O
19q13	O
.	O
3	O
and	O
its	O
relationship	B-UNK
to	O
twelve	O
polymorphic	B-UNK
loci	O
on	O
19q	O
.	O

The	O
order	B-UNK
of	O
fourteen	O
polymorphic	B-UNK
markers	I-UNK
localised	O
to	O
the	O
long	B-UNK
arm	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
19	O
has	O
been	O
established	O
by	O
multipoint	B-UNK
mapping	B-UNK
in	O
a	O
set	B-UNK
of	O
40	O
CEPH	O
(	O
Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain	O
,	O
Paris	O
)	O
reference	O
families	B-UNK
.	O

We	O
report	B-UNK
here	O
the	O
linkage	B-UNK
relationship	B-UNK
of	O
the	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
locus	B-UNK
to	O
twelve	O
of	O
these	O
markers	B-UNK
as	O
studied	O
in	O
45	O
families	B-UNK
with	O
DM	B-DISEASE
.	O

The	O
resulting	B-UNK
genetic	B-UNK
map	B-UNK
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	B-UNK
markers	I-UNK
in	O
a	O
panel	B-UNK
of	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
.	O

Ten	O
of	O
the	O
twelve	O
markers	B-UNK
have	O
been	O
shown	B-UNK
to	O
be	O
proximal	B-UNK
to	O
the	O
DM	B-UNK
gene	B-UNK
and	O
two	O
,	O
PRKCG	O
and	O
D19S22	O
,	O
distal	B-UNK
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	B-DISEASE
and	O
15	O
cM	B-DISEASE
,	O
respectively	O
.	O

The	O
closest	O
proximal	B-UNK
markers	B-UNK
are	O
APOC2	B-UNK
(	O
apolipoprotein	B-UNK
C	O
-	O
II	B-UNK
)	O
and	O
CKM	O
(	O
creatine	O
kinase	B-UNK
,	O
muscle	B-UNK
)	O
approximately	O
3	O
cM	B-DISEASE
and	O
2	O
cM	B-DISEASE
from	O
the	O
DM	B-UNK
gene	B-UNK
respectively	O
,	O
in	O
the	O
order	B-UNK
APOC2-CKM	O
-	O
DM	B-DISEASE
.	O

The	O
distance	O
between	O
APOC2	B-UNK
,	O
CKM	O
and	O
DM	B-UNK
(	O
of	O
the	O
order	B-UNK
of	O
2	O
million	O
base	B-UNK
pairs	B-UNK
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	B-UNK
walking	O
and	O
jumping	O
.	O

The	O
data	B-UNK
presented	B-UNK
here	O
should	O
enable	O
us	O
to	O
determine	B-UNK
whether	O
or	O
not	O
new	O
markers	B-UNK
are	O
distal	B-UNK
to	O
APOC2	B-UNK
/	O
CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	B-DISEASE
gene	B-UNK
..	O

Localization	B-UNK
of	O
histidase	O
to	O
human	B-UNK
chromosome	I-UNK
region	B-UNK
12q22	O
-	O
---q24	O
.	O
1	O
and	O
mouse	B-UNK
chromosome	I-UNK
region	B-UNK
10C2	O
-	O
---D1	O
.	O

The	O
human	B-UNK
gene	B-UNK
for	O
histidase	O
(	O
histidine	O
ammonia	O
-	O
lyase	O
;	O
HAL	O
)	O
,	O
the	O
enzyme	B-UNK
deficient	B-UNK
in	O
histidinemia	B-DISEASE
,	O
was	O
assigned	O
to	O
human	B-UNK
chromosome	I-UNK
12	O
by	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
of	O
human	B-UNK
X	O
mouse	B-UNK
somatic	B-UNK
cell	I-UNK
hybrid	O
DNA	B-UNK
.	O

The	O
gene	B-UNK
was	O
sublocalized	O
to	O
region	B-UNK
12q22	O
-	O
---q24	O
.	O

1	O
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
,	O
using	O
a	O
human	B-UNK
histidase	O
cDNA	O
.	O

The	O
homologous	B-UNK
locus	B-UNK
in	O
the	O
mouse	B-UNK
(	O
Hal	O
)	O
was	O
mapped	B-UNK
to	O
region	B-UNK
10C2	O
-	O
---D1	O
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
,	O
using	O
a	O
cell	B-UNK
line	I-UNK
from	O
a	O
mouse	B-UNK
homozygous	B-UNK
for	O
a	O
1	O
.	O

10	O
Robertsonian	O
translocation	B-UNK
.	O

These	O
assignments	O
extend	O
the	O
conserved	B-UNK
syntenic	O
region	B-UNK
between	O
human	B-UNK
chromosome	I-UNK
12	O
and	O
mouse	B-UNK
chromosome	I-UNK
10	O
that	O
includes	O
the	O
genes	B-UNK
for	O
phenylalanine	B-UNK
hydroxylase	I-UNK
,	O
gamma	B-UNK
interferon	O
,	O
peptidase	O
,	O
and	O
citrate	O
synthase	O
.	O

The	O
localization	B-UNK
of	O
histidase	O
to	O
mouse	B-UNK
chromosome	I-UNK
10	O
suggests	O
that	O
the	O
histidase	O
regulatory	O
locus	B-UNK
(	O
Hsd	O
)	O
and	O
the	O
histidinemia	B-DISEASE
mutation	B-UNK
(	O
his	O
)	O
,	O
which	O
are	O
both	O
known	O
to	O
be	O
on	O
chromosome	B-UNK
10	O
,	O
may	O
be	O
alleles	B-UNK
of	O
the	O
histidase	O
structural	B-UNK
gene	B-UNK
locus	B-UNK
.	O

Determination	B-UNK
of	O
the	O
mutations	B-UNK
responsible	B-UNK
for	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
in	O
17	O
subjects	B-UNK
.	O

Hypoxanthine	B-UNK
--	O
guanine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
is	O
a	O
purine	O
salvage	O
enzyme	B-UNK
that	O
catalyzes	O
the	O
conversion	O
of	O
hypoxanthine	B-UNK
to	O
inosine	O
monophosphate	O
and	O
guanine	B-UNK
to	O
guanosine	O
monophosphate	O
.	O

Previous	B-UNK
studies	B-UNK
of	O
mutant	B-UNK
HPRT	B-UNK
proteins	B-UNK
analyzed	B-UNK
at	O
the	O
molecular	B-UNK
level	B-UNK
have	O
shown	B-UNK
a	O
significant	B-UNK
heterogeneity	B-UNK
.	O

This	O
investigation	B-UNK
further	O
verifies	O
this	O
heterogeneity	B-UNK
and	O
identifies	O
insertions	O
,	O
deletions	O
,	O
and	O
point	B-UNK
mutations	I-UNK
.	O

The	O
direct	B-UNK
sequencing	I-UNK
of	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
amplified	O
product	B-UNK
of	O
reverse	B-UNK
-	O
transcribed	O
HPRT	B-UNK
mRNA	O
enabled	O
the	O
rapid	O
identification	B-UNK
of	O
the	O
mutations	B-UNK
found	O
in	O
17	O
previously	B-UNK
uncharacterized	O
cell	B-UNK
lines	I-UNK
derived	B-UNK
from	O
patients	B-UNK
with	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
..	O

Linkage	B-UNK
of	O
DNA	B-UNK
markers	I-UNK
at	O
Xq28	B-UNK
to	O
adrenoleukodystrophy	B-UNK
and	O
adrenomyeloneuropathy	O
present	B-UNK
within	O
the	O
same	O
family	B-UNK
.	O

We	O
present	B-UNK
a	O
large	B-UNK
kindred	O
that	O
contained	O
patients	B-UNK
with	O
either	O
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
or	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
.	O

The	O
pedigree	B-UNK
clearly	O
supported	O
the	O
X	O
-	O
linked	B-UNK
mode	O
of	O
inheritance	B-UNK
of	O
the	O
nonneonatal	O
form	B-UNK
of	O
ALD	B-UNK
/	O
AMN	B-UNK
.	O

Analysis	B-UNK
with	O
DNA	B-UNK
markers	I-UNK
at	O
Xq28	B-UNK
suggested	O
segregation	B-UNK
of	O
both	O
ALD	B-UNK
and	O
AMN	B-UNK
with	O
an	O
identical	B-UNK
haplotype	B-UNK
.	O

This	O
indicated	O
that	O
nonneonatal	O
ALD	B-UNK
and	O
AMN	B-UNK
are	O
caused	B-UNK
by	O
a	O
mutation	B-UNK
in	O
the	O
same	O
gene	B-UNK
at	O
Xq28	B-UNK
.	O

It	O
showed	O
,	O
furthermore	O
,	O
that	O
phenotypic	B-UNK
differences	B-UNK
between	O
ALD	B-UNK
and	O
AMN	B-UNK
are	O
not	O
necessarily	O
the	O
consequence	B-UNK
of	O
allelic	O
heterogeneity	B-UNK
due	O
to	O
different	O
mutations	B-UNK
within	O
the	O
same	O
gene	B-UNK
.	O

The	O
maximal	O
lod	B-UNK
score	I-UNK
for	O
linkage	B-UNK
of	O
the	O
ALD	B-UNK
/	O
AMN	B-UNK
gene	B-UNK
and	O
the	O
multiallelic	O
anonymous	O
DNA	B-UNK
marker	B-UNK
at	O
DXS52	O
was	O
3	O
.	O

0	O
at	O
a	O
recombination	B-UNK
fraction	B-UNK
of	O
0	O
.	O

00	O
.	O

This	O
made	O
a	O
prenatal	B-UNK
or	O
presymptomatic	O
diagnosis	B-UNK
and	O
heterozygote	B-UNK
detection	B-UNK
by	O
DNA	B-UNK
analysis	I-UNK
with	O
this	O
marker	B-UNK
reliable	O
.	O

Skewed	O
X	O
inactivation	B-UNK
in	O
a	O
female	O
MZ	O
twin	O
results	B-UNK
in	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

One	O
of	O
female	O
MZ	O
twins	O
presented	B-UNK
with	O
muscular	B-DISEASE
dystrophy	I-DISEASE
.	O

Physical	B-UNK
examination	B-UNK
,	O
creatine	O
phosphokinase	O
levels	B-UNK
,	O
and	O
muscle	B-UNK
biopsy	B-UNK
were	O
consistent	B-UNK
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

However	O
,	O
because	O
of	O
her	O
sex	B-UNK
she	O
was	O
diagnosed	O
as	O
having	O
limb	O
-	O
girdle	O
muscular	B-UNK
dystrophy	I-UNK
.	O

With	O
cDNA	O
probes	O
to	O
the	O
DMD	B-UNK
gene	B-UNK
,	O
a	O
gene	B-UNK
deletion	B-UNK
was	O
detected	B-UNK
in	O
the	O
twins	O
and	O
their	O
mother	O
.	O

The	O
de	O
novo	O
mutation	B-UNK
which	O
arose	O
in	O
the	O
mother	O
was	O
shown	B-UNK
by	O
novel	O
junction	O
fragments	O
generated	O
by	O
HindIII	O
,	O
PstI	O
,	O
or	O
TaqI	O
when	O
probed	O
with	O
cDNA8	O
.	O

Additional	O
evidence	B-UNK
of	O
a	O
large	B-UNK
gene	B-UNK
deletion	B-UNK
was	O
given	O
by	O
novel	O
SfiI	O
junction	O
fragments	O
detected	B-UNK
by	O
probes	O
p20	O
,	O
J	O
-	O
Bir	O
,	O
and	O
J-66	O
on	O
pulsed	O
-	O
field	B-UNK
gel	B-UNK
electrophoresis	I-UNK
(	O
PFGE	O
)	O
.	O

Immunoblot	O
analysis	B-UNK
of	O
muscle	B-UNK
from	O
the	O
affected	B-UNK
twin	O
showed	O
dystrophin	B-UNK
of	O
normal	B-UNK
size	B-UNK
but	O
of	O
reduced	O
amount	O
.	O

Immunofluorescent	O
visualization	O
of	O
dystrophin	B-UNK
revealed	B-UNK
foci	O
of	O
dystrophin	B-UNK
-	O
positive	O
fibers	O
adjacent	O
to	O
foci	O
of	O
dystrophin	B-UNK
-	O
negative	B-UNK
fibers	O
.	O

These	O
data	B-UNK
indicate	O
that	O
the	O
affected	B-UNK
twin	O
is	O
a	O
manifesting	O
carrier	B-UNK
of	O
an	O
abnormal	O
DMD	B-UNK
gene	B-UNK
,	O
her	O
myopathy	B-DISEASE
being	O
a	O
direct	B-UNK
result	B-UNK
of	O
underexpression	O
of	O
dystrophin	B-UNK
.	O

Cytogenetic	B-UNK
analysis	B-UNK
revealed	I-UNK
normal	B-UNK
karyotypes	O
,	O
eliminating	O
the	O
possibility	B-UNK
of	O
a	O
translocation	B-UNK
affecting	O
DMD	B-UNK
gene	B-UNK
function	B-UNK
.	O

Both	O
linkage	B-UNK
analysis	I-UNK
and	O
DNA	B-UNK
fingerprint	O
analysis	B-UNK
revealed	I-UNK
that	O
each	O
twin	O
has	O
two	O
different	O
X	O
chromosomes	O
,	O
eliminating	O
the	O
possibility	B-UNK
of	O
uniparental	B-UNK
disomy	I-UNK
as	O
a	O
mechanism	B-UNK
for	O
DMD	B-UNK
expression	B-UNK
.	O

On	O
the	O
basis	B-UNK
of	O
methylation	B-UNK
differences	B-UNK
of	O
the	O
paternal	O
and	O
maternal	O
X	O
chromosomes	O
in	O
these	O
MZ	O
twins	O
,	O
we	O
propose	O
uneven	O
lyonization	O
(	O
X	O
chromosome	B-UNK
inactivation	B-UNK
)	O
as	O
the	O
underlying	O
mechanism	B-UNK
for	O
disease	B-UNK
expression	B-UNK
in	O
the	O
affected	B-UNK
female	O
..	O

Adrenoleukodystrophy	B-UNK
and	O
adrenomyeloneuropathy	O
associated	O
with	O
partial	O
adrenal	B-DISEASE
insufficiency	I-DISEASE
in	O
three	O
generations	O
of	O
a	O
kindred	O
.	O

Four	O
cases	B-UNK
of	O
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
and	O
one	O
case	B-UNK
of	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
have	O
developed	O
in	O
a	O
kindred	O
over	O
three	O
generations	O
demonstrating	O
that	O
AMN	B-UNK
is	O
a	O
clinical	B-UNK
variant	O
of	O
ALD	B-UNK
.	O

Pituitary	O
-	O
adrenal	B-UNK
function	B-UNK
studies	B-UNK
were	O
performed	O
in	O
10	O
family	B-UNK
members	I-UNK
,	O
including	O
two	O
affected	B-UNK
males	I-UNK
and	O
four	O
females	O
identified	B-UNK
as	O
carriers	B-UNK
of	O
ALD	B-UNK
/	O
AMN	B-UNK
.	O

No	O
pituitary	O
-	O
adrenal	B-UNK
abnormality	O
was	O
found	O
in	O
the	O
carriers	B-UNK
.	O

However	O
,	O
basal	O
morning	O
plasma	O
adrenocorticotropic	O
hormone	B-UNK
(	O
ACTH	O
)	O
levels	B-UNK
were	O
markedly	B-UNK
elevated	B-UNK
in	O
the	O
two	O
males	B-UNK
with	O
ALD	B-UNK
and	O
AMN	B-UNK
,	O
despite	O
the	O
fact	B-UNK
that	O
they	O
had	O
no	O
clinical	B-UNK
signs	B-UNK
of	O
adrenal	B-DISEASE
insufficiency	I-DISEASE
and	O
that	O
morning	O
plasma	O
cortisol	O
levels	B-UNK
and	O
their	O
response	B-UNK
to	O
maximal	O
exogenous	O
ACTH	O
stimulation	O
appeared	B-UNK
to	O
be	O
normal	B-UNK
.	O

In	O
addition	B-UNK
,	O
the	O
integrated	O
24-hour	O
response	B-UNK
to	O
the	O
administration	O
were	O
also	O
subnormal	O
in	O
these	O
two	O
cases	B-UNK
.	O

Thus	O
,	O
people	O
with	O
ALD	B-UNK
and	O
AMN	B-UNK
may	O
have	O
subclinical	O
partial	O
adrenocrotical	O
insufficiency	B-DISEASE
.	O

No	O
other	O
endocrinologic	O
dysfunction	B-UNK
was	O
identified	B-UNK
..	O

Regional	O
localisation	O
of	O
the	O
Friedreich	B-UNK
ataxia	I-UNK
locus	B-UNK
to	O
human	B-UNK
chromosome	I-UNK
9q13	O
-	O
---q21	O
.	O
1	O
.	O

We	O
have	O
previously	B-UNK
assigned	O
the	O
Friedreich	B-UNK
ataxia	I-UNK
locus	B-UNK
(	O
FRDA	B-UNK
)	O
to	O
chromosome	B-UNK
9	O
;	O
the	O
current	B-UNK
maximal	O
lod	B-UNK
score	I-UNK
between	O
FRDA	B-UNK
and	O
MCT112	O
(	O
D9S15	O
)	O
is	O
greater	B-UNK
than	O
50	O
at	O
a	O
recombination	B-UNK
fraction	B-UNK
of	O
theta	B-UNK
=	O
0	O
.	O

The	O
physical	B-UNK
assignment	B-UNK
of	O
the	O
locus	B-UNK
defined	B-UNK
by	O
MCT112	O
,	O
and	O
hence	O
FRDA	B-UNK
,	O
has	O
not	O
been	O
determined	B-UNK
,	O
although	O
linkage	B-UNK
analysis	I-UNK
of	O
MCT112	O
with	O
other	O
chromosome	B-UNK
9	O
markers	B-UNK
inferred	O
a	O
location	B-UNK
close	B-UNK
to	O
the	O
centromere	O
.	O

We	O
have	O
used	O
in	O
situ	B-UNK
hybridisation	O
with	O
MCT112	O
,	O
a	O
corresponding	O
cosmid	O
MJ1	O
,	O
and	O
DR47	O
(	O
D9S5	O
)	O
,	O
coupled	O
with	O
mapping	B-UNK
studies	B-UNK
on	O
hybrid	O
cell	B-UNK
panels	O
,	O
to	O
define	B-UNK
more	O
precisely	O
the	O
location	B-UNK
of	O
the	O
disease	B-DISEASE
locus	B-UNK
.	O

The	O
in	O
situ	B-UNK
location	B-UNK
of	O
all	O
three	O
probes	O
is	O
9q13	O
-	O
---q21	O
.	O

1	O
,	O
distal	B-UNK
to	O
the	O
variable	B-UNK
heterochromatin	O
region	B-UNK
.	O

Physical	B-UNK
assignment	B-UNK
of	O
FRDA	B-UNK
will	O
allow	O
us	O
to	O
identify	B-UNK
hybrid	O
cell	B-UNK
lines	I-UNK
containing	O
the	O
mutated	B-UNK
gene	B-UNK
.	O

Increased	B-UNK
high	B-UNK
-	O
density	B-UNK
lipoprotein	B-UNK
levels	B-UNK
caused	B-UNK
by	O
a	O
common	B-UNK
cholesteryl	B-UNK
-	O
ester	O
transfer	B-UNK
protein	B-UNK
gene	B-UNK
mutation	B-UNK
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
plasma	O
cholesteryl	B-UNK
-	O
ester	O
transfer	B-UNK
protein	B-UNK
(	O
CETP	B-UNK
)	O
catalyzes	O
the	O
transfer	B-UNK
of	O
cholesteryl	B-UNK
esters	O
from	O
high	B-UNK
-	O
density	B-UNK
lipoprotein	B-UNK
(	O
HDL	B-UNK
)	O
to	O
other	O
lipoproteins	O
.	O

We	O
recently	O
described	O
a	O
Japanese	B-UNK
family	B-UNK
with	O
increased	B-UNK
HDL	B-UNK
levels	B-UNK
and	O
CETP	B-UNK
deficiency	I-UNK
due	O
to	O
a	O
splicing	B-UNK
defect	B-UNK
of	O
the	O
CETP	B-UNK
gene	B-UNK
.	O

To	O
assess	B-UNK
the	O
frequency	B-UNK
and	O
phenotype	B-UNK
of	O
this	O
condition	B-UNK
,	O
we	O
screened	B-UNK
11	O
additional	O
families	B-UNK
with	O
high	B-UNK
HDL	B-UNK
levels	B-UNK
by	O
means	B-UNK
of	O
a	O
radioimmunoassay	O
for	O
CETP	B-UNK
and	O
DNA	B-UNK
analysis	I-UNK
.	O

RESULTS	B-UNK
.	O

We	O
found	O
the	O
same	O
CETP	B-UNK
gene	B-UNK
mutation	B-UNK
in	O
four	O
families	B-UNK
from	O
three	O
different	O
regions	B-UNK
of	O
Japan	B-UNK
.	O

Analysis	B-UNK
of	O
restriction	B-UNK
-	O
fragment	B-UNK
-	O
length	B-UNK
polymorphisms	B-UNK
of	O
the	O
mutant	B-UNK
CETP	B-UNK
allele	B-UNK
showed	O
that	O
all	O
probands	O
were	O
homozygous	B-UNK
for	O
the	O
identical	B-UNK
haplotype	B-UNK
.	O

Family	B-UNK
members	I-UNK
homozygous	B-UNK
for	O
CETP	B-UNK
deficiency	I-UNK
(	O
n	O
=	O
10	O
)	O
had	O
moderate	B-UNK
hypercholesterolemia	B-DISEASE
(	O
mean	O
total	B-UNK
cholesterol	B-UNK
level	B-UNK
[	O
+	O
/-SD	O
]	O
,	O
7	O
.	O
01	O
+	O
/-0	O
.	O
83	O
mmol	O
per	O
liter	O
)	O
,	O
markedly	B-UNK
increased	B-UNK
levels	B-UNK
of	O
HDL	B-UNK
cholesterol	I-UNK
(	O
4	O
.	O
24	O
+	O
/-1	O
.	O
01	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	B-UNK
A	O
-	O
I	O
,	O
and	O
decreased	B-UNK
levels	B-UNK
of	O
low	B-UNK
-	O
density	B-UNK
lipoprotein	B-UNK
cholesterol	B-UNK
(	O
1	O
.	O
99	O
+	O
/-0	O
.	O
80	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	B-UNK
B.	O

Members	B-UNK
heterozygous	B-UNK
for	O
the	O
deficiency	B-UNK
(	O
n	O
=	O
20	O
)	O
,	O
whose	O
CETP	B-UNK
levels	B-UNK
were	O
in	O
the	O
lower	O
part	O
of	O
the	O
normal	B-UNK
range	B-UNK
,	O
had	O
moderately	O
increased	B-UNK
levels	B-UNK
of	O
HDL	B-UNK
cholesterol	I-UNK
and	O
apolipoprotein	B-UNK
A	O
-	O
I	O
and	O
an	O
increased	B-UNK
ratio	B-UNK
of	O
HDL	B-UNK
subclass	O
2	O
to	O
HDL	B-UNK
subclass	O
3	O
,	O
as	O
compared	B-UNK
with	O
unaffected	O
family	B-UNK
members	I-UNK
(	O
1	O
.	O
5	O
+	O
/-0	O
.	O
8	O
vs	O
.	O
0	O
.	O
7	O
+	O
/-0	O
.	O
4	O
)	O
.	O

CETP	B-UNK
deficiency	I-UNK
was	O
not	O
found	O
in	O
six	O
unrelated	B-UNK
subjects	B-UNK
with	O
elevated	B-UNK
HDL	B-UNK
cholesterol	I-UNK
levels	B-UNK
who	O
were	O
from	O
different	O
parts	O
of	O
the	O
United	O
States	O
.	O

CONCLUSIONS	B-UNK
.	O

CETP	B-UNK
deficiency	I-UNK
appears	B-UNK
to	O
be	O
a	O
frequent	B-UNK
cause	O
of	O
increased	B-UNK
HDL	B-UNK
levels	B-UNK
in	O
the	O
population	B-UNK
of	O
Japan	B-UNK
,	O
possibly	O
because	O
of	O
a	O
founder	B-UNK
effect	I-UNK
.	O

The	O
results	B-UNK
that	O
we	O
observed	B-UNK
in	O
heterozygotes	B-UNK
suggest	B-UNK
that	O
CETP	B-UNK
normally	O
plays	O
a	O
part	O
in	O
the	O
regulation	B-UNK
of	O
levels	B-UNK
of	O
HDL	B-UNK
subclass	O
2	O
.	O

There	O
was	O
no	O
evidence	B-UNK
of	O
premature	B-DISEASE
atherosclerosis	I-DISEASE
in	O
the	O
families	B-UNK
with	O
CETP	B-UNK
deficiency	I-UNK
.	O

In	O
fact	B-UNK
,	O
the	O
lipoprotein	B-UNK
profile	O
of	O
persons	O
with	O
CETP	B-UNK
deficiency	I-UNK
is	O
potentially	O
antiatherogenic	O
and	O
may	O
be	O
associated	O
with	O
an	O
increased	B-UNK
life	B-UNK
span	O
.	O

Further	O
mapping	B-UNK
of	O
an	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
locus	B-UNK
to	O
the	O
chromosome	B-UNK
11q23	O
region	B-UNK
.	O

We	O
recently	O
mapped	B-UNK
the	O
gene	B-UNK
for	O
ataxia	B-UNK
-	O
telangiectasia	B-DISEASE
group	B-UNK
A	O
(	O
ATA	O
)	O
to	O
chromosome	B-UNK
11q22	O
-	O
23	O
by	O
linkage	B-UNK
analysis	I-UNK
,	O
using	O
the	O
genetic	B-UNK
markers	B-UNK
THY1	O
and	O
pYNB3	O
.	O

12	O
(	O
D11S144	O
)	O
.	O

The	O
most	O
likely	O
order	B-UNK
was	O
cent	O
-	O
AT	O
-	O
S144-THY1	O
.	O

The	O
present	B-UNK
paper	O
describes	O
further	O
mapping	B-UNK
of	O
the	O
AT	O
locus	B-UNK
by	O
means	B-UNK
of	O
a	O
panel	B-UNK
of	O
10	O
markers	B-UNK
that	O
span	O
approximately	O
60	O
cM	B-DISEASE
in	O
the	O
11q22	O
-	O
23	O
region	B-UNK
centered	O
around	O
S144	O
and	O
THY1	O
.	O

Location	B-UNK
scores	B-UNK
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[	O
S144-THY1	O
]	O
segment	O
,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
THY1	O
,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
AT	O
locus	B-UNK
,	O
while	O
the	O
more	O
centromeric	O
[	O
STMY	O
-	O
S144	O
]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
AT	O
locus	B-UNK
.	O

These	O
data	B-UNK
,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	B-UNK
and	O
physical	B-UNK
maps	B-UNK
of	O
11q22	O
-	O
23	O
,	O
place	O
the	O
AT	O
locus	B-UNK
at	O
11q23	O
.	O

Recurrent	O
meningitis	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
congenital	B-UNK
deficiency	B-UNK
of	O
the	O
C9	B-UNK
component	B-UNK
of	I-UNK
complement	I-UNK
.	O

First	O
case	B-UNK
of	O
C9	B-UNK
deficiency	I-UNK
in	O
Europe	B-UNK
.	O

We	O
describe	O
the	O
first	O
cases	B-UNK
,	O
to	O
our	O
knowledge	B-UNK
,	O
of	O
C9	B-UNK
deficiency	I-UNK
in	O
Europe	B-UNK
that	O
were	O
detected	B-UNK
in	O
a	O
Swiss	O
family	B-UNK
,	O
of	O
which	O
two	O
members	B-UNK
--	O
one	O
with	O
a	O
complete	O
deficiency	B-UNK
and	O
the	O
other	O
with	O
approximately	O
half	B-UNK
-	O
normal	B-UNK
C9	B-UNK
levels	B-UNK
--	O
experienced	O
bacterial	B-UNK
meningitis	B-DISEASE
.	O

The	O
index	O
patient	B-UNK
,	O
a	O
56-year	O
-	O
old	O
white	B-UNK
man	B-UNK
with	O
a	O
history	B-UNK
of	O
purulent	O
meningitis	B-DISEASE
at	O
the	O
age	B-UNK
of	O
23	O
years	O
,	O
presented	B-UNK
with	O
an	O
acute	B-UNK
meningococcal	B-UNK
meningitis	B-DISEASE
.	O

No	O
impairment	B-UNK
of	O
cellular	O
immunity	O
or	O
immunoglobulin	O
deficiency	B-UNK
could	O
be	O
found	O
.	O

Complement	B-UNK
assays	O
showed	O
a	O
complete	O
deficiency	B-UNK
of	O
the	O
C9	B-UNK
component	B-UNK
,	O
while	O
the	O
other	O
individual	O
component	B-UNK
levels	B-UNK
were	O
normal	B-UNK
and	O
the	O
hemolytic	B-DISEASE
activity	B-UNK
(	O
measured	O
using	O
the	O
CH50	O
assay	B-UNK
)	O
was	O
only	O
slightly	O
reduced	O
.	O

A	O
family	B-UNK
study	B-UNK
revealed	B-UNK
complete	O
C9	B-UNK
deficiency	I-UNK
in	O
the	O
patients	B-UNK
healthy	O
brother	B-UNK
and	O
half	B-UNK
-	O
normal	B-UNK
C9	B-UNK
concentrations	O
in	O
his	O
sister	O
,	O
his	O
son	O
(	O
who	O
also	O
had	O
experienced	O
an	O
episode	O
of	O
bacterial	B-UNK
meningitis	B-DISEASE
)	O
,	O
and	O
his	O
niece	O
,	O
consistent	B-UNK
with	O
an	O
inherited	B-UNK
C9	B-UNK
deficiency	I-UNK
.	O

This	O
first	O
case	B-UNK
of	O
recurrent	O
meningitis	B-DISEASE
in	O
a	O
white	B-UNK
patient	B-UNK
with	O
complete	O
C9	B-UNK
deficiency	I-UNK
suggests	O
that	O
this	O
complement	B-UNK
defect	B-UNK
may	O
also	O
be	O
a	O
risk	B-UNK
factor	B-UNK
for	O
bacterial	B-UNK
,	O
especially	O
neisserial	O
,	O
infections	B-DISEASE
..	O

Detection	B-UNK
of	O
98	O
%	O
of	O
DMD	B-UNK
/	O
BMD	B-UNK
gene	B-UNK
deletions	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
.	O

We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	B-UNK
promoter	O
of	O
the	O
dystrophin	B-UNK
gene	I-UNK
in	O
a	O
single	B-UNK
multiplex	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
.	O

When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	B-UNK
,	O
these	O
two	O
multiplex	O
reactions	O
detect	B-UNK
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	B-UNK
with	O
Duchenne	B-UNK
or	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
,	O
BMD	B-UNK
)	O
.	O

Furthermore	O
,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	B-UNK
prone	O
"	O
hot	O
spot	O
"	O
region	B-UNK
around	O
exons	O
44	O
to	O
53	O
,	O
allowing	O
determination	B-UNK
of	O
deletion	B-UNK
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	B-UNK
on	O
the	O
translational	O
reading	B-UNK
frame	I-UNK
.	O

Thus	O
,	O
use	O
of	O
these	O
PCR	B-UNK
-	O
based	B-UNK
assays	O
will	O
allow	O
deletion	B-UNK
detection	B-UNK
and	O
prenatal	B-UNK
diagnosis	I-UNK
for	O
most	O
DMD	B-UNK
/	O
BMD	B-UNK
patients	B-UNK
in	O
a	O
fraction	B-UNK
of	O
the	O
time	O
required	B-UNK
for	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
..	O

Genetic	B-UNK
heterogeneity	I-UNK
at	O
the	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
locus	B-UNK
in	O
southern	B-UNK
Italy	O
:	O
a	O
study	B-UNK
on	O
a	O
population	B-UNK
from	O
the	O
Matera	O
district	O
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
has	O
been	O
analyzed	B-UNK
by	O
gel	B-UNK
electrophoresis	I-UNK
and	O
by	O
quantitative	B-UNK
assay	B-UNK
in	O
an	O
unselected	O
sample	O
of	O
1524	O
schoolboys	O
from	O
the	O
province	O
of	O
Matera	O
(	O
Lucania	O
)	O
in	O
southern	B-UNK
Italy	O
.	O

We	O
have	O
identified	B-UNK
43	O
subjects	B-UNK
with	O
a	O
G6PD	B-UNK
variant	O
.	O

Of	O
these	O
,	O
31	O
had	O
severe	B-UNK
G6PD	B-UNK
deficiency	I-UNK
,	O
nine	O
had	O
mild	O
to	O
moderate	B-UNK
deficiency	B-UNK
,	O
and	O
three	O
had	O
a	O
non-deficient	O
electrophoretic	B-UNK
variant	O
.	O

The	O
overall	O
rate	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
was	O
2	O
.	O

6	O
%	O
.	O

The	O
frequency	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
,	O
ranging	O
from	O
7	O
.	O

2	O
%	O
on	O
the	O
Ionian	O
Coast	O
to	O
zero	O
on	O
the	O
eastern	B-UNK
side	O
of	O
the	O
Lucanian	O
Apennines	O
,	O
appears	B-UNK
to	O
be	O
inversely	O
related	B-UNK
to	O
the	O
distance	O
of	O
each	O
town	O
examined	O
from	O
the	O
Ionian	O
Coast	O
,	O
suggesting	O
that	O
this	O
geographic	O
distribution	B-UNK
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
gene	B-UNK
flow	O
from	O
Greek	O
settlers	O
.	O

Biochemical	O
characterization	B-UNK
has	O
shown	B-UNK
that	O
most	O
of	O
the	O
G6PD	B-UNK
deficiency	I-UNK
in	O
this	O
population	B-UNK
is	O
accounted	O
for	O
by	O
G6PD	B-UNK
Mediterranean	I-UNK
.	O

In	O
addition	B-UNK
,	O
we	O
have	O
found	O
several	O
examples	O
of	O
two	O
other	O
known	O
polymorphic	B-UNK
variants	B-UNK
(	O
G6PD	B-UNK
Cagliari	O
and	O
G6PD	B-UNK
A-	O
)	O
;	O
three	O
new	O
polymorphic	B-UNK
variants	B-UNK
,	O
G6PD	B-UNK
Metaponto	O
(	O
class	O
III	B-UNK
)	O
,	O
G6PD	B-UNK
Montalbano	O
(	O
class	O
III	B-UNK
)	O
,	O
and	O
G6PD	B-UNK
Pisticci	O
(	O
class	O
IV	O
)	O
;	O
and	O
two	O
sporadic	B-UNK
variants	B-UNK
,	O
G6PD	B-UNK
Tursi	O
(	O
class	O
III	B-UNK
)	O
and	O
G6PD	B-UNK
Ferrandina	O
(	O
class	O
II	B-UNK
)	O
.	O

These	O
data	B-UNK
provide	B-UNK
further	O
evidence	B-UNK
for	O
the	O
marked	B-UNK
genetic	B-UNK
heterogeneity	I-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
within	O
a	O
relatively	O
narrow	O
geographic	O
area	B-UNK
and	O
they	O
prove	O
the	O
presence	O
in	O
the	O
Italian	B-UNK
peninsula	O
of	O
a	O
gene	B-UNK
(	O
GdA-	O
)	O
regarded	O
as	O
characteristically	O
African	B-UNK
.	O

Deficiency	B-UNK
of	O
the	O
murine	O
fifth	O
complement	B-UNK
component	B-UNK
(	O
C5	B-UNK
)	O
.	O

A	O
2-base	O
pair	B-UNK
gene	B-UNK
deletion	B-UNK
in	O
a	O
5	O
'	O
-exon	O
.	O

To	O
ascertain	O
the	O
molecular	B-UNK
mechanism	B-UNK
that	O
causes	O
murine	O
C5	B-UNK
deficiency	B-UNK
,	O
genomic	B-UNK
and	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
mouse	B-UNK
liver	B-UNK
DNA	B-UNK
and	O
mRNA	O
employing	O
the	O
congenic	O
strains	O
B10	O
.	O

D2	B-UNK
/	O
nSnJ	O
and	O
B10	O
.	O

D2	B-UNK
/	O
oSnJ	O
that	O
are	O
sufficient	O
and	O
deficient	B-UNK
for	O
C5	B-UNK
,	O
respectively	O
.	O

Genomic	B-UNK
fragments	O
were	O
isolated	B-UNK
which	O
correspond	O
to	O
PvuII	O
and	O
HindIII	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
associated	O
with	O
C5	B-UNK
deficiency	B-UNK
.	O

Sequence	B-UNK
analyses	O
demonstrated	O
that	O
each	O
of	O
these	O
polymorphisms	B-UNK
resulted	B-UNK
from	O
single	B-UNK
base	I-UNK
pair	B-UNK
substitutions	B-UNK
and	O
that	O
neither	O
substitution	B-UNK
would	O
probably	O
cause	O
or	O
contribute	B-UNK
to	O
the	O
C5	B-UNK
deficiency	B-UNK
.	O

Sequence	B-UNK
analyses	O
of	O
C5	B-UNK
sufficient	O
and	O
deficient	B-UNK
cDNAs	O
revealed	B-UNK
a	O
2	O
base	B-UNK
-	O
pair	B-UNK
deletion	B-UNK
in	O
the	O
deficient	B-UNK
cDNAs	O
.	O

The	O
"	O
TA	O
"	O
deletion	B-UNK
was	O
located	B-UNK
near	O
the	O
5	O
end	B-UNK
of	O
the	O
cDNA	O
.	O

This	O
deletion	B-UNK
shifts	O
the	O
reading	B-UNK
frame	I-UNK
of	O
the	O
C5	B-UNK
mRNA	O
so	O
that	O
the	O
termination	B-UNK
codon	I-UNK
UGA	O
is	O
present	B-UNK
4	O
base	B-UNK
pairs	B-UNK
downstream	O
from	O
the	O
deletion	B-UNK
.	O

Genomic	B-UNK
DNA	I-UNK
was	O
amplified	O
and	O
sequenced	O
corresponding	O
to	O
the	O
area	B-UNK
surrounding	O
the	O
2-base	O
pair	B-UNK
deletion	B-UNK
.	O

Six	O
C5-deficient	O
strains	O
,	O
A	O
/	O
HeJ	O
,	O
AKR	O
/	O
J	O
,	O
DBA/2J	O
,	O
NZB	O
/	O
B1NJ	O
,	O
SWR	O
/	O
J	O
,	O
and	O
B10	O
.	O

D2	B-UNK
/	O
oSnJ	O
,	O
and	O
four	O
C5-sufficient	O
strains	O
,	O
Balb	O
/	O
CJ	O
,	O
C57Bl/6J	O
,	O
DBA/1J	O
,	O
and	O
B10	O
.	O

D2	B-UNK
/	O
nSnJ	O
,	O
were	O
analyzed	B-UNK
.	O

The	O
sequencing	B-UNK
data	B-UNK
revealed	B-UNK
that	O
the	O
2	O
base	B-UNK
pairs	B-UNK
were	O
deleted	B-UNK
from	O
the	O
C5	B-UNK
gene	B-UNK
of	O
each	O
deficient	B-UNK
mouse	B-UNK
tested	O
but	O
not	O
from	O
the	O
C5	B-UNK
gene	B-UNK
of	O
any	O
sufficient	O
mouse	B-UNK
.	O

These	O
data	B-UNK
demonstrate	B-UNK
that	O
1	O
)	O
there	O
is	O
an	O
identical	B-UNK
2-base	O
pair	B-UNK
deletion	B-UNK
in	O
an	O
exon	B-UNK
of	O
the	O
C5	B-UNK
gene	B-UNK
in	O
several	O
different	O
C5-deficient	O
mouse	B-UNK
strains	O
;	O
2	O
)	O
the	O
mRNA	O
transcribed	O
from	O
the	O
C5D	O
gene	B-UNK
retains	O
this	O
deletion	B-UNK
;	O
and	O
3	O
)	O
this	O
mutation	B-UNK
should	O
result	B-UNK
in	O
C5	B-UNK
protein	B-DISEASE
deficiency	I-DISEASE
.	O

Molecular	B-UNK
genetics	B-UNK
of	O
PKU	B-UNK
in	O
eastern	B-UNK
Europe	B-UNK
:	O
a	O
nonsense	B-UNK
mutation	I-UNK
associated	O
with	O
haplotype	B-UNK
4	O
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
a	O
genetic	B-UNK
disorder	I-UNK
secondary	O
to	O
a	O
deficiency	B-UNK
of	O
hepatic	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

Several	O
mutations	B-UNK
in	O
the	O
PAH	B-UNK
gene	B-UNK
have	O
recently	O
been	O
reported	B-UNK
,	O
and	O
linkage	B-UNK
disequilibrium	I-UNK
was	O
observed	B-UNK
between	O
RFLP	B-UNK
haplotypes	O
and	O
specific	B-UNK
mutations	B-UNK
.	O

A	O
new	O
molecular	B-UNK
lesion	O
has	O
been	O
identified	B-UNK
in	O
exon	B-UNK
7	O
of	O
the	O
PAH	B-UNK
gene	B-UNK
in	O
a	O
Hungarian	O
PKU	B-UNK
patient	B-UNK
by	O
direct	B-UNK
sequencing	I-UNK
of	O
PCR	B-UNK
-	O
amplified	O
DNA	B-UNK
.	O

The	O
C	O
-	O
to	O
-T	O
transition	B-UNK
causes	O
the	O
substitution	B-UNK
of	O
Arg243	O
to	O
a	O
termination	B-UNK
codon	I-UNK
,	O
and	O
the	O
mutant	B-UNK
allele	B-UNK
is	O
associated	O
with	O
haplotype	B-UNK
4	O
of	O
the	O
PAH	B-UNK
gene	B-UNK
.	O

The	O
mutation	B-UNK
is	O
present	B-UNK
in	O
two	O
of	O
nine	O
mutant	B-UNK
haplotype	B-UNK
4	O
alleles	B-UNK
among	O
Eastern	B-UNK
Europeans	O
and	O
is	O
not	O
present	B-UNK
among	O
Western	B-UNK
Europeans	O
and	O
Asians	O
.	O

The	O
rarity	O
of	O
this	O
mutant	B-UNK
allele	B-UNK
and	O
its	O
restricted	O
geographic	O
distribution	B-UNK
suggest	B-UNK
that	O
the	O
mutational	O
event	O
occurred	B-UNK
recently	O
on	O
a	O
normal	B-UNK
haplotype	B-UNK
4	O
background	O
in	O
Eastern	B-UNK
Europe	B-UNK
..	O

The	O
red	B-UNK
-	O
green	O
visual	B-UNK
pigment	B-UNK
gene	B-UNK
region	B-UNK
in	O
adrenoleukodystrophy	B-UNK
.	O

Although	O
recent	O
data	B-UNK
established	O
that	O
a	O
specific	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acyl	B-UNK
-	O
CoA	B-UNK
synthetase	O
is	O
defective	O
in	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
(	O
ALD	B-UNK
)	O
,	O
the	O
ALD	B-UNK
gene	B-UNK
is	O
still	O
unidentified	O
.	O

The	O
ALD	B-UNK
locus	B-UNK
has	O
been	O
mapped	B-UNK
to	O
Xq28	B-UNK
,	O
like	O
the	O
red	B-UNK
and	O
green	O
color	B-UNK
pigment	B-UNK
genes	B-UNK
.	O

Abnormal	O
color	B-UNK
vision	I-UNK
has	O
been	O
observed	B-UNK
in	O
12	O
of	O
27	O
patients	B-UNK
with	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
,	O
a	O
milder	B-UNK
form	B-UNK
of	O
ALD	B-UNK
.	O

Furthermore	O
,	O
rearrangements	O
of	O
the	O
color	B-UNK
vision	I-UNK
gene	B-UNK
cluster	B-UNK
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	B-UNK
kindreds	O
.	O

This	O
led	B-UNK
us	O
to	O
propose	O
that	O
a	O
single	B-UNK
DNA	B-UNK
rearrangement	B-UNK
could	O
underlie	O
both	O
ALD	B-UNK
and	O
abnormal	O
color	B-UNK
vision	I-UNK
in	O
these	O
patients	B-UNK
.	O

Study	B-UNK
of	O
34	O
French	B-UNK
ALD	B-UNK
patients	B-UNK
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	B-UNK
of	O
green	O
/	O
red	B-UNK
visual	B-UNK
pigment	B-UNK
rearrangements	O
3	O
to	O
the	O
red	B-UNK
/	O
green	O
color	B-UNK
vision	I-UNK
gene	B-UNK
complex	O
.	O

The	O
previous	B-UNK
report	B-UNK
of	O
such	O
rearrangements	O
was	O
based	B-UNK
on	O
small	O
numbers	O
and	O
lack	B-UNK
of	O
knowledge	B-UNK
that	O
the	O
frequency	B-UNK
of	O
"	O
abnormal	O
"	O
color	B-UNK
vision	I-UNK
arrays	O
on	O
molecular	B-UNK
analysis	I-UNK
was	O
twice	O
as	O
high	B-UNK
as	O
expected	O
on	O
the	O
basis	B-UNK
of	O
the	O
frequency	B-UNK
of	O
phenotypic	B-UNK
color	B-DISEASE
vision	I-DISEASE
defects	I-DISEASE
.	O

The	O
red	B-UNK
/	O
green	O
color	B-UNK
pigment	B-UNK
(	O
R	O
/	O
GCP	O
)	O
region	B-UNK
was	O
studied	O
by	O
pulsed	O
-	O
field	B-UNK
gel	B-UNK
electrophoresis	I-UNK
in	O
14	O
of	O
these	O
patients	B-UNK
,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	B-UNK
size	B-UNK
difference	O
between	O
the	O
patients	B-UNK
and	O
normal	B-UNK
individuals	B-UNK
who	O
have	O
the	O
same	O
number	B-UNK
of	O
pigment	B-UNK
genes	B-UNK
.	O

The	O
R	O
/	O
GCP	O
region	B-UNK
was	O
also	O
analyzed	B-UNK
in	O
29	O
French	B-UNK
and	O
seven	O
North	B-UNK
American	B-UNK
ALD	B-UNK
patients	B-UNK
by	O
using	O
six	O
genomic	B-UNK
DNA	I-UNK
probes	O
,	O
isolated	B-UNK
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	B-UNK
vision	I-UNK
genes	B-UNK
.	O

No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	B-UNK
genes	B-UNK
.	O

One	O
of	O
the	O
eight	O
previously	B-UNK
reported	I-UNK
ALD	B-UNK
individuals	B-UNK
has	O
a	O
long	B-UNK
deletion	B-UNK
5	O
of	O
the	O
red	B-UNK
pigment	B-UNK
gene	B-UNK
,	O
a	O
deletion	B-UNK
causing	B-UNK
blue	O
cone	O
monochromacy	O
.	O

This	O
finding	O
and	O
the	O
previous	B-UNK
findings	B-UNK
of	O
a	O
45	O
%	O
frequency	B-UNK
of	O
phenotypic	B-UNK
color	B-DISEASE
vision	I-DISEASE
defects	I-DISEASE
in	O
patients	B-UNK
with	O
AMN	B-UNK
may	O
suggest	B-UNK
that	O
the	O
ALD	B-UNK
/	O
AMN	B-UNK
gene	B-UNK
lies	O
5	O
to	O
the	O
red	B-UNK
pigment	B-UNK
gene	B-UNK
and	O
that	O
the	O
frequent	B-UNK
phenotypic	B-UNK
color	B-UNK
vision	I-UNK
anomalies	B-UNK
owe	O
their	O
origin	O
to	O
deleted	B-UNK
DNA	B-UNK
that	O
includes	O
regulatory	O
genes	B-UNK
for	O
color	B-UNK
vision	I-UNK
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	B-UNK
color	B-UNK
vision	I-UNK
anomalies	B-UNK
in	O
AMN	B-UNK
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	B-UNK
or	O
neural	O
involvement	B-UNK
by	O
the	O
disease	B-DISEASE
.	O

The	O
single	B-UNK
case	B-UNK
of	O
blue	O
cone	O
monochromacy	O
may	O
therefore	O
be	O
a	O
fortuitous	O
coincidence	O
of	O
two	O
diseases	B-UNK
..	O

Paroxysmal	O
nocturnal	O
haemoglobinuria	O
with	O
coexisting	O
deficiency	B-UNK
of	O
the	O
ninth	O
component	B-UNK
of	I-UNK
complement	I-UNK
:	O
lack	B-UNK
of	O
massive	O
haemolytic	O
attack	O
.	O

A	O
47-year	O
-	O
old	O
woman	O
with	O
paroxysmal	O
nocturnal	O
haemoglobinuria	O
(	O
PNH	O
)	O
was	O
found	O
to	O
have	O
an	O
inherited	B-UNK
deficiency	B-UNK
in	O
the	O
ninth	O
complement	B-UNK
component	B-UNK
(	O
C9	B-UNK
)	O
.	O

In	O
complement	B-UNK
-	O
sensitivity	O
lysis	O
tests	O
,	O
80	O
%	O
of	O
her	O
erythrocytes	O
were	O
markedly	B-UNK
complement	B-UNK
-	O
sensitive	B-UNK
(	O
PNH	O
-	O
III	B-UNK
)	O
.	O

Laser	O
cytofluorimetry	O
with	O
a	O
monoclonal	O
antibody	B-UNK
against	O
decay	O
-	O
accelerating	O
factor	B-UNK
(	O
DAF	O
)	O
revealed	B-UNK
that	O
95	O
%	O
of	O
her	O
erythrocytes	O
were	O
DAF	O
-	O
negative	B-UNK
.	O

Surprisingly	O
,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	B-DISEASE
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	B-DISEASE
.	O

Gross	O
haemoglobinuria	O
and	O
jaundice	B-DISEASE
occurred	B-UNK
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood	B-UNK
.	O

In	O
her	O
serum	B-UNK
,	O
C9	B-UNK
was	O
not	O
detectable	O
either	O
by	O
immunological	O
or	O
by	O
functional	O
assays	O
.	O

Both	O
the	O
Ham	O
test	B-UNK
and	O
the	O
sugar	O
water	O
test	B-UNK
using	O
normal	B-UNK
human	B-UNK
serum	B-UNK
or	O
plasma	O
yielded	O
marked	B-UNK
haemolysis	B-DISEASE
of	O
the	O
patients	B-UNK
erythrocytes	O
.	O

When	O
the	O
patients	B-UNK
serum	B-UNK
or	O
plasma	O
was	O
used	O
,	O
only	O
a	O
trace	O
of	O
lysis	O
was	O
detected	B-UNK
.	O

Addition	B-UNK
of	O
purified	O
human	B-UNK
C9	B-UNK
to	O
her	O
plasma	O
fully	O
restored	O
haemolysis	B-DISEASE
.	O

These	O
observations	B-UNK
indicated	O
that	O
C9	B-UNK
may	O
play	O
a	O
critical	B-UNK
role	B-UNK
in	O
haemolytic	O
attacks	O
in	O
patients	B-UNK
with	O
PNH	O
and	O
that	O
characteristic	B-UNK
haemolysis	B-DISEASE
in	O
PNH	O
may	O
be	O
tempered	O
by	O
coexisting	O
C9	B-UNK
deficiency	I-UNK
..	O

Duplicational	O
mutation	B-UNK
at	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
locus	B-UNK
:	O
its	O
frequency	B-UNK
,	O
distribution	B-UNK
,	O
origin	O
,	O
and	O
phenotypegenotype	O
correlation	B-UNK
.	O

Partial	O
gene	B-UNK
deletion	B-UNK
is	O
the	O
major	B-UNK
cause	O
of	O
mutation	B-UNK
leading	B-UNK
to	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
BMD	B-UNK
)	O
.	O

Partial	O
gene	B-UNK
duplication	B-UNK
has	O
also	O
been	O
recognized	O
in	O
a	O
few	O
cases	B-UNK
.	O

We	O
have	O
conducted	O
a	O
survey	O
for	O
duplication	B-UNK
in	O
72	O
unrelated	B-UNK
nondeletion	O
patients	B-UNK
,	O
analyzed	B-UNK
by	O
Southern	B-UNK
blot	I-UNK
hybridization	B-UNK
with	O
clones	O
representing	O
the	O
entire	O
DMD	B-UNK
cDNA	O
.	O

With	O
careful	O
quantitative	B-UNK
analysis	B-UNK
of	O
hybridization	B-UNK
band	O
intensity	O
,	O
10	O
cases	B-UNK
were	O
found	O
to	O
carry	B-UNK
a	O
duplication	B-UNK
of	O
part	O
of	O
the	O
gene	B-UNK
,	O
a	O
frequency	B-UNK
of	O
14	O
%	O
for	O
nondeletion	O
cases	B-UNK
(	O
10/72	O
)	O
,	O
or	O
6	O
%	O
for	O
all	O
cases	B-UNK
(	O
10/181	O
)	O
.	O

The	O
extent	O
of	O
these	O
duplications	O
has	O
been	O
characterized	B-UNK
according	O
to	O
the	O
published	O
exon	B-UNK
-	O
containing	O
HindIII	O
fragment	B-UNK
map	B-UNK
,	O
and	O
in	O
six	O
of	O
the	O
10	O
duplications	O
a	O
novel	O
restriction	B-UNK
fragment	I-UNK
that	O
spanned	O
the	O
duplication	B-UNK
junction	O
was	O
detected	B-UNK
.	O

The	O
resulting	B-UNK
translational	O
reading	B-UNK
frame	I-UNK
of	O
mRNA	O
has	O
been	O
predicted	B-UNK
for	O
nine	O
duplications	O
.	O

A	O
shift	O
of	O
the	O
reading	B-UNK
frame	I-UNK
was	O
predicted	B-UNK
in	O
four	O
of	O
the	O
six	O
DMD	B-UNK
cases	B-UNK
and	O
in	O
one	O
of	O
the	O
two	O
intermediate	O
cases	B-UNK
,	O
while	O
the	O
reading	B-UNK
frame	I-UNK
remained	O
uninterrupted	O
in	O
both	O
BMD	B-UNK
cases	B-UNK
.	O

RFLP	B-UNK
and	O
quantitative	B-UNK
Southern	B-UNK
blot	I-UNK
analyses	O
revealed	B-UNK
a	O
grandpaternal	O
origin	O
of	O
duplication	B-UNK
in	O
four	O
families	B-UNK
and	O
grandmaternal	O
origin	O
in	O
one	O
family	B-UNK
.	O

In	O
all	O
five	O
families	B-UNK
,	O
the	O
duplication	B-UNK
was	O
found	O
to	O
originate	O
from	O
a	O
single	B-UNK
X	O
chromosome	B-UNK
.	O

Unequal	O
sister	O
-	O
chromatid	O
exchange	O
is	O
proposed	O
to	O
be	O
the	O
mechanism	B-UNK
for	O
the	O
formation	B-UNK
of	O
these	O
duplications	O
..	O

Glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
variants	B-UNK
:	O
Gd	B-UNK
(	O
+	O
)	O
Alexandra	O
associated	O
with	O
neonatal	B-UNK
jaundice	B-DISEASE
and	O
Gd	B-UNK
(	O
-	O
)	O
Camperdown	O
in	O
a	O
young	B-UNK
man	B-UNK
with	O
lamellar	O
cataracts	B-DISEASE
.	O

Two	O
male	B-UNK
subjects	B-UNK
are	O
described	O
,	O
with	O
unusual	O
clinical	B-UNK
presentations	O
and	O
with	O
hitherto	O
undescribed	O
G6PD	B-UNK
variants	I-UNK
.	O

The	O
first	O
,	O
of	O
Italian	B-UNK
extraction	O
,	O
suffered	O
from	O
severe	B-UNK
neonatal	B-UNK
jaundice	B-DISEASE
following	O
maternal	O
ingestion	O
of	O
fresh	O
broad	O
beans	O
(	O
Vicia	O
fava	O
)	O
both	O
prenatally	O
and	O
postnatally	O
the	O
expression	B-UNK
of	O
the	O
enzymatic	B-UNK
defect	B-UNK
was	O
much	O
more	O
severe	B-UNK
in	O
the	O
neonatal	B-UNK
period	O
than	O
on	O
retesting	O
in	O
adolescence	O
,	O
when	O
biochemical	O
characterization	B-UNK
showed	O
unique	O
features	B-UNK
which	O
justify	O
designation	O
as	O
a	O
new	O
variant	O
Gd	B-UNK
(	O
+	O
)	O
Alexandra	O
.	O

The	O
second	O
patient	B-UNK
,	O
a	O
boy	B-UNK
of	O
Maltese	O
extraction	O
who	O
was	O
found	O
to	O
have	O
bilateral	O
lamellar	O
cataracts	B-DISEASE
at	O
the	O
age	B-UNK
of	O
4	O
years	O
,	O
was	O
identified	B-UNK
as	O
G6PD	B-UNK
deficient	B-UNK
only	O
as	O
a	O
result	B-UNK
of	O
a	O
survey	O
of	O
children	O
of	O
Mediterranean	B-UNK
origin	O
with	O
unexplained	O
cataract	B-DISEASE
formation	B-UNK
;	O
he	O
has	O
approximately	O
15	O
%	O
of	O
normal	B-UNK
enzyme	B-UNK
activity	I-UNK
,	O
with	O
another	O
unique	O
combination	B-UNK
of	O
biochemical	O
characteristics	B-UNK
which	O
has	O
led	B-UNK
to	O
its	O
designation	O
as	O
Gd	B-UNK
(	O
-	O
)	O
Camperdown	O
.	O

Although	O
this	O
association	B-UNK
may	O
be	O
coincidental	O
,	O
it	O
prompts	O
further	O
attention	O
to	O
the	O
possibility	B-UNK
that	O
under	O
certain	O
circumstances	O
G6PD	B-UNK
deficiency	I-UNK
may	O
favor	O
cataract	B-DISEASE
formation	B-UNK
.	O

The	O
two	O
cases	B-UNK
illustrate	O
the	O
value	O
of	O
characterization	B-UNK
of	O
the	O
mutant	B-UNK
enzyme	B-UNK
whenever	O
unexpected	O
clinical	B-UNK
or	O
laboratory	O
results	B-UNK
are	O
obtained	B-UNK
..	O

Statistical	O
analysis	B-UNK
of	O
the	O
two	O
stage	B-UNK
mutation	B-UNK
model	B-UNK
in	O
von	B-DISEASE
Hippel	I-DISEASE
-	I-DISEASE
Lindau	I-DISEASE
disease	I-DISEASE
,	O
and	O
in	O
sporadic	B-UNK
cerebellar	B-UNK
haemangioblastoma	O
and	O
renal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O

Analysis	B-UNK
of	O
the	O
age	B-UNK
incidence	B-UNK
curves	O
for	O
unilateral	O
and	O
bilateral	O
retinoblastoma	B-DISEASE
led	B-UNK
Knudson	O
to	O
propose	O
that	O
hereditary	B-UNK
tumours	B-DISEASE
may	O
arise	O
by	O
a	O
single	B-UNK
event	O
and	O
sporadic	B-UNK
tumours	B-DISEASE
by	O
a	O
two	O
stage	B-UNK
mutation	B-UNK
process	B-UNK
.	O

It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B-UNK
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
may	O
arise	O
from	O
a	O
two	O
stage	B-UNK
mutation	B-UNK
process	B-UNK
.	O

We	O
analysed	O
the	O
age	B-UNK
incidence	B-UNK
curves	O
for	O
symptomatic	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B-UNK
haemangioblastoma	O
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	B-UNK
with	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
disease	B-UNK
,	O
and	O
compared	B-UNK
them	O
to	O
104	O
patients	B-UNK
with	O
sporadic	B-UNK
renal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
and	O
43	O
patients	B-UNK
with	O
sporadic	B-UNK
cerebellar	B-UNK
haemangioblastoma	O
.	O

The	O
age	B-UNK
incidence	B-UNK
curves	O
for	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
and	O
cerebellar	B-UNK
haemangioblastoma	O
in	O
VHL	B-UNK
disease	B-UNK
were	O
compatible	B-UNK
with	O
a	O
single	B-UNK
mutation	B-UNK
model	B-UNK
,	O
whereas	O
the	O
age	B-UNK
incidence	B-UNK
curves	O
for	O
sporadic	B-UNK
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
and	O
cerebellar	B-UNK
haemangioblastoma	O
suggested	O
a	O
two	O
stage	B-UNK
mutation	B-UNK
process	B-UNK
.	O

These	O
data	B-UNK
are	O
compatible	B-UNK
with	O
the	O
VHL	B-UNK
gene	B-UNK
functioning	O
as	O
a	O
recessive	B-UNK
tumour	B-UNK
suppressor	I-UNK
gene	B-UNK
.	O

Sporadic	B-UNK
cerebellar	B-UNK
haemangioblastoma	O
and	O
some	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
may	O
arise	O
from	O
somatic	B-UNK
mutations	I-UNK
inactivating	O
both	O
alleles	B-UNK
at	O
the	O
VHL	B-UNK
locus	B-UNK
..	O

Screening	B-UNK
for	O
carriers	B-UNK
of	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
among	O
Ashkenazi	B-UNK
Jews	B-UNK
.	O

A	O
comparison	B-UNK
of	O
DNA	B-UNK
-	O
based	B-UNK
and	O
enzyme	B-UNK
-	O
based	B-UNK
tests	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
prevention	O
of	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
GM2	O
gangliosidosis	O
,	O
type	B-UNK
1	O
)	O
depends	O
on	O
the	O
identification	B-UNK
of	O
carriers	B-UNK
of	O
the	O
gene	B-UNK
for	O
this	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
.	O

We	O
compared	B-UNK
the	O
enzyme	B-UNK
-	O
based	B-UNK
test	B-UNK
widely	O
used	O
in	O
screening	B-UNK
for	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
with	O
a	O
test	B-UNK
based	B-UNK
on	O
analysis	B-UNK
of	O
DNA	B-UNK
.	O

We	O
developed	O
methods	O
to	O
detect	B-UNK
the	O
three	O
mutations	B-UNK
in	O
the	O
HEXA	B-UNK
gene	B-UNK
that	O
occur	B-UNK
with	O
high	B-UNK
frequency	I-UNK
among	O
Ashkenazi	B-UNK
Jews	B-UNK
two	O
mutations	B-UNK
cause	O
infantile	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
,	O
and	O
the	O
third	O
causes	O
the	O
adult	B-UNK
-	O
onset	B-UNK
form	B-UNK
of	O
the	O
disease	B-UNK
.	O

DNA	B-UNK
segments	O
containing	O
these	O
mutation	B-UNK
sites	O
were	O
amplified	O
with	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
and	O
analyzed	B-UNK
for	O
the	O
presence	O
of	O
the	O
mutations	B-UNK
.	O

RESULTS	B-UNK
.	O

Among	O
62	O
Ashkenazi	B-UNK
obligate	B-UNK
carriers	B-UNK
of	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
,	O
the	O
three	O
specific	B-UNK
mutations	B-UNK
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	B-UNK
alleles	I-UNK
(	O
98	O
percent	B-UNK
)	O
.	O

In	O
216	O
Ashkenazi	B-UNK
carriers	B-UNK
identified	B-UNK
by	O
the	O
enzyme	B-UNK
test	B-UNK
,	O
DNA	B-UNK
analysis	I-UNK
showed	O
that	O
177	O
(	O
82	O
percent	B-UNK
)	O
had	O
one	O
of	O
the	O
identified	B-UNK
mutations	B-UNK
.	O

Of	O
the	O
177	O
,	O
79	O
percent	B-UNK
had	O
the	O
exon	B-UNK
11	O
insertion	O
mutation	B-UNK
,	O
18	O
percent	B-UNK
had	O
the	O
intron	B-UNK
12	O
splice	B-UNK
-	O
junction	O
mutation	B-UNK
,	O
and	O
3	O
percent	B-UNK
had	O
the	O
less	O
severe	B-UNK
exon	B-UNK
7	O
mutation	B-UNK
associated	O
with	O
adult	B-UNK
-	O
onset	B-UNK
disease	B-DISEASE
.	O

The	O
results	B-UNK
of	O
the	O
enzyme	B-UNK
tests	O
in	O
the	O
39	O
subjects	B-UNK
(	O
18	O
percent	B-UNK
)	O
who	O
were	O
defined	B-UNK
as	O
carriers	B-UNK
but	O
in	O
whom	O
DNA	B-UNK
analysis	I-UNK
did	O
not	O
identify	B-UNK
a	O
mutant	B-UNK
allele	B-UNK
were	O
probably	O
false	O
positive	O
(	O
although	O
there	O
remains	O
some	O
possibility	B-UNK
of	O
unidentified	O
mutations	B-UNK
)	O
.	O

In	O
addition	B-UNK
,	O
of	O
152	O
persons	O
defined	B-UNK
as	O
noncarriers	O
by	O
the	O
enzyme	B-UNK
-	O
based	B-UNK
test	B-UNK
,	O
1	O
was	O
identified	B-UNK
as	O
a	O
carrier	B-UNK
by	O
DNA	B-UNK
analysis	I-UNK
(	O
i.	O
e	O
e.	O
,	O
a	O
false	O
negative	B-UNK
enzyme	B-UNK
-	O
test	B-UNK
result	B-UNK
)	O
.	O

CONCLUSIONS	B-UNK
.	O

The	O
increased	B-UNK
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA	B-UNK
-	O
based	B-UNK
test	B-UNK
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	B-UNK
tests	O
currently	O
used	O
to	O
screen	B-UNK
for	O
carriers	B-UNK
of	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
.	O

Total	B-UNK
deficiency	B-UNK
of	O
plasma	O
cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
in	O
subjects	B-UNK
homozygous	B-UNK
and	O
heterozygous	B-UNK
for	O
the	O
intron	B-UNK
14	O
splicing	B-UNK
defect	B-UNK
.	O

The	O
molecular	B-UNK
basis	I-UNK
of	O
cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
(	O
CETP	B-UNK
)	O
deficiency	B-UNK
was	O
investigated	O
in	O
4	O
unrelated	B-UNK
CETP	B-UNK
-	O
deficient	B-UNK
families	B-UNK
.	O

The	O
high	B-UNK
density	I-UNK
lipoprotein	B-UNK
-	O
cholesterol	B-UNK
levels	B-UNK
of	O
the	O
probands	O
exceeded	O
150	O
mg	B-UNK
/	O
dl	O
.	O

The	O
plasma	O
of	O
the	O
probands	O
was	O
totally	O
deficient	B-UNK
in	O
CETP	B-UNK
activity	B-UNK
and	O
mass	B-UNK
.	O

The	O
genomic	B-UNK
DNA	I-UNK
of	O
the	O
patients	B-UNK
was	O
amplified	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
,	O
using	O
two	O
oligonucleotide	O
primers	O
located	B-UNK
in	O
the	O
intron	B-UNK
12	O
and	O
14	O
of	O
the	O
CETP	B-UNK
gene	B-UNK
,	O
and	O
the	O
amplified	O
products	B-UNK
were	O
directly	O
sequenced	O
.	O

Two	O
patients	B-UNK
were	O
homozygous	B-UNK
for	O
a	O
G	O
-	O
to	O
-	O
A	O
change	B-UNK
at	O
the	O
5-splice	O
donor	B-UNK
site	B-UNK
of	O
the	O
intron	B-UNK
14	O
.	O

The	O
G	O
-	O
to	O
-	O
A	O
change	B-UNK
would	O
cause	O
impaired	B-UNK
splicing	B-UNK
of	O
pre	O
-	O
messenger	B-UNK
RNA	I-UNK
.	O

The	O
other	O
two	O
probands	O
were	O
heterozygous	B-UNK
for	O
the	O
mutation	B-UNK
,	O
but	O
totally	O
lacked	O
CETP	B-UNK
.	O

Their	O
lipoprotein	B-UNK
patterns	B-UNK
were	O
also	O
similar	B-UNK
to	O
those	O
of	O
the	O
two	O
homozygotes	O
.	O

Thus	O
,	O
other	O
genetic	B-UNK
defects	B-UNK
or	O
metabolic	B-UNK
factors	O
influencing	O
CETP	B-UNK
expression	B-UNK
are	O
implicated	B-UNK
.	O

The	O
data	B-UNK
suggest	B-UNK
that	O
the	O
G	O
-	O
to	O
-	O
A	O
mutation	B-UNK
may	O
be	O
common	B-UNK
in	O
human	B-UNK
plasma	O
CETP	B-UNK
deficiency	I-UNK
.	O

Furthermore	O
,	O
there	O
could	O
be	O
compound	B-UNK
heterozygotes	I-UNK
who	O
totally	O
lack	B-UNK
plasma	O
CETP	B-UNK
and	O
have	O
lipoprotein	B-UNK
profiles	O
similar	B-UNK
to	O
those	O
of	O
homozygotes	O
..	O

Molecular	B-UNK
genetics	B-UNK
of	O
the	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
Mediterranean	B-UNK
variant	O
and	O
description	O
of	O
a	O
new	O
G6PD	B-UNK
mutant	B-UNK
,	O
G6PD	B-UNK
Andalus1361A.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
;	O
E.	O
C.	O
1	O
.	O
1	O
.	O
1	O
.	O
49	O
)	O
deficiency	B-UNK
is	O
the	O
most	O
common	B-UNK
human	B-UNK
enzymopathy	O
;	O
more	O
than	O
300	O
different	O
biochemical	O
variants	B-UNK
of	O
the	O
enzyme	B-UNK
have	O
been	O
described	O
.	O

In	O
many	O
parts	O
of	O
the	O
world	O
the	O
Mediterranean	B-UNK
type	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
is	O
prevalent	O
.	O

However	O
,	O
G6PD	B-UNK
Mediterranean	I-UNK
has	O
come	O
to	O
be	O
regarded	O
as	O
a	O
generic	O
term	O
applied	O
to	O
similar	B-UNK
G6PD	B-UNK
mutations	B-UNK
thought	B-UNK
,	O
however	O
,	O
to	O
represent	O
a	O
somewhat	O
heterogeneous	O
group	B-UNK
.	O

A	O
C----T	O
mutation	B-UNK
at	O
nucleotide	B-UNK
563	O
of	O
G6PD	B-UNK
Mediterranean	I-UNK
has	O
been	O
identified	B-UNK
by	O
Vulliamy	O
et	O
al	B-DISEASE
.	O
,	O
and	O
the	O
same	O
mutation	B-UNK
has	O
been	O
found	O
by	O
De	O
Vita	O
et	O
al	B-DISEASE
.	O
in	O
G6PD	B-UNK
Mediterranean	I-UNK
,	O
G6PD	B-UNK
Sassari	O
,	O
and	O
G6PD	B-UNK
Cagliari	O
.	O

The	O
latter	O
subjects	B-UNK
had	O
an	O
additional	O
mutation	B-UNK
,	O
at	O
nucleotide	B-UNK
1311	O
,	O
that	O
did	O
not	O
produce	B-UNK
a	O
coding	B-UNK
change	B-UNK
.	O

We	O
have	O
examined	O
genomic	B-UNK
DNA	I-UNK
of	O
five	O
patients	B-UNK
--	O
four	O
of	O
Spanish	O
origin	O
and	O
one	O
of	O
Jewish	B-UNK
origin	O
--	O
having	O
enzymatically	O
documented	O
G6PD	B-UNK
Mediterranean	I-UNK
.	O

All	O
had	O
both	O
the	O
mutation	B-UNK
at	O
nucleotide	B-UNK
563	O
and	O
that	O
at	O
nucleotide	B-UNK
1311	O
.	O

A	O
sixth	O
sample	O
,	O
resembling	O
G6PD	B-UNK
Mediterranean	I-UNK
kinetically	O
but	O
with	O
a	O
slightly	O
rapid	O
electrophoretic	B-UNK
mobility	O
,	O
was	O
designated	O
G6PD	B-UNK
Andalus	O
and	O
was	O
found	O
to	O
have	O
a	O
different	O
mutation	B-UNK
,	O
a	O
G----A	O
transition	B-UNK
at	O
nucleotide	B-UNK
1361	O
,	O
producing	O
an	O
arginine	O
-	O
to	O
-	O
histidine	O
substitution	B-UNK
.	O

These	O
studies	B-UNK
suggest	B-UNK
that	O
G6PD	B-UNK
Mediterranean	I-UNK
is	O
,	O
after	O
all	O
,	O
relatively	O
homogeneous	O
.	O

A	O
normal	B-UNK
male	B-UNK
with	O
an	O
inherited	B-UNK
deletion	B-UNK
of	O
one	O
exon	B-UNK
within	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

We	O
describe	O
two	O
brothers	O
with	O
identical	B-UNK
inherited	B-UNK
deletions	O
of	O
one	O
single	B-UNK
exon	B-UNK
within	O
the	O
middle	O
of	O
the	O
DMD	B-UNK
gene	B-UNK
;	O
one	O
brother	B-UNK
has	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
diagnosed	O
at	O
11	O
years	O
of	O
age	B-UNK
,	O
whereas	O
the	O
older	O
brother	B-UNK
is	O
normal	B-UNK
at	O
18	O
.	O

These	O
results	B-UNK
have	O
implications	B-UNK
for	O
genetic	B-UNK
counselling	O
and	O
prenatal	B-UNK
diagnosis	I-UNK
in	O
families	B-UNK
with	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
..	O

Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
expression	I-UNK
in	O
normal	B-UNK
and	O
diseased	O
human	B-UNK
muscle	B-UNK
.	O

A	O
probe	O
for	O
the	O
5	O
end	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
was	O
used	O
to	O
study	B-UNK
expression	B-UNK
of	O
the	O
gene	B-UNK
in	O
normal	B-UNK
human	B-UNK
muscle	B-UNK
,	O
myogenic	O
cell	B-UNK
cultures	O
,	O
and	O
muscle	B-UNK
from	O
patients	B-UNK
with	O
DMD	B-UNK
.	O

Expression	B-UNK
was	O
found	O
in	O
RNA	B-UNK
from	O
normal	B-UNK
fetal	O
muscle	B-UNK
,	O
adult	B-UNK
cardiac	B-UNK
and	O
skeletal	B-UNK
muscle	I-UNK
,	O
and	O
cultured	O
muscle	B-UNK
after	O
myoblast	O
fusion	B-UNK
.	O

In	O
DMD	B-UNK
muscle	B-UNK
,	O
expression	B-UNK
of	O
this	O
portion	B-UNK
of	O
the	O
gene	B-UNK
was	O
also	O
revealed	B-UNK
by	O
in	O
situ	B-UNK
RNA	B-UNK
hybridization	B-UNK
,	O
particularly	O
in	O
regenerating	O
muscle	B-UNK
fibers	O
..	O

Molecular	B-UNK
and	O
phenotypic	B-UNK
analysis	B-UNK
of	O
patients	B-UNK
with	O
deletions	O
within	O
the	O
deletion	B-UNK
-	O
rich	O
region	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
.	O

Eighty	O
unrelated	B-UNK
individuals	B-UNK
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
or	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
BMD	B-UNK
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	B-UNK
deletion	B-UNK
-	O
rich	O
region	B-UNK
of	O
the	O
DMD	B-UNK
locus	B-UNK
.	O

This	O
region	B-UNK
includes	O
the	O
last	O
five	O
exons	O
detected	B-UNK
by	O
cDNA5b-7	O
,	O
all	O
exons	O
detected	B-UNK
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	B-UNK
by	O
cDNA9	O
.	O

These	O
80	O
individuals	B-UNK
account	B-UNK
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	B-UNK
,	O
detected	B-UNK
among	O
181	O
patients	B-UNK
analyzed	B-UNK
with	O
the	O
entire	O
dystrophin	B-UNK
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	B-UNK
using	O
two	O
genomic	B-UNK
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	B-DISEASE
.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	B-UNK
paper	O
)	O
.	O

Clinical	B-UNK
findings	B-UNK
are	O
presented	B-UNK
for	O
all	O
80	O
patients	B-UNK
allowing	O
a	O
correlation	B-UNK
of	O
phenotypic	B-UNK
severity	B-UNK
with	O
the	O
genotype	B-UNK
.	O

Thirty	O
-	O
eight	O
independent	O
patients	B-UNK
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B-UNK
,	O
BMD	B-UNK
,	O
or	O
intermediate	O
phenotype	B-UNK
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	B-UNK
/	O
exon	B-UNK
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B-UNK
patients	B-UNK
and	O
one	O
intermediate	O
patient	B-UNK
had	O
gene	B-UNK
deletions	O
predicted	B-UNK
to	O
leave	O
the	O
reading	B-UNK
frame	I-UNK
intact	O
,	O
while	O
21	O
DMD	B-UNK
patients	B-UNK
,	O
7	O
intermediate	O
patients	B-UNK
,	O
and	O
1	O
BMD	B-UNK
patient	B-UNK
had	O
gene	B-UNK
deletions	O
predicted	B-UNK
to	O
disrupt	O
the	O
reading	B-UNK
frame	I-UNK
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	B-UNK
deletions	O
of	O
the	O
gene	B-UNK
resulted	B-UNK
in	O
more	O
severe	B-UNK
phenotype	I-UNK
than	O
did	O
in	O
-	O
frame	B-UNK
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	B-UNK
by	O
Baumbach	O
et	O
al	B-DISEASE
.	O
and	O
Koenig	O
et	O
al	B-DISEASE
.	O
but	O
is	O
in	O
contrast	B-UNK
to	O
findings	B-UNK
,	O
by	O
Malhotra	O
et	O
al	B-DISEASE
.	O
at	O
the	O
5	O
'	O
end	B-UNK
of	O
the	O
gene	B-UNK
.	O

Cloning	B-UNK
of	O
breakpoints	O
of	O
a	O
chromosome	B-UNK
translocation	B-UNK
identifies	O
the	O
AN2	B-UNK
locus	B-UNK
.	O

Chromosome	B-UNK
translocations	O
involving	O
11p13	O
have	O
been	O
associated	O
with	O
familial	B-UNK
aniridia	B-DISEASE
in	O
two	O
kindreds	O
highlighting	O
the	O
chromosomal	B-UNK
localization	B-UNK
of	O
the	O
AN2	B-UNK
locus	B-UNK
.	O

This	O
locus	B-UNK
is	O
also	O
part	O
of	O
the	O
WAGR	O
complex	O
(	O
Wilms	B-DISEASE
tumor	I-DISEASE
,	O
aniridia	B-DISEASE
,	O
genitourinary	O
abnormalities	B-UNK
,	O
and	O
mental	B-UNK
retardation	I-UNK
)	O
.	O

In	O
one	O
kindred	O
,	O
the	O
translocation	B-UNK
is	O
associated	O
with	O
a	O
deletion	B-UNK
,	O
and	O
probes	O
for	O
this	O
region	B-UNK
were	O
used	O
to	O
identify	B-UNK
and	O
clone	O
the	O
breakpoints	O
of	O
the	O
translocation	B-UNK
in	O
the	O
second	O
kindred	O
.	O

Comparison	B-UNK
of	O
phage	O
restriction	B-UNK
maps	B-UNK
exclude	O
the	O
presence	O
of	O
any	O
sizable	O
deletion	B-UNK
in	O
this	O
case	B-UNK
.	O

Sequences	O
at	O
the	O
chromosome	B-UNK
11	O
breakpoint	O
are	O
conserved	B-UNK
in	O
multiple	B-UNK
species	B-UNK
,	O
suggesting	O
that	O
the	O
translocation	B-UNK
falls	O
within	O
the	O
AN2	B-UNK
gene	B-UNK
..	O

Linkage	B-UNK
analysis	I-UNK
of	O
the	O
apolipoprotein	B-UNK
C2	B-UNK
gene	B-UNK
and	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
on	O
human	B-UNK
chromosome	I-UNK
19	O
reveals	O
linkage	B-UNK
disequilibrium	I-UNK
in	O
a	O
French	B-UNK
-	O
Canadian	B-UNK
population	B-UNK
.	O

The	O
gene	B-UNK
for	O
human	B-UNK
apolipoprotein	B-UNK
C2	B-UNK
(	O
APOC2	B-UNK
)	O
,	O
situated	O
on	O
the	O
proximal	B-UNK
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
19	O
,	O
is	O
closely	B-UNK
linked	I-UNK
to	O
the	O
gene	B-UNK
for	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
adult	B-UNK
muscular	B-UNK
dystrophy	I-UNK
,	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
.	O

Six	O
APOC2	B-UNK
RFLPs	B-UNK
(	O
TaqI	O
,	O
BglI	O
,	O
BanI	O
,	O
BamHI	O
,	O
NcoI	O
,	O
and	O
AvaII	O
)	O
have	O
been	O
identified	B-UNK
to	O
date	B-UNK
.	O

We	O
have	O
conducted	O
a	O
comprehensive	O
DM	B-DISEASE
linkage	B-UNK
study	B-UNK
utilizing	O
all	O
six	O
RFLPs	B-UNK
and	O
involving	O
50	O
families	B-UNK
and	O
372	O
individuals	B-UNK
.	O

The	O
most	O
informative	O
RFLPs	B-UNK
are	O
,	O
in	O
descending	O
order	B-UNK
,	O
NcoI	O
(	O
lod	B-UNK
=	O
6	O
.	O
64	O
,	O
theta	B-UNK
=	O
0	O
.	O
05	O
)	O
,	O
BglI	O
(	O
lod	B-UNK
=	O
6	O
.	O
12	O
,	O
theta	B-UNK
=	O
0	O
.	O
05	O
)	O
,	O
AvaII	O
(	O
lod	B-UNK
=	O
6	O
.	O
02	O
,	O
theta	B-UNK
=	O
0	O
.	O
03	O
)	O
,	O
BanI	O
(	O
lod	B-UNK
=	O
5	O
.	O
76	O
,	O
theta	B-UNK
=	O
0	O
.	O
04	O
)	O
,	O
TaqI	O
(	O
lod	B-UNK
=	O
4	O
.	O
29	O
,	O
theta	B-UNK
=	O
0	O
.	O
06	O
)	O
,	O
and	O
BamHI	O
(	O
lod	B-UNK
=	O
1	O
.	O
75	O
,	O
theta	B-UNK
=	O
0	O
.	O
01	O
)	O
.	O

A	O
substantial	O
increase	B-UNK
in	O
the	O
lod	B-UNK
scores	I-UNK
over	O
those	O
seen	O
with	O
the	O
individual	O
RFLPs	B-UNK
was	O
obtained	B-UNK
when	O
the	O
linkage	B-UNK
of	O
the	O
entire	O
APOC2	B-UNK
haplotype	B-UNK
(	O
composed	O
of	O
the	O
six	O
RFLPs	B-UNK
)	O
was	O
studied	O
(	O
lod	B-UNK
=	O
17	O
.	O
87	O
,	O
theta	B-UNK
=	O
0	O
.	O
04	O
)	O
.	O

We	O
have	O
observed	B-UNK
significant	B-UNK
inter	O
-	O
APOC2	B-UNK
RFLP	B-UNK
linkage	B-UNK
disequilibrium	I-UNK
.	O

Consequently	O
,	O
the	O
three	O
most	O
informative	O
RFLPs	B-UNK
have	O
been	O
found	O
to	O
be	O
BanI	O
,	O
TaqI	O
,	O
and	O
either	O
BglI	O
,	O
AvaII	O
,	O
or	O
NcoI	O
polymorphisms	B-UNK
.	O

We	O
also	O
demonstrate	B-UNK
linkage	B-UNK
disequilibrium	I-UNK
between	O
DM	B-UNK
and	O
APOC2	B-UNK
in	O
our	O
French	B-UNK
-	O
Canadian	B-UNK
population	B-UNK
(	O
standardized	O
disequilibrium	B-UNK
constant	O
phi	O
=	O
.	O
22	O
,	O
chi	O
2	O
=	O
5	O
.	O
12	O
,	O
df	O
=	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
04	O
)	O
.	O

This	O
represents	O
the	O
first	O
evidence	B-UNK
of	O
linkage	B-UNK
disequilibrium	I-UNK
between	O
APOC2	B-UNK
and	O
the	O
DM	B-DISEASE
locus	B-UNK
.	O

Phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
haplotypes	O
in	O
Polynesians	O
:	O
evolutionary	O
origins	O
and	O
absence	B-UNK
of	O
alleles	B-UNK
associated	O
with	O
severe	B-UNK
phenylketonuria	O
.	O

A	O
total	B-UNK
of	O
630	O
haplotypes	O
for	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
gene	B-UNK
locus	B-UNK
were	O
established	O
in	O
five	O
groups	B-UNK
of	O
Polynesians	O
comprising	O
Samoans	O
,	O
Tongans	O
,	O
Cook	O
Islanders	O
,	O
Maori	O
,	O
and	O
Niueans	O
.	O

Considerable	B-UNK
genetic	B-UNK
continuity	O
was	O
demonstrated	O
between	O
these	O
widely	O
dispersed	O
populations	O
,	O
since	O
three	O
common	B-UNK
haplotypes	O
(	O
4	O
,	O
1	O
,	O
and	O
7	O
)	O
constituted	O
over	O
95	O
%	O
of	O
alleles	B-UNK
.	O

A	O
control	B-UNK
group	B-UNK
of	O
individuals	B-UNK
from	O
Southeast	O
Asia	O
shared	O
the	O
same	O
major	B-UNK
haplotypes	O
,	O
4	O
,	O
1	O
,	O
and	O
7	O
,	O
with	O
Polynesians	O
.	O

These	O
data	B-UNK
provide	B-UNK
further	O
support	O
for	O
the	O
theories	O
of	O
genetic	B-UNK
homogeneity	O
and	O
of	O
Asian	O
affinities	O
of	O
the	O
Polynesian	O
precursor	O
populations	O
.	O

The	O
absence	B-UNK
of	O
severe	B-UNK
phenylketonuria	O
(	O
PKU	B-UNK
)	O
in	O
both	O
Polynesians	O
and	O
Southeast	O
Asians	O
is	O
consistent	B-UNK
with	O
the	O
lack	B-UNK
of	O
PAH	B-UNK
haplotypes	O
2	O
and	O
3	O
,	O
on	O
which	O
the	O
severe	B-UNK
PKU	B-UNK
mutants	O
have	O
arisen	O
among	O
Caucasians	B-UNK
..	O

Preferential	O
germline	B-UNK
mutation	I-UNK
of	O
the	O
paternal	O
allele	B-UNK
in	O
retinoblastoma	B-DISEASE
.	O

The	O
event	O
triggering	O
malignant	B-UNK
proliferation	O
in	O
70	O
%	O
of	O
retinoblastoma	B-DISEASE
tumours	B-DISEASE
is	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
for	O
chromosome	B-UNK
13q14	O
,	O
whereby	O
the	O
normal	B-UNK
retinoblastoma	B-DISEASE
gene	B-UNK
(	O
RB1	B-UNK
)	O
allele	B-UNK
is	O
lost	O
and	O
an	O
already	O
mutated	B-UNK
RB1	B-UNK
allele	B-UNK
remains	O
in	O
the	O
tumour	B-DISEASE
.	O

The	O
first	O
allele	B-UNK
suffers	O
a	O
mutational	O
event	O
--	O
deletion	B-UNK
,	O
duplication	B-UNK
or	O
point	B-UNK
mutation	I-UNK
(	O
manuscript	O
in	O
preparation)--either	O
in	O
the	O
germ	B-UNK
line	I-UNK
(	O
all	O
bilateral	O
patients	B-UNK
)	O
or	O
in	O
a	O
somatic	B-UNK
retinal	B-UNK
cell	B-UNK
(	O
most	O
unilateral	O
patients	B-UNK
)	O
.	O

Most	O
bilateral	O
patients	B-UNK
have	O
no	O
family	B-UNK
history	B-UNK
of	O
retinoblastoma	B-DISEASE
and	O
are	O
presumed	O
to	O
have	O
new	O
germline	B-UNK
mutations	I-UNK
which	O
arose	O
in	O
the	O
egg	O
,	O
sperm	O
or	O
early	B-UNK
embryo	O
.	O

We	O
have	O
determined	B-UNK
the	O
parental	O
origin	O
of	O
the	O
retained	O
allele	B-UNK
in	O
nine	O
retinoblastoma	B-DISEASE
tumours	B-DISEASE
from	O
eight	O
unrelated	B-UNK
non-familial	O
cases	B-UNK
by	O
using	O
RB1-linked	O
genetic	B-UNK
markers	B-UNK
.	O

Six	O
tumours	B-DISEASE
retained	O
the	O
paternal	O
allele	B-UNK
and	O
three	O
retained	O
the	O
maternal	O
allele	B-UNK
.	O

Of	O
the	O
three	O
unilateral	O
tumours	B-DISEASE
,	O
only	O
one	O
retained	O
the	O
paternal	O
RB1	B-UNK
allele	B-UNK
.	O

Thus	O
,	O
there	O
is	O
no	O
evidence	B-UNK
that	O
the	O
paternal	O
RB1	B-UNK
allele	B-UNK
is	O
preferentially	O
retained	O
in	O
retinoblastoma	B-DISEASE
,	O
as	O
has	O
been	O
suggested	O
to	O
be	O
the	O
case	B-UNK
in	O
osteosarcoma	B-DISEASE
.	O

By	O
contrast	B-UNK
,	O
tumours	B-DISEASE
from	O
four	O
of	O
the	O
five	O
bilateral	O
patients	B-UNK
retained	O
the	O
paternal	O
RB1	B-UNK
allele	B-UNK
.	O

This	O
suggests	O
either	O
that	O
new	O
germline	B-UNK
RB1	B-UNK
mutations	B-UNK
arise	O
more	O
frequently	O
during	O
spermatogenesis	O
than	O
during	O
oogenesis	O
,	O
or	O
that	O
imprinting	B-UNK
in	O
the	O
early	B-UNK
embryo	O
affects	O
chromosomal	B-UNK
susceptibility	B-UNK
to	O
mutation	B-UNK
..	O

Haplotype	B-UNK
analysis	I-UNK
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
in	O
Turkish	O
phenylketonuria	O
families	B-UNK
.	O

We	O
have	O
estimated	B-UNK
the	O
haplotype	B-UNK
distribution	B-UNK
of	O
mutant	B-UNK
and	O
normal	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
alleles	B-UNK
for	O
17	O
Turkish	O
phenylketonuria	O
(	O
PKU	B-UNK
)	O
families	B-UNK
20	O
normal	B-UNK
and	O
27	O
mutated	B-UNK
PAH	B-UNK
alleles	B-UNK
could	O
be	O
identified	B-UNK
.	O

Of	O
the	O
latter	O
,	O
the	O
most	O
prevalent	O
were	O
associated	O
with	O
haplotype	B-UNK
6	O
(	O
29	O
.	O
6	O
%	O
)	O
,	O
1	O
(	O
18	O
.	O
5	O
%	O
)	O
and	O
36	O
(	O
11	O
.	O
1	O
%	O
)	O
,	O
while	O
the	O
normal	B-UNK
alleles	B-UNK
were	O
preferentially	O
associated	O
with	O
haplotype	B-UNK
1	O
(	O
20	O
%	O
)	O
.	O

Of	O
the	O
19	O
different	O
haplotypes	O
observed	B-UNK
,	O
5	O
have	O
not	O
been	O
described	O
previously	B-UNK
.	O

The	O
haplotype	B-UNK
distribution	B-UNK
differed	O
significantly	O
from	O
that	O
of	O
the	O
Northern	B-UNK
European	B-UNK
population	B-UNK
.	O

Two	O
of	O
the	O
eight	O
polymorphic	B-UNK
sites	O
were	O
in	O
association	B-UNK
with	O
PKU	B-UNK
.	O

No	O
deletions	O
of	O
exon	B-UNK
sequences	O
were	O
found	O
in	O
the	O
families	B-UNK
analysed	O
.	O

Huntington	B-DISEASE
disease	I-DISEASE
:	O
no	O
evidence	B-UNK
for	O
locus	B-UNK
heterogeneity	B-UNK
.	O

A	O
total	B-UNK
of	O
63	O
families	B-UNK
with	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
were	O
examined	O
for	O
linkage	B-UNK
between	O
HD	B-UNK
and	O
G8	O
(	O
D4S10	O
)	O
.	O

The	O
families	B-UNK
included	O
57	O
Caucasian	B-UNK
,	O
four	O
Black	B-UNK
American	B-UNK
,	O
and	O
two	O
Japanese	B-UNK
.	O

The	O
combined	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
was	O
87	O
.	O

69	O
at	O
theta	B-UNK
=	O
0	O
.	O

04	O
(	O
99	O
%	O
confidence	B-UNK
interval	I-UNK
0	O
.	O
018	O
-	O
0	O
.	O
071	O
)	O
.	O

The	O
maximum	B-UNK
frequency	B-UNK
of	O
recombination	B-UNK
was	O
0	O
.	O

03	O
in	O
males	B-UNK
and	O
0	O
.	O

05	O
in	O
females	O
.	O

Fifty	O
-	O
seven	O
families	B-UNK
gave	O
positive	O
lod	B-UNK
scores	I-UNK
;	O
five	O
small	O
families	B-UNK
gave	O
mildly	O
negative	B-UNK
lod	B-UNK
scores	I-UNK
.	O

The	O
maximum	B-UNK
likelihood	O
estimate	O
of	O
alpha	B-UNK
,	O
the	O
proportion	B-UNK
of	O
linked	B-UNK
loci	O
,	O
was	O
1	O
.	O

0	O
with	O
a	O
lower	O
99	O
%	O
confidence	B-UNK
interval	I-UNK
of	O
0	O
.	O

88	O
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
there	O
is	O
only	O
one	O
HD	B-UNK
locus	B-UNK
,	O
although	O
a	O
second	O
rare	B-UNK
locus	B-UNK
cannot	O
be	O
ruled	O
out	O
.	O

Haplotype	B-UNK
and	O
multipoint	B-UNK
linkage	B-UNK
analysis	I-UNK
in	O
Finnish	B-UNK
choroideremia	B-UNK
families	B-UNK
.	O

Multipoint	B-UNK
linkage	B-UNK
analysis	I-UNK
of	O
choroideremia	B-DISEASE
(	O
TCD	B-UNK
)	O
and	O
seven	O
X	O
chromosomal	B-UNK
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
(	O
RFLPs	B-UNK
)	O
was	O
carried	O
out	O
in	O
18	O
Finnish	B-UNK
TCD	B-UNK
families	B-UNK
.	O

The	O
data	B-UNK
place	O
TCD	B-UNK
distal	B-UNK
to	O
PGK	O
and	O
DXS72	O
,	O
very	O
close	B-UNK
to	O
DXYS1	O
and	O
DXYS5	O
(	O
Zmax	O
=	O
24	O
at	O
theta	B-UNK
=	O
0	O
)	O
and	O
proximal	B-UNK
to	O
DXYS4	O
and	O
DXYS12	O
.	O

This	O
agrees	O
with	O
the	O
data	B-UNK
obtained	B-UNK
from	O
other	O
linkage	B-UNK
studies	B-UNK
and	O
from	O
physical	B-UNK
mapping	B-UNK
.	O

All	O
the	O
TCD	B-UNK
males	B-UNK
and	O
carrier	B-UNK
females	O
studied	O
have	O
the	O
same	O
DXYS1	O
allele	B-UNK
in	O
coupling	O
with	O
TCD	B-UNK
.	O

In	O
Northeastern	O
Finland	O
,	O
66/69	O
chromosomes	O
carrying	B-UNK
TCD	B-UNK
had	O
the	O
same	O
haplotype	B-UNK
at	O
loci	O
DXS72	O
,	O
DXYS1	O
,	O
DXYS4	O
,	O
and	O
DXYS12	O
.	O

The	O
same	O
haplotype	B-UNK
is	O
seen	O
in	O
only	O
15/99	O
chromosomes	O
not	O
carrying	B-UNK
TCD	B-UNK
.	O

Moreover	O
,	O
in	O
71/104	O
non-TCD	O
chromosomes	O
,	O
the	O
haplotype	B-UNK
at	O
six	O
marker	B-UNK
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
TCD	B-UNK
chromosomes	O
.	O

This	O
supports	O
the	O
previously	B-UNK
described	O
hypothesis	B-UNK
that	O
the	O
large	B-UNK
Northern	B-UNK
Finnish	B-UNK
choroideremia	B-DISEASE
pedigrees	O
,	O
comprising	O
a	O
total	B-UNK
of	O
over	O
80	O
living	O
patients	B-UNK
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
TCD	B-UNK
patients	B-UNK
described	O
worldwide	O
,	O
carry	B-UNK
the	O
same	O
mutation	B-UNK
.	O

These	O
linkage	B-UNK
and	O
haplotype	B-UNK
data	B-UNK
provide	B-UNK
improved	O
opportunities	O
for	O
prenatal	B-UNK
diagnosis	I-UNK
based	B-UNK
on	O
RFLP	B-UNK
studies	B-UNK
..	O

Autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
linked	B-UNK
to	O
the	O
chromosome	B-UNK
11p13	O
markers	B-UNK
catalase	O
and	O
D11S151	O
in	O
a	O
large	B-UNK
Dutch	B-UNK
family	B-UNK
.	O

In	O
a	O
large	B-UNK
pedigree	B-UNK
with	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
,	O
we	O
found	O
close	B-UNK
linkage	I-UNK
between	O
the	O
aniridia	B-DISEASE
locus	B-UNK
AN2	B-UNK
and	O
the	O
markers	B-UNK
catalase	O
(	O
CAT	O
)	O
(	O
zeta	O
=	O
7	O
.	O
27	O
at	O
theta	B-UNK
=	O
0	O
.	O
00	O
)	O
and	O
D11S151	O
(	O
zeta	O
=	O
3	O
.	O
86	O
at	O
theta	B-UNK
=	O
0	O
.	O
10	O
)	O
flanking	O
the	O
AN2	B-UNK
locus	B-UNK
on	O
11p13	O
.	O

Positive	O
lod	B-UNK
scores	I-UNK
were	O
also	O
obtained	B-UNK
for	O
the	O
11p13	O
-	O
---11p14	O
markers	B-UNK
D11S16	O
and	O
FSHB	O
with	O
the	O
linkage	B-UNK
group	B-UNK
CAT	O
/	O
AN2	B-UNK
/	O
D11S151	O
.	O

We	O
conclude	O
that	O
the	O
autosomal	B-UNK
dominant	I-UNK
aniridia	B-DISEASE
in	O
this	O
family	B-UNK
is	O
due	O
to	O
a	O
mutation	B-UNK
at	O
the	O
AN2	B-UNK
locus	B-UNK
on	O
11p13	O
.	O

We	O
have	O
excluded	O
linkage	B-UNK
(	O
zeta	O
less	O
than-2	O
at	O
theta	B-UNK
less	O
than	O
0	O
.	O
18	O
)	O
between	O
the	O
aniridia	B-DISEASE
and	O
the	O
chromosome	B-UNK
2p25	O
marker	B-UNK
D2S1	O
(	O
linked	B-UNK
to	O
ACP1	O
)	O
.	O

Recombination	B-UNK
events	O
that	O
locate	O
myotonic	B-UNK
dystrophy	I-UNK
distal	B-UNK
to	O
APOC2	B-UNK
on	O
19q	O
.	O

We	O
previously	B-UNK
reported	I-UNK
a	O
recombination	B-UNK
in	O
an	O
individual	O
with	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-DISEASE
)	O
which	O
placed	O
the	O
markers	B-UNK
D19S19	O
and	O
APOC2	B-UNK
on	O
the	O
same	O
side	O
of	O
the	O
DM	B-UNK
locus	B-UNK
.	O

Haplotyping	O
of	O
this	O
family	B-UNK
with	O
more	O
recently	O
characterized	B-UNK
probes	O
which	O
are	O
either	O
tightly	B-UNK
linked	I-UNK
to	O
DM	B-DISEASE
or	O
distal	B-UNK
to	O
the	O
linkage	B-UNK
group	B-UNK
at	O
q13	B-UNK
.	O

2	O
shows	O
that	O
the	O
DM	B-DISEASE
locus	B-UNK
is	O
distal	B-UNK
to	O
APOC2	B-UNK
.	O

This	O
is	O
confirmed	B-UNK
by	O
other	O
recombinants	O
where	O
DM	B-DISEASE
segregates	O
with	O
distal	B-UNK
probes	O
.	O

Additional	O
marker	B-UNK
to	O
marker	B-UNK
recombinations	O
in	O
unaffected	O
individuals	B-UNK
are	O
reported	B-UNK
and	O
support	O
the	O
order	B-UNK
and	O
orientation	O
of	O
the	O
DM	B-DISEASE
linkage	B-UNK
group	B-UNK
as	O
pter-(INSR	O
,	O
LDLR	O
,	O
S9)-(S19	O
,	O
BCL3	O
,	O
APOC2)-(CKMM	O
,	O
DM)-(S22	O
,	O
+	O
+	O
+	O
PRKCG)-qter	O
.	O

The	O
data	B-UNK
presented	B-UNK
here	O
cannot	O
determine	B-UNK
whether	O
DM	B-UNK
is	O
proximal	B-UNK
or	O
distal	B-UNK
to	O
CKMM	O
.	O

The	O
consequences	O
of	O
this	O
probe	O
order	B-UNK
for	O
antenatal	O
diagnosis	B-UNK
and	O
future	O
research	O
aiming	O
to	O
isolate	O
the	O
gene	B-UNK
which	O
is	O
affected	B-UNK
in	O
DM	B-DISEASE
are	O
discussed	O
.	O

Mutations	B-UNK
in	O
the	O
RB1	B-UNK
gene	B-UNK
and	O
their	O
effects	B-UNK
on	O
transcription	B-UNK
.	O

Inactivation	B-UNK
of	O
both	O
alleles	B-UNK
of	O
the	O
RB1	B-UNK
gene	B-UNK
during	O
normal	B-UNK
retinal	B-UNK
development	B-UNK
initiates	O
the	O
formation	B-UNK
of	O
a	O
retinoblastoma	B-DISEASE
(	O
RB	O
)	O
tumor	B-DISEASE
.	O

To	O
identify	B-UNK
the	O
mutations	B-UNK
which	O
inactivate	O
RB1	B-UNK
,	O
21	O
RB	O
tumors	B-UNK
isolated	B-UNK
from	O
19	O
patients	B-UNK
were	O
analyzed	B-UNK
with	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
or	O
an	O
RNase	O
protection	O
assay	B-UNK
or	O
both	O
.	O

Mutations	B-UNK
were	O
identified	B-UNK
in	O
13	O
of	O
21	O
RB	O
tumors	B-DISEASE
;	O
in	O
8	O
tumors	B-DISEASE
,	O
the	O
precise	O
errors	O
in	O
nucleotide	B-UNK
sequence	I-UNK
were	O
characterized	B-UNK
.	O

Each	O
of	O
four	O
germ	B-UNK
line	I-UNK
mutations	B-UNK
involved	B-UNK
a	O
small	O
deletion	B-UNK
or	O
duplication	B-UNK
,	O
while	O
three	O
somatic	B-UNK
mutations	I-UNK
were	O
point	B-UNK
mutations	I-UNK
leading	B-UNK
to	O
splice	B-UNK
alterations	B-UNK
and	O
loss	B-UNK
of	O
an	O
exon	B-UNK
from	O
the	O
mature	O
RB1	B-UNK
mRNA	O
.	O

We	O
were	O
unable	O
to	O
detect	B-UNK
expression	B-UNK
of	O
the	O
mutant	B-UNK
allele	B-UNK
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	B-UNK
patients	B-UNK
,	O
although	O
the	O
mutation	B-UNK
was	O
present	B-UNK
in	O
the	O
genomic	B-UNK
DNA	I-UNK
and	O
transcripts	O
containing	O
the	O
mutations	B-UNK
were	O
obvious	O
in	O
the	O
RB	O
tumors	B-DISEASE
in	O
the	O
absence	B-UNK
of	O
a	O
normal	B-UNK
RB1	B-UNK
allele	B-UNK
.	O

The	O
variations	O
in	O
the	O
level	B-UNK
of	O
expression	B-UNK
of	O
mutant	B-UNK
transcripts	O
suggest	B-UNK
deregulation	O
of	O
RB1	B-UNK
transcription	B-UNK
in	O
the	O
absence	B-UNK
of	O
a	O
functional	O
RB1	B-UNK
gene	B-UNK
product	I-UNK
..	O

Partial	O
deletion	B-UNK
8q	O
without	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
:	O
a	O
recognisable	O
syndrome	B-DISEASE
.	O

We	O
report	B-UNK
two	O
de	O
novo	O
cases	B-UNK
of	O
del	O
(	O
8)	O
(	O
pter----q24	O
.	O
1	O
)	O
with	O
breakpoints	O
involving	O
the	O
distal	B-UNK
part	O
of	O
band	O
8q24	O
.	O

1	O
1	O
.	O

The	O
clinical	B-UNK
features	I-UNK
were	O
similar	B-UNK
and	O
there	O
were	O
no	O
obvious	O
stigmata	O
of	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
(	O
LGS	O
)	O
.	O

There	O
are	O
three	O
other	O
cases	B-UNK
reported	B-UNK
with	O
a	O
deletion	B-UNK
of	O
chromosome	B-UNK
8	O
at	O
approximately	O
the	O
same	O
breakpoint	O
,	O
one	O
without	O
LGS	O
and	O
some	O
similarities	O
to	O
our	O
cases	B-UNK
,	O
the	O
other	O
two	O
with	O
LGS	O
.	O

Our	O
findings	B-UNK
would	O
support	O
the	O
observation	O
that	O
the	O
critical	B-UNK
segment	O
for	O
the	O
assignment	B-UNK
of	O
LGS	O
is	O
proximal	B-UNK
to	O
or	O
involves	O
the	O
proximal	B-UNK
part	O
of	O
8q24	O
.	O

1	O
,	O
but	O
a	O
review	O
of	O
published	O
reports	O
suggests	O
that	O
the	O
aetiology	O
of	O
LGS	O
may	O
be	O
a	O
more	O
complex	O
issue	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
is	O
closely	B-UNK
linked	I-UNK
to	O
the	O
gene	B-UNK
for	O
muscle	B-UNK
-	O
type	B-UNK
creatine	O
kinase	B-UNK
(	O
CKMM	O
)	O
.	O

We	O
have	O
studied	O
genetic	B-UNK
linkage	I-UNK
between	O
the	O
gene	B-UNK
for	O
creatine	O
kinase	B-UNK
muscle	B-UNK
type	B-UNK
(	O
CKMM	O
)	O
and	O
the	O
gene	B-UNK
for	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
.	O

In	O
a	O
panel	B-UNK
of	O
65	O
myotonic	B-UNK
dystrophy	I-UNK
families	B-UNK
from	O
Canada	O
and	O
the	O
Netherlands	O
,	O
a	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
(	O
Zmax	O
)	O
of	O
22	O
.	O

8	O
at	O
a	O
recombination	B-UNK
frequency	B-UNK
(	O
theta	B-UNK
)	O
of	O
0	O
.	O

03	O
was	O
obtained	B-UNK
.	O

Tight	O
linkage	B-UNK
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	B-UNK
for	O
apolipoprotein	B-UNK
C2	B-UNK
(	O
ApoC2	B-UNK
)	O
.	O

This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	B-UNK
for	O
myotonic	B-DISEASE
dystrophy	I-DISEASE

Color	B-DISEASE
vision	I-DISEASE
defects	I-DISEASE
in	O
adrenomyeloneuropathy	O
.	O

The	O
relationship	B-UNK
between	O
abnormal	O
color	B-UNK
vision	I-UNK
and	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
was	O
investigated	O
in	O
27	O
AMN	B-UNK
patients	B-UNK
and	O
31	O
age	B-UNK
-	O
matched	O
controls	O
by	O
using	O
the	O
Farnsworth	O
-	O
Munsell	O
100	O
Hue	O
test	B-UNK
.	O

Twelve	O
(	O
44	O
%	O
)	O
of	O
27	O
patients	B-UNK
showed	O
test	B-UNK
scores	B-UNK
significantly	O
above	O
normal	B-UNK
.	O

The	O
axes	O
of	O
bipolarity	O
determined	B-UNK
by	O
the	O
testing	B-UNK
differed	O
widely	O
between	O
the	O
patients	B-UNK
with	O
abnormal	O
scores	B-UNK
,	O
compatible	B-UNK
with	O
the	O
notion	O
that	O
different	O
alterations	B-UNK
in	O
visual	B-UNK
pigment	B-UNK
genes	B-UNK
occur	B-UNK
in	O
different	O
AMN	B-UNK
kindreds	O
.	O

These	O
observations	B-UNK
confirm	O
our	O
earlier	O
impression	O
that	O
the	O
frequency	B-UNK
of	O
abnormal	O
color	B-UNK
vision	I-UNK
is	O
increased	B-UNK
in	O
these	O
kindreds	O
,	O
and	O
it	O
supports	O
our	O
contentions	O
that	O
(	O
1	O
)	O
AMN	B-UNK
(	O
and	O
its	O
companion	O
,	O
adrenoleukodystrophy	B-DISEASE
)	O
are	O
very	O
closely	B-UNK
linked	I-UNK
to	O
the	O
visual	B-UNK
pigment	B-UNK
loci	O
at	O
Xq28	B-UNK
and	O
(	O
2	O
)	O
this	O
proximity	O
might	O
provide	B-UNK
the	O
opportunity	O
to	O
observe	O
contiguous	O
gene	B-UNK
defects	B-UNK
..	O

Molecular	B-UNK
analysis	I-UNK
of	O
a	O
female	O
Lesch	O
-	O
Nyhan	O
patient	B-UNK
.	O

We	O
report	B-UNK
the	O
identification	B-UNK
of	O
a	O
female	O
patient	B-UNK
with	O
the	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
(	O
hypoxanthine	B-UNK
phosphoribosyltransferase	O
[	O
HPRT	B-UNK
]	O
deficiency	B-UNK
)	O
.	O

Cytogenetic	B-UNK
and	O
carrier	B-UNK
studies	B-UNK
revealed	B-UNK
structurally	O
normal	B-UNK
chromosomes	O
for	O
this	O
patient	B-UNK
and	O
her	O
parents	O
and	O
demonstrated	O
that	O
this	O
mutation	B-UNK
arose	O
through	O
a	O
de	O
novo	O
gametic	O
event	O
.	O

Comparison	B-UNK
of	O
this	O
patients	B-UNK
DNA	B-UNK
with	O
the	O
DNA	B-UNK
of	O
her	O
parents	O
revealed	B-UNK
that	O
a	O
microdeletion	O
,	O
which	O
occurred	B-UNK
within	O
a	O
maternal	O
gamete	O
and	O
involved	B-UNK
the	O
entire	O
HPRT	B-UNK
gene	B-UNK
,	O
was	O
partially	O
responsible	B-UNK
for	O
the	O
disease	B-DISEASE
in	O
this	O
patient	B-UNK
.	O

Somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
,	O
generated	O
to	O
separate	O
maternal	O
and	O
paternal	O
X	O
chromosomes	O
,	O
showed	O
that	O
expression	B-UNK
of	O
two	O
additional	O
X	O
-	O
linked	B-UNK
enzymes	B-UNK
,	O
phosphoglycerate	O
kinase	B-UNK
and	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
,	O
were	O
expressed	B-UNK
only	O
in	O
cells	B-UNK
that	O
contained	O
the	O
maternal	O
X	O
chromosome	B-UNK
,	O
suggesting	O
the	O
presence	O
of	O
a	O
functionally	O
inactive	O
paternal	O
X	O
chromosome	B-UNK
.	O

Furthermore	O
,	O
comparison	B-UNK
of	O
methylation	B-UNK
patterns	B-UNK
within	O
a	O
region	B-UNK
of	O
the	O
HPRT	B-UNK
gene	B-UNK
known	O
to	O
be	O
important	O
in	O
gene	B-UNK
regulation	B-UNK
revealed	B-UNK
differences	B-UNK
between	O
DNA	B-UNK
from	O
the	O
father	O
and	O
the	O
patient	B-UNK
,	O
in	O
keeping	O
with	O
an	O
active	B-UNK
HPRT	B-UNK
locus	B-UNK
in	O
the	O
father	O
and	O
an	O
inactive	O
HPRT	B-UNK
locus	B-UNK
in	O
the	O
patient	B-UNK
.	O

Together	O
these	O
data	B-UNK
indicate	O
that	O
nonrandom	O
inactivation	B-UNK
of	O
the	O
cytogenetically	O
normal	B-UNK
paternal	O
X	O
chromosome	B-UNK
and	O
a	O
microdeletion	O
of	O
the	O
HPRT	B-UNK
gene	B-UNK
on	O
an	O
active	B-UNK
maternal	O
X	O
chromosome	B-UNK
were	O
responsible	B-UNK
for	O
the	O
absence	B-UNK
of	O
HPRT	B-UNK
in	O
this	O
patient	B-UNK
..	O

Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
:	O
an	O
X	O
-	O
linked	B-UNK
neurologic	O
disorder	B-UNK
of	O
myelin	B-UNK
metabolism	B-UNK
with	O
a	O
novel	O
mutation	B-UNK
in	O
the	O
gene	B-UNK
encoding	B-UNK
proteolipid	B-UNK
protein	I-UNK
.	O

The	O
nosology	O
of	O
the	O
inborn	O
errors	O
of	O
myelin	B-UNK
metabolism	B-UNK
has	O
been	O
stymied	O
by	O
the	O
lack	B-UNK
of	O
molecular	B-UNK
genetic	I-UNK
analysis	B-UNK
.	O

Historically	O
,	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
has	O
encompassed	O
a	O
host	O
of	O
neurologic	O
disorders	B-UNK
that	O
present	B-UNK
with	O
a	O
deficit	O
of	O
myelin	B-UNK
,	O
the	O
membrane	B-UNK
elaborated	O
by	O
glial	O
cells	B-UNK
that	O
encircles	O
and	O
successively	O
enwraps	O
axons	O
.	O

We	O
describe	O
here	O
a	O
Pelizaeus	O
-	O
Merzbacher	O
pedigree	B-UNK
of	O
the	O
classical	O
type	B-UNK
,	O
with	O
X	O
-	O
linked	B-UNK
inheritance	B-UNK
,	O
a	O
typical	O
clinical	B-UNK
progression	B-UNK
,	O
and	O
a	O
pathologic	O
loss	B-UNK
of	O
myelinating	O
cells	B-UNK
and	O
myelin	B-UNK
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
.	O

To	O
discriminate	O
variants	B-UNK
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
,	O
a	O
set	B-UNK
of	O
oligonucleotide	O
primers	O
was	O
constructed	O
to	O
polymerase	O
-	O
chain	B-UNK
-	O
reaction	B-UNK
(	O
PCR	B-UNK
)	O
amplify	O
and	O
sequence	B-UNK
the	O
gene	B-UNK
encoding	B-UNK
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
,	O
a	O
structural	B-UNK
protein	B-UNK
that	O
comprises	O
half	B-UNK
of	O
the	O
protein	B-UNK
of	O
the	O
myelin	B-UNK
sheath	O
.	O

The	O
PLP	B-UNK
gene	B-UNK
in	O
one	O
of	O
two	O
affected	B-UNK
males	I-UNK
and	O
the	O
carrier	B-UNK
mother	O
of	O
this	O
family	B-UNK
exhibited	O
a	O
single	B-UNK
base	I-UNK
difference	O
in	O
the	O
more	O
than	O
2	O
kb	B-UNK
of	O
the	O
PLP	B-UNK
gene	B-UNK
sequenced	O
,	O
a	O
C----T	O
transition	B-UNK
that	O
would	O
create	O
a	O
serine	O
substitution	B-UNK
for	O
proline	O
at	O
the	O
carboxy	O
end	B-UNK
of	O
the	O
protein	B-UNK
.	O

Our	O
results	B-UNK
delineate	O
the	O
clinical	B-UNK
features	I-UNK
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
,	O
define	B-UNK
the	O
possible	O
molecular	B-UNK
pathology	O
of	O
this	O
dysmyelinating	O
disorder	B-UNK
,	O
and	O
address	O
the	O
molecular	B-UNK
classification	O
of	O
inborn	O
errors	O
of	O
myelin	B-UNK
metabolism	B-UNK
.	O

Patients	B-UNK
with	O
the	O
classical	O
form	B-UNK
(	O
type	B-UNK
I	O
)	O
and	O
the	O
more	O
severely	O
affected	B-UNK
,	O
connatal	O
variant	O
of	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
(	O
type	B-UNK
II	I-UNK
)	O
would	O
be	O
predicted	B-UNK
to	O
display	O
mutation	B-UNK
at	O
the	O
PLP	B-UNK
locus	B-UNK
.	O

The	O
other	O
variants	B-UNK
(	O
types	B-UNK
III	B-UNK
-	O
VI	O
)	O
,	O
which	O
have	O
sometimes	O
been	O
categorized	O
as	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
,	O
may	O
represent	O
mutations	B-UNK
in	O
genes	B-UNK
encoding	B-UNK
other	O
structural	B-UNK
myelin	B-UNK
proteins	B-UNK
or	O
proteins	B-UNK
critical	B-UNK
to	O
myelination	O
..	O

Molecular	B-UNK
basis	I-UNK
of	O
human	B-UNK
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
:	O
analysis	B-UNK
of	O
platelet	B-UNK
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
mRNA	O
.	O

von	B-UNK
Willebrand	I-UNK
disease	I-UNK
(	O
vWD	O
)	O
,	O
the	O
most	O
common	B-UNK
inherited	B-UNK
bleeding	B-DISEASE
disorder	B-UNK
in	O
humans	B-UNK
,	O
can	O
result	B-UNK
from	O
either	O
a	O
quantitative	B-UNK
or	O
a	O
qualitative	O
defect	B-UNK
in	O
the	O
adhesive	O
glycoprotein	O
,	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
(	O
vWF	B-UNK
)	O
.	O

Molecular	B-UNK
studies	B-UNK
of	O
vWD	O
have	O
been	O
limited	O
by	O
the	O
large	B-UNK
size	B-UNK
of	O
the	O
vWF	B-UNK
gene	B-UNK
and	O
difficulty	O
in	O
obtaining	O
the	O
vWF	B-UNK
mRNA	O
from	O
patients	B-UNK
.	O

By	O
use	O
of	O
an	O
adaptation	O
of	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
,	O
vWF	B-UNK
mRNA	O
was	O
amplified	O
and	O
sequenced	O
from	O
peripheral	B-UNK
blood	I-UNK
platelets	O
.	O

A	O
silent	O
vWF	B-UNK
allele	B-UNK
was	O
identified	B-UNK
,	O
resulting	B-UNK
from	O
a	O
cis	B-UNK
defect	B-UNK
in	O
vWF	B-UNK
mRNA	O
transcription	B-UNK
or	O
processing	O
.	O

In	O
two	O
type	B-UNK
IIA	O
vWD	O
patients	B-UNK
,	O
two	O
different	O
but	O
adjacent	O
missense	B-UNK
mutations	I-UNK
were	O
identified	B-UNK
,	O
the	O
locations	O
of	O
which	O
may	O
identify	B-UNK
an	O
important	O
vWF	B-UNK
functional	O
domain	B-UNK
.	O

Expression	B-UNK
in	O
heterologous	O
cells	B-UNK
of	O
recombinant	B-UNK
vWF	B-UNK
containing	O
one	O
of	O
these	O
latter	O
mutations	B-UNK
reproduced	O
the	O
characteristic	B-UNK
structural	B-UNK
abnormality	O
seen	O
in	O
type	B-UNK
IIA	O
vWD	O
plasma	O
..	O

Familial	B-UNK
deficiency	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
associated	O
with	O
recurrent	O
meningococcal	B-DISEASE
infections	I-DISEASE
.	O

We	O
describe	O
an	O
11-year	O
-	O
old	O
girl	O
suffering	O
from	O
recurrent	O
meningitis	B-DISEASE
with	O
a	O
complete	O
absence	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C7	B-UNK
)	O
.	O

Diagnosis	B-UNK
was	O
established	O
by	O
haemolytic	O
titration	O
and	O
western	B-UNK
blotting	O
.	O

The	O
patients	B-UNK
serum	B-UNK
lacked	O
the	O
85	O
kDa	O
C7	B-UNK
chain	B-UNK
.	O

Haemolytic	O
activity	B-UNK
of	O
serum	B-UNK
was	O
reconstituted	O
with	O
either	O
pooled	O
normal	B-UNK
human	B-UNK
serum	B-UNK
or	O
with	O
purified	O
C7	B-UNK
.	O

The	O
relatives	B-UNK
(	O
parents	O
and	O
one	O
sister	O
)	O
had	O
half	B-UNK
-	O
normal	B-UNK
levels	B-UNK
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	B-UNK
C7	B-UNK
,	O
indicating	O
a	O
heterozygous	B-UNK
state	B-UNK
for	O
C7	B-UNK
deficiency	I-UNK
..	O

Translocation	B-UNK
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	B-UNK
.	O
1	O
;	O
p13	O
)	O
associated	O
with	O
familial	B-UNK
isolated	B-UNK
aniridia	B-DISEASE
.	O

A	O
father	O
and	O
daughter	O
with	O
isolated	B-UNK
aniridia	B-DISEASE
were	O
observed	B-UNK
to	O
have	O
an	O
apparently	O
balanced	O
,	O
reciprocal	O
translocation	B-UNK
involving	O
chromosomes	O
5	O
and	O
11	O
[	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	B-UNK
.	O
1	O
;	O
p13)].	O

No	O
other	O
clinical	B-UNK
characteristics	B-UNK
often	O
associated	O
with	O
the	O
deletion	B-UNK
of	O
11p13	O
were	O
observed	B-UNK
in	O
this	O
family	B-UNK
.	O

This	O
finding	O
,	O
in	O
association	B-UNK
with	O
3	O
other	O
instances	O
of	O
single	B-UNK
breaks	O
at	O
11p13	O
and	O
aniridia	B-DISEASE
,	O
supports	O
the	O
assignment	B-UNK
of	O
AN2	B-UNK
to	O
11p13	O
.	O

Homozygous	B-UNK
hypobetalipoproteinemia	O
:	O
a	O
disease	B-DISEASE
distinct	O
from	O
abetalipoproproteinemia	O
at	O
the	O
molecular	B-UNK
level	B-UNK
.	O

apoB	O
DNA	B-UNK
,	O
RNA	B-UNK
,	O
and	O
protein	B-UNK
from	O
two	O
patients	B-UNK
with	O
homozygous	B-UNK
hypobetalipoproteinemia	O
(	O
HBL	O
)	O
were	O
evaluated	O
and	O
compared	B-UNK
with	O
normal	B-UNK
individuals	B-UNK
.	O

Southern	B-UNK
blot	I-UNK
analysis	I-UNK
with	O
10	O
different	O
cDNA	O
probes	O
revealed	B-UNK
a	O
normal	B-UNK
gene	B-UNK
without	O
major	B-UNK
insertions	O
,	O
deletions	O
,	O
or	O
rearrangements	O
.	O

Northern	B-UNK
and	O
slot	O
blot	B-UNK
analyses	O
of	O
total	B-UNK
liver	B-UNK
mRNA	O
from	O
HBL	O
patients	B-UNK
documented	O
a	O
normal	B-UNK
size	B-UNK
apoB	O
mRNA	O
that	O
was	O
present	B-UNK
in	O
greatly	O
reduced	O
quantities	O
.	O

ApoB	O
protein	B-UNK
was	O
detected	B-UNK
within	O
HBL	O
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques	O
;	O
however	O
,	O
it	O
was	O
markedly	B-UNK
reduced	O
in	O
quantity	O
when	O
compared	B-UNK
with	O
control	B-UNK
samples	B-UNK
.	O

No	O
apoB	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
HBL	O
individuals	B-UNK
with	O
an	O
ELISA	O
assay	B-UNK
.	O

These	O
data	B-UNK
are	O
most	O
consistent	B-UNK
with	O
a	O
mutation	B-UNK
in	O
the	O
coding	B-UNK
portion	B-UNK
of	O
the	O
apoB	O
gene	B-UNK
in	O
HBL	O
patients	B-UNK
,	O
leading	B-UNK
to	O
an	O
abnormal	O
apoB	O
protein	B-UNK
and	O
apoB	O
mRNA	O
instability	B-UNK
.	O

These	O
results	B-UNK
are	O
distinct	O
from	O
those	O
previously	B-UNK
noted	O
in	O
abetalipoproteinemia	B-DISEASE
,	O
which	O
was	O
characterized	B-UNK
by	O
an	O
elevated	B-UNK
level	B-UNK
of	O
hepatic	B-UNK
apoB	O
mRNA	O
and	O
accumulation	B-UNK
of	O
intracellular	O
hepatic	B-UNK
apoB	O
protein	B-UNK
..	O

Spontaneous	O
reversion	O
of	O
novel	O
Lesch	O
-	O
Nyhan	O
mutation	B-UNK
by	O
HPRT	B-UNK
gene	B-UNK
rearrangement	B-UNK
.	O

Molecular	B-UNK
analysis	I-UNK
of	O
an	O
unusual	O
patient	B-UNK
with	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
has	O
suggested	O
that	O
the	O
mutation	B-UNK
is	O
due	O
to	O
a	O
partial	O
HPRT	B-UNK
gene	B-UNK
duplication	B-UNK
.	O

We	O
now	O
report	B-UNK
the	O
cloning	B-UNK
and	O
sequencing	B-UNK
of	O
the	O
mutant	B-UNK
HPRT	B-UNK
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	B-UNK
of	O
exons	O
2	O
and	O
3	O
.	O

This	O
mutation	B-UNK
is	O
the	O
result	B-UNK
of	O
an	O
internal	O
duplication	B-UNK
of	O
16	O
-	O
20	O
kilobases	O
of	O
the	O
gene	B-UNK
.	O

The	O
structure	B-UNK
of	O
the	O
mutant	B-UNK
gene	B-UNK
suggests	O
that	O
the	O
duplication	B-UNK
was	O
not	O
generated	O
by	O
a	O
single	B-UNK
unequal	O
crossing	O
-	O
over	O
event	O
between	O
two	O
normal	B-UNK
HPRT	B-UNK
alleles	B-UNK
.	O

Growth	B-UNK
of	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
lymphoblasts	O
from	O
this	O
patient	B-UNK
in	O
selective	O
medium	O
has	O
permitted	O
isolation	B-UNK
of	O
spontaneous	O
HPRT	B-UNK
+	O
revertants	O
of	O
this	O
mutation	B-UNK
.	O

The	O
reversion	O
event	O
involves	O
a	O
second	O
major	B-UNK
HPRT	B-UNK
gene	B-UNK
rearrangement	B-UNK
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	B-UNK
of	O
the	O
mutant	B-UNK
gene	B-UNK
is	O
deleted	B-UNK
.	O

The	O
original	O
mutation	B-UNK
therefore	O
has	O
the	O
potential	B-UNK
for	O
spontaneous	O
somatic	B-UNK
reversion	O
.	O

This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	B-UNK
of	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
exhibited	O
by	O
this	O
patient	B-UNK
..	O

Complex	O
glycerol	B-DISEASE
kinase	I-DISEASE
deficiency	I-DISEASE
:	O
molecular	B-UNK
-	O
genetic	B-UNK
,	O
cytogenetic	B-UNK
,	O
and	O
clinical	B-UNK
studies	B-UNK
of	O
five	O
Japanese	B-UNK
patients	B-UNK
.	O

Five	O
male	B-UNK
Japanese	B-UNK
patients	B-UNK
with	O
complex	O
glycerol	B-DISEASE
kinase	I-DISEASE
deficiency	I-DISEASE
(	O
CGKD	O
)	O
and	O
their	O
relatives	B-UNK
were	O
studied	O
clinically	O
,	O
cytogenetically	O
,	O
and	O
molecular	B-UNK
-	O
genetically	B-UNK
.	O

All	O
patients	B-UNK
had	O
muscular	B-DISEASE
dystrophy	I-DISEASE
or	O
muscle	B-DISEASE
weakness	I-DISEASE
,	O
mental	B-UNK
retardation	I-UNK
,	O
congenital	B-UNK
adrenal	B-UNK
hypoplasia	B-UNK
,	O
and	O
glycerol	B-DISEASE
kinase	I-DISEASE
deficiency	I-DISEASE
.	O

High	B-UNK
-	O
resolution	O
GTG	O
-	O
banded	O
chromosomes	O
showed	O
a	O
microdeletion	O
in	O
the	O
Xp21	B-UNK
region	B-UNK
in	O
all	O
four	O
patients	B-UNK
examined	O
and	O
in	O
all	O
five	O
mothers	O
.	O

Southern	B-UNK
hybridizations	O
,	O
after	O
digestions	O
by	O
restriction	B-UNK
endonucleases	O
,	O
with	O
various	O
cloned	O
DNAs	O
(	O
D2	B-UNK
,	O
99	O
-	O
6	O
,	O
B24	O
,	O
C7	B-UNK
,	O
L1	B-UNK
-	O
4	O
,	O
cDMD13	O
-	O
14	O
,	O
J66-HI	O
,	O
P20	O
,	O
J	O
-	O
Bir	O
,	O
ERT87	O
-	O
30	O
,	O
ERT87	O
-	O
15	O
,	O
ERT87	O
-	O
8	O
,	O
ERT87	O
-	O
1	O
,	O
XJ-1	O
.	O
1	O
,	O
754	O
,	O
cx5	O
.	O
7	O
,	O
and	O
OTC-1	O
)	O
that	O
are	O
located	B-UNK
around	O
Xp21	B-UNK
also	O
showed	O
a	O
deletion	B-UNK
in	O
the	O
genome	B-UNK
of	O
all	O
patients	B-UNK
and	O
mothers	O
.	O

Although	O
the	O
deletion	B-UNK
differed	O
in	O
size	B-UNK
among	O
patients	B-UNK
,	O
a	O
segment	O
commonly	O
absent	O
was	O
located	B-UNK
between	O
the	O
genomic	B-UNK
sequences	O
corresponding	O
to	O
L1	B-UNK
-	O
4	O
and	O
cDMD13	O
-	O
14	O
.	O

This	O
finding	O
indicated	O
that	O
the	O
gene	B-UNK
coding	B-UNK
for	O
glycerol	B-UNK
kinase	B-UNK
(	O
GK	O
)	O
is	O
located	B-UNK
within	O
this	O
segment	O
.	O

A	O
comparison	B-UNK
of	O
the	O
clinical	B-UNK
manifestations	I-UNK
of	O
the	O
present	B-UNK
five	O
patients	B-UNK
and	O
reported	B-UNK
CGKD	O
or	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
patients	B-UNK
with	O
DNA	B-UNK
deletion	B-UNK
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	B-UNK
responsible	B-UNK
for	O
gonadotropin	O
deficiency	B-UNK
(	O
GTD	O
)	O
.	O

The	O
result	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
and	O
results	B-UNK
of	O
previous	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
genes	B-UNK
for	O
ornithine	O
transcarbamylase	O
(	O
OTC	O
)	O
,	O
DMD	B-UNK
,	O
and	O
GK	O
and	O
putative	O
genes	B-UNK
responsible	B-UNK
for	O
congenital	B-UNK
adrenal	B-UNK
hypoplasia	B-UNK
(	O
AHC	O
)	O
and	O
GTD	O
are	O
arranged	O
from	O
telomere	O
to	O
centromere	O
as	O
pter	O
--	O
GTD	O
--	O
AHC	O
--	O
GK	O
--	O
DMD	B-UNK
--	O
OTC	O
--	O
cen	O

Genetically	B-UNK
determined	B-UNK
low	B-UNK
C4	B-UNK
:	O
a	O
predisposing	O
factor	B-UNK
to	O
autoimmune	B-UNK
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
.	O

Of	O
26	O
patients	B-UNK
with	O
autoimmune	B-UNK
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
(	O
CAH	O
)	O
starting	O
in	O
childhood	O
18	O
(	O
69	O
%	O
)	O
had	O
low	B-UNK
C4	B-UNK
and	O
5	O
(	O
19	O
%	O
)	O
had	O
low	B-UNK
C3	B-UNK
serum	B-UNK
levels	B-UNK
.	O

Impaired	B-UNK
hepatic	B-UNK
synthesis	B-UNK
and	O
immune	B-UNK
-	O
consumption	O
were	O
unlikely	O
since	O
transferrin	O
levels	B-UNK
were	O
normal	B-UNK
in	O
all	O
patients	B-UNK
,	O
albumin	O
levels	B-UNK
were	O
persistently	O
low	B-UNK
in	O
only	O
3	O
,	O
and	O
only	O
3	O
had	O
raised	O
levels	B-UNK
of	O
activation	O
fragment	B-UNK
C3d	O
.	O

C4d	O
was	O
normal	B-UNK
in	O
all	O
patients	B-UNK
studied	O
.	O

In	O
the	O
families	B-UNK
of	O
12	O
probands	O
with	O
low	B-UNK
C4	B-UNK
,	O
7	O
parents	O
had	O
low	B-UNK
C4	B-UNK
and	O
2	O
had	O
levels	B-UNK
which	O
were	O
at	O
the	O
lower	O
limit	O
of	O
normal	B-UNK
.	O

5	O
of	O
10	O
siblings	O
from	O
5	O
families	B-UNK
had	O
low	B-UNK
C4	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
low	B-UNK
C4	B-UNK
levels	B-UNK
in	O
CAH	O
are	O
genetically	B-UNK
determined	B-UNK
.	O

C4	B-UNK
phenotyping	O
in	O
20	O
patients	B-UNK
and	O
in	O
26	O
parents	O
showed	O
that	O
90	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
had	O
null	O
allotypes	O
at	O
either	O
the	O
C4A	O
or	O
C4B	O
locus	B-UNK
compared	B-UNK
with	O
59	O
%	O
in	O
controls	O
,	O
indicating	O
that	O
defective	O
expression	B-UNK
of	O
structural	B-UNK
genes	B-UNK
may	O
contribute	B-UNK
to	O
the	O
observed	B-UNK
C4	B-UNK
deficiency	B-UNK
..	O

An	O
amino	B-UNK
-	O
acid	B-UNK
substitution	B-UNK
involved	B-UNK
in	O
phenylketonuria	O
is	O
in	O
linkage	B-UNK
disequilibrium	I-UNK
with	O
DNA	B-UNK
haplotype	B-UNK
2	O
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
human	B-UNK
genetic	B-UNK
disorder	I-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
hepatic	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
,	O
phenylalanine	B-UNK
4-monooxygenase	O
,	O
EC	B-UNK
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

PKU	B-UNK
is	O
a	O
common	B-UNK
inborn	O
error	O
of	O
amino	B-UNK
-	O
acid	B-UNK
metabolism	B-UNK
in	O
caucasian	B-UNK
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	B-UNK
are	O
carriers	B-UNK
of	O
a	O
PKU	B-UNK
allele	B-UNK
.	O

To	O
define	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
of	O
PKU	B-UNK
,	O
we	O
characterized	B-UNK
twelve	O
restriction	B-UNK
fragment	I-UNK
-	O
length	B-UNK
polymorphism	B-UNK
(	O
RFLP	B-UNK
)	O
haplotypes	O
of	O
the	O
PAH	B-UNK
locus	B-UNK
in	O
the	O
northern	B-UNK
European	B-UNK
population	B-UNK
and	O
observed	B-UNK
that	O
90	O
%	O
of	O
the	O
PKU	B-UNK
alleles	B-UNK
in	O
this	O
population	B-UNK
are	O
confined	O
to	O
four	O
common	B-UNK
RFLP	B-UNK
haplotypes	O
.	O

We	O
have	O
recently	O
reported	B-UNK
a	O
splicing	B-UNK
mutation	B-UNK
in	O
the	O
PAH	B-UNK
gene	B-UNK
that	O
is	O
associated	O
with	O
RFLP	B-UNK
haplotype	B-UNK
3	O
which	O
is	O
present	B-UNK
at	O
about	O
40	O
%	O
of	O
mutant	B-UNK
alleles	I-UNK
.	O

We	O
now	O
report	B-UNK
the	O
molecular	B-UNK
lesion	O
associated	O
with	O
the	O
RFLP	B-UNK
haplotype	B-UNK
2	O
mutant	B-UNK
allele	B-UNK
.	O

This	O
defect	B-UNK
is	O
caused	B-UNK
by	O
a	O
C	O
-	O
to	O
-T	O
transition	B-UNK
in	O
exon	B-UNK
12	O
resulting	B-UNK
in	O
an	O
amino	B-UNK
-	O
acid	B-UNK
substitution	B-UNK
(	O
Arg	B-UNK
to	O
Trp	O
)	O
at	O
residue	O
408	O
of	O
PAH	B-UNK
.	O

Direct	B-UNK
hybridization	B-UNK
analysis	B-UNK
of	O
the	O
point	B-UNK
mutation	I-UNK
using	O
a	O
specific	B-UNK
oligonucleotide	O
probe	O
demonstrated	O
that	O
this	O
mutation	B-UNK
is	O
also	O
in	O
linkage	B-UNK
disequilibrium	I-UNK
with	O
RFLP	B-UNK
haplotype	B-UNK
2	O
alleles	B-UNK
that	O
make	O
up	O
about	O
20	O
%	O
of	O
mutant	B-UNK
PAH	B-UNK
genes	B-UNK

Choroideremia	B-UNK
:	O
close	B-UNK
linkage	I-UNK
to	O
DXYS1	O
and	O
DXYS12	O
demonstrated	O
by	O
segregation	B-UNK
analysis	B-UNK
and	O
historical	O
-	O
genealogical	O
evidence	B-UNK
.	O

Linkage	B-UNK
studies	B-UNK
using	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
were	O
conducted	O
in	O
the	O
X	O
-	O
linked	B-UNK
disorder	B-UNK
,	O
choroideremia	B-UNK
,	O
designated	O
TCD	B-UNK
for	O
Progressive	B-UNK
Tapeto	O
-	O
Choroidal	O
Dystrophy	B-UNK
.	O

Previously	B-UNK
demonstrated	O
close	B-UNK
linkage	I-UNK
with	O
locus	B-UNK
DXYS1	O
was	O
confirmed	B-UNK
(	O
lod	B-UNK
11	O
.	O
44	O
at	O
0	O
recombination	B-UNK
distance	O
)	O
.	O

In	O
addition	B-UNK
,	O
locus	B-UNK
DXYS12	O
was	O
found	O
to	O
be	O
closely	B-UNK
linked	I-UNK
with	O
TCD	B-UNK
(	O
lod	B-UNK
3	O
.	O
31	O
at	O
0	O
recombination	B-UNK
distance	O
)	O
.	O

The	O
disease	B-DISEASE
mainly	O
occurs	O
in	O
three	O
large	B-UNK
kindreds	O
in	O
remote	O
Northern	B-UNK
Finland	O
.	O

While	O
formal	O
genealogical	O
proof	O
is	O
lacking	O
,	O
all	O
presently	O
living	O
(	O
more	O
than	O
80	O
affected	B-UNK
males	I-UNK
and	O
120	O
carrier	B-UNK
females	O
)	O
probably	O
originate	O
from	O
a	O
common	B-UNK
founder	B-UNK
couple	O
born	O
in	O
1644	O
and	O
1646	O
,	O
twelve	O
generations	O
ago	O
.	O

All	O
36	O
patients	B-UNK
and	O
48	O
carriers	B-UNK
tested	O
from	O
the	O
three	O
kindreds	O
had	O
the	O
same	O
haplotype	B-UNK
(	O
TCD	B-UNK
/	O
DXYS1	O
,	O
11kb	O
/	O
DXYS12	O
,	O
1	O
.	O
6	O
kb	B-UNK
)	O
.	O

Given	O
that	O
at	O
least	O
105	O
female	O
meioses	O
transmitting	O
TCD	B-UNK
have	O
occurred	B-UNK
since	O
1650	O
in	O
these	O
kindreds	O
,	O
extremely	O
close	B-UNK
linkage	I-UNK
between	O
TCD	B-UNK
,	O
DXYS1	O
and	O
DXYS12	O
is	O
suggested	O
.	O

The	O
above	O
haplotype	B-UNK
is	O
a	O
very	O
useful	O
diagnostic	B-UNK
tool	O
in	O
these	O
TCD	B-UNK
families	B-UNK
.	O

We	O
suggest	B-UNK
that	O
our	O
historical	O
-	O
genealogical	O
approach	O
to	O
linkage	B-UNK
analysis	I-UNK
may	O
be	O
possible	O
elsewhere	O
in	O
similar	B-UNK
isolated	B-UNK
populations	O

Von	B-DISEASE
Hippel	I-DISEASE
-	I-DISEASE
Lindau	I-DISEASE
disease	I-DISEASE
maps	B-UNK
to	O
the	O
region	B-UNK
of	O
chromosome	B-UNK
3	O
associated	O
with	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
.	O

Von	B-DISEASE
Hippel	I-DISEASE
-	I-DISEASE
Lindau	I-DISEASE
disease	I-DISEASE
(	O
VHL	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
disorder	B-UNK
with	O
inherited	B-UNK
susceptibility	B-UNK
to	O
various	O
forms	B-UNK
of	O
cancer	B-DISEASE
,	O
including	O
hemangioblastomas	O
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
phaeochromocytomas	O
,	O
pancreatic	B-UNK
malignancies	B-DISEASE
,	O
and	O
renal	B-UNK
cell	I-UNK
carcinomas	I-UNK
.	O

Renal	B-UNK
cell	I-UNK
carcinomas	I-UNK
constitute	O
a	O
particularly	O
frequent	B-UNK
cause	O
of	O
death	B-UNK
in	O
this	O
disorder	B-UNK
,	O
occurring	O
as	O
bilateral	O
and	O
multifocal	O
tumours	B-DISEASE
,	O
and	O
presenting	B-UNK
at	O
an	O
earlier	O
age	B-UNK
than	O
in	O
sporadic	B-UNK
,	O
non-familial	O
cases	B-UNK
of	O
this	O
tumour	B-UNK
type	B-UNK
.	O

We	O
report	B-UNK
here	O
that	O
the	O
VHL	B-UNK
gene	B-UNK
is	O
linked	B-UNK
to	O
the	O
locus	B-UNK
encoding	B-UNK
the	O
human	B-UNK
homologoue	O
of	O
the	O
RAF1	O
oncogene	O
,	O
which	O
maps	B-UNK
to	O
chromosome	B-UNK
3p25	O
(	O
ref	O
.	O
4	O
)	O
.	O

Crossovers	O
with	O
the	O
VHL	B-UNK
locus	B-UNK
suggest	B-UNK
that	O
the	O
defect	B-UNK
responsible	B-UNK
for	O
the	O
VHL	B-UNK
phenotype	B-UNK
is	O
not	O
a	O
mutation	B-UNK
in	O
the	O
RAF1	O
gene	B-UNK
itself	O
.	O

An	O
alternative	B-UNK
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	B-UNK
formation	B-UNK
may	O
be	O
the	O
inactivation	B-UNK
of	O
a	O
putative	O
tumour	B-UNK
suppressor	I-UNK
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	B-UNK
and	O
sporadic	B-UNK
forms	B-UNK
of	O
the	O
cancer	B-DISEASE
.	O

Sporadic	B-UNK
renal	B-UNK
cell	I-UNK
carcinomas	I-UNK
have	O
previously	B-UNK
been	O
associated	O
with	O
the	O
loss	B-UNK
of	O
regions	B-UNK
on	O
chromosome	B-UNK
3p	O
(	O
refs	O
5	O
,	O
6	O
)	O
.	O

Consequently	O
,	O
sporadic	B-UNK
and	O
VHL	B-UNK
-	O
associated	O
forms	B-UNK
of	O
renal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
might	O
both	O
result	B-UNK
from	O
alterations	B-UNK
causing	B-UNK
loss	B-UNK
of	O
function	B-UNK
of	O
the	O
same	O
tumour	B-UNK
suppressor	I-UNK
gene	B-UNK
on	O
this	O
chromosome	B-UNK
..	O

Tightly	B-UNK
linked	I-UNK
flanking	O
markers	B-UNK
for	O
the	O
Lowe	O
oculocerebrorenal	B-DISEASE
syndrome	I-DISEASE
,	O
with	O
application	O
to	O
carrier	B-UNK
assessment	O
.	O

The	O
Lowe	O
oculocerebrorenal	B-DISEASE
syndrome	I-DISEASE
(	O
OCRL	B-UNK
)	O
is	O
characterized	B-UNK
by	O
congenital	B-UNK
cataract	B-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
and	O
defective	O
renal	B-UNK
tubular	O
function	B-UNK
.	O

A	O
map	B-UNK
assignment	B-UNK
of	O
OCRL	B-UNK
to	O
Xq24-q26	O
has	O
been	O
made	O
previously	B-UNK
by	O
linkage	B-UNK
analysis	I-UNK
with	O
DXS42	O
at	O
Xq24-q26	O
(	O
theta	B-UNK
=	O
0	O
,	O
z	O
=	O
5	O
.	O
09	O
)	O
and	O
with	O
DXS10	O
at	O
Xq26	O
(	O
theta	B-UNK
=	O
0	O
,	O
z	O
=	O
6	O
.	O
45	O
)	O
.	O

Two	O
additional	O
families	B-UNK
were	O
studied	O
and	O
three	O
additional	O
polymorphisms	B-UNK
were	O
identified	B-UNK
at	O
DXS42	O
by	O
using	O
a	O
35-kb	O
sequence	B-UNK
isolated	B-UNK
with	O
the	O
probe	O
detecting	O
the	O
original	O
polymorphism	B-UNK
at	O
DXS42	O
.	O

With	O
additional	O
OCRL	B-UNK
families	B-UNK
made	O
informative	O
for	O
DXS42	O
,	O
theta	B-UNK
remained	O
0	O
with	O
z	O
=	O
6	O
.	O

63	O
;	O
and	O
for	O
DXS10	O
theta	B-UNK
=	O
0	O
.	O

03	O
and	O
z	O
=	O
7	O
.	O

07	O
.	O

Evidence	B-UNK
for	O
placing	O
OCRL	B-UNK
at	O
Xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
Lowe	O
syndrome	B-UNK
and	O
an	O
X	O
;	O
3	O
translocation	B-UNK
.	O

We	O
have	O
used	O
the	O
Xq25	O
breakpoint	O
in	O
this	O
patient	B-UNK
to	O
determine	B-UNK
the	O
position	B-UNK
of	O
OCRL	B-UNK
relative	B-UNK
to	O
the	O
two	O
linked	B-UNK
markers	B-UNK
.	O

Each	O
derivative	O
chromosome	B-UNK
was	O
isolated	B-UNK
away	O
from	O
its	O
normal	B-UNK
counterpart	O
in	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
.	O

DXS42	O
was	O
mapped	B-UNK
to	O
the	O
derivative	O
chromosome	B-UNK
X	O
containing	O
Xpterq25	O
,	O
and	O
DXS10	O
was	O
mapped	B-UNK
to	O
the	O
derivative	O
chromosome	B-UNK
3	O
containing	O
Xq25-qter	O
.	O

The	O
markers	B-UNK
DXS10	O
and	O
DXS42	O
therefore	O
show	O
tight	O
linkage	B-UNK
with	O
OCRL	B-UNK
in	O
six	O
families	B-UNK
and	O
flank	O
the	O
Xq25	O
breakpoint	O
in	O
a	O
female	O
patient	B-UNK
with	O
an	O
X	O
;	O
3	O
translocation	B-UNK
.	O

Linkage	B-UNK
analysis	I-UNK
with	O
flanking	O
markers	B-UNK
was	O
used	O
to	O
assess	B-UNK
OCRL	B-UNK
carrier	B-UNK
status	I-UNK
in	O
women	B-UNK
at	O
risk	B-UNK
.	O

Results	B-UNK
,	O
when	O
compared	B-UNK
with	O
carrier	B-UNK
determination	B-UNK
by	O
ophthalmologic	O
examination	B-UNK
,	O
indicated	O
that	O
the	O
slit	O
-	O
lamp	O
exam	O
can	O
be	O
a	O
sensitive	B-UNK
and	O
specific	B-UNK
method	O
of	O
carrier	B-UNK
determination	B-UNK
in	O
many	O
cases	B-UNK

Identification	B-UNK
of	O
a	O
single	B-UNK
nucleotide	I-UNK
change	B-UNK
in	O
the	O
hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
gene	B-UNK
(	O
HPRTYale	O
)	O
responsible	B-UNK
for	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

Complete	O
deficiency	B-UNK
of	O
hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
causes	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

Previous	B-UNK
characterization	B-UNK
of	O
a	O
mutant	B-UNK
form	B-UNK
of	O
HPRT	B-UNK
,	O
HPRTYale	O
,	O
from	O
a	O
subject	O
with	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
revealed	B-UNK
normal	B-UNK
mRNA	O
and	O
protein	B-UNK
concentrations	O
,	O
no	O
residual	B-UNK
catalytic	O
activity	B-UNK
,	O
and	O
cathodal	O
migration	O
upon	O
PAGE	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
HPRTYale	O
cDNA	O
.	O

The	O
nucleotide	B-UNK
sequence	I-UNK
of	O
full	O
-	O
length	B-UNK
HPRTYale	O
cDNA	O
revealed	B-UNK
a	O
single	B-UNK
nucleotide	I-UNK
substitution	B-UNK
compared	B-UNK
with	O
normal	B-UNK
HPRT	B-UNK
cDNA	O
G----C	O
at	O
nucleotide	B-UNK
position	I-UNK
211	O
.	O

This	O
transversion	B-UNK
predicts	O
substitution	B-UNK
of	O
arginine	O
for	O
glycine	O
at	O
amino	B-UNK
acid	I-UNK
position	B-UNK
71	O
,	O
explaining	O
the	O
cathodal	O
migration	O
of	O
HPRTYale	O
.	O

Chou-Fasman	O
secondary	O
structure	B-UNK
analysis	B-UNK
predicts	O
a	O
change	B-UNK
in	O
the	O
probability	B-UNK
of	O
beta-turn	O
formation	B-UNK
in	O
the	O
region	B-UNK
containing	O
the	O
mutation	B-UNK
.	O

Inclusion	O
of	O
the	O
bulky	O
arginine	O
side	O
chain	B-UNK
in	O
place	O
of	O
glycine	O
probably	O
disrupts	O
protein	B-UNK
folding	O
as	O
well	O
.	O

Cloning	B-UNK
mutant	B-UNK
forms	B-UNK
of	O
cDNA	O
allows	O
identification	B-UNK
of	O
specific	B-UNK
mutations	B-UNK
,	O
provides	O
insight	O
into	O
mutational	O
mechanisms	O
,	O
and	O
facilitates	O
structure	B-UNK
-	O
function	B-UNK
analysis	B-UNK
of	O
mutant	B-UNK
proteins	B-UNK
..	O

Two	O
point	B-UNK
mutations	I-UNK
are	O
responsible	B-UNK
for	O
G6PD	B-UNK
polymorphism	B-UNK
in	O
Sardinia	O
.	O

The	O
human	B-UNK
X	O
-	O
linked	B-UNK
gene	B-UNK
encoding	B-UNK
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
is	O
highly	B-UNK
polymorphic	B-UNK
;	O
more	O
than	O
300	O
G6PD	B-UNK
variants	I-UNK
have	O
been	O
identified	B-UNK
.	O

G6PD	B-UNK
deficiency	I-UNK
in	O
different	O
geographical	O
areas	O
appears	B-UNK
to	O
have	O
arisen	O
through	O
independent	O
mutational	O
events	O
,	O
but	O
within	O
the	O
same	O
population	B-UNK
it	O
may	O
also	O
be	O
heterogeneous	O
.	O

One	O
example	O
is	O
the	O
island	B-UNK
of	O
Sardinia	O
,	O
where	O
careful	O
clinical	B-UNK
and	O
biochemical	O
studies	B-UNK
have	O
identified	B-UNK
four	O
different	O
G6PD	B-UNK
variants	I-UNK
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
four	O
G6PD	B-UNK
variants	I-UNK
from	O
Sardinia	O
and	O
found	O
that	O
only	O
two	O
mutations	B-UNK
are	O
responsible	B-UNK
for	O
G6PD	B-UNK
deficiency	I-UNK
in	O
this	O
area	B-UNK
one	O
mutation	B-UNK
is	O
the	O
cause	O
of	O
the	O
G6PD	B-UNK
Seattle	O
-	O
like	O
phenotype	B-UNK
,	O
a	O
milder	B-UNK
form	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
;	O
the	O
other	O
mutation	B-UNK
is	O
responsible	B-UNK
for	O
all	O
forms	B-UNK
of	O
very	O
severe	B-UNK
G6PD	B-UNK
deficiency	I-UNK
in	O
Sardinia	O
and	O
,	O
possibly	O
,	O
in	O
the	O
Mediterranean	B-UNK
..	O

Chronic	B-UNK
nonspherocytic	O
hemolytic	B-UNK
anemia	I-UNK
(	O
CNSHA	O
)	O
and	O
glucose	B-UNK
6	I-UNK
phosphate	I-UNK
dehydrogenase	I-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
a	O
patient	B-UNK
with	O
familial	B-UNK
amyloidotic	O
polyneuropathy	B-DISEASE
(	O
FAP	B-UNK
)	O
.	O

Molecular	B-UNK
study	B-UNK
of	O
a	O
new	O
variant	O
(	O
G6PD	B-UNK
Clinic	O
)	O
with	O
markedly	B-UNK
acidic	O
pH	B-UNK
optimum	O
.	O

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
variant	O
with	O
severe	B-UNK
erythrocytic	O
G6PD	B-UNK
deficiency	I-UNK
and	O
a	O
unique	O
pH	B-UNK
optimum	O
is	O
described	O
in	O
a	O
young	B-UNK
patient	B-UNK
with	O
chronic	B-UNK
nonspherocytic	O
hemolytic	B-UNK
anemia	I-UNK
(	O
CNSHA	O
)	O
and	O
familial	B-UNK
amyloidotic	O
polyneuropathy	B-DISEASE
(	O
FAP	B-UNK
)	O
.	O

Chronic	B-UNK
hemolysis	B-DISEASE
was	O
present	B-UNK
in	O
the	O
absence	B-UNK
of	O
infections	B-DISEASE
,	O
oxidant	O
drugs	O
or	O
ingestion	O
of	O
faba	O
beans	O
.	O

Residual	B-UNK
enzyme	B-UNK
activity	I-UNK
was	O
about	O
2	O
.	O

6	O
%	O
and	O
63	O
%	O
of	O
normal	B-UNK
activity	B-UNK
in	O
erythrocytes	O
and	O
leucocytes	O
,	O
respectively	O
.	O

A	O
molecular	B-UNK
study	B-UNK
using	O
standard	O
methods	O
showed	O
G6PD	B-UNK
in	O
the	O
patient	B-UNK
to	O
have	O
normal	B-UNK
electrophoretic	B-UNK
mobility	O
(	O
at	O
pH	B-UNK
7	O
.	O
0	O
,	O
8	O
.	O
0	O
and	O
8	O
.	O
8)	O
,	O
normal	B-UNK
apparent	O
affinity	B-UNK
for	O
substrates	O
(	O
Km	O
,	O
G6P	O
and	O
NADP	O
)	O
and	O
a	O
slightly	O
abnormal	O
utilization	O
of	O
substrate	O
analogues	O
(	O
decreased	B-UNK
deamino	O
-	O
NADP	O
and	O
increased	B-UNK
2-deoxyglucose-6-phosphate	O
utilization	O
)	O
.	O

Heat	O
stability	O
was	O
found	O
to	O
be	O
markedly	B-UNK
decreased	B-UNK
(	O
8	O
%	O
of	O
residual	B-UNK
activity	B-UNK
after	O
20	O
min	O
of	O
incubation	O
at	O
46	O
degrees	O
C	O
)	O
and	O
a	O
particular	O
characteristic	B-UNK
of	O
this	O
enzyme	B-UNK
was	O
a	O
biphasic	O
pH	B-UNK
curve	O
with	O
a	O
greatly	O
increased	B-UNK
activity	B-UNK
at	O
low	B-UNK
pH.	O

Although	O
molecular	B-UNK
characteristics	B-UNK
of	O
this	O
variant	O
closely	B-UNK
resemble	O
those	O
of	O
G6PD	B-UNK
Bangkok	O
and	O
G6PD	B-UNK
Duarte	B-UNK
,	O
it	O
can	O
be	O
distinguished	O
from	O
these	O
and	O
all	O
other	O
previously	B-UNK
reported	I-UNK
variants	B-UNK
by	O
virtue	O
of	O
its	O
unusual	O
pH	B-UNK
curve	O
.	O

Therefore	O
the	O
present	B-UNK
variant	O
has	O
been	O
designated	O
G6PD	B-UNK
Clinic	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	B-UNK
variants	I-UNK
previously	B-UNK
described	O

Molecular	B-UNK
detection	B-UNK
of	O
chromosomal	B-UNK
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	B-DISEASE
susceptibility	B-UNK
locus	B-UNK
.	O

A	O
candidate	B-UNK
DNA	B-UNK
sequence	I-UNK
with	O
many	O
of	O
the	O
properties	B-UNK
predicted	B-UNK
for	O
the	O
retinoblastoma	B-DISEASE
susceptibility	B-UNK
(	O
RB1	B-UNK
)	O
locus	B-UNK
has	O
been	O
cloned	O
(	O
S.	O
H.	O
Friend	O
,	O
R.	O
Bernards	O
,	O
S.	O
Rogelj	O
,	O
R.	O
A.	O
Weinberg	O
,	O
J.	O
M.	O
Rapaport	O
,	O
D.	O
M.	O
Albert	O
,	O
and	O
T.	O
P.	O
Dryja	O
,	O
Nature	B-UNK
[	O
London	O
]	O
323	O
643	O
-	O
645	O
,	O
1986	O
)	O
.	O

The	O
large	B-UNK
size	B-UNK
of	O
this	O
gene	B-UNK
(	O
ca	O
.	O
200	O
kilobases	O
[	O
kb	B-UNK
]	O
)	O
and	O
its	O
multiple	B-UNK
dispersed	O
exons	O
(	O
Wiggs	O
et	O
al	B-DISEASE
.	O
,	O
N.	O
Engl	O
.	O
J.	O
Med	O
.	O
318	O
151	O
-	O
157	O
,	O
1988	O
)	O
complicate	O
molecular	B-UNK
screening	B-UNK
strategies	O
important	O
in	O
prenatal	B-UNK
and	O
presymptomatic	O
diagnosis	B-UNK
and	O
in	O
carrier	B-UNK
detection	I-UNK
.	O

Here	O
we	O
used	O
field	B-UNK
inversion	O
gel	B-UNK
electrophoresis	I-UNK
(	O
FIGE	O
)	O
to	O
construct	O
a	O
restriction	B-UNK
map	B-UNK
of	O
approximately	O
1	O
,	O
000	O
kb	B-UNK
of	O
DNA	B-UNK
surrounding	O
the	O
RB1	B-UNK
locus	B-UNK
and	O
to	O
detect	B-UNK
the	O
translocation	B-UNK
breakpoints	O
in	O
three	O
retinoblastoma	B-DISEASE
patients	B-UNK
.	O

DNA	B-UNK
probes	O
from	O
either	O
the	O
5	O
or	O
3	O
end	B-UNK
of	O
the	O
gene	B-UNK
were	O
used	O
to	O
detect	B-UNK
a	O
250-kb	O
EagI	O
restriction	B-UNK
fragment	I-UNK
in	O
DNA	B-UNK
from	O
unaffected	O
individuals	B-UNK
.	O

Both	O
probes	O
identified	B-UNK
an	O
additional	O
hybridizing	O
fragment	B-UNK
in	O
the	O
DNA	B-UNK
from	O
each	O
patient	B-UNK
,	O
permitting	O
the	O
breakpoints	O
in	O
all	O
three	O
to	O
be	O
mapped	B-UNK
within	O
the	O
cloned	O
RB1	B-UNK
gene	B-UNK
.	O

Analysis	B-UNK
of	O
the	O
breakpoint	O
in	O
one	O
translocation	B-UNK
cell	B-UNK
line	I-UNK
allowed	O
the	O
RB1	B-UNK
gene	B-UNK
to	O
be	O
oriented	O
with	O
its	O
5	O
end	B-UNK
toward	O
the	O
centromere	O
.	O

The	O
5	O
end	B-UNK
of	O
the	O
gene	B-UNK
also	O
appeared	B-UNK
to	O
be	O
associated	O
with	O
a	O
clustering	O
of	O
sites	O
for	O
several	O
infrequently	O
cleaving	O
restriction	B-UNK
enzymes	B-UNK
,	O
indicating	O
the	O
presence	O
of	O
an	O
HpaII	O
tiny	O
fragment	B-UNK
island	B-UNK
.	O

The	O
detection	B-UNK
and	O
mapping	B-UNK
of	O
the	O
translocation	B-UNK
breakpoints	O
of	O
all	O
three	O
retinoblastoma	B-DISEASE
patients	B-UNK
to	O
within	O
the	O
putative	O
RB1	B-UNK
gene	B-UNK
substantiated	O
the	O
authenticity	O
of	O
this	O
candidate	B-UNK
sequence	B-UNK
and	O
demonstrated	O
the	O
utility	O
of	O
FIGE	O
in	O
detecting	O
chromosomal	B-UNK
rearrangements	O
affecting	O
this	O
locus	B-UNK
.	O

Inherited	B-UNK
C3	B-UNK
deficiency	I-UNK
with	O
recurrent	O
infections	B-DISEASE
and	O
glomerulonephritis	B-DISEASE
.	O

A	O
10-year	O
-	O
old	O
Laotian	O
boy	B-UNK
had	O
homozygous	B-UNK
deficiency	B-UNK
of	O
the	O
third	O
component	B-UNK
of	I-UNK
complement	I-UNK
and	O
recurrent	O
bacterial	B-DISEASE
infections	I-DISEASE
beginning	O
at	O
age	B-UNK
5	O
months	O
.	O

Cellular	O
and	O
humoral	O
immunity	O
were	O
normal	B-UNK
,	O
as	O
were	O
polymorphonuclear	O
leukocyte	O
chemotaxis	O
and	O
bactericidal	O
activities	O
.	O

Serum	B-UNK
complement	B-UNK
-	O
mediated	O
hemolytic	B-DISEASE
,	O
chemotactic	O
,	O
and	O
opsonic	O
activities	O
were	O
deficient	B-UNK
.	O

In	O
vitro	O
addition	B-UNK
of	O
purified	O
C3	B-UNK
to	O
patient	B-UNK
serum	B-UNK
restored	O
hemolytic	B-UNK
complement	B-UNK
to	O
normal	B-UNK
levels	B-UNK
,	O
and	O
plasma	O
infusion	O
during	O
each	O
of	O
four	O
episodes	O
of	O
pneumonia	B-DISEASE
significantly	O
enhanced	O
serum	B-UNK
opsonic	O
activity	B-UNK
for	O
as	O
long	B-UNK
as	O
36	O
hours	O
.	O

A	O
renal	B-UNK
biopsy	B-UNK
specimen	O
revealed	B-UNK
mesangiopathic	O
glomerulonephritis	B-DISEASE
,	O
although	O
significant	B-UNK
levels	B-UNK
of	O
circulating	O
IgG	O
immune	B-UNK
complexes	O
were	O
not	O
detected	B-UNK
.	O

These	O
findings	B-UNK
further	O
support	O
the	O
association	B-UNK
of	O
C3	B-UNK
deficiency	I-UNK
with	O
immune	B-UNK
-	O
complex	O
disease	B-UNK
and	O
suggest	B-UNK
that	O
plasma	O
infusion	O
may	O
be	O
an	O
adjunct	O
to	O
antibiotic	O
therapy	B-UNK
in	O
the	O
management	O
of	O
severe	B-UNK
pyogenic	O
infections	B-UNK
in	O
patients	B-UNK
with	O
C3	B-UNK
deficiency	I-UNK
..	O

DNA	B-UNK
restriction	B-UNK
fragments	O
associated	O
with	O
alpha	B-UNK
1-antitrypsin	O
indicate	O
a	O
single	B-UNK
origin	O
for	O
deficiency	B-UNK
allele	B-UNK
PI	O
Z.	O

The	O
alpha	B-UNK
1-protease	O
inhibitor	O
,	O
or	O
alpha	B-UNK
-	O
antitrypsin	O
(	O
AAT	O
)	O
,	O
a	O
major	B-UNK
plasma	O
inhibitor	O
of	O
leukocyte	O
elastase	O
and	O
bacterial	B-UNK
proteases	O
,	O
is	O
encoded	B-UNK
at	O
the	O
PI	O
locus	B-UNK
on	O
chromosome	B-UNK
14	O
(	O
14q24	O
.	O
3-q32	O
.	O
1	O
)	O
.	O

A	O
deficiency	B-UNK
of	O
AAT	O
in	O
individuals	B-UNK
homozygous	B-UNK
for	O
the	O
PI	O
Z	O
allele	B-UNK
occurs	O
in	O
about	O
1	O
in	O
2	O
,	O
000	O
-	O
8	O
,	O
000	O
caucasians	B-UNK
and	O
is	O
associated	O
with	O
an	O
increased	B-UNK
risk	B-UNK
of	O
early	B-UNK
adult	B-UNK
onset	I-UNK
emphysema	B-DISEASE
and	O
liver	B-DISEASE
disease	I-DISEASE
in	O
childhood	O
.	O

We	O
have	O
now	O
used	O
DNA	B-UNK
polymorphisms	B-UNK
associated	O
with	O
the	O
AAT	O
gene	B-UNK
to	O
investigate	B-UNK
the	O
origin	O
of	O
the	O
PI	O
Z	O
allele	B-UNK
.	O

Using	O
two	O
genomic	B-UNK
probes	O
extending	O
into	O
the	O
5	O
and	O
3	O
flanking	O
regions	B-UNK
,	O
respectively	O
,	O
we	O
have	O
identified	B-UNK
eight	O
polymorphic	B-UNK
restriction	B-UNK
sites	O
.	O

Extensive	B-UNK
linkage	B-UNK
disequilibrium	I-UNK
occurs	O
throughout	O
the	O
probed	O
region	B-UNK
with	O
the	O
PI	O
Z	O
allele	B-UNK
,	O
but	O
not	O
with	O
normal	B-UNK
PI	O
M	O
alleles	B-UNK
.	O

The	O
Z	O
allele	B-UNK
occurs	O
mainly	O
with	O
one	O
haplotype	B-UNK
,	O
indicating	O
a	O
single	B-UNK
,	O
relatively	O
recent	O
,	O
origin	O
in	O
caucasians	B-UNK

Segregation	B-UNK
analysis	B-UNK
of	O
a	O
marker	B-UNK
localised	O
Xp21	B-UNK
.	O
2-Xp21	O
.	O
3	O
in	O
Duchenne	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
families	B-UNK
.	O

A	O
DNA	B-UNK
marker	B-UNK
C7	B-UNK
,	O
localised	O
Xp21	B-UNK
.	O

1-Xp21	O
.	O

3	O
,	O
has	O
been	O
studied	O
in	O
kindreds	O
segregating	O
for	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
BMD	B-UNK
)	O
.	O

In	O
DMD	B-UNK
families	B-UNK
four	O
crossovers	O
were	O
observed	B-UNK
in	O
38	O
informative	O
meioses	O
between	O
C7	B-UNK
and	O
the	O
DMD	B-UNK
locus	B-UNK
(	O
theta	B-UNK
=	O
0	O
.	O
12	O
,	O
z	O
max	O
=	O
+	O
2	O
.	O
72	O
)	O
.	O

In	O
BMD	B-UNK
families	B-UNK
no	O
recombinants	O
were	O
observed	B-UNK
in	O
the	O
16	O
informative	O
meioses	O
studied	O
.	O

These	O
data	B-UNK
are	O
consistent	B-UNK
with	O
the	O
localisation	O
of	O
the	O
mutations	B-UNK
in	O
these	O
disorders	B-UNK
being	O
in	O
the	O
same	O
region	B-UNK
of	O
Xp21	B-UNK
.	O

Studies	B-UNK
in	O
families	B-UNK
also	O
segregating	O
for	O
the	O
DNA	B-UNK
marker	B-UNK
754	O
support	O
the	O
previously	B-UNK
reported	I-UNK
physical	B-UNK
order	B-UNK
of	O
these	O
loci	O
as	O
X	O
centromere-754-DMD	O
-	O
BMD	B-UNK
-	O
C7-X	O
telomere	O
.	O

A	O
recombination	B-UNK
fraction	B-UNK
of	O
0	O
.	O

11	O
(	O
z	O
max	O
=	O
+	O
5	O
.	O
58	O
)	O
was	O
found	O
between	O
DMD-754	O
by	O
combining	O
our	O
previously	B-UNK
published	O
data	B-UNK
with	O
the	O
data	B-UNK
presented	B-UNK
here	O
.	O

C7	B-UNK
and	O
754	O
thus	O
provide	B-UNK
good	O
bridging	O
markers	B-UNK
for	O
the	O
diagnosis	B-UNK
of	O
DMD	B-UNK
and	O
BMD	B-UNK

Isolation	B-UNK
of	O
molecular	B-UNK
probes	O
associated	O
with	O
the	O
chromosome	B-UNK
15	O
instability	B-UNK
in	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

Flow	O
cytometry	O
and	O
recombinant	B-UNK
DNA	B-UNK
techniques	O
have	O
been	O
used	O
to	O
obtain	O
reagents	O
for	O
a	O
molecular	B-UNK
analysis	I-UNK
of	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

HindIII	O
total	B-UNK
-	O
digest	O
libraries	O
were	O
prepared	O
in	O
lambda	O
phage	O
Charon	O
21A	O
from	O
flow	O
-	O
sorted	O
inverted	O
duplicated	O
no	O
.	O
15	O
human	B-UNK
chromosomes	O
and	O
propagated	O
on	O
recombination	B-UNK
-	O
proficient	O
(	O
LE392	O
)	O
and	O
recBC-	O
,	O
sbcB-(DB1257	O
)	O
bacteria	O
.	O

Twelve	O
distinct	O
chromosome	B-UNK
15-specific	O
probes	O
have	O
been	O
isolated	B-UNK
.	O

Eight	O
localized	B-UNK
to	O
the	O
region	B-UNK
15q11	B-UNK
-	O
---13	O
.	O

Four	O
of	O
these	O
eight	O
sublocalized	O
to	O
band	O
15q11	B-UNK
.	O

2	O
and	O
are	O
shown	B-UNK
to	O
be	O
deleted	B-UNK
in	O
DNA	B-UNK
of	O
one	O
of	O
two	O
patients	B-UNK
examined	O
with	O
the	O
PWS	B-UNK
.	O

Heteroduplex	B-UNK
analysis	I-UNK
of	O
two	O
of	O
these	O
clones	O
,	O
which	O
grew	O
on	O
DB1257	O
but	O
not	O
on	O
LE392	O
,	O
revealed	B-UNK
stem	B-UNK
-	O
loop	O
structures	O
in	O
the	O
inserts	O
,	O
indicative	O
of	O
inverted	O
,	O
repeated	O
DNA	B-UNK
elements	O
.	O

Such	O
DNA	B-UNK
repeats	B-UNK
might	O
account	B-UNK
for	O
some	O
of	O
the	O
cloning	B-UNK
instability	B-UNK
of	O
DNA	B-UNK
segments	O
from	O
proximal	B-UNK
15q	O
.	O

Analysis	B-UNK
of	O
the	O
genetic	B-UNK
and	O
physical	B-UNK
instability	B-UNK
associated	O
with	O
the	O
repeated	O
sequences	O
we	O
have	O
isolated	B-UNK
from	O
band	O
15q11	B-UNK
.	O

2	O
may	O
elucidate	O
the	O
molecular	B-UNK
basis	I-UNK
for	O
the	O
instability	B-UNK
of	O
this	O
chromosomal	B-UNK
region	B-UNK
in	O
patients	B-UNK
with	O
the	O
PWS	B-UNK
or	O
other	O
diseases	B-UNK
associated	O
with	O
chromosomal	B-UNK
abnormalities	B-UNK
in	O
the	O
proximal	B-UNK
long	B-UNK
arm	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
15	O

Analysis	B-UNK
of	O
deletions	O
in	O
DNA	B-UNK
from	O
patients	B-UNK
with	O
Becker	B-UNK
and	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
genetic	B-UNK
disorder	I-UNK
for	O
which	O
the	O
biochemical	O
defect	B-UNK
is	O
as	O
yet	O
unknown	O
.	O

Recently	O
,	O
two	O
cloned	O
segments	O
of	O
human	B-UNK
X	O
-	O
chromosome	B-UNK
DNA	B-UNK
have	O
been	O
described	O
which	O
detect	B-UNK
structural	B-UNK
alterations	B-UNK
within	O
or	O
near	O
the	O
genetic	B-UNK
locus	B-UNK
responsible	B-UNK
for	O
the	O
disorder	B-UNK
.	O

Both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	B-UNK
linked	I-UNK
to	O
the	O
locus	B-UNK
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
DNA	B-UNK
of	O
boys	O
affected	B-UNK
with	O
DMD	B-UNK
.	O

In	O
an	O
attempt	O
to	O
determine	B-UNK
more	O
precisely	O
the	O
occurrence	B-UNK
of	O
these	O
deletions	O
within	O
a	O
large	B-UNK
population	B-UNK
of	O
DMD	B-UNK
patients	B-UNK
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments	O
,	O
DXS164	O
(	O
pERT87	O
)	O
,	O
in	O
determining	O
the	O
inheritance	B-UNK
of	O
the	O
DMD	B-UNK
X	O
chromosome	B-UNK
,	O
the	O
subclones	O
1	O
,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world	O
.	O

Here	O
we	O
describe	O
the	O
combined	O
results	B-UNK
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	B-UNK
of	O
deletions	O
at	O
the	O
DXS164	O
locus	B-UNK
in	O
DNA	B-UNK
samples	B-UNK
isolated	B-UNK
from	O
patients	B-UNK
with	O
DMD	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
BMD	B-UNK
)	O
.	O

The	O
results	B-UNK
indicate	O
that	O
the	O
DXS164	O
locus	B-UNK
apparently	O
recombines	O
with	O
DMD	B-UNK
5	O
%	O
of	O
the	O
time	O
,	O
but	O
is	O
probably	O
located	B-UNK
between	O
independent	O
sites	O
of	O
mutation	B-UNK
which	O
yield	O
DMD	B-UNK
.	O

The	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
DXS164	O
locus	B-UNK
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
DMD	B-UNK
locus	B-UNK
are	O
frequent	B-UNK
and	O
extremely	O
large	B-UNK
..	O

A	O
potential	B-UNK
animal	B-UNK
model	I-UNK
for	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
through	O
introduction	O
of	O
HPRT	B-UNK
mutations	B-UNK
into	O
mice	B-UNK
.	O

The	O
human	B-UNK
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	B-UNK
neurological	B-UNK
and	O
behavioural	O
disorder	B-UNK
,	O
affecting	O
only	O
males	B-UNK
,	O
which	O
is	O
caused	B-UNK
by	O
an	O
inherited	B-UNK
deficiency	B-UNK
in	O
the	O
level	B-UNK
of	O
activity	B-UNK
of	O
the	O
purine	O
salvage	O
enzyme	B-UNK
hypoxanthine	B-UNK
-	O
guanosine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	B-UNK
)	O
.	O

How	O
the	O
resulting	B-UNK
alterations	B-UNK
in	O
purine	O
metabolism	B-UNK
lead	B-UNK
to	O
the	O
severe	B-UNK
symptoms	B-UNK
characteristic	B-UNK
of	O
Lesch	O
-	O
Nyhan	O
patients	B-UNK
is	O
still	O
not	O
understood	O
.	O

No	O
mutations	B-UNK
at	O
the	O
Hprt	B-UNK
locus	B-UNK
leading	B-UNK
to	O
loss	B-UNK
of	O
activity	B-UNK
have	O
been	O
described	O
in	O
laboratory	O
animals	O
.	O

To	O
derive	O
an	O
animal	B-UNK
model	I-UNK
for	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
,	O
we	O
have	O
used	O
cultured	O
mouse	B-UNK
embryonic	B-UNK
stem	B-UNK
cells	B-UNK
,	O
mutagenized	O
by	O
retroviral	O
insertion	O
and	O
selected	O
for	O
loss	B-UNK
of	O
HPRT	B-UNK
activity	B-UNK
,	O
to	O
construct	O
chimaeric	O
mice	B-UNK
.	O

Two	O
clonal	O
lines	B-UNK
carrying	B-UNK
different	O
mutant	B-UNK
Hprt	B-UNK
alleles	B-UNK
have	O
given	O
rise	B-UNK
to	O
germ	B-UNK
cells	B-UNK
in	O
chimaeras	O
,	O
allowing	O
the	O
derivation	O
of	O
strains	O
of	O
mutant	B-UNK
mice	I-UNK
having	O
the	O
same	O
biochemical	O
defect	B-UNK
as	O
Lesch	O
-	O
Nyhan	O
patients	B-UNK
.	O

Male	B-UNK
mice	B-UNK
carrying	I-UNK
the	O
mutant	B-UNK
alleles	I-UNK
are	O
viable	O
and	O
analysis	B-UNK
of	O
their	O
cells	B-UNK
shows	O
a	O
total	B-UNK
lack	B-UNK
of	O
HPRT	B-UNK
activity	B-UNK
..	O

Re-evaluation	O
of	O
the	O
sublocalization	O
of	O
esterase	O
D	O
and	O
its	O
relation	O
to	O
the	O
retinoblastoma	B-DISEASE
locus	B-UNK
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
.	O

In	B-UNK
situ	I-UNK
hybridization	I-UNK
of	O
a	O
cDNA	O
probe	O
for	O
the	O
esterase	O
D	O
gene	B-UNK
(	O
ESD	O
)	O
was	O
carried	O
out	O
on	O
human	B-UNK
chromosomes	O
.	O

The	O
probe	O
hybridized	O
most	O
strongly	O
to	O
13q14	O
.	O

2	O
and	O
13q14	O
.	O

3	O
.	O

This	O
observation	O
raises	O
doubts	O
concerning	O
the	O
most	O
recently	O
published	O
assignment	B-UNK
of	O
ESD	O
to	O
13q14	O
.	O

1	O
.	O

A	O
deletion	B-UNK
in	O
an	O
individual	O
with	O
retinoblastoma	B-DISEASE
was	O
reported	B-UNK
to	O
separate	O
the	O
closely	B-UNK
linked	I-UNK
ESD	O
and	O
retinoblastoma	B-DISEASE
(	O
RB1	B-UNK
)	O
loci	O
,	O
placing	O
ESD	O
proximal	B-UNK
to	O
RB1	B-UNK
.	O

Quantitative	B-UNK
in	B-UNK
situ	I-UNK
hybridization	I-UNK
studies	B-UNK
of	O
this	O
deletion	B-UNK
do	O
not	O
confirm	O
this	O
interpretation	O
.	O

Rather	O
,	O
they	O
suggest	B-UNK
that	O
ESD	O
is	O
missing	O
from	O
the	O
deleted	B-UNK
chromosome	B-UNK
13	O
and	O
duplicated	O
on	O
the	O
normal	B-UNK
homolog	O
.	O

From	O
these	O
findings	B-UNK
,	O
we	O
conclude	O
that	O
the	O
deletion	B-UNK
in	O
this	O
individual	O
cannot	O
be	O
used	O
to	O
determine	B-UNK
the	O
orientation	O
nor	O
the	O
sublocalization	O
of	O
ESD	O
and	O
RB1	B-UNK
within	O
the	O
13q14	O
region	B-UNK
.	O

Hereditary	B-UNK
C2	B-UNK
deficiency	I-UNK
associated	O
with	O
common	B-DISEASE
variable	I-DISEASE
immunodeficiency	I-DISEASE
.	O

Homozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
in	O
a	O
19-year	O
-	O
old	O
boy	B-UNK
was	O
associated	O
with	O
variable	B-UNK
immunodeficiency	B-UNK
manifested	O
by	O
marked	B-UNK
hypoimmunoglobulinemia	O
and	O
impaired	B-UNK
antibody	B-UNK
responses	B-UNK
,	O
normal	B-UNK
circulating	O
B	O
lymphocytes	O
,	O
and	O
subnormal	O
T	O
-	O
cell	B-UNK
functions	O
.	O

Neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	B-UNK
abnormalities	B-UNK
were	O
found	O
.	O

Serum	B-UNK
immunoglobulin	O
levels	B-UNK
were	O
within	O
normal	B-UNK
limits	O
in	O
his	O
parents	O
and	O
brother	B-UNK
who	O
were	O
heterozygous	B-UNK
for	O
C2	B-UNK
deficiency	I-UNK
.	O

The	O
patients	B-UNK
lymphocytes	O
were	O
homozygous	B-UNK
at	O
the	O
HLA	B-UNK
-	O
D	O
locus	B-UNK
but	O
expressed	B-UNK
an	O
antigen	O
different	O
from	O
DW2	O
..	O

Mild	O
and	O
severe	B-UNK
muscular	B-UNK
dystrophy	I-UNK
associated	O
with	O
deletions	O
in	O
Xp21	B-UNK
of	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
.	O

We	O
have	O
analysed	O
over	O
300	O
patients	B-UNK
suffering	O
from	O
Duchenne	B-UNK
or	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
or	O
BMD	B-UNK
)	O
.	O

Deletions	O
have	O
been	O
characterised	O
which	O
encompass	O
either	O
the	O
pERT87	O
(	O
DXS164	O
)	O
locus	B-UNK
only	O
,	O
the	O
XJ1	O
.	O

1	O
(	O
DXS206	O
)	O
and	O
HIP25	O
loci	O
only	O
,	O
or	O
all	O
three	O
loci	O
.	O

These	O
loci	O
have	O
been	O
shown	B-UNK
to	O
lie	O
within	O
the	O
DMD	B-UNK
region	B-UNK
covering	O
several	O
hundred	O
kilobases	O
(	O
kb	B-UNK
)	O
of	O
DNA	B-UNK
.	O

One	O
mildly	O
affected	B-UNK
BMD	B-UNK
patient	B-UNK
possesses	O
a	O
deletion	B-UNK
of	O
at	O
least	O
110	O
kb	B-UNK
including	O
exons	O
of	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

Other	O
patients	B-UNK
with	O
similar	B-UNK
exon	B-UNK
deletions	O
,	O
or	O
smaller	O
deletions	O
,	O
show	O
the	O
more	O
severe	B-UNK
phenotype	I-UNK
typical	O
of	O
DMD	B-UNK
.	O

We	O
conclude	O
from	O
these	O
studies	B-UNK
that	O
the	O
severity	B-UNK
of	O
the	O
clinical	B-UNK
phenotype	B-UNK
cannot	O
be	O
explained	O
on	O
the	O
basis	B-UNK
of	O
the	O
size	B-UNK
of	O
the	O
deletion	B-UNK
.	O

We	O
discuss	O
this	O
in	O
the	O
context	O
of	O
candidate	B-UNK
gene	I-UNK
sequences	O
.	O

Patterns	B-UNK
of	O
exon	B-UNK
deletions	O
in	O
Duchenne	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

A	O
panel	B-UNK
of	O
patients	B-UNK
with	O
Duchenne	B-UNK
and	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
and	O
BMD	B-UNK
)	O
has	O
been	O
screened	B-UNK
with	O
the	O
cDNA	O
probes	O
Cf56a	O
and	O
Cf23a	O
,	O
which	O
detect	B-UNK
exons	O
in	O
the	O
central	B-UNK
part	O
of	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

One	O
or	O
more	O
exons	O
were	O
deleted	B-UNK
in	O
60	O
%	O
of	O
patients	B-UNK
.	O

The	O
deletions	O
were	O
mapped	B-UNK
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	B-UNK
and	O
extent	O
,	O
particularly	O
in	O
DMD	B-UNK
.	O

Deletions	O
specific	B-UNK
to	O
DMD	B-UNK
and	O
to	O
BMD	B-UNK
are	O
described	O
.	O

Half	B-UNK
of	O
all	O
BMD	B-UNK
patients	B-UNK
have	O
a	O
deletion	B-UNK
of	O
one	O
particular	O
small	O
group	B-UNK
of	O
exons	O
;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	B-UNK
produce	B-UNK
the	O
more	O
severe	B-UNK
DMD	B-UNK
..	O

Hereditary	B-UNK
deficiency	B-UNK
of	O
the	O
third	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
a	O
child	B-UNK
with	O
fever	B-DISEASE
,	O
skin	B-DISEASE
rash	I-DISEASE
,	O
and	O
arthralgias	B-DISEASE
:	O
response	B-UNK
to	O
transfusion	O
of	O
whole	O
blood	B-UNK
.	O

A	O
previously	B-UNK
well	O
34-month	O
-	O
old	O
male	B-UNK
presenting	B-UNK
with	O
fever	B-UNK
,	O
skin	B-DISEASE
rash	I-DISEASE
,	O
and	O
arthralgias	B-DISEASE
was	O
found	O
to	O
lack	B-UNK
C3	B-UNK
by	O
immunochemical	O
(	O
undetectable	O
)	O
and	O
hemolytic	B-UNK
(	O
1	O
%	O
normal	B-UNK
)	O
assays	O
.	O

No	O
infectious	O
agent	O
could	O
be	O
demonstrated	O
.	O

Protein	B-UNK
levels	B-UNK
of	O
Clq	O
.	O

C4	B-UNK
,	O
C5	B-UNK
,	O
properdin	O
,	O
and	O
C3b	O
-	O
INA	O
and	O
hemolytic	B-DISEASE
activities	O
of	O
complement	B-UNK
components	O
C1	O
to	O
C9	B-UNK
except	O
C3	B-UNK
were	O
normal	B-UNK
or	O
elevated	B-UNK
;	O
total	B-UNK
hemolytic	B-UNK
complement	B-UNK
activity	B-UNK
was	O
13	O
%	O
of	O
normal	B-UNK
and	O
was	O
reconstituted	O
by	O
purified	O
C3	B-UNK
.	O

Properdin	O
factor	B-UNK
B	O
was	O
702	O
(	O
normal	B-UNK
175	O
to	O
275	O
)	O
mug	O
/	O
ml	O
,	O
and	O
was	O
not	O
cleaver	O
upon	O
addition	B-UNK
of	O
zymosan	O
or	O
cobra	O
venom	O
factor	B-UNK
.	O

The	O
serum	B-UNK
had	O
normal	B-UNK
immune	B-UNK
adherence	O
activity	B-UNK
,	O
but	O
was	O
deficient	B-UNK
in	O
ability	B-UNK
to	O
opsonize	O
Candida	O
albicans	O
for	O
uptake	O
and	O
Escherichia	O
coli	B-UNK
for	O
killing	O
by	O
neurophils	O
,	O
generate	O
neutrophil	O
chemotactic	O
factors	O
and	O
inhibit	O
the	O
growth	B-UNK
of	O
E.	B-DISEASE
coli	I-DISEASE
;	O
these	O
activities	O
were	O
restored	O
by	O
purified	O
C3	B-UNK
.	O

A	O
transfusion	O
of	O
320	O
ml	O
1-hour	O
-	O
old	O
normal	B-UNK
whole	O
blood	B-UNK
on	O
the	O
fifty	O
-	O
second	O
day	O
resulted	B-UNK
in	O
transitory	O
elevation	O
of	O
the	O
C3	B-UNK
level	B-UNK
to	O
25	O
mg	B-UNK
/	O
dl	O
with	O
a	O
fall	O
-	O
off	O
(	O
approximately	O
2	O
1/2	O
%	O
per	O
hour	O
)	O
to	O
undetectable	O
levels	B-UNK
by	O
69	O
hours	O
;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	B-DISEASE
rash	I-DISEASE
and	O
arthralgias	B-DISEASE
and	O
return	O
to	O
normal	B-UNK
of	O
the	O
previously	B-UNK
elevated	B-UNK
temperature	O
and	O
CRP	O
levels	B-UNK
.	O

C3	B-UNK
levels	B-UNK
in	O
family	B-UNK
members	I-UNK
(	O
seven	O
of	O
24	O
half	B-UNK
-	O
normal	B-UNK
)	O
,	O
lack	B-UNK
of	O
anti	B-UNK
-	O
C3	B-UNK
activity	B-UNK
,	O
normal	B-UNK
C3b	O
-	O
INA	O
levels	B-UNK
and	O
a	O
normal	B-UNK
rate	B-UNK
of	O
catabolism	O
of	O
transfused	O
C3	B-UNK
indicated	O
that	O
the	O
deficiency	B-UNK
was	O
inherited	B-UNK
with	O
autosomal	B-UNK
codominance	O
and	O
involved	B-UNK
decreased	B-UNK
synthesis	B-UNK
of	O
C3	B-UNK
.	O

Thus	O
,	O
this	O
child	B-UNK
is	O
a	O
unique	O
individual	O
with	O
inherited	B-UNK
C3	B-UNK
deficiency	I-UNK
presenting	B-UNK
with	O
absence	B-UNK
of	O
repeated	O
infections	B-UNK
,	O
whose	O
symptoms	B-UNK
of	O
fever	B-UNK
,	O
skin	B-DISEASE
rash	I-DISEASE
,	O
and	O
arthralgia	B-DISEASE
were	O
abated	O
by	O
whole	O
blood	B-UNK
transfusion	O
..	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
variants	B-UNK
and	O
their	O
frequency	B-UNK
in	O
Guangdong	O
,	O
China	O
.	O

Erythrocyte	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
was	O
characterized	B-UNK
in	O
blood	B-UNK
samples	B-UNK
obtained	B-UNK
from	O
97	O
randomly	O
selected	O
males	B-UNK
with	O
enzyme	B-UNK
deficiency	I-UNK
from	O
various	O
regions	B-UNK
of	O
Guangdong	O
Province	O
,	O
China	O
.	O

Nine	O
new	O
variants	B-UNK
(	O
Gd	B-UNK
Kaiping	O
,	O
Gd	B-UNK
Boluo	O
,	O
Gd	B-UNK
Huiyang	O
,	O
Gd	B-UNK
Gaomin	O
,	O
Gd	B-UNK
Qing	O
-	O
Baijiang	O
,	O
Gd	B-UNK
Gaozhou	O
,	O
Gd	B-UNK
Huazhou	O
,	O
Gd	B-UNK
Nanhai	O
,	O
and	O
Gd	B-UNK
Guangzhou	O
)	O
were	O
identified	B-UNK
.	O

Of	O
the	O
31	O
variants	B-UNK
found	O
in	O
this	O
province	O
,	O
Gd	B-UNK
Kaiping	O
,	O
Gd	B-UNK
Taiwan	O
-	O
Hakka	O
,	O
Gd	B-UNK
Haad	O
Yai	O
,	O
Gd	B-UNK
Haad	O
Yai	O
-	O
like	O
and	O
Gd	B-UNK
Huiyang	O
occurred	B-UNK
most	O
frequently	O
.	O

The	O
frequency	B-UNK
of	O
each	O
variant	O
was	O
calculated	O
.	O

The	O
results	B-UNK
demonstrated	O
that	O
the	O
genetic	B-UNK
heterogeneity	I-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
was	O
high	B-UNK
in	O
this	O
area	B-UNK
..	O

Homozygous	B-UNK
and	O
heterozygous	B-UNK
deletions	O
of	O
the	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
gene	B-UNK
in	O
patients	B-UNK
and	O
carriers	B-UNK
of	O
severe	B-UNK
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
.	O

Severe	B-UNK
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
is	O
characterized	B-UNK
by	O
undetectable	O
or	O
trace	O
quantities	O
of	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
in	O
plasma	O
and	O
tissue	B-UNK
stores	O
.	O

We	O
have	O
studied	O
the	O
genomic	B-UNK
DNA	I-UNK
of	O
10	O
affected	B-UNK
individuals	I-UNK
from	O
six	O
families	B-UNK
with	O
this	O
disorder	B-UNK
using	O
probes	O
from	O
the	O
5	O
and	O
3	O
ends	O
of	O
the	O
vWF	B-UNK
cDNA	O
and	O
with	O
a	O
probe	O
extending	O
from	O
the	O
5	O
end	B-UNK
into	O
the	O
central	B-UNK
region	B-UNK
.	O

Southern	B-UNK
blots	O
of	O
restriction	B-UNK
endonuclease	O
digests	O
and	O
gene	B-UNK
dosage	O
analysis	B-UNK
measurements	O
carried	O
out	O
with	O
quantitative	B-UNK
slot	O
blots	O
of	O
undigested	O
genomic	B-UNK
DNA	I-UNK
separated	O
these	O
patients	B-UNK
into	O
three	O
groups	B-UNK
.	O

The	O
first	O
group	B-UNK
consisted	O
of	O
a	O
family	B-UNK
with	O
complete	O
homozygous	B-UNK
deletions	O
of	O
the	O
vWF	B-UNK
gene	B-UNK
in	O
the	O
four	O
probands	O
.	O

Gene	B-UNK
dosage	O
analysis	B-UNK
was	O
consistent	B-UNK
with	O
heterozygous	B-UNK
deletions	O
in	O
both	O
of	O
the	O
asymptomatic	B-UNK
parents	O
and	O
four	O
asymptomatic	B-UNK
siblings	O
of	O
this	O
kindred	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
second	O
group	B-UNK
was	O
comprised	O
of	O
a	O
family	B-UNK
in	O
which	O
there	O
was	O
a	O
complete	O
heterozygous	B-UNK
deletion	B-UNK
of	O
the	O
vWF	B-UNK
gene	B-UNK
in	O
the	O
proband	B-UNK
and	O
one	O
asymptomatic	B-UNK
parent	O
,	O
suggesting	O
that	O
a	O
different	O
type	B-UNK
of	O
genetic	B-UNK
abnormality	O
was	O
inherited	B-UNK
from	O
the	O
other	O
parent	O
.	O

Thus	O
,	O
the	O
patient	B-UNK
appeared	B-UNK
to	O
be	O
doubly	O
heterozygous	B-UNK
for	O
interacting	O
genetic	B-UNK
abnormalities	B-UNK
affecting	O
vWF	B-UNK
expression	B-UNK
.	O

In	O
the	O
third	O
group	B-UNK
,	O
no	O
gene	B-UNK
deletions	O
could	O
be	O
detected	B-UNK
.	O

Alloantibodies	O
developed	O
only	O
in	O
the	O
kindred	O
with	O
homozygous	B-UNK
deletions	O
.	O

These	O
techniques	O
should	O
prove	O
useful	O
in	O
identifying	O
carriers	B-UNK
of	O
severe	B-UNK
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
and	O
also	O
in	O
defining	O
patients	B-UNK
predictably	O
at	O
risk	B-UNK
of	O
developing	O
alloantibodies	O
to	O
vWF	B-UNK
.	O

Sjogren	B-DISEASE
-	I-DISEASE
Larsson	I-DISEASE
syndrome	I-DISEASE
.	O

Impaired	B-UNK
fatty	B-UNK
alcohol	O
oxidation	B-UNK
in	O
cultured	O
fibroblasts	B-UNK
due	O
to	O
deficient	B-UNK
fatty	B-UNK
alcohol	O
:	O
nicotinamide	O
adenine	O
dinucleotide	B-UNK
oxidoreductase	O
activity	B-UNK
.	O

Lipid	O
metabolism	B-UNK
was	O
studied	O
in	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
from	O
patients	B-UNK
with	O
the	O
inherited	B-UNK
disorder	B-UNK
,	O
Sjogren	B-DISEASE
-	I-DISEASE
Larsson	I-DISEASE
syndrome	I-DISEASE
(	O
SLS	B-UNK
)	O
.	O

Intact	O
SLS	B-UNK
fibroblasts	B-UNK
incubated	O
in	O
the	O
presence	O
of	O
[	O
1	O
-	O
14C	O
]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	B-UNK
cells	B-UNK
,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered	O
.	O

The	O
hexadecanol	O
content	O
of	O
SLS	B-UNK
fibroblasts	B-UNK
was	O
abnormally	O
elevated	B-UNK
.	O

Hexadecanol	O
accumulation	B-UNK
was	O
not	O
due	O
to	O
increased	B-UNK
fatty	B-UNK
alcohol	O
synthesis	B-UNK
nor	O
its	O
deficient	B-UNK
utilization	O
for	O
glycerol	B-UNK
ether	O
synthesis	B-UNK
.	O

The	O
half	B-UNK
-	O
life	B-UNK
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
SLS	B-UNK
fibroblasts	B-UNK
was	O
increased	B-UNK
(	O
70	O
min	O
)	O
compared	B-UNK
with	O
normal	B-UNK
(	O
15	O
min	O
)	O
,	O
and	O
intact	O
SLS	B-UNK
fibroblasts	B-UNK
showed	O
impaired	B-UNK
oxidation	B-UNK
of	O
[	O
14C]-hexadecanol	O
to	O
fatty	B-UNK
acid	B-UNK
.	O

Fatty	B-UNK
alcohol	O
NAD	O
+	O
oxidoreductase	O
,	O
the	O
enzyme	B-UNK
catalyzing	O
this	O
reaction	B-UNK
,	O
was	O
deficient	B-UNK
in	O
SLS	B-UNK
fibroblasts	B-UNK
.	O

Mean	O
total	B-UNK
activity	B-UNK
in	O
SLS	B-UNK
fibroblasts	B-UNK
(	O
n	O
=	O
5	O
)	O
was	O
13	O
%	O
of	O
that	O
in	O
normal	B-UNK
fibroblasts	B-UNK
,	O
and	O
palmitoyl	O
CoA	B-UNK
-	O
inhibitable	O
activity	B-UNK
was	O
1	O
%	O
of	O
normal	B-UNK
.	O

Fibroblasts	B-UNK
from	O
two	O
obligate	B-UNK
SLS	B-UNK
heterozygotes	B-UNK
had	O
enzyme	B-UNK
activities	O
intermediate	O
between	O
that	O
in	O
normal	B-UNK
fibroblasts	B-UNK
and	O
individuals	B-UNK
with	O
SLS	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
primary	B-UNK
defect	B-UNK
in	O
SLS	B-UNK
is	O
deficiency	B-UNK
of	O
fatty	B-UNK
alcohol	O
NAD	O
+	O
oxidoreductase	O
.	O

SLS	B-UNK
represents	O
the	O
first	O
inherited	B-UNK
disorder	B-UNK
in	O
man	B-UNK
associated	O
with	O
an	O
isolated	B-UNK
abnormality	O
in	O
fatty	B-UNK
alcohol	O
metabolism	B-UNK
..	O

Germinal	O
mosaicism	O
in	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

We	O
have	O
identified	B-UNK
a	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
pedigree	B-UNK
where	O
the	O
disease	B-UNK
is	O
associated	O
with	O
a	O
molecular	B-UNK
deletion	B-UNK
within	O
the	O
DMD	B-UNK
locus	B-UNK
.	O

We	O
have	O
examined	O
the	O
meiotic	B-UNK
segregation	B-UNK
products	B-UNK
of	O
the	O
common	B-UNK
female	O
ancestor	O
using	O
marker	B-UNK
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
(	O
RFLPs	B-UNK
)	O
detected	B-UNK
by	O
probes	O
that	O
lie	O
within	O
this	O
deletion	B-UNK
.	O

These	O
studies	B-UNK
show	O
that	O
this	O
female	O
has	O
transmitted	O
three	O
distinct	O
types	B-UNK
of	O
X	O
chromosome	B-UNK
to	O
her	O
offspring	O
.	O

This	O
observation	O
may	O
be	O
explained	O
by	O
postulating	O
that	O
the	O
mutation	B-UNK
arose	O
as	O
a	O
postzygotic	O
deletion	B-UNK
within	O
this	O
common	B-UNK
ancestor	O
,	O
who	O
was	O
consequently	O
germinally	O
mosaic	O
..	O

Nebulin	O
seen	O
in	O
DMD	B-UNK
males	B-UNK
including	O
one	O
patient	B-UNK
with	O
a	O
large	B-UNK
DNA	B-UNK
deletion	B-UNK
encompassing	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

The	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	B-UNK
specimen	O
from	O
a	O
patient	B-UNK
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
due	O
to	O
a	O
large	B-UNK
deletion	B-UNK
precludes	O
the	O
possibility	B-UNK
that	O
this	O
protein	B-UNK
is	O
the	O
DMD	B-UNK
gene	B-UNK
product	I-UNK
..	O

Expression	B-UNK
of	O
the	O
murine	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
in	O
muscle	B-UNK
and	O
brain	B-UNK
.	O

Complementary	O
DNA	B-UNK
clones	O
were	O
isolated	B-UNK
that	O
represent	O
the	O
5	O
terminal	B-UNK
2	O
.	O

5	O
kilobases	O
of	O
the	O
murine	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
Dmd	B-UNK
)	O
messenger	B-UNK
RNA	I-UNK
(	O
mRNA	O
)	O
.	O

Mouse	B-UNK
Dmd	B-UNK
mRNA	O
was	O
detectable	O
in	O
skeletal	B-UNK
and	O
cardiac	B-UNK
muscle	B-UNK
and	O
at	O
a	O
level	B-UNK
approximately	O
90	O
percent	B-UNK
lower	O
in	O
brain	B-UNK
.	O

Dmd	B-UNK
mRNA	O
is	O
also	O
present	B-UNK
,	O
but	O
at	O
much	O
lower	O
than	O
normal	B-UNK
levels	B-UNK
,	O
in	O
both	O
the	O
muscle	B-UNK
and	O
brain	B-UNK
of	O
three	O
different	O
strains	O
of	O
dystrophic	O
mdx	O
mice	B-UNK
.	O

The	O
identification	B-UNK
of	O
Dmd	B-UNK
mRNA	O
in	O
brain	B-UNK
raises	O
the	O
possibility	B-UNK
of	O
a	O
relation	O
between	O
human	B-UNK
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
expression	I-UNK
and	O
the	O
mental	B-UNK
retardation	I-UNK
found	O
in	O
some	O
DMD	B-UNK
males	B-UNK
.	O

These	O
results	B-UNK
also	O
provide	B-UNK
evidence	I-UNK
that	O
the	O
mdx	O
mutations	B-UNK
are	O
allelic	O
variants	B-UNK
of	O
mouse	B-UNK
Dmd	B-UNK
gene	B-UNK
mutations	B-UNK
.	O

Glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
and	O
incidence	B-UNK
of	O
hematologic	O
malignancy	B-DISEASE
.	O

We	O
have	O
evaluated	O
the	O
hypothesis	B-UNK
of	O
a	O
negative	B-UNK
association	B-UNK
between	O
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
and	O
cancer	B-DISEASE
in	O
a	O
cohort	B-UNK
of	O
481	O
Sardinian	O
males	B-UNK
with	O
hematological	B-DISEASE
malignancies	I-DISEASE
.	O

The	O
frequency	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
in	O
the	O
patients	B-UNK
was	O
not	O
different	O
from	O
the	O
incidence	B-UNK
in	O
a	O
group	B-UNK
of	O
16	O
,	O
219	O
controls	O
.	O

The	O
same	O
conclusion	B-UNK
resulted	B-UNK
from	O
the	O
comparison	B-UNK
of	O
the	O
frequency	B-UNK
of	O
expression	B-UNK
of	O
the	O
GdB	O
gene	B-UNK
in	O
23	O
heterozygous	B-UNK
women	B-UNK
having	O
a	O
clonal	O
hematologic	O
disease	B-DISEASE
and	O
a	O
control	B-UNK
group	B-UNK
of	O
37	O
healthy	O
heterozygotes	B-UNK
.	O

Therefore	O
at	O
present	B-UNK
there	O
is	O
no	O
evidence	B-UNK
that	O
G6PD	B-UNK
deficiency	I-UNK
has	O
a	O
protective	O
effect	B-UNK
against	O
development	B-UNK
of	O
hematologic	B-DISEASE
neoplasms	I-DISEASE
..	O

Hepatoblastoma	B-DISEASE
,	O
pigmented	O
ocular	O
fundus	O
lesions	B-UNK
and	O
jaw	O
lesions	B-UNK
in	O
Gardner	B-DISEASE
syndrome	I-DISEASE
.	O

Hepatoblastoma	B-DISEASE
is	O
a	O
rare	B-UNK
neoplasm	B-DISEASE
of	O
infants	O
and	O
children	O
only	O
recently	O
documented	O
in	O
association	B-UNK
with	O
hereditary	B-UNK
adenomatous	B-UNK
polyposis	I-UNK
of	O
the	O
colon	B-UNK
[	O
Kingston	O
et	O
al	B-DISEASE
.	O
,	O
1983].	O

We	O
report	B-UNK
four	O
children	O
with	O
hepatoblastoma	B-DISEASE
from	O
four	O
unrelated	B-UNK
families	I-UNK
with	O
Gardner	B-DISEASE
syndrome	I-DISEASE
(	O
GS	B-UNK
)	O
.	O

One	O
child	B-UNK
,	O
now	O
19	O
years	O
old	O
,	O
survived	O
after	O
a	O
resection	O
of	O
a	O
hepatoblastoma	B-DISEASE
in	O
infancy	O
and	O
recently	O
was	O
found	O
to	O
have	O
GS	B-UNK
.	O

He	O
has	O
an	O
associated	O
odontoma	B-DISEASE
and	O
pigmented	O
ocular	O
fundus	O
lesions	B-UNK
,	O
both	O
of	O
which	O
have	O
been	O
shown	B-UNK
to	O
be	O
clinical	B-UNK
markers	B-UNK
of	O
GS	B-UNK
.	O

Many	O
individuals	B-UNK
in	O
these	O
four	O
GS	B-UNK
families	B-UNK
,	O
both	O
affected	B-UNK
and	O
at	O
risk	B-UNK
,	O
have	O
osteomatous	O
jaw	O
lesions	B-UNK
and	O
pigmented	O
ocular	O
fundus	O
lesions	B-UNK
.	O

A	O
search	O
for	O
colonic	B-DISEASE
polyps	I-DISEASE
should	O
be	O
made	O
in	O
families	B-UNK
of	O
infants	O
and	O
children	O
with	O
hepatoblastoma	B-DISEASE
.	O

If	O
the	O
child	B-UNK
survives	O
,	O
he	O
or	O
she	O
should	O
be	O
monitored	O
for	O
the	O
later	O
appearance	O
of	O
colonic	B-DISEASE
polyps	I-DISEASE
.	O

The	O
finding	O
of	O
jaw	O
lesions	B-UNK
and	O
/	O
or	O
pigmented	O
ocular	O
fundus	O
lesions	B-UNK
in	O
relatives	B-UNK
at	O
risk	B-UNK
are	O
indications	O
of	O
the	O
possible	O
presence	O
of	O
the	O
GS	B-UNK
gene	B-UNK
.	O

Identification	B-UNK
of	O
an	O
altered	O
splice	B-UNK
site	I-UNK
in	O
Ashkenazi	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
.	O

Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
genetic	B-UNK
disorder	I-UNK
resulting	B-UNK
from	O
mutation	B-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
encoding	B-UNK
the	O
alpha	B-UNK
-	O
subunit	B-UNK
of	O
the	O
lysosomal	B-UNK
enzyme	B-UNK
,	O
beta-N-acetylhexosaminidase	O
A	O
(	O
ref	O
.	O
1	O
)	O
.	O

A	O
relatively	O
high	B-UNK
frequency	I-UNK
of	O
carriers	B-UNK
(	O
1/27	O
)	O
of	O
a	O
lethal	O
,	O
infantile	B-UNK
form	B-UNK
of	O
the	O
disease	B-UNK
is	O
found	O
in	O
the	O
Ashkenazi	B-UNK
Jewish	I-UNK
population	B-UNK
,	O
but	O
it	O
is	O
not	O
yet	O
evident	O
whether	O
this	O
has	O
resulted	B-UNK
from	O
a	O
founder	B-UNK
effect	I-UNK
and	O
random	B-UNK
genetic	B-UNK
drift	O
or	O
from	O
a	O
selective	O
advantage	B-UNK
of	O
heterozygotes	B-UNK
.	O

We	O
have	O
identified	B-UNK
a	O
single	B-UNK
-	O
base	B-UNK
mutation	B-UNK
in	O
a	O
cloned	O
fragment	B-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
from	O
an	O
Ashkenazi	B-UNK
Jewish	I-UNK
patient	B-UNK
.	O

This	O
change	B-UNK
,	O
the	O
substitution	B-UNK
of	O
a	O
C	O
for	O
G	O
in	O
the	O
first	O
nucleotide	B-UNK
of	O
intron	B-UNK
12	O
is	O
expected	O
to	O
result	B-UNK
in	O
defective	O
splicing	B-UNK
of	O
the	O
messenger	B-UNK
RNA	I-UNK
.	O

A	O
test	B-UNK
for	O
the	O
mutant	B-UNK
allele	B-UNK
based	B-UNK
on	O
amplification	B-UNK
of	O
DNA	B-UNK
by	O
the	O
polymerase	B-UNK
chain	I-UNK
rection	O
and	O
cleavage	O
of	O
a	O
DdeI	O
restriction	B-UNK
site	B-UNK
generated	O
by	O
the	O
mutation	B-UNK
revealed	B-UNK
that	O
this	O
case	B-UNK
and	O
two	O
other	O
cases	B-UNK
of	O
the	O
Ashkenazi	B-UNK
,	O
infantile	B-UNK
form	B-UNK
of	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
are	O
heterozygous	B-UNK
for	O
two	O
different	O
mutations	B-UNK
.	O

The	O
occurrence	B-UNK
of	O
multiple	B-UNK
mutant	B-UNK
alleles	I-UNK
warrants	O
further	O
examination	B-UNK
of	O
the	O
selective	O
advantage	B-UNK
hypothesis	B-UNK
..	O

X	O
-	O
linked	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
in	O
Mus	O
musculus	O
.	O

A	O
mouse	B-UNK
with	O
X	O
-	O
linked	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1-ethyl-1-nitrosourea	O
-	O
treated	O
male	B-UNK
mice	B-UNK
.	O

The	O
activity	B-UNK
alteration	O
was	O
detected	B-UNK
in	O
blood	B-UNK
but	O
can	O
also	O
be	O
observed	B-UNK
in	O
other	O
tissue	B-UNK
extracts	B-UNK
.	O

Hemizygous	B-UNK
,	O
heterozygous	B-UNK
,	O
and	O
homozygous	B-UNK
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	B-UNK
remaining	O
activity	B-UNK
in	O
the	O
blood	B-UNK
as	O
compared	B-UNK
to	O
the	O
wild	B-UNK
type	I-UNK
.	O

Erythrocyte	B-UNK
indices	O
did	O
not	O
show	O
differences	B-UNK
between	O
mutants	O
and	O
wild	B-UNK
types	B-UNK
.	O

The	O
mutation	B-UNK
does	O
not	O
affect	O
the	O
electrophoretic	B-UNK
migration	O
,	O
the	O
isoelectric	O
point	B-UNK
,	O
or	O
the	O
thermal	O
stability	O
.	O

Kinetic	O
properties	B-UNK
,	O
such	O
as	O
the	O
Km	O
for	O
glucose-6-phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	B-UNK
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	B-UNK
between	O
wild	B-UNK
types	B-UNK
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	B-UNK
utilization	O
of	O
deamino	O
-	O
NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O

This	O
is	O
presently	O
the	O
only	O
animal	B-UNK
model	I-UNK
for	O
X	O
-	O
linked	B-UNK
G6PD	B-UNK
deficiency	I-UNK
in	O
humans	B-UNK
..	O

Diverse	B-UNK
point	B-UNK
mutations	I-UNK
in	O
the	O
human	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
gene	B-UNK
cause	O
enzyme	B-UNK
deficiency	I-UNK
and	O
mild	O
or	O
severe	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
;	O
EC	B-UNK
1	O
.	O
1	O
.	O
1	O
.	O
49	O
)	O
deficiency	B-UNK
is	O
a	O
common	B-UNK
genetic	B-UNK
abnormality	O
affecting	O
an	O
estimated	B-UNK
400	O
million	O
people	O
worldwide	O
.	O

Clinical	B-UNK
and	O
biochemical	O
analyses	O
have	O
identified	B-UNK
many	O
variants	B-UNK
exhibiting	O
a	O
range	B-UNK
of	O
phenotypes	O
,	O
which	O
have	O
been	O
well	O
characterized	B-UNK
from	O
the	O
hematological	O
point	B-UNK
of	O
view	O
.	O

However	O
,	O
until	O
now	O
,	O
their	O
precise	O
molecular	B-UNK
basis	I-UNK
has	O
remained	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
seven	O
mutant	B-UNK
G6PD	B-UNK
alleles	B-UNK
.	O

In	O
the	O
nondeficient	O
polymorphic	B-UNK
African	B-UNK
variant	O
G6PD	B-UNK
A	O
we	O
have	O
found	O
a	O
single	B-UNK
point	B-UNK
mutation	I-UNK
.	O

The	O
other	O
six	O
mutants	O
investigated	O
were	O
all	O
associated	O
with	O
enzyme	B-UNK
deficiency	I-UNK
.	O

In	O
one	O
of	O
the	O
commonest	O
,	O
G6PD	B-UNK
Mediterranean	I-UNK
,	O
which	O
is	O
associated	O
with	O
favism	B-DISEASE
among	O
other	O
clinical	B-UNK
manifestations	I-UNK
,	O
a	O
single	B-UNK
amino	B-UNK
acid	I-UNK
replacement	O
was	O
found	O
(	O
serine----phenylalanine	O
)	O
it	O
must	O
be	O
responsible	B-UNK
for	O
the	O
decreased	B-UNK
stability	O
and	O
the	O
reduced	O
catalytic	O
efficiency	O
of	O
this	O
enzyme	B-UNK
.	O

Single	B-UNK
point	B-UNK
mutations	I-UNK
were	O
also	O
found	O
in	O
G6PD	B-UNK
Metaponto	O
(	O
Southern	B-UNK
Italy	O
)	O
and	O
in	O
G6PD	B-UNK
Ilesha	O
(	O
Nigeria	O
)	O
,	O
which	O
are	O
asymptomatic	B-UNK
,	O
and	O
in	O
G6PD	B-UNK
Chatham	O
,	O
which	O
was	O
observed	B-UNK
in	O
an	O
Indian	O
boy	B-UNK
with	O
neonatal	B-UNK
jaundice	B-DISEASE
.	O

In	O
G6PD	B-UNK
"	O
Matera	O
,	O
"	O
which	O
is	O
now	O
known	O
to	O
be	O
the	O
same	O
as	O
G6PD	B-UNK
A-	O
,	O
two	O
separate	O
point	B-UNK
mutations	I-UNK
were	O
found	O
,	O
one	O
of	O
which	O
is	O
the	O
same	O
as	O
in	O
G6PD	B-UNK
A.	O

In	O
G6PD	B-UNK
Santiago	O
,	O
a	O
de	O
novo	O
mutation	B-UNK
(	O
glycine----arginine	O
)	O
is	O
associated	O
with	O
severe	B-UNK
chronic	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O

The	O
mutations	B-UNK
observed	B-UNK
show	O
a	O
striking	O
predominance	O
of	O
C----T	O
transitions	O
,	O
with	O
CG	O
doublets	O
involved	B-UNK
in	O
four	O
of	O
seven	O
cases	B-UNK
.	O

Thus	O
,	O
diverse	B-UNK
point	B-UNK
mutations	I-UNK
may	O
account	B-UNK
largely	O
for	O
the	O
phenotypic	B-UNK
heterogeneity	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
.	O

Tight	O
linkage	B-UNK
between	O
myotonic	B-UNK
dystrophy	I-UNK
and	O
apolipoprotein	B-UNK
E	O
genes	B-UNK
revealed	B-UNK
with	O
allele	B-UNK
-	O
specific	B-UNK
oligonucleotides	O
.	O

In	O
16	O
families	B-UNK
with	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
a	O
novel	O
approach	O
based	B-UNK
on	O
use	O
of	O
allele	B-UNK
-	O
specific	B-UNK
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	B-UNK
the	O
linkage	B-UNK
relationship	B-UNK
between	O
the	O
apolipoprotein	B-UNK
E	O
(	O
APOE	B-UNK
)	O
gene	B-UNK
and	O
DM	B-DISEASE
.	O

Synthetic	O
oligonucleotides	O
,	O
designed	O
to	O
discriminate	O
between	O
APOE	B-UNK
alleles	B-UNK
epsilon	O
3	O
and	O
epsilon	O
4	O
,	O
enabled	O
us	O
to	O
distinguish	O
heterozygous	B-UNK
carriers	B-UNK
in	O
a	O
hybridization	B-UNK
assay	B-UNK
.	O

In	O
a	O
subset	O
of	O
families	B-UNK
,	O
the	O
relevant	O
segment	O
of	O
the	O
APOE	B-UNK
gene	B-UNK
was	O
enzymatically	O
amplified	O
to	O
increase	B-UNK
the	O
sensitivity	O
of	O
the	O
method	O
.	O

For	O
DM	B-DISEASE
and	O
APOE	B-UNK
,	O
a	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
(	O
zmax	O
of	O
7	O
.	O

47	O
was	O
obtained	B-UNK
at	O
a	O
recombination	B-UNK
frequency	B-UNK
(	O
theta	B-UNK
)	O
of	O
0	O
.	O

047	O
(	O
male	B-UNK
theta	B-UNK
=	O
female	O
theta	B-UNK
)	O
.	O

No	O
recombination	B-UNK
(	O
maximum	B-UNK
lod	B-UNK
score	I-UNK
of	O
5	O
.	O
61	O
at	O
theta	B-UNK
=	O
0	O
.	O
0	O
)	O
was	O
found	O
between	O
APOE	B-UNK
and	O
the	O
apolipoprotein	B-UNK
CII	O
(	O
APOC2	B-UNK
)	O
gene	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
,	O
in	O
addition	B-UNK
to	O
APOC2	B-UNK
,	O
APOE	B-UNK
is	O
a	O
useful	O
marker	B-UNK
for	O
presymptomatic	O
DM	B-UNK
diagnosis	B-UNK
.	O

Regional	O
localization	B-UNK
of	O
polymorphic	B-UNK
DNA	B-UNK
loci	O
on	O
the	O
proximal	B-UNK
long	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
using	O
deletions	O
associated	O
with	O
choroideremia	B-UNK
.	O

In	O
two	O
unrelated	B-UNK
families	I-UNK
,	O
males	B-UNK
have	O
been	O
identified	B-UNK
who	O
suffer	O
from	O
choroideremia	B-DISEASE
and	O
at	O
the	O
same	O
time	O
have	O
an	O
interstitial	O
deletion	B-UNK
on	O
the	O
proximal	B-UNK
long	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
.	O

By	O
high	B-UNK
-	O
resolution	O
banding	O
we	O
have	O
characterized	B-UNK
the	O
deletion	B-UNK
chromosomes	O
as	O
del	O
(	O
X	O
)	O
(	O
q21	B-UNK
.	O
1-q21	O
1-q21	O
.	O
33	O
)	O
and	O
del	O
(	O
X	O
)	O
(	O
q21	B-UNK
.	O
2-q21	O
2-q21	O
.	O
31	O
)	O
respectively	O
.	O

By	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
we	O
have	O
mapped	B-UNK
ten	O
different	O
polymorphic	B-UNK
DNA	B-UNK
loci	O
relative	B-UNK
to	O
the	O
position	B-UNK
of	O
the	O
deletion	B-UNK
and	O
the	O
choroideremia	B-DISEASE
locus	B-UNK
TCD	B-UNK
.	O

One	O
probe	O
,	O
p31	O
,	O
was	O
shown	B-UNK
to	O
cover	O
one	O
of	O
the	O
breakpoints	O
of	O
the	O
smallest	O
deletion	B-UNK
.	O

The	O
following	O
order	B-UNK
of	O
the	O
loci	O
was	O
suggested	O
by	O
deletion	B-UNK
mapping	B-UNK
cen	O
-	O
DXS106-DXS72-TCD-(DXYS1	O
/	O
DXYS23	O
/	O
DXYS5)-DXYS2-(DXYS12	O
/	O
DXS3)-(DXS17	O
/	O
DXS101)-Xqter	O
.	O

Retroviral	O
-	O
mediated	O
gene	B-UNK
transfer	B-UNK
of	O
human	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
into	O
NIH	O
3T3	O
and	O
hepatoma	B-DISEASE
cells	B-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
caused	B-UNK
by	O
deficiency	B-UNK
of	O
the	O
hepatic	B-UNK
enzyme	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

A	O
full	O
-	O
length	B-UNK
human	B-UNK
PAH	B-UNK
cDNA	O
sequence	B-UNK
has	O
been	O
inserted	O
into	O
pzip	O
-	O
neoSV	O
(	O
X	O
)	O
,	O
which	O
is	O
a	O
retroviral	O
vector	O
containing	O
the	O
bacterial	B-UNK
neo	O
gene	B-UNK
.	O

The	O
recombinant	B-UNK
has	O
been	O
transfected	O
into	O
psi	O
2	O
cells	B-UNK
,	O
which	O
provide	B-UNK
synthesis	B-UNK
of	O
the	O
retroviral	O
capsid	O
.	O

Recombinant	B-UNK
virus	O
was	O
detected	B-UNK
in	O
the	O
culture	B-UNK
medium	O
of	O
the	O
transfected	O
psi	O
2	O
cells	B-UNK
,	O
which	O
is	O
capable	O
of	O
transmitting	O
the	O
human	B-UNK
PAH	B-UNK
gene	B-UNK
into	O
mouse	B-UNK
NIH	O
3T3	O
cells	B-UNK
by	O
infection	B-DISEASE
leading	B-UNK
to	O
stable	B-UNK
incorporation	O
of	O
the	O
recombinant	B-UNK
provirus	O
.	O

Infected	O
cells	B-UNK
express	O
PAH	B-UNK
mRNA	O
,	O
immunoreactive	O
PAH	B-UNK
protein	B-UNK
,	O
and	O
exhibit	O
pterin	O
-	O
dependent	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
activity	B-UNK
.	O

The	O
recombinant	B-UNK
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	B-UNK
hepatoma	B-DISEASE
cell	B-UNK
line	I-UNK
that	O
does	O
not	O
normally	O
synthesize	O
PAH	B-UNK
.	O

PAH	B-UNK
activity	B-UNK
is	O
present	B-UNK
in	O
the	O
cellular	O
extracts	B-UNK
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	B-DISEASE
cells	B-UNK
infected	O
with	O
the	O
recombinant	B-UNK
viruses	O
.	O

Thus	O
,	O
recombinant	B-UNK
viruses	O
containing	O
human	B-UNK
PAH	B-UNK
cDNA	O
provide	B-UNK
a	O
means	B-UNK
for	O
introducing	O
functional	O
PAH	B-UNK
into	O
mammalian	O
cells	B-UNK
of	O
hepatic	B-UNK
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	B-UNK
for	O
somatic	B-UNK
gene	B-UNK
therapy	B-UNK
for	O
PKU	B-UNK
..	O

Estimation	O
of	O
the	O
male	B-UNK
to	O
female	O
ratio	B-UNK
of	O
mutation	B-UNK
rates	O
from	O
the	O
segregation	B-UNK
of	O
X	O
-	O
chromosomal	B-UNK
DNA	B-UNK
haplotypes	O
in	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
families	B-UNK
.	O

A	O
novel	O
procedure	O
is	O
presented	B-UNK
to	O
estimate	O
the	O
ratio	B-UNK
of	O
male	B-UNK
to	O
female	O
mutation	B-UNK
rates	O
for	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

X	O
-	O
specific	B-UNK
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
are	O
used	O
to	O
establish	O
DNA	B-UNK
haplotypes	O
in	O
three	O
-	O
generation	O
DMD	B-UNK
families	B-UNK
.	O

From	O
the	O
proportion	B-UNK
of	O
DMD	B-UNK
patients	B-UNK
who	O
have	O
inherited	B-UNK
their	O
maternal	O
grandfathers	O
X	O
chromosome	B-UNK
,	O
the	O
ratio	B-UNK
of	O
mutation	B-UNK
rates	O
can	O
be	O
calculated	O
.	O

In	O
contrast	B-UNK
to	O
classical	O
methods	O
,	O
the	O
proposed	O
procedure	O
is	O
not	O
restricted	O
to	O
sporadic	B-UNK
or	O
familiar	O
cases	B-UNK
nor	O
is	O
any	O
information	B-UNK
on	O
the	O
carrier	B-UNK
status	I-UNK
of	O
female	O
relatives	B-UNK
required	B-UNK
..	O

Deletions	O
of	O
a	O
DNA	B-UNK
sequence	I-UNK
in	O
retinoblastomas	O
and	O
mesenchymal	B-DISEASE
tumors	I-DISEASE
:	O
organization	B-UNK
of	O
the	O
sequence	B-UNK
and	O
its	O
encoded	B-UNK
protein	B-UNK
.	O

Retinoblastoma	B-DISEASE
is	O
a	O
childhood	O
tumor	B-DISEASE
that	O
can	O
arise	O
because	O
of	O
mutant	B-UNK
alleles	I-UNK
acquired	O
as	O
somatic	B-UNK
or	O
germinal	O
mutations	B-UNK
.	O

The	O
mutant	B-UNK
allele	B-UNK
can	O
be	O
carried	O
in	O
the	O
germ	B-UNK
line	I-UNK
.	O

The	O
mutations	B-UNK
creating	O
these	O
alleles	B-UNK
act	O
by	O
inactivating	O
copies	O
of	O
a	O
recessive	B-UNK
oncogene	O
located	B-UNK
within	O
band	O
q14	O
of	O
chromosome	B-UNK
13	O
and	O
termed	O
the	O
RB1	B-UNK
locus	B-UNK
.	O

We	O
have	O
reported	B-UNK
isolation	B-UNK
of	O
a	O
cDNA	O
fragment	B-UNK
that	O
recognizes	O
chromosomal	B-UNK
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	B-DISEASE
gene	B-UNK
associated	O
with	O
the	O
RB1	B-UNK
locus	B-UNK
.	O

We	O
now	O
report	B-UNK
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	B-UNK
mutations	I-UNK
in	O
mesenchymal	B-DISEASE
tumors	I-DISEASE
among	O
patients	B-UNK
having	O
no	O
apparent	O
predisposition	B-UNK
to	O
retinoblastoma	B-DISEASE
and	O
no	O
previous	B-UNK
evidence	B-UNK
of	O
retinoblastoma	B-DISEASE
.	O

These	O
tumors	B-DISEASE
provide	B-UNK
additional	O
evidence	B-UNK
that	O
the	O
cloned	O
sequences	O
are	O
representative	O
of	O
a	O
gene	B-UNK
that	O
is	O
a	O
frequent	B-UNK
target	O
of	O
inactivation	B-UNK
during	O
tumorigenesis	O
.	O

Sequence	B-UNK
analysis	I-UNK
of	O
this	O
cDNA	O
provides	O
little	O
insight	O
into	O
its	O
normal	B-UNK
functional	O
role	B-UNK
..	O

Treatment	O
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
with	O
growth	B-UNK
hormone	B-UNK
inhibitors	O
.	O

A	O
controlled	O
,	O
double-blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol	O
,	O
a	O
growth	B-UNK
hormone	B-UNK
inhibitor	O
,	O
was	O
performed	O
in	O
a	O
pair	B-UNK
of	O
7	O
1/2	O
year	O
-	O
old	O
monozygotic	O
twins	O
,	O
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

The	O
rationale	O
for	O
this	O
trial	O
was	O
based	B-UNK
on	O
a	O
patient	B-UNK
(	O
reported	B-UNK
previously	B-UNK
)	O
affected	B-UNK
simultaneously	O
with	O
DMD	B-UNK
and	O
growth	B-UNK
hormone	B-UNK
(	O
GH	O
)	O
deficiency	B-UNK
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	O
process	B-UNK
and	O
is	O
still	O
walking	O
at	O
18	O
years	O
.	O

One	O
of	O
the	O
twins	O
received	O
2	O
mg	B-UNK
of	O
mazindol	O
daily	O
,	O
while	O
the	O
other	O
received	O
a	O
placebo	O
.	O

The	O
assessment	O
,	O
repeated	O
every	O
2	O
months	O
,	O
included	O
weight	O
and	O
height	O
measurements	O
,	O
functional	O
and	O
motor	O
ability	B-UNK
tests	O
,	O
ergometry	O
and	O
determinations	O
of	O
serum	B-UNK
enzymes	B-UNK
and	O
GH	O
levels	B-UNK
.	O

After	O
one	O
year	O
of	O
trial	O
the	O
code	O
was	O
broken	O
and	O
it	O
was	O
seen	O
that	O
the	O
twin	O
under	O
placebo	O
treatment	O
was	O
strikingly	O
worse	O
than	O
his	O
brother	B-UNK
,	O
the	O
progression	B-UNK
of	O
whose	O
condition	B-UNK
was	O
practically	O
arrested	O
.	O

These	O
results	B-UNK
strongly	O
suggest	B-UNK
that	O
treatment	O
with	O
a	O
GH	O
inhibitor	O
is	O
beneficial	O
for	O
DMD	B-UNK
patients	B-UNK
..	O

Identification	B-UNK
and	O
localization	B-UNK
of	O
mutations	B-UNK
at	O
the	O
Lesch	O
-	O
Nyhan	O
locus	B-UNK
by	O
ribonuclease	O
A	O
cleavage	O
.	O

Many	O
mutations	B-UNK
leading	B-UNK
to	O
human	B-UNK
disease	B-DISEASE
are	O
the	O
result	B-UNK
of	O
single	B-UNK
DNA	B-UNK
base	B-UNK
pair	I-UNK
changes	O
that	O
cannot	O
be	O
identified	B-UNK
by	O
Southern	B-UNK
analysis	B-UNK
.	O

This	O
has	O
prompted	O
the	O
development	B-UNK
of	O
alternative	B-UNK
assays	O
for	O
point	B-UNK
mutation	I-UNK
detection	B-UNK
.	O

The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid	B-UNK
-	O
paper	O
affinity	B-UNK
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	B-UNK
the	O
mutational	O
lesions	B-UNK
in	O
the	O
hypoxanthine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
)	O
messenger	B-UNK
RNAs	O
of	O
patients	B-UNK
with	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	B-UNK
were	O
identified	B-UNK
in	O
messenger	B-UNK
RNA	I-UNK
from	O
5	O
of	O
14	O
Lesch	O
-	O
Nyhan	O
patients	B-UNK
who	O
were	O
chosen	O
because	O
no	O
HPRT	B-UNK
Southern	B-UNK
or	O
Northern	B-UNK
blotting	O
pattern	B-UNK
changes	O
had	O
been	O
found	O
.	O

This	O
approach	O
now	O
allows	O
HPRT	B-UNK
mutation	B-UNK
detection	I-UNK
in	O
50	O
percent	B-UNK
of	O
the	O
cases	B-UNK
of	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
polyuridylic	O
acid	B-UNK
-	O
paper	O
affinity	B-UNK
procedure	O
provides	O
a	O
general	B-UNK
method	O
for	O
analysis	B-UNK
of	O
low	B-UNK
abundance	O
messenger	B-UNK
RNAs	O
..	O

Two	O
new	O
variants	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
associated	O
with	O
hereditary	B-UNK
non-spherocytic	O
hemolytic	B-DISEASE
anemia	I-DISEASE
:	O
G6PD	B-UNK
Wayne	O
and	O
G6PD	B-UNK
Huron	O
.	O

Two	O
new	O
deficient	B-UNK
variants	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
causing	B-UNK
hereditary	B-UNK
nonspherocytic	O
hemolytic	B-DISEASE
anemia	I-DISEASE
(	O
HNSHA	O
)	O
are	O
described	O
.	O

Both	O
of	O
these	O
are	O
unique	O
and	O
they	O
have	O
been	O
named	O
G6PD	B-UNK
Wayne	O
and	O
G6PD	B-UNK
Huron	O
.	O

Patients	B-UNK
with	O
G6PD	B-UNK
Wayne	O
underwent	O
splenectomy	O
and	O
no	O
objective	B-UNK
improvement	O
was	O
noted	O
.	O

The	O
patients	B-UNK
with	O
G6PD	B-UNK
Huron	O
were	O
under	O
medical	O
observation	O
for	O
a	O
considerable	B-UNK
period	O
of	O
time	O
without	O
the	O
diagnosis	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
being	O
entertained	O
because	O
the	O
family	B-UNK
was	O
of	O
Northern	B-UNK
European	B-UNK
origin	O
.	O

Since	O
sporadic	B-UNK
variants	B-UNK
of	O
G6PD	B-UNK
causing	B-UNK
HNSHA	O
show	O
no	O
special	O
racial	O
predilection	O
,	O
the	O
diagnosis	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
should	O
always	O
be	O
considered	O
in	O
patients	B-UNK
with	O
this	O
syndrome	B-UNK
..	O

Sialophorin	O
,	O
a	O
surface	O
sialoglycoprotein	O
defective	O
in	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
,	O
is	O
involved	B-UNK
in	O
human	B-UNK
T	O
lymphocyte	B-UNK
proliferation	O
.	O

The	O
mAb	O
L10	O
was	O
used	O
to	O
determine	B-UNK
the	O
distribution	B-UNK
and	O
the	O
function	B-UNK
of	O
sialophorin	O
,	O
the	O
heavily	O
glycosylated	O
surface	O
molecule	O
that	O
is	O
deficient	B-UNK
/	O
defective	O
in	O
lymphocytes	O
of	O
patients	B-UNK
with	O
the	O
X	O
-	O
linked	B-UNK
immunodeficiency	B-DISEASE
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
.	O

Dual	O
-	O
parameter	O
FACS	O
analysis	B-UNK
indicated	O
that	O
sialophorin	O
is	O
expressed	B-UNK
on	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
,	O
on	O
a	O
subpopulation	O
of	O
peripheral	B-UNK
blood	I-UNK
B	O
lymphocytes	O
,	O
on	O
all	O
thymocytes	O
,	O
and	O
on	O
a	O
subpopulation	O
of	O
bone	B-UNK
marrow	O
cells	B-UNK
.	O

Functional	O
studies	B-UNK
demonstrated	O
that	O
L10	O
mAb	O
stimulates	O
the	O
proliferation	O
of	O
peripheral	B-UNK
blood	I-UNK
T	O
lymphocytes	O
as	O
measured	O
by	O
stimulation	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
.	O

The	O
time	O
course	O
and	O
magnitude	O
of	O
increased	B-UNK
[	O
3H	O
]	O
thymidine	O
incorporation	O
by	O
T	O
lymphocytes	O
in	O
response	B-UNK
to	O
L10	O
mAb	O
paralleled	O
that	O
induced	O
by	O
anti	B-UNK
-	O
CD3	O
mAb	O
.	O

Effective	O
stimulation	O
was	O
dependent	B-UNK
on	O
the	O
presence	O
of	O
monocytes	O
and	O
the	O
Fc	O
portion	B-UNK
of	O
L10	O
mAb	O
.	O

Stimulation	O
of	O
lymphocytes	O
by	O
L10	O
,	O
like	O
stimulation	O
by	O
anti	B-UNK
-	O
CD3	O
mAb	O
,	O
involves	O
increased	B-UNK
expression	B-UNK
of	O
4F2	O
,	O
HLA	B-UNK
-	O
DR	O
,	O
and	O
IL-2-R.	O

These	O
observations	B-UNK
suggest	B-UNK
that	O
sialophorin	O
functions	O
in	O
T	O
cell	B-UNK
activation	O
..	O

Hypopigmentation	B-DISEASE
in	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

Cutaneous	O
and	O
ocular	O
pigmentation	O
were	O
evaluated	O
in	O
29	O
individuals	B-UNK
with	O
the	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

Criteria	O
for	O
hypopigmentation	B-DISEASE
included	O
the	O
presence	O
of	O
type	B-UNK
I	O
or	O
II	B-UNK
skin	B-UNK
,	O
the	O
lightest	O
skin	B-UNK
type	B-UNK
in	O
the	O
family	B-UNK
by	O
history	B-UNK
,	O
and	O
iris	O
translucency	O
on	O
globe	O
transillumination	O
.	O

On	O
the	O
basis	B-UNK
of	O
these	O
criteria	O
,	O
48	O
%	O
of	O
the	O
PWS	B-UNK
individuals	B-UNK
were	O
hypopigmented	O
.	O

The	O
presence	O
of	O
hypopigmentation	B-DISEASE
correlated	B-UNK
with	O
a	O
small	O
interstitial	O
deletion	B-UNK
on	O
the	O
proximal	B-UNK
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
15	O
;	O
however	O
,	O
this	O
deletion	B-UNK
was	O
also	O
found	O
in	O
individuals	B-UNK
who	O
did	O
not	O
meet	O
the	O
full	O
criteria	O
for	O
hypopigmentation	B-DISEASE
.	O

Hairbulb	O
tyrosinase	O
activity	B-UNK
and	O
glutathione	O
content	O
,	O
as	O
well	O
as	O
urine	O
cysteinyldopa	O
excretion	O
,	O
were	O
low	B-UNK
in	O
PWS	B-UNK
individuals	B-UNK
with	O
and	O
without	O
hypopigmentation	B-DISEASE
and	O
did	O
not	O
separate	O
these	O
two	O
groups	B-UNK
.	O

We	O
conclude	O
that	O
hypopigmentation	B-DISEASE
is	O
found	O
in	O
a	O
significant	B-UNK
proportion	B-UNK
of	O
individuals	B-UNK
with	O
PWS	B-UNK
and	O
that	O
the	O
hypopigmentation	B-DISEASE
may	O
be	O
associated	O
with	O
a	O
deletion	B-UNK
of	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
15	O
.	O

The	O
mechanism	B-UNK
for	O
the	O
hypopigmentation	B-DISEASE
is	O
unknown	O
..	O

Phenotype	B-UNK
heterogeneity	B-UNK
among	O
hemizygotes	O
in	O
a	O
family	B-UNK
biochemically	O
screened	B-UNK
for	O
adrenoleukodystrophy	B-UNK
.	O

We	O
report	B-UNK
on	O
two	O
clinically	O
,	O
neurologically	O
normal	B-UNK
relatives	B-UNK
of	O
a	O
boy	B-UNK
affected	B-UNK
by	O
adrenoleukodystrophy	B-DISEASE
(	O
ALD	B-UNK
)	O
;	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	B-UNK
of	O
an	O
ALD	B-UNK
hemizygote	O
.	O

The	O
assay	B-UNK
consisted	O
in	O
the	O
determination	B-UNK
of	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
in	O
lyophilized	O
and	O
reconstituted	O
plasma	O
.	O

While	O
no	O
evidence	B-UNK
of	O
neurologic	O
disease	B-DISEASE
(	O
leukodystrophy	B-UNK
or	O
myeloneuropathy	O
)	O
was	O
present	B-UNK
in	O
these	O
hemizygotes	O
,	O
adrenocortical	O
insufficiency	B-DISEASE
provoking	O
compensatory	O
high	B-UNK
ACTH	O
release	O
was	O
found	O
in	O
both	O
.	O

These	O
findings	B-UNK
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	B-UNK
families	B-UNK
in	O
which	O
cases	B-UNK
with	O
clinically	O
expressed	B-UNK
ALD	B-UNK
are	O
represented	O
in	O
several	O
generations	O
..	O

The	O
mapping	B-UNK
of	O
a	O
cDNA	O
from	O
the	O
human	B-UNK
X	O
-	O
linked	B-UNK
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
to	O
the	O
mouse	B-UNK
X	O
chromosome	B-UNK
.	O

The	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
in	O
humans	B-UNK
has	O
opened	O
up	O
the	O
possibility	B-UNK
of	O
a	O
detailed	B-UNK
molecular	B-UNK
analysis	I-UNK
of	O
the	O
genes	B-UNK
in	O
humans	B-UNK
and	O
in	O
related	B-UNK
mammalian	O
species	B-UNK
.	O

Until	O
relatively	O
recently	O
,	O
there	O
was	O
no	O
obvious	O
mouse	B-UNK
model	I-UNK
of	O
this	O
genetic	B-UNK
disease	B-UNK
for	O
the	O
development	B-UNK
of	O
therapeutic	O
strategies	O
.	O

The	O
identification	B-UNK
of	O
a	O
mouse	B-UNK
X	O
-	O
linked	B-UNK
mutant	B-UNK
showing	O
muscular	B-UNK
dystrophy	I-UNK
,	O
mdx	O
,	O
has	O
provided	O
a	O
candidate	B-UNK
mouse	B-UNK
genetic	B-UNK
homologue	B-UNK
to	O
the	O
DMD	B-UNK
locus	B-UNK
;	O
the	O
relatively	O
mild	O
pathological	O
features	B-UNK
of	O
mdx	O
suggest	B-UNK
it	O
may	O
have	O
more	O
in	O
common	B-UNK
with	O
mutations	B-UNK
of	O
the	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
type	B-UNK
at	O
the	O
same	O
human	B-UNK
locus	B-UNK
,	O
however	O
.	O

But	O
the	O
close	B-UNK
genetic	B-UNK
linkage	I-UNK
of	O
mdx	O
to	O
G6PD	B-UNK
and	O
Hprt	B-UNK
on	O
the	O
mouse	B-UNK
X	O
chromosome	B-UNK
,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology	O
,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	B-UNK
may	O
instead	O
correspond	O
to	O
Emery	B-UNK
Dreifuss	I-UNK
muscular	I-UNK
dystrophy	I-UNK
which	O
itself	O
is	O
closely	B-UNK
linked	I-UNK
to	O
DNA	B-UNK
markers	I-UNK
at	O
Xq28-qter	O
in	O
the	O
region	B-UNK
of	O
G6PD	B-UNK
on	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
.	O

Using	O
an	O
interspecific	O
mouse	B-UNK
domesticus	O
/	O
spretus	O
cross	O
,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	B-UNK
on	O
the	O
mouse	B-UNK
X	O
chromosome	B-UNK
,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	B-UNK
X	O
chromosome	B-UNK
sequences	O
homologous	B-UNK
to	O
a	O
DMD	B-UNK
cDNA	O
clone	O
.	O

These	O
sequences	O
map	B-UNK
provocatively	O
close	B-UNK
to	O
the	O
mdx	O
mutation	B-UNK
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur	O
,	O
spf	O
,	O
the	O
mouse	B-UNK
homologue	B-UNK
of	O
OTC	O
(	O
ornithine	O
transcarbamylase	O
)	O
which	O
is	O
closely	B-UNK
linked	I-UNK
to	O
DMD	B-UNK
on	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
..	O

Localization	B-UNK
of	O
the	O
region	B-UNK
homologous	B-UNK
to	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
locus	B-UNK
on	O
the	O
mouse	B-UNK
X	O
chromosome	B-UNK
.	O

Recent	O
progress	O
has	O
resulted	B-UNK
in	O
part	O
of	O
the	O
gene	B-UNK
mutated	B-UNK
in	O
Duchenne	B-UNK
and	O
the	O
milder	B-UNK
Becker	B-UNK
muscular	B-DISEASE
dystrophies	I-DISEASE
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	B-UNK
itself	O
extends	O
over	O
1	O
,	O
000	O
to	O
2	O
,	O
000	O
kilobases	O
(	O
kb	B-UNK
)	O
.	O

To	O
study	B-UNK
how	O
mutations	B-UNK
in	O
this	O
gene	B-UNK
affect	O
muscle	B-UNK
development	B-UNK
and	O
integrity	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	B-UNK
model	I-UNK
of	O
the	O
human	B-UNK
disease	B-UNK
.	O

The	O
mouse	B-UNK
mdx	O
mutation	B-UNK
affects	O
muscle	B-UNK
and	O
confers	O
a	O
mild	O
dystrophic	O
syndrome	B-DISEASE
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	B-UNK
is	O
equivalent	O
to	O
Duchenne	B-UNK
/	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
in	O
man	B-UNK
.	O

Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	B-UNK
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
that	O
cross-hybridize	O
to	O
mouse	B-UNK
X	O
-	O
linked	B-UNK
sequences	O
to	O
localize	O
the	O
gene	B-UNK
homologous	B-UNK
to	O
DMD	B-UNK
in	O
the	O
mouse	B-UNK
.	O

Both	O
sequences	O
map	B-UNK
to	O
the	O
region	B-UNK
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(	O
Ta	O
)	O
and	O
St14	O
-	O
1	O
(	O
DxPas8	O
)	O
loci	O
,	O
close	B-UNK
to	O
the	O
phosphorylase	O
b	O
kinase	B-UNK
locus	B-UNK
(	O
Phk	O
)	O
.	O

By	O
analogy	O
with	O
the	O
human	B-UNK
X	O
-	O
chromosome	B-UNK
,	O
we	O
conclude	O
that	O
the	O
region	B-UNK
in	O
the	O
mouse	B-UNK
around	O
the	O
G6pd	B-UNK
and	O
St14	O
-	O
1	O
loci	O
may	O
contain	O
two	O
genes	B-UNK
corresponding	O
to	O
distinct	O
human	B-UNK
myopathies	O
Emery	B-UNK
Dreifuss	I-UNK
muscular	I-UNK
dystrophy	I-UNK
which	O
is	O
known	O
to	O
be	O
closely	B-UNK
linked	I-UNK
to	O
St14	O
-	O
1	O
in	O
man	B-UNK
and	O
the	O
DMD	B-UNK
homologue	B-UNK
described	O
here	O
..	O

GT	B-UNK
to	O
AT	O
transition	B-UNK
at	O
a	O
splice	B-UNK
donor	I-UNK
site	I-UNK
causes	O
skipping	O
of	O
the	O
preceding	O
exon	B-UNK
in	O
phenylketonuria	O
.	O

Classical	O
Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
human	B-UNK
genetic	B-UNK
disorder	I-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
hepatic	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

We	O
isolated	B-UNK
several	O
mutant	B-UNK
PAH	B-UNK
cDNA	O
clones	O
from	O
a	O
PKU	B-UNK
carrier	B-UNK
individual	O
and	O
showed	O
that	O
they	O
contained	O
an	O
internal	O
116	O
base	B-UNK
pair	I-UNK
deletion	I-UNK
,	O
corresponding	O
precisely	O
to	O
exon	B-UNK
12	O
of	O
the	O
human	B-UNK
chromosomal	B-UNK
PAH	B-UNK
gene	B-UNK
.	O

The	O
deletion	B-UNK
causes	O
the	O
synthesis	B-UNK
of	O
a	O
truncated	O
protein	B-UNK
lacking	O
the	O
C	O
-	O
terminal	B-UNK
52	O
amino	B-UNK
acids	I-UNK
.	O

Gene	B-UNK
transfer	B-UNK
and	O
expression	B-UNK
studies	B-UNK
using	O
the	O
mutant	B-UNK
PAH	B-UNK
cDNA	O
indicated	O
that	O
the	O
deletion	B-UNK
abolishes	O
PAH	B-UNK
activity	B-UNK
in	O
the	O
cell	B-UNK
as	O
a	O
result	B-UNK
of	O
protein	B-UNK
instability	B-UNK
.	O

To	O
determine	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
of	O
the	O
deletion	B-UNK
,	O
the	O
mutant	B-UNK
chromosomal	B-UNK
PAH	B-UNK
gene	B-UNK
was	O
isolated	B-UNK
from	O
this	O
individual	O
and	O
shown	B-UNK
to	O
contain	O
a	O
GT	B-UNK
--	O
greater	B-UNK
than	O
AT	O
substitution	B-UNK
at	O
the	O
5	O
splice	B-UNK
donor	I-UNK
site	I-UNK
of	O
intron	B-UNK
12	O
.	O

Thus	O
,	O
the	O
consequence	B-UNK
of	O
the	O
splice	B-UNK
donor	I-UNK
site	I-UNK
mutation	B-UNK
in	O
the	O
human	B-UNK
liver	B-UNK
is	O
the	O
skipping	O
of	O
the	O
preceding	O
exon	B-UNK
during	O
RNA	B-UNK
splicing	B-UNK
..	O

Conservation	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
in	O
mice	B-UNK
and	O
humans	B-UNK
.	O

A	O
portion	B-UNK
of	O
the	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
gene	B-UNK
transcript	B-UNK
from	O
human	B-UNK
fetal	O
skeletal	B-UNK
muscle	I-UNK
and	O
mouse	B-UNK
adult	B-UNK
heart	B-UNK
was	O
sequenced	O
,	O
representing	O
approximately	O
25	O
percent	B-UNK
of	O
the	O
total	B-UNK
,	O
14-kb	O
DMD	B-UNK
transcript	B-UNK
.	O

The	O
nucleic	O
acid	B-UNK
and	O
predicted	B-UNK
amino	B-UNK
acid	I-UNK
sequences	O
from	O
the	O
two	O
species	B-UNK
are	O
nearly	O
90	O
percent	B-UNK
homologous	B-UNK
.	O

The	O
amino	B-UNK
acid	I-UNK
sequence	B-UNK
that	O
is	O
predicted	B-UNK
from	O
this	O
portion	B-UNK
of	O
the	O
DMD	B-UNK
gene	B-UNK
indicates	O
that	O
the	O
protein	B-UNK
product	I-UNK
might	O
serve	O
a	O
structural	B-UNK
role	B-UNK
in	O
muscle	B-UNK
,	O
but	O
the	O
abundance	O
and	O
tissue	B-UNK
distribution	B-UNK
of	O
the	O
messenger	B-UNK
RNA	I-UNK
suggests	O
that	O
the	O
DMD	B-UNK
protein	B-UNK
is	O
not	O
nebulin	O
..	O

Familial	B-UNK
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
with	O
apparently	O
normal	B-UNK
chromosomes	O
.	O

We	O
report	B-UNK
on	O
4	O
sibs	O
(	O
2F	O
,	O
2	O
M	O
)	O
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

Diagnosis	B-UNK
was	O
made	O
clinically	O
on	O
the	O
basis	B-UNK
of	O
history	B-UNK
,	O
behavior	O
,	O
and	O
physical	B-UNK
findings	B-UNK
in	O
3	O
of	O
the	O
sibs	O
.	O

The	O
other	O
child	B-UNK
had	O
died	O
at	O
age	B-UNK
10	O
months	O
with	O
a	O
history	B-UNK
and	O
clinical	B-UNK
findings	B-UNK
typical	O
of	O
first	O
phase	B-UNK
of	O
PWS	B-UNK
.	O

Results	B-UNK
of	O
chromosome	B-UNK
studies	B-UNK
on	O
the	O
parents	O
and	O
surviving	O
sibs	O
were	O
normal	B-UNK
.	O

The	O
implications	B-UNK
of	O
this	O
unusual	O
familial	B-UNK
occurrence	B-UNK
for	O
our	O
understanding	B-UNK
of	O
PWS	B-UNK
are	O
discussed	O
..	O

Nebulin	O
and	O
titin	O
expression	B-UNK
in	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
appears	B-UNK
normal	B-UNK
.	O

Monoclonal	O
antibodies	B-UNK
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	B-UNK
staining	O
patterns	B-UNK
on	O
frozen	O
sections	O
of	O
three	O
muscle	B-UNK
biopsies	O
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

Gel	B-UNK
electrophoresis	I-UNK
and	O
immunoblotting	O
performed	O
on	O
two	O
of	O
these	O
muscle	B-UNK
biopsies	O
show	O
the	O
normal	B-UNK
pattern	B-UNK
of	O
titin	O
and	O
nebulin	O
polypeptides	O
.	O

Since	O
the	O
donor	B-UNK
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	B-UNK
deletion	B-UNK
of	O
the	O
5-region	O
of	O
the	O
DMD	B-UNK
gene	B-UNK
,	O
our	O
results	B-UNK
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	B-UNK
mutated	B-UNK
in	O
DMD	B-UNK
..	O

Heterozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
associated	O
with	O
angioedema	B-DISEASE
,	O
myasthenia	B-DISEASE
gravis	I-DISEASE
,	O
and	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
.	O

We	O
describe	O
a	O
patient	B-UNK
with	O
myasthenia	B-DISEASE
gravis	I-DISEASE
,	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
,	O
and	O
angioedema	B-DISEASE
associated	O
with	O
heterozygous	B-UNK
complement	B-UNK
factor	B-UNK
2	O
(	O
C2	B-UNK
)	O
deficiency	B-UNK
.	O

The	O
significance	O
of	O
this	O
association	B-UNK
is	O
controversial	O
,	O
though	O
the	O
association	B-UNK
of	O
C2	B-UNK
deficiency	I-UNK
with	O
certain	O
histocompatibility	B-UNK
antigens	O
suggests	O
possible	O
linkage	B-UNK
to	O
immune	B-UNK
response	B-UNK
genes	B-UNK
.	O

To	O
our	O
knowledge	B-UNK
this	O
is	O
the	O
first	O
report	B-UNK
of	O
heterozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
in	O
association	B-UNK
with	O
this	O
combination	B-UNK
of	O
autoimmune	B-UNK
disorders	B-UNK
,	O
and	O
we	O
discuss	O
the	O
aetiological	O
implications	B-UNK
..	O

Genetic	B-UNK
analysis	I-UNK
of	O
an	O
inherited	B-UNK
deficiency	B-UNK
of	O
the	O
third	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
Brittany	O
spaniel	O
dogs	O
.	O

Genetically	B-UNK
determined	B-UNK
C3	B-UNK
deficiency	I-UNK
in	O
Brittany	O
spaniel	O
dogs	O
shares	O
a	O
number	B-UNK
of	O
biochemical	O
and	O
clinical	B-UNK
characteristics	B-UNK
with	O
the	O
human	B-UNK
disorder	B-UNK
.	O

In	O
humans	B-UNK
,	O
the	O
gene	B-UNK
for	O
C3	B-UNK
deficiency	I-UNK
is	O
a	O
null	O
gene	B-UNK
that	O
is	O
allelic	O
to	O
the	O
structural	B-UNK
gene	B-UNK
for	O
C3	B-UNK
and	O
is	O
not	O
linked	B-UNK
to	O
the	O
major	B-UNK
histocompatibility	B-UNK
locus	B-UNK
.	O

The	O
current	B-UNK
study	B-UNK
used	O
allotype	O
analysis	B-UNK
of	O
canine	O
C3	B-UNK
in	O
order	B-UNK
to	O
demonstrate	B-UNK
that	O
the	O
gene	B-UNK
for	O
C3	B-UNK
deficiency	I-UNK
in	O
these	O
dogs	O
is	O
also	O
a	O
null	O
gene	B-UNK
allelic	O
to	O
the	O
structural	B-UNK
gene	B-UNK
for	O
C3	B-UNK
.	O

In	O
addition	B-UNK
,	O
preliminary	O
pedigree	B-UNK
analysis	B-UNK
suggests	O
that	O
the	O
gene	B-UNK
for	O
canine	O
C3	B-UNK
deficiency	I-UNK
is	O
apparently	O
not	O
closely	B-UNK
linked	I-UNK
to	O
the	O
major	B-UNK
histocompatibility	B-UNK
complex	O
of	O
the	O
dog	O
.	O

Thus	O
,	O
it	O
appears	B-UNK
that	O
C3	B-UNK
deficiency	I-UNK
in	O
Brittany	O
spaniel	O
dogs	O
not	O
only	O
shares	O
biochemical	O
and	O
clinical	B-UNK
features	I-UNK
with	O
C3	B-UNK
deficiency	I-UNK
in	O
humans	B-UNK
,	O
but	O
also	O
shares	O
some	O
genetic	B-UNK
characteristics	B-UNK
with	O
the	O
human	B-UNK
disorder	B-UNK
..	O

Gene	B-UNK
transfer	B-UNK
and	O
expression	B-UNK
of	O
human	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
caused	B-UNK
by	O
a	O
genetic	B-UNK
deficiency	B-UNK
of	O
the	O
enzyme	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
.	O

A	O
full	O
-	O
length	B-UNK
complementary	O
DNA	B-UNK
clone	O
of	O
human	B-UNK
PAH	B-UNK
was	O
inserted	O
into	O
a	O
eukaryotic	O
expression	B-UNK
vector	O
and	O
transferred	O
into	O
mouse	B-UNK
NIH3T3	O
cells	B-UNK
which	O
do	O
not	O
normally	O
express	O
PAH	B-UNK
.	O

The	O
transformed	O
mouse	B-UNK
cells	B-UNK
expressed	B-UNK
PAH	B-UNK
messenger	B-UNK
RNA	I-UNK
,	O
immunoreactive	O
protein	B-UNK
,	O
and	O
enzymatic	B-UNK
activity	I-UNK
that	O
are	O
characteristic	B-UNK
of	O
the	O
normal	B-UNK
human	B-UNK
liver	B-UNK
products	B-UNK
,	O
demonstrating	O
that	O
a	O
single	B-UNK
gene	B-UNK
contains	O
all	O
of	O
the	O
necessary	O
genetic	B-UNK
information	B-UNK
to	O
code	O
for	O
functional	O
PAH	B-UNK
.	O

These	O
results	B-UNK
support	O
the	O
use	O
of	O
the	O
human	B-UNK
PAH	B-UNK
probe	O
in	O
prenatal	B-UNK
diagnosis	I-UNK
and	O
detection	B-UNK
of	O
carriers	B-UNK
,	O
to	O
provide	B-UNK
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	B-UNK
of	O
normal	B-UNK
and	O
mutant	B-UNK
enzymes	B-UNK
,	O
and	O
in	O
the	O
investigation	B-UNK
of	O
alternative	B-UNK
genetic	B-UNK
therapies	O
for	O
PKU	B-UNK
..	O

Regional	O
mapping	B-UNK
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
and	O
the	O
phenylketonuria	O
locus	B-UNK
in	O
the	O
human	B-UNK
genome	B-UNK
.	O

Phenylketonuria	O
(	O
PKU	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-DISEASE
of	I-DISEASE
amino	I-DISEASE
acid	I-DISEASE
metabolism	I-DISEASE
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
the	O
hepatic	B-UNK
enzyme	B-UNK
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
;	O
phenylalanine	B-UNK
4-monooxygenase	O
,	O
EC	B-UNK
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

A	O
cDNA	O
clone	O
for	O
human	B-UNK
PAH	B-UNK
has	O
previously	B-UNK
been	O
used	O
to	O
assign	O
the	O
corresponding	O
gene	B-UNK
to	O
human	B-UNK
chromosome	I-UNK
12	O
.	O

To	O
define	B-UNK
the	O
regional	O
map	B-UNK
position	B-UNK
of	O
the	O
disease	B-UNK
locus	B-UNK
and	O
the	O
PAH	B-UNK
gene	B-UNK
on	O
human	B-UNK
chromosome	I-UNK
12	O
,	O
DNA	B-UNK
was	O
isolated	B-UNK
from	O
human	B-UNK
-	O
hamster	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
with	O
various	O
deletions	O
of	O
human	B-UNK
chromosome	I-UNK
12	O
and	O
was	O
analyzed	B-UNK
by	O
Southern	B-UNK
blot	I-UNK
analysis	I-UNK
using	O
the	O
human	B-UNK
cDNA	O
PAH	B-UNK
clone	O
as	O
a	O
hybridization	B-UNK
probe	O
.	O

From	O
these	O
results	B-UNK
,	O
together	O
with	O
detailed	B-UNK
biochemical	O
and	O
cytogenetic	B-UNK
characterization	B-UNK
of	O
the	O
hybrid	O
cells	B-UNK
,	O
the	O
region	B-UNK
on	O
chromosome	B-UNK
12	O
containing	O
the	O
human	B-UNK
PAH	B-UNK
gene	B-UNK
has	O
been	O
defined	B-UNK
as	O
12q14	O
.	O

3	O
-	O
---qter	O
3	O
-	O
---qter	O
.	O

The	O
PAH	B-UNK
map	B-UNK
position	B-UNK
on	O
chromosome	B-UNK
12	O
was	O
further	O
localized	B-UNK
by	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
of	O
125I	O
-	O
labeled	O
human	B-UNK
PAH	B-UNK
cDNA	O
to	O
chromosomes	O
prepared	O
from	O
a	O
human	B-UNK
lymphoblastoid	O
cell	B-UNK
line	I-UNK
.	O

Results	B-UNK
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	B-UNK
on	O
chromosome	B-UNK
12	O
containing	O
the	O
PAH	B-UNK
gene	B-UNK
and	O
the	O
PKU	B-UNK
locus	B-UNK
in	O
man	B-UNK
is	O
12q22	O
-	O
---12q24	O
.	O

1	O
.	O

These	O
results	B-UNK
not	O
only	O
provide	B-UNK
a	O
regionalized	O
map	B-UNK
position	B-UNK
for	O
a	O
major	B-UNK
human	B-UNK
disease	B-UNK
locus	B-UNK
but	O
also	O
can	O
serve	O
as	O
a	O
reference	O
point	B-UNK
for	O
linkage	B-UNK
analysis	I-UNK
with	O
other	O
DNA	B-UNK
markers	I-UNK
on	O
human	B-UNK
chromosome	I-UNK
12	O

Heterogeneity	B-UNK
of	O
type	B-UNK
I	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
:	O
evidence	B-UNK
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
.	O

Type	B-UNK
I	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
(	O
vWD	O
)	O
is	O
characterized	B-UNK
by	O
equally	O
low	B-UNK
plasma	O
concentrations	O
of	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
antigen	O
(	O
vWF	B-UNK
Ag	I-UNK
)	O
and	O
ristocetin	O
cofactor	O
(	O
RiCof	B-UNK
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	B-UNK
multimers	O
in	O
sodium	B-UNK
dodecyl	O
sulfate	B-UNK
(	O
SDS)-agarose	O
gel	B-UNK
electrophoresis	I-UNK
.	O

For	O
17	O
patients	B-UNK
(	O
13	O
kindreds	O
)	O
diagnosed	O
with	O
these	O
criteria	O
,	O
we	O
have	O
studied	O
the	O
platelet	B-UNK
contents	O
of	O
vWF	B-UNK
Ag	I-UNK
and	O
RiCof	B-UNK
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
.	O

Platelet	B-UNK
vWF	B-UNK
Ag	I-UNK
and	O
RiCof	B-UNK
were	O
normal	B-UNK
in	O
four	O
kindreds	O
(	O
called	O
"	O
platelet	B-UNK
normal	B-UNK
"	O
subgroup	O
)	O
;	O
following	O
1-deamino-8-D	O
-	O
arginine	O
vasopressin	O
;	O
plasma	O
vWF	B-UNK
Ag	I-UNK
,	O
RiCof	B-UNK
and	O
the	O
bleeding	B-DISEASE
time	O
(	O
BT	O
)	O
became	O
normal	B-UNK
.	O

In	O
six	O
kindreds	O
,	O
platelet	B-UNK
vWF	B-UNK
Ag	I-UNK
and	O
RiCof	B-UNK
were	O
equally	O
low	B-UNK
(	O
platelet	B-UNK
low	B-UNK
)	O
;	O
after	O
DDAVP	O
,	O
plasma	O
vWF	B-UNK
Ag	I-UNK
and	O
RiCof	B-UNK
remained	O
low	B-UNK
,	O
and	O
the	O
BT	O
was	O
prolonged	O
.	O

In	O
three	O
additional	O
kindreds	O
,	O
platelets	O
contained	O
normal	B-UNK
concentrations	O
of	O
vWF	B-UNK
Ag	I-UNK
,	O
but	O
RiCof	B-UNK
was	O
very	O
low	B-UNK
(	O
platelet	B-UNK
discordant	O
)	O
;	O
even	O
though	O
a	O
complete	O
set	B-UNK
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets	O
,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	B-UNK
multimers	O
.	O

After	O
DDAVP	O
,	O
plasma	O
vWF	B-UNK
Ag	I-UNK
became	O
normal	B-UNK
,	O
but	O
RiCof	B-UNK
remained	O
low	B-UNK
and	O
the	O
BT	O
was	O
very	O
prolonged	O
.	O

These	O
findings	B-UNK
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	B-UNK
(	O
RiCof	B-UNK
less	O
than	O
vWF	B-UNK
Ag	I-UNK
)	O
even	O
in	O
type	B-UNK
I	O
vWD	O
,	O
coexisting	O
with	O
a	O
complete	O
set	B-UNK
of	O
vWF	B-UNK
multimers	O
(	O
platelet	B-UNK
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vWF	B-UNK
can	O
be	O
shown	B-UNK
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
;	O
and	O
that	O
DDAVP	O
normalizes	O
the	O
BT	O
only	O
in	O
those	O
patients	B-UNK
with	O
normal	B-UNK
platelet	B-UNK
levels	B-UNK
of	O
both	O
vWF	B-UNK
Ag	I-UNK
and	O
RiCof	B-UNK
(	O
platelet	B-UNK
normal	B-UNK
)	O
..	O

Genetic	B-UNK
analysis	I-UNK
in	O
families	B-UNK
with	O
van	B-UNK
der	I-UNK
Woude	I-UNK
syndrome	I-UNK
.	O

We	O
have	O
brought	O
together	O
information	B-UNK
on	O
864	O
affected	B-UNK
individuals	I-UNK
in	O
164	O
families	B-UNK
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	B-UNK
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	B-UNK
with	O
what	O
was	O
later	O
called	O
van	B-DISEASE
der	I-DISEASE
Woude	I-DISEASE
syndrome	I-DISEASE
(	O
VWS	B-UNK
)	O
.	O

Both	O
types	B-UNK
of	O
oral	B-UNK
cleft	B-UNK
,	O
cleft	B-DISEASE
palate	I-DISEASE
(	O
CP	B-UNK
)	O
and	O
cleft	B-DISEASE
lip	I-DISEASE
with	O
or	O
without	O
CP	B-UNK
(	O
CLP	O
)	O
,	O
segregate	O
in	O
these	O
families	B-UNK
together	O
with	O
lower	O
lip	B-UNK
pits	O
or	O
fistulae	O
in	O
an	O
autosomal	B-UNK
dominant	I-UNK
mode	O
with	O
high	B-UNK
penetrance	O
estimated	B-UNK
to	O
be	O
K	O
=	O
.	O

89	O
and	O
.	O

99	O
by	O
different	O
methods	O
.	O

Cleft	B-UNK
types	B-UNK
(	O
CLP	O
and	O
CP	B-DISEASE
)	O
occur	B-UNK
in	O
VWS	B-UNK
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	B-UNK
non-VWS	O
population	B-UNK
,	O
ie	B-DISEASE
,	O
about	O
twice	O
as	O
many	O
cleft	B-UNK
-	O
bearing	O
individuals	B-UNK
have	O
CLP	O
as	O
have	O
CP	B-UNK
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	B-UNK
excess	B-UNK
of	O
females	O
with	O
CP	B-UNK
and	O
excess	B-UNK
of	O
males	B-UNK
with	O
CLP	O
;	O
in	O
VWS	B-UNK
the	O
sex	B-UNK
ratios	O
are	O
more	O
nearly	O
equal	O
.	O

Lip	B-UNK
pits	O
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O

Affected	B-UNK
males	I-UNK
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	B-UNK
.	O

However	O
,	O
there	O
is	O
an	O
excess	B-UNK
of	O
less	O
severely	O
affected	B-UNK
individuals	I-UNK
among	O
transmitters	O
and	O
a	O
deficiency	B-UNK
of	O
more	O
severely	O
affected	B-UNK
,	O
brought	O
about	O
by	O
a	O
proband	B-UNK
bias	O
and	O
differential	B-UNK
fecundity	O
.	O

The	O
expression	B-UNK
of	O
VWS	B-UNK
is	O
significantly	O
modified	O
by	O
the	O
genetic	B-UNK
background	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	B-UNK
more	O
extreme	O
expression	B-UNK
in	O
their	O
children	O
.	O

For	O
a	O
VWS	B-UNK
gene	B-UNK
carrier	B-UNK
the	O
relative	B-UNK
risk	B-UNK
of	O
transmitting	O
a	O
cleft	B-UNK
is	O
26	O
.	O

45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B-UNK
pits	O
is	O
23	O
.	O

55	O
%	O
.	O

Three	O
pedigrees	O
of	O
lip	B-UNK
pits	O
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	B-UNK
number	B-UNK
of	O
affected	B-UNK
individuals	I-UNK
.	O

Control	B-UNK
of	O
gene	B-UNK
expression	I-UNK
in	O
VWS	B-UNK
in	O
the	O
three	O
target	O
tissues	O
appears	B-UNK
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O

Mutation	B-UNK
rate	B-UNK
of	O
the	O
VWS	B-UNK
gene	B-UNK
is	O
calculated	O
to	O
be	O
1	O
.	O

8	O
X	O
10	O
(	O
-5	O
)	O

Hereditary	B-UNK
C7	B-UNK
deficiency	I-UNK
.	O

Diagnosis	B-UNK
and	O
HLA	B-UNK
studies	B-UNK
in	O
a	O
French	B-UNK
-	O
Canadian	B-UNK
family	B-UNK
.	O

The	O
serum	B-UNK
of	O
a	O
44-yr	O
-	O
old	O
woman	O
of	O
French	B-UNK
-	O
Canadian	B-UNK
descent	O
having	O
a	O
B-27	O
positive	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
was	O
deficient	B-UNK
in	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C7	B-UNK
)	O
as	O
determined	B-UNK
by	O
hemolytic	B-DISEASE
and	O
immunochemical	O
methods	O
.	O

No	O
inhibitor	O
against	O
C7	B-UNK
was	O
detected	B-UNK
,	O
and	O
the	O
levels	B-UNK
of	O
all	O
other	O
complement	B-UNK
components	O
were	O
normal	B-UNK
.	O

No	O
deficiency	B-UNK
in	O
the	O
opsonic	O
activity	B-UNK
of	O
the	O
serum	B-UNK
was	O
found	O
,	O
and	O
the	O
results	B-UNK
of	O
basic	O
coagulation	O
studies	B-UNK
of	O
the	O
plasma	O
were	O
normal	B-UNK
.	O

On	O
investigation	B-UNK
of	O
the	O
patients	B-UNK
family	B-UNK
,	O
two	O
sisters	O
were	O
found	O
to	O
have	O
the	O
same	O
deficiency	B-UNK
but	O
were	O
otherwise	O
in	O
good	O
health	O
.	O

The	O
seven	O
other	O
siblings	O
were	O
heterozygous	B-UNK
for	O
C7	B-UNK
deficiency	I-UNK
,	O
while	O
the	O
paternal	O
aunt	O
had	O
a	O
normal	B-UNK
C7	B-UNK
level	B-UNK
.	O

In	O
the	O
third	O
generation	O
,	O
six	O
children	O
of	O
the	O
three	O
homozygous	B-UNK
sisters	O
and	O
five	O
children	O
of	O
heterozygotes	B-UNK
were	O
available	O
for	O
testing	B-UNK
.	O

Studies	B-UNK
of	O
the	O
HLA	B-UNK
antigens	O
in	O
all	O
the	O
22	O
subjects	B-UNK
and	O
in	O
three	O
spouses	O
indicated	O
no	O
close	B-UNK
linkage	I-UNK
between	O
the	O
CM	B-DISEASE
deficienty	O
and	O
the	O
HLA	B-UNK
system	O
.	O

In	O
addition	B-UNK
,	O
the	O
simultaneous	O
occurrence	B-UNK
of	O
two	O
hereditary	B-UNK
complement	B-UNK
deficiencies	B-UNK
(	O
C2	B-UNK
and	O
C7	B-UNK
)	O
was	O
discovered	O
in	O
one	O
family	B-UNK
of	O
this	O
remarkable	O
kindred	O
..	O

Genetic	B-UNK
defect	B-UNK
in	O
secretion	O
of	O
complement	B-UNK
C5	B-UNK
in	O
mice	B-UNK
.	O

A	O
genetic	B-UNK
deficiency	B-UNK
of	O
the	O
fifth	O
(	O
C5	B-UNK
)	O
component	B-UNK
of	O
complement1	O
-	O
3	O
,	O
a	O
serum	B-UNK
glycoprotein	O
of	O
molecular	B-UNK
weight	O
(	O
MW	O
)	O
220	O
,	O
000	O
(	O
ref	O
.	O
4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O

Sera	B-UNK
of	O
deficient	B-UNK
mice	I-UNK
lack	B-UNK
detectable	O
C5	B-UNK
activity	B-UNK
and	O
protein2	O
,	O
3	O
.	O

In	O
addition	B-UNK
deficient	B-UNK
mice	I-UNK
produce	B-UNK
antibody	B-UNK
to	O
mouse	B-UNK
C5	B-UNK
when	O
injected	O
with	O
sera	B-UNK
from	O
C5	B-UNK
sufficient	O
(	O
normal	B-UNK
)	O
strains	O
.	O

Levy	O
et	O
al	B-DISEASE
.	O

5	O
showed	O
that	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
between	O
C5	B-UNK
deficient	B-UNK
(	O
B10	O
.	O
D2	B-UNK
/	O
old	O
line	B-UNK
)	O
macrophages	O
and	O
either	O
C5	B-UNK
sufficient	O
(	O
B10	O
.	O
D2	B-UNK
/	O
new	O
line	B-UNK
)	O
mouse	B-UNK
kidney	B-UNK
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	B-UNK
mouse	B-UNK
C5	B-UNK
in	O
vitro	O
.	O

Several	O
possible	O
molecular	B-UNK
mechanisms	O
to	O
account	B-UNK
for	O
the	O
findings	B-UNK
were	O
considered	O
,	O
but	O
insufficient	O
direct	B-UNK
data	B-UNK
were	O
available	O
to	O
choose	O
among	O
them	O
.	O

We	O
recently	O
reported	B-UNK
that	O
mouse	B-UNK
(	O
CD	B-UNK
.	O
1	O
strain	O
)	O
peritoneal	O
cells	B-UNK
in	O
culture	B-UNK
synthesise	O
and	O
secrete	O
a	O
single	B-UNK
chain	B-UNK
precursor	O
,	O
pro	O
-	O
C5	B-UNK
(	O
MW	O
approximately	O
210	O
,	O
000	O
)	O
,	O
of	O
the	O
two	O
-	O
chain	B-UNK
(	O
alpha	B-UNK
chain	B-UNK
,	O
125	O
,	O
000	O
and	O
beta	B-UNK
chain	B-UNK
83	O
,	O
000	O
MW	O
)	O
C5	B-UNK
protein6	O
.	O

Radiolabelled	O
precursor	O
C5	B-UNK
was	O
contained	O
within	O
the	O
cells	B-UNK
and	O
was	O
secreted	O
into	O
the	O
tissue	B-UNK
culture	B-UNK
media	O
.	O

Using	O
similar	B-UNK
methods	O
,	O
we	O
now	O
find	O
that	O
C5	B-UNK
deficiency	B-UNK
in	O
each	O
of	O
five	O
different	O
mouse	B-UNK
strains	O
(	O
AKR	O
,	O
SWR	O
,	O
DBA/2J8	O
A	O
/	O
HeJ	O
and	O
B10	O
.	O
D2	B-UNK
/	O
old	O
line	B-UNK
)	O
is	O
due	O
to	O
a	O
failure	B-UNK
in	O
secretion	O
of	O
C5	B-UNK
protein	B-UNK
and	O
not	O
to	O
a	O
failure	B-UNK
in	O
biosynthesis	O
of	O
pro	O
-	O
C5	B-UNK

Recurrent	O
meningococcal	B-UNK
meningitis	B-DISEASE
with	O
absence	B-UNK
of	O
the	O
sixth	O
component	B-UNK
of	I-UNK
complement	I-UNK
:	O
an	O
evaluation	B-UNK
of	O
underlying	O
immunologic	O
mechanisms	O
.	O

A	O
51/2-year	O
-	O
old	O
black	B-UNK
girl	O
with	O
recurrent	O
meningococcal	B-UNK
meningitis	B-DISEASE
and	O
absence	B-UNK
of	O
the	O
sixth	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C6	B-UNK
)	O
is	O
reported	B-UNK
.	O

To	O
explore	O
the	O
pathogenesis	B-UNK
of	O
recurrent	O
neisserial	O
infections	B-UNK
in	O
C6	B-UNK
deficiency	I-UNK
,	O
a	O
detailed	B-UNK
analysis	B-UNK
of	O
her	O
immune	B-UNK
competence	O
was	O
conducted	O
.	O

Her	O
serum	B-UNK
had	O
normal	B-UNK
chemotactic	O
,	O
opsonic	O
,	O
alternative	B-UNK
complement	B-UNK
pathway	B-UNK
,	O
and	O
specific	B-UNK
antibody	B-UNK
activity	B-UNK
,	O
but	O
lacked	O
complement	B-UNK
-	O
mediated	O
bacteriolytic	O
activity	B-UNK
.	O

In	O
addition	B-UNK
,	O
her	O
C6-deficient	O
serum	B-UNK
was	O
indistinguishable	O
from	O
normal	B-UNK
serum	B-UNK
in	O
a	O
complement	B-UNK
-	O
dependent	B-UNK
assay	B-UNK
of	O
phagocyte	O
bactericidal	O
activity	B-UNK
.	O

Absent	O
bacteriolysis	O
remains	O
the	O
only	O
consistent	B-UNK
defect	B-UNK
associated	O
with	O
recurrent	O
neisserial	O
infections	B-DISEASE
and	O
absence	B-UNK
of	O
one	O
of	O
the	O
late	B-UNK
-	O
acting	O
complement	B-UNK
components	O
..	O

Deficiency	B-UNK
of	O
the	O
fifth	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
human	B-UNK
subjects	B-UNK
.	O

Clinical	B-UNK
,	O
genetic	B-UNK
and	O
immunologic	O
studies	B-UNK
in	O
a	O
large	B-UNK
kindred	O
.	O

The	O
discovery	O
of	O
a	O
large	B-UNK
kindred	O
with	O
a	O
heritable	O
deficiency	B-UNK
of	O
the	O
fifth	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C5	B-UNK
)	O
has	O
permitted	O
the	O
accumulation	B-UNK
of	O
new	O
clinical	B-UNK
,	O
genetic	B-UNK
and	O
immunologic	O
data	B-UNK
concerning	O
the	O
role	B-UNK
of	O
C5	B-UNK
in	O
human	B-UNK
subjects	B-UNK
.	O

The	O
proband	B-UNK
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	O
infection	B-DISEASE
,	O
has	O
a	O
hemolytic	B-DISEASE
C5	B-UNK
level	B-UNK
of	O
approximately	O
0	O
.	O

5	O
per	O
cent	O
of	O
normal	B-UNK
.	O

No	O
C5	B-UNK
protein	B-UNK
was	O
detectable	O
,	O
but	O
low	B-UNK
levels	B-UNK
of	O
functional	O
C5	B-UNK
activity	B-UNK
could	O
be	O
found	O
using	O
a	O
sensitive	B-UNK
bactericidal	O
assay	B-UNK
.	O

The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	B-UNK
levels	B-UNK
of	O
hemolytic	B-DISEASE
C5	B-UNK
(	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
normal	B-UNK
)	O
,	O
but	O
both	O
these	O
subjects	B-UNK
have	O
been	O
healthy	O
.	O

Hemolytic	B-UNK
complement	B-UNK
and	O
bacteriolytic	O
activity	B-UNK
could	O
be	O
restored	O
by	O
the	O
addition	B-UNK
of	O
purified	O
C5	B-UNK
.	O

No	O
chemotactic	O
activity	B-UNK
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5-deficient	O
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	B-UNK
or	O
alternative	B-UNK
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	B-UNK
in	O
human	B-UNK
subjects	B-UNK
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O

The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	B-UNK
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed	B-DISEASE
.	O

Twenty	O
-	O
two	O
of	O
32	O
other	O
family	B-UNK
members	I-UNK
from	O
three	O
generations	O
had	O
depressed	B-DISEASE
whole	O
hemolytic	B-DISEASE
complement	B-UNK
levels	B-UNK
.	O

In	O
19	O
of	O
30	O
family	B-UNK
members	I-UNK
,	O
levels	B-UNK
of	O
hemolytic	B-UNK
C5	B-UNK
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal	B-UNK
.	O

No	O
linkage	B-UNK
for	O
C5	B-UNK
deficiency	B-UNK
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	B-UNK
histocompatibility	B-UNK
complex	O
could	O
be	O
found	O
.	O

These	O
data	B-UNK
suggest	B-UNK
an	O
autosomal	B-UNK
codominant	O
mode	O
of	O
inheritance	B-UNK
of	O
C5	B-UNK
deficiency	B-UNK
.	O

Deficiency	B-UNK
of	O
C5	B-UNK
is	O
compatible	B-UNK
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	O
infection	B-DISEASE

Incidence	B-UNK
and	O
characteristics	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
variants	B-UNK
in	O
Japan	B-UNK
.	O

A	O
total	B-UNK
of	O
3000	O
men	B-UNK
living	O
in	O
Yamaguchi	O
were	O
screened	B-UNK
for	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
using	O
Beutlers	O
spot	O
test	B-UNK
and	O
three	O
types	B-UNK
of	O
starch	O
gel	B-UNK
electrophoresis	I-UNK
.	O

These	O
electrophoresis	B-UNK
used	O
a	O
phosphate	B-UNK
buffer	O
system	O
at	O
pH	B-UNK
7	O
.	O

0	O
,	O
a	O
TRIS	O
-	O
EDTA	O
-	O
borate	O
buffer	O
system	O
at	O
pH	B-UNK
8	O
.	O

6	O
,	O
and	O
a	O
TRIS	O
-	O
hydrochloride	O
buffer	O
system	O
at	O
pH	B-UNK
8	O
..	O

Fifteen	O
G6PD	B-UNK
-	O
deficient	B-UNK
variants	B-UNK
were	O
found	O
at	O
the	O
rate	B-UNK
of	O
0	O
.	O

5	O
%	O
and	O
classified	O
into	O
four	O
groups	B-UNK
.	O

As	O
new	O
variants	B-UNK
,	O
G6PD	B-UNK
Konan	O
,	O
Kamiube	O
,	O
and	O
Kiwa	O
were	O
identified	B-UNK
.	O

These	O
three	O
variants	B-UNK
had	O
a	O
mild	O
to	O
moderate	B-UNK
G6PD	B-UNK
deficiency	I-UNK
and	O
were	O
not	O
associated	O
with	O
any	O
clinical	B-UNK
signs	B-UNK
.	O

G6PD	B-UNK
Konan	O
had	O
fast	O
electrophoretic	B-UNK
mobility	O
as	O
compared	B-UNK
with	O
normal	B-UNK
levels	B-UNK
,	O
G6PD	B-UNK
Kiwa	O
had	O
slightly	O
elevated	B-UNK
electrophoretic	B-UNK
mobility	O
,	O
and	O
G6PD	B-UNK
Kamiube	O
had	O
normal	B-UNK
electrophoretic	B-UNK
mobility	O
.	O

These	O
three	O
variants	B-UNK
had	O
normal	B-UNK
levels	B-UNK
of	O
Km	O
G6P	O
,	O
Km	O
NADP	O
,	O
and	O
Ki	O
NADPH	O
,	O
normal	B-UNK
utilizations	O
of	O
both	O
2-deoxy	O
-	O
G6P	O
and	O
deamino	O
-	O
NAPD	O
,	O
normal	B-UNK
heat	O
stability	O
,	O
and	O
a	O
normal	B-UNK
pH	B-UNK
curve	O
.	O

The	O
other	O
variant	O
was	O
G6PD	B-UNK
Ube	O
,	O
which	O
we	O
had	O
previously	B-UNK
found	O
in	O
Yamaguchi	O
(	O
Nakashima	O
et	O
al	B-DISEASE
.	O
,	O
1977	O
)	O
.	O

One	O
boy	B-UNK
with	O
G6PD	B-UNK
Ube	O
was	O
Korean	O

Utilization	O
of	O
purines	O
by	O
an	O
HPRT	B-UNK
variant	O
in	O
an	O
intelligent	O
,	O
nonmutilative	O
patient	B-UNK
with	O
features	B-UNK
of	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
patient	B-UNK
,	O
H.	O

Chr	O
.	O

B.	O
,	O
was	O
among	O
the	O
first	O
reported	B-UNK
with	O
hyperuricemia	B-DISEASE
and	O
central	B-UNK
nervous	I-UNK
system	I-UNK
symptoms	B-UNK
.	O

He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	B-UNK
guanine	I-UNK
phosphoribosyl	O
transferase	O
(	O
HPRT	B-UNK
;	O
E.	O
C.	O
2	O
.	O
4	O
.	O
2	O
.	O
8)	O
distinct	O
from	O
the	O
enzyme	B-UNK
present	B-UNK
in	O
patients	B-UNK
with	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
patient	B-UNK
had	O
chroeoathetosis	O
,	O
spasticity	B-DISEASE
,	O
dysarthric	O
speech	O
,	O
and	O
hyperuricemia	B-DISEASE
.	O

However	O
,	O
his	O
intelligence	O
was	O
normal	B-UNK
and	O
he	O
had	O
no	O
evidence	B-UNK
of	O
self	O
-	O
mutilation	O
.	O

There	O
was	O
no	O
activity	B-UNK
of	O
HPRT	B-UNK
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	B-UNK
when	O
analyzed	B-UNK
in	O
the	O
usual	O
manner	O
.	O

Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	B-UNK
of	O
purine	O
metabolism	B-UNK
in	O
intact	O
cultured	O
cells	B-UNK
,	O
this	O
patient	B-UNK
was	O
found	O
to	O
metabolize	O
some	O
9	O
%	O
of	O
8	O
-	O
14C	O
-	O
hypoxanthine	B-UNK
,	O
and	O
90	O
%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	B-UNK
nucleotides	O
.	O

In	O
contrast	B-UNK
,	O
cells	B-UNK
from	O
patients	B-UNK
with	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	B-UNK
to	O
nucleotides	O
.	O

The	O
patients	B-UNK
fibroblasts	B-UNK
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	B-UNK
of	O
8	O
-	O
14C	O
-	O
guanine	B-UNK
,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27	O
%	O
,	O
over	O
80	O
%	O
of	O
which	O
was	O
converted	O
to	O
guanine	B-UNK
and	O
adenine	O
nucleotides	O
.	O

The	O
growth	B-UNK
of	O
the	O
cultured	O
fibroblasts	B-UNK
of	O
this	O
patient	B-UNK
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	B-UNK
aminopterin	O
thymidine	O
(	O
HAT	O
)	O
,	O
whereas	O
the	O
growth	B-UNK
of	O
Lesch	O
-	O
Nyhan	O
cells	B-UNK
was	O
inhibited	O
and	O
normal	B-UNK
cells	B-UNK
grew	O
normally	O
.	O

Similarly	O
in	O
8-azaguanine	O
,	O
6-thioguanine	O
,	O
and	O
8-azahypoxanthine	O
,	O
the	O
growth	B-UNK
of	O
the	O
patients	B-UNK
cells	B-UNK
was	O
intermediate	O
between	O
normal	B-UNK
and	O
Lesch	O
-	O
Nyhan	O
cells	B-UNK
.	O

These	O
observations	B-UNK
provide	B-UNK
further	O
evidence	B-UNK
for	O
genetic	B-UNK
heterogeneity	I-UNK
among	O
patients	B-UNK
with	O
disorders	B-UNK
in	O
purine	O
metabolism	B-UNK
involving	O
the	O
HPRT	B-UNK
gene	B-UNK
.	O

They	O
document	O
that	O
this	O
famous	O
patient	B-UNK
did	O
not	O
have	O
the	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE

Localisation	O
of	O
the	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
gene	B-UNK
on	O
the	O
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
by	O
linkage	B-UNK
to	O
cloned	O
DNA	B-UNK
sequences	O
.	O

A	O
linkage	B-UNK
study	B-UNK
in	O
30	O
Becker	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
BMD	B-UNK
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	B-UNK
sequences	O
from	O
the	O
X	O
chromosome	B-UNK
which	O
demonstrate	B-UNK
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphisms	B-UNK
(	O
RFLPs	B-UNK
)	O
,	O
suggests	O
that	O
the	O
BMD	B-UNK
gene	B-UNK
is	O
located	B-UNK
on	O
the	O
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
,	O
in	O
the	O
p21	O
region	B-UNK
.	O

The	O
genes	B-UNK
for	O
Becker	B-UNK
and	O
Duchenne	B-UNK
dystrophies	O
must	O
therefore	O
be	O
closely	B-UNK
linked	I-UNK
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
DNA	B-UNK
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	B-UNK
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O

The	O
linkage	B-UNK
analysis	I-UNK
also	O
provides	O
data	B-UNK
on	O
the	O
frequency	B-UNK
of	O
recombination	B-UNK
along	O
the	O
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
,	O
and	O
across	O
the	O
centromeric	O
region	B-UNK
..	O

Molecular	B-UNK
evidence	B-UNK
for	O
new	O
mutation	B-UNK
at	O
the	O
hprt	B-UNK
locus	B-UNK
in	O
Lesch	O
-	O
Nyhan	O
patients	B-UNK
.	O

Hypoxanthine	B-UNK
-	O
guanine	B-UNK
phosphoribosyltransferase	O
(	O
HPRT	B-UNK
;	O
EC2	O
.	O
4	O
.	O
2	O
.	O
8)	O
,	O
which	O
functions	O
in	O
the	O
metabolic	B-UNK
salvage	O
of	O
purines	O
,	O
is	O
encoded	B-UNK
by	O
an	O
X	O
-	O
linked	B-UNK
gene	B-UNK
in	O
man	B-UNK
.	O

Partial	O
HPRT	B-UNK
deficiencies	B-UNK
are	O
associated	O
with	O
gouty	B-DISEASE
arthritis	I-DISEASE
,	O
while	O
absence	B-UNK
of	O
activity	B-UNK
results	B-UNK
in	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
(	O
L	O
-	O
N	O
)	O
.	O

L	O
-	O
N	O
patients	B-UNK
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	B-UNK
state	B-UNK
appears	B-UNK
to	O
confer	O
no	O
selective	O
advantage	B-UNK
.	O

Thus	O
,	O
Haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	B-UNK
at	O
the	O
hprt	B-UNK
locus	B-UNK
must	O
occur	B-UNK
frequently	O
in	O
order	B-UNK
for	O
L	O
-	O
N	B-DISEASE
syndrome	I-DISEASE
to	O
be	O
maintained	O
in	O
the	O
population	B-UNK
.	O

This	O
constant	O
introduction	O
of	O
new	O
mutations	B-UNK
would	O
be	O
expected	O
to	O
result	B-UNK
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	B-UNK
lesions	B-UNK
,	O
some	O
of	O
which	O
may	O
be	O
novel	O
.	O

As	O
we	O
report	B-UNK
here	O
,	O
the	O
mutations	B-UNK
in	O
the	O
hprt	B-UNK
gene	B-UNK
of	O
seven	O
L	O
-	O
N	O
patients	B-UNK
,	O
selected	O
from	O
an	O
initial	O
survey	O
of	O
28	O
patients	B-UNK
,	O
have	O
been	O
characterized	B-UNK
and	O
all	O
were	O
found	O
to	O
be	O
distinctly	O
different	O
,	O
as	O
predicted	B-UNK
.	O

The	O
origin	O
of	O
one	O
unusual	O
mutation	B-UNK
has	O
been	O
identified	B-UNK
by	O
analysis	B-UNK
of	O
DNA	B-UNK
from	O
four	O
generations	O
of	O
family	B-UNK
members	I-UNK
.	O

Further	O
molecular	B-UNK
analysis	I-UNK
of	O
the	O
origin	O
of	O
new	O
mutations	B-UNK
at	O
the	O
hprt	B-UNK
locus	B-UNK
should	O
aid	O
in	O
resolving	O
the	O
issue	O
of	O
an	O
apparent	O
difference	O
in	O
the	O
frequency	B-UNK
of	O
hprt	B-UNK
mutations	B-UNK
in	O
males	B-UNK
and	O
females	O

Allelic	O
exclusion	O
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
in	O
platelets	O
and	O
T	O
lymphocytes	O
from	O
a	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
carrier	B-UNK
.	O

An	O
obligate	B-UNK
carrier	B-UNK
of	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
who	O
was	O
also	O
heterozygous	B-UNK
for	O
the	O
A	O
and	O
B	O
types	B-UNK
of	O
X	O
-	O
linked	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
was	O
found	O
.	O

With	O
her	O
it	O
became	O
possible	O
to	O
determine	B-UNK
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell	B-UNK
-	O
types	B-UNK
of	O
the	O
WAS	O
carrier	B-UNK
.	O

If	O
so	O
,	O
the	O
remaining	O
cells	B-UNK
of	O
a	O
particular	O
cell	B-UNK
-	O
type	B-UNK
would	O
express	O
only	O
the	O
normal	B-UNK
X	O
chromosome	B-UNK
and	O
only	O
one	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
isoenzyme	O
would	O
be	O
demonstrable	O
.	O

This	O
carrier	B-UNK
had	O
only	O
the	O
B	O
isoenzyme	O
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
in	O
platelets	O
and	O
thymus	O
-	O
derived	B-UNK
T	O
lymphocytes	O
,	O
although	O
both	O
isoenzymes	O
A	O
and	O
B	O
were	O
present	B-UNK
in	O
erythrocytes	O
and	O
neutrophils	O
.	O

These	O
findings	B-UNK
suggest	B-UNK
that	O
selection	B-UNK
against	O
the	O
WAS	O
gene	B-UNK
occurs	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	B-UNK
T	O
lymphocytes	O
and	O
that	O
the	O
defects	B-UNK
associated	O
with	O
WAS	O
expressed	B-UNK
in	O
these	O
cell	B-UNK
-	O
types	B-UNK
may	O
be	O
implicated	B-UNK
in	O
the	O
genesis	O
of	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
..	O

Complement	B-UNK
deficiency	B-UNK
and	O
nephritis	B-DISEASE
.	O

A	O
report	B-UNK
of	O
a	O
family	B-UNK
.	O

A	O
family	B-UNK
is	O
described	O
in	O
which	O
three	O
children	O
had	O
homozygous	B-UNK
deficiency	B-UNK
of	O
C3	B-UNK
and	O
in	O
which	O
both	O
parents	O
and	O
two	O
other	O
children	O
were	O
heterozygous	B-UNK
for	O
the	O
C3	B-UNK
null	O
gene	B-UNK
.	O

One	O
child	B-UNK
with	O
heterozygous	B-UNK
C3	B-UNK
deficiency	I-UNK
was	O
found	O
to	O
have	O
membranoproliferative	O
glomerulonephritis	B-DISEASE
;	O
proteinuria	B-DISEASE
and	O
/	O
or	O
microscopical	O
haematuria	B-DISEASE
was	O
present	B-UNK
in	O
all	O
three	O
homozygous	B-UNK
C3-deficient	O
children	O
.	O

All	O
children	O
with	O
homozygous	B-UNK
or	O
heterozygous	B-UNK
C3	B-UNK
deficiency	I-UNK
were	O
,	O
to	O
a	O
varying	O
degree	B-UNK
,	O
susceptible	O
to	O
infection	B-UNK
.	O

The	O
only	O
child	B-UNK
of	O
the	O
family	B-UNK
with	O
normal	B-UNK
complement	B-UNK
had	O
no	O
increased	B-UNK
risk	B-UNK
of	O
infection	B-DISEASE
and	O
no	O
renal	B-DISEASE
disease	I-DISEASE
.	O

This	O
family	B-UNK
study	B-UNK
provides	O
further	O
support	O
for	O
the	O
proposal	O
that	O
C3	B-UNK
deficiency	I-UNK
predisposes	O
to	O
nephritis	B-DISEASE
..	O

Heterogeneity	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
in	O
Algeria	O
.	O

Study	B-UNK
in	O
Northern	B-UNK
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants	B-UNK
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
was	O
found	O
in	O
3	O
.	O

2	O
%	O
of	O
the	O
male	B-UNK
population	B-UNK
living	O
in	O
the	O
urban	O
area	B-UNK
of	O
Algiers	O
.	O

The	O
deficient	B-UNK
subjects	B-UNK
originated	O
from	O
multiple	B-UNK
geographic	O
regions	B-UNK
of	O
Northern	B-UNK
Algeria	O
,	O
with	O
prevalence	B-UNK
of	O
individuals	B-UNK
of	O
Berber	O
-	O
Kabyle	O
origin	O
.	O

Red	B-UNK
blood	B-UNK
cell	B-UNK
G6PD	B-UNK
was	O
partially	O
purified	O
and	O
characterized	B-UNK
in	O
deficient	B-UNK
males	B-UNK
from	O
17	O
families	B-UNK
,	O
and	O
six	O
different	O
variants	B-UNK
were	O
found	O
.	O

Among	O
them	O
,	O
only	O
one	O
,	O
the	O
Gd	B-UNK
(	O
-	O
)	O
Kabyle	O
variant	O
,	O
had	O
been	O
previously	B-UNK
described	O
.	O

It	O
was	O
detected	B-UNK
in	O
nine	O
families	B-UNK
.	O

The	O
other	O
five	O
variants	B-UNK
were	O
new	O
Gd	B-UNK
(	O
-	O
)	O
Laghouat	O
(	O
four	O
cases	B-UNK
)	O
,	O
Gd	B-UNK
(	O
-	O
)	O
Blida	O
(	O
one	O
case	B-UNK
)	O
,	O
Gd	B-UNK
(	O
-	O
)	O
Thenia	O
(	O
one	O
case	B-UNK
)	O
,	O
Gd	B-UNK
(	O
-	O
)	O
Titteri	O
(	O
one	O
case	B-UNK
)	O
,	O
and	O
Gd	B-UNK
(	O
-	O
)	O
Alger	O
(	O
two	O
brothers	O
)	O
.	O

Strikingly	O
,	O
the	O
common	B-UNK
Mediterranean	B-UNK
variant	O
was	O
not	O
found	O
.	O

G6PD	B-UNK
deficiency	I-UNK
is	O
heterogeneous	O
in	O
northern	B-UNK
Algeria	O
where	O
autochtonous	O
variants	B-UNK
seem	O
to	O
prevail	O
.	O

The	O
Kabyle	O
variant	O
may	O
be	O
common	B-UNK
in	O
this	O
country	O
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
inhibits	O
in	O
vitro	O
growth	B-UNK
of	O
Plasmodium	O
falciparum	O
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
;	O
EC	B-UNK
1	O
.	O
1	O
.	O
1	O
.	O
49)-deficient	O
red	B-UNK
blood	B-UNK
cells	B-UNK
from	O
male	B-UNK
hemizygotes	O
and	O
female	O
heterozygotes	B-UNK
from	O
the	O
island	B-UNK
of	O
Sardinia	O
were	O
studied	O
for	O
their	O
ability	B-UNK
to	O
support	O
growth	B-UNK
in	O
vitro	O
of	O
the	O
malaria	B-DISEASE
-	O
causing	B-UNK
organism	O
Plasmodium	O
falciparum	O
.	O

Parasite	O
growth	B-UNK
was	O
approximately	O
one	O
-	O
third	O
of	O
normal	B-UNK
in	O
both	O
hemi	O
-	O
and	O
heterozygotes	B-UNK
for	O
G6PD	B-UNK
deficiency	I-UNK
.	O

In	O
Sardinians	O
with	O
the	O
beta	B-UNK
0-thalassemia	O
trait	O
,	O
parasite	O
growth	B-UNK
was	O
normal	B-UNK
except	O
when	O
G6PD	B-UNK
deficiency	I-UNK
occurred	B-UNK
together	O
with	O
the	O
thalassemia	B-DISEASE
trait	O
.	O

The	O
data	B-UNK
support	O
the	O
hypothesis	B-UNK
that	O
G6PD	B-UNK
deficiency	I-UNK
may	O
confer	O
a	O
selective	O
advantage	B-UNK
in	O
a	O
malarious	O
area	B-UNK
;	O
the	O
female	O
heterozygote	B-UNK
may	O
be	O
at	O
a	O
particular	O
advantage	B-UNK
because	O
resistance	O
to	O
malaria	B-DISEASE
equals	O
that	O
of	O
male	B-UNK
hemizygotes	O
,	O
but	O
the	O
risk	B-UNK
of	O
fatal	B-UNK
hemolysis	B-DISEASE
may	O
be	O
less	O
.	O

However	O
,	O
more	O
female	O
heterozygotes	B-UNK
must	O
be	O
studied	O
to	O
confirm	O
this	O
hypothesis	B-UNK
.	O

No	O
protective	O
effect	B-UNK
of	O
beta	B-UNK
0-thalassemia	O
trait	O
could	O
be	O
demonstrated	O
in	O
vitro	O
.	O

Bone	B-UNK
marrow	O
transplant	O
in	O
adrenoleukodystrophy	B-UNK
.	O

An	O
allogeneic	O
bone	B-UNK
marrow	O
transplant	O
(	O
BMT	O
)	O
from	O
a	O
normal	B-UNK
HLA	B-UNK
identical	B-UNK
sibling	O
donor	B-UNK
was	O
performed	O
in	O
a	O
13-year	O
-	O
old	O
boy	B-UNK
with	O
rapidly	O
progressive	B-UNK
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
.	O

Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	B-UNK
within	O
4	O
weeks	O
,	O
but	O
neurologic	B-DISEASE
deterioration	I-DISEASE
continued	O
.	O

The	O
patient	B-UNK
died	O
of	O
an	O
adenovirus	B-DISEASE
infection	I-DISEASE
141	O
days	O
after	O
BMT	O
.	O

ALD	B-UNK
is	O
characterized	B-UNK
by	O
abnormally	O
high	B-UNK
plasma	O
levels	B-UNK
of	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
(	O
VLCFA	O
)	O
as	O
a	O
result	B-UNK
of	O
impaired	B-UNK
capacity	O
to	O
degrade	O
them	O
.	O

Ten	O
days	O
after	O
BMT	O
,	O
the	O
white	B-UNK
blood	B-UNK
cell	B-UNK
VLCFA	O
levels	B-UNK
and	O
enzyme	B-UNK
activity	I-UNK
became	O
normal	B-UNK
;	O
after	O
3	O
months	O
,	O
there	O
was	O
progressive	B-UNK
reduction	B-UNK
of	O
plasma	O
VLCFA	O
to	O
levels	B-UNK
only	O
slightly	O
above	O
normal	B-UNK
..	O

[	O
Gd	B-UNK
-	O
allele	B-UNK
distribution	B-UNK
patterns	B-UNK
in	O
Azerbaijan	O
.	O
III	B-UNK
.	O
The	O
identification	B-UNK
of	O
mutant	B-UNK
forms	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
]	O

In	O
28	O
families	B-UNK
with	O
G6PD	B-UNK
deficiency	I-UNK
living	O
in	O
3	O
settlements	O
of	O
Shekii	O
district	O
of	O
Azerbaijan	O
11	O
G6PD	B-UNK
variants	I-UNK
of	O
II	B-UNK
and	O
III	B-UNK
classes	O
differing	O
by	O
kinetic	O
properties	B-UNK
were	O
identified	B-UNK
according	O
WHO	O
program	O
.	O

9	O
of	O
them	O
are	O
characterized	B-UNK
with	O
the	O
same	O
electrophoretic	B-UNK
mobility	O
.	O

Comparison	B-UNK
of	O
G6PD	B-UNK
spectra	O
in	O
two	O
subpopulations	O
and	O
in	O
a	O
mixed	O
group	B-UNK
permits	O
to	O
make	O
a	O
conclusion	B-UNK
about	O
existence	O
of	O
common	B-UNK
and	O
rare	B-UNK
G6PD	B-UNK
alleles	B-UNK
in	O
examined	O
population	B-UNK
.	O

They	O
distribute	O
by	O
gene	B-UNK
drift	O
supported	O
by	O
natural	O
selection	B-UNK
.	O

Among	O
7	O
samples	B-UNK
of	O
G6PD	B-UNK
with	O
normal	B-UNK
and	O
increased	B-UNK
activity	B-UNK
two	O
new	O
variants	B-UNK
of	O
IV	O
class	O
--	O
Nukha	O
and	O
Bash	O
-	O
Kungut	O
--	O
were	O
found	O
..	O

Adrenoleukodystrophy	B-UNK
:	O
survey	O
of	O
303	O
cases	B-UNK
:	O
biochemistry	O
,	O
diagnosis	B-UNK
,	O
and	O
therapy	B-UNK
.	O

Adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
is	O
a	O
genetically	B-UNK
determined	B-UNK
disorder	B-UNK
associated	O
with	O
progressive	B-UNK
central	B-UNK
demyelination	O
and	O
adrenal	B-UNK
cortical	O
insufficiency	B-UNK
.	O

All	O
affected	B-UNK
persons	O
show	O
increased	B-UNK
levels	B-UNK
of	O
saturated	O
unbranched	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
,	O
particularly	O
hexacosanoate	O
(	O
C26	O
0	O
)	O
,	O
because	O
of	O
impaired	B-UNK
capacity	O
to	O
degrade	O
these	O
acids	B-UNK
.	O

This	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome	O
,	O
and	O
ALD	B-UNK
,	O
together	O
with	O
Zellwegers	O
cerebrohepatorenal	O
syndrome	B-DISEASE
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	B-DISEASE
disorders	I-DISEASE
.	O

Biochemical	O
assays	O
permit	O
prenatal	B-UNK
diagnosis	I-UNK
,	O
as	O
well	O
as	O
identification	B-UNK
of	O
most	O
heterozygotes	B-UNK
.	O

We	O
have	O
identified	B-UNK
303	O
patients	B-UNK
with	O
ALD	B-UNK
in	O
217	O
kindreds	O
.	O

These	O
patients	B-UNK
show	O
a	O
wide	B-UNK
phenotypic	B-UNK
variation	B-UNK
.	O

Sixty	O
percent	B-UNK
of	O
patients	B-UNK
had	O
childhood	O
ALD	B-UNK
and	O
17	O
%	O
adrenomyeloneuropathy	O
,	O
both	O
of	O
which	O
are	O
X	O
-	O
linked	B-UNK
,	O
with	O
the	O
gene	B-UNK
mapped	B-UNK
to	O
Xq28	B-UNK
.	O

Neonatal	B-UNK
ALD	B-UNK
,	O
a	O
distinct	O
entity	O
with	O
autosomal	B-UNK
recessive	I-UNK
inheritance	B-UNK
and	O
points	O
of	O
resemblance	O
to	O
Zellwegers	O
syndrome	B-UNK
,	O
accounted	O
for	O
7	O
%	O
of	O
the	O
cases	B-UNK
.	O

Although	O
excess	B-UNK
C26	O
0	O
in	O
the	O
brain	B-UNK
of	O
patients	B-UNK
with	O
ALD	B-UNK
is	O
partially	O
of	O
dietary	O
origin	O
,	O
dietary	O
C26	O
0	O
restriction	B-UNK
did	O
not	O
produce	B-UNK
clear	O
benefit	O
.	O

Bone	B-UNK
marrow	O
transplant	O
lowered	O
the	O
plasma	O
C26	O
0	O
level	B-UNK
but	O
failed	O
to	O
arrest	O
neurological	B-UNK
progression	B-UNK
..	O

Genetic	B-UNK
polymorphism	B-UNK
of	O
G6PD	B-UNK
in	O
a	O
Bulgarian	O
population	B-UNK
.	O

Considerable	B-UNK
genetic	B-UNK
heterogeneity	I-UNK
in	O
G6PD	B-UNK
was	O
found	O
in	O
the	O
Bulgarian	O
population-14	O
G6PD	B-UNK
variants	I-UNK
isolated	B-UNK
from	O
117	O
hemizygous	B-UNK
carriers	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
.	O

Of	O
these	O
,	O
G6PD	B-UNK
Mediterranean	I-UNK
type	B-UNK
was	O
a	O
polymorphic	B-UNK
variant	O
and	O
G6PD	B-UNK
Corinth	O
occurred	B-UNK
with	O
high	B-UNK
frequency	I-UNK
.	O

Two	O
new	O
variants	B-UNK
were	O
identified	B-UNK
-	O
G6PD	B-UNK
Rudosem	O
and	O
G6PD	B-UNK
Nedelino	O
.	O

In	O
a	O
selected	O
group	B-UNK
of	O
78	O
subjects	B-UNK
with	O
clinical	B-UNK
manifestations	I-UNK
,	O
four	O
variants	B-UNK
were	O
established	O
G6PD	B-UNK
Mediterranian	O
,	O
G6PD	B-UNK
Corinth	O
,	O
G6PD	B-UNK
Seattle	O
and	O
G6PD	B-UNK
Ohut	O
II	B-UNK
..	O

Clinical	B-UNK
use	O
of	O
DNA	B-UNK
markers	I-UNK
linked	B-UNK
to	O
the	O
gene	B-UNK
for	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
.	O

Seventy	O
families	B-UNK
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
known	O
to	O
the	O
Institute	O
of	O
Child	B-UNK
Health	O
fall	O
into	O
three	O
categories	O
with	O
respect	O
to	O
potential	B-UNK
linkage	B-UNK
analysis	I-UNK
with	O
the	O
X	O
chromosome	B-UNK
DNA	B-UNK
markers	I-UNK
RC8	O
and	O
L1	B-UNK
.	O

28	O
that	O
bridge	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

Families	B-UNK
in	O
which	O
there	O
is	O
at	O
least	O
one	O
obligatory	O
female	O
heterozygote	B-UNK
(	O
n	O
=	O
13	O
)	O
.	O

Here	O
prediction	O
and	O
exclusion	O
of	O
DMD	B-UNK
gene	B-UNK
transmission	B-UNK
may	O
be	O
possible	O
,	O
the	O
accuracy	O
being	O
dependent	B-UNK
on	O
the	O
closeness	O
of	O
the	O
linkage	B-UNK
of	O
the	O
DNA	B-UNK
marker	B-UNK
(	O
s	O
)	O
to	O
the	O
DMD	B-UNK
gene	B-UNK
;	O
an	O
illustrative	O
case	B-UNK
is	O
reported	B-UNK
.	O

Families	B-UNK
in	O
which	O
there	O
is	O
a	O
single	B-UNK
affected	B-UNK
boy	B-UNK
,	O
who	O
also	O
has	O
one	O
or	O
more	O
healthy	O
brothers	O
(	O
n	O
=	O
26	O
)	O
.	O

Given	O
an	O
informative	O
restriction	B-UNK
fragment	I-UNK
length	I-UNK
polymorphism	B-UNK
(	O
RFLP	B-UNK
)	O
,	O
the	O
probability	B-UNK
that	O
the	O
boy	B-UNK
represents	O
a	O
new	O
mutation	B-UNK
can	O
be	O
reassessed	O
;	O
it	O
is	O
also	O
possible	O
to	O
exclude	O
the	O
DMD	B-UNK
gene	B-UNK
in	O
a	O
sister	O
.	O

Families	B-UNK
with	O
a	O
single	B-UNK
affected	B-UNK
boy	B-UNK
with	O
no	O
brother	B-UNK
(	O
n	O
=	O
30	O
)	O
.	O

Here	O
exclusion	O
of	O
the	O
DMD	B-UNK
gene	B-UNK
in	O
a	O
sister	O
may	O
be	O
possible	O
.	O

Only	O
in	O
one	O
family	B-UNK
was	O
there	O
no	O
possibility	B-UNK
of	O
useful	O
linkage	B-UNK
analysis	I-UNK
.	O

The	O
linkage	B-UNK
analysis	I-UNK
required	B-UNK
is	O
described	O
,	O
and	O
the	O
need	O
to	O
check	O
DMD	B-UNK
families	B-UNK
for	O
informative	O
RFLPs	B-UNK
is	O
stressed	O
.	O

Family	B-UNK
studies	B-UNK
in	O
Bechterew'	O
s	O
syndrome	B-DISEASE
(	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
)	O
III	B-UNK
.	O

Genetics	B-UNK
.	O

The	O
results	B-UNK
of	O
segregation	B-UNK
analyses	O
in	O
75	O
families	B-UNK
where	O
the	O
proband	B-UNK
had	O
ankylosing	B-UNK
spondylitis	I-UNK
,	O
are	O
presented	B-UNK
.	O

Of	O
the	O
278	O
adult	B-UNK
,	O
living	O
first	O
degree	B-UNK
relatives	B-UNK
,	O
approximately	O
85	O
%	O
cooperated	O
in	O
the	O
study	B-UNK
.	O

Clinical	B-UNK
and	O
radiographical	O
examinations	O
were	O
performed	O
and	O
HLA	B-UNK
typing	O
was	O
conducted	O
.	O

The	O
results	B-UNK
were	O
in	O
agreement	O
with	O
our	O
hypothesis	B-UNK
that	O
ankylosing	B-UNK
spondylitis	I-UNK
is	O
part	O
of	O
a	O
syndrome	B-DISEASE
where	O
different	O
genetic	B-UNK
factors	O
interact	O
.	O

Such	O
known	O
factors	O
are	O
HLA	B-UNK
B27	B-UNK
associated	O
disease	B-DISEASE
susceptibility	I-DISEASE
,	O
susceptibility	B-UNK
to	O
psoriatic	B-DISEASE
arthropathy	O
and	O
susceptibility	B-UNK
to	O
entero	O
-	O
arthropathy	O
.	O

Radiographical	O
sacro	O
-	O
iliitis	O
was	O
restricted	O
to	O
HLA	B-UNK
B27	B-UNK
positive	O
relatives	B-UNK
,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	B-UNK
to	O
probands	O
with	O
psoriasis	B-DISEASE
than	O
in	O
relatives	B-UNK
to	O
probands	O
without	O
psoriasis	B-DISEASE
.	O

Environmental	O
factors	O
(	O
intestinal	O
bacteria	O
)	O
are	O
known	O
to	O
trigger	O
the	O
disease	B-DISEASE
at	O
least	O
in	O
some	O
persons	O
,	O
and	O
we	O
have	O
postulated	O
that	O
all	O
or	O
most	O
of	O
them	O
have	O
the	O
predisposition	B-UNK
to	O
develop	O
disease	B-DISEASE
.	O

Thus	O
,	O
the	O
syndrome	B-DISEASE
has	O
a	O
multifactorial	O
etiology	O
.	O

The	O
phenotypic	B-UNK
expressions	O
of	O
the	O
different	O
genetic	B-UNK
predispositions	O
involved	B-UNK
,	O
include	O
sacro	O
-	O
iliitis	O
,	O
psoriasis	B-DISEASE
,	O
acute	B-UNK
anterior	O
uveitis	B-DISEASE
,	O
peripheral	B-UNK
arthropathy	O
and	O
inflammatory	B-DISEASE
bowel	I-DISEASE
disease	I-DISEASE
.	O

We	O
suggest	B-UNK
the	O
descriptive	O
name	O
HEREDITARY	B-UNK
MULTIFOCAL	O
RELAPSING	O
INFLAMMATION	B-DISEASE
(	O
HEMRI	O
)	O
for	O
this	O
syndrome	B-DISEASE
.	O

Ankylosing	B-DISEASE
spondylitis	I-DISEASE
,	O
psoriatic	B-DISEASE
arthropathy	O
and	O
entero	O
-	O
arthropathy	O
may	O
be	O
regarded	O
as	O
clinical	B-UNK
sub-types	O
of	O
the	O
syndrome	B-UNK
..	O

Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
and	O
chromosome	B-UNK
15	O
.	O

A	O
clinical	B-UNK
discussion	O
of	O
20	O
cases	B-UNK
.	O

A	O
chromosome	B-UNK
15	O
anomaly	B-UNK
was	O
observed	B-UNK
in	O
12	O
of	O
20	O
patients	B-UNK
,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

The	O
clinical	B-UNK
features	I-UNK
of	O
eight	O
cases	B-UNK
with	O
15q11	B-UNK
-	O
12	O
deletion	B-UNK
were	O
very	O
similar	B-UNK
to	O
those	O
originally	O
described	O
in	O
PWS	B-UNK
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
group	B-UNK
of	O
normal	B-UNK
karyotype	O
patients	B-UNK
is	O
heterogeneous	O
,	O
and	O
their	O
features	B-UNK
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	B-UNK
definition	O
of	O
PWS	B-UNK
.	O

However	O
,	O
the	O
hypothesis	B-UNK
that	O
PWS	B-UNK
is	O
associated	O
with	O
deletion	B-UNK
of	O
15q11	B-UNK
-	O
12	O
can	O
neither	O
explain	O
the	O
apparently	O
balanced	O
translocations	O
of	O
chromosome	B-UNK
15	O
nor	O
account	B-UNK
for	O
the	O
small	O
supernumerary	O
metacentric	O
chromosomes	O
corresponding	O
to	O
an	O
isochromosome	O
15	O
for	O
band	O
15q11	B-UNK
observed	B-UNK
in	O
some	O
cases	B-UNK
..	O

The	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
gene	B-UNK
in	O
North	B-UNK
American	B-UNK
Jewish	B-UNK
populations	O
:	O
geographic	O
variations	O
and	O
origin	O
.	O

From	O
data	B-UNK
collected	O
in	O
a	O
North	B-UNK
American	B-UNK
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
heterozygote	B-UNK
screening	B-UNK
program	O
,	O
the	O
TSD	B-UNK
carrier	B-UNK
frequency	I-UNK
among	O
46	O
,	O
304	O
Jewish	B-UNK
individuals	B-UNK
was	O
found	O
to	O
be	O
.	O

0324	O
(	O
1	O
in	O
31	O
individuals	B-UNK
)	O
.	O

This	O
frequency	B-UNK
is	O
consistent	B-UNK
with	O
earlier	O
estimates	O
based	B-UNK
on	O
TSD	B-UNK
incidence	B-UNK
data	B-UNK
.	O

TSD	B-UNK
carrier	B-UNK
frequencies	O
were	O
then	O
examined	O
by	O
single	B-UNK
country	O
and	O
single	B-UNK
region	B-UNK
of	O
origin	O
in	O
28	O
,	O
029	O
Jews	B-UNK
within	O
this	O
sample	O
for	O
whom	O
such	O
data	B-UNK
were	O
available	O
for	O
analysis	B-UNK
.	O

Jews	B-UNK
with	O
Polish	O
and	O
/	O
or	O
Russian	O
ancestry	O
constituted	O
88	O
%	O
of	O
this	O
sample	O
and	O
had	O
a	O
TSD	B-UNK
carrier	B-UNK
frequency	I-UNK
of	O
.	O

0327	O
.	O

No	O
TSD	B-UNK
carriers	B-UNK
were	O
observed	B-UNK
among	O
the	O
166	O
Jews	B-UNK
of	O
Near	O
Eastern	B-UNK
origins	O
.	O

Relative	B-UNK
to	O
Jews	B-UNK
of	O
Polish	O
and	O
Russian	O
origins	O
,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	B-UNK
in	O
the	O
TSD	B-UNK
carrier	B-UNK
frequency	I-UNK
in	O
Jews	B-UNK
of	O
Austrian	O
,	O
Hungarian	O
,	O
and	O
Czechoslovakian	O
origins	O
(	O
P	O
less	O
than	O
.	O
005	O
)	O
.	O

These	O
findings	B-UNK
suggest	B-UNK
that	O
the	O
TSD	B-UNK
gene	B-UNK
proliferated	O
among	O
the	O
antecedents	O
of	O
modern	O
Ashkenazi	B-UNK
Jewry	O
after	O
the	O
Second	O
Diaspora	O
(	O
70	O
A.	O
D.	O
)	O
and	O
before	O
their	O
major	B-UNK
migrations	O
to	O
regions	B-UNK
of	O
Poland	O
and	O
Russia	O
(	O
before	O
1100	O
A.	O
D.	O
)	O
.	O

Human	B-UNK
deficiency	B-UNK
of	O
the	O
sixth	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
a	O
patient	B-UNK
with	O
meningococcal	B-UNK
meningitis	B-DISEASE
and	O
no	O
haemostasis	O
abnormality	O
.	O

A	O
case	B-UNK
of	O
human	B-UNK
complete	O
C6	B-UNK
deficiency	I-UNK
is	O
reported	B-UNK
.	O

The	O
patient	B-UNK
,	O
a	O
31	O
year	O
old	O
white	B-UNK
male	B-UNK
,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	B-UNK
episode	O
of	O
meningococcal	B-UNK
meningitis	B-DISEASE
.	O

Serum	B-UNK
complement	B-UNK
hemolytic	B-DISEASE
and	O
bactericidal	O
activities	O
were	O
lacking	O
and	O
could	O
be	O
restored	O
to	O
normal	B-UNK
by	O
addition	B-UNK
of	O
appropriate	O
amounts	B-UNK
of	O
purified	O
C6	B-UNK
.	O

No	O
hemostatic	O
abnormalities	B-UNK
were	O
observed	B-UNK
..	O

Absence	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
a	O
patient	B-UNK
with	O
chronic	B-UNK
meningococcemia	O
presenting	B-UNK
as	O
vasculitis	B-DISEASE
.	O

A	O
previously	B-UNK
healthy	O
40-year	O
-	O
old	O
man	B-UNK
presenting	B-UNK
with	O
fever	B-UNK
,	O
arthritis	B-DISEASE
,	O
and	O
cutaneous	O
vasculitis	B-DISEASE
was	O
found	O
to	O
have	O
chronic	B-UNK
meningococcemia	O
.	O

Evaluation	B-UNK
of	O
his	O
complement	B-UNK
system	O
showed	O
an	O
absence	B-UNK
of	O
functional	O
and	O
antigenic	O
C7	B-UNK
,	O
compatible	B-UNK
with	O
a	O
complete	O
deficiency	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
.	O

Study	B-UNK
of	O
the	O
patients	B-UNK
family	B-UNK
spanning	O
four	O
generations	O
showed	O
heterozygous	B-UNK
deficiency	B-UNK
of	O
C7	B-UNK
in	O
five	O
members	B-UNK
.	O

Chronic	B-UNK
neisserial	O
infection	B-DISEASE
can	O
be	O
associated	O
with	O
C7	B-UNK
deficiency	I-UNK
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	O
vasculitis	B-DISEASE
..	O

Familial	B-UNK
discoid	O
lupus	B-DISEASE
erythematosus	I-DISEASE
associated	O
with	O
heterozygote	B-UNK
C2	B-UNK
deficiency	I-UNK
.	O

Two	O
siblings	O
with	O
chronic	B-UNK
discoid	O
lupus	B-DISEASE
erythematosus	I-DISEASE
and	O
several	O
family	B-UNK
members	I-UNK
were	O
found	O
with	O
heterozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
.	O

An	O
association	B-UNK
with	O
histocompatibility	B-UNK
markers	B-UNK
HLA	B-UNK
-	O
B18	O
and	O
HLA	B-UNK
-	O
Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	B-UNK
B	O
was	O
present	B-UNK
.	O

Linkage	B-UNK
studies	B-UNK
in	O
this	O
family	B-UNK
suggested	O
a	O
close	B-UNK
linkage	I-UNK
between	O
the	O
C2	B-UNK
deficiency	I-UNK
gene	B-UNK
and	O
genes	B-UNK
coding	B-UNK
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O

One	O
HLA	B-UNK
-	O
ACB	O
/	O
DBf	O
recombinant	B-UNK
was	O
observed	B-UNK
showing	O
closer	O
linkage	B-UNK
between	O
HLA	B-UNK
-	O
D	O
and	O
Bf	O
than	O
between	O
HLA	B-UNK
-	O
B	O
and	O
Bf	O
..	O

Severe	B-UNK
-	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
associated	O
with	O
chronic	B-UNK
hemolytic	B-UNK
anemia	I-UNK
,	O
granulocyte	O
dysfunction	B-UNK
,	O
and	O
increased	B-UNK
susceptibility	B-UNK
to	O
infections	B-DISEASE
:	O
description	O
of	O
a	O
new	O
molecular	B-UNK
variant	O
(	O
G6PD	B-UNK
Barcelona	O
)	O
.	O

Molecular	B-UNK
,	O
kinetic	O
,	O
and	O
functional	O
studies	B-UNK
were	O
carried	O
out	O
on	O
erythrocytes	O
and	O
leukocytes	O
in	O
a	O
Spanish	O
male	B-UNK
with	O
G6PD	B-UNK
deficiency	I-UNK
,	O
congenital	B-UNK
nonspherocytic	O
hemolytic	B-UNK
anemia	I-UNK
(	O
CNSHA	O
)	O
,	O
and	O
increased	B-UNK
susceptibility	B-UNK
to	O
infections	B-DISEASE
.	O

G6PD	B-UNK
activity	B-UNK
was	O
absent	O
in	O
patients	B-UNK
red	B-UNK
cells	B-UNK
and	O
was	O
about	O
2	O
%	O
of	O
normal	B-UNK
in	O
leukocytes	O
.	O

Molecular	B-UNK
studies	B-UNK
using	O
standard	O
methods	O
(	O
WHO	O
,	O
1967	O
)	O
showed	O
G6PD	B-UNK
in	O
the	O
patient	B-UNK
to	O
have	O
a	O
slightly	O
fast	O
electrophoretic	B-UNK
mobility	O
at	O
pH	B-UNK
8	O
.	O

0	O
with	O
otherwise	O
normal	B-UNK
properties	B-UNK
(	O
heat	O
stability	O
at	O
46	O
degrees	O
C	O
,	O
apparent	O
affinity	B-UNK
for	O
substrates	O
,	O
optimum	O
pH	B-UNK
,	O
and	O
utilization	O
of	O
substrate	O
analogues	O
)	O
.	O

Other	O
tests	O
showed	O
the	O
patients	B-UNK
granulocytes	O
to	O
engulf	O
latex	O
particles	O
normally	O
,	O
but	O
to	O
have	O
impaired	B-UNK
reduction	B-UNK
of	O
nitroblue	O
tetrazolium	O
and	O
ferricytochrome	O
-	O
c	O
as	O
well	O
as	O
reduced	O
iodination	O
.	O

Chemotaxis	O
and	O
random	B-UNK
migration	O
of	O
the	O
patients	B-UNK
granulocytes	O
were	O
normal	B-UNK
as	O
were	O
myeloperoxidase	O
,	O
leukocyte	O
alkaline	O
phosphatase	B-UNK
(	O
LAP	O
)	O
,	O
and	O
ultrastructural	O
features	B-UNK
.	O

The	O
molecular	B-UNK
characteristics	B-UNK
of	O
G6PD	B-UNK
in	O
the	O
patient	B-UNK
differed	O
from	O
those	O
of	O
all	O
previously	B-UNK
reported	I-UNK
variants	B-UNK
associated	O
with	O
CNSHA	O
,	O
so	O
the	O
present	B-UNK
variant	O
was	O
provisionally	O
called	O
G6PD	B-UNK
Barcelona	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	B-UNK
variants	I-UNK
previously	B-UNK
described	O
.	O

Possible	O
mechanisms	O
for	O
the	O
severe	B-UNK
deficiency	B-UNK
of	O
G6PD	B-UNK
in	O
erythrocytes	O
and	O
granulocytes	O
was	O
investigated	O
by	O
studies	B-UNK
on	O
the	O
immunologic	O
specific	B-UNK
activity	B-UNK
of	O
the	O
mutant	B-UNK
enzyme	B-UNK
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
in	O
Papua	O
New	O
Guinea	O
.	O

The	O
description	O
of	O
13	O
new	O
variants	B-UNK
.	O

A	O
total	B-UNK
of	O
362	O
males	B-UNK
from	O
various	O
regions	B-UNK
of	O
Papua	O
New	O
Guinea	O
were	O
screened	B-UNK
for	O
red	B-UNK
cell	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
activity	B-UNK
.	O

Twenty	O
-	O
six	O
G6PD	B-UNK
deficient	B-UNK
individuals	B-UNK
were	O
identified	B-UNK
.	O

Biochemical	O
characterization	B-UNK
of	O
G6PD	B-UNK
purified	O
from	O
these	O
subjects	B-UNK
has	O
revealed	B-UNK
13	O
new	O
variants	B-UNK
and	O
several	O
copies	O
of	O
previously	B-UNK
described	O
forms	B-UNK
of	O
G6PD	B-UNK
.	O

This	O
study	B-UNK
illustrates	O
the	O
extreme	O
heterogeneity	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
among	O
the	O
people	O
of	O
Papua	O
New	O
Guinea	O
..	O

Heterogeneity	B-UNK
of	O
"	O
Mediterranean	B-UNK
type	B-UNK
"	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
Spain	O
and	O
description	O
of	O
two	O
new	O
variants	B-UNK
associated	O
with	O
favism	B-DISEASE
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
;	O
EC	B-UNK
1	O
.	O

1	O
.	O

1	O
.	O

49	O
from	O
thirty	O
-	O
six	O
unrelated	B-UNK
Spanish	O
males	B-UNK
was	O
partially	O
purified	O
from	O
blood	B-UNK
,	O
and	O
the	O
variants	B-UNK
were	O
characterized	B-UNK
biochemically	O
and	O
electrophoretically	O
according	O
to	O
the	O
methods	O
recommended	O
by	O
the	O
world	O
Health	O
Organization	B-UNK
.	O

Subjects	B-UNK
were	O
from	O
multiple	B-UNK
geographic	O
regions	B-UNK
within	O
Spain	O
,	O
and	O
all	O
suffered	O
from	O
hemolytic	B-DISEASE
anemia	I-DISEASE
,	O
either	O
acute	B-UNK
(	O
34	O
cases	B-UNK
)	O
or	O
chronic	B-UNK
nonspherocytic	O
(	O
2	O
cases	B-UNK
)	O
.	O

Almost	O
all	O
the	O
variants	B-UNK
studied	O
presented	B-UNK
residual	B-UNK
erythrocyte	B-UNK
G6PD	B-UNK
activity	B-UNK
ranging	O
from	O
0	O
to	O
10	O
%	O
of	O
normal	B-UNK
,	O
and	O
five	O
different	O
mutants	O
were	O
responsible	B-UNK
for	O
the	O
deficient	B-UNK
phenotype	B-UNK
.	O

Three	O
variants	B-UNK
were	O
similar	B-UNK
to	O
others	O
previously	B-UNK
described	O
G6PD	B-UNK
Mediterranean	I-UNK
(	O
11	O
cases	B-UNK
)	O
,	O
G6PD	B-UNK
Athens	O
-	O
like	O
(	O
3	O
cases	B-UNK
)	O
,	O
and	O
G6PD	B-UNK
Union	O
(	O
2	O
cases	B-UNK
)	O
.	O

The	O
remaining	O
variants	B-UNK
were	O
different	O
from	O
the	O
numerous	O
variants	B-UNK
already	O
reported	B-UNK
and	O
have	O
been	O
considered	O
as	O
new	O
mutants	O
.	O

Provisionally	O
they	O
are	O
called	O
G6PD	B-UNK
Betica	O
(	O
19	O
cases	B-UNK
)	O
and	O
G6PD	B-UNK
Menorca	O
(	O
1	O
case	B-UNK
)	O
.	O

The	O
present	B-UNK
study	B-UNK
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	B-UNK
G6PD	B-UNK
variants	I-UNK
found	O
in	O
Spain	O
and	O
supplies	O
new	O
data	B-UNK
on	O
the	O
relationship	B-UNK
between	O
molecular	B-UNK
characteristics	B-UNK
of	O
deficient	B-UNK
variants	B-UNK
and	O
their	O
clinical	B-UNK
manifestations	I-UNK
.	O

The	O
most	O
important	O
findings	B-UNK
can	O
be	O
summarized	O
as	O
follows	O
(	O
1	O
)	O
The	O
Spanish	O
population	B-UNK
is	O
characterized	B-UNK
by	O
an	O
important	O
heterogeneity	B-UNK
in	O
G6PD	B-UNK
deficiency	I-UNK
.	O

(	O
2	O
)	O
Although	O
G6PD	B-UNK
Mediterranean	I-UNK
is	O
very	O
frequent	B-UNK
,	O
it	O
presents	O
a	O
relatively	O
high	B-UNK
degree	B-UNK
of	O
polymorphism	B-UNK
.	O

(	O
3	O
)	O
Favism	B-DISEASE
has	O
been	O
observed	B-UNK
associated	O
with	O
all	O
kinds	O
of	O
variants	B-UNK
described	O
here	O
.	O

(	O
4	O
)	O
G6PD	B-UNK
Betica	O
,	O
which	O
is	O
the	O
most	O
frequent	B-UNK
variant	O
found	O
in	O
subjects	B-UNK
of	O
Southern	B-UNK
Spanish	O
origin	O
,	O
has	O
been	O
observed	B-UNK
associated	O
with	O
favism	B-DISEASE
in	O
all	O
cases	B-UNK
except	O
one	O
.	O

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
variant	O
(	O
G6PD	B-UNK
Nagano	O
)	O
associated	O
with	O
congenital	B-UNK
hemolytic	B-UNK
anemia	I-UNK
.	O

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
variant	O
associated	O
with	O
chronic	B-UNK
nonspherocytic	O
hemolytic	B-UNK
anemia	I-UNK
was	O
reported	B-UNK
.	O

The	O
patient	B-UNK
,	O
a	O
6-year	O
-	O
old	O
Japanese	B-UNK
male	B-UNK
,	O
was	O
noticed	O
to	O
have	O
hemolytic	B-UNK
anemia	I-UNK
soon	O
after	O
birth	O
,	O
and	O
a	O
diagnosis	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
was	O
made	O
at	O
the	O
age	B-UNK
of	O
2	O
.	O

He	O
had	O
episodes	O
of	O
hemolytic	B-UNK
crisis	O
several	O
times	O
after	O
upper	O
respiratory	O
infection	B-DISEASE
.	O

G6PD	B-UNK
activity	B-UNK
of	O
the	O
patient	B-UNK
was	O
5	O
.	O

5	O
%	O
of	O
normal	B-UNK
.	O

The	O
enzymatic	B-UNK
characteristics	B-UNK
were	O
examined	O
when	O
he	O
was	O
5	O
years	O
old	O
,	O
and	O
his	O
G6PD	B-UNK
showed	O
faster	O
-	O
than	O
-	O
normal	B-UNK
electrophoretic	B-UNK
mobility	O
,	O
low	B-UNK
Km	O
G6P	O
,	O
high	B-UNK
Km	O
NADP	O
,	O
low	B-UNK
Ki	O
NADPH	O
,	O
normal	B-UNK
utilization	O
of	O
substrate	O
analogues	O
,	O
heat	O
instability	B-UNK
,	O
and	O
a	O
normal	B-UNK
pH	B-UNK
optimum	O
curve	O
.	O

From	O
these	O
results	B-UNK
,	O
this	O
was	O
considered	O
to	O
be	O
a	O
new	O
variant	O
and	O
was	O
designated	O
G6PD	B-UNK
Nagano	O
.	O

Infection	B-UNK
-	O
induced	O
hemolysis	B-DISEASE
and	O
chronic	B-UNK
hemolytic	B-UNK
anemia	I-UNK
seem	O
to	O
be	O
due	O
to	O
markedly	B-UNK
impaired	B-UNK
enzyme	B-UNK
activity	I-UNK
and	O
thermal	O
instability	B-UNK
.	O

Heterozygous	B-UNK
C2-deficiency	O
and	O
myasthenia	B-DISEASE
gravis	I-DISEASE
.	O

Complement	B-UNK
deficiency	B-UNK
states	O
in	O
myasthenia	B-DISEASE
gravis	I-DISEASE
(	O
MG	B-UNK
)	O
have	O
not	O
been	O
reported	B-UNK
previously	B-UNK
.	O

We	O
describe	O
a	O
19-year	O
-	O
old	O
woman	O
with	O
typical	O
MG	B-UNK
and	O
heterozygous	B-UNK
C2	B-UNK
deficiency	I-UNK
,	O
along	O
with	O
HLA	B-UNK
typing	O
of	O
the	O
patient	B-UNK
and	O
her	O
immediate	O
family	B-UNK
..	O

Adrenoleukodystrophy	B-UNK
:	O
increased	B-UNK
plasma	O
content	O
of	O
saturated	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
.	O

With	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
hemizygotes	O
,	O
ALD	B-UNK
heterozygotes	B-UNK
,	O
and	O
controls	O
.	O

ALD	B-UNK
hemizygotes	O
showed	O
increased	B-UNK
levels	B-UNK
of	O
hexacosanoate	O
(	O
C26	O
fatty	B-UNK
acid	B-UNK
)	O
which	O
represented	O
0	O
.	O

081	O
+	O
/-0	O
.	O

0066	O
%	O
(	O
SEM	O
)	O
of	O
total	B-UNK
fatty	B-UNK
acids	I-UNK
,	O
compared	B-UNK
to	O
0	O
.	O

015	O
+	O
/-0	O
.	O

0032	O
%	O
in	O
the	O
controls	O
.	O

C25	O
,	O
C24	O
,	O
and	O
C23	O
fatty	B-UNK
acids	I-UNK
were	O
also	O
increased	B-UNK
,	O
but	O
the	O
C22	O
and	O
C20	O
fatty	B-UNK
acids	I-UNK
were	O
normal	B-UNK
.	O

C26	O
levels	B-UNK
were	O
also	O
increased	B-UNK
in	O
most	O
ALD	B-UNK
heterozygotes	B-UNK
,	O
with	O
a	O
mean	O
level	B-UNK
0	O
.	O

057	O
+	O
/-0	O
.	O

0063	O
%	O
of	O
total	B-UNK
fatty	B-UNK
acids	I-UNK
.	O

The	O
technique	O
can	O
be	O
used	O
for	O
diagnosis	B-UNK
and	O
carrier	B-UNK
identification	B-UNK
,	O
and	O
in	O
the	O
evaluation	B-UNK
of	O
therapy	B-UNK
.	O

Abnormal	O
high	B-UNK
density	I-UNK
lipoproteins	O
in	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
.	O

The	O
plasma	O
lipoprotein	B-UNK
profiles	O
and	O
high	B-UNK
density	I-UNK
lipoproteins	O
(	O
HDL	B-UNK
)	O
were	O
characterized	B-UNK
in	O
patients	B-UNK
with	O
the	O
genetic	B-UNK
disease	B-DISEASE
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
)	O
.	O

Abnormalities	B-UNK
in	O
the	O
HDL	B-UNK
may	O
contribute	B-UNK
to	O
their	O
increased	B-UNK
atherogenesis	B-DISEASE
and	O
excessive	O
deposits	O
of	O
tissue	B-UNK
sterols	O
in	O
the	O
presence	O
of	O
low	B-UNK
or	O
low	B-UNK
-	O
normal	B-UNK
concentrations	O
of	O
plasma	O
cholesterol	B-UNK
(	O
165	O
+	O
/-25	O
mg	B-UNK
/	O
dl	O
)	O
and	O
low	B-UNK
density	B-UNK
lipoproteins	O
(	O
LDL	O
)	O
.	O

The	O
mean	O
HDL	B-UNK
-	O
cholesterol	B-UNK
concentration	O
in	O
the	O
CTX	B-UNK
plasmas	O
was	O
14	O
.	O

5	O
+	O
/-3	O
.	O

2	O
mg	B-UNK
/	O
dl	O
,	O
about	O
one	O
-	O
third	O
the	O
normal	B-UNK
value	O
.	O

The	O
low	B-UNK
HDL	B-UNK
-	O
cholesterol	B-UNK
reflects	O
a	O
low	B-UNK
concentration	O
and	O
an	O
abnormal	O
lipid	O
composition	O
of	O
the	O
plasma	O
HDL	B-UNK
.	O

Relative	B-UNK
to	O
normal	B-UNK
HDL	B-UNK
,	O
the	O
cholesteryl	B-UNK
esters	O
are	O
low	B-UNK
,	O
free	O
cholesterol	B-UNK
and	O
phospholipids	O
essentially	O
normal	B-UNK
,	O
and	O
triglycerides	O
increased	B-UNK
.	O

The	O
ratio	B-UNK
of	O
apoprotein	O
(	O
apo	O
)	O
to	O
total	B-UNK
cholesterol	B-UNK
in	O
the	O
HDL	B-UNK
of	O
CTX	B-UNK
was	O
two	O
to	O
three	O
times	O
greater	B-UNK
than	O
normal	B-UNK
.	O

In	O
the	O
CTX	B-UNK
HDL	B-UNK
,	O
the	O
ratio	B-UNK
of	O
apoAI	O
to	O
apoAII	O
was	O
high	B-UNK
,	O
the	O
proportion	B-UNK
of	O
apoC	O
low	B-UNK
,	O
and	O
a	O
normally	O
minor	O
form	B-UNK
of	O
apoAI	O
increased	B-UNK
relative	B-UNK
to	O
other	O
forms	B-UNK
.	O

The	O
HDL	B-UNK
in	O
electron	O
micrographs	O
appeared	B-UNK
normal	B-UNK
morphologically	O
and	O
in	O
particle	O
size	B-UNK
.	O

The	O
abnormalities	B-UNK
in	O
lipoprotein	B-UNK
distribution	B-UNK
profile	O
and	O
composition	O
of	O
the	O
plasma	O
HDL	B-UNK
result	B-UNK
from	O
metabolic	B-UNK
defects	B-UNK
that	O
are	O
not	O
understood	O
but	O
may	O
be	O
linked	B-UNK
to	O
the	O
genetic	B-UNK
defect	B-UNK
in	O
bile	O
acid	B-UNK
synthesis	B-UNK
in	O
CTX	B-UNK
.	O

As	O
a	O
consequence	B-UNK
,	O
it	O
is	O
probable	O
that	O
the	O
normal	B-UNK
functions	O
of	O
the	O
HDL	B-UNK
,	O
possibly	O
including	O
modulation	O
of	O
LDL	O
-	O
cholesterol	B-UNK
uptake	O
and	O
the	O
removal	O
of	O
excess	B-UNK
cholesterol	B-UNK
from	O
peripheral	B-UNK
tissues	O
,	O
are	O
perturbed	O
significantly	O
in	O
this	O
disease	B-UNK
.	O

Genetics	B-UNK
of	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
):	O
an	O
autosomal	B-UNK
recessive	I-UNK
trait	O
with	O
high	B-UNK
gene	B-UNK
frequency	B-UNK
in	O
Sephardim	O
of	O
Moroccan	B-UNK
origin	O
.	O

We	O
described	O
6	O
patients	B-UNK
(	O
from	O
3	O
families	B-UNK
)	O
affected	B-UNK
with	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
)	O
.	O

All	O
are	O
Sephardic	O
Jews	B-UNK
of	O
Moroccan	B-UNK
extraction	O
.	O

In	O
view	O
of	O
the	O
small	O
number	B-UNK
of	O
CTX	B-UNK
patients	B-UNK
diagnosed	O
in	O
the	O
world	O
(	O
a	O
total	B-UNK
of	O
50	O
including	O
our	O
6	O
patients	B-UNK
)	O
,	O
we	O
are	O
probably	O
dealing	O
with	O
an	O
ethnic	B-UNK
subgroup	O
with	O
a	O
high	B-UNK
CTX	B-UNK
gene	B-UNK
frequency	B-UNK
,	O
which	O
we	O
have	O
estimated	B-UNK
to	O
be	O
1/108	O
.	O

Since	O
there	O
are	O
differences	B-UNK
in	O
expression	B-UNK
in	O
this	O
disease	B-DISEASE
,	O
we	O
recommend	O
cholestanol	O
study	B-UNK
in	O
cases	B-UNK
of	O
undiagnosed	O
cataract	B-DISEASE
or	O
tendinous	O
xanthomas	O
in	O
childhood	O
or	O
early	B-UNK
adolescence	O
.	O

The	O
diagnosis	B-UNK
in	O
CTX	B-UNK
is	O
important	O
not	O
only	O
for	O
genetic	B-UNK
counseling	I-UNK
,	O
but	O
also	O
in	O
veiw	O
of	O
possible	O
treatment	O
..	O

New	O
genetic	B-UNK
variants	B-UNK
of	O
glucose	B-UNK
6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
in	O
Italy	O
.	O

Six	O
new	O
variants	B-UNK
of	O
human	B-UNK
erythrocyte	B-UNK
G6PD	B-UNK
have	O
been	O
characterized	B-UNK
.	O

All	O
of	O
them	O
were	O
found	O
in	O
Italian	B-UNK
males	B-UNK
and	O
all	O
were	O
associated	O
with	O
enzyme	B-UNK
deficiency	I-UNK
,	O
but	O
only	O
two	O
with	O
signs	B-UNK
of	O
haemolysis	B-DISEASE
.	O

These	O
and	O
other	O
variants	B-UNK
reported	B-UNK
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	B-UNK
,	O
are	O
found	O
to	O
map	B-UNK
in	O
parts	O
of	O
Italy	O
where	O
common	B-UNK
types	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
are	O
also	O
prevalent	O
..	O

Variants	B-UNK
of	O
erythrocyte	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
in	O
Bulgarian	O
populations	O
.	O

Ten	O
variants	B-UNK
of	O
erythrocyte	B-UNK
glucose-6-phosphate	O
dehydrogenase	B-UNK
were	O
identified	B-UNK
in	O
22	O
patients	B-UNK
with	O
G6PD	B-UNK
deficiency	I-UNK
from	O
three	O
districts	O
of	O
Bulgaria	O
.	O

Corinth	O
-	O
like	O
and	O
Fayoum	O
-	O
like	O
variants	B-UNK
were	O
the	O
most	O
frequent	B-UNK
;	O
Mediterranean	B-UNK
,	O
Ohut	O
II	B-UNK
,	O
Kilgore	O
,	O
Boston	O
,	O
Poznan	O
,	O
and	O
Panay	O
variants	B-UNK
and	O
two	O
new	O
variants	B-UNK
,	O
Petrich	O
and	O
Gotze	O
Delchev	O
,	O
were	O
each	O
found	O
in	O
one	O
or	O
two	O
carriers	B-UNK
.	O

No	O
correlation	B-UNK
was	O
revealed	B-UNK
between	O
clinical	B-UNK
and	O
biochemical	O
polymorphism	B-UNK
..	O

Nephropathy	B-DISEASE
in	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
.	O

Nephropathy	B-DISEASE
was	O
detected	B-UNK
in	O
five	O
of	O
32	O
patients	B-UNK
with	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
who	O
were	O
participating	O
in	O
a	O
study	B-UNK
of	O
transfer	B-UNK
factor	B-UNK
(	O
TF	B-UNK
)	O
therapy	B-UNK
.	O

In	O
two	O
patients	B-UNK
,	O
nephropathy	B-DISEASE
was	O
present	B-UNK
before	O
TF	B-UNK
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	B-UNK
therapy	B-UNK
.	O

One	O
of	O
these	O
patients	B-UNK
subsequently	B-UNK
developed	O
progressive	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
requiring	O
dialysis	O
beginning	O
5	O
1/2	O
years	O
after	O
TF	B-UNK
therapy	B-UNK
.	O

In	O
two	O
patients	B-UNK
,	O
decreased	B-DISEASE
renal	I-DISEASE
function	I-DISEASE
appeared	B-UNK
very	O
soon	O
after	O
the	O
administration	O
of	O
TF	B-UNK
.	O

One	O
patient	B-UNK
showed	O
gradually	O
decreasing	O
renal	B-UNK
function	B-UNK
beginning	O
after	O
two	O
years	O
of	O
TF	B-UNK
therapy	B-UNK
.	O

An	O
additional	O
patient	B-UNK
was	O
identified	B-UNK
who	O
died	O
with	O
renal	B-DISEASE
failure	I-DISEASE
without	O
having	O
received	O
TF	B-UNK
.	O

The	O
results	B-UNK
suggest	B-UNK
that	O
renal	B-DISEASE
failure	I-DISEASE
occurs	O
in	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	B-UNK
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B-DISEASE
disease	I-DISEASE
in	O
patients	B-UNK
with	O
this	O
syndrome	B-DISEASE
..	O

Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
:	O
cellular	O
impairments	O
and	O
their	O
implication	O
for	O
carrier	B-UNK
detection	I-UNK
.	O

A	O
family	B-UNK
in	O
which	O
two	O
male	B-UNK
siblings	O
were	O
affected	B-UNK
with	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
was	O
studied	O
using	O
G-6-PD	O
isoenzymes	O
as	O
an	O
X	O
-	O
linked	B-UNK
marker	B-UNK
in	O
order	B-UNK
to	O
investigate	B-UNK
the	O
nature	B-UNK
of	O
cellular	O
abnormalities	B-UNK
.	O

Isolated	B-UNK
peripheral	B-UNK
blood	I-UNK
cell	B-UNK
types	B-UNK
from	O
the	O
doubly	O
heterozygous	B-UNK
mother	O
of	O
the	O
affected	B-UNK
males	I-UNK
seemingly	O
failed	O
to	O
express	O
the	O
G-6-PD	O
allele	B-UNK
in	O
cis	B-UNK
position	B-UNK
with	O
the	O
WAS	O
allele	B-UNK
while	O
her	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
expressed	B-UNK
both	O
G-6-PD	O
alleles	B-UNK
.	O

Additionally	O
,	O
a	O
histogram	O
analysis	B-UNK
of	O
platelet	B-UNK
size	B-UNK
revealed	B-UNK
a	O
single	B-UNK
population	B-UNK
of	O
abnormally	O
small	O
platelets	O
in	O
the	O
affected	B-UNK
propositus	O
,	O
whereas	O
the	O
heterozygous	B-UNK
mother	O
had	O
no	O
appreciable	O
small	O
platelet	B-UNK
subpopulation	O
.	O

In	O
vitro	O
culture	B-UNK
of	O
hemopoietic	O
progenitor	O
cells	B-UNK
of	O
the	O
heterozygous	B-UNK
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	B-UNK
did	O
not	O
express	O
the	O
WAS	O
allele	B-UNK
.	O

However	O
,	O
a	O
small	O
number	B-UNK
of	O
cells	B-UNK
expressing	O
the	O
G-6-PD	O
type	B-UNK
linked	B-UNK
with	O
the	O
WAS	O
allele	B-UNK
were	O
detected	B-UNK
.	O

The	O
proportion	B-UNK
of	O
the	O
latter	O
progenitors	O
was	O
significantly	O
higher	O
among	O
more	O
primitive	O
progenitors	O
(	O
those	O
giving	O
rise	B-UNK
to	O
later	O
appearing	O
colonies	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
selection	B-UNK
against	O
cells	B-UNK
expressing	O
the	O
Wiskott	O
-	O
Aldrich	O
defect	B-UNK
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	B-UNK
female	O
and	O
offers	O
a	O
possible	O
means	B-UNK
of	O
carrier	B-UNK
detection	I-UNK
in	O
some	O
women	B-UNK
.	O

Linkage	B-UNK
studies	B-UNK
in	O
this	O
family	B-UNK
revealed	B-UNK
one	O
example	O
of	O
probable	O
recombination	B-UNK
between	O
the	O
loci	O
for	O
WAS	O
and	O
G-6-PD	O
among	O
three	O
informative	O
subjects	B-UNK
,	O
suggesting	O
that	O
these	O
two	O
loci	O
may	O
not	O
be	O
closely	B-UNK
linked	I-UNK
on	O
the	O
X	O
-	O
chromosome	B-UNK
..	O

A	O
new	O
CT	B-UNK
pattern	B-UNK
in	O
adrenoleukodystrophy	B-DISEASE
.	O

A	O
new	O
CT	B-UNK
pattern	B-UNK
was	O
observed	B-UNK
in	O
2	O
patients	B-UNK
with	O
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
.	O

This	O
pattern	B-UNK
,	O
which	O
the	O
authors	O
call	O
Type	B-UNK
II	I-UNK
,	O
is	O
characterized	B-UNK
by	O
the	O
absence	B-UNK
of	O
posterior	O
periventricular	O
areas	O
of	O
decreased	B-UNK
attenuation	O
around	O
the	O
trigone	O
on	O
non-contrast	O
scans	O
after	O
contrast	B-UNK
infusion	O
,	O
however	O
,	O
there	O
is	O
striking	O
enhancement	O
of	O
various	O
white	B-UNK
-	O
matter	O
structures	O
(	O
tracts	O
or	O
fiber	O
systems	O
)	O
such	O
as	O
the	O
internal	O
capsules	O
,	O
corpus	O
callosum	O
,	O
corona	O
radiata	O
,	O
forceps	O
major	B-UNK
,	O
and	O
cerebral	B-UNK
peduncles	O
.	O

This	O
is	O
different	O
from	O
numerous	O
previous	B-UNK
descriptions	O
of	O
the	O
CT	B-UNK
pattern	B-UNK
in	O
ALD	B-UNK
.	O

Type	B-UNK
II	I-UNK
ALD	B-UNK
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	B-DISEASE
and	O
is	O
probably	O
specific	B-UNK
for	O
a	O
phenotypic	B-UNK
variant	O
or	O
an	O
evolving	O
stage	B-UNK
of	O
ALD	B-UNK
..	O

Further	O
evidence	B-UNK
for	O
heterogeneity	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
deficiency	B-UNK
in	O
Papua	O
New	O
Guinea	O
.	O

Four	O
new	O
G6PD	B-UNK
variants	I-UNK
have	O
been	O
characterized	B-UNK
in	O
individuals	B-UNK
from	O
Papua	O
New	O
Guinea	O
.	O

This	O
study	B-UNK
demonstrates	O
that	O
the	O
previously	B-UNK
reported	I-UNK
Markham	O
variant	O
and	O
the	O
newly	O
characterized	B-UNK
Salata	O
variant	O
may	O
be	O
widely	O
distributed	O
in	O
Papua	O
New	O
Guinea	O
.	O

Th	O
data	B-UNK
presented	B-UNK
here	O
together	O
with	O
those	O
of	O
previously	B-UNK
published	O
studies	B-UNK
demonstrate	B-UNK
a	O
degree	B-UNK
of	O
heterogeneity	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	B-UNK
of	O
the	O
world	O
where	O
G6PD	B-UNK
deficiency	I-UNK
is	O
common	B-UNK
..	O

Increased	B-UNK
incidence	B-UNK
of	O
cataracts	B-DISEASE
in	O
male	B-UNK
subjects	B-UNK
deficient	B-UNK
in	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	B-UNK
cataractous	O
patients	B-UNK
than	O
in	O
672	O
control	B-UNK
subjects	B-UNK
of	O
Sardinian	O
origin	O
.	O

The	O
frequency	B-UNK
of	O
the	O
deficiency	B-UNK
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B-DISEASE
.	O

In	O
the	O
G6PD	B-UNK
-	O
deficient	B-UNK
group	B-UNK
,	O
the	O
incidence	B-UNK
of	O
cortical	O
and	O
total	B-UNK
cataracts	B-DISEASE
was	O
also	O
increased	B-UNK
.	O

It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	B-UNK
activity	B-UNK
in	O
the	O
lens	O
,	O
which	O
accompanies	O
its	O
deficiency	B-UNK
in	O
the	O
erythrocyte	B-UNK
,	O
might	O
play	O
a	O
role	B-UNK
in	O
the	O
cataracto	O
-	O
genesis	O
of	O
these	O
patients	B-UNK
.	O

Moreover	O
,	O
G6PD	B-UNK
deficiency	I-UNK
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	O
states	O
and	O
riboflavin	B-DISEASE
deficiency	I-DISEASE
,	O
where	O
cataracts	B-DISEASE
represent	O
a	O
sensitive	B-UNK
indicator	O
of	O
metabolic	B-DISEASE
abnormalities	I-DISEASE
of	O
the	O
RBC	O
..	O

Molecular	B-UNK
basis	I-UNK
of	O
human	B-UNK
mitochondrial	B-UNK
very	O
-	O
long	B-DISEASE
-	I-DISEASE
chain	I-DISEASE
acyl	I-DISEASE
-	I-DISEASE
CoA	I-DISEASE
dehydrogenase	I-DISEASE
deficiency	I-DISEASE
causing	B-UNK
cardiomyopathy	B-UNK
and	O
sudden	B-DISEASE
death	I-DISEASE
in	O
childhood	O
.	O

beta-Oxidation	O
of	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
provides	O
the	O
major	B-UNK
source	O
of	O
energy	O
in	O
the	O
heart	B-UNK
.	O

Defects	B-UNK
in	O
enzymes	B-UNK
of	O
the	O
beta-oxidation	O
pathway	B-UNK
cause	O
sudden	O
,	O
unexplained	O
death	B-DISEASE
in	O
childhood	O
,	O
acute	B-UNK
hepatic	B-DISEASE
encephalopathy	I-DISEASE
or	O
liver	B-DISEASE
failure	I-DISEASE
,	O
skeletal	B-UNK
myopathy	B-DISEASE
,	O
and	O
cardiomyopathy	B-UNK
.	O

Very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
CoA	B-UNK
dehydrogenase	I-UNK
[	O
VLCAD	B-UNK
;	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
-	O
acyl	B-UNK
-	O
CoA	B-UNK
(	O
acceptor	B-UNK
)	O
2	O
,	O
3-oxidoreductase	O
,	O
EC	B-UNK
1	O
.	O
3	O
3	O
.	O
99	O
99	O
.	O
13	O
]	O
catalyzes	O
the	O
first	O
step	O
in	O
beta-oxidation	O
.	O

We	O
have	O
isolated	B-UNK
the	O
human	B-UNK
VLCAD	B-UNK
cDNA	O
and	O
gene	B-UNK
and	O
determined	B-UNK
the	O
complete	O
nucleotide	B-UNK
sequences	O
.	O

Polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
amplification	B-UNK
of	O
VLCAD	B-UNK
mRNA	O
and	O
genomic	B-UNK
exons	O
defined	B-UNK
the	O
molecular	B-UNK
defects	B-UNK
in	O
two	O
patients	B-UNK
with	O
VLCAD	B-UNK
deficiency	I-UNK
who	O
presented	B-UNK
with	O
unexplained	O
cardiac	B-DISEASE
arrest	I-DISEASE
and	O
cardiomyopathy	B-UNK
.	O

In	O
one	O
,	O
a	O
homozygous	B-UNK
mutation	B-UNK
in	O
the	O
consensus	B-UNK
dinucleotide	B-UNK
of	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
(	O
g	O
+	O
1	O
-	O
-	O
>	O
a	O
)	O
was	O
associated	O
with	O
universal	O
skipping	O
of	O
the	O
prior	O
exon	B-UNK
(	O
exon	B-UNK
11	O
)	O
.	O

The	O
second	O
patient	B-UNK
was	O
a	O
compound	B-UNK
heterozygote	B-UNK
,	O
with	O
a	O
missense	B-UNK
mutation	I-UNK
,	O
C1837	O
-	O
-	O
>	O
T	O
,	O
changing	O
the	O
arginine	O
at	O
residue	O
613	O
to	O
tryptophan	O
on	O
one	O
allele	B-UNK
and	O
a	O
single	B-UNK
base	I-UNK
deletion	B-UNK
at	O
the	O
intron	B-UNK
-	O
exon	B-UNK
6	O
boundary	O
as	O
the	O
second	O
mutation	B-UNK
.	O

This	O
initial	O
delineation	O
of	O
human	B-UNK
mutations	B-UNK
in	O
VLCAD	B-UNK
suggests	O
that	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
reduces	O
myocardial	O
fatty	B-UNK
acid	B-UNK
beta-oxidation	O
and	O
energy	O
production	O
and	O
is	O
associated	O
with	O
cardiomyopathy	B-DISEASE
and	O
sudden	B-DISEASE
death	I-DISEASE
in	O
childhood	O
.	O

Aberrant	B-UNK
subcellular	O
localization	B-UNK
of	O
BRCA1	B-UNK
in	O
breast	B-UNK
cancer	I-UNK
.	O

The	O
BRCA1	B-UNK
gene	B-UNK
product	I-UNK
was	O
identified	B-UNK
as	O
a	O
220-kilodalton	O
nuclear	B-UNK
phosphoprotein	O
in	O
normal	B-UNK
cells	B-UNK
,	O
including	O
breast	B-UNK
ductal	O
epithelial	B-UNK
cells	B-UNK
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B-UNK
cell	B-UNK
lines	I-UNK
derived	B-UNK
from	O
tissues	O
other	O
than	O
breast	B-UNK
and	O
ovary	O
.	O

In	O
16	O
of	O
17	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
lines	B-UNK
and	O
17	O
of	O
17	O
samples	B-UNK
of	O
cells	B-UNK
obtained	B-UNK
from	O
malignant	B-UNK
effusions	O
,	O
however	O
,	O
BRCA1	B-UNK
localized	B-UNK
mainly	O
in	O
cytoplasm	O
.	O

Absence	B-UNK
of	O
BRCA1	B-UNK
or	O
aberrant	B-UNK
subcellular	O
location	B-UNK
was	O
also	O
observed	B-UNK
to	O
a	O
variable	B-UNK
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B-UNK
cancer	I-UNK
biopsies	O
.	O

These	O
findings	B-UNK
suggest	B-UNK
that	O
BRCA1	B-UNK
abnormalities	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
many	O
breast	B-UNK
cancers	B-DISEASE
,	O
sporadic	B-UNK
as	O
well	O
as	O
familial	B-UNK
..	O

Mapping	B-UNK
of	O
the	O
mouse	B-UNK
homologue	B-UNK
of	O
the	O
Wilson	B-DISEASE
disease	I-DISEASE
gene	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
8	O
.	O

ATP7B	B-UNK
,	O
the	O
gene	B-UNK
altered	O
in	O
Wilson	B-UNK
disease	I-UNK
(	O
WD	O
)	O
patients	B-UNK
,	O
lies	O
in	O
a	O
block	O
of	O
homology	B-UNK
shared	O
between	O
human	B-UNK
chromosome	I-UNK
13q14	O
and	O
the	O
central	B-UNK
region	B-UNK
of	O
mouse	B-UNK
chromosome	I-UNK
14	O
.	O

However	O
,	O
we	O
have	O
mapped	B-UNK
the	O
murine	O
homologue	B-UNK
of	O
ATP7B	B-UNK
(	O
Atp7b	B-UNK
)	O
to	O
mouse	B-UNK
chromosome	I-UNK
8	O
by	O
somatic	B-UNK
cell	I-UNK
hybrid	O
analysis	B-UNK
.	O

Analysis	B-UNK
of	O
80	O
interspecific	O
backcross	O
offspring	O
was	O
used	O
to	O
position	B-UNK
Atp7b	B-UNK
close	B-UNK
to	O
D8Mit3	O
and	O
another	O
ATPase	O
locus	B-UNK
,	O
Atp4b	O
,	O
on	O
mouse	B-UNK
chromosome	I-UNK
8	O
.	O

ATP4B	O
lies	O
in	O
13q34	O
and	O
is	O
separated	O
from	O
ATP7B	B-UNK
by	O
several	O
loci	O
whose	O
mouse	B-UNK
homologues	O
map	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
14	O
.	O

The	O
assignment	B-UNK
of	O
Atp7b	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
8	O
identifies	O
a	O
previously	B-UNK
unrecognized	O
region	B-UNK
of	O
homology	B-UNK
between	O
this	O
chromosome	B-UNK
and	O
human	B-UNK
chromosome	I-UNK
13	O
.	O

This	O
assignment	B-UNK
suggests	O
a	O
possible	O
location	B-UNK
for	O
the	O
toxic	O
milk	B-UNK
mutation	B-UNK
in	O
the	O
mouse	B-UNK
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
homologue	B-UNK
of	O
WD	O
..	O

Germline	B-UNK
mutations	I-UNK
of	O
the	O
BRCA1	B-UNK
gene	B-UNK
in	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
families	B-UNK
provide	B-UNK
evidence	I-UNK
for	O
a	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlation	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
,	O
discovered	O
in	O
1994	O
,	O
are	O
associated	O
with	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	B-UNK
of	O
breast	B-UNK
cancer	I-UNK
.	O

We	O
have	O
analysed	O
60	O
families	B-UNK
with	O
a	O
history	B-UNK
of	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
for	O
germline	B-UNK
mutations	I-UNK
in	O
BRCA1	B-UNK
.	O

Twenty	O
-	O
two	O
different	O
mutations	B-UNK
were	O
detected	B-UNK
in	O
32	O
families	B-UNK
(	O
53	O
%	O
)	O
,	O
of	O
which	O
14	O
are	O
previously	B-UNK
unreported	O
.	O

We	O
observed	B-UNK
a	O
significant	B-UNK
correlation	B-UNK
between	O
the	O
location	B-UNK
of	O
the	O
mutation	B-UNK
in	O
the	O
gene	B-UNK
and	O
the	O
ratio	B-UNK
of	O
breast	B-UNK
to	O
ovarian	B-DISEASE
cancer	I-DISEASE
incidence	B-UNK
within	O
each	O
family	B-UNK
.	O

Our	O
data	B-UNK
suggest	B-UNK
a	O
transition	B-UNK
in	O
risk	B-UNK
such	O
that	O
mutations	B-UNK
in	O
the	O
3	O
third	O
of	O
the	O
gene	B-UNK
are	O
associated	O
with	O
a	O
lower	O
proportion	B-UNK
of	O
ovarian	B-UNK
cancer	I-UNK
.	O

Haplotype	B-UNK
analysis	I-UNK
supports	O
previous	B-UNK
data	B-UNK
which	O
suggest	B-UNK
some	O
BRCA1	B-UNK
mutation	B-UNK
carriers	B-UNK
have	O
common	B-UNK
ancestors	O
;	O
however	O
,	O
we	O
have	O
found	O
at	O
least	O
two	O
examples	O
where	O
recurrent	O
mutations	B-UNK
appear	O
to	O
have	O
arisen	O
independently	O
..	O

Hereditary	B-UNK
deficiency	B-UNK
of	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
and	O
recurrent	O
meningococcal	B-UNK
infection	B-DISEASE
:	O
investigations	O
of	O
an	O
Irish	B-UNK
family	B-UNK
using	O
a	O
novel	O
haemolytic	O
screening	B-UNK
assay	B-UNK
for	O
complement	B-UNK
activity	B-UNK
and	O
C7	B-UNK
M	O
/	O
N	O
allotyping	O
.	O

Terminal	B-UNK
complement	B-UNK
component	B-UNK
deficiency	B-UNK
predisposes	O
to	O
meningococcal	B-UNK
infection	B-UNK
and	O
is	O
inherited	B-UNK
in	O
an	O
autosomal	B-UNK
co-dominant	O
manner	O
.	O

An	O
Irish	B-UNK
family	B-UNK
is	O
described	O
,	O
in	O
which	O
2	O
of	O
3	O
brothers	O
had	O
recurrent	O
meningococcal	B-UNK
infection	B-DISEASE
.	O

A	O
novel	O
screening	B-UNK
assay	B-UNK
was	O
used	O
to	O
investigate	B-UNK
for	O
terminal	B-UNK
complement	B-UNK
deficiency	B-UNK
and	O
the	O
2	O
affected	B-UNK
brothers	O
were	O
found	O
to	O
be	O
completely	O
deficient	B-UNK
in	O
the	O
seventh	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C7	B-UNK
)	O
.	O

Enzyme	B-UNK
-	O
linked	B-UNK
immunosorbent	O
assay	B-UNK
for	O
C7	B-UNK
revealed	B-UNK
lower	O
than	O
normal	B-UNK
levels	B-UNK
in	O
the	O
remaining	O
brother	B-UNK
and	O
parents	O
.	O

C7	B-UNK
M	O
/	O
N	O
protein	B-UNK
polymorphism	B-UNK
allotyping	O
,	O
used	O
to	O
investigate	B-UNK
the	O
segregation	B-UNK
of	O
the	O
C7	B-UNK
deficiency	I-UNK
genes	B-UNK
,	O
showed	O
that	O
the	O
apparently	O
complement	B-UNK
sufficient	O
brother	B-UNK
was	O
heterozygous	B-UNK
C7	B-UNK
deficient	B-UNK
and	O
a	O
carrier	B-UNK
of	O
one	O
of	O
the	O
deficiency	B-UNK
genes	B-UNK
.	O

Complement	B-UNK
screening	B-UNK
should	O
be	O
carried	O
out	O
in	O
any	O
individual	O
suffering	O
recurrent	O
meningococcal	B-UNK
infection	B-DISEASE
or	O
infection	B-DISEASE
with	O
an	O
uncommon	O
meningococcal	B-UNK
serogroup	O
.	O

Identification	B-UNK
of	O
complement	B-UNK
deficient	B-UNK
patients	B-UNK
allows	O
the	O
implementation	O
of	O
strategies	O
to	O
prevent	O
recurrent	O
infection	B-UNK
..	O

Molecular	B-UNK
basis	I-UNK
of	O
subtotal	O
complement	B-UNK
C6	B-UNK
deficiency	I-UNK
.	O

A	O
carboxy	O
-	O
terminally	O
truncated	O
but	O
functionally	O
active	B-UNK
C6	B-UNK
.	O

Individuals	B-UNK
with	O
subtotal	O
complement	B-UNK
C6	B-UNK
deficiency	I-UNK
possess	O
a	O
C6	B-UNK
molecule	O
that	O
is	O
14	O
%	O
shorter	O
than	O
normal	B-UNK
C6	B-UNK
and	O
present	B-UNK
in	O
low	B-UNK
but	O
detectable	O
concentrations	O
(	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	B-UNK
mean	O
)	O
.	O

We	O
now	O
show	O
that	O
this	O
dysmorphic	O
C6	B-UNK
is	O
bactericidally	O
active	B-UNK
and	O
lacks	O
an	O
epitope	O
that	O
was	O
mapped	B-UNK
to	O
the	O
most	O
carboxy	O
-	O
terminal	B-UNK
part	O
of	O
C6	B-UNK
using	O
C6	B-UNK
cDNA	O
fragments	O
expressed	B-UNK
as	O
fusion	B-UNK
proteins	B-UNK
in	O
the	O
pUEX	O
expression	B-UNK
system	O
.	O

We	O
thus	O
predicted	B-UNK
that	O
the	O
abnormal	O
C6	B-UNK
molecule	O
might	O
be	O
carboxy	O
-	O
terminally	O
truncated	O
and	O
sought	O
a	O
mutation	B-UNK
in	O
an	O
area	B-UNK
approximately	O
14	O
%	O
from	O
the	O
carboxy	O
-	O
terminal	B-UNK
end	B-UNK
of	O
the	O
coding	B-UNK
sequence	I-UNK
.	O

By	O
sequencing	B-UNK
PCR	B-UNK
-	O
amplified	O
products	B-UNK
from	O
this	O
region	B-UNK
,	O
we	O
found	O
,	O
in	O
three	O
individuals	B-UNK
from	O
two	O
families	B-UNK
,	O
a	O
mutation	B-UNK
that	O
might	O
plausibly	O
be	O
responsible	B-UNK
for	O
the	O
defect	B-UNK
.	O

All	O
three	O
have	O
an	O
abnormal	O
5	O
splice	B-UNK
donor	I-UNK
site	I-UNK
of	O
intron	B-UNK
15	O
,	O
which	O
would	O
probably	O
prevent	O
splicing	B-UNK
.	O

An	O
in	O
-	O
frame	B-UNK
stop	B-UNK
codon	I-UNK
is	O
found	O
17	O
codons	O
downstream	O
from	O
the	O
intron	B-UNK
boundary	O
,	O
which	O
would	O
lead	B-UNK
to	O
a	O
truncated	O
polypeptide	O
13	O
.	O

5	O
%	O
smaller	O
than	O
normal	B-UNK
C6	B-UNK
.	O

This	O
result	B-UNK
was	O
unexpected	O
,	O
as	O
earlier	O
studies	B-UNK
mapped	B-UNK
the	O
C5b	O
binding	B-UNK
site	B-UNK
,	O
or	O
a	O
putative	O
enzymatic	B-UNK
region	B-UNK
,	O
to	O
this	O
part	O
of	O
C6	B-UNK
.	O

Interestingly	B-UNK
,	O
all	O
three	O
subjects	B-UNK
were	O
probably	O
heterozygous	B-UNK
for	O
both	O
subtotal	O
C6	B-UNK
and	O
complete	O
C6	B-UNK
deficiency	I-UNK
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
:	O
evidence	B-UNK
for	O
a	O
possible	O
dominant	B-UNK
-	O
negative	B-UNK
RNA	B-UNK
mutation	B-UNK
.	O

The	O
trinucleotide	B-UNK
expansion	B-UNK
mutation	B-UNK
causing	I-UNK
myotonic	B-UNK
dystrophy	I-UNK
is	O
in	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
of	O
a	O
protein	B-UNK
kinase	I-UNK
gene	B-UNK
.	O

The	O
molecular	B-UNK
mechanisms	O
by	O
which	O
the	O
expanded	B-UNK
repeat	B-UNK
causes	O
the	O
clinically	O
variable	B-UNK
and	O
multisystemic	O
disease	B-DISEASE
,	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
,	O
are	O
not	O
understood	O
.	O

It	O
has	O
been	O
particularly	O
difficult	O
to	O
rationalize	O
the	O
dominant	B-UNK
inheritance	B-UNK
with	O
the	O
fact	B-UNK
that	O
the	O
expansion	B-UNK
mutation	B-UNK
lies	O
outside	O
of	O
the	O
protein	B-UNK
-	O
encoding	B-UNK
gene	B-UNK
elements	O
,	O
and	O
should	O
not	O
be	O
translated	O
into	O
protein	B-UNK
.	O

Here	O
we	O
use	O
muscle	B-UNK
biopsies	O
from	O
classical	O
adult	B-UNK
-	O
onset	B-UNK
myotonic	B-UNK
dystrophy	I-UNK
patients	B-UNK
to	O
study	B-UNK
the	O
accumulation	B-UNK
of	O
transcripts	O
from	O
both	O
the	O
normal	B-UNK
and	O
expanded	B-UNK
DM	B-UNK
kinase	I-UNK
genes	B-UNK
in	O
patient	B-UNK
muscle	B-UNK
,	O
and	O
compare	O
the	O
results	B-UNK
to	O
normal	B-UNK
and	O
myopathic	B-DISEASE
controls	O
.	O

We	O
found	O
relatively	O
small	O
decreases	O
of	O
DM	B-UNK
kinase	I-UNK
RNA	B-UNK
in	O
the	O
total	B-UNK
RNA	B-UNK
pool	O
from	O
muscle	B-UNK
;	O
however	O
,	O
these	O
reductions	O
were	O
not	O
disease	B-DISEASE
specific	B-UNK
.	O

Analysis	B-UNK
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	B-UNK
showed	O
dramatic	O
decreases	O
of	O
both	O
the	O
mutant	B-UNK
and	O
normal	B-UNK
DM	B-UNK
kinase	I-UNK
RNAs	O
,	O
and	O
these	O
changes	O
were	O
disease	B-DISEASE
-	O
specific	B-UNK
.	O

Our	O
findings	B-UNK
are	O
consistent	B-UNK
with	O
a	O
novel	O
molecular	B-UNK
pathogenetic	O
mechanism	B-UNK
for	O
myotonic	B-UNK
dystrophy	I-UNK
both	O
the	O
normal	B-UNK
and	O
expanded	B-UNK
DM	B-UNK
kinase	I-UNK
genes	B-UNK
are	O
transcribed	O
in	O
patient	B-UNK
muscle	B-UNK
,	O
but	O
the	O
abnormal	O
expansion	B-UNK
-	O
containing	O
RNA	B-UNK
has	O
a	O
dominant	B-UNK
effect	B-UNK
on	O
RNA	B-UNK
metabolism	B-UNK
by	O
preventing	O
the	O
accumulation	B-UNK
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	B-UNK
.	O

The	O
ability	B-UNK
of	O
the	O
expansion	B-UNK
mutation	B-UNK
to	O
alter	O
accumulation	B-UNK
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	B-UNK
in	O
trans	O
suggests	O
that	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
may	O
be	O
the	O
first	O
example	O
of	O
a	O
dominant	B-UNK
-	O
negative	B-UNK
mutation	B-UNK
manifested	O
at	O
the	O
RNA	B-UNK
level	B-UNK
..	O

A	O
strong	B-UNK
candidate	B-UNK
for	O
the	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
gene	I-UNK
BRCA1	B-UNK
.	O

A	O
strong	B-UNK
candidate	B-UNK
for	O
the	O
17q	O
-	O
linked	B-UNK
BRCA1	B-UNK
gene	B-UNK
,	O
which	O
influences	O
susceptibility	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
,	O
has	O
been	O
identified	B-UNK
by	O
positional	O
cloning	B-UNK
methods	O
.	O

Probable	O
predisposing	O
mutations	B-UNK
have	O
been	O
detected	B-UNK
in	O
five	O
of	O
eight	O
kindreds	O
presumed	O
to	O
segregate	O
BRCA1	B-UNK
susceptibility	B-UNK
alleles	B-UNK
.	O

The	O
mutations	B-UNK
include	O
an	O
11-base	O
pair	B-UNK
deletion	B-UNK
,	O
a	O
1-base	O
pair	B-UNK
insertion	O
,	O
a	O
stop	B-UNK
codon	I-UNK
,	O
a	O
missense	B-UNK
substitution	B-UNK
,	O
and	O
an	O
inferred	O
regulatory	O
mutation	B-UNK
.	O

The	O
BRCA1	B-UNK
gene	B-UNK
is	O
expressed	B-UNK
in	O
numerous	O
tissues	O
,	O
including	O
breast	B-UNK
and	O
ovary	O
,	O
and	O
encodes	B-UNK
a	O
predicted	B-UNK
protein	B-UNK
of	O
1863	O
amino	B-UNK
acids	I-UNK
.	O

This	O
protein	B-UNK
contains	O
a	O
zinc	B-UNK
finger	I-UNK
domain	B-UNK
in	O
its	O
amino	B-UNK
-	O
terminal	B-UNK
region	B-UNK
,	O
but	O
is	O
otherwise	O
unrelated	B-UNK
to	O
previously	B-UNK
described	O
proteins	B-UNK
.	O

Identification	B-UNK
of	O
BRCA1	B-UNK
should	O
facilitate	O
early	B-UNK
diagnosis	B-UNK
of	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
in	O
some	O
individuals	B-UNK
as	O
well	O
as	O
a	O
better	O
understanding	B-UNK
of	O
breast	B-UNK
cancer	I-UNK
biology	O
..	O

Molecular	B-UNK
characterization	B-UNK
of	O
galactosemia	O
(	O
type	B-UNK
1	O
)	O
mutations	B-UNK
in	O
Japanese	B-UNK
.	O

We	O
characterized	B-UNK
two	O
novel	O
mutations	B-UNK
of	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	B-UNK
)	O
gene	B-UNK
in	O
two	O
Japanese	B-UNK
patients	B-UNK
with	O
GALT	B-UNK
deficiency	B-UNK
and	O
identified	B-UNK
N314D	B-UNK
and	O
R333W	O
mutations	B-UNK
,	O
previously	B-UNK
found	O
in	O
Caucasians	B-UNK
.	O

One	O
novel	O
missense	B-UNK
mutation	I-UNK
was	O
an	O
G	O
-	O
to	O
-	O
A	O
transition	B-UNK
in	O
exon	B-UNK
8	O
,	O
resulting	B-UNK
in	O
the	O
substitution	B-UNK
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	B-UNK
231	O
(	O
R231H	O
)	O
.	O

GALT	B-UNK
activity	B-UNK
of	O
the	O
R231H	O
mutant	B-UNK
construct	O
was	O
reduced	O
to	O
15	O
%	O
of	O
normal	B-UNK
controls	O
in	O
a	O
COS	B-UNK
cell	B-UNK
expression	B-UNK
system	O
.	O

The	O
other	O
was	O
a	O
splicing	B-UNK
mutation	B-UNK
,	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	B-UNK
at	O
the	O
38th	O
nucleotide	B-UNK
in	O
exon	B-UNK
3	O
(	O
318A--	O
>	O
G	O
)	O
,	O
resulting	B-UNK
in	O
a	O
38-bp	O
deletion	B-UNK
in	O
the	O
GALT	B-UNK
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	B-UNK
acceptor	I-UNK
site	B-UNK
.	O

In	O
seven	O
Japanese	B-UNK
families	B-UNK
(	O
14	O
alleles	B-UNK
for	O
classic	B-UNK
form	B-UNK
and	O
one	O
allele	B-UNK
for	O
Duarte	B-UNK
variant	O
)	O
with	O
GALT	B-UNK
deficiency	B-UNK
,	O
the	O
R231H	O
and	O
318A--	O
>	O
G	O
mutations	B-UNK
were	O
found	O
only	O
on	O
both	O
alleles	B-UNK
of	O
the	O
proband	B-UNK
.	O

The	O
N314D	B-UNK
and	O
R333W	O
mutations	B-UNK
were	O
found	O
on	O
one	O
allele	B-UNK
each	O
.	O

The	O
Q188R	B-UNK
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	B-UNK
patients	B-UNK
.	O

The	O
N314D	B-UNK
mutation	B-UNK
was	O
associated	O
with	O
the	O
Duarte	B-UNK
variant	O
in	O
Japanese	B-UNK
persons	O
,	O
as	O
well	O
as	O
in	O
the	O
United	O
States	O
.	O

We	O
speculate	O
that	O
classic	B-UNK
galactosemia	O
mutations	B-UNK
appear	O
to	O
differ	O
between	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
patients	B-UNK
.	O

Our	O
limited	O
data	B-UNK
set	B-UNK
on	O
galactosemia	O
mutations	B-UNK
in	O
Japanese	B-UNK
suggests	O
that	O
the	O
N314D	B-UNK
GALT	B-UNK
mutation	B-UNK
encoding	B-UNK
the	O
Duarte	B-UNK
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	B-UNK
people	O
diverged	O
and	O
that	O
classic	B-UNK
galactosemia	O
mutations	B-UNK
arose	O
and	O
/	O
or	O
accumulated	O
after	O
the	O
divergence	O
of	O
Asian	O
and	O
Caucasian	B-UNK
populations	O
..	O

Three	O
novel	O
aniridia	B-DISEASE
mutations	B-UNK
in	O
the	O
human	B-UNK
PAX6	B-UNK
gene	B-UNK
.	O

Aniridia	B-DISEASE
(	O
iris	O
hypoplasia	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
dominant	I-UNK
congenital	B-DISEASE
disorder	I-DISEASE
of	O
the	O
eye	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
human	B-UNK
aniridia	B-DISEASE
(	O
PAX6	B-UNK
)	O
gene	B-UNK
have	O
now	O
been	O
identified	B-UNK
in	O
many	O
patients	B-UNK
from	O
various	O
ethnic	B-UNK
groups	I-UNK
.	O

In	O
the	O
study	B-UNK
reported	B-UNK
here	O
we	O
describe	O
PAX6	B-UNK
mutations	B-UNK
in	O
one	O
sporadic	B-UNK
and	O
five	O
familial	B-UNK
cases	I-UNK
with	O
aniridia	B-DISEASE
.	O

Of	O
the	O
four	O
different	O
mutations	B-UNK
identified	B-UNK
,	O
one	O
was	O
identical	B-UNK
to	O
a	O
previously	B-UNK
reported	I-UNK
mutation	B-UNK
(	O
C--	O
>	O
T	O
transition	B-UNK
at	O
codon	B-UNK
240	O
)	O
,	O
and	O
three	O
were	O
novel	O
two	O
in	O
the	O
glycine	O
-	O
rich	O
region	B-UNK
and	O
one	O
in	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
(	O
PST	O
)	O
region	B-UNK
.	O

One	O
PAX6	B-UNK
mutation	B-UNK
found	O
in	O
the	O
PST	O
region	B-UNK
was	O
associated	O
with	O
cataracts	B-DISEASE
in	O
an	O
aniridia	B-DISEASE
family	B-UNK
.	O

Another	O
splice	B-UNK
mutation	B-UNK
in	O
the	O
PST	O
domain	B-UNK
occurred	B-UNK
in	O
an	O
aniridia	B-DISEASE
patient	B-UNK
with	O
anosmia	B-DISEASE
(	O
inability	O
to	O
smell	O
)	O
.	O

The	O
six	O
new	O
aniridia	B-DISEASE
cases	B-UNK
reported	B-UNK
here	O
have	O
mutations	B-UNK
predicted	B-UNK
to	O
generate	O
incomplete	O
PAX6	B-UNK
proteins	B-UNK
.	O

These	O
results	B-UNK
support	O
the	O
theory	O
that	O
human	B-UNK
aniridia	B-DISEASE
is	O
caused	B-UNK
by	O
haploinsufficiency	O
of	O
PAX6	B-UNK
..	O

The	O
carrier	B-UNK
frequency	I-UNK
of	O
the	O
BRCA1	B-UNK
185delAG	O
mutation	B-UNK
is	O
approximately	O
1	O
percent	B-UNK
in	O
Ashkenazi	B-UNK
Jewish	I-UNK
individuals	B-UNK
.	O

Since	O
BRCA1	B-UNK
,	O
the	O
first	O
major	B-UNK
gene	B-UNK
responsible	B-UNK
for	O
inherited	B-UNK
breast	B-UNK
cancer	I-UNK
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	B-UNK
have	O
been	O
detected	B-UNK
in	O
the	O
germline	B-UNK
of	O
individuals	B-UNK
with	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
.	O

In	O
high	B-UNK
-	O
risk	B-UNK
pedigrees	O
,	O
female	O
carriers	B-UNK
of	O
BRCA1	B-UNK
mutations	B-UNK
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	B-UNK
of	O
ovarian	B-UNK
cancer	I-UNK
.	O

However	O
,	O
the	O
mutation	B-UNK
stats	O
of	O
individuals	B-UNK
unselected	O
for	O
breast	B-UNK
or	O
ovarian	B-UNK
cancer	I-UNK
has	O
not	O
been	O
determined	B-UNK
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	B-UNK
in	O
such	O
individuals	B-UNK
confer	O
the	O
same	O
risk	B-UNK
of	O
cancer	B-DISEASE
as	O
in	O
individuals	B-UNK
from	O
the	O
high	B-UNK
-	O
risk	B-UNK
families	B-UNK
studied	O
so	O
far	O
.	O

Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	B-UNK
mutation	I-UNK
in	O
several	O
Ashkenazi	B-UNK
Jewish	I-UNK
breast	B-UNK
/	O
ovarian	B-UNK
families	B-UNK
,	O
we	O
have	O
determined	B-UNK
the	O
frequency	B-UNK
of	O
this	O
mutation	B-UNK
in	O
858	O
Ashkenazim	O
seeking	O
genetic	B-UNK
testing	B-UNK
for	O
conditions	O
unrelated	B-UNK
to	O
cancer	B-UNK
,	O
and	O
in	O
815	O
reference	O
individuals	B-UNK
not	O
selected	O
for	O
ethnic	B-UNK
origin	O
.	O

We	O
observed	B-UNK
the	O
185delAG	O
mutation	B-UNK
in	O
0	O
.	O

9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	B-UNK
.	O

Our	O
results	B-UNK
suggest	B-UNK
that	O
one	O
in	O
a	O
hundred	O
women	B-UNK
of	O
Ashkenazi	B-UNK
descent	O
may	O
be	O
at	O
especially	O
high	B-UNK
risk	I-UNK
of	O
developing	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
.	O

Identification	B-UNK
and	O
localization	B-UNK
of	O
huntingtin	O
in	O
brain	B-UNK
and	O
human	B-UNK
lymphoblastoid	O
cell	B-UNK
lines	I-UNK
with	O
anti-fusion	O
protein	B-UNK
antibodies	B-UNK
.	O

The	O
Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
phenotype	B-UNK
is	O
associated	O
with	O
expansion	B-UNK
of	O
a	O
trinucleotide	B-UNK
repeat	I-UNK
in	O
the	O
IT15	O
gene	B-UNK
,	O
which	O
is	O
predicted	B-UNK
to	O
encode	O
a	O
348-kDa	O
protein	B-UNK
named	O
huntington	B-UNK
.	O

We	O
used	O
polyclonal	O
and	O
monoclonal	O
anti-fusion	O
protein	B-UNK
antibodies	B-UNK
to	O
identify	B-UNK
native	O
huntingtin	O
in	O
rat	O
,	O
monkey	O
,	O
and	O
human	B-UNK
.	O

Western	B-UNK
blots	O
revealed	B-UNK
a	O
protein	B-UNK
with	O
the	O
expected	O
molecular	B-UNK
weight	O
which	O
is	O
present	B-UNK
in	O
the	O
soluble	O
fraction	B-UNK
of	O
rat	O
and	O
monkey	O
brain	B-UNK
tissues	O
and	O
lymphoblastoid	O
cells	B-UNK
from	O
control	B-UNK
cases	B-UNK
.	O

In	O
lymphoblastoid	O
cell	B-UNK
lines	I-UNK
from	O
juvenile	O
-	O
onset	B-UNK
heterozygote	B-UNK
HD	B-UNK
cases	B-UNK
,	O
both	O
normal	B-UNK
and	O
mutant	B-UNK
huntingtin	O
are	O
expressed	B-UNK
,	O
and	O
increasing	O
repeat	B-UNK
expansion	I-UNK
leads	B-UNK
to	O
lower	O
levels	B-UNK
of	O
the	O
mutant	B-UNK
protein	B-UNK
.	O

Immunocytochemistry	O
indicates	O
that	O
huntingtin	O
is	O
located	B-UNK
in	O
neurons	O
throughout	O
the	O
brain	B-UNK
,	O
with	O
the	O
highest	O
levels	B-UNK
evident	O
in	O
larger	O
neurons	O
.	O

In	O
the	O
human	B-UNK
striatum	O
,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch	O
-	O
like	O
distribution	B-UNK
,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	B-UNK
in	O
HD	B-UNK
.	O

Subcellular	O
localization	B-UNK
of	O
huntingtin	O
is	O
consistent	B-UNK
with	O
a	O
cytosolic	O
protein	B-UNK
primarily	O
found	O
in	O
somatodendritic	O
regions	B-UNK
.	O

Huntingtin	O
appears	B-UNK
to	O
particularly	O
associate	O
with	O
microtubules	O
,	O
although	O
some	O
is	O
also	O
associated	O
with	O
synaptic	O
vesicles	O
.	O

On	O
the	O
basis	B-UNK
of	O
the	O
localization	B-UNK
of	O
huntingtin	O
in	O
association	B-UNK
with	O
microtubules	O
,	O
we	O
speculate	O
that	O
the	O
mutation	B-UNK
impairs	O
the	O
cytoskeletal	O
anchoring	O
or	O
transport	B-UNK
of	O
mitochondria	O
,	O
vesicles	O
,	O
or	O
other	O
organelles	O
or	O
molecules	O
..	O

Marked	B-UNK
phenotypic	B-UNK
heterogeneity	B-UNK
associated	O
with	O
expansion	B-UNK
of	O
a	O
CAG	B-UNK
repeat	I-UNK
sequence	B-UNK
at	O
the	O
spinocerebellar	O
ataxia	B-DISEASE
3	O
/	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
locus	B-UNK
.	O

The	O
spinocerebellar	O
ataxia	B-UNK
3	O
locus	B-UNK
(	O
SCA3	B-UNK
)	O
for	O
type	B-UNK
I	O
autosomal	B-UNK
dominant	I-UNK
cerebellar	B-DISEASE
ataxia	I-DISEASE
(	O
ADCA	O
type	B-UNK
I	O
)	O
,	O
a	O
clinically	O
and	O
genetically	B-UNK
heterogeneous	O
group	B-UNK
of	O
neurodegenerative	B-DISEASE
disorders	I-DISEASE
,	O
has	O
been	O
mapped	B-UNK
to	O
chromosome	B-UNK
14q32	O
.	O

1	O
1	O
.	O

ADCA	O
type	B-UNK
I	O
patients	B-UNK
from	O
families	B-UNK
segregating	O
SCA3	B-UNK
share	O
clinical	B-UNK
features	I-UNK
in	O
common	B-UNK
with	O
those	O
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
,	O
the	O
gene	B-UNK
of	O
which	O
maps	B-UNK
to	O
the	O
same	O
region	B-UNK
.	O

We	O
show	O
here	O
that	O
the	O
disease	B-DISEASE
gene	B-UNK
segregating	O
in	O
each	O
of	O
three	O
French	B-UNK
ADCA	O
type	B-UNK
I	O
kindreds	O
and	O
in	O
a	O
French	B-UNK
family	B-UNK
with	O
neuropathological	O
findings	B-UNK
suggesting	O
the	O
ataxochoreic	O
form	B-UNK
of	O
dentatorubropallidoluysian	O
atrophy	B-DISEASE
carries	O
an	O
expanded	B-UNK
CAG	B-UNK
repeat	I-UNK
sequence	B-UNK
located	B-UNK
at	O
the	O
same	O
locus	B-UNK
as	O
that	O
for	O
MJD	B-UNK
.	O

Analysis	B-UNK
of	O
the	O
mutation	B-UNK
in	O
these	O
families	B-UNK
shows	O
a	O
strong	B-UNK
negative	B-UNK
correlation	B-UNK
between	O
size	B-UNK
of	O
the	O
expanded	B-UNK
CAG	B-UNK
repeat	I-UNK
and	O
age	B-UNK
at	O
onset	B-UNK
of	O
clinical	B-UNK
disease	B-DISEASE
.	O

Instability	B-UNK
of	O
the	O
expanded	B-UNK
triplet	O
repeat	B-UNK
was	O
not	O
found	O
to	O
be	O
affected	B-UNK
by	O
sex	B-UNK
of	O
the	O
parent	O
transmitting	O
the	O
mutation	B-UNK
.	O

Evidence	B-UNK
was	O
found	O
for	O
somatic	B-UNK
and	O
gonadal	O
mosaicism	O
for	O
alleles	B-UNK
carrying	B-UNK
expanded	B-UNK
trinucleotide	B-UNK
repeats	B-UNK
.	O

Overexpression	B-UNK
of	O
DM20	O
messenger	B-UNK
RNA	I-UNK
in	O
two	O
brothers	O
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
.	O

Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
is	O
a	O
rare	B-UNK
,	O
sex	B-UNK
-	O
linked	B-UNK
recessive	B-UNK
,	O
dysmyelinating	O
disease	B-DISEASE
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
that	O
has	O
been	O
associated	O
with	O
mutations	B-UNK
in	O
the	O
myelin	B-UNK
proteolipid	B-UNK
protein	I-UNK
(	O
PLP	B-UNK
)	O
gene	B-UNK
.	O

Only	O
25	O
%	O
of	O
patients	B-UNK
studied	O
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
have	O
exonic	O
mutations	B-UNK
in	O
this	O
gene	B-UNK
,	O
the	O
underlying	O
cause	O
of	O
the	O
disease	B-DISEASE
in	O
the	O
remaining	O
patients	B-UNK
is	O
unknown	O
.	O

The	O
PLP	B-UNK
gene	B-UNK
encodes	B-UNK
two	O
major	B-UNK
alternatively	O
spliced	O
transcripts	O
called	O
PLP	B-UNK
and	O
DM20	O
.	O

PLP	B-UNK
messenger	B-UNK
RNA	I-UNK
is	O
specifically	B-UNK
expressed	B-UNK
in	O
central	B-UNK
nervous	I-UNK
system	I-UNK
tissue	B-UNK
,	O
whereas	O
DM20	O
messenger	B-UNK
RNA	I-UNK
is	O
found	O
in	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
cardiac	B-UNK
,	O
and	O
other	O
tissues	O
.	O

We	O
studied	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
from	O
2	O
brothers	O
with	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
who	O
exhibited	O
no	O
detectable	O
exonic	O
mutation	B-UNK
of	O
the	O
PLP	B-UNK
gene	B-UNK
.	O

Examination	B-UNK
of	O
RNA	B-UNK
from	O
these	O
cells	B-UNK
showed	O
that	O
the	O
level	B-UNK
of	O
DM20	O
messenger	B-UNK
RNA	I-UNK
is	O
elevated	B-UNK
sixfold	O
relative	B-UNK
to	O
male	B-UNK
control	B-UNK
skin	B-UNK
fibroblasts	I-UNK
.	O

An	O
unrelated	B-UNK
female	O
carrier	B-UNK
,	O
also	O
with	O
no	O
detectable	O
exonic	O
mutation	B-UNK
,	O
showed	O
a	O
threefold	O
increase	B-UNK
in	O
DM20	O
messenger	B-UNK
RNA	I-UNK
in	O
cultured	O
skin	B-UNK
fibroblasts	I-UNK
.	O

Our	O
findings	B-UNK
suggest	B-UNK
that	O
in	O
some	O
patients	B-UNK
,	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
is	O
caused	B-UNK
by	O
overexpression	B-UNK
of	O
PLP	B-UNK
gene	B-UNK
transcripts	O
,	O
and	O
that	O
in	O
these	O
families	B-UNK
a	O
50	O
%	O
increase	B-UNK
of	O
DM20	O
messenger	B-UNK
RNA	I-UNK
in	O
females	O
,	O
relative	B-UNK
to	O
the	O
increase	B-UNK
in	O
affected	B-UNK
males	I-UNK
,	O
can	O
identify	B-UNK
a	O
female	O
carrier	B-UNK
..	O

The	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
and	O
X	O
-	O
linked	B-UNK
congenital	B-UNK
thrombocytopenia	B-DISEASE
are	O
caused	B-UNK
by	O
mutations	B-UNK
of	O
the	O
same	O
gene	B-UNK
.	O

The	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
recessive	B-UNK
disorder	B-UNK
characterized	B-UNK
by	O
thrombocytopenia	B-DISEASE
,	O
small	O
platelets	O
,	O
eczema	B-DISEASE
,	O
recurrent	O
infections	B-DISEASE
,	O
and	O
immunodeficiency	B-UNK
.	O

Besides	O
the	O
classic	B-UNK
WAS	O
phenotype	B-UNK
,	O
there	O
is	O
a	O
group	B-UNK
of	O
patients	B-UNK
with	O
congenital	B-UNK
X	O
-	O
linked	B-UNK
thrombocytopenia	B-DISEASE
(	O
XLT	O
)	O
who	O
have	O
small	O
platelets	O
but	O
only	O
transient	O
eczema	B-DISEASE
,	O
if	O
any	O
,	O
and	O
minimal	O
immune	B-UNK
deficiency	B-UNK
.	O

Because	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
WAS	O
has	O
been	O
sequenced	O
,	O
it	O
was	O
possible	O
to	O
correlate	O
the	O
WAS	O
phenotypes	O
with	O
WAS	O
gene	B-UNK
mutations	B-UNK
.	O

Using	O
a	O
fingerprinting	O
screening	B-UNK
technique	O
,	O
we	O
determined	B-UNK
the	O
approximate	O
location	B-UNK
of	O
the	O
mutation	B-UNK
in	O
13	O
unrelated	B-UNK
WAS	O
patients	B-UNK
with	O
mild	O
to	O
severe	B-UNK
clinical	B-UNK
symptoms	B-UNK
.	O

Direct	B-UNK
sequence	B-UNK
analysis	I-UNK
of	O
cDNA	O
and	O
genomic	B-UNK
DNA	I-UNK
obtained	B-UNK
from	O
patient	B-UNK
-	O
derived	B-UNK
cell	B-UNK
lines	I-UNK
showed	O
12	O
unique	O
mutations	B-UNK
distributed	O
throughout	O
the	O
WAS	O
gene	B-UNK
,	O
including	O
insertions	O
,	O
deletions	O
,	O
and	O
point	B-UNK
mutations	I-UNK
resulting	B-UNK
in	O
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
,	O
termination	B-UNK
,	O
exon	B-UNK
skipping	O
,	O
or	O
splicing	B-UNK
defects	B-UNK
.	O

Of	O
4	O
unrelated	B-UNK
patients	B-UNK
with	O
the	O
XLT	O
phenotype	B-UNK
,	O
3	O
had	O
missense	B-UNK
mutations	I-UNK
affecting	O
exon	B-UNK
2	O
and	O
1	O
had	O
a	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
affecting	O
exon	B-UNK
9	O
.	O

Patients	B-UNK
with	O
classic	B-UNK
WAS	O
had	O
more	O
complex	O
mutations	B-UNK
,	O
resulting	B-UNK
in	O
termination	B-UNK
codons	O
,	O
frameshift	B-UNK
,	O
and	O
early	B-UNK
termination	B-UNK
.	O

These	O
findings	B-UNK
provide	B-UNK
direct	B-UNK
evidence	B-UNK
that	O
XLT	O
and	O
WAS	O
are	O
caused	B-UNK
by	O
mutations	B-UNK
of	O
the	O
same	O
gene	B-UNK
and	O
suggest	B-UNK
that	O
severe	B-UNK
clinical	B-UNK
phenotypes	O
are	O
associated	O
with	O
complex	O
mutations	B-UNK
..	O

Myotonia	B-UNK
levior	O
is	O
a	O
chloride	B-UNK
channel	B-UNK
disorder	B-UNK
.	O

The	O
group	B-UNK
of	O
dominant	B-UNK
non-dystrophic	O
myotonias	O
,	O
comprising	O
disorders	B-UNK
characterized	B-UNK
by	O
clinically	O
similar	B-UNK
forms	B-UNK
of	O
myogenic	O
muscle	B-UNK
stiffness	O
,	O
is	O
genetically	B-UNK
inhomogeneous	O
.	O

Dominant	B-UNK
myotonia	B-DISEASE
congenita	I-DISEASE
(	O
Thomsens	O
disease	B-DISEASE
)	O
is	O
linked	B-UNK
to	O
CLCN1	O
,	O
the	O
gene	B-UNK
encoding	B-UNK
the	O
major	B-UNK
muscle	B-UNK
chloride	B-UNK
channel	B-UNK
,	O
localized	B-UNK
on	O
chromosome	B-UNK
7q35	O
.	O

In	O
contrast	B-UNK
,	O
dominant	B-UNK
myotonias	O
sensitive	B-UNK
to	O
potassium	O
are	O
caused	B-UNK
by	O
point	B-UNK
mutations	I-UNK
in	O
SCN4A	O
on	O
chromosome	B-UNK
17q	O
,	O
the	O
gene	B-UNK
for	O
the	O
alpha	B-UNK
subunit	I-UNK
of	O
the	O
adult	B-UNK
skeletal	B-UNK
muscle	I-UNK
sodium	B-UNK
channel	B-UNK
.	O

No	O
linkage	B-UNK
or	O
molecular	B-UNK
genetic	I-UNK
data	B-UNK
are	O
as	O
yet	O
available	O
on	O
myotonia	B-DISEASE
levior	O
characterized	B-UNK
by	O
milder	B-UNK
symptoms	B-UNK
and	O
later	O
onset	B-UNK
of	O
myotonia	B-UNK
than	O
in	O
Thomsens	O
disease	B-UNK
,	O
and	O
absence	B-UNK
of	O
muscle	B-DISEASE
hypertrophy	I-DISEASE
.	O

We	O
report	B-UNK
a	O
CLCN1	O
Gln-552-Arg	O
substitution	B-UNK
for	O
a	O
family	B-UNK
with	O
dominant	B-UNK
inheritance	B-UNK
previously	B-UNK
diagnosed	O
to	O
have	O
myotonia	B-UNK
levior	O
.	O

Thus	O
,	O
this	O
disorder	B-UNK
appears	B-UNK
as	O
a	O
variant	O
of	O
Thomsens	O
disease	B-UNK
due	O
to	O
mutations	B-UNK
leading	B-UNK
to	O
low	B-UNK
clinical	B-UNK
expressivity	O
.	O

In	O
addition	B-UNK
,	O
we	O
report	B-UNK
a	O
novel	O
Ile-290-Met	O
CLCN1	O
mutation	B-UNK
for	O
a	O
typical	O
Thomsen	O
pedigree	B-UNK
.	O

In	O
another	O
family	B-UNK
previously	B-UNK
diagnosed	O
as	O
having	O
Thomsens	O
disease	B-DISEASE
,	O
we	O
unexpectedly	O
found	O
a	O
CLCN1	O
14	O
bp	B-UNK
deletion	I-UNK
known	O
to	O
cause	O
recessive	B-UNK
myotonia	B-UNK
,	O
and	O
a	O
rare	B-UNK
Trp-118-Gly	O
polymorphism	B-UNK
..	O

Southern	B-UNK
analysis	B-UNK
reveals	O
a	O
large	B-UNK
deletion	B-UNK
at	O
the	O
hypoxanthine	B-UNK
phosphoribosyltransferase	O
locus	B-UNK
in	O
a	O
patient	B-UNK
with	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

Whole	O
genomic	B-UNK
hprt	B-UNK
clones	O
were	O
used	O
in	O
Southern	B-UNK
analysis	B-UNK
to	O
screen	B-UNK
the	O
integrity	O
of	O
the	O
hprt	B-UNK
gene	B-UNK
in	O
a	O
family	B-UNK
that	O
includes	O
a	O
patient	B-UNK
with	O
HPRT	B-UNK
enzyme	B-UNK
deficiency	I-UNK
causal	O
to	O
Lesch	B-DISEASE
-	I-DISEASE
Nyhan	I-DISEASE
syndrome	I-DISEASE
.	O

A	O
5	O
kb	B-UNK
DNA	B-UNK
sequence	I-UNK
deletion	B-UNK
was	O
found	O
to	O
have	O
its	O
endpoints	O
in	O
the	O
first	O
and	O
third	O
introns	O
.	O

The	O
probes	O
identified	B-UNK
the	O
carrier	B-UNK
status	I-UNK
of	O
female	O
family	B-UNK
members	I-UNK
,	O
aided	O
by	O
an	O
RFLP	B-UNK
carried	O
by	O
the	O
mothers	O
normal	B-UNK
X	O
-	O
chromosome	B-UNK
..	O

Characterisation	O
of	O
molecular	B-UNK
defects	B-UNK
in	O
X	O
-	O
linked	B-UNK
amelogenesis	B-DISEASE
imperfecta	I-DISEASE
(	O
AIH1	O
)	O
.	O

Amelogenins	O
are	O
an	O
heterogenous	O
family	B-UNK
of	O
proteins	B-UNK
produced	O
by	O
ameloblasts	O
of	O
the	O
enamel	O
organ	O
during	O
tooth	O
development	B-UNK
.	O

Disturbances	O
of	O
enamel	O
formation	B-UNK
occur	B-UNK
in	O
amelogenesis	B-DISEASE
imperfecta	I-DISEASE
,	O
a	O
clinically	O
heterogenous	O
group	B-UNK
of	O
inherited	B-UNK
disorders	B-UNK
characterised	O
by	O
defective	O
enamel	O
biomineralisation	O
.	O

An	O
amelogenin	O
gene	B-UNK
,	O
AMGX	O
,	O
has	O
been	O
mapped	B-UNK
to	O
the	O
short	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
(	O
Xp22	O
.	O
1-p22	O
.	O
3	O
)	O
and	O
has	O
been	O
implicated	B-UNK
in	O
the	O
molecular	B-UNK
pathology	O
of	O
X	O
-	O
linked	B-UNK
amelogenesis	B-DISEASE
imperfecta	I-DISEASE
(	O
AIH1	O
)	O
.	O

We	O
have	O
identified	B-UNK
three	O
families	B-UNK
exhibiting	O
AIH1	O
and	O
screened	B-UNK
the	O
AMGX	O
gene	B-UNK
for	O
mutations	B-UNK
using	O
single	B-UNK
-	O
strand	B-UNK
conformational	B-UNK
polymorphism	B-UNK
analysis	B-UNK
and	O
DNA	B-UNK
sequencing	I-UNK
.	O

Three	O
novel	O
mutations	B-UNK
were	O
identified	B-UNK
a	O
C	O
-T	O
substitution	B-UNK
in	O
exon	B-UNK
5	O
,	O
and	O
a	O
G	O
-T	O
substitution	B-UNK
and	O
single	B-UNK
cytosine	O
deletion	B-UNK
in	O
exon	B-UNK
6	O
,	O
confirming	O
the	O
existence	O
of	O
extensive	B-UNK
allelic	O
heterogeneity	B-UNK
in	O
this	O
condition	B-UNK
.	O

The	O
identification	B-UNK
of	O
family	B-UNK
-	O
specific	B-UNK
mutations	B-UNK
will	O
enable	O
early	B-UNK
identification	B-UNK
of	O
affected	B-UNK
individuals	I-UNK
and	O
correlation	B-UNK
of	O
clinical	B-UNK
phenotype	B-UNK
with	O
genotype	B-UNK
will	O
facilitate	O
an	O
objective	B-UNK
system	O
of	O
disease	B-UNK
classification	O
.	O

Frequency	B-UNK
of	O
exon	B-UNK
15	O
missense	B-UNK
mutation	I-UNK
(	O
442D	O
:	O
G	O
)	O
in	O
cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
gene	B-UNK
in	O
hyperalphalipoproteinemic	O
Japanese	B-UNK
subjects	B-UNK
.	O

Cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
(	O
CETP	B-UNK
)	O
transfers	O
cholesteryl	B-UNK
ester	I-UNK
from	O
high	B-UNK
density	I-UNK
lipoprotein	B-UNK
(	O
HDL	B-UNK
)	O
to	O
apo	O
B	O
-	O
containing	O
lipoproteins	O
.	O

The	O
hyperalphalipoproteinemia	O
caused	B-UNK
by	O
CETP	B-UNK
deficiency	I-UNK
is	O
fairly	O
common	B-UNK
in	O
Japan	B-UNK
and	O
one	O
of	O
the	O
most	O
common	B-UNK
mutations	B-UNK
in	O
the	O
CETP	B-UNK
gene	B-UNK
is	O
the	O
splicing	B-UNK
defect	B-UNK
of	O
the	O
intron	B-UNK
14	O
,	O
the	O
allelic	O
frequency	B-UNK
of	O
which	O
has	O
been	O
shown	B-UNK
to	O
be	O
0	O
.	O

0049	O
in	O
the	O
Japanese	B-UNK
general	B-UNK
population	B-UNK
.	O

Recently	O
,	O
we	O
have	O
reported	B-UNK
a	O
missense	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
15	O
of	O
the	O
CETP	B-UNK
gene	B-UNK
(	O
442D	O
G	O
)	O
,	O
showing	O
a	O
dominant	B-UNK
effect	B-UNK
on	O
the	O
CETP	B-UNK
activity	B-UNK
and	O
HDL	B-UNK
-	O
cholesterol	B-UNK
level	B-UNK
.	O

In	O
the	O
current	B-UNK
study	B-UNK
,	O
we	O
determined	B-UNK
the	O
frequency	B-UNK
of	O
this	O
new	O
mutation	B-UNK
in	O
Japanese	B-UNK
hyperalphalipoproteinemic	O
(	O
HDL	B-UNK
-	O
cholesterol	B-UNK
>	O
or	O
=	O
100	O
mg	B-UNK
/	O
dl	O
)	O
subjects	B-UNK
.	O

A	O
rapid	O
and	O
easy	O
screening	B-UNK
method	O
for	O
this	O
new	O
mutation	B-UNK
was	O
developed	O
using	O
a	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR)-mediated	O
site	B-UNK
-	O
directed	O
mutagenesis	O
.	O

Among	O
117	O
Japanese	B-UNK
hyperalphalipoproteinemic	O
subjects	B-UNK
(	O
HDL	B-UNK
-	O
cholesterol	B-UNK
;	O
116	O
.	O
7	O
+	O
/-16	O
.	O
5	O
mg	B-UNK
/	O
dl	O
,	O
mean	O
+	O
/-S.	O
D.	O
)	O
without	O
the	O
intron	B-UNK
14	O
splice	B-UNK
defect	B-UNK
,	O
three	O
homozygotes	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
34	O
heterozygotes	B-UNK
(	O
29	O
.	O
1	O
%	O
)	O
were	O
found	O
to	O
have	O
the	O
442D	O
G	O
mutation	B-UNK
.	O

The	O
relative	B-UNK
allelic	O
frequency	B-UNK
of	O
this	O
mutation	B-UNK
was	O
calculated	O
to	O
be	O
0	O
.	O

17	O
.	O

One	O
of	O
the	O
homozygotes	O
for	O
the	O
442D	O
G	O
mutation	B-UNK
was	O
the	O
patient	B-UNK
previously	B-UNK
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	O
with	O
corneal	B-DISEASE
opacity	I-DISEASE
and	O
coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
.	O

This	O
was	O
the	O
first	O
reported	B-UNK
subject	O
homozygous	B-UNK
for	O
the	O
CETP	B-UNK
deficiency	I-UNK
who	O
also	O
demonstrated	O
atherosclerotic	B-DISEASE
symptoms	B-UNK
.	O

In	O
homozygous	B-UNK
subjects	B-UNK
,	O
CETP	B-UNK
activity	B-UNK
ranged	O
from	O
37	O
%	O
to	O
62	O
%	O
of	O
the	O
normal	B-UNK
value	O
,	O
which	O
was	O
consistent	B-UNK
with	O
the	O
results	B-UNK
obtained	B-UNK
from	O
the	O
transient	O
expression	B-UNK
experiment	O
previously	B-UNK
reported	I-UNK
;	O
however	O
,	O
the	O
specific	B-UNK
activity	B-UNK
of	O
CETP	B-UNK
was	O
not	O
as	O
low	B-UNK
as	O
expected	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mucopolysaccharidosis	B-UNK
type	B-UNK
IVA	B-UNK
:	O
common	B-UNK
double	B-UNK
deletion	B-UNK
in	O
the	O
N	O
-	O
acetylgalactosamine-6-sulfatase	O
gene	B-UNK
(	O
GALNS	B-UNK
)	O
.	O

Mucopolysaccharidosis	B-UNK
IVA	B-UNK
(	O
MPS	B-UNK
IVA	I-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
in	O
N	O
-	O
acetylgalactosamine-6-sulfatase	O
(	O
GALNS	B-UNK
)	O
.	O

We	O
found	O
two	O
separate	O
deletions	O
of	O
nearly	O
8	O
.	O

0	O
and	O
6	O
.	O

0	O
kb	B-UNK
in	O
the	O
GALNS	B-UNK
gene	B-UNK
,	O
including	O
some	O
exons	O
.	O

There	O
are	O
Alu	B-UNK
repetitive	O
elements	O
near	O
the	O
breakpoints	O
of	O
the	O
8	O
.	O

0-kb	O
deletion	B-UNK
,	O
and	O
this	O
deletion	B-UNK
resulted	B-UNK
from	O
an	O
Alu	B-UNK
-	O
Alu	B-UNK
recombination	B-UNK
.	O

The	O
other	O
6	O
.	O

0-kb	O
deletion	B-UNK
involved	B-UNK
illegitimate	O
recombinational	O
events	O
between	O
incomplete	O
short	B-UNK
direct	B-UNK
repeats	B-UNK
of	O
8	O
bp	B-UNK
at	O
deletion	B-UNK
breakpoints	O
.	O

The	O
same	O
rearrangement	B-UNK
has	O
been	O
observed	B-UNK
in	O
a	O
heteroallelic	O
state	B-UNK
in	O
four	O
unrelated	B-UNK
patients	B-UNK
.	O

This	O
is	O
the	O
first	O
documentation	O
of	O
a	O
common	B-UNK
double	B-UNK
deletion	B-UNK
a	O
gene	B-UNK
that	O
is	O
not	O
a	O
member	B-UNK
of	O
a	O
gene	B-UNK
cluster	B-UNK
.	O

Detection	B-UNK
of	O
eight	O
BRCA1	B-UNK
mutations	B-UNK
in	O
10	O
breast	B-UNK
/	O
ovarian	B-UNK
cancer	I-UNK
families	B-UNK
,	O
including	O
1	O
family	B-UNK
with	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
.	O

Genetic	B-UNK
epidemiological	O
evidence	B-UNK
suggests	O
that	O
mutations	B-UNK
in	O
BRCA1	B-UNK
may	O
be	O
responsible	B-UNK
for	O
approximately	O
one	O
half	B-UNK
of	O
early	B-UNK
onset	I-UNK
familial	B-UNK
breast	B-UNK
cancer	I-UNK
and	O
the	O
majority	O
of	O
familial	B-UNK
breast	B-UNK
/	O
ovarian	B-UNK
cancer	I-UNK
.	O

The	O
recent	O
cloning	B-UNK
of	O
BRCA1	B-UNK
allows	O
for	O
the	O
direct	B-UNK
detection	B-UNK
of	O
mutations	B-UNK
,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	B-UNK
for	O
cancer	B-UNK
susceptibility	I-UNK
is	O
unknown	O
.	O

We	O
analyzed	B-UNK
genomic	B-UNK
DNA	I-UNK
from	O
one	O
affected	B-UNK
individual	O
from	O
each	O
of	O
24	O
families	B-UNK
with	O
at	O
least	O
three	O
cases	B-UNK
of	O
ovarian	B-UNK
or	O
breast	B-UNK
cancer	I-UNK
,	O
using	O
SSCP	B-UNK
assays	O
.	O

Variant	O
SSCP	B-UNK
bands	O
were	O
subcloned	O
and	O
sequenced	O
.	O

Allele	B-UNK
-	O
specific	B-UNK
oligonucleotide	O
hybridization	B-UNK
was	O
used	O
to	O
verify	O
sequence	B-UNK
changes	O
and	O
to	O
screen	B-UNK
DNA	B-UNK
from	O
control	B-UNK
individuals	B-UNK
.	O

Six	O
frameshift	B-UNK
and	O
two	O
missense	B-UNK
mutations	I-UNK
were	O
detected	B-UNK
in	O
10	O
different	O
families	B-UNK
.	O

A	O
frameshift	B-UNK
mutation	I-UNK
was	O
detected	B-UNK
in	O
a	O
male	B-UNK
proband	B-UNK
affected	B-UNK
with	O
both	O
breast	B-UNK
and	O
prostate	B-UNK
cancer	I-UNK
.	O

A	O
40-bp	O
deletion	B-UNK
was	O
detected	B-UNK
in	O
a	O
patient	B-UNK
who	O
developed	O
intra-abdominal	O
carcinomatosis	O
1	O
year	O
after	O
prophylactic	O
oophorectomy	O
.	O

Mutations	B-UNK
were	O
detected	B-UNK
throughout	O
the	O
gene	B-UNK
,	O
and	O
only	O
one	O
was	O
detected	B-UNK
in	O
more	O
than	O
a	O
single	B-UNK
family	B-UNK
.	O

These	O
results	B-UNK
provide	I-UNK
further	O
evidence	B-UNK
that	O
inherited	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
can	O
occur	B-UNK
as	O
a	O
consequence	B-UNK
of	O
a	O
wide	B-UNK
array	O
of	O
BRCA1	B-UNK
mutations	B-UNK
.	O

These	O
results	B-UNK
suggests	O
that	O
development	B-UNK
of	O
a	O
screening	B-UNK
test	B-UNK
for	O
BRCA1	B-UNK
mutations	B-UNK
will	O
be	O
technically	O
challenging	O
.	O

The	O
finding	O
of	O
a	O
mutation	B-UNK
in	O
a	O
family	B-UNK
with	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
,	O
not	O
previously	B-UNK
thought	B-UNK
to	O
be	O
related	B-UNK
to	O
BRCA1	B-UNK
,	O
also	O
illustrates	O
the	O
potential	B-UNK
difficulties	O
of	O
genetic	B-UNK
counseling	I-UNK
for	O
individuals	B-UNK
known	O
to	O
carry	B-UNK
mutations	B-UNK
..	O

Natural	O
selection	B-UNK
of	O
hemi	O
-	O
and	O
heterozygotes	B-UNK
for	O
G6PD	B-UNK
deficiency	I-UNK
in	O
Africa	B-UNK
by	O
resistance	O
to	O
severe	B-DISEASE
malaria	I-DISEASE
.	O

Glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
,	O
the	O
most	O
common	B-UNK
enzymopathy	O
of	O
humans	B-UNK
,	O
affects	O
over	O
400	O
million	O
people	O
.	O

The	O
geographical	O
correlation	B-UNK
of	O
its	O
distribution	B-UNK
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B-DISEASE
suggests	O
that	O
this	O
disorder	B-UNK
has	O
risen	O
in	O
frequency	B-UNK
through	O
natural	O
selection	B-UNK
by	O
malaria	B-DISEASE
.	O

However	O
,	O
attempts	O
to	O
confirm	O
that	O
G6PD	B-UNK
deficiency	I-UNK
is	O
protective	O
in	O
case	B-UNK
-	O
control	B-UNK
studies	B-UNK
of	O
malaria	B-UNK
have	O
yielded	O
conflicting	O
results	B-UNK
.	O

Hence	O
,	O
for	O
this	O
X	O
-	O
linked	B-UNK
disorder	B-UNK
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	B-UNK
hemizygotes	O
and	O
female	O
heterozygotes	B-UNK
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O

Furthermore	O
,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown	O
.	O

Here	O
we	O
report	B-UNK
that	O
,	O
in	O
two	O
large	B-UNK
case	B-UNK
-	O
control	B-UNK
studies	B-UNK
of	O
over	O
2	O
,	O
000	O
African	B-UNK
children	O
,	O
the	O
common	B-UNK
African	B-UNK
form	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
(	O
G6PD	B-UNK
A-	O
)	O
is	O
associated	O
with	O
a	O
46	O
-	O
58	O
%	O
reduction	B-UNK
in	O
risk	B-UNK
of	O
severe	B-DISEASE
malaria	I-DISEASE
for	O
both	O
female	O
heterozygotes	B-UNK
and	O
male	B-UNK
hemizygotes	O
.	O

A	O
mathematical	O
model	B-UNK
incorporating	O
the	O
measured	O
selective	O
advantage	B-UNK
against	O
malaria	B-UNK
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B-UNK
deficiency	I-UNK
,	O
has	O
retarded	O
its	O
rise	B-UNK
in	O
frequency	B-UNK
in	O
malaria	B-DISEASE
-	O
endemic	O
regions	B-UNK
.	O

Although	O
G6PD	B-UNK
deficiency	I-UNK
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	B-UNK
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
..	O

The	O
alveolar	O
rhabdomyosarcoma	B-DISEASE
PAX3	B-UNK
/	O
FKHR	B-UNK
fusion	B-UNK
protein	B-UNK
is	O
a	O
transcriptional	O
activator	O
.	O

Chimeric	O
transcription	B-UNK
factors	O
,	O
created	O
by	O
gene	B-UNK
fusions	O
as	O
the	O
result	B-UNK
of	O
chromosomal	B-UNK
translocations	O
,	O
have	O
been	O
implicated	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
several	O
pathologically	O
disparate	O
solid	O
tumors	B-UNK
.	O

The	O
PAX3	B-UNK
/	O
FKHR	B-UNK
fusion	B-UNK
gene	B-UNK
,	O
formed	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
in	O
alveolar	O
rhabdomyosarcoma	B-DISEASE
,	O
encodes	B-UNK
a	O
hybrid	O
protein	B-UNK
that	O
contains	O
both	O
PAX3	B-UNK
DNA	B-UNK
binding	I-UNK
domains	B-UNK
,	O
the	O
paired	O
box	O
and	O
homeodomain	O
,	O
linked	B-UNK
to	O
the	O
bisected	O
DNA	B-UNK
binding	I-UNK
domain	B-UNK
of	O
FKHR	B-UNK
,	O
a	O
member	B-UNK
of	O
the	O
forkhead	O
family	B-UNK
of	O
transcription	B-UNK
factors	O
.	O

Here	O
we	O
report	B-UNK
that	O
PAX3	B-UNK
and	O
PAX3	B-UNK
/	O
FKHR	B-UNK
display	O
similar	B-UNK
,	O
but	O
not	O
identical	B-UNK
transactivation	O
activities	O
when	O
tested	O
with	O
model	B-UNK
Pax	O
recognition	O
sequences	O
.	O

No	O
functional	O
role	B-UNK
could	O
be	O
ascribed	O
solely	O
to	O
the	O
residual	B-UNK
FKHR	B-UNK
binding	B-UNK
domain	I-UNK
present	B-UNK
in	O
the	O
fusion	B-UNK
protein	B-UNK
,	O
but	O
FKHR	B-UNK
was	O
found	O
to	O
contribute	B-UNK
a	O
strong	B-UNK
carboxyl	O
terminal	B-UNK
activation	O
domain	B-UNK
replacing	O
the	O
one	O
located	B-UNK
in	O
the	O
unrearranged	O
PAX3	B-UNK
gene	B-UNK
.	O

We	O
show	O
that	O
the	O
native	O
PAX3	B-UNK
/	O
FKHR	B-UNK
protein	B-UNK
present	B-UNK
in	O
tumor	B-DISEASE
cells	B-UNK
with	O
this	O
translocation	B-UNK
has	O
transcriptional	O
characteristics	B-UNK
similar	B-UNK
to	O
the	O
in	O
vitro	O
expressed	B-UNK
protein	B-UNK
.	O

The	O
ability	B-UNK
of	O
the	O
PAX3	B-UNK
/	O
FKHR	B-UNK
hybrid	O
protein	B-UNK
to	O
bind	O
DNA	B-UNK
in	O
a	O
sequence	B-UNK
specific	B-UNK
manner	O
and	O
to	O
transactivate	O
the	O
expression	B-UNK
of	O
artificial	O
reporter	O
genes	B-UNK
suggests	O
that	O
its	O
aberrant	B-UNK
expression	B-UNK
could	O
subvert	O
the	O
transcriptional	O
programs	O
that	O
normally	O
control	B-UNK
the	O
growth	B-UNK
,	O
differentiation	B-UNK
,	O
and	O
survival	B-UNK
of	O
primitive	O
myogenic	O
precursors	O
in	O
vivo	B-UNK
..	O

A	O
p16INK4a	B-UNK
-	O
insensitive	O
CDK4	B-UNK
mutant	B-UNK
targeted	B-UNK
by	O
cytolytic	O
T	O
lymphocytes	O
in	O
a	O
human	B-UNK
melanoma	B-DISEASE
.	O

A	O
mutated	B-UNK
cyclin	O
-	O
dependent	B-UNK
kinase	B-UNK
4	O
(	O
CDK4	B-UNK
)	O
was	O
identified	B-UNK
as	O
a	O
tumor	B-DISEASE
-	O
specific	B-UNK
antigen	O
recognized	O
by	O
HLA	B-UNK
-	O
A2	O
.	O

1-restricted	O
autologous	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
in	O
a	O
human	B-UNK
melanoma	B-DISEASE
.	O

The	O
mutated	B-UNK
CDK4	B-UNK
allele	B-UNK
was	O
present	B-UNK
in	O
autologous	O
cultured	O
melanoma	B-UNK
cells	B-UNK
and	O
metastasis	B-DISEASE
tissue	B-UNK
,	O
but	O
not	O
in	O
the	O
patients	B-UNK
lymphocytes	O
.	O

The	O
mutation	B-UNK
,	O
an	O
arginine	O
-	O
to	O
-	O
cysteine	B-UNK
exchange	O
at	O
residue	O
24	O
,	O
was	O
part	O
of	O
the	O
CDK4	B-UNK
peptide	B-UNK
recognized	O
by	O
CTLs	O
and	O
prevented	O
binding	B-UNK
of	O
the	O
CDK4	B-UNK
inhibitor	O
p16INK4a	B-UNK
,	O
but	O
not	O
of	O
p21	O
or	O
of	O
p27KIP1	O
.	O

The	O
same	O
mutation	B-UNK
was	O
found	O
in	O
one	O
additional	O
melanoma	B-UNK
among	O
28	O
melanomas	O
analyzed	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
mutation	B-UNK
of	O
CDK4	B-UNK
can	O
create	O
a	O
tumor	B-UNK
-	O
specific	B-UNK
antigen	O
and	O
can	O
disrupt	O
the	O
cell	B-UNK
-	O
cycle	O
regulation	B-UNK
exerted	O
by	O
the	O
tumor	B-UNK
suppressor	I-UNK
p16INK4a	B-UNK
..	O

Rapid	O
detection	B-UNK
of	O
BRCA1	B-UNK
mutations	B-UNK
by	O
the	O
protein	B-UNK
truncation	I-UNK
test	I-UNK
.	O

More	O
than	O
75	O
%	O
of	O
the	O
reported	B-UNK
mutations	B-UNK
in	O
the	O
hereditary	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
gene	B-UNK
,	O
BRCA1	B-UNK
,	O
result	B-UNK
in	O
truncated	O
proteins	B-UNK
.	O

We	O
have	O
used	O
the	O
protein	B-UNK
truncation	I-UNK
test	I-UNK
(	O
PTT	B-UNK
)	O
to	O
screen	B-UNK
for	O
mutations	B-UNK
in	O
exon	B-UNK
11	O
,	O
which	O
encodes	B-UNK
61	O
%	O
of	O
BRCA1	B-UNK
.	O

In	O
45	O
patients	B-UNK
from	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
families	B-UNK
we	O
found	O
six	O
novel	O
mutations	B-UNK
two	O
single	B-UNK
nucleotide	I-UNK
insertions	O
,	O
three	O
small	O
deletions	O
(	O
1	O
-	O
5	O
bp	B-UNK
)	O
and	O
a	O
nonsense	B-UNK
mutation	I-UNK
identified	B-UNK
two	O
unrelated	B-UNK
families	I-UNK
.	O

Furthermore	O
,	O
we	O
were	O
able	O
to	O
amplify	O
the	O
remaining	O
coding	B-UNK
region	I-UNK
by	O
RT	O
-	O
PCR	B-UNK
using	O
lymphocyte	B-UNK
RNA	B-UNK
.	O

Combined	O
with	O
PTT	B-UNK
,	O
we	O
detected	B-UNK
aberrantly	O
spliced	O
products	B-UNK
affecting	O
exons	O
5	O
and	O
6	O
in	O
one	O
of	O
two	O
BRCA1-linked	O
families	B-UNK
examined	O
.	O

The	O
protein	B-UNK
truncation	I-UNK
test	I-UNK
promises	O
to	O
become	O
a	O
valuable	O
technique	O
in	O
detecting	O
BRCA1	B-UNK
mutations	B-UNK
..	O

Cloning	B-UNK
of	O
human	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
coenzyme	O
A	O
dehydrogenase	B-UNK
and	O
molecular	B-UNK
characterization	B-UNK
of	O
its	O
deficiency	B-UNK
in	O
two	O
patients	B-UNK
.	O

Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	B-UNK
and	O
736	O
bp	B-UNK
,	O
respectively	O
)	O
encoding	B-UNK
the	O
precursor	O
of	O
human	B-UNK
mitochondrial	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
coenzyme	O
A	O
dehydrogenase	B-UNK
(	O
VLCAD	B-UNK
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	B-UNK
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	B-UNK
the	O
entire	O
protein	B-UNK
of	O
655	O
amino	B-UNK
acids	I-UNK
,	O
including	O
a	O
40-amino	O
acid	B-UNK
leader	O
peptide	B-UNK
and	O
a	O
615-amino	O
acid	B-UNK
mature	O
polypeptide	O
.	O

PCR	B-UNK
-	O
amplified	O
VLCAD	B-UNK
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	B-UNK
from	O
two	O
VLCAD	B-UNK
-	O
deficient	B-UNK
patients	B-UNK
.	O

In	O
both	O
patients	B-UNK
,	O
a	O
105-bp	O
deletion	B-UNK
encompassing	O
bases	O
1078	O
-	O
1182	O
in	O
VLCAD	B-UNK
cDNA	O
was	O
identified	B-UNK
.	O

The	O
deletion	B-UNK
seems	O
to	O
occur	B-UNK
due	O
to	O
exon	B-UNK
skipping	O
during	O
processing	O
of	O
VLCAD	B-UNK
pre	O
-	O
mRNA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	B-UNK
causing	I-UNK
VLCAD	B-UNK
deficiency	I-UNK
.	O

Quantitative	B-UNK
cDNA	O
expression	B-UNK
of	O
normal	B-UNK
human	B-UNK
VLCAD	B-UNK
was	O
performed	O
in	O
the	O
patients	B-UNK
fibroblasts	B-UNK
,	O
using	O
vaccinia	B-DISEASE
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-UNK
of	O
the	O
normal	B-UNK
VLCAD	B-UNK
protein	B-UNK
causes	O
impaired	B-UNK
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acid	B-UNK
beta-oxidation	O
activity	B-UNK
in	O
the	O
patients	B-UNK
fibroblasts	B-UNK
.	O

In	O
patient	B-UNK
fibroblasts	B-UNK
,	O
raising	O
VLCAD	B-UNK
activity	B-UNK
to	O
approximately	O
20	O
%	O
of	O
normal	B-UNK
control	B-UNK
fibroblast	O
activity	B-UNK
raised	O
palmitic	O
acid	B-UNK
beta-oxidation	O
flux	O
to	O
the	O
level	B-UNK
found	O
in	O
control	B-UNK
fibroblasts	B-UNK
,	O
which	O
may	O
offer	O
important	O
information	B-UNK
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	B-UNK
gene	B-UNK
therapy	B-UNK
for	O
VLCAD	B-UNK
deficiency	I-UNK
..	O

Brain	B-UNK
disease	B-DISEASE
and	O
molecular	B-UNK
analysis	I-UNK
in	O
myotonic	B-UNK
dystrophy	I-UNK
.	O

Abnormal	O
amplification	B-UNK
of	O
a	O
CTG	B-UNK
repeat	I-UNK
on	O
chromosome	B-UNK
19	O
is	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
.	O

Expansion	B-UNK
of	O
the	O
repeat	B-UNK
has	O
been	O
correlated	B-UNK
with	O
severity	B-UNK
of	O
several	O
clinical	B-UNK
features	I-UNK
of	O
the	O
disease	B-DISEASE
.	O

We	O
performed	O
extensive	B-UNK
cognitive	B-UNK
testing	B-UNK
,	O
cerebral	B-UNK
magnetic	O
resonance	O
imaging	O
(	O
MRI	B-UNK
)	O
and	O
a	O
molecular	B-UNK
analysis	I-UNK
in	O
28	O
cases	B-UNK
of	O
DM	B-DISEASE
to	O
determine	B-UNK
the	O
relationship	B-UNK
between	O
the	O
molecular	B-UNK
defect	B-UNK
and	O
brain	B-UNK
disease	B-UNK
.	O

Performance	O
in	O
two	O
or	O
more	O
cognitive	B-UNK
tests	O
was	O
pathological	O
in	O
10	O
cases	B-UNK
.	O

Fourteen	O
patients	B-UNK
had	O
subcortical	O
white	B-UNK
matter	O
lesions	B-UNK
on	O
MRI	B-UNK
,	O
14	O
had	O
cerebral	B-UNK
atrophy	B-DISEASE
.	O

Amplification	B-UNK
of	O
the	O
CTG	B-UNK
repeat	I-UNK
showed	O
a	O
strong	B-UNK
correlation	B-UNK
with	O
cognitive	B-UNK
test	B-UNK
deficits	O
when	O
exceeding	O
a	O
length	B-UNK
of	O
over	O
1000	O
trinucleotides	O
.	O

MRI	B-UNK
lesions	B-UNK
were	O
associated	O
with	O
impaired	B-UNK
psychometric	O
performance	O
,	O
but	O
MRI	B-UNK
and	O
molecular	B-UNK
findings	B-UNK
were	O
only	O
weakly	O
related	B-UNK
.	O

Disease	B-UNK
duration	O
influenced	O
the	O
appearance	O
and	O
amount	O
of	O
white	B-UNK
matter	O
lesions	B-UNK
on	O
MRI	B-UNK
.	O

Quantification	O
of	O
CTG	B-UNK
repeat	I-UNK
size	B-UNK
may	O
allow	O
an	O
early	B-UNK
estimate	O
on	O
the	O
probability	B-UNK
of	O
brain	B-UNK
involvement	B-UNK
in	O
DM	B-UNK
;	O
cognitive	B-DISEASE
dysfunction	I-DISEASE
is	O
associated	O
with	O
white	B-UNK
matter	O
lesions	B-UNK
and	O
cerebral	B-UNK
atrophy	B-DISEASE
later	O
on	O
in	O
the	O
course	O
..	O

Mutations	B-UNK
in	O
the	O
gene	B-UNK
for	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
in	O
patients	B-UNK
with	O
different	O
clinical	B-UNK
phenotypes	O
.	O

Recently	O
,	O
the	O
gene	B-UNK
for	O
the	O
most	O
common	B-UNK
peroxisomal	B-UNK
disorder	B-UNK
,	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
(	O
X	O
-	O
ALD	B-UNK
)	O
,	O
has	O
been	O
described	O
encoding	B-UNK
a	O
peroxisomal	B-UNK
membrane	B-UNK
transporter	B-UNK
protein	B-UNK
.	O

We	O
analyzed	B-UNK
the	O
entire	O
protein	B-UNK
-	O
coding	B-UNK
sequence	I-UNK
of	O
this	O
gene	B-UNK
by	O
reverse	B-UNK
-	O
transcription	B-UNK
PCR	B-UNK
,	O
SSCP	B-UNK
,	O
and	O
DNA	B-UNK
sequencing	I-UNK
in	O
five	O
patients	B-UNK
with	O
different	O
clinical	B-UNK
expression	B-UNK
of	O
X	O
-	O
ALD	B-UNK
and	O
in	O
their	O
female	O
relatives	B-UNK
;	O
these	O
clinical	B-UNK
expressions	O
were	O
cerebral	B-UNK
childhood	O
ALD	B-UNK
,	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
,	O
and	O
"	O
Addison	B-DISEASE
disease	I-DISEASE
only	O
"	O
(	O
ADO	O
)	O
phenotype	B-UNK
.	O

In	O
the	O
three	O
patients	B-UNK
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	B-UNK
childhood	O
ALD	B-UNK
we	O
identified	B-UNK
in	O
the	O
5	O
portion	B-UNK
of	O
the	O
X	O
-	O
ALD	B-UNK
gene	B-UNK
a	O
38-bp	O
deletion	B-UNK
that	O
causes	O
a	O
frameshift	B-UNK
mutation	I-UNK
,	O
a	O
3-bp	O
deletion	B-UNK
leading	B-UNK
to	O
a	O
deletion	B-UNK
of	O
an	O
amino	B-UNK
acid	I-UNK
in	O
the	O
ATP	B-UNK
-	O
binding	B-UNK
domain	I-UNK
of	O
the	O
ALD	B-UNK
protein	B-UNK
,	O
and	O
a	O
missense	B-UNK
mutation	I-UNK
.	O

In	O
the	O
patient	B-UNK
with	O
the	O
clinical	B-UNK
phenotype	B-UNK
of	O
AMN	B-UNK
,	O
a	O
nonsense	B-UNK
mutation	I-UNK
in	O
codon	B-UNK
212	O
,	O
along	O
with	O
a	O
second	O
site	B-UNK
mutation	B-UNK
at	O
codon	B-UNK
178	O
,	O
was	O
observed	B-UNK
.	O

Analysis	B-UNK
of	O
the	O
patient	B-UNK
with	O
the	O
ADO	O
phenotype	B-UNK
revealed	B-UNK
a	O
further	O
missense	B-UNK
mutation	I-UNK
at	O
a	O
highly	B-UNK
conserved	I-UNK
position	B-UNK
in	O
the	O
ALDP	O
/	O
PMP70	O
comparison	B-UNK
.	O

The	O
disruptive	O
nature	B-UNK
of	O
two	O
mutations	B-UNK
(	O
i.	O
e.	O
,	O
the	O
frameshift	B-UNK
and	O
the	O
nonsense	B-UNK
mutation	I-UNK
)	O
in	O
patients	B-UNK
with	O
biochemically	O
proved	O
childhood	O
ALD	B-UNK
and	O
AMN	B-UNK
further	O
strongly	O
supports	O
the	O
hypothesis	B-UNK
that	O
alterations	B-UNK
in	O
this	O
gene	B-UNK
play	O
a	O
crucial	O
role	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
X	O
-	O
ALD	B-UNK
.	O

Since	O
the	O
current	B-UNK
biochemical	O
techniques	O
for	O
X	O
-	O
ALD	B-UNK
carrier	B-UNK
detection	I-UNK
in	O
affected	B-UNK
families	B-UNK
lack	B-UNK
sufficient	O
reliability	O
,	O
our	O
procedure	O
described	O
for	O
systematic	O
mutation	B-UNK
scanning	O
is	O
also	O
capable	O
of	O
improving	O
genetic	B-UNK
counseling	I-UNK
and	O
prenatal	B-UNK
diagnosis	I-UNK

Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
and	O
myotonic	B-UNK
dystrophy	I-UNK
in	O
the	O
same	O
patient	B-UNK
.	O

We	O
report	B-UNK
on	O
the	O
first	O
patient	B-UNK
identified	B-UNK
with	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
and	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

The	O
family	B-UNK
of	O
the	O
propositus	O
had	O
a	O
strong	B-UNK
history	B-UNK
of	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	B-UNK
of	O
the	O
responsible	B-UNK
CTG	B-UNK
repeat	I-UNK
between	O
the	O
mildly	O
affected	B-UNK
mother	O
(	O
160	O
repeats	B-UNK
;	O
normal	B-UNK
27	O
repeats	B-UNK
)	O
and	O
her	O
more	O
severely	O
affected	B-UNK
son	O
(	O
650	O
repeats	B-UNK
)	O
,	O
and	O
his	O
sister	O
(	O
650	O
repeats	B-UNK
)	O
.	O

The	O
propositus	O
was	O
an	O
isolated	B-UNK
case	B-UNK
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
with	O
marked	B-UNK
dystrophin	B-UNK
deficiency	B-UNK
in	O
muscle	B-UNK
biopsy	B-UNK
.	O

The	O
patient	B-UNK
was	O
still	O
ambulatory	O
post	O
age	B-UNK
16	O
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	B-UNK
of	O
Duchenne	B-DISEASE
dystrophy	I-DISEASE
.	O

However	O
,	O
other	O
interpretations	O
are	O
possible	O
.	O

Twelve	O
percent	B-UNK
of	O
dystrophin	B-UNK
revertant	O
fibers	O
as	O
observed	B-UNK
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
DMD	B-UNK
clinical	B-UNK
severity	B-UNK
,	O
or	O
the	O
patient	B-UNK
may	O
present	B-UNK
a	O
somatic	B-UNK
mosaic	O
.	O

The	O
pathophysiological	O
interactions	O
of	O
these	O
two	O
unlinked	O
disorders	B-UNK
are	O
discussed	O
at	O
the	O
clinical	B-UNK
and	O
histopathological	O
levels	B-UNK
..	O

Age	B-UNK
at	I-UNK
diagnosis	I-UNK
as	O
an	O
indicator	O
of	O
eligibility	O
for	O
BRCA1	B-UNK
DNA	B-UNK
testing	B-UNK
in	O
familial	B-UNK
breast	B-UNK
cancer	I-UNK
.	O

We	O
searched	O
for	O
criteria	O
that	O
could	O
indicate	O
breast	B-DISEASE
cancer	I-DISEASE
families	B-UNK
with	O
a	O
high	B-UNK
prior	O
probability	B-UNK
of	O
being	O
caused	B-UNK
by	O
the	O
breast	B-UNK
/	O
ovarian	B-UNK
cancer	I-UNK
susceptibility	B-UNK
locus	B-UNK
BRCA1	B-UNK
on	O
chromosome	B-UNK
17	O
.	O

To	O
this	O
end	B-UNK
,	O
we	O
performed	O
a	O
linkage	B-UNK
study	B-UNK
with	O
59	O
consecutively	O
collected	O
Dutch	B-UNK
breast	B-UNK
cancer	I-UNK
families	B-UNK
,	O
including	O
16	O
with	O
at	O
least	O
one	O
case	B-UNK
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

We	O
used	O
an	O
intake	O
cut	O
-	O
off	O
of	O
at	O
least	O
three	O
first	O
-	O
degree	B-UNK
relatives	B-UNK
with	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
at	O
any	O
age	B-UNK
.	O

Significant	B-UNK
evidence	B-UNK
for	O
linkage	B-UNK
was	O
found	O
only	O
among	O
the	O
13	O
breast	B-DISEASE
cancer	I-DISEASE
families	B-UNK
with	O
a	O
mean	O
age	B-UNK
at	I-UNK
diagnosis	I-UNK
of	O
less	O
than	O
45	O
years	O
.	O

An	O
unexpectedly	O
low	B-UNK
proportion	B-UNK
of	O
the	O
breast	B-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
families	B-UNK
were	O
estimated	B-UNK
to	O
be	O
linked	B-UNK
to	O
BRCA1	B-UNK
,	O
which	O
could	O
be	O
due	O
to	O
a	O
founder	B-UNK
effect	I-UNK
in	O
the	O
Dutch	B-UNK
population	B-UNK
.	O

Given	O
the	O
expected	O
logistical	O
problems	O
in	O
clinical	B-UNK
management	O
now	O
that	O
BRCA1	B-UNK
has	O
been	O
identified	B-UNK
,	O
we	O
propose	O
an	O
interim	O
period	O
in	O
which	O
only	O
families	B-UNK
with	O
a	O
strong	B-UNK
positive	O
family	B-UNK
history	B-UNK
for	O
early	B-UNK
onset	I-UNK
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
will	O
be	O
offered	O
BRCA1	B-UNK
mutation	B-UNK
testing	B-UNK
..	O

Linkage	B-UNK
analysis	I-UNK
of	O
26	O
Canadian	B-UNK
breast	B-UNK
and	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
families	B-UNK
.	O

We	O
have	O
examined	O
26	O
Canadian	B-UNK
families	B-UNK
with	O
hereditary	B-UNK
breast	I-UNK
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
for	O
linkage	B-UNK
to	O
markers	B-UNK
flanking	O
the	O
BRCA1	B-UNK
gene	B-UNK
on	O
chromosome	B-UNK
17q12-q21	O
.	O

Of	O
the	O
15	O
families	B-UNK
that	O
contain	O
cases	B-UNK
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
94	O
%	O
were	O
estimated	B-UNK
to	O
be	O
linked	B-UNK
to	O
BRCA1	B-UNK
.	O

In	O
contrast	B-UNK
,	O
there	O
was	O
no	O
overall	O
evidence	B-UNK
of	O
linkage	B-UNK
in	O
the	O
group	B-UNK
of	O
10	O
families	B-UNK
with	O
breast	B-DISEASE
cancer	I-DISEASE
without	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

A	O
genetic	B-UNK
recombinant	B-UNK
in	O
a	O
breast	B-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
family	B-UNK
indicates	O
a	O
placement	O
of	O
BRCA1	B-UNK
telomeric	O
to	O
D17S776	O
,	O
and	O
helps	O
to	O
define	B-UNK
the	O
region	B-UNK
of	O
assignment	B-UNK
of	O
the	O
cancer	B-UNK
susceptibility	I-UNK
gene	I-UNK
.	O

Other	O
cancers	B-DISEASE
of	O
interest	O
that	O
appeared	B-UNK
in	O
the	O
BRCA1-linked	O
families	B-UNK
included	O
primary	B-UNK
peritoneal	O
cancer	B-UNK
,	O
cancer	B-DISEASE
of	O
the	O
fallopian	O
tube	O
,	O
and	O
malignant	B-UNK
melanoma	B-DISEASE
..	O

Structural	B-UNK
analysis	B-UNK
of	O
the	O
5	O
'	O
region	B-UNK
of	O
mouse	B-UNK
and	O
human	B-UNK
Huntington	B-UNK
disease	I-UNK
genes	B-UNK
reveals	O
conservation	B-UNK
of	O
putative	O
promoter	O
region	B-UNK
and	O
di-and	O
trinucleotide	B-UNK
polymorphisms	B-UNK
.	O

We	O
have	O
previously	B-UNK
cloned	O
and	O
characterized	B-UNK
the	O
murine	O
homologue	B-UNK
of	O
the	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
gene	B-UNK
and	O
shown	B-UNK
that	O
it	O
maps	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
5	O
within	O
a	O
region	B-UNK
of	O
conserved	B-UNK
synteny	O
with	O
human	B-UNK
chromosome	I-UNK
4p16	O
.	O

3	O
3	O
.	O

Here	O
we	O
present	B-UNK
a	O
detailed	B-UNK
comparison	B-UNK
of	O
the	O
sequence	B-UNK
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	B-UNK
of	O
the	O
5	O
genomic	B-UNK
region	B-UNK
of	O
the	O
murine	O
(	O
Hdh	O
)	O
and	O
human	B-UNK
HD	B-UNK
genes	B-UNK
encompassing	O
the	O
first	O
five	O
exons	O
.	O

We	O
show	O
that	O
in	O
this	O
region	B-UNK
these	O
two	O
genes	B-UNK
share	O
identical	B-UNK
exon	B-UNK
boundaries	O
,	O
but	O
have	O
different	O
-	O
size	B-UNK
introns	O
.	O

Two	O
dinucleotide	B-UNK
(	O
CT	B-UNK
)	O
and	O
one	O
trinucleotide	B-UNK
intronic	O
polymorphism	B-UNK
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	B-UNK
in	O
the	O
HD	B-UNK
gene	B-UNK
were	O
identified	B-UNK
.	O

Comparison	B-UNK
of	O
940-bp	O
sequence	B-UNK
5	O
to	O
the	O
putative	O
translation	O
start	O
site	B-UNK
reveals	O
a	O
highly	B-UNK
conserved	I-UNK
region	B-UNK
(	O
78	O
.	O
8	O
%	O
nucleotide	B-UNK
identity	O
)	O
between	O
Hdh	O
and	O
the	O
HD	B-UNK
gene	B-UNK
from	O
nucleotide-56	O
to-206	O
(	O
of	O
Hdh	O
)	O
.	O

Neither	O
Hdh	O
nor	O
the	O
HD	B-UNK
gene	B-UNK
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	B-UNK
site	B-UNK
and	O
numerous	O
potential	B-UNK
Sp1	B-UNK
binding	B-UNK
sites	O
.	O

The	O
high	B-UNK
sequence	B-UNK
identity	O
between	O
Hdh	O
and	O
the	O
HD	B-UNK
gene	B-UNK
for	O
approximately	O
200	O
bp	B-UNK
5	O
to	O
the	O
putative	O
translation	O
start	O
site	B-UNK
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	B-UNK
in	O
regulating	O
expression	B-UNK
of	O
the	O
Huntington	B-DISEASE
disease	I-DISEASE
gene	B-UNK

The	O
protein	B-UNK
deficient	B-UNK
in	O
Lowe	O
syndrome	B-DISEASE
is	O
a	O
phosphatidylinositol-4	O
,	O
5-bisphosphate	O
5-phosphatase	O
.	O

Lowe	O
syndrome	B-DISEASE
,	O
also	O
known	O
as	O
oculocerebrorenal	B-DISEASE
syndrome	I-DISEASE
,	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
X	O
chromosome	B-UNK
-	O
encoded	B-UNK
OCRL	B-UNK
gene	B-UNK
.	O

The	O
OCRL	B-UNK
protein	B-UNK
is	O
51	O
%	O
identical	B-UNK
to	O
inositol	O
polyphosphate	O
5-phosphatase	O
II	B-UNK
(	O
5-phosphatase	O
II	B-UNK
)	O
from	O
human	B-UNK
platelets	O
over	O
a	O
span	O
of	O
744	O
aa	O
,	O
suggesting	O
that	O
OCRL	B-UNK
may	O
be	O
a	O
similar	B-UNK
enzyme	B-UNK
.	O

We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	B-UNK
cDNA	O
that	O
encodes	B-UNK
amino	B-UNK
acids	I-UNK
homologous	B-UNK
to	O
the	O
platelet	B-UNK
5-phosphatase	O
for	O
expression	B-UNK
in	O
baculovirus	O
-	O
infected	O
Sf9	O
insect	O
cells	B-UNK
.	O

This	O
cDNA	O
encodes	B-UNK
aa	O
264	O
-	O
968	O
of	O
the	O
OCRL	B-UNK
protein	B-UNK
.	O

The	O
recombinant	B-UNK
protein	B-UNK
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	B-UNK
5-phosphatase	O
II	B-UNK
.	O

Thus	O
OCRL	B-UNK
converts	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate	O
to	O
inositol	O
1	O
,	O
4-bisphosphate	O
,	O
and	O
it	O
converts	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5-tetrakisphosphate	O
to	O
inositol	O
1	O
,	O
3	O
,	O
4-trisphosphate	O
.	O

Most	O
important	O
,	O
the	O
enzyme	B-UNK
converts	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
to	O
phosphatidylinositol	O
4-phosphate	O
.	O

The	O
relative	B-UNK
ability	B-UNK
of	O
OCRL	B-UNK
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5-phosphatase	O
II	B-UNK
and	O
from	O
that	O
of	O
another	O
5-phosphatase	O
isoenzyme	O
from	O
platelets	O
,	O
5-phosphatase	O
I.	O

The	O
recombinant	B-UNK
OCRL	B-UNK
protein	B-UNK
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10-to	O
30-fold	O
better	O
than	O
5-phosphatase	O
II	B-UNK
,	O
and	O
5-phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all	O
.	O

We	O
also	O
show	O
that	O
OCRL	B-UNK
functions	O
as	O
a	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
5-phosphatase	O
in	O
OCRL	B-UNK
-	O
expressing	O
Sf9	O
cells	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
OCRL	B-UNK
is	O
mainly	O
a	O
lipid	O
phosphatase	B-UNK
that	O
may	O
control	B-UNK
cellular	O
levels	B-UNK
of	O
a	O
critical	B-UNK
metabolite	O
,	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
.	O

Deficiency	B-UNK
of	O
this	O
enzyme	B-UNK
apparently	O
causes	O
the	O
protean	O
manifestations	B-UNK
of	O
Lowe	O
syndrome	B-DISEASE
..	O

New	O
founder	B-UNK
haplotypes	O
at	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
locus	B-UNK
in	O
southern	B-UNK
Africa	B-UNK
.	O

The	O
association	B-UNK
between	O
normal	B-UNK
alleles	B-UNK
at	O
the	O
CTG	B-UNK
repeat	I-UNK
and	O
two	O
nearby	O
polymorphisms	B-UNK
in	O
the	O
myotonin	O
protein	B-UNK
kinase	I-UNK
gene	B-UNK
,	O
the	O
Alu	B-UNK
insertion	O
/	O
deletion	B-UNK
polymorphism	B-UNK
and	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
kinase	B-UNK
(	O
DMK	O
)	O
(	O
G	O
/	O
T	O
)	O
intron	B-UNK
9	O
/	O
HinfI	O
polymorphism	B-UNK
,	O
has	O
been	O
analyzed	B-UNK
in	O
South	O
African	B-UNK
Negroids	O
,	O
a	O
population	B-UNK
in	O
which	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-DISEASE
)	O
has	O
not	O
been	O
described	O
.	O

South	O
African	B-UNK
Negroids	O
have	O
a	O
CTG	B-UNK
allelic	O
distribution	B-UNK
that	O
is	O
significantly	O
different	O
from	O
that	O
in	O
Caucasoids	O
and	O
Japanese	B-UNK
the	O
CTG	B-UNK
repeat	I-UNK
lengths	O
of	O
>	O
or	O
=	O
19	O
are	O
very	O
rare	B-UNK
.	O

The	O
striking	O
linkage	B-UNK
disequilibrium	I-UNK
between	O
specific	B-UNK
alleles	B-UNK
at	O
the	O
Alu	B-UNK
polymorphism	B-UNK
(	O
Alu	B-UNK
(	O
ins	O
)	O
and	O
Alu	B-UNK
(	O
del	O
)	O
)	O
,	O
the	O
HinfI	O
polymorphism	B-UNK
(	O
HinfI-1	O
and	O
HinfI-2	O
)	O
,	O
and	O
the	O
CTG	B-UNK
repeat	I-UNK
polymorphism	B-UNK
seen	O
in	O
Caucasoid	O
(	O
Europeans	O
and	O
Canadians	O
)	O
populations	O
was	O
also	O
found	O
in	O
the	O
South	O
African	B-UNK
Negroid	O
population	B-UNK
.	O

Numerous	O
haplotypes	O
,	O
not	O
previously	B-UNK
described	O
in	O
Europeans	O
,	O
were	O
,	O
however	O
,	O
found	O
.	O

It	O
thus	O
seems	O
likely	O
that	O
only	O
a	O
small	O
number	B-UNK
of	O
these	O
"	O
African	B-UNK
"	O
chromosomes	O
were	O
present	B-UNK
in	O
the	O
progenitors	O
of	O
all	O
non-African	O
peoples	O
.	O

These	O
data	B-UNK
provide	B-UNK
support	O
for	O
the	O
"	O
out	O
of	O
Africa	B-UNK
"	O
model	B-UNK
for	O
the	O
origin	O
of	O
modern	O
humans	B-UNK
and	O
suggest	B-UNK
that	O
the	O
rare	B-UNK
ancestral	O
DM	B-DISEASE
mutation	B-UNK
event	O
may	O
have	O
occurred	B-UNK
after	O
the	O
migration	O
from	O
Africa	B-UNK
,	O
hence	O
the	O
absence	B-UNK
of	O
DM	B-DISEASE
in	O
sub-Saharan	O
Negroid	O
peoples	O
..	O

Discordant	O
clinical	B-UNK
outcome	O
in	O
myotonic	B-UNK
dystrophy	I-UNK
relatives	B-UNK
showing	O
(	O
CTG	B-UNK
)	O
n	O
>	O
700	O
repeats	B-UNK
.	O

A	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
family	B-UNK
is	O
described	O
in	O
which	O
discordant	O
DM	B-DISEASE
phenotypes	O
were	O
found	O
in	O
the	O
children	O
of	O
two	O
affected	B-UNK
sisters	O
with	O
similar	B-UNK
CTG	B-UNK
expansion	B-UNK
and	O
clinical	B-UNK
manifestations	I-UNK
.	O

In	O
this	O
family	B-UNK
,	O
congenital	B-UNK
as	O
well	O
as	O
early	B-UNK
severe	B-UNK
childhood	O
and	O
later	O
childhood	O
onset	B-UNK
DM	B-DISEASE
coexist	O
.	O

This	O
observation	O
strengthens	O
the	O
limited	O
ability	B-UNK
of	O
lymphocytes	O
CTG	B-UNK
repeat	I-UNK
number	B-UNK
analysis	B-UNK
in	O
predicting	O
genotype	B-UNK
-	O
phenotype	B-UNK
correlations	B-UNK
in	O
DM	B-UNK
patients	B-UNK
..	O

Purification	O
of	O
human	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
coenzyme	O
A	O
dehydrogenase	B-UNK
and	O
characterization	B-UNK
of	O
its	O
deficiency	B-UNK
in	O
seven	O
patients	B-UNK
.	O

Mitochondrial	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
coenzyme	O
A	O
dehydrogenase	B-UNK
(	O
VLCAD	B-UNK
)	O
was	O
purified	O
from	O
human	B-UNK
liver	B-UNK
.	O

The	O
molecular	B-UNK
masses	O
of	O
the	O
native	O
enzyme	B-UNK
and	O
the	O
subunit	B-UNK
were	O
estimated	B-UNK
to	O
be	O
154	O
and	O
70	O
kD	O
,	O
respectively	O
.	O

The	O
enzyme	B-UNK
was	O
found	O
to	O
catalyze	O
the	O
major	B-UNK
part	O
of	O
mitochondrial	B-UNK
palmitoylcoenzyme	O
A	O
dehydrogenation	O
in	O
liver	B-UNK
,	O
heart	B-UNK
,	O
skeletal	B-UNK
muscle	I-UNK
,	O
and	O
skin	B-UNK
fibroblasts	I-UNK
(	O
89	O
-	O
97	O
,	O
86	O
-	O
99	O
,	O
96	O
-	O
99	O
,	O
and	O
78	O
-	O
87	O
%	O
,	O
respectively	O
)	O
.	O

Skin	B-UNK
fibroblasts	I-UNK
from	O
26	O
patients	B-UNK
suspected	O
of	O
having	O
a	O
disorder	B-UNK
of	O
mitochondrial	B-UNK
beta-oxidation	O
were	O
analyzed	B-UNK
for	O
VLCAD	B-UNK
protein	B-UNK
using	O
immunoblotting	O
,	O
and	O
7	O
of	O
them	O
contained	O
undetectable	O
or	O
trace	O
levels	B-UNK
of	O
the	O
enzyme	B-UNK
.	O

The	O
seven	O
deficient	B-UNK
fibroblast	O
lines	B-UNK
were	O
characterized	B-UNK
by	O
measuring	O
acyl	B-UNK
-	O
coenzyme	O
A	O
dehydrogenation	O
activities	O
,	O
overall	O
palmitic	O
acid	B-UNK
oxidation	B-UNK
,	O
and	O
VLCAD	B-UNK
protein	B-UNK
synthesis	B-UNK
using	O
pulse	O
-	O
chase	O
,	O
further	O
confirming	O
the	O
diagnosis	B-UNK
of	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
.	O

These	O
results	B-UNK
suggested	O
the	O
heterogenous	O
nature	B-UNK
of	O
the	O
mutations	B-UNK
causing	B-UNK
the	O
deficiency	B-UNK
in	O
the	O
seven	O
patients	B-UNK
.	O

Clinically	O
,	O
all	O
patients	B-UNK
with	O
VLCAD	B-UNK
deficiency	I-UNK
exhibited	O
cardiac	B-DISEASE
disease	I-DISEASE
.	O

At	O
least	O
four	O
of	O
them	O
presented	B-UNK
with	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
.	O

This	O
frequency	B-UNK
(	O
>	O
57	O
%	O
)	O
was	O
much	O
higher	O
than	O
that	O
observed	B-UNK
in	O
patients	B-UNK
with	O
other	O
disorders	B-UNK
of	O
mitochondrial	B-UNK
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acid	B-UNK
oxidation	B-UNK
that	O
may	O
be	O
accompanied	O
by	O
cardiac	B-DISEASE
disease	I-DISEASE
in	O
infants	O
..	O

Hereditary	B-UNK
deficiency	B-UNK
of	O
the	O
fifth	O
component	B-UNK
of	I-UNK
complement	I-UNK
in	O
man	B-UNK
.	O

II	B-UNK
.	O

Biological	O
properties	B-UNK
of	O
C5-deficient	O
human	B-UNK
serum	B-UNK
.	O

The	O
first	O
known	O
human	B-UNK
kindred	O
with	O
hereditary	B-UNK
deficiency	B-UNK
of	O
the	O
fifth	O
component	B-UNK
of	I-UNK
complement	I-UNK
(	O
C5	B-UNK
)	O
was	O
documented	O
in	O
the	O
accompanying	O
report	B-UNK
.	O

This	O
study	B-UNK
examines	O
several	O
biological	O
properties	B-UNK
of	O
C5-deficient	O
(	O
C5D	O
)	O
human	B-UNK
serum	B-UNK
,	O
particularly	O
sera	B-UNK
obtained	B-UNK
from	O
two	O
C5D	O
homozygotes	O
.	O

The	O
proband	B-UNK
,	O
who	O
has	O
inactive	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
is	O
completely	O
lacking	O
C5	B-UNK
,	O
while	O
her	O
healthy	O
half	B-UNK
-	O
sister	O
has	O
1	O
-	O
2	O
%	O
of	O
normal	B-UNK
levels	B-UNK
.	O

Both	O
sera	B-UNK
were	O
severely	O
impaired	B-UNK
in	O
their	O
ability	B-UNK
to	O
generate	O
chemotactic	O
activity	B-UNK
for	O
normal	B-UNK
human	B-UNK
neutrophils	O
upon	O
incubation	O
with	O
aggregated	O
human	B-UNK
gamma	B-UNK
-	O
globulin	O
or	O
Escherichia	O
coli	B-UNK
endotoxin	O
.	O

This	O
function	B-UNK
was	O
fully	O
restored	O
in	O
the	O
siblings	O
serum	B-UNK
,	O
and	O
substantially	O
improved	O
in	O
the	O
probands	O
serum	B-UNK
,	O
by	O
addition	B-UNK
of	O
highly	B-UNK
purified	O
human	B-UNK
C5	B-UNK
to	O
normal	B-UNK
serum	B-UNK
concentrations	O
.	O

Sera	B-UNK
from	O
eight	O
family	B-UNK
members	I-UNK
who	O
were	O
apparently	O
heterozygous	B-UNK
for	O
C5	B-UNK
deficiency	B-UNK
gave	O
normal	B-UNK
chemotactic	O
scores	B-UNK
.	O

The	O
ability	B-UNK
of	O
C5D	O
serum	B-UNK
to	O
opsonize	O
Saccharomyces	O
cerevisiae	O
(	O
bakers	O
yeast	B-UNK
)	O
or	O
Candida	O
albicans	O
for	O
ingestion	O
by	O
normal	B-UNK
neutrophils	O
was	O
completely	O
normal	B-UNK
.	O

In	O
addition	B-UNK
,	O
C5D	O
serum	B-UNK
was	O
capable	O
of	O
promoting	O
normal	B-UNK
phagocytosis	O
and	O
intracellular	O
killing	O
of	O
Staphylococcus	O
aureus	O
.	O

The	O
probands	O
serum	B-UNK
was	O
incapable	O
of	O
mediating	O
lysis	O
of	O
erythrocytes	O
from	O
a	O
patient	B-UNK
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	B-DISEASE
in	O
both	O
the	O
sucrose	O
hemolysia	O
and	O
acid	B-UNK
hemolysis	B-DISEASE
tests	O
,	O
and	O
also	O
lacked	O
bactericidal	O
activity	B-UNK
against	O
sensitized	O
or	O
unsensitized	O
Salmonella	O
typhi	O
.	O

The	O
siblings	O
serum	B-UNK
,	O
containing	O
only	O
1	O
-	O
2	O
%	O
of	O
normal	B-UNK
C5	B-UNK
,	O
effectively	O
lysed	O
S.	O
typhi	O
,	O
but	O
only	O
at	O
eightfold	O
lower	O
serum	B-UNK
dilutions	O
as	O
compared	B-UNK
to	O
normals	O
.	O

These	O
findings	B-UNK
underscore	O
the	O
critical	B-UNK
role	B-UNK
of	O
C5	B-UNK
in	O
the	O
generation	O
of	O
chemotactic	O
activity	B-UNK
and	O
in	O
cytolytic	O
reactions	O
,	O
as	O
opposed	O
to	O
a	O
nonobligatory	O
or	O
minimal	O
role	B-UNK
in	O
opsonization	O
,	O
at	O
least	O
for	O
the	O
organisms	O
under	O
study	B-UNK
..	O

Human	B-UNK
peroxisomal	B-UNK
targeting	B-UNK
signal-1	O
receptor	B-UNK
restores	O
peroxisomal	B-UNK
protein	B-UNK
import	O
in	O
cells	B-UNK
from	O
patients	B-UNK
with	O
fatal	B-UNK
peroxisomal	B-DISEASE
disorders	I-DISEASE
.	O

Two	O
peroxisomal	B-UNK
targeting	B-UNK
signals	O
,	O
PTS1	O
and	O
PTS2	O
,	O
are	O
involved	B-UNK
in	O
the	O
import	O
of	O
proteins	B-UNK
into	O
the	O
peroxisome	O
matrix	O
.	O

Human	B-UNK
patients	B-UNK
with	O
fatal	B-UNK
generalized	B-UNK
peroxisomal	B-UNK
deficiency	B-UNK
disorders	B-UNK
fall	O
into	O
at	O
least	O
nine	O
genetic	B-UNK
complementation	O
groups	B-UNK
.	O

Cells	B-UNK
from	O
many	O
of	O
these	O
patients	B-UNK
are	O
deficient	B-UNK
in	O
the	O
import	O
of	O
PTS1-containing	O
proteins	B-UNK
,	O
but	O
the	O
causes	O
of	O
the	O
protein	B-UNK
-	O
import	O
defect	B-UNK
in	O
these	O
patients	B-UNK
are	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	B-UNK
cDNA	O
homologue	B-UNK
(	O
PTS1R	O
)	O
of	O
the	O
Pichia	O
pastoris	O
PAS8	O
gene	B-UNK
,	O
the	O
PTS1	O
receptor	B-UNK
(	O
McCollum	O
,	O
D.	O
,	O
E.	O
Monosov	O
,	O
and	O
S.	O
Subramani	O
.	O
1993	O
.	O
J.	O
Cell	B-UNK
Biol	O
.	O
121	O
761	O
-	O
774	O
)	O
.	O

The	O
PTS1R	O
mRNA	O
is	O
expressed	B-UNK
in	O
all	O
human	B-UNK
tissues	O
examined	O
.	O

Antibodies	B-UNK
to	O
the	O
human	B-UNK
PTS1R	O
recognize	O
this	O
protein	B-UNK
in	O
human	B-UNK
,	O
monkey	O
,	O
rat	O
,	O
and	O
hamster	O
cells	B-UNK
.	O

The	O
protein	B-UNK
is	O
localized	B-UNK
mainly	O
in	O
the	O
cytosol	O
but	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
peroxisomes	O
.	O

Part	O
of	O
the	O
peroxisomal	B-UNK
PTS1R	O
protein	B-UNK
is	O
tightly	B-UNK
bound	O
to	O
the	O
peroxisomal	B-UNK
membrane	B-UNK
.	O

Antibodies	B-UNK
to	O
PTS1R	O
inhibit	O
peroxisomal	B-UNK
protein	B-UNK
-	O
import	O
of	O
PTS1-containing	O
proteins	B-UNK
in	O
a	O
permeabilized	O
CHO	O
cell	B-UNK
system	O
.	O

In	O
vitro	O
-	O
translated	O
PTS1R	O
protein	B-UNK
specifically	B-UNK
binds	O
a	O
serine	O
-	O
lysine	O
-	O
leucine	O
-	O
peptide	B-UNK
.	O

A	O
PAS8-PTS1R	O
fusion	B-UNK
protein	B-UNK
complements	O
the	O
P.	O
pastoris	O
pas8	O
mutant	B-UNK
.	O

The	O
PTS1R	O
cDNA	O
also	O
complements	O
the	O
PTS1	O
protein	B-UNK
-	O
import	O
defect	B-UNK
in	O
skin	B-UNK
fibroblasts	I-UNK
from	O
patients	B-UNK
--	O
belonging	O
to	O
complementation	O
group	B-UNK
two	O
--	O
diagnosed	O
as	O
having	O
neonatal	B-UNK
adrenoleukodystrophy	B-UNK
or	O
Zellweger	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
PTS1R	O
gene	B-UNK
has	O
been	O
localized	B-UNK
to	O
a	O
chromosomal	B-UNK
location	B-UNK
where	O
no	O
other	O
peroxisomal	B-UNK
disorder	B-UNK
genes	B-UNK
are	O
known	O
to	O
map	B-UNK
.	O

Our	O
findings	B-UNK
represent	O
the	O
only	O
case	B-UNK
in	O
which	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
the	O
protein	B-UNK
-	O
import	O
deficiency	B-UNK
in	O
human	B-UNK
peroxisomal	B-DISEASE
disorders	I-DISEASE
is	O
understood	O
.	O

Spectrum	B-UNK
of	O
germline	B-UNK
mutations	I-UNK
in	O
the	O
RB1	B-UNK
gene	B-UNK
:	O
a	O
study	B-UNK
of	O
232	O
patients	B-UNK
with	O
hereditary	B-UNK
and	O
non	O
hereditary	B-UNK
retinoblastoma	B-DISEASE
.	O

Germline	B-UNK
mutations	I-UNK
in	O
the	O
RB1	B-UNK
gene	B-UNK
confer	O
hereditary	B-UNK
predisposition	B-UNK
to	O
retinoblastoma	B-DISEASE
.	O

We	O
have	O
performed	O
a	O
mutation	B-UNK
survey	O
of	O
the	O
RB1	B-UNK
gene	B-UNK
in	O
232	O
patients	B-UNK
with	O
hereditary	B-UNK
or	O
non	O
hereditary	B-UNK
retinoblastoma	B-DISEASE
.	O

We	O
systematically	O
explored	O
all	O
27	O
exons	O
and	O
flanking	O
sequences	O
as	O
well	O
as	O
the	O
promotor	O
.	O

All	O
types	B-UNK
of	O
point	B-UNK
mutations	I-UNK
are	O
represented	O
and	O
are	O
found	O
unequally	O
distributed	O
along	O
the	O
RB1	B-UNK
gene	B-UNK
sequence	B-UNK
.	O

In	O
the	O
population	B-UNK
we	O
studied	O
,	O
exons	O
3	O
,	O
8	O
,	O
18	O
and	O
19	O
are	O
preferentially	O
altered	O
.	O

The	O
range	B-UNK
of	O
frequency	B-UNK
of	O
detection	B-UNK
of	O
germline	B-UNK
mutations	I-UNK
is	O
about	O
20	O
%	O
,	O
indicating	O
that	O
other	O
mechanisms	O
of	O
inactivation	B-UNK
of	O
RB1	B-UNK
should	O
be	O
involved	B-UNK
.	O

The	O
spectrum	B-UNK
of	O
mutations	B-UNK
presented	B-UNK
here	O
should	O
help	O
to	O
improve	O
the	O
clinical	B-UNK
management	O
of	O
retinoblastoma	B-DISEASE
and	O
to	O
understand	O
the	O
molecular	B-UNK
mechanisms	O
leading	B-UNK
to	O
tumorigenesis	O
..	O

Aniridia	B-DISEASE
-	O
associated	O
cytogenetic	B-UNK
rearrangements	O
suggest	B-UNK
that	O
a	O
position	B-UNK
effect	B-UNK
may	O
cause	O
the	O
mutant	B-UNK
phenotype	B-UNK
.	O

Current	B-UNK
evidence	B-UNK
suggests	O
that	O
aniridia	B-DISEASE
(	O
absence	B-UNK
of	O
iris	O
)	O
is	O
caused	B-UNK
by	O
loss	B-UNK
of	O
function	B-UNK
of	O
one	O
copy	B-UNK
of	O
the	O
PAX6	B-UNK
gene	B-UNK
,	O
which	O
maps	B-UNK
to	O
11p13	O
.	O

We	O
present	B-UNK
the	O
further	O
characterisation	O
of	O
two	O
aniridia	B-DISEASE
pedigrees	O
in	O
which	O
the	O
disease	B-DISEASE
segregates	O
with	O
chromosomal	B-UNK
rearrangements	O
which	O
involve	O
11p13	O
but	O
do	O
not	O
disrupt	O
the	O
PAX6	B-UNK
gene	B-UNK
.	O

We	O
have	O
isolated	B-UNK
three	O
human	B-UNK
YAC	B-UNK
clones	O
which	O
encompass	O
the	O
PAX6	B-UNK
locus	B-UNK
and	O
we	O
have	O
used	O
these	O
to	O
show	O
that	O
in	O
both	O
cases	B-UNK
the	O
chromosomal	B-UNK
breakpoint	O
is	O
at	O
least	O
85	O
kb	B-UNK
distal	B-UNK
of	O
the	O
3	O
end	B-UNK
of	O
PAX6	B-UNK
.	O

In	O
addition	B-UNK
,	O
the	O
open	O
reading	B-UNK
frame	I-UNK
of	O
PAX6	B-UNK
is	O
apparently	O
free	O
of	O
mutations	B-UNK
.	O

We	O
propose	O
that	O
the	O
PAX6	B-UNK
gene	B-UNK
on	O
the	O
rearranged	O
chromosome	B-UNK
11	O
is	O
in	O
an	O
inappropriate	O
chromatin	O
environment	O
for	O
normal	B-UNK
expression	B-UNK
and	O
therefore	O
that	O
a	O
position	B-UNK
effect	B-UNK
is	O
the	O
underlying	O
mechanism	B-UNK
of	O
disease	B-DISEASE
in	O
these	O
families	B-UNK
..	O

Somatic	B-UNK
mutations	I-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
in	O
sporadic	B-UNK
ovarian	B-UNK
tumours	B-DISEASE
.	O

The	O
BRCA1	B-UNK
gene	B-UNK
on	O
chromosome	B-UNK
17q21	O
is	O
responsible	B-UNK
for	O
an	O
autosomal	B-UNK
dominant	I-UNK
syndrome	B-UNK
of	O
increased	B-UNK
susceptibility	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
but	O
no	O
somatic	B-UNK
mutations	I-UNK
in	O
tumours	B-DISEASE
have	O
yet	O
been	O
described	O
.	O

To	O
study	B-UNK
the	O
potential	B-UNK
role	B-UNK
of	O
BRCA1	B-UNK
in	O
sporadic	B-UNK
carcinogenesis	B-DISEASE
,	O
we	O
analysed	O
the	O
genomic	B-UNK
DNA	I-UNK
of	O
tumour	B-UNK
and	O
normal	B-UNK
fractions	O
of	O
47	O
ovarian	B-UNK
cancers	I-UNK
for	O
mutations	B-UNK
in	O
BRCA1	B-UNK
using	O
the	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
technique	O
.	O

We	O
now	O
describe	O
somatic	B-UNK
mutations	I-UNK
in	O
the	O
DNA	B-UNK
of	O
four	O
tumours	B-DISEASE
which	O
also	O
had	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
(	O
LOH	B-UNK
)	O
at	O
a	O
BRCA1	B-UNK
intragenic	O
marker	B-UNK
.	O

Our	O
data	B-UNK
support	O
a	O
tumour	B-UNK
suppressor	I-UNK
mechanism	B-UNK
for	O
BRCA1	B-UNK
;	O
somatic	B-UNK
mutations	I-UNK
and	O
LOH	B-UNK
may	O
result	B-UNK
in	O
inactivation	B-UNK
of	O
BRCA1	B-UNK
in	O
at	O
least	O
a	O
small	O
number	B-UNK
of	O
ovarian	B-UNK
cancers	I-UNK
..	O

Decreased	B-UNK
expression	B-UNK
of	O
BRCA1	B-UNK
accelerates	O
growth	B-UNK
and	O
is	O
often	O
present	B-UNK
during	O
sporadic	B-UNK
breast	I-UNK
cancer	B-UNK
progression	B-UNK
.	O

We	O
have	O
characterized	B-UNK
expression	B-UNK
of	O
the	O
familial	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
gene	B-UNK
,	O
BRCA1	B-UNK
,	O
in	O
cases	B-UNK
of	O
non-hereditary	O
(	O
sporadic	B-UNK
)	O
breast	B-UNK
cancer	I-UNK
and	O
analyzed	B-UNK
the	O
effect	B-UNK
of	O
antisense	O
inhibition	O
of	O
BRCA1	B-UNK
on	O
the	O
proliferative	O
rate	B-UNK
of	O
mammary	O
epithelial	B-UNK
cells	B-UNK
.	O

BRCA1	B-UNK
mRNA	O
levels	B-UNK
are	O
markedly	B-UNK
decreased	B-UNK
during	O
the	O
transition	B-UNK
from	O
carcinoma	B-DISEASE
in	I-DISEASE
situ	I-DISEASE
to	O
invasive	O
cancer	B-DISEASE
.	O

Experimental	O
inhibition	O
of	O
BRCA1	B-UNK
expression	B-UNK
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	B-UNK
of	O
normal	B-UNK
and	O
malignant	B-UNK
mammary	O
cells	B-UNK
,	O
but	O
had	O
no	O
effect	B-UNK
on	O
non-mammary	O
epithelial	B-UNK
cells	B-UNK
.	O

These	O
studies	B-UNK
suggest	B-UNK
that	O
BRCA1	B-UNK
may	O
normally	O
serve	O
as	O
a	O
negative	B-UNK
regulator	O
of	O
mammary	O
epithelial	B-UNK
cell	B-UNK
growth	B-UNK
whose	O
function	B-UNK
is	O
compromised	O
in	O
breast	B-UNK
cancer	I-UNK
either	O
by	O
direct	B-UNK
mutation	B-UNK
or	O
alterations	B-UNK
in	O
gene	B-UNK
expression	I-UNK
..	O

Additional	O
case	B-UNK
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	B-UNK
manifestations	I-UNK
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
due	O
to	O
opposite	O
X	O
-	O
chromosome	B-UNK
inactivation	B-UNK
.	O

A	O
pair	B-UNK
of	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
,	O
heterozygous	B-UNK
carriers	B-UNK
for	O
a	O
deletion	B-UNK
in	O
the	O
DMD	B-UNK
gene	B-UNK
and	O
discordant	O
for	O
the	O
clinical	B-UNK
manifestations	I-UNK
of	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
,	O
were	O
analyzed	B-UNK
by	O
molecular	B-UNK
studies	B-UNK
,	O
in	B-UNK
situ	I-UNK
hybridization	I-UNK
,	O
and	O
methylation	B-UNK
pattern	B-UNK
of	O
X	O
chromosomes	O
to	O
search	O
for	O
opposite	O
X	O
inactivation	B-UNK
as	O
an	O
explanation	O
of	O
their	O
clinical	B-UNK
discordance	O
.	O

Results	B-UNK
in	O
lymphocytes	O
and	O
skin	B-UNK
fibroblast	O
cell	B-UNK
lines	I-UNK
suggest	B-UNK
a	O
partial	O
mirror	O
inactivation	B-UNK
with	O
the	O
normal	B-UNK
X	O
chromosome	B-UNK
preferentially	O
active	B-UNK
in	O
the	O
unaffected	O
twin	O
,	O
and	O
the	O
maternal	O
deleted	B-UNK
X	O
chromosome	B-UNK
preferentially	O
active	B-UNK
in	O
the	O
affected	B-UNK
twin	O
.	O

A	O
review	O
shows	O
that	O
MZ	O
female	O
twins	O
discordant	O
for	O
X	O
-	O
linked	B-UNK
diseases	B-DISEASE
are	O
not	O
uncommon	O
.	O

Twinning	O
and	O
X	O
inactivation	B-UNK
may	O
be	O
interrelated	O
and	O
could	O
explain	O
the	O
female	O
twins	O
discordant	O
for	O
X	O
-	O
linked	B-UNK
traits	O
..	O

X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
):	O
a	O
novel	O
mutation	B-UNK
of	O
the	O
ALD	B-UNK
gene	B-UNK
in	O
6	O
members	B-UNK
of	O
a	O
family	B-UNK
presenting	B-UNK
with	O
5	O
different	O
phenotypes	O
.	O

Fragments	O
of	O
the	O
adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
cDNA	O
from	O
a	O
patient	B-UNK
with	O
adolescent	O
ALD	B-UNK
were	O
amplified	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
and	O
subcloned	O
.	O

Bidirectional	O
sequencing	B-UNK
of	O
the	O
entire	O
coding	B-UNK
ALD	B-UNK
gene	B-UNK
disclosed	O
a	O
cytosine	O
to	O
guanine	B-UNK
transversion	B-UNK
at	O
nucleotide	B-UNK
1451	O
in	O
exon	B-UNK
five	O
,	O
resulting	B-UNK
in	O
substitution	B-UNK
of	O
proline	O
484	O
by	O
arginine	O
.	O

Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	B-UNK
,	O
comprising	O
two	O
cerebral	B-UNK
ALD	I-UNK
,	O
one	O
adrenomyeloneuropathy	O
,	O
one	O
Addison	O
only	O
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
)	O
carried	O
this	O
mutation	B-UNK
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	B-UNK
ALD	B-UNK
patients	B-UNK
,	O
and	O
in	O
twenty	O
controls	O
.	O

We	O
propose	O
that	O
this	O
missense	B-UNK
mutation	I-UNK
generated	O
the	O
disease	B-DISEASE
per	O
se	B-DISEASE
as	O
well	O
as	O
the	O
metabolic	B-UNK
defect	B-UNK
;	O
the	O
different	O
phenotypes	O
,	O
however	O
,	O
must	O
have	O
originated	O
by	O
means	B-UNK
of	O
additional	O
pathogenetic	O
factors	O
..	O

Novel	O
mutation	B-UNK
at	O
the	O
initiation	O
codon	B-UNK
in	O
the	O
Norrie	B-DISEASE
disease	I-DISEASE
gene	B-UNK
in	O
two	O
Japanese	B-UNK
families	B-UNK
.	O

We	O
have	O
identified	B-UNK
a	O
new	O
mutation	B-UNK
of	O
Norrie	B-DISEASE
disease	I-DISEASE
(	O
ND	O
)	O
gene	B-UNK
in	O
two	O
Japanese	B-UNK
males	B-UNK
from	O
unrelated	B-UNK
families	I-UNK
;	O
they	O
showed	O
typical	O
ocular	O
features	B-UNK
of	O
ND	O
but	O
no	O
mental	B-DISEASE
retardation	I-DISEASE
or	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

A	O
mutation	B-UNK
was	O
found	O
in	O
both	O
patients	B-UNK
at	O
the	O
initiation	O
codon	B-UNK
of	O
exon	B-UNK
2	O
of	O
the	O
ND	O
gene	B-UNK
(	O
ATG	O
to	O
GTG	O
)	O
,	O
with	O
otherwise	O
normal	B-UNK
nucleotide	B-UNK
sequences	O
.	O

Their	O
mothers	O
had	O
the	O
normal	B-UNK
and	O
mutant	B-UNK
types	B-UNK
of	O
the	O
gene	B-UNK
,	O
which	O
was	O
expected	O
for	O
heterozygotes	B-UNK
of	O
the	O
disease	B-UNK
.	O

The	O
mutation	B-UNK
of	O
the	O
initiation	O
codon	B-UNK
would	O
cause	O
the	O
failure	B-UNK
of	O
ND	O
gene	B-UNK
expression	I-UNK
or	O
a	O
defect	B-UNK
in	O
translation	O
thereby	O
truncating	B-UNK
the	O
amino	B-UNK
terminus	O
of	O
ND	O
protein	B-UNK
.	O

In	O
view	O
of	O
the	O
rarity	O
and	O
marked	B-UNK
heterogeneity	B-UNK
of	O
mutations	B-UNK
in	O
the	O
ND	O
gene	B-UNK
,	O
the	O
present	B-UNK
apparently	O
unrelated	B-UNK
Japanese	B-UNK
families	B-UNK
who	O
have	O
lived	O
in	O
the	O
same	O
area	B-UNK
for	O
over	O
two	O
centuries	O
presumably	O
share	O
the	O
origin	O
of	O
the	O
mutation	B-UNK
..	O

Anticipation	B-UNK
resulting	B-UNK
in	O
elimination	O
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
gene	B-UNK
:	O
a	O
follow	O
up	O
study	B-UNK
of	O
one	O
extended	O
family	B-UNK
.	O

We	O
have	O
re-examined	O
an	O
extended	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
family	B-UNK
,	O
previously	B-UNK
described	O
in	O
1955	O
,	O
in	O
order	B-UNK
to	O
study	B-UNK
the	O
long	B-UNK
term	O
effects	B-UNK
of	O
anticipation	B-UNK
in	O
DM	B-UNK
and	O
in	O
particular	O
the	O
implications	B-UNK
for	O
families	B-UNK
affected	B-UNK
by	O
this	O
disease	B-UNK
.	O

This	O
follow	O
up	O
study	B-UNK
provides	O
data	B-UNK
on	O
35	O
gene	B-UNK
carriers	B-UNK
and	O
46	O
asymptomatic	B-UNK
at	O
risk	B-UNK
family	B-UNK
members	I-UNK
in	O
five	O
generations	O
.	O

Clinical	B-UNK
anticipation	B-UNK
,	O
defined	B-UNK
as	O
the	O
cascade	O
of	O
mild	O
,	O
adult	B-UNK
,	O
childhood	O
,	O
or	O
congenital	B-UNK
disease	B-UNK
in	O
subsequent	B-UNK
generations	O
,	O
appeared	B-UNK
to	O
be	O
a	O
relentless	O
process	B-UNK
,	O
occurring	O
in	O
all	O
affected	B-UNK
branches	O
of	O
the	O
family	B-UNK
.	O

The	O
cascade	O
was	O
found	O
to	O
proceed	O
asynchronously	O
in	O
the	O
different	O
branches	O
,	O
mainly	O
because	O
of	O
an	O
unequal	O
number	B-UNK
of	O
generations	O
with	O
mild	O
disease	B-DISEASE
.	O

The	O
transition	B-UNK
from	O
the	O
mild	O
to	O
the	O
adult	B-UNK
type	B-UNK
was	O
associated	O
with	O
transmission	B-UNK
through	O
a	O
male	B-UNK
parent	O
.	O

Stable	B-UNK
transmission	B-UNK
of	O
the	O
asymptomatic	B-UNK
/	O
mild	O
phenotype	B-UNK
showed	O
a	O
female	O
transmission	B-UNK
bias	O
.	O

We	O
further	O
examined	O
the	O
extent	O
and	O
causes	O
of	O
gene	B-UNK
loss	B-UNK
in	O
this	O
pedigree	B-UNK
.	O

Gene	B-UNK
loss	B-UNK
in	O
the	O
patient	B-UNK
group	B-UNK
was	O
complete	O
,	O
owing	O
to	O
infertility	B-DISEASE
of	O
the	O
male	B-UNK
patients	B-UNK
with	O
adult	B-UNK
onset	I-UNK
disease	B-UNK
and	O
the	O
fact	B-UNK
that	O
mentally	O
retarded	O
patients	B-UNK
did	O
not	O
procreate	O
.	O

Out	O
of	O
the	O
46	O
at	O
risk	B-UNK
subjects	B-UNK
in	O
the	O
two	O
youngest	O
generations	O
,	O
only	O
one	O
was	O
found	O
to	O
have	O
a	O
full	O
mutation	B-UNK
.	O

This	O
is	O
the	O
only	O
subject	O
who	O
may	O
transmit	O
the	O
gene	B-UNK
to	O
the	O
sixth	O
generation	O
.	O

No	O
protomutation	O
carriers	B-UNK
were	O
found	O
in	O
the	O
fourth	B-UNK
and	O
fifth	O
generations	O
.	O

Therefore	O
it	O
is	O
highly	B-UNK
probable	O
that	O
the	O
DM	B-UNK
gene	B-UNK
will	O
be	O
eliminated	O
from	O
this	O
pedigree	B-UNK
within	O
one	O
generation	O
.	O

The	O
high	B-UNK
population	B-UNK
frequency	B-UNK
of	O
DM	B-DISEASE
can	O
at	O
present	B-UNK
not	O
be	O
explained	O
by	O
the	O
contribution	O
of	O
asymptomatic	B-UNK
cases	B-UNK
in	O
the	O
younger	O
generations	O
of	O
known	O
families	B-UNK
,	O
but	O
is	O
probably	O
caused	B-UNK
by	O
the	O
events	O
in	O
the	O
ancestral	O
generations	O
..	O

The	O
gene	B-UNK
for	O
spinal	B-UNK
cerebellar	B-DISEASE
ataxia	I-DISEASE
3	O
(	O
SCA3	B-UNK
)	O
is	O
located	B-UNK
in	O
a	O
region	B-UNK
of	O
approximately	O
3	O
cM	B-DISEASE
on	O
chromosome	B-UNK
14q24	O
.	O
3-q32	O
.	O
2	O
.	O

SCA3	B-UNK
,	O
the	O
gene	B-UNK
for	O
spinal	B-UNK
cerebellar	B-DISEASE
ataxia	I-DISEASE
3	O
,	O
was	O
recently	O
mapped	B-UNK
to	O
a	O
15-cM	O
interval	B-UNK
between	O
D14S67	O
and	O
D14S81	O
on	O
chromosome	B-UNK
14q	O
,	O
by	O
linkage	B-UNK
analysis	I-UNK
in	O
two	O
families	B-UNK
of	O
French	B-UNK
ancestry	O
.	O

The	O
SCA3	B-UNK
candidate	B-UNK
region	B-UNK
has	O
now	O
been	O
refined	O
by	O
linkage	B-UNK
analysis	I-UNK
with	O
four	O
new	O
microsatellite	B-UNK
markers	I-UNK
(	O
D14S256	O
,	O
D14S291	O
,	O
D14S280	O
,	O
and	O
AFM343vf1	O
)	O
in	O
the	O
same	O
two	O
families	B-UNK
,	O
in	O
which	O
19	O
additional	O
individuals	B-UNK
were	O
genotyped	O
,	O
and	O
in	O
a	O
third	O
French	B-UNK
family	B-UNK
.	O

Combined	O
two	O
-	O
point	B-UNK
linkage	B-UNK
analyses	O
show	O
that	O
the	O
new	O
markers	B-UNK
,	O
D14S280	O
and	O
AFM343vf1	O
,	O
are	O
tightly	B-UNK
linked	I-UNK
to	O
the	O
SCA3	B-UNK
locus	B-UNK
,	O
with	O
maximal	O
lod	B-UNK
scores	I-UNK
,	O
at	O
recombination	B-UNK
fraction	B-UNK
,	O
(	O
theta	B-UNK
)	O
=	O
.	O

00	O
,	O
of	O
7	O
.	O

05	O
and	O
13	O
.	O

70	O
,	O
respectively	O
.	O

Combined	O
multipoint	B-UNK
and	O
recombinant	B-UNK
haplotype	B-UNK
analyses	O
localize	O
the	O
SCA3	B-UNK
locus	B-UNK
to	O
a	O
3-cM	O
interval	B-UNK
flanked	O
by	O
D14S291	O
and	O
D14S81	O
.	O

The	O
same	O
allele	B-UNK
for	O
D14S280	O
segregates	O
with	O
the	O
disease	B-UNK
locus	B-UNK
in	O
the	O
three	O
kindreds	O
.	O

This	O
allele	B-UNK
is	O
frequent	B-UNK
in	O
the	O
French	B-UNK
population	B-UNK
,	O
however	O
,	O
and	O
linkage	B-UNK
disequilibrium	I-UNK
is	O
not	O
clearly	O
established	O
.	O

The	O
SCA3	B-UNK
locus	B-UNK
remains	O
within	O
the	O
29-cM	O
region	B-UNK
on	O
14q24	O
.	O

3-q32	O
.	O

2	O
containing	O
the	O
gene	B-UNK
for	O
the	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
,	O
which	O
is	O
clinically	O
related	B-UNK
to	O
the	O
phenotype	B-UNK
determined	B-UNK
by	O
SCA3	B-UNK
,	O
but	O
it	O
cannot	O
yet	O
be	O
concluded	O
that	O
both	O
diseases	B-DISEASE
result	B-UNK
from	O
alterations	B-UNK
of	O
the	O
same	O
gene	B-UNK

An	O
evaluation	B-UNK
of	O
genetic	B-UNK
heterogeneity	I-UNK
in	O
145	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
families	B-UNK
.	O

Breast	B-DISEASE
Cancer	I-DISEASE
Linkage	B-UNK
Consortium	O
.	O

The	O
breast	B-UNK
-	O
ovary	O
cancer	B-DISEASE
-	O
family	B-UNK
syndrome	B-UNK
is	O
a	O
dominant	B-UNK
predisposition	B-UNK
to	O
cancer	B-UNK
of	O
the	O
breast	B-UNK
and	O
ovaries	O
which	O
has	O
been	O
mapped	B-UNK
to	O
chromosome	B-UNK
region	B-UNK
17q12-q21	O
.	O

The	O
majority	O
,	O
but	O
not	O
all	O
,	O
of	O
breast	B-UNK
-	O
ovary	O
cancer	B-DISEASE
families	B-UNK
show	O
linkage	B-UNK
to	O
this	O
susceptibility	B-UNK
locus	B-UNK
,	O
designated	O
BRCA1	B-UNK
.	O

We	O
report	B-UNK
here	O
the	O
results	B-UNK
of	O
a	O
linkage	B-UNK
analysis	I-UNK
of	O
145	O
families	B-UNK
with	O
both	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
.	O

These	O
families	B-UNK
contain	O
either	O
a	O
total	B-UNK
of	O
three	O
or	O
more	O
cases	B-UNK
of	O
early	B-UNK
-	O
onset	B-UNK
(	O
before	O
age	B-UNK
60	O
years	O
)	O
breast	B-UNK
cancer	I-UNK
or	O
ovarian	B-UNK
cancer	I-UNK
.	O

All	O
families	B-UNK
contained	O
at	O
least	O
one	O
case	B-UNK
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

Overall	O
,	O
an	O
estimated	B-UNK
76	O
%	O
of	O
the	O
145	O
families	B-UNK
are	O
linked	B-UNK
to	O
the	O
BRCA1	B-UNK
locus	B-UNK
.	O

None	O
of	O
the	O
13	O
families	B-UNK
with	O
cases	B-UNK
of	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
appear	O
to	O
be	O
linked	B-UNK
,	O
but	O
it	O
is	O
estimated	B-UNK
that	O
92	O
%	O
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
76%-100	O
%	O
)	O
of	O
families	B-UNK
with	O
no	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
and	O
with	O
two	O
or	O
more	O
ovarian	B-UNK
cancers	I-UNK
are	O
linked	B-UNK
to	O
BRCA1	B-UNK
.	O

These	O
data	B-UNK
suggest	B-UNK
that	O
the	O
breast	B-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
-	O
family	B-UNK
syndrome	B-DISEASE
is	O
genetically	B-UNK
heterogeneous	O
.	O

However	O
,	O
the	O
large	B-UNK
majority	O
of	O
families	B-UNK
with	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
and	O
with	O
two	O
or	O
more	O
cases	B-UNK
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
are	O
likely	O
to	O
be	O
due	O
to	O
BRCA1	B-UNK
mutations	B-UNK
..	O

Molecular	B-UNK
basis	I-UNK
of	O
essential	B-UNK
fructosuria	B-DISEASE
:	O
molecular	B-UNK
cloning	B-UNK
and	O
mutational	O
analysis	B-UNK
of	O
human	B-UNK
ketohexokinase	O
(	O
fructokinase	O
)	O
.	O

Essential	B-UNK
fructosuria	B-DISEASE
is	O
one	O
of	O
the	O
oldest	O
known	O
inborn	O
errors	O
of	O
metabolism	B-UNK
.	O

It	O
is	O
a	O
benign	O
condition	B-UNK
which	O
is	O
believed	O
to	O
result	B-UNK
from	O
deficiency	B-UNK
of	O
hepatic	B-UNK
fructokinase	O
(	O
ketohexokinase	O
,	O
KHK	O
,	O
E.	O
C.	O
2	O
.	O
7	O
.	O
1	O
.	O
3	O
)	O
.	O

This	O
enzyme	B-UNK
catalyses	O
the	O
first	O
step	O
of	O
metabolism	B-UNK
of	O
dietary	O
fructose	O
,	O
conversion	O
of	O
fructose	O
to	O
fructose-1-phosphate	O
.	O

Despite	O
the	O
early	B-UNK
recognition	O
of	O
this	O
disorder	B-UNK
,	O
the	O
primary	B-UNK
structure	B-UNK
of	O
human	B-UNK
KHK	O
and	O
the	O
molecular	B-UNK
basis	I-UNK
of	O
essential	B-UNK
fructosuria	B-DISEASE
have	O
not	O
been	O
previously	B-UNK
defined	B-UNK
.	O

In	O
this	O
report	B-UNK
,	O
the	O
isolation	B-UNK
and	O
sequencing	B-UNK
of	O
full	O
-	O
length	B-UNK
cDNA	O
clones	O
encoding	B-UNK
human	B-UNK
ketohexokinase	O
are	O
described	O
.	O

Alternative	B-UNK
mRNA	O
species	B-UNK
and	O
alternative	B-UNK
KHK	O
isozymes	O
are	O
produced	O
by	O
alternative	B-UNK
polyadenylation	O
and	O
splicing	B-UNK
of	O
the	O
KHK	O
gene	B-UNK
.	O

The	O
KHK	O
proteins	B-UNK
show	O
a	O
high	B-UNK
level	B-UNK
of	O
sequence	B-UNK
conservation	B-UNK
relative	B-UNK
to	O
rat	O
KHK	O
.	O

Direct	B-UNK
evidence	B-UNK
that	O
mutation	B-UNK
of	O
the	O
KHK	O
structural	B-UNK
gene	B-UNK
is	O
the	O
cause	O
of	O
essential	B-UNK
fructosuria	B-DISEASE
was	O
also	O
obtained	B-UNK
.	O

In	O
a	O
well	O
-	O
characterized	B-UNK
family	B-UNK
,	O
in	O
which	O
three	O
of	O
eight	O
siblings	O
have	O
fructosuria	B-DISEASE
,	O
all	O
affected	B-UNK
individuals	I-UNK
are	O
compound	B-UNK
heterozygotes	I-UNK
for	O
two	O
mutations	B-UNK
Gly40Arg	O
and	O
Ala43Thr	O
.	O

Both	O
mutations	B-UNK
result	B-UNK
from	O
G--	O
>	O
A	O
transitions	O
,	O
and	O
each	O
alters	O
the	O
same	O
conserved	B-UNK
region	B-UNK
of	O
the	O
KHK	O
protein	B-UNK
.	O

Neither	O
mutation	B-UNK
was	O
seen	O
in	O
a	O
sample	O
of	O
52	O
unrelated	B-UNK
control	B-UNK
individuals	B-UNK
.	O

An	O
additional	O
conservative	O
amino	B-UNK
acid	I-UNK
change	B-UNK
(	O
Val49IIe	O
)	O
was	O
present	B-UNK
on	O
the	O
KHK	O
allele	B-UNK
bearing	O
Ala43Thr	O

Homozygous	B-UNK
presence	O
of	O
the	O
crossover	O
(	O
fusion	B-UNK
gene	B-UNK
)	O
mutation	B-UNK
identified	B-UNK
in	O
a	O
type	B-UNK
II	I-UNK
Gaucher	B-DISEASE
disease	I-DISEASE
fetus	O
:	O
is	O
this	O
analogous	O
to	O
the	O
Gaucher	O
knock-out	O
mouse	B-UNK
model	I-UNK
?	O

Gaucher	B-DISEASE
disease	I-DISEASE
(	O
GD	B-UNK
)	O
is	O
an	O
inherited	B-UNK
deficiency	B-UNK
of	O
beta-glucocerebrosidase	O
(	O
EC	B-UNK
3	O
.	O
1	O
.	O
2	O
.	O
45	O
,	O
gene	B-UNK
symbol	O
GBA	O
)	O
.	O

In	O
type	B-UNK
I	O
GD	B-UNK
,	O
the	O
CNS	O
is	O
not	O
involved	B-UNK
(	O
nonneuronopathic	O
)	O
,	O
whereas	O
in	O
type	B-UNK
II	I-UNK
GD	B-UNK
(	O
acute	B-UNK
neuronopathic	O
)	O
CNS	O
involvement	B-UNK
is	O
early	B-UNK
and	O
rapidly	O
progressive	B-UNK
,	O
while	O
in	O
type	B-UNK
III	B-UNK
GD	B-UNK
(	O
subacute	O
neuronopathic	O
)	O
CNS	O
involvement	B-UNK
occurs	O
later	O
and	O
is	O
slowly	O
progressive	B-UNK
.	O

The	O
T6433C	O
(	O
L444P	O
)	O
substitution	B-UNK
is	O
prevalent	O
in	O
type	B-UNK
GD	B-UNK
II	B-UNK
.	O

It	O
may	O
occur	B-UNK
alone	O
as	O
a	O
single	B-UNK
base	I-UNK
-	O
pair	B-UNK
mutation	B-UNK
but	O
often	O
is	O
found	O
as	O
part	O
of	O
a	O
complex	O
allele	B-UNK
containing	O
additional	O
GBA	O
nucleotide	B-UNK
substitutions	B-UNK
,	O
G6468C	O
(	O
A456P	O
)	O
and	O
G6482C	O
(	O
V460V	O
)	O
,	O
without	O
(	O
recNciI	O
)	O
or	O
with	O
(	O
recTL	O
)	O
G5957C	O
(	O
D409H	O
)	O
.	O

This	O
complex	O
allele	B-UNK
is	O
presumed	O
to	O
have	O
formed	O
by	O
recombination	B-UNK
(	O
crossover	O
,	O
fusion	B-UNK
)	O
of	O
the	O
structural	B-UNK
gene	B-UNK
with	O
the	O
pseudogene	O
,	O
which	O
contains	O
the	O
mutated	B-UNK
sequences	O
.	O

Two	O
complex	O
alleles	B-UNK
have	O
never	O
been	O
demonstrated	O
to	O
coexist	O
in	O
any	O
individual	O
.	O

We	O
devised	O
a	O
selective	O
PCR	B-UNK
method	O
for	O
the	O
specific	B-UNK
amplification	B-UNK
of	O
the	O
normal	B-UNK
and	O
/	O
or	O
fusion	B-UNK
gene	B-UNK
.	O

Using	O
this	O
procedure	O
we	O
demonstrated	O
the	O
fusion	B-UNK
gene	B-UNK
in	O
homozygous	B-UNK
form	B-UNK
for	O
the	O
first	O
time	O
,	O
in	O
a	O
Macedonian	O
/	O
Ashkenazi	B-UNK
Jewish	I-UNK
GD	B-UNK
type	B-UNK
II	I-UNK
fetus	O
.	O

Both	O
parents	O
were	O
carriers	B-UNK
of	O
the	O
recombination	B-UNK
.	O

This	O
was	O
confirmed	B-UNK
by	O
direct	B-UNK
sequence	B-UNK
analysis	I-UNK
.	O

A	O
previous	B-UNK
conceptus	O
in	O
this	O
family	B-UNK
was	O
stillborn	O
at	O
36	O
weeks	O
,	O
with	O
features	B-UNK
of	O
severe	B-UNK
type	B-UNK
II	I-UNK
GD	B-UNK
.	O

Neonates	O
showing	O
a	O
severe	B-UNK
clinical	B-UNK
phenotype	B-UNK
,	O
analogous	O
to	O
the	O
early	B-UNK
neonatal	B-UNK
lethal	O
disease	B-UNK
occurring	O
in	O
mice	B-UNK
homozygous	B-UNK
for	O
a	O
null	O
allele	B-UNK
produced	O
by	O
targeted	B-UNK
disruption	O
of	O
GBA	O
,	O
have	O
been	O
described	O
elsewhere	O
,	O
but	O
the	O
specific	B-UNK
mutations	B-UNK
in	O
these	O
cases	B-UNK
have	O
not	O
yet	O
been	O
characterized	B-UNK
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Late	B-UNK
infantile	I-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
in	O
Israel	O
.	O

Metachromatic	B-UNK
Leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
is	O
a	O
neurodegenerative	B-DISEASE
disease	I-DISEASE
in	O
which	O
the	O
lysosomal	B-UNK
enzyme	B-UNK
,	O
Aryl	O
sulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
is	O
deficient	B-UNK
.	O

The	O
disease	B-DISEASE
is	O
inherited	B-UNK
as	O
an	O
autosomal	B-UNK
recessive	I-UNK
trait	O
and	O
its	O
frequency	B-UNK
is	O
estimated	B-UNK
to	O
be	O
1/40	O
,	O
000	O
live	O
births	O
.	O

The	O
gene	B-UNK
of	O
ARSA	B-UNK
has	O
been	O
cloned	O
and	O
up	O
to	O
now	O
eight	O
mutations	B-UNK
causing	B-UNK
MLD	B-UNK
have	O
been	O
reported	B-UNK
.	O

Another	O
mutation	B-UNK
,	O
PD	B-DISEASE
,	O
leads	B-UNK
to	O
the	O
deficiency	B-UNK
of	O
the	O
enzyme	B-UNK
in	O
vitro	O
(	O
pseudodeficiency	O
)	O
without	O
any	O
known	O
clinical	B-UNK
effect	B-UNK
.	O

The	O
PD	B-DISEASE
mutation	B-UNK
is	O
frequent	B-UNK
in	O
all	O
populations	O
.	O

In	O
Israel	O
,	O
late	B-UNK
infantile	I-UNK
MLD	B-UNK
was	O
found	O
to	O
be	O
very	O
frequent	B-UNK
in	O
a	O
small	O
Jewish	B-UNK
isolate	O
,	O
the	O
Habbanite	O
Jews	B-UNK
(	O
1/75	O
live	O
births	O
)	O
.	O

The	O
molecular	B-UNK
analysis	I-UNK
demonstrated	O
that	O
in	O
the	O
Habbanite	O
population	B-UNK
,	O
the	O
mutation	B-UNK
occurred	B-UNK
on	O
an	O
allele	B-UNK
with	O
the	O
PD	B-DISEASE
mutation	B-UNK
.	O

The	O
loss	B-UNK
of	O
ARSA	B-UNK
activity	B-UNK
is	O
due	O
to	O
a	O
point	B-UNK
mutation	I-UNK
C	O
>	O
T	O
leading	B-UNK
to	O
a	O
change	B-UNK
of	O
proline	O
to	O
leucine	O
.	O

MLD	B-UNK
is	O
also	O
frequent	B-UNK
among	O
Moslem	O
Arabs	O
in	O
Jerusalem	O
.	O

The	O
mutation	B-UNK
is	O
a	O
transition	B-UNK
G	O
>	O
A	O
destroying	O
the	O
splice	B-UNK
donor	I-UNK
site	I-UNK
of	O
exon	B-UNK
2	O
.	O

This	O
mutation	B-UNK
has	O
been	O
reported	B-UNK
in	O
patients	B-UNK
with	O
the	O
late	B-UNK
infantile	I-UNK
MLD	B-UNK
from	O
different	O
ethnic	B-UNK
groups	I-UNK
.	O

The	O
Christian	O
Arabs	O
in	O
Israel	O
also	O
have	O
a	O
high	B-UNK
incidence	B-UNK
of	O
the	O
disease	B-DISEASE
(	O
1/10	O
,	O
000	O
live	O
births	O
)	O
;	O
the	O
mutation	B-UNK
in	O
this	O
population	B-UNK
is	O
still	O
unknown	O
.	O

Knowledge	B-UNK
of	O
the	O
different	O
mutations	B-UNK
causing	B-UNK
MLD	B-UNK
in	O
these	O
defined	B-UNK
populations	O
will	O
allow	O
a	O
carrier	B-UNK
screening	B-UNK
program	O
to	O
be	O
carried	O
out	O
and	O
prevent	O
the	O
birth	O
of	O
additional	O
affected	B-UNK
children	O
..	O

A	O
single	B-UNK
amino	B-UNK
acid	I-UNK
substitution	I-UNK
(	O
G103D	O
)	O
in	O
the	O
type	B-UNK
II	I-UNK
collagen	O
triple	O
helix	O
produces	O
Kniest	B-DISEASE
dysplasia	I-DISEASE
.	O

Kniest	B-DISEASE
dysplasia	I-DISEASE
is	O
a	O
moderately	O
severe	B-UNK
chondrodysplasia	O
phenotype	B-UNK
that	O
results	B-UNK
from	O
mutations	B-UNK
in	O
the	O
gene	B-UNK
for	O
type	B-UNK
II	I-UNK
collagen	O
,	O
COL2A1	O
.	O

Characteristics	B-UNK
of	O
the	O
disorder	B-UNK
include	O
a	O
short	B-UNK
trunk	O
and	O
extremities	O
,	O
mid	O
-	O
face	O
hypoplasia	B-UNK
,	O
cleft	B-DISEASE
palate	I-DISEASE
,	O
myopia	B-DISEASE
,	O
retinal	B-DISEASE
detachment	I-DISEASE
,	O
and	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	B-UNK
12	O
have	O
been	O
identified	B-UNK
in	O
individuals	B-UNK
with	O
Kniest	B-DISEASE
dysplasia	I-DISEASE
,	O
suggesting	O
that	O
mutations	B-UNK
within	O
this	O
region	B-UNK
of	O
the	O
protein	B-UNK
may	O
primarily	O
result	B-UNK
in	O
the	O
Kniest	B-DISEASE
dysplasia	I-DISEASE
phenotype	B-UNK
.	O

We	O
used	O
SSCP	B-UNK
to	O
analyze	O
an	O
amplified	O
genomic	B-UNK
DNA	I-UNK
fragment	B-UNK
containing	O
exon	B-UNK
12	O
from	O
seven	O
individuals	B-UNK
with	O
Kniest	B-DISEASE
dysplasia	I-DISEASE
.	O

An	O
abnormality	O
was	O
identified	B-UNK
in	O
one	O
patient	B-UNK
.	O

DNA	B-UNK
sequence	I-UNK
analysis	B-UNK
demonstrated	O
that	O
the	O
patient	B-UNK
was	O
heterozygous	B-UNK
for	O
a	O
G	O
to	O
A	O
transition	B-UNK
that	O
implied	O
substitution	B-UNK
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	B-UNK
by	O
aspartate	O
.	O

The	O
mutation	B-UNK
was	O
not	O
observed	B-UNK
in	O
DNA	B-UNK
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	B-UNK
.	O

Protein	B-UNK
microsequencing	O
demonstrated	O
expression	B-UNK
of	O
the	O
abnormal	O
allele	B-UNK
in	O
cartilage	O
.	O

These	O
data	B-UNK
demonstrate	B-UNK
that	O
point	B-UNK
mutations	I-UNK
which	O
result	B-UNK
in	O
single	B-UNK
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
can	O
produce	B-UNK
Kniest	B-UNK
dysplasia	I-UNK
and	O
further	O
support	O
the	O
hypothesis	B-UNK
that	O
alteration	O
of	O
a	O
domain	B-UNK
,	O
which	O
includes	O
the	O
region	B-UNK
encoded	B-UNK
by	O
exon	B-UNK
12	O
,	O
in	O
the	O
type	B-UNK
II	I-UNK
collagen	O
protein	B-UNK
leads	B-UNK
to	O
this	O
disorder	B-UNK
..	O

CAG	B-UNK
expansions	O
in	O
a	O
novel	O
gene	B-UNK
for	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
at	O
chromosome	B-UNK
14q32	O
.	O
1	O
.	O

We	O
have	O
identified	B-UNK
a	O
novel	O
gene	B-UNK
containing	O
CAG	B-UNK
repeats	I-UNK
and	O
mapped	B-UNK
it	O
to	O
chromosome	B-UNK
14q32	O
.	O

1	O
,	O
the	O
genetic	B-UNK
locus	B-UNK
for	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
.	O

In	O
normal	B-UNK
individuals	B-UNK
the	O
gene	B-UNK
contains	O
between	O
13	O
and	O
36	O
CAG	B-UNK
repeats	I-UNK
,	O
whereas	O
most	O
of	O
the	O
clinically	O
diagnosed	O
patients	B-UNK
and	O
all	O
of	O
the	O
affected	B-UNK
members	B-UNK
of	O
a	O
family	B-UNK
with	O
the	O
clinical	B-UNK
and	O
pathological	O
diagnosis	B-UNK
of	O
MJD	B-UNK
show	O
expansion	B-UNK
of	O
the	O
repeat	B-UNK
-	O
number	B-UNK
(	O
from	O
68	O
-	O
79	O
)	O
.	O

Southern	B-UNK
blot	I-UNK
analyses	O
and	O
genomic	B-UNK
cloning	B-UNK
demonstrates	O
the	O
existence	O
of	O
related	B-UNK
genes	B-UNK
.	O

These	O
results	B-UNK
raise	O
the	O
possibility	B-UNK
that	O
similar	B-UNK
abnormalities	B-UNK
in	O
related	B-UNK
genes	B-UNK
may	O
give	O
rise	B-UNK
to	O
diseases	B-DISEASE
similar	B-UNK
to	O
MJD	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
in	O
families	B-UNK
with	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
.	O

We	O
analysed	O
50	O
probands	O
with	O
a	O
family	B-UNK
history	B-UNK
of	O
breast	B-UNK
and	O
/	O
or	O
ovarian	B-UNK
cancer	I-UNK
for	O
germline	B-UNK
mutations	I-UNK
in	O
the	O
coding	B-UNK
region	I-UNK
of	O
the	O
BRCA1	B-UNK
candidate	B-UNK
gene	I-UNK
,	O
using	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
analysis	B-UNK
on	O
PCR	B-UNK
-	O
amplified	O
genomic	B-UNK
DNA	I-UNK
.	O

A	O
total	B-UNK
of	O
eight	O
putative	O
disease	B-DISEASE
-	O
causing	B-UNK
alterations	B-UNK
were	O
identified	B-UNK
four	O
of	O
these	O
are	O
frameshifts	O
and	O
two	O
are	O
nonsense	B-UNK
mutations	I-UNK
.	O

In	O
addition	B-UNK
,	O
we	O
found	O
two	O
missense	B-UNK
mutations	I-UNK
,	O
one	O
of	O
which	O
changes	O
the	O
final	O
cysteine	B-UNK
of	O
the	O
BRCA1	B-UNK
zinc	B-UNK
finger	I-UNK
motif	B-UNK
to	O
glycine	O
.	O

These	O
data	B-UNK
are	O
consistent	B-UNK
with	O
a	O
tumour	B-UNK
suppressor	I-UNK
model	B-UNK
,	O
and	O
support	O
the	O
notion	O
that	O
this	O
candidate	B-UNK
gene	I-UNK
is	O
in	O
fact	B-UNK
BRCA1	B-UNK
.	O

The	O
heterogeneity	B-UNK
of	O
mutations	B-UNK
,	O
coupled	O
with	O
the	O
large	B-UNK
size	B-UNK
of	O
the	O
gene	B-UNK
,	O
indicates	O
that	O
clinical	B-UNK
application	O
of	O
BRCA1	B-UNK
mutation	B-UNK
testing	B-UNK
will	O
be	O
technically	O
challenging	O
..	O

Confirmation	O
of	O
BRCA1	B-UNK
by	O
analysis	B-UNK
of	O
germline	B-UNK
mutations	I-UNK
linked	B-UNK
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
in	O
ten	O
families	B-UNK
.	O

We	O
provide	B-UNK
genetic	B-UNK
evidence	B-UNK
supporting	O
the	O
identity	O
of	O
the	O
candidate	B-UNK
gene	I-UNK
for	O
BRCA1	B-UNK
through	O
the	O
characterization	B-UNK
of	O
germline	B-UNK
mutations	I-UNK
in	O
63	O
breast	B-DISEASE
cancer	I-DISEASE
patients	B-UNK
and	O
10	O
ovarian	B-DISEASE
cancer	I-DISEASE
patients	B-UNK
in	O
ten	O
families	B-UNK
with	O
cancer	B-DISEASE
linked	B-UNK
to	O
chromosome	B-UNK
17q21	O
.	O

Nine	O
different	O
mutations	B-UNK
were	O
detected	B-UNK
by	O
screening	B-UNK
BRCA1	B-UNK
DNA	B-UNK
and	O
RNA	B-UNK
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
analysis	B-UNK
and	O
direct	B-UNK
sequencing	I-UNK
.	O

Seven	O
mutations	B-UNK
lead	B-UNK
to	O
protein	B-UNK
truncations	O
at	O
sites	O
throughout	O
the	O
gene	B-UNK
.	O

One	O
missense	B-UNK
mutation	I-UNK
(	O
which	O
occurred	B-UNK
independently	O
in	O
two	O
families	B-UNK
)	O
leads	B-UNK
to	O
loss	B-UNK
of	O
a	O
cysteine	B-UNK
in	O
the	O
zinc	B-UNK
binding	B-UNK
domain	I-UNK
.	O

An	O
intronic	O
single	B-UNK
basepair	O
substitution	B-UNK
destroys	O
an	O
acceptor	B-UNK
site	B-UNK
and	O
activates	O
a	O
cryptic	O
splice	B-UNK
site	I-UNK
,	O
leading	B-UNK
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	B-UNK
termination	B-UNK
.	O

The	O
four	O
families	B-UNK
with	O
both	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
had	O
chain	B-UNK
termination	B-UNK
mutations	B-UNK
in	O
the	O
N	O
-	O
terminal	B-UNK
half	B-UNK
of	O
the	O
protein	B-UNK
..	O

High	B-UNK
resolution	O
genetic	B-UNK
analysis	I-UNK
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	B-UNK
for	O
the	O
origin	O
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
mutation	B-UNK
.	O

The	O
mutation	B-UNK
causing	I-UNK
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
has	O
been	O
identified	B-UNK
as	O
an	O
amplification	B-UNK
of	O
an	O
unstable	O
trinucleotide	B-UNK
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
in	O
over	O
99	O
%	O
of	O
the	O
global	O
DM	B-DISEASE
population	B-UNK
.	O

It	O
is	O
in	O
complete	O
linkage	B-UNK
disequilibrium	I-UNK
with	O
an	O
Alu	B-UNK
element	O
polymorphism	B-UNK
within	O
the	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
,	O
suggesting	O
that	O
DM	B-UNK
is	O
a	O
consequence	B-UNK
of	O
one	O
or	O
few	O
ancestral	O
mutations	B-UNK
.	O

A	O
recent	O
analysis	B-UNK
utilizing	O
this	O
polymorphism	B-UNK
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	B-UNK
marker	B-UNK
,	O
suggested	O
that	O
similar	B-UNK
to	O
Fragile	B-DISEASE
X	I-DISEASE
syndrome	I-DISEASE
,	O
DM	B-UNK
exhibited	O
a	O
founder	B-UNK
effect	I-UNK
(	O
Imbert	O
et	O
al	B-DISEASE
.	O
,	O
1993	O
Nature	B-UNK
Genet	B-UNK
.	O
4	O
,	O
72	O
-	O
76	O
)	O
.	O

In	O
contrast	B-UNK
,	O
the	O
low	B-UNK
reproductive	O
fitness	O
of	O
individuals	B-UNK
with	O
congenital	B-UNK
DM	B-DISEASE
(	O
the	O
endpoint	O
of	O
genetic	B-UNK
anticipation	B-UNK
in	O
myotonic	B-UNK
dystrophy	I-UNK
)	O
suggests	O
a	O
higher	O
rate	B-UNK
of	O
new	O
mutations	B-UNK
.	O

We	O
present	B-UNK
a	O
high	B-UNK
resolution	O
genetic	B-UNK
analysis	I-UNK
of	O
the	O
DM	B-UNK
locus	B-UNK
using	O
PCR	B-UNK
based	B-UNK
assays	O
of	O
nine	O
polymorphisms	B-UNK
,	O
spanning	O
a	O
physical	B-UNK
distance	O
of	O
30	O
kb	B-UNK
,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
.	O

The	O
persistent	O
complete	O
allelic	O
association	B-UNK
of	O
the	O
DM	B-UNK
mutation	B-UNK
with	O
all	O
these	O
polymorphisms	B-UNK
provides	O
further	O
support	O
to	O
previous	B-UNK
observations	B-UNK
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	B-DISEASE
mutation	B-UNK
occurred	B-UNK
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	B-UNK
in	O
which	O
the	O
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	B-UNK
.	O

Genetic	B-UNK
instability	B-UNK
in	O
human	B-UNK
ovarian	B-UNK
cancer	I-UNK
cell	B-UNK
lines	I-UNK
.	O

We	O
have	O
analyzed	B-UNK
the	O
stability	O
of	O
microsatellites	O
in	O
cell	B-UNK
lines	I-UNK
derived	B-UNK
from	O
human	B-UNK
ovarian	B-UNK
cancers	I-UNK
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	B-UNK
tumor	B-DISEASE
cell	B-UNK
lines	I-UNK
are	O
genetically	B-UNK
unstable	O
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed	B-UNK
.	O

In	O
clones	O
and	O
subclones	O
derived	B-UNK
serially	O
from	O
one	O
of	O
these	O
cell	B-UNK
lines	I-UNK
(	O
2774	O
;	O
serous	O
cystadenocarcinoma	B-DISEASE
)	O
,	O
a	O
very	O
high	B-UNK
proportion	B-UNK
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	B-UNK
of	O
the	O
genome	B-UNK
change	B-UNK
their	O
size	B-UNK
in	O
a	O
mercurial	O
fashion	O
.	O

We	O
conclude	O
that	O
genomic	B-DISEASE
instability	I-DISEASE
in	O
ovarian	B-UNK
tumors	B-UNK
is	O
a	O
dynamic	O
and	O
ongoing	O
process	B-UNK
whose	O
high	B-UNK
frequency	I-UNK
may	O
have	O
been	O
previously	B-UNK
underestimated	O
by	O
PCR	B-UNK
-	O
based	B-UNK
allelotyping	O
of	O
bulk	O
tumor	B-UNK
tissue	B-UNK
.	O

We	O
have	O
identified	B-UNK
the	O
source	O
of	O
the	O
genetic	B-UNK
instability	B-UNK
in	O
one	O
ovarian	B-UNK
tumor	B-UNK
as	O
a	O
point	B-UNK
mutation	I-UNK
(	O
R524P	O
)	O
in	O
the	O
human	B-UNK
mismatch	O
-	O
repair	B-UNK
gene	B-UNK
MSH2	B-UNK
(	O
Salmonella	O
MutS	O
homologue	B-UNK
)	O
,	O
which	O
has	O
recently	O
been	O
shown	B-UNK
to	O
be	O
involved	B-UNK
in	O
hereditary	B-UNK
nonpolyposis	O
colorectal	B-DISEASE
cancer	I-DISEASE
.	O

Patient	B-UNK
2774	O
was	O
a	O
38-year	O
-	O
old	O
heterozygote	B-UNK
,	O
and	O
her	O
normal	B-UNK
tissue	B-UNK
carried	O
both	O
mutant	B-UNK
and	O
wild	B-UNK
-	O
type	B-UNK
alleles	B-UNK
of	O
the	O
human	B-UNK
MSH2	B-UNK
gene	B-UNK
.	O

However	O
the	O
wild	B-UNK
-	O
type	B-UNK
allele	B-UNK
was	O
lost	O
at	O
some	O
point	B-UNK
early	B-UNK
during	O
tumorigenesis	O
so	O
that	O
DNA	B-UNK
isolated	B-UNK
either	O
from	O
the	O
patients	B-UNK
ovarian	B-UNK
tumor	B-UNK
or	O
from	O
the	O
2774	O
cell	B-UNK
line	I-UNK
carries	O
only	O
the	O
mutant	B-UNK
allele	B-UNK
of	O
the	O
human	B-UNK
MSH2	B-UNK
gene	B-UNK
.	O

The	O
genetic	B-UNK
instability	B-UNK
observed	B-UNK
in	O
the	O
tumor	B-UNK
and	O
cell	B-UNK
line	I-UNK
DNA	B-UNK
,	O
together	O
with	O
the	O
germ	B-UNK
-	O
line	B-UNK
mutation	B-UNK
in	O
a	O
mismatch	O
-	O
repair	B-UNK
gene	B-UNK
,	O
suggest	B-UNK
that	O
the	O
MSH2	B-UNK
gene	B-UNK
is	O
involved	B-UNK
in	O
the	O
onset	B-UNK
and	O
/	O
or	O
progression	B-UNK
in	O
a	O
subset	O
of	O
ovarian	B-UNK
cancer	I-UNK
..	O

BRCA1	B-UNK
mutations	B-UNK
in	O
primary	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
carcinomas	B-UNK
.	O

Loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
data	B-UNK
from	O
familial	B-UNK
tumors	B-UNK
suggest	B-UNK
that	O
BRCA1	B-UNK
,	O
a	O
gene	B-UNK
that	O
confers	O
susceptibility	B-UNK
to	O
ovarian	B-UNK
and	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
,	O
encodes	B-UNK
a	O
tumor	B-UNK
suppressor	I-UNK
.	O

The	O
BRCA1	B-UNK
region	B-UNK
is	O
also	O
subject	O
to	O
allelic	O
loss	B-UNK
in	O
sporadic	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
,	O
an	O
indication	O
that	O
BRCA1	B-UNK
mutations	B-UNK
may	O
occur	B-UNK
somatically	O
in	O
these	O
tumors	B-UNK
.	O

The	O
BRCA1	B-UNK
coding	B-UNK
region	I-UNK
was	O
examined	O
for	O
mutations	B-UNK
in	O
primary	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
tumors	B-UNK
that	O
show	O
allele	B-UNK
loss	B-UNK
at	O
the	O
BRCA1	B-UNK
locus	B-UNK
.	O

Mutations	B-UNK
were	O
detected	B-UNK
in	O
3	O
of	O
32	O
breast	B-UNK
and	O
1	O
of	O
12	O
ovarian	B-UNK
carcinomas	B-UNK
;	O
all	O
four	O
mutations	B-UNK
were	O
germline	B-UNK
alterations	B-UNK
and	O
occurred	B-UNK
in	O
early	B-UNK
-	O
onset	B-UNK
cancers	B-UNK
.	O

These	O
results	B-UNK
suggest	B-UNK
that	O
mutation	B-UNK
of	O
BRCA1	B-UNK
may	O
not	O
be	O
critical	B-UNK
in	O
the	O
development	B-UNK
of	O
the	O
majority	O
of	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancers	I-UNK
that	O
arise	O
in	O
the	O
absence	B-UNK
of	O
a	O
mutant	B-UNK
germline	B-UNK
allele	B-UNK
..	O

PAX6	B-UNK
gene	B-UNK
dosage	O
effect	B-UNK
in	O
a	O
family	B-UNK
with	O
congenital	B-UNK
cataracts	B-DISEASE
,	O
aniridia	B-DISEASE
,	O
anophthalmia	B-DISEASE
and	O
central	B-UNK
nervous	I-UNK
system	I-UNK
defects	B-UNK
.	O

The	O
human	B-UNK
eye	B-UNK
malformation	O
aniridia	B-DISEASE
results	B-UNK
from	O
haploinsufficiency	O
of	O
PAX6	B-UNK
,	O
a	O
paired	O
box	O
DNA	B-UNK
-	O
binding	B-UNK
protein	B-UNK
.	O

To	O
study	B-UNK
this	O
dosage	O
effect	B-UNK
,	O
we	O
characterized	B-UNK
two	O
PAX6	B-UNK
mutations	B-UNK
in	O
a	O
family	B-UNK
segregating	O
aniridia	B-DISEASE
and	O
a	O
milder	B-UNK
syndrome	B-UNK
consisting	O
of	O
congenital	B-UNK
cataracts	B-DISEASE
and	O
late	B-UNK
onset	I-UNK
corneal	O
dystrophy	B-UNK
.	O

The	O
nonsense	B-UNK
mutations	I-UNK
,	O
at	O
codons	O
103	O
and	O
353	O
,	O
truncate	O
PAX6	B-UNK
within	O
the	O
N	O
-	O
terminal	B-UNK
paired	O
and	O
C	O
-	O
terminal	B-UNK
PST	O
domains	B-UNK
,	O
respectively	O
.	O

The	O
wild	B-UNK
-	O
type	B-UNK
PST	O
domain	B-UNK
activates	O
transcription	B-UNK
autonomously	O
and	O
the	O
mutant	B-UNK
form	B-UNK
has	O
partial	O
activity	B-UNK
.	O

A	O
compound	B-UNK
heterozygote	B-UNK
had	O
severe	B-UNK
craniofacial	O
and	O
central	B-UNK
nervous	I-UNK
system	I-UNK
defects	B-UNK
and	O
no	O
eyes	O
.	O

The	O
pattern	B-UNK
of	O
malformations	B-DISEASE
is	O
similar	B-UNK
to	O
that	O
in	O
homozygous	B-UNK
Sey	O
mice	B-UNK
and	O
suggests	O
a	O
critical	B-UNK
role	B-UNK
for	O
PAX6	B-UNK
in	O
controlling	O
the	O
migration	O
and	O
differentiation	B-UNK
of	O
specific	B-UNK
neuronal	B-UNK
progenitor	O
cells	B-UNK
in	O
the	O
brain	B-UNK
..	O

A	O
physical	B-UNK
map	B-UNK
and	O
candidate	B-UNK
genes	B-UNK
in	O
the	O
BRCA1	B-UNK
region	B-UNK
on	O
chromosome	B-UNK
17q12	O
-	O
21	O
.	O

We	O
have	O
constructed	O
a	O
physical	B-UNK
map	B-UNK
of	O
a	O
4	O
cM	B-DISEASE
region	B-UNK
on	O
chromosome	B-UNK
17q12	O
-	O
21	O
that	O
contains	O
the	O
hereditary	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
gene	B-UNK
BRCA1	B-UNK
.	O

The	O
map	B-UNK
comprises	O
a	O
contig	O
of	O
137	O
overlapping	O
yeast	B-UNK
artificial	O
chromosomes	O
and	O
P1	O
clones	O
,	O
onto	O
which	O
we	O
have	O
placed	O
112	O
PCR	B-UNK
markers	B-UNK
.	O

We	O
have	O
localized	B-UNK
more	O
than	O
20	O
genes	B-UNK
on	O
this	O
map	B-UNK
,	O
ten	O
of	O
which	O
had	O
not	O
been	O
mapped	B-UNK
to	O
the	O
region	B-UNK
previously	B-UNK
,	O
and	O
have	O
isolated	B-UNK
30	O
cDNA	O
clones	O
representing	O
partial	O
sequences	O
of	O
as	O
yet	O
unidentified	O
genes	B-UNK
.	O

Two	O
genes	B-UNK
that	O
lie	O
within	O
a	O
narrow	O
region	B-UNK
defined	B-UNK
by	O
meiotic	B-UNK
breakpoints	O
in	O
BRCA1	B-UNK
patients	B-UNK
have	O
been	O
sequenced	O
in	O
breast	B-UNK
cancer	I-UNK
patients	B-UNK
without	O
revealing	O
any	O
deleterious	O
mutations	B-UNK
.	O

These	O
new	O
reagents	O
should	O
facilitate	O
the	O
identification	B-UNK
of	O
BRCA1	B-UNK
..	O

The	O
LEC	O
rat	O
has	O
a	O
deletion	B-UNK
in	O
the	O
copper	B-UNK
transporting	O
ATPase	O
gene	B-UNK
homologous	B-UNK
to	O
the	O
Wilson	B-UNK
disease	I-UNK
gene	B-UNK
.	O

The	O
Long	B-UNK
-	O
Evans	O
Cinnamon	O
(	O
LEC	O
)	O
rat	O
shows	O
similarity	O
to	O
Wilson	B-UNK
disease	I-UNK
in	O
many	O
clinical	B-UNK
and	O
biochemical	O
features	B-UNK
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
the	O
rat	O
gene	B-UNK
(	O
Atp7b	B-UNK
)	O
homologous	B-UNK
to	O
the	O
human	B-UNK
Wilson	B-UNK
disease	I-UNK
gene	B-UNK
(	O
ATP7B	B-UNK
)	O
and	O
have	O
used	O
them	O
to	O
identify	B-UNK
a	O
partial	O
deletion	B-UNK
in	O
the	O
Atp7b	B-UNK
gene	B-UNK
in	O
the	O
LEC	O
rat	O
.	O

The	O
deletion	B-UNK
removes	O
at	O
least	O
900	O
bp	B-UNK
of	O
the	O
coding	B-UNK
region	I-UNK
at	O
the	O
3	O
end	B-UNK
,	O
includes	O
the	O
crucial	O
ATP	B-UNK
binding	B-UNK
domain	I-UNK
and	O
extends	O
downstream	O
of	O
the	O
gene	B-UNK
.	O

Our	O
results	B-UNK
provide	I-UNK
convincing	O
evidence	B-UNK
for	O
defining	O
the	O
LEC	O
rat	O
as	O
an	O
animal	B-UNK
model	I-UNK
for	O
Wilson	B-UNK
disease	I-UNK
.	O

This	O
model	B-UNK
will	O
be	O
important	O
for	O
studying	O
liver	B-UNK
pathophysiology	O
,	O
for	O
developing	O
therapy	B-UNK
for	O
Wilson	B-UNK
disease	I-UNK
and	O
for	O
studying	O
the	O
pathway	B-UNK
of	O
copper	B-UNK
transport	B-UNK
and	O
its	O
possible	O
interaction	O
with	O
other	O
heavy	O
metals	O
..	O

Genomic	B-UNK
organization	B-UNK
of	O
the	O
adrenoleukodystrophy	B-DISEASE
gene	B-UNK
.	O

Adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
,	O
the	O
most	O
frequent	B-UNK
peroxisomal	B-UNK
disorder	B-UNK
,	O
is	O
a	O
severe	B-UNK
neurodegenerative	B-DISEASE
disease	I-DISEASE
associated	O
with	O
an	O
impairment	B-UNK
of	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
beta-oxidation	O
.	O

We	O
have	O
recently	O
identified	B-UNK
by	O
positional	O
cloning	B-UNK
the	O
gene	B-UNK
responsible	B-UNK
for	O
ALD	B-UNK
,	O
located	B-UNK
in	O
Xq28	B-UNK
.	O

It	O
encodes	B-UNK
a	O
new	O
member	B-UNK
of	O
the	O
"	O
ABC	O
"	O
superfamily	O
of	O
membrane	B-UNK
-	O
associated	O
transporters	O
that	O
shows	O
,	O
in	O
particular	O
,	O
significant	B-UNK
homology	B-UNK
to	O
the	O
70-kDa	O
peroxisomal	B-UNK
membrane	B-UNK
protein	I-UNK
(	O
PMP70	O
)	O
.	O

We	O
report	B-UNK
here	O
a	O
detailed	B-UNK
characterization	B-UNK
of	O
the	O
ALD	B-UNK
gene	B-UNK
structure	B-UNK
.	O

It	O
extends	O
over	O
21	O
kb	B-UNK
and	O
consists	O
of	O
10	O
exons	O
.	O

To	O
facilitate	O
the	O
detection	B-UNK
of	O
mutations	B-UNK
in	O
ALD	B-UNK
patients	B-UNK
,	O
we	O
have	O
determined	B-UNK
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	B-UNK
of	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region	B-UNK
.	O

Sequences	O
present	B-UNK
in	O
distal	B-UNK
exons	O
cross-hybridize	O
strongly	O
to	O
additional	O
sequences	O
in	O
the	O
human	B-UNK
genome	B-UNK
.	O

The	O
ALD	B-UNK
gene	B-UNK
has	O
been	O
positioned	O
on	O
a	O
pulsed	O
-	O
field	B-UNK
map	B-UNK
between	O
DXS15	O
and	O
the	O
L1CAM	O
gene	B-UNK
,	O
about	O
650	O
kb	B-UNK
upstream	O
from	O
the	O
color	B-UNK
pigment	B-UNK
genes	B-UNK
.	O

The	O
frequent	B-UNK
occurrence	B-UNK
of	O
color	B-UNK
vision	I-UNK
anomalies	B-UNK
observed	B-UNK
in	O
patients	B-UNK
with	O
adrenomyeloneuropathy	O
(	O
the	O
adult	B-UNK
onset	I-UNK
form	B-UNK
of	O
ALD	B-UNK
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	O
gene	B-UNK
syndrome	B-UNK
but	O
a	O
secondary	O
manifestation	B-UNK
of	O
ALD	B-UNK
..	O

The	O
murine	O
homologues	O
of	O
the	O
Huntington	B-UNK
disease	I-UNK
gene	B-UNK
(	O
Hdh	O
)	O
and	O
the	O
alpha	B-UNK
-	O
adducin	O
gene	B-UNK
(	O
Add1	O
)	O
map	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
5	O
within	O
a	O
region	B-UNK
of	O
conserved	B-UNK
synteny	O
with	O
human	B-UNK
chromosome	I-UNK
4p16	O
.	O
3	O
.	O

Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
is	O
a	O
severe	B-UNK
autosomal	B-UNK
dominant	I-UNK
neurodegenerative	B-DISEASE
disorder	I-DISEASE
associated	O
with	O
a	O
novel	O
gene	B-UNK
(	O
IT15	O
)	O
.	O

Recently	O
,	O
we	O
reported	B-UNK
the	O
cloning	B-UNK
of	O
Hdh	O
,	O
the	O
murine	O
homologue	B-UNK
of	O
IT15	O
.	O

Here	O
,	O
using	O
an	O
interspecific	O
backcross	O
,	O
we	O
have	O
mapped	B-UNK
both	O
Hdh	O
and	O
the	O
mouse	B-UNK
homologue	B-UNK
of	O
human	B-UNK
alpha	B-UNK
-	O
adducin	O
(	O
Add1	O
)	O
,	O
a	O
membrane	B-UNK
-	O
associated	O
cytoskeletal	O
protein	B-UNK
gene	B-UNK
.	O

Both	O
of	O
these	O
genes	B-UNK
map	B-UNK
in	O
the	O
same	O
position	B-UNK
on	O
mouse	B-UNK
chromosome	I-UNK
5	O
in	O
a	O
region	B-UNK
associated	O
with	O
ancestral	O
chromosomal	B-UNK
rearrangements	O
and	O
show	O
no	O
recombination	B-UNK
with	O
D5H4S43	O
,	O
D5H4S115	O
,	O
and	O
D5H4S62	O
,	O
the	O
murine	O
homologues	O
of	O
D4S43	O
,	O
D4S115	O
,	O
and	O
D4S62	O
,	O
respectively	O
.	O

Further	O
mapping	B-UNK
studies	B-UNK
of	O
humans	B-UNK
,	O
mice	B-UNK
,	O
and	O
other	O
mammalian	O
species	B-UNK
should	O
reveal	O
the	O
nature	B-UNK
of	O
the	O
rearrangements	O
affecting	O
this	O
chromosomal	B-UNK
segment	O
during	O
mammalian	O
evolution	O
..	O

Genetic	B-UNK
cholesteryl	B-DISEASE
ester	I-DISEASE
transfer	I-DISEASE
protein	I-DISEASE
deficiency	I-DISEASE
caused	B-UNK
by	O
two	O
prevalent	O
mutations	B-UNK
as	O
a	O
major	B-UNK
determinant	O
of	O
increased	B-UNK
levels	B-UNK
of	O
high	B-UNK
density	I-UNK
lipoprotein	B-UNK
cholesterol	B-UNK
.	O

Genetic	B-UNK
determinants	O
of	O
HDL	B-UNK
cholesterol	I-UNK
(	O
HDL	B-UNK
-	O
C	O
)	O
levels	B-UNK
in	O
the	O
general	B-UNK
population	B-UNK
are	O
poorly	O
understood	O
.	O

We	O
previously	B-UNK
described	O
plasma	O
cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
(	O
CETP	B-UNK
)	O
deficiency	B-UNK
due	O
to	O
an	O
intron	B-UNK
14	O
G	O
(	O
+	O
1)-to	O
-	O
A	O
mutation	B-UNK
(	O
Int14	B-UNK
A	O
)	O
in	O
several	O
families	B-UNK
with	O
very	O
high	B-UNK
HDL	B-UNK
-	O
C	O
levels	B-UNK
in	O
Japan	B-UNK
.	O

Subjects	B-UNK
with	O
HDL	B-UNK
-	O
C	O
>	O
or	O
=	O
100	O
mg	B-UNK
/	O
dl	O
(	O
n	O
=	O
130	O
)	O
were	O
screened	B-UNK
by	O
PCR	B-UNK
single	B-UNK
strand	I-UNK
conformational	B-UNK
polymorphism	B-UNK
analysis	B-UNK
of	O
the	O
CETP	B-UNK
gene	B-UNK
.	O

Two	O
other	O
mutations	B-UNK
were	O
identified	B-UNK
by	O
DNA	B-UNK
sequencing	I-UNK
or	O
primer	O
-	O
mediated	O
restriction	B-UNK
map	B-UNK
modification	O
of	O
PCR	B-UNK
products	I-UNK
a	O
novel	O
intron	B-UNK
14	O
splice	B-UNK
donor	I-UNK
site	I-UNK
mutation	B-UNK
caused	B-UNK
by	O
a	O
T	O
insertion	O
at	O
position	B-UNK
+	O
3	O
from	O
the	O
exon14	O
/	O
intron14	O
boundary	O
(	O
Int14	B-UNK
T	O
)	O
and	O
a	O
missense	B-UNK
mutation	I-UNK
(	O
Asp442	O
to	O
Gly	B-UNK
)	O
within	O
exon	B-UNK
15	O
(	O
D442	B-UNK
G	I-UNK
)	O
.	O

The	O
Int14	B-UNK
T	O
mutation	B-UNK
was	O
only	O
found	O
in	O
one	O
family	B-UNK
.	O

However	O
,	O
the	O
D442	B-UNK
G	I-UNK
and	O
Int14	B-UNK
A	O
mutations	B-UNK
were	O
highly	B-UNK
prevalent	O
in	O
subjects	B-UNK
with	O
HDL	B-UNK
-	O
C	O
>	O
or	O
=	O
60	O
mg	B-UNK
/	O
dl	O
,	O
with	O
combined	O
allele	B-UNK
frequencies	O
of	O
9	O
%	O
,	O
12	O
%	O
,	O
21	O
%	O
and	O
43	O
%	O
for	O
HDL	B-UNK
-	O
C	O
60	O
-	O
79	O
,	O
80	O
-	O
99	O
,	O
100	O
-	O
119	O
,	O
and	O
>	O
or	O
=	O
120	O
mg	B-UNK
/	O
dl	O
,	O
respectively	O
.	O

Furthermore	O
,	O
prevalences	O
of	O
the	O
D442	B-UNK
G	I-UNK
and	O
Int14	B-UNK
A	O
mutations	B-UNK
were	O
extremely	O
high	B-UNK
in	O
a	O
general	B-UNK
sample	O
of	O
Japanese	B-UNK
men	B-UNK
(	O
n	O
=	O
236	O
)	O
,	O
with	O
heterozygote	B-UNK
frequencies	O
of	O
7	O
%	O
and	O
2	O
%	O
,	O
respectively	O
.	O

These	O
two	O
mutations	B-UNK
accounted	O
for	O
about	O
10	O
%	O
of	O
the	O
total	B-UNK
variance	O
of	O
HDL	B-UNK
-	O
C	O
in	O
this	O
population	B-UNK
.	O

The	O
phenotype	B-UNK
in	O
a	O
genetic	B-UNK
compound	B-UNK
heterozygote	B-UNK
(	O
Int14	B-UNK
T	O
and	O
Int14	B-UNK
A	O
)	O
was	O
similar	B-UNK
to	O
that	O
of	O
Int14	B-UNK
A	O
homozygotes	O
(	O
no	O
detectable	O
CETP	B-UNK
and	O
markedly	B-UNK
increased	B-UNK
HDL	B-UNK
-	O
C	O
)	O
,	O
indicating	O
that	O
the	O
Int14	B-UNK
T	O
produces	O
a	O
null	O
allele	B-UNK
.	O

In	O
four	O
D442	B-UNK
G	I-UNK
homozygotes	O
,	O
mean	O
HDL	B-UNK
-	O
C	O
levels	B-UNK
(	O
86	O
+	O
/-26	O
mg	B-UNK
/	O
dl	O
)	O
were	O
lower	O
than	O
in	O
Int14	B-UNK
A	O
homozygotes	O
(	O
158	O
+	O
/-35	O
mg	B-UNK
/	O
dl	O
)	O
,	O
reflecting	O
residual	B-UNK
CETP	B-UNK
activity	B-UNK
in	O
plasma	O
.	O

In	O
47	O
D442	B-UNK
G	I-UNK
heterozygotes	B-UNK
,	O
mean	O
HDL	B-UNK
-	O
C	O
levels	B-UNK
were	O
91	O
+	O
/-23	O
mg	B-UNK
/	O
dl	O
,	O
similar	B-UNK
to	O
the	O
level	B-UNK
in	O
D442	B-UNK
G	I-UNK
homozygotes	O
,	O
and	O
significantly	O
greater	B-UNK
than	O
mean	O
HDL	B-UNK
-	O
C	O
levels	B-UNK
in	O
Int14	B-UNK
A	O
heterozygotes	B-UNK
(	O
69	O
+	O
/-15	O
mg	B-UNK
/	O
dl	O
)	O
.	O

Thus	O
,	O
the	O
D442	B-UNK
G	I-UNK
mutation	B-UNK
acts	O
differently	O
to	O
the	O
null	O
mutations	B-UNK
with	O
weaker	O
effects	B-UNK
on	O
HDL	B-UNK
in	O
the	O
homozygous	B-UNK
state	B-UNK
and	O
stronger	O
effects	B-UNK
in	O
the	O
heterozygotes	B-UNK
,	O
suggesting	O
dominant	B-UNK
expression	B-UNK
of	O
a	O
partially	O
defective	O
allele	B-UNK
.	O

CETP	B-UNK
deficiency	I-UNK
,	O
reflecting	O
two	O
prevalent	O
mutations	B-UNK
(	O
D442	B-UNK
G	I-UNK
and	O
Int14	B-UNK
A	O
)	O
,	O
is	O
the	O
first	O
example	O
of	O
a	O
genetic	B-UNK
deficiency	B-UNK
state	B-UNK
which	O
is	O
sufficiently	O
common	B-UNK
to	O
explain	O
a	O
significant	B-UNK
fraction	B-UNK
of	O
the	O
variation	B-UNK
in	O
HDL	B-UNK
-	O
C	O
in	O
the	O
general	B-UNK
population	B-UNK
..	O

Treatment	O
of	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
:	O
effects	B-UNK
of	O
chenodeoxycholic	O
acid	B-UNK
,	O
pravastatin	O
,	O
and	O
combined	O
use	O
.	O

Treatments	O
by	O
oral	B-UNK
administration	O
of	O
chenodeoxycholic	O
acid	B-UNK
(	O
CDCA	O
)	O
alone	O
,	O
3-hydroxy-3-methylglutaryl	O
(	O
HMG	O
)	O
CoA	B-UNK
reductase	O
inhibitor	O
(	O
pravastatin	O
)	O
alone	O
,	O
and	O
combination	B-UNK
of	O
the	O
two	O
drugs	O
were	O
attempted	O
for	O
7	O
patients	B-UNK
with	O
cerebrotendinous	B-UNK
xanthomatosis	I-UNK
(	O
CTX	B-UNK
)	O
.	O

CDCA	O
treatment	O
at	O
a	O
dose	O
of	O
300	O
mg	B-UNK
/	O
day	O
reduced	O
serum	B-UNK
cholestanol	O
(	O
67	O
.	O
3	O
%	O
reduction	B-UNK
)	O
,	O
lathosterol	O
(	O
50	O
.	O
8	O
%	O
)	O
,	O
campesterol	O
(	O
61	O
.	O
7	O
%	O
)	O
and	O
sitosterol	O
(	O
12	O
.	O
7	O
%	O
)	O
.	O

However	O
,	O
the	O
sera	B-UNK
of	O
the	O
patients	B-UNK
changed	O
to	O
be	O
"	O
atherogenic	O
"	O
;	O
total	B-UNK
cholesterol	B-UNK
,	O
triglyceride	O
and	O
low	B-UNK
-	O
density	B-UNK
lipoprotein	B-UNK
(	O
LDL)-cholesterol	O
were	O
increased	B-UNK
,	O
while	O
high	B-UNK
-	O
density	B-UNK
lipoprotein	B-UNK
(	O
HDL)-cholesterol	O
was	O
decreased	B-UNK
.	O

Contrarily	O
,	O
pravastatin	O
at	O
a	O
dose	O
of	O
10	O
mg	B-UNK
/	O
day	O
improved	O
the	O
sera	B-UNK
of	O
the	O
patients	B-UNK
to	O
be	O
markedly	B-UNK
"	O
anti-atherogenic	O
"	O
,	O
but	O
the	O
reductions	O
of	O
cholestanol	O
(	O
30	O
.	O
4	O
%	O
)	O
,	O
lathosterol	O
(	O
44	O
.	O
0	O
%	O
)	O
,	O
campesterol	O
(	O
22	O
.	O
9	O
%	O
)	O
and	O
sitosterol	O
(	O
9	O
.	O
6	O
%	O
)	O
were	O
inadequate	O
.	O

Combined	O
treatment	O
with	O
CDCA	O
and	O
pravastatin	O
showed	O
good	O
overlapping	O
of	O
the	O
effects	B-UNK
of	O
each	O
drug	O
alone	O
.	O

The	O
sera	B-UNK
of	O
the	O
patients	B-UNK
were	O
apparently	O
more	O
"	O
anti-atherogenic	O
"	O
than	O
those	O
after	O
CDCA	O
treatment	O
.	O

Serum	B-UNK
cholestanol	O
concentration	O
was	O
still	O
2	O
.	O

7	O
times	O
higher	O
than	O
in	O
controls	O
,	O
but	O
the	O
serum	B-UNK
lathosterol	O
level	B-UNK
was	O
within	O
the	O
normal	B-UNK
range	B-UNK
,	O
indicating	O
that	O
the	O
enhancement	O
of	O
overall	O
cholesterol	B-UNK
synthesis	B-UNK
in	O
the	O
patients	B-UNK
was	O
sufficiently	O
suppressed	O
.	O

Plant	O
sterol	O
levels	B-UNK
were	O
also	O
within	O
the	O
normal	B-UNK
range	B-UNK
.	O

The	O
combination	B-UNK
of	O
CDCA	O
and	O
pravastatin	O
was	O
a	O
good	O
treatment	O
for	O
CTX	B-UNK
,	O
based	B-UNK
on	O
the	O
improvement	O
of	O
serum	B-UNK
lipoprotein	B-UNK
metabolism	B-UNK
,	O
the	O
suppression	O
of	O
cholesterol	B-UNK
synthesis	B-UNK
,	O
and	O
reductions	O
of	O
cholestanol	O
and	O
plant	O
sterol	O
levels	B-UNK
.	O

In	O
all	O
of	O
7	O
patients	B-UNK
,	O
the	O
progression	B-UNK
of	O
disease	B-UNK
was	O
arrested	O
,	O
but	O
dramatic	O
effects	B-UNK
on	O
clinical	B-UNK
manifestations	I-UNK
,	O
xanthoma	O
,	O
and	O
electrophysiological	O
findings	B-UNK
could	O
not	O
be	O
found	O
after	O
the	O
treatment	O
of	O
these	O
drugs	O

Mutation	B-UNK
spectrum	B-UNK
in	O
the	O
CHM	B-UNK
gene	B-UNK
of	O
Danish	O
and	O
Swedish	O
choroideremia	B-UNK
patients	B-UNK
.	O

The	O
recent	O
isolation	B-UNK
of	O
the	O
complete	O
open	O
reading	B-UNK
frame	I-UNK
of	O
the	O
choroideremia	B-DISEASE
(	O
CHM	B-UNK
)	O
gene	B-UNK
and	O
the	O
characterization	B-UNK
of	O
the	O
exon	B-UNK
-	O
intron	B-UNK
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	B-UNK
detection	I-UNK
in	O
patients	B-UNK
with	O
classical	O
choroideremia	B-UNK
.	O

We	O
have	O
performed	O
mutation	B-UNK
screening	B-UNK
in	O
patients	B-UNK
from	O
15	O
Danish	O
and	O
Swedish	O
families	B-UNK
by	O
using	O
Southern	B-UNK
blot	I-UNK
hybridization	B-UNK
and	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
(	O
PCR	B-UNK
-	O
SSCP	B-UNK
)	O
technique	O
.	O

Causative	O
mutations	B-UNK
in	O
the	O
CHM	B-UNK
gene	B-UNK
were	O
detected	B-UNK
in	O
at	O
least	O
12	O
families	B-UNK
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	B-UNK
can	O
be	O
identified	B-UNK
by	O
this	O
approach	O
.	O

In	O
four	O
of	O
these	O
families	B-UNK
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O

Thus	O
,	O
in	O
one	O
patient	B-UNK
,	O
the	O
deletion	B-UNK
resulted	B-UNK
in	O
the	O
absence	B-UNK
of	O
only	O
one	O
exon	B-UNK
,	O
while	O
in	O
another	O
the	O
deletion	B-UNK
comprised	O
the	O
entire	O
CHM	B-UNK
gene	B-UNK
.	O

Mapping	B-UNK
of	O
the	O
deletion	B-UNK
endpoints	O
in	O
these	O
four	O
patients	B-UNK
and	O
in	O
another	O
11	O
male	B-UNK
patients	B-UNK
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	B-UNK
map	B-UNK
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O

In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	B-UNK
at	O
least	O
8	O
causative	O
mutations	B-UNK
were	O
found	O
by	O
PCR	B-UNK
-	O
SSCP	B-UNK
analysis	B-UNK
and	O
direct	B-UNK
sequencing	I-UNK
.	O

Interestingly	B-UNK
,	O
all	O
CHM	B-UNK
gene	B-UNK
mutations	B-UNK
detected	B-UNK
thus	O
far	O
in	O
choroideremia	B-UNK
patients	B-UNK
give	O
rise	B-UNK
to	O
the	O
introduction	O
of	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
..	O

Predominance	O
of	O
the	O
adrenomyeloneuropathy	O
phenotype	B-UNK
of	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
in	O
The	O
Netherlands	O
:	O
a	O
survey	O
of	O
30	O
kindreds	O
.	O

X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-UNK
(	O
X	O
-	O
ALD	B-UNK
)	O
is	O
an	O
inherited	B-UNK
disorder	B-UNK
of	O
peroxisomal	B-UNK
beta-oxidation	O
associated	O
with	O
accumulation	B-UNK
of	O
saturated	O
very	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
,	O
which	O
results	B-UNK
in	O
central	B-UNK
and	O
peripheral	B-UNK
demyelination	O
and	O
in	O
impaired	B-UNK
function	B-UNK
of	O
adrenal	B-UNK
cortex	O
and	O
testes	O
.	O

The	O
phenotypic	B-UNK
expression	B-UNK
is	O
highly	B-UNK
variable	B-UNK
,	O
childhood	O
cerebral	B-UNK
ALD	I-UNK
(	O
CCALD	O
)	O
and	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
being	O
the	O
main	O
variants	B-UNK
.	O

We	O
explored	O
the	O
30	O
Dutch	B-UNK
kindreds	O
well	O
known	O
to	O
the	O
Dutch	B-UNK
X	O
-	O
ALD	B-UNK
/	O
AMN	B-UNK
Study	B-UNK
Group	B-UNK
and	O
phenotyped	O
77	O
male	B-UNK
patients	B-UNK
35	O
(	O
46	O
%	O
)	O
had	O
AMN	B-UNK
and	O
24	O
(	O
31	O
%	O
)	O
CCALD	O
or	O
adolescent	O
cerebral	B-UNK
ALD	I-UNK
(	O
AdolCALD	O
)	O
.	O

These	O
percentages	O
differ	O
significantly	O
from	O
previous	B-UNK
reports	O
,	O
in	O
which	O
25	O
to	O
28	O
%	O
of	O
the	O
patients	B-UNK
developed	O
AMN	B-UNK
and	O
53	O
to	O
57	O
%	O
CCALD	O
or	O
AdolCALD	O
.	O

Our	O
findings	B-UNK
indicate	O
that	O
--	O
at	O
least	O
in	O
the	O
Netherlands	O
--	O
AMN	B-UNK
may	O
be	O
the	O
most	O
frequent	B-UNK
phenotype	B-UNK
of	O
X	O
-	O
ALD	B-UNK
..	O

Adrenoleukodystrophy	B-UNK
gene	B-UNK
encodes	B-UNK
an	O
80	O
kDa	O
membrane	B-UNK
protein	I-UNK
.	O

An	O
antibody	B-UNK
against	O
the	O
synthetic	O
C	O
-	O
terminal	B-UNK
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
(	O
ALD	B-UNK
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	B-UNK
of	O
the	O
ALD	B-UNK
gene	B-UNK
.	O

The	O
antibody	B-UNK
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	B-UNK
in	O
control	B-UNK
fibroblasts	B-UNK
,	O
while	O
no	O
bands	O
were	O
detected	B-UNK
in	O
the	O
fibroblasts	B-UNK
from	O
a	O
patient	B-UNK
with	O
ALD	B-UNK
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	B-UNK
gene	B-UNK
was	O
undetectable	O
based	B-UNK
on	O
Northern	B-UNK
blot	B-UNK
analysis	B-UNK
.	O

The	O
293	O
T	O
cells	B-UNK
transfected	O
with	O
the	O
full	O
-	O
coding	B-UNK
cDNA	O
inserted	O
in	O
the	O
expression	B-UNK
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	B-UNK
,	O
as	O
detected	B-UNK
by	O
Western	B-UNK
blot	B-UNK
.	O

In	O
an	O
immunocytological	O
study	B-UNK
,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	B-UNK
,	O
in	O
the	O
normal	B-UNK
fibroblasts	B-UNK
.	O

However	O
,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	B-UNK
.	O

These	O
data	B-UNK
thus	O
indicate	O
that	O
the	O
ALD	B-UNK
gene	B-UNK
encodes	B-UNK
an	O
80	O
kDa	O
membrane	B-UNK
protein	I-UNK
..	O

Isolation	B-UNK
of	O
the	O
gene	B-UNK
for	O
McLeod	O
syndrome	B-UNK
that	O
encodes	B-UNK
a	O
novel	O
membrane	B-UNK
transport	B-UNK
protein	B-UNK
.	O

McLeod	O
syndrome	B-DISEASE
is	O
an	O
X	O
-	O
linked	B-UNK
multisystem	O
disorder	B-UNK
characterized	B-UNK
by	O
abnormalities	B-UNK
in	O
the	O
neuromuscular	O
and	O
hematopoietic	O
systems	O
.	O

We	O
have	O
assembled	O
a	O
cosmid	O
contig	O
of	O
360	O
kb	B-UNK
that	O
encompasses	O
the	O
McLeod	O
gene	B-UNK
locus	B-UNK
.	O

A	O
50	O
kb	B-UNK
deletion	B-UNK
was	O
detected	B-UNK
by	O
screening	B-UNK
DNA	B-UNK
from	O
patients	B-UNK
with	O
radiolabeled	O
whole	O
cosmids	O
,	O
and	O
two	O
transcription	B-UNK
units	O
were	O
identified	B-UNK
within	O
this	O
deletion	B-UNK
.	O

The	O
mRNA	O
expression	B-UNK
pattern	B-UNK
of	O
one	O
of	O
them	O
,	O
designated	O
as	O
XK	O
,	O
correlates	O
closely	B-UNK
to	O
the	O
McLeod	O
phenotype	B-UNK
.	O

XK	O
encodes	B-UNK
a	O
novel	O
protein	B-UNK
with	O
structural	B-UNK
characteristics	B-UNK
of	O
prokaryotic	O
and	O
eukaryotic	O
membrane	B-UNK
transport	B-UNK
proteins	B-UNK
.	O

Nucleotide	B-UNK
sequence	I-UNK
analysis	B-UNK
of	O
XK	O
from	O
two	O
unrelated	B-UNK
McLeod	O
patients	B-UNK
has	O
identified	B-UNK
point	B-UNK
mutations	I-UNK
at	O
conserved	B-UNK
splice	B-UNK
donor	I-UNK
and	O
acceptor	B-UNK
sites	O
.	O

These	O
findings	B-UNK
provide	B-UNK
direct	B-UNK
evidence	B-UNK
that	O
XK	O
is	O
responsible	B-UNK
for	O
McLeod	O
syndrome	B-DISEASE
..	O

X	O
-	O
linked	B-UNK
spastic	O
paraplegia	B-DISEASE
and	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
are	O
allelic	O
disorders	B-UNK
at	O
the	O
proteolipid	B-UNK
protein	I-UNK
locus	B-UNK
.	O

Three	O
forms	B-UNK
of	O
X	O
-	O
linked	B-UNK
spastic	O
paraplegia	B-DISEASE
(	O
SPG	O
)	O
have	O
been	O
defined	B-UNK
.	O

One	O
locus	B-UNK
(	O
SPG	O
1	O
)	O
maps	B-UNK
to	O
Xq28	B-UNK
while	O
two	O
clinically	O
distinct	O
forms	B-UNK
map	B-UNK
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O

A	O
rare	B-UNK
X	O
-	O
linked	B-UNK
dysmyelinating	O
disorder	B-UNK
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
Pelizaeus	B-DISEASE
-	I-DISEASE
Merzbacher	I-DISEASE
disease	I-DISEASE
(	O
PMD	B-UNK
)	O
,	O
has	O
also	O
been	O
mapped	B-UNK
to	O
Xq21-q22	O
,	O
and	O
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
proteolipid	B-UNK
protein	I-UNK
gene	B-UNK
(	O
PLP	B-UNK
)	O
which	O
encodes	B-UNK
two	O
myelin	B-UNK
proteins	B-UNK
,	O
PLP	B-UNK
and	O
DM20	O
.	O

While	O
narrowing	O
the	O
genetic	B-UNK
interval	B-UNK
containing	O
SPG2	O
in	O
a	O
large	B-UNK
pedigree	B-UNK
,	O
we	O
found	O
that	O
PLP	B-UNK
was	O
the	O
closest	O
marker	B-UNK
to	O
the	O
disease	B-UNK
locus	B-UNK
,	O
implicating	O
PLP	B-UNK
as	O
a	O
possible	O
candidate	B-UNK
gene	I-UNK
.	O

We	O
have	O
found	O
that	O
a	O
point	B-UNK
mutation	I-UNK
(	O
His139Tyr	O
)	O
in	O
exon	B-UNK
3B	O
of	O
an	O
affected	B-UNK
male	B-UNK
produces	O
a	O
mutant	B-UNK
PLP	B-UNK
but	O
a	O
normal	B-UNK
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	B-DISEASE
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	B-UNK
=	O
0	O
.	O
00	O
)	O
.	O

It	O
appears	B-UNK
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B-UNK
are	O
allelic	O
disorders	B-UNK

Canavan	B-DISEASE
disease	I-DISEASE
:	O
mutations	B-UNK
among	O
Jewish	B-UNK
and	O
non-Jewish	O
patients	B-UNK
.	O

Canavan	B-DISEASE
disease	I-DISEASE
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
leukodystrophy	B-UNK
caused	B-UNK
by	O
the	O
deficiency	B-UNK
of	O
aspartoacylase	O
(	O
ASPA	B-UNK
)	O
.	O

Sixty	O
-	O
four	O
probands	O
were	O
analyzed	B-UNK
for	O
mutations	B-UNK
in	O
the	O
ASPA	B-UNK
gene	B-UNK
.	O

Three	O
point	B-UNK
mutations--693C--	O
>	O
A	O
,	O
854A--	O
>	O
C	O
,	O
and	O
914C--	O
>	O
A	O
--	O
were	O
identified	B-UNK
in	O
the	O
coding	B-UNK
sequence	I-UNK
.	O

The	O
693C--	O
>	O
A	O
and	O
914C--	O
>	O
A	O
base	B-UNK
changes	O
,	O
resulting	B-UNK
in	O
nonsense	B-UNK
tyr231	O
-	O
-	O
>	O
ter	O
and	O
missense	B-UNK
ala305	O
-	O
-	O
>	O
glu	B-UNK
mutations	B-UNK
,	O
respectively	O
,	O
lead	B-UNK
to	O
complete	O
loss	B-UNK
of	O
ASPA	B-UNK
activity	B-UNK
in	O
in	O
vitro	O
expression	B-UNK
studies	B-UNK
.	O

The	O
854A--	O
>	O
C	O
transversion	B-UNK
converted	O
glu	B-UNK
to	O
ala	B-UNK
in	O
codon	B-UNK
285	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	B-UNK
mutant	B-UNK
ASPA	B-UNK
has	O
2	O
.	O

5	O
%	O
of	O
the	O
activity	B-UNK
expressed	B-UNK
by	O
the	O
wild	B-UNK
-	O
type	B-UNK
enzyme	B-UNK
.	O

A	O
fourth	B-UNK
mutation	B-UNK
,	O
433	O
-	O
-2	O
(	O
A--	O
>	O
G	O
)	O
transition	B-UNK
,	O
was	O
identified	B-UNK
at	O
the	O
splice	B-UNK
-	O
acceptor	B-UNK
site	B-UNK
in	O
intron	B-UNK
2	O
.	O

The	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
would	O
lead	B-UNK
to	O
skipping	O
of	O
exon	B-UNK
3	O
,	O
accompanied	O
by	O
a	O
frameshift	B-UNK
,	O
and	O
thus	O
would	O
produce	B-UNK
aberrant	B-UNK
ASPA	B-UNK
.	O

Of	O
the	O
128	O
unrelated	B-UNK
Canavan	B-UNK
chromosomes	O
analyzed	B-UNK
,	O
88	O
were	O
from	O
probands	O
of	O
Ashkenazi	B-UNK
Jewish	I-UNK
descent	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	B-UNK
mutation	B-UNK
was	O
predominant	O
(	O
82	O
.	O
9	O
%	O
)	O
in	O
this	O
population	B-UNK
,	O
followed	O
by	O
the	O
tyr231	O
-	O
-	O
>	O
ter	O
(	O
14	O
.	O
8	O
%	O
)	O
and	O
433	O
-	O
-2	O
(	O
A--	O
>	O
G	O
)	O
(	O
1	O
.	O
1	O
%	O
)	O
mutations	B-UNK
.	O

The	O
three	O
mutations	B-UNK
account	B-UNK
for	O
98	O
.	O

8	O
%	O
of	O
the	O
Canavan	B-UNK
chromosomes	O
of	O
Ashkenazi	B-UNK
Jewish	I-UNK
origin	O
.	O

The	O
ala305	O
-	O
-	O
>	O
glu	B-UNK
mutation	B-UNK
was	O
found	O
exclusively	O
in	O
non-Jewish	O
probands	O
of	O
European	B-UNK
descent	O
and	O
constituted	O
60	O
%	O
of	O
the	O
40	O
mutant	B-UNK
chromosomes	O
.	O

Predominant	O
occurrence	B-UNK
of	O
certain	O
mutations	B-UNK
among	O
Ashkenazi	B-UNK
Jewish	I-UNK
and	O
non-Jewish	O
patients	B-UNK
with	O
Canavan	B-UNK
disease	I-UNK
would	O
suggest	B-UNK
a	O
founding	O
-	O
father	O
effect	B-UNK
in	O
propagation	O
of	O
these	O
mutant	B-UNK
chromosomes	O

Intelligence	O
quotient	O
profile	O
in	O
myotonic	B-UNK
dystrophy	I-UNK
,	O
intergenerational	O
deficit	O
,	O
and	O
correlation	B-UNK
with	O
CTG	B-UNK
amplification	B-UNK
.	O

An	O
abbreviated	O
Wechsler	O
Adult	B-UNK
Intelligence	O
Scale	O
Revised	O
(	O
WAIS	O
-	O
R	O
)	O
was	O
used	O
to	O
assess	B-UNK
verbal	O
and	O
arithmetical	O
cognitive	B-UNK
performance	O
in	O
55	O
subjects	B-UNK
with	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
,	O
covering	O
all	O
grades	O
of	O
disease	B-UNK
severity	B-UNK
,	O
and	O
31	O
controls	O
at	O
50	O
%	O
risk	B-UNK
of	O
inheriting	O
DM	B-UNK
.	O

Scaled	O
scores	B-UNK
from	O
the	O
assessment	O
were	O
converted	O
into	O
an	O
intelligence	O
quotient	O
(	O
IQ	B-UNK
)	O
estimation	O
on	O
each	O
person	O
.	O

Significant	B-UNK
IQ	B-UNK
differences	B-UNK
were	O
found	O
between	O
(	O
1	O
)	O
all	O
55	O
DM	B-DISEASE
subjects	B-UNK
(	O
mean	O
90	O
.	O
2	O
,	O
SD	B-DISEASE
16	O
.	O
1	O
)	O
and	O
31	O
controls	O
(	O
102	O
.	O
6	O
,	O
SD	B-DISEASE
9	O
.	O
4	O
)	O
,	O
with	O
no	O
sex	B-UNK
differences	B-UNK
in	O
either	O
group	B-UNK
;	O
(	O
2	O
)	O
15	O
affected	B-UNK
parents	O
(	O
99	O
.	O
3	O
,	O
SD	B-DISEASE
12	O
.	O
2	O
)	O
and	O
their	O
affected	B-UNK
children	O
(	O
88	O
.	O
1	O
,	O
SD	B-DISEASE
17	O
.	O
2	O
)	O
,	O
where	O
significance	O
was	O
dependent	B-UNK
on	O
parental	O
sex	B-UNK
being	O
female	O
;	O
and	O
(	O
3	O
)	O
15	O
pairs	B-UNK
of	O
affected	B-UNK
sibs	O
(	O
89	O
.	O
6	O
,	O
SD	B-DISEASE
13	O
.	O
2	O
)	O
and	O
their	O
normal	B-UNK
sibs	O
(	O
100	O
.	O
2	O
,	O
SD	B-DISEASE
7	O
.	O
6	O
)	O
.	O

IQ	B-UNK
steadily	O
declined	O
as	O
(	O
1	O
)	O
the	O
age	B-UNK
of	I-UNK
onset	I-UNK
of	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
decreased	B-UNK
,	O
and	O
(	O
2	O
)	O
the	O
CTG	B-UNK
expansion	B-UNK
size	B-UNK
increased	B-UNK
.	O

The	O
correlation	B-UNK
appeared	B-UNK
to	O
be	O
more	O
linear	O
with	O
age	B-UNK
of	I-UNK
onset	I-UNK
.	O

The	O
correlation	B-UNK
of	O
IQ	B-UNK
difference	O
and	O
CTG	B-UNK
expansion	B-UNK
difference	O
in	O
both	O
the	O
DM	B-DISEASE
parent	O
-	O
child	B-UNK
pairs	B-UNK
and	O
normal	B-UNK
sib	O
-	O
affected	B-UNK
sib	O
pairs	B-UNK
was	O
poor	O
,	O
indicating	O
that	O
CTG	B-UNK
expansion	B-UNK
is	O
not	O
a	O
reliable	O
predictor	O
of	O
IQ	B-UNK
either	O
in	O
individual	O
persons	O
or	O
families	B-UNK
.	O

Further	O
analysis	B-UNK
of	O
cognitive	B-UNK
function	B-UNK
in	O
DM	B-UNK
is	O
required	B-UNK
to	O
clarify	O
specific	B-UNK
deficits	O
characteristic	B-UNK
of	O
this	O
patient	B-UNK
group	B-UNK

Adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
and	O
a	O
cytogenetic	B-UNK
deletion	B-UNK
of	O
chromosome	B-UNK
5	O
resulting	B-UNK
from	O
a	O
maternal	O
intrachromosomal	O
insertion	O
.	O

We	O
present	B-UNK
the	O
clinical	B-UNK
and	O
laboratory	O
findings	B-UNK
in	O
an	O
institutionalised	O
adult	B-UNK
patient	B-UNK
originally	O
referred	O
for	O
autism	B-DISEASE
.	O

A	O
high	B-UNK
risk	I-UNK
of	O
colorectal	B-UNK
cancer	I-UNK
was	O
predicted	B-UNK
when	O
an	O
interstitial	O
deletion	B-UNK
of	O
the	O
long	B-UNK
arm	I-UNK
of	I-UNK
chromosome	I-UNK
5	O
,	O
del	O
(	O
5	O
)	O
(	O
q15q22	O
.	O
3	O
)	O
,	O
was	O
detected	B-UNK
in	O
her	O
lymphocytes	O
and	O
deletion	B-UNK
of	O
the	O
MCC	O
and	O
APC	B-UNK
genes	B-UNK
confirmed	B-UNK
by	O
molecular	B-UNK
analysis	I-UNK
.	O

Adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
and	O
carcinoma	B-DISEASE
of	O
the	O
rectum	O
were	O
subsequently	B-UNK
diagnosed	O
in	O
the	O
patient	B-UNK
.	O

She	O
was	O
profoundly	O
mentally	O
retarded	O
,	O
autistic	O
,	O
and	O
had	O
minor	O
dysmorphic	O
features	B-UNK
consistent	B-UNK
with	O
those	O
of	O
previous	B-UNK
patients	B-UNK
with	O
similar	B-UNK
deletions	O
.	O

The	O
deletion	B-UNK
arose	O
as	O
a	O
result	B-UNK
of	O
recombination	B-UNK
within	O
the	O
small	O
insertion	O
loop	O
formed	O
at	O
meiosis	O
by	O
the	O
direct	B-UNK
insertion	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q22	O
.	O
3q14	O
.	O
2q15	O
)	O
)	O
found	O
in	O
the	O
patients	B-UNK
mother	O
.	O

This	O
family	B-UNK
further	O
confirms	O
the	O
cytogenetic	B-UNK
mapping	B-UNK
of	O
both	O
MCC	O
and	O
APC	B-UNK
genes	B-UNK
to	O
5q22	O
and	O
comparison	B-UNK
with	O
other	O
recent	O
cases	B-UNK
suggests	O
that	O
both	O
genes	B-UNK
and	O
their	O
closely	B-UNK
linked	I-UNK
markers	B-UNK
lie	O
within	O
the	O
5q22	O
.	O

1	O
subband	O

Familial	B-UNK
male	B-UNK
breast	I-UNK
cancer	I-UNK
is	O
not	O
linked	B-UNK
to	O
the	O
BRCA1	B-UNK
locus	B-UNK
on	O
chromosome	B-UNK
17q	O
.	O

Breast	B-DISEASE
cancer	I-DISEASE
in	O
men	B-UNK
is	O
about	O
a	O
hundredfold	O
less	O
common	B-UNK
than	O
in	O
women	B-UNK
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	B-UNK
basis	B-UNK
.	O

We	O
have	O
examined	O
22	O
families	B-UNK
with	O
at	O
least	O
one	O
case	B-UNK
of	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
for	O
linkage	B-UNK
to	O
the	O
hereditary	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
locus	B-UNK
,	O
BRCA1	B-UNK
,	O
on	O
chromosome	B-UNK
17q	O
.	O

We	O
found	O
strong	B-UNK
evidence	B-UNK
against	O
linkage	B-UNK
to	O
BRCA1	B-UNK
(	O
lod	B-UNK
score-16	O
.	O
63	O
)	O
and	O
the	O
best	O
estimate	O
of	O
the	O
proportion	B-UNK
of	O
linked	B-UNK
families	B-UNK
was	O
0	O
%	O
(	O
95	O
%	O
CI	O
0	O
-	O
18	O
%	O
)	O
.	O

Our	O
results	B-UNK
indicate	O
that	O
there	O
is	O
a	O
gene	B-UNK
(	O
s	O
)	O
other	O
than	O
BRCA1	B-UNK
which	O
predisposes	O
to	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
in	O
women	B-UNK
and	O
which	O
confers	O
a	O
higher	O
risk	B-UNK
of	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
.	O

Identification	B-UNK
of	O
additional	O
pedigrees	O
that	O
include	O
cases	B-UNK
of	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
may	O
therefore	O
facilitate	O
the	O
mapping	B-UNK
and	O
isolation	B-UNK
of	O
this	O
gene	B-UNK
.	O

The	O
EWS	B-UNK
gene	B-UNK
,	O
involved	B-UNK
in	O
Ewing	O
family	B-UNK
of	O
tumors	B-UNK
,	O
malignant	B-UNK
melanoma	B-DISEASE
of	O
soft	O
parts	O
and	O
desmoplastic	O
small	O
round	O
cell	B-UNK
tumors	B-DISEASE
,	O
codes	O
for	O
an	O
RNA	B-UNK
binding	B-UNK
protein	B-UNK
with	O
novel	O
regulatory	O
domains	B-UNK
.	O

The	O
EWS	B-UNK
gene	B-UNK
,	O
which	O
maps	B-UNK
to	O
band	O
q12	O
of	O
human	B-UNK
chromosome	I-UNK
22	O
,	O
is	O
involved	B-UNK
in	O
a	O
wide	B-UNK
variety	O
of	O
human	B-UNK
solid	O
tumors	B-UNK
including	O
Ewing	B-DISEASE
sarcoma	I-DISEASE
,	O
related	B-UNK
primitive	O
neuroectodermal	B-DISEASE
tumors	I-DISEASE
,	O
malignant	B-UNK
melanoma	B-UNK
of	O
soft	O
parts	O
and	O
desmoplastic	O
small	O
round	O
cell	B-UNK
tumors	B-DISEASE
.	O

In	O
these	O
tumors	B-DISEASE
,	O
the	O
EWS	B-UNK
is	O
fused	O
to	O
genes	B-UNK
encoding	B-UNK
transcriptional	O
activators	O
/	O
repressors	O
,	O
like	O
Fli-1	O
or	O
erg	B-UNK
or	O
ATF	O
1	O
or	O
wt1	B-UNK
.	O

To	O
better	O
understand	O
the	O
function	B-UNK
of	O
the	O
EWS	B-UNK
protein	B-UNK
,	O
we	O
cloned	O
the	O
EWS	B-UNK
cDNA	O
.	O

Sequence	B-UNK
analysis	I-UNK
of	O
this	O
cDNA	O
revealed	B-UNK
differential	B-UNK
splicing	B-UNK
involving	O
two	O
exons	O
encoding	B-UNK
72	O
amino	B-UNK
acids	I-UNK
.	O

Both	O
alternatively	O
spliced	O
transcripts	O
,	O
EWS	B-UNK
and	O
EWS	B-UNK
-	O
b	O
,	O
are	O
expressed	B-UNK
in	O
a	O
variety	O
of	O
cells	B-UNK
.	O

Because	O
EWS	B-UNK
proteins	B-UNK
contain	O
putative	O
conserved	B-UNK
RNA	B-UNK
binding	B-UNK
motifs	O
,	O
we	O
studied	O
the	O
RNA	B-UNK
binding	B-UNK
properties	B-UNK
of	O
the	O
EWS	B-UNK
protein	B-UNK
.	O

The	O
EWS	B-UNK
-	O
b	O
protein	B-UNK
binds	O
to	O
RNA	B-UNK
in	O
vitro	O
and	O
,	O
specifically	B-UNK
,	O
to	O
poly	O
G	O
and	O
poly	O
U.	O

The	O
RNA	B-UNK
binding	B-UNK
activity	B-UNK
was	O
localized	B-UNK
to	O
the	O
carboxy	O
terminal	B-UNK
86	O
amino	B-UNK
acids	I-UNK
,	O
which	O
constitute	O
RGG	O
box	O
.	O

Thus	O
the	O
amino	B-UNK
terminal	B-UNK
domain	B-UNK
of	O
EWS	B-UNK
(	O
NTD	O
-	O
EWS	B-UNK
)	O
,	O
which	O
is	O
involved	B-UNK
in	O
chromosome	B-UNK
translocation	B-UNK
may	O
regulate	O
the	O
specificity	O
of	O
RNA	B-UNK
binding	B-UNK
activity	B-UNK
of	O
EWS	B-UNK
.	O

An	O
EWS	B-UNK
-	O
erg	B-UNK
chimeric	O
protein	B-UNK
,	O
which	O
is	O
found	O
in	O
Ewings	O
sarcoma	B-DISEASE
cells	B-UNK
,	O
functions	O
as	O
a	O
transcriptional	O
activator	O
.	O

Mutational	O
analysis	B-UNK
of	O
EWS	B-UNK
-	O
erg	B-UNK
chimeric	O
protein	B-UNK
revealed	B-UNK
that	O
NTD	O
-	O
EWS	B-UNK
functions	O
as	O
a	O
regulatory	O
domain	B-UNK
for	O
the	O
transcriptional	O
activation	O
properties	B-UNK
of	O
EWS	B-UNK
-	O
erg	B-UNK
chimeric	O
protein	B-UNK
..	O

Canavan	B-DISEASE
disease	I-DISEASE
:	O
genomic	B-UNK
organization	B-UNK
and	O
localization	B-UNK
of	O
human	B-UNK
ASPA	B-UNK
to	O
17p13-ter	O
and	O
conservation	B-UNK
of	O
the	O
ASPA	B-UNK
gene	B-UNK
during	O
evolution	O
.	O

Canavan	B-DISEASE
disease	I-DISEASE
,	O
or	O
spongy	O
degeneration	B-UNK
of	O
the	O
brain	B-UNK
,	O
is	O
a	O
severe	B-UNK
leukodystrophy	B-UNK
caused	B-UNK
by	O
the	O
deficiency	B-UNK
of	O
aspartoacylase	O
(	O
ASPA	B-UNK
)	O
.	O

Recently	O
,	O
a	O
missense	B-UNK
mutation	I-UNK
was	O
identified	B-UNK
in	O
human	B-UNK
ASPA	B-UNK
coding	B-UNK
sequence	I-UNK
from	O
patients	B-UNK
with	O
Canavan	B-UNK
disease	I-UNK
.	O

The	O
human	B-UNK
ASPA	B-UNK
gene	B-UNK
has	O
been	O
cloned	O
and	O
found	O
to	O
span	O
29	O
kb	B-UNK
of	O
the	O
genome	B-UNK
.	O

Human	B-UNK
aspartoacylase	O
is	O
coded	O
by	O
six	O
exons	O
intervened	O
by	O
five	O
introns	O
.	O

The	O
exons	O
vary	O
from	O
94	O
(	O
exon	B-UNK
III	B-UNK
)	O
to	O
514	O
(	O
exon	B-UNK
VI	O
)	O
bases	O
.	O

The	O
exon	B-UNK
/	O
intron	B-UNK
splice	B-UNK
junction	O
sites	O
follow	O
the	O
gt	B-UNK
/	O
ag	B-UNK
consensus	B-UNK
sequence	B-UNK
rule	O
.	O

Southern	B-UNK
blot	I-UNK
analysis	I-UNK
of	O
genomic	B-UNK
DNA	I-UNK
from	O
human	B-UNK
/	O
mouse	B-UNK
somatic	B-UNK
cell	I-UNK
hybrid	O
cell	B-UNK
lines	I-UNK
localized	B-UNK
ASPA	B-UNK
to	O
human	B-UNK
chromosome	I-UNK
17	O
.	O

The	O
human	B-UNK
ASPA	B-UNK
locus	B-UNK
was	O
further	O
mapped	B-UNK
in	O
the	O
17p13-ter	O
region	B-UNK
by	O
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
.	O

The	O
bovine	O
aspa	B-UNK
gene	B-UNK
has	O
also	O
been	O
cloned	O
,	O
and	O
its	O
exon	B-UNK
/	O
intron	B-UNK
organization	B-UNK
is	O
identical	B-UNK
to	O
that	O
of	O
the	O
human	B-UNK
gene	B-UNK
.	O

The	O
500-base	O
sequence	B-UNK
upstream	O
of	O
the	O
initiator	O
ATG	O
codon	B-UNK
in	O
the	O
human	B-UNK
gene	B-UNK
and	O
that	O
in	O
the	O
bovine	O
gene	B-UNK
are	O
77	O
%	O
identical	B-UNK
.	O

Human	B-UNK
ASPA	B-UNK
coding	B-UNK
sequences	O
cross-hybridize	O
with	O
genomic	B-UNK
DNA	I-UNK
from	O
yeast	B-UNK
,	O
chicken	O
,	O
rabbit	O
,	O
cow	O
,	O
dog	O
,	O
mouse	B-UNK
,	O
rat	O
,	O
and	O
monkey	O
.	O

The	O
specificity	O
of	O
cross-species	O
hybridization	B-UNK
of	O
coding	B-UNK
sequences	O
suggests	O
that	O
aspartoacylase	O
has	O
been	O
conserved	B-UNK
during	O
evolution	O
.	O

It	O
should	O
now	O
be	O
possible	O
to	O
identify	B-UNK
mutations	B-UNK
in	O
the	O
noncoding	O
genomic	B-UNK
sequences	O
that	O
lead	B-UNK
to	O
Canavan	B-DISEASE
disease	I-DISEASE
and	O
to	O
study	B-UNK
the	O
regulation	B-UNK
of	O
ASPA	B-UNK
..	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
:	O
size	B-UNK
-	O
and	O
sex	B-UNK
-	O
dependent	B-UNK
dynamics	O
of	O
CTG	B-UNK
meiotic	B-UNK
instability	B-UNK
,	O
and	O
somatic	B-UNK
mosaicism	O
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
is	O
a	O
progressive	B-UNK
neuromuscular	O
disorder	B-UNK
which	O
results	B-UNK
from	O
elongations	O
of	O
an	O
unstable	O
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
,	O
located	B-UNK
in	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
of	O
the	O
DM	B-DISEASE
gene	B-UNK
.	O

A	O
correlation	B-UNK
has	O
been	O
demonstrated	O
between	O
the	O
increase	B-UNK
in	O
the	O
repeat	B-UNK
number	B-UNK
of	O
this	O
sequence	B-UNK
and	O
the	O
severity	B-UNK
of	O
the	O
disease	B-UNK
.	O

However	O
,	O
the	O
clinical	B-UNK
status	B-UNK
of	O
patients	B-UNK
cannot	O
be	O
unambiguously	O
ascertained	O
solely	O
on	O
the	O
basis	B-UNK
of	O
the	O
number	B-UNK
of	O
CTG	B-UNK
repeats	B-UNK
.	O

Moreover	O
,	O
the	O
exclusive	O
maternal	O
inheritance	B-UNK
of	O
the	O
congenital	B-UNK
form	B-UNK
remains	O
unexplained	O
.	O

Our	O
observation	O
of	O
differently	O
sized	O
repeats	B-UNK
in	O
various	O
DM	B-DISEASE
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	B-UNK
of	O
the	O
mutation	B-UNK
observed	B-UNK
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	B-UNK
and	O
nature	B-UNK
of	O
symptoms	B-UNK
.	O

Through	O
a	O
molecular	B-UNK
and	O
genetic	B-UNK
study	B-UNK
of	O
142	O
families	B-UNK
including	O
418	O
DM	B-DISEASE
patients	B-UNK
,	O
we	O
have	O
investigated	O
the	O
dynamics	O
of	O
the	O
CTG	B-UNK
repeat	I-UNK
meiotic	B-UNK
instability	B-UNK
.	O

A	O
positive	O
correlation	B-UNK
between	O
the	O
size	B-UNK
of	O
the	O
repeat	B-UNK
and	O
the	O
intergenerational	O
enlargement	O
was	O
observed	B-UNK
similarly	O
through	O
male	B-UNK
and	O
female	O
meioses	O
for	O
<	O
or	O
=	O
0	O
.	O

5-kb	O
CTG	B-UNK
sequences	O
.	O

Beyond	O
0	O
.	O

5	O
kb	B-UNK
,	O
the	O
intergenerational	O
variation	B-UNK
was	O
more	O
important	O
through	O
female	O
meioses	O
,	O
whereas	O
a	O
tendency	O
to	O
compression	O
was	O
observed	B-UNK
almost	O
exclusively	O
in	O
male	B-UNK
meioses	O
,	O
for	O
>	O
or	O
=	O
1	O
.	O

5-kb	O
fragments	O
.	O

This	O
implies	O
a	O
size	B-UNK
-	O
and	O
sex	B-UNK
-	O
dependent	B-UNK
meiotic	B-UNK
instability	B-UNK
.	O

Moreover	O
,	O
segregation	B-UNK
analysis	B-UNK
supports	O
the	O
hypothesis	B-UNK
of	O
a	O
maternal	O
as	O
well	O
as	O
a	O
familial	B-UNK
predisposition	B-UNK
for	O
the	O
occurrence	B-UNK
of	O
the	O
congenital	B-UNK
form	B-UNK
.	O

Finally	B-UNK
,	O
this	O
analysis	B-UNK
reveals	O
a	O
significant	B-UNK
excess	B-UNK
of	O
transmitting	O
grandfathers	O
partially	O
accounted	O
for	O
by	O
increased	B-UNK
fertility	O
in	O
affected	B-UNK
males	I-UNK

Illegitimate	O
transcription	B-UNK
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
gene	B-UNK
in	O
lymphocytes	O
for	O
identification	B-UNK
of	O
mutations	B-UNK
in	O
phenylketonuria	O
.	O

Taking	O
advantage	B-UNK
of	O
the	O
illegitimate	O
transcription	B-UNK
of	O
the	O
phenylalanine	B-UNK
hydroxylase	I-UNK
(	O
PAH	B-UNK
)	O
gene	B-UNK
,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
PAH	B-UNK
cDNA	O
sequence	B-UNK
of	O
hyperphenylalaninemic	O
children	O
in	O
circulating	O
lymphocytes	O
.	O

Using	O
this	O
approach	O
,	O
we	O
have	O
also	O
identified	B-UNK
3	O
novel	O
mutations	B-UNK
in	O
cDNA	O
from	O
liver	B-UNK
and	O
lymphocytes	O
of	O
two	O
patients	B-UNK
.	O

One	O
mutation	B-UNK
,	O
detected	B-UNK
by	O
the	O
abnormal	O
pattern	B-UNK
of	O
migration	O
of	O
an	O
amplified	O
fragment	B-UNK
,	O
is	O
a	O
C	O
to	O
T	O
transition	B-UNK
in	O
the	O
splice	B-UNK
acceptor	I-UNK
site	B-UNK
of	O
intron	B-UNK
10	O
,	O
which	O
resulted	B-UNK
in	O
the	O
skipping	O
of	O
exon	B-UNK
11	O
with	O
the	O
premature	B-UNK
termination	I-UNK
of	O
RNA	B-UNK
translation	O
downstream	O
from	O
exon	B-UNK
12	O
(	O
-3	O
IVS10	O
)	O
.	O

The	O
other	O
two	O
mutations	B-UNK
are	O
missense	B-UNK
mutations	I-UNK
in	O
exons	O
10	O
and	O
11	O
(	O
respectively	O
,	O
L333F	O
and	O
E390	O
G	O
)	O
.	O

The	O
present	B-UNK
study	B-UNK
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
PAH	B-UNK
gene	B-UNK
transcripts	O
whose	O
nucleotide	B-UNK
sequence	I-UNK
is	O
identical	B-UNK
to	O
that	O
reported	B-UNK
in	O
liver	B-UNK
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	B-UNK
genetic	I-UNK
studies	B-UNK
in	O
phenylketonuria	O
..	O

High	B-UNK
residual	B-UNK
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
activity	B-UNK
in	O
a	O
patient	B-UNK
with	O
late	B-UNK
-	O
infantile	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
.	O

We	O
identified	B-UNK
a	O
patient	B-UNK
suffering	O
from	O
late	B-UNK
-	O
infantile	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
who	O
has	O
a	O
residual	B-UNK
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
activity	B-UNK
of	O
about	O
10	O
%	O
.	O

Fibroblasts	B-UNK
of	O
the	O
patient	B-UNK
show	O
significant	B-UNK
sulfatide	O
degradation	O
activity	B-UNK
exceeding	O
that	O
of	O
adult	B-UNK
MLD	B-UNK
patients	B-UNK
.	O

Analysis	B-UNK
of	O
the	O
ARSA	B-UNK
gene	B-UNK
in	O
this	O
patient	B-UNK
revealed	B-UNK
heterozygosity	B-UNK
for	O
two	O
new	O
mutant	B-UNK
alleles	I-UNK
in	O
one	O
allele	B-UNK
,	O
deletion	B-UNK
of	O
C	O
447	O
in	O
exon	B-UNK
2	O
leads	B-UNK
to	O
a	O
frameshift	B-UNK
and	O
to	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
at	O
amino	B-UNK
acid	I-UNK
position	B-UNK
105	O
;	O
in	O
the	O
second	O
allele	B-UNK
,	O
a	O
G--	O
>	O
A	O
transition	B-UNK
in	O
exon	B-UNK
5	O
causes	O
a	O
Gly309	O
-	O
-	O
>	O
Ser	O
substitution	B-UNK
.	O

Transient	O
expression	B-UNK
of	O
the	O
mutant	B-UNK
Ser309-ARSA	O
resulted	B-UNK
in	O
only	O
13	O
%	O
enzyme	B-UNK
activity	I-UNK
of	O
that	O
observed	B-UNK
in	O
cells	B-UNK
expressing	O
normal	B-UNK
ARSA	B-UNK
.	O

The	O
mutant	B-UNK
ARSA	B-UNK
is	O
correctly	O
targeted	B-UNK
to	O
the	O
lysosomes	O
but	O
is	O
unstable	O
.	O

These	O
findings	B-UNK
are	O
in	O
contrast	B-UNK
to	O
previous	B-UNK
results	B-UNK
showing	O
that	O
the	O
late	B-UNK
-	O
infantile	B-UNK
type	B-UNK
of	O
MLD	B-UNK
is	O
always	O
associated	O
with	O
the	O
complete	O
absence	B-UNK
of	O
ARSA	B-UNK
activity	B-UNK
.	O

The	O
expression	B-UNK
of	O
the	O
mutant	B-UNK
ARSA	B-UNK
protein	B-UNK
may	O
be	O
influenced	O
by	O
particular	O
features	B-UNK
of	O
oligodendrocytes	O
,	O
such	O
that	O
the	O
level	B-UNK
of	O
mutant	B-UNK
enzyme	B-UNK
is	O
lower	O
in	O
these	O
cells	B-UNK
than	O
in	O
others	O
..	O

An	O
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
)	O
missense	B-UNK
mutation	I-UNK
(	O
T274	O
M	O
)	O
causing	B-UNK
late	B-UNK
-	O
infantile	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
.	O

Metachromatic	B-UNK
leukodystrophy	I-UNK
(	O
MLD	B-UNK
)	O
is	O
an	O
autosomal	B-UNK
recessive	I-UNK
lysosomal	B-UNK
storage	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
a	O
deficiency	B-UNK
of	O
arylsulfatase	O
A	O
(	O
ARSA	B-UNK
;	O
EC	B-UNK
3	O
.	O
1	O
.	O
6	O
.	O
8)	O
.	O

The	O
8	O
ARSA	B-UNK
exons	O
and	O
adjacent	O
intron	B-UNK
boundaries	O
from	O
a	O
patient	B-UNK
with	O
late	B-UNK
-	O
infantile	B-UNK
metachromatic	B-UNK
leukodystrophy	I-UNK
were	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
amplified	O
in	O
seven	O
discrete	O
reactions	O
.	O

Amplified	O
ARSA	B-UNK
exons	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
sequence	B-UNK
alterations	B-UNK
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
analysis	B-UNK
,	O
followed	O
by	O
direct	B-UNK
sequencing	I-UNK
of	O
PCR	B-UNK
products	I-UNK
.	O

The	O
patient	B-UNK
was	O
found	O
to	O
be	O
homozygous	B-UNK
for	O
a	O
C--	O
>	O
T	O
transition	B-UNK
in	O
exon	B-UNK
IV	O
that	O
results	B-UNK
in	O
the	O
substitution	B-UNK
of	O
a	O
highly	B-UNK
conserved	I-UNK
threonine	O
residue	O
at	O
amino	B-UNK
acid	I-UNK
274	O
with	O
a	O
methionine	O
(	O
T274	O
M	O
)	O
.	O

Analysis	B-UNK
of	O
a	O
further	O
29	O
MLD	B-UNK
patients	B-UNK
revealed	B-UNK
the	O
presence	O
of	O
five	O
additional	O
homozygotes	O
for	O
T274M.	O

All	O
6	O
T274	O
M	O
homozygotes	O
(	O
representing	O
four	O
families	B-UNK
)	O
were	O
of	O
Lebanese	O
descent	O
,	O
and	O
all	O
were	O
known	O
to	O
be	O
the	O
result	B-UNK
of	O
consanguineous	O
marriages	O
.	O

The	O
altered	O
amino	B-UNK
acid	I-UNK
is	O
rigidly	O
conserved	B-UNK
among	O
10	O
sulfatases	O
from	O
Escherichia	O
coli	B-UNK
to	O
humans	B-UNK
;	O
therefore	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
resultant	O
mutant	B-UNK
protein	B-UNK
will	O
have	O
little	O
or	O
no	O
enzyme	B-UNK
activity	I-UNK
.	O

This	O
is	O
consistent	B-UNK
with	O
the	O
very	O
low	B-UNK
ARSA	B-UNK
activity	B-UNK
measured	O
in	O
these	O
patients	B-UNK
and	O
their	O
uniformly	O
severe	B-UNK
clinical	B-UNK
presentation	O

Mutations	B-UNK
in	O
the	O
PAX6	B-UNK
gene	B-UNK
in	O
patients	B-UNK
with	O
hereditary	B-UNK
aniridia	B-DISEASE
.	O

The	O
14	O
exons	O
of	O
the	O
PAX6	B-UNK
gene	B-UNK
have	O
been	O
analysed	O
exon	B-UNK
-	O
by	O
-	O
exon	B-UNK
using	O
SSCP	B-UNK
in	O
6	O
aniridia	B-DISEASE
families	B-UNK
.	O

In	O
each	O
family	B-UNK
band	O
shifts	O
were	O
observed	B-UNK
on	O
the	O
SSCP	B-UNK
gels	O
for	O
only	O
one	O
exon	B-UNK
and	O
direct	B-UNK
PCR	B-UNK
-	O
sequencing	B-UNK
revealed	B-UNK
mutations	B-UNK
in	O
each	O
case	B-UNK
.	O

Two	O
mutations	B-UNK
involved	B-UNK
C--	O
>	O
T	O
transitions	O
in	O
CGAarg	O
codons	O
in	O
exons	O
9	O
and	O
11	O
.	O

Another	O
C--	O
>	O
T	O
transition	B-UNK
converted	O
a	O
CAG	B-UNK
-	O
glutamine	O
to	O
a	O
TAG	O
-	O
stop	B-UNK
in	O
exon	B-UNK
7	O
.	O

Small	O
insertions	O
created	O
frameshifts	O
which	O
produced	O
downstream	O
stop	B-UNK
codons	O
in	O
another	O
two	O
patients	B-UNK
and	O
an	O
A--	O
>	O
T	O
mutation	B-UNK
disrupted	O
the	O
splice	B-UNK
donor	I-UNK
site	I-UNK
of	O
exon	B-UNK
5	O
in	O
the	O
remaining	O
family	B-UNK
.	O

Thus	O
,	O
complete	O
inactivation	B-UNK
of	O
the	O
PAX6	B-UNK
gene	B-UNK
is	O
predicted	B-UNK
in	O
all	O
cases	B-UNK
.	O

Analysis	B-UNK
of	O
other	O
affected	B-UNK
members	B-UNK
of	O
the	O
families	B-UNK
showed	O
that	O
,	O
in	O
each	O
case	B-UNK
,	O
all	O
affected	B-UNK
individuals	I-UNK
carried	O
the	O
same	O
family	B-UNK
-	O
specific	B-UNK
mutation	B-UNK
.	O

One	O
polymorphism	B-UNK
was	O
found	O
in	O
exon	B-UNK
7	O
.	O

This	O
data	B-UNK
strongly	O
supports	O
the	O
candidature	O
of	O
PAX6	B-UNK
as	O
the	O
gene	B-UNK
responsible	B-UNK
for	O
hereditary	B-UNK
aniridia	B-DISEASE
..	O

Three	O
novel	O
mutations	B-UNK
in	O
five	O
unrelated	B-UNK
subjects	B-UNK
with	O
hereditary	B-UNK
protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
type	B-UNK
I.	O

A	O
panel	B-UNK
of	O
eight	O
unrelated	B-UNK
subjects	B-UNK
with	O
inherited	B-UNK
type	B-UNK
I	O
protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
was	O
screened	B-UNK
for	O
mutations	B-UNK
in	O
the	O
PROS1	O
gene	B-UNK
.	O

In	O
five	O
subjects	B-UNK
an	O
abnormality	O
was	O
found	O
but	O
mutations	B-UNK
were	O
not	O
detected	B-UNK
in	O
the	O
remaining	O
three	O
subjects	B-UNK
.	O

Two	O
subjects	B-UNK
shared	O
a	O
G--	O
>	O
A	O
transition	B-UNK
at	O
position	B-UNK
+	O
5	O
of	O
the	O
donor	B-UNK
splice	I-UNK
site	I-UNK
consensus	B-UNK
sequence	B-UNK
of	O
intron	B-UNK
10	O
.	O

Also	O
in	O
two	O
subjects	B-UNK
an	O
A--	O
>	O
T	O
transversion	B-UNK
was	O
detected	B-UNK
in	O
the	O
stopcodon	O
of	O
the	O
PROS1	O
gene	B-UNK
;	O
this	O
transversion	B-UNK
predicts	O
a	O
protein	B-UNK
S	O
molecule	O
that	O
is	O
extended	O
by	O
14	O
amino	B-UNK
acids	I-UNK
.	O

The	O
fifth	O
subject	O
was	O
found	O
to	O
possess	O
two	O
sequence	B-UNK
abnormalities	B-UNK
.	O

One	O
allele	B-UNK
carried	O
a	O
G--	O
>	O
A	O
transition	B-UNK
near	O
the	O
donor	B-UNK
splice	B-UNK
junction	O
of	O
intron	B-UNK
2	O
,	O
but	O
this	O
abnormality	O
is	O
probably	O
neutral	O
,	O
since	O
it	O
was	O
inherited	B-UNK
from	O
the	O
parent	O
with	O
normal	B-UNK
protein	B-UNK
S	O
antigen	O
levels	B-UNK
.	O

In	O
the	O
other	O
allele	B-UNK
a	O
single	B-UNK
T	O
insertion	O
in	O
codon-25	O
was	O
found	O
.	O

Analysis	B-UNK
of	O
platelet	B-UNK
RNA	B-UNK
showed	O
that	O
only	O
the	O
mRNA	O
with	O
the	O
A--	O
>	O
T	O
mutation	B-UNK
in	O
the	O
stopcodon	O
is	O
present	B-UNK
in	O
amounts	B-UNK
comparable	O
to	O
wildtype	O
RNA	B-UNK
.	O

mRNA	O
from	O
the	O
alleles	B-UNK
with	O
the	O
other	O
two	O
mutations	B-UNK
was	O
either	O
undetectable	O
or	O
present	B-UNK
in	O
greatly	O
reduced	O
amounts	B-UNK
.	O

The	O
latter	O
indicates	O
that	O
a	O
mRNA	O
based	B-UNK
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	B-UNK
analysis	I-UNK
of	O
protein	B-DISEASE
S	I-DISEASE
deficiency	I-DISEASE
type	B-UNK
I	O
..	O

Characteristics	B-UNK
of	O
intergenerational	O
contractions	O
of	O
the	O
CTG	B-UNK
repeat	I-UNK
in	O
myotonic	B-UNK
dystrophy	I-UNK
.	O

In	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
,	O
the	O
size	B-UNK
of	O
a	O
CTG	B-UNK
repeat	I-UNK
in	O
the	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	B-UNK
evidence	B-UNK
of	O
anticipation	B-UNK
.	O

However	O
,	O
there	O
have	O
also	O
been	O
cases	B-UNK
with	O
an	O
intergenerational	O
contraction	O
of	O
the	O
repeat	B-UNK
.	O

We	O
examined	O
1	O
,	O
489	O
DM	B-DISEASE
parent	O
-	O
offspring	O
pairs	B-UNK
,	O
of	O
which	O
95	O
(	O
6	O
.	O
4	O
%	O
)	O
showed	O
such	O
contractions	O
in	O
peripheral	B-UNK
blood	I-UNK
leukocytes	O
(	O
PBL	O
)	O
.	O

In	O
56	O
of	O
the	O
95	O
pairs	B-UNK
,	O
clinical	B-UNK
data	B-UNK
allowed	O
an	O
analysis	B-UNK
of	O
their	O
anticipation	B-UNK
status	B-UNK
.	O

It	O
is	O
surprising	O
that	O
anticipation	B-UNK
occurred	B-UNK
in	O
27	O
(	O
48	O
%	O
)	O
of	O
these	O
56	O
pairs	B-UNK
,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	B-UNK
of	O
DM	B-DISEASE
in	O
the	O
symptomatic	O
offspring	O
.	O

The	O
contraction	O
occurred	B-UNK
in	O
76	O
(	O
10	O
%	O
)	O
of	O
753	O
paternal	O
transmissions	O
and	O
in	O
19	O
(	O
3	O
%	O
)	O
of	O
736	O
maternal	O
transmissions	O
.	O

Anticipation	B-UNK
was	O
observed	B-UNK
more	O
frequently	O
in	O
maternal	O
(	O
85	O
%	O
)	O
than	O
in	O
paternal	O
(	O
37	O
%	O
)	O
transmissions	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
parental	O
repeat	B-UNK
size	B-UNK
correlated	B-UNK
with	O
the	O
size	B-UNK
of	O
intergenerational	O
contraction	O
(	O
r2	O
=	O
.	O
50	O
,	O
P	O
<	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
slope	O
of	O
linear	O
regression	O
was	O
steeper	O
in	O
paternal	O
(	O
-	O
.	O
62	O
)	O
than	O
in	O
maternal	O
(	O
-	O
.	O
30	O
)	O
transmissions	O
(	O
P	O
<	O
<	O
.	O
001	O
)	O
.	O

Sixteen	O
DM	B-DISEASE
parents	O
had	O
multiple	B-UNK
DM	B-DISEASE
offspring	O
with	O
the	O
CTG	B-UNK
repeat	I-UNK
contractions	O
.	O

This	O
frequency	B-UNK
was	O
higher	O
than	O
the	O
frequency	B-UNK
expected	O
from	O
the	O
probability	B-UNK
of	O
the	O
repeat	B-UNK
contractions	O
(	O
6	O
.	O
4	O
%	O
)	O
and	O
the	O
size	B-UNK
of	O
DM	B-DISEASE
sib	O
population	B-UNK
(	O
1	O
.	O
54	O
DM	B-UNK
offspring	O
per	O
DM	B-UNK
parent	O
,	O
in	O
968	O
DM	B-DISEASE
parents	O
)	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
intergenerational	O
contractions	O
of	O
the	O
CTG	B-UNK
repeat	I-UNK
in	O
leukocyte	O
DNA	B-UNK
frequently	O
accompanies	O
apparent	O
anticipation	B-UNK
,	O
especially	O
when	O
DM	B-UNK
is	O
maternally	O
transmitted	O
,	O
and	O
(	O
2	O
)	O
the	O
paternal	O
origin	O
of	O
the	O
repeat	B-UNK
and	O
the	O
presence	O
of	O
the	O
repeat	B-UNK
contraction	O
in	O
a	O
sibling	O
increase	B-UNK
the	O
probability	B-UNK
of	O
the	O
CTG	B-UNK
repeat	I-UNK
contraction	O

Gonosomal	O
mosaicism	O
in	O
myotonic	B-UNK
dystrophy	I-UNK
patients	B-UNK
:	O
involvement	B-UNK
of	O
mitotic	O
events	O
in	O
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
variation	B-UNK
and	O
selection	B-UNK
against	O
extreme	O
expansion	B-UNK
in	O
sperm	O
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
is	O
caused	B-UNK
by	O
abnormal	O
expansion	B-UNK
of	O
a	O
polymorphic	B-UNK
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
,	O
located	B-UNK
in	O
the	O
DM	B-UNK
protein	B-UNK
kinase	I-UNK
gene	B-UNK
.	O

We	O
determined	B-UNK
the	O
(	O
CTG	B-UNK
)	O
n	O
repeat	B-UNK
lengths	O
in	O
a	O
broad	O
range	B-UNK
of	O
tissue	B-UNK
DNAs	O
from	O
patients	B-UNK
with	O
mild	O
,	O
classical	O
,	O
or	O
congenital	B-UNK
manifestation	B-UNK
of	O
DM	B-UNK
.	O

Differences	B-UNK
in	O
the	O
repeat	B-UNK
length	I-UNK
were	O
seen	O
in	O
somatic	B-UNK
tissues	O
from	O
single	B-UNK
DM	B-DISEASE
individuals	B-UNK
and	O
twins	O
.	O

Repeats	B-UNK
appeared	B-UNK
to	O
expand	O
to	O
a	O
similar	B-UNK
extent	O
in	O
tissues	O
originating	O
from	O
the	O
same	O
embryonal	O
origin	O
.	O

In	O
most	O
male	B-UNK
patients	B-UNK
carrying	B-UNK
intermediate	O
-	O
or	O
small	O
-	O
sized	O
expansions	O
in	O
blood	B-UNK
,	O
the	O
repeat	B-UNK
lengths	O
covered	O
a	O
markedly	B-UNK
wider	O
range	B-UNK
in	O
sperm	O
.	O

In	O
contrast	B-UNK
,	O
male	B-UNK
patients	B-UNK
with	O
large	B-UNK
allele	B-UNK
expansions	O
in	O
blood	B-UNK
(	O
>	O
700	O
CTGs	O
)	O
had	O
similar	B-UNK
or	O
smaller	O
repeats	B-UNK
in	O
sperm	O
,	O
when	O
detectable	O
.	O

Sperm	O
alleles	B-UNK
with	O
>	O
1	O
,	O
000	O
CTGs	O
were	O
not	O
seen	O
.	O

We	O
conclude	O
that	O
DM	B-DISEASE
patients	B-UNK
can	O
be	O
considered	O
gonosomal	O
mosaics	O
,	O
i.	O

e	O
e.	O
,	O
combined	O
somatic	B-UNK
and	O
germ	B-UNK
-	O
line	B-UNK
tissue	B-UNK
mosaics	O
.	O

Most	O
remarkably	O
,	O
we	O
observed	B-UNK
multiple	B-UNK
cases	B-UNK
where	O
the	O
length	B-UNK
distributions	O
of	O
intermediate	O
-	O
or	O
small	O
-	O
sized	O
alleles	B-UNK
in	O
fathers	O
sperm	O
were	O
significantly	O
different	O
from	O
that	O
in	O
their	O
offsprings	O
blood	B-UNK
.	O

Our	O
combined	O
findings	B-UNK
indicate	O
that	O
intergenerational	O
length	B-UNK
changes	O
in	O
the	O
unstable	O
CTG	B-UNK
repeat	I-UNK
are	O
most	O
likely	O
to	O
occur	B-UNK
during	O
early	B-UNK
embryonic	B-UNK
mitotic	O
divisions	O
in	O
both	O
somatic	B-UNK
and	O
germ	B-UNK
-	O
line	B-UNK
tissue	B-UNK
formation	B-UNK
.	O

Both	O
the	O
initial	O
CTG	B-UNK
length	B-UNK
,	O
the	O
overall	O
number	B-UNK
of	O
cell	B-UNK
divisions	O
involved	B-UNK
in	O
tissue	B-UNK
formation	B-UNK
,	O
and	O
perhaps	O
a	O
specific	B-UNK
selection	B-UNK
process	B-UNK
in	O
spermatogenesis	O
may	O
influence	O
the	O
dynamics	O
of	O
this	O
process	B-UNK
.	O

A	O
model	B-UNK
explaining	O
mitotic	O
instability	B-UNK
and	O
sex	B-UNK
-	O
dependent	B-UNK
segregation	B-UNK
phenomena	O
in	O
DM	B-DISEASE
manifestation	B-UNK
is	O
discussed	O

Regionally	O
clustered	O
APC	B-UNK
mutations	B-UNK
are	O
associated	O
with	O
a	O
severe	B-UNK
phenotype	I-UNK
and	O
occur	B-UNK
at	O
a	O
high	B-UNK
frequency	I-UNK
in	O
new	O
mutation	B-UNK
cases	B-UNK
of	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
.	O

Germline	B-UNK
mutation	I-UNK
in	O
APC	B-UNK
at	O
5q21	O
-	O
22	O
results	B-UNK
in	O
the	O
dominantly	O
inherited	B-UNK
syndrome	B-UNK
adenomatous	B-UNK
polyposis	I-UNK
coli	I-UNK
(	O
APC	B-UNK
)	O
.	O

Somatic	B-UNK
mutation	B-UNK
in	O
this	O
gene	B-UNK
is	O
an	O
early	B-UNK
event	O
in	O
colorectal	B-UNK
tumourigenesis	O
.	O

Both	O
types	B-UNK
of	O
mutation	B-UNK
are	O
concentrated	O
in	O
the	O
5	O
half	B-UNK
of	O
exon	B-UNK
15	O
.	O

We	O
have	O
used	O
single	B-UNK
strand	I-UNK
conformational	B-UNK
polymorphism	B-UNK
(	O
SSCP	B-UNK
)	O
and	O
heteroduplex	B-UNK
analysis	I-UNK
to	O
screen	B-UNK
for	O
variants	B-UNK
in	O
this	O
region	B-UNK
of	O
the	O
gene	B-UNK
in	O
a	O
total	B-UNK
of	O
45	O
affected	B-UNK
but	O
unrelated	B-UNK
individuals	B-UNK
.	O

Eighteen	O
patients	B-UNK
had	O
no	O
family	B-UNK
history	B-UNK
of	O
the	O
disease	B-DISEASE
;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	B-UNK
phenotype	I-UNK
,	O
based	B-UNK
on	O
an	O
early	B-UNK
age	B-UNK
at	O
presentation	O
or	O
cancer	B-UNK
development	B-UNK
.	O

This	O
compared	B-UNK
with	O
6	O
of	O
27	O
familial	B-UNK
cases	I-UNK
.	O

A	O
5	O
bp	B-UNK
deletion	I-UNK
at	O
codon	B-UNK
1309	O
reported	B-UNK
to	O
occur	B-UNK
in	O
10	O
-	O
15	O
%	O
of	O
unselected	O
APC	B-UNK
patients	B-UNK
worldwide	O
,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	B-UNK
cases	B-UNK
and	O
4	O
of	O
the	O
27	O
familial	B-UNK
cases	I-UNK
all	O
nine	O
were	O
classed	O
as	O
severe	B-UNK
.	O

A	O
further	O
3	O
new	O
mutations	B-UNK
and	O
1	O
familial	B-UNK
mutation	B-UNK
were	O
located	B-UNK
downstream	O
from	O
codon	B-UNK
1309	O
,	O
these	O
individuals	B-UNK
similarly	O
being	O
classed	O
as	O
phenotypically	O
severe	B-UNK
.	O

In	O
contrast	B-UNK
all	O
of	O
the	O
APC	B-UNK
mutations	B-UNK
detected	B-UNK
in	O
affected	B-UNK
individuals	I-UNK
with	O
an	O
average	O
phenotype	B-UNK
were	O
located	B-UNK
prior	O
to	O
codon	B-UNK
1309	O
.	O

The	O
frequent	B-UNK
association	B-UNK
of	O
a	O
severe	B-UNK
phenotype	I-UNK
with	O
fresh	O
mutation	B-UNK
may	O
explain	O
the	O
apparent	O
conflict	O
of	O
a	O
high	B-UNK
mutation	B-UNK
rate	B-UNK
(	O
20	O
-	O
30	O
%	O
)	O
in	O
a	O
condition	B-UNK
,	O
which	O
on	O
average	O
,	O
is	O
lethal	O
at	O
a	O
post-reproductive	O
age	B-UNK
..	O

Mutations	B-UNK
at	O
the	O
PAX6	B-UNK
locus	B-UNK
are	O
found	O
in	O
heterogeneous	O
anterior	O
segment	O
malformations	B-DISEASE
including	O
Peters	O
'	O
anomaly	B-UNK
.	O

Mutation	B-UNK
or	O
deletion	B-UNK
of	O
the	O
PAX6	B-UNK
gene	B-UNK
underlies	O
many	O
cases	B-UNK
of	O
aniridia	B-DISEASE
.	O

Three	O
lines	B-UNK
of	O
evidence	B-UNK
now	O
converge	O
to	O
implicate	O
PAX6	B-UNK
more	O
widely	O
in	O
anterior	O
segment	O
malformations	B-DISEASE
including	O
Peters	B-DISEASE
anomaly	I-DISEASE
.	O

First	O
,	O
a	O
child	B-UNK
with	O
Peters	B-DISEASE
anomaly	I-DISEASE
is	O
deleted	B-UNK
for	O
one	O
copy	B-UNK
of	O
PAX6	B-UNK
.	O

Second	O
,	O
affected	B-UNK
members	B-UNK
of	O
a	O
family	B-UNK
with	O
dominantly	O
inherited	B-UNK
anterior	O
segment	O
malformations	B-DISEASE
,	O
including	O
Peters	B-DISEASE
anomaly	I-DISEASE
are	O
heterozygous	B-UNK
for	O
an	O
R26	O
G	O
mutation	B-UNK
in	O
the	O
PAX6	B-UNK
paired	O
box	O
.	O

Third	O
,	O
a	O
proportion	B-UNK
of	O
Sey/+	O
Smalleye	O
mice	B-UNK
,	O
heterozygous	B-UNK
for	O
a	O
nonsense	B-UNK
mutation	I-UNK
in	O
murine	O
Pax-6	O
,	O
have	O
an	O
ocular	O
phenotype	B-UNK
resembling	O
Peters	B-DISEASE
anomaly	I-DISEASE
.	O

We	O
therefore	O
propose	O
that	O
a	O
variety	O
of	O
anterior	O
segment	O
anomalies	B-UNK
may	O
be	O
associated	O
with	O
PAX6	B-UNK
mutations	B-UNK
..	O

Huntington	B-DISEASE
disease	I-DISEASE
without	O
CAG	B-UNK
expansion	B-UNK
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	B-UNK
?	O

Huntington	B-DISEASE
disease	I-DISEASE
(	O
HD	B-UNK
)	O
has	O
been	O
shown	B-UNK
to	O
be	O
associated	O
with	O
an	O
expanded	B-UNK
CAG	B-UNK
repeat	I-UNK
within	O
a	O
novel	O
gene	B-UNK
on	O
4p16	O
.	O

3	O
(	O
IT15	O
)	O
.	O

A	O
total	B-UNK
of	O
30	O
of	O
1	O
,	O
022	O
affected	B-UNK
persons	O
(	O
2	O
.	O
9	O
%	O
of	O
our	O
cohort	B-UNK
)	O
did	O
not	O
have	O
an	O
expanded	B-UNK
CAG	B-UNK
in	O
the	O
disease	B-UNK
range	B-UNK
.	O

The	O
reasons	O
for	O
not	O
observing	O
expansion	B-UNK
in	O
affected	B-UNK
individuals	I-UNK
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	B-UNK
length	I-UNK
both	O
for	O
diagnosis	B-UNK
of	O
affected	B-UNK
patients	B-UNK
and	O
for	O
predictive	O
testing	B-UNK
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	B-UNK
of	O
the	O
molecular	B-UNK
mechanism	B-UNK
underlying	O
HD	B-UNK
.	O

Here	O
we	O
show	O
that	O
the	O
majority	O
(	O
18	O
)	O
of	O
the	O
individuals	B-UNK
with	O
normal	B-UNK
sized	O
alleles	B-UNK
represent	O
misdiagnosis	O
,	O
sample	O
mix	O
-	O
up	O
,	O
or	O
clerical	O
error	O
.	O

The	O
remaining	O
12	O
patients	B-UNK
represent	O
possible	O
phenocopies	O
for	O
HD	B-UNK
.	O

In	O
at	O
least	O
four	O
cases	B-UNK
,	O
family	B-UNK
studies	B-UNK
of	O
these	O
phenocopies	O
excluded	O
4p16	O
.	O

3	O
as	O
the	O
region	B-UNK
responsible	B-UNK
for	O
the	O
phenotype	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
HD	B-UNK
gene	B-UNK
that	O
are	O
other	O
than	O
CAG	B-UNK
expansion	B-UNK
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	B-UNK
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	B-UNK
clinical	B-UNK
features	I-UNK
identified	B-UNK
characteristics	B-UNK
not	O
typical	O
for	O
HD	B-UNK
.	O

This	O
study	B-UNK
shows	O
that	O
on	O
rare	B-UNK
occasions	O
mutations	B-UNK
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	B-UNK
can	O
present	B-UNK
with	O
a	O
clinical	B-UNK
phenotype	B-UNK
very	O
similar	B-UNK
to	O
that	O
of	O
HD	B-UNK

Frequent	B-UNK
detection	B-UNK
of	O
codon	B-UNK
877	O
mutation	B-UNK
in	O
the	O
androgen	O
receptor	B-UNK
gene	B-UNK
in	O
advanced	O
prostate	B-UNK
cancers	B-DISEASE
.	O

Prostatic	O
tissue	B-UNK
specimens	O
derived	B-UNK
from	O
transurethral	O
resections	O
of	O
patients	B-UNK
with	O
metastatic	O
prostate	B-UNK
cancer	I-UNK
were	O
analyzed	B-UNK
for	O
genetic	B-UNK
alterations	B-UNK
in	O
the	O
hormone	B-UNK
-	O
binding	B-UNK
domain	I-UNK
of	O
the	O
androgen	O
receptor	B-UNK
(	O
AR	O
)	O
gene	B-UNK
.	O

Direct	B-UNK
sequencing	I-UNK
of	O
the	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
-	O
derived	B-UNK
DNAs	O
of	O
6	O
of	O
24	O
specimens	O
revealed	B-UNK
a	O
codon	B-UNK
877	O
mutation	B-UNK
(	O
ACT--	O
>	O
GCT	O
,	O
Thr--	O
>	O
Ala	B-UNK
)	O
in	O
the	O
hormone	B-UNK
-	O
binding	B-UNK
domain	I-UNK
of	O
the	O
AR	O
gene	B-UNK
.	O

This	O
same	O
AR	O
mutation	B-UNK
has	O
been	O
reported	B-UNK
previously	B-UNK
in	O
a	O
metastatic	O
prostate	B-UNK
cancer	I-UNK
cell	B-UNK
line	I-UNK
,	O
LNCaP	O
,	O
where	O
this	O
mutation	B-UNK
confers	O
upon	O
the	O
AR	O
an	O
altered	O
ligand	O
-	O
binding	B-UNK
specificity	O
which	O
is	O
stimulated	O
by	O
estrogens	O
,	O
progestagens	O
,	O
and	O
antiandrogens	O
.	O

It	O
is	O
possible	O
that	O
analogous	O
to	O
an	O
activated	O
/	O
altered	O
growth	B-UNK
factor	I-UNK
receptor	B-UNK
oncogene	O
,	O
codon	B-UNK
877	O
mutant	B-UNK
AR	O
with	O
altered	O
ligand	O
binding	B-UNK
may	O
provide	B-UNK
a	O
selective	O
growth	B-UNK
advantage	B-UNK
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	O
prostate	B-UNK
cancer	I-UNK
.	O

Although	O
estrogens	O
are	O
used	O
infrequently	O
,	O
antiandrogens	O
are	O
used	O
increasingly	O
in	O
hormonal	O
therapy	B-UNK
for	O
patients	B-UNK
with	O
advanced	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O

The	O
stimulatory	O
effect	B-UNK
of	O
these	O
therapeutic	O
agents	O
on	O
the	O
codon	B-UNK
877	O
mutant	B-UNK
AR	O
further	O
suggests	O
that	O
this	O
frequently	O
observed	B-UNK
AR	O
mutation	B-UNK
may	O
contribute	B-UNK
to	O
the	O
treatment	O
refractory	O
disease	B-UNK
..	O

The	O
human	B-UNK
gene	B-UNK
for	O
alkaptonuria	B-DISEASE
(	O
AKU	O
)	O
maps	B-UNK
to	O
chromosome	B-UNK
3q	O
.	O

Alkaptonuria	B-UNK
(	O
AKU	O
;	O
McKusick	O
no	O
.	O
203500	O
)	O
is	O
a	O
rare	B-UNK
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
caused	B-UNK
by	O
the	O
lack	B-UNK
of	O
homogentisic	O
acid	B-UNK
oxidase	O
activity	B-UNK
.	O

Patients	B-UNK
excrete	O
large	B-UNK
amounts	B-UNK
of	O
homogentisic	O
acid	B-UNK
in	O
their	O
urine	O
and	O
a	O
black	B-UNK
ochronotic	O
pigment	B-UNK
is	O
deposited	O
in	O
their	O
cartilage	O
and	O
collagenous	O
tissues	O
.	O

Ochronosis	B-DISEASE
is	O
the	O
predominant	O
clinical	B-UNK
complication	O
of	O
the	O
disease	B-DISEASE
leading	B-UNK
to	O
ochronotic	O
arthropathy	O
,	O
dark	O
urine	O
,	O
pigment	B-UNK
changes	O
of	O
the	O
skin	B-UNK
,	O
and	O
other	O
clinical	B-UNK
features	I-UNK
.	O

A	O
mutation	B-UNK
causing	I-UNK
alkaptonuria	B-UNK
in	O
the	O
mouse	B-UNK
has	O
mapped	B-UNK
to	O
chromosome	B-UNK
16	O
.	O

Considering	O
conserved	B-UNK
synteny	O
,	O
we	O
were	O
able	O
to	O
map	B-UNK
the	O
human	B-UNK
gene	B-UNK
to	O
chromosome	B-UNK
3q	O
in	O
six	O
alkaptonuria	B-UNK
pedigrees	O
of	O
Slovak	O
origin	O
..	O

Structure	B-UNK
of	O
the	O
human	B-UNK
Na	B-UNK
+	O
/glucose	O
cotransporter	O
gene	B-UNK
SGLT1	B-UNK
.	O

Intestinal	O
uptake	O
of	O
dietary	O
glucose	B-UNK
and	O
galactose	B-UNK
is	O
mediated	O
by	O
the	O
SGLT1	B-UNK
Na	B-UNK
+	O
/glucose	O
cotransporter	O
of	O
the	O
brush	O
border	O
.	O

An	O
SGLT1	B-UNK
missense	B-UNK
mutation	I-UNK
underlies	O
hereditary	B-UNK
glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
,	O
characterized	B-UNK
by	O
potentially	O
fatal	B-UNK
diarrhea	B-DISEASE
;	O
conversely	O
,	O
oral	B-UNK
rehydration	O
therapy	B-UNK
exploits	O
normal	B-UNK
transport	B-UNK
to	O
alleviate	O
life	B-UNK
-	O
threatening	O
diarrhea	B-DISEASE
of	O
infectious	O
origin	O
.	O

We	O
have	O
mapped	B-UNK
the	O
entire	O
human	B-UNK
SGLT1	B-UNK
Na	B-UNK
+	O
/glucose	O
cotransporter	O
gene	B-UNK
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	B-UNK
region	B-UNK
of	O
112	O
kilobases	O
.	O

Transcription	B-UNK
initiation	O
occurred	B-UNK
from	O
a	O
site	B-UNK
27	O
base	B-UNK
pairs	B-UNK
3	O
of	O
a	O
TATAA	O
sequence	B-UNK
.	O

All	O
exon	B-UNK
-	O
flanking	O
regions	B-UNK
were	O
sequenced	O
,	O
and	O
the	O
entire	O
112-kilobase	O
region	B-UNK
mapped	B-UNK
with	O
four	O
restriction	B-UNK
enzymes	B-UNK
.	O

SGLT1	B-UNK
is	O
comprised	O
of	O
15	O
exons	O
(	O
spanning	O
72	O
kilobases	O
)	O
;	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six	O
-	O
membrane	B-UNK
-	O
span	O
ancestral	O
precursor	O
via	O
a	O
gene	B-UNK
duplication	B-UNK
event	O
is	O
suggested	O
from	O
comparison	B-UNK
of	O
exons	O
against	O
protein	B-UNK
secondary	O
structure	B-UNK
and	O
from	O
sequence	B-UNK
considerations	O
.	O

A	O
new	O
missense	B-UNK
mutation	I-UNK
in	O
exon	B-UNK
1	O
causing	B-UNK
glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
is	O
also	O
described	O
.	O

This	O
is	O
the	O
first	O
Na	B-UNK
(	O
+	O
)	O
-dependent	O
cotransporter	O
gene	B-UNK
structure	B-UNK
reported	B-UNK
.	O

These	O
data	B-UNK
facilitate	O
the	O
search	O
for	O
new	O
glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
-	O
related	B-UNK
mutations	B-UNK
in	O
this	O
important	O
gene	B-UNK
and	O
provide	B-UNK
a	O
basis	B-UNK
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
Na	B-UNK
(	O
+	O
)	O
-dependent	O
cotransporters	O
..	O

Four	O
novel	O
PEPD	O
alleles	B-UNK
causing	B-UNK
prolidase	B-DISEASE
deficiency	I-DISEASE
.	O

Mutations	B-UNK
at	O
the	O
PEPD	O
locus	B-UNK
cause	O
prolidase	B-DISEASE
deficiency	I-DISEASE
(	O
McKusick	O
170100	O
)	O
,	O
a	O
rare	B-UNK
autosomal	B-UNK
recessive	I-UNK
disorder	B-UNK
characterized	B-UNK
by	O
iminodipeptiduria	O
,	O
skin	B-UNK
ulcers	B-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
and	O
recurrent	O
infections	B-DISEASE
.	O

Four	O
PEPD	O
mutations	B-UNK
from	O
five	O
severely	O
affected	B-UNK
individuals	I-UNK
were	O
characterized	B-UNK
by	O
analysis	B-UNK
of	O
reverse	B-UNK
-	O
transcribed	O
,	O
PCR	B-UNK
-	O
amplified	O
(	O
RT	O
-	O
PCR	B-UNK
)	O
cDNA	O
.	O

We	O
used	O
SSCP	B-UNK
analysis	B-UNK
on	O
four	O
overlapping	O
cDNA	O
fragments	O
covering	O
the	O
entire	O
coding	B-UNK
region	I-UNK
of	O
the	O
PEPD	O
gene	B-UNK
and	O
detected	B-UNK
abnormal	O
SSCP	B-UNK
bands	O
for	O
the	O
fragment	B-UNK
spanning	O
all	O
or	O
part	O
of	O
exons	O
13	O
-	O
15	O
in	O
three	O
of	O
the	O
probands	O
.	O

Direct	B-UNK
sequencing	I-UNK
of	O
the	O
mutant	B-UNK
cDNAs	O
showed	O
a	O
G--	O
>	O
A	O
,	O
1342	O
substitution	B-UNK
(	O
G448R	O
)	O
in	O
two	O
patients	B-UNK
and	O
a	O
3-bp	O
deletion	B-UNK
(	O
delta	O
E452	O
or	O
delta	O
E453	O
)	O
in	O
another	O
.	O

In	O
the	O
other	O
two	O
probands	O
the	O
amplified	O
products	B-UNK
were	O
of	O
reduced	O
size	B-UNK
.	O

Direct	B-UNK
sequencing	I-UNK
of	O
these	O
mutant	B-UNK
cDNAs	O
revealed	B-UNK
a	O
deletion	B-UNK
of	O
exon	B-UNK
5	O
in	O
one	O
patient	B-UNK
and	O
of	O
exon	B-UNK
7	O
in	O
the	O
other	O
.	O

Intronic	O
sequences	O
flanking	O
exons	O
5	O
and	O
7	O
were	O
identified	B-UNK
using	O
inverse	O
PCR	B-UNK
followed	O
by	O
direct	B-UNK
sequencing	I-UNK
.	O

Conventional	O
PCR	B-UNK
and	O
direct	B-UNK
sequencing	I-UNK
then	O
established	O
the	O
intron	B-UNK
-	O
exon	B-UNK
borders	O
of	O
the	O
mutant	B-UNK
genomic	B-UNK
DNA	I-UNK
revealing	O
two	O
splice	B-UNK
acceptor	I-UNK
mutations	B-UNK
a	O
G--	O
>	O
C	O
substitution	B-UNK
at	O
position-1	O
of	O
intron	B-UNK
4	O
and	O
an	O
A--	O
>	O
G	O
substitution	B-UNK
at	O
position-2	O
of	O
intron	B-UNK
6	O
.	O

Our	O
results	B-UNK
indicate	O
that	O
the	O
severe	B-UNK
form	B-UNK
of	O
prolidase	B-DISEASE
deficiency	I-DISEASE
is	O
caused	B-UNK
by	O
multiple	B-UNK
PEPD	O
alleles	B-UNK
.	O

In	O
this	O
report	B-UNK
we	O
attempt	O
to	O
begin	O
the	O
process	B-UNK
of	O
describing	O
these	O
alleles	B-UNK
and	O
cataloging	O
their	O
phenotypic	B-UNK
expression	B-UNK
..	O

Recombinations	O
in	O
individuals	B-UNK
homozygous	B-UNK
by	O
descent	O
localize	O
the	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
locus	B-UNK
in	O
a	O
cloned	O
450-kb	O
interval	B-UNK
.	O

The	O
locus	B-UNK
for	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
(	O
FRDA	B-UNK
)	O
,	O
a	O
severe	B-UNK
neurodegenerative	B-DISEASE
disease	I-DISEASE
,	O
is	O
tightly	B-UNK
linked	I-UNK
to	O
markers	B-UNK
D9S5	O
and	O
D9S15	O
,	O
and	O
analysis	B-UNK
of	O
rare	B-UNK
recombination	B-UNK
events	O
has	O
suggested	O
the	O
order	B-UNK
cen	O
-	O
FRDA	B-UNK
-	O
D9S5-D9S15-qter	O
.	O

We	O
report	B-UNK
here	O
the	O
construction	O
of	O
a	O
YAC	B-UNK
contig	O
extending	O
800	O
kb	B-UNK
centromeric	O
to	O
D9S5	O
and	O
the	O
isolation	B-UNK
of	O
five	O
new	O
microsatellite	B-UNK
markers	I-UNK
from	O
this	O
region	B-UNK
.	O

In	O
order	B-UNK
to	O
map	B-UNK
these	O
markers	B-UNK
with	O
respect	O
to	O
the	O
FRDA	B-UNK
locus	B-UNK
,	O
all	O
within	O
a	O
1-cM	O
confidence	B-UNK
interval	I-UNK
,	O
we	O
sought	O
to	O
increase	B-UNK
the	O
genetic	B-UNK
information	B-UNK
of	O
available	O
FRDA	B-UNK
families	B-UNK
by	O
considering	O
homozygosity	B-UNK
by	O
descent	O
and	O
association	B-UNK
with	O
founder	B-UNK
haplotypes	O
in	O
isolated	B-UNK
populations	O
.	O

This	O
approach	O
allowed	O
us	O
to	O
identify	B-UNK
one	O
phase	B-UNK
-	O
known	O
recombination	B-UNK
and	O
one	O
probable	O
historic	O
recombination	B-UNK
on	O
haplotypes	O
from	O
Reunion	O
Island	B-UNK
patients	B-UNK
,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	B-UNK
proximal	B-UNK
to	O
FRDA	B-UNK
.	O

This	O
represents	O
the	O
first	O
identification	B-UNK
of	O
close	B-UNK
FRDA	B-UNK
flanking	O
markers	B-UNK
on	O
the	O
centromeric	O
side	O
.	O

The	O
two	O
other	O
markers	B-UNK
allowed	O
us	O
to	O
narrow	O
the	O
breakpoint	O
of	O
a	O
previously	B-UNK
identified	I-UNK
distal	B-UNK
recombination	B-UNK
that	O
is	O
>	O
180	O
kb	B-UNK
from	O
D9S5	O
(	O
26P	O
)	O
.	O

Taken	O
together	O
,	O
the	O
results	B-UNK
place	O
the	O
FRDA	B-UNK
locus	B-UNK
in	O
a	O
450-kb	O
interval	B-UNK
,	O
which	O
is	O
small	O
enough	O
for	O
direct	B-UNK
search	O
of	O
candidate	B-UNK
genes	B-UNK
.	O

A	O
detailed	B-UNK
rare	B-UNK
cutter	O
restriction	B-UNK
map	B-UNK
and	O
a	O
cosmid	O
contig	O
covering	O
this	O
interval	B-UNK
were	O
constructed	O
and	O
should	O
facilitate	O
the	O
search	O
of	O
genes	B-UNK
in	O
this	O
region	B-UNK
..	O

Investigation	B-UNK
of	O
thermoregulatory	O
characteristics	B-UNK
in	O
patients	B-UNK
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

A	O
survey	O
instrument	O
is	O
used	O
to	O
assess	B-UNK
temperature	O
regulation	B-UNK
characteristics	B-UNK
in	O
children	O
with	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
compared	B-UNK
to	O
3	O
control	B-UNK
groups	B-UNK
sibs	O
of	O
PWS	B-UNK
patients	B-UNK
(	O
SIB	O
)	O
,	O
neurodevelopmentally	O
handicapped	O
children	O
(	O
ND	O
)	O
,	O
and	O
age	B-UNK
and	O
gender	O
matched	O
well	O
children	O
(	O
WC	O
)	O
.	O

Significant	B-UNK
differences	B-UNK
were	O
found	O
between	O
PWS	B-UNK
patients	B-UNK
,	O
SIB	O
controls	O
,	O
and	O
WC	O
controls	O
in	O
the	O
prevalence	B-UNK
of	O
febrile	O
convulsions	B-DISEASE
,	O
fever	B-DISEASE
-	O
associated	O
symptoms	B-UNK
,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
F.	O

No	O
differences	B-UNK
were	O
noted	O
in	O
any	O
variable	B-UNK
between	O
the	O
PWS	B-UNK
patients	B-UNK
and	O
the	O
ND	O
controls	O
,	O
suggesting	O
that	O
these	O
abnormalities	B-UNK
are	O
not	O
unique	O
to	O
PWS	B-UNK
,	O
but	O
can	O
occur	B-UNK
in	O
any	O
neurodevelopmentally	O
handicapped	O
individual	O
,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome	B-DISEASE
-	O
specific	B-UNK
hypothalamic	O
abnormalities	B-UNK
..	O

Phenotypic	B-UNK
variation	B-UNK
including	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
pattern	B-UNK
dystrophy	B-UNK
,	O
and	O
fundus	O
flavimaculatus	O
in	O
a	O
single	B-UNK
family	B-UNK
with	O
a	O
deletion	B-UNK
of	O
codon	B-UNK
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	B-UNK
gene	B-UNK
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Mutations	B-UNK
of	O
the	O
peripherin	O
/	O
RDS	B-UNK
gene	B-UNK
have	O
been	O
reported	B-UNK
in	O
autosomal	B-UNK
dominant	I-UNK
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
pattern	B-UNK
macular	B-UNK
dystrophy	B-UNK
,	O
and	O
retinitis	B-DISEASE
punctata	O
albescens	O
.	O

We	O
report	B-UNK
herein	O
the	O
occurrence	B-UNK
of	O
three	O
separate	O
phenotypes	O
within	O
a	O
single	B-UNK
family	B-UNK
with	O
a	O
novel	O
3-base	O
pair	B-UNK
deletion	B-UNK
of	O
codon	B-UNK
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	B-UNK
gene	B-UNK
.	O

DESIGN	O
Case	B-UNK
reports	O
with	O
clinical	B-UNK
features	I-UNK
,	O
fluorescein	O
angiography	O
,	O
kinetic	O
perimetry	O
,	O
electrophysiological	O
studies	B-UNK
,	O
and	O
molecular	B-UNK
genetics	B-UNK
.	O

SETTING	O
University	O
medical	O
centers	O
.	O

PATIENTS	B-UNK
A	O
75-year	O
-	O
old	O
woman	O
,	O
her	O
two	O
daughters	O
(	O
aged	O
44	O
and	O
50	O
years	O
)	O
,	O
and	O
her	O
49-year	O
-	O
old	O
son	O
were	O
screened	B-UNK
for	O
peripherin	O
/	O
RDS	B-UNK
mutations	B-UNK
because	O
of	O
the	O
presence	O
of	O
multiple	B-UNK
phenotypes	O
within	O
the	O
same	O
family	B-UNK
.	O

RESULTS	B-UNK
The	O
mother	O
presented	B-UNK
at	O
age	B-UNK
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(	O
ERG	B-UNK
)	O
and	O
adult	B-UNK
-	O
onset	B-UNK
retinitis	B-DISEASE
pigmentosa	I-DISEASE
that	O
progressed	O
dramatically	O
over	O
12	O
years	O
,	O
with	O
marked	B-UNK
loss	B-UNK
of	O
peripheral	B-UNK
visual	B-UNK
field	B-UNK
.	O

One	O
daughter	O
developed	O
pattern	B-UNK
macular	B-UNK
dystrophy	B-UNK
at	O
age	B-UNK
31	O
years	O
.	O

At	O
age	B-UNK
44	O
years	O
,	O
her	O
ERG	B-UNK
was	O
moderately	O
abnormal	O
but	O
her	O
clinical	B-UNK
disease	B-UNK
was	O
limited	O
to	O
the	O
macula	O
.	O

Another	O
daughter	O
presented	B-UNK
at	O
age	B-UNK
42	O
years	O
with	O
macular	B-DISEASE
degeneration	I-DISEASE
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	B-UNK
picture	O
of	O
fundus	O
flavimaculatus	O
.	O

Her	O
peripheral	B-UNK
visual	B-UNK
field	B-UNK
was	O
preserved	O
but	O
her	O
ERG	B-UNK
was	O
moderately	O
abnormal	O
.	O

The	O
son	O
had	O
onset	B-UNK
of	O
macular	B-DISEASE
degeneration	I-DISEASE
at	O
age	B-UNK
44	O
years	O
.	O

Pericentral	O
scotomas	O
were	O
present	B-UNK
and	O
the	O
ERG	B-UNK
was	O
markedly	B-UNK
abnormal	O
.	O

Fluorescein	O
angiography	O
revealed	B-UNK
punctate	O
pigment	B-UNK
epithelial	B-UNK
transmission	B-UNK
defects	B-UNK
.	O

CONCLUSIONS	B-UNK
A	O
3-base	O
pair	B-UNK
deletion	B-UNK
of	O
codon	B-UNK
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	B-UNK
gene	B-UNK
can	O
produce	B-UNK
clinically	O
disparate	O
phenotypes	O
even	O
within	O
the	O
same	O
family	B-UNK
..	O

Assignment	B-UNK
of	O
the	O
human	B-UNK
Na	B-UNK
+	O
/glucose	O
cotransporter	O
gene	B-UNK
SGLT1	B-UNK
to	O
chromosome	B-UNK
22q13	O
.	O
1	O
.	O

The	O
Na	B-UNK
+	O
/glucose	O
cotransporter	O
gene	B-UNK
SGLT1	B-UNK
encodes	B-UNK
the	O
primary	B-UNK
carrier	B-UNK
protein	B-UNK
responsible	B-UNK
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	B-UNK
and	O
galactose	B-UNK
from	O
the	O
intestinal	O
lumen	O
.	O

SGLT1	B-UNK
transport	B-UNK
activity	B-UNK
is	O
currently	O
exploited	O
in	O
oral	B-UNK
rehydration	O
therapy	B-UNK
.	O

The	O
75-kDa	O
glycoprotein	O
is	O
localized	B-UNK
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	B-UNK
to	O
comprise	O
12	O
membrane	B-UNK
spans	O
.	O

In	O
two	O
patients	B-UNK
with	O
the	O
autosomal	B-UNK
recessive	I-UNK
disease	B-UNK
glucose	B-UNK
/	O
galactose	B-UNK
malabsorption	O
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	B-UNK
mutation	I-UNK
in	O
SGLT1	B-UNK
,	O
and	O
the	O
Asp28	O
-	O
-	O
>	O
Asn	O
change	B-UNK
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	B-UNK
transport	B-UNK
activity	B-UNK
.	O

The	O
SGLT1	B-UNK
gene	B-UNK
was	O
previously	B-UNK
shown	B-UNK
to	O
reside	O
on	O
the	O
distal	B-UNK
q	O
arm	B-UNK
of	O
chromosome	B-UNK
22	O
(	O
11	O
.	O
2	O
-	O
-	O
>	O
qter	O
)	O
.	O

We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
,	O
which	O
refines	O
the	O
localization	B-UNK
to	O
22q13	O
.	O

1	O
,	O
and	O
provide	B-UNK
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	B-UNK
probe	O
as	O
a	O
diagnostic	B-UNK
for	O
genetic	B-UNK
diseases	B-DISEASE
associated	O
with	O
translocations	O
of	O
chromosome	B-UNK
22	O
.	O

Restriction	B-UNK
of	O
ocular	O
fundus	O
lesions	B-UNK
to	O
a	O
specific	B-UNK
subgroup	O
of	O
APC	B-UNK
mutations	B-UNK
in	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
patients	B-UNK
.	O

In	O
humans	B-UNK
,	O
alteration	O
of	O
the	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
,	O
APC	B-UNK
,	O
causes	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
,	O
a	O
condition	B-UNK
causing	B-UNK
predisposition	B-UNK
to	O
colorectal	B-UNK
cancer	I-UNK
.	O

The	O
syndrome	B-DISEASE
inconsistently	O
associates	O
characteristic	B-UNK
patches	O
of	O
congenital	B-UNK
hypertrophy	B-DISEASE
of	O
the	O
retinal	B-UNK
pigment	B-UNK
epithelium	O
(	O
CHRPE	O
)	O
.	O

Ocular	O
examination	B-UNK
revealed	B-UNK
that	O
patients	B-UNK
expressing	O
CHRPE	O
tend	O
to	O
cluster	B-UNK
within	O
specific	B-UNK
families	B-UNK
.	O

The	O
exact	O
APC	B-UNK
mutation	B-UNK
was	O
identified	B-UNK
in	O
42	O
unrelated	B-UNK
patients	B-UNK
.	O

In	O
all	O
cases	B-UNK
these	O
mutations	B-UNK
were	O
predicted	B-UNK
to	O
lead	B-UNK
to	O
the	O
synthesis	B-UNK
of	O
a	O
truncated	O
protein	B-UNK
.	O

The	O
extent	O
of	O
CHRPE	O
was	O
found	O
to	O
be	O
dependent	B-UNK
on	O
the	O
position	B-UNK
of	O
the	O
mutation	B-UNK
along	O
the	O
coding	B-UNK
sequence	I-UNK
.	O

CHRPE	O
lesions	B-UNK
are	O
almost	O
always	O
absent	O
if	O
the	O
mutation	B-UNK
occurs	O
before	O
exon	B-UNK
9	O
,	O
but	O
are	O
systematically	O
present	B-UNK
if	O
it	O
occurs	O
after	O
this	O
exon	B-UNK
.	O

Thus	O
,	O
the	O
range	B-UNK
of	O
phenotypic	B-UNK
expression	B-UNK
observed	B-UNK
among	O
affected	B-UNK
patients	B-UNK
may	O
result	B-UNK
in	O
part	O
from	O
different	O
allelic	O
manifestations	B-UNK
of	O
APC	B-UNK
mutations	B-UNK
..	O

The	O
effects	B-UNK
of	O
dystrophin	B-UNK
gene	I-UNK
mutations	B-UNK
on	O
the	O
ERG	B-UNK
in	O
mice	B-UNK
and	O
humans	B-UNK
.	O

PURPOSE	O
.	O

The	O
authors	O
earlier	O
findings	B-UNK
of	O
a	O
negative	B-UNK
electroretinogram	O
(	O
ERG	B-UNK
)	O
in	O
a	O
boy	B-UNK
with	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
led	B-UNK
them	O
to	O
investigate	B-UNK
dystrophin	B-UNK
gene	I-UNK
deletions	O
and	O
ERGs	O
in	O
five	O
boys	O
with	O
DMD	B-UNK
.	O

The	O
authors	O
wanted	O
to	O
determined	B-UNK
whether	O
there	O
were	O
similar	B-UNK
ERG	B-UNK
findings	B-UNK
in	O
an	O
animal	B-UNK
model	I-UNK
for	O
DMD	B-UNK
,	O
the	O
mdx	O
mouse	B-UNK
.	O

METHODS	O
.	O

Ganzfeld	O
ERGs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
DMD	B-UNK
after	O
a	O
complete	O
ophthalmic	O
examination	B-UNK
.	O

The	O
dystrophin	B-UNK
gene	I-UNK
was	O
analyzed	B-UNK
by	O
Southern	B-UNK
blot	I-UNK
hybridization	B-UNK
.	O

ERGs	O
were	O
recorded	O
in	O
anesthetized	O
mdx	O
and	O
control	B-UNK
mice	B-UNK
with	O
a	O
modified	O
Grass	O
photostimulator	O
(	O
Grass	O
Instrument	O
Company	O
,	O
Quincy	O
,	O
MA	O
)	O
.	O

RESULTS	B-UNK
.	O

Ophthalmic	O
examinations	O
in	O
all	O
five	O
boys	O
had	O
normal	B-UNK
findings	B-UNK
,	O
yet	O
an	O
abnormal	O
negative	B-UNK
ERG	B-UNK
was	O
recorded	O
for	O
each	O
subject	O
.	O

The	O
subjects	B-UNK
gene	B-UNK
deletions	O
were	O
variable	B-UNK
,	O
ranging	O
from	O
large	B-UNK
deletions	O
to	O
no	O
detectable	O
deletions	O
.	O

The	O
ERGs	O
of	O
the	O
mdx	O
mice	B-UNK
were	O
normal	B-UNK
and	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
the	O
control	B-UNK
mice	B-UNK
.	O

CONCLUSIONS	B-UNK
.	O

The	O
authors	O
believe	O
the	O
unique	O
ERG	B-UNK
recorded	O
for	O
the	O
human	B-UNK
subjects	B-UNK
is	O
a	O
manifestation	B-UNK
of	O
DMD	B-UNK
associated	O
with	O
defects	B-UNK
at	O
the	O
dystrophin	B-UNK
gene	I-UNK
locus	B-UNK
and	O
represents	O
a	O
new	O
clinical	B-UNK
entity	O
.	O

The	O
ERG	B-UNK
of	O
the	O
mdx	O
mouse	B-UNK
may	O
be	O
spared	O
for	O
several	O
reasons	O
,	O
including	O
milder	B-UNK
effects	B-UNK
of	O
the	O
mouse	B-UNK
gene	B-UNK
defect	B-UNK
,	O
differences	B-UNK
in	O
muscle	B-UNK
and	O
retinal	B-UNK
gene	B-UNK
product	I-UNK
,	O
or	O
species	B-UNK
differences	B-UNK
in	O
the	O
biochemical	O
role	B-UNK
of	O
dystrophin	B-UNK
.	O

The	O
ERG	B-UNK
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	B-UNK
tool	O
for	O
DMD	B-UNK
and	O
its	O
milder	B-UNK
allelic	O
forms	B-UNK
..	O

Association	B-UNK
of	O
the	O
APC	B-UNK
tumor	B-UNK
suppressor	I-UNK
protein	B-UNK
with	O
catenins	O
.	O

Mutations	B-UNK
of	O
APC	B-UNK
appear	O
to	O
initiate	O
sporadic	B-UNK
and	O
inherited	B-UNK
forms	B-UNK
of	O
human	B-UNK
colorectal	B-UNK
cancer	I-UNK
.	O

Although	O
these	O
mutations	B-UNK
have	O
been	O
well	O
characterized	B-UNK
,	O
little	O
is	O
known	O
about	O
the	O
function	B-UNK
of	O
the	O
APC	B-UNK
gene	B-UNK
product	I-UNK
.	O

Two	O
cellular	O
proteins	B-UNK
that	O
associate	O
with	O
APC	B-UNK
were	O
identified	B-UNK
by	O
nucleotide	B-UNK
sequence	I-UNK
analysis	B-UNK
and	O
peptide	B-UNK
mapping	B-UNK
as	O
the	O
E-cadherin-associated	O
proteins	B-UNK
alpha	B-UNK
-	O
and	O
beta-catenin	O
.	O

A	O
27-residue	O
fragment	B-UNK
of	O
APC	B-UNK
containing	O
a	O
15-amino	O
acid	B-UNK
repeat	B-UNK
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins	O
.	O

These	O
results	B-UNK
suggest	B-UNK
an	O
important	O
link	O
between	O
tumor	B-UNK
initiation	O
and	O
cell	B-UNK
adhesion	O
..	O

Difference	O
in	O
methylation	B-UNK
patterns	B-UNK
within	O
the	O
D15S9	O
region	B-UNK
of	O
chromosome	B-UNK
15q11	B-UNK
-	O
13	O
in	O
first	O
cousins	O
with	O
Angelman	B-DISEASE
syndrome	I-DISEASE
and	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
.	O

Abnormalities	B-UNK
of	O
chromosome	B-UNK
region	B-UNK
15q11	B-UNK
-	O
13	O
are	O
associated	O
with	O
Angelman	B-DISEASE
syndrome	I-DISEASE
(	O
AS	O
)	O
and	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
(	O
PWS	B-UNK
)	O
.	O

Differences	B-UNK
between	O
the	O
methylation	B-UNK
patterns	B-UNK
of	O
the	O
region	B-UNK
of	O
chromosome	B-UNK
15q11	B-UNK
-	O
13	O
which	O
hybridizes	O
to	O
the	O
highly	B-UNK
conserved	I-UNK
DNA	B-UNK
,	O
DN34	O
,	O
in	O
normal	B-UNK
individuals	B-UNK
and	O
in	O
patients	B-UNK
with	O
AS	O
and	O
PWS	B-UNK
have	O
been	O
described	O
.	O

We	O
report	B-UNK
on	O
a	O
family	B-UNK
in	O
which	O
first	O
cousins	O
are	O
affected	B-UNK
by	O
AS	O
and	O
PWS	B-UNK
as	O
a	O
result	B-UNK
of	O
a	O
familial	B-UNK
paracentric	O
inversion	O
of	O
15q11-q13	O
.	O

The	O
results	B-UNK
of	O
the	O
studies	B-UNK
on	O
this	O
family	B-UNK
demonstrate	B-UNK
the	O
differences	B-UNK
in	O
the	O
methylation	B-UNK
patterns	B-UNK
in	O
the	O
2	O
conditions	O
and	O
the	O
phenomenon	O
of	O
genomic	B-UNK
imprinting	B-UNK
,	O
whereby	O
genetic	B-UNK
information	B-UNK
is	O
expressed	B-UNK
differently	O
dependent	B-UNK
on	O
the	O
parent	O
of	O
origin	O
..	O

Haplotype	B-UNK
studies	B-UNK
in	O
Wilson	B-UNK
disease	I-UNK
.	O

In	O
51	O
families	B-UNK
with	O
Wilson	B-UNK
disease	I-UNK
,	O
we	O
have	O
studied	O
DNA	B-UNK
haplotypes	O
of	O
dinucleotide	B-UNK
repeat	B-UNK
polymorphisms	B-UNK
(	O
CA	O
repeats	B-UNK
)	O
in	O
the	O
13q14	O
.	O

3	O
region	B-UNK
,	O
to	O
examine	O
these	O
markers	B-UNK
for	O
association	B-UNK
with	O
the	O
Wilson	B-UNK
disease	I-UNK
gene	B-UNK
(	O
WND	O
)	O
.	O

In	O
addition	B-UNK
to	O
a	O
marker	B-UNK
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	B-UNK
polymorphic	B-UNK
markers	I-UNK
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	B-UNK
to	O
the	O
WND	O
locus	B-UNK
.	O

We	O
have	O
examined	O
the	O
distribution	B-UNK
of	O
marker	B-UNK
alleles	B-UNK
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	B-UNK
on	O
chromosomes	O
carrying	B-UNK
the	O
WND	O
mutation	B-UNK
.	O

We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	B-UNK
and	O
have	O
found	O
that	O
there	O
are	O
highly	B-UNK
significant	B-UNK
differences	B-UNK
between	O
WND	O
and	O
normal	B-UNK
haplotypes	O
in	O
northern	B-UNK
European	B-UNK
families	B-UNK
.	O

These	O
findings	B-UNK
have	O
important	O
implications	B-UNK
for	O
mutation	B-UNK
detection	I-UNK
and	O
molecular	B-UNK
diagnosis	B-UNK
in	O
families	B-UNK
with	O
Wilson	B-UNK
disease	I-UNK
.	O

Genetic	B-UNK
analysis	I-UNK
of	O
the	O
BRCA1	B-UNK
region	B-UNK
in	O
a	O
large	B-UNK
breast	B-UNK
/	O
ovarian	B-UNK
family	B-UNK
:	O
refinement	O
of	O
the	O
minimal	O
region	B-UNK
containing	O
BRCA1	B-UNK
.	O

We	O
have	O
analyzed	B-UNK
a	O
single	B-UNK
multi-affected	O
breast	B-UNK
/	O
ovarian	B-UNK
cancer	I-UNK
pedigree	B-UNK
(	O
BOV3	O
)	O
and	O
have	O
shown	B-UNK
consistent	B-UNK
inheritance	B-UNK
of	O
markers	B-UNK
on	O
chromosome	B-UNK
17q	O
with	O
the	O
disease	B-UNK
confirming	O
that	O
this	O
family	B-UNK
is	O
due	O
to	O
the	O
BRCA1	B-UNK
gene	B-UNK
.	O

Analysis	B-UNK
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	B-UNK
event	O
in	O
a	O
bilateral	O
breast	B-UNK
cancer	I-UNK
case	B-UNK
which	O
suggests	O
that	O
the	O
BRCA1	B-UNK
gene	B-UNK
lies	O
distal	B-UNK
to	O
D17S857	O
;	O
D17S857	O
is	O
thus	O
the	O
new	O
proximal	B-UNK
boundary	O
for	O
the	O
region	B-UNK
containing	O
BRCA1	B-UNK
.	O

Combining	O
this	O
information	B-UNK
with	O
previously	B-UNK
published	O
mapping	B-UNK
information	B-UNK
suggests	O
that	O
BRCA1	B-UNK
is	O
contained	O
in	O
a	O
region	B-UNK
estimated	B-UNK
at	O
1	O
-	O
1	O
.	O

5	O
Mb	B-DISEASE
in	O
length	B-UNK
.	O

All	O
seven	O
breast	B-UNK
tumour	B-UNK
/	O
blood	B-UNK
pairs	B-UNK
examined	O
from	O
this	O
family	B-UNK
show	O
loss	B-UNK
of	I-UNK
heterozygosity	I-UNK
in	O
the	O
tumours	B-DISEASE
.	O

The	O
allel	O
retained	O
in	O
each	O
tumour	B-DISEASE
was	O
from	O
the	O
disease	B-UNK
-	O
bearing	O
chromosome	B-UNK
implicating	O
BRCA1	B-UNK
as	O
a	O
tumour	B-UNK
suppressor	I-UNK
gene	B-UNK
.	O

We	O
have	O
sequenced	O
the	O
17	O
beta-oestradiol	O
dehydrogenase	B-UNK
genes	B-UNK
(	O
EDH17B1	O
and	O
EDH17B2	O
)	O
which	O
have	O
been	O
suggested	O
as	O
candidate	B-UNK
genes	B-UNK
for	O
BRCA1	B-UNK
in	O
four	O
members	B-UNK
of	O
this	O
family	B-UNK
.	O

No	O
germline	B-UNK
mutations	I-UNK
were	O
detected	B-UNK
.	O

Myotonic	B-DISEASE
dystrophy	I-DISEASE
kinase	B-UNK
is	O
a	O
component	B-UNK
of	O
neuromuscular	O
junctions	O
.	O

The	O
clinical	B-UNK
manifestation	B-UNK
of	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
)	O
is	O
correlated	B-UNK
to	O
the	O
extent	O
of	O
expansion	B-UNK
of	O
an	O
unstable	O
[	O
CTG	B-UNK
]	O
n	O
DNA	B-UNK
motif	B-UNK
.	O

Recent	O
studies	B-UNK
have	O
demonstrated	O
that	O
this	O
trinucleotide	B-UNK
motif	B-UNK
forms	B-UNK
part	O
of	O
the	O
last	O
,	O
3	O
untranslated	B-UNK
exon	B-UNK
of	O
a	O
gene	B-UNK
which	O
potentially	O
encodes	B-UNK
multiple	B-UNK
protein	B-UNK
isoforms	O
of	O
a	O
serine	O
/	O
threonine	O
protein	B-UNK
kinase	I-UNK
(	O
myotonic	B-UNK
dystrophy	I-UNK
protein	B-UNK
kinase	I-UNK
,	O
DM	B-UNK
-	O
PK	O
)	O
.	O

We	O
report	B-UNK
here	O
on	O
the	O
development	B-UNK
of	O
antisera	O
against	O
synthetic	O
DM	B-UNK
-	O
PK	O
peptide	B-UNK
antigens	O
and	O
their	O
use	O
in	O
biochemical	O
and	O
histochemical	O
studies	B-UNK
.	O

Immunoreactive	O
DM	B-DISEASE
-	O
kinase	B-UNK
protein	B-UNK
of	O
53	O
kD	O
is	O
present	B-UNK
at	O
low	B-UNK
levels	B-UNK
in	O
skeletal	B-UNK
and	O
cardiac	B-UNK
muscle	B-UNK
extracts	B-UNK
of	O
DM	B-UNK
patients	B-UNK
and	O
normal	B-UNK
controls	O
.	O

Immunohistochemical	O
staining	O
revealed	B-UNK
that	O
DM	B-DISEASE
-	O
PK	O
is	O
localised	O
prominently	O
at	O
sites	O
of	O
neuromuscular	O
and	O
myotendinous	O
junctions	O
(	O
NMJs	O
and	O
MTJs	O
)	O
of	O
human	B-UNK
and	O
rodent	O
skeletal	B-UNK
muscles	O
.	O

Furthermore	O
,	O
very	O
low	B-UNK
levels	B-UNK
of	O
immunoreactive	O
DM	B-UNK
-	O
PK	O
protein	B-UNK
are	O
present	B-UNK
in	O
the	O
sarcoplasm	O
of	O
predominantly	O
type	B-UNK
I	O
fibres	O
in	O
various	O
muscles	O
.	O

Strikingly	O
,	O
presence	O
of	O
the	O
protein	B-UNK
can	O
also	O
be	O
demonstrated	O
for	O
NMJs	O
of	O
muscular	B-UNK
tissues	O
of	O
adult	B-UNK
and	O
congenital	B-UNK
cases	B-UNK
of	O
DM	B-DISEASE
,	O
with	O
no	O
gross	O
changes	O
in	O
structural	B-UNK
organisation	O
.	O

Our	O
findings	B-UNK
provide	B-UNK
a	O
basis	B-UNK
for	O
further	O
characterisation	O
of	O
the	O
role	B-UNK
of	O
the	O
kinase	B-UNK
in	O
protein	B-UNK
assembly	O
processes	O
or	O
signal	B-UNK
mediation	O
at	O
synaptic	O
sites	O
and	O
ultimately	O
for	O
the	O
understanding	B-UNK
of	O
the	O
complex	O
pathophysiology	O
of	O
DM	B-DISEASE
..	O

Markedly	B-UNK
accelerated	O
catabolism	O
of	O
apolipoprotein	B-UNK
A	O
-	O
II	B-UNK
(	O
ApoA	O
-	O
II	B-UNK
)	O
and	O
high	B-UNK
density	I-UNK
lipoproteins	O
containing	O
ApoA	O
-	O
II	B-UNK
in	O
classic	B-UNK
lecithin	O
:	O
cholesterol	B-UNK
acyltransferase	O
deficiency	B-UNK
and	O
fish	B-UNK
-	O
eye	B-UNK
disease	B-UNK
.	O

Classic	B-UNK
(	O
complete	O
)	O
lecithin	O
cholesterol	B-UNK
acyltransferase	O
(	O
LCAT	O
)	O
deficiency	B-UNK
and	O
Fish	B-UNK
-	O
eye	B-UNK
disease	B-DISEASE
(	O
partial	O
LCAT	O
deficiency	B-UNK
)	O
are	O
genetic	B-UNK
syndromes	O
associated	O
with	O
markedly	B-UNK
decreased	B-UNK
plasma	O
levels	B-UNK
of	O
high	B-UNK
density	I-UNK
lipoprotein	B-UNK
(	O
HDL	B-UNK
)	O
cholesterol	B-UNK
but	O
not	O
with	O
an	O
increased	B-UNK
risk	B-UNK
of	O
atherosclerotic	B-DISEASE
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O

We	O
investigated	O
the	O
metabolism	B-UNK
of	O
the	O
HDL	B-UNK
apolipoproteins	O
(	O
apo	O
)	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	B-UNK
in	O
a	O
total	B-UNK
of	O
five	O
patients	B-UNK
with	O
LCAT	O
deficiency	B-UNK
,	O
one	O
with	O
classic	B-UNK
LCAT	O
deficiency	B-UNK
and	O
four	O
with	O
Fish	B-UNK
-	O
eye	B-UNK
disease	B-DISEASE
.	O

Plasma	O
levels	B-UNK
of	O
apoA	O
-	O
II	B-UNK
were	O
decreased	B-UNK
to	O
a	O
proportionately	O
greater	B-UNK
extent	O
(	O
23	O
%	O
of	O
normal	B-UNK
)	O
than	O
apoA	O
-	O
I	O
(	O
30	O
%	O
of	O
normal	B-UNK
)	O
.	O

In	O
addition	B-UNK
,	O
plasma	O
concentrations	O
of	O
HDL	B-UNK
particles	O
containing	O
both	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	B-UNK
(	O
LpA	O
-	O
I	O
A	O
-	O
II	B-UNK
)	O
were	O
much	O
lower	O
(	O
18	O
%	O
of	O
normal	B-UNK
)	O
than	O
those	O
of	O
particles	O
containing	O
only	O
apoA	O
-	O
I	O
(	O
LpA	O
-	O
I	O
)	O
(	O
51	O
%	O
of	O
normal	B-UNK
)	O
.	O

The	O
metabolic	B-UNK
basis	B-UNK
for	O
the	O
low	B-UNK
levels	B-UNK
of	O
apoA	O
-	O
II	B-UNK
and	O
LpA	O
-	O
I	O
A	O
-	O
II	B-UNK
was	O
investigated	O
in	O
all	O
five	O
patients	B-UNK
using	O
both	O
exogenous	O
radiotracer	O
and	O
endogenous	O
stable	B-UNK
isotope	O
labeling	O
techniques	O
.	O

The	O
mean	O
plasma	O
residence	O
time	O
of	O
apoA	O
-	O
I	O
was	O
decreased	B-UNK
at	O
2	O
.	O

08	O
+	O
/-0	O
.	O

27	O
d	O
(	O
controls	O
4	O
.	O
74	O
+	O
/-0	O
.	O
65	O
days	O
)	O
;	O
however	O
,	O
the	O
residence	O
time	O
of	O
apoA	O
-	O
II	B-UNK
was	O
even	O
shorter	O
at	O
1	O
.	O

66	O
+	O
/-0	O
.	O

24	O
d	O
(	O
controls	O
5	O
.	O
25	O
+	O
/-0	O
.	O
61	O
d	O
)	O
.	O

In	O
addition	B-UNK
,	O
the	O
catabolism	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I	O
A	O
-	O
II	B-UNK
was	O
substantially	O
faster	O
than	O
that	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I.	O

In	O
summary	O
,	O
genetic	B-UNK
syndromes	O
of	O
either	O
complete	O
or	O
partial	O
LCAT	O
deficiency	B-UNK
result	B-UNK
in	O
low	B-UNK
levels	B-UNK
of	O
HDL	B-UNK
through	O
preferential	O
hypercatabolism	O
of	O
apoA	O
-	O
II	B-UNK
and	O
HDL	B-UNK
particles	O
containing	O
apoA	O
-	O
II	B-UNK
.	O

Because	O
LpA	O
-	O
I	O
has	O
been	O
proposed	O
to	O
be	O
more	O
protective	O
than	O
LpA	O
-	O
I	O
A	O
-	O
II	B-UNK
against	O
atherosclerosis	B-DISEASE
,	O
this	O
selective	O
effect	B-UNK
on	O
the	O
metabolism	B-UNK
of	O
LpA	O
-	O
I	O
A	O
-	O
II	B-UNK
may	O
provide	B-UNK
a	O
potential	B-UNK
explanation	O
why	O
patients	B-UNK
with	O
classic	B-UNK
LCAT	O
deficiency	B-UNK
and	O
Fish	B-UNK
-	O
eye	B-UNK
disease	B-UNK
are	O
not	O
at	O
increased	B-UNK
risk	B-UNK
for	O
premature	B-DISEASE
atherosclerosis	I-DISEASE
despite	O
markedly	B-UNK
decreased	B-UNK
levels	B-UNK
of	O
HDL	B-UNK
cholesterol	I-UNK
and	O
apoA	O
-	O
I	O

X	O
linked	B-UNK
recessive	B-UNK
thrombocytopenia	B-DISEASE
.	O

A	O
Saudi	O
Arab	O
boy	B-UNK
presented	B-UNK
in	O
early	B-UNK
childhood	O
with	O
thrombocytopenia	B-DISEASE
,	O
morphologically	O
large	B-UNK
and	O
normal	B-UNK
sized	O
platelets	O
,	O
increased	B-UNK
mean	O
platelet	B-UNK
volume	O
,	O
and	O
a	O
hypermegakaryocytic	O
bone	B-UNK
marrow	O
.	O

There	O
was	O
no	O
clinical	B-UNK
and	O
laboratory	O
evidence	B-UNK
of	O
any	O
significant	B-UNK
immunological	O
abnormalities	B-UNK
.	O

Similar	B-UNK
findings	B-UNK
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
X	O
linked	B-UNK
recessive	B-UNK
thrombocytopenic	O
disorder	B-UNK
.	O

Results	B-UNK
of	O
DNA	B-UNK
analysis	I-UNK
with	O
the	O
probe	O
M27	O
beta	B-UNK
are	O
consistent	B-UNK
with	O
X	O
linkage	B-UNK
and	O
indicate	O
also	O
that	O
the	O
locus	B-UNK
of	O
the	O
relevant	O
gene	B-UNK
lies	O
close	B-UNK
to	O
or	O
is	O
identical	B-UNK
to	O
the	O
locus	B-UNK
of	O
the	O
gene	B-UNK
for	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
.	O

Because	O
of	O
various	O
features	B-UNK
which	O
include	O
the	O
presence	O
of	O
large	B-UNK
and	O
normal	B-UNK
sized	O
platelets	O
(	O
rather	O
than	O
small	O
platelets	O
)	O
and	O
freedom	O
from	O
significant	B-UNK
immune	B-UNK
deficiencies	B-UNK
,	O
it	O
is	O
likely	O
that	O
the	O
X	O
linked	B-UNK
recessive	B-UNK
thrombocytopenia	B-DISEASE
in	O
this	O
family	B-UNK
is	O
an	O
isolated	B-UNK
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
WAS	O
phenotype	B-UNK
.	O

However	O
,	O
a	O
modified	O
expression	B-UNK
of	O
the	O
WAS	O
gene	B-UNK
producing	O
a	O
mild	O
phenotypic	B-UNK
variant	O
cannot	O
be	O
excluded	O
entirely	O
..	O

Macular	B-UNK
dystrophy	B-UNK
associated	O
with	O
mutations	B-UNK
at	O
codon	B-UNK
172	O
in	O
the	O
human	B-UNK
retinal	B-DISEASE
degeneration	I-DISEASE
slow	O
gene	B-UNK
.	O

BACKGROUND	O
Recently	O
,	O
mutations	B-UNK
in	O
the	O
retinal	B-DISEASE
degeneration	I-DISEASE
slow	O
(	O
rds	B-UNK
)	O
gene	B-UNK
which	O
codes	O
for	O
peripherin	O
-	O
rds	B-UNK
have	O
been	O
implicated	B-UNK
as	O
a	O
cause	O
of	O
autosomal	B-UNK
dominant	I-UNK
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Because	O
this	O
gene	B-UNK
is	O
expressed	B-UNK
in	O
both	O
rods	O
and	O
cones	O
,	O
mutations	B-UNK
in	O
the	O
rds	B-UNK
gene	B-UNK
might	O
be	O
expected	O
to	O
cause	O
degeneration	B-UNK
affecting	O
either	O
the	O
scotopic	O
or	O
photopic	O
systems	O
.	O

Mutations	B-UNK
at	O
codon	B-UNK
172	O
of	O
the	O
rds	B-UNK
gene	B-UNK
have	O
been	O
identified	B-UNK
in	O
three	O
families	B-UNK
with	O
autosomal	B-UNK
dominantly	O
inherited	B-UNK
,	O
progressive	B-UNK
macular	B-UNK
dystrophy	B-UNK
.	O

METHODS	O
Affected	B-UNK
individuals	I-UNK
underwent	O
ophthalmic	O
examination	B-UNK
,	O
scotopic	O
perimetry	O
,	O
dark	O
adaptometry	O
,	O
measurement	O
of	O
color	B-UNK
-	O
contrast	B-UNK
sensitivity	O
,	O
and	O
electroretinography	O
to	O
characterize	O
the	O
photoreceptor	B-UNK
dysfunction	B-UNK
.	O

RESULTS	B-UNK
In	O
all	O
but	O
one	O
affected	B-UNK
member	B-UNK
,	O
symptoms	B-UNK
of	O
progressive	B-UNK
central	B-UNK
visual	B-DISEASE
loss	I-DISEASE
developed	O
in	O
the	O
third	O
or	O
fourth	B-UNK
decade	O
of	O
life	B-UNK
accompanied	O
by	O
central	B-UNK
scotoma	B-DISEASE
and	O
well	O
-	O
demarcated	O
atrophy	B-DISEASE
of	O
the	O
retinal	B-UNK
pigment	B-UNK
epithelium	O
and	O
choriocapillaris	O
of	O
the	O
macula	O
.	O

In	O
general	B-UNK
,	O
cone	O
and	O
rod	O
thresholds	O
were	O
elevated	B-UNK
,	O
and	O
color	B-UNK
-	O
contrast	B-UNK
sensitivity	O
was	O
absent	O
in	O
the	O
central	B-UNK
visual	B-UNK
field	B-UNK
.	O

Peripherally	O
,	O
the	O
scotopic	O
sensitivities	O
were	O
normal	B-UNK
,	O
as	O
was	O
the	O
recovery	O
from	O
bleach	O
.	O

Cone	O
electroretinograms	O
were	O
diminished	O
in	O
amplitude	O
,	O
and	O
delayed	O
in	O
all	O
affected	B-UNK
adults	O
except	O
one	O
.	O

Rod	O
electroretinograms	O
were	O
normal	B-UNK
or	O
near	O
normal	B-UNK
in	O
amplitude	O
,	O
and	O
had	O
normal	B-UNK
implicit	O
times	O
.	O

Affected	B-UNK
asymptomatic	B-UNK
children	O
had	O
macular	B-UNK
changes	O
,	O
abnormal	O
color	B-UNK
-	O
contrast	B-UNK
sensitivity	O
,	O
and	O
reduced	O
pattern	B-UNK
and	O
cone	O
electroretinograms	O
.	O

CONCLUSION	B-UNK
These	O
results	B-UNK
indicate	O
that	O
mutations	B-UNK
in	O
the	O
rds	B-UNK
gene	B-UNK
can	O
be	O
expressed	B-UNK
as	O
a	O
macular	B-UNK
dystrophy	B-UNK
,	O
with	O
evidence	B-UNK
of	O
primary	B-UNK
cone	O
dysfunction	B-UNK
and	O
preservation	O
of	O
peripheral	B-UNK
rod	O
function	B-UNK
..	O

Anonymous	O
marker	B-UNK
loci	O
within	O
400	O
kb	B-UNK
of	O
HLA	B-UNK
-	O
A	O
generate	O
haplotypes	O
in	O
linkage	B-UNK
disequilibrium	I-UNK
with	O
the	O
hemochromatosis	B-UNK
gene	B-UNK
(	O
HFE	B-UNK
)	O

The	O
hemochromatosis	B-DISEASE
gene	B-UNK
(	O
HFE	B-UNK
)	O
maps	B-UNK
to	O
6p21	O
.	O

3	O
and	O
is	O
less	O
than	O
1	O
cM	B-DISEASE
from	O
the	O
HLA	B-UNK
class	O
I	O
genes	B-UNK
;	O
however	O
,	O
the	O
precise	O
physical	B-UNK
location	B-UNK
of	O
the	O
gene	B-UNK
has	O
remained	O
elusive	O
and	O
controversial	O
.	O

The	O
unambiguous	O
identification	B-UNK
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	B-DISEASE
families	B-UNK
is	O
very	O
difficult	O
;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	B-UNK
of	O
the	O
phenotypic	B-UNK
expression	B-UNK
as	O
well	O
as	O
by	O
the	O
sex	B-UNK
-	O
and	O
age	B-UNK
-	O
related	B-UNK
penetrance	O
of	O
the	O
disease	B-DISEASE
.	O

For	O
these	O
practical	O
considerations	O
,	O
traditional	O
linkage	B-UNK
analysis	I-UNK
could	O
prove	O
of	O
limited	O
value	O
in	O
further	O
refining	O
the	O
extrapolated	O
physical	B-UNK
position	B-UNK
of	O
HFE	B-UNK
.	O

We	O
therefore	O
embarked	O
upon	O
a	O
linkage	B-UNK
-	O
disequilibrium	B-UNK
analysis	B-UNK
of	O
HFE	B-UNK
and	O
normal	B-UNK
chromosomes	O
from	O
the	O
Brittany	O
population	B-UNK
.	O

In	O
the	O
present	B-UNK
report	B-UNK
,	O
66	O
hemochromatosis	B-UNK
families	B-UNK
yielding	O
151	O
hemochromatosis	B-UNK
chromosomes	O
and	O
182	O
normal	B-UNK
chromosomes	O
were	O
RFLP	B-UNK
-	O
typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	B-UNK
polymorphic	B-UNK
markers	I-UNK
from	O
the	O
6	O
.	O

7	O
and	O
HLA	B-UNK
-	O
F	O
loci	O
located	B-UNK
150	O
and	O
250	O
kb	B-UNK
telomeric	O
to	O
HLA	B-UNK
-	O
A	O
,	O
respectively	O
.	O

The	O
results	B-UNK
suggest	B-UNK
a	O
strong	B-UNK
peak	O
of	O
existing	O
linkage	B-UNK
disequilibrium	I-UNK
focused	O
within	O
the	O
i82-to-6	O
.	O

7	O
interval	B-UNK
(	O
approximately	O
250	O
kb	B-UNK
)	O
.	O

The	O
zone	O
of	O
linkage	B-UNK
disequilibrium	I-UNK
is	O
flanked	O
by	O
the	O
i97	O
locus	B-UNK
,	O
positioned	O
30	O
kb	B-UNK
proximal	B-UNK
to	O
i82	O
,	O
and	O
the	O
HLA	B-UNK
-	O
F	O
gene	B-UNK
,	O
found	O
250	O
kb	B-UNK
distal	B-UNK
to	O
HLA	B-UNK
-	O
A	O
,	O
markers	B-UNK
of	O
which	O
display	O
no	O
significant	B-UNK
association	B-UNK
with	O
HFE	B-UNK
.	O

These	O
data	B-UNK
support	O
the	O
possibility	B-UNK
that	O
HFE	B-UNK
resides	O
within	O
the	O
400-kb	O
expanse	O
of	O
DNA	B-UNK
between	O
i97	O
and	O
HLA	B-UNK
-	O
F.	O

Alternatively	O
,	O
the	O
very	O
tight	O
association	B-UNK
of	O
HLA	B-UNK
-	O
A3	O
and	O
allele	B-UNK
1	O
of	O
the	O
6	O
.	O

7	O
locus	B-UNK
,	O
both	O
of	O
which	O
are	O
comprised	O
by	O
the	O
major	B-UNK
ancestral	O
or	O
founder	B-UNK
HFE	B-UNK
haplotype	B-UNK
in	O
Brittany	O
,	O
supports	O
the	O
possibility	B-UNK
that	O
the	O
disease	B-DISEASE
gene	B-UNK
may	O
reside	O
immediately	O
telomeric	O
to	O
the	O
6	O
.	O

7	O
locus	B-UNK
within	O
the	O
linkage	B-UNK
-	O
disequilibrium	B-UNK
zone	O
.	O

Additionally	O
,	O
hemochromatosis	B-DISEASE
haplotypes	O
possessing	O
HLA	B-UNK
-	O
A11	O
and	O
the	O
low	B-UNK
-	O
frequency	B-UNK
HLA	B-UNK
-	O
F	O
polymorphism	B-UNK
(	O
allele	B-UNK
2	O
)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	B-UNK
chromosome	B-UNK
containing	O
a	O
second	O
,	O
independently	O
arising	O
mutant	B-UNK
allele	B-UNK
.	O

Overall	O
,	O
the	O
establishment	O
of	O
a	O
likely	O
"	O
hemochromatosis	B-DISEASE
critical	B-UNK
region	I-UNK
"	O
centromeric	O
boundary	O
and	O
the	O
identification	B-UNK
of	O
a	O
linkage	B-UNK
-	O
disequilibrium	B-UNK
zone	O
both	O
significantly	O
contribute	B-UNK
to	O
a	O
reduction	B-UNK
in	O
the	O
amount	O
of	O
DNA	B-UNK
required	B-UNK
to	O
be	O
searched	O
for	O
novel	O
coding	B-UNK
sequences	O
constituting	O
the	O
HFE	B-UNK
defect	B-UNK

Genomic	B-UNK
structure	B-UNK
of	O
the	O
EWS	B-UNK
gene	B-UNK
and	O
its	O
relationship	B-UNK
to	O
EWSR1	O
,	O
a	O
site	B-UNK
of	O
tumor	B-DISEASE
-	O
associated	O
chromosome	B-UNK
translocation	B-UNK
.	O

The	O
EWS	B-UNK
gene	B-UNK
has	O
been	O
identified	B-UNK
based	B-UNK
on	O
its	O
location	B-UNK
at	O
the	O
chromosome	B-UNK
22	O
breakpoint	O
of	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
(	O
q24	O
;	O
q12	O
)	O
translocation	B-UNK
that	O
characterizes	O
Ewing	B-DISEASE
sarcoma	I-DISEASE
and	O
related	B-UNK
neuroectodermal	B-DISEASE
tumors	I-DISEASE
.	O

The	O
EWS	B-UNK
gene	B-UNK
spans	O
about	O
40	O
kb	B-UNK
of	O
DNA	B-UNK
and	O
is	O
encoded	B-UNK
by	O
17	O
exons	O
.	O

The	O
nucleotide	B-UNK
sequence	I-UNK
of	O
the	O
exons	O
is	O
identical	B-UNK
to	O
that	O
of	O
the	O
previously	B-UNK
described	O
cDNA	O
.	O

The	O
first	O
7	O
exons	O
encode	O
the	O
N	O
-	O
terminal	B-UNK
domain	B-UNK
of	O
EWS	B-UNK
,	O
which	O
consists	O
of	O
a	O
repeated	O
degenerated	O
polypeptide	O
of	O
7	O
to	O
12	O
residues	O
rich	O
in	O
tyrosine	O
,	O
serine	O
,	O
threonine	O
,	O
glycine	O
,	O
and	O
glutamine	O
.	O

Exons	O
11	O
,	O
12	O
,	O
and	O
13	O
encode	O
the	O
putative	O
RNA	B-UNK
binding	B-UNK
domain	I-UNK
.	O

The	O
three	O
glycine	O
-	O
and	O
arginine	O
-	O
rich	O
motifs	O
of	O
the	O
gene	B-UNK
are	O
mainly	O
encoded	B-UNK
by	O
exons	O
8	O
-	O
9	O
,	O
14	O
,	O
and	O
16	O
.	O

The	O
DNA	B-UNK
sequence	I-UNK
in	O
the	O
5	O
region	B-UNK
of	O
the	O
gene	B-UNK
has	O
features	B-UNK
of	O
a	O
CpG	B-UNK
-	O
rich	O
island	B-UNK
and	O
lacks	O
canonical	O
promoter	O
elements	O
,	O
such	O
as	O
TATA	O
and	O
CCAAT	O
consensus	B-UNK
sequences	O
.	O

Positions	O
of	O
the	O
chromosome	B-UNK
22	O
breakpoints	O
were	O
determined	B-UNK
for	O
19	O
Ewing	O
tumors	B-DISEASE
.	O

They	O
were	O
localized	B-UNK
in	O
introns	O
7	O
or	O
8	O
in	O
18	O
cases	B-UNK
and	O
in	O
intron	B-UNK
10	O
in	O
1	O
case	B-UNK
..	O

Norrie	B-DISEASE
disease	I-DISEASE
gene	B-UNK
:	O
characterization	B-UNK
of	O
deletions	O
and	O
possible	O
function	B-UNK
.	O

Positional	O
cloning	B-UNK
experiments	O
have	O
resulted	B-UNK
recently	O
in	O
the	O
isolation	B-UNK
of	O
a	O
candidate	B-UNK
gene	I-UNK
for	O
Norrie	B-UNK
disease	I-UNK
(	O
pseudoglioma	O
;	O
NDP	B-UNK
)	O
,	O
a	O
severe	B-UNK
X	O
-	O
linked	B-UNK
neurodevelopmental	B-DISEASE
disorder	I-DISEASE
.	O

Here	O
we	O
report	B-UNK
the	O
isolation	B-UNK
and	O
analysis	B-UNK
of	O
human	B-UNK
genomic	B-UNK
DNA	I-UNK
clones	O
encompassing	O
the	O
NDP	B-UNK
gene	B-UNK
.	O

The	O
gene	B-UNK
spans	O
28	O
kb	B-UNK
and	O
consists	O
of	O
3	O
exons	O
,	O
the	O
first	O
of	O
which	O
is	O
entirely	O
contained	O
within	O
the	O
5	O
untranslated	B-UNK
region	B-UNK
.	O

Detailed	B-UNK
analysis	B-UNK
of	O
genomic	B-UNK
deletions	O
in	O
Norrie	B-UNK
patients	B-UNK
shows	O
that	O
they	O
are	O
heterogeneous	O
,	O
both	O
in	O
size	B-UNK
and	O
in	O
position	B-UNK
.	O

By	O
PCR	B-UNK
analysis	B-UNK
,	O
we	O
found	O
that	O
expression	B-UNK
of	O
the	O
NDP	B-UNK
gene	B-UNK
was	O
not	O
confined	O
to	O
the	O
eye	B-UNK
or	O
to	O
the	O
brain	B-UNK
.	O

An	O
extensive	B-UNK
DNA	B-UNK
and	O
protein	B-UNK
sequence	B-UNK
comparison	B-UNK
between	O
the	O
human	B-UNK
NDP	B-UNK
gene	B-UNK
and	O
related	B-UNK
genes	B-UNK
from	O
the	O
database	O
revealed	B-UNK
homology	B-UNK
with	O
cysteine	B-UNK
-	O
rich	O
protein	B-UNK
-	O
binding	B-UNK
domains	B-UNK
of	O
immediate	O
--	O
early	B-UNK
genes	B-UNK
implicated	B-UNK
in	O
the	O
regulation	B-UNK
of	O
cell	B-UNK
proliferation	O
.	O

We	O
propose	O
that	O
NDP	B-UNK
is	O
a	O
molecule	O
related	B-UNK
in	O
function	B-UNK
to	O
these	O
genes	B-UNK
and	O
may	O
be	O
involved	B-UNK
in	O
a	O
pathway	B-UNK
that	O
regulates	O
neural	O
cell	B-UNK
differentiation	B-UNK
and	O
proliferation	O
..	O

The	O
normal	B-UNK
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
allele	B-UNK
,	O
or	O
a	O
closely	B-UNK
linked	I-UNK
gene	B-UNK
,	O
influences	O
age	B-UNK
at	O
onset	B-UNK
of	O
HD	B-UNK
.	O

We	O
evaluated	O
the	O
hypothesis	B-UNK
that	O
Huntington	B-UNK
disease	I-UNK
(	O
HD	B-UNK
)	O
is	O
influenced	O
by	O
the	O
normal	B-UNK
HD	B-UNK
allele	B-UNK
by	O
comparing	O
transmission	B-UNK
patterns	B-UNK
of	O
genetically	B-UNK
linked	B-UNK
markers	B-UNK
at	O
the	O
D4S10	O
locus	B-UNK
in	O
the	O
normal	B-UNK
parent	O
against	O
age	B-UNK
at	O
onset	B-UNK
in	O
the	O
affected	B-UNK
offspring	O
.	O

Analysis	B-UNK
of	O
information	B-UNK
from	O
21	O
sibships	O
in	O
14	O
kindreds	O
showed	O
a	O
significant	B-UNK
tendency	O
for	O
sibs	O
who	O
have	O
similar	B-UNK
onset	B-UNK
ages	O
to	O
share	O
the	O
same	O
D4S10	O
allele	B-UNK
from	O
the	O
normal	B-UNK
parent	O
.	O

Affected	B-UNK
sibs	O
who	O
inherited	B-UNK
different	O
D4S10	O
alleles	B-UNK
from	O
the	O
normal	B-UNK
parent	O
tended	O
to	O
have	O
more	O
variable	B-UNK
ages	O
at	O
onset	B-UNK
.	O

These	O
findings	B-UNK
suggest	B-UNK
that	O
the	O
expression	B-UNK
of	O
HD	B-UNK
is	O
modulated	O
by	O
the	O
normal	B-UNK
HD	B-UNK
allele	B-UNK
or	O
by	O
a	O
closely	B-UNK
linked	I-UNK
locus	B-UNK
..	O

Further	O
investigation	B-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
intron	B-UNK
9	O
donor	B-UNK
splice	I-UNK
site	I-UNK
mutation	B-UNK
frequently	O
found	O
in	O
non-Jewish	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
patients	B-UNK
from	O
the	O
British	B-UNK
Isles	O
.	O

In	O
a	O
previous	B-UNK
study	B-UNK
we	O
found	O
that	O
a	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	B-UNK
)	O
causing	B-UNK
mutation	B-UNK
in	O
the	O
intron	B-UNK
9	O
donor	B-UNK
splice	I-UNK
site	I-UNK
of	O
the	O
HEXA	B-UNK
gene	B-UNK
occurs	O
at	O
high	B-UNK
frequency	I-UNK
in	O
non-Jewish	O
patients	B-UNK
and	O
carriers	B-UNK
from	O
the	O
British	B-UNK
Isles	O
.	O

It	O
was	O
found	O
more	O
frequently	O
in	O
subjects	B-UNK
of	O
Irish	B-UNK
,	O
Scottish	O
,	O
and	O
Welsh	O
origin	O
compared	B-UNK
with	O
English	O
origin	O
(	O
63	O
%	O
and	O
31	O
%	O
respectively	O
)	O
.	O

We	O
have	O
now	O
tested	O
,	O
in	O
a	O
blind	B-DISEASE
study	B-UNK
,	O
26	O
American	B-UNK
TSD	B-UNK
carriers	B-UNK
and	O
28	O
non-carriers	O
who	O
have	O
British	B-UNK
ancestry	O
for	O
the	O
intron	B-UNK
9	O
splice	B-UNK
site	I-UNK
mutation	I-UNK
.	O

Six	O
of	O
the	O
carriers	B-UNK
and	O
none	O
of	O
the	O
controls	O
were	O
positive	O
for	O
the	O
mutation	B-UNK
.	O

All	O
six	O
had	O
Irish	B-UNK
ancestry	O
,	O
compared	B-UNK
with	O
nine	O
of	O
the	O
20	O
other	O
(	O
intron	B-UNK
9	O
mutation	B-UNK
negative	B-UNK
)	O
TSD	B-UNK
carriers	B-UNK
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	B-UNK
confirm	O
the	O
previously	B-UNK
found	O
high	B-UNK
frequency	I-UNK
of	O
the	O
intron	B-UNK
9	O
mutation	B-UNK
in	O
non-Jewish	O
TSD	B-UNK
families	B-UNK
of	O
British	B-UNK
Isles	O
,	O
particularly	O
Irish	B-UNK
,	O
origin	O
,	O
and	O
reinforce	O
the	O
need	O
to	O
screen	B-UNK
such	O
families	B-UNK
for	O
this	O
mutation	B-UNK
.	O

Molecular	B-UNK
mechanisms	O
of	O
oncogenic	O
mutations	B-UNK
in	O
tumors	B-UNK
from	O
patients	B-UNK
with	O
bilateral	O
and	O
unilateral	O
retinoblastoma	B-DISEASE
.	O

The	O
RB1	B-UNK
gene	B-UNK
from	O
12	O
human	B-UNK
retinoblastoma	B-DISEASE
tumors	B-UNK
has	O
been	O
analyzed	B-UNK
exon	B-UNK
-	O
by	O
-	O
exon	B-UNK
with	O
the	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
technique	O
.	O

Mutations	B-UNK
were	O
found	O
in	O
all	O
tumors	B-DISEASE
,	O
and	O
one	O
-	O
third	O
of	O
the	O
tumors	B-UNK
had	O
independent	O
mutations	B-UNK
in	O
both	O
alleles	B-UNK
neither	O
of	O
which	O
were	O
found	O
in	O
the	O
germ	B-UNK
line	I-UNK
,	O
confirming	O
their	O
true	O
sporadic	B-UNK
nature	B-UNK
.	O

In	O
the	O
remaining	O
two	O
-	O
thirds	O
of	O
the	O
tumors	B-DISEASE
only	O
one	O
mutation	B-UNK
was	O
found	O
,	O
consistent	B-UNK
with	O
the	O
loss	B-UNK
-	O
of	O
-	O
heterozygosity	B-UNK
theory	O
of	O
tumorigenesis	O
.	O

Point	B-UNK
mutations	I-UNK
,	O
the	O
majority	O
of	O
which	O
were	O
C--	O
>	O
T	O
transitions	O
,	O
were	O
the	O
most	O
common	B-UNK
abnormality	O
and	O
usually	O
resulted	B-UNK
in	O
the	O
conversion	O
of	O
an	O
arginine	O
codon	B-UNK
to	O
a	O
stop	B-UNK
codon	I-UNK
.	O

Small	O
deletions	O
were	O
the	O
second	O
most	O
common	B-UNK
abnormality	O
and	O
most	O
often	O
created	O
a	O
downstream	O
stop	B-UNK
codon	I-UNK
as	O
the	O
result	B-UNK
of	O
a	O
reading	B-UNK
frameshift	B-UNK
.	O

Deletions	O
and	O
point	B-UNK
mutations	I-UNK
also	O
affected	B-UNK
splice	B-UNK
junctions	O
.	O

Direct	B-UNK
repeats	B-UNK
were	O
present	B-UNK
at	O
the	O
breakpoint	O
junctions	O
in	O
the	O
majority	O
of	O
deletions	O
,	O
supporting	O
a	O
slipped	O
-	O
mispairing	O
mechanism	B-UNK
.	O

Point	B-UNK
mutations	I-UNK
generally	O
produced	O
DNA	B-UNK
sequences	O
which	O
resulted	B-UNK
in	O
perfect	O
homology	B-UNK
with	O
endogenous	O
sequences	O
which	O
lay	O
within	O
14	O
bp	B-UNK
..	O

PAX6	B-UNK
mutations	B-UNK
in	O
aniridia	B-DISEASE
.	O

Aniridia	B-DISEASE
is	O
a	O
congenital	B-UNK
malformation	O
of	O
the	O
eye	B-UNK
,	O
chiefly	O
characterised	O
by	O
iris	O
hypoplasia	B-UNK
,	O
which	O
can	O
cause	O
blindness	B-DISEASE
.	O

The	O
PAX6	B-UNK
gene	B-UNK
was	O
isolated	B-UNK
as	O
a	O
candidate	B-UNK
aniridia	B-DISEASE
gene	B-UNK
by	O
positional	O
cloning	B-UNK
from	O
the	O
smallest	O
region	B-UNK
of	O
overlap	O
of	O
aniridia	B-DISEASE
-	O
associated	O
deletions	O
.	O

Subsequently	B-UNK
PAX6	B-UNK
intragenic	O
mutations	B-UNK
were	O
demonstrated	O
in	O
Smalleye	O
,	O
a	O
mouse	B-UNK
mutant	B-UNK
which	O
is	O
an	O
animal	B-UNK
model	I-UNK
for	O
aniridia	B-DISEASE
,	O
and	O
six	O
human	B-UNK
aniridia	B-DISEASE
patients	B-UNK
.	O

In	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
PAX6	B-UNK
point	B-UNK
mutations	I-UNK
in	O
aniridia	B-DISEASE
patients	B-UNK
,	O
both	O
sporadic	B-UNK
and	O
familial	B-UNK
.	O

These	O
mutations	B-UNK
highlight	O
regions	B-UNK
of	O
the	O
gene	B-UNK
which	O
are	O
essential	B-UNK
for	O
normal	B-UNK
PAX6	B-UNK
function	B-UNK
.	O

In	O
addition	B-UNK
,	O
the	O
frequency	B-UNK
at	O
which	O
we	O
have	O
found	O
PAX6	B-UNK
mutations	B-UNK
suggests	O
that	O
lesions	B-UNK
in	O
PAX6	B-UNK
will	O
account	B-UNK
for	O
most	O
cases	B-UNK
of	O
aniridia	B-DISEASE
..	O

Detection	B-UNK
of	O
a	O
novel	O
arginine	O
vasopressin	O
defect	B-UNK
by	O
dideoxy	O
fingerprinting	O
.	O

Autosomal	B-UNK
dominant	I-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
is	O
a	O
familial	B-UNK
form	B-UNK
of	O
diabetes	B-DISEASE
insipidus	I-DISEASE
.	O

This	O
disorder	B-UNK
is	O
associated	O
with	O
variable	B-UNK
levels	B-UNK
of	O
arginine	O
vasopressin	O
(	O
AVP	B-UNK
)	O
and	O
diabetes	B-UNK
insipidus	I-UNK
of	O
varying	O
severity	B-UNK
,	O
which	O
responds	O
to	O
exogenous	O
AVP	B-UNK
.	O

To	O
determine	B-UNK
the	O
molecular	B-UNK
basis	I-UNK
of	O
autosomal	B-UNK
dominant	I-UNK
neurohypophyseal	B-UNK
diabetes	I-UNK
insipidus	I-UNK
,	O
the	O
AVP	B-UNK
genes	B-UNK
of	O
members	B-UNK
of	O
a	O
large	B-UNK
kindred	O
were	O
analyzed	B-UNK
.	O

A	O
new	O
method	O
,	O
called	O
dideoxy	O
fingerprinting	O
,	O
was	O
used	O
to	O
detect	B-UNK
an	O
AVP	B-UNK
mutation	B-UNK
that	O
was	O
characterized	B-UNK
by	O
DNA	B-UNK
sequencing	I-UNK
.	O

The	O
novel	O
defect	B-UNK
found	O
changes	O
the	O
last	O
codon	B-UNK
of	O
the	O
AVP	B-UNK
signal	B-UNK
peptide	B-UNK
from	O
alanine	O
to	O
threonine	O
,	O
which	O
should	O
perturb	O
cleavage	O
of	O
mature	O
AVP	B-UNK
from	O
its	O
precursor	O
protein	B-UNK
and	O
inhibit	O
its	O
secretion	O
or	O
action	O
..	O

Germinal	O
mosaicism	O
in	O
a	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
family	B-UNK
:	O
implications	B-UNK
for	O
genetic	B-UNK
counselling	O
.	O

In	O
this	O
study	B-UNK
we	O
describe	O
a	O
three	O
-	O
generation	O
family	B-UNK
in	O
which	O
two	O
siblings	O
were	O
affected	B-UNK
by	O
Duchenne	B-UNK
muscular	I-UNK
dystrophy	I-UNK
(	O
DMD	B-UNK
)	O
.	O

Immunohistochemical	O
analysis	B-UNK
of	O
muscle	B-UNK
dystrophin	B-UNK
and	O
haplotype	B-UNK
analysis	I-UNK
of	O
the	O
DMD	B-UNK
locus	B-UNK
revealed	B-UNK
that	O
the	O
X	O
chromosome	B-UNK
carrying	B-UNK
the	O
DMD	B-UNK
gene	B-UNK
was	O
transmitted	O
from	O
the	O
healthy	O
maternal	O
grandfather	O
to	O
his	O
three	O
daughters	O
,	O
including	O
the	O
probands	O
mother	O
.	O

These	O
findings	B-UNK
indicate	O
that	O
the	O
grandfather	O
was	O
a	O
germinal	O
mosaic	O
for	O
the	O
DMD	B-UNK
gene	B-UNK
.	O

The	O
definition	O
of	O
the	O
carrier	B-UNK
status	I-UNK
in	O
two	O
possible	O
carriers	B-UNK
led	B-UNK
us	O
to	O
give	O
accurate	O
genetic	B-UNK
counselling	O
and	O
to	O
prevent	O
the	O
birth	O
of	O
an	O
affected	B-UNK
boy	B-UNK
.	O

The	O
results	B-UNK
of	O
this	O
study	B-UNK
demonstrate	B-UNK
the	O
usefulness	O
of	O
haplotype	B-UNK
analysis	I-UNK
and	O
immunohistochemical	O
muscle	B-UNK
dystrophin	B-UNK
studies	B-UNK
to	O
detect	B-UNK
hidden	O
germinal	O
mosaicism	O
and	O
to	O
improve	O
genetic	B-UNK
counselling	O
..	O

Genetic	B-UNK
mapping	B-UNK
of	O
the	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
syndrome	B-DISEASE
to	O
a	O
small	O
interval	B-UNK
on	O
chromosome	B-UNK
17q12	O
-	O
21	O
:	O
exclusion	O
of	O
candidate	B-UNK
genes	B-UNK
EDH17B2	O
and	O
RARA	O
.	O

A	O
susceptibility	B-UNK
gene	I-UNK
for	O
hereditary	B-UNK
breast	I-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
BRCA1	B-UNK
,	O
has	O
been	O
assigned	O
by	O
linkage	B-UNK
analysis	I-UNK
to	O
chromosome	B-UNK
17q21	O
.	O

Candidate	B-UNK
genes	B-UNK
in	O
this	O
region	B-UNK
include	O
EDH17B2	O
,	O
which	O
encodes	B-UNK
estradiol	O
17	O
beta-hydroxysteroid	O
dehydrogenase	B-UNK
II	B-UNK
(	O
17	O
beta-HSD	O
II	B-UNK
)	O
,	O
and	O
RARA	O
,	O
the	O
gene	B-UNK
for	O
retinoic	O
acid	B-UNK
receptor	B-UNK
alpha	B-UNK
.	O

We	O
have	O
typed	O
22	O
breast	B-UNK
and	O
breast	B-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
families	B-UNK
with	O
eight	O
polymorphisms	B-UNK
from	O
the	O
chromosome	B-UNK
17q12	O
-	O
21	O
region	B-UNK
,	O
including	O
two	O
in	O
the	O
EDH17B2	O
gene	B-UNK
.	O

Genetic	B-UNK
recombination	B-UNK
with	O
the	O
breast	B-UNK
cancer	I-UNK
trait	O
excludes	O
RARA	O
from	O
further	O
consideration	O
as	O
a	O
candidate	B-UNK
gene	I-UNK
for	O
BRCA1	B-UNK
.	O

Both	O
BRCA1	B-UNK
and	O
EDH17B2	O
map	B-UNK
to	O
a	O
6	O
cM	B-DISEASE
interval	B-UNK
(	O
between	O
THRA1	O
and	O
D17S579	O
)	O
and	O
no	O
recombination	B-UNK
was	O
observed	B-UNK
between	O
the	O
two	O
genes	B-UNK
.	O

However	O
,	O
direct	B-UNK
sequencing	I-UNK
of	O
overlapping	O
PCR	B-UNK
products	I-UNK
containing	O
the	O
entire	O
EDH17B2	O
gene	B-UNK
in	O
four	O
unrelated	B-UNK
affected	B-UNK
women	B-UNK
did	O
not	O
uncover	O
any	O
sequence	B-UNK
variation	B-UNK
,	O
other	O
than	O
previously	B-UNK
described	O
polymorphisms	B-UNK
.	O

Mutations	B-UNK
in	O
the	O
EDH17B2	O
gene	B-UNK
,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	B-UNK
for	O
the	O
hereditary	B-UNK
breast	I-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
syndrome	B-DISEASE
.	O

Single	B-UNK
meiotic	B-UNK
crossovers	O
in	O
affected	B-UNK
women	B-UNK
suggest	B-UNK
that	O
BRCA1	B-UNK
is	O
flanked	O
by	O
the	O
loci	O
RARA	O
and	O
D17S78	O
..	O

A	O
missense	B-UNK
mutation	I-UNK
in	O
the	O
cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
gene	B-UNK
with	O
possible	O
dominant	B-UNK
effects	B-UNK
on	O
plasma	O
high	B-UNK
density	I-UNK
lipoproteins	O
.	O

Plasma	O
HDL	B-UNK
are	O
a	O
negative	B-UNK
risk	B-UNK
factor	B-UNK
for	O
atherosclerosis	B-DISEASE
.	O

Cholesteryl	B-UNK
ester	I-UNK
transfer	I-UNK
protein	I-UNK
(	O
CETP	B-UNK
;	O
476	O
amino	B-UNK
acids	I-UNK
)	O
transfers	O
cholesteryl	B-UNK
ester	I-UNK
from	O
HDL	B-UNK
to	O
other	O
lipoproteins	O
.	O

Subjects	B-UNK
with	O
homozygous	B-UNK
CETP	B-UNK
deficiency	I-UNK
caused	B-UNK
by	O
a	O
gene	B-UNK
splicing	B-UNK
defect	B-UNK
have	O
markedly	B-UNK
elevated	B-UNK
HDL	B-UNK
;	O
however	O
,	O
heterozygotes	B-UNK
have	O
only	O
mild	O
increases	O
in	O
HDL	B-UNK
.	O

We	O
describe	O
two	O
probands	O
with	O
a	O
CETP	B-UNK
missense	B-UNK
mutation	I-UNK
(	O
442	O
D	O
G	O
)	O
.	O

Although	O
heterozygous	B-UNK
,	O
they	O
have	O
threefold	O
increases	O
in	O
HDL	B-UNK
concentration	O
and	O
markedly	B-UNK
decreased	B-UNK
plasma	O
CETP	B-UNK
mass	B-UNK
and	O
activity	B-UNK
,	O
suggesting	O
that	O
the	O
mutation	B-UNK
has	O
dominant	B-UNK
effects	B-UNK
on	O
CETP	B-UNK
and	O
HDL	B-UNK
in	O
vivo	B-UNK
.	O

Cellular	O
expression	B-UNK
of	O
mutant	B-UNK
cDNA	O
results	B-UNK
in	O
secretion	O
of	O
only	O
30	O
%	O
of	O
wild	B-UNK
type	I-UNK
CETP	B-UNK
activity	B-UNK
.	O

Moreover	O
,	O
coexpression	O
of	O
wild	B-UNK
type	I-UNK
and	O
mutant	B-UNK
cDNAs	O
leads	B-UNK
to	O
inhibition	O
of	O
wild	B-UNK
type	I-UNK
secretion	O
and	O
activity	B-UNK
.	O

The	O
dominant	B-UNK
effects	B-UNK
of	O
the	O
CETP	B-UNK
missense	B-UNK
mutation	I-UNK
during	O
cellular	O
expression	B-UNK
probably	O
explains	O
why	O
the	O
probands	O
have	O
markedly	B-UNK
increased	B-UNK
HDL	B-UNK
in	O
the	O
heterozygous	B-UNK
state	B-UNK
,	O
and	O
suggests	O
that	O
the	O
active	B-UNK
molecular	B-UNK
species	B-UNK
of	O
CETP	B-UNK
may	O
be	O
multimeric	O
..	O

Familial	B-UNK
Mediterranean	I-UNK
fever	I-UNK
in	O
the	O
colchicine	B-UNK
era	O
:	O
the	O
fate	O
of	O
one	O
family	B-UNK
.	O

In	O
order	B-UNK
to	O
demonstrate	B-UNK
the	O
effect	B-UNK
of	O
prophylactic	O
colchicine	B-UNK
treatment	O
on	O
the	O
natural	O
history	B-UNK
of	O
familial	B-DISEASE
Mediterranean	I-DISEASE
fever	I-DISEASE
(	O
FMF	B-UNK
)	O
,	O
a	O
family	B-UNK
is	O
presented	B-UNK
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	B-UNK
by	O
FMF	B-UNK
.	O

Each	O
patient	B-UNK
represents	O
a	O
different	O
stage	B-UNK
of	O
the	O
amyloidotic	O
kidney	B-DISEASE
disease	I-DISEASE
of	O
FMF	B-UNK
and	O
the	O
effect	B-UNK
of	O
continuous	O
colchicine	B-UNK
treatment	O
on	O
its	O
course	O
.	O

Considered	O
together	O
,	O
the	O
members	B-UNK
of	O
this	O
family	B-UNK
present	B-UNK
an	O
almost	O
complete	O
clinical	B-UNK
,	O
genetic	B-UNK
,	O
and	O
behavioral	B-UNK
picture	O
of	O
the	O
disease	B-DISEASE
..	O

Detection	B-UNK
of	O
a	O
new	O
submicroscopic	B-UNK
Norrie	B-UNK
disease	I-UNK
deletion	B-UNK
interval	B-UNK
with	O
a	O
novel	O
DNA	B-UNK
probe	O
isolated	B-UNK
by	O
differential	B-UNK
Alu	B-UNK
PCR	B-UNK
fingerprint	O
cloning	B-UNK
.	O

Differential	B-UNK
Alu	B-UNK
PCR	B-UNK
fingerprint	O
cloning	B-UNK
was	O
used	O
to	O
isolate	O
a	O
DNA	B-UNK
probe	O
from	O
the	O
Xp11	O
.	O

4	O
-	O
-	O
>	O
p11	O
.	O

21	O
region	B-UNK
of	O
the	O
human	B-UNK
X	O
chromosome	B-UNK
.	O

This	O
novel	O
sequence	B-UNK
,	O
cpXr318	O
(	O
DXS742	O
)	O
,	O
detects	O
a	O
new	O
submicroscopic	B-UNK
deletion	B-UNK
interval	B-UNK
at	O
the	O
Norrie	B-DISEASE
disease	I-DISEASE
locus	B-UNK
(	O
NDP	B-UNK
)	O
.	O

Combining	O
our	O
data	B-UNK
with	O
the	O
consensus	B-UNK
genetic	B-UNK
map	B-UNK
of	O
the	O
proximal	B-UNK
short	B-UNK
arm	B-UNK
of	O
the	O
X	O
chromosome	B-UNK
,	O
we	O
propose	O
the	O
physical	B-UNK
order	B-UNK
Xcen	O
-	O
DXS14-DXS255-(DXS426	O
,	O
TIMP)-(DXS742-([MAOB	O
-	O
MAOA	O
-	O
DXS7	B-UNK
]	O
,	O
NDP)-DXS77-DXS228)-DXS209-DXS148-DXS196-+	O
+	O
+	O
Xpter	O
.	O

The	O
cpXr318	O
probe	O
and	O
a	O
subclone	O
from	O
a	O
cosmid	O
corresponding	O
to	O
the	O
DXS7	B-UNK
locus	B-UNK
were	O
converted	O
into	O
sequence	B-UNK
-	O
tagged	O
sites	O
.	O

Finally	B-UNK
,	O
DXS742	O
,	O
DSX7	O
,	O
DXS77	O
,	O
and	O
MAOA	O
were	O
integrated	O
into	O
a	O
physical	B-UNK
map	B-UNK
spanning	O
the	O
Norrie	B-UNK
disease	I-UNK
locus	B-UNK

Putative	O
X	O
-	O
linked	B-UNK
adrenoleukodystrophy	B-DISEASE
gene	B-UNK
shares	O
unexpected	O
homology	B-UNK
with	O
ABC	O
transporters	O
.	O

Adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
is	O
an	O
X	O
-	O
linked	B-UNK
disease	B-UNK
affecting	O
1/20	O
,	O
000	O
males	B-UNK
either	O
as	O
cerebral	B-UNK
ALD	I-UNK
in	O
childhood	O
or	O
as	O
adrenomyeloneuropathy	O
(	O
AMN	B-UNK
)	O
in	O
adults	O
.	O

Childhood	O
ALD	B-UNK
is	O
the	O
more	O
severe	B-UNK
form	B-UNK
,	O
with	O
onset	B-UNK
of	O
neurological	B-DISEASE
symptoms	I-DISEASE
between	O
5	O
-	O
12	O
years	O
of	O
age	B-UNK
.	O

Central	B-UNK
nervous	I-UNK
system	I-UNK
demyelination	O
progresses	O
rapidly	O
and	O
death	B-DISEASE
occurs	O
within	O
a	O
few	O
years	O
.	O

AMN	B-UNK
is	O
a	O
milder	B-UNK
form	B-UNK
of	O
the	O
disease	B-UNK
with	O
onset	B-UNK
at	O
15	O
-	O
30	O
years	O
of	O
age	B-UNK
and	O
a	O
more	O
progressive	B-UNK
course	O
.	O

Adrenal	B-DISEASE
insufficiency	I-DISEASE
(	O
Addisons	O
disease	B-DISEASE
)	O
may	O
remain	O
the	O
only	O
clinical	B-UNK
manifestation	B-UNK
of	O
ALD	B-UNK
.	O

The	O
principal	O
biochemical	O
abnormality	O
of	O
ALD	B-UNK
is	O
the	O
accumulation	B-UNK
of	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
fatty	B-UNK
acids	I-UNK
(	O
VLCFA	O
)	O
because	O
of	O
impaired	B-UNK
beta-oxidation	O
in	O
peroxisomes	O
.	O

The	O
normal	B-UNK
oxidation	B-UNK
of	O
VLCFA	O
-	O
CoA	B-UNK
in	O
patients	B-UNK
fibroblasts	B-UNK
suggested	O
that	O
the	O
gene	B-UNK
coding	B-UNK
for	O
the	O
VLCFA	O
-	O
CoA	B-UNK
synthetase	O
could	O
be	O
a	O
candidate	B-UNK
gene	I-UNK
for	O
ALD	B-UNK
.	O

Here	O
we	O
use	O
positional	O
cloning	B-UNK
to	O
identify	B-UNK
a	O
gene	B-UNK
partially	O
deleted	B-UNK
in	O
6	O
of	O
85	O
independent	O
patients	B-UNK
with	O
ALD	B-UNK
.	O

In	O
familial	B-UNK
cases	I-UNK
,	O
the	O
deletions	O
segregated	O
with	O
the	O
disease	B-UNK
.	O

An	O
identical	B-UNK
deletion	B-UNK
was	O
detected	B-UNK
in	O
two	O
brothers	O
presenting	B-UNK
with	O
different	O
clinical	B-UNK
ALD	B-UNK
phenotypes	O
.	O

Candidate	B-UNK
exons	O
were	O
identified	B-UNK
by	O
computer	O
analysis	B-UNK
of	O
genomic	B-UNK
sequences	O
and	O
used	O
to	O
isolate	O
complementary	O
DNAs	O
by	O
exon	B-UNK
connection	O
and	O
screening	B-UNK
of	O
cDNA	O
libraries	O
.	O

The	O
deduced	O
protein	B-UNK
sequence	B-UNK
shows	O
significant	B-UNK
sequence	B-UNK
identity	O
to	O
a	O
peroxisomal	B-UNK
membrane	B-UNK
protein	I-UNK
of	O
M	O
(	O
r	O
)	O
70	O
K	O
that	O
is	O
involved	B-UNK
in	O
peroxisome	O
biogenesis	O
and	O
belongs	O
to	O
the	O
ATP	B-UNK
-	O
binding	B-UNK
cassette	O
superfamily	O
of	O
transporters	O
..	O

Targeted	B-UNK
modification	O
of	O
the	O
apolipoprotein	B-UNK
B	O
gene	B-UNK
results	B-UNK
in	O
hypobetalipoproteinemia	O
and	O
developmental	O
abnormalities	B-UNK
in	O
mice	B-UNK
.	O

Familial	B-UNK
hypobetalipoproteinemia	O
is	O
an	O
autosomal	B-UNK
codominant	O
disorder	B-UNK
resulting	B-UNK
in	O
a	O
dramatic	O
reduction	B-UNK
in	O
plasma	O
concentrations	O
of	O
apolipoprotein	B-UNK
(	O
apo	O
)	O
B	O
,	O
cholesterol	B-UNK
,	O
and	O
beta-migrating	O
lipoproteins	O
.	O

A	O
benefit	O
of	O
hypobetalipoproteinemia	O
is	O
that	O
mildly	O
affected	B-UNK
individuals	I-UNK
may	O
be	O
protected	O
from	O
coronary	O
vascular	O
disease	B-DISEASE
.	O

We	O
have	O
used	O
gene	B-UNK
targeting	B-UNK
to	O
generate	O
mice	B-UNK
with	O
a	O
modified	O
Apob	O
allele	B-UNK
.	O

Mice	B-UNK
containing	O
this	O
allele	B-UNK
display	O
all	O
of	O
the	O
hallmarks	O
of	O
human	B-UNK
hypobetalipoproteinemia	O
they	O
produce	B-UNK
a	O
truncated	O
apoB	O
protein	B-UNK
,	O
apoB70	O
,	O
and	O
have	O
markedly	B-UNK
decreased	B-UNK
plasma	O
concentrations	O
of	O
apoB	O
,	O
beta-lipoproteins	O
,	O
and	O
total	B-UNK
cholesterol	B-UNK
.	O

In	O
addition	B-UNK
,	O
the	O
mice	B-UNK
manifest	O
several	O
characteristics	B-UNK
that	O
are	O
occasionally	O
observed	B-UNK
in	O
human	B-UNK
hypobetalipoproteinemia	O
,	O
including	O
reduced	O
plasma	O
triglyceride	O
concentrations	O
,	O
fasting	O
chylomicronemia	O
,	O
and	O
reduced	O
high	B-UNK
density	I-UNK
lipoprotein	B-UNK
cholesterol	B-UNK
.	O

An	O
unexpected	O
finding	O
is	O
that	O
the	O
modified	O
Apob	O
allele	B-UNK
is	O
strongly	O
associated	O
with	O
exencephalus	O
and	O
hydrocephalus	B-DISEASE
.	O

These	O
mice	B-UNK
should	O
help	O
increase	B-UNK
our	O
understanding	B-UNK
of	O
hypobetalipoproteinemia	O
,	O
atherogenesis	B-DISEASE
,	O
and	O
the	O
etiology	O
of	O
exencephalus	O
and	O
hydrocephalus	B-DISEASE
..	O

A	O
novel	O
disease	B-DISEASE
with	O
deficiency	B-UNK
of	O
mitochondrial	B-UNK
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
CoA	B-UNK
dehydrogenase	I-UNK
.	O

Palmitoyl	O
-	O
CoA	B-UNK
dehydrogenase	I-UNK
activity	B-UNK
in	O
skin	B-UNK
fibroblasts	I-UNK
from	O
seven	O
patients	B-UNK
with	O
unidentified	O
defects	B-UNK
of	O
fatty	B-UNK
acid	B-UNK
oxidation	B-UNK
was	O
measured	O
in	O
the	O
presence	O
and	O
absence	B-UNK
of	O
antibodies	B-UNK
against	O
medium	O
-	O
chain	B-UNK
,	O
long	B-UNK
-	O
chain	B-UNK
,	O
and	O
very	O
-	O
long	B-UNK
-	O
chain	B-UNK
acyl	B-UNK
-	O
CoA	B-UNK
dehydrogenases	O
(	O
VLCAD	B-UNK
)	O
.	O

Two	O
of	O
the	O
patients	B-UNK
,	O
4	O
-	O
5	O
month	O
old	O
boys	O
,	O
were	O
found	O
to	O
have	O
a	O
novel	O
disease	B-DISEASE
,	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
,	O
as	O
judged	O
from	O
the	O
results	B-UNK
of	O
very	O
low	B-UNK
palmitoyl	O
-	O
CoA	B-UNK
dehydrogenase	I-UNK
activity	B-UNK
and	O
the	O
lack	B-UNK
of	O
immunoreactivity	O
toward	O
antibody	B-UNK
raised	O
to	O
purified	O
VLCAD	B-UNK
..	O

Molecular	B-UNK
characterization	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
deficiency	B-UNK
in	O
patients	B-UNK
of	O
Chinese	B-UNK
descent	O
and	O
identification	B-UNK
of	O
new	O
base	B-UNK
substitutions	B-UNK
in	O
the	O
human	B-UNK
G6PD	B-UNK
gene	B-UNK
.	O

The	O
underlying	O
DNA	B-UNK
changes	O
associated	O
with	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD)-deficient	O
Asians	O
have	O
not	O
been	O
extensively	O
investigated	O
.	O

To	O
fill	O
this	O
gap	O
,	O
we	O
sequenced	O
the	O
G6PD	B-UNK
gene	B-UNK
of	O
43	O
G6PD	B-UNK
-	O
deficient	B-UNK
Chinese	B-UNK
whose	O
G6PD	B-UNK
was	O
well	O
characterized	B-UNK
biochemically	O
.	O

DNA	B-UNK
samples	B-UNK
were	O
obtained	B-UNK
from	O
peripheral	B-UNK
blood	I-UNK
of	O
these	O
individuals	B-UNK
for	O
sequencing	B-UNK
using	O
a	O
direct	B-UNK
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
sequencing	B-UNK
procedure	O
.	O

From	O
these	O
43	O
samples	B-UNK
,	O
we	O
have	O
identified	B-UNK
five	O
different	O
types	B-UNK
of	O
nucleotide	B-UNK
substitutions	B-UNK
in	O
the	O
G6PD	B-UNK
gene	B-UNK
at	O
cDNA	O
1388	O
from	O
G	O
to	O
A	O
(	O
Arg	B-UNK
to	O
His	O
)	O
;	O
at	O
cDNA	O
1376	O
from	O
G	O
to	O
T	O
(	O
Arg	B-UNK
to	O
Leu	B-UNK
)	O
;	O
at	O
cDNA	O
1024	O
from	O
C	O
to	O
T	O
(	O
Leu	B-UNK
to	O
Phe	O
)	O
;	O
at	O
cDNA	O
392	O
from	O
G	O
to	O
T	O
(	O
Gly	B-UNK
to	O
Val	B-UNK
)	O
;	O
at	O
cDNA	O
95	O
from	O
A	O
to	O
G	O
(	O
His	O
to	O
Arg	B-UNK
)	O
.	O

These	O
five	O
nucleotide	B-UNK
substitutions	B-UNK
account	B-UNK
for	O
over	O
83	O
%	O
of	O
our	O
43	O
G6PD	B-UNK
-	O
deficient	B-UNK
samples	B-UNK
and	O
these	O
substitutions	B-UNK
have	O
not	O
been	O
reported	B-UNK
in	O
non-Asians	O
.	O

The	O
substitutions	B-UNK
found	O
at	O
cDNA	O
392	O
and	O
cDNA	O
1024	O
are	O
new	O
findings	B-UNK
.	O

The	O
substitutions	B-UNK
at	O
cDNA	O
1376	O
and	O
1388	O
account	B-UNK
for	O
over	O
50	O
%	O
of	O
the	O
43	O
samples	B-UNK
examined	O
indicating	O
a	O
high	B-UNK
prevalence	B-UNK
of	O
these	O
two	O
alleles	B-UNK
among	O
G6PD	B-UNK
-	O
deficient	B-UNK
Chinese	B-UNK
.	O

Our	O
findings	B-UNK
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	B-UNK
point	B-UNK
mutations	I-UNK
may	O
account	B-UNK
largely	O
for	O
much	O
of	O
the	O
phenotypic	B-UNK
heterogeneity	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
..	O

Identification	B-UNK
of	O
mutations	B-UNK
in	O
Danish	O
choroideremia	B-DISEASE
families	B-UNK
.	O

We	O
have	O
searched	O
for	O
mutations	B-UNK
in	O
the	O
choroideremia	B-UNK
gene	B-UNK
(	O
CHM	B-UNK
)	O
in	O
patients	B-UNK
from	O
12	O
Danish	O
families	B-UNK
in	O
which	O
CHM	B-UNK
is	O
segregating	O
.	O

Employing	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
,	O
single	B-UNK
strand	I-UNK
conformation	I-UNK
polymorphism	I-UNK
(	O
SSCP	B-UNK
)	O
analysis	B-UNK
,	O
and	O
direct	B-UNK
DNA	B-UNK
sequencing	I-UNK
,	O
different	O
mutations	B-UNK
have	O
been	O
identified	B-UNK
in	O
6	O
patients	B-UNK
.	O

All	O
the	O
mutations	B-UNK
will	O
interfere	O
with	O
the	O
correct	O
translation	O
of	O
the	O
mRNA	O
predicting	O
a	O
truncated	O
protein	B-UNK
or	O
no	O
gene	B-UNK
product	I-UNK
at	O
all	O
..	O

Structure	B-UNK
and	O
genomic	B-UNK
sequence	B-UNK
of	O
the	O
myotonic	B-UNK
dystrophy	I-UNK
(	O
DM	B-UNK
kinase	I-UNK
)	O
gene	B-UNK
.	O

The	O
mutation	B-UNK
causing	I-UNK
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-UNK
)	O
has	O
recently	O
been	O
identified	B-UNK
as	O
an	O
unstable	O
CTG	B-UNK
trinucleotide	B-UNK
repeat	I-UNK
located	B-UNK
in	O
the	O
3	O
untranslated	B-UNK
region	B-UNK
of	O
a	O
gene	B-UNK
encoding	B-UNK
for	O
a	O
protein	B-UNK
with	O
putative	O
serine	O
-	O
threonine	O
protein	B-UNK
kinase	I-UNK
activity	B-UNK
.	O

In	O
this	O
report	B-UNK
we	O
present	B-UNK
the	O
genomic	B-UNK
sequences	O
of	O
the	O
human	B-UNK
and	O
murine	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
.	O

A	O
comparison	B-UNK
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cDNA	O
sequences	O
from	O
both	O
species	B-UNK
,	O
led	B-UNK
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon	B-UNK
,	O
as	O
well	O
as	O
determine	B-UNK
the	O
organization	B-UNK
of	O
the	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
.	O

Several	O
polymorphisms	B-UNK
within	O
the	O
human	B-UNK
DM	B-UNK
kinase	I-UNK
gene	B-UNK
have	O
been	O
identified	B-UNK
,	O
and	O
PCR	B-UNK
assays	O
to	O
detect	B-UNK
two	O
of	O
these	O
are	O
described	O
.	O

The	O
complete	O
sequence	B-UNK
and	O
characterization	B-UNK
of	O
the	O
structure	B-UNK
of	O
the	O
DM	B-UNK
kinase	I-UNK
gene	B-UNK
,	O
as	O
well	O
as	O
the	O
identification	B-UNK
of	O
novel	O
polymorphisms	B-UNK
within	O
the	O
gene	B-UNK
,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	B-UNK
of	O
the	O
genetics	B-UNK
of	O
myotonic	B-UNK
dystrophy	I-UNK
and	O
the	O
molecular	B-UNK
biology	O
of	O
the	O
gene	B-UNK
..	O

Autosomal	B-UNK
recessive	I-UNK
transmission	B-UNK
of	O
hemophilia	B-DISEASE
A	I-DISEASE
due	O
to	O
a	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
mutation	B-UNK
.	O

The	O
differential	B-UNK
diagnosis	B-UNK
of	O
the	O
genetic	B-UNK
bleeding	B-DISEASE
disorders	B-UNK
,	O
hemophilia	B-DISEASE
A	I-DISEASE
and	O
von	B-UNK
Willebrand	I-UNK
disease	I-UNK
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	B-UNK
molecular	B-UNK
relationship	B-UNK
of	O
coagulation	O
factor	B-UNK
VIII	O
and	O
von	B-UNK
Willebrand	I-UNK
factor	I-UNK
(	O
vWF	B-UNK
)	O
.	O

This	O
report	B-UNK
describes	O
the	O
autosomal	B-UNK
inheritance	B-UNK
of	O
a	O
hemophilia	B-DISEASE
A	I-DISEASE
phenotype	B-UNK
due	O
to	O
a	O
mutation	B-UNK
of	O
vWF	B-UNK
that	O
results	B-UNK
in	O
defective	O
factor	B-UNK
VIII	O
binding	B-UNK
.	O

The	O
proband	B-UNK
was	O
a	O
female	O
patient	B-UNK
with	O
low	B-UNK
levels	B-UNK
of	O
factor	B-UNK
VIII	O
activity	B-UNK
.	O

Polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
(	O
PCR	B-UNK
)	O
amplification	B-UNK
and	O
DNA	B-UNK
sequencing	I-UNK
were	O
employed	O
to	O
examine	O
exons	O
encoding	B-UNK
the	O
putative	O
factor	B-UNK
VIII	O
binding	B-UNK
domain	I-UNK
of	O
vWF	B-UNK
.	O

The	O
patient	B-UNK
was	O
found	O
to	O
be	O
homozygous	B-UNK
for	O
a	O
single	B-UNK
point	B-UNK
mutation	I-UNK
causing	B-UNK
a	O
Thr--	O
>	O
Met	B-UNK
substitution	B-UNK
at	O
amino	B-UNK
acid	I-UNK
position	B-UNK
28	O
in	O
the	O
mature	O
vWF	B-UNK
subunit	B-UNK
.	O

The	O
phenotypic	B-UNK
expression	B-UNK
of	O
the	O
mutation	B-UNK
was	O
determined	B-UNK
to	O
be	O
recessive	B-UNK
because	O
heterozygous	B-UNK
family	B-UNK
members	I-UNK
were	O
clinically	O
unaffected	O
.	O

Recombinant	B-UNK
vWF	B-UNK
containing	O
the	O
observed	B-UNK
amino	B-UNK
acid	I-UNK
substitution	I-UNK
was	O
expressed	B-UNK
in	O
COS-1	O
cells	B-UNK
.	O

The	O
mutant	B-UNK
vWF	B-UNK
was	O
processed	O
and	O
secreted	O
normally	O
,	O
and	O
was	O
functionally	O
equivalent	O
to	O
wild	B-UNK
-	O
type	B-UNK
vWF	B-UNK
in	O
its	O
ability	B-UNK
to	O
bind	O
to	O
platelets	O
.	O

However	O
,	O
the	O
mutant	B-UNK
failed	O
to	O
bind	O
factor	B-UNK
VIII	O
,	O
demonstrating	O
that	O
the	O
mutation	B-UNK
was	O
functionally	O
related	B-UNK
to	O
the	O
observed	B-UNK
hemophilia	O
phenotype	B-UNK
.	O

The	O
family	B-UNK
we	O
describe	O
demonstrates	O
the	O
recessive	B-UNK
inheritance	B-UNK
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	B-UNK
bleeding	B-DISEASE
disorders	B-UNK
,	O
we	O
call	O
"	O
autosomal	B-UNK
hemophilia	O
.	O

"	O
We	O
conclude	O
that	O
vWF	B-UNK
mutation	B-UNK
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	O
,	O
especially	O
in	O
cases	B-UNK
where	O
the	O
inheritance	B-UNK
pattern	B-UNK
is	O
not	O
consistent	B-UNK
with	O
X	O
-	O
linked	B-UNK
transmission	B-UNK
.	O

Somatic	B-UNK
von	O
Hippel	O
-	O
Lindau	O
mutation	B-UNK
in	O
clear	O
cell	B-UNK
papillary	O
cystadenoma	B-DISEASE
of	O
the	O
epididymis	O
.	O

Papillary	O
cystadenoma	B-DISEASE
of	O
the	O
epididymis	O
is	O
an	O
uncommon	O
benign	O
lesion	O
that	O
may	O
occur	B-UNK
sporadically	O
or	O
as	O
a	O
manifestation	B-UNK
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	B-UNK
)	O
disease	B-UNK
.	O

Neither	O
immunohistochemical	O
studies	B-UNK
nor	O
molecular	B-UNK
genetic	I-UNK
analyses	O
of	O
the	O
VHL	B-UNK
gene	B-UNK
have	O
been	O
reported	B-UNK
previously	B-UNK
for	O
this	O
lesion	O
.	O

The	O
authors	O
describe	O
two	O
cases	B-UNK
of	O
clear	O
cell	B-UNK
papillary	O
cystadenoma	B-DISEASE
of	O
the	O
epididymis	O
,	O
both	O
of	O
which	O
were	O
initially	O
confused	O
with	O
metastatic	O
renal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O

Both	O
lesions	B-UNK
showed	O
positive	O
immunohistochemical	O
staining	O
for	O
low	B-UNK
and	O
intermediate	O
molecular	B-UNK
weight	O
keratins	O
(	O
Cam	O
5	O
.	O
2	O
and	O
AE1	O
/	O
AE3	O
)	O
,	O
EMA	O
,	O
vimentin	O
,	O
alpha	B-UNK
1-antitrypsin	O
,	O
and	O
alpha	B-UNK
1-antichymotrypsin	O
.	O

Each	O
was	O
negative	B-UNK
for	O
CEA	O
.	O

Because	O
clear	O
cell	B-UNK
papillary	O
cystadenoma	B-DISEASE
is	O
similar	B-UNK
to	O
renal	B-UNK
cell	I-UNK
carcinoma	I-UNK
histologically	O
,	O
and	O
because	O
both	O
occur	B-UNK
as	O
components	O
of	O
the	O
von	B-DISEASE
Hippel	I-DISEASE
-	I-DISEASE
Lindau	I-DISEASE
disease	I-DISEASE
complex	O
,	O
the	O
authors	O
analyzed	B-UNK
both	O
cases	B-UNK
for	O
the	O
presence	O
of	O
mutations	B-UNK
in	O
the	O
VHL	B-UNK
gene	B-UNK
.	O

A	O
somatic	B-UNK
VHL	B-UNK
gene	B-UNK
mutation	B-UNK
was	O
detected	B-UNK
in	O
one	O
of	O
the	O
two	O
tumors	B-DISEASE
by	O
polymerase	B-UNK
chain	I-UNK
reaction	I-UNK
followed	O
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphism	B-UNK
analysis	B-UNK
.	O

Direct	B-UNK
sequencing	I-UNK
revealed	B-UNK
a	O
cytosine	O
to	O
thymine	O
transition	B-UNK
at	O
nucleotide	B-UNK
694	O
,	O
resulting	B-UNK
in	O
the	O
replacement	O
of	O
an	O
arginine	O
with	O
a	O
stop	B-UNK
codon	I-UNK
after	O
the	O
sixth	O
amino	B-UNK
acid	I-UNK
of	O
exon	B-UNK
3	O
.	O

As	O
the	O
VHL	B-UNK
gene	B-UNK
is	O
believed	O
to	O
function	B-UNK
as	O
a	O
tumor	B-UNK
suppressor	I-UNK
gene	I-UNK
,	O
VHL	B-UNK
gene	B-UNK
mutations	B-UNK
may	O
play	O
a	O
role	B-UNK
in	O
the	O
initiation	O
of	O
tumorigenesis	O
in	O
sporadic	B-UNK
cystadenomas	O
of	O
the	O
epididymis	O
.	O

Identification	B-UNK
of	O
WASP	B-UNK
mutations	B-UNK
in	O
patients	B-UNK
with	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
and	O
isolated	B-UNK
thrombocytopenia	B-DISEASE
reveals	O
allelic	O
heterogeneity	B-UNK
at	O
the	O
WAS	O
locus	B-UNK
.	O

Mutation	B-UNK
in	O
the	O
gene	B-UNK
encoding	B-UNK
the	O
recently	O
isolated	B-UNK
WASP	B-UNK
protein	B-UNK
has	O
now	O
been	O
identified	B-UNK
as	O
the	O
genetic	B-UNK
defect	B-UNK
responsible	B-UNK
for	O
the	O
X	O
-	O
linked	B-UNK
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
,	O
a	O
primary	B-UNK
immunodeficiency	B-UNK
disease	B-UNK
associated	O
with	O
extensive	B-UNK
phenotypic	B-UNK
variability	B-UNK
.	O

To	O
elucidate	O
the	O
range	B-UNK
of	O
WASP	B-UNK
mutations	B-UNK
responsible	B-UNK
for	O
WAS	O
,	O
we	O
used	O
PCR	B-UNK
-	O
SSCP	B-UNK
analysis	B-UNK
to	O
screen	B-UNK
for	O
WASP	B-UNK
gene	B-UNK
mutation	B-UNK
in	O
19	O
unrelated	B-UNK
boys	O
with	O
the	O
diagnosis	B-UNK
of	O
classical	O
or	O
attenuated	B-UNK
WAS	O
or	O
isolated	B-UNK
thrombocytopenia	B-DISEASE
.	O

All	O
19	O
patients	B-UNK
had	O
WASP	B-UNK
mutations	B-UNK
,	O
each	O
of	O
which	O
localized	B-UNK
to	O
the	O
initial	O
three	O
or	O
terminal	B-UNK
three	O
exons	O
of	O
the	O
gene	B-UNK
,	O
and	O
the	O
majority	O
of	O
which	O
were	O
unique	O
in	O
each	O
case	B-UNK
.	O

However	O
,	O
a	O
missense	B-UNK
mutation	I-UNK
which	O
results	B-UNK
in	O
substitution	B-UNK
of	O
the	O
arginine	O
at	O
WAS	O
codon	B-UNK
86	O
was	O
identified	B-UNK
in	O
three	O
boys	O
with	O
severe	B-UNK
WAS	O
as	O
well	O
as	O
in	O
one	O
boy	B-UNK
presenting	B-UNK
with	O
thrombocytopenia	B-DISEASE
alone	O
.	O

While	O
the	O
three	O
mutations	B-UNK
found	O
in	O
the	O
isolated	B-UNK
thrombocytopenia	B-DISEASE
patients	B-UNK
leave	O
the	O
reading	B-UNK
frame	I-UNK
intact	O
,	O
about	O
one	O
-	O
half	B-UNK
of	O
the	O
gene	B-UNK
alterations	B-UNK
detected	B-UNK
in	O
both	O
severe	B-UNK
and	O
attenuated	B-UNK
WAS	O
patients	B-UNK
result	B-UNK
in	O
frameshifted	O
transcript	B-UNK
and	O
premature	B-UNK
translation	O
termination	B-UNK
.	O

These	O
findings	B-UNK
therefore	O
confirm	O
the	O
association	B-UNK
of	O
WAS	O
with	O
WASP	B-UNK
mutation	B-UNK
and	O
identify	B-UNK
WASP	B-UNK
mutation	B-UNK
as	O
a	O
cause	O
for	O
isolated	B-UNK
congenital	B-UNK
thrombocytopenia	B-DISEASE
in	O
males	B-UNK
.	O

While	O
the	O
WASP	B-UNK
gene	B-UNK
defects	B-UNK
responsible	B-UNK
for	O
isolated	B-UNK
thrombocytopenia	B-DISEASE
and	O
other	O
mild	O
presentations	O
of	O
WAS	O
do	O
not	O
appear	O
distinct	O
from	O
those	O
resulting	B-UNK
in	O
severe	B-UNK
WAS	O
,	O
these	O
data	B-UNK
indicate	O
that	O
analysis	B-UNK
of	O
WASP	B-UNK
gene	B-UNK
mutation	B-UNK
provides	O
a	O
valuable	O
tool	O
for	O
distinguishing	O
the	O
spectrum	B-UNK
of	O
WAS	O
patients	B-UNK
and	O
the	O
subset	O
of	O
males	B-UNK
with	O
isolated	B-UNK
thrombocytopenia	B-DISEASE
who	O
represent	O
mild	O
cases	B-UNK
of	O
WAS	O
..	O

WASP	B-UNK
gene	B-UNK
mutations	B-UNK
in	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
and	O
X	O
-	O
linked	B-UNK
thrombocytopenia	B-DISEASE
.	O

The	O
WASP	B-UNK
gene	B-UNK
has	O
been	O
recently	O
cloned	O
from	O
Xp11	O
.	O

23	O
and	O
shown	B-UNK
to	O
be	O
mutated	B-UNK
in	O
three	O
patients	B-UNK
with	O
the	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
(	O
WAS	O
)	O
.	O

We	O
have	O
developed	O
a	O
screening	B-UNK
protocol	O
for	O
identifying	O
WASP	B-UNK
gene	B-UNK
alterations	B-UNK
in	O
genomic	B-UNK
DNA	I-UNK
and	O
have	O
identified	B-UNK
a	O
spectrum	B-UNK
of	O
novel	O
mutations	B-UNK
in	O
12	O
additional	O
unrelated	B-UNK
families	I-UNK
.	O

These	O
missense	B-UNK
,	O
nonsense	B-UNK
and	O
frameshift	B-UNK
mutations	B-UNK
involve	O
eight	O
of	O
the	O
12	O
exons	O
of	O
the	O
gene	B-UNK
.	O

Two	O
mutations	B-UNK
creating	O
premature	B-UNK
termination	I-UNK
codons	O
were	O
associated	O
with	O
lack	B-UNK
of	O
detectable	O
mRNA	O
on	O
Northern	B-UNK
blots	O
.	O

Four	O
amino	B-UNK
acid	I-UNK
substitutions	I-UNK
,	O
Leu27Phe	O
,	O
Thr48Ile	O
,	O
Val75Met	O
and	O
Arg477Lys	O
,	O
were	O
found	O
in	O
patients	B-UNK
with	O
congenital	B-UNK
thrombocytopenia	B-DISEASE
and	O
no	O
clinically	O
evident	O
immune	B-UNK
defect	B-UNK
indicating	O
that	O
the	O
WASP	B-UNK
gene	B-UNK
is	O
the	O
site	B-UNK
for	O
mutations	B-UNK
in	O
X	O
-	O
linked	B-UNK
thrombocytopenia	B-DISEASE
as	O
well	O
as	O
in	O
WAS	O
.	O

A	O
T	O
-	O
cell	B-UNK
line	I-UNK
from	O
a	O
WAS	O
patient	B-UNK
contained	O
two	O
independent	O
DNA	B-UNK
alterations	B-UNK
,	O
a	O
constitutional	B-UNK
frameshift	B-UNK
mutation	I-UNK
,	O
also	O
present	B-UNK
in	O
peripheral	B-UNK
blood	I-UNK
leukocytes	O
from	O
the	O
patient	B-UNK
,	O
and	O
compensatory	O
splice	B-UNK
site	I-UNK
mutation	I-UNK
unique	O
to	O
the	O
cell	B-UNK
line	I-UNK
.	O

The	O
distribution	B-UNK
of	O
eight	O
missense	B-UNK
mutations	I-UNK
provides	O
valuable	O
information	B-UNK
on	O
amino	B-UNK
acids	I-UNK
which	O
are	O
essential	B-UNK
for	O
normal	B-UNK
protein	B-UNK
function	B-UNK
,	O
and	O
suggests	O
that	O
sites	O
in	O
the	O
first	O
two	O
exons	O
are	O
hot	O
-	O
spots	O
for	O
mutation	B-UNK
.	O

Evidence	B-UNK
for	O
inter-generational	O
instability	B-UNK
in	O
the	O
CAG	B-UNK
repeat	I-UNK
in	O
the	O
MJD1	O
gene	B-UNK
and	O
for	O
conserved	B-UNK
haplotypes	O
at	O
flanking	O
markers	B-UNK
amongst	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
.	O

The	O
size	B-UNK
of	O
the	O
(	O
CAG	B-UNK
)	O
n	O
repeat	B-UNK
array	O
in	O
the	O
3	O
'	O
end	B-UNK
of	O
the	O
MJD1	O
gene	B-UNK
and	O
the	O
haplotype	B-UNK
at	O
a	O
series	B-UNK
of	O
microsatellite	B-UNK
markers	I-UNK
surrounding	O
the	O
MJD1	O
gene	B-UNK
were	O
examined	O
in	O
a	O
large	B-UNK
cohort	B-UNK
of	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
affected	B-UNK
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
.	O

Our	O
data	B-UNK
provide	B-UNK
five	O
novel	O
observations	B-UNK
.	O

First	O
,	O
MJD	B-UNK
is	O
associated	O
with	O
expansion	B-UNK
fo	O
the	O
array	O
from	O
the	O
normal	B-UNK
range	B-UNK
of	O
14	O
-	O
37	O
repeats	B-UNK
to	O
68	O
-	O
84	O
repeats	B-UNK
in	O
most	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
,	O
but	O
no	O
subjects	B-UNK
were	O
observed	B-UNK
with	O
expansions	O
intermediate	O
in	O
size	B-UNK
between	O
those	O
of	O
the	O
normal	B-UNK
and	O
MJD	B-UNK
affected	B-UNK
groups	B-UNK
.	O

Second	O
,	O
the	O
expanded	B-UNK
allele	B-UNK
associated	O
with	O
MJD	B-UNK
displays	O
inter-generational	O
instability	B-UNK
,	O
particularly	O
in	O
male	B-UNK
meioses	O
,	O
and	O
this	O
instability	B-UNK
was	O
associated	O
with	O
the	O
clinical	B-UNK
phenomenon	O
of	O
anticipation	B-UNK
.	O

Third	O
,	O
the	O
size	B-UNK
of	O
the	O
expanded	B-UNK
allele	B-UNK
is	O
not	O
only	O
inversely	O
correlated	B-UNK
with	O
the	O
age	B-UNK
-	O
of	O
-	O
onset	B-UNK
of	O
MJD	B-UNK
(	O
r	O
=	O
-0	O
.	O
738	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
is	O
also	O
correlated	B-UNK
with	O
the	O
frequency	B-UNK
of	O
other	O
clinical	B-UNK
features	I-UNK
[	O
e.	O
g.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	B-UNK
were	O
more	O
frequent	B-UNK
in	O
subjects	B-UNK
with	O
large	B-UNK
repeats	B-UNK
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
05	O
respectively)].	O

Fourth	B-UNK
,	O
the	O
disease	B-UNK
phenotype	B-UNK
is	O
significantly	O
more	O
severe	B-UNK
and	O
had	O
an	O
early	B-UNK
age	B-UNK
of	I-UNK
onset	I-UNK
(	O
16	O
years	O
)	O
in	O
a	O
subject	O
homozygous	B-UNK
for	O
the	O
expanded	B-UNK
allele	B-UNK
,	O
which	O
contrasts	O
with	O
Huntington	B-UNK
disease	I-UNK
and	O
suggests	O
that	O
the	O
expanded	B-UNK
allele	B-UNK
in	O
the	O
MJD1	O
gene	B-UNK
could	O
exert	O
its	O
effect	B-UNK
either	O
by	O
a	O
dominant	B-UNK
negative	I-UNK
effect	B-UNK
(	O
putatively	O
excluded	O
in	O
HD	B-UNK
)	O
or	O
by	O
a	O
gain	O
of	O
function	B-UNK
effect	B-UNK
as	O
proposed	O
for	O
HD	B-UNK
.	O

Finally	B-UNK
,	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
affected	B-UNK
with	O
MJD	B-UNK
share	O
haplotypes	O
at	O
several	O
markers	B-UNK
surrounding	O
the	O
MJD1	O
gene	B-UNK
,	O
which	O
are	O
uncommon	O
in	O
the	O
normal	B-UNK
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
population	B-UNK
,	O
and	O
which	O
suggests	O
the	O
existence	O
either	O
of	O
common	B-UNK
founders	O
in	O
these	O
populations	O
or	O
of	O
chromosomes	O
susceptible	O
to	O
pathologic	O
expansion	B-UNK
of	O
the	O
CAG	B-UNK
repeat	I-UNK
in	O
the	O
MJD1	O
gene	B-UNK
.	O

Evidence	B-UNK
for	O
inter-generational	O
instability	B-UNK
in	O
the	O
CAG	B-UNK
repeat	I-UNK
in	O
the	O
MJD1	O
gene	B-UNK
and	O
for	O
conserved	B-UNK
haplotypes	O
at	O
flanking	O
markers	B-UNK
amongst	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
.	O

The	O
size	B-UNK
of	O
the	O
(	O
CAG	B-UNK
)	O
n	O
repeat	B-UNK
array	O
in	O
the	O
3	O
'	O
end	B-UNK
of	O
the	O
MJD1	O
gene	B-UNK
and	O
the	O
haplotype	B-UNK
at	O
a	O
series	B-UNK
of	O
microsatellite	B-UNK
markers	I-UNK
surrounding	O
the	O
MJD1	O
gene	B-UNK
were	O
examined	O
in	O
a	O
large	B-UNK
cohort	B-UNK
of	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
affected	B-UNK
with	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
(	O
MJD	B-UNK
)	O
.	O

Our	O
data	B-UNK
provide	B-UNK
five	O
novel	O
observations	B-UNK
.	O

First	O
,	O
MJD	B-UNK
is	O
associated	O
with	O
expansion	B-UNK
fo	O
the	O
array	O
from	O
the	O
normal	B-UNK
range	B-UNK
of	O
14	O
-	O
37	O
repeats	B-UNK
to	O
68	O
-	O
84	O
repeats	B-UNK
in	O
most	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
,	O
but	O
no	O
subjects	B-UNK
were	O
observed	B-UNK
with	O
expansions	O
intermediate	O
in	O
size	B-UNK
between	O
those	O
of	O
the	O
normal	B-UNK
and	O
MJD	B-UNK
affected	B-UNK
groups	B-UNK
.	O

Second	O
,	O
the	O
expanded	B-UNK
allele	B-UNK
associated	O
with	O
MJD	B-UNK
displays	O
inter-generational	O
instability	B-UNK
,	O
particularly	O
in	O
male	B-UNK
meioses	O
,	O
and	O
this	O
instability	B-UNK
was	O
associated	O
with	O
the	O
clinical	B-UNK
phenomenon	O
of	O
anticipation	B-UNK
.	O

Third	O
,	O
the	O
size	B-UNK
of	O
the	O
expanded	B-UNK
allele	B-UNK
is	O
not	O
only	O
inversely	O
correlated	B-UNK
with	O
the	O
age	B-UNK
-	O
of	O
-	O
onset	B-UNK
of	O
MJD	B-UNK
(	O
r	O
=	O
-0	O
.	O
738	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
is	O
also	O
correlated	B-UNK
with	O
the	O
frequency	B-UNK
of	O
other	O
clinical	B-UNK
features	I-UNK
[	O
e.	O
g.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	B-UNK
were	O
more	O
frequent	B-UNK
in	O
subjects	B-UNK
with	O
large	B-UNK
repeats	B-UNK
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
05	O
respectively)].	O

Fourth	B-UNK
,	O
the	O
disease	B-UNK
phenotype	B-UNK
is	O
significantly	O
more	O
severe	B-UNK
and	O
had	O
an	O
early	B-UNK
age	B-UNK
of	I-UNK
onset	I-UNK
(	O
16	O
years	O
)	O
in	O
a	O
subject	O
homozygous	B-UNK
for	O
the	O
expanded	B-UNK
allele	B-UNK
,	O
which	O
contrasts	O
with	O
Huntington	B-UNK
disease	I-UNK
and	O
suggests	O
that	O
the	O
expanded	B-UNK
allele	B-UNK
in	O
the	O
MJD1	O
gene	B-UNK
could	O
exert	O
its	O
effect	B-UNK
either	O
by	O
a	O
dominant	B-UNK
negative	I-UNK
effect	B-UNK
(	O
putatively	O
excluded	O
in	O
HD	B-UNK
)	O
or	O
by	O
a	O
gain	O
of	O
function	B-UNK
effect	B-UNK
as	O
proposed	O
for	O
HD	B-UNK
.	O

Finally	B-UNK
,	O
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
subjects	B-UNK
affected	B-UNK
with	O
MJD	B-UNK
share	O
haplotypes	O
at	O
several	O
markers	B-UNK
surrounding	O
the	O
MJD1	O
gene	B-UNK
,	O
which	O
are	O
uncommon	O
in	O
the	O
normal	B-UNK
Japanese	B-UNK
and	I-UNK
Caucasian	I-UNK
population	B-UNK
,	O
and	O
which	O
suggests	O
the	O
existence	O
either	O
of	O
common	B-UNK
founders	O
in	O
these	O
populations	O
or	O
of	O
chromosomes	O
susceptible	O
to	O
pathologic	O
expansion	B-UNK
of	O
the	O
CAG	B-UNK
repeat	I-UNK
in	O
the	O
MJD1	O
gene	B-UNK
.	O

A	O
4-megabase	O
YAC	B-UNK
contig	O
that	O
spans	O
the	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
region	B-UNK
on	O
human	B-UNK
chromosome	I-UNK
8q24	O
.	O
1	O
:	O
use	O
in	O
refining	O
the	O
location	B-UNK
of	O
the	O
trichorhinophalangeal	O
syndrome	B-UNK
and	O
multiple	B-UNK
exostoses	B-DISEASE
genes	B-UNK
(	O
TRPS1	O
and	O
EXT1	O
)	O
.	O

We	O
have	O
constructed	O
a	O
physical	B-UNK
map	B-UNK
covering	O
over	O
4	O
Mb	B-UNK
of	O
human	B-UNK
chromosome	I-UNK
8q24	O
.	O

1	O
and	O
used	O
this	O
map	B-UNK
to	O
refine	O
the	O
locations	O
of	O
the	O
genes	B-UNK
responsible	B-UNK
for	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
map	B-UNK
is	O
composed	O
of	O
overlapping	O
YAC	B-UNK
clones	O
that	O
were	O
identified	B-UNK
and	O
ordered	O
in	O
relation	O
to	O
sequence	B-UNK
tagged	O
sites	O
mapped	B-UNK
to	O
the	O
Langer	O
-	O
Giedion	O
chromosomal	B-UNK
region	B-UNK
on	O
somatic	B-UNK
cell	I-UNK
hybrids	I-UNK
.	O

The	O
minimal	O
region	B-UNK
of	O
overlap	O
of	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
deletions	O
,	O
previously	B-UNK
identified	I-UNK
by	O
analysis	B-UNK
of	O
15	O
patients	B-UNK
,	O
was	O
placed	O
on	O
the	O
map	B-UNK
by	O
analysis	B-UNK
of	O
2	O
patients	B-UNK
whose	O
deletions	O
define	B-UNK
the	O
endpoints	O
.	O

The	O
chromosome	B-UNK
8	O
breakpoint	O
of	O
a	O
balanced	O
t	O
(	O
8	O
;	O
9	O
)	O
(	O
q24	O
.	O
11	O
;	O
q33	O
.	O
3	O
)	O
translocation	B-UNK
from	O
a	O
patient	B-UNK
with	O
trichorhinophalangeal	O
syndrome	B-UNK
(	O
TRPS	O
I	O
)	O
was	O
found	O
to	O
be	O
located	B-UNK
just	O
within	O
the	O
proximal	B-UNK
end	B-UNK
of	O
the	O
minimal	O
deletion	B-UNK
region	B-UNK
.	O

A	O
deletion	B-UNK
of	O
8q24	O
.	O

11-q24	O
.	O

3	O
in	O
a	O
patient	B-UNK
with	O
multiple	B-UNK
exostoses	B-DISEASE
was	O
found	O
to	O
overlap	O
the	O
distal	B-UNK
end	B-UNK
of	O
the	O
LGS	O
deletion	B-UNK
region	B-UNK
,	O
indicating	O
that	O
the	O
EXT1	O
gene	B-UNK
is	O
distal	B-UNK
to	O
the	O
TRPS1	O
gene	B-UNK
and	O
supporting	O
the	O
hypothesis	B-UNK
that	O
Langer	B-DISEASE
-	I-DISEASE
Giedion	I-DISEASE
syndrome	I-DISEASE
is	O
due	O
to	O
loss	B-UNK
of	O
functional	O
copies	O
of	O
both	O
the	O
TRPS1	O
and	O
the	O
EXT1	O
genes	B-UNK

BRCA1	B-UNK
mutations	B-UNK
in	O
a	O
population	B-UNK
-	O
based	B-UNK
sample	O
of	O
young	B-UNK
women	B-UNK
with	O
breast	B-UNK
cancer	I-UNK
.	O

BACKGROUND	O
.	O

Inherited	B-UNK
mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
are	O
associated	O
with	O
a	O
high	B-UNK
risk	I-UNK
of	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
in	O
some	O
families	B-UNK
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
BRCA1	B-UNK
mutations	B-UNK
to	O
breast	B-UNK
cancer	I-UNK
in	O
the	O
general	B-UNK
population	B-UNK
.	O

We	O
analyzed	B-UNK
DNA	B-UNK
samples	B-UNK
from	O
women	B-UNK
enrolled	O
in	O
a	O
population	B-UNK
-	O
based	B-UNK
study	B-UNK
of	O
early	B-UNK
-	O
onset	B-UNK
breast	B-DISEASE
cancer	I-DISEASE
to	O
assess	B-UNK
the	O
spectrum	B-UNK
and	O
frequency	B-UNK
of	O
germ	B-UNK
-	O
line	B-UNK
BRCA1	B-UNK
mutations	B-UNK
in	O
young	B-UNK
women	B-UNK
with	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

METHODS	O
.	O

We	O
studied	O
80	O
women	B-UNK
in	O
whom	O
breast	B-UNK
cancer	I-UNK
was	O
diagnosed	O
before	O
the	O
age	B-UNK
of	O
35	O
,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	B-UNK
of	O
family	B-UNK
history	B-UNK
.	O

Genomic	B-UNK
DNA	I-UNK
was	O
studied	O
for	O
BRCA1	B-UNK
mutations	B-UNK
by	O
analysis	B-UNK
involving	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
polymorphisms	B-UNK
and	O
with	O
allele	B-UNK
-	O
specific	B-UNK
assays	O
.	O

Alterations	B-UNK
were	O
defined	B-UNK
by	O
DNA	B-UNK
sequencing	I-UNK
.	O

RESULTS	B-UNK
.	O

Germ	B-UNK
-	O
line	B-UNK
BRCA1	B-UNK
mutations	B-UNK
were	O
identified	B-UNK
in	O
6	O
of	O
the	O
80	O
women	B-UNK
.	O

Four	O
additional	O
rare	B-UNK
sequence	B-UNK
variants	B-UNK
of	O
unknown	O
functional	O
importance	O
were	O
also	O
identified	B-UNK
.	O

Two	O
of	O
the	O
mutations	B-UNK
and	O
three	O
of	O
the	O
rare	B-UNK
sequence	B-UNK
variants	B-UNK
were	O
found	O
among	O
the	O
39	O
women	B-UNK
who	O
reported	B-UNK
no	O
family	B-UNK
history	B-UNK
of	O
breast	B-UNK
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

None	O
of	O
the	O
mutations	B-UNK
and	O
only	O
one	O
of	O
the	O
rare	B-UNK
variants	B-UNK
was	O
identified	B-UNK
in	O
a	O
reference	O
population	B-UNK
of	O
73	O
unrelated	B-UNK
subjects	B-UNK
.	O

CONCLUSIONS	B-UNK
.	O

Alterations	B-UNK
in	O
BRCA1	B-UNK
were	O
identified	B-UNK
in	O
approximately	O
10	O
percent	B-UNK
of	O
this	O
cohort	B-UNK
of	O
young	B-UNK
women	B-UNK
with	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

The	O
risk	B-UNK
of	O
harboring	O
a	O
mutation	B-UNK
was	O
not	O
limited	O
to	O
women	B-UNK
with	O
family	B-UNK
histories	O
of	O
breast	B-UNK
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

These	O
results	B-UNK
represent	O
a	O
minimal	O
estimate	O
of	O
the	O
frequency	B-UNK
of	O
BRCA1	B-UNK
mutations	B-UNK
in	O
this	O
population	B-UNK
.	O

Comprehensive	O
methods	O
of	O
identifying	O
BRCA1	B-UNK
mutations	B-UNK
and	O
understanding	B-UNK
their	O
importance	O
will	O
be	O
needed	O
before	O
testing	B-UNK
of	O
women	B-UNK
in	O
the	O
general	B-UNK
population	B-UNK
can	O
be	O
undertaken	O
..	O

Novel	O
inherited	B-UNK
mutations	B-UNK
and	O
variable	B-UNK
expressivity	O
of	O
BRCA1	B-UNK
alleles	B-UNK
,	O
including	O
the	O
founder	B-UNK
mutation	B-UNK
185delAG	O
in	O
Ashkenazi	B-UNK
Jewish	I-UNK
families	B-UNK
.	O

Thirty	O
-	O
seven	O
families	B-UNK
with	O
four	O
or	O
more	O
cases	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
or	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
were	O
analyzed	B-UNK
for	O
mutations	B-UNK
in	O
BRCA1	B-UNK
.	O

Twelve	O
different	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
,	O
four	O
novel	O
and	O
eight	O
previously	B-UNK
observed	B-UNK
,	O
were	O
detected	B-UNK
in	O
16	O
families	B-UNK
.	O

Five	O
families	B-UNK
of	O
Ashkenazi	B-UNK
Jewish	I-UNK
descent	O
carried	O
the	O
185delAG	O
mutation	B-UNK
and	O
shared	O
the	O
same	O
haplotype	B-UNK
at	O
eight	O
polymorphic	B-UNK
markers	I-UNK
spanning	O
approximately	O
850	O
kb	B-UNK
at	O
BRCA1	B-UNK
.	O

Expressivity	O
of	O
185delAG	O
in	O
these	O
families	B-UNK
varied	O
,	O
from	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
without	O
ovarian	B-UNK
cancer	I-UNK
.	O

Mutation	B-UNK
4184delTCAA	O
occurred	B-UNK
independently	O
in	O
two	O
families	B-UNK
.	O

In	O
one	O
family	B-UNK
,	O
penetrance	O
was	O
complete	O
,	O
with	O
females	O
developing	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
and	O
the	O
male	B-UNK
carrier	B-UNK
developing	O
prostatic	O
cancer	B-UNK
,	O
whereas	O
,	O
in	O
the	O
other	O
family	B-UNK
,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	B-DISEASE
cancer	I-DISEASE
occurred	B-UNK
,	O
diagnosed	O
at	O
ages	O
38	O
-	O
81	O
years	O
.	O

Two	O
novel	O
nonsense	B-UNK
mutations	I-UNK
led	B-UNK
to	O
the	O
loss	B-UNK
of	O
mutant	B-UNK
BRCA1	B-UNK
transcript	B-UNK
in	O
families	B-UNK
with	O
10	O
and	O
6	O
cases	B-UNK
of	O
early	B-UNK
-	O
onset	B-UNK
breast	B-UNK
cancer	I-UNK
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

A	O
665-nt	O
segment	O
of	O
the	O
BRCA1	B-UNK
3-UTR	O
and	O
1	O
.	O

3	O
kb	B-UNK
of	O
genomic	B-UNK
sequence	B-UNK
including	O
the	O
putative	O
promoter	O
region	B-UNK
were	O
invariant	O
by	O
single	B-UNK
-	O
strand	B-UNK
conformation	B-UNK
analysis	B-UNK
in	O
13	O
families	B-UNK
without	O
coding	B-UNK
-	O
sequence	B-UNK
mutations	B-UNK
.	O

Overall	O
in	O
our	O
series	B-UNK
,	O
BRCA1	B-UNK
mutations	B-UNK
have	O
been	O
detected	B-UNK
in	O
26	O
families	B-UNK
16	O
with	O
positive	O
BRCA1	B-UNK
lod	B-UNK
scores	I-UNK
,	O
7	O
with	O
negative	B-UNK
lod	B-UNK
scores	I-UNK
(	O
reflecting	O
multiple	B-UNK
sporadic	B-UNK
breast	I-UNK
cancers	B-UNK
)	O
,	O
and	O
3	O
not	O
tested	O
for	O
linkage	B-UNK
.	O

Three	O
other	O
families	B-UNK
have	O
positive	O
lod	B-UNK
scores	I-UNK
for	O
linkage	B-UNK
to	O
BRCA2	B-UNK
,	O
but	O
13	O
families	B-UNK
without	O
detected	B-UNK
BRCA1	B-UNK
mutations	B-UNK
have	O
negative	B-UNK
lod	B-UNK
scores	I-UNK
for	O
both	O
BRCA1	B-UNK
and	I-UNK
BRCA2	I-UNK
.	O

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
variant	O
,	O
G6PD	B-UNK
Orissa	O
(	O
44	O
Ala--	O
>	O
Gly	B-UNK
)	O
,	O
is	O
the	O
major	B-UNK
polymorphic	B-UNK
variant	O
in	O
tribal	O
populations	O
in	O
India	O
.	O

Deficiency	B-UNK
of	O
glucose-6-phosphate	O
dehydrogenase	B-UNK
(	O
G6PD	B-UNK
)	O
is	O
usually	O
found	O
at	O
high	B-UNK
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	B-UNK
has	O
been	O
endemic	O
.	O

The	O
frequency	B-UNK
and	O
genetic	B-UNK
basis	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
have	O
been	O
studied	O
in	O
Africa	B-UNK
,	O
around	O
the	O
Mediterranean	B-UNK
,	O
and	O
in	O
the	O
Far	O
East	O
,	O
but	O
little	O
such	O
information	B-UNK
is	O
available	O
about	O
the	O
situation	O
in	O
India	O
.	O

To	O
determine	B-UNK
the	O
extent	O
of	O
heterogeneity	B-UNK
of	O
G6PD	B-UNK
,	O
we	O
have	O
studied	O
several	O
different	O
Indian	O
populations	O
by	O
screening	B-UNK
for	O
G6PD	B-UNK
deficiency	I-UNK
,	O
followed	O
by	O
molecular	B-UNK
analysis	I-UNK
of	O
deficient	B-UNK
alleles	B-UNK
.	O

The	O
frequency	B-UNK
of	O
G6PD	B-UNK
deficiency	I-UNK
varies	O
between	O
3	O
%	O
and	O
15	O
%	O
in	O
different	O
tribal	O
and	O
urban	O
groups	B-UNK
.	O

Remarkably	O
,	O
a	O
previously	B-UNK
unreported	O
deficient	B-UNK
variant	O
,	O
G6PD	B-UNK
Orissa	O
(	O
44	O
Ala--	O
>	O
Gly	B-UNK
)	O
,	O
is	O
responsible	B-UNK
for	O
most	O
of	O
the	O
G6PD	B-UNK
deficiency	I-UNK
in	O
tribal	O
Indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations	O
,	O
where	O
most	O
of	O
the	O
G6PD	B-UNK
deficiency	I-UNK
is	O
due	O
to	O
the	O
G6PD	B-UNK
Mediterranean	I-UNK
(	O
188	O
Ser--	O
>	O
Phe	O
)	O
variant	O
.	O

The	O
KmNADP	O
of	O
G6PD	B-UNK
Orissa	O
is	O
fivefold	O
higher	O
than	O
that	O
of	O
the	O
normal	B-UNK
enzyme	B-UNK
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	B-UNK
that	O
the	O
alanine	O
residue	O
that	O
is	O
replaced	O
by	O
glycine	O
is	O
part	O
of	O
a	O
putative	O
coenzyme	O
-	O
binding	B-UNK
site	B-UNK
..	O

Evidence	B-UNK
for	O
linkage	B-UNK
of	O
bipolar	B-DISEASE
disorder	I-DISEASE
to	O
chromosome	B-UNK
18	O
with	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	B-UNK
.	O

A	O
susceptibility	B-UNK
gene	I-UNK
on	O
chromosome	B-UNK
18	O
and	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	B-UNK
have	O
been	O
suggested	O
for	O
bipolar	B-DISEASE
affective	B-DISEASE
disorder	I-DISEASE
(	O
BPAD	O
)	O
.	O

We	O
have	O
studied	O
28	O
nuclear	B-UNK
families	B-UNK
selected	O
for	O
apparent	O
unilineal	O
transmission	B-UNK
of	O
the	O
BPAD	O
phenotype	B-UNK
,	O
by	O
using	O
31	O
polymorphic	B-UNK
markers	I-UNK
spanning	O
chromosome	B-UNK
18	O
.	O

Evidence	B-UNK
for	O
linkage	B-UNK
was	O
tested	O
with	O
affected	B-UNK
-	O
sib	O
-	O
pair	B-UNK
and	O
LOD	B-UNK
score	I-UNK
methods	O
under	O
two	O
definitions	O
of	O
the	O
affected	B-UNK
phenotype	B-UNK
.	O

The	O
affected	B-UNK
-	O
sibpair	O
analyses	O
indicated	O
excess	B-UNK
allele	B-UNK
sharing	O
for	O
markers	B-UNK
on	O
18p	O
within	O
the	O
region	B-UNK
reported	B-UNK
previously	B-UNK
.	O

The	O
greatest	O
sharing	O
was	O
at	O
D18S37	O
64	O
%	O
in	O
bipolar	B-DISEASE
and	O
recurrent	O
unipolar	O
(	O
RUP	O
)	O
sib	O
pairs	B-UNK
(	O
P	O
=	O
.	O
0006	O
)	O
.	O

In	O
addition	B-UNK
,	O
excess	B-UNK
sharing	O
of	O
the	O
paternally	O
,	O
but	O
not	O
maternally	O
,	O
transmitted	O
alleles	B-UNK
was	O
observed	B-UNK
at	O
three	O
markers	B-UNK
on	O
18q	O
at	O
D18S41	O
,	O
51	O
bipolar	B-DISEASE
and	O
RUP	O
sib	O
pairs	B-UNK
were	O
concordant	O
for	O
paternally	O
transmitted	O
alleles	B-UNK
,	O
and	O
21	O
pairs	B-UNK
were	O
discordant	O
(	O
P	O
=	O
0004	O
)	O
.	O

The	O
evidence	B-UNK
for	O
linkage	B-UNK
to	O
loci	O
on	O
both	O
18p	O
and	O
18q	O
was	O
strongest	O
in	O
the	O
11	O
paternal	O
pedigrees	O
,	O
i.	O

e	O
e.	O
,	O
those	O
in	O
which	O
the	O
father	O
or	O
one	O
of	O
the	O
fathers	O
sibs	O
is	O
affected	B-UNK
.	O

In	O
these	O
pedigrees	O
,	O
the	O
greatest	O
allele	B-UNK
sharing	O
(	O
81	O
%	O
;	O
P	O
=	O
.	O
00002	O
)	O
and	O
the	O
highest	O
LOD	B-UNK
score	I-UNK
(	O
3	O
.	O
51	O
;	O
phi	O
=	O
0	O
.	O
0	O
)	O
were	O
observed	B-UNK
at	O
D18S41	O
.	O

Our	O
results	B-UNK
provide	I-UNK
further	O
support	O
for	O
linkage	B-UNK
of	O
BPAD	O
to	O
chromosome	B-UNK
18	O
and	O
the	O
first	O
molecular	B-UNK
evidence	B-UNK
for	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	B-UNK
operating	O
in	O
this	O
disorder	B-UNK
.	O

The	O
number	B-UNK
of	O
loci	O
involved	B-UNK
,	O
and	O
their	O
precise	O
location	B-UNK
,	O
require	O
further	O
study	B-UNK

A	O
prevalent	O
mutation	B-UNK
for	O
galactosemia	O
among	O
black	B-UNK
Americans	O
.	O

OBJECTIVE	B-UNK
To	O
define	B-UNK
the	O
mutation	B-UNK
causing	I-UNK
galactosemia	O
in	O
patients	B-UNK
of	O
black	B-UNK
American	B-UNK
origin	O
who	O
have	O
no	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	B-UNK
)	O
activity	B-UNK
in	O
erythrocytes	O
but	O
good	O
clinical	B-UNK
outcome	O
.	O

METHODS	O
We	O
discovered	O
a	O
mutation	B-UNK
caused	B-UNK
by	O
a	O
C--	O
>	O
T	O
transition	B-UNK
at	O
base	B-UNK
-	O
pair	B-UNK
1158	O
of	O
the	O
GALT	B-UNK
gene	B-UNK
that	O
results	B-UNK
in	O
a	O
serine	O
-	O
to	O
-	O
leucine	O
substitution	B-UNK
at	O
codon	B-UNK
135	O
(	O
S135L	B-UNK
)	O
.	O

We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	B-UNK
populations	O
for	O
its	O
prevalence	B-UNK
.	O

We	O
compared	B-UNK
galactose-1-phosphate	O
uridyltransferase	O
among	O
erythrocytes	O
,	O
leukocytes	O
,	O
and	O
transformed	O
lymphoblasts	O
,	O
as	O
well	O
as	O
total	B-UNK
body	O
oxidation	B-UNK
of	O
D-(13C)-galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	B-UNK
(	O
S135L	B-UNK
/	O
S135L	B-UNK
,	O
Q188R	B-UNK
/	O
Q188R	B-UNK
,	O
and	O
Normal	B-UNK
/	O
Normal	B-UNK
)	O
.	O

RESULTS	B-UNK
We	O
found	O
a	O
48	O
%	O
prevalence	B-UNK
of	O
the	O
S135L	B-UNK
mutation	B-UNK
among	O
17	O
black	B-UNK
American	B-UNK
patients	B-UNK
with	O
classic	B-UNK
galactosemia	O
and	O
a	O
1	O
%	O
prevalence	B-UNK
in	O
a	O
population	B-UNK
of	O
50	O
black	B-UNK
Americans	O
without	O
galactosemia	O
.	O

The	O
S135L	B-UNK
mutation	B-UNK
was	O
not	O
found	O
in	O
84	O
white	B-UNK
patients	B-UNK
with	O
G	O
/	O
G	O
galactosemia	O
nor	O
in	O
87	O
white	B-UNK
control	B-UNK
subjects	B-UNK
without	O
galactosemia	O
.	O

We	O
found	O
normal	B-UNK
whole	O
body	O
oxidation	B-UNK
of	O
D-(13C)-galactose	O
by	O
the	O
patient	B-UNK
homozygous	B-UNK
for	O
S135L	B-UNK
and	O
various	O
degrees	O
of	O
enzyme	B-UNK
impairment	B-UNK
among	O
different	O
tissues	O
.	O

CONCLUSIONS	B-UNK
The	O
S135L	B-UNK
mutation	B-UNK
in	O
the	O
GALT	B-UNK
gene	B-UNK
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	O
among	O
black	B-UNK
patients	B-UNK
.	O

Because	O
GALT	B-UNK
activity	B-UNK
varies	O
in	O
different	O
tissues	O
of	O
patients	B-UNK
homozygous	B-UNK
for	O
S135L	B-UNK
,	O
they	O
may	O
have	O
a	O
better	O
clinical	B-UNK
outcome	O
than	O
patients	B-UNK
who	O
are	O
homozygous	B-UNK
for	O
Q188R	B-UNK
when	O
both	O
are	O
treated	O
from	O
infancy	O
..	O

A	O
high	B-UNK
incidence	B-UNK
of	O
BRCA1	B-UNK
mutations	B-UNK
in	O
20	O
breast	B-UNK
-	O
ovarian	B-DISEASE
cancer	I-DISEASE
families	B-UNK
.	O

We	O
have	O
analyzed	B-UNK
20	O
breast	B-UNK
-	O
ovarian	B-UNK
cancer	I-UNK
families	B-UNK
,	O
the	O
majority	O
of	O
which	O
show	O
positive	O
evidence	B-UNK
of	O
linkage	B-UNK
to	O
chromosome	B-UNK
17q12	O
for	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
BRCA1	B-UNK
gene	B-UNK
.	O

BRCA1	B-UNK
mutations	B-UNK
cosegregating	O
with	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
were	O
identified	B-UNK
in	O
16	O
families	B-UNK
,	O
including	O
1	O
family	B-UNK
with	O
a	O
case	B-UNK
of	O
male	B-UNK
breast	I-UNK
cancer	I-UNK
.	O

Nine	O
of	O
these	O
mutations	B-UNK
have	O
not	O
been	O
reported	B-UNK
previously	B-UNK
.	O

The	O
majority	O
of	O
mutations	B-UNK
were	O
found	O
to	O
generate	O
a	O
premature	B-UNK
stop	I-UNK
codon	I-UNK
leading	B-UNK
to	O
the	O
formation	B-UNK
of	O
a	O
truncated	O
BRCA1	B-UNK
protein	B-UNK
of	O
2%-88	O
%	O
of	O
the	O
expected	O
normal	B-UNK
length	B-UNK
.	O

Two	O
mutations	B-UNK
altered	O
the	O
RING	O
finger	B-UNK
domain	B-UNK
.	O

Sequencing	B-UNK
of	O
genomic	B-UNK
DNA	I-UNK
led	B-UNK
to	O
the	O
identification	B-UNK
of	O
a	O
mutation	B-UNK
in	O
the	O
coding	B-UNK
region	I-UNK
of	O
BRCA1	B-UNK
in	O
12	O
families	B-UNK
,	O
and	O
cDNA	O
analysis	B-UNK
revealed	I-UNK
an	O
abnormal	O
or	O
missing	O
BRCA1	B-UNK
transcript	B-UNK
in	O
4	O
of	O
the	O
8	O
remaining	O
families	B-UNK
.	O

A	O
total	B-UNK
of	O
eight	O
mutations	B-UNK
were	O
associated	O
with	O
a	O
reduced	O
quantity	O
of	O
BRCA1	B-UNK
transcript	B-UNK
.	O

We	O
were	O
unable	O
to	O
detect	B-UNK
BRCA1	B-UNK
mutations	B-UNK
in	O
4	O
of	O
the	O
20	O
families	B-UNK
,	O
but	O
only	O
1	O
of	O
these	O
was	O
clearly	O
linked	B-UNK
to	O
BRCA1	B-UNK
.	O

It	O
is	O
expected	O
that	O
the	O
majority	O
of	O
clear	O
examples	O
of	O
the	O
breast	B-UNK
-	O
ovarian	B-UNK
syndrome	B-DISEASE
will	O
be	O
associated	O
with	O
germ	B-UNK
-	O
line	B-UNK
mutations	B-UNK
in	O
the	O
coding	B-UNK
region	I-UNK
of	O
BRCA1	B-UNK
..	O

Brca1	B-UNK
deficiency	B-UNK
results	B-UNK
in	O
early	B-UNK
embryonic	B-UNK
lethality	O
characterized	B-UNK
by	O
neuroepithelial	O
abnormalities	B-UNK
.	O

The	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
gene	I-UNK
,	O
BRCA1	B-UNK
,	O
has	O
been	O
cloned	O
and	O
shown	B-UNK
to	O
encode	O
a	O
zinc	B-UNK
-	O
finger	B-UNK
protein	B-UNK
of	O
unknown	O
function	B-UNK
.	O

Mutations	B-UNK
in	O
BRCA1	B-UNK
account	B-UNK
for	O
at	O
least	O
80	O
%	O
of	O
families	B-UNK
with	O
both	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
,	O
as	O
well	O
as	O
some	O
non-familial	O
sporadic	B-UNK
ovarian	B-UNK
cancers	I-UNK
.	O

The	O
loss	B-UNK
of	O
wild	B-UNK
-	O
type	B-UNK
BRCA1	B-UNK
in	O
tumours	B-DISEASE
of	O
individuals	B-UNK
carrying	B-UNK
one	O
nonfunctional	O
BRCA1	B-UNK
allele	B-UNK
suggests	O
that	O
BRCA1	B-UNK
encodes	B-UNK
a	O
tumour	B-UNK
suppressor	I-UNK
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	B-UNK
cells	B-UNK
.	O

To	O
examine	O
the	O
role	B-UNK
of	O
BRCA1	B-UNK
in	O
normal	B-UNK
tissue	B-UNK
growth	B-UNK
and	O
differentiation	B-UNK
,	O
and	O
to	O
generate	O
a	O
potential	B-UNK
model	B-UNK
for	O
the	O
cancer	B-UNK
susceptibility	I-UNK
associated	O
with	O
loss	B-UNK
of	O
BRCA1	B-UNK
function	B-UNK
,	O
we	O
have	O
created	O
a	O
mouse	B-UNK
line	B-UNK
carrying	B-UNK
a	O
mutation	B-UNK
in	O
one	O
Brca1	B-UNK
allele	B-UNK
.	O

Analysis	B-UNK
of	O
mice	B-UNK
homozygous	B-UNK
for	O
the	O
mutant	B-UNK
allele	B-UNK
indicate	O
that	O
Brca1	B-UNK
is	O
critical	B-UNK
for	O
normal	B-UNK
development	B-UNK
,	O
as	O
these	O
mice	B-UNK
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10-E13	O
)	O
.	O

Abnormalities	B-UNK
in	O
Brca1-deficient	O
embryos	B-UNK
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	B-UNK
presenting	B-UNK
with	O
varying	O
degrees	O
of	O
spina	O
bifida	O
and	O
anencephaly	B-DISEASE
.	O

In	O
addition	B-UNK
,	O
the	O
neuroepithelium	O
in	O
Brca1-deficient	O
embryos	B-UNK
appeared	B-UNK
disorganized	O
,	O
with	O
signs	B-UNK
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	B-UNK
death	B-DISEASE
..	O

Identification	B-UNK
of	O
mutations	B-UNK
in	O
the	O
ALD	B-UNK
-	O
gene	B-UNK
of	O
20	O
families	B-UNK
with	O
adrenoleukodystrophy	B-DISEASE
/	O
adrenomyeloneuropathy	O
.	O

Adrenoleukodystrophy	B-UNK
(	O
ALD	B-UNK
)	O
,	O
an	O
X	O
-	O
linked	B-UNK
inherited	B-UNK
metabolic	B-UNK
disorder	B-UNK
,	O
is	O
the	O
most	O
frequent	B-UNK
inborn	O
peroxisomal	B-UNK
disease	B-UNK
.	O

It	O
leads	B-UNK
to	O
demyelination	O
in	O
the	O
central	B-UNK
and	O
peripheral	B-UNK
nervous	O
system	O
.	O

Defective	O
beta-oxidation	O
of	O
saturated	O
very	B-UNK
long	I-UNK
chain	I-UNK
fatty	I-UNK
acids	I-UNK
(	O
VLCFAs	O
;	O
C22	O
0-C26	O
0	O
)	O
in	O
peroxisomes	O
has	O
been	O
shown	B-UNK
to	O
lead	B-UNK
to	O
an	O
accumulation	B-UNK
of	O
VLCFAs	O
in	O
leukoid	O
areas	O
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
,	O
peripheral	B-UNK
nerves	O
,	O
adrenal	B-UNK
gland	O
,	O
and	O
blood	B-UNK
.	O

The	O
ALD	B-UNK
gene	B-UNK
has	O
been	O
recently	O
identified	B-UNK
and	O
encodes	B-UNK
a	O
745-amino	O
-	O
acid	B-UNK
protein	B-UNK
.	O

We	O
screened	B-UNK
patients	B-UNK
with	O
adrenoleukodystrophy	B-DISEASE
/	O
adrenomyeloneuropathy	O
(	O
ALD	B-UNK
/	O
AMN	B-UNK
)	O
from	O
20	O
kindreds	O
for	O
mutations	B-UNK
in	O
the	O
ALD	B-UNK
gene	B-UNK
.	O

Eleven	O
missense	B-UNK
and	O
two	O
nonsense	B-UNK
mutations	I-UNK
,	O
five	O
deletions	O
,	O
and	O
one	O
insertion	O
were	O
detected	B-UNK
by	O
direct	B-UNK
sequencing	I-UNK
of	O
eight	O
reverse	B-UNK
transcribed	O
fragments	O
of	O
the	O
ALD	B-UNK
-	O
gene	B-UNK
mRNA	O
.	O

Four	O
mutations	B-UNK
could	O
be	O
shown	B-UNK
to	O
be	O
de	O
novo	O
.	O

All	O
mutations	B-UNK
could	O
be	O
confirmed	B-UNK
in	O
carriers	B-UNK
by	O
sequencing	B-UNK
genomic	B-UNK
DNA	I-UNK
.	O

No	O
correlation	B-UNK
between	O
the	O
type	B-UNK
of	O
mutation	B-UNK
and	O
the	O
severity	B-UNK
of	O
the	O
phenotype	B-UNK
could	O
be	O
observed	B-UNK
.	O

The	O
mutations	B-UNK
were	O
not	O
detected	B-UNK
in	O
the	O
ALD	B-UNK
gene	B-UNK
of	O
30	O
healthy	O
persons	O
..	O

The	O
murine	O
homolog	O
of	O
the	O
human	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
gene	I-UNK
Brca1	B-UNK
maps	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
11D.	O

The	O
recently	O
cloned	O
human	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
susceptibility	B-UNK
gene	I-UNK
,	O
BRCA1	B-UNK
,	O
is	O
located	B-UNK
on	O
human	B-UNK
chromosome	I-UNK
17q21	O
.	O

We	O
have	O
isolated	B-UNK
murine	O
genomic	B-UNK
clones	O
containing	O
Brca1	B-UNK
as	O
a	O
first	O
step	O
in	O
generating	O
a	O
mouse	B-UNK
model	I-UNK
for	O
the	O
loss	B-UNK
of	O
BRCA1	B-UNK
function	B-UNK
.	O

A	O
mouse	B-UNK
genomic	B-UNK
library	O
was	O
screened	B-UNK
using	O
probes	O
corresponding	O
to	O
exon	B-UNK
11	O
of	O
the	O
human	B-UNK
BRCA1	B-UNK
gene	B-UNK
.	O

Two	O
overlapping	O
mouse	B-UNK
clones	O
were	O
identified	B-UNK
that	O
hybridized	O
to	O
human	B-UNK
BRCA1	B-UNK
exons	O
9	O
-	O
12	O
.	O

Sequence	B-UNK
analysis	I-UNK
of	O
1	O
.	O

4	O
kb	B-UNK
of	O
the	O
region	B-UNK
of	O
these	O
clones	O
corresponding	O
to	O
part	O
of	O
human	B-UNK
exon	B-UNK
11	O
revealed	B-UNK
72	O
%	O
nucleic	O
acid	B-UNK
identity	O
but	O
only	O
50	O
%	O
amino	B-UNK
acid	I-UNK
identity	O
with	O
the	O
human	B-UNK
gene	B-UNK
.	O

The	O
longest	O
of	O
the	O
mouse	B-UNK
Brca1	B-UNK
genomic	B-UNK
clones	O
maps	B-UNK
to	O
chromosome	B-UNK
11D	O
,	O
as	O
determined	B-UNK
by	O
two	O
-	O
color	B-UNK
fluorescence	B-UNK
in	I-UNK
situ	I-UNK
hybridization	I-UNK
.	O

The	O
synteny	O
to	O
human	B-UNK
chromosome	I-UNK
17	O
was	O
confirmed	B-UNK
by	O
cohybridization	O
with	O
the	O
mouse	B-UNK
probe	O
for	O
the	O
NF1-gene	O
.	O

This	O
comparative	O
study	B-UNK
confirms	O
that	O
the	O
relative	B-UNK
location	B-UNK
of	O
the	O
BRCA1	B-UNK
gene	B-UNK
has	O
been	O
conserved	B-UNK
between	O
mice	B-UNK
and	O
humans	B-UNK
.	O

Atelosteogenesis	O
type	B-UNK
II	I-UNK
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
diastrophic	B-UNK
dysplasia	I-UNK
sulfate	B-UNK
-	O
transporter	B-UNK
gene	B-UNK
(	O
DTDST	B-UNK
):	O
evidence	B-UNK
for	O
a	O
phenotypic	B-UNK
series	B-UNK
involving	O
three	O
chondrodysplasias	O
.	O

Atelosteogenesis	O
type	B-UNK
II	I-UNK
(	O
AO	B-UNK
II	B-UNK
)	O
is	O
a	O
neonatally	O
lethal	O
chondrodysplasia	O
whose	O
clinical	B-UNK
and	O
histological	O
characteristics	B-UNK
resemble	O
those	O
of	O
another	O
chondrodysplasia	O
,	O
the	O
much	O
less	O
severe	B-UNK
diastrophic	B-UNK
dysplasia	I-UNK
(	O
DTD	B-UNK
)	O
.	O

The	O
similarity	O
suggests	O
a	O
shared	O
pathogenesis	B-UNK
involving	O
lesions	B-UNK
in	O
the	O
same	O
biochemical	O
pathway	B-UNK
and	O
perhaps	O
the	O
same	O
gene	B-UNK
.	O

DTD	B-UNK
is	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
the	O
recently	O
identified	B-UNK
diastrophic	B-UNK
dysplasia	I-UNK
sulfate	B-UNK
-	O
transporter	B-UNK
gene	B-UNK
(	O
DTDST	B-UNK
)	O
.	O

Here	O
,	O
we	O
report	B-UNK
that	O
AOII	O
patients	B-UNK
also	O
have	O
DTDST	B-UNK
mutations	B-UNK
,	O
which	O
lead	B-UNK
to	O
defective	O
uptake	O
of	O
inorganic	O
sulfate	B-UNK
and	O
insufficient	O
sulfation	O
of	O
macromolecules	O
by	O
patient	B-UNK
mesenchymal	O
cells	B-UNK
in	O
vitro	O
.	O

Together	O
with	O
our	O
recent	O
observation	O
that	O
a	O
third	O
even	O
more	O
severe	B-UNK
chondrodysplasia	O
,	O
achondrogenesis	B-DISEASE
type	B-UNK
IB	O
,	O
is	O
also	O
caused	B-UNK
by	O
mutations	B-UNK
in	O
DTDST	B-UNK
,	O
these	O
results	B-UNK
demonstrate	B-UNK
a	O
phenotypic	B-UNK
series	B-UNK
of	O
three	O
chondrodysplasias	O
of	O
increasing	O
severity	B-UNK
caused	B-UNK
by	O
lesions	B-UNK
in	O
a	O
single	B-UNK
sulfate	B-UNK
-	O
transporter	B-UNK
gene	B-UNK
.	O

The	O
severity	B-UNK
of	O
the	O
phenotype	B-UNK
appears	B-UNK
to	O
be	O
correlated	B-UNK
with	O
the	O
predicted	B-UNK
effect	B-UNK
of	O
the	O
mutations	B-UNK
on	O
the	O
residual	B-UNK
activity	B-UNK
of	O
the	O
DTDST	B-UNK
protein	B-UNK
..	O

Haplotype	B-UNK
and	O
phenotype	B-UNK
analysis	B-UNK
of	O
six	O
recurrent	O
BRCA1	B-UNK
mutations	B-UNK
in	O
61	O
families	B-UNK
:	O
results	B-UNK
of	O
an	O
international	O
study	B-UNK
.	O

Several	O
BRCA1	B-UNK
mutations	B-UNK
have	O
now	O
been	O
found	O
to	O
occur	B-UNK
in	O
geographically	O
diverse	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
families	B-UNK
.	O

To	O
investigate	B-UNK
mutation	B-UNK
origin	O
and	O
mutation	B-UNK
-	O
specific	B-UNK
phenotypes	O
due	O
to	O
BRCA1	B-UNK
,	O
we	O
constructed	O
a	O
haplotype	B-UNK
of	O
nine	O
polymorphic	B-UNK
markers	I-UNK
within	O
or	O
immediately	O
flanking	O
the	O
BRCA1	B-UNK
locus	B-UNK
in	O
a	O
set	B-UNK
of	O
61	O
breast	B-UNK
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
families	B-UNK
selected	O
for	O
having	O
one	O
of	O
six	O
recurrent	O
BRCA1	B-UNK
mutations	B-UNK
.	O

Tests	O
of	O
both	O
mutations	B-UNK
and	O
family	B-UNK
-	O
specific	B-UNK
differences	B-UNK
in	O
age	B-UNK
at	I-UNK
diagnosis	I-UNK
were	O
not	O
significant	B-UNK
.	O

A	O
comparison	B-UNK
of	O
the	O
six	O
mutations	B-UNK
in	O
the	O
relative	B-UNK
proportions	O
of	O
cases	B-UNK
of	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
was	O
suggestive	O
of	O
an	O
effect	B-UNK
(	O
P	O
=	O
.	O
069	O
)	O
,	O
with	O
57	O
%	O
of	O
women	B-UNK
presumed	O
affected	B-UNK
because	O
of	O
the	O
1294	O
del	O
40	O
BRCA1	B-UNK
mutation	B-UNK
having	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
compared	B-UNK
with	O
14	O
%	O
of	O
affected	B-UNK
women	B-UNK
with	O
the	O
splice	B-UNK
-	O
site	B-UNK
mutation	B-UNK
in	O
intron	B-UNK
5	O
of	O
BRCA1	B-UNK
.	O

For	O
the	O
BRCA1	B-UNK
mutations	B-UNK
studied	O
here	O
,	O
the	O
individual	O
mutations	B-UNK
are	O
estimated	B-UNK
to	O
have	O
arisen	O
9	O
-	O
170	O
generations	O
ago	O
.	O

In	O
general	B-UNK
,	O
a	O
high	B-UNK
degree	B-UNK
of	O
haplotype	B-UNK
conservation	B-UNK
across	O
the	O
region	B-UNK
was	O
observed	B-UNK
,	O
with	O
haplotype	B-UNK
differences	B-UNK
most	O
often	O
due	O
to	O
mutations	B-UNK
in	O
the	O
short	B-UNK
-	O
tandem	O
-	O
repeat	B-UNK
markers	B-UNK
,	O
although	O
some	O
likely	O
instances	O
of	O
recombination	B-UNK
also	O
were	O
observed	B-UNK
.	O

For	O
several	O
of	O
the	O
instances	O
,	O
there	O
was	O
evidence	B-UNK
for	O
multiple	B-UNK
,	O
independent	O
,	O
BRCA1	B-UNK
mutational	O
events	O
.	O

Isolation	B-UNK
of	O
the	O
mouse	B-UNK
homologue	B-UNK
of	O
BRCA1	B-UNK
and	O
genetic	B-UNK
mapping	B-UNK
to	O
mouse	B-UNK
chromosome	I-UNK
11	O
.	O

The	O
BRCA1	B-UNK
gene	B-UNK
is	O
in	O
large	B-UNK
part	O
responsible	B-UNK
for	O
hereditary	B-UNK
human	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
.	O

Here	O
we	O
report	B-UNK
the	O
isolation	B-UNK
of	O
the	O
murine	O
Brca1	B-UNK
homologue	B-UNK
cDNA	O
clones	O
.	O

In	O
addition	B-UNK
,	O
we	O
identified	B-UNK
genomic	B-UNK
P1	O
clones	O
that	O
contain	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
mouse	B-UNK
Brca1	B-UNK
locus	B-UNK
.	O

DNA	B-UNK
sequence	I-UNK
analysis	B-UNK
revealed	I-UNK
that	O
the	O
mouse	B-UNK
and	O
human	B-UNK
coding	B-UNK
regions	B-UNK
are	O
75	O
%	O
identical	B-UNK
at	O
the	O
nucleotide	B-UNK
level	B-UNK
while	O
the	O
predicted	B-UNK
amino	B-UNK
acid	I-UNK
identity	O
is	O
only	O
58	O
%	O
.	O

A	O
DNA	B-UNK
sequence	I-UNK
variant	O
in	O
the	O
Brca1	B-UNK
locus	B-UNK
was	O
identified	B-UNK
and	O
used	O
to	O
map	B-UNK
this	O
gene	B-UNK
on	O
a	O
(	O
Mus	O
m.	O
musculus	O
Czech	O
II	B-UNK
x	O
C57BL	O
/	O
KsJ	O
)	O
F1	O
x	O
C57BL	O
/	O
KsJ	O
intersubspecific	O
backcross	O
to	O
distal	B-UNK
mouse	B-UNK
chromosome	I-UNK
11	O
.	O

The	O
mapping	B-UNK
of	O
this	O
gene	B-UNK
to	O
a	O
region	B-UNK
highly	B-UNK
syntenic	O
with	O
human	B-UNK
chromosome	I-UNK
17	O
,	O
coupled	O
with	O
Southern	B-UNK
and	O
Northern	B-UNK
analyses	O
,	O
confirms	O
that	O
we	O
isolated	B-UNK
the	O
murine	O
Brca1	B-UNK
homologue	B-UNK
rather	O
than	O
a	O
related	B-UNK
RING	O
finger	B-UNK
gene	B-UNK
.	O

The	O
isolation	B-UNK
of	O
the	O
mouse	B-UNK
Brca1	B-UNK
homologue	B-UNK
will	O
facilitate	O
the	O
creation	O
of	O
mouse	B-UNK
models	O
for	O
germline	B-UNK
BRCA1	B-UNK
defects	B-UNK
..	O

Emerin	O
deficiency	B-UNK
at	O
the	O
nuclear	B-UNK
membrane	I-UNK
in	O
patients	B-UNK
with	O
Emery	O
-	O
Dreifuss	O
muscular	B-UNK
dystrophy	I-UNK
.	O

Mutations	B-UNK
in	O
the	O
STA	O
gene	B-UNK
at	O
the	O
Xq28	B-UNK
locus	B-UNK
have	O
been	O
found	O
in	O
patients	B-UNK
with	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Emery	I-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
(	O
EDMD	B-UNK
)	O
.	O

This	O
gene	B-UNK
encodes	B-UNK
a	O
hitherto	O
unknown	O
protein	B-UNK
named	O
emerin	O
.	O

To	O
elucidate	O
the	O
subcellular	O
localization	B-UNK
of	O
emerin	O
,	O
we	O
raised	O
two	O
antisera	O
against	O
synthetic	O
peptide	B-UNK
fragments	O
predicted	B-UNK
from	O
emerin	O
cDNA	O
.	O

Using	O
both	O
antisera	O
,	O
we	O
found	O
positive	O
nuclear	B-UNK
membrane	I-UNK
staining	O
in	O
skeletal	B-UNK
,	O
cardiac	B-UNK
and	O
smooth	O
muscles	O
in	O
the	O
normal	B-UNK
controls	O
and	O
in	O
patients	B-UNK
with	O
neuromuscular	B-DISEASE
diseases	I-DISEASE
other	O
than	O
EDMD	B-UNK
.	O

In	O
contrast	B-UNK
,	O
a	O
deficiency	B-UNK
in	O
immunofluorescent	O
staining	O
of	O
skeletal	B-UNK
and	O
cardiac	B-UNK
muscle	B-UNK
from	O
EDMD	B-UNK
patients	B-UNK
was	O
observed	B-UNK
.	O

A	O
34	O
kD	O
protein	B-UNK
is	O
immunoreactive	O
with	O
the	O
antisera	O
--	O
the	O
protein	B-UNK
is	O
equivalent	O
to	O
that	O
predicted	B-UNK
for	O
emerin	O
.	O

Together	O
,	O
our	O
findings	B-UNK
suggest	B-UNK
the	O
specific	B-UNK
deficiency	B-UNK
of	O
emerin	O
in	O
the	O
nuclear	B-UNK
membrane	I-UNK
of	O
muscle	B-UNK
cells	B-UNK
in	O
patients	B-UNK
with	O
EDMD	B-UNK
..	O

Growth	B-DISEASE
retardation	I-DISEASE
and	O
tumour	B-UNK
inhibition	O
by	O
BRCA1	B-UNK
.	O

Inherited	B-UNK
mutations	B-UNK
in	O
BRCA1	B-UNK
predispose	O
to	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
,	O
but	O
the	O
role	B-UNK
of	O
BRCA1	B-UNK
in	O
sporadic	B-UNK
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
has	O
previously	B-UNK
been	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
retroviral	O
transfer	B-UNK
of	O
the	O
wild	B-UNK
-	O
type	B-UNK
BRCA1	B-UNK
gene	B-UNK
inhibits	O
growth	B-UNK
in	O
vitro	O
of	O
all	O
breast	B-UNK
and	I-UNK
ovarian	I-UNK
cancer	I-UNK
cell	B-UNK
lines	I-UNK
tested	O
,	O
but	O
not	O
colon	B-UNK
or	O
lung	B-DISEASE
cancer	I-DISEASE
cells	B-UNK
or	O
fibroblasts	B-UNK
.	O

Mutant	B-UNK
BRCA1	B-UNK
has	O
no	O
effect	B-UNK
on	O
growth	B-UNK
of	O
breast	B-UNK
cancer	I-UNK
cells	B-UNK
;	O
ovarian	B-DISEASE
cancer	I-DISEASE
cell	B-UNK
growth	B-UNK
is	O
not	O
affected	B-UNK
by	O
BRCA1	B-UNK
mutations	B-UNK
in	O
the	O
5	O
portion	B-UNK
of	O
the	O
gene	B-UNK
,	O
but	O
is	O
inhibited	O
by	O
3	O
BRCA1	B-UNK
mutations	B-UNK
.	O

Development	B-UNK
of	O
MCF-7	O
tumours	B-DISEASE
in	O
nude	O
mice	B-UNK
is	O
inhibited	O
when	O
MCF-7	O
cells	B-UNK
are	O
transfected	O
with	O
wild	B-UNK
-	O
type	B-UNK
,	O
but	O
not	O
mutant	B-UNK
,	O
BRCA1	B-UNK
.	O

Most	O
importantly	O
,	O
among	O
mice	B-UNK
with	O
established	O
MCF-7	O
tumours	B-DISEASE
,	O
peritoneal	O
treatment	O
with	O
a	O
retroviral	O
vector	O
expressing	O
wild	B-UNK
-	O
type	B-UNK
BRCA1	B-UNK
significantly	O
inhibits	O
tumour	B-DISEASE
growth	B-UNK
and	O
increased	B-UNK
survival	B-UNK
..	O

